Drug_ID	Drug_Name	PubChem_CID	Synonymous	Drug_Status	Drug_Status_num	Highest_phase_class	Highest_phase	Drug_Type	ChEBI_ID	DrugBank_ID	VARIDT_ID	INTEDE_ID	Molecular_Weight	Formula	Polararea	Complexity	xlogp	Heavycnt	Hbonddonor	Hbondacc	Rotbonds	InChI	isosmiles	InChIKey
DG00001	Triclosan	5564	"Triclosan; 3380-34-5; 5-CHLORO-2-(2,4-DICHLOROPHENOXY)PHENOL; 2,4,4'-Trichloro-2'-hydroxydiphenyl ether; Irgasan; Cloxifenolum; Triclosanum; Irgasan DP300; Stri-Dex Face Wash; Phenol, 5-chloro-2-(2,4-dichlorophenoxy)-; Lexol 300; Stri-Dex Cleansing Bar; 5-Chloro-2-(2,4-dichloro-phenoxy)-phenol; Triclosanum [INN-Latin]; CH 3565; DP-300; Caswell No 186A; C12H7Cl3O2; UNII-4NM5039Y5X; HSDB 7194; CHEBI:164200; Ether, 2'-hydroxy-2,4,4'-trichlorodiphenyl; Phenyl ether, 2'-hydroxy-2,4,4'-trichloro-; EINECS 222-182-2; CHEMBL849; EPA; Aquasept; Cliniclean; Cloxifenol; Manusept; Sapoderm; TCL; Trisan; Clearasil DailyFace Wash; Dermtek Brand of Triclosan; GlaxoSmithKline Brand of Triclosan; Microshield T; Oxy Skin Wash; Pharmachem Brand of Triclosan; Reckitt Brand of Triclosan; SSL Brand of Triclosan; Ster Zac Bath Concentrate; SterZac Bath Concentrate; Trans Canaderm Brand of Triclosan; Triclosan Pharmachem Brand; Triclosan Reckitt Brand; IN1424; Irgasan DP 300; CH-3565; Johnson & Johnson Brand of Triclosan; Procter & Gamble Brand of Triclosan; Ster-Zac Bath Concentrate; Stri-Dex cleansing bar (TN); Triclosan (USP/INN); Triclosan [USAN:BAN:INN]; 2,4,4'-Trichloro-2'-hydroxy diphenyl ether; 2-Hydroxy-2',4,4'-trichlorodiphenyl Ether; WL-1001"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:164200	DB08604	.	.	289.5	C12H7Cl3O2	29.5	252	5	17	1	2	2	"1S/C12H7Cl3O2/c13-7-1-3-11(9(15)5-7)17-12-4-2-8(14)6-10(12)16/h1-6,16H"	C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl	XEFQLINVKFYRCS-UHFFFAOYSA-N
DG00002	Melphalan	460612	"Alkeran; Levofalan; Levofolan; Levopholan; Melfalan; Melfalano; Melphalanum; Alanine Nitrogen Mustard; Phenylalanine mustard; Phenylalanine nitrogen mu stard; Phenylalanine nitrogen mustard; AY3360000; CB 3025; ALKERAN (TN); Alkeran (TN); At-290; CB-3025; L-PAM; L-Phenylalanine mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Melfalano [INN-Spanish]; Melphalanum [INN-Latin]; SK-15673; TRANSGENIC MODEL EVALUATION (MELPHALAN); MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)); P-L-Sarcolysin; P-L-sarcolysine; TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN); Melphalan (JP15/USP/INN); Melphalan [USAN:INN:BAN:JAN]; P-Bis(beta-chloroethyl)aminophenylalanine; P-N-Di(chloroethyl)aminophenylalanine; P-N-di(chloroethyl)aminophenylala nine; P-Di-(2-chloroethyl)amino-L-phenylalanine; P-N-Bis(2-chloroethyl)amino-L-phenylalanine; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; P-N,N-bis(2-chloroethyl)amino-L-phenylalanine; (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:28876	DB01042	DR00379	DR1021	305.2	C13H18Cl2N2O2	66.6	265	-0.5	19	2	4	8	"1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1"	C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl	SGDBTWWWUNNDEQ-LBPRGKRZSA-N
DG00003	Capecitabine	60953	"Capecitabin; Capecitabina; Capecitabinum; Capecitibine; Capiibine; Caxeta; Xabine; Xeloda; Capecitabine [USAN]; R340;R-340; RG-340; Ro 09-1978; Xeloda (TN); Ro 09-1978/000; Ro-09-1978; Xeloda, Captabin, Capecitabine; Capecitabine (JAN/USAN/INN); Ro-09-1978/000; N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine; Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester; Pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate; (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine; 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine; Capecitabine (Fluoropyrimidine)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31348	DB01101	DR00380	DR0266	359.35	C15H22FN3O6	121	582	0.6	25	3	7	7	"1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1"	CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@H]2[C@@H]([C@@H]([C@H](O2)C)O)O	GAGWJHPBXLXJQN-UORFTKCHSA-N
DG00004	Mezlocillin	656511	"Mezlin; Mezlocilina; Mezlocillinum; Mezlocillin (USAN/INN); (2S,5R,6R)-3,3-dimethyl-6-[[(2R)-2-[(3-methylsulfonyl-2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-6-{[(2R)-2-({[3-(methylsulfonyl)-2-oxoimidazolidin-1-yl]carbonyl}amino)-2-phenylacetyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{(2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid; 6beta-{(2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}penicillanic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6919	DB00948	.	.	539.6	C21H25N5O8S2	207	1080	-0.2	36	3	9	6	"1S/C21H25N5O8S2/c1-21(2)14(18(29)30)26-16(28)13(17(26)35-21)22-15(27)12(11-7-5-4-6-8-11)23-19(31)24-9-10-25(20(24)32)36(3,33)34/h4-8,12-14,17H,9-10H2,1-3H3,(H,22,27)(H,23,31)(H,29,30)/t12-,13-,14+,17-/m1/s1"	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCN(C4=O)S(=O)(=O)C)C(=O)O)C	YPBATNHYBCGSSN-VWPFQQQWSA-N
DG00005	Benzylpenicillin	5904	Penicillin g; Benzylpenicillinic acid; Free penicillin II; Pencillin G; 61-33-6; Benzylpenicillin G; Bencilpenicilina; Benzylpenicillinum; Benzyl penicillin; Free penicillin G; Dropcillin; Pharmacillin; Gelacillin; Liquacillin; Benzopenicillin; Cilopen; Pradupen; Benzylpenicilline; Specilline G; Cilloral; Cosmopen; Ursopen; Galofak; Free benzylpenicillin; Compocillin G; Phenylacetamidopenicillanic acid; 6-(2-Phenylacetamido)penicillanic acid; Pfizerpen; Benzyl-6-aminopenicillinic acid	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:18208	DB01053	DR00488	DR2164	334.4	C16H18N2O4S	112	530	1.8	23	2	5	4	"1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1"	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C	JGSARLDLIJGVTE-MBNYWOFBSA-N
DG00006	Apigenin	5280443	"Apigenin; 520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:18388	DB07352	DR00822	.	270.24	C15H10O5	87	411	1.7	20	3	5	1	"1S/C15H10O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-7,16-18H"	C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O	KZNIFHPLKGYRTM-UHFFFAOYSA-N
DG00007	Nilotinib	644241	"NIL; Nilotinibum; Tasigna (Novartis); Nilotinib (INN/USAN); Nilotinib, AMN107, Tasigna; Tasigna, AMN-107, Nilotinib; L-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-(9CI); 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazo; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; Nilotinib (BCR-ABL inhibitor 2nd gen)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:52172	DB04868	DR00013	.	529.5	C28H22F3N7O	97.6	817	4.9	39	2	9	6	"1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)"	CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5	HHZIURLSWUIHRB-UHFFFAOYSA-N
DG00008	Adefovir	60172	"ADEFOVIR; 106941-25-7; PMEA; ((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid; 9-(2-Phosphonylmethoxyethyl)adenine; GS-0393; GS 0393; GS 393; 9-(2-(Phosphonomethoxy)ethyl)adenine; N-(2-Phosphonylmethoxyethyl)adenine; DRG-0156; UNII-6GQP90I798; C8H12N5O4P; HSDB 8079; CHEMBL484; 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid; BRN 3561094; {[2-(6-Amino-9h-Purin-9-Yl)ethoxy]methyl}phosphonic Acid; N-(2-Phophonomethoxyethyl-2,6-diaminopurine); Phosphonic acid, [[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]-; 6GQP90I798"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:2469	DB13868	DR00015	.	273.19	C8H12N5O4P	136	327	-2	18	3	8	5	"1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16)"	C1=NC(=C2C(=N1)N(C=N2)CCOCP(=O)(O)O)N	SUPKOOSCJHTBAH-UHFFFAOYSA-N
DG00009	Pulvomycin	5282056	Pulvomycin; AC1NQZFA; C12070; 11006-66-9; CHEBI:29668	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:29668	.	.	.	839	C47H66O13	199	1700	5	60	5	13	13	"1S/C47H66O13/c1-29-20-19-21-31(3)42(53)38(50)24-17-11-10-12-18-25-40(60-41(52)27-26-30(2)39(51)28-29)33(5)43(54)32(4)36(48)22-15-13-14-16-23-37(49)34(6)58-47-46(57-9)44(55)45(56-8)35(7)59-47/h10-24,26,28,32-35,37-40,43-47,49-51,54-55H,25,27H2,1-9H3/b11-10+,14-13+,18-12+,20-19+,22-15+,23-16+,24-17+,29-28+,30-26-,31-21+/t32 ,33 ,34 ,35-,37 ,38 ,39 ,40 ,43 ,44+,45+,46-,47-/m1/s1"	C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)OC(C)C(/C=C/C=C/C=C/C(=O)C(C)C(C(C)C2C/C=C/C=C/C=C/C(C(=O)/C(=C/C=C/C(=C/C(/C(=C\\CC(=O)O2)/C)O)/C)/C)O)O)O)OC)O)OC	FXSFWUNCIOIMAC-YHQXOMPPSA-N
DG00010	Baicalein	5281605	"Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Noroxylin; Biacalein; BaiKalein; Baicelein; UNII-49QAH60606; NSC661431; NSC 661431; CHEMBL8260; 5,6,7-trihydroxy-2-phenylchromen-4-one; CHEBI:2979; FXNFHKRTJBSTCS-UHFFFAOYSA-N; MFCD00017459; 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl-; 49QAH60606; 5,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-chromen-4-one; Sho-saiko-to; SMR000112462; SR-01000597499; Baicalein, 8; Baicalein,(S); 3WL; Baicalein, 14; Baicalein, 98%; AC1NQYPP; Tocris-1761"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:2979	DB16101	.	.	270.24	C15H10O5	87	413	1.7	20	3	5	1	"1S/C15H10O5/c16-9-6-11(8-4-2-1-3-5-8)20-12-7-10(17)14(18)15(19)13(9)12/h1-7,17-19H"	C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O	FXNFHKRTJBSTCS-UHFFFAOYSA-N
DG00011	Dolutegravir	54726191	"1051375-16-6; GSK1349572; Tivicay; S/GSK1349572; Dolutegravir (GSK1349572); S-349572; GSK-1349572; GSK 1349572; UNII-DKO1W9H7M1; (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide; CHEBI:76010; DKO1W9H7M1; Tivicay (TN); (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; Dolutegravir Sodium ("	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:76010	DB08930	DR00383	.	419.4	C20H19F2N3O5	99.2	829	2.4	30	2	8	3	"1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1"	C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O	RHWKPHLQXYSBKR-BMIGLBTASA-N
DG00012	Caspofungin	2826718	"CASPO; Cancidas; Capsofungin; Caspofungin [INN]; M991; Cancidas (TM); Cancidas (TN); Caspofungin (INN); MK-0991; L-743,872; [1(R)-hydroxyethyl]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0(9,13)]heptacosane-2,5,8,14,17,23-hexaone diacetate; Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-(9CI); (4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; (4R,5S)-5-((2-aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:474180	DB00520	DR00493	.	1093.3	C52H88N10O15	412	1900	0.3	77	16	18	23	"1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28 ,29 ,30-,33-,34+,35+,36-,37+,38-,40+,41+,42+,43+,44+,45+,46+/m1/s1"	CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@H]([C@H](NC(=O)[C@@H]2[C@H](CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)[C@@H](CCN)O)O)NCCN)O	JYIKNQVWKBUSNH-OGZDCFRISA-N
DG00013	Terbinafine	1549008	"Bramazil; Lamasil; TerbiFoam; Terbina; Lamisil AT; Lamisil Tablet; Ternbinafine HCl; Lamasil (TN); Lamisil (TN); SF 86-327; Terbisil (TN); Zabel (TN); SF-86-327; Terbinafine (USAN/INN); Terbinafine [USAN:BAN:INN]; Lamisil, Terbinex, Corbinal, Zabel, Terbinafine; Terbinafine, SF-86-327, Lamisil, TBNF; (2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)-2-hepten-4-yn-1-amine; (2E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine; (E)-N-(6,6-dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9448	DB00857	.	.	291.4	C21H25N	3.2	428	5.6	22	0	1	5	"1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+"	CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21	DOMXUEMWDBAQBQ-WEVVVXLNSA-N
DG00014	Ginsenoside Rg3	9918693	(20S)-ginsenoside Rg3	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:67991	.	.	DR2671	785	C42H72O13	219	1370	4	55	9	13	10	"1S/C42H72O13/c1-21(2)10-9-14-42(8,51)22-11-16-41(7)29(22)23(45)18-27-39(5)15-13-28(38(3,4)26(39)12-17-40(27,41)6)54-37-35(33(49)31(47)25(20-44)53-37)55-36-34(50)32(48)30(46)24(19-43)52-36/h10,22-37,43-51H,9,11-20H2,1-8H3/t22-,23+,24+,25+,26-,27+,28-,29-,30+,31+,32-,33-,34+,35+,36-,37-,39-,40+,41+,42-/m0/s1"	CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O)C	RWXIFXNRCLMQCD-JBVRGBGGSA-N
DG00015	Teniposide	452548	"PTG; Teniposido; Teniposidum; Vehem; Vumon; Demethyl Epipodophyllotoxin Thenylidine Glucoside; VM 26; Teniposido [INN-Spanish]; Teniposidum [INN-Latin]; VM-26; Vee M-26; Veham-Sandoz; Vumon (TN); Teniposide (USAN/INN); Teniposide [USAN:BAN:INN]; VM-26 (TN); Vumon, VM-26, Vehem, NSC 122819, Teniposide; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin thenylidene glucoside; 4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside; 4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin; 4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00444	DR00021	DR1550	656.7	C32H32O13S	189	1090	1.2	46	3	14	6	"1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1"	COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O	NRUKOCRGYNPUPR-QBPJDGROSA-N
DG00016	Cephapirin	30699	"CEPR; Cefa; Cefadyl; Cefapirin; Cefapirina; Cefapirine; Cefapirinum; Cefaprin; Cephapirine; Metricure; CEPHAPIRIN SODIUM; Cefaprinsodium; Cephapirin Monosodium Salt; ANTIBIOTIC BL-P1322; BL-P 1322; Cefa-ak; Cefadyl (TN); Cefapirin (BAN); Cefapirin [INN:BAN]; Cefapirina [INN-Spanish]; Cefapirine [INN-French]; Cefapirinum [INN-Latin]; Metricure (TN); (6R,7R)-3-(Acetoxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-pyridin-4-ylsulfanylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-{[(pyridin-4-ylthio)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-acetoxymethyl-7-[(pyridin-4-ylsulfanyl)acetamido]-3,4-didehydrocepham-4-carboxylic acid; 3-(Hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamidol-5-thia-1-azabicyclo(4.2.0)oct-2-en-2carbonsaeure acetat; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-, acetate (ester); 7-(2-(4-Pyridylthio)acetamido)cephalosporanic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:554446	DB01139	DR00495	.	423.5	C17H17N3O6S2	177	707	-1.1	28	2	9	8	"1S/C17H17N3O6S2/c1-9(21)26-6-10-7-28-16-13(15(23)20(16)14(10)17(24)25)19-12(22)8-27-11-2-4-18-5-3-11/h2-5,13,16H,6-8H2,1H3,(H,19,22)(H,24,25)/t13-,16-/m1/s1"	CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CSC3=CC=NC=C3)SC1)C(=O)O	UQLLWWBDSUHNEB-CZUORRHYSA-N
DG00017	Vinorelbine	5311497	"Eunades; Exelbine; NVB; Navelbine; Vinorelbin; Vinorelbina; Vinorelbinum; Navelbine base; Vinorelbina [Spanish]; Vinorelbine Ditartarate; Vinorelbine ditartrate; Vinorelbine tartrate; Vinorelbinum [Latin]; KW 2307; KW 2307 base; ANX-530; KW-2307; Navelbine (TN); SDP-012; Vinorelbine (INN); Vinorelbine [INN:BAN]; Aspidospermidine-3-carboxylic acid; Nor-5'-anhydrovinblastine; Methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; Methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:480999	DB00361	DR01343	.	778.9	C45H54N4O8	134	1690	3.6	57	2	11	10	"1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45-/m0/s1"	CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC	GBABOYUKABKIAF-IELIFDKJSA-N
DG00018	Raltitrexed	135400182	"Tomudex; 112887-68-0; ZD1694; ZD-1694; ICI-D1694; D-1694; ZD 1694; ICI D1694; UNII-FCB9EGG971; D1694; D 1694; CHEBI:5847; Raltitrexed (Tomudex); C21H22N4O6S; ZD-16; (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; FCB9EGG971; CHEMBL225071; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; ICI-D-1694; NSC-639186; NCGC00229704-01; DSSTox_RID_81653; DSSTox_CID_26482; DSSTox_GSID_46482"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:5847	DB00293	DR00958	.	458.5	C21H22N4O6S	177	790	1.4	32	4	9	9	"1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1"	CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)N1	IVTVGDXNLFLDRM-HNNXBMFYSA-N
DG00019	Fexofenadine	3348	"Carboxyterfenadine; Fexofendine; Terfenadine acid metabolite; Terfenadine carboxylate; F 9427; MDL 16455; Allegra (TN); Fastofen (TN); Fexofenadine (INN); Fexofenadine [INN:BAN]; Telfast (TN); Terfenadine-COOH; Terfenidine carboxylate, MDL 16455; Tilfur (TN); 2-[4-(1-hydroxy-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butyl)phenyl]-2-methylpropanoic acid; 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid; 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:5050	DB00950	DR00026	.	501.7	C32H39NO4	81	678	3	37	3	5	10	"1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)"	CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O	RWTNPBWLLIMQHL-UHFFFAOYSA-N
DG00020	Carmustine	2578	"Carmustine; carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; BCNU; Injectable carmustine, Direct Therapeutics"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3423	DB00262	.	DR0278	214.05	C5H9Cl2N3O2	61.8	156	1.5	12	1	3	4	"1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)"	C(CCl)NC(=O)N(CCCl)N=O	DLGOEMSEDOSKAD-UHFFFAOYSA-N
DG00021	Cefalotin	6024	"Cefalothin; Cefalotina; Cefalotine; Cefalotinum; Cemastin; Cephalothinum; Cephalotin; Coaxin; Cefalotina fabra; Cephalothin Monosodium Salt; Averon-1; Cefalotin (BAN); Cefalotina [INN-Spanish]; Cefalotina fabra (TN); Cefalotine [INN-French]; Cefalotinum [INN-Latin]; Keflin (TN); (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-(Acetoxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-(Hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate; 3-ACETOXYMETHYL-8-OXO-7-(2-THIOPHEN-2-YL-ACETYLAMINO)-5-THIA-1-AZA-BICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLIC ACID; 3-Acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-, acetate (ester); 6R-trans-3-((Acetyloxy)methyl)-8-oxo-7-((2-thienylacetyl)amino)-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-carboxylic acid; 7-(2-(2-Thienyl)acetylamido)cephalosporanic acid; 7-(2-Thienylacetamido)cephalosporanic acid; 7-(Thiophene-2-acetamido)cephalosporanic acid; 7-(Thiophene-2-acetamido)cephalosporin; 7beta-(thiophen-2-ylacetamido)-3-acetoxymethyl-3,4-didehydrocepham-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:124991	DB00456	.	DR2178	396.4	C16H16N2O6S2	167	680	-0.4	26	2	8	7	"1S/C16H16N2O6S2/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23)/t12-,15-/m1/s1"	CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC3=CC=CS3)SC1)C(=O)O	XIURVHNZVLADCM-IUODEOHRSA-N
DG00022	Copper	23978	Cu-7; Paragard T 380a; Tatum-t	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:28694	DB09130	.	.	63.55	Cu	0	0	.	1	0	0	0	1S/Cu	[Cu]	RYGMFSIKBFXOCR-UHFFFAOYSA-N
DG00023	Daunorubicin	30323	"Daunorubicin; Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Acetyladriamycin; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:41977	DB00694	DR00284	DR0424	527.5	C27H29NO10	186	960	1.8	38	5	11	4	"1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1"	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O	STQGQHZAVUOBTE-VGBVRHCVSA-N
DG00024	Zidovudine	35370	"Zidovudine; Azidothymidine; 30516-87-1; 3'-Azido-3'-deoxythymidine; Retrovir; AZT; Zidovudinum; Compound S; Thymidine, 3'-azido-3'-deoxy-; ZIDOVUDINE [AZT]; zidovudin; BW A509U; Zidovudinum [Latin]; Zidovudina [Spanish]; BWA509U; DRG-0004; 3'-Azido-2',3'-Dideoxythymidine; ZDV; UNII-4B9XT59T7S; 3'-Deoxy-3'-azidothymidine; CCRIS 105; Aztec; BW-A509U; BW-A-509U; HSDB 6515; 3'-Azido-3'-deoxythymidine (AIDS); CHEMBL129; NSC 602670; BW-A 509U; MLS000028548; 4B9XT59T7S; AZT; Antiviral; Azidodeoxythymidine; ZVD; Zidovudin; Zidovudina; AZT Antiviral; AZT TRANSPLACENTAL CARCINOGENESIS STUDY; Antiviral AZT; Cpd S; Racemic Liposomal AZT; Zidovudine EP III; BWA 509U; K7 [P Ti2 W10 O40]; AZT & EPO; AZT & HPA; AZT & Lymphoblastoid Interferon; AZT & SST; AZT & rsT4; AZT & sCD4; AZT & srCD4; AZT (Antiviral); AZT+PRO 140; AZT, Antiviral; Apo-Zidovudine; BWA-509U; Intron A & AZT; Novo-Azt; Propolis+AZT; Retrovir (TN); Retrovir(TM); Retrovis (TN); Zidovudine+PRO 140; AZT & Colony-stimulating factor 2; AZT & Concanavalin A (ConA); AZT & GM-CSF; AZT & IFN-alpha; AZT & IL-1; AZT & IL-2; AZT & IL-6; AZT & Li & EPO; AZT & NP (from PHCA or HSA); AZT & PM-19; DS-4152 & AZT; Liposomal AZT-SN-1; Liposomal AZT-SN-3; PC-SOD+AZT;RIFN-beta seron & AZT; AZT & CD4(178)-PE 40; AZT & Li & GM-CSF; AZT & Li & IL-1; AZT & Li & IL-6; AZT & rIFNalpha2; Racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle); Zidovudine (JAN/USP/INN); Zidovudine [USAN:INN:BAN:JAN]; AZT & rsCD4 & rIFNalphaA; SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle); SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle); AZT & Interferon-alpha-2; Met-SDF-1beta & AZT; Met-SDF-1beta & Zidovudine; Interferon AD + 3'-azido-3'-deoxythymidine; 1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine; 3′-Azido-3′-deoxythymidine; 3' Azido 2',3' Dideoxythymidine; 3' Azido 3' deoxythymidine; 3'-Azido-3'-deoxythymidine & Concanavalin A; 3'-Azido-3'-deoxythymidine & Erythropoietin; 3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19; 3'-Azido-3'-deoxythymidine & Interleukin-1; 3'-Azido-3'-deoxythymidine & Interleukin-2; 3'-Azido-3'-deoxythymidine & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon; 3'-Azido-3'-deoxythymidine & Sho-Saiko-To; 3'-Azido-3'deoxythymidine & Interferon-alpha; 3'-Azidothymidine; 3'-azido-3'-deoxythymidine, AZT; 3-Azido-3-deoxythymidine; Dendrigen; CTCE-0422"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:10110	DB00495	DR00296	DR1729	267.24	C10H13N5O4	93.2	484	0	19	2	6	3	"1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1"	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-]	HBOMLICNUCNMMY-XLPZGREQSA-N
DG00025	Chlorpromazine	2726	Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3647	DB00477	DR00502	.	318.9	C17H19ClN2S	31.8	339	5.2	21	0	3	4	"1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3"	CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl	ZPEIMTDSQAKGNT-UHFFFAOYSA-N
DG00026	Silibinin	31553	"Silibinin; Silybin; 22888-70-6; Flavobin; Silymarin I; Silybin A; Silybine; Silibinine; Silliver; Silibinin A; Silibininum; Silibinina; Flavobin Spofa; Silymarine I; Silibinin [INN]; Silymarine; Silibininum [INN-Latin]; Silibinine [INN-French]; Silibinina [INN-Spanish]; 7C3MT; UNII-33X338MNE4; EINECS 245-302-5; NSC 651520; Silimarin; Silibin; CHEBI:9144; 33X338MNE4; Silibinin (INN); NSC651520; C25H22O10; NCGC00091057-01; DSSTox_CID_6018; DSSTox_RID_77985; DSSTox_GSID_26018; (2R,3R)-3,5,7-trihydroxy-2-((2R,3R)-3-(4-hydroxy-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9144	DB09298	DR00388	.	482.4	C25H22O10	155	750	2.4	35	5	10	4	"1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1"	COC1=C(C=CC(=C1)[C@@H]2[C@H](OC3=C(O2)C=C(C=C3)[C@@H]4[C@H](C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O	SEBFKMXJBCUCAI-HKTJVKLFSA-N
DG00027	Tretinoin	444795	"Retinoic acid; tretinoin; 302-79-4; Vitamin A acid; all-trans-Retinoic acid; trans-Retinoic acid; ATRA; Airol; Retin-A; Vesanoid; Renova; Dermairol; Aknoten; Eudyna; Aberel; all-trans-Vitamin A acid; Aknefug; All-trans Retinoic Acid; Cordes vas; Epi-aberel; Atralin; Vitamin A1 acid, all-trans-; Tretin M; Retin-A Micro; all-trans-Vitamin A1 acid; Vitamin A acid, all-trans-; all-trans-Tretinoin; Effederm; Retionic acid; TRETINON; Retinoic acid, all-trans-; Alltrans-retinoic acid; beta-Ra; all-(E)-Retinoic acid; beta-Retinoic acid; Avitoin; Aberela; Acnavit; Atragen; Betarretin; Lsotretinoin; Nexret; Panretyn; REA; Retacnyl; Retinoate; Retinova; Solage; Tretinoina; Tretinoine; Tretinoino; Tretinoinum; Vesnaroid; Vitinoin; Aberela [Norway]; Accutane Roche; Acnavit [Denmark]; All Trans Retinoic Acid; Avita Gel; Avitoin [Norway]; Beta all trans Retinoic Acid; Cordes VAS [Germany]; Effederm [France]; Panretin Gel; Retin A; Trans Retinoic Acid; Tretinoin Potassium Salt; Tretinoin Sodium Salt; Tretinoin Zinc Salt; Tretinoin liposome; AGN100335; AGN 192013; ALRT 1057; BAL4079; LGD 100057; R 2625; [3H]Retinoic acid; A-Vitaminsyre; A-Vitaminsyre [Denmark]; AT-RA; Aberela (TN); Acid, Retinoic; Acid, Vitamin A; All trans-Retinoic acid; Atra-IV; Avita (TN); B-Retinoic acid; BML2-E05; Beta-Ra; Beta-Retinoic acid; Potassium Salt, Tretinoin; RETINOIC ACID, ALL TRANS; Renova (TN); Retin A (TN); Retisol-A; Ro 1-5488; Salt, Tretinoin Potassium; Salt, Tretinoin Sodium; Salt, Tretinoin Zinc; Sodium Salt, Tretinoin; Stieva-A; Stieva-a Forte; Trans-Retinoicacid; Tretinoin (TN); Tretinoina [INN-Spanish]; Tretinoine [INN-French]; Tretinoino [INN-Spanish]; Tretinoinum [INN-Latin]; Tri-Luma; Vesanoid (TN); Zinc Salt, Tretinoin; A-Acido (Argentina); Acid A Vit (Belgium, Netherlands); Acid, trans-Retinoic; Acide retinoique (French) (DSL); All-trans-Retinoic acid; All-trans-Tretinoin; All-trans-Vitamin A acid; All-trans-Vitamin A1 acid; PDT-002-002; Retin-A (TN); Stieva-A (TN); Tretinoin 01% cream or placebo; Tretinoin [USAN:INN:BAN]; Tretinoin/All-Trans Retinoic Acid; Tretinoine (French) (EINECS); Acid, all-trans-Retinoic; All-(E)-Retinoic acid; All-trans-b-Retinoic acid; All-trans-beta-Retinoic acid; Beta-all-trans-Retinoic acid; Tretinoin (JAN/USP/INN); Acid, beta-all-trans-Retinoic; Retinoic acid, all-trans-(8CI); Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin; 15-Apo-beta-caroten-15-oic acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; 9(Z)-Retinoic acid; 9-cis-RA; 9-trans-retinoic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:15367	DB00755	DR00154	DR1634	300.4	C20H28O2	37.3	567	6.3	22	1	2	5	"1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+"	CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C	SHGAZHPCJJPHSC-YCNIQYBTSA-N
DG00029	Glutathione	124886	Glutathione; 70-18-8; Glutathion; Isethion; Tathion; Glutathione-SH; Glutinal; reduced glutathione; Neuthion; Deltathione; Copren; L-Glutathione reduced; Glutide; Tathione; Triptide; Ledac; Glutatione; GSH; Glutatiol; Panaron; gamma-L-Glutamyl-L-cysteinylglycine; Glutathione SH; L-Glutatione; Glutathione (reduced); Agifutol S; L-gamma-glutamyl-L-cysteinylglycine; gamma-L-glutamyl-L-cysteinyl-glycine; 5-L-Glutamyl-L-cysteinylglycine; Glutathione [JAN]; glutathione red; gamma-L-Glutamylcysteinylglycine; red. glutathione	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:16856	DB00143	DR00039	DR2036	307.33	C10H17N3O6S	160	389	-4.5	20	6	8	9	"1S/C10H17N3O6S/c11-5(10(18)19)1-2-7(14)13-6(4-20)9(17)12-3-8(15)16/h5-6,20H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)/t5-,6-/m0/s1"	C(CC(=O)N[C@@H](CS)C(=O)NCC(=O)O)[C@@H](C(=O)O)N	RWSXRVCMGQZWBV-WDSKDSINSA-N
DG00030	Digoxin	2724385	"Digoxin; 20830-75-5; 12beta-Hydroxydigitoxin; Digoxine; Lanoxin; Lanoxicaps; Digossina; Digoxina; Digoxinum; Digosin; Lanicor; Digacin; Dilanacin; CHEBI:4551; MLS000069819; Lanacordin; Cardiogoxin; Eudigox; Davoxin; SMR000059217; Rougoxin; Mapluxin; Lenoxin; Lanacrist; Dynamos; Vanoxin; Neo-Lanicor; Lanoxin PG; Digoxin Pediatric; Digoxin Nativelle; SK-Digoxin; UNII-73K4184T59; Homolle's digitalin; Hemigoxine Nativelle; MFCD00003674; Digitek (TN); Lanoxicaps (TN); Lanoxin (TN); Digoxin (JP15/USP); (3beta,5beta,12beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8700^{2,7}; [3H]digoxin"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4551	DB00390	DR00148	DR0498	780.9	C41H64O14	203	1450	1.3	55	6	14	7	"1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1"	C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O	LTMHDMANZUZIPE-PUGKRICDSA-N
DG00031	Spectinomycin	15541	"Actinospectacin; Actinospectacina; Adspec; Espectinomicina; Prospec; SCM; SPCM; Spectam; Spectinomicina; Spectinomycine; Spectinomycinum; Spectogard; Stanilo; Togamycin; Trobicin; Actinospectacina [Italian]; Spectam Scour Halt; Spectinomicina [Italian]; Spectinomycin Di HCl; Spectinomycin HCl; Spectinomycin dihydrochloride; Spectinomycin hydrochloride; Spectinomycin hydrochloride anhydrous; Spectinomycin monohydrochloride; Spectinomycin sulfate; Antibiotic 2233wp; M 141; U 18409; U 18409 E; Actinospectacin, hydrochloride; Adspec (TN); Espectinomicina [INN-Spanish]; M-141; Prospec (TN); Spectinomycin (INN); Spectinomycin Dihydrochloride, Anhydrous; Spectinomycin Dihydrochloride, Pentahydrate; SpectinomycinHCl/ Sulphate; Spectinomycin Hydrochloride (anhydrous); Spectinomycin [INN:BAN]; Spectinomycine [INN-French]; Spectinomycinum [INN-Latin]; Trobicin (TN); U-18409AE; XK 43-1; Togamycin sulfate (1:1); ACTINOSPECTACIN, ESPECTINOMICINA, CHX-3101; (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)decahydro-4H-pyrano[2,3-b][1,4]benzodioxin-4-one; (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))-Decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-4H-pyrano(2,3-b)(1,4)benzodioxin-4-one monohydrochloride; 4H-Pyrano[2,3-b][1,4]benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, [2R-(2.alpha.,4a.beta.,5a.beta.,6.beta.,7.beta.,8.beta.,9.alpha.,9a.alpha.,10a.beta.)]-, sulfate (1:1) (salt)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9215	DB00919	.	DR2379	332.35	C14H24N2O7	130	478	-3.1	23	5	9	2	"1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1"	C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O	UNFWWIHTNXNPBV-WXKVUWSESA-N
DG00032	Topotecan	60700	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63632	DB01030	DR00044	.	421.4	C23H23N3O5	103	867	0.5	31	2	7	3	"1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1"	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O	UCFGDBYHRUNTLO-QHCPKHFHSA-N
DG00033	Levofloxacin	149096	"Aeroquin; Cravit; Elequine; Floxacin; Floxel; Iquix; LFX; LVX; Leroxacin; Lesacin; Levaquin; Levofloxacine; Levofloxacino; Levofloxacinum; Levokacin; Levox; Levoxacin; Mosardal; Nofaxin; Oftaquix; Quixin; Reskuin; Tavanic; Volequin; Cravit Ophthalmic; DR 3354; DR3355; HR 355; Cravit (TN); D-Levofloxacin; DR-3355; HR-355; Iquix (TN); L-Ofloxacin; LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Levaquin (TN); Levofloxacin (INN); Levofloxacin tablet, suspension or intravenous; Levofloxacine [INN-French]; Levofloxacino [INN-Spanish]; Levofloxacinum [INN-Latin]; MP-376; Oftaquix (TN); Quixin (TN); R-Ofloxacin; RWJ 25213-097; RWJ-25213; Tavanic (TN); Levofloxacin [USAN:INN:JAN]; DR-3355: L-isomer of ofloxacin; Ofloxacin S-(-)-form; S-(-)-Ofloxacin; (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; (R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (R)-isomer; (S)-(-)-Ofloxacin; (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (S)-Ofloxacin"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63598	DB01137	DR00046	DR2456	361.4	C18H20FN3O4	73.3	634	-0.4	26	1	8	2	"1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1"	C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O	GSDSWSVVBLHKDQ-JTQLQIEISA-N
DG00034	Abiraterone	132971	Abiraterone (AR inhibitor)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:68642	DB05812	.	.	349.5	C24H31NO	33.1	636	4.6	26	1	2	1	"1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1"	C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)O	GZOSMCIZMLWJML-VJLLXTKPSA-N
DG00035	Carbenicillin	20824	"CBPC; Carbenicilina; Carbenicillina; Carbenicilline; Carbenicillinum; Carboxybenzylpenicillin; Pyopen; Carbenicillina [DCIT]; Carboxybenzyl Penicillin; Carboxybenzylpenicillin acid; Alpha-Carboxybenzylpencillin; Alpha-Carboxybenzylpenicillin solution; Carbenicilina [INN-Spanish]; Carbenicillin (INN); Carbenicillin [INN:BAN]; Carbenicilline [INN-French]; Carbenicillinum [INN-Latin]; Alpha-Phenyl(carboxymethylpenicillin); N-(2-Carboxy-3,3-dimethyl-7-oxo-4-thia-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid;N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid; (2S,5R,6R)-6-[(3-hydroxy-3-oxo-2-phenylpropanoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[carboxy(phenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(alpha-Carboxyphenylacetamido)penicillanic acid; 6beta-(2-carboxy-2-phenylacetamido)-2,2-dimethylpenam-3alpha-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3393	DB00578	DR00995	DR2390	378.4	C17H18N2O6S	149	645	1.1	26	3	7	5	"1S/C17H18N2O6S/c1-17(2)11(16(24)25)19-13(21)10(14(19)26-17)18-12(20)9(15(22)23)8-6-4-3-5-7-8/h3-7,9-11,14H,1-2H3,(H,18,20)(H,22,23)(H,24,25)/t9 ,10-,11+,14-/m1/s1"	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)O)C(=O)O)C	FPPNZSSZRUTDAP-UWFZAAFLSA-N
DG00036	Rezafungin	78318119	"CD-101; CD101; SP-3025; CHEMBL3989945; HY-108009; CS-0027142; J3.555.717B; J3.599.425D; (4R,5R)-N2-[4-(4'-Pentoxy-1,1'-biphenyl-4-yl)benzoyl]-5-[2-(trimethylaminio)ethoxy]-4-hydroxy-cyclo[L-Orn*-[(3R)-3-methyl-L-Ser-]-[(4R)-4-hydroxy-L-Pro-]-2-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-L-Gly-[(3R)-3-methyl-L-Ser-]-[(3S,4S)-3-hydroxy-4-methyl-L-Pro-]-]"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB16310	.	.	1226.4	C63H85N8O17+	366	2300	2.9	88	13	17	18	"1S/C63H84N8O17/c1-8-9-10-28-87-45-25-21-40(22-26-45)38-13-11-37(12-14-38)39-15-17-42(18-16-39)56(80)64-46-31-48(76)61(88-29-27-71(5,6)7)68-60(84)52-53(77)34(2)32-70(52)63(86)50(36(4)73)66-59(83)51(55(79)54(78)41-19-23-43(74)24-20-41)67-58(82)47-30-44(75)33-69(47)62(85)49(35(3)72)65-57(46)81/h11-26,34-36,44,46-55,61,72-73,75-79H,8-10,27-33H2,1-7H3,(H5-,64,65,66,67,68,74,80,81,82,83,84)/p+1/t34-,35+,36+,44+,46-,47-,48+,49-,50-,51-,52-,53-,54-,55-,61+/m0/s1"	CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)OCC[N+](C)(C)C)O	LNFCWEXGZIEGJW-TXSVMFMRSA-O
DG00037	Cefoxitin	441199	"Mefoxin; Mefoxitin; CEFOXITIN SODIUM; Cefoxitin sodium salt; Mefoxin (TN); Cefoxitin (USAN/INN); Cefoxitin sodium (JAN/USP); (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-3-{[(aminocarbonyl)oxy]methyl}-7-(methyloxy)-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(2-thienylacetyl)amino]-3,4-didehydrocepham-4-carboxylate; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(thiophen-2-yl)acetamido]-3,4-didehydrocepham-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:209807	DB01331	DR00828	DR2492	427.5	C16H17N3O7S2	202	744	0	28	3	9	8	"1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1"	CO[C@@]1([C@@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3	WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
DG00038	Erythromycin	12560	"Abboticin; Abomacetin; Acneryne; Acnesol; Aknemycin; Aknin; AustriaS; Benzamycin; Derimer; Deripil; Dotycin; Dumotrycin; ERY; ERYC; Emgel; Emuvin; Emycin; Endoeritrin; Erecin; Erisone; Eritomicina; Eritrocina; Eritromicina; Ermycin; Eros; Eryacne; Eryacnen; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erydermer; Erygel; Eryhexal; Erymax; Erymed; Erysafe; Erytab; Erythro; Erythroderm; Erythrogran; Erythroguent; Erythromid; Erythromycine; Erythromycinum; Erytop; Erytrociclin; Ilocaps; Iloticina; Ilotycin; Inderm; IndermRetcin; Latotryd; Lederpax; Mephamycin; Mercina; Oftamolets; Paediathrocin; Pantoderm; Pantodrin; Pantomicina; Pharyngocin; Primacine; Propiocine; Proterytrin; Retcin; Robimycin; Romycin; Sansac; Staticin; Stiemicyn; Stiemycin; Tiloryth; Tiprocin; Torlamicina; Wemid; Akne Cordes Losung; Aknederm Ery Gel; Benzamycin Pak; ERYTHROMYCIN STEARATE; Eryc Sprinkles; Erythromycin A; Erythromycin Lactate; Erythromycin Ointment; Erythromycin base; Erythromycin intravenous; Erythromycin sodium lauryl sulfate; Inderm Gel; Oftalmolosa Cusi Eritromicina; Skid Gel E; Theramycin Z; Udima Ery Gel; E0751; Eryc 125; Erythromast 36; Ak-Mycin; Akne-Mycin; Del-Mycin; E-Base; E-Glades; E-Mycin; E-Solve 2; ERYC (base); Emu-V; Emu-Ve; Erimycin-T; Eritromicina [INN-Spanish]; Ery-B; Ery-Diolan; Ery-Sol; Ery-Tab; Ery-maxin; Eryc (TN); Eryc-125; Eryc-250; Erygel (TN); Erythra-Derm; Erythro-Statin; Erythro-Teva; Erythromycin & VRC3375; Erythromycine [INN-French]; Erythromycinum [INN-Latin]; Ilosone (TN); Ilosone (estolate); Ilotycin T.S; Kesso-Mycin; N-Methylerythromycin A; PCE Dispertab (base); Pce (TN); R-P Mycin; Sans-acne; Staticin (TN); T-Stat; Taimoxin-F; A/T/S; Akne-mycin (TN); C-Solve-2; E-Base (base); E-Mycin (base); Ery-Tab (base); Erythromycin [INN:BAN:JAN]; Ilotycin T.S.; T-stat (TN); E-mycin, Erycin, Robimysin; Erythromycin (JP15/USP/INN); Erythromycin, compd. with monododecyl sulfate, sodium salt; Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin; Adecane-2,10-dione (non-preferred name); Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279; Ery"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:42355	DB00199	DR00050	.	733.9	C37H67NO13	194	1180	2.7	51	5	14	7	"1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1"	CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O	ULGZDMOVFRHVEP-RWJQBGPGSA-N
DG00039	Sulfasalazine	5339	Sulfasalazine; 599-79-1; Salicylazosulfapyridine; Salazosulfapyridine; Azulfidine; Asulfidine; Salazopyridin; Sulcolon; Azopyrin; Accucol; Colo-Pleon; Salazopiridazin; Salisulf; Reupirin; Benzosulfa; Azopyrine; Salazosulfapyridin; Sulfasalazina; w-t Sasp oral; Sulfasalazinum; Sulfasalazin; Azulfidine EN; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Sas-500; Salazosulfapyridinum; Azosulfidin; SASP; Salazo-sulfapyridinum; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; SAS-500; Sulfasalizine	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9334	DB00795	DR00201	DR1513	398.4	C18H14N4O5S	150	657	-0.7	28	3	9	6	"1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)"	C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O	NCEXYHBECQHGNR-UHFFFAOYSA-N
DG00040	Thioguanine	2723601	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9555	DB00352	DR00510	DR1597	167.19	C5H5N5S	111	225	-0.1	11	3	2	0	"1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)"	C1=NC2=C(N1)C(=S)N=C(N2)N	WYWHKKSPHMUBEB-UHFFFAOYSA-N
DG00041	Quinine	3034034	"Aflukin; Chinin; Chinine; Chininum; Conchinin; Conquinine; Quindan; Quinidex; Quinidine; Quinimax; Quinina; Quinineanhydrous; Quinora; Quniacridine; Chinin [German]; Kinder Quinina; QUININE MONO HCL; Quinine Dab; Quinine [BAN]; Quinine anhydrous; Quinine bisulfate; Quinine sulfate; Quinine sulphate; Quinoline alkaloid; LT00645788;Q0028; SB01652; Beta-Quinine; Cin-Quin; Coco-Quinine; IBS-L0034250; Kinder Quinina (TN); Legatrin (TN); Quinine (BAN); Quinine, Anhydrous; Quinine, polymers; Quinine, tannate; Biquinate (*Bisulfate heptathydrate*); Dentojel (*Bisulfate heptathydrate*); Quinamm (*2:1 Sulfate salt*), dihydrate; Quine (*2:1 Sulfate salt*, dihydrate); Quinsan (*2:1 Sulfate salt*), dihydrate; Alpha-(6-Methoxy-4-quinoyl)-5-vinyl-2-quinclidinemethanol; Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, sulfate; (+)-Quinidine; (-)-Quinine; (1R)-(6-Methoxyquinolin-4-yl)((1S,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (3A,8A,9r)-6'-methoxycinchonan-9-ol; (5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (8-alpha,9R)-6'-Methoxycinchonan-9-ol; (8.alpha.,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-Quinine; (9R)-6'-methoxy-8alpha-cinchonan-9-ol; (R)-(-)-Quinine, 6-methoxycinchonidine; (R)-(-)-quinine; (R)-(6-Methoxy-quinolin-4-yl)-((2S,5S)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; (R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol; (R)-[(2S,4R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (S)-(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (S)-[(2R,4R,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; 6'-Methoxycinchonan-9-ol; 6'-Methoxycinchonidine; 6'-Methoxycinchonine; 6-Methoxycinchonine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:15854	DB00468	DR00054	.	324.4	C20H24N2O2	45.6	457	2.9	24	1	4	4	"1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19-,20+/m0/s1"	COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O	LOUPRKONTZGTKE-WZBLMQSHSA-N
DG00042	Vismodegib	24776445	879085-55-9; GDC-0449; Erivedge; 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide; Vismodegib (GDC-0449); HhAntag691; GDC0449; GDC 0449; UNII-25X868M3DS; CHEMBL473417; CHEBI:66903; 25X868M3DS; NSC755986; AK-77261; 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide; C19H14Cl2N2O3S; 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide; 2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)benzamide; Erivedge (TN); Vismodegib (SHH inhibitor); Gdc-0449	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:66903	DB08828	DR00234	DR1698	421.3	C19H14Cl2N2O3S	84.5	625	3.8	27	1	4	4	"1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)"	CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl	BPQMGSKTAYIVFO-UHFFFAOYSA-N
DG00043	Zithromax	447043	Azithromycin; Zithromax; 83905-01-5; Azithromycinum; Azithromycine; Sumamed; Zitromax; Zmax; Hemomycin; Azitrocin; Azasite; Azenil; Aritromicina; Zitrotek; Zithrax; Mixoterin; Setron; Aziwok; Zitrim; Aztrin; Zifin; Tobil; Zmas; Zeto; Azithromycinum [Latin]; Azithromycine [French]; Zithromax IV; AZITHROMYCIN DIHYDRATE; Misultina; Azitromax; Z-Pak; Tromix; Aritromicina [Spanish]; Azitromicina; CP-62993; UNII-J2KLZ20U1M; DRG-0104; CCRIS 1961; HSDB 7205; Azithromycin (anhydrous); C38H72N2O12; BRN 5387583; J2KLZ20U1M; Azythromycin; CHEBI:2955	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:2955	DB00207	DR00367	DR0168	749	C38H72N2O12	180	1150	4	52	5	14	7	"1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1"	CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O	MQTOSJVFKKJCRP-BICOPXKESA-N
DG00044	Darunavir	213039	"206361-99-1; TMC114; Prezista; TMC-114; UIC-94017; Darunavirum; TMC 114; Darunavirum [INN-Latin]; UNII-YO603Y8113; AIDS073035; CHEMBL1323; (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE; CHEBI:367163; Darunavir-d9; YO603Y8113; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate; NCGC00168773-01; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl; Darunavirum; Darunavir [USAN]; UIC 94017; Prezista(TM); UIC-96017; Darunavir (USAN/INN); Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester; {(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(330)oct-2-yloxy)carboxamide; [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester; (3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:367163	DB01264	DR00514	DR0420	547.7	C27H37N3O7S	149	853	2.9	38	3	9	12	"1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1"	CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N	CJBJHOAVZSMMDJ-HEXNFIEUSA-N
DG00045	Sirolimus	5284616	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9168	DB00877	DR00262	DR1489	914.2	C51H79NO13	195	1760	6	65	3	13	6	"1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1"	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC	QFJCIRLUMZQUOT-HPLJOQBZSA-N
DG00047	Ofloxacin	4583	"Bactocin; DEXTROFLOXACINE; Danoflox; Effexin; Exocin; Exocine; Flobacin; Flodemex; Flotavid; Flovid; Floxal; Floxil; Floxin; Floxstat; Fugacin; Inoflox; Kinflocin; Kinoxacin; Liflox; Loxinter; Marfloxacin; Medofloxine; Mergexin; Novecin; Nufafloqo; OFLX; OFX; Obide; Occidal; Ocuflox; Ofcin; Oflin; Oflocee; Oflocet; Oflocin; Oflodal; Oflodex; Oflodura; Oflox; Ofloxacina; Ofloxacine; Ofloxacino; Ofloxacinum; Ofloxin; Ofus; Onexacin; Operan; Orocin; Otonil; Oxaldin; Pharflox; Praxin; Puiritol; Qinolon; Qipro; Quinolon; Quotavil; Rilox; Sinflo; Tabrin; Taravid; Tariflox; Tarivid; Telbit; Tructum; Viotisone; Visiren; XED; Zanocin; Floxin otic; Ofloxacin Otic; Ofloxacina [DCIT]; Ofloxacine [French]; Ofloxacino [Spanish]; Ofloxacinum [Latin]; Uro Tarivid; DL 8280; HOE 280; O 8757; ORF 18489; PT 01; DL-8280; FLOXIN IN DEXTROSE 5%; FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Floxin Otic (TN); HOE-280; Hoe-280; Marfloxacin (TN); O-Flox; ORF-28489; Ocuflox (TN); Ru-43280; WP-0405; Ofloxacin (JP15/USP/INN); Ofloxacin [USAN:BAN:INN:JAN]; Ofloxacin, (S)-Isomer; DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin; (+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; (+/-)-Floxin; (-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7731	DB01165	DR00517	DR2298	361.4	C18H20FN3O4	73.3	634	-0.4	26	1	8	2	"1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)"	CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O	GSDSWSVVBLHKDQ-UHFFFAOYSA-N
DG00048	Doripenem	73303	"Doribax; S 4661; S-4661; Doripenem (USAN/INN); (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:135928	DB06211	.	DR0534	420.5	C15H24N4O6S2	196	780	-3.4	27	5	10	7	"1S/C15H24N4O6S2/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25)/t6-,7-,8+,9+,10-,11-/m1/s1"	C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)CNS(=O)(=O)N)C(=O)O)[C@@H](C)O	AVAACINZEOAHHE-VFZPANTDSA-N
DG00049	Gemcitabine	60750	Gemcitabine hydrochloride; DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:175901	DB00441	DR00063	DR0765	263.2	C9H11F2N3O4	108	426	-1.5	18	3	6	2	"1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1"	C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F	SDUQYLNIPVEERB-QPPQHZFASA-N
DG00050	Crizotinib	11626560	Xalkori (TN); novel ALK inhibitors	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:64310	DB08865	DR00523	DR0387	450.3	C21H22Cl2FN5O	78	558	3.7	30	2	6	5	"1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1"	C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N	KTEIFNKAUNYNJU-GFCCVEGCSA-N
DG00051	Cerulenin	5282054	"Helicocerin; Cerulenin, Cephalosporium caerulens; Oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, (2R-(2-alpha,3-alpha(4E,7E)))-(9CI); (2R,3S)-2,3-Epoxy-4-oxo-7E,10E-dodecadienamide; (2R,3S)-3-((4E,7E)-Nona-4,7-dienoyl)-oxirane-2-carboxylic acid amide; (2R,3S)-3-((4E,7E)-nona-4,7-dienoyl)oxirane-2-carboxamide; (2R,3S)-3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; (2R,3S)-3-nona-4,7-dienoyloxirane-2-carboxamide; (2R,3S,E,E)-2,3-Epoxy-4-oxo-7,10-dodecadienamide; (2R-(2alpha,3alpha(4E,7E)))-3-(1-Oxonona-4,7-dienyl)oxirane-2-carboxamide; (2S)(3R)-2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; (2S,3R)-2,3-epoxy-4-oxy-7,10-dodecadienoylamide; (2r,3s)-3-(nona-4,7-dienoyl)oxirane-2-carboxamide; 2,3-Epoxy-4-oxo-7,10-dodecadienamide; 2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; 3-(1-Oxo-4,7-nonadienyl)oxiranecarboxamide; 3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; 3-nona-4,7-dienoyloxirane-2-carboxamide"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:171741	DB01034	.	.	223.27	C12H17NO3	72.7	320	0.8	16	1	3	7	"1S/C12H17NO3/c1-2-3-4-5-6-7-8-9(14)10-11(16-10)12(13)15/h2-3,5-6,10-11H,4,7-8H2,1H3,(H2,13,15)/b3-2+,6-5+/t10-,11-/m1/s1"	C/C=C/C/C=C/CCC(=O)[C@@H]1[C@@H](O1)C(=O)N	GVEZIHKRYBHEFX-NQQPLRFYSA-N
DG00052	Luteolin	5280445	"Luteolin; luteolin; 491-70-3; Luteolol; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one; Luteoline; Digitoflavone; Flacitran; Weld Lake; Cyanidenon 1470; Salifazide; Yama kariyasu; 5,7,3',4'-Tetrahydroxyflavone; UNII-KUX1ZNC9J2; CI Natural Yellow 2; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; 7-Tetrahydroxyflavone; CCRIS 3790; EINECS 207-741-0; KUX1ZNC9J2; CHEMBL151; BRN 0292084; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:15864	DB15584	.	.	286.24	C15H10O6	107	447	1.4	21	4	6	1	"1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H"	C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O	IQPNAANSBPBGFQ-UHFFFAOYSA-N
DG00053	Lorlatinib	71731823	SCHEMBL15274056	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:143117	DB12130	.	DR0980	406.4	C21H19FN6O2	110	700	1.5	30	1	7	0	"1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1"	C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C	IIXWYSCJSQVBQM-LLVKDONJSA-N
DG00054	Gentian violet	11057	Crystal violet; gentian violet; 548-62-9; Basic violet 3; Aniline Violet; Hexamethylpararosaniline chloride; Methylrosaniline chloride; Hexamethyl Violet; Gentiaverm; Pyoktanin; Vianin; Atmonil; Viocid; Avermin; Adergon; Axuris; Badil; Bismuth Violet; Methyl Violet 10B; Basic Violet BN; methylrosanilinium chloride; Gentioletten; Gentersal; Oxycolor; Genticid; Vermicid; Oxiuran; Oxyozyl; Calcozine Violet C; Meroxyl-Wander; Meroxylan-Wander; Brilliant Violet 5B; Hecto Violet R; Calcozine Violet 6BN; Violet CP; Crystal Violet O; Paper Blue R	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:41688	DB00406	.	.	408	C25H30ClN3	9.5	542	.	29	0	3	4	"1S/C25H30N3.ClH/c1-26(2)22-13-7-19(8-14-22)25(20-9-15-23(16-10-20)27(3)4)21-11-17-24(18-12-21)28(5)6;/h7-18H,1-6H3;1H/q+1;/p-1"	CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)C.[Cl-]	ZXJXZNDDNMQXFV-UHFFFAOYSA-M
DG00055	Rifaximin	6436173	"RCIFAX; Rifaximin (bioadhesive/ gastrointestinal extended release); Rifaximin (bioadhesive/ gastrointestinal extended release), Salix Pharmaceuticals"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:75246	DB01220	DR00073	.	785.9	C43H51N3O11	198	1590	6.9	57	5	12	3	"1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1"	C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)/C	NZCRJKRKKOLAOJ-XRCRFVBUSA-N
DG00056	Ceritinib	57379345	"Ceritinib; LDK378; 1032900-25-6; ZYKADIA; NVP-LDK378-NX; LDK-378; UNII-K418KG2GET; LDK378(Ceritinib); LDK 378; Eritinib (LDK378); 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; K418KG2GET; CHEMBL2403108; CHEBI:78432; AK174337; ceritinib; C28H36ClN5O3S; 5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine; 5-Chloro-N2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-N4-(2-(propane-2-sulfonyl)phenyl)pyrim"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:78432	DB09063	DR00228	.	558.1	C28H36ClN5O3S	114	835	6.4	38	3	8	9	"1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)"	CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl	VERWOWGGCGHDQE-UHFFFAOYSA-N
DG00057	Paromomycin	165580	"Aminosidin; Catenulin; Humatin; Hydroxymycin sulfate; Paramomycin Sulfate; Paromomycin I; Paromomycin sulfate Rx346208; Aminosidine, sulfate; HATT & Paromomycin; Humatin (TN); Paromomycin (INN); Paromomycin (TN); Paromomycin (complex); PA1-PA2-PA3-PA4; Human .alpha.-1-antitrypsin & Paromomyin; PAROMOMYCIN I, AMMINOSIDIN, CATENULIN, CRESTOMYCIN, MONOMYCIN A, NEOMYCIN E; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside; (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol; O-2-Amino-2-deoxy-.alpha.-D-glucopyranosyl-(1->4)-O-[O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1->3)-.beta.D-ribofuranosyl(1->5)]-2-deoxy-D-streptamine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7934	DB01421	.	.	615.6	C23H45N5O14	347	870	-8.7	42	13	19	9	"1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1"	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N	UOZODPSAJZTQNH-LSWIJEOBSA-N
DG00058	Amodiaquine	2165	"Amodiachin; Amodiachinum; Amodiaquin; Amodiaquina; Amodiaquinum; Basoquin; CQA; Camochin; Camoquin; Camoquinal; Camoquine; Flavoquin; Flavoquine; Miaquin; Sunoquine; Amodiaquine hydrochloride; Amodiaquine USP24; SN 10751; AMODIAQUINE, FLAVOQUINE; Amodiaquina [INN-Spanish]; Amodiaquinum [INN-Latin]; CAM-AQ 1; CAM-AQI; Cam-AQ1; Camoquin (TN); Flavoquine (TN); SN 10,751; WR-002977; Amodiaquine (USAN/INN); Amodiaquine [USAN:INN:BAN]; Amodiaquine, ring-closed; S. N. 10751"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:2674	DB00613	DR00976	DR0102	355.9	C20H22ClN3O	48.4	406	2.6	25	2	4	6	"1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)"	CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O	OVCDSSHSILBFBN-UHFFFAOYSA-N
DG00059	Pefloxacin	51081	"Abactal; Labocton; PERFLOXACIN; PFLX; Peflacine; Pefloxacine; Pefloxacino; Pefloxacinum; Pefloxacin methanesulfonate; Silver Pefloxacin; AM-725; EU-5306; Pefloxacin [INN-French]; Pefloxacino [INN-Spanish]; Pefloxacinum [INN-Latin]; Pefloxacin (USAN/INN); Pefloxacin [USAN:BAN:INN]; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-methyl-1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:50199	DB00487	.	.	333.36	C17H20FN3O3	64.099	545	0.3	24	1	7	3	"1S/C17H20FN3O3/c1-3-20-10-12(17(23)24)16(22)11-8-13(18)15(9-14(11)20)21-6-4-19(2)5-7-21/h8-10H,3-7H2,1-2H3,(H,23,24)"	CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O	FHFYDNQZQSQIAI-UHFFFAOYSA-N
DG00060	Pyrimethamine/Sulfadoxine	65404	"Fansidar; Suldox; Pyrimethamine-sulfadoxine; 37338-39-9; Pyrimethamine mixture with sulfadoxine; Pyrimethamine combination with sulfadoxine; Benzenesulfonamide, 4-amino-N-(5,6-dimethoxy-4-pyrimidinyl)-, mixt. with 5-(4-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine; sulphadoxine-pyrimethamine; sulfadoxine/pyrimethamine; Sulphadoxyne-pyrimethamine; sulfadoxine / pyrimethamine; Pyrimethamine / sulfadoxine; Sulphadoxine / pyrimethamine; Pyrimethamine-sulfadoxine mixt.; Sulfadoxine-pyrimethamine mixt.; Fansidar (TN)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	559	C24H27ClN8O4S	203	662	.	38	4	12	7	"1S/C12H13ClN4.C12H14N4O4S/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7;1-19-10-11(14-7-15-12(10)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-6H,2H2,1H3,(H4,14,15,16,17);3-7H,13H2,1-2H3,(H,14,15,16)"	CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl.COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N	LUBUTTBEBGYNJN-UHFFFAOYSA-N
DG00062	Piperacillin	43672	"PIPC; Peperacillin; Peracin; Pipercillin; Pipracil; Pipril; PIPERACILLIN SODIUM; Piperacillin Monosodium Salt; Piperacillin anhydrous; Cl-227193; Peracin (TN); Piperacillin (INN); Piperacillin (anhydrous); Pipracil, Piper; T-1220; Zobactin (TN); (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S-(2alpha,5alpha,6beta(S*)))-6-(((((4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 4-ethyl-2,3-dioxopiperazine carbonyl ampicillin; 6-(D-(-)-alpha-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanicacid; 6beta-{(2R)-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8232	DB00319	DR00857	DR2410	517.6	C23H27N5O7S	182	982	0.5	36	3	8	6	"1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1"	CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O	IVBHGBMCVLDMKU-GXNBUGAJSA-N
DG00063	Dalfopristin	6323289	"5-(2-DIETHYLAMINO-ETHANESULFONYL)-21-HYDROXY-10-ISOPROPYL-11,19-DIMETHYL-9,26-DIOXA-3,15,28-TRIAZA-TRICYCLO[23.2.1.00,255]OCTACOSA-1(27),12,17,19,25(28)-PENTAENE-2,8,14,23-TETRAONE"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4309	DB01764	.	.	690.8	C34H50N4O9S	185	1340	2.2	48	2	11	7	"1S/C34H50N4O9S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b10-9+,12-11+,23-18+/t24-,25-,28-,31-,32-/m1/s1"	CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@@H]([C@@H](/C=C/C(=O)NC/C=C/C(=C/[C@H](CC(=O)CC3=NC(=CO3)C2=O)O)/C)C)C(C)C	SUYRLXYYZQTJHF-VMBLUXKRSA-N
DG00064	Rifabutin	135398743	"Alfacid; Ansamycin; Ansatipin; Ansatipine; Assatipin; Mycobutin; RBT; Rifabutina; Rifabutine; Rifabutinum; Grunenthal Brand of Rifabutin; Kenfarma Brand of Rifabutin; Pfizer Brand of Rifabutin; Rifabutin Pfizer Brand; Rifabutina [Spanish]; Rifabutine [French]; Rifabutinum [Latin]; Antibiotic LM 427; LM 427; LM427; DRG-0085; LM-427; Mycobutin (TN); Rifabutin [USAN:BAN:INN]; Rifabutin (JAN/USP/INN); Mycobutin, Ansamycin, LM 427, Ansatipine, Rifabutin; (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6,18,20-trihydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethyl-5,10,26-trioxo-3,5,9,10-tetrahydrospiro[9,4-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[1,2-d]imidazole-2,4'-piperidin; Spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione, 16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptameth; 1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV; 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S; 4-N-isobutylspiropiperidylrifamycin S"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00615	.	DR1418	847	C46H62N4O11	209	2110	4.7	61	5	14	5	"1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,48,52-55H,16-19,21H2,1-11H3/b13-12+,20-15+,24-14-,47-36 /t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1"	C[C@H]1/C=C/C=C(\\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C	ZWBTYMGEBZUQTK-PVLSIAFMSA-N
DG00065	Pentamidine	4735	"Lomidine; Nebupent; PENTAM; PNT; Pentacarinat; Pentamide; Pentamidin; Pentamidina; Pentamidinum; Pneumopent; PENTAMIDINE ISETHIONATE; Pentamidina [DCIT]; Pentamidine isetionate; Pentamidine mesylate; MB 800; Pentam 300; Lomidine (TN); MB-800; Nebupent (as isethionate); Pentacarinat (as isethionate); Pentam 300 (as isethionate); Pentamidine (INN); Pentamidinum [INN-Latin]; RP-2512; Nebupent (*Isethionate); Pentacarinat (*Isethionate); Pentam 300 (*Isethionate); Pentamidine Isethionate 2-Hydroxy-Ethanesulfonic Acid;Pentamidine [INN:BAN:DCF]; RP 2512 (*Isethionate); P,p'-(Pentamethylenedioxy)bis[benzamidine]; P,p'-(Pentamethylenedioxy)dibenzamidine; P,p'-(Pentamethylene-dioxy)bis-benzamidine; Benzenecarboximidamide, 4,4'-(1,5-pentanediylbis(oxy))bis-(9CI); 1,3-BIS(4-AMIDINOPHENOXY)PENTANE; 4, 4'-Diamidinodiphenoxypentane; 4,4'-(1,5-Pentanediylbis(oxy))bis-benzenecarboximidamide; 4,4'-(Pentamethylenedioxy)dibenzamide; 4,4'-(Pentamethylenedioxy)dibenzamidine; 4,4'-Diamidino-.alpha.,.omega.-diphenoxypentane; 4,4'-Diamidinodiphenoxypentane; 4,4'-[pentane-1,5-diylbis(oxy)]dibenzenecarboximidamide; 4-[5-(4-Carbamimidoylphenoxy)pentoxy]benzenecarboximidamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:45081	DB00738	DR00085	.	340.4	C19H24N4O2	118	376	2.6	25	4	4	10	"1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)"	C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N	XDRYMKDFEDOLFX-UHFFFAOYSA-N
DG00066	Daptomycin	16134395	"Cidecin; Cubicin; Dapcin; Daptomicina; Daptomycine; Daptomycinum; Deptomycin; Daptomicina [Spanish]; Daptomycine [French]; Daptomycinum [Latin]; LY146032; Cubicin (TN); LY-146032; MK-3009; Daptomycin [USAN:INN:BAN]; Daptomycin (JAN/USAN/INN); N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon1-lactone; N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon(1)-lactone; N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine 1.13-3.4-lactone; N-decanoyl-L-tryptophyl-L-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-ox"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:600103	DB00080	.	DR2142	1620.7	C72H101N17O26	702	3480	-5.1	115	22	28	35	"1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1"	CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]3[C@H](OC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)[C@H](C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C	DOAKLVKFURWEDJ-RWDRXURGSA-N
DG00067	Ceftibuten	5282242	"CETB; Cedax; Ceftem; Ceftibutene; Ceftibuteno; Ceftibutenum; Cephem; Ceprifran; Isocef; Keimax; Antibiotic 7432S; S 7432; Sch 39720; Cedax (TN); Ceftibutene [INN-French]; Ceftibuteno [INN-Spanish]; Ceftibutenum [INN-Latin]; Cephalosporin 7432-S; Cis-Ceftibutin; Cis-ceftibuten; Sch-39720; Trans-Ceftibuten; Ceftibuten(USAN/INN); Ceftibuten [USAN:INN:BAN]; (+)-(6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-4-carboxycrotonamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7432-S; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-3,4-didehydrocepham-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3510	DB01415	.	.	410.4	C15H14N4O6S2	217	755	-0.3	27	4	10	6	"1S/C15H14N4O6S2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25)/b6-1-/t10-,13-/m1/s1"	C1C=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)/C(=C\\CC(=O)O)/C3=CSC(=N3)N)C(=O)O	UNJFKXSSGBWRBZ-BJCIPQKHSA-N
DG00068	Framycetin	8378	"Neomycin; neomycin; NEOMYCIN B; Soframycin; Actiline; Mycifradin; Fradiomycin; Soframycine; Framycetinum; Framycetine; Framicetina; Neomas; Fradiomycinum; Antibiotique; Nivemycin; Actilin; Neolate; Enterfram; Myacyne; Framygen; Caswell No 595; Vonamycin powder V; Neomycin B sulfate; Neomin; Neomcin; Fradiomycin B; Neo-Rx; Neomicina [DCIT]; Framycetinum [INN-Latin]; PIMAVECORT; Neobrettin; Neo-Fradin; 119-04-0; Neomycine [INN-French]; Neomycinum [INN-Latin]; Framycetine [INN-French]; Framicetina [INN-Spanish]; USAF CB-19; Endomixin; Fraquinol; Myacine; Myciguent; NMY; Neobiotic; Neomicina; Neomycinum; Tuttomycin; VONAMYCIN; NEOMYCIN AND POLYMYXIN B SULFATES; NEOMYCIN SULFATE; Neomycin solution; Soframycin Ophthalmic; Antibiotic 10676; Antibiotic produced by Streptomyces decaris Neomycin B; Framycetin (INN); Soframycin (TN); Framycetin [INN:BAN:DCF]; Sofra-Tulle (TN); BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG; BDG-(1-4)NEB-(5-1)RIB-(3-1)NED; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside; (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol; D-Streptamine, O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1->3)-O-beta-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1->4)]-2-deoxy"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7508	DB00994	.	DR2158	614.6	C23H46N6O13	353	872	-9	42	13	19	9	"1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1"	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N	PGBHMTALBVVCIT-VCIWKGPPSA-N
DG00069	Fluorouracil	3385	"5-Fluorouracil; 51-21-8; fluorouracil; 5-FU; Fluoroplex; Adrucil; Efudex; Carac; Fluracil; Fluoroblastin; 5-fluoropyrimidine-2,4(1H,3H)-dione; Kecimeton; Timazin; Carzonal; Efudix; Arumel; Fluril; Queroplex; Fluracilum; Ulup; 5-Fluoracil; Phthoruracil; Fluro Uracil; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; Ftoruracil; Fluorouracilum; Efurix; Fluri; 5 Fluorouracil; Effluderm (free base); 5-fluoro-1H-pyrimidine-2,4-dione; Fluorouracilo; Fluroblastin; Phtoruracil; 2,4-Dihydroxy-5-fluoropyrimidine; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-; Adrucil; Effluderm; Fluorouracile; Fluoruracil; Fluracedyl; Flurodex; Neofluor; Onkofluor; Ribofluor; Tetratogen; URF; Allergan Brand of Fluorouracil; Biosyn Brand of Fluorouracil; CSP Brand of Fluorouracil; Cinco FU; Dakota Brand of Fluorouracil; Dermatech Brand of Fluorouracil; Dermik Brandof Fluorouracil; Ferrer Brand of Fluorouracil; Fluoro Uracile ICN; Fluorouracil GRY; Fluorouracil Mononitrate; Fluorouracil Monopotassium Salt; Fluorouracil Monosodium Salt; Fluorouracil Potassium Salt; Fluorouracil Teva Brand; Fluorouracile Dakota; Fluorouracile [DCIT]; Fluorouracilo Ferrer Far; Gry Brand of Fluorouracil; Haemato Brand of Fluorouracil; Haemato fu; Hexal Brand of Fluorouracil; ICN Brand of Fluorouracil; Inhibits thymilidate synthetase; Medac Brand of Fluorouracil; Neocorp Brand of Fluorouracil; Onkoworks Brand of Fluorouracil; Ribosepharm Brand of Fluorouracil; Riemser Brand of Fluorouracil; Roche Brand of Fluorouracil; Teva Brand of Fluorouracil; F 6627; F0151; IN1335; U 8953; Adrucil (TN); Carac (TN); Dakota, Fluorouracile; Efudex (TN); Fluoro-Uracile ICN; Fluoro-uracile; Fluoro-uracilo; Fluoroplex (TN); Fluorouracil-GRY; Fluorouracilo [INN-Spanish]; Fluorouracilum [INN-Latin]; Haemato-fu; Ro 2-9757; U-8953; Ro-2-9757; Fluorouracil (JP15/USP/INN); Fluorouracil [USAN:INN:BAN:JAN]; 1-fluoro-1h-pyrimidine-2,4-dione; 2,4-Dioxo-5-fluoropryimidine; 2,4-Dioxo-5-fluoropyrimidine; 5 FU Lederle; 5 FU medac; 5 Fluorouracil biosyn; 5 HU Hexal; 5-FU (TN); 5-FU Lederle; 5-FU medac; 5-Faracil; 5-Fluor-2,4(1H,3H)-pyrimidindion; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; 5-Fluor-2,4-dihydroxypyrimidin; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; 5-Fluor-2,4-pyrimidindiol; 5-Fluor-2,4-pyrimidindiol [Czech]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoro-2,4-pyrimidinedione; 5-Fluoropyrimidin-2,4-diol; 5-Fluoropyrimidine-2,4-dione; 5-Fluorouracil-biosyn; 5-Fluoruracil; 5-Fluoruracil [German]; 5-Ftouracyl; 5-HU Hexal; 5-fluoro uracil; 5FU"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:46345	DB00544	DR00153	DR0020	130.08	C4H3FN2O2	58.2	199	-0.9	9	2	3	0	"1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)"	C1=C(C(=O)NC(=O)N1)F	GHASVSINZRGABV-UHFFFAOYSA-N
DG00071	Olmutinib	54758501	.	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB13164	.	.	486.6	C26H26N6O2S	111	712	4.7	35	2	8	7	"1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)"	CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)SC=C4	FDMQDKQUTRLUBU-UHFFFAOYSA-N
DG00072	Dabrafenib	44462760	"1195765-45-7; Dabrafenib (GSK2118436); Tafinlar; GSK2118436A; UNII-QGP4HA4G1B; GSK 2118436; QGP4HA4G1B; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; CHEBI:75045; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; GSK-2118436A; Dabrafenib [USAN:INN]; GSK2118436"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:75045	DB08912	DR00164	.	519.6	C23H20F3N5O2S2	148	817	4.8	35	2	11	6	"1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)"	CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F	BFSMGDJOXZAERB-UHFFFAOYSA-N
DG00073	Cefmetazole	42008	"CMZ; Cefmetazolo; Cefmetazolum; Cefmetazole Monosodium Salt; CS 1170; SKF 83088; U 72791; CS-1170; Cefmetazole [USAN:INN]; Cefmetazolo [INN-Spanish]; Cefmetazolum [INN-Latin]; U-72791A; Cefmetazole (USP/INN); (6R,7S)-7-(2-((Cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-(2-((Cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, sodium salt; (6R,7S)-7-({[(cyanomethyl)sulfanyl]acetyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[(cyanomethyl)thio]acetyl}amino)-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[2-(cyanomethylsulfanyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 6beta-{[(cyanomethyl)sulfanyl]acetamido}-6alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3489	DB00274	DR00539	.	471.5	C15H17N7O5S3	239	818	-0.6	30	2	12	9	"1S/C15H17N7O5S3/c1-21-14(18-19-20-21)30-6-8-5-29-13-15(27-2,17-9(23)7-28-4-3-16)12(26)22(13)10(8)11(24)25/h13H,4-7H2,1-2H3,(H,17,23)(H,24,25)/t13-,15+/m1/s1"	CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O	SNBUBQHDYVFSQF-HIFRSBDPSA-N
DG00074	Afatinib	10184653	"Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:61390	DB08916	DR00354	.	485.9	C24H25ClFN5O3	88.6	702	3.6	34	2	8	8	"1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1"	CN(C)C/C=C/C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4	ULXXDDBFHOBEHA-CWDCEQMOSA-N
DG00075	Didanosine	135398739	"Didanosine; 69655-05-6; DIDEOXYINOSINE; Videx; Videx EC; Inosine, 2',3'-dideoxy-; ddIno; Didanosina; Didanosinum; DDI; BMY-40900; UNII-K3GDH6OH08; K3GDH6OH08; Didanosinum [INN-Latin]; Didanosina [INN-Spanish]; CHEBI:490877; 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine; NSC 612049; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE; NCGC00159514-02; NCGC00090691-03; DRG-0016; BMY 40900; DSSTox_CID_2927"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:490877	DB00900	DR01175	.	236.23	C10H12N4O3	88.7	348	-1.2	17	2	5	2	"1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1"	C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2N=CNC3=O	BXZVVICBKDXVGW-NKWVEPMBSA-N
DG00076	Fidaxomicin	10034073	Dificid (TN)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB08874	DR00545	.	1058	C52H74Cl2O18	267	1970	6.4	72	7	18	15	"1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3/b16-15+,25-19+,26-22+,27-21+,31-17+/t28-,29-,30+,33+,34+,40-,41+,42+,43+,44-,45+,46+,50-,51-/m1/s1"	CC[C@H]1/C=C(/[C@H](C/C=C/C=C(/C(=O)O[C@@H](C/C=C(/C=C(/[C@@H]1O[C@H]2[C@H]([C@H]([C@@H](C(O2)(C)C)OC(=O)C(C)C)O)O)\\C)\\C)[C@@H](C)O)\\CO[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)\\C	ZVGNESXIJDCBKN-UUEYKCAUSA-N
DG00077	Lumefantrine	6437380	"Benflumetol; Coartem; Dl-Benflumelol; Lumefantrine (INN); Lumefantrine [INN:BAN]; (+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha((dibutylamino)methyl)fluorene-4-methanol; (+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol; 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl]ethanol; 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol; 2-Dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol; 2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:156095	DB06708	.	DR0992	528.9	C30H32Cl3NO	23.5	671	8.7	35	1	2	10	"1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15-"	CCCCN(CCCC)CC(C1=CC(=CC\\2=C1C3=C(/C2=C/C4=CC=C(C=C4)Cl)C=C(C=C3)Cl)Cl)O	DYLGFOYVTXJFJP-MYYYXRDXSA-N
DG00078	Cefixime	5362065	"CFIX; Cefixima; Cefiximum; Denvar; Necopen; Tricef; CL-284635; FK-027; FR-17027; Ofex (TN); Suprax (TN); Cefixime (JP15/USP/INN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl}amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethyloxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(carboxymethyl)oxy]imino}acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6r,7r)-7-[-2-(2-amino-thiazol-4-yl)-2-carboxymethoxyimino-acetylamino]-8-oxo-3-vinyl-5-thia-1-aza-b; 7beta-{(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido}-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:472657	DB00671	DR00546	.	453.5	C16H15N5O7S2	238	861	-0.7	30	4	12	8	"1S/C16H15N5O7S2/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7/h2,5,10,14H,1,3-4H2,(H2,17,18)(H,19,24)(H,22,23)(H,26,27)/b20-9-/t10-,14-/m1/s1"	C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OCC(=O)O)/C3=CSC(=N3)N)SC1)C(=O)O	OKBVVJOGVLARMR-QSWIMTSFSA-N
DG00079	Micafungin	477468	Mycamine; FK463; FK-463; Mycamine (TN); Mycamine(TM)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:600520	DB01141	.	DR1083	1270.3	C56H71N9O23S	519	2580	-1.6	89	16	24	18	"1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+/m0/s1"	CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O	PIEUQSKUWLMALL-YABMTYFHSA-N
DG00080	Meticillin	6087	"Dimocillin; MII; Metacillin; Methicillin; Methicillinum; Methycillin; Meticilina; Meticillina; Meticilline; Meticillinum; Staphcillin; Methicillin [BAN]; Meticillin [INN]; Meticillina [DCIT]; BRL 1241; Methicillin Monohydrate, Monosodium Salt; Meticilina [INN-Spanish]; Meticilline [INN-French]; Meticillinum [INN-Latin]; Penicillin, Dimethoxyphenyl; (2,6-Dimethoxyphenyl)penicillin; (2S,5R,6R)-6-[(2,6-dimethoxybenzoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2,6-dimethoxyphenyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2,3-Dimethoxybenzamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(2,6-Dimethoxybenzamido)penicillanic acid; 6beta-(2,6-dimethoxybenzamido)-2,2-dimethylpenam-3alpha-carboxylic acid; 6beta-(2,6-dimethoxybenzamido)penicillanic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6827	DB01603	.	.	380.4	C17H20N2O6S	131	600	1.2	26	2	7	5	"1S/C17H20N2O6S/c1-17(2)12(16(22)23)19-14(21)11(15(19)26-17)18-13(20)10-8(24-3)6-5-7-9(10)25-4/h5-7,11-12,15H,1-4H3,(H,18,20)(H,22,23)/t11-,12+,15-/m1/s1"	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3=C(C=CC=C3OC)OC)C(=O)O)C	RJQXTJLFIWVMTO-TYNCELHUSA-N
DG00081	Bleomycin	5360373	BLM; Blenoxane; Bleo; Bleocin; Bleogin; Bleomicin; Bleomicina; Bleomycine; Bleomycins; Bleomycinum; Bleomycin sulfate; Bleomycin a2; Pingyangmyvin A2; Zhengguangmycin A2; Zhengguangmycin A2 [Chinese]; Blenoxane (TN); Bleomicina [INN-Spanish]; Bleomycin A(2); Bleomycin A2 & Bleomycin B2; Bleomycin B(2); Bleomycine [INN-French]; Bleomycinum [INN-Latin]; NDC 0015-3010; N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide; N1-(3-(Dimethylsulfonio)propyl)bleomycinamide	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00290	DR00409	DR0217	1415.6	C55H84N17O21S3+	685	2580	-7.5	96	20	31	36	"1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29 ,30 ,34-,35-,36-,37 ,38 ,39 ,40 ,41-,42 ,43 ,53 ,54 /m0/s1"	CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O	OYVAGSVQBOHSSS-WXFSZRTFSA-O
DG00082	Tesevatinib	10458325	"Tesevatinib; XL647; XL-647; 781613-23-8; EXEL-7647; UNII-F6XM2TN5A1; KD-019; XL 647; F6XM2TN5A1; 651031-01-5; 7-[[(3aS,6aR)-2-methyl-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-5-yl]methoxy]-N-(3,4-dichloro-2-fluorophenyl)-6-methoxyquinazolin-4-amine; Tesevatinib [USAN:INN]; EXEL 7647; 874286-84-7; KD 019; 1000599-06-3; SCHEMBL721994; SCHEMBL721993; SCHEMBL721992; C24H25Cl2FN4O2; GTPL7944; CHEMBL3544983; EX-A172; QCR-153; MolPort-044-724-458; BCP23438; ZINC38912363; 2809AH; AKOS027255007"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB11973	.	.	491.4	C24H25Cl2FN4O2	59.5	652	5.8	33	1	7	6	"1S/C24H25Cl2FN4O2/c1-31-9-14-5-13(6-15(14)10-31)11-33-21-8-19-16(7-20(21)32-2)24(29-12-28-19)30-18-4-3-17(25)22(26)23(18)27/h3-4,7-8,12-15H,5-6,9-11H2,1-2H3,(H,28,29,30)/t13 ,14-,15+"	CN1C[C@H]2CC(C[C@H]2C1)COC3=C(C=C4C(=C3)N=CN=C4NC5=C(C(=C(C=C5)Cl)Cl)F)OC	HVXKQKFEHMGHSL-GOOCMWNKSA-N
DG00083	Cycloheximide	6197	Naramycin A; NSC 185; FT 3422-2; NM-MCD 80	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:27641	.	DR01367	.	281.35	C15H23NO4	83.5	404	0.5	20	2	4	3	"1S/C15H23NO4/c1-8-3-9(2)15(20)11(4-8)12(17)5-10-6-13(18)16-14(19)7-10/h8-12,17H,3-7H2,1-2H3,(H,16,18,19)/t8-,9-,11-,12+/m0/s1"	C[C@H]1C[C@@H](C(=O)[C@@H](C1)[C@@H](CC2CC(=O)NC(=O)C2)O)C	YPHMISFOHDHNIV-FSZOTQKASA-N
DG00084	Posaconazole	468595	"Noxafil; Spriafil; Posaconazole SP; Posaconazole in combination with MGCD290; SCH56592; Sch 56592; X2N; Noxafil (TN); Noxafil, Posaconazole; SCH-56592; Posaconazole (USAN/INN); Posaconazole [USAN:INN:BAN]; 1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one; 4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one; 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one; 4-[4-[4-[4-[[(5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:64355	DB01263	DR00111	DR1316	700.8	C37H42F2N8O4	112	1170	4.6	51	1	11	12	"1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1"	CC[C@@H]([C@H](C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5C[C@](OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F	RAGOYPUPXAKGKH-XAKZXMRKSA-N
DG00085	Ceftriaxone	5479530	"Biotrakson; CTRX; Cefatriaxone; Ceftriaxon; Ceftriaxona; Ceftriaxonum; Ceftriazone; Longacef; Longaceph; Rocefin; Rocephin; Rocephine; CEFTRIAXONE SODIUM; Ceftriaxone intravenous; Ro 139904; Ceftriaxona [INN-Spanish]; Ceftriaxone (INN); Ceftriaxone (TN); Ceftriaxone [USAN:JAN]; Ceftriaxone, Disodium Salt; Ceftriaxonum [INN-Latin]; DRG-0071; Ro13-9904; Rocephin (TN); Ceftriaxone, Disodium Salt, Hemiheptahydrate; Ro-13-9904; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime), sesquaterhydrate; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:29007	DB01212	DR00553	DR2655	554.6	C18H18N8O7S3	288	1110	-1.3	36	4	13	8	"1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1"	CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O	VAAUVRVFOQPIGI-SPQHTLEESA-N
DG00086	Tobramycin	36294	"Aktob; Brulamycin; Distobram; Gotabiotic; NEBRAMYCIN; Nebcin; Nebicin; Obracin; Obramycin; Sybryx; TOY; Tenebrimycin;Tenemycin; Tobacin; Tobi; Tobracin; Tobradex; Tobradistin; Tobralex; Tobramaxin; Tobramicin; Tobramicina; Tobramitsetin; Tobramycetin; Tobramycine; Tobramycinum; Tobrased; Tobrasone; Tobrex; Deoxykanamycin B; Nebramycin VI; TOBRAMYCIN SULFATE; Tobramycin for Inhalation; Tobramycin solution for inhalation; A 12253A; Lilly 47663; NF 6; Nebramycin 6; Nebramycin factir 6; Nebramycin factor 6; Nebcin (Sulfate); SPRC-AB01; TobraDex (TN); Tobracin (TN); Tobramicina [INN-Spanish]; Tobramycin, Free Base; Tobramycine [INN-French]; Tobramycinum [INN-Latin]; Tobrex (TN); Tobramycin (JP15/USP); Tobramycin[USAN:BAN:INN:JAN]; TOA-(1-6)2TB-(4-1)TOC; TOA-(1-6)TOB-(4-1)TOC; 1-Epitobramycin; 3'-Deoxykanamycin B"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:28864	DB00684	.	DR1606	467.5	C18H37N5O9	268	609	-6.2	32	10	14	6	"1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1"	C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N	NLVFBUXFDBBNBW-PBSUHMDJSA-N
DG00087	Progesterone	5994	"Progesterone; 57-83-0; Agolutin; Pregn-4-ene-3,20-dione; Luteohormone; Crinone; 4-Pregnene-3,20-dione; Utrogestan; Syngesterone; Progestin; Luteol; Corpus luteum hormone; Progesterol; Progesteronum; Pregnenedione; Glanducorpin; Prometrium; Corlutin; Cyclogest; Progestron; Gestormone; Progestone; Gestone; Progestasert; Progestronol; Methylpregnone; Hormoflaveine; Syngestrets; Proluton; Progekan; Nalutron; Lutoform; Gynlutin; Gesterol; Fologenon; Corporin; Corlutina; Syntolutan; Prolidon; Membrettes; Lutocyclin; Luteodyn; Lucorteum; Corluvite; LPCN-1107; Progesterone (oral, preterm labor); Progesterone (oral, preterm labor), Lipocine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:17026	DB00396	DR00281	DR1346	314.5	C21H30O2	34.1	589	3.9	23	0	2	1	"1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1"	CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C	RJKFOVLPORLFTN-LEKSSAKUSA-N
DG00088	Irinotecan	60838	"Biotecan; Camptosar; Irinotecanum; IRINOTECAN HYDROCHLORIDE Trihydrate; Irinotecan Hcl; Irinotecan hydrochloride; CP0; Biotecan (TN); Campto (TN); Camptosar (TN); Irinotecan (INN); Irinotecan [INN:BAN]; Irinotecanum [INN-Latin]; IRINOTECAN, CPT-11; Camptosar, Campto, CPT-11, Irinotecan; (+)-Irinotecan; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Irinotecan (TOPO1 inhibitor); Onivyde"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:80630	DB00762	DR00112	.	586.7	C33H38N4O6	113	1200	3	43	1	8	5	"1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1"	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7	UWKQSNNFCGGAFS-XIFFEERXSA-N
DG00089	Efavirenz	64139	"EFV; EFZ; Eravirenz; Stocrin; Sustiva; DMP 266; L 743726; DMP-266; L-741211; L-743725; L-743726; Stocrin (TN); Strocin (TM); Sustiva (TM); Sustiva (TN); Efavirenz (JAN/INN); L-743,726; Zoxazin-2-one; Efavirenz, (S)-isomer; Met-SDF-1.beta. & Efavirenz; Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz; (-)-Efavirenz; (4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one; (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben; (S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-(9; 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:119486	DB00625	DR00412	DR0560	315.67	C14H9ClF3NO2	38.3	519	4	21	1	5	1	"1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1"	C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F	XPOQHMRABVBWPR-ZDUSSCGKSA-N
DG00090	Hydroxycamptothecin	97226	"10-Hydroxycamptothecin; 19685-09-7; (S)-10-Hydroxycamptothecin; Hydroxycamptothecin; 10-hydroxycamptothecine; 10-Hydroxy camptothecin; Hydroxycamptothecine; Camptothecin, hydroxy-; 10-Hydroxy-Camptothecin; (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; Camptothecin, 10-hydroxy-; Camptothecine, 10-hydroxy-; UNII-9Z01632KRV; NSC 107124; HCPT; (4S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-Hydroxycamptothecin hydrate; NSC107124"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:81395	DB12385	DR01489	.	364.4	C20H16N2O5	100	774	0.6	27	2	6	1	"1S/C20H16N2O5/c1-2-20(26)14-7-16-17-11(5-10-6-12(23)3-4-15(10)21-17)8-22(16)18(24)13(14)9-27-19(20)25/h3-7,23,26H,2,8-9H2,1H3/t20-/m0/s1"	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=CC(=CC5=C4)O)O	HAWSQZCWOQZXHI-FQEVSTJZSA-N
DG00091	Atazanavir	148192	"198904-31-3; Latazanavir; Zrivada; Reyataz; BMS-232632; BMS 232632; Atazanavir [INN:BAN]; CGP 73547; Atazanavir Base; UNII-QZU4H47A3S; CGP-73547; HSDB 7339; Reyataz (TN); ATV; QZU4H47A3S; CHEMBL1163; CHEBI:37924; (3S,8S,9S,12S)-3,12-BIS(1,1-DIMETHYLETHYL)-8-HYDROXY-4,11-DIOXO-9-(PHENYLMETHYL)-6-[[4-(2-PYRIDINYL)PHENYL]METHYL]-2,5,6,10,13-PENTAAZATETRADECANEDIOIC ACID DIMETHYL ESTER; NCGC00182552-01; AK174307; DSSTox_CID_28617; DSSTox_RID_82887; DSSTox_GSID_48691; DR7; atazanavirum; ATZ; Atazanavirum; Atazanavir (INN); Reyataz, BMS-232632, Atazanavir; Reyataz(TM) (*1:1 sulfate*); Dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-[4-(2-pyridyl)benzyl]-2,5,6,10,13-pentaazatetradecanedioate; METHYL [(1S,4S,5S,10S)-4-BENZYL-1,10-DI-TERT-BUTYL-5-HYDROXY-2,9,12-TRIOXO-7-(4-PYRIDIN-2-YLBENZYL)-13-OXA-3,7,8,11-TETRAAZATETRADEC-1-YL]CARBAMATE; Methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate; (2S)-N-(3-{[(2S)-2-(Methoxycarbonylamino)-3,3-dimethylbutanoylamino][(4-(2-pyridyl)phenyl)methyl]amino}(1S,2S)-2-hydroxy-1-benzylpropyl)-2-(methoxycarbonylamino)-3,3-dimethylbutanamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:37924	DB01072	DR00413	DR0150	704.9	C38H52N6O7	171	1110	5.6	51	5	9	18	"1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1"	CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC	AXRYRYVKAWYZBR-GASGPIRDSA-N
DG00092	Nalidixic acid	4421	"Betaxina; Cybis; Dixiben; Dixinal; Eucistin; Innoxalon; Jicsron; Kusnarin; Nalidicron; Nalidixan; Nalidixane; Nalidixate; Nalidixic; Nalidixin; Nalitucsan; Nalix; Nalurin; Narigix; Naxuril; NegGram; Negram; Nevigramon; Nicelate; Nogram; Poleon; Sicmylon; Specifen; Specifin; Unaserus; Uralgin; Uriben; Uriclar; Urisal; Urodixin; Uroman; Uroneg; Uronidix; Uropan; Wintomylon; Wintron; Acide nalidixico; Acide nalidixico [Italian]; Acide nalidixique; Acide nalidixique [French]; Acido nalidissico; Acido nalidissico [DCIT]; Acido nalidixico; Acidum nalidixicum; NALIDIXATE SODIUM; Naladixic acid; Naldixic acid; Nalidic acid; Nalidixinic acid; Nalidixic acid USP27; WIN 183203; Acid, Nalidixic; Acide nalidixique [INN-French]; Acido nalidixico [INN-Spanish]; Acidum nalidixicum [INN-Latin]; N-1200; NegGram (TN); Neggram (TN); Sodium Nalidixic Acid, Anhydrous; Sodium Nalidixic Acid, Monohydrate; Sodium,Nalidixate; WIN 18,320; WIN-18320; Wil 18,320; Wintomylon (TN); ZERO/002632; WIN-18320 (TN); Nalidixic acid (JP15/USP/INN); Nalidixic acid [USAN:INN:BAN:JAN]; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]; 1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; 1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-ca rboxylic acid; 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:100147	DB00779	.	DR2296	232.23	C12H12N2O3	70.5	378	1.4	17	1	5	2	"1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)"	CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O	MHWLWQUZZRMNGJ-UHFFFAOYSA-N
DG00093	Arbekacin	68682	Habekacin (TN)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:37922	DB06696	.	DR0130	552.6	C22H44N6O10	297	757	-6.8	38	11	15	10	"1S/C22H44N6O10/c23-4-3-12(30)20(34)28-11-5-10(26)18(37-21-9(25)2-1-8(6-24)35-21)17(33)19(11)38-22-16(32)14(27)15(31)13(7-29)36-22/h8-19,21-22,29-33H,1-7,23-27H2,(H,28,34)/t8-,9+,10-,11+,12-,13+,14-,15+,16+,17-,18+,19-,21+,22+/m0/s1"	C1C[C@H]([C@H](O[C@@H]1CN)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)NC(=O)[C@H](CCN)O)N)N	MKKYBZZTJQGVCD-XTCKQBCOSA-N
DG00094	Netilmicin	441306	"NTL; Netilmicina; Netilmicine; Netilmicinum; Netilyn; Netira; Nettacin; Vectacin; NETILMICIN SULFATE; Sch 20569; Netilmicin (INN); Netilmicin [INN:BAN]; Netilmicina [INN-Spanish]; Netilmicine [INN-French]; Netilmicinum [INN-Latin]; Netira (TN); Nettacin (TN); Sch-20569; O-(2,6-Diamino-2,3,4,6-tetradesoxy-alpha-glycero-4-hexenopyranosyl-(1-4)-O-(3-desoxy-4-C-methyl-3-methylamino-beta-L-arabinopyranosyl-(1-6)-2-desoxy-N1-ethyl-D-streptamin; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3S,4S,5S)-2-[(1S,2R,3S,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 1-N-Aethylsisomicin; 1-N-Ethylsisomicin; 2-[4-amino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 4-amino-3-{[3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy}-6-(ethylamino)-2-hydroxycyclohexyl 3-deoxy-4-c-methyl-3-(methylamino)pentopyranoside"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00955	.	DR1139	475.6	C21H41N5O7	200	673	-4.2	33	8	12	8	"1S/C21H41N5O7/c1-4-26-13-7-12(24)16(32-19-11(23)6-5-10(8-22)31-19)14(27)17(13)33-20-15(28)18(25-3)21(2,29)9-30-20/h5,11-20,25-29H,4,6-9,22-24H2,1-3H3/t11-,12+,13-,14+,15-,16-,17+,18-,19-,20-,21+/m1/s1"	CCN[C@@H]1C[C@@H]([C@H]([C@@H]([C@H]1O[C@@H]2[C@@H]([C@H]([C@@](CO2)(C)O)NC)O)O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N	CIDUJQMULVCIBT-MQDUPKMGSA-N
DG00095	Tamoxifen	2733526	"Tamoxifen; 10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; Citofen; Nourytam; Novaldex; Tamone; Tamoxifeno;Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Trans-Tamoxifen; Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:41774	DB00675	DR00193	.	371.5	C26H29NO	12.5	463	7.1	28	0	2	8	"1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-"	CC/C(=C(\\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3	NKANXQFJJICGDU-QPLCGJKRSA-N
DG00096	Quizartinib	24889392	Quizartinib	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:90217	DB12874	.	.	560.7	C29H32N6O4S	134	849	5.6	40	2	8	8	"1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)"	CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3	CVWXJKQAOSCOAB-UHFFFAOYSA-N
DG00098	Halofantrine	37393	"Halfan; Halofantrino; HALOFANTRINE HYDROCHLORIDE; Halofantrine HCl; Halofantrine Hydrochloride [USAN]; Halofantrine [USAN]; Halofantrino [Spanish]; WR 171669; Dl-WR 171669; Halfan (TN); Halofantrine hydrochloride (USAN); WR 171,699; WR-171669; WR-171699; SK&F-102866; WR-171,669; (+-)-Halofantrine hydrochloride; (1)-Halofantrine; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenanthrene-methanol; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenathrenemethanol; 1,3-Dichloro-6-trifluoromethyl-9-(3-(dibutylamino)-1-hydroxypropyl)phenanthrene HCl; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-9-phenanthrenemethanol hydrochloride; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)phenanthren-1-methanol hydrochloride; 1-(1,3-Dichloro-6-trifluoromethyl-9-phenanthryl)-3-(di-n-butylamino)propanol hydrochloride; 1-(1,3-dichloro-6-trifluoromethyl-9-phenanthryl)-3-di(n-butyl)aminopropanol HCl; 3-(Dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol hydrochloride; 9-(3-(dibutylamino)-1-hydroxypropyl)-1,3-dichloro-6-(trifluoromethyl)phenanthrene hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-(1); 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-, hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-,hydrochloride"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:94392	DB01218	DR00770	DR0799	500.4	C26H30Cl2F3NO	23.5	584	8.6	33	1	5	10	"1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3"	CCCCN(CCCC)CCC(C1=C2C=CC(=CC2=C3C=C(C=C(C3=C1)Cl)Cl)C(F)(F)F)O	FOHHNHSLJDZUGQ-UHFFFAOYSA-N
DG00099	Solamargine	73611	Curaderm (TN)	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:9185	DB12700	.	.	868.1	C45H73NO15	239	1610	1.1	61	9	16	7	"1S/C45H73NO15/c1-19-9-14-45(46-17-19)20(2)30-28(61-45)16-27-25-8-7-23-15-24(10-12-43(23,5)26(25)11-13-44(27,30)6)57-42-39(60-41-36(53)34(51)32(49)22(4)56-41)37(54)38(29(18-47)58-42)59-40-35(52)33(50)31(48)21(3)55-40/h7,19-22,24-42,46-54H,8-18H2,1-6H3/t19-,20+,21+,22+,24+,25-,26+,27+,28+,29-,30+,31+,32+,33-,34-,35-,36-,37+,38-,39-,40+,41+,42-,43+,44+,45-/m1/s1"	C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)O)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)C)C)C)NC1	MBWUSSKCCUMJHO-ZGXDEBHDSA-N
DG00100	Sulphadoxine	17134	"2447-57-6; Sulforthomidine; Fanasil; Sulphormethoxine; 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide; Sulfadoxinum; Sulfadoxina; Sulfadoxin; Fanzil; Solfadossina; Ro 4-4393; Solfadossina [DCIT]; Sulfadoxinum [INN-Latin]; Sulfadoxina [INN-Spanish]; 4-Sulfanilamido-5,6-dimethoxypyrimidine; 4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(5,6-dimethoxy-4-pyrimidinyl)-; WR 4873; N'-(5,6-Dimethoxy-4-pyrimidyl)sulfanilamide; UNII-88463U4SM5; Orthosulfin; Sulformethoxine; Sulformetoxine; Sulphormetoxin; Sulphorthodimethoxine; WR 4073; Ro-4-4393; Sanasil: Sulfadoxine: Sulformetoxin; Sulfadoxine (JAN/USP/INN); Sulfadoxine [USAN:INN:BAN:JAN]; N1-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; N(sup 1)-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; 4-amino-N-[5,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide; 6-(4-Aminobenzenesulfonamido)-4,5-dimethoxypyrimidine; RS-1653"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9329	DB01299	.	.	310.33	C12H14N4O4S	125	420	0.7	21	2	8	5	"1S/C12H14N4O4S/c1-19-10-11(14-7-15-12(10)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)"	COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N	PJSFRIWCGOHTNF-UHFFFAOYSA-N
DG00101	Erlotinib	176870	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-Quinazolinamine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:114785	DB00530	DR00558	.	393.4	C22H23N3O4	74.7	525	3.3	29	1	7	11	"1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)"	COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC	AAKJLRGGTJKAMG-UHFFFAOYSA-N
DG00102	Teriflunomide	54684141	.	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:68540	DB08880	DR00092	.	270.21	C12H9F3N2O2	73.1	426	3.3	19	2	6	2	"1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-"	C/C(=C(\\C#N)/C(=O)NC1=CC=C(C=C1)C(F)(F)F)/O	UTNUDOFZCWSZMS-YFHOEESVSA-N
DG00103	Curcumin	969516	"Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	Phase 4	4	Approved Drug(s)	Phase 4	Small molecular drug	CHEBI:3962	DB11672	DR00559	DR1941	368.4	C21H20O6	93.1	507	3.2	27	2	6	8	"1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+"	COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O	VFLDPWHFBUODDF-FCXRPNKRSA-N
DG00104	Lividomycin A	72394	Lividomycin A; Lividomycin; Quintomycin B; Mannosyldeoxyparomomycin; Antibiotic 503-2; Antibiotic SF 767 A; Lividomycinum; Lividomycine; 36441-41-5; Lividomicina; SF 767 A; Livodymycin; Lividomycin [INN:DCF]; Lividomycinum [INN-Latin]; Lividomycine [INN-French]; Lividomicina [INN-Spanish]; UNII-A606AJ494W; BRN 6763509; CHEBI:71961; Lividomycin A sulfate salt; A606AJ494W	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:71961	DB04728	.	.	761.8	C29H55N5O18	406	1130	-9.9	52	15	23	12	"1S/C29H55N5O18/c30-3-11-23(51-28-20(43)19(42)17(40)13(5-36)47-28)18(41)15(34)27(45-11)50-24-14(6-37)48-29(21(24)44)52-25-16(39)7(31)1-8(32)22(25)49-26-9(33)2-10(38)12(4-35)46-26/h7-29,35-44H,1-6,30-34H2/t7-,8+,9-,10+,11+,12-,13-,14-,15-,16+,17-,18-,19+,20+,21-,22-,23-,24-,25-,26-,27-,28-,29+/m1/s1"	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H](C[C@@H]([C@H](O2)CO)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O[C@@H]5[C@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)N)O)O)N	DBLVDAUGBTYDFR-SWMBIRFSSA-N
DG00105	Lamivudine	60825	"Lamivudine; 134678-17-4; Epivir; Zeffix; Heptovir; Epivir-HBV; Hepitec; Heptodin; BCH-189; 3TC; Heptivir; CIS-LAMIVUDINE; (-)-2'-Deoxy-3'-thiacytidine; 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; GR-109714X; 3'-Thia-2',3'-dideoxycytidine; (-)-BCH-189; Lamivudine [USAN:BAN:INN]; GR109714X; beta-L-3'-Thia-2',3'-dideoxycytidine; beta-L-2',3'-Dideoxy-3'-thiacytidine; (-)NGPB-21; 136891-12-8; 2',3'-Dideoxy-3'-thiacytidine; (-)-BCH 189; UNII-2T8Q726O95; HSDB 7155; GR 109714X; DTHC; LMV; Lamivir; Zefix; BCH 189; BCH189; BCH-790; DRG-0126; Epivir (TN); Epivir(TM); GG-714; HHA & 3TC; HHA & Lamivudine; Heptovir (TN); Lamivudine & GNA; Zeffix (TN); Epivir-HBV (TN); Lamivudine [USAN:INN:BAN]; Lamivudine (JAN/USP/INN); Lamivudine, (2S-cis)-Isomer; Beta-L-2',3'-Dideoxy-3'-thiacytidine; Beta-L-3'-Thia-2',3'-dideoxycytidine; Beta-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; (+/-)-(Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (+/-)-3TC; (+/-)-BCH-189; (+/-)-SddC; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-NGPB-21; (-)-SddC; (-)-beta-L-2',3'-Dideoxy-3'-thiacytidine; (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2',3' Dideoxy 3' thiacytidine; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-)-(Cis); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Galanthus Nivalis Agglutinin (GNA); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Hippeastrum hybrid agglutinin(HHA); 3TC & GNA; 3TC & SST; 3TC (AIDS INITIATIVE) (AIDS INITIATIVE); 3TC and NV-01; 3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; Efavirenz/lamivudine/tenofovir fumarate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63577	DB00709	DR00116	DR0912	229.26	C8H11N3O3S	113	331	-0.9	15	2	4	2	"1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1"	C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N	JTEGQNOMFQHVDC-NKWVEPMBSA-N
DG00106	Linezolid	441401	"Linezlid; ZLD; Zyvox; Zyvoxa; Zyvoxam; Zyvoxid; PNU 100766; U 100766; Linezolid & VRC3375; Linezolid [USAN:INN]; PNU-100766; U-100766; Zyvox (TN); Zyvoxam (TN); Zyvoxid (TN); NDA 21-130 Zyvox (linezolid tablets); NDA 21-131 Zyvox for injection (linezolid injection); NDA 21-132 Zyvox oral suspension (linzolid oral suspension); Linezolid (JAN/USAN/INN); PNU-100766, U-100766, Zyvoxid, Zyvoxam, Linezolid; N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide; N-({5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, N-[[(S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; (S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; 111GE017"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63607	DB00601	DR00748	.	337.35	C16H20FN3O4	71.1	472	0.7	24	1	6	4	"1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1"	CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F	TYZROVQLWOKYKF-ZDUSSCGKSA-N
DG00107	Isavuconazole	6918485	"Isavuconazole; 241479-67-4; isavuconazol; BAL 4815; BAL-4815; UNII-60UTO373KE; Isavuconazole [INN]; 60UTO373KE; Isavuconazole(BAL-4815; RO-0094815); RO 0094815; CHEBI:85979; Isavuconazole (INN); RO-0094815; 4-[2-[(1R,2R)-2-(2,5-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile; 1286730-05-9; 4-[2-[(2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:85979	DB11633	.	DR0883	437.5	C22H17F2N5OS	116	657	3.5	31	1	8	6	"1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-8-17(23)6-7-19(18)24/h2-8,10,12-14,30H,11H2,1H3/t14-,22+/m0/s1"	C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](CN3C=NC=N3)(C4=C(C=CC(=C4)F)F)O	DDFOUSQFMYRUQK-RCDICMHDSA-N
DG00108	Arsenic trioxide	14888	Arsenox; Arsentrioxide; Naonobin; Trisenox; Trixenox; Acide arsenieux [French]; Anhydride arsenieux [French]; Arseni trioxydum; Arsenic blanc [French]; Arsenic trioxide [JAN]; Arsenigen saure [German]; Arsenious Acid Anhydride; Arsenious trioxide; Arsenous oxide [ISO]; Oxyde Arsenieux; Arsenic trioxide [UN1561] [Poison]; Arsenic oxide (As2O3); Arsenic(III) trioxide; Oxyde Arsenieux [ISO-French]; Trisenox (TN); Arsenic trioxide (JP15/USAN); Arsenic(3+)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB01169	DR00119	.	197.84	As2O3	3	0	.	5	0	3	0	1S/2As.3O/q2*+3;3*-2	[O-2].[O-2].[O-2].[As+3].[As+3]	QTLQKAJBUDWPIB-UHFFFAOYSA-N
DG00109	Doxorubicin	31703	"Doxorubicin; 23214-92-8; Doxil; Doxorubicine; Adriablastin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicina; Adriamycin semiquinone; Doxorubicinum [INN-Latin]; Doxorubicine [INN-French]; Doxorubicina [INN-Spanish]; Myocet; FI 106; Doxorubicin [USAN:INN:BAN]; CCRIS 739; NDC 38242-874; HSDB 3070; UNII-80168379AG; NCI-C01514; EINECS 245-495-6; CHEMBL53463; CHEBI:28748; 5,12-Naphthacenedione,; ADM; ADR; ThermoDox; Aerosolized Doxorubicin; Doxorubicin citrate; RDF Rubex; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Cantide + adriamycin"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:28748	DB00997	DR00301	DR0546	543.5	C27H29NO11	206	977	1.3	39	6	12	5	"1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1"	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O	AOJJSUZBOXZQNB-TZSSRYMLSA-N
DG00112	Cytarabine	6253	"Alexan; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; Citarabina; Cytarabin; Cytarabina; Cytarabinoside; Cytarabinum; Cytarbel; Cytonal; Cytosar; Cytosinearabinoside; DepoCyte; Depocyt; Erpalfa; Iretin; Spongocytidine; Tarabine; Udicil; Arabinosyl Cytosine; Cytarabine liposome injection; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; AR3; BTB15125; CHX 3311; U 19920A; Ara-C; Ara-Cytidine; Beta-Ara C; Beta-Arabinosylcytosine; Beta-cytosine arabinoside; Citarabina [INN-Spanish]; Cytarabinum [INN-Latin]; Cytosar-U; Cytosine arabinoside (VAN); Depocyt (TN); Depocyt (liposomal); Intrathecal (injected into the spinal fluid) DepoCyt; U-19920; Beta-D-Arabinosylcytosine; Cytosar-U (TN); Cytosine beta-D-arabinofuranoside; Cytosine beta-D-arabinofuranoside hydrochloride; Cytosine beta-D-arabinoside; Cytosine-beta-arabinoside; Intrathecal cytarabine (also known as ara-C); U-19,920; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); Cytarabine (JP15/USP/INN); Cytarabine [USAN:INN:BAN:JAN]; Cytosine 1-beta-D-arabinofuranoside; Cytosine, beta-D-arabinoside; Cytosine-beta-D-arabinofuranoside; Cytosine-1-beta-D-arabinofuranoside; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; (beta-D-Arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; 1-beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:28680	DB00987	DR00416	DR0398	243.22	C9H13N3O5	129	383	-2.1	17	4	5	2	"1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1"	C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O	UHDGCWIWMRVCDJ-CCXZUQQUSA-N
DG00115	Lapatinib	208908	"FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:49603	DB01259	DR00120	.	581.1	C29H26ClFN4O4S	115	898	5.1	40	2	9	11	"1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)"	CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl	BCFGMOOMADDAQU-UHFFFAOYSA-N
DG00116	Cabotegravir	54713659	"Cabotegravir; 1051375-10-0; GSK1265744; UNII-HMH0132Z1Q; GSK744; GSK1265744A; GSK-1265744; HMH0132Z1Q; Cabotegravir (GSK744, GSK1265744); CAB; Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-;Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-; Cabotegravir [USAN:INN]; GSK744 LAP; GSK744 LA; S/GSK1265744; GSK 744; 744 LA; GSK 1265"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11751	.	DR1829	405.4	C19H17F2N3O5	99.2	814	2.1	29	2	8	3	"1S/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1"	C[C@H]1CO[C@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O	WCWSTNLSLKSJPK-LKFCYVNXSA-N
DG00117	Minocycline	54675783	"Borymycin; MINO; MIY; Minociclina; Minociclinum; Minocin; Minocline; Minocyclin; Minocyclinum; Minocycline Monohydrochloride; CL 59806; Lactoferrin B & Minocycline; Lactoferrin H & Minocycline; Minociclina [INN-Spanish]; Minocin (Hydrochloride); Minocin (TN); Minocyclinum [INN-Latin]; Vectrin (Hydrochloride); CRL-1605 & Minocycline; Minocycline (USAN/INN); Minocycline [USAN:BAN:INN]; (2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE; 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; 7-Dimethylamino-6-demethyl-6-deoxytetracycline"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:50694	DB01017	.	.	457.5	C23H27N3O7	165	971	-0.6	33	5	9	3	"1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27-28,31,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1"	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C	FFTVPQUHLQBXQZ-KVUCHLLUSA-N
DG00118	Tetracycline	54675776	"Amycin; Biocycline; Bristaciclin; Bristaciclina; Bristacycline; Ciclibion; Copharlan; Cyclomycin; Cytome; Dumocyclin; Enterocycline; Medocycline; Resteclin; Robitet; Sanclomycine; Tetrachel; Veracin; Bristaciclin alpha; Cefracycline suspension; Component of Tetrastatin; Sumycin syrup; Tetracycline Free Base; Tetracycline I; Tetracycline II; Tetracycline Monohydrochloride; Achromycin (naphthacene derivative); Achromycin, naphthacene derivative; Centet (base); Lemtrex (base); Liquamycin (Veterinary); Liquamycin, veterinary; Panmycin (TN); Piracaps (base); Polycycline (VAN); Polycycline (antibiotic); Polycycline, antibiotic; SK-Tetracycline; Sumycin (TN); T-125; Tetra-Co; Tetraciclina [INN-Spanish]; Tetracycline & VRC3375; Tetracycline (internal use); Tetracyclinum [INN-Latin]; Tetracyn (TN); Vetquamycin-324 (free base); Tetracycline (JAN/USP/INN); Tetracycline [USAN:INN:BAN:JAN]; Methyl-1,11-dioxo-2-naphthacenecarboxamide; 6-Methyl-1,11-dioxy-2-naphthacenecarboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:27902	DB00759	DR00127	DR1568	444.4	C22H24N2O8	182	971	-2	32	6	9	2	"1S/C22H24N2O8/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28/h4-6,9-10,15,25-26,29,31-32H,7H2,1-3H3,(H2,23,30)/t9-,10-,15-,21+,22-/m0/s1"	C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O	NWXMGUDVXFXRIG-WESIUVDSSA-N
DG00119	Ribostamycin	33042	"Ribostamycin; Vistamycin; Hetangmycin; Xylostatin; Antibiotic SF 733; Ribostamycinum; Ribostamicina; Ribostamycine; Ribastamin; Dekamycin IV; SF 733; 25546-65-0; ribostamycin A; Ribostamycin [INN:BAN]; Bu 1709; Ribostamycine [INN-French]; Ribostamycinum [INN-Latin]; UNII-2Q5JOU7T53; SF-733; Ribostamicina [INN-Spanish]; C17H34N4O10; EINECS 247-091-5; NSC 138925; BRN 1357280; 2Q5JOU7T53; CHEBI:45257; NSC138925; O-2,6-Diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1->4)-O-(beta-D-ribofuranosyl-(1->5))-2-deoxystreptamine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:45257	DB03615	.	.	454.5	C17H34N4O10	262	593	-6.3	31	10	14	6	"1S/C17H34N4O10/c18-2-6-10(24)12(26)8(21)16(28-6)30-14-5(20)1-4(19)9(23)15(14)31-17-13(27)11(25)7(3-22)29-17/h4-17,22-27H,1-3,18-21H2/t4-,5+,6-,7-,8-,9+,10-,11-,12-,13-,14-,15-,16-,17+/m1/s1"	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)O)N	NSKGQURZWSPSBC-VVPCINPTSA-N
DG00120	Epidermal growth factor	56841751	"62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB14145	.	DR1921	6046	C257H381N73O83S7	2560	15400	-19.6	420	96	96	193	"1S/C257H381N73O83S7/c1-20-123(15)203(245(404)283-103-192(351)285-157(80-127-42-52-135(339)53-43-127)222(381)313-171(104-331)210(369)281-101-191(350)287-167(92-198(360)361)228(387)290-146(37-27-70-273-255(265)266)213(372)318-177(110-414)238(397)292-148(62-65-185(259)344)217(376)327-205(125(17)337)249(408)294-147(38-28-71-274-256(267)268)212(371)309-168(93-199(362)363)229(388)298-153(76-117(3)4)218(377)289-145(36-26-69-272-254(263)264)211(370)303-162(86-133-96-277-144-35-25-23-33-141(133)144)226(385)304-161(85-132-95-276-143-34-24-22-32-140(132)143)225(384)291-149(63-66-195(354)355)214(373)297-154(77-118(5)6)219(378)296-152(253(412)413)39-29-72-275-257(269)270)326-247(406)202(122(13)14)324-242(401)181(114-418)320-227(386)165(90-188(262)347)307-241(400)180(113-417)322-250(409)206(126(18)338)328-231(390)160(83-130-48-58-138(342)59-49-130)302-234(393)174(107-334)315-230(389)169(94-200(364)365)310-221(380)155(78-119(7)8)299-233(392)173(106-333)314-215(374)150(64-67-196(356)357)295-248(407)204(124(16)21-2)325-232(391)163(87-134-97-271-116-284-134)305-216(375)151(68-75-420-19)293-239(398)179(112-416)321-246(405)201(121(11)12)323-194(353)99-278-189(348)98-279-208(367)164(89-187(261)346)306-220(379)156(79-120(9)10)300-240(399)178(111-415)319-223(382)158(81-128-44-54-136(340)55-45-128)286-190(349)100-280-209(368)166(91-197(358)359)308-224(383)159(82-129-46-56-137(341)57-47-129)301-235(394)175(108-335)316-237(396)176(109-336)317-244(403)184-41-31-74-330(184)252(411)182(115-419)288-193(352)102-282-243(402)183-40-30-73-329(183)251(410)170(84-131-50-60-139(343)61-51-131)311-236(395)172(105-332)312-207(366)142(258)88-186(260)345/h22-25,32-35,42-61,95-97,116-126,142,145-184,201-206,276-277,331-343,414-419H,20-21,26-31,36-41,62-94,98-115,258H2,1-19H3,(H2,259,344)(H2,260,345)(H2,261,346)(H2,262,347)(H,271,284)(H,278,348)(H,279,367)(H,280,368)(H,281,369)(H,282,402)(H,283,404)(H,285,351)(H,286,349)(H,287,350)(H,288,352)(H,289,377)(H,290,387)(H,291,384)(H,292,397)(H,293,398)(H,294,408)(H,295,407)(H,296,378)(H,297,373)(H,298,388)(H,299,392)(H,300,399)(H,301,394)(H,302,393)(H,303,370)(H,304,385)(H,305,375)(H,306,379)(H,307,400)(H,308,383)(H,309,371)(H,310,380)(H,311,395)(H,312,366)(H,313,381)(H,314,374)(H,315,389)(H,316,396)(H,317,403)(H,318,372)(H,319,382)(H,320,386)(H,321,405)(H,322,409)(H,323,353)(H,324,401)(H,325,391)(H,326,406)(H,327,376)(H,328,390)(H,354,355)(H,356,357)(H,358,359)(H,360,361)(H,362,363)(H,364,365)(H,412,413)(H4,263,264,272)(H4,265,266,273)(H4,267,268,274)(H4,269,270,275)/t123-,124-,125+,126+,142-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,201-,202-,203-,204-,205-,206-/m0/s1"	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N	VBEQCZHXXJYVRD-GACYYNSASA-N
DG00121	Ticarcillin	36921	"TIPC; Ticarcilina; Ticarcilline; Ticarcillinum; Ticarcillin Supplement; Ticillin [veterinary]; BRL-2288; Ticarcilina[INN-Spanish]; Ticarcillin (INN); Ticarcillin [INN:BAN]; Ticarcilline [INN-French]; Ticarcillinum [INN-Latin]; Ticillin [veterinary] (TN); Timentin (TN); A-carboxy-3-thienylmethylpenicillin; Alpha-carboxy-3-thienylmethylpenicillin; (2S,5R,6R)-6-[[(2R)-3-hydroxy-3-oxo-2-thiophen-3-ylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-carboxy-2-(3-thienyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-2,2-dimethylpenam-3alpha-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9587	DB01607	.	DR2409	384.4	C15H16N2O6S2	178	640	0.8	25	3	8	5	"1S/C15H16N2O6S2/c1-15(2)9(14(22)23)17-11(19)8(12(17)25-15)16-10(18)7(13(20)21)6-3-4-24-5-6/h3-5,7-9,12H,1-2H3,(H,16,18)(H,20,21)(H,22,23)/t7-,8-,9+,12-/m1/s1"	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CSC=C3)C(=O)O)C(=O)O)C	OHKOGUYZJXTSFX-KZFFXBSXSA-N
DG00122	LFF571	42638236	.	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB13013	.	.	1366.6	C60H63N13O13S6	539	2570	5.4	92	8	26	17	"1S/C60H63N13O13S6/c1-28(2)44-58-72-47(39(92-58)23-85-5)51(80)62-22-42(75)69-48(49(78)30-11-7-6-8-12-30)57-67-38(26-89-57)55-65-36(24-88-55)46-33(53-66-37(25-87-53)50(79)64-35(21-41(74)61-4)56-71-45(29(3)91-56)52(81)70-44)18-19-34(63-46)54-68-40(27-90-54)73(20-10-9-13-43(76)77)60(84)86-32-16-14-31(15-17-32)59(82)83/h6-8,11-12,18-19,24-28,31-32,35,44,48-49,78H,9-10,13-17,20-23H2,1-5H3,(H,61,74)(H,62,80)(H,64,79)(H,69,75)(H,70,81)(H,76,77)(H,82,83)/t31 ,32 ,35-,44-,48-,49-/m0/s1"	CC1=C2C(=O)N[C@H](C3=NC(=C(S3)COC)C(=O)NCC(=O)N[C@H](C4=NC(=CS4)C5=NC(=CS5)C6=C(C=CC(=N6)C7=NC(=CS7)N(CCCCC(=O)O)C(=O)OC8CCC(CC8)C(=O)O)C9=NC(=CS9)C(=O)N[C@H](C(=N2)S1)CC(=O)NC)[C@H](C1=CC=CC=C1)O)C(C)C	GNLYKLDXQZHYTR-QWSGWXDSSA-N
DG00123	Epigallocatechin gallate	65064	.	Phase 4	4	Approved Drug(s)	Phase 4	Small molecular drug	CHEBI:4806	DB12116	.	.	458.4	C22H18O11	197	667	1.2	33	8	11	4	"1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1"	C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O	WMBWREPUVVBILR-WIYYLYMNSA-N
DG00124	Colchicine	6167	"Colchicin; Colchicina; Colchicinum; Colchineos; Colchisol; Colchysat; Colcin; Colcrys; Colsaloid; Colstat; Condylon; Goutnil; Kolkicin; LOC; Binds to tubulin; Colchicin [German]; Colchicina [Italian]; Colchicine [JAN]; Inhibits microtubular assembly; Spindle poison; C 9754; Colchicine (TN); Colchicine, Colchicum autumnale; MPC-004; N-Acetyl trimethylcolchicinic acid methylether; Colchicine (JP15/USP); Colchicine, (R)-Isomer; Benzo(a)heptalen-9(5H)-one; Colchicine, (+-)-Isomer; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide; N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-acetamide; N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-acetamide; (S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide; 7-alpha-H-Colchicine; 7.alpha.H-Colchicine; 7alphaH-Colchicine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:27882	DB01394	.	.	399.4	C22H25NO6	83.1	740	1	29	1	6	5	"1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1"	CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC	IAKHMKGGTNLKSZ-INIZCTEOSA-N
DG00125	Chloroquine	2719	Amokin; Aralen; Aralen HCl; Arechin; Arechine; Arequin; Arolen; Arthrochin; Artrichin; Avlochlor; Avloclor; Bemaco; Bemaphate; Bemasulph; Benaquin; Bipiquin; CU-01000012392-2; Capquin; Chemochin; Chingamin; Chloraquine; Chlorochin; Chlorochine; Chlorochinum; Chloroin; Chloroquin; Chloroquina; Chloroquine (USP/INN); Chloroquine (VAN); Chloroquine Bis-Phosphoric Acid; Chloroquine FNA (TN); Chloroquine [USAN:INN:BAN]; Chloroquine phosphate; Chloroquinium; Chloroquinum; Chloroquinum [INN-Latin]; Chlorquin; Cidanchin; Clorochina; Clorochina [DCIT]; Cloroquina; Cloroquina [INN-Spanish]; Cocartrit; Dawaquin (TN); Delagil; Dichinalex; Elestol; Gontochin; Gontochin phosphate; Heliopar; Imagon; Ipsen 225; Iroquine; Khingamin; Klorokin; Lapaquin; Malaquin; Malaquin (*Diphosphate*); Malaren; Malarex; Mesylith; Miniquine; Neochin; Nivachine; Nivaquine B; Pfizerquine; Quinachlor; Quinagamin; Quinagamine; Quinercyl; Quingamine; Quinilon; Quinoscan; RP 3377; RP-3377; Resochen; Resochin; Resochin (TN); Resoquina; Resoquine; Reumachlor; Reumaquin; Rivoquine; Ro 01-6014/N2; Ronaquine; Roquine; SN 6718; SN-7618; ST 21; ST 21 (pharmaceutical); Sanoquin; Silbesan;Siragan; Solprina; Sopaquin; Tanakan; Tanakene; Tresochin; Trochin; W 7618;WIN 244	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3638	DB00608	DR00572	DR0301	319.9	C18H26ClN3	28.2	309	4.6	22	1	3	8	"1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)"	CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl	WHTVZRBIWZFKQO-UHFFFAOYSA-N
DG00126	Clotrimazole	2812	Canesten; Canestene; Canestine; Canifug; Chlotrimazole; Cimitidine; Clomatin; Clotrimaderm; Clotrimazol; Clotrimazolum; Clotrimeizol; Cutistad; Empecid; Esparol; FemCare; Gynix; Kanesten; Klotrimazole; Lotrimax; Lotrimin; Monobaycuten; Mycelax; Mycelex; Mycofug; Mycosporin; Mykosporin; Nalbix; Pedisafe; Rimazole; Stiemazol; Tibatin; Trimysten; Canesten Cream; Canesten Solution; Clotrimazole Schering Brand; Desamix F; Fem Care; Gyne lotrimin; Lotrimin AF Cream; Lotrimin AF Lotion; Lotrimin AF Solution; Lotrimin Af; Lotrimin Cream; Lotrimin Lotion; Lotrimin Solution; Mycelex Cream; Mycelex G; Mycelex OTC; Mycelex Solution; Mycelex Troches; Mycelex Twin Pack; Myclo Cream; Myclo Solution; Myclo Spray Solution; Schering Brand of Clotrimazole; B 5097; Bay b 9057; Bayer Brand 1 of Clotrimazole; Bayer Brand 2 of Clotrimazole; C 6019; FB 5097; FB b 5097; Mycelex 7; Trivagizole 3; Bay-B 5097; Candid Vaginal (TN); Candinil (TN); Canesten (TN); Canesten 1-Day Therapy; Canesten 3-Day Therapy; Canesten 6-Day Therapy; Clobrate VT (TN); Clotrimazol [INN-Spanish]; Clotrimazolum [INN-Latin]; DRG-0072; Gino-Lotremine; Gyne-Lotrimin; Gyne-Lotrimin 3; Gyne-Lotrimin 3 Combination Pack; Gyne-Lotrimin Combination Pack; Lotrimin (TN); Lotrimin AF Jock-Itch Cream; Mono-baycuten; Mycelex (TN); Mycelex-7; Mycelex-7 Combination Pack; Mycelex-G; Mycelex: MycosporinRimazole; Myclo-Gyne; Neo-Zol Cream; Pan-Fungex; Cancap-VT (TN); Candid - V Gel (TN); Canesten 1-Day Cream Combi-Pak; Canesten Combi-Pak 1-Day Therapy; Canesten Combi-Pak 3-Day Therapy; Clotrimazole (JP15/USP/INN); Clotrimazole [USAN:INN:BAN:JAN]; (Chlorotrityl)imidazole; 1-(o-Chlorotrityl)imidazole	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3764	DB00257	DR00574	DR0362	344.8	C22H17ClN2	17.8	396	5	25	0	1	4	"1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H"	C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4	VNFPBHJOKIVQEB-UHFFFAOYSA-N
DG00127	Telithromycin	3002190	"Ketek; Levviax; TEL; HMR 3647; HMR3647; RU 66647; RU66647; HMR-3647; Ketek (TN); RU-66647; Telithromycin [USAN:BAN:INN]; Telithromycin (JAN/USAN/INN); (1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6R,7R,8R,10S,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2S,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; 11,12-Dideoxy-3-des(2,6-dideoxy-3-C,3-O-dimethyl-alpha-L-altropyranosyloxy)-6-O-methyl-3-oxo-12,11-(oxycarbonylimino)-N11-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]erythromycin A"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:29688	DB00976	DR00576	DR1544	812	C43H65N5O10	172	1440	4.2	58	1	13	11	"1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33-,36-,37-,38-,40+,42-,43-/m1/s1"	CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C	LJVAJPDWBABPEJ-PNUFFHFMSA-N
DG00128	Intedanib	135423438	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:85164	DB09079	DR00137	.	539.6	C31H33N5O4	102	892	4.3	40	2	7	8	"1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,33,38H,15-18,20H2,1-3H3"	CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O	CPMDPSXJELVGJG-UHFFFAOYSA-N
DG00129	Cefazolin	33255	"CEZ; Cefamezin; Cefamezine; Cefazolina; Cefazoline; Cefazolinum; Cephamezine; Cephazolidin; Cephazolin; Cephazoline; Elzogram; Cephazolin Sodium; Ancef (TN); Cefacidal (TN); Cefamezin (TN); Cefazolin (USP); Cefazolin [USAN:INN]; Cefazolin(usp); Cefazolina [INN-Spanish]; Cefazoline [INN-French]; Cefazolinum [INN-Latin]; Cefrina (TN); Elzogram (TN); Faxilen (TN); Gramaxin (TN); Kefazol (TN); Kefol (TN); Kefzol (TN); Kefzolan (TN); Kezolin (TN); Novaporin (TN); Zolicef (TN); (6R, 7R)-3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[[1H-tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-trans)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(((1H-tetrazol-1-yl)acetyl)-amino)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-7beta-[(1H-tetrazol-1-ylacetyl)amino]-3,4-didehydrocepham-4-carboxylic acid; 7-(1-(1H-)-Tetrazolylacetamido)-3-(2-(5-methyl-1,3,4-thiadiazolyl)thiomethyl)delta3-cephem-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:474053	DB01327	DR00577	DR2503	454.5	C14H14N8O4S3	235	740	-0.4	29	2	12	7	"1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1"	CC1=NN=C(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)O	MLYYVTUWGNIJIB-BXKDBHETSA-N
DG00130	Ibrutinib	24821094	PCI-32765; Ibrutinib (BTK inhibitor)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:76612	DB09053	DR01270	DR0843	440.5	C25H24N6O2	99.2	678	3.6	33	1	6	5	"1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1"	C=CC(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N	XYFPWWZEPKGCCK-GOSISDBHSA-N
DG00131	Fluconazole	3365	"Afungil; Alflucoz; Baten; Beagyne; Biocanol; Biozolene; Canzol; Cryptal; Diflazon; Diflucan; Dimycon; Elazor; FCZ; FLCZ; Flucazol; FlucoLich; Flucobeta; Fluconazol; Fluconazolum; Flucostat; Flukezol; Flunazul; Flunizol; Fluzone; Forcan; Fuconal; Fungata; Lavisa; Loitin; Mutum; Neofomiral; Oxifugol; Oxifungol; Pritenzol; Solacap; Syscan; TPF; Triflucan; Zemyc; Zoltec; Zonal; AbZ Brand of Fluconazole; Aliud Brand of Fluconazole; Alpharma Brand of Fluconazole; Apo Fluconazole; Apotex Brand of Fluconazole; Armstrong Brand of Fluconazole; Betapharm Brand of Fluconazole; Chemia Brand of Fluconazole; Ct Arzneimittel Brand of Fluconazole; Effik Brand of Fluconazole; Fluc Hexal; Fluconazol AL; Fluconazol AbZ; Fluconazol Isis; Fluconazol Stada; Fluconazol [Spanish]; Fluconazol ratiopharm; Fluconazol von ct; Fluconazolum [Latin]; Hexal Brand of Fluconazole; Lesvi Brand of Fluconazole; Lichtenstein Brand of Fluconazole; Mack Brand of Fluconazole; Pfizer Brand of Fluconazole; Pfleger Brand of Fluconazole; Ratiopharm Brand of Fluconazole; SAT Brand of Fluconazole; Silanes Brand of Fluconazole; Stada Brand of Fluconazole; Vita Brand of Fluconazole; F0677; Fluconazole in combination with MGCD290; UK 49858; UK49858; Alfumet (TN); Apo-Fluconazole; Ct-Arzneimittel Brand of Fluconazole; DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER; DRG-0005; Diflucan (TN); Fluconazol-Isis; Fluconazol-ratiopharm; Fluconazole & Bovine Lactoferrin; Fluconazole & Human recombinant granulocyte colony stimulating factor; Fluconazole & hGCSF; Fluconazole in dextrose 5% in plastic container; Flucytosine & Nyotran; GL663142 & Fluconazole; KS-1059; Trican (TN); UK-49858; DIFLUCAN IN SODIUM CHLORIDE 0.9%; DIFLUCAN IN SODIUM CHLORIDE 0.9%IN PLASTIC CONTAINER; Fluconazole in sodium chloride 0.9%; Fluconazole in sodium chloride 0.9% in plastic container; Flucytosine & Nyotran(Liposomal Nystatin); XMP.284 & Fluconazole; XMP.366 & Fluconazole; XMP.391 & Fluconazole; Diflucan, Trican, Alfumet, Fluconazole; Fluconazole & MC-510,011; Fluconazole (JAN/USAN/INN); Fluconazole [USAN:INN:BAN:JAN]; 2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; 2,4-difluoro-,1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; 2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL; 2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol; 2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol; 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:46081	DB00196	DR00578	DR0704	306.27	C13H12F2N6O	81.6	358	0.4	22	1	7	5	"1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2"	C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O	RFHAOTPXVQNOHP-UHFFFAOYSA-N
DG00132	Methadone	4095	"Adanon; Algovetin; Althose; Amidon; Amidone; Biscuits; Dextromethadone; Diaminon; Dollies; Dolly; Dolophin; Dolophine; Heptadone; Heptanon; Ketalgin; Levometadona; Levomethadonum; Levothyl; Metadona; Metadone; Metasedin; Methadon; Methadona; Methadonum; Methaquaione; Phenadone; Polamidone; Polamivet; Westadone; Dolophine HCL; Levomethadone [INN]; Metadona [Spanish]; Metadone [DCIT]; Methadona [Spanish]; Methadone HCL Intensol; Methadone M; Methadonum [Latin]; Racemic methadone; A 4624; AN 148; Hoechst 10820; K 174; Amidone (TN); D-Methadone; Dl-Methadone; Dolophine (TN); Heptadon (TN); Heptanon (pharmaceutical); L-Methadone; L-Polamidon; L-Polamivet; Levometadona [INN-Spanish]; Levomethadonum [INN-Latin]; Metadona [INN-Spanish]; Methadone (BAN); Methadone [INN:BAN]; Methadonum [INN-Latin]; Methadose (TN); Physeptone (TN); Sedo-Rapide; Symoron (TN); Dolophine (*Hydrochloride*); Fenadone (*Hydrochloride*); Heptadone (*Hydrochloride*); Heptanon (*Hydrochloride*); Hoescht 10820 (*Hydrochloride*); Phenadone (*Hydrochloride*); AN-148 (*Hydrochloride*); L-(+)-Methadone; S-(+)-Methadone; D-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; L-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (+)-Methadone; (+-)-Methadone; (+/-)-Methadone; (+/-)-Tussal; (-)-(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (-)-Methadone; (6R)-Methadone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-hetpanone; (S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; 3-Hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (R)-(9CI); 6-(Dimethylamino)-4,4-diphenyl-3-heptanone dl-mixture; 6-(dimethylamino)-4,4-diphenylheptan-3-one; 6-Dimethylamino-4,4-diphenyl-3-heptanone; 6-dimethylamino-4,4-di(phenyl)heptan-3-one; 6S-Methadone"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6807	DB00333	.	.	309.4	C21H27NO	20.3	346	3.9	23	0	2	7	"1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3"	CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2	USSIQXCVUWKGNF-UHFFFAOYSA-N
DG00133	Vincristine	5978	"LCR; Leurocristine; Marqibo; Oncovine; Tecnocris; VCR; VIN; Vincasar; Vincristina; Vincristinum; Vincrstine; Vincrystine; Vinkristin; Indole alkaloid; Liposomal Vincristine; Onco TCS; Vincristina [DCIT]; Oncovin (TN); Tecnocris (TN); Vincristine (INN); Vincristine [INN:BAN]; Vincristinum [INN-Latin]; Lilly37231 (1:1 sulfate salt); Oncovin (1:1 sulfate salt); Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Vincaleukoblastine, 22-oxo-22-Oxovincaleukoblastine; Z-D-Val-Lys(Z)-OH; 22-Oxovincaleukoblastine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:28445	DB00541	DR00143	.	825	C46H56N4O10	171	1750	2.8	60	3	12	10	"1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1"	CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O	OGWKCGZFUXNPDA-XQKSVPLYSA-N
DG00134	Mercaptopurine	667490	"6-mercaptopurine; Ismipur; Leukerin; Leupurin; Mercaleukim; Mercaleukin; Mercaptopurin; Mercaptopurina; Mercaptopurinum; Mercapurin; Merkaptopuryna; Mern; Purimethol; Purinethiol; Purinethol; Thiopurine; Leupu rin; Mercaptopurin [German]; Mercaptopurina Wellcome; Mercaptopurine anhydrous; Merkaptopuryna [Polish]; Puri Nethol; BW 57 323H; Glaxo Wellcome Brand of 6 Mercaptopurine; GlaxoSmithKline Brand of 6 Mercaptopurine; M0063; NCIMech_000025; PM6; Wellcome Brand of 6 Mercaptopurine; Glaxo Wellcome Brand of 6-Mercaptopurine; GlaxoSmithKline Brand of 6-Mercaptopurine; Mercaptopurina [INN-Spanish]; Mercaptopurine (INN); Mercaptopurine (VAN); Mercaptopurine (anhydrous); Mercaptopurinum [INN-Latin]; Puri-Nethol; Purineantimetabolite: inhibits nucleic acid replication; Purinethol (TN); U-4748; Wellcome Brand of 6-Mercaptopurine; AG-670/31547064; Purine-6-thiol; Leukerin, 99%-Carc; Purine-6(1H)-thione; Purinethol, 6-mercaptopurine, 6-MP, Mercaptopurine; 6 MP; 6 Mercaptopurine Monohydrate; 6 Thiohypoxanthine; 6 Thiopurine; 6-MERCAPTOPURINE MONOHYDRATE; 6-MP; 6-Mercaptopurin; 6-Merkaptopurin; 6-Merkaptopurin [Czech]; 6-Purinethiol; 6-Thiohypoxanthine; 6-Thiopurine; 6-Thioxopurine; Mercaptopurine (Purine analog)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:2208	DB01033	DR00145	DR1031	152.18	C5H4N4S	85.2	190	0	10	2	2	0	"1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)"	C1=NC2=C(N1)C(=S)N=CN2	GLVAUDGFNGKCSF-UHFFFAOYSA-N
DG00136	Isoniazid	3767	Abdizide; Andrazide; Anidrasona; Antimicina; Antituberkulosum; Armacide; Armazid; Armazide; Atcotibine; Azuren; Bacillen; Bacillin; Cedin; Cemidon; Chemiazid; Chemidon; Continazine; Cortinazine; Cotinazin; Cotinizin; Defonin; Dibutin; Diforin; Dinacrin; Ditubin; Ebidene; Eralon; Ertuban; Eutizon; Evalon; Fetefu; Fimalene; HIA; Hidranizil; Hidrasonil; Hidrulta; Hidrun; Hycozid; Hydra; Hydrazid; Hydrazide; Hyozid; Hyzyd; INH; Idrazil; Inah; Inizid; Iscotin; Isidrina; Ismazide; Isobicina; Isocid; Isocidene; Isocotin; Isohydrazide; Isokin; Isolyn; Isonerit; Isonex; Isoniacid; Isoniazida; Isoniazide; Isoniazidum; Isonicazide; Isonicid; Isonico; Isonicotan; Isonicotil; Isonicotinhydrazid; Isonicotinohydrazide; Isonide; Isonidrin; Isonikazid; Isonilex; Isonin; Isonindon; Isonirit; Isoniton; Isonizida; Isonizide; Isotamine; Isotebe; Isotebezid; Isotinyl; Isozid; Isozide; Isozyd; LANIZID; Laniazid; Laniozid; Mybasan; Neoteben; Neoxin; Neumandin; Nevin; Niadrin; Nicazide; Nicetal; Nicizina; Niconyl; Nicotibina; Nicotibine; Nicotisan; Nicozide; Nidaton; Nidrazid; Nikozid; Niplen; Nitadon; Niteban; Nydrazid; Nyscozid; Pelazid; Percin; Phthisen; Pycazide; Pyreazid; Pyricidin; Pyridicin; Pyrizidin; Raumanon; Razide; Retozide; Rimicid; Rimifon; Rimiphone; Rimitsid; Robiselin; Robisellin; Roxifen; Sanohidrazina; Sauterazid; Sauterzid; Stanozide; Tebecid; Tebemid; Tebenic; Tebexin; Tebilon; Tebos; Teebaconin; Tekazin; Tibazide; Tibemid; Tibiazide; Tibinide; Tibison; Tibivis; Tibizide; Tibusan; Tisin; Tisiodrazida; Tizide; Tubazid; Tubazide; Tubeco; Tubecotubercid; Tubercid; Tuberian; Tubicon; Tubilysin; Tubizid; Tubomel; Tyvid; Unicocyde; Unicozyde; Vazadrine; Vederon; Zidafimia; Zinadon; Zonazide; Hid rasonil; Isoco tin; Isoniazid SA; Isozid e; Nidra zid; Rimif on; BP 5015; Bp 5 015; FSR 3; I0138; INHd20; L 1945; Nitebannsc 9659; Preparation 6424; RP 5015; AZT + Isoniazid; Cedin (Aerosol); Dow-Isoniazid; FRS-3; FSR-3; Ido-tebin; In-73; Inh-Burgthal; Isoniazid & EEP; Isoniazid & Propolis; Laniazid (TN); Neo-Tizide; Nydrazid (TN); RP-5015; TB-Phlogin; TB-Razide; TB-Vis; Usaf cb-2; I.A.I; RU-EF-Tb; RY-EF-Tb; I.A.I.	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6030	DB00951	DR00422	DR0886	137.14	C6H7N3O	68	120	-0.7	10	2	3	1	"1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)"	C1=CN=CC=C1C(=O)NN	QRXWMOHMRWLFEY-UHFFFAOYSA-N
DG00137	Gefitinib	123631	"Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:49668	DB00317	DR00423	DR0764	446.9	C22H24ClFN4O3	68.7	545	4.1	31	1	8	8	"1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)"	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4	XGALLCVXEZPNRQ-UHFFFAOYSA-N
DG00138	Camptothecin	24360	"Camptothecin; Camptothecine; 7689-03-4; (S)-(+)-Camptothecin; Campathecin; d-Camptothecin; (+)-Camptothecine; (+)-Camptothecin; 20(S)-Camptothecine; 21,22-Secocamptothecin-21-oic acid lactone; NSC94600; (S)-Camptothecin; Camptothecine (8CI); 20(S)-Camptothecin; Camptothecine (S,+); CHEMBL65; UNII-XT3Z54Z28A; MLS000766223; (4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; XT3Z54Z28A; CHEBI:27656; VSJKWCGYPAHWDS-FQEVSTJZSA-N; Camptothecin, Camptotheca acuminata; NSC-94600; Camptothecin derivat"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:27656	DB04690	DR01383	.	348.4	C20H16N2O4	79.7	742	1	26	1	5	1	"1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m0/s1"	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O	VSJKWCGYPAHWDS-FQEVSTJZSA-N
DG00139	Cefepime	5479537	"Axepim; CFPM; Cefepima; Cefepimum; Cepimax; Cepimex; Maxcef; Maxipime; Cefepima [Spanish]; Cefepimum [Latin]; BMY 28142; Axepim (TN); BMY-28142; Cefepime [USAN:INN]; Cepimax (TN); Cepimex (TN); Maxcef (TN); Maxipime (TN); Cefepime (USAN/INN); (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 1-(((6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium hydroxide, inner salt, 7(sup 2)-(Z)-(O-methyloxime); 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:478164	DB01413	DR00585	.	480.6	C19H24N6O5S2	204	869	-0.1	32	2	10	6	"1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1"	C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)[O-]	HVFLCNVBZFFHBT-ZKDACBOMSA-N
DG00140	Propofol	4943	"Ampofol; Aquafol; Diisopropylphenol; Dipravan; Diprivan; Disoprivan; Disoprofol; Fresofol; Ivofol; PFL; Propofolum; Rapinovet; Recofol; Abbott Brand of Propofol; Alpha Brand of Propofol; Astra Brand of Propofol; AstraZeneca Brand of Propofol; Braun Brand of Propofol; Curamed Brand of Propofol; Diprivan Injectable emulsion; Fresenius Brand of Propofol; Fresenius Kabi Brand of Propofol; Juste Brand of Propofol; Parnell Brand of Propofol; Pisa Brand of Propofol; Propofol Abbott; Propofol Fresenius; Propofol MCT; Propofol Rovi; Propofolum [Latin]; Rovi Brand of Propofol; Schering Brand of Propofol; Zeneca Brand of Propofol; AM-149; DDS-04F; Diprivan (TN); Propofol IDD-D; Propofol-Lipuro; ZD-0859; Ghl.PD_Mitscher_leg0.558; Propofol [USAN:INN:BAN]; Propofol (JAN/USAN/INN); Propofol(2,6-Diisopropylphenol); 2, 6-Diisopropylphenol; 2,6 Diisopropylphenol; 2,6-Bis(1-methylethyl)phenol; 2,6-Bis(Isopropyl)-phenol; 2,6-DIISOPROPYLPHENOL; 2,6-Diisopropyl phenol; 2,6-Diisopropylphenol; 2,6-bis(1-methylethyl)-phenol; 2,6-di(propan-2-yl)phenol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:44915	DB00818	DR00424	DR1365	178.27	C12H18O	20.2	135	3.8	13	1	1	2	"1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3"	CC(C)C1=C(C(=CC=C1)C(C)C)O	OLBCVFGFOZPWHH-UHFFFAOYSA-N
DG00141	Abacavir	441300	"Trizivir; Ziagen; Abacavir [INN]; Abacavir (INN); Ziagen (TN); Ziagen (TM)(*Succinate salt*); [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol; {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; (+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; (+/-)-Abacavir; (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ABC"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:421707	DB01048	DR00588	DR0027	286.33	C14H18N6O	102	414	0.9	21	3	6	4	"1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m1/s1"	C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO	MCGSCOLBFJQGHM-SCZZXKLOSA-N
DG00142	Trimethoprim	5578	Abaprim; Alprim; Anitrim; Antrima; Antrimox; Bacdan; Bacidal; Bacide; Bacin; Bacta; Bacterial; Bacticel; Bactin; Bactoprim; Bactramin; Bencole; Bethaprim; Biosulten; Briscotrim; Chemotrin; Cidal; Colizole; Conprim; Cotrimel; Deprim; Duocide; Esbesul; Espectrin; Euctrim; Exbesul; Fermagex; Fortrim; Futin; Idotrim; Ikaprim; Instalac; Kombinax; Lagatrim; Lastrim; Methoprim; Metoprim; Monoprim; Monotrim; Monotrimin; Novotrimel; Omstat; Oraprim; Pancidim; Polytrim; Priloprim; Primosept; Primsol; Proloprim; Protrin; Purbal; Resprim; Roubac; Roubal; Salvatrim; Setprin; Sinotrim; Stopan; Streptoplus; Sugaprim; Sulfamar; Sulfamethoprim; Sulfoxaprim; Sulmeprim; Sulthrim; Sultrex; Syraprim; Tiempe; Toprim; Trimanyl; Trimethioprim; Trimethoprime; Trimethoprimum; Trimethopriom; Trimetoprim; Trimetoprima; Trimexazole; Trimexol; Trimezol; Trimogal; Trimono; Trimopan; Trimpex; Triprim; Trisul; Trisulcom; Trisulfam; Trisural; Uretrim; Urobactrim; Utetrin; Velaten; Wellcoprim; Wellcoprin; Xeroprim; Zamboprim; Bacterial [Antibiotic]; Colizole DS; Component of Bactrim; Component of Septra; Lagatrim Forte; ResprimForte; Septrin DS; Septrin Forte; Septrin S; Trimetoprim [DCIT]; Trimetoprim [Polish]; BW 5672; KUC103659N; NIH 204; T 7883; Trimpex 200; WR 5949; Alcorim-F; Apo-Sulfatrim; BW 56-72; Co-Trimoxizole; Monotrim (TN); NIH 204 (VAN); Proloprim (TN); Smz-Tmp; Sulfamethoxazole & Trimethoprim; TCMDC-125538; Tmp-Ratiopharm; Trimeth/Sulfa; Trimethopim(TMP); Trimethoprim & VRC3375; Trimethoprime [INN-French]; Trimethoprimum [INN-Latin]; Trimetoprima [INN-Spanish]; Trimez-IFSA; Trimpex (TN); Triprim (TN); U-Prin; Uro-D S; BW-56-72; KSC-4-158; AZT + TMP/SMX (mixture) combination; Trimethoprim (JAN/USP/INN); Trimethoprim [USAN:BAN:INN:JAN]	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:45924	DB00440	DR00590	DR1648	290.32	C14H18N4O3	106	307	0.9	21	2	7	5	"1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)"	COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N	IEDVJHCEMCRBQM-UHFFFAOYSA-N
DG00143	Cefotetan	53025	"Cefotetanum; Apatef (TN); Cefotan (TN); Cefotetan (JP15/USP/INN); (6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3499	DB01330	DR01386	.	575.6	C17H17N7O8S4	321	1090	0.1	36	4	15	9	"1S/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30)/t13 ,15-,17+/m1/s1"	CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)O)S4)OC)SC2)C(=O)O	SRZNHPXWXCNNDU-RHBCBLIFSA-N
DG00144	Imatinib	5291	Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:45783	DB00619	DR00032	.	493.6	C29H31N7O	86.3	706	3.5	37	2	7	7	"1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)"	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5	KTUFNOKKBVMGRW-UHFFFAOYSA-N
DG00145	Apramycin	3081545	AC1O533Z; XZNUGFQTQHRASN-PHTOHMOASA-N	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	CHEBI:2790	DB04626	.	.	539.6	C21H41N5O11	284	760	-7	37	11	16	6	"1S/C21H41N5O11/c1-26-11-14(30)18-8(33-20(11)37-21-16(32)13(29)10(25)9(4-27)34-21)3-7(24)19(36-18)35-17-6(23)2-5(22)12(28)15(17)31/h5-21,26-32H,2-4,22-25H2,1H3/t5-,6+,7-,8+,9-,10-,11+,12+,13+,14-,15-,16-,17-,18+,19+,20-,21-/m1/s1"	CN[C@H]1[C@H]([C@@H]2[C@H](C[C@H]([C@H](O2)O[C@@H]3[C@H](C[C@H]([C@@H]([C@H]3O)O)N)N)N)O[C@@H]1O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)N)O)O)O	XZNUGFQTQHRASN-XQENGBIVSA-N
DG00146	Vancomycin	14969	"Vancomycin (oral, MRSA), AuricX; Vancomycin (oral/pill, MSRA); Vancomycin (oral/pill, MSRA), AuricX/SRI International"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:28001	DB00512	.	DR2170	1449.2	C66H75Cl2N9O24	531	2960	-2.6	101	19	26	13	"1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1"	C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O	MYPYJXKWCTUITO-LYRMYLQWSA-N
DG00147	Ketoconazole	456201	"KCZ; KTZ; K 1003; R 41400; R41400; KS-1205; KW-1414; Perkhotal (TN); R 41,400; R-41400; R41,400; Ketoconazole [USAN:INN:BAN:JAN]; Nizoral, Extina, Xolegel, Kuric, Ketoconazole; Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine; Cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; CIS-1-ACETYL-4-(4-((2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZINE; (+-)-cis-1-Acetyl-4-(p-((2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine; (+/-)-cis-1-Acetyl-4-(4-[(2-[2,4-dichlorophenyl]-2-[1H-imidazol-1-ylmethyl]-1,3-dioxolan-4-yl)-methoxy]phenyl)piperazine; (+/-)-cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone; 1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:48336	DB01026	.	.	531.4	C26H28Cl2N4O4	69.1	735	4.3	36	0	6	7	"1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m0/s1"	CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl	XMAYWYJOQHXEEK-OZXSUGGESA-N
DG00148	Etoposide	36462	"Etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; Zuyeyidal; Etoposidum; Etoposido; Vepesid J; Eposin; Etoposidum [INN-Latin]; Etoposide (VP16); VP 16-213; VP 16 (pharmaceutical); Etoposido [INN-Spanish]; Etopophos (phosphate salt); VP-16-213; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; VP 16213; UNII-6PLQ3CP4P3; NK 171; NSC 141540; CCRIS 2392; HSDB 6517; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); EINECS 251-509-1; NSC-141540; Eposide; Etopol; Etosid; Vepeside; Demethyl EpipodophyllotoxinEthylidine Glucoside; E0675; Demethyl-epiodophyllotoxin ethylidene glucoside; Epipodophyllotoxin VP-16213; Eposin (TN); Etopophos (TN); Trans-Etoposide; VePESID (TN); Vepesid (TN); DEMETHY-EPIPODOPHYLLOTOXIN, ETHYLIDENE GLUCOSIDE; VP-16 (TN); Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; Etoposide (JP15/USP/INN); Etoposide [USAN:INN:BAN:JAN]; Eposin, Vepesid, VP-16, Toposar, Etoposide; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI); Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin ethylidene-beta-D-glucoside; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; 4-Demethylepipodophyllotoxin-beta-D-ethylideneglucoside"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4911	DB00773	DR00162	DR0669	588.6	C29H32O13	161	969	0.6	42	3	13	5	"1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1"	C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O	VJJPUSNTGOMMGY-MRVIYFEKSA-N
DG00149	Chlorpheniramine	2725	"Allergican; Allergisan; Antagonate; Chloropheniramine; Chlorophenylpyridamin; Chlorophenylpyridamine; Chloropiril; Chloroprophenpyridamine; Chlorphenamine; Chlorphenaminum; Chlorpheniraminum; Chlorprophenpyridamine; Clofeniramina; Clorfenamina; Clorfeniramina; Cloropiril; Haynon; Hayon; Histadur; ISOCLOR; Kloromin; Phenetron; PiriIton; Piriton; Polaronil; Telachlor; Teldrin; Chlorphenamine [INN]; Clorfeniramina [Italian]; Pediacare Allergy Formula; [3H]Chlorpheniramine; Aller-Chlor; Chlo-amine; Chlor-Pro; Chlor-Trimeton Repetabs; Chlor-trimeton; Chlorphenamine (INN); Chlorphenaminum [INN-Latin]; Clofeniramina (TN); Clorfenamina [INN-Spanish]; Comakin (TN); Gen-Allerate; Novo-Pheniram; Piriton (TN); Chlor-Trimeton (TN); Chlor-Tripolon (TN); CHLORPHENIRAMINE (SEE ALSO: CHLORPHENIRAMINE MALEATE (CAS113-92-8)); Gamma-(4-Chlorophenyl)-gamma-(2-pyridyl)propyldimethylamine; Gamma-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Chloro-alpha-(2-(dimethylamino)ethyl)benzyl)pyridine; 3-(4-chlorophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine; 4-Chloropheniramine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:52010	DB01114	.	DR0303	274.79	C16H19ClN2	16.1	249	3.4	19	0	2	5	"1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3"	CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2	SOYKEARSMXGVTM-UHFFFAOYSA-N
DG00150	Iprodione	37517	"IPRODIONE; 36734-19-7; Rovral; Glycophene; Glycophen; Promidione; Iprodial; Verisan; Kidan; Rovral flo; Rovral PM; Rovrol; Anfor; Rovral 50WP; Chipco 26019; 3-(3,5-Dichlorophenyl)-N-isopropyl-2,4-dioxoimidazolidine-1-carboxamide; NRC 910; LFA 2043; Iprodione [ANSI:BSI:ISO]; 3-(3,5-Dichlorophenyl)-N-(1-methylethyl)-2,4-dioxo-1-imidazolidinecarboxamide; Caswell No. 470A; Iprodine; ROP 500 F; MRC 910; UNII-S3AYV2A6EU; 26019 rp; RP 26019; FA 2071; 1-Imidazolidinecarboxamide, 3-(3,5-dichlorophenyl)-N-(1-methylethyl)-2,4-dioxo-; HSDB 6855"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:28909	DB00215	.	.	330.16	C13H13Cl2N3O3	69.7	448	3.1	21	1	3	2	"1S/C13H13Cl2N3O3/c1-7(2)16-12(20)17-6-11(19)18(13(17)21)10-4-8(14)3-9(15)5-10/h3-5,7H,6H2,1-2H3,(H,16,20)"	CC(C)NC(=O)N1CC(=O)N(C1=O)C2=CC(=CC(=C2)Cl)Cl	ONUFESLQCSAYKA-UHFFFAOYSA-N
DG00151	Paclitaxel	36314	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:45863	DB01229	DR00342	DR1227	853.9	C47H51NO14	221	1790	2.5	62	4	14	14	"1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1"	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C	RCINICONZNJXQF-MZXODVADSA-N
DG00153	Temozolomide	5394	"Methazolastone; Temodal; Temodar; Temozolamide; Temozolodida; Temozolomidum; Essex brand of temozolomide; Scheringbrand of temozolomide; Temozolodida [Spanish]; Temozolomidum [Latin]; M B 39831; MB 39831; Sch 52365; M & B 39831; M&B 39831; M-39831; Sch-52365; Schering-Plough brand of temozolomide; TMZ-Bioshuttle; Temodal (TN); Temodar (TN); Temozolomide [INN:BAN]; M&B-39831; Temozolomide (JAN/USAN/INN); 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; TMZ"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:72564	DB00853	.	.	194.15	C6H6N6O2	106	315	-1.1	14	1	5	1	"1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)"	CN1C(=O)N2C=NC(=C2N=N1)C(=O)N	BPEGJWRSRHCHSN-UHFFFAOYSA-N
DG00154	Epirubicin	41867	"Ellence; Epiadriamycin; Epidoxorubicin; Epirubicina; Epirubicine; Epirubicinum; Pidorubicin; Pidorubicina; Pidorubicine; Pidorubicinum; Ridorubicin; Epirubicina [Spanish]; Epirubicine [French]; Epirubicinum [Latin]; Pharmorubicin Pfs; IMI 28; WP 697; Ebewe (TN); Ellence (TN); Epi-DX; Epirubicin (INN); Epirubicin (TN); Epirubicin [INN:BAN]; Epirubicina [INN-Spanish]; Epirubicine [INN-French]; Epirubicinum [INN-Latin]; Farmorubicin (TN); Pharmorubicin (TN); Pidorubicina [INN-Spanish]; Pidorubicine [INN-French]; Pidorubicinum [INN-Latin]; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 4'-Epi-DXR; 4'-Epiadriamycin; 4'-epi-DX; 4'-epi-Doxorubicin; 4'-epidoxorubicin; 4-Epidoxorubicin"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:47898	DB00445	DR00170	DR0591	543.5	C27H29NO11	206	977	1.3	39	6	12	5	"1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1"	C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O	AOJJSUZBOXZQNB-VTZDEGQISA-N
DG00156	Ceftobiprole	135413542	"BAL 9141; BAL 9141-000; BAL-9141; Ro 63-9141; Ro-63-9141; Ro-63-9141/000; (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-ylidene)-2-nitrosoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-pyrrolidin-3-yl]pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:140407	DB04918	.	.	534.6	C20H22N8O6S2	257	1100	-2.4	36	5	13	6	"1S/C20H22N8O6S2/c21-20-24-14(26-36-20)11(25-34)15(29)23-12-17(31)28-13(19(32)33)9(7-35-18(12)28)5-8-2-4-27(16(8)30)10-1-3-22-6-10/h5,10,12,18,22,34H,1-4,6-7H2,(H,23,29)(H,32,33)(H2,21,24,26)/b8-5+,25-11-/t10-,12-,18-/m1/s1"	C1CNC[C@@H]1N2CC/C(=C\\C3=C(N4[C@@H]([C@@H](C4=O)NC(=O)/C(=N\\O)/C5=NSC(=N5)N)SC3)C(=O)O)/C2=O	VOAZJEPQLGBXGO-SDAWRPRTSA-N
DG00157	Telbivudine	159269	"Epavudine; LLT; LdT; Sebivo; Telbivudin; Tyzeka; Telbivudine [USAN]; LDT600; NB 02B; NV 02B; L-Deoxythymidine; L-Thymidine; L-dT; LDT-600; NV-02B; Tyzeka (TN); Beta-L-Thymidine; Telbivudine (USAN/INN); Tyzake/Sebivo (TN); Tyzeka, Sebivo, Telbivudine; 1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-(2-Deoxy-beta-L-erythropentafuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; 2'-Deoxy-L-thymidine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63624	DB01265	.	.	242.23	C10H14N2O5	99.1	381	-1.2	17	3	5	2	"1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1"	CC1=CN(C(=O)NC1=O)[C@@H]2C[C@H]([C@@H](O2)CO)O	IQFYYKKMVGJFEH-CSMHCCOUSA-N
DG00158	Loperamide	3955	Ioperamide; Loperacap; Loperamida; Loperamidum; Kaopectate II; Loperamide Monohydrochloride; Pepto Diarrhea Control; Apo-Loperamide; Diamide (TN); Diarr-Eze; Dimor (TN); Imodium (TN); Imodium A-D Caplets; Loperamida [INN-Spanish]; Loperamide (INN); Loperamide [INN:BAN]; Loperamidum [INN-Latin]; Lopex (TN); Maalox Anti-Diarrheal; Nu-Loperamide; PMS-Loperamide; Pepto (TN); R-18553; Rho-Loperamide	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6532	DB00836	DR00171	.	477	C29H33ClN2O2	43.8	623	5	34	1	3	7	"1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3"	CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4	RDOIQAHITMMDAJ-UHFFFAOYSA-N
DG00159	Cyclophosphamide	2907	"ASTA; Ciclofosfamida; Ciclophosphamide; Clafen; Claphene; Cycloblastin; Cyclophosphamid; Cyclophosphamides; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cytophosphan; Cytophosphane; Cytoxan; Endoxan; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Mitoxan; Neosar; Procytox; Revimmune; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; Ciclophosphamide [INN]; Cyclophosphamide Sterile; Cyclophosphamide anhydrous; Cyklofosfamid [Czech]; Cytoxan Lyoph; Endoxan R; Lyophilized Cytoxan; Zyklophosphamid [German]; ASTA B518; Asta B 518; B 518; C 0768; CB 4564; SK 20501; B-518; CB-4564; Ciclofosfamida [INN-Spanish]; Cyclophosphamide (INN); Cyclophosphamide (TN); Cyclophosphamide (anhydrous form); Cyclophosphamide (anhydrous); Cyclophosphamidum [INN-Latin]; Cytoxan (TN); Endoxan (TN); Endoxan-Asta; Neosar (TN); Occupation, cyclophosphamide exposure; Procytox (TN); Revimmune (TN); Bis(2-Chloroethyl)phosphami de cyclic propanolamide; Bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; D,L-Cyclophosphamide; Cyclophosphamide, (+-)-Isomer; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; (+-)-Cyclophosphamide; (-)-Cyclophosphamide; (RS)-Cyclophosphamide; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; 4-Hydroxy-cyclophosphan-mamophosphatide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4027	DB00531	DR00425	DR0391	261.08	C7H15Cl2N2O2P	41.6	212	0.6	14	1	4	5	"1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)"	C1CNP(=O)(OC1)N(CCCl)CCCl	CMSMOCZEIVJLDB-UHFFFAOYSA-N
DG00161	Epothilone B	448013	"Epothilone B; Patupilone; 152044-54-7; (-)-Epothilone B; Epo B; EpoB; EPO906; EPO 906; UNII-UEC0H0URSE; EPO 906A; GNF-PF-193; CHEBI:31550; UEC0H0URSE; AK163080; Epothilone B (EPO906, Patupilone); 7,11-DIHYDROXY-8,8,10,12,16-PENTAMETHYL-3-[1-METHYL-2-(2-METHYL-THIAZOL-4-YL)VINYL]-4,17-DIOXABICYCLO[14.1.0]HEPTADECANE-5,9-DIONE; Epothilon B; Patupilone [INN]; (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31550	DB03010	.	DR1795	507.7	C27H41NO6S	138	816	4.2	35	2	8	2	"1S/C27H41NO6S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)33-23(30)13-21(29)26(5,6)25(32)17(3)24(15)31/h11,14-15,17,20-22,24,29,31H,8-10,12-13H2,1-7H3/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1"	C[C@H]1CCC[C@@]2([C@@H](O2)C[C@H](OC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C3=CSC(=N3)C)/C)C	QXRSDHAAWVKZLJ-PVYNADRNSA-N
DG00162	Haloperidol	3559	Aldo; Aloperidin; Aloperidol; Aloperidolo; Aloperidon; Bioperidolo; Brotopon; Dozic; Dozix; Eukystol; Fortunan; Galoperidol; Haldol; Halidol; Halojust; Halol; Halopal; Haloperido; Haloperidolum; Halopidol; Halopoidol; Halosten; Keselan; Linton; Mixidol; Pekuces; Peluces; Peridol; Pernox; Serenace; Serenase; Serenelfi; Sernas; Sernel; Sigaperidol; Ulcolind; Uliolind; Vesalium; Aloperidolo [DCIT]; Aloperidolo [Italian]; Einalon S; Haldol La; Haldol Solutab; Lealgin compositum; Pms Haloperidol; H 1512; R 1625; Aloperidin (TN); Apo-Haloperidol; Bioperidolo (TN); Brotopon (TN); Dozic (TN); Duraperidol (TN); Einalon S (TN); Eukystol (TN); Haldol (TN); Haloperidolum [INN-Latin]; Halosten (TN); Keselan (TN); Linton (TN);Novo-Peridol; Peluces (TN); R-1625; Serenace (TN); Serenase (TN); Sigaperidol (TN); Haloperidol (JP15/USP); McN-JR-1625; Haloperidol (JP15/USP/INN); Haloperidol [USAN:INN:BAN:JAN]	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:5613	DB00502	DR00426	.	375.9	C21H23ClFNO2	40.5	451	3.2	26	1	4	6	"1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2"	C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F	LNEPOXFFQSENCJ-UHFFFAOYSA-N
DG00163	Cefotaxime	5742673	Cefotaxim; Cefotaxima; Cefotaximum; Cephotaxim; Cephotaxime; Claforan; Klaforan; Cefotaxim Hikma; Cefotaxime acid; CE3; RU 24662; Cefotaxim Hikma (TN); Cefotaxima [INN-Spanish]; Cefotaxime (INN); Cefotaxime [INN:BAN]; Cefotaximum [INN-Latin]; Claforan (TN); Ru-24756; Claforan (*Sodium salt*)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:204928	DB00493	.	DR2226	455.5	C16H17N5O7S2	227	833	-1.4	30	3	12	8	"1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1"	CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OC)/C3=CSC(=N3)N)SC1)C(=O)O	GPRBEKHLDVQUJE-QSWIMTSFSA-N
DG00164	Prednisolone	5755	"Nanocort; Prednisolone (injectable liposome formulation, rheumatoid arthritis); Prednisolone (injectable liposome formulation, rheumatoid arthritis), Enceladus; Prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8378	DB00860	DR00428	DR1332	360.4	C21H28O5	94.8	724	1.6	26	3	5	2	"1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1"	C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O	OIGNJSKKLXVSLS-VWUMJDOOSA-N
DG00165	Metformin	4091	"657-24-9; 1,1-Dimethylbiguanide; N,N-dimethylimidodicarbonimidic diamide; Metiguanide; Dimethylbiguanide; Glucophage; Haurymelin; Gliguanid; Fluamine; Glumetza; Flumamine; Melbin; Diabex; N,N-Dimethylbiguanide; Metformina; Metforminum; Metformine; Islotin; Glifage; Siofor; N1,N1-Dimethylbiguanide; DMGG; NNDG; Dimethyldiguanide; N,N-Dimethyldiguanide; Metformina [DCIT]; Imidodicarbonimidic diamide, N,N-dimethyl-; Metformina [Spanish]; Metforminum [INN-Latin]; Metformine [INN-French]; Metformin [USAN:INN:BAN]; 1,1-Dimethyl; Diabetosan; Dimethylbiguanidine; Dimethylguanylguanidine; Glycon; Diabex (TN); Diaformin (TN); Dianben (TN); Fortamet (TN); Gen-Metformin; Glucophage (TN); Glumetza (TN); LA-6023; Nu-Metformin; Obimet (TN); Riomet (TN); Metformin (USAN/INN); 1,1-Dimethyl biguanide; 3-(diaminomethylidene)-1,1-dimethylguanidine; [14C]metformin"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6801	DB00331	DR00133	.	129.16	C4H11N5	91.5	132	-1.3	9	3	1	2	"1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)"	CN(C)C(=N)N=C(N)N	XZWYZXLIPXDOLR-UHFFFAOYSA-N
DG00166	Tenofovir	464205	"Apropovir; PMPA; TFV; Tenefovir; GS 1275; GS 1278; GS1278; GNA & Tenofovir; HHA & Tenofovir; KS-5021; Viread (TN); Viread, Tenofovir; D,L-Tenofovir; PMPA-(R); Phosphonic acid, [[2-(6-amino-9H-purin-9; [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid; Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-(9CI); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Galanthus nivalis agglutinin (GNA); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Hippeastrum hybrid agglutinin(HHA); (R)-9-(2-Phosphonomethoxypropyl)adenine; (R)-9-(2-Phosphonylmethoxypropyl)adenine; (R)-PMPA"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63625	DB14126	DR00174	.	287.21	C9H14N5O4P	136	354	-1.6	19	3	8	5	"1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1"	C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O	SGOIRFVFHAKUTI-ZCFIWIBFSA-N
DG00167	Pyronaridine	107771	"Malaridine; Pyronaridine phosphate salt; Benzonaphthyridine 7351; 2-Methoxy-7-chloro-10-(3',5'-bis(pyrrolin-1-ylmethyl)-4'-hydroxyphenylamino)benzo(b)-1,5-naphthyridine; 4-((7-Chloro-2-methoxybenzo(b)-1,5-naphthyridin-10-yl)amino)-2,6-bis(1-pyrrolidinylmethyl)phenol; 4-[(7-chloro-2-methoxy-1,5-dihydrobenzo[b][1,5]naphthyridin-10-yl)imino]-2,6-bis(pyrrolidin-1-ylmethyl)cyclohexa-2,5-dien-1-one; 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:135951	DB12975	.	.	518	C29H32ClN5O2	73.8	707	5.3	37	2	7	7	"1S/C29H32ClN5O2/c1-37-26-9-8-24-28(33-26)27(23-7-6-21(30)16-25(23)32-24)31-22-14-19(17-34-10-2-3-11-34)29(36)20(15-22)18-35-12-4-5-13-35/h6-9,14-16,36H,2-5,10-13,17-18H2,1H3,(H,31,32)"	COC1=NC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NC4=CC(=C(C(=C4)CN5CCCC5)O)CN6CCCC6	DJUFPMUQJKWIJB-UHFFFAOYSA-N
DG00168	Fentanyl	3345	"Fentanyl; Fentanil; Phentanyl; Fentora; Sublimaze; Fentanila; Fentanest; Duragesic; Fentanylum; Durogesic; Sentonil; 437-38-7; Duragesic-100; IONSYS; Duragesic-25; Duragesic-75; Duragesic-50; Duragesic-12; Fentanyl-25; Fentanyl-75; Fentanyl-12; Fentanyl-50; Fentanylum [INN-Latin]; Fentanila [INN-Spanish]; Fentanyl-100; 1-Phenethyl-4-N-propionylanilinopiperidine; Matrifen; Sublimase; N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide; N-(1-Phenethyl-4-piperidyl)propionanilide; N-Phenethyl-4-(N-propionylanilino)piperidine; Fentanil [DCIT]; Subsys; Fentanyl-37; Fentanyl-62; Fentanyl-87; Abstral; Actiq; Lazanda; Onsolis; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Sublimaze Preservative Free; fentanyl (transmucosal film, pain), Auxilium Pharmaceuticals"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:119915	DB00813	DR00430	.	336.5	C22H28N2O	23.6	391	4	25	0	2	6	"1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3"	CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3	PJMPHNIQZUBGLI-UHFFFAOYSA-N
DG00169	Quinupristin	5388937	"Quinupristina; Quinupristine; Quinupristinum; SYB; RP 57669; Quinupristin [USAN:INN]; Quinupristina [INN-Spanish]; Quinupristine [INN-French]; Quinupristinum [INN-Latin]; RP-57669; Synercid (TN); Quinupristin (JAN/USAN/INN); 4-[4-(DIMETHYLAMINO)-N-METHYL-L-PHENYLALANINE]-5-[(2S,5R)-5-[[[(3S)-1-AZABICYCLO-[2.2.2]OCT-3-YL]THIO]METHYL]-4-OXO-2-PIPERIDINECARBOXYLIC ACID]VIRGINIAMYCIN; 5delta-(3-quinuclidinyl)thiomethylpristinamycin IA"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB01369	.	.	1022.2	C53H67N9O10S	257	2010	4.2	73	4	14	10	"1S/C53H67N9O10S/c1-6-37-50(68)61-23-11-14-38(61)51(69)59(5)40(26-32-16-18-36(19-17-32)58(3)4)52(70)62-28-35(30-73-43-29-60-24-20-33(43)21-25-60)42(64)27-39(62)47(65)57-45(34-12-8-7-9-13-34)53(71)72-31(2)44(48(66)55-37)56-49(67)46-41(63)15-10-22-54-46/h7-10,12-13,15-19,22,31,33,35,37-40,43-45,63H,6,11,14,20-21,23-30H2,1-5H3,(H,55,66)(H,56,67)(H,57,65)/t31-,35+,37-,38+,39+,40+,43-,44+,45+/m1/s1"	CC[C@@H]1C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)N3C[C@H](C(=O)C[C@H]3C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CS[C@@H]6CN7CCC6CC7)CC8=CC=C(C=C8)N(C)C)C	WTHRRGMBUAHGNI-LCYNINFDSA-N
DG00170	Cefditoren	9870843	"Cefditoren [USAN:INN]; Meiact (TN); Spectracef (TN); (+)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-((Z)-2-(4-methyl-5-thiazolyl)vinyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime); (6R-(3(Z),6alpha,7beta(Z)))-7-((2-Amino-4-thiazolyl)(methoxyimino)acetyl)amino-3-(2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:59343	DB01066	DR01394	.	506.6	C19H18N6O5S3	242	928	0.7	33	3	12	7	"1S/C19H18N6O5S3/c1-8-11(33-7-21-8)4-3-9-5-31-17-13(16(27)25(17)14(9)18(28)29)23-15(26)12(24-30-2)10-6-32-19(20)22-10/h3-4,6-7,13,17H,5H2,1-2H3,(H2,20,22)(H,23,26)(H,28,29)/b4-3-,24-12-/t13-,17-/m1/s1"	CC1=C(SC=N1)/C=C\\C2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O	KMIPKYQIOVAHOP-YLGJWRNMSA-N
DG00171	Platinum	23939	"Precision tolerogens (autoimmune disease), NaniRx"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:33364	DB12257	.	.	195.08	Pt	0	0	.	1	0	0	0	1S/Pt	[Pt]	BASFCYQUMIYNBI-UHFFFAOYSA-N
DG00173	Plazomicin	42613186	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB12615	.	DR2136	592.7	C25H48N6O10	269	873	-6.2	41	11	15	13	"1S/C25H48N6O10/c1-25(37)11-38-24(18(35)21(25)29-2)41-20-15(31-22(36)16(33)5-6-26)9-14(28)19(17(20)34)40-23-13(27)4-3-12(39-23)10-30-7-8-32/h3,13-21,23-24,29-30,32-35,37H,4-11,26-28H2,1-2H3,(H,31,36)/t13-,14+,15-,16+,17+,18-,19-,20+,21-,23-,24-,25+/m1/s1"	C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC=C(O3)CNCCO)N)N)NC(=O)[C@H](CCN)O)O	IYDYFVUFSPQPPV-PEXOCOHZSA-N
DG00174	Dasatinib	3062316	"Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:49375	DB01254	DR00182	DR0423	488	C22H26ClN7O2S	135	642	3.6	33	3	9	7	"1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)"	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO	ZBNZXTGUTAYRHI-UHFFFAOYSA-N
DG00175	Capreomycin	3000502	"Capreomycin Sulfate Standard; Capreomycin sulphate; Caprocin (Disulfate); Ogostal (Disulfate); (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide; (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00314	.	.	1321.4	C50H88N28O15	737	2470	.	93	27	23	19	"1S/C25H44N14O8.C25H44N14O7/c26-4-1-2-11(27)6-17(41)32-8-14-20(43)35-15(9-34-25(30)47)21(44)39-18(13-3-5-31-24(29)38-13)23(46)33-7-12(28)19(42)37-16(10-40)22(45)36-14;1-11-19(41)36-15(9-32-17(40)7-12(27)3-2-5-26)21(43)37-16(10-34-25(30)46)22(44)39-18(14-4-6-31-24(29)38-14)23(45)33-8-13(28)20(42)35-11/h9,11-14,16,18,40H,1-8,10,26-28H2,(H,32,41)(H,33,46)(H,35,43)(H,36,45)(H,37,42)(H,39,44)(H3,29,31,38)(H3,30,34,47);10-15,18H,2-9,26-28H2,1H3,(H,32,40)(H,33,45)(H,35,42)(H,36,41)(H,37,43)(H,39,44)(H3,29,31,38)(H3,30,34,46)/b15-9+;16-10+/t11-,12-,13+,14-,16-,18-;11-,12-,13-,14+,15-,18-/m00/s1"	C[C@H]1C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N[C@H](C(=O)NC[C@@H](C(=O)N1)N)[C@H]2CCN=C(N2)N)CNC(=O)C[C@H](CCCN)N.C1CN=C(N[C@H]1[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N2)CNC(=O)C[C@H](CCCN)N)CO)N)N	VCOPTHOUUNAYKQ-WBTCAYNUSA-N
DG00176	Vorinostat	5311	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:45716	DB02546	DR00769	DR1710	264.32	C14H20N2O3	78.4	276	1.9	19	3	3	8	"1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)"	C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO	WAEXFXRVDQXREF-UHFFFAOYSA-N
DG00177	Temsirolimus	6918289	Torisel	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:79699	DB06287	DR00432	DR1548	1030.3	C56H87NO16	242	2010	5.6	73	4	16	11	"1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1"	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC	CBPNZQVSJQDFBE-FUXHJELOSA-N
DG00178	Tipranavir	54682461	"Aptivus; TPV; PNU 140690; U 140690; Aptivus (Boehringer Ingelheim); Aptivus (TN); Aptivus(TM); PNU-140690; PNU-140690E; Tipranavir (INN); U-140690; N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-phenethyl-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide; N-(3-{(1R)-1-[(6R)-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-5,6-DIHYDRO-2H-PYRAN-3-YL]PROPYL}PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63628	DB00932	.	DR1601	602.7	C31H33F3N2O5S	114	1050	7	42	2	10	11	"1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1"	CCC[C@]1(CC(=C(C(=O)O1)[C@H](CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4	SUJUHGSWHZTSEU-FYBSXPHGSA-N
DG00179	Fludarabine	657237	"FaraA; Fludarabina; Fludarabinum; Fluradosa; Fludarabina [Spanish]; Fludarabine [INN]; Fludarabinum [Latin]; SQ Fludarabine; Fludara, Fludarabine; Fludarabine (INN); Fluradosa (TN); F-Ara-A; (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-F-ara-A; 2-Fluoro Ara-A; 2-Fluoro-9-beta-D-arabinofuranosyladenine; 9-beta-D-Arabinofuranosyl-2-fluoroadenine; 9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine; 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro-(9CI)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:94701	DB01073	DR00434	.	285.23	C10H12FN5O4	140	367	-0.6	20	4	9	2	"1S/C10H12FN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6+,9-/m1/s1"	C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N	HBUBKKRHXORPQB-FJFJXFQQSA-N
DG00180	Aztreonam	5742832	"Azactam; Primbactam; Azactam (TN); SQ-26776; Monobactam, SQ 26776, Squibb 26776, Aztreonam; [2S-[2alpha,3beta(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid; 2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid; 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:161680	DB00355	.	DR0169	435.4	C13H17N5O8S2	238	808	0.3	28	4	12	7	"1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8-/t5-,7-/m0/s1"	C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\\OC(C)(C)C(=O)O)/C2=CSC(=N2)N	WZPBZJONDBGPKJ-VEHQQRBSSA-N
DG00181	Fosamprenavir	131536	"Telzir; Amprenavir phosphate; Fosamprenavir [INN]; GW 433908; GW433908; VX 175; Fosamprenavir (INN); Lexiva (TM); Lexiva (TN); Telzir (TN); Telzir(TM); VX-175; GW433908A (*Sodium Salt*); GW433908G (*Calcium Salt*); [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester; ((3S)Oxolan-3-yloxy)-N-((1S,2R)-3-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-1-benzyl-2-(phosphonooxy)propyl)carboxamide; (3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:82941	DB01319	DR01274	DR0745	585.6	C25H36N3O9PS	186	912	1.8	39	4	11	14	"1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1"	CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N	MLBVMOWEQCZNCC-OEMFJLHTSA-N
DG00182	Spiramycin	6419898	"Spiramycin; 8025-81-8; ST075006; Spiramycinum; Spiramycine; Provamycin; Sequamycin; Espiramicin; Rovamycin; Antibiotic 799; NSC-64393; RP 5337; Rovamycine; Prestwick_121; 5337 R.P.; Prestwick2_000745; Prestwick3_000745; AC1O4WG0; Spiramycin antibiotic complex; BPBio1_000804; SCHEMBL5032756; AKOS015896378; K430; SR-01000872632; SR-01000872632-1; I06-1973; Spiramycin, European Pharmacopoeia (EP) Reference Standard; Spiramycin from Streptomyces sp., VETRANAL(TM), analytical standard; Spiramycin, Pharmaceutical Secondary Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB06145	.	.	843.1	C43H74N2O14	195	1370	2.1	59	4	16	11	"1S/C43H74N2O14/c1-24-21-29(19-20-46)39(59-42-37(49)36(45(9)10)38(27(4)56-42)58-35-23-43(6,51)41(50)28(5)55-35)40(52-11)31(47)22-33(48)53-25(2)15-13-12-14-16-32(24)57-34-18-17-30(44(7)8)26(3)54-34/h12-14,16,20,24-32,34-42,47,49-51H,15,17-19,21-23H2,1-11H3/b13-12+,16-14+/t24-,25-,26 ,27 ,28 ,29+,30 ,31-,32+,34 ,35 ,36 ,37 ,38 ,39+,40+,41 ,42 ,43 /m1/s1"	C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CC=O)C)OC4CCC(C(O4)C)N(C)C	ACTOXUHEUCPTEW-JMRHEKERSA-N
DG00183	Amoxicillin	33613	"AMPC; Actimoxi; Amoclen; Amolin; Amopen; Amopenixin; Amoxi; Amoxibiotic; Amoxicaps; Amoxicilina; Amoxicillanyl; Amoxicilline; Amoxicillinum; Amoxiden; Amoxil; Amoxivet; Amoxycillin; Anemolin; Aspenil; Biomox; Bristamox; Cemoxin; Clamoxyl; Delacillin; DisperMox; Efpenix; Flemoxin; Hiconcil; Histocillin; Hydroxyampicillin; Ibiamox; Imacillin; Lamoxy; Larotid; Moxacin; Moxal; Moxatag; Ospamox; Pamoxicillin; Piramox; Polymox; Robamox; Sumox; Tolodina; Trimox; Unicillin; Utimox; Vetramox; Wymox; AMOXICILLIN CRYSTALLINE; AMOXICILLIN PEDIATRIC; Amoxicillin anhydrous; Amoxicilline [INN]; Amoxycillin Trihydrate; Metafarma capsules; Metifarma capsules; Sawamox PM; BLP 1410; AMK (TN); Actimoxi (TN); Alphamox (TN); Amoksibos (TN); Amoksiklav (TN); Amoxi-Mast; Amoxibiotic (TN); Amoxicilina (TN); Amoxicilina [INN-Spanish]; Amoxicillin (INN); Amoxicillin (TN); Amoxicillin (anhydrous); Amoxicilline [INN-French]; Amoxicillinum [INN-Latin]; Amoxiclav (TN); Amoxidal (TN); Amoxil (TN); Amoxin (TN); Apo-Amoxi; Augmentin (TN); BL-P 1410; BRL-2333; Bactox (TN); Betalaktam (TN); Cilamox (TN); Clamoxyl (TN); Curam (TN); D-Amoxicillin; Dedoxil (TN); Dispermox (TN); Duomox (TN); Enhancin (TN); Geramox (TN); Gimalxina (TN); Hiconcil (TN); Isimoxin (TN); Klavox (TN); Lamoxy (TN); Moxatag (TN); Moxilen (TN); Moxypen (TN); Moxyvit (TN); Nobactam (TN); Novamoxin (TN); Ospamox (TN); P-Hydroxyampicillin; Pamoxicillin (TN); Panamox (TN); Panklav (TN); Polymox (TN); Ro 10-8756; Samthongcillin (TN); Sandoz (TN); Senox (TN); Sinacilin (TN); Tolodina (TN); Trimox (TN); Wymox (TN); Yucla (TN); Zerrsox (TN); Zimox (TN); Apo-Amoxi (TN); Alpha-Amino-p-hydroxybenzylpenicillin; D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid; D-(-)-alpha-Amino-p-hydroxybenzylpenicillin; (-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D-(8CI); 6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid; 6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin; 6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:2676	DB01060	DR00190	DR0104	365.4	C16H19N3O5S	158	590	-2	25	4	7	4	"1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1"	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C	LSQZJLSUYDQPKJ-NJBDSQKTSA-N
DG00184	Cephaloridine	5773	Cephaloridine; cefaloridine; Cefaloridin; Cephaloridin; Cephaloridinum; Cepaloridin; Cefalorizin; Cephalomycine; Cefaloridinum; Cepalorin; Cefaloridina; Loridine; Ceflorin; 50-59-9; Kefloridin; Glaxoridin; Ceporin; Vioviantine; Intrasporin; Sefacin; Keflordin; Deflorin; Cilifor; Ceporan; Sasperin; Faredina; Ceporine; Keflodin; Verolgin; Lloncefal; Kefspor; Ampligram; Betaine cephaloridine; CHEBI:3537; UNII-LVZ1VC61HB; Cefaloridinum [INN-Latin]; Cefaloridina [INN-Spanish]; N-(7-(2'-Thienylacetamidoceph-3-ylmethyl))-pyridinium-2-carboxylate; SCH 	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3537	DB09008	DR00612	DR0285	415.5	C19H17N3O4S2	147	687	1.9	28	1	6	5	"1S/C19H17N3O4S2/c23-14(9-13-5-4-8-27-13)20-15-17(24)22-16(19(25)26)12(11-28-18(15)22)10-21-6-2-1-3-7-21/h1-8,15,18H,9-11H2,(H-,20,23,25,26)/t15-,18-/m1/s1"	C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CS3)C(=O)[O-])C[N+]4=CC=CC=C4	CZTQZXZIADLWOZ-CRAIPNDOSA-N
DG00185	Anidulafungin	166548	Ecalta; Eraxis; Anidulafungin [USAN:INN]; Ecalta (TN); Eraxis (TN); LY-303366; V-Echinocandin; VER-002	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:55346	DB00362	.	.	1140.2	C58H73N7O17	377	2150	2.3	82	14	17	14	"1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1"	CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)O)O	JHVAMHSQVVQIOT-MFAJLEFUSA-N
DG00186	Rifampin	135398735	"Abrifam; Archidyn; Arficin; Arzide; Benemicin; Benemycin; Dipicin; Doloresum; Eremfat; Famcin; Fenampicin; RFP; RMP; Ramp; Rifa; Rifadin; Rifadine; Rifagen; Rifaldazin; Rifaldazine; Rifaldin; Rifam; Rifamor; Rifampicin; Rifampicina; Rifampicine; Rifampicinum; Rifamsolin; Rifaprodin; Rifcin; Rifinah; Rifobac; Rifoldin; Rifoldine; Riforal; Rimactan; Rimactane; Rimactazid; Rimactizid; Rimazid; Rimycin; Sinerdol; Tubocin; Rifamicin AMP; Rifampicin SV; Rifampicine [French]; Rifampin [USAN]; Rifamycin AMP; Ba 41166; AZT + Rifampin; BA-41166E; Ba 41166/E; DRG-0109; Dione 21-acetate; L-5103; L-5103 Lepetit; Piperine & Rifampicin; R-Cin; R/AMP; Reserpine & Rifampicin; Rifadin (TN); Rifadin I.V; Rifampicin & EEP; Rifampicin & Propolis; Rifampicina [INN-Spanish]; Rifampicinum [INN-Latin]; Rifampin (USP); Rimactan (TN); Rimactane (TN); Rimycin (TN); Sinerdol (TN); Tubocin (TN); Rifadin I.V.; Rifampicin (JP15/INN); Rifampicin[INN:BAN:JAN]; Rifadin, Rimactane, Rifampicin, Rifampin; 1-b]furan-21-yl acetate; 3-(((4-Methyl-1-piperazinyl)imino)-methyl)rifamycin; 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)-rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)rifamycin SV; 3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV; 3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV; 3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin; 8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 8-(4-Methylpiperazinyliminomethyl) rifamycin SV; 8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin; 8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv; 8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv; 8CI)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:28077	DB01045	DR00196	DR1420	822.9	C43H58N4O12	220	1620	4.9	59	6	15	5	"1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1"	C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C	JQXXHWHPUNPDRT-WLSIYKJHSA-N
DG00187	Tigecycline	54686904	"Tigilcycline; Tygacil; Tigecycline [USAN]; GAR 936; GAR-936; TBG-MINO; Tygacil (TN); Tygacil(TM); GAR-936,Tigecycline; Tigecycline (JAN/USAN); WAY-GAR-936; Tygacil, GAR-936, WAY-GAR-936, TBG-MINO, Tigecycline; N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide; (4S,12aS)-4,7-Bis(dimethylamino)-9-{2-[(tert-butyl)amino]acetylamino}-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide; (4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; (4S,4aS,5aR,12aS)-9-[(N-tert-butylglycyl)amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 9-t-Butylglycylamido minocycline"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:149836	DB00560	.	.	585.6	C29H39N5O8	206	1240	1.1	42	7	11	7	"1S/C29H39N5O8/c1-28(2,3)31-11-17(35)32-15-10-16(33(4)5)13-8-12-9-14-21(34(6)7)24(38)20(27(30)41)26(40)29(14,42)25(39)18(12)23(37)19(13)22(15)36/h10,12,14,21,31,36-37,40,42H,8-9,11H2,1-7H3,(H2,30,41)(H,32,35)/t12-,14-,21-,29-/m0/s1"	CC(C)(C)NCC(=O)NC1=CC(=C2C[C@H]3C[C@H]4[C@@H](C(=O)C(=C([C@]4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C	SOVUOXKZCCAWOJ-HJYUBDRYSA-N
DG00188	Thiostrepton	16129666	"Thiostrepton; Thiostrepton from Streptomyces azureus; Bryamycin; Thiactin; Alaninamide,; 1393-48-2; NSC81722; NSC170365; NSC 81722; NSC 170365; CHEMBL1981887; CHEBI:94340; MolPort-003-939-599; NSC-81722; NSC-170365; NCGC00485235-01; Thiostrepton from Streptomyces azureus, &gt"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB11467	.	.	1664.9	C72H85N19O18S5	701	3940	0.6	114	17	31	12	"1S/C72H85N19O18S5/c1-14-26(3)47-63(105)78-30(7)57(99)75-28(5)56(98)76-31(8)58(100)91-72-19-18-40(66-85-43(22-111-66)59(101)77-29(6)55(97)74-27(4)54(73)96)81-52(72)42-21-112-67(83-42)49(34(11)109-69(107)41-20-37(32(9)92)36-16-17-39(79-47)51(95)50(36)80-41)89-60(102)44-24-113-68(86-44)53(71(13,108)35(12)94)90-62(104)45-23-110-65(84-45)38(15-2)82-64(106)48(33(10)93)88-61(103)46-25-114-70(72)87-46/h15-17,20-22,24-26,30-35,39,45,47-49,51-53,79,92-95,108H,4-6,14,18-19,23H2,1-3,7-13H3,(H2,73,96)(H,74,97)(H,75,99)(H,76,98)(H,77,101)(H,78,105)(H,82,106)(H,88,103)(H,89,102)(H,90,104)(H,91,100)/b38-15+"	CCC(C)C1C(=O)NC(C(=O)NC(=C)C(=O)NC(C(=O)NC23CCC(=NC2C4=CSC(=N4)C(C(OC(=O)C5=NC6=C(C=CC(C6O)N1)C(=C5)C(C)O)C)NC(=O)C7=CSC(=N7)C(NC(=O)C8CSC(=N8)/C(=C\\C)/NC(=O)C(NC(=O)C9=CSC3=N9)C(C)O)C(C)(C(C)O)O)C1=NC(=CS1)C(=O)NC(=C)C(=O)NC(=C)C(=O)N)C)C	NSFFHOGKXHRQEW-DVRIZHICSA-N
DG00189	Cyclosporin A	5284373	Cyclosporin A; cyclosporine; Neoral; Cyclosporin; Ciclosporine; Sandimmun; Sang-35	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4031	DB00091	DR00448	DR0321	1202.6	C62H111N11O12	279	2330	7.5	85	5	12	15	"1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1"	CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C	PMATZTZNYRCHOR-CGLBZJNRSA-N
DG00190	Rifapentine	135403821	"RIFAPENTINE; Rifapentina; Rifapentinum; Cyclopentylrifampicin; Rifamycin AF/ACPP; Antibiotic DL 473IT; KTC 1; 61379-65-5; MDL 473; DRG-0283; DL 473; R-773; R 77-3; 3-(N-(4-Cyclopentyl-1-piperazinyl)formimidoyl)rifamycin; 3-(4-Cyclopentyl-1-piperazinyl)iminomethylrifamycin SV; 3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin; Rifapentin,(S); NCGC00167431-01; ZINC169621228; NCGC00167431-03; AN-15578; RPE"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:45304	DB01201	.	DR1421	877	C47H64N4O12	220	1730	6.7	63	6	15	6	"1S/C47H64N4O12/c1-24-13-12-14-25(2)46(59)49-37-32(23-48-51-20-18-50(19-21-51)31-15-10-11-16-31)41(56)34-35(42(37)57)40(55)29(6)44-36(34)45(58)47(8,63-44)61-22-17-33(60-9)26(3)43(62-30(7)52)28(5)39(54)27(4)38(24)53/h12-14,17,22-24,26-28,31,33,38-39,43,53-57H,10-11,15-16,18-21H2,1-9H3,(H,49,59)/b13-12+,22-17+,25-14-,48-23+/t24-,26+,27+,28+,33-,38-,39+,43+,47-/m0/s1"	C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C	WDZCUPBHRAEYDL-GZAUEHORSA-N
DG00191	Mefloquine	4046	"Lariam; Mefloquin; Mefloquina; Mefloquinone; Mefloquinum; Mephloquine; Racemic mefloquine; Ro 215998; WR 142490; Lariam (Hydrochloride); Lariam (TN); Mefaquin (TN); Mefloquina [INN-Spanish]; Mefloquinum [INN-Latin]; RO 13-7224; RO 13-7225; Ro 21-5998; SPB-80406; WR-142490; Mefloquine (USAN/INN); Mefloquine [USAN:INN:BAN]; RTI1169-1-1; RTI1172-1-1; RTI1173-1-1; RTI1174-1-1; RTI1188-1-1; RTI1189-1-1; Ro 21-5998 (Hydrochloride); WR-142,490; WR-177,602; Ro-21-5998-001; Alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; Alpha-2-Piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol; [2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol; Erthro-.alpha.-[2-piperidyl]-2,8-bis[trifluoromethyl]-4-quinolinemethanol; (+)-(11R,2'S)-erythro-Mefloquine; (+)-Mefloquine; (+)-Threo-Mefloquine; (-)-(11S,2'R)-erythro-Mefloquine; (-)-Mefloquine; (-)-Threo-Mefloquine; (DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2R)-piperidin-2-yl]methanol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63681	DB00358	.	.	378.31	C17H16F6N2O	45.2	483	3.6	26	2	9	2	"1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2"	C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O	XEEQGYMUWCZPDN-UHFFFAOYSA-N
DG00192	Ponatinib	24826799	Iclusig (TN)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:78543	DB08901	DR00204	.	532.6	C29H27F3N6O	65.8	910	4.1	39	1	8	6	"1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)"	CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5	PHXJVRSECIGDHY-UHFFFAOYSA-N
DG00193	Imipenem	104838	"Imipemide; Tienamycin; Imipenem anhydrous; Imipenem (INN); N-Formimidoylthienamycin; Primaxin (TN); Imipenem, N-Formimidoyl thienamycin; [5R-[5.alpha.,6.alpha.(R*)]]-6-(1-Hydroxyethyl)-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrate; (5R,6S)-3-(2-Formimidoylamino-ethylsulfanyl)-6-((R)-1-hydroxy-ethyl)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-6-((R)-1-Hydroxyethyl)-3-(2-(iminomethylamino)ethylthio)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carbonsaeure; (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid"	Phase 4	4	Approved Drug(s)	Phase 4	Small molecular drug	CHEBI:471744	DB01598	.	DR2447	299.35	C12H17N3O4S	142	491	-0.7	20	3	6	6	"1S/C12H17N3O4S/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19)/t6-,7-,9-/m1/s1"	C[C@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O	ZSKVGTPCRGIANV-ZXFLCMHBSA-N
DG00194	Ribavirin	37542	"Ribavirin; 36791-04-5; Tribavirin; Rebetol; Virazole; Ribavirine; Copegus; Vilona; Ribamide; Ribasphere; Ribamidil; Viramid; Ribamidyl; Ribavirinum; Ribavirina; Rebetron; Varazid; RTCA; Ribavirin Capsules; Ribavirinum [INN-Latin]; Ribavirine [INN-French]; Ribavirina [INN-Spanish]; ICN-1229; Rebretron; Virazid; Ribav; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; DRG-0028; 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; UNII-49717AWG6K; Ribavirin (Copegus); Copegus; Cotronak; RBV; RTC; Ravanex; Ribacine; Ribovirin; Viramide; Virazide; R 9644; SCH 18908; C-Virin; Copegus (TN); Drug: Ribavirin; KS-1104; R-964; RG-964; Rebetol (TN); Ribasphere (TN); Ribavirin [USAN:INN]; Vilona (TN); Virazole (Ribavirin) Inhalation Solution; Virazole (TN); AA-504/07617051; Ro 20-9963/000; Ro-20-9963; Ribavirin (JAN/USP/INN); 1-beta-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide; 1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide; RBI034 (2-5A antisense compound) + Ribavirin"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63580	DB00811	DR00176	DR1413	244.2	C8H12N4O5	144	304	-1.8	17	4	7	3	"1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1"	C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N	IWUCXVSUMQZMFG-AFCXAGJDSA-N
DG00195	OSI-027	135398516	.	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	CHEBI:91363	DB12387	.	.	406.4	C21H22N6O3	131	630	2	30	3	7	4	"1S/C21H22N6O3/c1-30-15-4-2-3-13-9-14(25-16(13)15)17-18-19(22)23-10-24-27(18)20(26-17)11-5-7-12(8-6-11)21(28)29/h2-4,9-12,25H,5-8H2,1H3,(H,28,29)(H2,22,23,24)"	COC1=CC=CC2=C1NC(=C2)C3=C4C(=NC=NN4C(=N3)C5CCC(CC5)C(=O)O)N	JROFGZPOBKIAEW-UHFFFAOYSA-N
DG00196	Benzenemethanol	119104	"1'-Acetoxychavicol acetate; 52946-22-2; 1'-Acetoxychavicol; UNII-SQV3080A20; CHEBI:469; 1'S-1'-Acetoxychavicol acetate; SQV3080A20; (alphaS)-4-(Acetyloxy)-alpha-ethenylbenzenemethanol; [4-[(1S)-1-acetyloxyprop-2-enyl]phenyl] acetate; Galangal acetate; (1S)-1-[4-(acetyloxy)phenyl]prop-2-en-1-yl acetate; Benzenemethanol, 4-(acetyloxy)-.alpha.-ethenyl-, acetate, (.alpha.S)-; CCRIS 7708; 1'-Acethoxychavicol; AC1Q60ZN; AC1L3O7Q; GTPL6298; CHEMBL323727; SCHEMBL17454871; (S)-1'-Acetoxychavicol Acetate; benzenemethanol, 4-(acetyloxy)-"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:469	.	.	.	234.25	C13H14O4	52.6	290	2.2	17	0	4	6	"1S/C13H14O4/c1-4-13(17-10(3)15)11-5-7-12(8-6-11)16-9(2)14/h4-8,13H,1H2,2-3H3/t13-/m0/s1"	CC(=O)OC1=CC=C(C=C1)[C@H](C=C)OC(=O)C	JAMQIUWGGBSIKZ-ZDUSSCGKSA-N
DG00197	Raltegravir	54671008	"RGV; MK 0518; Isentress(TM); K-0518; MK-0518; Raltegravir (INN); N-(2-(4-(4-fluorobenzylcarbamoyl); N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-4-pyrimidinecarboxamide; RAL"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB06817	.	.	444.4	C20H21FN6O5	150	836	1.1	32	3	9	6	"1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)"	CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F	CZFFBEXEKNGXKS-UHFFFAOYSA-N
DG00198	Celastrol	122724	"Tripterin; Tripterine; Celastrol, Celastrus scandens; (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid; (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid; 3-Hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic Acid"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:63959	.	.	.	450.6	C29H38O4	74.6	1100	5.9	33	2	4	1	"1S/C29H38O4/c1-17-18-7-8-21-27(4,19(18)15-20(30)23(17)31)12-14-29(6)22-16-26(3,24(32)33)10-9-25(22,2)11-13-28(21,29)5/h7-8,15,22,31H,9-14,16H2,1-6H3,(H,32,33)/t22-,25-,26-,27+,28-,29+/m1/s1"	CC1=C(C(=O)C=C2C1=CC=C3[C@]2(CC[C@@]4([C@@]3(CC[C@@]5([C@H]4C[C@](CC5)(C)C(=O)O)C)C)C)C)O	KQJSQWZMSAGSHN-JJWQIEBTSA-N
DG00199	Prednisone	5865	"Adasone; Ancortone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; Incocortyl; Juvason; Kortancyl; Lisacort; Lodotra; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisonum; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Dellacort A; Delta E; Delta cortelan; Liquid Pred; Origen Prednisone; Prednisone Intensol; Zenadrid [veterinary]; P1276; U 6020; Apo-Prednisone; Delta E.; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Di-Adreson; In-Sone; Me-Korti; Meticortelone (TN); Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Prednicen-M; Prednisona [INN-Spanish]; Prednisone [INN:BAN]; Prednisonum [INN-Latin]; SK-Prednisone; Zenadrid (veterinary); Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8382	DB00635	DR00438	DR1334	358.4	C21H26O5	91.7	764	1.5	26	2	5	2	"1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1"	C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C	XOFYZVNMUHMLCC-ZPOLXVRWSA-N
DG00200	Dexamethasone	5743	"Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:41879	DB01234	DR00215	.	392.5	C22H29FO5	94.8	805	1.9	28	3	6	2	"1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1"	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C	UREBDLICKHMUKA-CXSFZGCWSA-N
DG00201	Oxytetracycline	54675779	"Adamycin; Biostat; Dabicycline; Dalimycin; Fanterrin; Geomycin; Geotilin; Hydroxytetracycline; Imperacin; Lenocycline; Macocyn; OTC; Oksisyklin; Ossitetraciclina; Oxacycline; Oxitetraciclina; Oxitetracyclin; Oxitetracycline; Oxitetracyclinum; Oxymycin; Oxymykoin; Oxypam; Oxyterracin; Oxyterracine; Oxyterracyne; Oxytetracid; Oxytetracyclin; Oxytetracyclinum; Proteroxyna; Riomitsin; Ryomycin; Solkaciclina; Tarocyn; Tarosin; Teravit; Terrafungine; Terramitsin; Terramycin; Tetran; Unimycin; Ursocyclin; Ursocycline; Vendarcin; Biostat PA; Ossitetraciclina [DCIT]; Oxytetracycline HCl; Oxytetracycline [INN]; Oxytetracycline amphoteric; Oxytetracycline anhydrous; Oxytetracycline calcium; Terramycin im; Antibiotic TM 25; LA 200; Liquamycin LA 200; Mycoshield TMQTHC 20; Pennox 200; TM 5; Terramycin Q50; Geomycin (Streptomyces vimosus); OTC (antibiotic); Oxitetraciclina [INN-Spanish]; Oxytetracycline (anhydrous); Oxytetracycline (internal use); Oxytetracyclinum [INN-Latin]; Terramycin, Liquamycin, Oxytetracycline; (2E,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2E,4S,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aR,5S,5aR,6S,12aS)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 5-Hydroxytetracycline"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:27701	DB00595	.	DR2697	460.4	C22H24N2O9	202	1000	-1.6	33	7	10	2	"1S/C22H24N2O9/c1-21(32)7-5-4-6-8(25)9(7)15(26)10-12(21)17(28)13-14(24(2)3)16(27)11(20(23)31)19(30)22(13,33)18(10)29/h4-6,12-14,17,25-26,28,30,32-33H,1-3H3,(H2,23,31)/t12-,13-,14+,17+,21-,22+/m1/s1"	C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O	OWFJMIVZYSDULZ-PXOLEDIWSA-N
DG00202	Olaparib	23725625	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:83766	DB09074	DR00221	DR1188	434.5	C24H23FN4O3	82.1	790	1.9	32	1	5	4	"1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)"	C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F	FDLYAMZZIXQODN-UHFFFAOYSA-N
DG00203	Rosuvastatin	446157	"Astende; Cirantan; Cresadex; Creston; Crestor; Provisacor; Razel; Rosedex; Rosimol; Rosumed; Rosustatin; Rosuvas; Rosuvast; Rosvel; Rovartal; Simestat; Sinlip; Vivacor; Rosuvastatin [INN]; Rosuvastatin calcium; Rosuvastatin calcium [USAN]; Rosuvastatin hemicalcium; S 4522; ZD 4522; ZD4522; AZD-4522; Creston (TN);Crestor (TN); Pyrimidine Compound, 26; Rosuvastatin (INN); S-4522; ZD 4522, calcium salt; ZD-4522; Rosuvastatin calcium (JAN/USAN); Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhelpt-6-enoic acid] calcium salt; Calcium (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate; (3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (E,3R,5R)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (S-((R*,S*-(E)))-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl) amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); (S-(R*,S*-(E)))-7-(4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, (3R,5S,6E); 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:38545	DB01098	DR00223	DR1445	481.5	C22H28FN3O6S	149	767	1.6	33	3	10	10	"1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1"	CC(C)C1=NC(=NC(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C	BPRHUIZQVSMCRT-VEUZHWNKSA-N
DG00204	Fulvestrant	104741	"Faslodex; AstraZeneca brand of fulvestrant; Fulvestrant [USAN]; Ici 182780; ZD 182780; ZM 182780; Faslodex (TN); ZD-182780; ZD-9238; ZM-182780; Faslodex(ICI 182,780); Faslodex, ICI 182780, Fulvestrant; Fulvestrant (JAN/USAN/INN); (7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol; 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol; 7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol; ICI"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31638	DB00947	.	DR0756	606.8	C32H47F5O3S	76.7	854	9.2	41	2	9	14	"1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41 /m1/s1"	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F	VWUXBMIQPBEWFH-WCCTWKNTSA-N
DG00205	PD-0325901	9826528	"PD 0325901; PD 325901; PD0325901; PD325901; PD-325901; S06-0029; N-[((R)-2,3-dihydroxypropyl)oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide; N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodo-phenyl)amino]benzamide; N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:88249	DB07101	.	.	482.19	C16H14F3IN2O4	90.8	465	3	26	4	8	7	"1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1"	C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOC[C@@H](CO)O	SUDAHWBOROXANE-SECBINFHSA-N
DG00206	AZD-8055	25262965	"AZD8055; 1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	CHEBI:91329	DB12774	.	.	465.5	C25H31N5O4	93.1	659	2.6	34	1	9	5	"1S/C25H31N5O4/c1-16-14-33-10-8-29(16)24-20-5-6-21(18-4-7-22(32-3)19(12-18)13-31)26-23(20)27-25(28-24)30-9-11-34-15-17(30)2/h4-7,12,16-17,31H,8-11,13-15H2,1-3H3/t16-,17-/m0/s1"	C[C@H]1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=C(C=C4)OC)CO)N5CCOC[C@@H]5C	KVLFRAWTRWDEDF-IRXDYDNUSA-N
DG00207	Cefotiam	43708	"Aspil; CTM; Cefotiamum; Ceradolan; Haloapor; CEFOTIAM HYDROCHLORIDE; CGP 14221E; Abbott-48999; Aspil (TN); Cefotiam (INN); Cefotiam [INN:BAN]; Cefotiamum [INN-Latin]; SCE-963; CGP-14221-E; (6R,7R)-7-[2-(2-Amino-thiazol-4-yl)-acetylamino]-3-[1-(2-dimethylamino-ethyl)-1H-tetrazol-5-ylsulfanylmethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-(2-dimethylaminoethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}thio)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7b-[2-(aminothiazol-4-yl)acetamido]-3-[[[1-(2-dimethylaminoethyl)-1h-tetrazol-5-yl]thio]methyl]ceph-3-em-4-carboxylic acid; 7beta-(2-amino-1,3-thiazol-4-yl)acetamido-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl]-3,4-didehydrocepham-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:355510	DB00229	DR01194	.	525.6	C18H23N9O4S3	251	848	-2.4	34	3	13	10	"1S/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1"	CN(C)CCN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CC4=CSC(=N4)N)SC2)C(=O)O	QYQDKDWGWDOFFU-IUODEOHRSA-N
DG00208	Everolimus	6442177	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:68478	DB01590	DR00224	DR0674	958.2	C53H83NO14	205	1810	5.9	68	3	14	9	"1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1"	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC	HKVAMNSJSFKALM-GKUWKFKPSA-N
DG00209	Sparfloxacin	60464	"Esparfloxacino; SPFX; Spara; Sparfloxacine; Sparfloxacinum; Zagam; AT 4140; CP 103826; PD 131501; PD131501; AT-4140; CP-103826; DRG-0143; Esparfloxacino [INN-Spanish]; Liposome-encapsulated sparfloxacin; PD 1315-1; PD-131501; RP-64206; Respipac (TN); Sparfloxacin & RU 40555; Sparfloxacine [INN-French]; Sparfloxacinum [INN-Latin]; Zagam (TN); Sparfloxacin, cis-isomer; Sparfloxacin (JAN/USAN/INN); Sparfloxacin [USAN:BAN:INN:JAN]; Cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; (cis)-5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclohexyl-7-(cis-3,5-dimethylpiperazino)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid & RU 40555; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9212	DB01208	DR00791	.	392.4	C19H22F2N4O3	98.9	691	0.1	28	3	9	3	"1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)/t8-,9+"	C[C@@H]1CN(C[C@@H](N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F	DZZWHBIBMUVIIW-DTORHVGOSA-N
DG00210	Entecavir	135398508	"Baraclude; ETV; Entecavir hydrate; Entecavir monohydrate; BMS-200475; Baraclude (TN); Entecavir (INN); Entecavir (USAN); Entecavir hydrate (JAN); SQ-34676; 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one-water (1/1); 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one; 6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]; 9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)guanine monohydrate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:473990	DB00442	DR01277	.	277.28	C12H15N5O3	126	480	-1.3	20	4	5	2	"1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1"	C=C1[C@H](C[C@@H]([C@H]1CO)O)N2C=NC3=C2N=C(NC3=O)N	QDGZDCVAUDNJFG-FXQIFTODSA-N
DG00211	AQ-13	9820475	"AQ-13 Dihydrochloride; 169815-40-1; UNII-PKT9732S5K; AQ 13; PKT9732S5K; DTXSID10168761; (N1-(7-Chloroquinolin-4-yl)-3-(N3,N3-diethylamino)propylamine) dihydrochloride; HY-100358; CS-0018673; 1,3-Propanediamine, N'-(7-chloro-4-quinolinyl)-N,N-diethyl-, dihydrochloride"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	.	.	.	364.7	C16H24Cl3N3	28.2	270	.	22	3	3	7	"1S/C16H22ClN3.2ClH/c1-3-20(4-2)11-5-9-18-15-8-10-19-16-12-13(17)6-7-14(15)16;;/h6-8,10,12H,3-5,9,11H2,1-2H3,(H,18,19);2*1H"	CCN(CC)CCCNC1=C2C=CC(=CC2=NC=C1)Cl.Cl.Cl	ZNHBPWZRWNFJPN-UHFFFAOYSA-N
DG00212	Genistein	5280961	"Bonistein; GEN; Genestein; Genisteol; Genisterin; Prunetol; Sophoricol; Differenol A; G 6649; G10000; IN1327; NPI 031L; STO514; TNP00151; GENISTEIN (ENDOCRINE DISRUPTER); Lactoferrin-genistein; PTI G4660 (Genistein); PTI-G4660; SIPI 807-1; C.I. 75610; SIPI-9764-I; ENDOCRINE DISRUPTOR (GENISTEIN) (SEE ALSO GENISTEIN (446-72-0)); 4 inverted exclamation marka,5,7-Trihydroxyisoflavone; ,5,7-Trihydroxyisoflavone; 4',5, 7-Trihydroxyisoflavone; 4',5,7-Trihydroxy isoflavone; 4',5,7-Trihydroxyisoflavone; 4,5,7-Trihydroxyiso-flavone; 4,6,7-Trihydroxyisoflavone; 5,7,4'-Trihydroxyisoflavone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:28088	DB01645	DR00641	DR0768	270.24	C15H10O5	87	411	2.7	20	3	5	1	"1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H"	C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O	TZBJGXHYKVUXJN-UHFFFAOYSA-N
DG00213	Savolitinib	68289010	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB12048	.	.	345.4	C17H15N9	91.6	505	1.5	26	0	6	3	"1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1"	C[C@@H](C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C	XYDNMOZJKOGZLS-NSHDSACASA-N
DG00214	Saracatinib	10302451	"H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	.	DB11805	.	.	542	C27H32ClN5O5	90.4	743	4.1	38	1	10	8	"1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)"	CN1CCN(CC1)CCOC2=CC3=C(C(=C2)OC4CCOCC4)C(=NC=N3)NC5=C(C=CC6=C5OCO6)Cl	OUKYUETWWIPKQR-UHFFFAOYSA-N
DG00215	Bacitracin A	10909430	"Altracin; Baciguent; Baciquent; Citracin; Fortracin; Bacitracin A; Bacitracin A1; Bacitracin A2a; Neosporin (TN); Solu-Tracin 50; Partyl-, (10.4)-lactam; L-Asparagine, N-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-4-thiazolyl]carbonyl]-L-leucyl-D-.alpha.-glutamyl-L-isoleucyl-L-lysyl-D-ornithyl-L-isoleucyl-D-phenylalanyl-L-histidyl-D-.alpha.-as; 11702_FLUKA; 11702_SIGMA"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:35862	DB00626	.	.	1422.7	C66H103N17O16S	556	2850	-4.1	100	17	21	31	"1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35-,36-,37-,40-,41+,42+,43-,44+,45-,46-,47+,48-,52-,53-,54-/m0/s1"	CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCCCC[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSC(=N2)[C@H]([C@@H](C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4	CLKOFPXJLQSYAH-ABRJDSQDSA-N
DG00216	Rociletinib	57335384	"1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284"	Terminated	10	Discontinued Drug(s)	Terminated	Small molecular drug	.	DB11907	.	.	555.6	C27H28F3N7O3	112	871	4	40	3	11	8	"1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35)"	CC(=O)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F)OC	HUFOZJXAKZVRNJ-UHFFFAOYSA-N
DG00217	Parthenolide	7251185	"Parthenolide; 20554-84-1; (-)-Parthenolide; CHEBI:7939; Parthenolide, Tanacetum parthenium; 4,5-alpha-Epoxy-6-beta-hydroxygermacra-1(10),11(13)-dien-12-oic acid gamma-lactone; partenolide; C15H20O3; 29552-41-8; Prestwick2_000550; Prestwick3_000550; Epitope ID:115014; SCHEMBL8220; BSPBio_001308; BSPBio_000599; MLS002153872; CHEMBL465158; BPBio1_000659; SCHEMBL13367522; BCBcMAP01_000041; Parthenolide, > MolPort-008-268-168; MolPort-003-959-089; HMS1361B10; HMS3402B10; HMS1989B10; HMS1791B10; HMS1569N21; HMS2096N21"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:7939	DB13063	.	.	248.32	C15H20O3	38.8	437	2.3	18	0	3	0	"1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3/b9-5+/t11-,12-,13+,15+/m0/s1"	C/C/1=C\\CC[C@@]2([C@H](O2)[C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C	KTEXNACQROZXEV-PVLRGYAZSA-N
DG00218	Omacetaxine mepesuccinate	285033	Synribo (TN)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:71019	DB04865	.	.	545.6	C29H39NO9	124	968	0.8	39	2	10	11	"1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25-,28+,29-/m1/s1"	CC(C)(CCC[C@@](CC(=O)OC)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O	HYFHYPWGAURHIV-JFIAXGOJSA-N
DG00219	Dapsone	2955	"Aczone; Atrisone; Avlosulfon; Avlosulfone; Avlosulphone; Avsulfor; Croysulfone; Croysulphone; DADPS; DDS; Dapson; Dapsona; Dapsonum; Diaminodifenilsulfona; Diaminodiphenylsulfone; Diaphenylsulfon; Diaphenylsulfone; Diaphenylsulphon; Diaphenylsulphone; Diphenasone; Diphone; Disulone; Dubronax; Dubronaz; Dumitone; Eporal; Novophone; Protogen; Sulfadione; Sulfona; Sulfonyldianiline; Sulphadione; Sulphonyldianiline; Tarimyl; Udolac; Araldite HT; D SS; Diaminodifenilsulfona [Spanish]; Diaminodiphenyl sulfone;Fatol Brand of Dapsone; Metabolite C; Orsade Brand of Dapsone; Sulfone ucb; Sumicure S; Araldite HT 976; F 1358; HT 976; HY 976; Hardener HT 976; W R 448; WR 448; ALBB-005917; AZT + Dapsone cominbation; Aczone (TN); DDS (pharmaceutical); DDS, diaphenylsulfone; DDS, pharmaceutical; DSS (VAN); Dapsoderm-X; Dapson-Fatol; Dapsona [INN-Spanish]; Dapsone (USP); Dapsone [USAN:BAN]; Dapsonum [INN-Latin];Diamino-diphenyl sulphone; Diaphenylsulfone (JAN); IN-201; Mex-America Brand of Dapsone; P-Aminophenyl sulfone; Sulfanona-mae; Sulfon-mere; Sulfona-MAE; Sulphon-mere; Bis(4-aminophenyl) sulfone; Bis(4-aminophenyl)sulfone; Bis(4-aminophenyl)sulphone; Bis(p-aminophenyl) sulfone; Bis(p-aminophenyl)sulphone; Di(4-aminophenyl) sulfone; Di(4-aminophenyl)sulfone; Di(4-aminophenyl)sulphone; Di(p-aminophenyl) sulfone; Di(p-aminophenyl)sulphone; P,p-Diaminodiphenyl sulphone; P,p-Sulfonylbisbenzamine; P,p-Sulfonylbisbenzenamine; P,p-Sulphonylbisbenzamine; P,p-Sulphonylbisbenzenamine; P,p-Sulphonyldianiline; N, N'-Diphenyl sulfondiamide; N,N'-Diphenyl sulfondiamide; P, p'-Sulfonyldianiline; P,p'-Diaminodiphenyl sulfone; P,p'-sulfonyldianiline; Diamino-4,4'-diphenyl sulfone; Diamino-4,4'-diphenyl sulphone; Sulfone, 4,4'-Diaminophenyl; (4-sulfanilylphenyl)amine; 1,1'-Sulfonylbis(4-aminobenzene); 1,1'-Sulfonylbis[4-aminobenzene]; 1,1'-Sulphonylbis(4-aminobenzene); 4,4' Diaminophenyl Sulfone; 4,4'-Dapsone; 4,4'-Diaminodiphenyl sulfone; 4,4'-Diaminodiphenyl suphone; 4,4'-Diaminodiphenylsulfone; 4,4'-Sulfonylbisaniline; 4,4'-Sulfonylbisbenzamine; 4,4'-Sulfonylbisbenzenamine; 4,4'-Sulfonyldianiline;4,4'-Sulfonyldianiline (Dapsone); 4,4'-Sulphonylbisbenzamine; 4,4'-Sulphonylbisbenzenamine; 4,4'-Sulphonyldianiline; 4,4'-diaminophenyl sulfone; 4,4-Diaminodifenylsulfon; 4,4-Diaminodifenylsulfon [Czech]; 4,4-Sulfonyldianiline; 4-(4-aminophenyl)sulfonylaniline; 4-Aminop henyl sulfone; 4-Aminophenyl sulfone; 4-Aminophenylsulfone; 4-[(4-aminobenzene)sulfonyl]aniline; 4-[(4-aminophenyl)sulfonyl]aniline"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4325	DB00250	.	DR0415	248.3	C12H12N2O2S	94.6	306	1	17	2	4	2	"1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2"	C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N	MQJKPEGWNLWLTK-UHFFFAOYSA-N
DG00220	Oxacillin	6196	"Bactocill; Ossacillina; Oxacilina; Oxacilline; Oxacillinum; Oxazocillin; Oxazocilline; Prostaphlin; Prostaphlyn; OXACILLIN SODIUM; Ossacillina [DCIT]; Sodium oxacillin; Bactocill (TN); MPI-penicillin; MPi-PC; Oxacilina (TN); Oxacilina [INN-Spanish]; Oxacillin (INN); Oxacillin [INN:BAN]; Oxacilline [INN-French]; Oxacillinum [INN-Latin]; Penicillin, Methylphenylisoxazolyl; Oxacillin, Monosodium Salt, Anhydrous; (2S,5R,6R)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (5-methyl-3-phenyl-4-isoxazolyl)penicillin; 2,2-dimethyl-6beta-(5-methyl-3-phenyl-1,2-oxazole-4-carboxamido)penam-3alpha-carboxylic acid; 5-Methyl-3-phenyl-4-isoxazolyl-penicillin; 6beta-(5-methyl-3-phenylisoxazol-4-yl)penicillanic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7809	DB00713	DR00647	DR2321	401.4	C19H19N3O5S	138	681	2.4	28	2	7	4	"1S/C19H19N3O5S/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26)/t13-,14+,17-/m1/s1"	CC1=C(C(=NO1)C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O	UWYHMGVUTGAWSP-JKIFEVAISA-N
DG00221	Streptomycin	19649	"Agrept; Agrimycin; Gerox; Neodiestreptopab; SRY; Strepcen; Streptomicina; Streptomycine; Streptomycinum; Streptomyzin; Liposomal Streptomycin; Streptomicina [Italian]; Streptomycin A; Streptomycin A sulfate; Streptomycin Sesquisulfate Hydrate; Streptomycin sulfate; Streptomycin sulphate; Streptomyzin [German]; Agrept (TN); Estreptomicina [INN-Spanish]; Hokko-mycin; Plantomycin (TN); Rimosidin (TN); Streptomycin & EEP; Streptomycin & Propolis; Streptomycin (INN); Streptomycin (TN); Streptomycin [INN:BAN]; Streptomycin, Sulfate Salt; AS-50 (TN); STREPTOMYCIN SULFATE (2:3) SALT; Agri-mycin-17 (TN); O-2-Deoxy-2-(methylamino)-.alpha.-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-.alpha.-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-D-streptamine and Liposome; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-{5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyloxy}-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2S,3S,4S,5R)-3-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1S,2S,3R,4S,5S,6R)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1S,4S)-5-(diaminomethylideneamino)-2-[(2R,5S)-3-[(2S,5R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-3,4,6-trihydroxycyclohexyl]guanidine; [2-deoxy-2-(dimethylamino)-alpha-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl]-(1->4)-{N',N'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine}"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:17076	DB01082	.	DR2387	581.6	C21H39N7O12	336	940	-8	40	12	15	9	"1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1"	C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O	UCSJYZPVAKXKNQ-HZYVHMACSA-N
DG00222	Voriconazole	71616	"VCZ; Vfend; Pfizer brand of voriconazole; UK 109496; Voriconazole in combination with MGCD290; DRG-0301; UK 109,496; UK-109496; VFEND (TN); Vfend (TN); Vfend, Voriconazole; UK-109,496; Voriconazole [USAN:INN:BAN]; Voriconazole (JAN/USAN/INN); (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; VRC"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:10023	DB00582	DR00445	DR1709	349.31	C16H14F3N5O	76.7	448	1.5	25	1	8	5	"1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1"	C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O	BCEHBSKCWLPMDN-MGPLVRAMSA-N
DG00223	Dihydroartemisinin	3000518	"Artenimol; Cotecxin; Dihydroartemisinine; Dihydroqinghaosu; Dihydroquinghaosu; Dihydroquinghoasu; VM3352; Artenimol (INN); JAV-110; GNF-PF-5634; (3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-ol; [3R-(3.alpha.,5a.beta.,6.beta.,8a.beta.,9.alpha.,10.alpha.,12.beta.,12aR*)]-Decahydro-10-hydroxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4.3-j]-1,2-benzodioxepin; 1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol(Dihydroartemisinin)"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:135921	DB11638	.	.	284.35	C15H24O5	57.2	415	2.5	20	1	5	0	"1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12+,13-,14-,15-/m1/s1"	C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)O)C	BJDCWCLMFKKGEE-ISOSDAIHSA-N
DG00224	Trichostatin A	444732	"Trichostatin A; 58880-19-6; Trichostatin A (TSA); TSA; Trichostatin; Tricostatin A; UNII-3X2S926L3Z; CHEBI:46024; (2E,4E,6R)-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide; GNF-PF-1011; RTKIYFITIVXBLE-QEQCGCAPSA-N; 3X2S926L3Z; 7-(4-(Dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide; 2,4-Heptadienamide, 7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-; 7-[4-(DIMETHYLAMINO)PHENYL]-N-HYDROXY-4,6-DIMETHYL-7-OXO-2,4-HEPTADIENAMIDE"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	CHEBI:46024	DB04297	.	.	302.37	C17H22N2O3	69.6	447	2.7	22	2	4	6	"1S/C17H22N2O3/c1-12(5-10-16(20)18-22)11-13(2)17(21)14-6-8-15(9-7-14)19(3)4/h5-11,13,22H,1-4H3,(H,18,20)/b10-5+,12-11+/t13-/m1/s1"	C[C@H](/C=C(\\C)/C=C/C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C	RTKIYFITIVXBLE-QEQCGCAPSA-N
DG00225	Ciprofloxacin XR	2764	Ciprofloxacin; 85721-33-1; Ciprofloxacine; Ciprobay; Ciproxan; Ciprofloxacina; Ciprofloxacinum; Ciprofloxacino; Cipro IV; Ciproxina; Ciprinol; Bernoflox; Ciprodar; Cifloxin; Septicide; Bacquinor; Ciproquinol; Cipromycin; Ciprocinol; Cipro XR; Superocin; Ciprowin; Ciprolon; Ciproflox; Ciprecu; BAY q 3939; Spitacin; Quintor; Quinolid; Proflaxin; Probiox; Ipiflox; Zumaflox; Ciproxine; Ciprolin; Roxytal; Italnik; Fimoflox; Corsacin; Citopcin; Ciprogis; Rancif; Ciriax; Ciplus; Baflox; Loxan; Cilab; Cycin; Cixan; Unex; GW1843; Ciprofloxacin Hydrochloride; Ciprofloxacin intratympanic - Otonomy	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:100241	DB00537	DR00783	DR2273	331.34	C17H18FN3O3	72.9	571	-1.1	24	2	7	3	"1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)"	C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O	MYSWGUAQZAJSOK-UHFFFAOYSA-N
DG00226	Nevirapine	4463	"NEV; NVP; Viramune; Cahill May Roberts Brand of Nevirapine; Promeco Brand of Nevirapine; BI RG 587; BIRG 0587; BIRG 587; BIRG587; BIRG-0587; BIRG-587; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; Nevirapine & PRO 140; Nevirapine [USAN:INN]; Viramune (TN); Viramune(TM); BI-RG-587; Nevirapine & CD4-IgG; Nevirapine (JAN/USP/INN); Viramune, BI-RG 587, Nevirapine; BI-RG-587 & CD4-IgG; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63613	DB00238	DR00447	DR1142	266.3	C15H14N4O	58.1	397	2	20	1	4	1	"1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)"	CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4	NQDJXKOVJZTUJA-UHFFFAOYSA-N
DG00227	Meropenem	441130	"MEPM; MERONEM; Meropen; Merrem; Meropenem anhydrous; Mepem (TN); Meronem (TN); Meropen (TN); Meropenem (INN); Merrem (TN); Neopenem (TN); SM-7338; Meronem; Merrem I.V. (TN); (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid trihydrate; (2S,3R,4R)-2-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4-{[(3S,5R)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-3-methyl-3,4-dihydro-2H-pyrrole-5-carboxylic acid; (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((S)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (6S)-2-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:43968	DB00760	DR01200	DR2491	383.5	C17H25N3O5S	136	679	-2.4	26	3	7	5	"1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1"	C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O	DMJNNHOOLUXYBV-PQTSNVLCSA-N
DG00228	Docetaxel	148124	"EmDOC; TXL; Taxotere; Docetaxel anhydrous; ANX-514; Docetaxel (INN); Docetaxel, Trihydrate; RP-56976; SDP-014; Taxotere (TN); Taxotere(R); XRP-6976L; Docetaxel 114977-28-5; N-debenzoyl-N-Boc-10-deacetyl taxol; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4672	DB01248	DR00251	DR0520	807.9	C43H53NO14	224	1660	1.6	58	5	14	13	"1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1"	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O	ZDZOTLJHXYCWBA-VCVYQWHSSA-N
DG00229	Osimertinib	71496458	Tagrisso	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:90943	DB09330	DR00655	DR1207	499.6	C28H33N7O2	87.6	752	3.7	37	2	7	10	"1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)"	CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC	DUYJMQONPNNFPI-UHFFFAOYSA-N
DG00230	Bosutinib	5328940	"SKI 606; SKI606; Bosutinib (USAN); PF-5208763; SKI-606; Xy]-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propo; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib (BCR-ABL inhibitor 3rd gen)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:39112	DB06616	DR00253	DR0224	530.4	C26H29Cl2N5O3	82.9	734	5.4	36	1	8	9	"1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)"	CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC	UBPYILGKFZZVDX-UHFFFAOYSA-N
DG00231	Kirromycin	135484176	.	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	796.9	C43H60N2O12	224	1720	3.8	57	8	12	17	"1S/C43H60N2O12/c1-9-11-13-21-31-42(6,7)38(50)39(51)43(54,57-31)28(10-2)40(52)44-23-17-16-19-26(4)36(55-8)27(5)37-35(49)34(48)30(56-37)20-15-12-14-18-25(3)33(47)32-29(46)22-24-45-41(32)53/h9,11-22,24,27-28,30-31,34-39,48-51,54H,10,23H2,1-8H3,(H,44,52)(H2,45,46,53)/b11-9-,14-12+,17-16+,20-15+,21-13+,25-18+,26-19+/t27-,28-,30-,31+,34+,35+,36-,37+,38+,39-,43-/m1/s1"	CC[C@H](C(=O)NC/C=C/C=C(\\C)/[C@H]([C@@H](C)[C@H]1[C@H]([C@H]([C@H](O1)/C=C/C=C/C=C(\\C)/C(=O)C2=C(C=CNC2=O)O)O)O)OC)[C@@]3([C@@H]([C@@H](C([C@@H](O3)/C=C/C=C\\C)(C)C)O)O)O	HMSYAPGFKGSXAJ-PAHGNTJYSA-N
DG00232	Piperaquine	122262	"Piperaquinoline; Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-); Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-(9CI); 1,3-bis(1-(7-chloro-4'-quinolyl)-4'-piperazinyl)propane; 1,3-bis(4-(7'-chloro-4'-quinoline)-1-piperazine); 4,4'-(propane-1,3-diyldipiperazine-4,1-diyl)bis(7-chloroquinoline); 7-chloro-4-[4-[3-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propyl]piperazin-1-yl]quinoline"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:91231	DB13941	.	DR1296	535.5	C29H32Cl2N6	38.7	655	5.6	37	0	6	6	"1S/C29H32Cl2N6/c30-22-2-4-24-26(20-22)32-8-6-28(24)36-16-12-34(13-17-36)10-1-11-35-14-18-37(19-15-35)29-7-9-33-27-21-23(31)3-5-25(27)29/h2-9,20-21H,1,10-19H2"	C1CN(CCN1CCCN2CCN(CC2)C3=C4C=CC(=CC4=NC=C3)Cl)C5=C6C=CC(=CC6=NC=C5)Cl	UCRHFBCYFMIWHC-UHFFFAOYSA-N
DG00233	Co-trimoxazole	358641	.	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3770	.	.	.	543.6	C24H29N7O6S	212	653	.	38	4	13	8	"1S/C14H18N4O3.C10H11N3O3S/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15;1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h5-7H,4H2,1-3H3,(H4,15,16,17,18);2-6H,11H2,1H3,(H,12,13)"	CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N.COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N	WZRJTRPJURQBRM-UHFFFAOYSA-N
DG00234	Fluphenazine	3372	"FLUPHENAZINE; Triflumethazine; Fluorophenazine; Fluorphenazine; Fluorfenazine; Siqualon; Elinol; 69-23-8; Phthorphenazine; Vespazine; Ftorphenazine; Siqualine; Sevinol; Pacinol; Fluphenazinum; Flufenazina; Prolixin; Flufenazin; Dapotum; Flufenazina [DCIT]; Yespazine; SQ 4918; Fluphenazine [INN:BAN]; Moditen (Tabl or elixir); Fluphenazinum [INN-Latin]; 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; UNII-S79426A41Z; HSDB 3334; Dapotum; Prolixine; Fluphenazine hydrochloride; Moditen Hcl; Permitil Concentrate; Prolixin Concentrate; S94; Anatensol (TN); Apo-Fluphenazine; Dapotum (TN); Dapotum D (TN); Dapotum Injektion (TN); Decanoate (TN); Deconoate (TN); Enanthate (TN); Fludecate (TN); Flunanthate (TN); Fluphenazine (INN); Hydrochloride, Fluphenazine; Lyogen (TN); Modecate (TN); Moditen (TN); Moditen Enanthate Injection (TN); Omca (TN); Permitil (TN); Prolixin (TN); Sediten (TN); Selecten (TN); Sevinol (TN); Sinqualone (TN); Trancin (TN)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:5123	DB00623	DR00658	.	437.5	C22H26F3N3OS	55.2	544	4.4	30	1	8	6	"1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2"	C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO	PLDUPXSUYLZYBN-UHFFFAOYSA-N
DG00235	Ceftazidime	5481173	"Ceftazidima; Ceftazidimum; Ceptaz; Fortaz; Ceftazidime Sodium In Plastic Container; Ceftazidime anhydrous; Ceftazidime pentahydrate; Fortaz In Plastic Container; SN 401; CEFTAZIDIME (ARGININE FORMULATION); Ceftazidima [INN-Spanish]; Ceftazidime (INN); Ceftazidime (TN); Ceftazidimum [INN-Latin]; Cefzim (TN); Ceptaz (TN); Fortaz (TN); Fortum (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3508	DB00438	.	.	546.6	C22H22N6O7S2	245	1020	0.4	37	3	12	8	"1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1"	CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-]	ORFOPKXBNMVMKC-DWVKKRMSSA-N
DG00236	Isepamicin	3037209	Isepacin (TN)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB13540	.	.	569.6	C22H43N5O12	298	817	-6.9	39	12	16	9	"1S/C22H43N5O12/c1-22(35)6-36-20(15(33)18(22)26-2)39-17-8(27-19(34)9(28)4-23)3-7(25)16(14(17)32)38-21-13(31)12(30)11(29)10(5-24)37-21/h7-18,20-21,26,28-33,35H,3-6,23-25H2,1-2H3,(H,27,34)/t7-,8+,9-,10+,11+,12-,13+,14-,15+,16+,17-,18+,20+,21+,22-/m0/s1"	C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N)NC(=O)[C@H](CN)O)O	UDIIBEDMEYAVNG-ZKFPOVNWSA-N
DG00237	Lincomycin	3000540	"Cillimycin; Epilincomycin; Jiemycin; LCM; Lincocin; Lincocine; Lincolcina; Lincolnensin; Lincomicina; Lincomix; Lincomycine; Lincomycinum; Lincomyocin; Lincorex; Mycivin; Lincomycin A; Lincomycine [French]; CBMicro_021584; Lincomix 20; Pura Ject 100; Lincocin (TN); Lincomicina [INN-Spanish]; Lincomycine [INN-French]; Lincomycinum [INN-Latin]; U 10,149A; Lincomycin (USAN/INN); Lincomycin [USAN:INN:BAN]; Lincomycin, (2S-cis)-Isomer; Methyl 6,8-dideoxy-6-[(1-methyl-4-propylprolyl)amino]-1-thiooctopyranoside"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6472	DB01627	.	.	406.5	C18H34N2O6S	148	499	0.2	27	5	8	7	"1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1"	CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O	OJMMVQQUTAEWLP-KIDUDLJLSA-N
DG00238	Novobiocin	54675769	"Albamix; Albamycin; Cardelmycin; Cathocin; Cathomycin; Inamycin; NOV; Novobiocina; Novobiocine; Novobiocinum; Robiocina; Sirbiocina; Spheromycin; Stilbiocina; Streptonivicin; Crystallinic acid; Novobiocin sodium salt; PA 93; U 6391; Albamycin (TN); Antibiotic PA-93; Novo-R; Novobiocin [INN:BAN]; Novobiocina [INN-Spanish]; Novobiocine [INN-French]; Novobiocinum [INN-Latin]; Streptonivicin (*Sodium salt*); [(3R,4S,5R,6R)-5-hydroxy-6-[2-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-4-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] carbamate; N-[7-[[3-O-(Aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-.beta.-L-lyxo-hexopyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl]-4-hydroxy-3-(3-methyl-2-butenyl); (3R,4S,5R,6R)-5-hydroxy-6-{[4-hydroxy-3-({[4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl]carbonyl}amino)-8-methyl-2-oxo-2H-chromen-7-yl]oxy}-3-methoxy-2,2-dimethyltetrahydro-2H-pyran-4-yl carbamate; (3r,4s,5r,6r)-5-hydroxy-6-[(2-hydroxy-3-{[4-hydroxy-3-(3-methylbut-2-en-1-yl)benzoyl]amino}-8-methyl-4-oxo-4h-chromen-7-yl)oxy]-3-methoxy-2,2-dimethyltetrahydro-2h-pyran-4-yl carbamate(non-preferred name); 7-(3-(O-Carbamoyl)-4-(O-methyl)-5,5-dimethyl-alpha-L-lyxopyranosyloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methyl-2-butenyl)benzamidol)-8-methylcumarin; 7-(Carbamoyltetrahydro-3-hydroxy-5-methoxy-6,6-dimethylpyran-2-yloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methylbut-2-enyl)benzamide)-8-methyl-2H-chromen-2-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:28368	DB01051	.	.	612.6	C31H36N2O11	196	1150	3.3	44	5	11	9	"1S/C31H36N2O11/c1-14(2)7-8-16-13-17(9-11-19(16)34)27(37)33-21-22(35)18-10-12-20(15(3)24(18)42-28(21)38)41-29-23(36)25(43-30(32)39)26(40-6)31(4,5)44-29/h7,9-13,23,25-26,29,34-36H,8H2,1-6H3,(H2,32,39)(H,33,37)/t23-,25+,26-,29-/m1/s1"	CC1=C(C=CC2=C1OC(=O)C(=C2O)NC(=O)C3=CC(=C(C=C3)O)CC=C(C)C)O[C@H]4[C@@H]([C@@H]([C@H](C(O4)(C)C)OC)OC(=O)N)O	YJQPYGGHQPGBLI-KGSXXDOSSA-N
DG00239	Ertapenem	150610	"Ertapenem [INN]; Ertapenem (INN); Invanz (TN); (1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid; (4R,5S,6S)-3-((3S,5S)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-({(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:404903	DB00303	.	DR2457	475.5	C22H25N3O7S	182	893	-1.5	33	5	9	7	"1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1"	C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)NC4=CC=CC(=C4)C(=O)O)C(=O)O)[C@@H](C)O	JUZNIMUFDBIJCM-ANEDZVCMSA-N
DG00240	Norfloxacin	4539	"Baccidal; Barazan; Chibroxin; Fulgram; Lexinor; NFLX; Norflo; Norfloxacine; Norfloxacino; Norfloxacinum; Noroxin; Sebercim; Merck Brand of Norfloxacin; Norfloxacin Merck Brand; AM 0715; AM 715; AM0715; MK 0366; MK 366; MK0366; MK366; AM-0715; AM-715; Chibroxin (TN); Insensye (TN); MK-0366; MK-366; Norflohexal (TN); Norfloxacine [INN-French]; Norfloxacino [INN-Spanish]; Norfloxacinum [INN-Latin]; Norfocin (TN); Noroxin (TN); Nufloxib (TN); Roxin (TN); Utin (TN); Utinor (TN); Apo-Norflox (TN); Norfloxacin (JP15/USP/INN); Norfloxacin [USAN:BAN:INN:JAN]; Chibroxin, MK-366, Baccidal, Sebercim, Zoroxin, Norfloxacin; 1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:100246	DB01059	DR01204	DR1176	319.33	C16H18FN3O3	72.9	519	-1	23	2	7	3	"1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)"	CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O	OGJPXUAPXNRGGI-UHFFFAOYSA-N
DG00241	Lenalidomide	216326	"Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63791	DB00480	DR00261	.	259.26	C13H13N3O3	92.5	437	-0.5	19	2	4	1	"1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)"	C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N	GOTYRUGSSMKFNF-UHFFFAOYSA-N
DG00242	Macrolides	5280440	Tylosin; tylosin tartrate; Tilosina; Tylosinum; UNII-YEF4JXN031; Tylosine; Tylocine; Tylan; Tylosin A; 1401-69-0; YEF4JXN031; Fradizine; CHEBI:17658; Vubityl 200; Tylosinum [INN-Latin]; Tylosine [INN-French]; Tilosina [INN-Spanish]; HSDB 7022; EINECS 215-754-8; AI3-29799; SR-05000002057; Tylosin [USP:INN:BAN]; Tylan (TN); Tylosin (USP/INN); AC1NQX0W	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:17658	DB11475	.	.	916.1	C46H77NO17	239	1560	1	64	5	18	13	"1S/C46H77NO17/c1-13-33-30(22-58-45-42(57-12)41(56-11)37(52)26(5)60-45)18-23(2)14-15-31(49)24(3)19-29(16-17-48)39(25(4)32(50)20-34(51)62-33)64-44-38(53)36(47(9)10)40(27(6)61-44)63-35-21-46(8,55)43(54)28(7)59-35/h14-15,17-18,24-30,32-33,35-45,50,52-55H,13,16,19-22H2,1-12H3/b15-14+,23-18+/t24-,25+,26-,27-,28+,29+,30-,32-,33-,35+,36-,37-,38-,39-,40-,41-,42-,43+,44+,45-,46-/m1/s1"	CC[C@@H]1[C@H](/C=C(/C=C/C(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)O)N(C)C)O)CC=O)C)\\C)CO[C@H]4[C@@H]([C@@H]([C@@H]([C@H](O4)C)O)OC)OC	WBPYTXDJUQJLPQ-VMXQISHHSA-N
DG00244	Neratinib	9915743	Neratinib (ERBB2 inhibitor)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:61397	DB11828	.	DR1887	557	C30H29ClN6O3	112	881	4.9	40	2	8	11	"1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+"	CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C	JWNPDZNEKVCWMY-VQHVLOKHSA-N
DG00245	Amorolfine	54260	"Loceryl; Pekiron; MT-861; Amorolfine (cream, onychomycosis); Ro-14-4767; Amorolfine (cream, onychomycosis), Roche; Ro-14-4767/002"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:599440	DB09056	.	.	317.5	C21H35NO	12.5	336	5.7	23	0	2	6	"1S/C21H35NO/c1-7-21(5,6)20-10-8-19(9-11-20)12-16(2)13-22-14-17(3)23-18(4)15-22/h8-11,16-18H,7,12-15H2,1-6H3/t16 ,17-,18+"	CCC(C)(C)C1=CC=C(C=C1)CC(C)CN2C[C@H](O[C@H](C2)C)C	MQHLMHIZUIDKOO-AYHJJNSGSA-N
DG00246	Elvitegravir	5277135	EVG	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:72289	DB09101	.	DR0570	447.9	C23H23ClFNO5	87.1	702	5.3	31	2	7	7	"1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1"	CC(C)[C@@H](CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O	JUZYLCPPVHEVSV-LJQANCHMSA-N
DG00247	Enzalutamide	15951529	MDV3100; Enzalutamide (AR inhibitor)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:68534	DB08899	.	DR0583	464.4	C21H16F4N4O2S	109	839	3.6	32	1	8	3	"1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)"	CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C	WXCXUHSOUPDCQV-UHFFFAOYSA-N
DG00248	Isoarnebin 4	479503	"Shikonin; NSC 252844; Shikonin S; Shikonin,(S); Tokyo Violet"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:81068	.	.	.	288.29	C16H16O5	94.8	501	3	21	3	5	3	"1S/C16H16O5/c1-8(2)3-4-10(17)9-7-13(20)14-11(18)5-6-12(19)15(14)16(9)21/h3,5-7,10,17-19H,4H2,1-2H3/t10-/m1/s1"	CC(=CC[C@H](C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)O)C	NEZONWMXZKDMKF-SNVBAGLBSA-N
DG00249	Verapamil	2520	"Arpamyl; Calan; Calcan; Cordilox; Dexverapamil; Dilacoran; Drosteakard; Iproveratril; Isoptimo; Isoptin; Isotopin; Vasolan; Veracim; Verapamilo; Verapamilum; Veraptin; Verexamil; Bosoptin (TN); Calan (TN); D-365; Isoptin (TN); Verapamilo [INN-Spanish]; Verapamilum [INN-Latin]; Verelan (TN); CP-16533-1; Covera-HS (TN); Verapamil (USAN/INN); Verapamil [USAN:BAN:INN]; Verapamil [USAN:INN:BAN]; Alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; (+-)-Verapamil; (+/-)-VERAPAMIL; (1)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile; 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Verapamil (Na-Ca chanel blocker)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:77733	DB00661	DR00264	.	454.6	C27H38N2O4	64	606	3.8	33	0	6	13	"1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3"	CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC	SGTNSNPWRIOYBX-UHFFFAOYSA-N
DG00250	Sunitinib	5329102	"Sunitanib; Sunitinibum; Sutent; PDGF TK antagonist; SU 11248; SU11248; KS-5022; SU-11248; SU-11248J; SU-12662; Su-011248; Sunitinib (INN); Sunitinib (free base); Sutent (TN); N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; Sunitinib (Pan-TK inhibitor)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:38940	DB01268	DR00454	.	398.5	C22H27FN4O2	77.2	636	2.6	29	3	4	7	"1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-"	CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)F)NC2=O)C	WINHZLLDWRZWRT-ATVHPVEESA-N
DG00251	Clindamycin	446598	"Antirobe; CLDM; CLY; Chlolincocin; Chlorlincocin; Chlorodeoxylincomycin; Chlorolincomycin; Cleocin; ClindaDerm; Clindamicina; Clindamycine; Clindamycinum; Clinimycin; Dalacine; Klimicin; Sobelin; Zindaclin; Cleocin HCl; Cleocin T Gel; Cleocin T Lotion; Cleocin T Topical Solution; Clindamycine [French]; Dalacin C; Dalacin C Flavored Granules; Dalacin C Phosphate; Dalacin T Topical Solution; ResiDerm A; Klindan 300; U 21251; Cleocin (TN); Clindacin (TN); Clindamicina [INN-Spanish]; Clindamycin & Interleukin 12; Clindamycin & VRC3375; Clindamycine [INN-French]; Clindamycinum [INN-Latin]; Dalacin (TN); Evoclin (TN); U-21251; CLINDA & IL-12; Clindamycin (USAN/INN); Clindamycin [USAN:BAN:INN]; U-21,251; 7(S)-Chloro-7-deoxylincomycin; 7-CDL; 7-Chloro-7-deoxylincomycin; 7-Chlorolincomycin; 7-Deoxy-7(S)-chlorolincomycin"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB01190	.	DR0340	425	C18H33ClN2O5S	128	502	2.2	27	4	7	7	"1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1"	CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl	KDLRVYVGXIQJDK-AWPVFWJPSA-N
DG00252	Penicillin	2349	"Cillin; Pentids; 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3,3-Dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (Phenylmethyl)penicillin; 7005-30-3; NSC131815; (Phenylmethyl)penicillinic acid; 3,3-dimethyl-7-oxo-6-((phenylacetyl)amino)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; AC1L1DHC; AC1Q5UVJ; Penicilline G sodium salt; Oprea1_713794; Oprea1_861345; CHEMBL300052; SCHEMBL2109546; CTK2H5530"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB01053	.	.	334.4	C16H18N2O4S	112	530	1.8	23	2	5	4	"1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)"	CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C	JGSARLDLIJGVTE-UHFFFAOYSA-N
DG00253	NVP-TAE684	16038120	"761439-42-3; NVP-TAE684; NVP-TAE 684; TAE684; TAE-684; 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine; TAE684 (NVP-TAE684); TAE 684; UNII-EH1713MN4K; CHEMBL509032; EH1713MN4K; 5-Chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-2,4-pyrimidinediamine; C30H40ClN7O3S"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:91338	.	.	.	614.2	C30H40ClN7O3S	111	940	5.7	42	2	10	9	"1S/C30H40ClN7O3S/c1-21(2)42(39,40)28-8-6-5-7-26(28)33-29-24(31)20-32-30(35-29)34-25-10-9-23(19-27(25)41-4)37-13-11-22(12-14-37)38-17-15-36(3)16-18-38/h5-10,19-22H,11-18H2,1-4H3,(H2,32,33,34,35)"	CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC	QQWUGDVOUVUTOY-UHFFFAOYSA-N
DG00254	Mitoxantrone	4212	"DHAD; DHAQ; Dihydroxyanthraquinone; MIX; Misostol; Mitoxanthrone; Mitoxantron; Mitoxantrona; Mitoxantronum; Mitozantrone; DHAQ HCl; Mitoxantrone [INN]; Mitozantrone hydrochloride; Mitoxantrone 2HCl; Liposome Encapsulated Mitoxantrone (LEM); Misostol (TN); Mitoxantrona [INN-Spanish]; Mitoxantrone (INN); Mitoxantrone (free base); Mitoxantronum [INN-Latin]; Novantrone (TN); AN-584/42007670; Novantrone(R) (mitoxantrone for injection concentrate); DHAQ (*Diacetate salt*); MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE; 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-(9CI)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:50729	DB01204	DR00269	DR1102	444.5	C22H28N4O6	163	571	1	32	8	10	12	"1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2"	C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO	KKZJGLLVHKMTCM-UHFFFAOYSA-N
DG00255	Leucovorin	135403648	.	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:15640	DB00650	DR00238	.	473.4	C20H23N7O7	216	911	-1.2	34	7	10	9	"1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12 ,13-/m0/s1"	C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O	VVIAGPKUTFNRDU-ABLWVSNPSA-N
DG00256	Chlortetracycline	54675777	Aureomycin	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:27644	DB09093	.	.	478.9	C22H23ClN2O8	182	1010	-1.3	33	6	9	2	"1S/C22H23ClN2O8/c1-21(32)7-6-8-15(25(2)3)17(28)13(20(24)31)19(30)22(8,33)18(29)11(7)16(27)12-10(26)5-4-9(23)14(12)21/h4-5,7-8,15,26-27,30,32-33H,6H2,1-3H3,(H2,24,31)/t7-,8-,15-,21-,22-/m0/s1"	C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C(C=CC(=C41)Cl)O)O)O)O)C(=O)N)N(C)C)O	DHPRQBPJLMKORJ-XRNKAMNCSA-N
DG00257	Enoxacin	3229	"Almitil; Bactidan; Comprecin; Enoram; Enoxacine; Enoxacino; Enoxacinum; Enoxin; Enoxor; Flumark; Penetrex; Enoxacin Sesquihydrate; Enoxacine [French]; Enoxacino [Spanish]; Enoxacinum [Latin]; Faulding Brand of Enoxacin; Pierre Fabre Brand of Enoxacin Sesquihydrate; Rhone Poulenc Rorer Brand of Enoxacin Sesquihydrate; AT 2266; AT2266; CI919; CL23362; E0762; PD 107779; PD107779; AT-2266; Almitil (TN); Bactidan (TN); Bactidron (TN); Comprecin (TN); Enoksetin (TN); Enoxen (TN); Enoxin (TN); Enoxor (TN); Enroxil (TN); Flumark (TN); Gyramid (TN); PD-107779; Penetrex (TN); Rhone-Poulenc Rorer Brand of Enoxacin Sesquihydrate; Sesquihydrate, Enoxacin; Vinone (TN); Enoxacin (USAN/INN); Enoxacin [USAN:BAN:INN:JAN]; 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-4-oxo-7-piperazinyl; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:157175	DB00467	DR01280	.	320.32	C15H17FN4O3	85.8	521	-0.2	23	2	8	3	"1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)"	CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O	IDYZIJYBMGIQMJ-UHFFFAOYSA-N
DG00258	Sulfamethoxazole	5329	"Sulfamethoxazole; 723-46-6; Gantanol; Sulphamethoxazole; Sulfisomezole; Sulfamethoxazol; Metoxal; Sulfamethylisoxazole; Simsinomin; Radonil; Sinomin; Sulphamethoxazol; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; Sulpha-methoxizole; Sulfamethalazole; Azo-gantanol; Sulphamethylisoxazole; Urobak; Sulfamethoxizole; 3-Sulfanilamido-5-methylisoxazole; Gantanol-DS; 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide; Bactrimel; Gamazole; Sulphisomezole; Sulfametoxazol; Solfametossazolo; Sulfamethoxazolum; Ro 4-2130; SMX; Septran; Sulphamethalazole; Trib; Solfametossazolo [DCIT]; Sulfamethoxazole sodium; MS 53; Sulphamethoxazole BP 98; ALBB-002089; Apo-Sulfamethoxazole; Bactrim (TN); Septra (TN); Septrin (TN); Sulfamethoxazolum [INN-Latin]; Sulfametoxazol [INN-Spanish]; Ro 6-2580/11; Ro-4-2130; Sulfamethoxazole [USAN:INN:JAN]; Sulfamethoxazole (JP15/USP/INN); N1-(5-Methyl-3-isoxazolyl)sulfanilamide; N1-(5-Methylisoxazol-3-yl)sulfanilamide; SULFAMETHOXAZOLE (8064-90-2 (TRIMETHOPRIM/SULFAMETHOXAZOLE); N'-(5-Methyl-3-isoxazole)sulfanilamide; N'-(5-Methyl-3-isoxazolyl)sulfanilamide; N'-(5-Methylisoxazol-3-yl)sulphanilamide; N(sup 1)-(5-Methyl-3-isoxazolyl)sulfanilamide; N(sup 1)-(5-Methyl-3-isoxazolyl)sulphanilamide; N(sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)-(8CI); 3-(p-Aminophenylsulfonamido)-5-methylisoxazole; 3-(para-Aminophenylsulphonamido)-5-methylisoxazole; 3-Sulphanilamido-5-methylisoxazole; 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide; 4-Amino-N-[5-methyl-3-isoxazolyl]benzenesulfonamide; 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide; 5-Methyl-3-sulfanilamidoisoxazole; 5-Methyl-3-sulfanylamidoisoxazole; 5-Methyl-3-sulphanil-amidoisoxazole; Sulphameth oxazole"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9332	DB01015	DR01206	DR1511	253.28	C10H11N3O3S	107	346	0.9	17	2	6	3	"1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)"	CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N	JLKIGFTWXXRPMT-UHFFFAOYSA-N
DG00259	Demeclocycline	54680690	"Bioterciclin; Clortetrin; DMCT; DMCTC; Declomycin; Deganol; Demeclociclina; Demeclocyclinum; Demeclor; Demethylchlorotetracycline; Demethylchlortetracyclin; Demethylchlortetracycline; Demethylchlortetracyclinum; Demetraclin; Diuciclin; Ledermycin; Methylchlorotetracycline; Mexocine; Novotriclina; Perciclina; Sumaclina; Demeclocycline Monohydrochloride; Demethylchlortetracycline base; Ledermycin hydrochloride; RP 10192; DMCT (antibiotic); Declomycin (TN); Declostatin (TN); Demeclociclina [INN-Spanish]; Demeclocycline (USP); Demeclocycline [USAN:BAN]; Demeclocyclinum [INN-Latin]; Demethylchlortetracycline (JAN); Ledermycin (TN); Tri-demethylchlortetracycline; [4S-(4alpha,4aalpha,5aalpha,6beta,12aalpha)]-7-chloro-4-(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide; (2E)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2E,4S,4aS,5aS,6R,12aR)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2E,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; 6-Demethyl-7-chlorotetracycline; 6-Demethyl-7-chlortetracycline; 6-Demethylchlorotetracycline; 6-Demethylchlortetracycline; 6-Demetil-7-clorotetraciclina; 6-Demetil-7-clorotetraciclina [Italian]; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide; 7-Chloro-4-dimethylamino-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide; 7-Chloro-6-demethyltetracycline"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4392	DB00618	.	.	464.9	C21H21ClN2O8	182	961	0.7	32	6	9	2	"1S/C21H21ClN2O8/c1-24(2)14-7-5-6-10(16(27)12-9(25)4-3-8(22)11(12)15(6)26)18(29)21(7,32)19(30)13(17(14)28)20(23)31/h3-4,6-7,14-15,25-27,30,32H,5H2,1-2H3,(H2,23,31)/t6-,7-,14-,15-,21-/m0/s1"	CN(C)[C@H]1[C@@H]2C[C@@H]3[C@@H](C4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O	GUXHBMASAHGULD-SEYHBJAFSA-N
DG00260	Betulinic acid	64971	"Betulinic acid; 472-15-1; Mairin; Betulic acid; NSC 113090; CCRIS 6748; 3-Hydroxylup-20(29)-en-28-oic acid; UNII-4G6A18707N; 3beta-Hydroxy-20(29)-lupaene-28-oic acid; EINECS 207-448-8; NSC677578; als-357; NSC 677578; CHEMBL269277; CHEBI:3087; 3beta-Hydroxy-lup-20(29)-en-28-oic acid; 4G6A18707N; Lup-20(29)-en-28-oic acid, 3-hydroxy-, (3beta)-; AK-72848; Lupatic Acid; SMR000445624"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:3087	DB12480	.	.	456.7	C30H48O3	57.5	861	8.2	33	2	3	2	"1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)/t19-,20+,21-,22+,23-,24+,27-,28+,29+,30-/m0/s1"	CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)C(=O)O	QGJZLNKBHJESQX-FZFNOLFKSA-N
DG00261	Doxycycline	54671203	"Atridox; Azudoxat; DOXY; Deoxymykoin; Dossiciclina; Doxiciclina; Doxitard; Doxivetin; Doxycen; Doxychel; Doxycin; Doxycyclin; Doxycyclinum; Doxysol; Doxytec; Doxytetracycline; Hydramycin; Investin; Jenacyclin; Liviatin; Monodox; Oracea; Ronaxan; Spanor; Supracyclin; Vibramycin; Vibramycine; Vibravenos; DOXCYCLINE ANHYDROUS; DOXYCYCLINE CALCIUM; DOXYCYCLINE MONOHYDRATE; Dossiciclina [DCIT]; Doxiciclina [Italian]; Doxycycline anhydrous; Doxycycline hyclate; Vibramycin Novum; Alpha-Doxycycline; Alti-Doxycycline; Apo-Doxy; BMY-28689; BU-3839T; Doxiciclina [INN-Spanish]; Doxy-Caps; Doxy-Puren; Doxy-Tabs; Doxychel (TN); Doxycycline (INN); Doxycycline (TN); Doxycycline (anhydrous); Doxycycline (internal use); Doxycycline-Chinoin; Doxycyclinum [INN-Latin]; Novo-Doxylin; Nu-Doxycycline; Periostat (TN); Vibra-tabs; Alpha-6-Deoxyoxytetracycline; DMSC (*Fosfatex); Doxycycline (200mg/day) or Placebo; Monodox (*monohydrate); Vibramycin (*monohydrate); Vivox (*Hyclate); GS-3065 (*monohydrate); Alpha-6-Deoxy-5-hydroxytetracycline; (2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS); 5-Hydroxy-alpha-6-deoxytetracycline; 6-Deoxyoxytetracycline; 6-Deoxytetracycline; 6-alpha-Deoxy-5-oxytetracycline; 6alpha-Deoxy-5-oxytetracycline"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:50845	DB00254	DR00666	DR0547	444.4	C22H24N2O8	182	956	-0.7	32	6	9	2	"1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25-27,30,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1"	C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O	SGKRLCUYIXIAHR-AKNGSSGZSA-N
DG00262	Artemisinin	68827	"Arteannuin; Artemisine; Artemisinina; Artemisinine; Artemisininum; Artesin; Huanghuahaosu; Qinghaosu; Qinghosu; Quinghaosu; Artemisinin [INN]; Artemisinina [Spanish]; Artemisinine [French]; Artemisininum [Latin]; Qing Hau SU; Qing Hau Sau; Qing Hau Sau [Chinese]; Qinghaosu [Chinese]; Quing Hau Sau; Artemisinin (INN); Coartem, Artemisinin; Artemisia annua L., extract; GNF-PF-5671; GNF-Pf-5341; Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (+)-Arteannuin; (+)-Artemisinin; (3R,5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10(3H)-one; (3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one; 1,5,9-trimethyl-(1R,4S,5R,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one; 3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:223316	DB13132	.	.	282.33	C15H22O5	54	452	2.8	20	0	5	0	"1S/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H3/t8-,9-,10+,11+,13-,14-,15-/m1/s1"	C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)C	BLUAFEHZUWYNDE-NNWCWBAJSA-N
DG00263	Clofazimine	2794	"Clofazimine; 2030-63-9; Lamprene; Lampren; Chlofazimine; Clofazimina; Clofaziminum; Clofaziminum [INN-Latin]; B 663 (Pharmaceutical); Clofazimina [INN-Spanish]; B-663; NSC-141046; G 30320; UNII-D959AE5USF; B 663 (VAN); C27H22Cl2N4; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; B 663; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; EINECS 217-980-2; CFZ; SMP2_000339; B 663, pharmaceutical; G-30320; Lamprene (TN); Liposome-encapsulated clofazimine; Clofazimine [USAN:INN:BAN]; G-30,320; Clofazimine (JAN/USP/INN); N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(1-methylethyl)imino)-2-phenazinamine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; (3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; Riminophenazine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3749	DB00845	DR00669	DR0346	473.4	C27H22Cl2N4	40	829	7.1	33	1	4	4	"1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3"	CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl	WDQPAMHFFCXSNU-UHFFFAOYSA-N
DG00264	Flucytosine	3366	"Alcobon; Ancobon; Ancotil; Ancotyl; Flucitosina; Flucystine; Flucytosin; Flucytosinum; Flucytosone; Fluocytosine; Fluorcytosine; Fluorocytosine; Flucitosina [DCIT]; F0321; LT00771985; Ancobon (TN); Flucytosinum [INN-Latin]; GL663142 & 5FC; Ro 2-9915; Ro 29915 E/265601; Ro-2-9915; Flucytosine (JP15/USP/INN); Flucytosine [USAN:INN:BAN:JAN]; Cytosine, 5-fluoro-(6CI,7CI,8CI); GL663142 & 4-Amino-5-fluoropyrimidin-2(1H)-one; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-); 2-Hydroxy-4-amino-5-fluoropyrimidine; 4-Amino-5-fluoro-2(1H)-pyrimidinone; 4-Amino-5-fluoro-2-hydroxypyrimidine; 4-Amino-5-fluoro-2-hyroxypyrimidine; 4-Amino-5-fluoropyrimidin-2(1H)-one; 5-FC; 5-Flucytosine; 5-Fluorocystosine; 5-Fluorocytosin; 5-Fluorocytosine; 5-Fluorocytosine-6-3H; 5-Flurocytosine; 5-fluoro cytosine; 5987P; 6-Amino-2-oxo-5-fluoropyrimidine; 6-amino-5-fluoro-1H-pyrimidin-2-one; 9074P"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:5100	DB01099	.	DR2287	129.09	C4H4FN3O	67.5	208	-0.9	9	2	3	0	"1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)"	C1=NC(=O)NC(=C1F)N	XRECTZIEBJDKEO-UHFFFAOYSA-N
DG00265	Hygromycin B	56928061	AC1NUSSH	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11520	.	.	527.5	C20H37N3O13	272	756	-6.6	36	11	16	6	"1S/C20H37N3O13/c1-23-7-2-5(21)9(26)15(10(7)27)33-19-17-16(11(28)8(4-25)32-19)35-20(36-17)18(31)13(30)12(29)14(34-20)6(22)3-24/h5-19,23-31H,2-4,21-22H2,1H3/t5-,6+,7+,8-,9+,10-,11+,12-,13+,14-,15-,16+,17+,18-,19+,20 /m1/s1"	CN[C@H]1C[C@H]([C@@H]([C@H]([C@@H]1O)O[C@H]2[C@@H]3[C@H]([C@H]([C@H](O2)CO)O)OC4(O3)[C@@H]([C@H]([C@H]([C@H](O4)[C@H](CO)N)O)O)O)O)N	GRRNUXAQVGOGFE-HUCHGKBZSA-N
DG00266	Bortezomib	387447	"179324-69-7; Velcade; Bortezomib (PS-341); UNII-69G8BD63PP; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; CHEMBL325041; 69G8BD63PP; Boronic acid,; DPBA; PROSCRIPT BORONIC ACID; LPD 341; LPD-341; VELCADE (TN); Velcade (TN); Pyz-Phe-boroLeu; Bortezomib(JAN/USAN/INN); Velcade, MG-341, PS-341, Bortezomib; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; Bortezomib (Proteasome inhibitor); Peptide boronate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:52717	DB00188	DR01331	DR0221	384.2	C19H25BN4O4	124	500	.	28	4	6	9	"1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1"	B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O	GXJABQQUPOEUTA-RDJZCZTQSA-N
DG00267	Methotrexate	126941	"Methotrexate; 1959/5/2; Rheumatrex; Amethopterin; Metatrexan; Hdmtx; Abitrexate; Mexate; Methylaminopterinum; Methotrexatum; Antifolan; Metotrexato; Methylaminopterin; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Methotrexat; Amethopterine; Maxtrex; Rasuvo; L-Amethopterin; A-Methopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; N-Bismethylpteroylglutamic acid; Methotrexate, L-; Metotressato [DCIT]; Methotextrate; Mexate-Aq; [3H]methotrexate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:44185	DB00563	DR00082	DR1045	454.4	C20H22N8O5	211	704	-1.8	33	5	12	9	"1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1"	CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O	FBOZXECLQNJBKD-ZDUSSCGKSA-N
DG00268	Calcitriol	5280453	"Calcitriol; Rocaltrol; 32222-06-3; Calcijex; Topitriol; 1alpha,25-Dihydroxyvitamin D3; Silkis; Soltriol; 1alpha,25-Dihydroxycholecalciferol; Calcitriolum; Dihydroxyvitamin D3; 1,25-DHCC; 1,25-Dihydroxyvitamin D; Vectical; 1,25-DIHYDROXYCHOLECALCIFEROL; 1,25-Dihydroxyvitamin D3; 1alpha,25-Dihydroxyvitamin D; 1-alpha,25-Dihydroxyvitamin D3; Calcitriolum [INN-Latin]; UNII-FXC9231JVH; 1alpha,25(OH)2D3; DN-101; 1,25-Dihydroxycholecaliferol; CCRIS 5522; Ro 21-5535; HSDB 3482; 1-alpha,25-Dihydroxycholecalciferol; EINECS 250-963-8; DN 101; Calcitriol (chemotherapy-induced alopecia); Calcitriol (chemotherapy-induced alopecia), Cytotech Labs; Calcitriol (API-31543, drug-induced alopecia), Cytotech Labs; 1alpha,25 dihydroxyvitamin D(3)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:17823	DB00136	.	DR0260	416.6	C27H44O3	60.7	688	5.1	30	3	3	6	"1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1"	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C	GMRQFYUYWCNGIN-NKMMMXOESA-N
DG00269	Rilpivirine	6451164	"500287-72-9; TMC278; Edurant; TMC 278; UNII-FI96A8X663; R278474; TMC-278; 4-{[4-({4-[(E)-2-Cyanoethenyl]-2,6-Dimethylphenyl}amino)pyrimidin-2-Yl]amino}benzonitrile; CHEBI:68606; FI96A8X663; R 278474; 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile; (E)-4-((4-((4-(2-cyanovinyl)-2,6-dimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile; (E)-4-(4-(4-(2-cyanovinyl)-2,6-dimethylphenylamino)pyrimidin-2-ylamino)benzonitrile; W-202888; RPV; Mu O-conotoxin"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:68606	DB08864	.	.	366.4	C22H18N6	97.4	607	4.5	28	2	6	5	"1S/C22H18N6/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19/h3-9,11-13H,1-2H3,(H2,25,26,27,28)/b4-3+"	CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)/C=C/C#N	YIBOMRUWOWDFLG-ONEGZZNKSA-N
DG00270	Alectinib	49806720	"1256580-46-7; CH5424802; CH 5424802; AF-802; Alecensa; UNII-LIJ4CT1Z3Y; AF 802; LIJ4CT1Z3Y; Alectinib (CH5424802); 9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile; CHEMBL1738797; AF802; 9-Ethyl-6,6-Dimethyl-8-[4-(Morpholin-4-Yl)piperidin-1-Yl]-11-Oxo-6,11-Dihydro-5h-Benzo[b]carbazole-3-Carbonitrile; 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile; AK170451; C30H34N4O2; Alectinib; 9-ethyl-6,6-dimethyl-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:90936	DB11363	.	.	482.6	C30H34N4O2	72.4	867	5.2	36	1	5	3	"1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3"	CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C	KDGFLJKFZUIJMX-UHFFFAOYSA-N
DG00271	Capsaicin	1548943	"Capsaicin (transdermal patch formulation, neuropathic pain)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3374	DB06774	.	DR0268	305.4	C18H27NO3	58.6	341	3.6	22	2	3	9	"1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+"	CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC	YKPUWZUDDOIDPM-SOFGYWHQSA-N
DG00272	Lopinavir	92727	AIDS032937; Aluvia (TN); Aluviran; Kaletra (TN); Koletra; LPV; Lopinavir (JAN/USAN/INN); Lopinavir [USAN:INN:BAN]; RS-346; A 157378; A 157378.0; A-157378-0; A-157378.0; ABT 157378; ABT 378; ABT-378; ABT-378	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31781	DB01601	DR00290	DR0976	628.8	C37H48N4O5	120	940	5.9	46	4	5	15	"1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1"	CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O	KJHKTHWMRKYKJE-SUGCFTRWSA-N
DG00273	Cisplatin	5702198	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00515	.	.	300.05	Cl2H6N2Pt	2	2.8	.	5	2	2	0	1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2	N.N.Cl[Pt]Cl	LXZZYRPGZAFOLE-UHFFFAOYSA-L
DG00274	Midazolam	4192	"Dazolam; Dormicum; Midanium; Midazolamum; Midosed; Versed; Midazolam Base; Dormicum (TN); Hypnovel (TN); Midacum (TN); Midazolamum [INN-Latin]; Ro 21-3981; Versed (TN); Midazolam (JAN/INN); Midazolam [INN:BAN:JAN]; 4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate; 8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride; 8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine; 8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6931	DB00683	DR00684	.	325.8	C18H13ClFN3	30.2	471	2.5	23	0	3	1	"1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3"	CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F	DDLIGBOFAVUZHB-UHFFFAOYSA-N
DG00275	Thalidomide	5426	"Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:74947	DB01041	DR00461	DR1572	258.23	C13H10N2O4	83.6	449	0.3	19	1	4	1	"1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)"	C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O	UEJJHQNACJXSKW-UHFFFAOYSA-N
DG00276	Trospium chloride	5284631	Regurin; Sanctura	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:32270	DB00209	DR01284	.	428	C25H30ClNO3	46.5	553	.	30	1	4	5	"1S/C25H30NO3.ClH/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26;/h1-6,9-12,21-23,28H,7-8,13-18H2;1H/q+1;/p-1/t21-,22+,23 ;"	C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-]	RVCSYOQWLPPAOA-DHWZJIOFSA-M
DG00277	Abexinostat	11749858	PCI-24781; 783355-60-2; ABEXINOSTAT; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:92223	DB12565	.	.	397.4	C21H23N3O5	104	550	2.2	29	3	6	8	"1S/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25)"	CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO	MAUCONCHVWBMHK-UHFFFAOYSA-N
DG00278	Itraconazole	55283	"Canadiol; Hyphanox; ITCZ; ITZ; Intraconazole; Itraconazol; Itraconazolum; Itrizole; Oriconazole; Orungal; Prokanazol; Sempera; Spherazole; Sporal; Sporanos; Sporanox; Sporonox; Triasporn; Itraconazol [Spanish]; Itraconazole oral solution; Itraconazolum [Latin]; R 51211; Cis-Itraconazole; Itraconazole & Bovine Lactoferrin; Itraconazole & Nyotran; Itrizole (TN); R-51211; Sporanox (TN); Itraconazole & Nyotran(Liposomal Nystatin); Itraconazole (JAN/USAN); Oriconazole, R51211, Sporanox; Itraconazole [USAN:BAN:INN:JAN]; (+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one; (1)-cis-4-(4-(4-(4-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-2-sec-butyl-3H-1,2,4-triazol-3-one; 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl); 4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6076	DB01167	.	.	705.6	C35H38Cl2N8O4	101	1120	5.7	49	0	9	11	"1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25 ,31-,35-/m0/s1"	CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl	VHVPQPYKVGDNFY-ZPGVKDDISA-N
DG00279	Indinavir	5362440	"Crixivan; IDV; Indinavir [USAN]; L 735524; Crixivan (TM); Crixivan (TN); L-735 524; L-735524; MK-639; Propolis+Indinavir; RS-253; L-735,524; Indinavir, Sulfate (1:1); Indinavir (*1:1 Sulfate salt*); N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE; Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide; (1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide; (2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:44032	DB00224	DR00299	.	613.8	C36H47N5O4	118	952	2.8	45	4	7	12	"1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1"	CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5	CBVCZFGXHXORBI-PXQQMZJSSA-N
DG00280	Dactolisib	11977753	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:71952	DB11651	.	.	469.5	C30H23N5O	73.1	872	5.2	36	0	4	3	"1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3"	CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5	JOGKUKXHTYWRGZ-UHFFFAOYSA-N
DG00281	Beta-lapachone	3885	"ARQ 501; SL 11001; A-lapachone; LAPACHONE, BETA; AK-693/21096016; 2,2-dimethyl-3,4-dihydrobenzo[h]chromene-5,6-dione; 3,4-Dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione; 3,4-Dihydro-2,2-dimethyl-2H-naphtho[1,2-B]pyran-5,6-dione"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:10429	DB11948	.	DR1869	242.27	C15H14O3	43.4	445	2.2	18	0	3	0	"1S/C15H14O3/c1-15(2)8-7-11-13(17)12(16)9-5-3-4-6-10(9)14(11)18-15/h3-6H,7-8H2,1-2H3"	CC1(CCC2=C(O1)C3=CC=CC=C3C(=O)C2=O)C	QZPQTZZNNJUOLS-UHFFFAOYSA-N
DG00282	Sorafenib	216239	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:50924	DB00398	DR00304	DR1500	464.8	C21H16ClF3N4O3	92.4	646	4.1	32	3	7	5	"1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)"	CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F	MLDQJTXFUGDVEO-UHFFFAOYSA-N
DG00283	Cefpodoxime	6335986	"CPDX; Cefpodoxima; Cefpodoximum; Epoxim; Cefpodoxim acid; Cefpodoxima [Spanish]; Cefpodoximum [Latin]; RU 51807; Cefpodoxime (INN); Cefpodoxime [INN:BAN]; Epoxim (TN); Vantin (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-[(methyloxy)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-{[(2-amino-1,3-thiazol-4-yl)(methoxyimino)acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3504	DB01416	DR00974	DR2661	427.5	C15H17N5O6S2	210	744	-1.4	28	3	11	7	"1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1"	COCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OC)/C3=CSC(=N3)N)SC1)C(=O)O	WYUSVOMTXWRGEK-HBWVYFAYSA-N
DG00284	Alpelisib	56649450	"Alpelisib; 1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:93752	DB12015	.	DR0074	441.5	C19H22F3N5O2S	129	663	3.2	30	2	8	4	"1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1"	CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F	STUWGJZDJHPWGZ-LBPRGKRZSA-N
DG00285	Berberine	2353	"Berberine; 2086-83-1; Berberin; Umbellatine; UNII-0I8Y3P32UF; 0I8Y3P32UF; CHEBI:16118; EINECS 218-229-1; Berberal; BRN 3570374; ST055798; 9,10-Dimethoxy-2,3-(methylenedioxy)-7,8,13,13a-tetrahydroberbinium; Benzo(g)-1,3-benzodioxolo(5,6-a)quinolizinium, 5,6-dihydro-9,10-dimethoxy-; 9,10-dimethoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium; Berbamine sulphate acid; CHEMBL12089; 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenedioxy)berbinium; BERBINIUM, 7,8,13,13a-TETRAHYDRO-9,10-DIMETHOXY-2,3-(METHYLE"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:16118	DB04115	DR00307	.	336.4	C20H18NO4+	40.8	488	3.6	25	0	4	2	"1S/C20H18NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,7-10H,5-6,11H2,1-2H3/q+1"	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC	YBHILYKTIRIUTE-UHFFFAOYSA-N
DG00286	Vinblastine	13342	"Nincaluicolflastine; Rozevin; VLB; Vinblastin; Vinblastina; Vinblastinum; Vincaleucoblastin; Vincaleucoblastine; Vincaleukoblastine; Vincoblastine; Vinblastina [DCIT]; VR-8; Vinblastina (TN); Vinblastine (INN); Vinblastine [INN:BAN]; Vinblastinum [INN-Latin]; NDC 0002-1452-01; (2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; (2xi,3beta,4'beta,19xi)-vincaleukoblastine; 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00570	DR00308	.	811	C46H58N4O9	154	1700	3.7	59	3	12	10	"1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1"	CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O	JXLYSJRDGCGARV-CFWMRBGOSA-N
DG00287	Saquinavir	441243	"Fortovase; Invirase; ROC; SQV; Saguinavir; Ro 318959; Fortovase (TN); Fortovase(TM); Invirase (TN); Ro 31-8959; Invirase(TM)(monomesylate); Ro-31-8959; Saquinavir (JAN/USP/INN); QNC-ASN-HPH-DIQ-NTB; CIS-N-TERT-BUTYL-DECAHYDRO-2-[2(R)-HYDROXY-4-PHENYL-3(S)-[[N-2-QUINOLYLCARBONYL-L-ASPARAGINYL]AMINO]BUTYL]-(4AS)-ISOQUINOLINE-3(S)-CARBOXAMIDE; (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide; (2s)-N-[(2s,3r)-4-[(2s,3s,4as,8as)-3-(Tert-Butylcarbamoyl)-3,4,4a,5,6,7,8,8a-Octahydro-1h-Isoquinolin-2-Yl]-3-Hydroxy-1-Phenyl-Butan-2-Yl]-2-(Quinolin-2-Ylcarbonylamino)butanediamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63621	DB01232	DR00309	.	670.8	C38H50N6O5	167	1140	4.2	49	5	7	13	"1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1"	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O	QWAXKHKRTORLEM-UGJKXSETSA-N
DG00288	Cefdinir	6915944	"CFDN; Cefdinirum; Cefdinyl; Cefdirnir; Cefzon; Omnicef; BMY 28488; FK 482; PD 134393; Cefdinir [USAN:INN]; Cefdinirum [INN-Latin]; Cefzon (TN); FK-482; FR-80482; KS-1038; Omnicef (TN); PD-134393; Cefdinir (JP15/USAN/INN); Omnicef, FK-482, BMY-28488, PD 134393, CI-983, Cefdinir; (-)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-oxime; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(2 (2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid; 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetamido]-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3485	DB00535	DR00692	.	395.4	C14H13N5O5S2	212	739	0	26	4	10	5	"1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1"	C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\O)/C3=CSC(=N3)N)SC1)C(=O)O	RTXOFQZKPXMALH-GHXIOONMSA-N
DG00289	I-BET151	52912189	GSK1210151A	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:95083	.	.	.	415.4	C23H21N5O3	93.4	665	2.7	31	1	6	4	"1S/C23H21N5O3/c1-12-21(14(3)31-27-12)16-9-18-15(10-20(16)30-4)22-19(11-25-18)26-23(29)28(22)13(2)17-7-5-6-8-24-17/h5-11,13H,1-4H3,(H,26,29)/t13-/m1/s1"	CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)[C@H](C)C5=CC=CC=N5)OC	VUVUVNZRUGEAHB-CYBMUJFWSA-N
DG00290	Josamycin	5282165	"Josacine; Josamicina; Josamycine; Josamycinum; EN 141; Kitasamycin A3; Leucomycin A3; Turimycin A5; Antibiotic yl-704 A3; Iosalide (TN); Josacine (TN); Josalid (TN); Josamicina [INN-Spanish]; Josamina (TN); Josamy (TN); Josamycin (TN); Josamycine [INN-French]; Josamycinum [INN-Latin]; Wilprafen (TN); Yl-704 A3; Josamycin [USAN:INN:JAN]; Josamycin (JP15/USAN/INN); Dro-2H-pyran-3-yl 3-methylbutanoate; Leucomycin V, 3-acetate 4B-(3-methylbutanoate); Leucomycin V, 3-acetate 4(sup B)-(3-methylbutanoate); Leucomycin V,3-acetate 4(sup beta)-(3-methylbutanoate)"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:31739	DB01321	.	.	828	C42H69NO15	206	1390	2.9	58	3	16	14	"1S/C42H69NO15/c1-23(2)19-32(47)56-40-27(6)53-34(22-42(40,8)50)57-37-26(5)54-41(36(49)35(37)43(9)10)58-38-29(17-18-44)20-24(3)30(46)16-14-12-13-15-25(4)52-33(48)21-31(39(38)51-11)55-28(7)45/h12-14,16,18,23-27,29-31,34-41,46,49-50H,15,17,19-22H2,1-11H3/b13-12+,16-14+/t24-,25-,26-,27+,29+,30+,31-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1"	C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)OC(=O)C)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O)C)O	XJSFLOJWULLJQS-NGVXBBESSA-N
DG00291	Coumermycin	54675768	.	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:3907	DB13912	.	.	1110.1	C55H59N5O20	347	2440	4.6	80	9	20	16	"1S/C55H59N5O20/c1-21-12-16-29(57-21)48(67)77-42-38(63)52(79-54(6,7)44(42)71-10)73-31-18-14-26-36(61)34(50(69)75-40(26)24(31)4)59-46(65)28-20-56-33(23(28)3)47(66)60-35-37(62)27-15-19-32(25(5)41(27)76-51(35)70)74-53-39(64)43(45(72-11)55(8,9)80-53)78-49(68)30-17-13-22(2)58-30/h12-20,38-39,42-45,52-53,56-58,61-64H,1-11H3,(H,59,65)(H,60,66)/t38-,39-,42+,43+,44-,45-,52-,53-/m1/s1"	CC1=CC=C(N1)C(=O)O[C@H]2[C@H]([C@@H](OC([C@@H]2OC)(C)C)OC3=C(C4=C(C=C3)C(=C(C(=O)O4)NC(=O)C5=CNC(=C5C)C(=O)NC6=C(C7=C(C(=C(C=C7)O[C@H]8[C@@H]([C@@H]([C@H](C(O8)(C)C)OC)OC(=O)C9=CC=C(N9)C)O)C)OC6=O)O)O)C)O	WTIJXIZOODAMJT-DHFGXMAYSA-N
DG00292	Sulforaphane	5350	"Sulforafan; DL-Sulforaphane; 1-Isothiocyanato-4-(methylsulfinyl)butane; D,L-Sulforaphane; L-Sulforaphane; Sulforaphane (unspecified); R,S-Sulforaphane; C6H11NOS2; 1-isothiocyanato-4-methylsulfinylbutane; Sulforaphane Racemate; CCRIS 7221; 1-Isothiocyanato-4-(methylsulfinyl)-butane; Butane, 1-isothiocyanato-4-(methylsulfinyl)-; SUVMJBTUFCVSAD-UHFFFAOYSA-N; 4-(Methylsulfinyl)Butyl Isothiocyanate"	Phase 4	4	Approved Drug(s)	Phase 4	Small molecular drug	CHEBI:47807	DB12422	.	.	177.3	C6H11NOS2	80.7	152	1.4	10	0	4	5	"1S/C6H11NOS2/c1-10(8)5-3-2-4-7-6-9/h2-5H2,1H3"	CS(=O)CCCCN=C=S	SUVMJBTUFCVSAD-UHFFFAOYSA-N
DG00293	Chloramphenicol	5959	"Alficetyn; Ambofen; Amphenicol; Amphicol; Amseclor; Anacetin; Aquamycetin; Austracil; Austracol; Biocetin; Biophenicol; CAF; CLM; Catilan; Chemiceticol; Chemicetin; Chemicetina; Chlomin; Chlomycol; Chloramex; Chloramfenikol; Chloramficin; Chloramfilin; Chloramphenicolum; Chloramsaar; Chlorasol; Chloricol; Chlornitromycin; Chloroamphenicol; Chlorocaps; Chlorocid; Chlorocide; Chlorocol; Chlorofair; Chloromax; Chloromycetin; Chloromycetny; Chloromyxin; Chloronitrin; Chloroptic; Chlorovules; Chlorsig; Cidocetine; Ciplamycetin; Cloramfen; Cloramfenicol; Cloramfenicolo; Cloramficin; Cloramical; Cloramicol; Cloramidina; Cloranfenicol; Cloroamfenicolo; Clorocyn; Cloromisan; Cloromissan; Clorosintex; Comycetin; Cylphenicol; Desphen; Detreomycin; Detreomycine; Dextromycetin; Doctamicina; Duphenicol; Econochlor; Embacetin; Emetren; Enicol; Enteromycetin; Erbaplast; Ertilen; Farmicetina; Fenicol; Globenicol; Glorous; Halomycetin; Hortfenicol; Interomycetine; Intramycetin; Intramyctin; Isicetin; Ismicetina; Isophenicol; Juvamycetin; Kamaver; Kemicetina; Kemicetine; Kloramfenikol; Klorita; Laevomycetinum; Leukamycin; Leukomyan; Leukomycin; Levomicetina; Levomitsetin; Levomycetin; Loromicetina; Loromisan; Loromisin; Mastiphen; Mediamycetine; Medichol; Micloretin; Micochlorine; Micoclorina; Microcetina; Mychel; Mycinol; Myscel; Novochlorocap; Novomycetin; Novophenicol; Oftalent; Oleomycetin; Opclor; Opelor; Ophthochlor; Ophtochlor; Optomycin; Otachron; Otophen; Pantovernil; Paraxin; Pentamycetin; Quemicetina; Rivomycin; Romphenil; Ronfenil; Ronphenil; Septicol; Sificetina; Sintomicetina; Stanomycetin; Synthomycetin; Synthomycetine; Synthomycine; Syntomycin; Tevcocin; Tevcosin; Tifomycin; Tifomycine;Tiromycetin; Treomicetina; Unimycetin; Veticol; Viceton; Ch loramex; Chloramfenikol [Czech]; Chloramphenicol crystalline; Chlormycetin R; Chlorocid S; Chlorocidin C; Chlorocidin C tetran; Chloroject L; Chloromycetny [Polish]; Cloramfenicolo [DCIT]; Cloroamfenicolo [Italian]; F armicetina; Isopto fenicol; Klorocid S; Normimycin V; Sintomicetine R; Sno Phenicol; Vice ton; I 337A; Ak-chlor; Alficetyn (TN); Amphicol (TN); Biomicin (TN); Brochlor (TN); CAF (pharmaceutical); Cedoctine (TN); Chlora-tabs; Chloramex (TN); Chloramphenicol & VRC3375; Chloramphenicolum [INN-Latin]; Chlorbiotic (Veterinary); Chlornitromycin (TN); Chloro-25 vetag; Chloromycetin (TN); Chlorsig (TN); Cloramfenicol [INN-Spanish]; D-Chloramphenicol; Dispersadron C (TN); Econochlor (TN); Elase-Chloromycetin; Fenicol (TN); Golden Eye (TN); Isoptophenicol (TN); Kemicetine (TN); Laevomycetin (TN); Medicom (TN); Mychel-Vet; Nevimycin (TN); Oftan Chlora (TN); Optrex Infected Eyes (TN); Orchadexoline (TN); Phenicol (TN); Renicol (TN); Silmycetin (TN); Sno-Phenicol; Synthomycine (TN); Tea-Cetin; Tega-Cetin; Tifomycine (TN); U-6062; Vernacetin (TN); Veticol (TN); C.A.F; CHLOROPTIC S.O.P; Chloramphenicol [INN:BAN:JAN]; Chloromycetin® D-threo-Chloramphenicol; Alficetyn, Chlornitromycin, Chloromycetin, Chloramphenicol; Chloramphenicol (JP15/USP/INN); Chloroptic S.O.P.; D(-)-threo-Chloramphenicol; D-(-)-Chloramphenicol; D-(-)-threo-Chloramphenicol; D(-)-threo-2-dichloroacetamido-1-p-nitrophen yl-propanediol; D(-)-threo-2-dichloroacetamido-1-p-nitrophenyl-propanediol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:17698	DB00446	DR00989	DR0298	323.13	C11H12Cl2N2O5	115	342	1.1	20	3	5	5	"1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1"	C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-]	WIIZWVCIJKGZOK-RKDXNWHRSA-N
DG00294	Carboplatin	426756	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31355	DB00958	.	.	371.25	C6H12N2O4Pt	76.6	177	.	13	4	6	0	"1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H2;/q;2*-1;+2"	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]	VSRXQHXAPYXROS-UHFFFAOYSA-N
DG00295	Benzoic acid	243	"Phenylformate; benzoate anion; Benzoic acid, ion(1-); 766-76-7; Benzeneformate; Tennplas; Phenylcarboxylate; Benzenemethanoate; Retarded BA; Benzenecarboxylate; Phenyl carboxylic acid; benzoic acid anion; Oracyclic acid; 4-Carboxybenzenide; Benzene formic acid; AC1Q1HDY; AC1Q22CA; AC1L18SS; GTPL4565; DTXSID4043771; CHEBI:16150; BDBM36181; CTK2H9612; WPYMKLBDIGXBTP-UHFFFAOYSA-M; STL483236; ZINC328578076; NCGC00247905-01; ZB000218; CJ-00025; LS-190261; 3230-EP2374454A1; 3230-EP2372017A1; 3230-EP2316825A1; 3230-EP2316457A1"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:30746	DB03793	.	.	122.12	C7H6O2	37.3	104	1.9	9	1	2	1	"1S/C7H6O2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H,8,9)"	C1=CC=C(C=C1)C(=O)O	WPYMKLBDIGXBTP-UHFFFAOYSA-N
DG00296	Cefadroxil	47965	"CDX; Cefadroxilo; Cefadroxilum; Cephadroxil; Sumacef; Cefadroxil anhydrous; S 578; BL-S 578; BL-S578; Cefadroxil (JP15); Cefadroxilo [INN-Spanish]; Cefadroxilum [INN-Latin]; Curisafe (TN); D-Cefadroxil; S-578; Sumacef (TN); MJF-11567-3; (6R,7R)-7-((R)-2-Amino-2-(p-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,4-didehydrocepham-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3479	DB01140	DR00313	DR2413	363.4	C16H17N3O5S	158	629	-2.1	25	4	7	4	"1S/C16H17N3O5S/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24)/t10-,11-,15-/m1/s1"	CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O	BOEGTKLJZSQCCD-UEKVPHQBSA-N
DG00297	Mitomycin	5746	"Mitomycin C; mitomycin C; 1950/7/7; Mutamycin; Ametycine; Mitocin-C; Ametycin; Mitomycin-C; Mytozytrex; Mitomycinum; Mytomycin; Mitozytrex; Mitomycinum C; Mitocin C; Mitomycins; Mitamycin; MMC; Mitosol; Mitomycyna C; 7-Amino-9alpha-methoxymitosane; NSC-26980; Mitomycyna C [Polish]; Mito-C; Mit-C; Mitomycin (TN); Mitomycinum [INN-Latin]; Mitomycine [INN-French]; Mitomicina [INN-Spanish]; NCI-C04706; RCRA waste number U010; NSC26980; NSC 26980; Mitomycine; CCRIS 414; UNII-50SG953SK6; HSDB 3239; C15H18N4O5; EINECS 200-008-6; Mitomycin C,; Ametycin; Mitomicina; Muamycin; Mitomycin C from Streptomyces caespitosus; Mitomycin C (JP15); Mitomycin C, Streptomyces caespitosus; Muamycin (TN); Mitomycin (USP/INN); Mitomycin [USAN:INN:BAN]; Mitomycin C, Streptomyces caespitosus, Carrier-Free"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:27504	DB00305	DR01212	.	334.33	C15H18N4O5	147	757	-0.4	24	3	8	4	"1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1"	CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N	NWIBSHFKIJFRCO-WUDYKRTCSA-N
DG00299	Cefuroxime	5479529	"Anaptivan; Biociclin; Biofuroksym; Bioxima; CXM; Cefofix; Cefumax; Cefurex; Cefuril; Cefuroxim; Cefuroximesodium; Cefuroximine; Cefuroximo; Cefuroximum; Cephuroxime; Cetroxil; Colifossim; Curocef; Curoxim; Curoxima; Curoxime; Froxal; Furoxil; Kesint; Ketocef; Lifurox; Medoxim; Sharox; Spectrazolr; Ultroxim; Zinacef;CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER; CEFUROXIME SODIUM; Cefuroxim AJ; Cefuroxim Fresenius; Cefuroxim Genericsn; Cefuroxim Hexal; Cefuroxim Lilly; Cefuroxim MN; Cefuroxim Norcox; Cefuroxim curasan; Cefuroxima Fabra; Cefuroxima Richet; Cefuroxime for Injection and Dextrose for Injection in Duplex Container; Cefuroxime na; Cefuroxime sodium salt; KEFUROX IN PLASTIC CONTAINER; Sodium cefuroxime; ZINACEF IN PLASTIC CONTAINER; Zinacef Danmark; Ceftin (TN); Cefuroxim Norcox [inj.]; Cefuroxime (TN); Cefuroximo [INN-Spanish]; Cefuroximum [INN-Latin]; Cetroxil [inj.]; Froxal [inj.]; KS-1040; Sharox [inj.]; Zinacef (TN); Zinnat (TN); Zinnat [inj.]; Cefuroxime (USAN/INN); Cefuroxime [USAN:INN:BAN]; Cefuroxime sodium (JP15/USP); Cefuroxime sodium [USAN:BAN:JAN]; Sodium (6R-(6alpha,7beta(Z)))-3-(((aminocarbonyl)oxy)methyl)-7-(2-furyl(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate; Sodium (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), carbamate (ester); (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-(2-(2-Furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid 7(sup 2)-(Z)-(O-methyloxime) carbamate (ester); 3-[(carbamoyloxy)methyl]-7beta-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-3,4-didehydrocepham-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3515	DB01112	.	.	424.4	C16H16N4O8S	199	798	-0.2	29	3	10	8	"1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9-/t10-,14-/m1/s1"	CO/N=C(/C1=CC=CO1)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O	JFPVXVDWJQMJEE-IZRZKJBUSA-N
DG00300	Oxaliplatin	9887053	Eloxatin (TN); Medac (TN); Oxaliplatin (TN); Oxaliplatin (JAN/USAN/INN)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00526	.	.	397.29	C8H14N2O4Pt	76.6	191	.	15	4	6	0	"1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1"	C1CC[C@H]([C@@H](C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]	DRMCATBEKSVAPL-BNTLRKBRSA-N
DG00301	Amikacin	37768	"Amicacin; Amikacina; Amikacine; Amikacinum; Amikavet; Amikin; Arikace; Briclin; Kaminax; Lukadin; Mikavir; AMIKACIN SULFATE; Amikacin Base; Amikacin Dihydrate; ANTIBIOTIC BB-K8; Amiglyde-V; Amikacin & Tumor Necrosis Factor; Amikacin (USP); Amikacina [INN-Spanish]; Amikacine [INN-French]; Amikacinum [INN-Latin]; Amikin(Disulfate); Antibiotic BB-K 8; BB-K 8; BB-K8; Amiglyde-V (TN); Amikacin (USP/INN); Amikacin [USAN:BAN:INN]; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-6))-N(sup 3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->6))-N(3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-D-streptamine; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-{(1R,2S,3S,4R,5S)-5-amino-2-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-3-hydroxycyclohexyl}-2-hydroxybutanamide; 1-N-(L(-)-gamma-Amino-alpha-hydroxybutyryl)kanamycin A"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:2637	DB00479	.	DR2167	585.6	C22H43N5O13	332	819	-7.9	40	13	17	10	"1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1"	C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N	LKCWBDHBTVXHDL-RMDFUYIESA-N
DG00302	Ge2270a	16129640	GE 2770; GE-2270; 134861-34-0; SCHEMBL12519961; CHEBI:29584; LS-187584; LS-186934	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:29584	DB02975	.	.	1290.5	C56H55N15O10S6	520	2530	3.3	87	7	24	11	"1S/C56H55N15O10S6/c1-24(2)39-55-70-42(36(87-55)19-80-5)47(77)59-17-38(73)67-43(44(74)26-10-7-6-8-11-26)54-66-34(23-85-54)52-63-31(20-83-52)41-27(50-64-32(21-82-50)46(76)61-29(16-37(72)58-4)53-69-40(25(3)86-53)48(78)68-39)13-14-28(60-41)51-65-33(22-84-51)49-62-30(18-81-49)56(79)71-15-9-12-35(71)45(57)75/h6-8,10-11,13-14,20-24,29-30,35,39,43-44,74H,9,12,15-19H2,1-5H3,(H2,57,75)(H,58,72)(H,59,77)(H,61,76)(H,67,73)(H,68,78)"	CC1=C2C(=O)NC(C3=NC(=C(S3)COC)C(=O)NCC(=O)NC(C4=NC(=CS4)C5=NC(=CS5)C6=C(C=CC(=N6)C7=NC(=CS7)C8=NC(CO8)C(=O)N9CCCC9C(=O)N)C3=NC(=CS3)C(=O)NC(C(=N2)S1)CC(=O)NC)C(C1=CC=CC=C1)O)C(C)C	JMDULECOHIXMNX-UHFFFAOYSA-N
DG00303	Roxithromycin	6915744	"Assoral; Overall; RXM; Rossitrol; Roxithromycine; Roxithromycinum; Roxitromicina; Rulid; Rulide; Surlid; Roxithromycine [French]; Roxithromycinum [Latin]; Roxitromicina [Spanish]; RC2952; RU 28965; RU 965; Biaxsig (TN); Coroxin (TN); RU-28965; RU-965; Roxar (TN); Roximycin (TN); Roxithromycin & Tumor Necrosis Factor; Roxo (TN); Rulide (TN); Surlid (TN); Tirabicin (TN); Roxithromycin [USAN:INN:JAN]; Roxl-150 (TN); Roxithromycin (JP15/USAN/INN); Erythromycin 9-(-O-[2-methoxyethoxy]methyloxime);Erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime); Erythromycin, 9-(O-((2-methoxyethoxy)methyl)oxime); 9-(O-((2-Methoxyethoxy)methyl)oxime)erythromycin; 9-[O-(2-methoxyethoxymethyl)-oxime] of erythromycin"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:48935	DB00778	DR00708	DR1448	837	C41H76N2O15	217	1310	3.1	58	5	17	13	"1S/C41H76N2O15/c1-15-29-41(10,49)34(45)24(4)31(42-53-21-52-17-16-50-13)22(2)19-39(8,48)36(58-38-32(44)28(43(11)12)18-23(3)54-38)25(5)33(26(6)37(47)56-29)57-30-20-40(9,51-14)35(46)27(7)55-30/h22-30,32-36,38,44-46,48-49H,15-21H2,1-14H3/b42-31+/t22-,23-,24+,25+,26-,27+,28+,29-,30+,32-,33+,34-,35+,36-,38+,39-,40-,41-/m1/s1"	CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O	RXZBMPWDPOLZGW-XMRMVWPWSA-N
DG00304	Pemetrexed	135410875	"Alimta; LYA; LY 231514; LY231514; Alimta (TN); LY 231,514; LY-2315; LY-231514; Pemetrexed (INN); Pemetrexed [INN:BAN]; LY-231,514; N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid; (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63616	DB00642	DR00318	.	427.4	C20H21N5O6	187	748	0.2	31	6	7	9	"1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1"	C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O	WBXPDJSOTKVWSJ-ZDUSSCGKSA-N
DG00305	Dacarbazine	135398738	"Biocarbazin; Biocarbazine; DTIC; DTICDome; DTIE; Dacarbazino; Dacarbazinum; Dacatic; Decarbazine; Deticene; Dimethyltriazenoimidazolecarboxamide; ICDMT; ICDT; Biocarbazine R; DTIC Dome; Dimethyl Imidazole Carboxamide; Dimethyl Triazeno Imidazole Carboxamide; Imidazole carboxamide; HE1150000; Carboxamide (TN); Carboxamide, Dimethyl Imidazole; DIC (TN); DTIC (TN); DTIC-Dome; Dacarbazino [INN-Spanish]; Dacarbazinum [INN-Latin]; Imidazole (TN); Imidazole Carboxamide, Dimethyl; NPFAPI-05; DTIC-Dome (TN); Di-me-triazenoimidazolecarboxamide; Di-methyl-triazenoimidazolecarboxamide; Dtic-Dome (TN); DTIC, DTIC-Dome, Dacarbazine; Dacarbazine (JAN/USP/INN); Dacarbazine [USAN:INN:BAN:JAN]; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (Dimethyltriazeno)imidazolecarboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(Dimethyltriazeno)imidazole-5-c arboxamide; 4-(Dimethyltriazeno)imidazole-5-carboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide; 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide; 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; 5-(Dimethyltriazeno)-4-imidazolecarboxamide; 5-(Dimethyltriazeno)imidazole-4-carboxamide; 5-(Dimethyltriazeno)imidazole-4-carboximide; 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:94587	DB00851	.	DR0404	182.18	C6H10N6O	99.7	215	-0.6	13	2	5	3	"1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+"	CN(C)/N=N/C1=C(NC=N1)C(=O)N	FDKXTQMXEQVLRF-ZHACJKMWSA-N
DG00306	Vemurafenib	42611257	PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63637	DB08881	DR00711	DR1677	489.9	C23H18ClF2N3O3S	100	790	5	33	2	7	7	"1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)"	CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F	GPXBXXGIAQBQNI-UHFFFAOYSA-N
DG00308	Ampicillin	6249	"ABPC; Acillin; Adobacillin; Alpen; Amblosin; Amcill; Amfipen; Aminobenzylpenicillin; Ampen; Ampichel; Ampicil; Ampicilina; Ampicillanyl; Ampicillina; Ampicilline; Ampicillinum; Ampicin; Ampifarm; Ampikel; Ampimed; Ampipenin; Ampiscel; Ampisyn; Ampivax; Ampivet; Amplacilina; Amplin; Amplipenyl; Amplisom; Amplital; Austrapen; Binotal; Bonapicillin; Britacil; Campicillin; Cimex; Copharcilin; Delcillin; Deripen; Divercillin; Doktacillin; Duphacillin; Grampenil; Guicitrina; Guicitrine; Lifeampil; Morepen; Norobrittin; Nuvapen; Omnipen; Orbicilina; Penbristol; Penbritin; Penbrock; Penicline; Penimic; Pensyn; Pentrex; Pentrexl; Pentrexyl; Polycillin; Ponecil; Princillin; Principen; QIDamp; Racenacillin; Rosampline;Roscillin; Semicillin; Servicillin; Sumipanto; Supen; Synpenin; Texcillin; Tokiocillin; Tolomol; Totacillin; Totalciclina; Totapen; Trifacilina; Ukapen; Ultrabion; Ultrabron; Vampen; Viccillin; Wypicil; Amfipen V; Amipenix S; Ampicillin A; Ampicillin Anhydrous; Ampicillin Base; Ampicillin acid; Ampicillin anhydrate; Ampicillina [DCIT]; Anhydrous ampicillin; Olin Kid; Pen A; Pen A Oral; Pen Ampil;Penbritin paediatric; Penbritin syrup; Pfizerpen A; Semicillin R; Viccillin S; AY 6108; BA 7305; BRL 1341; Bayer 5427; HI 63; P 50; Principen 125; Principen 250; Principen 500; SQ 17382; AB-PC; AB-PCSol; AY-6108; Ambidrin (TN); Ampi-Co; Ampi-Tab; Ampi-bol; Ampicilina [INN-Spanish]; Ampicilline [INN-French]; Ampicillinum [INN-Latin]; Ampipenin, nt3; Ampy-Penyl; Anhydrous ampicillin (JP15); BRL-1341; D-Ampicillin; D-Cillin; KS-R1; Novo-ampicillin; OMNIPEN (AMPICILLIN); Omnipen (TN); Omnipen-N; P-50; Penbritin-S; Penicillin, Aminobenzyl; Pfizerpen-A; Polycillin-N; Polyflex (Veterinary); Ro-Ampen; SK-Ampicillin; Totacillin (sodium); Totacillin-N; WY-5103; Ampicillin (USP/INN); AMPICILLIN (SEE ALSO AMPICILLIN TRIHYDRATE 7177-48-2); Ampicillin [USAN:BAN:INN:JAN]; Ampicillin [USAN:INN:BAN:JAN];D-(-)-Ampicillin; D-(-)-alpha-Aminobenzylpenicillin; D-(-)-alpha-Aminopenicillin; D-(-)-6-(alpha-Aminophenylacetamido)penicillanic acid; 6-(D(-)-alpha-Aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:28971	DB00415	DR00712	DR2177	349.4	C16H19N3O4S	138	562	-1.1	24	3	6	4	"1S/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1"	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C	AVKUERGKIZMTKX-NJBDSQKTSA-N
DG00309	Canertinib	156414	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:61399	DB05424	.	.	485.9	C24H25ClFN5O3	88.6	671	3.9	34	2	8	9	"1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)"	C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4	OMZCMEYTWSXEPZ-UHFFFAOYSA-N
DG00310	Kanamycin	6032	"Aspidium; KAN; Kanamicina; Kanamycine; Kanamycinum; Kantrex; Klebcil; KANAMYCIN A; Kanamicina [Italian]; Kanamycin A tetracation; Kanamycin Base; Kanamycin monosulfate; Kanamycin sulfate; Kenamycin A; Liposomal Kanamycin; KM (the Antibiotic); Kanamycin [INN:BAN]; Kanamycin monosulfate (JP15); Kanamycinsulfate (JP15); Kanamycin sulfate (TN); Kanamycin sulfate (USP); Kanamycine [INN-French]; Kanamycinum [INN-Latin]; Kantrex (TN); Kantrex (1:1 sulfate); Klebcil (1:1 sulfate); O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-D-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy-D-streptamine; (1S,2R,3R,4S,6R)-4,6-diamino-3-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diamino-3-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diazaniumyl-3-(6-azaniumyl-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-azaniumyl-3-deoxy-alpha-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol; 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-D-glucoside; 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-D-glucopyranoside"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:17630	DB01172	.	DR2175	484.5	C18H36N4O11	283	638	-6.9	33	11	15	6	"1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1"	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N	SBUJHOSQTJFQJX-NOAMYHISSA-N
DG00311	Cefprozil	5281006	"Arzimol; Brisoral; Cefprozilo; Cefprozilum; Cefzil; Cronocef; Procef; Serozil; Cefprozil anhydrous; BMY 28100; Cefprozil (INN); Cefprozil (TN); Cefprozilo [INN-Spanish]; Cefprozilum [INN-Latin]; Cefzil (TN); Procef (TN); (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-8-oxo-3-(prop-1-en-1-yl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3506	DB01150	.	.	389.4	C18H19N3O5S	158	699	-1.4	27	4	7	5	"1S/C18H19N3O5S/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26)/b3-2+/t12-,13-,17-/m1/s1"	C/C=C/C1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O	WDLWHQDACQUCJR-ZAMMOSSLSA-N
DG00312	Clozapine	135398737	"Asaleptin; CLOZARIL; Clorazil; Clozapin; Clozapina; Clozapinum; Fazaclo; Iprox; Leponex; Lepotex; Fazaclo ODT; C 6305; HF1854; Clopine (TN); Clozapina [INN-Spanish]; Clozapine(tautomer); Clozapinum [INN-Latin]; Clozaril (TN); Denzapine (TN); Fazaclo (TN); Froidir (TN); HF-1854; KS-1166; Klozapol (TN); LEX-123; LX 100-129; Leponex (TN); W-801; Zaponex (TN); Clozapine [USAN:INN:BAN]; Clozapine (JAN/USP/INN); 3-chloro-6-(4-methylpiperazin-1-yl)-5H-benzo[b][1,4]benzodiazepine; 8-Chloro-11-(4-methyl)-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo (b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine; 8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; 8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3766	DB00363	DR00474	DR0363	326.8	C18H19ClN4	30.9	446	3.1	23	1	3	1	"1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3"	CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42	QZUDBNBUXVUHMW-UHFFFAOYSA-N
DG00313	Clarithromycin	84029	"Abbotic; Adel; Astromen; Biaxin; Bicrolid; CTY; Clacine; Clambiotic; Claribid; Claricide; Clarith; Clarithromycina; Clarithromycine; Clarithromycinum; Claritromicina; Clathromycin; Cyllid; Cyllind; Helas; Heliclar; Klacid; Klaciped; Klaricid; Klarid; Klarin; Klax; Kofron; Mabicrol; Macladin; Maclar; Mavid; Naxy;Veclam; Zeclar; Biaxin HP; Biaxin XL; Biaxin filmtab; Biaxin xl filmtab; Clarithromycin extended release; Clarithromycin suspension or tablets; Klaricid Pediatric; Klaricid XL; TE031; A-56268; ANX-015; Abbott-56268; Biaxin (TN); Clacid (TN); Claridar (TN); Claripen (TN); Clarithromycine [INN-French]; Clarithromycinum [INN-Latin]; Claritromicina [INN-Spanish]; Crixan (TN); DRG-0099; Fromilid (TN);Infex (TN); Klabax (TN); Klaricid (TN); Klaricid H.P; Lactoferrin B & Clarithromycin; Lactoferrin H & Clarithromycin; SDP-015; TE-031; Vikrol (TN); CLM & IL-12; CRL-1605 & Clarithromycin; Clarithromycin & Interleukin-12; Klaricid H.P.; O(6)-methylerythromycin; Clarithromycin (JP15/USP/INN); Clarithromycin [USAN:INN:BAN:JAN]; Hydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame; (14R)-14-Hydroxyclarithromycin; 6-O-Methylerythromycin; 6-O-Methylerythromycin a"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3732	DB01211	DR00713	DR0336	748	C38H69NO13	183	1190	3.2	52	4	14	8	"1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1"	CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O	AGOYDEPGAOXOCK-KCBOHYOISA-N
DG00314	Mitotane	4211	"Chloditan; Chlodithan; Chlodithane; Khloditan; Khlodithan; Lysodren; Mitotan; Mitotano; Mitotanum; Mytotan; Bristol Myers Squibb Brand of Mitotane; C 3010; CB 313; CB313; PS694_SUPELCO; Bristol-Myers Squibb Brand of Mitotane; CB-313; Lysodren (TN); Mitotano [INN-Spanish]; Mitotanum [INN-Latin]; Ortho,para DDD; Mitotane [USAN:INN:JAN]; O,p-DDD; O,p-Tde; Ortho,para-DDD; Mitotane (JAN/USP/INN); O,p'-DDD; O,p'-Dichlorodiphenyldichloroethane; O,p'-TDE; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-(8CI); (+-)-1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; (2,4'-Dichlorodiphenyl)dichloroethane; (o,p)-DDD; 1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane; 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; 1-Chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene; 2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane; 2,4'-Ddd; 2,4'-Dichlorodiphenyldichloroethane; 2,4'-Dichlorophenyldichlorethane; 2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane; 2-(o-Chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloroethane"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6954	DB00648	.	.	320	C14H10Cl4	0	248	6.2	18	0	0	3	"1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H"	C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl	JWBOIMRXGHLCPP-UHFFFAOYSA-N
DG00315	Stavudine	18283	"DdeThd; DdeTyd; Dideoxydidehydrothymidine; Estavudina; STV; Sanilvudine; Stavudinum; Zent; Zerit; Zerit Xr; Zerut XR; BMY 27857; BMY27857; D 1413; D 4T; BMY-27857; Bristol-Myers Brand of Stavudine; Bristol-Myers Squibb Brand of Stavudine; D 4T (nucleoside); Estavudina [INN-Spanish]; Sanilvudine (JAN); Stavudine, Monosodium Salt; Stavudinum [INN-Latin]; Zerit (TN); Zerit(TM); D4T & GM-CSF; D4TMBY-27857-3; Stavudine (USAN/INN); Stavudine [USAN:BAN:INN]; Stavudine [USAN:INN:BAN]; Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)-(7CI,8CI); 1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine; 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione; 1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2; 2',3' Didehydro 3' deoxythymidine; 2',3'-Anhydrothymidine; 2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI); 2',3'-Didehydro-2',3'-dideoxythmidine; 2',3'-Didehydro-3'-deoxythimidine; 2',3'-Didehydro-3'-deoxythymidine; 3'-Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor; 3'-Deoxy-2',3'-didehydrothymidine; 3'-Deoxy-2'-thymidinene; D4T"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63581	DB00649	.	.	224.21	C10H12N2O4	78.9	388	-0.8	16	2	4	2	"1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1"	CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO	XNKLLVCARDGLGL-JGVFFNPUSA-N
DG00316	Tyrphostin AG-1478	2051	"AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; Tyrphostin AG-1478; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:75404	.	DR01471	.	315.75	C16H14ClN3O2	56.3	360	4	22	1	5	4	"1S/C16H14ClN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20)"	COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl)OC	GFNNBHLJANVSQV-UHFFFAOYSA-N
DG00317	Monastrol	2987927	"Monastrol; 329689-23-8; 254753-54-3; ETHYL 4-(3-HYDROXYPHENYL)-6-METHYL-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXYLATE; 4-(3-Hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro-4H-pyrimidin-5-carboxylic Acid Ethyl Ester; CHEBI:75382; ( inverted exclamation markA)-Monastrol; SR-01000357662; AC1MGLGQ; Probes2_000257; Probes2_000376; Probes1_000312; Probes1_000042; Probes1_000001; Oprea1_487786; Lopac0_000821; KBioSS_000613; CBDivE_015834; KBioGR_000613; BSPBio_001273; MLS006011746; SCHEMBL3168349; KBio3_001085; KBio2_000613"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:75382	DB04331	.	.	292.36	C14H16N2O3S	103	436	1.6	20	3	4	4	"1S/C14H16N2O3S/c1-3-19-13(18)11-8(2)15-14(20)16-12(11)9-5-4-6-10(17)7-9/h4-7,12,17H,3H2,1-2H3,(H2,15,16,20)"	CCOC(=O)C1=C(NC(=S)NC1C2=CC(=CC=C2)O)C	LOBCDGHHHHGHFA-UHFFFAOYSA-N
DG00318	Moxifloxacin	152946	"Avelox; MFX; MXF; MXFX; Vigamox; Avalox (TN); Avelon (TN); Avelox (TN); Moxifloxacin [INN:BAN]; Vigamox (TN); Avelox I.V.; Actira (*Hydrochloride*); Avelox (*Hydrochloride*); (1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid; 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63611	DB00218	DR00800	.	401.4	C21H24FN3O4	82.1	727	0.6	29	2	8	4	"1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1"	COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O	FABPRXSRWADJSP-MEDUHNTESA-N
DG00319	Sitafloxacin	461399	"127254-12-0; Gracevit; Sitafloxacin Sesquihydrate; DU 6859; 163253-35-8; UNII-3GJC60U4Q8; DU-6859a; Sitafloxacin isomer II; DU 6859A; C19H18ClF2N3O3; 3GJC60U4Q8; CHEBI:4304; 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid; Sitafloxacin [INN]; 7-((S)-7-AMINO-5-AZASPIRO[2.4]HEPTAN-5-YL)-8-CHLORO-6-FLUORO-1-((1R,2S)-2-FLUOROCYCLOPROPYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; STFX; DU-6859; 127254-10-8; Sitafloxacin isomer III (RRS); 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo-3-quinolinecarboxylic acid; 7-[(7S)-7-azanyl-5-azaspiro[2.4]heptan-5-yl]-8-chloranyl-6-fluoranyl-1-[(1R,2S)-2-fluoranylcyclopropyl]-4-oxidanylidene-quinoline-3-carboxylic acid; SITAFLOXACIN ISOMER III(RRS); SITAFLOXACINISOMER; SCHEMBL74553; 7-((7S)-Amino-5-azaspiro(2,4)heptan-5-yl)-8-chloro-6-fluoro-1-((1R,2R)-cis-2-fluoro-1-cyclopropyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid; 7-(7-Amino-5-azaspiro(2.4)heptan-5-yl)-8-chloro-6-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid sesquihydrate; SITAFLOXACINISOMER(RRS); SITAFLOXACINISOMER(RSR); DU6859a; CHEMBL108821; AMSP00027; GTPL11040; HY-B0395; ZINC3795983; AKOS015962212; AC-1388; ACN-048224; AM85541; compound 33 [PMID: 7932562]; YF10030; (-)-7-((7S)-Amino-5-azaspiro(2,4)hept-5-yl)-8-chloro-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-1,4-dihydro-4-oxoq-3-uinolonecarboxylic acid; 3-Quinolinecarboxylic acid, 7-(7-amino-5-azaspiro(2.4)hept-5-yl)-8-chloro-6-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-4-oxo-, (1R-(1alpha(S*),2alpha))-; 3-Quinolinecarboxylic acid, 7-[(7S)-7-amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-; 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo-quinoline-3-carboxylic acid; AT-21032; AB01568244_01; 253S358; A805671; A805673; J-519022; (-)-7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluoro-1-cyclopropyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 273401-03-9; 3-Quinolinecarboxylic acid, 7-((7S)-7-amino-5-azaspiro(24)hept-5-yl)-8-chloro-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-1,4-dihydro-4-oxo-; 7-((7S)-7-Amino-5-azaspiro[2.4]hept-5-yl)-1-((1S,2S)-2-fluorocyclopropyl)-8-chloro-6-fluoro-4-oxohydroquinoline-3-carboxylic acid; 7-((S)-7-Amino-5-azaspiro[2.4]Heptan-5-yl)-8-chloro-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-[(7S)-7-Amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1 R,2S)-2-fluorocyclopropyl]-4-oxo-1,4-dihydro-3-quinolinecarboxyli c acid; rel-7-((R)-7-Amino-5-azaspiro[2.4]heptan-5-yl)-8-chloro-6-fluoro-1-((1S,2R)-2-fluorocyclopropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4304	DB13261	DR01687	.	409.8	C19H18ClF2N3O3	86.9	761	0.7	28	2	8	3	"1S/C19H18ClF2N3O3/c20-14-15-8(17(26)9(18(27)28)5-25(15)12-4-10(12)21)3-11(22)16(14)24-6-13(23)19(7-24)1-2-19/h3,5,10,12-13H,1-2,4,6-7,23H2,(H,27,28)/t10-,12+,13+/m0/s1"	C1CC12CN(C[C@H]2N)C3=C(C=C4C(=C3Cl)N(C=C(C4=O)C(=O)O)[C@@H]5C[C@@H]5F)F	PNUZDKCDAWUEGK-CYZMBNFOSA-N
DG00320	Dichloroacetate	25975	"2,2-dichloroacetate; Dichloracetate; Dichloroacetate ion; 13425-80-4; Dichloroacetic acid ion(1-); DCA; BRN 3903873; 2q8h; ACETIC ACID, DICHLORO-, ION(1-); 2,2-bis(chloranyl)ethanoate; GTPL4518; CHEBI:28240; DTXSID40158610; STL483470; NCGC00241105-01; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; Q27077050"	Phase 4	4	Approved Drug(s)	Phase 4	Small molecular drug	CHEBI:28240	DB08809	.	DR2512	127.93	C2HCl2O2-	40.1	55.1	1.8	6	0	2	0	"1S/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6)/p-1"	C(C(=O)[O-])(Cl)Cl	JXTHNDFMNIQAHM-UHFFFAOYSA-M
DG00321	Beta-elemene	10583	"Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1R,2R,4S)-rel-; 33880-83-0; beta-Elemene, (-)-; (- )-bete-elemene; EINECS 251-713-0; AC1L1VID; Cyclohexane, 2,4-diisopropenyl-1-methyl-1-vinyl-, (1S,2S,4R)-; OPFTUNCRGUEPRZ-UHFFFAOYSA-N; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1S-(1-alpha,2-beta,4-beta))-; (1alpha,2beta,4beta)-1-Methyl-2,4-bis(methylvinyl)-1-vinylcyclohexane; LS-56795; EN300-296339; 1-Methyl-1-vinyl-2,4-diisopropenylcyclohexane"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	204.35	C15H24	0	284	6.1	15	0	0	3	"1S/C15H24/c1-7-15(6)9-8-13(11(2)3)10-14(15)12(4)5/h7,13-14H,1-2,4,8-10H2,3,5-6H3"	CC(=C)C1CCC(C(C1)C(=C)C)(C)C=C	OPFTUNCRGUEPRZ-UHFFFAOYSA-N
DG00322	Carboxyamidotriazole orotate	11599548	.	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	.	.	.	.	580.8	C22H16Cl3N7O6	212	816	.	38	5	9	6	"1S/C17H12Cl3N5O2.C5H4N2O4/c18-10-3-1-9(2-4-10)15(26)13-11(19)5-8(6-12(13)20)7-25-16(21)14(17(22)27)23-24-25;8-3-1-2(4(9)10)6-5(11)7-3/h1-6H,7,21H2,(H2,22,27);1H,(H,9,10)(H2,6,7,8,11)"	C1=CC(=CC=C1C(=O)C2=C(C=C(C=C2Cl)CN3C(=C(N=N3)C(=O)N)N)Cl)Cl.C1=C(NC(=O)NC1=O)C(=O)O	MNWOBDDXRRBONM-UHFFFAOYSA-N
DG00323	Ormaplatin	13920603	TCDCP; Tetraplatin; Tetraplatinum; U-77233	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	451.1	C6H14Cl4N2Pt	52	82	.	13	2	2	0	"1S/C6H14N2.4ClH.Pt/c7-5-3-1-2-4-6(5)8;;;;;/h5-6H,1-4,7-8H2;4*1H;/q;;;;;+4/p-4"	C1CCC(C(C1)N)N.Cl[Pt](Cl)(Cl)Cl	VPOCYEOOFRNHNL-UHFFFAOYSA-J
DG00324	Bendamustine hydrochloride	65628	Treanda (TN)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB06769	.	DR0188	358.3	C16H21Cl2N3O2	58.4	380	2.9	23	1	4	9	"1S/C16H21Cl2N3O2/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23/h5-6,11H,2-4,7-10H2,1H3,(H,22,23)"	CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O	YTKUWDBFDASYHO-UHFFFAOYSA-N
DG00325	Bictegravir	90311989	"Bictegravir; 1611493-60-7; GS-9883; UNII-8GB79LOJ07; GS-9883-01; (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide; 8GB79LOJ07; (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide; Bictegravir [INN]; Bictegravir [USAN:INN]; bictegravirum; GS 9883; Bictegravir (USAN/INN); CHEMBL3989866; SCHEMBL15914278; GTPL11575; CHEBI:172943; BDBM330048; AMY12383; BCP25703; EX-A3161; GS9883; s5911; DB11799; DT-0020; 2,5-Methanopyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazepine-10-carboxamide, 2,3,4,5,7,9,13,13a-octahydro-8-hydroxy-7,9-dioxo-N-((2,4,6-trifluorophenyl)methyl)-, (2R,5S,13aR)-; AC-30658; HY-17605; CS-0014685; D10909; N16998; US9663528, 42; A902376; Q27270406; GS-9883; GS 9883; GS9883; GS-9883-01; (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.0(2),(1)(1).0 , ]hexadeca-4,7-diene-7-carboxamide; (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2, 1-b][1,3]oxazepine-10-carboxamide"	Phase 4	4	Approved Drug(s)	Phase 4	Small molecular drug	.	DB11799	.	.	449.4	C21H18F3N3O5	99.2	912	2.7	32	2	9	3	"1S/C21H18F3N3O5/c22-9-3-14(23)12(15(24)4-9)6-25-20(30)13-7-26-8-16-27(10-1-2-11(5-10)32-16)21(31)17(26)19(29)18(13)28/h3-4,7,10-11,16,29H,1-2,5-6,8H2,(H,25,30)/t10-,11+,16+/m0/s1"	C1C[C@@H]2C[C@H]1N3[C@H](O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F	SOLUWJRYJLAZCX-LYOVBCGYSA-N
DG00326	Nutlin-3	216345	"Nutlin-3; 548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:93777	.	.	.	581.5	C30H30Cl2N4O4	83.5	919	5.2	40	1	5	6	"1S/C30H30Cl2N4O4/c1-18(2)40-25-16-23(39-3)12-13-24(25)29-34-27(19-4-8-21(31)9-5-19)28(20-6-10-22(32)11-7-20)36(29)30(38)35-15-14-33-26(37)17-35/h4-13,16,18,27-28H,14-15,17H2,1-3H3,(H,33,37)"	CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl	BDUHCSBCVGXTJM-UHFFFAOYSA-N
DG00327	Temocapril hydrochloride	443873	Acecol (TN)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:32190	DB08836	.	.	513.1	C23H29ClN2O5S2	150	644	.	33	3	8	11	"1S/C23H28N2O5S2.ClH/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27;/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27);1H/t17-,18-,20-;/m0./s1"	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CS[C@@H](CN(C2=O)CC(=O)O)C3=CC=CS3.Cl	XDDQNOKKZKHBIX-ASBZXGSUSA-N
DG00328	Ceftolozane sulfate	11592969	"Ceftolozane; CXA-101; CXA-301; CXA-301); Cephalosporin derivatives, Astellas; Cephalosporinderivatives, Calixa Therapeutics; FR-193879; FR-264205; FR-295389; CXA-101 (inhaled), Calixa; CXA-101 (inhaled), Cubist; Cephalosporin derivative (H pylori/P aeruginosa infection), Astellas; CXA-101 (inhaled, bacterial lung infection), Cubist"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB09050	.	.	764.8	C23H32N12O12S3	439	1360	.	50	9	20	12	"1S/C23H30N12O8S2.H2O4S/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24;1-5(2,3)4/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42);(H2,1,2,3,4)/b31-11+;/t12-,18-;/m1./s1"	CC(C)(C(=O)O)O/N=C(\\C1=NSC(=N1)N)/C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC(=C(N4C)N)NC(=O)NCCN)C(=O)O.OS(=O)(=O)[O-]	UJDQGRLTPBVSFN-GZGOMJRCSA-N
DG00329	Levothyroxine	5819	"Eltroxin; Euthyrox; Forthyron; Laevothyroxinum; Laevoxin; Levolet; Levothroid; Levothyrox; Levothyroxin; Levoxyl; Oroxine; Synthroid; THX; Tetraiodothyronine; Thyratabs; Thyrax; Thyreoideum; Thyroxevan; Thyroxin; Thyroxinal; Levothyroxine sodium; Synthroid sodium; Thyroxine [BAN]; Thyroxine iodine; LT00440967; T4 levothyroxine; DL-Thyroxin; Eltroxin (TN); Euthyrox (TN); Eutirox (TN); Forthyron (TN); L-Thryoxin; L-Thyroxin; L-thyroxine; Laevothyroxinum (acid); Levaxin (TN); Levo-T; Levothyroxine (BAN); Levothyroxinum (acid); Levoxyl (TN); Synthroid (TN); T-3850; T4 (Hormone); Thyrax (TN); Thyrox (TN); Thyroxine (VAN); Thyroxine (l); L-thyroxine (TN); Levothyroxine Sodium (L-thyroxine); Levothroid (*Sodiumsalt*); Synthroid (*Sodium salt*); Thyroxine, L-(8CI); L-3,5,3',5'-Tetraiodothyronine; O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine; Beta-((3,5-Diiodo-4-hydroxyphenoxy)-3,5-diiodophenyl)alanine; O-(4-Hydroxy-3,5-diidophenyl)-3,5-diiodo-L-tyrosine; O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine; (-)-Thyroxine; (125I)T4; (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid; 2-amino-3-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-propanoic acid; 3,3',5,5""-Tetraiodo-L-thyronine; 3,3',5,5''-Tetraiodo-L-thyronine; 3,3',5,5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodothyronine; 3,5,3'5'-Tetraiodo-L-thyronine; 3-(4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)alanine; 3-[4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-L-alanine; 4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-L-phenylalanine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:18332	DB00451	.	DR1950	776.87	C15H11I4NO4	92.8	420	2.4	24	3	5	5	"1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1"	C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N	XUIIKFGFIJCVMT-LBPRGKRZSA-N
DG00330	Icotinib hydrochloride	44609731	Conmana; Conmanna; Icotinib; BPI-2009-H	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11737	.	.	427.9	C22H22ClN3O4	74.7	553	.	30	2	7	3	"1S/C22H21N3O4.ClH/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20;/h1,3-5,12-15H,6-11H2,(H,23,24,25);1H"	C#CC1=CC(=CC=C1)NC2=NC=NC3=CC4=C(C=C32)OCCOCCOCCO4.Cl	PNNGXMJMUUJHAV-UHFFFAOYSA-N
DG00331	Dovitinib lactate	135611162	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB05928	.	DR1815	500.5	C24H29FN6O5	149	737	.	36	6	10	3	"1S/C21H21FN6O.C3H6O3.H2O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29;1-2(4)3(5)6;/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29);2,4H,1H3,(H,5,6);1H2"	CC(C(=O)O)O.CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N.O	QDPVYZNVVQQULH-UHFFFAOYSA-N
DG00332	Pazopanib HCl	11525740	Votrient (TN)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:71217	DB06589	DR00185	.	474	C21H24ClN7O2S	127	717	.	32	3	8	5	"1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H"	CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.Cl	MQHIQUBXFFAOMK-UHFFFAOYSA-N
DG00333	Nelfinavir	64143	"Nelfinavir; nelfinavir; 159989-64-7; Viracept; Nelfinavir [INN:BAN]; AG1343; UNII-HO3OGH5D7I; AG-1343; C32H45N3O4S; NELFINAVIR MESYLATE AG1343; Viracept (TN); HO3OGH5D7I; CHEBI:7496; AG 1343; NLF; 1UN; 2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE; (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide; NFV; NFV; Nelfinavir Monomethane Sulfonate; AG1346; Nelfinavir (INN); Nelfinavir [BAN:INN]; AG1343 (*Mesylate salt*); Viracept (TM)(*Mesylate salt*); Met-SDF-1beta & Nelfinavir; Met-Stromal Cell-derived Factor-1beta (Human) & Nelfinavir; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide"	Approved	1	Approved Drug(s)	Approved	Antisense drug	.	DB00220	DR00420	.	567.8	C32H45N3O4S	127	830	5.7	40	4	6	10	"1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1"	CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O	QAGYKUNXZHXKMR-HKWSIXNMSA-N
DG00334	Veliparib dihydrochloride	45480520	Veliparib; 912444-00-9; ABT-888; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	.	DB07232	.	.	317.21	C13H18Cl2N4O	83.8	348	.	20	5	3	2	"1S/C13H16N4O.2ClH/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12;;/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17);2*1H/t13-;;/m1../s1"	C[C@@]1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N.Cl.Cl	DSBSVDCHFMEYBX-FFXKMJQXSA-N
DG00335	Viomycin sulfate	135524783	Viocin (TN)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB06827	.	.	783.8	C25H45N13O14S	476	1360	.	53	17	17	10	"1S/C25H43N13O10.H2O4S/c26-3-1-2-10(27)4-16(41)32-12-6-30-23(47)18(11-5-17(42)37-24(28)36-11)38-20(44)13(7-31-25(29)48)33-21(45)14(8-39)35-22(46)15(9-40)34-19(12)43;1-5(2,3)4/h7,10-12,14-15,17-18,39-40,42H,1-6,8-9,26-27H2,(H,30,47)(H,32,41)(H,33,45)(H,34,43)(H,35,46)(H,38,44)(H3,28,36,37)(H3,29,31,48);(H2,1,2,3,4)/b13-7-;/t10-,11+,12-,14-,15-,17-,18-;/m0./s1"	C1[C@@H](N=C(N[C@H]1O)N)[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)C[C@H](CCCN)N.OS(=O)(=O)O	AQONYROJHRNYQQ-QMAPKBLTSA-N
DG00336	Pleuromutilins	9886081	"BC-3004; BC-3080; BC-3291; Pleuromutilins (oral, bacterial infection); Pleuromutilins (oral, bacterial infection), Nabriva"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	378.5	C22H34O5	83.8	645	3.5	27	2	5	4	"1S/C22H34O5/c1-6-20(4)11-16(27-17(25)12-23)21(5)13(2)7-9-22(14(3)19(20)26)10-8-15(24)18(21)22/h6,13-14,16,18-19,23,26H,1,7-12H2,2-5H3/t13-,14+,16-,18+,19+,20-,21+,22+/m1/s1"	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CO)C	ZRZNJUXESFHSIO-BKUNHTPHSA-N
DG00337	Pirarubicin	636397	Pinorubicin (TN); Therarubucin (TN)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:32011	DB11616	DR01430	.	627.6	C32H37NO12	204	1120	2.7	45	5	13	7	"1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19-,21-,22-,31+,32-/m0/s1"	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O[C@H]6CCCCO6	KMSKQZKKOZQFFG-HSUXVGOQSA-N
DG00338	Rituximab	.	.	Approved	1	Approved Drug(s)	Approved	Antibody	.	DB00073	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00339	Trastuzumab emtansine	.	.	Approved	1	Approved Drug(s)	Approved	Antibody drug conjugate	.	DB05773	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00340	Cetuximab	.	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors	Approved	1	Approved Drug(s)	Approved	Antibody	.	DB00002	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00341	Panitumumab	.	Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	DB01269	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00342	Pertuzumab	.	Pertuzumab (genetical recombination); Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN); Pertuzumab (ERBB2 mAb inhibitor)	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	DB06366	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00343	L-asparaginase	.	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	Approved	1	Approved Drug(s)	Approved	Other protein based therapies	.	DB00023	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00344	Pembrolizumab	.	.	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	DB09037	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00345	Benzalkonium chloride	.	.	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11105	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00346	Trastuzumab	.	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	Approved	1	Approved Drug(s)	Approved	Antibody	.	DB00072	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00347	Matrine	91466	"Matrine; 519-02-8; (+)-Matrine; Matrinium; UNII-N390W430AC; CHEBI:6700; Matrene, (+)-; (7aS,13aR,13bR,13cS)-Dodecahydro-1H,5H,10H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one; N390W430AC; NSC 146051; BRN 0085851; Vegard; alpha-Matrine; cis-Neomatrine; trans-Neomatrine; a-Matrine; Matrine,(S); Matrine ((+)-Matrine); Matridin-15-one (9CI); 5-24-02-00301 (Beilstein Handbook Reference); SCHEMBL177907; CHEMBL204860; DTXSID00274188; HMS3884F13; AMY25701; BCP08193; HY-N0164; ZINC2083329; BDBM50249581; CM0087; MFCD00210527; NSC146051; s2322; AKOS007930266; CCG-208589; CS-1601; KS-5203; NSC-146051; NCGC00346593-01; O723; M2120; N1836; 19M028; (7aS,13aR,13bS,13cS)dodecahydro-1H,5H,10H-dipyrido[2,1-f:3,2,1-ij][1,6]naphthyridin-10-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	248.36	C15H24N2O	23.6	356	1.6	18	0	2	0	"1S/C15H24N2O/c18-14-7-1-6-13-12-5-3-9-16-8-2-4-11(15(12)16)10-17(13)14/h11-13,15H,1-10H2/t11-,12+,13+,15-/m0/s1"	C1C[C@@H]2[C@H]3CCCN4[C@H]3[C@@H](CCC4)CN2C(=O)C1	ZSBXGIUJOOQZMP-JLNYLFASSA-N
DG00348	Oxymatrine	114850	"Oxymatrine; 16837-52-8; Ammothamnine; Matrine N-oxide; Oxysophoridine; Matrine oxide; Oxymatrine,(S); Matrine 1beta-oxide; 54809-74-4; CHEBI:2672; (7aS,13aR,13bR,13cS)dodecahydro-1H,5H,10H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one 4-oxide; MFCD00210339; (1R,2R,9S,17S)-13-oxido-7-aza-13-azoniatetracyclo[7.7.1.02,7.013,17]heptadecan-6-one; (1R,2R,9S,13R,17S)-13-Oxido-7-aza-13-azoniatetracyclo[7.7.1.02,7.013,17]heptadecan-6-one; SMR000543093; Pachycarpidine; Matrine 1-oxide; MLS001215101; MLS006011817; Oxymatrine (Matrine N-oxide); CHEMBL458337; SCHEMBL13394285; DTXSID40937482; HMS2854E03; AMY25589; ZINC3881804; 7967AB; BBL030371; s2338; STK801916; AKOS004120031; AKOS022168212; AC-6063; CCG-267091; NCGC00346596-01; NCGC00346596-02; SOPHORIDINE N-OXIDE/OXYSOPHORIDINE; AS-15173; O357; AB0016411; A870349; Q-100202; Q15425294; (4(1)S,7aS,13aR,13bR)-10-oxohexadecahydrodipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridine 4-oxide; 1212383-03-3; 1H,5H,10H-Dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one,dodecahydro-, 4-oxide, (7aR,13aR,13bR,13cS)-; 4-Oxotetradecahydro-1H,10H-4lambda~5~-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one; rel-(41S,7aS,13aR,13bR)-10-Oxohexadecahydrodipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridine 4-oxide"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB16276	.	.	264.36	C15H24N2O2	38.4	400	1	19	0	2	0	"1S/C15H24N2O2/c18-14-7-1-6-13-12-5-3-9-17(19)8-2-4-11(15(12)17)10-16(13)14/h11-13,15H,1-10H2/t11-,12+,13+,15-,17 /m0/s1"	C1C[C@@H]2[C@H]3CCC[N+]4([C@H]3[C@@H](CCC4)CN2C(=O)C1)[O-]	XVPBINOPNYFXID-LHDUFFHYSA-N
DG00349	Calycosin	5280448	"Calycosin; 20575-57-9; 3'-hydroxyformononetin; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)chromen-4-one; UNII-09N3E8P7TA; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; 3',7-dihydroxy-4'-methoxyisoflavone; 09N3E8P7TA; CHEBI:17793; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-; 7-hydroxy-3-(3-hydroxy-4-methoxy-phenyl)chromen-4-one; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 7,3'-dihydroxy-4'-methoxyisoflavone; HSDB 8109; 3-Hydroxyformononetin; 3'-hydroxy-formononetin; SCHEMBL73013; MLS000876988; CHEMBL241608; MEGxp0_001325; ACon1_000650; DTXSID70174580; HMS2268B05; BCP28682; HY-N0519; ZINC6018563; LMPK12050056; MFCD00210598; s9038; AKOS015896719; 3',7-dihydroxy-4'-methoxy-isoflavone; AC-8043; CS-3715; MCULE-7559555984; NCGC00169494-01; LS-14468; SMR000440659; DB-045290; FT-0630465; N1412; X1103; C01562; 575C579; A814711; Q-100254; Q5024637; BRD-K05039497-001-01-6"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	.	.	.	284.26	C16H12O5	76	432	2.4	21	2	5	2	"1S/C16H12O5/c1-20-14-5-2-9(6-13(14)18)12-8-21-15-7-10(17)3-4-11(15)16(12)19/h2-8,17-18H,1H3"	COC1=C(C=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O)O	ZZAJQOPSWWVMBI-UHFFFAOYSA-N
DG00351	NSC141562	5458295	"NSC141562; NSC-141562; CHEMBL2003340; 1-[(2-methylquinolin-3-yl)methyl]-3,7-triaza-1-azoniatricyclo[3.3.1.13,7]decane, bromide"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	376.3	C17H22BrN5	22.6	398	.	23	0	5	2	"1S/C17H22N5.BrH/c1-14-16(6-15-4-2-3-5-17(15)18-14)7-22-11-19-8-20(12-22)10-21(9-19)13-22;/h2-6H,7-13H2,1H3;1H/q+1;/p-1"	CC1=NC2=CC=CC=C2C=C1C[N+]34CN5CN(C3)CN(C5)C4.[Br-]	IYASYYOEAXFOPQ-UHFFFAOYSA-M
DG00352	2-Bromo-4-fluorobenzaldehyde	2773319	"2-Bromo-4-fluorobenzaldehyde; 59142-68-6; 2-bromo-4-fluoro-benzaldehyde; 2-Bromo-4-Fluoro Benzaldehyde; Benzaldehyde, 2-bromo-4-fluoro-; MFCD00672923; 4-FLUORO-2-BROMOBENZALDEHYDE; Bromo-4-fluoro benzaldehyde; 2-Bromo-4-fluorobezaldehyde; 2-bromo4-fluoro-benzaldehyde; SCHEMBL249018; DTXSID70378369; ACT00250; BCP29430; ZINC2567808; BBL021382; STK894095; AKOS005144223; AB06851; AC-2291; AS03017; CM11837; CS-W007439; LS10393; MCULE-8213351363; PS-8173; VZ23974; 2-Bromo-4-fluorobenzaldehyde, AldrichCPR; BC002351; L203; SY014169; AB0014585; DB-024154; AM20060032; B3498; FT-0640583; 142B686; J-508293; 2-Bromo-4-Fluoro Benzaldehyde;Benzaldehyde, 2-bromo-4-fluoro-"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	203.01	C7H4BrFO	17.1	129	2.2	10	0	2	1	1S/C7H4BrFO/c8-7-3-6(9)2-1-5(7)4-10/h1-4H	C1=CC(=C(C=C1F)Br)C=O	OPZDXMCOWFPQPE-UHFFFAOYSA-N
DG00353	Cucurbitacin B	5281316	"Cucurbitacin B; 6199-67-3; Datisca principle B; Amarine; DATISCACIN; Datiscn Principle B; 1,2-Dihydro-alpha-elaterin; UNII-0115W5MABF; 0115W5MABF; CHEBI:3941; CUCURBITACIN R - DATISCA PRINCIPLE B; NSC49451; Cucurbitacin B hydrate; (R,E)-6-((2S,8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate; Cucurbitacine (B); Cucurbitacin-B; Cucurbitacine B; Cuc B; MLS002702988; HSDB 3476; 19-nor-9.beta.,23-diene-3,11,22-trione, 9-methyl-2.beta.,16.alpha.,20,25-tetrahydroxy-, 25-acetate; 19-Norlanosta-5,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (2.beta.,9.beta.,10.alpha.,16.alpha.,23E)-; C32H46O8; NSC 49451; NSC 144154; SCHEMBL231815; CHEMBL508185; HY-N0416; ZINC4097797; LMST01010104; MFCD07778083; NSC-49451; NSC144154; s8165; AKOS015897085; CCG-270043; CS-3816; NSC-144154; 25-(Acetyloxy)-2,16,20-trihydroxy-9-methyl-19-norlanosta-5,23-diene-3,11,22-trione; [(E,6R)-6-[(2S,8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-2,7,8,10,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl] acetate; 19-Nor-9beta,10alpha-lanosta-5,23-diene-3,11,22-trione, 2beta,16alpha,20,25-tetrahydroxy-9-methyl-, 25-acetate; 19-Norlanosta-5,23-diene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (2beta,9beta,10alpha,16alpha,23E)-; AC-34283; Cucurbitacin B hydrate, >=97% (HPLC); N2787; X1115; C08794; 199C673; A924078; Q-100715; Q27106259; UNII-W3RWP6CB48 component IXQKXEUSCPEQRD-DKRGWESNSA-N; (2S,4R,23E)-2,16beta,20-trihydroxy-9beta,10,14-trimethyl-1,11,22-trioxo-4,9-cyclo-9,10-secocholesta-5,23-dien-25-yl acetate; (3E,6R)-6-[(1R,2R,4S,10S,11S,13R,14R,15R)-4,13-dihydroxy-1,6,6,11,15-pentamethyl-5,17-dioxotetracyclo[8.7.0.0 , .0 , ]heptadec-7-en-14-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate; 19-Nor-9-beta,10-alpha-lanosta-5,23-diene-3,11,22-trione, 2-beta,16-alpha,20,25-tetrahydroxy-9-methyl-, 25-acetate; 19-Norlanosta-5,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, [2.beta.,.gamma.,.beta.,10.alpha.,16.alpha.]-; 19-Norlanosta-5,23-diene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (2beta,9beta,10alpha,16alpha,23E)- (9CI); 2beta,16alpha,20,25-tetrahydroxy-9-methyl-19-nor-9beta,10alpha-lanosta-5,23-diene-3,11,22-trione, 25-acetate; 2beta,16alpha,20,25-tetrahydroxy-9-methyl-3,11,22-trioxo-19-nor-9beta,10alpha-lanosta-5,23-dien-25-yl acetate"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	.	.	.	.	558.7	C32H46O8	138	1210	2.6	40	3	8	6	"1S/C32H46O8/c1-17(33)40-27(2,3)13-12-23(36)32(9,39)25-21(35)15-29(6)22-11-10-18-19(14-20(34)26(38)28(18,4)5)31(22,8)24(37)16-30(25,29)7/h10,12-13,19-22,25,34-35,39H,11,14-16H2,1-9H3/b13-12+/t19-,20+,21-,22+,25+,29+,30-,31+,32+/m1/s1"	CC(=O)OC(C)(C)/C=C/C(=O)[C@@](C)([C@H]1[C@@H](C[C@@]2([C@@]1(CC(=O)[C@@]3([C@H]2CC=C4[C@H]3C[C@@H](C(=O)C4(C)C)O)C)C)C)O)O	IXQKXEUSCPEQRD-DKRGWESNSA-N
DG00354	Iridium	23924	"7439-88-5; Ir; Iridium; Iridium black; iridium atom; Iridium wire; iridium ion (4+); Iridium, powder; MFCD00011062; Iridium metallicum; Iridium, elemental; Iridium, ion(Ir4 ); hydrido-iridium; Iridium powder; Iridium sponge; Iridium foil; Iridium-Mohr; iridium dihydride; Iridium Nanorods; Iridium compounds; HSDB 7067; Iridium Nanowires; iridium pentahydride; Iridium single crystal disc, 10mm (0.39in) dia, 1-2mm (0.04-0.08in) thick, (110) orientation, +/-0.5 degrees; EINECS 231-095-9; iridium(4+); iridium(iv) hydride; Iridium (IV) ion; Iridium Nanoparticles; UNII-44448S9773; Ir/C; Iridium powder, -60 mesh; Iridium powder, -325 mesh; Iridium sponge, -100 mesh; DTXSID0064674; CHEBI:49666; HSDB 7066; Ir(4+); 7282AH; Iridium, powder, puriss., 99.9%; Iridium powder, -22 mesh, Premion ; AKOS015833373; Iridium wire, 0.5mm (0.02in) dia; Iridium wire, 1.0mm (0.04in) dia; Iridium foil, 0.5mm (0.02in) thick; Iridium foil, 1.0mm (0.04in) thick; Iridium wire, 0.25mm (0.01in) dia; Q877; Iridium foil, 0.05mm (0.002in) thick; Iridium shot, 6-7mm (0.24-0.28in); Iridium wire, 0.075mm (0.003in) dia; Iridium wire, 0.125mm (0.005in) dia; CS-0082565; FT-0627287; Iridium, powder, 99.9% trace metals basis; Iridium foil, 0.25mm (0.01in) thick, hard; Iridium foil, 0.127mm (0.005in) thick, hard; Iridium pellet, approximately 1.3cm (0.5in) dia; Lanthanum Nickel Oxide (LaNiO3) Sputtering Targets; Q27461515; 44448S9773; I000000010; Iridium, sponge, -20 mesh, 99.9% trace metals basis; Iridium, AAS standard solution, Specpure , Ir 1000 g/ml; Iridium, rod, 100mm, diameter 2.0mm, as drawn, 99.9%; Iridium, rod, 100mm, diameter 3.0mm, as drawn, 99.9%; Iridium, rod, 25mm, diameter 2.0mm, as drawn, 99.9%; Iridium, rod, 25mm, diameter 3.0mm, as drawn, 99.9%; Iridium, rod, 50mm, diameter 2.0mm, as drawn, 99.9%; Iridium, rod, 50mm, diameter 3.0mm, as drawn, 99.9%; Iridium, wire, diam. 0.15 mm, 99.9% trace metals basis; Iridium, wire, diam. 0.5 mm, 99.9% trace metals basis; Iridium slug, 6.0mm (0.24in) dia x 6.0mm (0.24in) length; Iridium, black, powder, -200 mesh, >=99% trace metals basis; Iridium, foil, thickness 0.07 mm, 99.5% trace metals basis; Iridium, foil, thickness 0.1 mm, 99.5% trace metals basis; Iridium, foil, thickness 0.25 mm, 99.9% trace metals basis; Iridium, plasma standard solution, Specpure , Ir 10,000 g/ml; Iridium, plasma standard solution, Specpure , Ir 1000 g/ml; Iridium, rod, 4.0 mm diameter, length 25 mm, purity 99.9%; Iridium, rod, 4.0 mm diameter, length 50 mm, purity 99.9%; Iridium, wire reel, 0.1m, diameter 0.1mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.2mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.5mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.8mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 1.0mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 2.0mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.1mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.2mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.5mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.8mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 1.0mm, as drawn, 99.9%; Iridium, wire reel, 0.3m, diameter 0.5mm, as drawn, 99.9%; Iridium, wire reel, 0.4m, diameter 0.5mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.1mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.2mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.5mm, as drawn, 99.9%; Iridium, wire reel, 1m, diameter 0.075mm, as drawn, 99.9%; Iridium, wire reel, 1m, diameter 0.125mm, as drawn, 99.5%; Iridium, wire reel, 1m, diameter 0.125mm, as drawn, 99.9%; Iridium, wire reel, 1m, diameter 0.15mm, as drawn, 99.9%; Iridium, wire reel, 1m, diameter 0.177mm, as drawn, 99.9%; Iridium, wire reel, 1m, diameter 0.1mm, as drawn, 99.9%; Iridium, wire reel, 1m, diameter 0.25mm, as drawn, 99.9%; Iridium, wire reel, 1m, diameter 0.2mm, as drawn, 99.9%; Iridium, wire reel, 2m, diameter 0.125mm, as drawn, 99.5%; Iridium, wire reel, 2m, diameter 0.125mm, as drawn, 99.9%; Iridium, wire reel, 2m, diameter 0.15mm, as drawn, 99.9%; Iridium slug, 6.0mm (0.24in) dia x 12.0mm (0.48in) length; Iridium, foil, 25x25mm, thickness 0.125mm, as rolled, 99.9%; Iridium, foil, 25x25mm, thickness 0.15mm, as rolled, 99.9%; Iridium, foil, 25x25mm, thickness 0.25mm, as rolled, 99.9%; Iridium, foil, thickness 0.1 mm, size 25 x 25 mm, purity 99.9%; Iridium, wire reel, 0.025m, diameter 2.0mm, as drawn, 99.9%; Iridium, wire reel, 0.05m, diameter 0.075mm, as drawn, 99.9%; Iridium, wire reel, 0.05m, diameter 0.1mm, as drawn, 99.9%; Iridium, wire reel, 0.05m, diameter 0.8mm, as drawn, 99.9%; Iridium, wire reel, 0.05m, diameter 1.0mm, as drawn, 99.9%; Iridium, wire reel, 0.05m, diameter 2.0mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.075mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.125mm, as drawn, 99.5%; Iridium, wire reel, 0.1m, diameter 0.125mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.15mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.177mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.25mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.38mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.075mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.125mm, as drawn, 99.5%; Iridium, wire reel, 0.2m, diameter 0.125mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.15mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.177mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.25mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.38mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.075mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.125mm, as drawn, 99.5%; Iridium, wire reel, 0.5m, diameter 0.125mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.15mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.177mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.25mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.38mm, as drawn, 99.9%; Iridium, wire, 0.25 mm diameter, size 100 mm, purity 99.9%; Iridium, wire, 0.25 mm diameter, size 1000 mm, purity 99.9%; Iridium, wire, 0.25 mm diameter, size 200 mm, purity 99.9%; Iridium, wire, 0.25 mm diameter, size 500 mm, purity 99.9%; Iridium, wire, straight, 100mm, diameter 0.5mm, as drawn, 99.9%; Iridium, wire, straight, 100mm, diameter 0.6mm, as drawn, 99.9%; Iridium, wire, straight, 100mm, diameter 0.7mm, as drawn, 99.9%; Iridium, wire, straight, 100mm, diameter 0.8mm, as drawn, 99.9%; Iridium, wire, straight, 100mm, diameter 1.0mm, as drawn, 99.9%; Iridium, wire, straight, 200mm, diameter 0.5mm, as drawn, 99.9%; Iridium, wire, straight, 200mm, diameter 0.6mm, as drawn, 99.9%; Iridium, wire, straight, 200mm, diameter 0.7mm, as drawn, 99.9%; Iridium, wire, straight, 200mm, diameter 0.8mm, as drawn, 99.9%; Iridium, wire, straight, 200mm, diameter 1.0mm, as drawn, 99.9%; Iridium, wire, straight, 500mm, diameter 0.5mm, as drawn, 99.9%; Iridium, wire, straight, 50mm, diameter 0.6mm, as drawn, 99.9%; Iridium, wire, straight, 50mm, diameter 0.7mm, as drawn, 99.9%; Iridium, wire, straight, 50mm, diameter 0.8mm, as drawn, 99.9%; Iridium, wire, straight, 50mm, diameter 1.0mm, as drawn, 99.9%; Iridium, 0.5% on activated carbon powder, reduced, nominally 50% water wet; Iridium, foil, thickness 0.03 mm, size 25 x 25 mm, purity 99.9%; Iridium, powder, 50 max. part. size (micron), weight 5 g, purity 99.9%; Iridium, powder, max. particle size 50 micron, weight 1 g, purity 99.9%; Iridium, powder, max. particle size 50 micron, weight 2 g, purity 99.9%; Iridium, evaporation slug, diam. x L 0.6 cm x 1.2 cm, 99.9% trace metals basis; Iridium, foil, 0.025m coil, thickness 0.05mm, coil width .5mm, as rolled, 99.9%; Iridium, foil, 0.05m coil, thickness 0.05mm, coil width .5mm, as rolled, 99.9%; Iridium, foil, 0.18m coil, thickness 0.05mm, coil width .5mm, as rolled, 99.9%; Iridium, foil, 0.1m coil, thickness 0.05mm, coil width .5mm, as rolled, 99.9%; Iridium, foil, light tested, 25x25mm, thickness 0.025mm, as rolled, 99.9%; Iridium, foil, light tested, 25x25mm, thickness 0.05mm, as rolled, 99.9%; Iridium, foil, light tested, 50x50mm, thickness 0.025mm, as rolled, 99.9%; Iridium, foil, light tested, 50x50mm, thickness 0.05mm, as rolled, 99.9%; Iridium, powder, 850 max. part. size (micron), high purity 99.995%, weight 1 g; Iridium, powder, 850 max. part. size (micron), weight 2 g, high purity 99.995%; Iridium single crystal disc, 10mm (0.39in) dia, 1-2mm (0.04-0.08in) thick, (100) orientation, +/-0.5 degrees; Iridium single crystal disc, 10mm (0.39in) dia, 1-2mm (0.04-0.08in) thick, (111) orientation, +/-0.5 degrees; Iridium, microfoil, disks, 10mm, thinness 0.1mum, specific density 224mug/cm2, permanent mylar 3.5mum support, 99.9%; Iridium, microfoil, disks, 25mm, thinness 0.1mum, specific density 224mug/cm2, permanent mylar 3.5mum support, 99.9%"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	192.22	Ir	0	0	.	1	0	0	0	1S/Ir	[Ir]	GKOZUEZYRPOHIO-UHFFFAOYSA-N
DG00355	Taxane	9548828	"Taxane; 1605-68-1; (1S,3R,4R,8S,11S,12R)-4,8,12,15,15-pentamethyltricyclo[9.3.1.03,8]pentadecane; (4R,4aR,6S,9R,10S,12aR)-tetradecahydro-4,9,12a,13,13-pentamethyl-6,10-methanobenzocyclodecene; (4R-(4alpha,4abeta,6alpha,9alpha,10alpha,12aalpha))-tetradecahydro-4,9,12a,13,13-pentamethyl-6,10-methanobenzocyclodecene; CHEBI:36064; DTXSID70936327; BAY59-8862; 87501-EP2270018A1; 87501-EP2272537A2; 87501-EP2277507A1; 87501-EP2281820A2; 87501-EP2286795A1; 87501-EP2289876A1; 87501-EP2289892A1; 87501-EP2295416A2; 87501-EP2295417A1; 87501-EP2298748A2; 87501-EP2298754A1; 87501-EP2298780A1; 87501-EP2301940A1; 87501-EP2305642A2; 87501-EP2305689A1; Q27116688; 6,10-Methanobenzocyclodecene, tetradecahydro-4,9,12a,13,13-pentamethyl-, (4R,4aR,6S,9R,10S,12aR)-; 6,10-Methanobenzocyclodecene, tetradecahydro-4,9,12a,13,13-pentamethyl-, (4R-(4alpha,4abeta,6alpha,9alpha,10alpha,12aalpha))-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	276.5	C20H36	0	355	8.1	20	0	0	0	"1S/C20H36/c1-14-7-6-11-20(5)12-10-17-15(2)8-9-16(13-18(14)20)19(17,3)4/h14-18H,6-13H2,1-5H3/t14-,15-,16+,17+,18-,20+/m1/s1"	C[C@@H]1CCC[C@@]2([C@@H]1C[C@@H]3CC[C@H]([C@@H](C3(C)C)CC2)C)C	DKPFODGZWDEEBT-QFIAKTPHSA-N
DG00356	S-1	146157327	S-1; BMS 247616; S 1; S 1 (antitumor agent); TS 1; TS 1 (pharmaceutical)	Terminated	10	Discontinued Drug(s)	Terminated	Small molecular drug	.	.	.	.	544.9	C17H19ClFKN6O9	215	683	.	35	5	10	2	"1S/C8H11FN2O3.C5H4ClNO2.C4H5N3O4.K/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12;6-3-2-7-5(9)1-4(3)8;8-2(9)1-5-3(10)7-4(11)6-1;/h5-6H,1-4H2,(H,10,12,13);2H,1H2,(H,7,9);1H,(H,8,9)(H3,5,6,7,10,11);/q;;;+1/p-1"	C1CC(OC1)N2CC(C(=O)NC2=O)F.C1C(=O)C(=CNC1=O)Cl.C1(NC(=O)NC(=O)N1)C(=O)[O-].[K+]	IOYPGLLFUCOOCZ-UHFFFAOYSA-M
DG00357	Braf inhibitor	53438230	"BRAF inhibitor; N-[2,4-Difluoro-3-[[5-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]phenyl]-2-propanesulfonamide; C22H18F2N4O2S; N-(2,4-Difluoro-3-{[5-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}phenyl)-2-propanesulfonamide; SCHEMBL150401; BCP27823; EX-A2629; 5506AC; ZINC71257194; AKOS025117572; CS-0055; PLX-4032(RG7204); NCGC00378825-01; AC-25237; HY-10247; DB-003735; R7204; F12499; 505D610; 2-Propanesulfonamide, N-[2,4-difluoro-3-[[5-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]phenyl]-; N-(2,4-difluoro-3-(5-(pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)phenyl)propane-2-sulfonamide; propane-2-sulfonic acid [2,4-difluoro-3-(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-carbonyl)-phenyl]-amide; propane-2-sulfonic acid [2,4-difluoro-3-(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	456.5	C22H18F2N4O3S	113	778	3.2	32	2	8	6	"1S/C22H18F2N4O3S/c1-12(2)32(30,31)28-18-6-5-17(23)19(20(18)24)21(29)16-11-27-22-15(16)8-14(10-26-22)13-4-3-7-25-9-13/h3-12,28H,1-2H3,(H,26,27)"	CC(C)S(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CN=CC=C4)F	SUNCACOTKLUNHD-UHFFFAOYSA-N
DG00358	Tyrosine kinase inhibitor	24956525	"Tyrosine kinase inhibitor; 1021950-26-4; 1-N'-(4-fluorophenyl)-1-N-[4-[[2-(2-morpholin-4-ylethylcarbamoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]cyclopropane-1,1-dicarboxamide; SCHEMBL10108314; C31H31FN6O5; DTXSID40648066; BCP04781; EX-A2282; MDK-0264; 4136AH; NSC757436; ZINC43195804; CS-0524; NSC-757436; NCGC00390567-01; HY-10421; DB-058774; FT-0753909; EC-000.2366; 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N-[4-[[2-[[[2-(4-morpholinyl)ethyl]amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-; N'1-(4-fluorophenyl)-N1-{4-[(2-{[2-(morpholin-4-yl)ethyl]carbamoyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}cyclopropane-1,1-dicarboxamide; N~1~-(4-Fluorophenyl)-N'~1~-{4-[(2-{[2-(morpholin-4-yl)ethyl]carbamoyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}cyclopropane-1,1-dicarboxamide"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	586.6	C31H31FN6O5	138	978	3.8	43	4	8	10	"1S/C31H31FN6O5/c32-20-1-3-21(4-2-20)35-29(40)31(10-11-31)30(41)36-22-5-7-23(8-6-22)43-26-9-12-33-27-24(26)19-25(37-27)28(39)34-13-14-38-15-17-42-18-16-38/h1-9,12,19H,10-11,13-18H2,(H,33,37)(H,34,39)(H,35,40)(H,36,41)"	C1CC1(C(=O)NC2=CC=C(C=C2)OC3=C4C=C(NC4=NC=C3)C(=O)NCCN5CCOCC5)C(=O)NC6=CC=C(C=C6)F	PKOVTRMHYNEBDU-UHFFFAOYSA-N
DG00359	GDP-beta-L-galactose	135398680	"GDP-beta-L-galactose; Guanosine-5'-Diphosphate-Beta-L-Galactose; guanosine 5'-diphospho-beta-L-galactopyranoside; guanosine 5'-[3-(beta-L-galactopyranosyl) dihydrogen diphosphate]; [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl (2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl dihydrogen diphosphate (non-preferred name); GDC; CHEBI:42660; C02280; Q27120477"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	605.3	C16H25N5O16P2	327	1050	-6.2	39	10	18	9	"1S/C16H25N5O16P2/c17-16-19-12-6(13(28)20-16)18-3-21(12)14-10(26)8(24)5(34-14)2-33-38(29,30)37-39(31,32)36-15-11(27)9(25)7(23)4(1-22)35-15/h3-5,7-11,14-15,22-27H,1-2H2,(H,29,30)(H,31,32)(H3,17,19,20,28)/t4-,5+,7+,8+,9+,10+,11-,14+,15+/m0/s1"	C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O[C@@H]4[C@H]([C@@H]([C@@H]([C@@H](O4)CO)O)O)O)O)O)N=C(NC2=O)N	MVMSCBBUIHUTGJ-JGQUBWHWSA-N
DG00360	Arborcandin C	9941831	"Arborcandin C; 21,24-Bis(carbamoylmethyl)-15-(2-carbamoyl-2-hydroxyethyl)-9,12-bis(1-hydroxyethyl)-6-(3-hydroxydodecyl)-27-(8-hydroxytetradecyl)-18-methyl-1,4,7,10,13,16,19,22,25,28-decaazacyclohentriacontane-2,5,8,11,14,17,20,23,26,29-decone"	Terminated	10	Discontinued Drug(s)	Terminated	Small molecular drug	.	.	.	.	1284.5	C59H105N13O18	521	2320	0.9	90	18	18	33	"1S/C59H105N13O18/c1-6-8-10-12-13-15-20-24-38(76)26-27-40-53(84)64-33-48(81)63-29-28-47(80)66-39(25-21-17-14-16-19-23-37(75)22-18-11-9-7-2)54(85)69-43(32-46(61)79)56(87)70-42(31-45(60)78)55(86)65-34(3)52(83)68-41(30-44(77)51(62)82)57(88)71-50(36(5)74)59(90)72-49(35(4)73)58(89)67-40/h34-44,49-50,73-77H,6-33H2,1-5H3,(H2,60,78)(H2,61,79)(H2,62,82)(H,63,81)(H,64,84)(H,65,86)(H,66,80)(H,67,89)(H,68,83)(H,69,85)(H,70,87)(H,71,88)(H,72,90)"	CCCCCCCCCC(CCC1C(=O)NCC(=O)NCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)C(C)O)C(C)O)CC(C(=O)N)O)C)CC(=O)N)CC(=O)N)CCCCCCCC(CCCCCC)O)O	AHATVKJRQUTSJV-UHFFFAOYSA-N
DG00361	Brefeldin A	5287620	"Brefeldin A; Ascotoxin; Synergisidin; Decumbin; Nectrolide; Cyanein; 20350-15-6; Cyanaein; Brefeldin-A; Brefeldin A prodrug; (+)-Brefeldin A; Bredfeldin A; UNII-XG0D35F9K6; NSC-89671; MLS001074108; XG0D35F9K6; CHEBI:48080; SMR000653527; Pfizer B 174987; (1R,2E,6S,10E,11aS,13S,14aR)-1,13-dihydroxy-6-methyl-1,6,7,8,9,11a,12,13,14,14a-decahydro-4H-cyclopenta[f]oxacyclotridecin-4-one; Antibiotic from Penicillium cyaneum; NSC 56310; SR-01000000180; MLS002701937; MLS002702862; CCRIS 9386; NSC107456; NSC244390; 1,6,7,8,9,11a,12,13,14,14a-Decahydro-1,13-dihydroxy-6-methyl-4H-cyclopent[f]oxacyclotridecin-4-one; NSC 89671; B 174987; Probes1_000313; SCHEMBL29267; MLS002153500; CHEMBL19980; PFIZER B174987; BDBM97307; cid_5287620; DTXSID00880041; HMS2233O20; 60132-23-2; BFA; 2283AH; NSC-56310; s7046; ZINC12371944; AM84700; CCG-208161; CS-3783; DB07348; NSC 107456; NSC 244390; NSC-107456; NSC-244390; NCGC00022909-02; (1S,2E,7S,10E,12R,13R,15S)-12,15-dihydroxy-7-methyl-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-9-one; 4H-Cyclopent(f)oxacyclotridecin-4-one,1,6,7,8,9,11a-beta,12,13,14,14a-alpha-decahydro-1-beta-13-alpha-dihydroxy-6-beta-methyl-; HY-16592; SMR000768725; TOXIC SOLID, N.O.S. (BREFELDIN A); SW220015-1; C73840; Q168790; SR-01000000180-5; SR-01000000180-7; W-201775; BRD-K77841042-001-14-1; Brefeldin A, from Penicillium brefeldianum, >=99% (HPLC and TLC); Brefeldin A, >=99% (HPLC and TLC), BioXtra, for molecular biology; (1S,2E,7S,10E,12R,13R,15S)-7-methyl-12,15-bis(oxidanyl)-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-9-one; 11006-23-8; 4H-Cyclopent(f)oxacyclotridecin-4-one, 1,6,7,8,9,11a-beta,12,13,14,14a-alpha-decahydro-1-beta-13-alpha-dihydroxy-6-beta-methyl-; 4H-Cyclopent[f]oxacyclotridecin-4-one,6,7,8,9,11a,12,13, 14,14a-decahydro-1,13-dihydroxy-6-methyl-, [1R-(1R*,2E,6S*, 10E,11aS*,13S*,14aR*)]-; 4H-Cyclopent[f]oxacyclotridecin-4-one,6,7,8,9,11a.beta.,12,13,14,14a.alpha.-decahydro- 1.beta.,13.alpha.-dihydroxy-6.beta.-methyl-; Brefeldin A, from Penicillium brefeldianum, Ready Made Solution, 10 mg/mL in DMSO, 0.2 mum filtered; Pfizer B 174987 4H-Cyclopent[f]oxacyclotridecin-4-one,6,7,8,9,11a,12,13,14,14a-decahydro-1,13-dihydroxy-6-methyl-, (1R,2E,6S,10E,11aS,13S,14aR)-"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB07348	.	.	280.36	C16H24O4	66.8	388	2	20	2	4	0	"1S/C16H24O4/c1-11-5-3-2-4-6-12-9-13(17)10-14(12)15(18)7-8-16(19)20-11/h4,6-8,11-15,17-18H,2-3,5,9-10H2,1H3/b6-4+,8-7+/t11-,12+,13-,14+,15+/m0/s1"	C[C@H]1CCC/C=C/[C@@H]2C[C@@H](C[C@H]2[C@@H](/C=C/C(=O)O1)O)O	KQNZDYYTLMIZCT-KQPMLPITSA-N
DG00362	Nocodazole	4122	"Nocodazole; 31430-18-9; Oncodazole; R 17934; Nocodazolum; Nocodazol; NSC 238159; R 17,934; Methyl N-[6-(thiophene-2-carbonyl)-1H-benzimidazol-2-yl]carbamate; C14H11N3O3S; methyl (5-(thiophene-2-carbonyl)-1H-benzo[d]imidazol-2-yl)carbamate; UNII-SH1WY3R615; Methyl 5-(2-thenoyl)-2-benzimidazolecarbamate; Methyl N-(5-thenoyl-2-benzimidazolyl)carbamate; NSC-238159; Methyl [5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]carbamate; N-(5-(2-Thenoyl)-2-benzimidazolyl)carbamic acid methyl ester; NSC238159; Methyl (5-(2-thienylcarbonyl))-1H-benzimidazole-2-ylcarbamate; R-17934; 2-Benzimidazolecarbamic acid, 5-(2-thienylcarbonyl)-, methyl ester; CHEMBL9514; MLS001164242; SH1WY3R615; 2-Benzimidazolecarbamic acid, 5-(2-thenoyl)-, methyl ester; CHEBI:34892; Methyl (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl)carbamate; Carbamic acid, (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl)-, methyl ester; MFCD00005588; NCGC00015647-05; Nocidazole; SMR000326904; CAS-31430-18-9; [5-(2-Thienylcarbonyl)-1H-benzimidazol-2-yl]-carbamic acid methyl ester; methyl (6-(thiophene-2-carbonyl)-1H-benzo[d]imidazol-2-yl)carbamate; Carbamic acid, (5-(2-thienylcarbonyl)-1H-benzimidazole-2-yl)-, methyl ester; Carbamic acid, [5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]-, methyl ester; Methyl 5-(2-thienoyl)-2-benzimidazolecarbamate; DSSTox_CID_11800; DSSTox_RID_78890; DSSTox_GSID_31800; 2-Benzimidazolecarbamic acid, 5-(2-thienoyl)-, methyl ester; Methyl [5-(2-thienylcarbonyl)-1H- benzimidazol-2-yl]carbamate; methyl [6-(thiophen-2-ylcarbonyl)-1H-benzimidazol-2-yl]carbamate; N-(5-(2-Thienoyl)-2-benzimidazolyl)carbamic acid methyl ester; methyl N-[5-(thiophene-2-carbonyl)-1H-benzimidazol-2-yl]carbamate; Nocodazole [USAN:INN]; Nocodazol [INN-Spanish]; Nocodazolum [INN-Latin]; R17934; SR-01000075979; EINECS 250-626-5; NSC 238 159; Nococazole; Methyl(5-(2-thienylcarbonyl))-1H-benzimidazole-2-yl carbamate; Methyl[5-(2-thienylcarbonyl)]-1H-benzimidazole-2-yl carbamate; N-[5-(2-Thenoyl)-2-benzimidazolyl]carbamic acid methyl ester; N-[5-(2-Thienoyl)-2-benzimidazolyl]carbamic acid methyl ester; (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl)-carbamic acid methyl ester; Carbamic acid, (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl)-, methyl ester (9CI); Carbamic acid, [5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]-, methyl ester (9CI); NZO; Prestwick_359; Tocris-1228; 3ee2; Nocodazole (USAN/INN); Prestwick0_000100; Prestwick1_000100; Prestwick2_000100; Prestwick3_000100; Spectrum3_001768; Spectrum4_001060; Lopac-M-1404; ChemDiv1_000089; Probes1_000012; Probes1_000176; Probes2_000086; Probes2_000148; UPCMLD-DP111; Cambridge id 5175348; cid_4122; SCHEMBL9477; Lopac0_000733; Oprea1_483899; Oprea1_741554; BSPBio_000060; BSPBio_000982; BSPBio_003235; CBDivE_004971; CBDivE_008428; KBioGR_000322; KBioGR_001360; KBioSS_000322; MLS000860046; BIDD:GT0494; SPECTRUM1503266; Nocodazole Ready Made Solution; SPBio_001999; BPBio1_000066; DTXSID9031800; UPCMLD-DP111:001; BCBcMAP01_000161; BDBM97233; HMS587E01; KBio2_000322; KBio2_002890; KBio2_005458; KBio3_000643; KBio3_000644; KBio3_002735; ZINC56509; AOB6196; Bio1_000461; Bio1_000950; Bio1_001439; Bio2_000331; Bio2_000811; HMS1362B03; HMS1568C22; HMS1792B03; HMS1922O09; HMS1990B03; HMS2094G13; HMS2095C22; HMS2235E18; HMS3262C08; HMS3267F03; HMS3403B03; HMS3412A10; HMS3604E13; HMS3656J06; HMS3676A10; HMS3712C22; Pharmakon1600-01503266; BCP07558; EX-A5289; Tox21_110189; Tox21_500733; 2593AH; NSC759882; s2775; STK832483; Nocodazole, >=99% (TLC), powder; AKOS000538825; AKOS015901529; Tox21_110189_1; API0003615; CCG-101240; CCG-208075; CP-0076; CS-1893; DB08313; LP00733; MCULE-3133043736; NSC-759882; SB19455; SDCCGSBI-0050711.P003; IDI1_002086; QTL1_000062; SMP2_000261; NCGC00015647-01; NCGC00015647-02; NCGC00015647-03; NCGC00015647-04; NCGC00015647-06; NCGC00015647-07; NCGC00015647-08; NCGC00015647-09; NCGC00015647-10; NCGC00015647-11; NCGC00015647-12; NCGC00015647-13; NCGC00015647-14; NCGC00015647-15; NCGC00015647-18; NCGC00015647-33; NCGC00025058-01; NCGC00025058-02; NCGC00025058-03; NCGC00025058-04; NCGC00025058-05; NCGC00025058-06; NCGC00025058-07; NCGC00025058-08; NCGC00025058-09; NCGC00025058-10; NCGC00261418-01; AC-25615; AM807900; HY-13520; NCI60_001911; SBI-0050711.P002; AB0109635; EU-0100733; FT-0660415; SW102861-5; D05197; M 1404; 4-HYDROXY-3-IODO-BIPHENYL-4-CARBONITRILE; R17,934; Q2506092; SR-01000075979-1; SR-01000075979-3; SR-01000075979-6; SR-01000075979-9; W-202288; BRD-K12539581-001-06-2; BRD-K12539581-001-14-6; methyl 6-(thien-2-ylcarbonyl)-1H-benzimidazol-2-ylcarbamate; 2-Benzimidazolecarbamic acid, 5-(2-thenoyl)-, methyl ester (8CI); methyl [5-(thiophen-2-ylcarbonyl)-1H-benzimidazol-2-yl]carbamate; methyl N-(6-thiophen-2-ylcarbonyl-1H-benzimidazol-2-yl)carbamate; methyl(6-(thiophene-2-carbonyl)-1H-benzo[d]imidazol-2-yl)carbamate; N-[6-(2-thenoyl)-1H-benzimidazol-2-yl]carbamic acid methyl ester; [[5-(2-Thienylcarbonyl)-1H-benzimidazol-2-yl]]carbamic acid methyl ester; [5-(2-Thienylcarbonyl)-1H-benzimidazol-2-yl]carbonic acid, methyl ester; carbamic acid, [6-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]-, methyl ester; Carbamic acid, N-[5-(2-thenoyl)-1H-benzimidazol-2-yl]-, methyl ester; [5-(Thiophene-2-carbonyl)-1H-benzoimidazol-2-yl]-carbamic acid methyl ester; Carbamic acid, N-[6-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]-, methyl ester; N-[6-[oxo(thiophen-2-yl)methyl]-1H-benzimidazol-2-yl]carbamic acid methyl ester"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB08313	.	.	301.32	C14H11N3O3S	112	420	2.8	21	2	5	4	"1S/C14H11N3O3S/c1-20-14(19)17-13-15-9-5-4-8(7-10(9)16-13)12(18)11-3-2-6-21-11/h2-7H,1H3,(H2,15,16,17,19)"	COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CS3	KYRVNWMVYQXFEU-UHFFFAOYSA-N
DG00363	Cevipabulin	11488110	"Cevipabulin; 849550-05-6; UNII-P14M0DWS2J; TTI-237; P14M0DWS2J; 849550-05-6 (free base); 5-Chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1- methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine.; 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(2S)-1,1,1-trifluoropropan-2-yl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; Cevipabulin [INN]; TTI 237; 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(2S)-1,1,1-trifluoropropan-2-yl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; Cevipabulin(TTI 237); SCHEMBL4042827; CHEMBL1182714; AOB5715; DTXSID00233997; EX-A607; BCP28162; MFCD09832720; ZINC13981125; CS-4196; DB12533; HY-14949; B5922; A12591; 550C056; J-690362; Q27285989; TTI 237; TTI-237; TTI237; D06576; D 06576; D-06576; (S)-5-Chloro-6-(2,6-difluoro-4-(3-(methylamino)propoxy)phenyl)-N-(1,1,1-trifluoropropan-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; 5-chloro-6-{2,6-difluoro-4-[3-(methylamino) propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine; 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine; 5-chloro-6{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine"	Terminated	10	Discontinued Drug(s)	Terminated	Small molecular drug	.	DB12533	.	.	464.8	C18H18ClF5N6O	76.4	566	4.6	31	2	11	8	"1S/C18H18ClF5N6O/c1-9(18(22,23)24)28-16-14(15(19)29-17-26-8-27-30(16)17)13-11(20)6-10(7-12(13)21)31-5-3-4-25-2/h6-9,25,28H,3-5H2,1-2H3/t9-/m0/s1"	C[C@@H](C(F)(F)F)NC1=C(C(=NC2=NC=NN12)Cl)C3=C(C=C(C=C3F)OCCCNC)F	ZUZPCOQWSYNWLU-VIFPVBQESA-N
DG00364	Cadmium	23973	"7440-43-9; Cadmium; Cd; Colloidal cadmium; Cadmium, elemental; Kadmium; UNII-00BH33GNGH; Cadmium hydride (CdH2); MFCD00010914; 00BH33GNGH; Cadmium compounds; Kadmium [German]; 72172-64-6; cadmio; Cadmium powder; Cadmium, Reference Standard Solution; CCRIS 112; HSDB 282; 81271-94-5; Cadmium, mass of 135; EINECS 231-152-8; Cadmium metal; Cadmium pieces; C I 77180; Cadmium granules; C.I. 77180; Elemental cadmium; CD135; Cadmium single crystal, 15mm (0.59in) dia, 50mm (2.0in) long, (111) orientation, +/-2 degrees; Cadmium, p.a.; Cadmium metal-sticks; Cadmium shot, 3N5; Cadmium [Cadmium and cadmium compounds]; Cadmium powder 325 mesh; 48Cd; Cadmium, >=99.9%; EC 231-152-8; Cadmium powder - 100mesh; Cadmium [Cadmium and certain cadmium compounds]; Cadmium powder, -200 mesh; Cadmium powder, -325 mesh; Cadmium, thermovacuum aerosol; Aerosol of thermovacuum cadmium; Cadmium shot, 5cm (2in) dia; DTXSID1023940; NIOSH/EV3380000; CHEBI:22977; CHEBI:37249; Cadmium powder, 99.999%, 5N; 8234AF; AKOS015902734; Cadmium rod, 12.7mm (0.5in) dia; DB14085; Cadmium foil, 0.5mm (0.02in) thick; Cadmium shot, tear drop, -5+20 mesh; Cadmium shot, tear drop, 3mm (0.1in); Cadmium, granular, >=99%, 5-20 mesh; Cadmium, granular, 30-80 mesh, >=99%; Cadmium, purum p.a., for filling reductors; Cadmium rod, 8mm (0.3in) dia, Puratronic; EV33800000; Q1091; C01413; Cadmium, rod, 25mm, diameter 40mm, 99.9%; Cadmium, rod, 50mm, diameter 40mm, 99.9%; H11246; Cadmium, rod, 100mm, diameter 40mm, 99.9%; Cadmium shot, 1-3mm (0.04-0.1in), Puratronic ; Cadmium wire, 0.64mm (0.025in) dia, Puratronic; Cadmium, rod, 50mm, diameter 10.0mm, 99.999%; Cadmium, shot, 3 mm, 99.999% trace metals basis; Cadmium foil, 0.025mm (0.001in) thick, Puratronic; Cadmium, rod, 100mm, diameter 10.0mm, 99.999%; Cadmium, rod, 200mm, diameter 10.0mm, 99.999%; Cadmium, foil, 4mm disks, thickness 0.01mm, 99.7+%; Cadmium, foil, 6mm disks, thickness 0.01mm, 99.7+%; Cadmium, foil, 8mm disks, thickness 0.01mm, 99.7+%; Cadmium, powder, -100 mesh, 99.5% trace metals basis; Cadmium, foil, 10mm disks, thickness 0.005mm, 99.7+%; Cadmium, foil, 10mm disks, thickness 0.015mm, 99.7+%; Cadmium, foil, 10mm disks, thickness 0.01mm, 99.7+%; Cadmium, foil, 10mm disks, thickness 0.025mm, 99.7+%; Cadmium, foil, 15mm disks, thickness 0.005mm, 99.7+%; Cadmium, foil, 15mm disks, thickness 0.015mm, 99.7+%; Cadmium, foil, 15mm disks, thickness 0.01mm, 99.7+%; Cadmium, foil, 15mm disks, thickness 0.025mm, 99.7+%; Cadmium, foil, 4mm disks, thickness 0.005mm, 99.7+%; Cadmium, foil, 4mm disks, thickness 0.015mm, 99.7+%; Cadmium, foil, 4mm disks, thickness 0.025mm, 99.7+%; Cadmium, foil, 6mm disks, thickness 0.005mm, 99.7+%; Cadmium, foil, 6mm disks, thickness 0.015mm, 99.7+%; Cadmium, foil, 6mm disks, thickness 0.025mm, 99.7+%; Cadmium, foil, 8mm disks, thickness 0.005mm, 99.7+%; Cadmium, foil, 8mm disks, thickness 0.015mm, 99.7+%; Cadmium, foil, 8mm disks, thickness 0.025mm, 99.7+%; Cadmium, rod, diam. 4.0 mm, 99.999% trace metals basis; Cadmium, wire reel, 1m, diameter 0.5mm, hard, 99.95+%; Cadmium, wire reel, 1m, diameter 0.5mm, hard, 99.99+%; Cadmium, wire reel, 1m, diameter 1.0mm, hard, 99.999%; Cadmium, wire reel, 2m, diameter 0.5mm, hard, 99.95+%; Cadmium, wire reel, 2m, diameter 0.5mm, hard, 99.99+%; Cadmium, wire reel, 5m, diameter 0.5mm, hard, 99.95+%; Cadmium, wire reel, 5m, diameter 0.5mm, hard, 99.99+%; Cadmium wire, 0.5mm (0.02in) dia, 99.998% (metals basis); Cadmium wire, 1.0mm (0.04in) dia, 99.998% (metals basis); Cadmium wire, 2.0mm (0.08in) dia, 99.998% (metals basis); Cadmium, foil, 0.5m coil, thickness 0.5mm, as rolled, 100%; Cadmium, foil, 10mm disks, thickness 1.0mm, as rolled, 100%; Cadmium, foil, 15mm disks, thickness 1.0mm, as rolled, 100%; Cadmium, foil, 1m coil, thickness 0.5mm, as rolled, 100%; Cadmium, foil, 25mm disks, thickness 1.0mm, as rolled, 100%; Cadmium, foil, 2m coil, thickness 0.5mm, as rolled, 100%; Cadmium, foil, 4mm disks, thickness 1.0mm, as rolled, 100%; Cadmium, foil, 50mm disks, thickness 1.0mm, as rolled, 100%; Cadmium, foil, 50x50mm, thickness 3.0mm, as rolled, 99.9%; Cadmium, foil, 6mm disks, thickness 1.0mm, as rolled, 100%; Cadmium, foil, 8mm disks, thickness 1.0mm, as rolled, 100%; Cadmium, purum p.a., for metal reduction, 99.99%, granular; Cadmium, rod, 1000mm, diameter 5.0mm, as drawn, 99.99+%; Cadmium, rod, 100mm, diameter 5.0mm, as drawn, 99.99+%; Cadmium, rod, 150mm, diameter 10.0mm, as drawn, 99.99+%; Cadmium, rod, 200mm, diameter 5.0mm, as drawn, 99.99+%; Cadmium, rod, 300mm, diameter 10.0mm, as drawn, 99.99+%; Cadmium, rod, 500mm, diameter 5.0mm, as drawn, 99.99+%; Cadmium, wire reel, 0.1m, diameter 0.25mm, hard, 99.99+%; Cadmium, wire reel, 0.1m, diameter 0.5mm, hard, 99.95+%; Cadmium, wire reel, 0.1m, diameter 0.5mm, hard, 99.99+%; Cadmium, wire reel, 0.1m, diameter 1.0mm, hard, 99.999%; Cadmium, wire reel, 0.1m, diameter 2.0mm, hard, 99.99+%; Cadmium, wire reel, 0.2m, diameter 0.25mm, hard, 99.99+%; Cadmium, wire reel, 0.2m, diameter 0.5mm, hard, 99.95+%; Cadmium, wire reel, 0.2m, diameter 0.5mm, hard, 99.99+%; Cadmium, wire reel, 0.2m, diameter 1.0mm, hard, 99.999%; Cadmium, wire reel, 0.2m, diameter 2.0mm, hard, 99.99+%; Cadmium, wire reel, 0.5m, diameter 0.25mm, hard, 99.99+%; Cadmium, wire reel, 0.5m, diameter 0.5mm, hard, 99.95+%; Cadmium, wire reel, 0.5m, diameter 0.5mm, hard, 99.99+%; Cadmium, wire reel, 0.5m, diameter 1.0mm, hard, 99.999%; Cadmium, wire reel, 0.5m, diameter 2.0mm, hard, 99.99+%; Cadmium, wire reel, 10m, diameter 0.25mm, hard, 99.99+%; Cadmium, wire reel, 1m, diameter 0.125mm, as drawn, 99.9%; Cadmium, wire reel, 1m, diameter 0.25mm, hard, 99.99+%; Cadmium, wire reel, 1m, diameter 1.2mm, as drawn, 99.99+%; Cadmium, wire reel, 2m, diameter 0.125mm, as drawn, 99.9%; Cadmium, wire reel, 2m, diameter 1.2mm, as drawn, 99.99+%; Cadmium, wire reel, 5m, diameter 0.125mm, as drawn, 99.9%; Cadmium, wire reel, 5m, diameter 0.25mm, hard, 99.99+%; Cadmium, wire, diam. 1.0 mm, 99.999% trace metals basis; Cadmium foil, 0.05mm (0.002in) thick, 99.999% (metals basis); Cadmium foil, 0.1mm (0.004in) thick, 99.9975% (metals basis); Cadmium foil, 0.25mm (0.01in) thick, 99.9975% (metals basis); Cadmium foil, 0.5mm (0.02in) thick, 99.9975% (metals basis); Cadmium foil, 1.0mm (0.04in) thick, 15x15cm (5.9x5.9in); Cadmium foil, 1.0mm (0.04in) thick, 99.998% (metals basis); Cadmium foil, 2.0mm (0.08in) thick, 99.998% (metals basis); Cadmium ingot/button, ca. 36mm (1.4in) dia x 8mm (0.3in) thick; Cadmium wire, 0.3mm (0.013in) dia, 99.999% (metals basis); Cadmium, foil, 100x100mm, thickness 0.25mm, as rolled, 99.99%; Cadmium, foil, 100x100mm, thickness 0.5mm, as rolled, 99.95%; Cadmium, foil, 100x100mm, thickness 1.0mm, as rolled, 99.99%; Cadmium, foil, 100x100mm, thickness 2.0mm, as rolled, 99.99%; Cadmium, foil, 100x100mm, thickness 3.0mm, as rolled, 99.9%; Cadmium, foil, 10mm disks, thickness 0.05mm, as rolled, 99.99+%; Cadmium, foil, 10mm disks, thickness 0.125mm, as rolled, 99.95%; Cadmium, foil, 10mm disks, thickness 0.25mm, as rolled, 99.9%; Cadmium, foil, 10mm disks, thickness 0.25mm, as rolled, 99.95%; Cadmium, foil, 10mm disks, thickness 0.25mm, as rolled, 99.99+%; Cadmium, foil, 10mm disks, thickness 0.5mm, as rolled, 99.95%; Cadmium, foil, 10mm disks, thickness 1.0mm, as rolled, 99.95%; Cadmium, foil, 150x150mm, thickness 0.25mm, as rolled, 99.95%; Cadmium, foil, 150x150mm, thickness 0.5mm, as rolled, 99.99%; Cadmium, foil, 150x150mm, thickness 1.0mm, as rolled, 99.95%; Cadmium, foil, 150x150mm, thickness 3.0mm, as rolled, 99.9%; Cadmium, foil, 15mm disks, thickness 0.05mm, as rolled, 99.99+%; Cadmium, foil, 15mm disks, thickness 0.125mm, as rolled, 99.95%; Cadmium, foil, 15mm disks, thickness 0.25mm, as rolled, 99.9%; Cadmium, foil, 15mm disks, thickness 0.25mm, as rolled, 99.95%; Cadmium, foil, 15mm disks, thickness 0.25mm, as rolled, 99.99+%; Cadmium, foil, 15mm disks, thickness 0.5mm, as rolled, 99.95%; Cadmium, foil, 15mm disks, thickness 1.0mm, as rolled, 99.95%; Cadmium, foil, 195x200mm, thickness 1.0mm, as rolled, 99.95%; Cadmium, foil, 200x200mm, thickness 0.5mm, as rolled, 99.99%; Cadmium, foil, 200x200mm, thickness 1.0mm, as rolled, 99.99%; Cadmium, foil, 25mm disks, thickness 0.05mm, as rolled, 99.99+%; Cadmium, foil, 25mm disks, thickness 0.125mm, as rolled, 99.95%; Cadmium, foil, 25mm disks, thickness 0.25mm, as rolled, 99.9%; Cadmium, foil, 25mm disks, thickness 0.25mm, as rolled, 99.95%; Cadmium, foil, 25mm disks, thickness 0.25mm, as rolled, 99.99+%; Cadmium, foil, 25mm disks, thickness 0.5mm, as rolled, 99.95%; Cadmium, foil, 25mm disks, thickness 1.0mm, as rolled, 99.95%; Cadmium, foil, 25x25mm, thickness 0.125mm, as rolled, 99.99+%; Cadmium, foil, 25x25mm, thickness 0.25mm, as rolled, 99.9%; Cadmium, foil, 25x25mm, thickness 0.25mm, as rolled, 99.99+%; Cadmium, foil, 25x25mm, thickness 0.5mm, as rolled, 99.999%; Cadmium, foil, 25x25mm, thickness 1.0mm, as rolled, 99.999%; Cadmium, foil, 300x1000mm, thickness 2.0mm, as rolled, 99.99%; Cadmium, foil, 300x300mm, thickness 0.25mm, as rolled, 99.95%; Cadmium, foil, 300x300mm, thickness 0.5mm, as rolled, 99.99%; Cadmium, foil, 300x300mm, thickness 2.0mm, as rolled, 99.99%; Cadmium, foil, 30x100mm, thickness 0.5mm, as rolled, 99.999%; Cadmium, foil, 30x150mm, thickness 0.5mm, as rolled, 99.999%; Cadmium, foil, 30x50mm, thickness 0.5mm, as rolled, 99.999%; Cadmium, foil, 4mm disks, thickness 0.05mm, as rolled, 99.99+%; Cadmium, foil, 4mm disks, thickness 0.125mm, as rolled, 99.95%; Cadmium, foil, 4mm disks, thickness 0.125mm, as rolled, 99.99+%; Cadmium, foil, 4mm disks, thickness 0.25mm, as rolled, 99.9%; Cadmium, foil, 4mm disks, thickness 0.25mm, as rolled, 99.95%; Cadmium, foil, 4mm disks, thickness 0.25mm, as rolled, 99.99+%; Cadmium, foil, 4mm disks, thickness 0.5mm, as rolled, 99.95%; Cadmium, foil, 4mm disks, thickness 1.0mm, as rolled, 99.95%; Cadmium, foil, 50mm disks, thickness 0.05mm, as rolled, 99.99+%; Cadmium, foil, 50mm disks, thickness 0.125mm, as rolled, 99.95%; Cadmium, foil, 50mm disks, thickness 0.25mm, as rolled, 99.95%; Cadmium, foil, 50mm disks, thickness 0.5mm, as rolled, 99.95%; Cadmium, foil, 50x100mm, thickness 1.0mm, as rolled, 99.999%; Cadmium, foil, 50x200mm, "	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB14085	.	.	112.41	Cd	0	0	.	1	0	0	0	1S/Cd	[Cd]	BDOSMKKIYDKNTQ-UHFFFAOYSA-N
DG00365	Desethylamodiaquine	122068	"Desethylamodiaquine; Monodesethylamodiaquine; 79352-78-6; N-DESETHYL AMODIAQUINE; UNII-BY36SG7NP9; BY36SG7NP9; CHEMBL1235; 4-[(7-chloroquinolin-4-yl)amino]-2-(ethylaminomethyl)phenol; N-MONODESETHYLAMODIAQUINE (DEAQ); 4-((7-Chloroquinolin-4-yl)amino)-2-((ethylamino)methyl)phenol; N-Desethyl amodiaquine diHCl; N-desethylamodiaquine; bidesethylamodiaquine; 4-((7-Chloro-4-quinolinyl)amino)-2-((ethylamino)methyl)phenol; DESETHYL AMODIAQUINE; SCHEMBL14067597; DTXSID20229630; BCP34368; ZINC5139697; BDBM50056190; AKOS025401980; SB73009; AC-27753; HY-128554; CS-0095816; FT-0665940; A933931; 4-(7-Chloro-quinolin-4-ylamino)-2-ethylaminomethyl-phenol; 4-[(7-chloro-4-quinolyl)amino]-2-(ethylaminomethyl)phenol; Phenol, 4-((7-chloro-4-quinolinyl)amino)-2-((ethylamino)methyl)-; N-Desethyl Amodiaquine-d5 Phenol,2-(aminomethyl)-4-[(7-chloro-4-quinolinyl)amino]-"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	327.8	C18H18ClN3O	57.2	370	2.3	23	3	4	5	"1S/C18H18ClN3O/c1-2-20-11-12-9-14(4-6-18(12)23)22-16-7-8-21-17-10-13(19)3-5-15(16)17/h3-10,20,23H,2,11H2,1H3,(H,21,22)"	CCNCC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O	VRXFDHAGFYWGHT-UHFFFAOYSA-N
DG00366	Disorazole C1	101668901	Disorazole C1; 158181-52-3	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	774.9	C44H58N2O10	164	1350	8.9	56	2	12	8	"1S/C44H58N2O10/c1-9-21-35(47)43(3,4)37-25-19-15-11-13-17-23-32(52-8)28-40-46-34(30-54-40)42(50)56-38(44(5,6)36(48)22-10-2)26-20-16-12-14-18-24-31(51-7)27-39-45-33(29-53-39)41(49)55-37/h9-24,29-32,35-38,47-48H,25-28H2,1-8H3/b13-11-,14-12-,19-15-,20-16-,21-9+,22-10+,23-17-,24-18-/t31-,32-,35-,36-,37-,38-/m0/s1"	C/C=C/[C@H](O)C([C@H]1OC(=O)C2=COC(=N2)C[C@H](/C=C\\C=C/C=C\\C[C@H](OC(=O)C3=COC(=N3)C[C@H](/C=C\\C=C/C=C\\C1)OC)C([C@@H](O)/C=C/C)(C)C)OC)(C)C	FGVAPNZAWLGHCU-BBJFQTBJSA-N
DG00367	Disorazole A1	44566233	Disorazole A1; CHEMBL501853; SCHEMBL13593476	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	758.9	C43H54N2O10	167	1490	8.3	55	2	12	7	"1S/C43H54N2O10/c1-8-18-34(46)42(3,4)36-23-14-12-10-11-13-20-29(50-7)26-39-45-31(28-52-39)41(49)55-37(43(5,6)35(47)19-9-2)24-17-22-33-32(53-33)21-15-16-25-38-44-30(27-51-38)40(48)54-36/h8-22,25,27-29,32-37,46-47H,23-24,26H2,1-7H3/b11-10-,14-12-,18-8+,19-9+,20-13+,21-15+,22-17-,25-16-/t29-,32-,33+,34-,35-,36-,37-/m0/s1"	C/C=C/[C@@H](C(C)(C)[C@@H]1C/C=C\\C=C/C=C/[C@@H](CC2=NC(=CO2)C(=O)O[C@@H](C/C=C\\[C@@H]3[C@@H](O3)/C=C/C=C\\C4=NC(=CO4)C(=O)O1)C(C)(C)[C@H](/C=C/C)O)OC)O	FRFRWOXVYJSPCG-YEYPPUHMSA-N
DG00368	4-Nitroquinoline N-oxide	5955	"4-Nitroquinoline N-oxide; 56-57-5; 4-Nitroquinoline 1-oxide; 4-Nitroquinoline-1-oxide; 4-NITROQUINOLINE-N-OXIDE; Nitrochin; 4-NQO; Quinoline, 4-nitro-, 1-oxide; 4-Nitroquinoline oxide; 4-nitro-1-oxidoquinolin-1-ium; 4 NQO; 4-nitroquinolin-1-ium-1-olate; CHEBI:16907; 4-Nitroquinolin-1-oxide; Quinoline, 4-nitro-, oxide; CCRIS 458; 4-nitroquinolin-1-ol; HSDB 4316; 4-Nitrochinolin N-oxid; NSC 19645; AI3-60200; UNII-X5081510EV; 4-Nitrochinoline-N-oxide; BIDD:ER0541; SCHEMBL105454; CHEMBL127655; WLN: T66 BNJ BO ENW; DTXSID5025780; CS-D0398; EX-A4093; NSC19645; ZINC1529664; 4-Nitroquinoline N-oxide, >=98%; AB4039; MFCD00006738; NSC-19645; AKOS015897246; SB67483; X5081510EV; AS-58188; DB-052942; FT-0619297; N0250; Z2900; 4-Nitroquinoline N-oxide, analytical standard; C03474; 95599-EP2277881A1; 95599-EP2305672A1; AC-907/25014229; Quinoline, 4-nitro-, 1-oxide (6CI,8CI,9CI); J-515890; J-640451; J-800475; Q4637188; NQO"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	190.16	C9H6N2O3	71.3	229	1.1	14	0	3	0	1S/C9H6N2O3/c12-10-6-5-9(11(13)14)7-3-1-2-4-8(7)10/h1-6H	C1=CC=C2C(=C1)C(=CC=[N+]2[O-])[N+](=O)[O-]	YHQDZJICGQWFHK-UHFFFAOYSA-N
DG00369	Gentamicin C	3084091	"Gentamicin C; 11097-82-8; (2R,3S,4R,5R)-2-[(1S,2R,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; Gentamicin C complex"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	449.5	C19H39N5O7	214	592	-5	31	8	12	6	"1S/C19H39N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h8-18,24-27H,3-7,20-23H2,1-2H3/t8-,9+,10-,11+,12+,13-,14+,15-,16+,17+,18+,19-/m0/s1"	C[C@@]1(CO[C@@H]([C@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@H]2O)O[C@@H]3[C@@H](CC[C@H](O3)CN)N)N)N)O	VEGXETMJINRLTH-ALRICIOSSA-N
DG00370	Sisomicin	36119	"Sisomicin; Rickamicin; Sisomycin; 32385-11-8; Sissomicin; Antibiotic 6640; Antibiotic 66-40; Sch 13475; Dehydrogentamicin Cla; Sch-13475; UNII-X55XSL74YQ; X55XSL74YQ; CHEBI:9169; Sisomin; D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy-; Sisomicinum; Sisomicina; Sisomicine; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; Sch 13475 sulfate; Sisomicine [INN-French]; Sisomicinum [INN-Latin]; Salvamina; Sisomicina [INN-Spanish]; Siseptin sulfate; (1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yloxy]-2-hydroxycyclohexyl 3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranoside; (1s,2s,3r,4s,6r)-4,6-Diamino-3-{[(2s,3r)-3-Amino-6-(Aminomethyl)-3,4-Dihydro-2h-Pyran-2-Yl]oxy}-2-Hydroxycyclohexyl 3-Deoxy-4-C-Methyl-3-(Methylamino)-Beta-L-Arabinopyranoside; (2R,3R,4R,5R)-2-(((1S,2S,3R,4S,6R)-4,6-diamino-3-(((2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-5-methyl-4-(methylamino)tetrahydro-2H-pyran-3,5-diol; O-2,6-Diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-2-deoxy-D-streptamine; C19H37N5O7; EINECS 251-018-2; BRN 1357913; Sisomicin [USAN:INN:BAN]; Sch13475; sisomicin-sulfate; SiS; SISO; Sisomicin (USAN/INN); SCHEMBL49395; O-2,6-Diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-2-deoxy-D-streptamine; O-3-Deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-4)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-6))-2-deoxy-L-streptamine; CHEMBL221886; GTPL10858; ZINC56870809; AKOS015895179; DB12604; (2S-cis)-4-O-(3-Amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl)-2-deoxy-6-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl)-D-streptamine; 85S118; C00494; D02544; Q3962119; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-2-hydroxy-cyclohexoxy]-5-methyl-4-(methylamino)tetrahydropyran-3,5-diol; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB12604	.	DR2408	447.5	C19H37N5O7	214	643	-5.1	31	8	12	6	"1S/C19H37N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h3,9-18,24-27H,4-7,20-23H2,1-2H3/t9-,10+,11-,12+,13-,14-,15+,16-,17-,18-,19+/m1/s1"	C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N)N)O	URWAJWIAIPFPJE-YFMIWBNJSA-N
DG00371	Colistin A	202195	"Colistin A; Polymyxin E1; Colistin IV; Polymixin E1; CHEBI:59064; 4,10-anhydro{N-[(6R)-6-methyloctanoyl]-L-2,4-diaminobutanoyl-L-threonyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-D-leucyl-L-leucyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-threonine}; NCGC00161620-01; DSSTox_CID_29005; DSSTox_RID_83270; DSSTox_GSID_49079; SCHEMBL49226; CHEMBL3183122; Tox21_113638; CAS-7722-44-3; Q27126429"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	1169.5	C53H100N16O13	491	2070	-2.8	82	18	18	29	"1S/C53H100N16O13/c1-9-30(6)12-10-11-13-41(72)60-33(14-20-54)48(77)69-43(32(8)71)53(82)65-36(17-23-57)45(74)64-38-19-25-59-52(81)42(31(7)70)68-49(78)37(18-24-58)62-44(73)34(15-21-55)63-50(79)39(26-28(2)3)67-51(80)40(27-29(4)5)66-46(75)35(16-22-56)61-47(38)76/h28-40,42-43,70-71H,9-27,54-58H2,1-8H3,(H,59,81)(H,60,72)(H,61,76)(H,62,73)(H,63,79)(H,64,74)(H,65,82)(H,66,75)(H,67,80)(H,68,78)(H,69,77)/t30-,31-,32-,33+,34+,35+,36+,37+,38+,39+,40-,42+,43+/m1/s1"	CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O	XDJYMJULXQKGMM-RVYUQJQSSA-N
DG00372	Colistin B	25138298	"Colistin b; Polymyxin E2; 7239-48-7; UNII-B142O7Y03E; CHEBI:59673; B142O7Y03E; polymyxin E2 sulfate; N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide; 4,10-anhydro[N-(6-methylheptanoyl)-L-2,4-diaminobutanoyl-L-threonyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-D-leucyl-L-leucyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-threonine]; SCHEMBL1860364; CHEMBL1089240; Polymyxin E2 sulfate (P056); Q27126844; UNII-Z67X93HJG1 component KNIWPHSUTGNZST-SSWRVQTPSA-N; 30387-41-8"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	1155.4	C52H98N16O13	491	2050	-3.3	81	18	18	28	"1S/C52H98N16O13/c1-27(2)11-9-10-12-40(71)59-32(13-19-53)47(76)68-42(31(8)70)52(81)64-35(16-22-56)44(73)63-37-18-24-58-51(80)41(30(7)69)67-48(77)36(17-23-57)61-43(72)33(14-20-54)62-49(78)38(25-28(3)4)66-50(79)39(26-29(5)6)65-45(74)34(15-21-55)60-46(37)75/h27-39,41-42,69-70H,9-26,53-57H2,1-8H3,(H,58,80)(H,59,71)(H,60,75)(H,61,72)(H,62,78)(H,63,73)(H,64,81)(H,65,74)(H,66,79)(H,67,77)(H,68,76)/t30-,31-,32+,33+,34+,35+,36+,37+,38+,39-,41+,42+/m1/s1"	C[C@H]([C@H]1C(=O)NCC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCN)CCN)CC(C)C)CC(C)C)CCN)NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)CCCCC(C)C)O	KNIWPHSUTGNZST-SSWRVQTPSA-N
DG00373	Gentamicin B	11754987	"Gentamicin B; BETAMICIN; 36889-15-3; Gentamycin B; UNII-67W9DGG4C7; 67W9DGG4C7; Sch 14342; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol; Betamicina; Betamicine; Betamicinum; Betamicin [INN]; Betamicine [INN-French]; Betamicinum [INN-Latin]; Betamicina [INN-Spanish]; SCHEMBL509198; CHEMBL2110604; ZINC8214501; Q27264175; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-((1R,2R,3S,4R,6S)-4,6-diamino-3-((2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)tetrahydro-2H-pyran-2-yloxy)-2-hydroxycyclohexyloxy)tetrahydro-2H-pyran-3,4,5-triol; D-Streptamine, O-6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-2-deoxy-; O-6-Amino-6-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-2-deoxy-D-streptamine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	482.5	C19H38N4O10	248	652	-6.2	33	10	14	6	"1S/C19H38N4O10/c1-19(29)5-30-17(13(28)16(19)23-2)32-14-6(21)3-7(22)15(12(14)27)33-18-11(26)10(25)9(24)8(4-20)31-18/h6-18,23-29H,3-5,20-22H2,1-2H3/t6-,7+,8-,9-,10+,11-,12-,13-,14+,15-,16-,17-,18-,19+/m1/s1"	C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N)N)O	RHRAMPXHWHSKQB-GGEUKFTFSA-N
DG00374	Pristinamycin IIA	5459319	"Virginiamycin m1; Streptogramin A; Mikamycin A; Pristinamycin IIA; Ostreogrycin a; Virginiamycin Factor M1; 21411-53-0; UNII-8W4UOL59AZ; 8W4UOL59AZ; CHEBI:9997; VERNAMYCIN A; NSC87434; NSC 244426; Vernamycin A & B mixture; SCHEMBL673193; CHEMBL1236670; HY-N6686; EINECS 244-376-6; MFCD00869411; NSC 87432; NSC-87434; Vernamycin A & vernamycin B (1:1); DB01669; Vernamycin A, mixture with vernamycin B; VERNAMYCIN A & B MIXTURE (1:1); CS-0019826; Virginiamycin M1 100 microg/mL in Acetonitrile; UNII-4O8O7Q7IU4 component DAIKHDNSXMZDCU-FQTGFAPKSA-N; (3R,4R,5E,10E,12E,14S)-14-hydroxy-3-isopropyl-4,12-dimethyl-8,9,14,15,24,25-hexahydro-1H,3H,22H-21,18-(azeno)pyrrolo[2,1-c][1,8,4,19]dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone; (3R,4R,5E,10E,12E,14S)-14-hydroxy-4,12-dimethyl-3-(1-methylethyl)-8,9,14,15,24,25-hexahydro-1H,3H,22H-21,18-(azeno)pyrrolo[2,1-c][1,8,4,19]dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone; 8,9,14,15,24,25-Hexahydro-14-hydroxy-3-isopropyl-4,12-dimethyl-3H-21,18-nitrilo-1H,22H-pyrrolo(2,1-c)(1,8,4,19)dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone; 8,9,14,15,24,25-Hexahydro-14-hydroxy-4,12-dimethyl-3-(1-methylethyl)-3H-21,18-nitrilo-1H,22H-pyrrolo(2,1-c)(1,8,4,19)dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB01669	.	.	525.6	C28H35N3O7	139	1030	2.5	38	2	8	1	"1S/C28H35N3O7/c1-17(2)26-19(4)9-10-24(34)29-11-5-7-18(3)13-20(32)14-21(33)15-25-30-22(16-37-25)27(35)31-12-6-8-23(31)28(36)38-26/h5,7-10,13,16-17,19-20,26,32H,6,11-12,14-15H2,1-4H3,(H,29,34)/b7-5+,10-9+,18-13+/t19-,20-,26-/m1/s1"	C[C@@H]1/C=C/C(=O)NC/C=C/C(=C/[C@H](CC(=O)CC2=NC(=CO2)C(=O)N3CCC=C3C(=O)O[C@@H]1C(C)C)O)/C	DAIKHDNSXMZDCU-FQTGFAPKSA-N
DG00375	Dibekacin	470999	"Dibekacin; Panamicin; Dideoxykanamycin B; 34493-98-6; 3',4'-Dideoxykanamycin B; UNII-45ZFO9E525; BRN 1441606; CHEBI:37945; 45ZFO9E525; Debecacin; DKB; DKM; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranosyl-(1-6))-2-deoxy-L-streptamine; Dibekacina; Dibekacine; Dibekacinum; Kappati; (1R,2S,3S,4R,6S)-4,6-diamino-3-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranoside; (1R,2S,3S,4R,6S)-4,6-diamino-3-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranoside; Dibekacin [INN:BAN]; Dibekacine [INN-French]; Dibekacinum [INN-Latin]; Dibekacina [INN-Spanish]; Dibekacin (INN); D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranosyl)-(1-4)-2-deoxy-; EINECS 252-064-6; Spectrum_001398; Spectrum2_001528; Spectrum3_000960; Spectrum4_001074; Spectrum5_001613; NCGC00095276-01; DSSTox_CID_2915; DSSTox_RID_76787; DSSTox_GSID_22915; SCHEMBL49816; KBioGR_001428; KBioSS_001878; SPBio_001316; CHEMBL560976; DTXSID2022915; KBio2_001878; KBio2_004446; KBio2_007014; KBio3_002060; HY-B1129; ZINC8214383; Tox21_111496; AC-315; AKOS025402025; CCG-213771; CS-4725; DB13270; NCGC00389765-01; CAS-34493-98-6; D07811; AB01563356_01; Q3706873; (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]-6-(hydroxymethyl)tetrahydropyran-3,5-diol; 84D"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB13270	.	DR2603	451.5	C18H37N5O8	248	579	-5.8	31	9	13	6	"1S/C18H37N5O8/c19-4-6-1-2-7(20)17(28-6)30-15-8(21)3-9(22)16(14(15)27)31-18-13(26)11(23)12(25)10(5-24)29-18/h6-18,24-27H,1-5,19-23H2/t6-,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1"	C1C[C@H]([C@H](O[C@@H]1CN)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N)N)N	JJCQSGDBDPYCEO-XVZSLQNASA-N
DG00376	Streptothricin	475825	"STREPTOTHRICINS; Streptothricin; 54003-27-9; EINECS 258-911-6; DTXSID60202321; [6-[[(3aS,7R,7aS)-7-hydroxy-4-oxo-1,3a,5,6,7,7a-hexahydroimidazo[4,5-c]pyridin-2-yl]amino]-5-(3,6-diaminohexanoylamino)-4-hydroxy-2-(hydroxymethyl)oxan-3-yl] carbamate; [6-[(E)-[(3aS,7R,7aS)-7-hydroxy-4-oxo-3,3a,5,6,7,7a-hexahydro-1H-imidazo[4,5-c]pyridin-2-ylidene]amino]-5-(3,6-diaminohexanoylamino)-4-hydroxy-2-(hydroxymethyl)tetrahydropyran-3-yl] carbamate"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	502.5	C19H34N8O8	269	816	-5.5	35	10	11	11	"1S/C19H34N8O8/c20-3-1-2-7(21)4-10(30)24-13-14(31)15(35-18(22)33)9(6-28)34-17(13)27-19-25-11-8(29)5-23-16(32)12(11)26-19/h7-9,11-15,17,28-29,31H,1-6,20-21H2,(H2,22,33)(H,23,32)(H,24,30)(H2,25,26,27)/t7 ,8-,9 ,11-,12+,13 ,14 ,15 ,17 /m1/s1"	C1[C@H]([C@@H]2[C@@H](C(=O)N1)N=C(N2)NC3C(C(C(C(O3)CO)OC(=O)N)O)NC(=O)CC(CCCN)N)O	NRAUADCLPJTGSF-WJPMJIHPSA-N
DG00377	Butirosina	72393	"Butirosina; Ambutyrosin; Butirosin; 12772-35-9; (2R)-4-amino-N-[(1R,2S,3R,4R,5S)-5-amino-4-[(2R,3R,4R,5S,6R)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-2-hydroxycyclohexyl]-2-hydroxybutanamide; Butirosin [INN]; Butirosine; Butirosinum; Butirosine [INN-French]; Butirosinum [INN-Latin]; Butirosina [INN-Spanish]; DTXSID60925967; 4-Amino-N-{5-amino-4-[(2,6-diamino-2,6-dideoxyhexopyranosyl)oxy]-2-hydroxy-3-(pentofuranosyloxy)cyclohexyl}-2-hydroxybutanimidic acid"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	555.6	C21H41N5O12	312	772	-7.3	38	12	16	10	"1S/C21H41N5O12/c22-2-1-8(28)19(34)26-7-3-6(24)17(37-20-11(25)15(32)13(30)9(4-23)35-20)18(12(7)29)38-21-16(33)14(31)10(5-27)36-21/h6-18,20-21,27-33H,1-5,22-25H2,(H,26,34)/t6-,7+,8+,9+,10+,11+,12-,13+,14+,15+,16+,17+,18+,20+,21+/m0/s1"	C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@@H](CCN)O)O)O[C@@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)N)N	XEQLFNPSYWZPOW-NUOYRARPSA-N
DG00378	Florfenicol	114811	"Florfenicol; 73231-34-2; Nuflor; (-)-Florfenicol; Sch-25298; 76639-94-6; Sch 25298; Aquafen; Nuflor gold; C12H14Cl2FNO4S; UNII-9J97307Y1H; 2,2-dichloro-N-[(1R,2S)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]acetamide; CHEBI:87185; MFCD00864834; D-threo-2,2-Dichloro-N-(alpha-(fluoromethyl)-beta-hydroxy-p-(methylsulfonyl)phenethyl)acetamide; 9J97307Y1H; Acetamide, 2,2-dichloro-N-((1S,2R)-1-(fluoromethyl)-2-hydroxy-2-(4-(methylsulfonyl)phenyl)ethyl)-; 2,2-dichloro-N-[(1R,2S)-3-fluoro-1-hydroxy-1-(4-methanesulfonylphenyl)propan-2-yl]acetamide; 2,2-Dichloro-N-[(1R,2S)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)-2-propyl]acetamide; DSSTox_CID_25500; DSSTox_RID_80918; DSSTox_GSID_45500; 2,2-Dichloro-N-((1R,2S)-3-fluoro-1-hydroxy-1-(4-(methylsulfonyl)phenyl)propan-2-yl)acetamide; Florfenicol [USAN:INN:BAN]; 2,2-Dichloro-N-(1-(fluoromethyl)-2-hydroxy-2-(4-(methylsulfonyl)phenyl)ethyl)acetamide; NCGC00016922-01; CAS-73231-34-2; Nuflor (TN); Prestwick0_000955; Prestwick1_000955; Prestwick2_000955; Prestwick3_000955; Florfenicol (USAN/INN); SCHEMBL49425; BSPBio_000950; MLS002154071; SPBio_003099; BPBio1_001046; CHEMBL1241590; DTXSID9045500; SCHEMBL21835523; (-)-Florfenicol;SCH-25298; D-(-)-threo-2-Dichloroacetamido-3-fluoro-1-(4-methylsulfonylphenyl)-1-propanol; HMS1570P12; HMS2090I10; HMS2097P12; HMS2230K18; HMS3714P12; ZINC537733; ACT06682; HY-B1374; Aquafen; ; ; Nuflor; ; ; SCH-25298; Tox21_110683; s4201; AKOS015889457; Tox21_110683_1; AC-4340; CCG-220955; CS-4857; DB11413; KS-5028; NSC 759287; 2,2-dichloro-N-[(1S,2R)-1-(fluoromethyl)-2-hydroxy-2-(4-methylsulfonylphenyl)ethyl]acetamide; NCGC00179366-01; NCGC00179366-03; NCGC00179366-04; [R-(R*,S*)]-2,2-Dichloro-N-[1-(fluoromethyl)-2-hydroxy-2-[4-(methylsulfonyl)phenyl]ethyl]acetamide; 2,2-Dichloro-N-((alphaS,betaR)-alpha-(fluoromethyl)-beta-hydroxy-p-(methylsulfonyl)phenethyl)acetamide; 2,2-Dichloro-N-[(1S,2R)-1-(fluoromethyl)-2-hydroxy-2-[4-(methylsulfonyl)phenyl]ethyl]acetamide; Acetamide, 2,2-dichloro-N-(1-(fluoromethyl)-2-hydroxy-2-(4-(methylsulfonyl)phenyl)ethyl)-, (R-(R*,S*))-; Benzenesulfonic acid, 4-(2-((dichloroacetyl)amino)-3-fluoro-1-hydroxypropyl)-, methyl ester, (R-(R*,S*))-; BF166386; SMR001233384; AB0008500; (methylsulfonyl)phenyl)propan-2-yl)acetamide; AB00513976; F0811; SW197224-3; D04194; J10454; T72886; AB00513976_09; 231F342; A838774; Q408400; Florfenicol, analytical standard, for drug analysis; BRD-K11298197-001-03-9; 2,2-dichloro-N-((1R,2S)-3-fluoro-1-hydroxy-1-(4-; (1R,2S)-2-DICHLOROACETAMIDO-3-FLUORO-1-[4-(METHYLSULFONYL) PHENYL]-1-PROPANOL; (1R,2S)-2-dichloroacetamido-3-fluoro-1-[4-(methylsulfonyl)phenyl]-1-propanol; 2,2-Dichlor-N-((1R,2S)-3-fluor-1-hydroxy- 1-(4-(methylsulfonyl)-phenyl)-propan-2-yl)-ethanamide; 2,2-dichloro-N-[(1R,2R)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]acetamide; 2,2-dichloro-N-{(1R,2S)-3-fluoro-1-hydroxy-1-[4-(methanesulfonyl)phenyl]propan-2-yl}acetamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11413	.	.	358.2	C12H14Cl2FNO4S	91.8	447	0.8	21	2	5	6	"1S/C12H14Cl2FNO4S/c1-21(19,20)8-4-2-7(3-5-8)10(17)9(6-15)16-12(18)11(13)14/h2-5,9-11,17H,6H2,1H3,(H,16,18)/t9-,10-/m1/s1"	CS(=O)(=O)C1=CC=C(C=C1)[C@H]([C@@H](CF)NC(=O)C(Cl)Cl)O	AYIRNRDRBQJXIF-NXEZZACHSA-N
DG00379	Pristinamycin IA	11136668	"Pristinamycin IA; Streptogramin B; Ostreogrycin B; Antibiotic PA 114B; NSC 92554; UNII-V50XJ0NC3I; V50XJ0NC3I; CHEBI:8417; Mikamycin IA; 3131-03-1; Virginiamycin B; Vernamycin BA; Vernamycin B alpha; N-((6R,9S,10R,13S,15aS,22S,24aS)-22-(4-(dimethylamino)benzyl)-6-ethyl-10,23-dimethyl-5,8,12,15,17,21,24-heptaoxo-13-phenyldocosahydro-12H-pyrido[2,1-f]pyrrolo[2,1-l][1]oxa[4,7,10,13,16]pentaazacyclononadecin-9-yl)-3-hydroxypicolinamide; 4-(4-(Dimethylamino)-N-methyl-L-phenylalanine)virginiamycin S1; 4-[4-(Dimethylamino)-N-methyl-L-phenylalanine]virginiamycin S1; PA 114B; Antibiotic PA 114B1; Antibiotic PA 114 B1; CHEMBL1256399; SCHEMBL13176900; HY-A0279A; C45H54N8O10; ZINC9574677; CS-5850; BRN 0078387; X8445; 4-27-00-09718 (Beilstein Handbook Reference); J-018376; Q14035740; UNII-4O8O7Q7IU4 component YGXCETJZBDTKRY-DZCVGBHJSA-N; UNII-JN6G9U5358 component YGXCETJZBDTKRY-DZCVGBHJSA-N; Virginiamycin S1, 4-(4(dimethylamino)-N-methyl-L-phenylalanine)-; Vernamycin Balpha; Virginiamycin S1, 4-(4-(dimethylamino)-N-methyl-L-phenylalanine)- (9CI); N-[(3S,6S,12R,15S,16R,19S,22S)-3-[[4-(dimethylamino)phenyl]methyl]-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide; N-[(6R,9S,10R,13S,15aS,22S,24aS)-22-{[4-(dimethylamino)phenyl]methyl}-6-ethyl-10,23-dimethyl-5,8,12,15,17,21,24-heptaoxo-13-phenyldocosahydro-12H-pyrido[2,1-f]pyrrolo[2,1-l][1,4,7,10,13,16]oxapentaazacyclononadecin-9-yl]-3-hydroxypyridine-2-carboxamide"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	.	DB13704	.	.	867	C45H54N8O10	228	1700	2.8	63	4	12	7	"1S/C45H54N8O10/c1-6-31-42(59)52-22-11-14-32(52)43(60)51(5)34(24-27-16-18-29(19-17-27)50(3)4)44(61)53-23-20-30(54)25-33(53)39(56)49-37(28-12-8-7-9-13-28)45(62)63-26(2)36(40(57)47-31)48-41(58)38-35(55)15-10-21-46-38/h7-10,12-13,15-19,21,26,31-34,36-37,55H,6,11,14,20,22-25H2,1-5H3,(H,47,57)(H,48,58)(H,49,56)/t26-,31-,32+,33+,34+,36+,37+/m1/s1"	CC[C@@H]1C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)N3CCC(=O)C[C@H]3C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CC6=CC=C(C=C6)N(C)C)C	YGXCETJZBDTKRY-DZCVGBHJSA-N
DG00380	Bacitracin F	3082210	"Bacitracin F; 5-[[1-[[3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-butan-2-yl-6-(carboxymethyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-[[4-methyl-2-[[2-(2-methylbutanoyl)-1,3-thiazole-4-carbonyl]amino]pentanoyl]amino]-5-oxopentanoic acid; 22601-63-4; UNII-W7FFC6JWF9; W7FFC6JWF9; Bacitracin F (~75per cent); B021"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	1419.6	C66H98N16O17S	551	2830	-0.5	100	16	21	31	"1S/C66H98N16O17S/c1-9-35(6)52(82-58(92)42(22-23-50(84)85)73-59(93)43(26-34(4)5)75-63(97)48-32-100-66(80-48)54(88)37(8)11-3)64(98)74-40-20-15-16-25-70-55(89)46(29-49(68)83)77-62(96)47(30-51(86)87)78-61(95)45(28-39-31-69-33-71-39)76-60(94)44(27-38-18-13-12-14-19-38)79-65(99)53(36(7)10-2)81-57(91)41(21-17-24-67)72-56(40)90/h12-14,18-19,31-37,40-47,52-53H,9-11,15-17,20-30,67H2,1-8H3,(H2,68,83)(H,69,71)(H,70,89)(H,72,90)(H,73,93)(H,74,98)(H,75,97)(H,76,94)(H,77,96)(H,78,95)(H,79,99)(H,81,91)(H,82,92)(H,84,85)(H,86,87)"	CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCCCCC(C(=O)NC(C(=O)N1)CCCN)NC(=O)C(C(C)CC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C2=CSC(=N2)C(=O)C(C)CC)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4	FCLQHQCOKGKLHR-UHFFFAOYSA-N
DG00381	Enacyloxin IIA	5288163	"Enacyloxin iia; Q27459995; (1S,3R,4S)-3-{[(2E,4E,6E,8E,10Z,12S,13R,14S,17R,18S,19R,20E)-19-(carbamoyloxy)-11,18-dichloro-13,14,17-trihydroxy-6,12-dimethyl-15-oxotricosa-2,4,6,8,10,20-hexaenoyl]oxy}-4-hydroxycyclohexanecarboxylic acid"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	702.6	C33H45Cl2NO11	214	1240	3.7	47	6	11	20	"1S/C33H45Cl2NO11/c1-4-5-13-26(47-33(36)45)29(35)24(38)18-25(39)31(42)30(41)20(3)22(34)12-8-6-10-19(2)11-7-9-14-28(40)46-27-17-21(32(43)44)15-16-23(27)37/h5-14,20-21,23-24,26-27,29-31,37-38,41-42H,4,15-18H2,1-3H3,(H2,36,45)(H,43,44)/b8-6+,11-7+,13-5+,14-9+,19-10+,22-12-/t20-,21+,23+,24-,26-,27-,29+,30-,31-/m1/s1"	CC/C=C/[C@H]([C@H]([C@@H](CC(=O)[C@H]([C@@H]([C@H](C)/C(=C/C=C/C=C(\\C)/C=C/C=C/C(=O)O[C@@H]1C[C@H](CC[C@@H]1O)C(=O)O)/Cl)O)O)O)Cl)OC(=O)N	IWBADCVFZDCUTN-OCXJTLLTSA-N
DG00382	Kasugamycin	65174	"KASUGAMYCIN; 6980-18-3; Kasumin L; Kasumin 2L; Kasuminl; UNII-O957UYB9DY; alpha-D-lyxo-; O957UYB9DY; CHEBI:81419; 2-amino-2-[(2R,3S,5S,6R)-5-amino-2-methyl-6-[(2R,3S,5S,6S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyoxan-3-yl]iminoacetic acid; Kasu B; (1s,2r,3s,4r,5s,6s)-2,3,4,5,6-Pentahydroxycyclohexyl 2-Amino-4-{[carboxy(Imino)methyl]amino}-2,3,4,6-Tetradeoxy-Alpha-D-Arabino-Hexopyranoside; HSDB 6695; KSM; BRN 1403823; SR-05000001429; C14H25N3O9; EINECS 234-260-3; NSC 100858; SCHEMBL70535; CHEMBL1631109; DTXSID1040374; SCHEMBL12858482; SCHEMBL16011710; HMS2089A11; ZINC4216682; AKOS025310863; ZINC100042889; ZINC100045947; 11030-24-3; 3-O-(2-Amino-4-((carboxyiminomethyl)amino)-2,3,4,6-tetradeoxy-alpha-D-arabino-hexopyranosyl)-D-chiro-inositol sulphate; D-chiro-Inositol, 3-O-(2-amino-4-((carboxyiminomethyl)amino)-2,3,4,6-tetradeoxy-alpha-D-arabino-hexopyranosyl)-; X6751; C17968; Q3193879; SR-05000001429-1; (1S,2R,3S,4R,5S,6S)-2,3,4,5,6-PENTAHYDROXYCYCLOHEXYL; (1S,2R,3S,4R,5S,6S)-2,3,4,5,6-pentahydroxycyclohexyl 2-amino-4-{[(Z)-carboxy(imino)methyl]amino}-2,3,4,6-tetradeoxy-alpha-D-arabino-hexopyranoside; 2-((2R,3S,5S,6R)-5-amino-2-methyl-6-((1S,2R,3S,4R,5S,6S)-2,3,4,5,6-pentahydroxycyclohexyloxy)tetrahydro-2H-pyran-3-ylamino)-2-iminoacetic acid; 2-[[(2R,3S,5S,6R)-5-amino-2-methyl-6-[(2R,3S,5S,6S)-2,3,4,5,6-pentahydroxycyclohexoxy]tetrahydropyran-3-yl]amino]-2-imino-acetic acid; 2-AMINO-4-{[CARBOXY(IMINO)METHYL]AMINO}-2,3,4,6-TETRADEOXY-ALPHA-D-ARABINO-HEXOPYRANOSIDE; 3-O-[2-amino-4-[(carboxyiminomethyl)amino]-2,3,4,6-tetradeoxy-alpha-D-arabino-hexopyranosyl]-D-chiro-inositol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	379.36	C14H25N3O9	221	532	-6.7	26	8	11	4	"1S/C14H25N3O9/c1-3-5(17-12(16)13(23)24)2-4(15)14(25-3)26-11-9(21)7(19)6(18)8(20)10(11)22/h3-11,14,18-22H,2,15H2,1H3,(H2,16,17)(H,23,24)/t3-,4+,5+,6 ,7+,8+,9-,10+,11 ,14-/m1/s1"	C[C@@H]1[C@H](C[C@@H]([C@H](O1)OC2[C@@H]([C@H](C([C@@H]([C@@H]2O)O)O)O)O)N)N=C(C(=O)O)N	PVTHJAPFENJVNC-UQTMRZPGSA-N
DG00383	Matromycin	72493	"Oleandomycin; Amimycin; Matromycin; Romicil; Landomycin; 3922-90-5; UNII-P8ZQ646136; CHEBI:16869; P8ZQ646136; PA 775; Oleandomicina; Oleandomycine; Oleandomycinum; Oleandomycin [INN]; Antibiotic PA-105; Oleandomycine [French]; Oleandomycin [INN:BAN]; Oleandomycine [INN-French]; Oleandomycinum [INN-Latin]; Oleandomicina [INN-Spanish]; HSDB 7442; EINECS 223-495-7; AI3-50163; Prestwick3_000152; SCHEMBL3717; BSPBio_000284; BPBio1_000314; CHEMBL606258; Oleandomycin (chloroform solvate); BDBM234401; LMPK04000007; ZINC85432018; DB11442; NCGC00179617-01; 12-((2,6-Didesoxy-3-O-methyl-alpha-K-arabino-hexopyranosyl)oxy)-8-hydroxy-5,7,8,11,13,15-hexamethyl-14-((3,4,6-tridesoxy-3-dimethylamino-beta-D-xylo-hexopyranosyl)oxy)-1,9-dioxaspiro(2.13)hexadecan-4,10-dion; E704; HY-116010; AB00513809; CS-0063452; C01946; (3R,5R,6S,7R,8R,11R,12S,13R,14S,15S)-6-hydroxy-5,7,8,11,13,15-hexamethyl-4,10-dioxo-14-[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyloxy]-1,9-dioxaspiro[2.13]hexadec-12-yl 2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranoside"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11442	.	DR1189	687.9	C35H61NO12	166	1090	2.6	48	3	13	6	"1S/C35H61NO12/c1-16-14-35(15-43-35)32(40)19(4)27(37)18(3)22(7)46-33(41)21(6)31(47-26-13-25(42-11)28(38)23(8)45-26)20(5)30(16)48-34-29(39)24(36(9)10)12-17(2)44-34/h16-31,34,37-39H,12-15H2,1-11H3/t16-,17+,18-,19+,20+,21+,22+,23-,24-,25-,26-,27-,28-,29+,30-,31-,34-,35+/m0/s1"	C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)O)OC)C)C)C)O)C)C)O)N(C)C	RZPAKFUAFGMUPI-QESOVKLGSA-N
DG00384	Gentamicin A	12810388	"Gentamicin A; C01917; 13291-74-2; C18H36N4O10; ZINC56870883; Y1680; (2R,3S,4R,5R,6S)-5-amino-6-[(1R,2S,3S,4R,6S)-4,6-diamino-3-[(2R,3R,4S,5S)-3,5-dihydroxy-4-(methylamino)tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]-2-(hydroxymethyl)tetrahydropyran-3,4-diol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	468.5	C18H36N4O10	248	608	-6.4	32	10	14	6	"1S/C18H36N4O10/c1-22-10-7(24)4-29-18(13(10)27)32-16-6(20)2-5(19)15(14(16)28)31-17-9(21)12(26)11(25)8(3-23)30-17/h5-18,22-28H,2-4,19-21H2,1H3/t5-,6+,7+,8+,9+,10-,11+,12+,13+,14-,15+,16-,17+,18+/m0/s1"	CN[C@H]1[C@@H](CO[C@@H]([C@@H]1O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)N)N)N)O	LKKVGKXCMYHKSL-QVNYEEQUSA-N
DG00385	Piperacillin/Tazobactam	23724843	"Tazocin (TN); Zosyn (TN); Piperacillin-tazobactam; Piperacillin-tazobactam mixt.; Piperacillin-tazobactam mixture; NIOSH/XI0191450; Piperacillin sodium and tazobactam; DTXSID001016418; Tazobactam and piperacillin (JP17); Piperacillin-tazobactam mixt. (4:1); Tazobactam-piperacillin mixt. (1:4); XI01914500; D02505; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, (2S-(2-alpha,3-beta,5-alpha))-, mixt. with (2S-(2-alpha,5-alpha,6-beta(S*)))-6-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid (1:4)"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	839.8	C33H38N9NaO12S2	315	1560	.	57	3	15	9	"1S/C23H27N5O7S.C10H12N4O5S.Na/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28;1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19;/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34);2-3,7-8H,4-5H2,1H3,(H,16,17);/q;;+1/p-1/t13-,14+,15-,20+;7-,8+,10+;/m01./s1"	CCN1CCN(C(=O)C1=O)C(=O)N[C@@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3.[Na+]	TUPFOYXHAYOHIB-WZGOVNIISA-M
DG00386	Tiamulin	656958	"Tiamulin; 55297-95-5; Thiamutilin; Tiamulina; Tiamuline; Tiamulinum; Tiamulin pamoate; UNII-E38WZ4U54R; Denagard (TN); E38WZ4U54R; CHEBI:44137; Denagard; Tiavet P; (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyl-5-hydroxy-4,6,9,10-tetramethyl-1-oxodecahydro-3a,9-propanocyclopenta[8]annulen-8-yl {[2-(diethylamino)ethyl]sulfanyl}acetate; Tiamulina [Italian]; AC1LCVRY; Tiamuline [INN-French]; Tiamulinum [INN-Latin]; Tiamulina [INN-Spanish]; HSDB 7026; Tiamulin [USAN:USP:INN:BAN]; EINECS 259-580-0; BRN 2229396; Tiamulin (USP/INN); SQ 14055; CHEMBL1234521; DTXSID2046701; SCHEMBL18232392; 14-Deoxy-14-((2-diethylaminoethyl-thio)-acetoxy)mutiline; (hydroxy-tetramethyl-oxo-vinyl-[ ]yl) 2-(2-diethylaminoethylsulfanyl)acetate; HY-B2060; ZINC4217557; BBL036673; STL559052; DB11468; ((2-(Diethylamino)ethyl)thio)-, 6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester (3aS-(3aalpha,4beta,5alpha,6alpha,8beta,9alpha,9abeta,10S*))-; ((2-(Diethylamino)ethyl)thio)acetic acid 8-ester with (3aS,4R,5S,6S,8R,9R,9aR,10R)-octahydro-5,8-dihydroxy-4,6,9,10)-tetramethyl-6-vinyl-3a,9-propano-3aH-cyclopentacycloocten-1(4H)-one; ((2-(Diethylamino)ethyl)thio)acetic acid 8-ester with (3aS,4R,5S,6S,8R,9R,9aR,10R)-octahydro-5,8-dihydroxy-4,6,9,10-tetramethyl-6-vinyl-3a,9-propano-3aH-cyclopentacycloocten-1(4H)-one; Acetic acid, [[2-(diethylamino)ethyl]thio]-,(3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-ylester; SO 14055; CS-0014153; D06127; Q7800111; (3aS,4R,5S,6S,8R,9R,9aR,10R)-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-6-vinyldecahydro-3a,9-propanocyclopenta[8]annulen-8-yl {[2-(diethylamino)ethyl]sulfanyl}acetate; (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-Ethenyl-5-hydroxy- 4,6,9,10-tetramethyl-1-oxodecahydro-3a,9-propano-3aH-cyclopentacycloocten-8-yl [[2-(diethylamino)ethyl]sulfanyl]acetate; 3-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-2-hydroxy-3,3-dimethyl-butanoyl]amino]propanoylamino]ethylsulfanylcarbonyl]-4-hydroxy-4-(2-naphthyl)butanoic acid; Acetic acid, ((2-(diethylamino)ethyl)thio)-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester; Acetic acid, ((2-(diethylamino)ethyl)thio)-, 6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester (3aS-(3aalpha,4beta,5alpha,6alpha,8beta,9alpha,9abeta,10S*))-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11468	.	.	493.7	C28H47NO4S	92.1	770	5.6	34	1	6	10	"1S/C28H47NO4S/c1-8-26(6)17-22(33-23(31)18-34-16-15-29(9-2)10-3)27(7)19(4)11-13-28(20(5)25(26)32)14-12-21(30)24(27)28/h8,19-20,22,24-25,32H,1,9-18H2,2-7H3/t19-,20+,22-,24+,25+,26-,27+,28+/m1/s1"	CCN(CC)CCSCC(=O)O[C@@H]1C[C@@]([C@H]([C@@H]([C@@]23CC[C@H]([C@@]1([C@@H]2C(=O)CC3)C)C)C)O)(C)C=C	UURAUHCOJAIIRQ-QGLSALSOSA-N
DG00387	Methymycin	5282034	"Methymycin; UNII-16QGD97DXG; 497-72-3; 16QGD97DXG; CHEBI:29630; (3r,4s,5s,7r,9e,11s,12r)-12-Ethyl-11-Hydroxy-3,5,7,11-Tetramethyl-2,8-Dioxooxacyclododec-9-En-4-Yl 3,4,6-Trideoxy-3-(Dimethylamino)-Beta-D-Xylo-Hexopyranoside; (3R,4S,5S,7R,9E,11S,12R)-4-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-12-ethyl-11-hydroxy-3,5,7,11-tetramethyl-1-oxacyclododec-9-ene-2,8-dione; MT9; SCHEMBL654455; CHEMBL489347; LMPK04000037; Q27110190"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	469.6	C25H43NO7	106	711	2.7	33	2	8	4	"1S/C25H43NO7/c1-9-20-25(6,30)11-10-19(27)14(2)12-15(3)22(17(5)23(29)32-20)33-24-21(28)18(26(7)8)13-16(4)31-24/h10-11,14-18,20-22,24,28,30H,9,12-13H2,1-8H3/b11-10+/t14-,15+,16-,17-,18+,20-,21-,22+,24+,25+/m1/s1"	CC[C@@H]1[C@@](/C=C/C(=O)[C@@H](C[C@@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2[C@@H]([C@H](C[C@H](O2)C)N(C)C)O)C)C)(C)O	HUKYPYXOBINMND-HYUJHOPRSA-N
DG00388	Quinupristin/Dalfopristin	23724510	Quinupristin-dalfopristin; Quinupristin - dalfopristin mixt; Synercid (TN); 126602-89-9; CHEBI:8733; C08034; D00854; Q1763990	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	1713.1	C87H117N13O19S2	441	3350	.	121	6	25	17	"1S/C53H67N9O10S.C34H50N4O9S/c1-6-37-50(68)61-23-11-14-38(61)51(69)59(5)40(26-32-16-18-36(19-17-32)58(3)4)52(70)62-28-35(30-73-43-29-60-24-20-33(43)21-25-60)42(64)27-39(62)47(65)57-45(34-12-8-7-9-13-34)53(71)72-31(2)44(48(66)55-37)56-49(67)46-41(63)15-10-22-54-46;1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h7-10,12-13,15-19,22,31,33,35,37-40,43-45,63H,6,11,14,20-21,23-30H2,1-5H3,(H,55,66)(H,56,67)(H,57,65);9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b;10-9+,12-11+,23-18+/t31-,35 ,37-,38+,39 ,40+,43-,44+,45+;24-,25-,28-,31 ,32-/m11/s1"	CC[C@@H]1C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)N3CC(C(=O)CC3C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CS[C@@H]6CN7CCC6CC7)CC8=CC=C(C=C8)N(C)C)C.CCN(CC)CCS(=O)(=O)[C@@H]1CCN2C1C(=O)O[C@@H]([C@@H](/C=C/C(=O)NC/C=C/C(=C/[C@H](CC(=O)CC3=NC(=CO3)C2=O)O)/C)C)C(C)C	PPKJUHVNTMYXOD-HVWWIRKTSA-N
DG00389	Chalcomycin	5382748	"CHALCOMYCIN; NSC150439; (6E,14E)-12-hydroxy-2-[(5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl)oxymethyl]-9-(3-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy-3,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadeca-6,14-diene-5,13-dione; 20283-48-1; NSC-150439; 4,14-diene-5,13-dione, 2-[[(6-deoxy-2,3-di-O-methyl-.beta.-D-allopyranosyl)oxy]methyl]-9-[(4,6-dideoxy-3-O-methyl-.beta.-D-xylo-hexopyranosyl)oxy]-12-hydroxy-3,8,10,12-tetramethyl-"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	700.8	C35H56O14	181	1160	1.4	49	3	14	8	"1S/C35H56O14/c1-17-10-13-26(37)46-20(4)22(16-44-34-32(43-9)31(42-8)27(38)21(5)47-34)30-23(48-30)11-12-25(36)35(6,40)15-18(2)29(17)49-33-28(39)24(41-7)14-19(3)45-33/h10-13,17-24,27-34,38-40H,14-16H2,1-9H3/b12-11+,13-10+"	CC1CC(C(C(O1)OC2C(CC(C(=O)/C=C/C3C(O3)C(C(OC(=O)/C=C/C2C)C)COC4C(C(C(C(O4)C)O)OC)OC)(C)O)C)O)OC	KLGADJPDTCIJLO-JASOSIDASA-N
DG00390	Ticarcillin/Clavulanic acid	6437075	"Ticarcillin-clavulanic acid; 86482-18-0; BRL 28500; Clavulanic acid mixture with Ticarcillin; (2S,5R,6R)-6-[[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Clavulanic acid - ticarcillin mixt.; Ticarcillin - clavulanic acid mixt.; BRL-28500; Ticarcillin disodium and clavulanate potassium; Ticarcillin-clavulanic acid mixt.; TIMENTIN IN PLASTIC CONTAINER; TICAR & CA; Clavulanic acid & Ticarcillin; Ticarcillin & Clavulanic acid; Ticarcillin and clavulanic acid; SCHEMBL1650350; CHEMBL3137696; DTXSID10235588; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2R,3Z,5R)-, mixt. with (2S,5R,6R)-6-(((2R)-carboxy-3-thienylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2R-(2-alpha,3Z,5-alpha))-, mixt. with (2S-(2-alpha,5-alpha,6-beta(S*)))-6-((carboxy-3-thienylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; Timentin (Ticarcillin disodium/Clavulanate potassium); (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[(2R)-3-hydroxy-3-oxo-2-(3-thienyl)propanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2R-(2-alpha,3Z,5-alpha))-, & (2S-(2-alpha,5-alpha,6-beta(S*)))-6-((carboxy-3-thienylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	583.6	C23H25N3O11S2	265	963	.	39	5	13	7	"1S/C15H16N2O6S2.C8H9NO5/c1-15(2)9(14(22)23)17-11(19)8(12(17)25-15)16-10(18)7(13(20)21)6-3-4-24-5-6;10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h3-5,7-9,12H,1-2H3,(H,16,18)(H,20,21)(H,22,23);1,6-7,10H,2-3H2,(H,12,13)/b;4-1-/t7-,8-,9+,12-;6-,7-/m11/s1"	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CSC=C3)C(=O)O)C(=O)O)C.C1[C@@H]2N(C1=O)[C@H](/C(=C/CO)/O2)C(=O)O	XWMVMWTVLSLJGY-FAJPTIRJSA-N
DG00391	Benzoylecgonine	448223	"Benzoylecgonine; O-Benzoylecgonine; (-)-Benzoylecgonine; o-Benzoyl-(-)-ecgonine; Ecgonine benzoate; 519-09-5; 3-(Benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid; UNII-5353I8I6YS; CHEBI:41001; (1R,2R,3S,5S)-8-methyl-3-[(phenylcarbonyl)oxy]-8-azabicyclo[3.2.1]octane-2-carboxylic acid; 5353I8I6YS; Benzoylecgonine hydrate; Benzoylecgonine solution; DSSTox_CID_26758; DSSTox_RID_81882; DSSTox_GSID_46758; BEG; (1R,2R,3S,5S)-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid; (1S,3S,4R,5R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylic acid; CAS-519-09-5; Theracys; Cocaine metabolite; NCGC00168248-01; NCGC00168248-02; EINECS 208-263-5; Epitope ID:158630; SCHEMBL116803; CHEMBL1231248; DTXSID7046758; Ecgonine, benzoate (6CI,7CI); 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, [1R-(exo,exo)]-; ZINC2572652; Tox21_112607; Tox21_112853; MFCD00070263; AKOS030254449; Benzoylecgonine 0.1 mg/ml in Methanol; Benzoylecgonine 1.0 mg/ml in Methanol; DB01515; Q2499888; (1R,5S,8R)-2beta-Carboxy-3beta-(benzoyloxy)tropane; Benzoylecgonine solution, analytical standard, 1.0 mg/mL in methanol; 1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, benzoate (ester) (8CI); 3-beta-hydroxy-1-alpha-H,-5-alpha-H-tropane-2-beta-carboxylic acid benzoate; (1beta,5beta,8-anti)-3beta-Benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2beta-carboxylic acid; 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, (1R,2R,3S,5S)- (9CI); Benzoylecgonine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Benzoylecgonine solution, 100 mug/mL in methanol, ampule of 1 mL, certified reference material"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB01515	.	.	289.33	C16H19NO4	66.8	419	-0.3	21	1	5	4	"1S/C16H19NO4/c1-17-11-7-8-12(17)14(15(18)19)13(9-11)21-16(20)10-5-3-2-4-6-10/h2-6,11-14H,7-9H2,1H3,(H,18,19)/t11-,12+,13-,14+/m0/s1"	CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)O	GVGYEFKIHJTNQZ-RFQIPJPRSA-N
DG00392	Microcin J25	101038823	.	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	2107.3	C101H139N23O27	807	4990	8	151	25	47	21	"1S/C101H139N23O27/c1-11-55(7)84-98(148)108-50-80(134)119-86(58(10)126)101(151)124-38-20-26-74(124)96(146)122-85(56(8)12-2)99(149)117-72(51-125)94(144)116-68(39-59-21-15-13-16-22-59)90(140)113-67(41-61-27-31-64(127)32-28-61)88(138)106-46-76(130)103-45-75(129)104-47-77(131)110-57(9)87(137)105-48-78(132)111-71(43-63-44-102-52-109-63)93(143)121-83(54(5)6)100(150)123-37-19-25-73(123)95(145)112-66(35-36-81(135)136)89(139)114-69(42-62-29-33-65(128)34-30-62)91(141)115-70(40-60-23-17-14-18-24-60)92(142)120-82(53(3)4)97(147)107-49-79(133)118-84/h13-18,21-24,27-34,44,52-58,66-74,82-86,125-128H,11-12,19-20,25-26,35-43,45-51H2,1-10H3,(H,102,109)(H,103,130)(H,104,129)(H,105,137)(H,106,138)(H,107,147)(H,108,148)(H,110,131)(H,111,132)(H,112,145)(H,113,140)(H,114,139)(H,115,141)(H,116,144)(H,117,149)(H,118,133)(H,119,134)(H,120,142)(H,121,143)(H,122,146)(H,135,136)/t55-,56-,57-,58+,66-,67-,68-,69-,70-,71-,72-,73-,74-,82-,83-,84-,85-,86-/m0/s1"	CC[C@H](C)[C@H]1C(=NCC(=N[C@H](C(=O)N2CCC[C@H]2C(=N[C@H](C(=N[C@H](C(=N[C@H](C(=N[C@H](C(=NCC(=NCC(=NCC(=N[C@H](C(=NCC(=N[C@H](C(=N[C@H](C(=O)N3CCC[C@H]3C(=N[C@H](C(=N[C@H](C(=N[C@H](C(=N[C@H](C(=NCC(=N1)O)O)C(C)C)O)CC4=CC=CC=C4)O)CC5=CC=C(C=C5)O)O)CCC(=O)O)O)C(C)C)O)CC6=CN=CN6)O)O)C)O)O)O)O)CC7=CC=C(C=C7)O)O)CC8=CC=CC=C8)O)CO)O)[C@@H](C)CC)O)[C@@H](C)O)O)O	TVZWTTNULXZYTK-UBTJVNBSSA-N
DG00393	N-methyl-n-nitro-n-nitrosoguanidine	13146027	SCHEMBL1536062; SCHEMBL8581312; DTXSID00521861; 2-methyl-3-nitro-nitrosoguanidine; N-methyl-N'-nitro-N''-nitrosoguanidine; N''-Methyl-N-nitro-N'-nitrosoguanidine; 66542-13-0	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	147.09	C2H5N5O3	112	159	0	10	2	5	2	"1S/C2H5N5O3/c1-3-2(4-6-8)5-7(9)10/h1H3,(H2,3,4,5,8)"	CN=C(NN=O)N[N+](=O)[O-]	POJDZWIPNZWPAU-UHFFFAOYSA-N
DG00394	Dapt (Gsi IX)	5311272	"Dapt; 208255-80-5; DAPT (GSI-IX); GSI-IX; gamma-Secretase Inhibitor IX; CHEBI:86193; tert-butyl (2S)-2-[[(2S)-2-[[2-(3,5-difluorophenyl)acetyl]amino]propanoyl]amino]-2-phenylacetate; LY-374973; CHEMBL255682; MFCD04974585; (S)-tert-butyl 2-((S)-2-(2-(3,5-difluorophenyl)acetamido)propanamido)-2-phenylacetate; Glycine, N-[2-(3,5-difluorophenyl)acetyl]-L-alanyl-2-phenyl-, 1,1-dimethylethyl ester, (2S)-; tert-butyl (S)-2-((S)-2-(2-(3,5-difluorophenyl)acetamido)propanamido)-2-phenylacetate; N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine tert-butyl ester; DAPT (peptide); GSIIX; GSI IX; N-(2FPhAc)Ala-phenyl-Gly t-butyl ester; DAPT,GSI-IX; DAPT - GSI-IX; MLS006010075; QCR-29; SCHEMBL1360313; TB2634-GMP; GTPL11363; DTXSID00415519; EX-A324; C23H26F2N2O4; HMS3413L17; HMS3677L17; HMS3884P09; AOB33372; ZINC1549363; BDBM50478375; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; s2215; AKOS024457209; N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; CCG-264944; CS-0264; MRF-0000012; NCGC00167803-03; (3,5-Difluorophenylacetyl)-Ala-Phg-OtBu; AC-23163; AS-19399; HY-13027; SMR004701228; AB0033805; D4257; SW219339-1; X7572; AB01566837_01; J-013656; J-524356; Q27158972; (3,5-Difluorophenylacetyl)-L-alanyl-L-2-phenylglycine tert-Butyl Ester; (2S)-N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine 1,1-dimethylethyl ester; (2S)-N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-phenylglycine 1,1-dimethylethyl ester; N-[2-(3,5-Difluorophenyl)acetyl]-L-alanyl-L-(2-phenyl)glycine tert-butyl ester; N-{N-[2-(3,5-Difluorophenyl)acetyl]-(S)-alanyl}- (S)-phenylglycine tert-butyl ester; tert-butyl (2S)-({N-[(3,5-difluorophenyl)acetyl]-L-alanyl}amino)(phenyl)acetate; (S)-{(S)-2-[2-(3,5-Difluoro-phenyl)-acetylamino]-propionylamino}-phenyl-acetic acid tert-butyl ester; t-butyl (2s)-2-[[(2s)-2-[[2-(3,5-difluorophenyl)acetyl]amino]propanoyl]amino]-2-phenylacetate; tert-butyl (2R)-[((2S)-2-{[(3,5-difluorophenyl)acetyl]aMino}propanoyl)aMino](phenyl)ethanoate"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	432.5	C23H26F2N2O4	84.5	622	3.7	31	2	6	9	"1S/C23H26F2N2O4/c1-14(26-19(28)12-15-10-17(24)13-18(25)11-15)21(29)27-20(16-8-6-5-7-9-16)22(30)31-23(2,3)4/h5-11,13-14,20H,12H2,1-4H3,(H,26,28)(H,27,29)/t14-,20-/m0/s1"	C[C@@H](C(=O)N[C@@H](C1=CC=CC=C1)C(=O)OC(C)(C)C)NC(=O)CC2=CC(=CC(=C2)F)F	DWJXYEABWRJFSP-XOBRGWDASA-N
DG00395	Orthocresol	335	"O-cresol; 2-Methylphenol; 95-48-7; Orthocresol; 2-hydroxytoluene; Phenol, 2-methyl-; 2-Cresol; o-methylphenol; o-Cresylic acid; o-Oxytoluene; o-Toluol; o-Hydroxytoluene; o-Methylphenylol; 1-Hydroxy-2-methylbenzene; ortho-cresol; o-Kresol; 2-methyl phenol; Cresol, ortho-; Cresol, o-; o-Kresol [German]; 2-Hydroxy-1-methylbenzene; Cresylic acid; 2-methyl-phenol; Cresol, o-isomer; hydroxy toluene; Phenol, methyl-; UNII-YW84DH5I7U; NSC 23076; Cresol mixture of isomers; 1-Methyl-2-hydroxybenzene; YW84DH5I7U; CHEBI:28054; MFCD00002226; TOLUENE,2-HYDROXY (ORTHO-CRESOL); o-Cresol [UN2076] [Poison, Corrosive]; DSSTox_CID_1808; Cresol mixture of isomers;Methylphenol;Tricresol; DSSTox_RID_76341; WLN: QR B1; DSSTox_GSID_21808; CAS-95-48-7; Orthocresol [NF]; Cresols are organic compounds which are methylphenols. They are a widely occurring natural and manufactured group of aromatic organic compounds, which are categorized as phenols.; CCRIS 646; FEMA No. 3480; HSDB 1813; EINECS 202-423-8; ortho cresol; Methyl phenol; 2-methyiphenol; AI3-00137; JZ0; O-Cresol,(S); Carvacrol derivative, 9; o-Cresol, >=99%; bmse000433; UN 2076 (Related); EC 202-423-8; 2-Methylphenol (o-cresol); ortho-cresol,2-methylphenol; SCHEMBL16002; MLS002454426; o-Cresol, analytical standard; BIDD:ER0677; CHEMBL46931; 3C7H8O; DTXSID8021808; FEMA 3480; BDBM248166; HMS2268O24; LABOTEST-BB LTBB001400; ZINC901022; o-Cresol, for synthesis, 99.3%; 2-Methylphenol, analytical standard; NSC23076; NSC36809; Tox21_202305; Tox21_300021; NSC-23076; NSC-36809; STL194295; o-Cresol, ReagentPlus(R), >=99%; AKOS000119021; AS00217; MCULE-4124485112; NCGC00091534-01; NCGC00091534-02; NCGC00091534-03; NCGC00091534-04; NCGC00254140-01; NCGC00259854-01; o-Cresol, SAJ first grade, >=97.0%; SMR001252248; 2-Methylphenol 100 microg/mL in Methanol; FT-0656046; Z3651; 7520-EP2277867A2; 7520-EP2280003A2; 7520-EP2292227A2; 7520-EP2295426A1; 7520-EP2295427A1; 7520-EP2295435A1; 7520-EP2298751A2; 7520-EP2302015A1; 7520-EP2305683A1; 7520-EP2308861A1; 7520-EP2311839A1; 7520-EP2314584A1; 7520-EP2314589A1; 7520-EP2316470A2; 7520-EP2316832A1; 7520-EP2316833A1; 7520-EP2316837A1; C01542; 19034-EP2311811A1; 19034-EP2314576A1; 28670-EP2279750A1; 28670-EP2284146A2; 28670-EP2284147A2; 28670-EP2284165A1; 28670-EP2287159A1; 28670-EP2305673A1; 28670-EP2308838A1; 28670-EP2308865A1; 28670-EP2308877A1; 28670-EP2311815A1; 28670-EP2311834A1; 28670-EP2314579A1; 28670-EP2372017A1; 45193-EP2311821A1; 93911-EP2269977A2; 93911-EP2305625A1; 1-Hydroxyl 2-Methyl Benzene, 2-Hydroxyl Toluene; Q312708; J-006098; J-523819; F0001-2271; UNII-3JYG22FD73 component QWVGKYWNOKOFNN-UHFFFAOYSA-N; UNII-GF3CGH8D7Z component QWVGKYWNOKOFNN-UHFFFAOYSA-N"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	108.14	C7H8O	20.2	70.8	2	8	1	1	0	"1S/C7H8O/c1-6-4-2-3-5-7(6)8/h2-5,8H,1H3"	CC1=CC=CC=C1O	QWVGKYWNOKOFNN-UHFFFAOYSA-N
DG00396	Bisbenzimide (Hoechst 33258)	1464	"Hoechst 33342; 23491-52-3; Bisbenzimide; hoechst33342; UNII-99KZS6CNZX; Ho 342; 2'-(4-Ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-1H,1'H-2,5'-bibenzo[d]imidazole; EINECS 245-691-1; 99KZS6CNZX; 2'-(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-benzimidazole; CHEMBL343002; CHEBI:51232; 2'-(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-1H-benzimidazole; 2'-(4'-Ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bis-1H-benzimidazole trihydrochloride trihydrate"	Terminated	10	Discontinued Drug(s)	Terminated	Small molecular drug	CHEBI:51232	.	DR01292	.	452.6	C27H28N6O	73.1	664	4.6	34	2	5	5	"1S/C27H28N6O/c1-3-34-21-8-4-18(5-9-21)26-28-22-10-6-19(16-24(22)30-26)27-29-23-11-7-20(17-25(23)31-27)33-14-12-32(2)13-15-33/h4-11,16-17H,3,12-15H2,1-2H3,(H,28,30)(H,29,31)"	CCOC1=CC=C(C=C1)C2=NC3=C(N2)C=C(C=C3)C4=NC5=C(N4)C=C(C=C5)N6CCN(CC6)C	PRDFBSVERLRRMY-UHFFFAOYSA-N
DG00397	Anastrozole	2187	"Anastrazole; Anastrole; Anastrozol; Arimidex; Asiolex; Astra brand of anastrozole; AstraZeneca brand of anastrozole; Zeneca brand of anastrozole; ZD 1033; ZD1033; Zeneca ZD 1033; Arimidex (TN); Arimidex (Zeneca); Arimidex, Anastrozole; ZD-1033; Anastrozole [USAN:INN:BAN]; Anastrozole (JAN/USAN/INN); Alpha,alpha,alpha',alpha'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; Alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; 1,3-benzenediacetonitrile, a, a,a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl); 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile); 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:2704	DB01217	DR00464	DR0113	293.4	C17H19N5	78.3	456	2.1	22	0	4	4	"1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3"	CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N	YBBLVLTVTVSKRW-UHFFFAOYSA-N
DG00399	"4',6-Diamidino-2-phenylindole"	2954	"DAPI; 4',6-Diamidino-2-phenylindole; 47165-04-8; 2-(4-carbamimidoylphenyl)-1H-indole-6-carboximidamide; 4',6-Diamidinophenyl-indole; CHEBI:51231; 2-(4-(Aminoiminomethyl)phenyl)-1H-indole-6-carboximidamide; UNII-K9W25Z7ROH; K9W25Z7ROH; 6-AMIDINE-2-(4-AMIDINO-PHENYL)INDOLE; 2-(4-carbamimidoylphenyl)-1H-indole-6-carboxamidine; DATI; 4',6-Diamino-2-phenylindol; CCRIS 3826; antifade; BRN 3557399; Indole-6-carboximidamide, 2-(4-(aminoiminomethyl)phenyl)-; MolMap_000017; CHEMBL48217; SCHEMBL235865; GTPL5498; NPE759; ZINC56538; DTXSID50963757; BDBM50010058; AKOS025213592; SMP1_000093; A827164; Q238382"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	277.32	C16H15N5	116	413	1.6	21	5	2	3	"1S/C16H15N5/c17-15(18)10-3-1-9(2-4-10)13-7-11-5-6-12(16(19)20)8-14(11)21-13/h1-8,21H,(H3,17,18)(H3,19,20)"	C1=CC(=CC=C1C2=CC3=C(N2)C=C(C=C3)C(=N)N)C(=N)N	FWBHETKCLVMNFS-UHFFFAOYSA-N
DG00400	Gentamicin	3467	"Alcomicin; Apogen; Bristagen; Cidomycin; GENTAMYCIN; Garamycin; Garasol; Gentacidin; Gentacycol; Gentafair; Gentak; Gentamar; Gentamicina; Gentamicine; Gentamicins; Gentamicinum; Gentamycinum; Gentavet; Gentocin; Jenamicin; Refobacin; Uromycine; Garamycin Otic Solution; Genoptic Liquifilm; Gentamcin Sulfate; Gentamicin sulphate sterile; Refobacin TM; Gentamicin C1; G-Mycin; G-Myticin; Garamycin (TN); Gentamicin (BAN); Gentamicin (TN); Gentamicina [INN-Spanish]; Gentamicine [INN-French]; Gentamicinum [INN-Latin];Gentamycin-creme; Gentamycin-creme [German]; Ocu-Mycin; Spectro-Genta; U-Gencin; Genoptic S.O.P.; O-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-ribo-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-2-deoxy-D-streptamine; (1R,2S,3S,4R,6S)-4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyloxy]-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-beta-L-lyxo-heptopyranoside; (1R,2S,3S,4R,6S)-4,6-diamino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-2-hydroxycyclohexyl (6x)-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-erythro-heptopyranoside; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 4,6-diamino-3-{[3-deoxy-4-c-methyl-3-(methylamino)pentopyranosyl]oxy}-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00798	DR01198	DR2174	477.6	C21H43N5O7	200	636	-4.1	33	8	12	7	"1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3"	CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC	CEAZRRDELHUEMR-UHFFFAOYSA-N
DG00402	Rhodamine 6G	3806	"Juglone; juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS; JUGLONE"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	CHEBI:15794	DB03825	.	.	174.15	C10H6O3	54.4	280	1.9	13	1	3	0	"1S/C10H6O3/c11-7-4-5-9(13)10-6(7)2-1-3-8(10)12/h1-5,12H"	C1=CC2=C(C(=O)C=CC2=O)C(=C1)O	KQPYUDDGWXQXHS-UHFFFAOYSA-N
DG00403	Letrozole	3902	"Femara; Femera; Letoval; Letrozol; Novartis Brand of Letrozole; CGS 20267; CGS-20267; FEM-345; Femara (TN); Letrozole [USAN:INN]; CGS 20267, Femara, Piroxicam, Letrozole; Letrozole (JAN/USP/INN); 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole; 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile); 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole; 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile; 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6413	DB01006	.	DR0929	285.3	C17H11N5	78.3	420	2.7	22	0	4	3	"1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H"	C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3	HPJKCIUCZWXJDR-UHFFFAOYSA-N
DG00404	Probenecid	4911	"Apurina; Bencid; Benecid; Benemid; Benemide; Benuryl; Panuric; Parabenem; Probalan; Probampacin; Probecid; Proben; Probenecida; Probenecide; Probenecidum; Probenemid; Probenicid; Probenid; Probexin; Prolongine; Robenecid; Sulprin; Tubophan; Uricosid; Urocid; Biokanol Brand of Probenecid; ICN Brand of Probenecid; IDIS Brand of Probenecid; Major Brand of Probenecid; Martec Brand of Probenecid; Merck Brand of Probenecid; Ophthalmic Brand of Probenecid; Parmed Brand of Probenecid; Probenecid Major Brand; Probenecid Martec Brand; Probenecid Parmed Brand; Probenecid Weimer; Probenecid Zenith Brand; Probenecid acid; Synergid R; Valdecasas Brand of Probenecid; Zenith Brand of Probenecid; Benemid (TN); Benuryl (TN); Col-BENEMID; ColBenemid (co mponent of); ColBenemid (component of); P-[Dipropylsulfamoyl]benzoic acid; Polycillin-BRB; Pro-Cid; Probenecida [INN-Spanish]; Probenecide [INN-French]; Probenecidum [INN-Latin]; P-(Dipropylsulfamoyl)benzoic acid; P-(Dipropylsulfamyl)benzoic acid; Polycillin-PRB (component of); Probenecid [INN:BAN:JAN]; Probenecid (JP15/USP/INN); 4-((Dipropylamino)sulfonyl)benzoic acid;4-(Di-n-propylsulfamoyl)benzoesaeure; 4-(Dipropylsulfamoyl)benzoic acid; 4-(N,N-Dipropylsulfamoyl)benzoesaeure; 4-[(dipropylamino)sulfonyl]benzoic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8426	DB01032	DR00232	DR1341	285.36	C13H19NO4S	83.1	374	3.2	19	1	5	7	"1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)"	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O	DBABZHXKTCFAPX-UHFFFAOYSA-N
DG00405	Sanguinarine	5154	"SANGUINARINE; 2447-54-3; Pseudochelerythrine; Sanguinarin; sangvinarin; Veadent; Sanguiritrin; SANGUINARIUM; Dimethylenedioxy benzphenanthridine; UNII-AV9VK043SS; C20H14NO4; EINECS 219-503-3; Benzophenanthridine alkaloid; BRN 3915507; AV9VK043SS; CHEBI:17183; NCGC00015959-03; CAS-2447-54-3; [1,3]Benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, 13-methyl-; DSSTox_RID_80748; DSSTox_CID_25204; DSSTox_GSID_45204; 13-Methyl[1,3]benzodioxolo[5,6-C][1,3]dioxolo[4,5-I]phenanthridin-13-Ium; Sangrovit; y-Chelerythrine; SR-01000075650"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:17183	.	DR00919	.	332.3	C20H14NO4+	40.8	530	4.4	25	0	4	0	"1S/C20H14NO4/c1-21-8-15-12(4-5-16-20(15)25-10-22-16)13-3-2-11-6-17-18(24-9-23-17)7-14(11)19(13)21/h2-8H,9-10H2,1H3/q+1"	C[N+]1=C2C(=C3C=CC4=C(C3=C1)OCO4)C=CC5=CC6=C(C=C52)OCO6	INVGWHRKADIJHF-UHFFFAOYSA-N
DG00406	Sulfathiazole	5340	"Sulfathiazole; 72-14-0; Sulphathiazole; Sulfathiazol; 2-Sulfanilamidothiazole; Sulfanilamidothiazole; Thiazamide; Norsulfasol; Norsulfazole; 2-Sulfonamidothiazole; 4-Amino-N-(thiazol-2-yl)benzenesulfonamide; 2-(Sulfanilylamino)thiazole; Neostrepsan; Sulfocerol; Thiozamide; Sulzol; 2-Sulfanilamidothiazol; 2-(p-Aminobenzenesulfonamido)thiazole; Azoquimiol; Azoseptale; Norsulfazol; Poliseptil; Sanotiazol; Sulfathiazolum; Sulfatiazol; Thiacoccine; Thiasulfol; Wintrazole; Cerazole; Chemosept; Cibazol; Eleudron; Estafilol; Planomide; Septozol; Duatok; Dulana; N(1)-2-Thiazolylsulfanilamide; Coco-Thiazole; Formosulfathiazole; Streptosilthiazole; Sulfamul; 2-(p-Aminobenzenesulphonamido)thiazole; Usaf sn-9; 4-Amino-N-2-thiazolylbenzenesulfonamide; Cerazol (suspension); Ciba 3714; 4-Amino-N-(1,3-thiazol-2-yl)benzenesulfonamide; N1-(2-Thiazolyl)sulfanilamide; Benzenesulfonamide, 4-amino-N-2-thiazolyl-; 4-Amino-N-(1,3-Thiazol-2-Yl)Benzene-1-Sulfonamide; 4-amino-N-1,3-thiazol-2-ylbenzenesulfonamide; M&B 760; RP 2090; UNII-Y7FKS2XWQH; 4-Amino-N-thiazol-2-yl-benzenesulfonamide; 2090 R.P.; M+B 760; CHEBI:9337; Sulfanilamide, N1-2-thiazolyl-; Y7FKS2XWQH; Sodium sulfathiazole; CHEMBL437; N'-(2-Thiazolyl)sulfanilamide; N(sup1)-(2-Thiazolyl)sulfanilamide; MFCD00005319; NSC-31812; NSC683531; Sulfanilamide, N(sup1)-2-thiazolyl-; NSC-683531; CAS-72-14-0; NCGC00016309-02; NCGC00016309-06; Norsulfazolum; 4-Amino-N-(2-thiazolyl)benzenesulfonamide; DSSTox_CID_6068; DSSTox_RID_78004; DSSTox_GSID_26068; Solfatiazolo [DCIT]; Caswell No. 809B; Solfatiazolo; Sulfathiazol [INN-French]; Sulfatiazol [INN-Spanish]; N1-2-Thiazolylsulfanilamide; Sulfathiazolum [INN-Latin]; CCRIS 765; 2090 rp; 2-Sulfanilamidothiazol [German]; HSDB 4380; N(sup 1)-2-Thiazolylsulfanilamide; SR-05000001722; Sulfanilamide, N(1)-2-thiazolyl-; EINECS 200-771-5; NSC 31812; EPA Pesticide Chemical Code 077903; NSC 683531; Sulfanilamide, N(sup 1)-2-thiazolyl-; sulfthiazole; Enterobiocine; Sulfavitina; Cerazol; AI3-01050; Sulfathiazole [USP:INN:BAN]; 2-Sulfathiazole; YTZ; Prestwick_430; Sulfathiazole-13C6; Spectrum_001000; Prestwick0_000016; Prestwick1_000016; Prestwick2_000016; Prestwick3_000016; Spectrum2_000841; Spectrum3_001729; Spectrum4_000348; Spectrum5_001441; Sulfathiazole (USP/INN); N-2-Thiazolylsulfanilamide; Epitope ID:122234; Cambridge id 5251400; cid_5340; Oprea1_105970; Oprea1_297844; SCHEMBL94165; Triple sulfa (sulfathiazole); BSPBio_000051; BSPBio_003378; KBioGR_000755; KBioSS_001480; [(4-Aminophenyl)sulfonyl]-1,3-thiazol-2-ylamine; MLS002154174; N-1-2-Thiazolylsulfanilamide; DivK1c_000560; SPECTRUM1500553; Sulfathiazole-d4(benzene-d4); SPBio_000821; SPBio_001972; BPBio1_000057; WLN: T5N CSJ BMSWR DZ; DTXSID8026068; HMS501L22; KBio1_000560; KBio2_001480; KBio2_004048; KBio2_006616; KBio3_002598; N(sup1)-2-Thiazolylsulfanilamide; NINDS_000560; HMS1568C13; HMS1921C07; HMS2092K09; HMS2095C13; HMS2259A13; HMS3652A03; HMS3712C13; Pharmakon1600-01500553; ZINC121458; AMY33440; HY-B0507; NSC31812; SULFATHIAZOLE (TRIPLE SULFA); Tox21_110363; Tox21_202243; Tox21_303238; BDBM50027796; CCG-40296; NSC757331; s3116; STK043870; 2-(4-Aminobenzenesulfonamido)thiazole; AKOS000108630; Tox21_110363_1; DB06147; MCULE-1370710137; NSC-757331; SDCCGMLS-0065585.P001; IDI1_000560; NCGC00016309-01; NCGC00016309-03; NCGC00016309-04; NCGC00016309-05; NCGC00016309-07; NCGC00016309-08; NCGC00016309-09; NCGC00016309-10; NCGC00016309-14; NCGC00091133-01; NCGC00091133-02; NCGC00091133-03; NCGC00091133-04; NCGC00257187-01; NCGC00259792-01; Sulfanilamide, N1-2-thiazolyl- (8CI); AC-12783; DS-17245; K225; NCI60_002730; SMR000017368; Pyridine,2-(chloromethyl)-3,4-dimethoxy-; SBI-0051527.P004; Sulfanilamide, N1-4-thiazolin-2-ylidene-; DB-055610; 4-amino-N-(thiazol-2-yl)-benzenesulfonamide; AB00052102; BB 0245015; FT-0631310; Sulfathiazole 100 microg/mL in Acetonitrile; SW149625-4; 4-[(1,3-Thiazol-2-yl)aminosulfonyl]aniline; Sulfathiazole, analytical standard, >=98.0%; 9610-EP2295053A1; 9610-EP2308872A1; 9610-EP2316829A1; D01047; D70411; AB00052102_14; AB00052102_15; Q408427; Sulfathiazole, VETRANAL(TM), analytical standard; 4-Amino-N-(1,3-thiazol-2-yl)benzenesulfonamide #; Q-201765; SR-05000001722-1; SR-05000001722-3; Sulfathiazole, Antibiotic for Culture Media Use Only; BRD-K14705039-001-05-7; BRD-K14705039-001-08-1; F1443-4816; Sulfathiazole, European Pharmacopoeia (EP) Reference Standard; Sulfathiazole, United States Pharmacopeia (USP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB06147	.	.	255.3	C9H9N3O2S2	122	320	0.1	16	2	6	3	"1S/C9H9N3O2S2/c10-7-1-3-8(4-2-7)16(13,14)12-9-11-5-6-15-9/h1-6H,10H2,(H,11,12)"	C1=CC(=CC=C1N)S(=O)(=O)NC2=NC=CS2	JNMRHUJNCSQMMB-UHFFFAOYSA-N
DG00407	Sulfisomidine	5343	"SULFISOMIDINE; sulfisomidin; Sulfaisodimidine; 515-64-0; Sulphasomidine; Sulfasomidine; 4-amino-N-(2,6-dimethylpyrimidin-4-yl)benzenesulfonamide; Sulfadimetine; Sulfamethin; Sulfaisodimerazine; Elkosin; Domian; Sulfaisodimidinum; Solfisomidina; Aristamid; Aristogyn; Elcosine; Elkosine; Elkosil; Erycon; Mefenal; 4-Sulfa-2,6-dimethylpyrimidine; 2,4-Dimethyl-6-sulfanilamidopyrimidine; 2,6-Dimethyl-4-sulfanilamidopyrimidine; 4-Sulfanilamido-2,6-dimethylpyrimidine; 6-Sulfanilamido-2,4-dimethylpyrimidine; UNII-W03L3ODK6E; 6-(4-Aminobenzenesulfonamido)-2,4-dimethylpyrimidine; 6-(p-Aminobenzenesulfonamido)-2,4-dimethylpyrimidine; 6-(p-Aminobenzenesulfonyl)amino-2,4-dimethylpyrimidine; CHEBI:32166; Benzenesulfonamide, 4-amino-N-(2,6-dimethyl-4-pyrimidinyl)-; W03L3ODK6E; N(sup 1)-(2,6-Dimethyl-4-pyrimidinyl)sulfanilamide; (p-Aminobenzolsulfonyl)-4-amino-2,6-dimethylpyrimidin; Sulfaisomidine; N(1)-(2,6-Dimethyl-4-pyrimidinyl)sulfanilamide; (p-Aminobenzolsulfonyl)-4-amino-2,6-dimethylpyrimidine; Sulfanilamide, N(sup 1)-(2,6-dimethyl-4-pyrimidinyl)-; NCGC00164492-01; Sulfisomidina; Sulfisomidinum; Isosulf; Benzenesulfonamide, 4-amino-N-(2,6-dimethyl-4-pyrimidinyl)-(9CI); DSSTox_CID_26390; DSSTox_RID_81570; DSSTox_GSID_46390; Solfisomidina [DCIT]; Sulfisomidinum [INN-Latin]; Sulfisomidina [INN-Spanish]; CAS-515-64-0; EINECS 208-204-3; BRN 0261305; Aristamide; Elcosin; Domain; AI3-50168; Sulfisomidine [INN:BAN:JAN]; N1-(2,6-Dimethyl-4-pyrimidinyl)sulfanilamide; Sulfisomidine (TN); Sulfisomidine (JAN); 4-amino-N-(2,6-dimethylpyrimidin-4-yl)benzene-1-sulfonamide; (p-Aminobenzolsulfonyl)-4-amino-2,6-dimethylpyrimidin [German]; Oprea1_339670; SCHEMBL34791; 5-25-10-00216 (Beilstein Handbook Reference); MLS004773916; CHEMBL485696; DTXSID1046390; YZMCKZRAOLZXAZ-UHFFFAOYSA-; ZINC56658; ALBB-023545; HY-B1784; Tox21_112130; BDBM50548727; MFCD00010567; s5291; STL481971; AKOS000119092; Tox21_112130_1; CCG-267227; CS-7658; DB13283; MCULE-6011761791; SB58524; NCGC00164492-02; NCGC00164492-03; NCGC00186655-01; AS-10637; SMR001346487; AB0126295; DB-051990; FT-0632265; S0362; Sulfisomidine 100 microg/mL in Acetonitrile; A12593; D01526; Sulfisomidin, VETRANAL(TM), analytical standard; SR-01000940235; Q6577315; SR-01000940235-2; F1716-0354; 4-Amino-N-(2,6-dimethylpyrimidin-4-yl) benzenesulfonamide; 4-Amino-N-(2,6-dimethyl-4-pyrimidinyl)benzenesulfonamide (9CI)"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB13283	.	.	278.33	C12H14N4O2S	106	387	1.2	19	2	6	3	"1S/C12H14N4O2S/c1-8-7-12(15-9(2)14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7H,13H2,1-2H3,(H,14,15,16)"	CC1=CC(=NC(=N1)C)NS(=O)(=O)C2=CC=C(C=C2)N	YZMCKZRAOLZXAZ-UHFFFAOYSA-N
DG00413	Quinolones	6038	AC1MI0KP	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:16365	.	.	.	145.16	C9H7NO	29.1	198	1.3	11	1	1	0	"1S/C9H7NO/c11-9-6-5-7-3-1-2-4-8(7)10-9/h1-6H,(H,10,11)"	C1=CC=C2C(=C1)C=CC(=O)N2	LISFMEBWQUVKPJ-UHFFFAOYSA-N
DG00414	Methylene blue	6099	"Methylene blue; 61-73-4; Methylthioninium chloride; Swiss Blue; Chromosmon; Methylene Blue N; Methylenium ceruleum; Urolene blue; Methylene Blue chloride; Solvent blue 8; Bleu de methylene; Methylene Blue G; Methylene Blue A; External Blue 1; Methylene Blue D; Methylene Blue B; Methylene Blue anhydrous; CI Basic Blue 9; Methylene Blue ZF; Methylene Blue SP; Methylene Blue NZ; Methylene Blue BX; Methylene Blue BD; Methylene Blue SG; Tetramethylene Blue; Methylene Blue ZX; Methylene Blue FZ; Methylene Blue BP; Calcozine; 3,7-Bis-dimethylamino-phenothiazin-5-ylium"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6872	DB09241	.	.	319.9	C16H18ClN3S	43.9	483	.	21	0	4	1	"1S/C16H18N3S.ClH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;/h5-10H,1-4H3;1H/q+1;/p-1"	CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-]	CXKWCBBOMKCUKX-UHFFFAOYSA-M
DG00415	Cetrimide	14250	Cetrimonium bromide; 57-09-0; Cetyltrimethylammonium bromide; Hexadecyltrimethylammonium bromide; CTAB; Centimide; CETAB; Bromat; Ctmab; Cee dee; Cetavlon; Hexadecyl trimethyl ammonium bromide; Trimethylcetylammonium bromide; Cetyl trimethyl ammonium bromide; Quamonium; Lissolamine; Cetaflon; Lauroseptol; Suticide; Pollacid; Cetarol; Micol; Cetrimide bp; Lissolamine A; Lissolamin V; Cetavlon bromide; Cycloton V; Cirrasol OD; Acetoquat CTAB; Softex KW; Cetrimonii bromidum; N-Cetyltrimethylammonium bromide; Bromuro de cetrimonio; Cetrimida	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:3565	DB01718	.	.	336.4	C17H38BrN	0	158	.	19	0	1	13	"1S/C17H38N.BrH/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18(2,3)4;/h5-17H2,1-4H3;1H/q+1;/p-1"	CCCCCCCCCCCCCC[N+](C)(C)C.[Br-]	CXRFDZFCGOPDTD-UHFFFAOYSA-M
DG00416	Homidium bromide	14710	"ETHIDIUM BROMIDE; Homidium bromide; 1239-45-8; Dromilac; EtBr; 3,8-Diamino-5-ethyl-6-phenylphenanthridinium bromide; Ethydium bromide; 3,8-Diamino-5-ethyl-6-phenylphenanthridin-5-ium bromide; Phenanthridinium, 3,8-diamino-5-ethyl-6-phenyl-, bromide; 2,7-Diamino-10-ethyl-9-phenylphenanthridinium bromide; 2,7-Diamino-9-phenyl-10-ethylphenanthridinium bromide; UNII-059NUO2Z1L; MFCD00011724; 2,7-Diamino-9-phenylphenanthridine ethobromide; Ethidium bromide solution; MLS002702536; 059NUO2Z1L; CHEBI:4883; Phenanthridinium, 3,8-diamino-5-ethyl-6-phenyl-, bromide (1:1); NSC268986; NSC-268986; 5-ethyl-6-phenylphenanthridin-5-ium-3,8-diamine;bromide; NCGC00091387-01; NCGC00095070-01; DSSTox_CID_5258; DSSTox_RID_77719; DSSTox_GSID_25258; Homidii bromidum; CHEMBL284328; Bromure d'homidium; Bromuro de homidio; Homidium bromide [INN:BAN]; CAS-1239-45-8; Homidii bromidum [INN-Latin]; CCRIS 1017; 3,8-Diamino-1-ethyl-6-phenylphenantridinium bromide; HSDB 7297; Bromure d'homidium [INN-French]; Bromuro de homidio [INN-Spanish]; EINECS 214-984-6; 2,7-Diamino-9-Phenyl-10-Ethylphenanthridiniumbromide; NSC 268986; RD 1572; AI3-62997; Ethidium (bromide); Ethidium bromide, 98%; SCHEMBL20520; SPECTRUM1503806; Ethidium bromide, >=95.0%; SCHEMBL1505620; DTXSID8025258; HMS502O22; HMS1922I08; HMS3868D03; Pharmakon1600-01503806; Ethidium bromide, ~95% (HPLC); Ethidium bromide solution, 10mg/ml; HY-D0021; Tox21_111123; Tox21_111410; Tox21_202511; CCG-39365; NSC758630; Ethidium bromide solution 1% in H2O; Ethidium bromide solution, 10 mg/mL; AKOS015904050; Tox21_111410_1; AM84361; Ethidium bromide, electrophoresis grade; MCULE-8684380812; NSC-758630; Ethidium bromide solution, 0.625mg/ml; Ethidium bromide, for biochemistry, 98%; NCGC00091387-08; NCGC00095070-02; NCGC00260060-01; AS-79030; SMR001566146; DB-062201; E0370; FT-0614786; E-4000; F16485; Ethidium bromide, Vetec(TM) reagent grade, 95%; SR-01000872761; SR-01000872761-1; Ethidium bromide, for fluorescence, >=95.0% (HPLC); Phenanthridinium,8-diamino-5-ethyl-6-phenyl-, bromide; Ethidium bromide solution, for fluorescence, ~1% in H2O; WLN: T B666 HKJ EJ H2 IR& LZ &E &9/26; Ethidium bromide, ~10 mg/tablet ethidium bromide, tablet; Ethidium bromide, BioReagent, for molecular biology, powder; J Mol Biol 13: 269 (1965); 27: 87 (1967); Ethidium bromide solution, BioReagent, for molecular biology, 10 mg/mL in H2O; Ethidium bromide solution, BioReagent, for molecular biology, 500 mug/mL in H2O"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	DR01442	.	394.3	C21H20BrN3	55.9	419	.	25	2	3	2	"1S/C21H19N3.BrH/c1-2-24-20-13-16(23)9-11-18(20)17-10-8-15(22)12-19(17)21(24)14-6-4-3-5-7-14;/h3-13,23H,2,22H2,1H3;1H"	CC[N+]1=C2C=C(C=CC2=C3C=CC(=CC3=C1C4=CC=CC=C4)N)N.[Br-]	ZMMJGEGLRURXTF-UHFFFAOYSA-N
DG00417	Benzalkonium bromide	23705	"Benzyldodecyldimethylammonium bromide; 7281-04-1; Benzalkonium bromide; Benzododecinium bromide; Sterinol; N-Benzyl-N,N-dimethyldodecan-1-aminium bromide; Bacfor BL; Benzyldimethyldodecylammonium bromide; Sinnoquat BL 95; 8043-47-8; Benzenemethanaminium, N-dodecyl-N,N-dimethyl-, bromide; benzyl-dodecyl-dimethylazanium;bromide; Dodecyl dimethyl benzyl ammonium bromide; N-Dodecyl-N,N-dimethylbenzenemethanaminium bromide; Dimethyl laurylbenzene ammonium bromide; UNII-IRY12B2TQ6; IRY12B2TQ6; Ajatin; MFCD00011768; DSSTox_CID_28624; DSSTox_RID_82894; DSSTox_GSID_48698; Lauralkonium bromide; Sinnoquat BL 80; Benzenemethanaminium, N-dodecyl-N,N-dimethyl-, bromide (1:1); CAS-7281-04-1; Ammonyl BR 1244; Benzododecinium bromatum; Caswell No. 416B; NCGC00164245-02; EINECS 230-698-4; EPA Pesticide Chemical Code 069123; Ammonium, benzyldodecyldimethyl-, bromide; Bromek dwumetylolaurylobenzyloamoniowy [Polish]; Benzalkonium bromide (C12); SCHEMBL119589; CHEMBL2355417; DTXSID4048698; CHEBI:167207; dimethyldodecylbenzylammonium bromide; Tox21_113091; benzyl-dodecyldimethylammonium bromide; Bromek dwumetylolaurylobenzyloamoniowy; AKOS015891185; Tox21_113091_1; NCGC00164245-03; BS-44064; I017; DB-056433; B3748; BENZYL(DODECYL)DIMETHYLAZANIUM BROMIDE; FT-0733931; D87631; N-Benzyl-N,N-dimethyldodecan-1-amonium bromide; N-Benzyl-N,N-dimethyldodecan-1-ammonium bromide; Q-200699; Q4890794; Benzalkonium bromide Dimethyl benzyl lauryl ammonium bromide; UNII-151T1GQ42D component KHSLHYAUZSPBIU-UHFFFAOYSA-M"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB11105	.	.	384.4	C21H38BrN	0	240	.	23	0	1	13	"1S/C21H38N.BrH/c1-4-5-6-7-8-9-10-11-12-16-19-22(2,3)20-21-17-14-13-15-18-21;/h13-15,17-18H,4-12,16,19-20H2,1-3H3;1H/q+1;/p-1"	CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1.[Br-]	KHSLHYAUZSPBIU-UHFFFAOYSA-M
DG00418	Iodine-131	24855	"IODINE-131; Iodine 131; UNII-I5X6L61HUT; I5X6L61HUT; 10043-66-0; I-131; Iodine I 131; Radioactive iodine-I131; Radioactive iodine (131I); Iodine, mol. (131I2); Iodine, isotope of mass 131; Iodine, labeled with iodine-131; I 131; 15124-39-7"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	261.81	I2	0	0	1.7	2	0	0	0	"1S/I2/c1-2/i1+4,2+4"	[131I][131I]	PNDPGZBMCMUPRI-HVTJNCQCSA-N
DG00419	Cephalexin	27447	"Adcadina; Ades[prex; Alcephin; Alexin; Alsporin; Ambal; Aristosporin; Azabort; Bactopenor; Beliam; Biocef; CEX; Carnosporin; Cefablan; Cefacet; Cefadal; Cefadin; Cefadina; Cefalekey; Cefaleksin; Cefalessina; Cefalexgobens; Cefalexin; Cefalexina; Cefalexine; Cefalexinum; Cefalin; Cefalival; Cefaloto; Cefaseptin; Cefax; Ceffanex; Cefibacter; Ceflax; Ceforal; Cefovit; Celexin; Cepastar; Cepexin; Cephacillin; Cephalexine; Cephalexinum; Cephalobene; Cephanasten; Cephaxin; Cephin; Cepol; Ceporex; Ceporexin; Ceporexine; Check; Cophalexin; Domucef; Doriman; Durantel; Efemida; Erocetin; Factagard; Felexin; Fexin; Ibilex; Ibrexin; Inphalex; Karilexina; Kefalospes; Keflet; Keflex; Kefolan; Keforal; Keftab; Kekrinal; Kidolex; Lafarine; Larixin; Lenocef; Lexibiotico; Loisine; Lonflex; Lopilexin; Losporal; Madlexin; Maksipor; Mamalexin; Mamlexin; Medolexin; Medoxine; Neokef; Neolexina; Noveol; Novolexin; Nufex; Oracef; Oriphex; Oroxin; Ortisporina; Ospexin; Palitrex; Pectril; Prindex; Pyassan; Rilexine; Roceph; Rogevil; Sanaxin; Sartosona; Sencephalin; Sepexin; Servicef; Servispor; Sialexin; Sinthecillin; Sintolexyn; Sporicef; Sporidex; Syncl; Syncle; Synecl; Tepaxin; Theratrex; Tokiolexin; Uphalexin; Viosporine; Voxxim; Winlex; Zabytrex; Zozarine; Cefalessina [DCIT]; Cefalexin Scand Pharm; Cefalexin Sodium; Cefalexin generics; Cefalexin hydrate; Cefalexin monohydrate; Cefalexina Northia; Cefalexina Richet; Cephalex von ct; Cephalexin hydrate; Cephalexin monohydrate; Ceporex Forte; Durantel DS; Henina Oral; Panixine Disperdose; Roceph Distab; Lilly 66873; S 6437; SQ 20248; Cefa-iskia; Cefalexin (JP15); Cefalexin.H2O; Cefalexina [INN-Spanish]; Cefalexine [INN-French]; Cefalexinum [INN-Latin]; Cephalexin(USP); Cephalexin (anhydrous); Cephalexin 1-hydrate; Cephalexin 1-wasser; Cephalexin [USAN:BAN]; Cephalexin.H2O; Ceporexin-E; Cusisporina-Cefalox; Ed A-Ceph; KS-1134; Keflex (TN); Keftab (TN); L-Keflex; Panixine disperdose (TN); Sporidex (TN); Cephalexin, (6R-(6alpha,7beta))-Isomer; 7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta (sup 3)-cephem-4-carboxylic acid; 7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta3-cephem-4-carboxylic acid; 7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3534	DB00567	DR00330	DR0284	347.4	C16H17N3O4S	138	600	0.6	24	3	6	4	"1S/C16H17N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1"	CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O	ZAIPMKNFIOOWCQ-UEKVPHQBSA-N
DG00421	Cefradine	38103	"Anspor; Cefradin; Cefradina; Cefradinum; Cephradin; Cephradine; Eskacef; Sefril; Velosef; CEPHRADINE SODIUM; SKF D 39304; SQ 11436; VELOSEF 125; VELOSEF 250; VELOSEF 500; Anspor (TN); Cefradina [INN-Spanish]; Cefradinum [INN-Latin]; Cephradine (USP); Cephradine (anhydrous); Cephradine [USAN:BAN]; SQ-11436; SQ-22022; Velosef (TN); Cefradine (JAN/INN); SK&F D-39304; SK-D-39304; (6R,7R)-7-((R)-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(D-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-caboxylic acid; 7-(D-2-Amino-2-(1,4-cyclohexadienyl)acetamide)desacetoxycephalosporanicacid; 7beta-[(2R)-2-(cyclohexa-1,4-dienyl)-2-phenylacetamido]-3-methyl-3,4-didehydrocepham-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3547	DB01333	DR00544	.	349.4	C16H19N3O4S	138	697	0.4	24	3	6	4	"1S/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1"	CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CCC=CC3)N)SC1)C(=O)O	RDLPVSKMFDYCOR-UEKVPHQBSA-N
DG00422	Exemestane	60198	"Aromasil; Aromasin; Aromasine; EXE; Exemestance; Exemestano; Exemestanum; Nikidess; Pfizer brand of exemestane; Curator_000009; Fce 24304; Aromasin (TN); Aromasin, Exemestane; Exemestano [INN-Spanish]; Exemestanum [INN-Latin]; FCE-24304; PNU-155971; Exemestane [USAN:INN:BAN]; Exemestane (JAN/USP/INN); (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione; 6-Methylenandrosta-1,4-diene-3,17-dione; 6-Methyleneandrosta-1,4-diene-3,17-dione; 6-methylideneandrosta-1,4-diene-3,17-dione"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4953	DB00990	.	DR0675	296.4	C20H24O2	34.1	653	3.1	22	0	2	0	"1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1"	C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC(=C)C4=CC(=O)C=C[C@]34C	BFYIZQONLCFLEV-DAELLWKTSA-N
DG00424	Pentisomicin	65453	"Pentisomicin; 5-Episisomicin; Sch 22591; UNII-L5BS6WSR0E; 55870-64-9; L5BS6WSR0E; SCH-22591; Mutamicin 6; Mutamycin 6; 5-epi-Sisomicin; (2R,3R,4R,5R)-2-[(1S,2R,3R,4S,6R)-4,6-diamino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; Pentisomicina; Pentisomicine; Pentisomicinum; Pentisomicin [USAN:INN]; Pentisomicine [INN-French]; Pentisomicinum [INN-Latin]; Pentisomicina [INN-Spanish]; Pentisomicin (USAN/INN); O-3-Deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1->1)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1->3))-4,6-diamino-4,5,6-trideoxy-D-myo-inositol; SCHEMBL380284; CHEMBL2105403; DTXSID7046887; D-myo-Inositol, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1->1)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1->3))-4,6-diamino-4,5,6-trideoxy-; D-myo-Inositol, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-1)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-3))-4,6-diamino-4,5,6-trideoxy-; O-3-Deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-1)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-3))-4,6-diamino-4,5,6-trideoxy-D-myo-inositol; D05425; Q27282733"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	447.5	C19H37N5O7	214	643	-5.1	31	8	12	6	"1S/C19H37N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h3,9-18,24-27H,4-7,20-23H2,1-2H3/t9-,10+,11-,12-,13-,14-,15+,16-,17-,18-,19+/m1/s1"	C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@H]2O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N)N)O	URWAJWIAIPFPJE-VHLNBGGKSA-N
DG00425	Cephalosporin C	65536	"Cephalosporin C; 7-(5-Amino-5-carboxyvaleramido)cephalosporanic acid; 61-24-5; UNII-3XIY7HJT5L; CHEBI:15776; EINECS 200-501-6; 3XIY7HJT5L; BRN 0065348; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-((5-amino-5-carboxy-1-oxopentyl)amino)-8-oxo-, (6R-(6alpha,7beta(R*)))-; (6R,7R)-3-[(acetyloxy)methyl]-7-{[(5R)-5-amino-5-carboxypentanoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(5-amino-5-carboxyvaleramid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:15776	DB03313	.	.	415.4	C16H21N3O8S	202	737	-4.4	28	4	10	10	"1S/C16H21N3O8S/c1-7(20)27-5-8-6-28-14-11(13(22)19(14)12(8)16(25)26)18-10(21)4-2-3-9(17)15(23)24/h9,11,14H,2-6,17H2,1H3,(H,18,21)(H,23,24)(H,25,26)/t9-,11-,14-/m1/s1"	CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O	HOKIDJSKDBPKTQ-GLXFQSAKSA-N
DG00426	Enrofloxacin	71188	"Enrofloxacin; 93106-60-6; Baytril; Enrofloxacine; CFPQ; Enrofloxacino; Enrofloxacinum; BAY VP 2674; 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Enroxil; UNII-3DX3XEK1BN; Baytril (TN); N-Ethylciprofloxacin; ERFX; 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; C19H22FN3O3; MFCD00792463; 3DX3XEK1BN; 3-Quinolinecarboxylic acid, 1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-; MLS000069441; CHEBI:35720; NSC-758616; BAY Vp 2674;PD160788; endrofloxicin; NCGC00018143-04; CPD000059011; PD160788; SMR000059011; 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid; DSSTox_CID_25619; DSSTox_RID_81007; DSSTox_GSID_45619; 3-Quinolinecarboxylic acid, 1,4-dihydro-1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-4-oxo-; Enrofloxacine [French]; Enrofloxacinum [Latin]; Enrofloxacino [Spanish]; Bay-Vp-2674; 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic Acid; CAS-93106-60-6; Enrofloxacin [USAN:BAN:INN]; HSDB 6952; BRN 5307824; CCRIS 8214; Enrofloxacin [USAN:USP:INN:BAN]; Enrofloxacin-[d5]; Opera_ID_1106; Enrofloxacin (USP/INN); Enrofloxacin (USAN/INN); 1,4-Dihydro-1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-4-oxo-3-quinolinecarboxylic acid; BAY-Vp2674; MLS001076496; MLS001424169; CHEMBL15511; SCHEMBL149150; SPECTRUM1503721; Enrofloxacin for veterinary use; DTXSID1045619; HMS2052O09; HMS2090E12; HMS2093I21; HMS2234M11; HMS3373P14; HMS3394O09; HMS3715B18; Pharmakon1600-01503721; ZINC597112; ALBB-030792; BCP15457; HY-B0502; Enrofloxacin, >=98.0% (HPLC); Tox21_110831; BBL009982; DL-384; HTS028366; NSC758616; s3059; STK711109; AKOS005530685; BAY-Vp2674;PD160788; Tox21_110831_1; AC-7614; CCG-101102; DB11404; KS-5010; MCULE-6446074322; NC00352; NSC 758616; 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxo-quinoline-3-carboxylic acid; 1-cyclopropyl-7-(4-ethylpiperazinyl)-6-fluoro-4-oxohydroquinoline-3-carboxylic acid; NCGC00018143-01; NCGC00018143-02; NCGC00018143-03; NCGC00018143-05; NCGC00021632-03; H734; SBI-0206725.P001; AB0013220; DB-057368; B1742; E0786; FT-0625663; FT-0667862; D02473; AB00384269-16; AB00384269_17; AB00384269_18; Enrofloxacin, VETRANAL(TM), analytical standard; 106E606; A844445; Q414413; SR-01000000045; SR-01000000045-3; BRD-K76534306-001-11-0; Enrofloxacin, European Pharmacopoeia (EP) Reference Standard; Enrofloxacin, United States Pharmacopeia (USP) Reference Standard; 1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-4-oxo-3-quinolinecarboxylic acid; Enrofloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard; Enrofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)-3-quinoline-carboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)-3-quinolinecarboxylic acid; 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3- quinolonecarboxylic acid; 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, 9CI; 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoranyl-4-oxidanylidene-quinoline-3-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11404	DR01565	.	359.4	C19H22FN3O3	64.099	613	-0.2	26	1	7	4	"1S/C19H22FN3O3/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12/h9-12H,2-8H2,1H3,(H,25,26)"	CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F	SPFYMRJSYKOXGV-UHFFFAOYSA-N
DG00427	PD131628	72448	"127967-03-7; PD 131628; UNII-YS492L6CHP; YS492L6CHP; 1,8-Naphthyridine-3-carboxylic acid, 7-[(3S)-3-amino-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-; (S)-7-(3-Amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid; 7-[(3S)-3-aminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid; (S)-7-(3-aminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1,8-Naphthyridine-3-carboxylic acid, 7-((3S)-3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-; 7-(3-Amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid; CI-990 (Hydrochloride); CHEMBL51678; PD131628 (Hydrochloride); SCHEMBL9838735; DTXSID9074486; PD131628; PD131628-0002B; 1,8-Naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, (S)-; 1-Cyclopropyl-6-fluoro-7-[3beta-amino-1-pyrrolidinyl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid"	Terminated	10	Discontinued Drug(s)	Terminated	Small molecular drug	.	.	.	.	332.33	C16H17FN4O3	99.8	594	-0.1	24	2	8	3	"1S/C16H17FN4O3/c17-12-5-10-13(22)11(16(23)24)7-21(9-1-2-9)14(10)19-15(12)20-4-3-8(18)6-20/h5,7-9H,1-4,6,18H2,(H,23,24)/t8-/m0/s1"	C1CN(C[C@H]1N)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F	MUKSDTOOLRNSIO-QMMMGPOBSA-N
DG00429	Lestaurtinib	126565	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:91471	DB06469	.	.	439.5	C26H21N3O4	88.6	886	2.2	33	3	4	1	"1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1"	C[C@@]12[C@](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)O	UIARLYUEJFELEN-LROUJFHJSA-N
DG00430	Tetraphenylphosphonium chloride	164911	"Tetraphenylphosphonium chloride; 2001-45-8; Phosphonium, tetraphenyl-, chloride; tetraphenylphosphanium;chloride; MFCD00011916; tetraphenylphophonium chloride; EINECS 217-890-3; Ph4PCl; Tetraphenylphosphonium chloride, 98%; tetraphenylchlorophosphine; Phosphonium, tetraphenyl-, chloride (1:1); C24H20ClP; Tetraphenylphosphoniumchloride; tetraphenylphosphanium,chloride; SCHEMBL126056; CHEMBL223885; DTXSID00897533; AKOS015833164; TETRAPHENYL-PHOSPHONIUM-CHLORIDE; AS-15199; O459; SY032650; DB-045062; CS-0097966; FT-0633970; T1375; F15456; A855066; Q7706653; W-107657; Tetraphenylphosphonium chloride, for the spectrophotometric det. of Bi, Co, >=97.0%"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	374.8	C24H20ClP	0	301	.	26	0	1	4	"1S/C24H20P.ClH/c1-5-13-21(14-6-1)25(22-15-7-2-8-16-22,23-17-9-3-10-18-23)24-19-11-4-12-20-24;/h1-20H;1H/q+1;/p-1"	C1=CC=C(C=C1)[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4.[Cl-]	WAGFXJQAIZNSEQ-UHFFFAOYSA-M
DG00432	Aminodeoxykanamycin	439318	"Aminodeoxykanamycin; bekanamycin; Kanamycin B; nebramycin factor 5; Bekanamycine; Bekanamycinum; Becanamicina; Bekanamycinum [INN-Latin]; Bekanamycine [INN-French]; Becanamicina [INN-Spanish]; EINECS 225-170-5; BRN 0061646; Aminodeoxykanamycin sulfate; 4696-76-8; Antibiotic derived from Streptomyces kanamyceticus; AC1L2FQA; AC1Q57UP; Antibiotic derived from Streptomyces kanamyceticus. Kanamycin B; (1r,2s,4r,6s)-4,6-diamino-3-[(3-amino-3-deoxy-; A-d-glucopyranosyl)oxy]-2-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:28098	DB13673	.	.	483.5	C18H37N5O10	288	639	-7.2	33	11	15	6	"1S/C18H37N5O10/c19-2-6-11(26)12(27)9(23)17(30-6)32-15-4(20)1-5(21)16(14(15)29)33-18-13(28)8(22)10(25)7(3-24)31-18/h4-18,24-29H,1-3,19-23H2/t4-,5+,6+,7+,8-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+/m0/s1"	C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)N)N	SKKLOUVUUNMCJE-FQSMHNGLSA-N
DG00433	Acriflavine	443101	"Acriflavine; Xanthacridinum; Euflavine; Pantonsiletten; Flavinetten; Assiflavine; Choliflavin; Bialflavina; Vetaflavin; Buroflavin; Tolivalin; Isravin; Diacrid; Zoriflavin; Trachosept; Gonacin; Flavisept; Flavioform; Bovoflavin; Mediflavin; Bioacridin; Angiflan; Tripla-etilo; Glyco-flavine; Acriflavine neutral; Acriflavine [NF]; Caswell No. 008; Euflavin; Flavacridinum hydrochloricum; Trypaflavine Neutral; CCRIS 5617; UNII-1T3A50395T; EPA Pesticide Chemical Code 000501; Acridinium, 3,6-diamino-10-methyl-, chloride, mixt. with 3,6-acridined"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB13373	.	.	469	C27H25ClN6	121	486	.	34	4	6	0	"1S/C14H13N3.C13H11N3.ClH/c1-17-13-7-11(15)4-2-9(13)6-10-3-5-12(16)8-14(10)17;14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10;/h2-8H,1H3,(H3,15,16);1-7H,14-15H2;1H"	C[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N.C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N.[Cl-]	PEJLNXHANOHNSU-UHFFFAOYSA-N
DG00434	Decitabine	451668	"AzadC; Dacogen; Dezocitidine; NCGC_5ADOC; Dacogen (TN); E-7373; Decitabine (USAN/INN); Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine; 2'-Deoxy-5-azacytidine; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 5-AZAdC; 5-Aza-2′-Deoxycytidine; 5-Aza-2'-deoxycytidine; 5-Azadeoxycytidine; 5-Deoxy-2′-azacytidine; 5-aza-2-deoxycytidine; 5-aza-CdR; 5-aza-dC; 5A2dc"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:50131	DB01262	.	DR1763	228.21	C8H12N4O4	121	356	-1.2	16	3	4	2	"1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1"	C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)O	XAUDJQYHKZQPEU-KVQBGUIXSA-N
DG00435	Pyrimethamine/Atovaquone	456850	"Atovaquone & Pyrimethamine; 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-naphthalene-1,4-dione; 5-(4-chlorophenyl)-6-ethyl-pyrimidine-2,4-diamine"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	615.5	C34H32Cl2N4O3	132	837	.	43	3	7	4	"1S/C22H19ClO3.C12H13ClN4/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26;1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h1-4,9-13,15,24H,5-8H2;3-6H,2H2,1H3,(H4,14,15,16,17)"	CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl.C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O	BXDNHABGOUHQGH-UHFFFAOYSA-N
DG00436	IFN-alpha	826634	"IFN alpha-IFNAR-IN-1; 844882-93-5; IFN-alpha; CHEMBL1617534; DNDI1417107; N-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine; Methyl-[2-(naphthalen-1-ylsulfanyl)-benzyl]-amine; IFNAR-IN-1; ZINC346644; BDBM50014088; AKOS005066179; HY-12836; N-Methyl-2-(1-naphthylthio)benzenemethaneamine; A915034; N-methyl-1-(2-(naphthalen-1-ylthio)phenyl)methanamine; BENZENEMETHANAMINE,N-METHYL-2-(1-NAPHTHALENYLTHIO)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	279.4	C18H17NS	37.3	293	4.6	20	1	2	4	"1S/C18H17NS/c1-19-13-15-8-3-5-11-17(15)20-18-12-6-9-14-7-2-4-10-16(14)18/h2-12,19H,13H2,1H3"	CNCC1=CC=CC=C1SC2=CC=CC3=CC=CC=C32	OHDXDNUPVVYWOV-UHFFFAOYSA-N
DG00437	Tetraphenylphosphonium bromide	2724163	"Tetraphenylphosphonium bromide; 2751-90-8; Phosphonium, tetraphenyl-, bromide; Phosphonium, tetraphenyl-, bromide (1:1); tetraphenylphosphanium;bromide; MFCD00011915; Tetraphenylphosponium bromide; Tetraphenylphosphoniumbromide; tetraphenylphosphanium,bromide; EINECS 220-393-4; Ph4PBr; Bromotetraphenylphosphorane; C24H20BrP; Tetraphenylphosphorus bromide; SCHEMBL42616; CHEMBL456063; DTXSID30883722; BCP24497; Tetraphenylphosphonium bromide, 97%; NSC115672; TETRAPHENYL-PHOSPHONIUM-BROMIDE; AKOS015833052; AKOS025117489; CS-W013858; NSC 115672; NSC-115672; AS-12560; DB-047239; FT-0634467; T1069; A819099; W-107108; Tetraphenylphosphonium bromide, Vetec(TM) reagent grade, 97%"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	419.3	C24H20BrP	0	301	.	26	0	1	4	"1S/C24H20P.BrH/c1-5-13-21(14-6-1)25(22-15-7-2-8-16-22,23-17-9-3-10-18-23)24-19-11-4-12-20-24;/h1-20H;1H/q+1;/p-1"	C1=CC=C(C=C1)[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4.[Br-]	BRKFQVAOMSWFDU-UHFFFAOYSA-M
DG00438	Toremifene	3005573	"Acapodene; Estrimex; Farestone; Toremifeno; Toremifenum; Toremifene Base; Toremifeno [Spanish]; Toremifenum [Latin]; GTx 006; Acapodene (TN); FC-1157a; Fareston (TN); GTx-006; Toremifene (INN); Toremifene [INN:BAN]; Z-Toremifene; GTX-006 (Acapodene); Toremifene Citrate (1:1); {2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine; (Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; 2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-dimethyl-ethylamine citrate(1:1); 2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC); 2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine; 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9635	DB00539	DR01170	.	406	C26H28ClNO	12.5	483	7.2	29	0	2	9	"1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-"	CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\\C2=CC=CC=C2)/C3=CC=CC=C3	XFCLJVABOIYOMF-QPLCGJKRSA-N
DG00439	Thiopurine	3015569	"2-Mercaptopurine; 2-Thiopurine; 28128-19-0; 5-Mercaptopurine; Purine-2-thiol; 3,7-dihydropurine-2-thione; Thiopurine; UNII-81XK02929C; 81XK02929C; 2-Purinethiol; 7H-purine-2-thiol; 1,3-Dihydro-2H-purine-2-thione; 2-MP; 3,7-dihydro-2H-purine-2-thione; EINECS 248-855-0; NSC 23720; 2H-Purine-2-thione, 1,3-dihydro-; SCHEMBL3896; DTXSID60878767; NSC23720; MFCD00047145; NSC-23720; ZINC12955987; AKOS006275100; 2-Mercaptopurine, >=95%, crystalline; 2H-Purine-2-thione, 1,3-dihydro- (9CI); FT-0694524; W-202176; Q27269279"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	152.18	C5H4N4S	85.2	190	0.1	10	2	2	0	"1S/C5H4N4S/c10-5-6-1-3-4(9-5)8-2-7-3/h1-2H,(H2,6,7,8,9,10)"	C1=NC(=S)NC2=C1NC=N2	HDBQZGJWHMCXIL-UHFFFAOYSA-N
DG00440	Sulfonamides	3085933	"Sulfonamides, C12-18-alkane; (C12-18) Alkane sulfonamides; 73138-90-6"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	249.42	C12H27NO2S	68.5	165	5.5	16	2	4	12	"1S/C12H27NO2S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16(14)15/h13H,2-12H2,1H3,(H,14,15)"	CCCCCCCCCCCCNS(=O)O	DVMOOMUBCZHSBG-UHFFFAOYSA-N
DG00441	Sodium lauryl sulfate	3423265	Anticerumen; Dreft; Dupanal; Duponal; Duponol; Gardinol; Irium; NALS; Natriumlaurylsulfat; Neutrazyme; SDS; SLS; Syntapon; WAQE; Akyposal SDS; Aquarex ME; Aquarex methyl; Carsonol SLS; Carsonol SLS Paste B; Carsonol SLS Special; Conco Sulfate WAG; Conco Sulfate WAN; Conco Sulfate WAS; Conco sulfate WA; Conco sulfate WN; DODECYL SULFATE; Dupanol WAQ; Duponal WAQE; Duponol C; Duponol Me; Duponol QC; Duponol WA; Duponol WA dry; Duponol WAQ; Duponol WAQE; Duponol WAQM; Duponol methyl; Duponol qx; Duponol waqa; EMAL O; Empicol LPZ; Hexamol SLS; Incronol SLS; Laurylsiran sodny; Lauyl sodium sulfate; Maprobix NEU; Maprofix LK; Maprofix NEU; Maprofix WAC; Melanol CL; Montopol La Paste; Nikkol SLS; Orvus WA Paste; Perlandrol L; Perlankrol L; Richonol A; Richonol C; Richonol af; SDS Running Buffer; Sintapon L; Sipex OP; Sipex SP; Sipex UB; Sipex sb; Sipex sd; Sipon LS; Sipon LSB; Sipon PD; Sipon WD; Sodium Laurylsulfate; Solsol needles; Standapol WAQ; Stepanol ME; Stepanol ME Dry AW; Stepanol WA; Stepanol WA Paste; Stepanol me dry; Stepanol methyl; Stepanol wac; Stepanol waq; Sterling wa paste; Sulfotex wa; Texapon DL; Trepenol WA; Avirol 101; Avirol 118; Avirol 118 conc; Berol 452; CP 75424; Cycloryl 21; Cycloryl 31; Cycloryl 580; Cycloryl 585N; Detergent 66; Emal 10; Emersal 6400; Empicol LS 30; Empicol LX 28; Finasol osr2; MP SILICA RP 18; Maprofix 563; Melanol CL 30; Monagen Y 100; Monogen Y 100; Odoripon Al 95; Perklankrol ESD 60; Rewopol NLS 30; Sinnopon LS 100; Sinnopon LS 95; Sipon LS 100; Standapol 112; Standapol 112 conc; Standapol was 100; Steinapol NLS 90; Stepanol T 28; Sulfetal L 95; Sulfopon wa 1; Swascol 3L; Tarapon K 12; Tvm 474; Emulsifier no. 104; Finasol osr(sub 2); IPC-SDS;Jordanol SL-300; Lanette Wax-S; Maprofix WAC-LA; Product no. 161; Product no. 75; Quolac EX-UB; S-4600; Standapol wa-ac; Stepanol WA-100; Sterling WAQ-CH; Ultra sulfate sl-1	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8984	DB00815	.	.	288.38	C12H25NaO4S	74.8	249	.	18	0	4	12	"1S/C12H26O4S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15;/h2-12H2,1H3,(H,13,14,15);/q;+1/p-1"	CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]	DBMJMQXJHONAFJ-UHFFFAOYSA-M
DG00442	Tilmicosin	5282521	"Tilmicosin; 108050-54-0; Micotil 300; UNII-XL4103X2E3; EL-870; EL870; XL4103X2E3; Ly177370; LY-177370; Tilmicosina; Tilmicosine; Tilmicosinum; Tilmicosine [INN-French]; Tilmicosinum [INN-Latin]; Tilmicosina [INN-Spanish]; C46H80N2O13; HSDB 7446; NSC-759584; Tilmicosin [USAN:USP:INN:BAN]; NCGC00096003-01; (4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-[(2R,3R,4S,5S,6R)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-7-[2-[(3S,5R)-3,5-dimethylpiperidin-1-yl]ethyl]-16-ethyl-4-hydroxy-15-[[(2R,3R,4R,5R,6R)-5-hy; droxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-5,9,13-trimethyl-1-oxacyclohexadeca-11,13-diene-2,10-dione; LY-177370;EL-870; Micotil (TN); Tilmicosin (USP/INN); DSSTox_CID_26011; DSSTox_RID_81287; DSSTox_GSID_46011; 4(sup A)-O-de(2,6-Dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl)-20-deoxo-20-(cis-3,5-dimethylpiperidino)tylosin; SCHEMBL149192; CHEMBL1908333; DTXSID5046011; ACT06683; HY-B0905; Tox21_111546; s4122; ZINC238809114; ZINC245204941; CCG-270545; DB11471; NSC 759584; NCGC00348375-01; NCGC00348375-02; Tilmicosin 100 microg/mL in Acetonitrile; Tylosin, 4(sup A)-O-de(2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl)-20-deoxo-20-(3,5-dimethyl-1-piperidinyl)-, 20(cis)-; Tylosin, 4A-O-de(2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl)-20-deoxo-20-(3,5-dimethyl-1-piperidinyl)-; CAS-108050-54-0; D02492; AB01566912_01; 050T540; Q722387; Tilmicosine, Antibiotic for Culture Media Use Only; Q-100992; 20-Deoxo-20-(3,5-dimethyl-1-piperidinyl)desmycosin; Tylosin, 4A-O-de(2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl)-20-deoxo-20-((3R,5S)-3,5-dimethyl-1-piperidinyl)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11471	.	.	869.1	C46H80N2O13	186	1420	3.6	61	4	15	12	"1S/C46H80N2O13/c1-13-36-33(24-57-46-44(56-12)43(55-11)40(53)31(8)59-46)19-25(2)14-15-34(49)28(5)20-32(16-17-48-22-26(3)18-27(4)23-48)42(29(6)35(50)21-37(51)60-36)61-45-41(54)38(47(9)10)39(52)30(7)58-45/h14-15,19,26-33,35-36,38-46,50,52-54H,13,16-18,20-24H2,1-12H3/b15-14+,25-19+/t26-,27+,28-,29+,30-,31-,32+,33-,35-,36-,38+,39-,40-,41-,42-,43-,44-,45+,46-/m1/s1"	CC[C@@H]1[C@H](/C=C(/C=C/C(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O)N(C)C)O)CCN3C[C@@H](C[C@@H](C3)C)C)C)\\C)CO[C@H]4[C@@H]([C@@H]([C@@H]([C@H](O4)C)O)OC)OC	JTSDBFGMPLKDCD-XVFHVFLVSA-N
DG00443	Carbomycin	5287879	"Carbomycin A; CARBOMYCIN; Magnamycin; Magnamycin A; UNII-AIK0XUF3AV; Deltamycin A4; AIK0XUF3AV; Carbomycin acetate; M-4209; 4564-87-8; Carbomicina; Carbomycine; Carbomycinum; GS MAI 5201 52 3; GS-MAI 5201-52-3; (2S,3S,4R,6S)-6-(((2R,3S,4R,5R,6S)-6-(((1S,3R,7R,8S,9S,10R,12R,16S,E)-7-acetoxy-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl)oxy)-4-(dimethylamino)-5-hydroxy-2-methyltetrahydro-2H-pyran-3-yl)oxy)-4-hydroxy-2,4-dimethyltetrahydro-2H-pyran-3-yl 3-methylbutanoate; Carbomycin [INN]; Magnamycin (VAN); NSC 51001; Carbomycine [INN-French]; Carbomycinum [INN-Latin]; Carbomicina [INN-Spanish]; Carbomycin A (8CI); AI3-50160; CHEMBL1231649; Leucomycin V, 9-deoxy-12,13-epoxy-12,13-dihydro-9-oxo-, 3-acetate; DB11383; [(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-6-[[(1S,3R,7R,8S,9S,10R,12R,14E,16S)-7-acetyloxy-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimethyloxan-3-yl] 3-methylbutanoate; Leucomycin V, 9-deoxy-12,13-epoxy-12,13-dihydro-9-oxo-, 3-acetate 4B-(3-methylbutanoate), (12S,13S)-; UNII-3952621T3O component FQVHOULQCKDUCY-OGHXVOSASA-N; (2S,3S,4R,6S)-6-{[(2R,3S,4R,5R,6S)-6-{[(1S,3R,7R,8S,9S,10R,12R,14E,16S)-7-(acetyloxy)-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy}-4-(dimethylamino)-5-hydroxy-2-methyltetrahydro-2H-pyran-3-yl]oxy}-4-hydroxy-2,4-dimethyltetrahydro-2H-pyran-3-yl 3-methylbutanoate (non-preferred name); An antibiotic obtained from cultures of Streptomyces halstedii, or the same substance produced by any other means"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11383	.	.	842	C42H67NO16	215	1470	1.8	59	2	17	14	"1S/C42H67NO16/c1-21(2)16-32(47)57-40-25(6)53-34(20-42(40,8)50)58-37-24(5)54-41(36(49)35(37)43(9)10)59-38-27(14-15-44)17-22(3)28(46)12-13-29-30(56-29)18-23(4)52-33(48)19-31(39(38)51-11)55-26(7)45/h12-13,15,21-25,27,29-31,34-41,49-50H,14,16-20H2,1-11H3/b13-12+/t22-,23-,24-,25+,27+,29+,30+,31-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1"	C[C@@H]1C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O[C@@H](C[C@H]2[C@@H](O2)/C=C/C1=O)C)OC(=O)C)OC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C)O[C@H]4C[C@@]([C@H]([C@@H](O4)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O	FQVHOULQCKDUCY-OGHXVOSASA-N
DG00444	Colistin	5311054	"Colistin sulphate; Polymyxin E; Colistin sulfate, nonsterile; Polymyxin E. Sulfate; Coly-Mycin M Parenteral (TN)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00803	.	DR2644	1155.4	C52H98N16O13	491	2050	-3.3	81	18	18	28	"1S/C52H98N16O13/c1-9-29(6)11-10-12-40(71)59-32(13-19-53)47(76)68-42(31(8)70)52(81)64-35(16-22-56)44(73)63-37-18-24-58-51(80)41(30(7)69)67-48(77)36(17-23-57)61-43(72)33(14-20-54)62-49(78)38(25-27(2)3)66-50(79)39(26-28(4)5)65-45(74)34(15-21-55)60-46(37)75/h27-39,41-42,69-70H,9-26,53-57H2,1-8H3,(H,58,80)(H,59,71)(H,60,75)(H,61,72)(H,62,78)(H,63,73)(H,64,81)(H,65,74)(H,66,79)(H,67,77)(H,68,76)/t29 ,30-,31-,32+,33+,34+,35+,36+,37+,38+,39-,41+,42+/m1/s1"	CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O	YKQOSKADJPQZHB-QNPLFGSASA-N
DG00445	Furazolidone	5323714	"Bifuron; Corizium; Coryzium; Diafuron; Enterotoxon; Furall; Furaxon; Furaxone; Furazol; Furazolidine; Furazolidon; Furazolidona; Furazolidonum; Furazolum; Furazon; Furidon; Furovag; Furox; Furoxal; Furoxane; Furoxon; Furoxone; Furozolidine; Giardil; Giarlam; Medaron; Neftin; Nicolen; Nifulidone; Nifuran; Nifurazolidone; Nifurazolidonum; Nitrofurazolidone; Nitrofurazolidonum; Nitrofuroxon; Optazol; Ortazol; Puradin; Roptazol; Sclaventerol; Tikofuran; Topazone; Trichofuron; Tricofuron; Tricoron; Trifurox; Viofuragyn; Fiurox aerosol powder; Furoxone Liquid; Furoxone Swine Mix; NF 180 custom mix ten; F-8900; Furazolidona [INN-Spanish]; Furazolidone [INN:BAN]; Furazolidonum [INN-Latin]; Furox Aerosol Powder (Veterinary); Furoxone (TN); NF-180; Usaf ea-1; Dependal-M (TN); Furazolidone (USP/INN); N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone; N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one; 3-(((5-Nitro-2-furanyl)methylene)amino)-2-oxazolidinone; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidinone; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidone; 3-((5-Nitrofurylidene)amino)-2-oxazolidone; 3-(5'-Nitrofurfuralamino)-2-oxazolidone; 3-(5-Nitrofurfurylideneamino)-2-oxazolidinone; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone; 3-[(5-Nitrofurylidene)amino]-2-oxazolidone; 3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one; 3-[[(5-Nitro-2-furanyl)methylene]amino]-2-oxazolidinone; 3-{[(5-Nitro-2-furanyl)methylene]amino}-2-oxazolidinone; 3-{[(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one; 3-{[(E)-(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one; 5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:5195	DB00614	.	.	225.16	C8H7N3O5	101	326	-0.1	16	0	6	2	"1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+"	C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-]	PLHJDBGFXBMTGZ-WEVVVXLNSA-N
DG00447	Cefpirome	5479539	"CEFPIROME; 84957-29-9; Cefpiroma; Cefpiromum; Cefrom; HR 810; UNII-S72Q2F09HY; cefpirome sulfate; CHEBI:3503; S72Q2F09HY; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; cefpirome sulphate; HR-810; (6R,7R)-7-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-(6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 5H-Cyclopenta[b]pyridinium,1-[[(6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-6,7-dihydro-, inner salt; Cefpiromum [Latin]; Cefpiroma [Spanish]; Cefpirome [INN:BAN]; NCGC00181339-01; Broact; Keiten; Cefir; Cefpirome (INN); Cefir (TN); HR-810 FREE BASE; SCHEMBL49406; MLS006010792; CHEMBL65794; DTXSID2048244; SCHEMBL22207951; C22H22N6O5S2; AKOS016013926; DB13682; (6R,7R)-7-(()-2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-8-oxo-3-(2beta-trimethylenpyridinio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carboxylat; 1-(((6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-6,7-dihydro-5H-1-pyridinium hydroxide, inner salt; 5H-1-Pyrindinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-6,7-dihydro-, hydroxide, inner salt, (6R-(6alpha,7beta(Z)))-; H828; SMR004701476; 98753-19-6; D07649; 1-{[(6R,7R)-2-carboxylato-7-{[(2Z)-1-hydroxy-2-(2-imino-2,3-dihydro-1,3-thiazol-4-yl)-2-(methoxyimino)ethylidene]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-5H,6H,7H-cyclopenta[b]pyridin-1-ium; 5H-1-Pyrindinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-5,6,7,8-tetrahydro-, hydroxide, inner salt, (6R-(6alpha,7beta(Z)))-; 7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-(6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB13682	.	DR2656	514.6	C22H22N6O5S2	208	955	0.9	35	2	10	6	"1S/C22H22N6O5S2/c1-33-26-15(13-10-35-22(23)24-13)18(29)25-16-19(30)28-17(21(31)32)12(9-34-20(16)28)8-27-7-3-5-11-4-2-6-14(11)27/h3,5,7,10,16,20H,2,4,6,8-9H2,1H3,(H3-,23,24,25,29,31,32)/b26-15-/t16-,20-/m1/s1"	CO/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCC5)C(=O)[O-]	DKOQGJHPHLTOJR-WHRDSVKCSA-N
DG00448	Amoxicillin/Clavulanic acid	6435924	"Amoxicillin + clavulanic acid; Amoxicillin and clavulanic acid; 79198-29-1; Amoxicillin + clavulinic acid; (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Amoksiclav; Amoxyclav; Synulox; Amox-clav; Amoxicillin clavulanate; Augmentin (free acid); Amoxicillin & Clavulanate; Amoxicillin clavulanate acid; Amoxicillin & Clavulanic acid; SCHEMBL591660; CHEMBL2097107; Amoxicillin-clavulanic acid mixt.; DTXSID80872429; Amoxicillin mixture with Clavulanate; Clavulanate mixture with amoxicillin; Clavulanic acid - amoxicillin mixt.; NCGC00188989-01; (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2R,3Z,5R)-, mixt. with (2S,5R,6R)-6-(((2R)-amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2R-(2alpha,3Z,5alpha))-, mixt. with (2S-(2alpha,5alpha,6beta(S*))-6-((amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	564.6	C24H28N4O10S	245	914	.	39	6	12	6	"1S/C16H19N3O5S.C8H9NO5/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7;10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24);1,6-7,10H,2-3H2,(H,12,13)/b;4-1-/t9-,10-,11+,14-;6-,7-/m11/s1"	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C.C1[C@@H]2N(C1=O)[C@H](/C(=C/CO)/O2)C(=O)O	QJVHTELASVOWBE-AGNWQMPPSA-N
DG00449	Angolamycin	6438267	"Angolamycin; 1402-83-1; 2-[(14E)-9-[5-(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-3-ethyl-7-hydroxy-2-[(5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl)oxymethyl]-8,12,16-trimethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadec-14-en-10-yl]acetaldehyde; BRN 6045489; Angolamycin, BRN 6045489; 2-[(14E)-9-[5-(4,5-dihydroxy-4,6-dimethyl-tetrahydropyran-2-yl)oxy-4-(dimethylamino)-6-methyl-tetrahydropyran-2-yl]oxy-3-ethyl-7-hydroxy-2-[(5-hydroxy-3,4-dimethoxy-6-methyl-tetrahydropyran-2-yl)oxymethyl]-8,12,16-trimethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadec-14-en-10-yl]acetaldehyde; 2-[(2E)-8-[5-(4,5-dihydroxy-4,6-dimethyl-oxan-2-yl)oxy-4-dimethylamino -6-methyl-oxan-2-yl]oxy-14-et"	Terminated	10	Discontinued Drug(s)	Terminated	Small molecular drug	.	.	.	.	916.1	C46H77NO17	231	1570	1.2	64	4	18	13	"1S/C46H77NO17/c1-13-33-29(22-57-44-41(56-12)40(55-11)37(52)25(4)60-44)43-46(8,64-43)16-14-31(49)23(2)18-28(15-17-48)38(24(3)32(50)20-34(51)61-33)62-35-19-30(47(9)10)39(26(5)58-35)63-36-21-45(7,54)42(53)27(6)59-36/h14,16-17,23-30,32-33,35-44,50,52-54H,13,15,18-22H2,1-12H3/b16-14+"	CCC1C(C2C(O2)(/C=C/C(=O)C(CC(C(C(C(CC(=O)O1)O)C)OC3CC(C(C(O3)C)OC4CC(C(C(O4)C)O)(C)O)N(C)C)CC=O)C)C)COC5C(C(C(C(O5)C)O)OC)OC	KZXDKUWSAVUSKI-JQIJEIRASA-N
DG00450	Rosaramicin	6537204	Rosaramicin; Juvenimicin A3; ROSAMICIN	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:87084	.	.	.	581.7	C31H51NO9	135	941	2.3	41	2	10	6	"1S/C31H51NO9/c1-9-25-20(5)29-31(6,41-29)12-10-23(34)17(2)14-21(11-13-33)28(19(4)24(35)16-26(36)39-25)40-30-27(37)22(32(7)8)15-18(3)38-30/h10,12-13,17-22,24-25,27-30,35,37H,9,11,14-16H2,1-8H3/b12-10+/t17-,18-,19+,20-,21+,22+,24-,25-,27-,28-,29+,30+,31+/m1/s1"	CC[C@@H]1[C@H]([C@H]2[C@@](O2)(/C=C/C(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)CC=O)C)C)C	IUPCWCLVECYZRV-JZMZINANSA-N
DG00451	Tulathromycin A	9832301	"Tulathromycin A; 217500-96-4; Tulathromycin; Draxxin; UNII-897A3KN7AP; 897A3KN7AP; (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-5-(propylaminomethyl)oxan-2-yl]oxy-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecan-15-one; Tulathrmycin A; yl)oxan-2-yl]oxy-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecan-15-one; (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-5-(propylaminometh; CP 472295; Tulathromycin A [USAN]; SCHEMBL14672085; DTXSID60274184; EX-A243; CHEBI:182495; AMY19375; Tulathromycin A, >=95% (HPLC); s3712; ZINC94313254; CCG-270497; CS-1622; DB11474; HY-15662; CP-472,295; A12279; C21788; T-8800; Tulathromycin A 100 microg/mL in Acetonitrile; 500T964; A849260; Q7851973; Tulathromycin, Antibiotic for Culture Media Use Only; UNII-Q839I13422 component GUARTUJKFNAVIK-QPTWMBCESA-N; (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2RChemicalbook,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-5-(propylaminomethyl)oxan-2-yl]oxy-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecan-15-one; (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-4-C-((propylamino)methyl)-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one; 1-Oxa-6-azacyclopentadecan-15-one, 13-((2,6-dideoxy-3-C-methyl-3-O-methyl-4-C-((propylamino)methyl)-alpha-l-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl)oxy)-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-; 1-OXA-6-AZACYCLOPENTADECAN-15-ONE,13-[[2,6-DIDEOXY-3-C-METHYL-3-O-METHYL-4-C-[(PROPYLAMINO)METHYL]-A-L-RIBO-HEXOPYRANOSYL]OXY]-2-ETHYL-3,4,10-TRIHYDROXY-3,5,8,10,12,14-HEXAMETHYL-11-[[3,4,6-TRIDEOXY-3-(DIMETHYLAMINO)-B-D-XYLO-HEXOPYRANOSYL]OXY]-, (2R,3S; 1-Oxa-6-azacyclopentadecan-15-one,13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-4-C-[(propylamino)methyl]-a-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11474	.	.	806.1	C41H79N3O12	201	1240	3.8	56	7	15	11	"1S/C41H79N3O12/c1-15-17-42-22-41(50)28(8)53-31(20-39(41,10)51-14)55-33-25(5)35(56-37-32(45)29(44(12)13)18-24(4)52-37)38(9,48)19-23(3)21-43-27(7)34(46)40(11,49)30(16-2)54-36(47)26(33)6/h23-35,37,42-43,45-46,48-50H,15-22H2,1-14H3/t23-,24-,25+,26-,27-,28+,29+,30-,31+,32-,33+,34-,35-,37+,38-,39-,40-,41+/m1/s1"	CCCNC[C@@]1([C@@H](O[C@H](C[C@@]1(C)OC)O[C@H]2[C@@H]([C@H]([C@](C[C@H](CN[C@@H]([C@H]([C@]([C@H](OC(=O)[C@@H]2C)CC)(C)O)O)C)C)(C)O)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)C)C)O	GUARTUJKFNAVIK-QPTWMBCESA-N
DG00452	Linopristin	9919429	"Linopristin; UNII-312V80FR4J; 325965-23-9; 312V80FR4J; Linopristin [INN]; DTXSID10186288; Q6554731; N-((6R,9S,10R,13S,15aS,22S,24aS)-22-((4-(dimethylamino)phenyl)methyl)-6-ethyl-10,23-dimethyl-18-((morpholin-4-yl)methyl)-5,8,12,15,21,24-hexaoxo-13-phenyl-1,2,3,5,6,7,8,9,10,11,12,13,14,15,15a,16,19,21,22,23,24,24a-docosahydropyrido(2,1-f)pyrrolo(2,1-l)(1,4,7,10,13,16)oxapentaazacyclononadecin-9-yl)-3-hydroxypyridine-2-carboxamide; N-((6R,9S,10R,13S,15aS,22S,24aS)-22-(4-(dimethylamino)benzyl)-6-ethyl-10,23-dimethyl-18-(morpholinomethyl)-5,8,12,15,21,24-hexaoxo-13-phenyl-1,2,3,5,6,7,8,9,10,13,14,15,15a,16,19,21,22,23,24,24a-icosahydro-12H-pyrido[2,1-f]pyrrolo[2,1-l][1]oxa[4,7,10,13,16]pentaazacyclononadecin-9-yl)-3-hydroxypicolinamide; N-[(3S,6S,12R,15S,16R,19S,22S)-3-[[4-(dimethylamino)phenyl]methyl]-12-ethyl-4,16-dimethyl-25-(morpholin-4-ylmethyl)-2,5,11,14,18,21-hexaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacos-24-en-15-yl]-3-hydroxypyridine-2-carboxamide"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	950.1	C50H63N9O10	223	1860	3.1	69	4	13	9	"1S/C50H63N9O10/c1-6-36-47(64)58-23-11-14-38(58)48(65)56(5)39(28-32-16-19-35(20-17-32)55(3)4)49(66)59-30-33(29-57-24-26-68-27-25-57)18-21-37(59)44(61)54-42(34-12-8-7-9-13-34)50(67)69-31(2)41(45(62)52-36)53-46(63)43-40(60)15-10-22-51-43/h7-10,12-13,15-20,22,31,36-39,41-42,60H,6,11,14,21,23-30H2,1-5H3,(H,52,62)(H,53,63)(H,54,61)/t31-,36-,37+,38+,39+,41+,42+/m1/s1"	CC[C@@H]1C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)N3CC(=CC[C@H]3C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CN6CCOCC6)CC7=CC=C(C=C7)N(C)C)C	NVGNYGXBILPHOS-VXNAYKIUSA-N
DG00454	6'-N-Ethylnetilmicin	15344654	6'-N-Ethylnetilmicin	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	503.6	C23H45N5O7	186	703	-3.3	35	8	12	10	"1S/C23H45N5O7/c1-5-27-10-12-7-8-13(24)21(33-12)34-18-14(25)9-15(28-6-2)19(16(18)29)35-22-17(30)20(26-4)23(3,31)11-32-22/h7,13-22,26-31H,5-6,8-11,24-25H2,1-4H3/t13-,14+,15-,16+,17-,18-,19+,20-,21-,22-,23+/m1/s1"	CCNCC1=CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)NCC)N)N	RZXCDENQJDMFQY-OLUUFXIRSA-N
DG00455	Lankamycin	15560071	"Lankamycin; UNII-68DQY2P51C; 30042-37-6; 68DQY2P51C; Kujimycin B; Lankavamycin; (2R,3S,4S,5R,7S,9S,10S,11R,12S,13R)-12-(((2R,4R,5R,6S)-5-acetoxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-7-hydroxy-10-(((2S,3R,4S,6R)-3-hydroxy-4-methoxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-((2S,3S)-3-hydroxybutan-2-yl)-3,5,7,9,11,13-hexamethyl-6,14-dioxooxacyclotetradecan-4-yl acetate; Antibiotic A-20338-N2; A-20338-N2; CHEBI:80017; Q27149163; [(2R,3S,4S,5R,7S,9S,10S,11R,12S,13R)-12-[(2R,4R,5R,6S)-5-acetyloxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-hydroxy-2-[(2S,3S)-3-hydroxybutan-2-yl]-10-[(2S,3R,4S,6R)-3-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-6,14-dioxo-oxacyclotetradec-4-yl] acetate"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	833	C42H72O16	212	1390	3.9	58	3	16	12	"1S/C42H72O16/c1-19-17-41(12,49)37(47)24(6)35(54-28(10)44)23(5)34(21(3)26(8)43)57-39(48)25(7)36(22(4)33(19)58-40-32(46)30(50-14)16-20(2)52-40)56-31-18-42(13,51-15)38(27(9)53-31)55-29(11)45/h19-27,30-36,38,40,43,46,49H,16-18H2,1-15H3/t19-,20+,21-,22+,23-,24+,25+,26-,27-,30-,31-,32+,33-,34+,35-,36-,38+,40-,41-,42+/m0/s1"	C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@](C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]3C[C@@]([C@@H]([C@@H](O3)C)OC(=O)C)(C)OC)C)[C@@H](C)[C@H](C)O)C)OC(=O)C)C)(C)O)C)O)OC	JQMACDQCTNFQMM-QAOHEUSVSA-N
DG00456	Sodium deoxycholate	23668196	"Sodium deoxycholate; 302-95-4; Deoxycholic acid sodium salt; Sodium desoxycholate; Deoxycholate sodium; Desoxycholate sodium; Sodium 7-deoxycholate; Deoxycholic acid, sodium salt; UNII-436LS6U35Y; 7-Deoxycholic acid sodium salt; CHEBI:9177; 3-alpha,12-alpha-Dihydroxy-5-beta-cholan-24-oic acid sodium salt; 436LS6U35Y; MFCD00064139; NCGC00091038-01; ATX 101; Cholan-24-oic acid, 3,12-dihydroxy-, monosodium salt, (3a,5b,12a)-; 3,12-Dihydroxy-cholan-24-oic acid monosodium salt, (3-alpha,5-beta,12-alpha)- (9CI); DSSTox_CID_13389; DSSTox_RID_79069; DSSTox_GSID_33389; Sodium deoxycholic acid; Na-Desoxycholat; Na-Desoxycholat [German]; Sodiumdeoxycholate; CAS-302-95-4; CCRIS 655; Deoxycholic acid sodium salt monohydrate; Desoxycholic acid sodium salt; EINECS 206-132-7; sodium (3alpha,5beta,12alpha)-3,12-dihydroxycholan-24-oate; Dihydroxy 3-12 cholanate de Na [French]; Dihydroxy 3-12 cholanate de Na; Natrium-3-alpha,12-alpha-dihydroxycholanat [German]; deoxycholic acid sodium; Sodium 3-alpha,12-alpha-dihydroxy-5-beta-cholan-24-oate; Natrium-3-alpha,12-alpha-dihydroxycholanat; 145224-92-6; SCHEMBL37482; MLS002695906; 3alpha,12alpha-Dihydroxy-5beta-cholanic acid sodium salt; CHEMBL1365278; DTXSID5033389; HY-N0593A; Deoxycholic acid sodium salt hydrate; Tox21_111066; Tox21_200896; 5-beta-Cholan-24-oic acid, 3-alpha,12-alpha-dihydroxy-, sodium salt; AKOS002391107; AKOS017345123; CS-8046; NSC 681065; Cholan-24-oic acid, 3,12-dihydroxy-, monosodium salt, (3alpha,5beta,12alpha)-; NCGC00258450-01; AC-24206; BP-31018; O134; SMR001562102; Sodium deoxycholate, >=97% (titration); 68512-EP2275413A1; 68512-EP2308855A1; Deoxycholic acid sodium salt, for electrophoresis; Sodium 3- ,12- -dihydroxy-5- -cholan-24-oate; Q-200935; Q25474151; sodium 3alpha,12alpha-dihydroxy-5beta-cholan-24-oate; Sodium deoxycholate, Vetec(TM) reagent grade, >=97%; Sodium deoxycholate, BioXtra, >=98.0% (dry matter, NT); Cholan-24-oic acid, 3,12-dihydroxy-, monosodium salt, (3-alpha,5-beta,12-alpha)- (9CI); Sodium deoxycholate, Suitable for manufacturing of diagnostic kits and reagents; sodium (4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate; Sodium deoxycholate, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production; sodium(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate; Sodium;(4R)-4-[(3R,5R,10S,12S,13R,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate; sodium;(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	414.6	C24H39NaO4	80.6	612	.	29	2	4	4	"1S/C24H40O4.Na/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3;/h14-21,25-26H,4-13H2,1-3H3,(H,27,28);/q;+1/p-1/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-;/m1./s1"	C[C@H](CCC(=O)[O-])[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C.[Na+]	FHHPUSMSKHSNKW-SMOYURAASA-M
DG00457	Arylomycin C16	54586211	Arylomycin C16; CHEMBL1784531; SCHEMBL14234622; BDBM50441139	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	881.1	C46H68N6O11	255	1500	6.4	63	8	11	23	"1S/C46H68N6O11/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-39(56)51(4)36(28-53)44(60)48-29(2)42(58)47-27-40(57)52(5)41-32-21-23-38(55)34(26-32)33-24-31(20-22-37(33)54)25-35(46(62)63)50-43(59)30(3)49-45(41)61/h20-24,26,29-30,35-36,41,53-55H,6-19,25,27-28H2,1-5H3,(H,47,58)(H,48,60)(H,49,61)(H,50,59)(H,62,63)/t29-,30+,35+,36-,41+/m1/s1"	CCCCCCCCCCCCCCCC(=O)N(C)[C@H](CO)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@H]1C2=CC(=C(C=C2)O)C3=C(C=CC(=C3)C[C@H](NC(=O)[C@@H](NC1=O)C)C(=O)O)O	HGWCKYGOWQEYSJ-JBWZRHCTSA-N
DG00459	Corticostatin	56841867	"Corticostatin; 68563-24-6; 113255-28-0; (7-28)-Corticotropin; Acth(7-38); Defensin; Acth (7-38); Corticostatin-I; Corticotripin-inhibiting peptide; Corticotropin-inhibiting peptide; CIP peptide; ACTH (7-38) (human); Corticotropin-Inhibiting Peptide (CIP); FRWGKPVGKKRRPVKVYPNGAEDESAEAFPLE-OH; 103220-14-0; alpha7-38-Corticotropin (pig), 31-L-serine-; H-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-OH"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	3659.1	C167H257N47O46	1510	8780	-18.5	260	51	54	120	"1S/C167H257N47O46/c1-87(2)75-113(150(245)200-112(164(259)260)59-63-131(227)228)203-153(248)120-48-31-73-213(120)162(257)117(77-95-37-16-13-17-38-95)205-138(233)93(11)188-142(237)107(56-60-128(221)222)192-137(232)92(10)189-152(247)119(86-215)207-148(243)109(58-62-130(225)226)197-151(246)116(81-132(229)230)202-147(242)108(57-61-129(223)224)193-136(231)91(9)187-125(218)83-184-141(236)115(80-124(173)217)204-154(249)121-49-32-74-214(121)163(258)118(78-96-52-54-98(216)55-53-96)206-159(254)134(89(5)6)208-149(244)104(43-22-26-66-170)198-158(253)135(90(7)8)210-156(251)123-51-34-72-212(123)161(256)111(47-30-70-182-167(178)179)199-145(240)106(46-29-69-181-166(176)177)196-144(239)103(42-21-25-65-169)195-143(238)102(41-20-24-64-168)190-126(219)85-186-157(252)133(88(3)4)209-155(250)122-50-33-71-211(122)160(255)110(44-23-27-67-171)191-127(220)84-185-140(235)114(79-97-82-183-101-40-19-18-39-99(97)101)201-146(241)105(45-28-68-180-165(174)175)194-139(234)100(172)76-94-35-14-12-15-36-94/h12-19,35-40,52-55,82,87-93,100,102-123,133-135,183,215-216H,20-34,41-51,56-81,83-86,168-172H2,1-11H3,(H2,173,217)(H,184,236)(H,185,235)(H,186,252)(H,187,218)(H,188,237)(H,189,247)(H,190,219)(H,191,220)(H,192,232)(H,193,231)(H,194,234)(H,195,238)(H,196,239)(H,197,246)(H,198,253)(H,199,240)(H,200,245)(H,201,241)(H,202,242)(H,203,248)(H,204,249)(H,205,233)(H,206,254)(H,207,243)(H,208,244)(H,209,250)(H,210,251)(H,221,222)(H,223,224)(H,225,226)(H,227,228)(H,229,230)(H,259,260)(H4,174,175,180)(H4,176,177,181)(H4,178,179,182)/t91-,92-,93-,100-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,133-,134-,135-/m0/s1"	C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC9=CC=CC=C9)N	ZKALIGRYJXFMNS-XBDDSDALSA-N
DG00460	Lincosamides	56842237	Lincosamides; D055231000	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	831.5	C36H67ClN4O11S2	275	1000	.	54	9	15	14	"1S/C18H33ClN2O5S.C18H34N2O6S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4;1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25);9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9 ,10-,11+,12 ,13+,14-,15-,16-,18-;9-,10-,11+,12-,13+,14-,15-,16-,18-/m11/s1"	CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O.CCC[C@@H]1C[C@H](N(C1)C)C(=O)NC([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)C(C)Cl	MMYMXHAXTQPVRO-DGXIQQDPSA-N
DG00461	Insulin	.	"BrioDurance; Insulin (agglomerated vesicle technology, diabetes), Cense Biosciences; Insulin (subcutaneous/nanoparticle/suspension/sustained release formulation, diabetes); Insulin (subcutaneous/nanoparticle/suspension/sustained release formulation, diabetes), Cense Biosciences"	Approved	1	Approved Drug(s)	Approved	Hormones/Insulins	.	DB00030	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00462	Niclosamide	4477	"Niclosamide; 50-65-7; 5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide; Niclocide; Bayluscid; Phenasal; Tredemine; Fenasal; Yomesan; Dichlosale; Helmiantin; Atenase; Cestocid; Devermin; Devermine; Iomesan; Iomezan; Mansonil; Radeverm; Sagimid; Vermitid; Lintex; Nasemo; Sulqui; Mato; Fedal-Telmin; Bayer 73; Zestocarp; Bayer 2353; 2',5-Dichloro-4'-nitrosalicylanilide; BAY 2353; Chemagro 2353; Benzamide, 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-; C13H8Cl2N2O4; 5-Chloro-2'-chloro-4'-nitrosalicylanilide; nicolsamide; HL 2447; WR 46234; UNII-8KK8CQ2K8G; ENT 25823; 2-Hydroxy-5-chloro-N-(2-chloro-4-nitrophenyl)benzamide; N-(2-Chloro-4-nitrophenyl)-5-chlorosalicylamide; Niclosamide Anhydrous; 2-Chloro-4-nitrophenylamide-6-chlorosalicylic acid; Salicylanilide, 2',5-dichloro-4'-nitro-; 2',5-Dichlor-4'-nitro-salizylsaeureanilid; 5-Chloro-N-(2'-chloro-4'-nitrophenyl)salicylamide; 8KK8CQ2K8G; SR 73; Radewerm; N-(2'-Chlor-4'-nitrophenyl)-5-chlorsalicylamid; MFCD00057597; NSC-178296; CAS-50-65-7; NCGC00015735-07; DSSTox_CID_20362; DSSTox_RID_79485; DSSTox_GSID_40362; N-(2'-Chloro-4'-nitrophenyl)-5-chlorosalicylamide; Niclosamida; Niclosamidum; Cestocide; Niclosamidum [INN-Latin]; Niclosamida [INN-Spanish]; Nitrophenyl chlorsalicylamide; Niclosamide [USAN:INN:BAN]; CCRIS 3437; HSDB 1572; SR-01000076024; Niclosamide [BSI:ISO]; EINECS 200-056-8; NSC 178296; BRN 2820605; Yomensan; niclo-samide; AI3-25823; 5-Chlorosalicyloyl-(o-chloro-p-nitranilide); B 2353; Niclocide (TN); Prestwick_354; 2',5-Dichlor-4'-nitro-salizylsaeureanilid [German]; Niclosamidum anhydrous; Mollutox (Salt/Mix); Niclosamide, anhydrous; N-(2'-Chlor-4'-nitrophenyl)-5-chlorsalicylamid [German]; Spectrum_000239; Niclosamide (anhydrous); Niclosamide (Niclocide); Clonitralid (Salt/Mix); Clonitralide (Salt/Mix); Prestwick0_000040; Prestwick1_000040; Prestwick2_000040; Prestwick3_000040; Spectrum2_001183; Spectrum3_000667; Spectrum4_000196; Spectrum5_001083; Lopac-N-3510; Niclosamide (USAN/INN); CHEMBL1448; Lopac0_000866; Oprea1_259151; SCHEMBL67182; BSPBio_000139; BSPBio_002333; KBioGR_000771; KBioSS_000719; MLS002154181; DivK1c_000709; SPECTRUM1503265; SPBio_001225; SPBio_002060; BPBio1_000153; CHEBI:7553; GTPL8494; DTXSID7040362; SCHEMBL18563900; WLN: WNR CG DMVR BQ EG; BDBM11242; HMS502D11; KBio1_000709; KBio2_000719; KBio2_003287; KBio2_005855; KBio3_001553; 5-Chloro-N-(2-chloro-4-nitro-phenyl)-2-hydroxy-benzamide; Niclosamide - CAS 50-65-7; NINDS_000709; BDBM513089; HMS1568G21; HMS2093A21; HMS2095G21; HMS2231H06; HMS3262N13; HMS3373P08; HMS3712G21; KUC107299N; Pharmakon1600-01503265; BAY-2353; BCP22958; HY-B0497; ZINC3874496; Tox21_110209; Tox21_300749; Tox21_500866; BBL004110; CCG-39641; NSC178296; NSC758440; s3030; Salicylanilide,5-dichloro-4'-nitro-; STK396676; 2,5-dichloro-4-nitrosalicylanilide  ; AKOS003589004; Tox21_110209_1; AT15436; BCP9000068; DB06803; KS-5210; LP00866; MCULE-9985514311; NSC-758440; SB19414; SDCCGSBI-0050841.P004; 2',5'-Dichloro-4'-nitrosalicylanilide; IDI1_000709; SMP2_000228; 5-chloro-N-(2-chloro-4-nitrophenyl)-; NCGC00015735-01; NCGC00015735-02; NCGC00015735-03; NCGC00015735-04; NCGC00015735-05; NCGC00015735-06; NCGC00015735-08; NCGC00015735-09; NCGC00015735-11; NCGC00015735-12; NCGC00015735-24; NCGC00094190-01; NCGC00094190-02; NCGC00094190-03; NCGC00094190-04; NCGC00254654-01; NCGC00261551-01; I012; KSC-18-157-2; SMR000058390; Niclosamide 100 microg/mL in Acetonitrile; SBI-0050841.P003; AB0013423; DB-051812; VU0243604; AB00052340; EU-0100866; FT-0603220; EN300-92958; D00436; N 3510; AB00052340_08; AB00052340_09; A828227; Q418523; Q-201469; SR-01000076024-1; SR-01000076024-3; SR-01000076024-6; BRD-K35960502-001-06-9; BRD-K35960502-001-11-9; Z57902203; 5-Chloro-N-(2-chloro-4-nitrophenyl) -2-hydroxybenzamide; 5-chloranyl-N-(2-chloranyl-4-nitro-phenyl)-2-oxidanyl-benzamide; Niclosamide (anhydrous), European Pharmacopoeia (EP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB06803	.	.	327.12	C13H8Cl2N2O4	95.2	404	4	21	2	4	2	"1S/C13H8Cl2N2O4/c14-7-1-4-12(18)9(5-7)13(19)16-11-3-2-8(17(20)21)6-10(11)15/h1-6,18H,(H,16,19)"	C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O	RJMUSRYZPJIFPJ-UHFFFAOYSA-N
DG00463	Anastrazola/Goserelin	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00464	Carboplatin/Liposomal doxorubicin	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00465	Carboplatin/Paclitaxel	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00466	Cefoxitin/Clavulanate	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00467	Cefoxitin/Sulbactam	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00468	Cefoxitin/Tazobactam	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00469	Ceftazidime/Cloxacillin	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00470	Dapsone/Rifampin	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00471	Exemestane/Everolimus	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00472	Gefitinib/Pemetrexed	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00473	Lapatinib/Capecitabine	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00474	Rituximab/Doxorubicin	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00475	Tamoxifen/Goserelin	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00476	Tamoxifen/Trastuzumab	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00477	6-N-ethyl-netilmicin	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00478	Anti-EGFR treatment	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00479	Bacitracin methylene disalicylate	11980094	"Bacitracin methylene disalicylate; Bacitracin methylene disalicylate; 55852-84-1; MD bacitracin; Kemitracin 10; Caswell No. 066D; Fortracin (bacitracin-MD); Bacitracin, methylenebis(2-hydroxybenzoate); Bacitracin methylenedisalicylate; Bacitracin methylenedisalicylic acid; EINECS 259-862-3; Methylenebis(2-hydroxybenzoate)bacitracin; Bacitracin, methylenebis(2-hydroxybenzoate) (salt)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00626	.	.	1729	C81H117N17O23S	683	3170	.	122	20	29	54	"1S/C66H105N17O17S.C15H12O6/c1-9-35(6)52(70)65-81-48(32-101-65)62(96)76-43(26-34(4)5)58(92)74-42(22-23-50(85)86)57(91)83-53(36(7)10-2)63(97)75-40(20-15-16-24-67)55(89)73-41(21-17-25-68)56(90)82-54(37(8)11-3)64(98)79-44(27-38-18-13-12-14-19-38)59(93)77-45(28-39-31-71-33-72-39)60(94)78-46(30-51(87)88)61(95)80-47(66(99)100)29-49(69)84;16-12-7-3-1-5-10(12)14(18)20-9-21-15(19)11-6-2-4-8-13(11)17/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67-68,70H2,1-8H3,(H2,69,84)(H,71,72)(H,73,89)(H,74,92)(H,75,97)(H,76,96)(H,77,93)(H,78,94)(H,79,98)(H,80,95)(H,82,90)(H,83,91)(H,85,86)(H,87,88)(H,99,100);1-8,16-17H,9H2/t35 ,36-,37-,40-,41+,42+,43-,44+,45-,46+,47-,48 ,52 ,53-,54-;/m0./s1"	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C3CSC(=N3)C(C(C)CC)N.C1=CC=C(C(=C1)C(=O)OCOC(=O)C2=CC=CC=C2O)O	.
DG00480	BPI-derived peptide P2	.	.	Terminated	10	Discontinued Drug(s)	Terminated	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00481	Cefametazole	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00482	Ciprofloxacin	2764	Ciprofloxacin; 85721-33-1; Ciprofloxacine; Ciprobay; Ciproxan; Ciprofloxacina; Ciprofloxacinum; Ciprofloxacino; Cipro IV; Ciproxina; Ciprinol; Bernoflox; Ciprodar; Cifloxin; Septicide; Bacquinor; Ciproquinol; Cipromycin; Ciprocinol; Cipro XR; Superocin; Ciprowin; Ciprolon; Ciproflox; Ciprecu; BAY q 3939; Spitacin; Quintor; Quinolid; Proflaxin; Probiox; Ipiflox; Zumaflox; Ciproxine; Ciprolin; Roxytal; Italnik; Fimoflox; Corsacin; Citopcin; Ciprogis; Rancif; Ciriax; Ciplus; Baflox; Loxan; Cilab; Cycin; Cixan; Unex; GW1843; Ciprofloxacin Hydrochloride; Ciprofloxacin intratympanic - Otonomy	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:100241	DB00537	DR00783	DR2273	331.34	C17H18FN3O3	72.9	571	-1.1	24	2	7	3	"1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)"	C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O	MYSWGUAQZAJSOK-UHFFFAOYSA-N
DG00483	Cortiosteroids	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00484	Elfamycin	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00485	FGFR inhibitors	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00486	Fluoroquinolone	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00487	Fluoroquinolones	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00488	Gefitinib/S-1	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00489	HER2 inhibitors	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00490	Huaier	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00491	Huaier extract	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00492	Moenomycin	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00493	Moenomycin A	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00494	MPA	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00495	Oncolytic vaccinia virus	.	.	Phase 2	7	Clinical Trial Drug(s)	Phase 2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00496	Pristinamycin I	.	.	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00497	Purine analogues	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00498	RAWQ01	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00499	Sulfamethizole/Sulfadiazine	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00500	Sulphonamides	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00501	Tetracycline/Minocycline	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00502	TKIS	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00503	TRAIL	.	Tumor necrosis factor-related apoptosis-inducing ligand	phase 3	5	Clinical Trial Drug(s)	phase 3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00504	Tunicamycin	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	DB13172	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00505	SARS-CoV-2-neutralizing antibody S2E12	.	SARS-CoV-2-neutralizing antibody S2E12; mAbS2E12	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00506	COV2-2196	.	COV2-2196	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00507	COV2-3025	.	COV2-3025	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00508	COV2-2381	.	COV2-2381	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00509	SARS-CoV-2-neutralizing antibody S2H58	.	SARS-CoV-2-neutralizing antibody S2H58; S2H58; mAbS2H58	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00510	COV2-2050	.	COV2-2050	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00511	SARS-CoV-2-neutralizing antibody 1B07	.	SARS-CoV-2-neutralizing antibody 1B07; 1B07; mAb1B07	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00512	COVOX-384	.	COVOX-384	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00513	SARS-CoV-2-neutralizing antibody SARS2-10	.	SARS-CoV-2-neutralizing antibody SARS2-10; SARS2-10; mAbSARS2-10	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00514	COVOX-40	.	COVOX-40	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00515	SARS-CoV-2-neutralizing antibody 5-24	.	SARS-CoV-2-neutralizing monoclonal antibody 5-24; 5-24; mAb5-24	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00516	SARS-CoV-2-neutralizing antibody 4-8	.	SARS-CoV-2-neutralizing monoclonal antibody 4-8; 4-8; mAb4-8	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00517	SARS-CoV-2-neutralizing antibody 4A8	.	SARS-CoV-2-neutralizing antibody 4A8; mAb4A8	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00518	SARS-CoV-2-neutralizing antibody 2-17	.	SARS-CoV-2-neutralizing monoclonal antibody 2-17; 2-17; mAb2-17	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00519	SARS-CoV-2-neutralizing antibody 4-19	.	SARS-CoV-2-neutralizing monoclonal antibody 4-19; 4-19; mAb4-19	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00520	SARS-CoV-2-neutralizing antibody 5-7	.	SARS-CoV-2-neutralizing monoclonal antibody 5-7; 5-7; mAb5-7	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00521	Casirivimab	.	Casirivimab; REGN10933	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	DB15941	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00522	SARS-CoV-2-neutralizing antibody 910-30	.	SARS-CoV-2-neutralizing antibody 910-30; mAb910-30	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00523	SARS-CoV-2-neutralizing antibody 2-15	.	SARS-CoV-2-neutralizing monoclonal antibody 2-15; 2-15; mAb 2-15	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00524	Bamlanivimab	.	LY-CoV555; LY3819253	Phase 4	4	Approved Drug(s)	Phase 4	Monoclonal antibody	.	DB15718	.	.	146000	C6498H10068N1732O2032S46	.	.	.	.	.	.	.	.	.	.
DG00525	SARS-CoV-2-neutralizing antibody C121	.	SARS-CoV-2-neutralizing antibody C121; C121; mAbC121	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00526	Tocilizumab	.	Atlizumab; ocilizumab	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	DB06273	.	.	148000	C6428H9976N1720O2018S42	.	.	.	.	.	.	.	.	.	.
DG00527	Tixagevimab/Cilgavimab	.	.	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	DB16394; DB16393	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00528	Sarilumab	.	REGN88; SAR153191; Sarilumab	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	DB11767	.	.	150000	C6388H9918N1718O1998S44	.	.	.	.	.	.	.	.	.	.
DG00529	Casirivimab/Imdevimab	.	.	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	DB15941;DB15940	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00530	Canakinumab	.	ACZ-885; ACZ885	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	DB06168	.	.	145200	C6452H9958N1722O2010S42	.	.	.	.	.	.	.	.	.	.
DG00531	Anakinra	.	Anakinra; IL-1RA; Interleukin-1 receptor antagonist anakinra	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	DB00026	.	.	17257.6	.	.	.	.	.	.	.	.	.	.	.
DG00532	Remdesivir	121304016	"1809249-37-3; 3QKI37EEHE; GS 5734; GS 5734 [WHO-DD]; GS-5734; GS5734; Remdesivir; REMDESIVIR [INN]; Remdesivir [USAN]; REMDESIVIR [WHO-DD]; remdesivirum; UNII-3QKI37EEHE; Veklury; 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate; 2-Ethylbutyl (2S)-2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate; 2-ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate; Veklury (TN); Remdesivir (JAN/USAN); Remdesivir (GS-5734); CHEMBL4065616; SCHEMBL17712225; GTPL10715; med.21724, Compound 178; CHEBI:145994; BDBM429505; EX-A3265; MFCD31657351; NSC825151; s8932; AT11308; BCP24975-1; DB14761; DT-0049; NSC-825151; compound 4b [PMID: 28124907]; NCGC00686694-01; 2-ethylbutyl (2S)-2-(((2R, 3S, 4R, 5R)-5-(4-aminopyrrolo(2,1-f) (1,2,4)triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl) methoxy)(phenoxy) phosphoryl) amino) propanoate; AC-31297; GS- 5734; L-Alanine, N-((S)-hydroxyphenoxyphosphinyl)-, 2-ethylbutyl ester, 6-ester with 2-C-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2,5-anhydro-D-altrononitrile; HY-104077; CS-0028115; D11472; (2S)-2-{(2R,3S,4R,5R)-[5-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]phenoxy-(S)-phosphorylamino}propionic acid 2-ethyl-butyl ester; (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate; (S)-2-Ethylbutyl 2-((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; 2-ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-{4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl}-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate; 2-ethylbutyl N-[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]-L-alaninate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB14761	.	.	602.6	C27H35N6O8P	204	1010	1.9	42	4	13	14	"1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1"	CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4	RWWYLEGWBNMMLJ-YSOARWBDSA-N
DG00534	Molnupiravir	145996610	"EIDD 2801; EIDD-2801; EIDD2801; molnupiravir; 2349386-89-4; MK-4482; UNII-YA84KI1VEW; YA84KI1VEW; Eidd 1931-isopropyl ester; Molnupiravir [USAN]; ((2R,3S,4R,5R)-3,4-Dihydroxy-5-(4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate; [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate; 2492423-29-5; WHO 11853; ((2R,3S,4R,5R)-3,4-Dihydroxy-5-(4-(hydroxyamino)-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate; molnupiravirum; Lagevrio; Molnupiravir [INN]; Molnupiravir [WHO-DD]; pro-EIDD-1931; EIDD-2801(Molnupiravir); CHEMBL4650320; EIDD 1931 5'-isopropylester; GTPL10737; med.21724, Compound 182; CHEBI:180653; BDBM429508; BCP32744; EX-A3432; MFCD32663515; MK4482; s8969; AT13078; N(4)-hydroxycytidine 5'-isopropylester; N4-Hydroxycytidine, 5'-isopropyl ester; AC-35171; CS-0114880; beta-D-N4 Hydroxycytidine-5'-isopropyl ester; beta-D-N(4)-hydroxycytidine-5'-isopropyl ester; A936190; Uridine, 4-oxime, 5'-(2-methylpropanoate), (4Z)-; N-hydroxy-5'-O-(2-methylpropanoyl)-3,4-dihydrocytidine; EIDD 2801; EIDD2801; Uridine, 4-oxime, 5'-(2-methylpropanoate; ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((4Z)-4-(hydroxyimino)-2-oxo-3,4- dihydropyrimidin-1(2H)-yl)oxolan-2-yl)methyl 2-methylpropanoate; ((2R,3S,4R,5R)-3,4-dihydroxy-5-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate; {(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl]tetrahydrofuran-2-yl}methyl 2-methylpropanoate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB15661	.	.	329.31	C13H19N3O7	141	534	-0.8	23	4	7	6	"1S/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)16-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H,14,15,20)/t7-,9-,10-,11-/m1/s1"	CC(C)C(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)NO)O)O	HTNPEHXGEKVIHG-QCNRFFRDSA-N
DG00535	SARS-CoV-2-neutralizing antibody SARS2-31	.	SARS-CoV-2-neutralizing antibody SARS2-31; SARS2-31; mAbSARS2-31	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00536	Sotrovimab	.	Sotrovimab	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	DB16355	.	.	149000	.	.	.	.	.	.	.	.	.	.	.
DG00537	Favipiravir	492405	"Favipiravir; 259793-96-9; 6-FLUORO-3-HYDROXYPYRAZINE-2-CARBOXAMIDE; T-705; 6-fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide; avigan; Favipiravir (T-705); 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide; T 705; UNII-EW5GL2X7E0; Pyrazinecarboxamide, 6-fluoro-3,4-dihydro-3-oxo-; 6-fluoro-3-hydroxy-pyrazine-2-carboxamide; Favipiravir; T-705; EW5GL2X7E0; T705; MFCD12032148; 2-Pyrazinecarboxamide, 6-fluoro-3-hydroxy-; 6-Fluoro-3,4-dihydro-3-oxo-2-pyrazinecarboxamide; T-705 cpd; Fapilavir; Favilavir; Favipiravir [USAN:INN:JAN]; Avigan (TN); SCHEMBL587913; Favipiravir (JAN/USAN/INN); AMPZ0004; CHEMBL221722; SCHEMBL15157866; GTPL11139; AOB2076; DTXSID60948878; CHEBI:134722; BCPP000056; BCP02422; EX-A2285; BBL104098; QC-771; s7975; STL557913; ZINC13915654; AKOS005166863; AKOS015995178; ZINC584639712; ZINC584639713; ACN-041491; CCG-266269; CS-0612; DB12466; PB25591; NCGC00373041-03; NCGC00373041-06; AC-28900; DA-19682; HY-14768; MS-20791; SY110833; AM20080851; FT-0686297; FT-0701282; A25520; D09537; 6-fluoro-3,4-dihydro-3-oxo-Pyrazinecarboxamide; 793P969; A902150; J-518718; T 705,CAS;259793-96-9; Q16934561"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB12466	.	.	157.1	C5H4FN3O2	84.6	282	-0.6	11	2	4	1	"1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)"	C1=C(N=C(C(=O)N1)C(=O)N)F	ZCGNOVWYSGBHAU-UHFFFAOYSA-N
DG00538	Baricitinib	44205240	"Baricitinib; 1187594-09-7; INCB028050; olumiant; LY3009104; 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile; INCB 028050; INCB-028050; 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile; LY-3009104; UNII-ISP4442I3Y; Baricitinib (LY3009104, INCB028050); ISP4442I3Y; 2-[1-ETHYLSULFONYL-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PYRAZOL-1-YL]AZETIDIN-3-YL]ACETONITRILE; LY 3009104; LY3009104 (phosphate);INCB028050 (phosphate); C16H17N7O2S; 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-; Baricitinib [USAN:INN]; INCB 28050; Olumiant (TN); 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]-; 3JW; MLS006011247; SCHEMBL871150; Baricitinib (JAN/USAN/INN); Baricitinib (LY3009104); Baricitinib (INCB028050); GTPL7792; CHEMBL2105759; AMMD00005; CHEBI:95341; DTXSID30152228; EX-A413; QCR-197; HMS3651L17; HMS3672M15; HMS3747G21; AOB87724; BCP04686; BDBM50021656; MFCD21608464; NSC799357; s2851; ZINC73069247; AKOS022186127; AKOS025401933; AM81232; BCP9000380; CCG-268312; CS-0724; DB11817; DS-7641; NSC-799357; PB27275; SB10845; NCGC00345839-01; NCGC00345839-14; NCGC00345839-16; 2-(3-(4-(3H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile; AC-27404; HY-15315; SMR004703006; BCP0726000031; AB0035958; Baricitinib (INCB28050, LY3009104); FT-0775037; SW220096-1; Y0439; D10308; A892931; J-503551; Q4860707; (1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)ethanenitrile; {1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile; INCB 28050; INCB28050; LY-3009104;1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile; INCB-028050; ; ; LY-3009104; ; ; 2-[1-Ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11817	.	.	371.4	C16H17N7O2S	129	678	-0.5	26	1	7	5	"1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)"	CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3	XUZMWHLSFXCVMG-UHFFFAOYSA-N
DG00539	Nirmatrelvir/Ritonavir	.	.	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB16691; DB00503	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00540	Gemtuzumab ozogamicin	.	Gemtuzumab ozogamicin	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	DB00056	.	.	150500	.	.	.	.	.	.	.	.	.	.	.
DG00541	Brentuximab vedotin	.	"Brentuximab; Brentuximab vedotin; Brentuximab vedotin brentuximab; Brentuximab vedotina; cAC10-vcMMAE; Moab, chimeric, SGN-30, to CD30 antigen; Monoclonal antibody SGN-30"	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	DB08870	.	.	.	C6476H9930N1690O2030S40	.	.	.	.	.	.	.	.	.	.
DG00542	Inotuzumab ozogamicin	.	Inotuzumab ozogamicin	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	DB05889	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00543	Loncastuximab tesirine	.	Loncastuximab tesirine; loncastuximab tesirine-lpyl	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	DB16222	.	.	151000	.	.	.	.	.	.	.	.	.	.	.
DG00544	Erlotinib HCI	176871	"Erlotinib hydrochloride; 183319-69-9; erlotinib HCl; Tarceva; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride; OSI-774; OSI 774; Erlotinib (Hydrochloride); CP 358774; CP-358774; UNII-DA87705X9K; erlotinib, hydrochloride salt; Erlotinib HCl (OSI-744); Tarceva (Erlotinib Hydrochloride); NSC 718781; DA87705X9K; 6,7-bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline hydrochloride; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;hydrochloride; MFCD07781272; 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, hydrochloride (1:1); NSC-718781; 6,7-bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline hcl; 183319-69-9 (HCl); CP-358,774-01; C22H24ClN3O4; [6,7-BIS-(2-METHOXY-ETHOXY)-QUINAZOLIN-4-YL]-(3-ETHYNYL-PHENYL)-AMINE HYDROCHLORIDE; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine Monohydrochloride.; CHEBI:53509; OSI-744; SMR002529980; NSC718781; 4-(m-Ethynylanilino)-6,7-bis(2-methoxyethoxy)quinazoline monohydrochloride; RG-1415; 183319-69-9 pound not183321-74-6; R-1415; Erlotinib, HCl; erlotinib hcl salt; Erlotinib hydrochloride [USAN:INN]; Tarceva (OSI); tarceva hydrochloride; erlotonib hydrochloride; Erlotinib hydrochlroide; Erlotinib(OSI-744); MLS003899192; MLS004774139; C22H23N3O4.HCl; CHEMBL1079742; NSC 718781) HCl; DTXSID10171412; EX-A064; SYN1039; Erlotinib Hydrochloride (Tarceva); BCPP000238; AOB87784; BCP02600; AC-400; CP-358; s1023; AKOS015849087; BCP9000658; CCG-269002; CS-0123; KS-1202; MCULE-9498970160; PB30965; SB16917; 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride; Ro-50-8231; BE164421; BP-30224; HY-12008; M375; (CP358774; DB-011534; AM20090622; FT-0651479; EC-000.2313; CP-358774-01; E-4007; J10200; 319E699; Q27124083; F0001-2385; Erlotinib Hydrochloride,CP-358774, OSI-774, NSC 718781; 6,7-Bis-(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline hydrochloride; [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl- phenyl)amine hydrochloride; N-(3-Ethynylphenyl)-6,7-bis(1-methoxyethoxy)-4-quinazolinamine hydrochloride; N-(3-ETHYNYLPHENYL)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, monohydrochloride; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-quinazolin-4-amine hydrochloride"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	DR0603	429.9	C22H24ClN3O4	74.7	525	.	30	2	7	11	"1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H"	COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC.Cl	GTTBEUCJPZQMDZ-UHFFFAOYSA-N
DG00545	PKI-587	44516953	"Gedatolisib; 1197160-78-3; PKI-587; PF-05212384; PKI 587; PKI587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); PKI-587; PF-05212384; 1-(4-((4-(dimethylamino)piperidin-1-yl)carbonyl)phenyl)-3-(4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl)urea; Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-; Gedatolisib [USAN:INN]; 1-(4-{[4-(Dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; Urea, N-[4-[[4-(dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]-; PK 587; PK 1587; Gedatolisib(PKI-587); Gedatolisib (USAN/INN); Gedatolisib (PKI-587); SCHEMBL32393; GTPL7940; AOB5085; DTXSID40152557; EX-A028; QCR-208; C32H41N9O4; HMS3748M11; BCP01986; BDBM50308135; MFCD16875679; NSC758256; NSC801014; s2628; ZINC49757175; AKOS005766013; CCG-264662; CS-0449; DB11896; FE-0013; NSC-758256; NSC-801014; SB16571; NCGC00370777-01; NCGC00370777-04; AC-31519; HY-10681; FT-0700110; PKI-587,PF-05212384; X7445; A25474; D10635; J-004182; J-523339; Q27077788; PKI-587; 1197160-78-3; PKI587; PKI 587; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]urea; N-{4-[4,6-bis(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-N'-{4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl}urea; VL1"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB11896	.	.	615.7	C32H41N9O4	128	913	2.4	45	2	10	7	"1S/C32H41N9O4/c1-38(2)27-11-13-39(14-12-27)29(42)24-5-9-26(10-6-24)34-32(43)33-25-7-3-23(4-8-25)28-35-30(40-15-19-44-20-16-40)37-31(36-28)41-17-21-45-22-18-41/h3-10,27H,11-22H2,1-2H3,(H2,33,34,43)"	CN(C)C1CCN(CC1)C(=O)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=NC(=NC(=N4)N5CCOCC5)N6CCOCC6	DWZAEMINVBZMHQ-UHFFFAOYSA-N
DG00546	MK1775	24856436	"MK-1775; 955365-80-7; Adavosertib; MK1775; MK 1775; AZD1775; AZD 1775; AZD-1775; UNII-K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; MFCD17215200; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-2-(prop-2-en-1-yl)pyrazolo[3,4-d]pyrimidin-3-one; 1-[6-(2-Hydroxypropan-2-Yl)pyridin-2-Yl]-6-{[4-(4-Methylpiperazin-1-Yl)phenyl]amino}-2-(Prop-2-En-1-Yl)-1,2-Dihydro-3h-Pyrazolo[3,4-D]pyrimidin-3-One; 3H-Pyrazolo(3,4-d)pyrimidin-3-one, 1,2-dihydro-1-(6-(1-hydroxy-1-methylethyl)-2-pyridinyl)-6-((4-(4-methyl-1-piperazinyl)phenyl)amino)-2-(2-propen-1-yl)-; 3H-Pyrazolo[3,4-d]pyrimidin-3-one, 1,2-dihydro-1-[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]-6-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-2-(2-propen-1-yl)-; 8X7; Adavosertib (USAN); Kinome_2656; Adavosertib (MK-1775); MLS006011025; GTPL7702; QCR-46; SCHEMBL1504444; CHEMBL1976040; CHEBI:91414; DTXSID30241868; EX-A331; C27H32N8O2; HMS3295K03; HMS3654H20; HMS3744I13; AOB87173; BCP01928; BDBM50240826; MK-1775 (WEE-1); NSC754352; NSC800793; s1525; ZINC63539231; AKOS024259153; MK-1775(AZD-1775,Adavosertib); Adavosertib pound MK-1775 pound(c); AM90274; BCP9000937; CCG-264905; CS-0105; DB11740; NSC-754352; NSC-800793; SB16663; NCGC00263183-01; NCGC00263183-09; NCGC00263183-10; 2-allyl-1-(6-(2-hydroxy-2-propanyl)-2-pyridinyl)-6-((4-(4-methyl-1-piperazinyl)phenyl)amino)-1,2-dihydro-3H-pyrazolo(3,4-d)pyrimidin-3-one; 2-Allyl-1-[6-(2-hydroxy-2-propyl)-2-pyridyl]-6-[[4-(4-methyl-1-piperazinyl)phenyl]amino]pyrazolo[3,4-d]pyrimidin-3(2H)-one; AC-28416; AS-17001; BM161385; HY-10993; SMR004702820; SY258875; FT-0699265; SW218122-2; X7493; D11361; BRD-K54256913-001-01-2; Q27074716; 1075739-30-8; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1,2-dihydropyrazolo[3,4-d]pyrimidin-3-one; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazo; 2-Allyl-1-[6-(1-hydroxy-1-methyl-ethyl)-pyridin-2-yl]-6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-1,2-dihydro-pyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-[6-(1-hydroxy-1-methylethyl)pyridin-2-yl]-6-[[4-(4-methylpiperazin-1-yl)phenyl]amino]-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:91414	DB11740	.	.	500.6	C27H32N8O2	101	795	3.1	37	2	9	7	"1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)"	CC(C)(C1=NC(=CC=C1)N2C3=NC(=NC=C3C(=O)N2CC=C)NC4=CC=C(C=C4)N5CCN(CC5)C)O	BKWJAKQVGHWELA-UHFFFAOYSA-N
DG00547	Dovitinib	135398510	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; Chir 258; Dovitinib (TKI-258, CHIR-258); CHIR258; TKI258; UNII-I35H55G906; Dovitinib lactate; CHEMBL522892; 804551-71-1; CHEMBL4578973; MFCD10565680; I35H55G906; TKI 258; 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one; 4-Amino-5-Fluoro-3-(6-(4-Methylpiperazin-1-yl)-1H-Benzo[D]Imidazol-2-yl)Quinolin-2(1H)-One; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; (3Z)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one; 1027263-12-2; C21H21FN6O; Dovitinib [INN]; 4-AMINO-5-FLUORO-3-[ 5- (4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]QUINOLIN-2(1H)-ONE; 38O; TK-258; Kinome_1513; Dovitinib (TKI-258); NVP-TKI258; MLS006009991; SCHEMBL172687; GFKI-258; GTPL5962; SCHEMBL9975396; SCHEMBL20399550; BDBM25118; CHEBI:91395; AOB6730; QCR-175; SYN1029; BCPP000286; BDBM153731; CHIR-258(Dovitinib,TKI258); Dovitinib,TKI258, CHIR-258; HMS3295E21; HMS3651E03; BCP01981; EX-A2051; ZINC3816310; CHIR-258, TKI258, Dovitinib; CHIR258 (TKI-258); BDBM50507579; NSC759661; NSC800092; NSC807408; s1018; ZINC18710083; Dovitinib; TKI-258; CHIR-258; AKOS005146311; AKOS015951093; ZINC100270141; BCP9000518; CCG-264778; CS-0120; DB05928; NSC-759661; NSC-800092; NSC-807408; PB13248; SB20297; 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one; NCGC00249685-01; NCGC00249685-02; NCGC00249685-11; (3E)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one; 1447274-99-8; AC-32059; AS-19556; HY-50905; SMR004701066; FT-0667782; SW219787-1; Y0345; EC-000.2257; A24080; C75053; TKI-258;CHIR-258;Unii-I35H55G906; 169A166; 326D834; 1,3-benzodiazol-2-yl]-1,2-dihydroquinolin-2-one; J-514396; BRD-K85402309-001-01-7; Q27077102; Q27163255; Q27453625; 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-; B2693-091881; 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2 (1h)-one; 4-amino-5-fluoro-3-[6(4-methyl-1-piperazinyl)-1h-benzimidazol-2-yl]-2(1h)-quinolinone; 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one; 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazole-2-yl]quinolin-2(1H)-one; (3Z)-4-amino-5-fluoro-3-[5-(4-methylpiperazino)-1,3-dihydrobenzimidazol-2-ylidene]carbostyril; 4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydrobenzimidazol-2-ylidene]-2-quinolinone; 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-1,3-benzodiazol-2-ylidene]-2,3-dihydroquinolin-2-one; 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-1,3-benzodiazol-2-yl]-1,2-dihydroquinolin-2-one"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB05928	.	.	392.4	C21H21FN6O	90.3	678	1.6	29	3	6	2	"1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29)"	CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N	PIQCTGMSNWUMAF-UHFFFAOYSA-N
DG00548	Aspirin	2244	"Aspirin; ACETYLSALICYLIC ACID; 50-78-2; 2-Acetoxybenzoic acid; 2-(Acetyloxy)benzoic acid; O-Acetylsalicylic acid; Acetylsalicylate; o-Acetoxybenzoic acid; Acylpyrin; Easprin; Ecotrin; Acenterine; Acetophen; Polopiryna; Acetosal; Colfarit; Salicylic acid acetate; o-Carboxyphenyl acetate; Enterosarein; Aceticyl; Acetonyl; Acetosalin; Acetylin; Aspergum; Aspirdrops; Benaspir; Micristin; Pharmacin; Premaspin; Salcetogen; Temperal; Ecolen; Empirin; Endydol; Rhodine; Saletin; Rheumintabletten; Solprin acid; Acidum acetylsalicylicum; Benzoic acid, 2-(acetyloxy)-; Acetisal; Acetylsal; Aspirine; Bialpirina; Bialpirinia; Claradin; Clariprin; Entericin; Enterophen; Enterosarine; Globentyl; Measurin; Neuronika; Salacetin; Solpyron; Acesal; Acisal; Asagran; Asteric; Cemirit; Decaten; Duramax; Extren; Globoid; Helicon; Idragin; Levius; Pirseal; Rhonal; Solfrin; Adiro; Aspec; Aspro; Novid; Yasta; Acetosalic acid; 2-acetyloxybenzoic acid; Triple-sal; Spira-Dine; ZORprin; Bi-prin; Acetilum acidulatum; Acimetten; Delgesic; Entrophen; Persistin; 2-Carboxyphenyl acetate; Acetilsalicilico; Dolean pH 8; A.S.A. empirin; XAXA; Acido acetilsalicilico; Contrheuma retard; Acide acetylsalicylique; Endosprin; Kapsazal; Bayer; ASA; Acetylsalicylsaure; aspirin (acetylsalicylic acid); Solprin; Triaminicin; Asatard; Tasprin; Nu-seals aspirin; Salicylic acid, acetate; Acido O-acetil-benzoico; Kyselina acetylsalicylova; 2-Acetoxybenzenecarboxylic acid; St. Joseph Aspirin for Adults; A.S.A.; St. Joseph; Kyselina 2-acetoxybenzoova; SP 189; Acetard; AC 5230; Acetylsalicylsaeure; Azetylsalizylsaeure; S-211; UNII-R16CO5Y76E; ECM; CHEBI:15365; 2-(acetyloxy)benzoate; o-(Acetyloxy)benzoic acid; acide 2-(acetyloxy)benzoique; R16CO5Y76E; Aspirin form II; component of Midol; NSC27223; component of Synirin; MFCD00002430; NSC-27223; 8-hour Bayer; component of Zactirin; NSC-406186; component of Coricidin; component of Persistin; component of Robaxisal; o-Acetoxybenzoate; NCGC00015067-04; o-acetyl-salicylic acid; Acetysal; Istopirin; Magnecyl; Medisyl; Polopirin; Ronal; Bayer Buffered; DSSTox_CID_108; Aspro Clear; component of Ascodeen-30; Bayer Plus; WLN: QVR BOV1; Rheumin tabletten; AcetylsalicylicAcid; DSSTox_RID_75372; DSSTox_GSID_20108; Aspirina 03; Acetylsalycilic acid; acetyl salicylic acid; component of Darvon with A.S.A; Bayer Aspirin 8 Hour; Asaphen; Aspalon; Durlaza; Asprin; Bayer Children's Aspirin; Nu-seals; component of St. Joseph Cold Tablets; Aspir-Mox; Durlaza ER; Acetylsalicylsaure [German]; CAS-50-78-2; Acetoxybenzoic acid; Acetysalicylic acid; 11126-35-5; 1173022-25-7; AIN; SMR000059138; Ascoden-30; Benzoicacid, 2-(acetyloxy)-; Acetylsalicyclic acid; CCRIS 3243; HSDB 652; Acide acetylsalicylique [French]; Acido acetilsalicilico [Italian]; Kyselina acetylsalicylova [Czech]; Acido O-acetil-benzoico [Italian]; SR-01000075668; Kyselina 2-acetoxybenzoova [Czech]; Bayer Extra Strength Aspirin for Migraine Pain; EINECS 200-064-1; NSC 27223; Aspirin [USP:BAN:JAN]; Bayer Enteric 325 mg Regular Strength; BRN 0779271; Bay E4465; Aspropharm; Bayer Enteric 81 mg Adult Low Strength; Cardioaspirin; Cardioaspirina; Acetyonyl; Asacard; Ascolong; Bayer Enteric 500 mg Arthritis Strength; Colsprin; Miniasal; Salospir; Acesan; Toldex; AI3-02956; acetyl salicylate; 1oxr; 2-Acetoxybenzoate; 99512-66-0; Aspirin,(S); Aspalon (JAN); Durlaza (TN); Easprin (TN); acetyl-salicylic acid; Aspirin USP-26; acetyl salicyclic acid; o-(Acetyloxy)benzoate; Percodan (Salt/Mix); Ascriptin (Salt/Mix); Micrainin (Salt/Mix); 2-acetoxy benzoic acid; Acetylsalicylicum acidum; Spectrum_001245; 2-Acetylsalicyclic acid; Salicylic acid, acetyl-; CHEMBL25; Spectrum2_001899; Spectrum3_001295; Spectrum4_000099; Spectrum5_000740; Aspirin (JP17/USP); Lopac-A-5376; Salycylacetylsalicylic acid; benzoic acid, 2-acetoxy-; Epitope ID:114151; Percodan Demi (Salt/Mix); Soma Compound (Salt/Mix); ZINC53; EC 200-064-1; Acetylsalicylic acid, 99%; Aspirin USP (3080); cid_2244; Pravigard PAC (Salt/Mix); SCHEMBL1353; 2-(Acetyloxy)-benzoic acid; Aspirin USP (2080B); Bay-e-4465; Acetylsalicylic acid-[13C]; Lopac0_000038; KBioGR_000398; KBioGR_002271; KBioSS_001725; KBioSS_002272; 4-10-00-00138 (Beilstein Handbook Reference); MLS001055329; MLS001066332; MLS001336045; MLS001336046; Acetylsalicylic acid (who-ip); BIDD:GT0118; DivK1c_000555; SPECTRUM1500130; SPBio_001838; Acetylsalicylic acid, >=99%; GTPL4139; (non-d)Acetylsalicylic Acid-d3; O-Acetylsalicylic acid; Aspirin; DTXSID5020108; Acetylsalicylic acid-carboxy-14c; BDBM22360; HMS501L17; KBio1_000555; KBio2_001725; KBio2_002271; KBio2_004293; KBio2_004839; KBio2_006861; KBio2_007407; KBio3_002149; KBio3_002751; Empirin with Codeine (Salt/Mix); Acetylsalicylic acid, >=99.0%; cMAP_000006; component of Zactirin (Salt/Mix); NINDS_000555; HMS1920E13; HMS2090G03; HMS2091K13; HMS2233L18; HMS3260G17; HMS3372N15; HMS3656N14; HMS3715P19; HMS3866L03; HMS3885G03; Pharmakon1600-01500130; BCP21790; STR01551; ACETYLSALICYLIC ACID; ASPIRIN; Tox21_110076; Tox21_202117; Tox21_300146; Tox21_500038; CCG-39490; NSC406186; NSC755899; s3017; STL137674; AKOS000118884; component of Ascodeen-30 (Salt/Mix); Tox21_110076_1; BAY1019036; CS-2001; DB00945; LP00038; MCULE-3199019536; NSC-755899; PL-2200; SDCCGSBI-0050027.P005; BAY-1019036; IDI1_000555; Acetylsalicylic acid, analytical standard; NCGC00015067-01; NCGC00015067-02; NCGC00015067-03; NCGC00015067-05; NCGC00015067-06; NCGC00015067-07; NCGC00015067-08; NCGC00015067-09; NCGC00015067-10; NCGC00015067-11; NCGC00015067-12; NCGC00015067-13; NCGC00015067-14; NCGC00015067-24; NCGC00015067-26; NCGC00090977-01; NCGC00090977-02; NCGC00090977-03; NCGC00090977-04; NCGC00090977-05; NCGC00090977-06; NCGC00090977-07; NCGC00254034-01; NCGC00259666-01; NCGC00260723-01; Aspirin, meets USP testing specifications; H740; HY-14654; NCI60_002222; SBI-0050027.P004; DS-017139; UNM-0000306102; component of Darvon with A.S.A (Salt/Mix); EU-0100038; FT-0655181; FT-0661360; SW199665-2; A 5376; Acetylsalicylic Acid 1.0 mg/ml in Acetonitrile; C01405; D00109; Q18216; AB00051918-08; AB00051918_09; AB00051918_10; Arthritis Pain Formula Maximum Strength (Salt/Mix); SR-01000075668-1; SR-01000075668-4; SR-01000075668-6; Acetylsalicylic acid, Vetec(TM) reagent grade, >=99%; Aspirin, British Pharmacopoeia (BP) Reference Standard; F2191-0068; Z234893989; Aspirin, United States Pharmacopeia (USP) Reference Standard; D41527A7-A9EB-472D-A7FC-312821130549; Acetylsalicylic acid, European Pharmacopoeia (EP) Reference Standard; Acetylsalicylic acid, BioReagent, plant cell culture tested, >=99.0%; Acetylsalicylic acid for peak identification, European Pharmacopoeia (EP) Reference Standard; Aspirin (Acetyl Salicylic Acid), Pharmaceutical Secondary Standard; Certified Reference Material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:15365	DB00945	DR00203	DR1749	180.16	C9H8O4	63.6	212	1.2	13	1	4	3	"1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)"	CC(=O)OC1=CC=CC=C1C(=O)O	BSYNRYMUTXBXSQ-UHFFFAOYSA-N
DG00549	Clopidogrel	60606	"Clopidogrel; 113665-84-2; Plavix; (S)-Clopidogrel; Zyllt; Clopidogrel bisulfate; Clopidogrel Acino; Clopidogrel Hexal; (+)-Clopidogrel; CLOPIDOGREL SULFATE; (+)-(S)-Clopidogrel; UNII-A74586SNO7; Clopidogrel BMS; SR 25990; methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate; CHEBI:37941; SR-25990C; A74586SNO7; Isocover; R 130964; (S)-Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate; Clopidogrel (TN); Plavix (TN); methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate; Thrombo; Clopidogrel [INN:BAN]; clopidogrel Sandoz; CHEMBL1083385; methyl (2S)-2-(2-chlorophenyl)-2-{4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}acetate; SMR000550475; Clopidogrel Winthrop; Clopidogrel 1A Pharma; HSDB 7430; NSC-758613; Clopidogrel ratiopharm GmbH; Plavix® Clopidogrel apotex; (+) clopidogrel; CGE; Clopidogrel Teva (hydrogen sulphate); Clopidogrel-ratiopharm; Clopidogrel 1a-pharma; Spectrum_000105; CPD000550475; Clopidogrel (USP/INN); Spectrum2_000512; Spectrum3_001606; Spectrum4_000175; SCHEMBL4769; THIAMINELAURYLSULPHATE; CHEMBL1771; methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate; BSPBio_003211; KBioGR_000689; KBioSS_000545; MLS001165708; MLS001195633; MLS001304711; MLS006011891; BIDD:GT0284; DivK1c_000787; SPBio_000463; GTPL7150; DTXSID6022848; HMS502H09; KBio1_000787; KBio2_000545; KBio2_003113; KBio2_005681; KBio3_002431; AMY8913; NINDS_000787; HMS2090O21; HMS2234N16; HMS3259B08; HMS3715J08; BBL010770; BDBM50318910; BDBM50397662; MFCD05662337; NSC748298; STK580572; ZINC34781704; AKOS005504280; CCG-221243; CS-0656; DB00758; MCULE-9061369538; NC00703; NSC 758613; NSC-748298; IDI1_000787; Methyl (+)-(S)-alpha-(o-chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4H)-acetate; NCGC00163329-02; NCGC00163329-04; AC-19024; DS-13362; HY-15283; Thieno(3,2-c)pyridine-5(4H)-acetic acid, alpha-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (S)-; SBI-0052755.P002; D07729; N11780; AB00053786-07; AB00053786-08; AB00053786_09; AB00053786_10; Q410237; R-130964; BRD-K27721098-065-02-9; BRD-K27721098-065-05-2; UNII-MX75HY8K68 component GKTWGGQPFAXNFI-HNNXBMFYSA-N; methyl (2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate; (S)-(+)-Methyl (2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate; (S)-(+)-Methyl (2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate; methyl (+)-(S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate; methyl (+)-(s)-alpha-(o-chlorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4h)-acetate; methyl (S)-(+)-alpha-(o-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-acetate; methyl(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h) acetate; methyl-(S)-(+)-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridine-5-yl)-acetate; (+)-(S)-(2-Chlorophenyl) (6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetic acid methyl ester; (+)-(S)-2-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetic acid methyl ester; Thieno[3,2-c]pyridine-5(4H)-acetic acid, .alpha.-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (.alpha.S)-; Thieno[3,2-c]pyridine-5(4H)-acetic acid, alpha-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (alphaS)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:37941	DB00758	DR00245	.	321.8	C16H16ClNO2S	57.8	381	3.8	21	0	4	4	"1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1"	COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3	GKTWGGQPFAXNFI-HNNXBMFYSA-N
DG00550	Infigratinib	53235510	"NVP-BGJ398; Infigratinib; 872511-34-7; BGJ398; BGJ-398; BGJ 398; Infigratinib free base; 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea; UNII-A4055ME1VK; BGJ398 (NVP-BGJ398); MVP-BGJ398; A4055ME1VK; CHEBI:63451; 872511-34-7 (free base); 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)-1-methylurea; 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)-1-methylurea; 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea; C26H31Cl2N7O3; Truseltiq; CHEMBL1834657; 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea.; 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea; Infigratinib [INN]; Infigratinib [USAN]; Infigratinib (BGJ398); Infigratinib (USAN/INN); Infigratinib [USAN:INN]; NVP-BGJ389; NVP-BGJ398(Infigratinib); MLS006010953; SCHEMBL374435; GTPL7877; QCR-48; CHEMBL1852688; DTXSID70236238; EX-A057; SYN1152; BGJ398, BGJ-398; HMS3295O21; AMY10737; AOB87703; BCP03602; BGJ398 - NVP-BGJ398; BDBM50355393; FD5035; MFCD22123241; NSC764487; s2183; WHO 10032; ZINC72105034; AKOS025149513; AKOS032949944; BCP9000399; CS-0586; DB11886; NSC-764487; SB16612; NCGC00274030-01; NCGC00274030-11; 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea; AC-28417; AS-16290; HY-13311; SMR004702757; Urea, N'-(2,6-dichloro-3,5-dimethoxyphenyl)-N-(6-((4-(4-ethyl-1-piperazinyl)phenyl)amino)-4-pyrimidinyl)-N-methyl-; BCP0726000187; FT-0699366; Y0313; D11589; J-510477; BRD-K42728290-001-01-8; Q27075200; 07J; 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63451	DB11886	.	.	560.5	C26H31Cl2N7O3	95.1	724	4.7	38	2	8	8	"1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)"	CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl	QADPYRIHXKWUSV-UHFFFAOYSA-N
DG00551	Leflunomide	3899	"Leflunomide; 75706-12-6; Arava; lefunamide; Leflunomida; Leflunomidum; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; HWA 486; Leflunomidum [INN-Latin]; HWA-486; Repso; SU101; Arava (TN); 5-methyl-N-(4-(trifluoromethyl)phenyl)isoxazole-4-carboxamide; 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-; alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; UNII-G162GK9U4W; SU-101; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide; RS-34821; CHEMBL960; MLS000069648; CHEBI:6402; G162GK9U4W; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); MFCD00867593; NSC-677411; NSC-759864; NCGC00015610-02; SMR000058209; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl)-; CAS-75706-12-6; leflunomide medac; DSSTox_CID_3201; DSSTox_RID_76923; DSSTox_GSID_23201; Leflunomida [INN-Spanish]; SU 101 (pharmaceutical); Lefunomide [Inn-Spanish]; HSDB 7289; SR-01000000191; Arabloc; HWA486; Leflunomide teva; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; L04AA13; Prestwick_87; Leflunomide [USAN:USP:INN:BAN]; Leflunomide winthrop; SU 101; SULOL; Leflunomide ratiopharm; Spectrum_000322; Opera_ID_1709; Prestwick0_000772; Prestwick1_000772; Prestwick2_000772; Prestwick3_000772; Spectrum5_000850; Lopac-L-5025; L 5025; SCHEMBL5057; BIDD:PXR0189; Lopac0_000649; BSPBio_000844; KBioSS_000802; Leflunomide, Immunosuppressant; MLS001076267; DivK1c_000916; Leflunomide (JAN/USP/INN); SPECTRUM1503927; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; SPBio_002783; BPBio1_000930; GTPL6825; ZINC4840; DTXSID9023201; HMS502N18; KBio1_000916; KBio2_000802; KBio2_003370; KBio2_005938; AOB5964; NINDS_000916; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; HMS1570K06; HMS1922M06; HMS2090O12; HMS2097K06; HMS2235C07; HMS3262A19; HMS3268D12; HMS3371F21; HMS3414P03; HMS3654F07; HMS3673M17; HMS3678N21; HMS3714K06; HMS3865I13; Pharmakon1600-01503927; ALBB-019233; BCP22241; HY-B0083; Tox21_110182; Tox21_301873; Tox21_500649; BDBM50054601; DL-433; NSC677411; NSC759864; s1247; STL426823; AKOS000265193; Tox21_110182_1; AC-6796; BCP9000846; CCG-204736; CS-1781; DB01097; KS-1076; LP00649; MCULE-9490869974; NSC 677411; NSC 759864; SB17287; SDCCGSBI-0050629.P003; IDI1_000916; NCGC00015610-01; NCGC00015610-03; NCGC00015610-04; NCGC00015610-05; NCGC00015610-06; NCGC00015610-07; NCGC00015610-08; NCGC00015610-09; NCGC00015610-10; NCGC00015610-11; NCGC00015610-12; NCGC00015610-13; NCGC00015610-14; NCGC00015610-17; NCGC00015610-18; NCGC00015610-30; NCGC00022625-03; NCGC00022625-04; NCGC00022625-05; NCGC00022625-06; NCGC00022625-07; NCGC00022625-08; NCGC00255370-01; NCGC00261334-01; BM164612; H527; Leflunomide 100 microg/mL in Acetonitrile; A9622; AB00052389; EU-0100649; FT-0621959; L0250; SW196399-3; C07905; D00749; MLS-0003109.0001; AB00052389-17; AB00052389-18; AB00052389_19; AB00052389_21; 706L126; Q248550; Q-201289; SR-01000000191-2; SR-01000000191-4; SR-01000000191-7; BRD-K78692225-001-03-9; BRD-K78692225-001-11-2; 5-methyl-4-(4-trifluoromethyl-phenyl)aminocarbonylisoxazole; 5-methyl-4-(4-trifluoromethylphenyl)aminocarbonylisoxazole; Leflunomide, European Pharmacopoeia (EP) Reference Standard; N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; 5-Methyl-N-[4-(trifluoromethyl)-phenyl]isoxazole-4-carboxamide; 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)-anilide; N-(4-trifluoromethylphenyl)-5-methylisoxa-zole-4-carboxamide; Isoxazole-4-carboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-; Leflunomide, United States Pharmacopeia (USP) Reference Standard; 5-methyl-N-(4-(trifluoromethyl)phenyl)isoxazole-4-carboxamide;Leflunomide; HWA486; RS-34821; SU101;HWA 486; RS 34821; SU 101; Leflunomide, Pharmaceutical Secondary Standard; Certified Reference Material; Leflunomide for peak identification, European Pharmacopoeia (EP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6402	DB01097	DR00130	DR0921	270.21	C12H9F3N2O2	55.1	327	2.5	19	1	6	2	"1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)"	CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F	VHOGYURTWQBHIL-UHFFFAOYSA-N
DG00552	Steroid	.	.	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00553	Pexidartinib	25151352	"Pexidartinib; 1029044-16-3; PLX3397; PLX-3397; Pexidartinib (PLX3397); Turalio; UNII-6783M2LV5X; CML-261; 5-((5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)pyridin-2-amine; CHEMBL3813873; 6783M2LV5X; 5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine; 5-[(5-Chloro-1h-Pyrrolo[2,3-B]pyridin-3-Yl)methyl]-N-{[6-(Trifluoromethyl)pyridin-3-Yl]methyl}pyridin-2-Amine; 5-({5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl}methyl)-N-{[6-(trifluoromethyl)pyridin-3-yl]methyl}pyridin-2-amine; Pexidartinib [INN]; pexidartinibum; Pexidartinib [USAN]; Pexidartinib(PLX3397); Pexidartinib (USAN/INN); Pexidartinib [USAN:INN]; GTPL8710; SCHEMBL1267310; EX-A589; CHEBI:145373; HMS3886D19; BCP15183; PLX 3397; BDBM50177716; MFCD28900745; NSC789300; NSC793434; NSC800843; s7818; AKOS026750359; ZINC115705166; CCG-268862; DB12978; NSC-789300; NSC-793434; NSC-800843; SB19178; NCGC00480774-01; NCGC00480774-06; 3-Pyridinemethanamine, N-(5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-2-pyridinyl)-6-(trifluoromethyl)-; AC-30300; AS-74915; DA-48267; HY-16749; B5854; FT-0699505; PLX 3397;PLX3397;PL-X3397; D11270; A856116; J-690008; Q25100640; B0084-470807; 2(S)-Amino-3-(4-{2-amino-6-[2,2,2-trifluoro-1-(3'-fluoro-biphenyl-4-yl)-ethoxy]-pyrimidin-4-yl}-phenyl)-propionic acid hydrochloride; 5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)-3-pyridyl]methyl]pyridin-2-amine; N-[5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-2-pyridinyl]-6-(trifluoromethyl)-3-pyridinemethanamine; N-[5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-2-pyridinyl]-6-(trifluoromethyl)-3-pyridinemethanamine;Pexidartinib"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:145373	DB12978	.	DR1269	417.8	C20H15ClF3N5	66.5	537	4.5	29	2	7	5	"1S/C20H15ClF3N5/c21-15-6-16-14(10-28-19(16)29-11-15)5-12-2-4-18(26-7-12)27-9-13-1-3-17(25-8-13)20(22,23)24/h1-4,6-8,10-11H,5,9H2,(H,26,27)(H,28,29)"	C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)C(F)(F)F	JGWRKYUXBBNENE-UHFFFAOYSA-N
DG00554	Erdafitinib	67462786	"Erdafitinib; 1346242-81-6; JNJ-42756493; Balversa; UNII-890E37NHMV; 890E37NHMV; JNJ42756493; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine; N1-(3,5-dimethoxyphenyl)-N2-isopropyl-N1-(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)ethane-1,2-diamine; Erdafitinib [USAN:INN]; Balversa (TN); Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; Erdafitinib; JNJ-42756493; JNJ-42756493 (Erdafitinib); AMY31119; BCP20346; EX-A2564; BDBM50525939; MFCD28502040; NSC781556; s8401; compound 4 [WO2011135376]; ZINC168520308; CCG-269200; CS-4988; DB12147; NSC-781556; SB16854; NCGC00475735-01; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; AC-30222; AS-35040; HY-18708; JNJ 42756493; D10927; A857165; Q27077213; B0084-470835; 5SF; N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine; N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine;Erdafitinib"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB12147	.	DR0595	446.5	C25H30N6O2	77.3	583	3.2	33	1	7	9	"1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3"	CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC	OLAHOMJCDNXHFI-UHFFFAOYSA-N
DG00555	"8-methyl-cipro [1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-(1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid]"	.	.	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00556	"8-methoxy-cipro [1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid]"	.	.	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00557	"Cipro-dione [3-amino-7-(1-piperazinyl)-1-cyclopropyl-6-fluoro-2,4(1H,3H)-quinazolinedione]"	.	.	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00558	"8-H-moxi {1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid}"	.	.	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00559	"8-methyl-moxi {1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid}"	.	.	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00560	"Moxi-dione {3-amino-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-2,4(1H,3H)-quinazolinedione}"	.	.	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00561	"3'-(AM)P-quinolone {1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-[(3S)-3-(aminomethyl)-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid}"	.	.	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00562	"3'-(AM)P-dione {3-amino-7-[(3S)-3-(aminomethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-8-methyl-2,4(1H,3H)-quinazolinedione}"	.	.	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00563	Ombitasvir	54767916	"Ombitasvir; 1258226-87-7; ABT-267; Ombitasvir(ABT-267); ABT267; CHEBI:85183; UNII-2302768XJ8; ABT 267; 2302768XJ8; L-Prolinamide, 2,2'-[[(2S,5S)-1-[4-(1,1-dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-L-valyl-; L-Prolinamide,2,2'-(((2S,5S)-1-(4-(1,1-dimethylethyl)phenyl)-2,5-pyrrolidinediyl)di-4,1-phenylene)bis(N-(methoxycarbonyl)-L-valyl-; dimethyl ([(2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl]bis{(4,1-phenylene)carbamoyl(2S)pyrrolidine-2,1-diyl[(2S)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate; methyl N-[(2S)-1-[(2S)-2-[[4-[(2S,5S)-1-(4-tert-butylphenyl)-5-[4-[[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]phenyl]pyrrolidin-2-yl]phenyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate; Ombitasvir [USAN:INN]; Ombitasvir (USAN); SCHEMBL8542284; CHEMBL3127326; GTPL11272; AMY6935; EX-A5846; BDBM50453112; s5403; ZINC150601177; CCG-270561; CS-5330; DB09296; ABT-267;ABT267;ABT 267; compound 38 [PMID: 24400777]; NCGC00510316-01; NCGC00510316-02; Carbamic acid, N,N'-(((2S,5S)-1-(4-(1,1-dimethylethyl)phenyl)-2,5-pyrrolidinediyl)bis(4,1-phenyleneiminocarbonyl-(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,C'-dimethyl ester; HY-13997; C72037; D10576; Technivie (ombitasvir + paritaprevir + ritonavir); Q19598175; ABT 267; ; ; Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(((((2S,5S)-1-(4-(tert-butyl)phenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azanediyl))bis(carbonyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate; Methyl ((S)-1-((S)-2-((4-((2S,5S)-1-(4-(tert-butyl)phenyl)-5-(4-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidine-2-carboxamido)phenyl)pyrrolidin-2-yl)phenyl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate; methyl N-[(1S)-1-[(2S)-2-[[4-[(2S,5S)-1-(4-tert-butylphenyl)-5-[4-[[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidine-2-carbonyl]amino]phenyl]pyrrolidin-2-yl]phenyl]carbamoyl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:85183	DB09296	DR01311	DR1193	894.1	C50H67N7O8	179	1540	7.9	65	4	9	16	"1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1"	CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)NC2=CC=C(C=C2)[C@@H]3CC[C@H](N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC	PIDFDZJZLOTZTM-KHVQSSSXSA-N
DG00564	Daclatasvir	25154714	"Daclatasvir; 1009119-64-5; Daclatasvir (BMS-790052); BMS-790052; Daklinza; EBP 883; 1214735-16-6; BMS790052; BMS 790052; CHEBI:82977; methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate; UNII-LI2427F9CI; Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester; C40H50N8O6; Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dica; 1009119-65-6; LI2427F9CI; methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate; Daclatasvir (USAN); dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate; MLS006011140; EBP883; SCHEMBL2756027; CHEMBL2023898; SCHEMBL17897804; GTPL11266; EBP-883; EX-A410; AMY36655; AOB87747; dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate; Dimethyl N,N'-(biphenyl-4,4'-diylbis{1H-imidazole-5,2-diyl-((2S)-pyrrolidine-2,1- diyl)((1S)-1-(1-methylethyl)-2-oxoethane-2,1-diyl)})dicarbamate; 3503AH; BDBM50387084; MFCD17129086; s1482; ZINC68204830; CA10002; CCG-270425; CS-0588; DB09102; NCGC00346533-07; NCGC00346533-09; AC-28958; AS-75298; BMS 790052; EBP 883; HY-10466; SMR004702917; SW219754-1; X7549; D10065; J-520204; Q5207712; methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate; methyl [(2s)-1-{(2s)-2-[4-(4'-{2-[(2s)-1-{(2s)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1h-imidazol-4-yl}-4-biphenylyl)-1h-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]carbamate; methyl [(2S)-1-{(2S)-2-[4-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-4-yl}biphenyl-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate; Methyl [(2S)-1-{(2S)-2-[5-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}biphenyl-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate; methyl N-[(2S)-1-[(2S)-2-[5-(4'-{2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl}-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate; methyl-N-[(2s)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl] pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1himidazol-2-yl]pyrrolidin-1-yl]3-methyl-1-oxobutan-2-yl]carbamate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:82977	DB09102	DR00144	.	738.9	C40H50N8O6	175	1190	5.1	54	4	8	13	"1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1"	CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC	FKRSSPOQAMALKA-CUPIEXAXSA-N
DG00565	Ledipasvir	67505836	"Ledipasvir; 1256388-51-8; GS-5885; GS5885; UNII-013TE6E4WV; Ledipasvir acetonate; GS 5885; CHEBI:85089; WHO 9796; 013TE6E4WV; methyl N-[(2S)-1-[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-2-azabicyclo[2.2.1]heptan-3-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate; methyl [(2S)-1-{(6S)-6-[4-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-5-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate; Methyl N-[(2S)-1-[(6S)-6-[5-[9,9-Difluoro-7-[2-[(1S,2S,4R)-3-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-3-azabicyclo[2.2.1]heptan-2-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate; Ledipasvir [USAN:INN]; Ledipasvir (USAN); SCHEMBL2706494; CHEMBL2374220; SCHEMBL15116943; GTPL11271; DTXSID90154829; EX-A411; C49H54F2N8O6; Harvoni (ledipasvir + sofosbuvir); 3774AH; BDBM50505966; MFCD25976756; ZINC150338819; CS-1653; DB09027; NCGC00378990-02; NCGC00378990-05; AC-28378; AS-56214; HY-15602; (non-Isotopelabelled)Ledipasvir-13C2, d6; D10442; Q15409409; Carbamic acid, N-((1S)-1-(((6S)-6-(5-(9,9-difluoro-7-(2-((1R,3S,4S)-2-((2S)-2-((methoxycarbonyl)amino)-3-methyl-1-oxobutyl)-2-azabicyclo(2.2.1)hept-3-yl)-1H-benzimidazol-6-yl)-9H-fluoren-2-yl)-1H-imidazol-2-yl)-5-azaspiro(2.4)hept-5-yl)carbonyl)-2-methylpropyl)-, methyl ester; Methyl ((1S)-1-((1R,3S,4S)-3-(5-(9,9-difluoro-7-(2-((6S)-5-(N-(methoxycarbonyl)- l-valyl)-5-azaspiro(2.4)hept-6-yl)-1H-imidazol-4-yl)-9H-fluoren-2-yl)-1H-benzimidazol-2-yl)-2-azabicyclo(2.2.1)heptane-2-carbonyl)-2-methylpropyl)carbamate; Methyl ((S)-1-((S)-6-(5-(9,9-difluoro-7-(2-((1R,3S,4S)-2-((methoxycarbonyl)-L-valyl)-2-azabicyclo[2.2.1]heptan-3-yl)-1H-benzo[d]imidazol-6-yl)-9H-fluoren-2-yl)-1H-imidazol-2-yl)-5-azaspiro[2, AldrichCPR; Methyl ((S)-1-((S)-6-(5-(9,9-difluoro-7-(2-((1R,3S,4S)-2-((methoxycarbonyl)-L-valyl)-2-azabicyclo[2.2.1]heptan-3-yl)-1H-benzo[d]imidazol-6-yl)-9H-fluoren-2-yl)-1H-imidazol-2-yl)-5-azaspiro[2.4]heptan-5-yl)-3-methyl-1-oxobutan-2-yl)carbamate; methyl N-[(1S)-1-[(5S)-5-[5-[9,9-difluoro-7-[2-[(1S,2S,4R)-3-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]-3-azabicyclo[2.2.1]heptan-2-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-6-azaspiro[2.4]heptane-6-carbonyl]-2-methyl-propyl]carbamate; Methyl=[(2S)-1-[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[N-(methoxycarbonyl)-L-valyl]-2-azabicyclo[2.2.1]heptane-3-yl]-1H-benzoimidazole-6-yl]-9H-fluorene-2-yl]-1H-imidazole-2-yl]-5-azaspiro[2.4]heptane-5-yl]-3-methyl-1-oxobutane-2-yl]carbamate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:85089	DB09027	DR01290	.	889	C49H54F2N8O6	175	1820	7.4	65	4	10	12	"1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)/t29-,30+,38-,39-,40-,41-/m0/s1"	CC(C)[C@@H](C(=O)N1CC2(CC2)C[C@H]1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)[C@@H]9[C@H]1CC[C@H](C1)N9C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC	VRTWBAAJJOHBQU-KMWAZVGDSA-N
DG00566	Elbasvir	71661251	"Elbasvir; 1370468-36-2; MK-8742; UNII-632L571YDK; MK 8742; 632L571YDK; MK8742; Methyl ((1S)-1-(((2S)-2-(4-((6S)-10-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-4-yl)-6-phenyl-6H-indolo(1,2-c)(1,3)benzoxazin-3-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)carbonyl)-2-methylpropyl)carbamate; Carbamic acid, N,N'-[[(6S)-6-phenyl-6H-indolo[1,2-c][1,3]benzoxazine-3,10-diyl]bis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester; Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-((S)-6-phenyl-6H-benzo[5,6][1,3]oxazino[3,4-a]indole-3,10-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate; Elbasvir [USAN:INN]; Carbamic acid, N,N'-(((6S)-6-phenyl-6H-indolo(1,2-c)(1,3)benzoxazine-3,10-diyl)bis(1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,C'-dimethyl ester; MK8742; Elbasvir; Elbasvir(MK-8742); CHEMBL3039514; SCHEMBL17429773; CHEBI:132967; EX-A2889; methyl N-[(2S)-1-[(2S)-2-[5-[(6S)-3-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-6-phenyl-6H-indolo[1,2-c][1,3]benzoxazin-10-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate; BDBM50531952; s5652; ZINC150588351; CCG-270552; CS-5332; DB11574; NCGC00510317-02; HY-15789; MK8742; ; ; MK-8742; A16855; Q19904043; Dimethyl N,N'-(((6S)-6-phenylindolo(1,2-c)(1,3)benzoxazine-3,10-diyl)bis(1H-imidazole-5,2-diyl-(2S)-pyrrolidine-2,1-diyl((2S)-3-methyl-1-oxobutane-1,2-diyl)))dicarbamate; METHYL ((S)-1-((S)-2-(4-((S)-10-(2-((S)-1-((METHOXYCARBONYL)-L-VALYL)PYRROLIDIN-2-YL)-1H-IMIDAZOL-5-YL)-6-PHENYL-6H-BENZO[5,6][1,3]OXAZINO[3,4-A]INDOL-3-YL)-1H-IMIDAZOL-2-YL)PYRROLIDIN-1-YL)-3-METHYL-1-OXOBUTAN-2-YL)CARBAMATE; methyl {(2S)-1-[(2S)-2-{4-[(6S)-3-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-4-yl}-6-phenyl-6H-indolo[1,2-c][1,3]benzoxazin-10-yl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:132967	DB11574	.	DR0561	882	C49H55N9O7	189	1680	6.7	65	4	9	13	"1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)/t37-,38-,41-,42-,47-/m0/s1"	CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC4=C(C=C3)N5[C@@H](OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)[C@@H]8CCCN8C(=O)[C@H](C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC	BVAZQCUMNICBAQ-PZHYSIFUSA-N
DG00567	Velpatasvir	67683363	"Velpatasvir; 1377049-84-7; GS-5816; GS5816; UNII-KCU0C7RS7Z; KCU0C7RS7Z; GS 5816; methyl ((R)-2-((2S,4S)-2-(5-(2-((2S,5S)-1-((methoxycarbonyl)-L-valyl)-5-methylpyrrolidin-2-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl)-4-(methoxymethyl)pyrrolidin-1-yl)-2-oxo-1-phenylethyl)carbamate; Methyl N-[(1R)-2-[(2S,4S)-2-[5-[6-[(2S,5S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),5,9,11,14(19),15,17-nonaen-17-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate; Velpatasvir [USAN:INN]; Verpatasvir; Methyl ((2S)-1-((2S,5S)-2-(9-(2-((2S,4S)-1-((2R)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-4-(methoxymethyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate; Methyl [(2S)-1-[(2S,5S)-2-[9-[2-[(2S,4S)-1-[(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl]-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate; methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate; Velpatasvir(GS5816); Velpatasvir; GS-5816; Velpatasvir (JAN/USAN/INN); SCHEMBL8756902; CHEMBL3545062; SCHEMBL19236068; GTPL11269; AMY4211; CHEBI:133009; Epclusa (sofosbuvir + velpatasvir); BCP13813; EX-A2320; BDBM50521720; MFCD28411371; s3724; ZINC203686879; CCG-270553; CS-5977; DB11613; NCGC00522503-01; NCGC00522503-02; AC-28744; AS-35237; HY-12530; FT-0700879; J3.631.686A; D10806; GS-5816;GS5816;GS 5816; Vosevi (sofosbuvir + velpatasvir + voxilaprevi); A886410; Q25018296; Carbamic acid, N-[(1R)-2-[(2S,4S)-2-[5-[1,11-dihydro-2-[(2S,5S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-5-methyl-2-pyrrolidinyl][2]benzopyrano[4,3:6,7]naphth[1,2-d]imidazol-9-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)-1-pyrrolidinyl]-2-oxo-1-phenylethyl]-, methyl ester; methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate; methyl N-[(1R)-2-[(2S,4S)-2-(5-{6-[(2S,5S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.0 ,  .0 , .0  ,  ]henicosa-1,3,6,8,10,12,14,16,18-nonaen-17-yl}-1H-imidazol-2-yl)-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate; methyl N-[(1R)-2-[(2S,4S)-2-(5-{6-[(2S,5S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.03,11.0 , .01 ,1 ]henicosa-1,3,6,8,10,12,14,16,18-nonaen-17-yl}-1H-imidazol-2-yl)-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate; methyl{(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:133009	DB11613	DR01314	DR1676	883	C49H54N8O8	193	1690	6.2	65	4	10	13	"1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1"	C[C@H]1CC[C@H](N1C(=O)[C@H](C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)[C@@H]8C[C@@H](CN8C(=O)[C@@H](C9=CC=CC=C9)NC(=O)OC)COC	FHCUMDQMBHQXKK-CDIODLITSA-N
DG00568	Pibrentasvir	58031952	"Pibrentasvir; 1353900-92-1; ABT-530; ABT 530; UNII-2WU922TK3L; A-1325912.0; 2WU922TK3L; 1353900-92-1 (free); dimethyl ((2S,2'S,3R,3'R)-((2S,2'S)-(((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis(6-fluoro-1H-benzo[d]imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methoxy-1-oxobutane-1,2-diyl))dicarbamate; methyl N-[(2S,3R)-1-[(2S)-2-[6-[(2R,5R)-1-[3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl]-5-[6-fluoro-2-[(2S)-1-[(2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]pyrrolidin-2-yl]-5-fluoro-1H-benzimidazol-2-yl]pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl]carbamate; Pibrentasvir [USAN]; ABT-530;Pibrentasvir; Pibrentasvir(ABT-530); Pibrentasvir (ABT-530); Pibrentasvir (JAN/USAN/INN); SCHEMBL2756579; CHEMBL3545123; SCHEMBL17639956; GTPL11268; EX-A865; C57H65F5N10O8; BDBM50453100; s9641; CS-8135; DB13878; AC-33418; BS-15250; Dimethyl N,N'-(((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis((6-fluoro-1H-benzimidazole-5,2-diyl)((2S)-pyrrolidine-2,1-diyl)((2S,3R)-3-methoxy-1-oxobutane-1,2-diyl)))biscarbamate; J3.646.121G; D10816; J-690144; Q47495788; A 1325912.0; Carbamic acid, N,N'-(((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)-1-piperidinyl)phenyl)-2,5-pyrrolidinediyl)bis((6-fluoro-1H-benzimidazole-5,2-diyl)-(2S)-2,1-pyrrolidinediyl((1S)-1-((1R)-1-methoxyethyl)-2-oxo-2,1-ethanediyl)))bis-, C,C'-dimethyl ester; Methyl ((2S,3R)-1-((2S)-2-(5-((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)-5-(6-fluoro-2-((2S)-1-(N-(methoxycarbonyl)-O-methyl-L-threonyl)pyrrolidin-2-yl)-1H-benzimidazol-5-yl)pyrrolidin-2-yl)-6-fluoro-1H-benzimidazol-2-yl)pyrrolidin-1-yl)-3-methoxy-1-oxobutan-2-yl)carbamate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB13878	DR01291	.	1113.2	C57H65F5N10O8	200	2000	7.4	80	4	17	17	"1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1"	C[C@H]([C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C(=C3)F)[C@H]4CC[C@@H](N4C5=CC(=C(C(=C5)F)N6CCC(CC6)C7=CC=C(C=C7)F)F)C8=CC9=C(C=C8F)N=C(N9)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)OC)NC(=O)OC)NC(=O)OC)OC	VJYSBPDEJWLKKJ-NLIMODCCSA-N
DG00569	Cefozopran	9571080	"Cefozopran; CZOP; 113359-04-9; Cefozopran [INN]; SCE 2787; cefozopranum; UNII-1LG87K28LW; Cefozopran (INN); 1LG87K28LW; CHEBI:3502; Imidazo[1,2-b]pyridazinium,1-[[(6R,7R)-7-[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt; CCRIS 6737; C19H17N9O5S2; SCHEMBL49106; (-)-1-(((6R,7R)-7-(2-(5-Amino-1,2,4-thiadiazol-3-yl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1H-imidazo(1,2-b)pyridazin-4-ium hydroxide inner salt, 7(sup 2)-(Z)-(O-methyloxime); Imidazo(1,2-b)pyridazinium, 1-((6R,7R)-7-(((2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt; CHEMBL1276663; (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetyl]amino]-3-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; HY-B0771; AKOS015896118; DB13667; H710; Imidazo(1,2-b)pyridazinium, 1-((7-(((5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, (6R-(6alpha,7beta(Z)))-; D01052; J-504081; (6R,7R)-7-{[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(methoxyimino)acetyl]amino}-3-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 1-[[(6R,7R)-7-[[(2Z)-(5-Amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3 -yl]methyl]-imidazo[1,2-B]pyridazinium hydroxide inner salt; 7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3502	.	.	.	515.5	C19H17N9O5S2	238	960	0.7	35	2	12	6	"1S/C19H17N9O5S2/c1-33-24-11(14-23-19(20)35-25-14)15(29)22-12-16(30)28-13(18(31)32)9(8-34-17(12)28)7-26-5-6-27-10(26)3-2-4-21-27/h2-6,12,17H,7-8H2,1H3,(H3-,20,22,23,25,29,31,32)/b24-11-/t12-,17-/m1/s1"	CO/N=C(/C1=NSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=C5C=CC=NN5C=C4)C(=O)[O-]	QDUIJCOKQCCXQY-WHJQOFBOSA-N
DG00570	Flomoxef	65864	"Flomoxef; 99665-00-6; Flomoxefum; FMOX; Flomoxef [INN]; UNII-V9E5U5XF42; V9E5U5XF42; Flomoxef (INN); flomoxef sodium; (6R,7R)-7-[[2-(difluoromethylsulfanyl)acetyl]amino]-3-[[1-(2-hydroxyethyl)tetrazol-5-yl]sulfanylmethyl]-7-methoxy-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Flomoxefo; 5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(difluoromethyl)thio]acetyl]amino]-3-[[[1-(2-hydroxyethyl)-1H-tetrazol-5-yl]thio]methyl]-7-methoxy-8-oxo-, (6r-cis)-; 5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[[(difluoromethyl)thio]acetyl]amino]-3-[[[1-(2-hydroxyethyl)-1H-tetrazol-5-yl]thio]methyl]-7-methoxy-8-oxo-, (6R,7R)-; Flomoxefum [Latin]; Flomoxefo [Spanish]; C15H18F2N6O7S2; NCGC00182999-01; SCHEMBL49438; CHEMBL15413; CHEBI:135813; BCP20920; HY-B0706; ZINC3874302; AKOS015896442; DB11935; AC-15832; K789; CS-0009596; D07963; 665F006; A846063; Q5459999; (-)-(6R,7R)-7-(2-((Difluoromethyl)thio)acetamido)-3-(((1-(2-hydroxyethyl)-1H-tetrazol-5-yl)thio)methyl)-7-methoxy-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(difluoromethylthio)-1-oxoethyl]amino]-3-[[[1-(2-hydroxyethyl)-5-tetrazolyl]thio]methyl]-7-methoxy-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[2-[bis(fluoranyl)methylsulfanyl]ethanoylamino]-3-[[1-(2-hydroxyethyl)-1,2,3,4-tetrazol-5-yl]sulfanylmethyl]-7-methoxy-8-oxidanylidene-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{2-[(difluoromethyl)sulfanyl]acetamido}-3-({[1-(2-hydroxyethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-7-methoxy-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (7R)-7-(2-(difluoromethylthio)acetamido)-3-((1-(2-hydroxyethyl)-1H-tetrazol-5-ylthio)methyl)-7-methoxy-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	Investigative	1	Investigative Drug(s)	Investigative	Small molecular drug	.	DB11935	.	.	496.5	C15H18F2N6O7S2	220	793	-1.3	32	3	14	11	"1S/C15H18F2N6O7S2/c1-29-15(18-8(25)6-31-13(16)17)11(28)23-9(10(26)27)7(4-30-12(15)23)5-32-14-19-20-21-22(14)2-3-24/h12-13,24H,2-6H2,1H3,(H,18,25)(H,26,27)/t12-,15+/m1/s1"	CO[C@@]1([C@@H]2N(C1=O)C(=C(CO2)CSC3=NN=NN3CCO)C(=O)O)NC(=O)CSC(F)F	UHRBTBZOWWGKMK-DOMZBBRYSA-N
DG00571	Intravenous immunoglobulin	.	.	Approved	1	Approved Drug(s)	Approved	Biotech	.	DB00028	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00572	Amphotericin B	5280965	"Amphotericin b; 1397-89-3; Amphotericin; Amphotericine B; Fungizone; Amfotericina B; Amphotericinum B; AMPH-B; Liposomal Amphotericin B; Amphotericin-B; Abelcet; Ambisome; Fungilin; Ampho-Moronal; UNII-7XU7A7DROE; Amphotec; Halizon; MFCD00877763; 7XU7A7DROE; NSC 527017; NCGC00090808-01; Abelecet; C47H73NO17; DSSTox_CID_2601; DSSTox_RID_76653; DSSTox_GSID_22601; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; Amphotericin B trihydrate; Amphortericin B; Anfotericine B; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-(((2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; IAB; Fungisome; Amfotericina B [INN-Spanish]; Amphotericine B [INN-French]; Amphotericinum B [INN-Latin]; CCRIS 5963; HSDB 3008; Amphotericin B [USP:INN:JAN]; Fungizone (TN); Amphotec (TN); (1S,3R,4E,6E,8E,10E,12E,14E,16E,18S,19R,20R,21S,25R,27R,30R,31R,33S,35R,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,12,14,16-heptaene-38-carboxylic acid; AmBisome (TN); Amp B; CAS-1397-89-3; EINECS 215-742-2; NS 718; BRN 0078342; AI3-26528; Prestwick3_000410; Amphotericin B (85%); Amphotericin B solubilized; SCHEMBL17973; BSPBio_000340; 5-18-10-00525 (Beilstein Handbook Reference); BIDD:GT0351; BPBio1_000374; NKTR-024; Amphotericin B and cinnamon oil; DTXSID9022601; HMS2096A22; HMS3713A22; Amphotericin B (JP17/USP/INN); HY-B0221; Amphotericin B, Streptomyces nodosus; Tox21_111027; Tox21_202484; Amphotericin B from Streptomyces sp.; LMPK06000002; s1636; AKOS024464746; ZINC253387843; CCG-220410; DB00681; NCGC00260033-01; (1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*,18S*,19E,21E,23E,25E,27E,29E,31E,33R*,35S*,36R*,37S*))-33-((3-Amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo(33.3.1)nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; 14,39-Dioxabicyclo(33.3.1)nonatriaconta-19,21,23,25,2 7,29,31-heptaene-36-carboxylic acid, 33-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-(1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*,18S*,19E,21E,23E, 25E-27E,29E,31E,33R*,35S*,36R*,37S*))-; AB00513832; C06573; D00203; J10140; AB00513832_02; 397A893; Q412223; 1397-89-3, C47H73NO17; Amphotericin B from Streptomyces sp., ~80% (HPLC), powder; Amphotericin B from Streptomyces sp., BioReagent, suitable for cell culture, ~80% (HPLC); Amphotericin B solubilized, powder, gamma-irradiated, BioXtra, suitable for cell culture; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-Amino-3,6-dideoxy- -D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-he; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-hept; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,33R,35S,36R,37S)-33-{[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carbo; (1S,3R,4E,6E,8E,10E,12E,14E,16E,18S,19R,20R,21S,25R,27R,30R,31R,33S,35R,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-; 23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,12,14,16-heptaene-38-carboxylic acid; Amphotericin B from Streptomyces sp., Vetec(TM) reagent grade, BioReagent, suitable for cell culture, ~80%; Amphotericin B solution, 250 mug/mL in deionized water, sterile-filtered, BioReagent, suitable for cell culture"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00681	DR01468	DR2632	924.1	C47H73NO17	320	1670	0	65	12	18	3	"1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1"	C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O	APKFDSVGJQXUKY-INPOYWNPSA-N
DG00573	Ivermectin	6321424	"IVERMECTIN; Ivermectin B1a; 70288-86-7; Dihydroavermectin B1a; 22,23-Dihydroavermectin B1a; avermectin H2B1a; 71827-03-7; UNII-91Y2202OUW; 70161-11-4; Ivermectin Component B1a; CHEBI:63941; 91Y2202OUW; (2ae,4e,5's,6s,6'r,7s,8e,11r,13r,15s,17ar,20r,20ar,20bs)-6'-[(2s)-Butan-2-Yl]-20,20b-Dihydroxy-5',6,8,19-Tetramethyl-17-Oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-Tetradecahydro-2h,7h-Spiro[11,15-Methanofuro[4,3,2-Pq][2,6]benzodioxacyclooctadecine-13,2'-Pyran]-7-Yl 2,6-Dideoxy-4-O-(2,6-Dideoxy-3-O-Methyl-Alpha-L-Arabino-Hexopyranosyl)-3-O-Methyl-Alpha-L-Arabino-Hexopyranoside; 5-O-demethyl-22,23-dihydroavermectin A1a; MK-933; (1R,4S,5'S,6R,6'R,8R,10E,12S,13S,14E,16E,20R,21R,24S)-6'-[(2S)-butan-2-yl]-21,24-dihydroxy-12-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one; C48H74O14 (B1a form); Ivermectin B1a-d2; C48H74O14; 22,23-Dihydroavermectin B(1)a; NCGC00163233-01; Ivermectin (IVM); IVM; EINECS 276-046-2; dihydro avermectin Bla; BRN 4643153; 22,23-Dihydro-5-O-demethylavermectin A1a; H2B1a; Prestwick3_000156; DSSTox_CID_3181; Ivermectin (MK-0933); DSSTox_RID_76909; DSSTox_GSID_23181; BSPBio_000292; SCHEMBL312795; BPBio1_000322; CHEMBL263291; DTXSID8023181; CHEBI:94551; HMS2089M09; HMS2095O14; HMS3712O14; WCA82703; Tox21_112034; BDBM50409816; MFCD00869511; s1351; AKOS027470116; ZINC238808778; ZINC252286706; AC-6014; CCG-220156; NCGC00186639-01; NCGC00186639-03; AS-14167; BI166167; CAS-71827-03-7; HY-126937; AB00513813; CS-0108408; J10179; 22,23-DIHYDROAVERMECTIN B1A; IVERMECTIN; AB00513813-02; AB00513813-03; AB00513813_04; Avermectin A1a, 22,23-dihydro-5-O-demethyl-; 288I867; Ivermectin, Antibiotic for Culture Media Use Only; Q-201262; BRD-K24652731-001-02-7; BRD-K85554912-001-08-9; Q27132923; Ivermectin, British Pharmacopoeia (BP) Reference Standard; Ivermectin, European Pharmacopoeia (EP) Reference Standard; UNII-8883YP2R6D component AZSNMRSAGSSBNP-XPNPUAGNSA-N; Ivermectin, United States Pharmacopeia (USP) Reference Standard; Ivermectin, Pharmaceutical Secondary Standard; Certified Reference Material; (2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-6'-[(2S)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17; 22,23-Dihydroavermectin B1; ; ; Heartgard 30; ; ; Ivomec; ; ; Ivosint; ; ; Mectizan; ; ; Stromectol; ; ; Uvemec; ; ; Vermic; ; ; Zimecterin; clooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63941	DB00602	DR00147	DR0899	875.1	C48H74O14	170	1680	4.1	62	3	14	8	"1S/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1"	CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\\C)C	AZSNMRSAGSSBNP-XPNPUAGNSA-N
DG00574	Levedopa	6047	"Levodopa; L-dopa; 59-92-7; 3,4-dihydroxy-L-phenylalanine; 3-Hydroxy-L-tyrosine; Dopar; Bendopa; Larodopa; Levopa; Brocadopa; Cidandopa; Insulamina; Maipedopa; Dopaidan; Dopalina; Dopasol; Eldopal; Eldopar; Pardopa; Prodopa; Syndopa; 3-(3,4-Dihydroxyphenyl)-L-alanine; 3,4-Dihydroxyphenylalanine; (-)-Dopa; Dihydroxy-L-phenylalanine; Helfo-Dopa; Dopaflex; Deadopa; Dopal-fher; Doparkine; Dopaston; Dopastral; Eldopatec; Eurodopa; Doparl; Doprin; Veldopa; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; L-3,4-Dihydroxyphenylalanine; Levedopa; Levodopum; L-o-Hydroxytyrosine; Dopa; Ledopa; (-)-3-(3,4-Dihydroxyphenyl)-L-alanine; L-Tyrosine, 3-hydroxy-; 3,4-Dihydroxyphenyl-L-alanine; Dopaston SE; beta-(3,4-Dihydroxyphenyl)-L-alanine; L-(o-Dihydroxyphenyl)alanine; L-(-)-Dopa; L-3-Hydroxytyrosine; L-beta-(3,4-Dihydroxyphenyl)alanine; Weldopa; Parda; L-Dihydroxyphenylalanine; L-3-(3,4-Dihydroxyphenyl)alanine; C9H11NO4; Ro 4-6316; beta-(3,4-Dihydroxyphenyl)alanine; (S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; alanine, 3-(3,4-dihydroxyphenyl)-, L-; component of Sinemet; Dopar (TN); CHEBI:15765; CVT-301; beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine; L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine; UNII-46627O600J; Alanine, 3-(3,4-dihydroxyphenyl)-, (-)-; L(-)-Dopa; (-)-(3,4-Dihydroxyphenyl)alanine; dihydroxyphenylalanine; MFCD00002598; L-3,4-Dihydrophenylalanine; L-.beta.-(3,4-Dihydroxyphenyl)alanine; CHEMBL1009; .beta.-(3,4-Dihydroxyphenyl)-L-alanine; L-(3,4-Dihydroxyphenyl)alanine; L-Tyrosine, 3-hydroxy-, homopolymer; NSC118381; .beta.-(3,4-Dihydroxyphenyl)alanine; NSC-118381; CAS-59-92-7; NCGC00016270-04; Biodopa; Cerepap; Laradopa; Sobiodopa; L-(3,4-Dihydroxyphenyl)-.alpha.-alanine; 46627O600J; Helfo DOPA; beta-(3,4-Dihydroxyphenyl)-alpha-alanine; Atamet; Levodopum [INN-Latin]; BDBM50130192; L-O-Dihydroxyphenylalanine; L Dopa; 65170-01-6; CCRIS 3766; HSDB 3348; WLN: QVYZ1R CQ DQ; 3,4-Dihydroxyphenylalanine (VAN); SR-01000075384; EINECS 200-445-2; NSC 118381; Dopastone; Dopicar; Inbrija; Prolopa; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate; Prestwick_185; Levodopa (Sinemet); L-DOPA; Levodopa; Madopa (Salt/Mix); Levodopa [USAN:USP:INN:BAN:JAN]; Spectrum_000454; 4-dihydroxyphenylalanine; Carbidopa EP Impurity A; Prestwick0_000017; Prestwick1_000017; Prestwick2_000017; Prestwick3_000017; Spectrum2_000496; Spectrum4_000539; Spectrum5_001899; Lopac-D-9628; Levodopa (JP15/USP); DSSTox_CID_3209; bmse000322; Epitope ID:150927; 3, 4-Dihydroxyphenylalanine; Alanine,4-dihydroxyphenyl)-; DSSTox_RID_76926; DSSTox_GSID_23209; Lopac0_000454; SCHEMBL22655; BSPBio_000053; BSPBio_002354; KBioGR_001177; KBioSS_000934; L-4-5-Dihydroxyphenylalanine; MLS000028514; BIDD:GT0158; DivK1c_000452; SPECTRUM2300205; Levodopa (JP17/USP/INN); SPBio_000391; SPBio_001974; BPBio1_000059; GTPL3639; b-(3,4-Dihydroxyphenyl)alanine; DTXSID9023209; WLN: QVYZ1R CQ DQ -L; 3, 4-Dihydroxy-L-phenylalanine; BDBM60928; HMS501G14; KBio1_000452; KBio2_000934; KBio2_003502; KBio2_006070; Alanine,4-dihydroxyphenyl)-, L-; L-(3, 4-Dihydroxyphenyl)alanine; NINDS_000452; 3-Ethoxy-4-fluorophenylboronicacid; HMS1568C15; HMS1922J14; HMS2090O08; HMS2093N04; HMS2095C15; HMS2230B04; HMS3261K10; HMS3712C15; Pharmakon1600-02300205; ZINC895199; H-Phe{3,4-(OH)2}-OH; HY-N0304; Levodopa;3,4-Dihydroxyphenylalanine; b-(3,4-Dihydroxyphenyl)-L-alanine; Inbrija (levodopa inhalation powder); Tox21_110338; Tox21_500454; CCG-39571; L-3-(3,4-dihydroxy-phenyl)alanine; L-3-(3,4-dihydroxyphenyl)-Alanine; NSC759573; PDSP1_001541; PDSP2_001525; s1726; Alanine, 3-(3,4-dihydroxyphenyl)-; Alanine,4-dihydroxyphenyl)-, (-)-; AKOS010396267; b-(3,4-Dihydroxyphenyl)-a-L-alanine; L-b-(3,4-Dihydroxyphenyl)-a-alanine; .beta.-(3, 4-Dihydroxyphenyl)alanine; AC-8432; AM82124; CS-1945; DB01235; LP00454; MCULE-4743781842; NSC-759573; SDCCGMLS-0066924.P001; SDCCGSBI-0050439.P004; IDI1_000452; NCGC00015384-01; NCGC00016270-01; NCGC00016270-06; NCGC00016270-07; NCGC00016270-09; NCGC00016270-10; NCGC00016270-22; NCGC00093869-04; NCGC00261139-01; AS-13287; BP-12850; H813; SMR000058312; SBI-0050439.P003; L-(3, 4-Dihydroxyphenyl)-.alpha.-alanine; D0600; D9628; EU-0100454; N1648; 59L927; Alanine, 3-(3, 4-dihydroxyphenyl)-, (-)-; C00355; D 9628; D00059; D70595; J10404; V-1512; 3,4-Dihydroxy-L-phenylalanine, >=98% (TLC); AB00052418-06; AB00052418-07; AB00052418_08; AB00052418_09; A832543; Q300989; Q-201294; SR-01000075384-1; SR-01000075384-4; SR-01000075384-6; SR-01000075384-7; (S)-2-Amino-3-(3,4-dihydroxy-phenyl)-propionic acid; F0347-4695; Levodopa, British Pharmacopoeia (BP) Reference Standard; Levodopa, European Pharmacopoeia (EP) Reference Standard; Z1762772338; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acidL-dopa; UNII-QI9C343R60 component WTDRDQBEARUVNC-LURJTMIESA-N; 1E83F927-C221-46AA-B90A-81B33C5F3868; 3,4-Dihydroxy-L-phenylalanine, Vetec(TM) reagent grade, 98%; Levodopa, United States Pharmacopeia (USP) Reference Standard; 3,4-Dihydroxy-L-phenylalanine, certified reference material, TraceCERT(R); Levodopa, Pharmaceutical Secondary Standard; Certified Reference Material; 122769-74-8; L-Methyldopa ; (2S)-2-Amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; 3-(3,4-Dihydroxyphenyl)- -methyl-L-alanine; 3-Hydroxy-a-methyl-L-tyrosine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB01235	DR00125	DR0939	197.19	C9H11NO4	104	209	-2.7	14	4	5	3	"1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1"	C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O	WTDRDQBEARUVNC-LURJTMIESA-N
DG00575	Metronidazole	4173	"Metronidazole; 443-48-1; Flagyl; Metronidazol; 2-Methyl-5-nitroimidazole-1-ethanol; Anagiardil; Gineflavir; Trichazol; MetroGel; Bayer 5360; Deflamon; Meronidal; Metronidaz; Novonidazol; Trichopol; Trivazol; Danizol; Mexibol; Orvagil; Vagilen; Clont; Flagemona; Giatricol; Metronidazolo; Sanatrichom; Takimetol; Trichocide; Trichomol; Trikacide; Acromona; Atrivyl; Efloran; Entizol; Flagesol; Monagyl; Monasin; Trichex; Tricocet; Trikamon; Trikojol; Trikozol; Trimeks; Vagimid; Vertisal; Wagitran; Arilin; Bexon; Elyzol; Eumin; Flagil; Klion; Klont; Nalox; Tricom; 2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethanol; neo-Tric; Tricowas B; Deflamon-wirkstoff; Protostat; Satric; MetroCream; MetroLotion; MetroGel-Vaginal; CONT; NIDA; Methronidazole; Metromidol; Trichopal; Flegyl; Fossyol; 1H-Imidazole-1-ethanol, 2-methyl-5-nitro-; Flagyl Er; Metronidazolum; Metro I.V.; Metrolyl; 2-(2-methyl-5-nitroimidazol-1-yl)ethanol; Metric 21; Trichomonacid 'pharmachim'; 1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazole; RP 8823; NSC-50364; Metronidazole in Plastic Container; 2-Methyl-1-(2-hydroxyethyl)-5-nitroimidazole; 2-Methyl-3-(2-hydroxyethyl)-4-nitroimidazole; SC 10295; 1-(beta-Ethylol)-2-methyl-5-nitro-3-azapyrrole; 1-(2-Hydroxy-1-ethyl)-2-methyl-5-nitroimidazole; 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethan-1-ol; 2-(2-methyl-5-nitro-1-imidazolyl)ethanol; MFCD00009750; 1-(beta-Hydroxyethyl)-2-methyl-5-nitroimidazole; 1-Hydroxyethyl-2-methyl-5-nitroimidazole; Imidazole-1-ethanol, 2-methyl-5-nitro-; FLAGYL I.V. RTU IN PLASTIC CONTAINER; 1-(beta-Oxyethyl)-2-methyl-5-nitroimidazole; NSC 50364; UNII-140QMO216E; 2-(2-methyl-5-nitro-imidazol-1-yl)ethanol; BAY-5360; NSC69587; Noritate; MLS000028590; CHEBI:6909; 140QMO216E; Metro Gel; NSC50364; NSC-69587; NCGC00016446-06; CAS-443-48-1; Metrolag; Metrotop; Rathimed; SMR000058175; Vandazole; Zadstat; Tricho cordes; DSSTox_CID_892; Metronidazolo [DCIT]; Tricho-gynaedron; DSSTox_RID_75848; DSSTox_GSID_20892; Mexibol 'silanes'; Metro I.V. In Plastic Container; 1-(.beta.-Ethylol)-2-methyl-5-nitro-3-azapyrrole; 1-(.beta.-Hydroxyethyl)-2-methyl-5-nitroimidazole; Metronidazol [INN-Spanish]; Metronidazolum [INN-Latin]; Flagyl I.V. RTU; Flagyl 375; Trichobrol; Florazole; Mepagyl; Nidagyl; Rosased; Zidoval; Caswell No. 579AA; WLN: T5N CNJ A2Q B1 ENW; Noritate (TN); CCRIS 410; Metro cream & gel; Flagyl (TN); HSDB 3129; WLN: T6NTJ DQ ANU1- ET5N CNJ A1 BNW; SR-01000000244; EINECS 207-136-1; NSC 69587; EPA Pesticide Chemical Code 120401; BRN 0611683; Polibiotic; Trikhopol; Donnan; Flazol; CB-01-14 MMX; Metro IV; Vandazole (TN); Metronidazole,(S); Prestwick_334; Nuvessa (TN); IDR-90105; Cimetrol 500LPCI; Metronidazole solution; RP-8823; Metronidazole, BioXtra; Metronidazole (Flagyl); Spectrum_001035; Metronidazole [USAN:USP:INN:BAN:JAN]; HELIDAC (Salt/Mix); 2-(2-methyl-5-nitroimidazolyl)ethan-1-ol; Maybridge1_001999; Opera_ID_1585; Prestwick0_000081; Prestwick1_000081; Prestwick2_000081; Prestwick3_000081; Spectrum2_000883; Spectrum3_000506; Spectrum4_000060; Spectrum5_001289; M0924; CHEMBL137; NCIOpen2_000337; SCHEMBL23042; BSPBio_000002; BSPBio_002031; KBioGR_000559; KBioSS_001515; 5-23-05-00063 (Beilstein Handbook Reference); MLS000758286; MLS001424018; BIDD:GT0107; DivK1c_000007; SPECTRUM1500412; SPBio_000666; SPBio_001941; BAYER-5360; BPBio1_000004; DTXSID2020892; Flagyl I.V. RTU (Salt/Mix); BCBcMAP01_000184; GTPL10914; HMS500A09; HMS547C19; KBio1_000007; KBio2_001515; KBio2_004083; KBio2_006651; KBio3_001531; Metronidazole (JP17/USP/INN); Metronidazole, analytical standard; NINDS_000007; HMS1568A04; HMS1920N19; HMS2051G07; HMS2090B19; HMS2091F14; HMS2095A04; HMS2231E11; HMS3373O05; HMS3393G07; HMS3655E22; HMS3712A04; Pharmakon1600-01500412; ZINC113442; BCP13757; HY-B0318; Tox21_110441; Tox21_202413; Tox21_302794; BBL005452; BDBM50375309; CCG-40016; FP-250; NSC757118; s1907; STK177359; Metronidazole 2.0 mg/ml in Methanol; AKOS000269646; AKOS005169650; Tox21_110441_1; DB00916; KS-5140; MCULE-6891596695; NC00020; NSC-757118; IDI1_000007; SMP1_000189; NCGC00016446-01; NCGC00016446-02; NCGC00016446-03; NCGC00016446-04; NCGC00016446-05; NCGC00016446-07; NCGC00016446-08; NCGC00016446-09; NCGC00016446-11; NCGC00016446-12; NCGC00016446-17; NCGC00022059-03; NCGC00022059-04; NCGC00022059-05; NCGC00256513-01; NCGC00259962-01; AC-23968; SY002821; SBI-0051447.P003; DB-051212; Metronidazole, SAJ first grade, >=99.0%; AB00052046; BB 0218386; FT-0603394; SW196613-4; C07203; D00409; AB00052046-17; AB00052046_18; AB00052046_19; A826552; Metronidazole, VETRANAL(TM), analytical standard; Q169569; 2-(2-methyl-5-nitro-1H-imidazol-1-yl)-1-ethanol; 2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethanol #; Metronidazole, Antibiotic for Culture Media Use Only; Q-201403; SR-01000000244-4; SR-01000000244-5; BRD-K52020312-001-05-2; BRD-K52020312-001-15-1; Z87001124; F1773-0073; Metronidazole, certified reference material, TraceCERT(R); Metronidazole, British Pharmacopoeia (BP) Reference Standard; Metronidazole, European Pharmacopoeia (EP) Reference Standard; Metronidazole, United States Pharmacopeia (USP) Reference Standard; Metronidazole solution, 2.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Metronidazole, Pharmaceutical Secondary Standard; Certified Reference Material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6909	DB00916	.	DR1073	171.15	C6H9N3O3	83.9	170	0	12	1	4	2	"1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3"	CC1=NC=C(N1CCO)[N+](=O)[O-]	VAOCPAMSLUNLGC-UHFFFAOYSA-N
DG00576	Amprenavir	65016	"Amprenavir; 161814-49-9; Agenerase; Prozei; VX-478; 141W94; Amprenavir (agenerase); KVX-478; VX 478; UNII-5S0W860XNR; CHEBI:40050; (3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate; 5S0W860XNR; Vertex VX478; AMV; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester; 141 W94; (3S)-oxolan-3-yl N-[(2S,3R)-3-hydroxy-4-[N-(2-methylpropyl)(4-aminobenzene)sulfonamido]-1-phenylbutan-2-yl]carbamate; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL ESTER; DRG-0258; Agenerase (TM); Agenerase (TN); (S)-tetrahydrofuran-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; [(3S)-tetrahydrofuran-3-yl] N-[(1S,2R)-3-[(4-aminophenyl)sulfonyl-isobutyl-amino]-1-benzyl-2-hydroxy-propyl]carbamate; GNA & Amprenavir; HHA & Amprenavir; HSDB 7157; Amprenavir (JAN/USAN/INN); Amprenavir [USAN:INN:BAN]; Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate; 1hpv; 3ekp; 3ekv; 3nuj; 3nuo; VX478; NCGC00159461-02; (3S-(3R*(1R*,2S*)))-(3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate; 1t7j; 3nu3; 3nu4; 3nu5; 3nu6; 3nu9; 3sm2; APV & AAG; APV & HSA; CHEMBL116; SCHEMBL34151; (3S)-Tetrahydro-3-furyl ((alphaS)-alpha-((1R-1-hydroxy-2-(N(sup 1)-isobutylsulfanilamido)ethyl)phenethyl)carbamate; MLS006011492; BIDD:GT0398; Amprenavir & human serum albumin; J05AE05; 3s43; 3s45; HMS2090N10; ZINC3809192; BDBM50215393; MFCD00934214; s1639; Amprenavir & alpha1-acid glycoprotein; AKOS000280844; AM84544; BCP9000297; CCG-269742; CS-1410; DB00701; MCULE-8147835017; NCGC00159461-07; NCGC00159461-08; (3S)-oxolan-3-yl N-[(2S,3R)-3-hydroxy-4-[N-(2-methylpropyl)4-aminobenzenesulfonamido]-1-phenylbutan-2-yl]carbamate; 4-Amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide; Amprenavir 100 microg/mL in Acetonitrile; AS-30915; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Galanthus nivalis agglutinin (GNA); Carbamic acid, (3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, tetrahydro-3-furanyl ester, (3S-(3R*(1S*,2R*)))-; Carbamic acid, N-[(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S)-tetrahydro-3-furanyl ester; HY-17430; SMR003885056; BCP0726000051; SW219687-1; C08086; D00894; AB01275534-01; AB01275534_02; 814A499; A810295; Q422198; SR-05000001530; SR-05000001530-1; Z1557399789; (3S)-tetrahydrofuran-3-yl [(1S,2R)-3-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-1-benzyl-2-hydroxypropyl]carbamate; (3S)-tetrahydrofuran-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-oxidanyl-1-phenyl-butan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Hippeastrum hybrid agglutinin( HHA); Carbamic acid,[(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-,(3S)-tetrahydro-3-furanyl ester; N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamic acid [(3S)-3-oxolanyl] ester"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:40050	DB00701	DR00584	DR0107	505.6	C25H35N3O6S	140	745	2.9	35	3	8	12	"1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1"	CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N	YMARZQAQMVYCKC-OEMFJLHTSA-N
DG00577	Ritonavir	392622	"Ritonavir; 155213-67-5; Norvir; ABT-538; Abbott 84538; A-84538; ABBOTT-84538; ABT 538; RTV; UNII-O3J8G9O825; CHEBI:45409; 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate; O3J8G9O825; MFCD00927142; NSC693184; NSC-693184; 2,7,10,12-Tetraazatridecanoic acid, 4-hydroxy-12-methyl-9-(1-methylethyl)-13-[2-(1-methylethyl)-4-thiazolyl]-8,11-dioxo-3,6-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (3S,4S,6S,9S)-; thiazol-5-ylmethyl ((2S,3S,5S)-3-hydroxy-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1,6-diphenylhexan-2-yl)carbamate; NCGC00159462-02; NCGC00183130-01; Norvir Softgel; DSSTox_CID_28553; DSSTox_RID_82825; DSSTox_GSID_48627; N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide; RIT; ABT538; DRG-0244; 2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (5S-(5R*,8R*,10R*,11R*))-; SMR000466395; thiazol-5-ylmethyl (2S,3S,5S)-3-hydroxy-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1,6-diphenylhexan-2-ylcarbamate; thiazol-5-ylmethyl N-[(1S,2S,4S)-1-benzyl-2-hydroxy-4-[[(2S)-2-[[(2-isopropylthiazol-4-yl)methyl-methyl-carbamoyl]amino]-3-methyl-butanoyl]amino]-5-phenyl-pentyl]carbamate; Norvir (TM); Norvir (TN); CAS-155213-67-5; HSDB 7160; 1,3-Thiazol-5-ylmethyl N-[(2S,3S,5R)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenyl-hexan-2-yl]carbamate; Ritonavirum; TMC 114r; Empetus; Ritomune; Ritovir; Viekirax; Viriton; 1hxw; 3prs; 3tne; 4eyr; Ritonavir [USAN:USP:INN:BAN]; Ritonavir- Bio-X; 2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolylmethyl ester, [5S-(5R*,8R*,10R*,11R*)]-; Ritonavir & PLGA; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 1sh9; Abbot 84538; CHEMBL163; SCHEMBL6679; Ritonavir (JAN/USP/INN); BIDD:PXR0023; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; MLS000759541; MLS001424063; MLS006011764; BIDD:GT0387; GTPL8804; DTXSID1048627; Ritonavir, >=98% (HPLC); AOB1044; HMS2051B08; HMS2235O10; HMS3715L22; Pharmakon1600-01502391; Ritonavir related compounds mixture; ZINC3944422; Tox21_112969; Tox21_113431; AC-733; BDBM50088504; NSC760369; s1185; STK634209; AKOS000280930; Ritonavir & Poly-lactide-co-glycolide; Tox21_112969_1; CCG-101007; CS-0432; DB00503; KS-5017; MCULE-9029064305; NC00257; NSC 693184; NSC 760369; NSC-760369; MRF-0000287; NCGC00159462-03; NCGC00159462-04; NCGC00159462-07; NCGC00159462-20; Ritonavir 100 microg/mL in Acetonitrile; BR164353; HY-90001; MLS000759541-02; R0116; SW197637-2; C07240; D00427; AB00639991-06; AB00639991-08; AB00639991_09; AB00639991_10; 213R675; A 84538; A904691; Q422618; J-009178; BRD-K51485625-001-07-6; Ritonavir solution, 1.0 mg/mL in acetonitrile, certified reference material; (2S, 3S, 5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinvl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; (2S,3S,5S )-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl) methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl) methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; (2S,3S,5S)-5-(N-(N((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; (2S,3S,5S)-5-(N-(N-((N-MethyI-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1.6-diphenyl-3-hydroxyhexane; (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl) methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino )-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1 .6-diphenyl-3-hydroxyhexane; (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3hydroxyhexane; (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1.6-diphenyl-3-hydroxyhexane; 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[(2S)-3-methyl-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}butanamido]-1,6-diphenylhexan-2-yl]carbamate; 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-di(phenyl)hexan-2-yl]carbamate; 5-Thiazolylmethyl (3S,4S,6S,9S)-4-hydroxy-12-methyl-9-(1-methylethyl)-13-[2-(1-methylethyl)-4-thiazolyl]-8,11-dioxo-3,6-bis(phenylmethyl)-2,7,10,12-tetraazatridecanoate; N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N(2)-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide; N1-((1S,3S,4S)-1-benzyl-3-hydroxy-5-phenyl-4-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}pentyl)-N2-{[[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)amino]carbonyl}-L-valinamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:45409	DB00503	DR00332	DR1430	720.9	C37H48N6O5S2	202	1040	6	50	4	9	18	"1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1"	CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O	NCDNCNXCDXHOMX-XGKFQTDJSA-N
DG00578	Tenofovir disoproxil fumarate	6398764	"Tenofovir Disoproxil Fumarate; 202138-50-9; Viread; Tenofovir DF; UNII-OTT9J7900I; OTT9J7900I; Tenofovir Disoproxil (fumarate); Tenofovir (Disoproxil Fumarate); GS-4331-05; CHEBI:63718; GSK-548470; 9-((R)-2-((bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine fumarate; (R)-(((((1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphoryl)bis(oxy))bis(methylene) diisopropyl dicarbonate fumarate; 2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-, 1,9-bis(1-methylethyl) ester, 5-oxide, (2E)-2-butenedioate (1:1); Tenofovir Disoproxil Fumarate; (2E)-but-2-enedioic acid bis({[(propan-2-yloxy)carbonyl]oxy}methyl) {[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methanephosphonate; [[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;(E)-but-2-enedioic acid; HSDB 7165; Tenofovirdisoproxilfumarate; C19H30N5O10P.C4H4O4; Tenofovir Disoproxil Fumarate [USAN]; Virea; GS 4331-05; GSK548470; Viread (TN); PMPA-PRODRUG; tenofovir-disoproxil-fumarate; CHEMBL1486; SCHEMBL40021; Tenofoviri disoproxili fumaras; MLS004774141; GS-1278 Disoproxil Fumarate; SCHEMBL2670560; AOB5580; EX-A590; s1400; Tenofovir disoproxil fumarate- Bio-X; AKOS016340707; AKOS025149493; CCG-270300; CS-1346; GS-US-104-0321; KS-1246; 9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine, fumarate; (R)-5-((2-(6-Amino-9H-purin-9-yl)-1-methylethoxy)methyl)-2,4,6,8-tetraoxa-5-phosphanonanedioic acid, bis(1-methylethyl) ester, 5-oxide, (E)-2-butenedioate (1:1); 9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine fumarate (1:1); Bis(hydroxymethyl) (((R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)phosphonate, bis(isopropyl carbonate) (ester), fumarate (1:1); BT164457; HY-13782; SMR003500786; Tenofovir disoproxil fumarate (JAN/USAN); BCP0726000258; AM20090676; V1698; GS-4331-05-; D01982; Tenofovir disoproxil fumarate, >=98% (HPLC); Q-201788; Q27132754; [[(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-(isopropoxycarbonyloxymethoxy)phosphoryl]oxymethyl isopropyl carbonate; fumaric acid; 9-[(R)-2[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinyl]methoxy]propyl]adenine fumarate (1:1); bis({[(propan-2-yloxy)carbonyl]oxy}methyl) ({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonate (2E)-but-2-enedioate; Tenofovir disoproxil fumarate, Pharmaceutical Secondary Standard; Certified Reference Material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63718	DB00300	.	DR1554	635.5	C23H34N5O14P	260	817	.	43	3	18	19	"1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1"	C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C.C(=C/C(=O)O)\\C(=O)O	VCMJCVGFSROFHV-WZGZYPNHSA-N
DG00579	Carbobenzoxy (Z)-D-Phe-L-Phe-Gly	474878	"75539-79-6; Carbobenzoxyphenylalanyl-phenylalanyl-glycine; Z-D-Phe-Phe-Gly-OH; 2-[[(2S)-3-phenyl-2-[[(2R)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]propanoyl]amino]acetic acid; Cbz-phe-phe-gly; Z-Phe-phe-gly; Carbobenzoxy-phe-phe-gly; N-CBZ-D-PHE-PHE-GLY; Benzyloxycarbonyl-phe-phe-gly; Virus replication inhibitory peptide ppg; Z-D-Phe-L-Phe-Gly; Carbobenzoxy-D-Phe-L-Phe-Gly; SCHEMBL10521480; DTXSID00997002; ZINC4537280; Glycine, N-[(phenylmethoxy)carbonyl]-D-phenylalanyl-L-phenylalanyl-; MFCD00063351; carbobenzoxy-d-phenylalanyl-l-phenylalanylglycine; A811423; Glycine, N-(N-(N-((phenylmethoxy)carbonyl)-D-phenylalanyl)-L-phenylalanyl)-; 2-[[(2S)-1-oxo-2-[[(2R)-1-oxo-3-phenyl-2-(phenylmethoxycarbonylamino)propyl]amino]-3-phenylpropyl]amino]acetic acid; 2-[[(2S)-2-[[(2R)-2-(benzyloxycarbonylamino)-3-phenyl-propanoyl]amino]-3-phenyl-propanoyl]amino]acetic acid; 2-[[(2S)-3-phenyl-2-[[(2R)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]propanoyl]amino]ethanoic acid; N-{2-[(2-{[(Benzyloxy)(hydroxy)methylidene]amino}-1-hydroxy-3-phenylpropylidene)amino]-1-hydroxy-3-phenylpropylidene}glycine"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	503.5	C28H29N3O6	134	742	3.3	37	4	6	13	"1S/C28H29N3O6/c32-25(33)18-29-26(34)23(16-20-10-4-1-5-11-20)30-27(35)24(17-21-12-6-2-7-13-21)31-28(36)37-19-22-14-8-3-9-15-22/h1-15,23-24H,16-19H2,(H,29,34)(H,30,35)(H,31,36)(H,32,33)/t23-,24+/m0/s1"	C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)OCC3=CC=CC=C3	ZSOSVHOISBSKID-BJKOFHAPSA-N
DG00580	Bromocriptine	31101	"Bromocriptine; Bromocryptine; 25614-03-3; Bromocriptin; Bromoergocryptine; Bromoergocriptine; Bromergocryptine; 2-Bromo-alpha-ergocryptine; Parlodel; 2-Bromo-alpha-ergokryptine; Bromocriptina; Bromocriptinum; 2-Bromo-alpha-ergokryptin; Bromocriptinum [INN-Latin]; Bromocriptina [INN-Spanish]; Bagren; Bromocriptine methanesulfonate; UNII-3A64E3G5ZO; CB-154; 2-Bromoergocryptine; Ergocryptine, 2-bromo-; 3A64E3G5ZO; CHEBI:3181; Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'alpha)-; Ergoset; Bromergon; CB 154; 22260-51-1; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman; 2-Bromo-.alpha.-ergocryptine; Bromocriptine (mesylate); C32H40BrN5O5; CCRIS 3244; NSC169774; EINECS 247-128-5; Bromocriptine (USAN/INN); SR-01000075356; Bromocriptine [USAN:INN:BAN]; NCGC00024584-03; 08Y; 2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione; Bromocriptine+ (GTP-); Prestwick0_000121; Prestwick1_000121; Prestwick2_000121; Carboprost Methylate,(S); DSSTox_CID_2687; Biomol-NT_000005; CHEMBL493; GTPL35; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman; DSSTox_RID_76692; DSSTox_GSID_22687; Lopac0_000171; SCHEMBL25297; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; BIDD:GT0464; SPBio_002101; BPBio1_001131; DTXSID1022687; SANDOZ 15-754; BDBM81993; Ergocryptine, 2-bromo- (8CI); Tox21_110907; PDSP2_001500; ZINC53683151; AKOS015961273; CCG-204266; DB01200; SDCCGSBI-0050159.P003; dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo; NCGC00024584-04; NCGC00024584-05; NCGC00024584-07; NCGC00024584-09; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman; (6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide; AC-13601; NCI60_001365; 10b-hydroxy-5-isobutyl-2-isopropyl-3,6-; CAS-25614-03-3; C06856; D03165; hexahydroindolo[4,3-fg]quinoline-9-carboxamide; Q413581; J-016067; SR-01000075356-5; (6aR,9R)-5-bromo-N-((2R,5S,10aS,10bS)-; [2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-; BRD-K14496212-001-01-1; BRD-K14496212-066-04-8; (4R,7R)-10-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide; (5alpha,5'beta)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)ergotaman; (6aR,9R)-5-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide; N-[(2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxo-8,9,10,10a-tetrahydro-5H-oxazolo[[ ]]pyrrolo[[ ]]pyrazin-2-yl]-bromo-methyl-[ ]carboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3181	DB01200	DR00550	.	654.6	C32H40BrN5O5	118	1230	3.8	43	3	6	5	"1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1"	CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O	OZVBMTJYIDMWIL-AYFBDAFISA-N
DG00581	TAS-120	71621331	"Futibatinib; TAS-120; 1448169-71-8; FGFR-IN-1; TAS120; UNII-4B93MGE4AL; 4B93MGE4AL; TAS 120; 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one; 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one; 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one; Futibatinib [USAN]; Futibatinib (JAN/USAN/INN); GTPL9786; CHEMBL3701238; SCHEMBL15345470; TAS 120 [WHO-DD]; BDBM161389; AMY16930; BCP17213; EX-A1862; NSC813488; WHO 10879; ZINC207800318; CS-6031; DB15149; Example 2 [WO2013108809]; NSC-813488; (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one; BS-15425; HY-100818; D11725; D77976; US9108973, 2; 2-Propen-1-one, 1-((3S)-3-(4-amino-3-(2-(3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-1-pyrrolidinyl)-"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB15149	.	.	418.4	C22H22N6O3	108	723	2	31	1	7	6	"1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)/t15-/m0/s1"	COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)[C@H]4CCN(C4)C(=O)C=C)OC	KEIPNCCJPRMIAX-HNNXBMFYSA-N
DG00582	Bimatoprost	5311027	"Bimatoprost; 155206-00-1; Lumigan; Latisse; AGN 192024; UNII-QXS94885MZ; AGN-192024; (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide; QXS94885MZ; CHEBI:51230; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide; (E)-7-[3,5-dihydroxy-2-[(E)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide; bimatoprostum; Prostamide; (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-N-ethylhept-5-enamide; (5z)-7-{(1r,2r,3r,5s)-3,5-Dihydroxy-2-[(1e,3s)-3-Hydroxy-5-Phenylpent-1-Enyl]cyclopentyl}-N-Ethylhept-5-Enamide; Lumigan (TN); (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide; Bimatoprost [USAN:INN:BAN:JAN]; Latisse (TN); LS-181817; SCHEMBL24425; 5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-; MLS006010039; US9271961, Bimatoprost; Bimatoprost (JAN/USAN/INN); GTPL1958; CHEMBL1200963; DTXSID30895042; BDBM220120; EX-A1769; HY-B0191; ZINC4474405; MFCD03411999; AKOS015995566; AM84507; DB00905; NCGC00181745-01; NCGC00181745-03; 5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (5Z)-; 5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-1(alpha(Z),2beta(1E,3S*)3alpha,5alpha))-; AS-35082; M052; SMR000058996; D02724; 206B001; SR-01000942224; Q2393348; SR-01000942224-1; 17-PHENYL TRINOR PROSTAGLANDIN F2ALPHA ETHYL AMIDE; 17-Phenyl-tri-norprostaglandin F2alpha-ethyl amide, >=95%, solid; 15M; 5-Heptenamide, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-, (5Z)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:51230	DB00905	.	DR0213	415.6	C25H37NO4	89.8	541	2.8	30	4	4	12	"1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1"	CCNC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](CCC2=CC=CC=C2)O)O)O	AQOKCDNYWBIDND-FTOWTWDKSA-N
DG00583	Latanoprost	5311221	"Latanoprost; 130209-82-4; Xalatan; PhXA41; PHXA-41; PhXA 41; XA41; UNII-6Z5B6HVF6O; propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate; 6Z5B6HVF6O; Latanoprost, ethanol solution; latanoprost (isopropyl ester); CHEBI:6384; propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate; MFCD00216074; XA-41; T-2345; 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 1-methylethyl ester, (5Z)-; isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate; Catioprost; (Z)-isopropyl 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate; SMR000466354; Xalatan (TN); latanoprostum; Nova-21027; Latanoprost [USAN:INN:BAN]; XA 41; PhXA34 [as 15(R,S)-isomer]; propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; AR-202; L-PPDS; Latanoprost, (+/-)-; CHEMBL1051; SCHEMBL24698; MLS000759468; MLS001424106; Latanoprost (JAN/USP/INN); GTPL1961; DTXSID1041057; HMS2051H11; HMS2089J17; HMS3715N22; AMY30089; EX-A1770; HY-B0577; BDBM50240648; s4709; ZINC12468792; Latanoprost, >=98% (HPLC), oil; AKOS024458331; CCG-100946; DB00654; NC00196; NCGC00246969-01; NCGC00246969-06; (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptanoic acid 1-methylethyl ester; AS-75099; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate; L0262; D00356; AB00640005-04; AB00640005-06; 209L824; A806039; Q634959; SR-01000759428; J-005764; SR-01000759428-4; UNII-8S5FB3XXG8 component GGXICVAJURFBLW-CEYXHVGTSA-N; Latanoprost, United States Pharmacopeia (USP) Reference Standard; Tris(2,4-dimethylphenyl)phosphine-5,5',5''''-trisulfonic acid trisodium salt; (1R,2R,3R,5S,3''R)-7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pentyl)-cyclopentyl]-hept-5-enoic acid isopropyl ester; (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoic acid propan-2-yl ester; 155551-81-8; 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester; 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester, (1R-(1-alpha(Z),2-beta(R*),3-alpha,5-alpha))-; Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-bis(oxidanyl)-2-[(3R)-3-oxidanyl-5-phenyl-pentyl]cyclopentyl]hept-5-enoate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6384	DB00654	.	.	432.6	C26H40O5	87	526	4.3	31	3	5	14	"1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1"	CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1CC[C@H](CCC2=CC=CC=C2)O)O)O	GGXICVAJURFBLW-CEYXHVGTSA-N
DG00584	Dasabuvir	56640146	"Dasabuvir; 1132935-63-7; ABT-333; N-(6-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; exviera; ABT333; Dasabuvir (ABT-333); UNII-DE54EQW8T1; CHEBI:85182; ABT 333; Dasabuvir sodium monohydrate; DE54EQW8T1; N-(6-(3-tert-Butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; N-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide; N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide; C26H27N3O5S; Dasabuvir [INN]; Dasabuvir [USAN:INN]; Dasabuvir(ABT-333); Dasabuvir (USAN/INN); EC 805-439-9; SCHEMBL351053; CHEMBL3137312; GTPL11270; AMY6937; EX-A432; BCP09324; BDBM50549803; MFCD27923655; s5402; ZINC95616937; AKOS022178299; CCG-269640; DB09183; SB16833; NCGC00378604-01; NCGC00378604-04; AC-28957; AM808018; AS-55916; DA-35359; HY-13998; Methanesulfonamide, N-(6-(5-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-3-(1,1-dimethylethyl)-2-methoxyphenyl)-2-naphthalenyl)-; N-(6-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)met; FT-0726471; Y1902; D10553; A894448; Q19462214; ABT 333; ; ; N-[6-[3-tert-Butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide; N-(6-(3-tert-butyl-5(2,4-dioxo -3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; N-(6-(3-tert-butyl-5-(2, 4-dioxo -3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; N-(6-(3-tert-butyl-5-(2,4-dioxo -3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; N-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxy-phenyl]-2-naphthyl]methanesulfonamide; Sodium 3-(3-tert-butyl-4-methoxy-5-{6- [(methylsulfonyl)amino]naphthalene-2-yl}phenyl)-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-ide hydrate (1:1:1)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:85182	DB09183	DR01289	DR0422	493.6	C26H27N3O5S	113	938	4.3	35	2	6	6	"1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31)"	CC(C)(C)C1=CC(=CC(=C1OC)C2=CC3=C(C=C2)C=C(C=C3)NS(=O)(=O)C)N4C=CC(=O)NC4=O	NBRBXGKOEOGLOI-UHFFFAOYSA-N
DG00585	Sofosbuvir	45375808	"SOFOSBUVIR; PSI-7977; 1190307-88-0; SOVALDI; GS-7977; PSI 7977; UNII-WJ6CA3ZU8B; GS7977; WJ6CA3ZU8B; CHEBI:85083; GS 7977; propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate; Sofosbuvir [USAN:INN]; C22H29FN3O9P; Hepcinat; Hepcvir; Resof; SoviHep; HSDB 8226; PSI7977; Sovaldi (TN); Sofosbuvir (JAN/USAN); Sofosbuvir(PSI-7977); Sofosbuvir (GS-7977); 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester; GTPL7368; SCHEMBL2010114; SofosbuvirPSI7977GS-7977; CHEMBL1259059; AMMD00019; EX-A389; (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate; isopropyl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydrofuran-2-yl]methoxy-phenoxy-phosphoryl]amino]propanoate; s2794; AKOS024464753; ZINC100074252; AM84279; CCG-269909; CS-0554; DB08934; GI 7977; GI-7977; Sofosbuvir (PSI-7977, GS-7977); Sofosbuvir (PSI-7977; GS-7977); BS165550; HY-15005; SW219116-1; D10366; Q2502747; (S)-2-{[(1R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-(R)-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy]phenoxyphosphorylamino}propionic acid (S)-isopropyl ester; (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-h; (S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; isopropyl ((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate; isopropyl (2S)-2-{[(S)-{[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate; S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4- dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)- (phenoxy)phosphorylamino)propanoate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:85083	DB08934	DR00372	DR1495	529.5	C22H29FN3O9P	153	913	1	36	3	11	11	"1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1"	C[C@@H](C(=O)OC(C)C)N[P@](=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3	TTZHDVOVKQGIBA-IQWMDFIBSA-N
DG00586	Corticosteroids	.	.	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00587	Penicillin V	6869	"Penicillin v; Phenoxymethylpenicillin; Oracillin; Penicillin phenoxymethyl; 87-08-1; Phenomycilline; Fenospen; Phenoxymethyl penicillin; V-Cillin; Vebecillin; Distaquaine V; Beromycin; Phenoxymethylenepenicillinic acid; Phenoximethylpenicillinum; Phenoxymethylpenicillinum; Fenoximetilpenicilina; Pen-V; phenoxymethylpenicillinic acid; Phenoxymethylpenicilline; Phenopenicillin; 6-Phenoxyacetamidopenicillanic acid; Penapar-Vk; Meropenin; Fenossimetilpenicillina [DCIT]; phenoxomethylpenicillin; Phenocillin; Stabicillin; Fenacilin; Oratren; Apopen; Ospen; Fenoximetilpenicilina [INN-Spanish]; Eskacillian V; V-Tablopen; Pen-vee; Acipen V; Pen-Oral; V-Cyline; Penicillin-Vk; V-Cil; Betapen-VK; Beepen-VK; Veetids; UNII-Z61I075U2W; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; CHEBI:27446; Calcipen; Rocilin; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Compocillin V; Eskacillin V; Crystapen V; V-Cylina; Phenoxymethylpenicillin (INN); (2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID; Z61I075U2W; P-Mega-Tablinen; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; PNV; Fenossimetilpenicillina; Phenoxymethylpenicillin [INN]; Penicillanic acid, 6-phenoxyacetamido-; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(phenyloxy)acetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Phenoxymethylpenicilline [INN-French]; Phenoxymethylpenicillinum [INN-Latin]; CCRIS 752; V-Cillin (TN); Penicillin V (USP); HSDB 6314; phenoxomethylpenicillanyl; phenoxymethylpenicillanyl; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-; EINECS 201-722-0; BRN 0096259; Penicillin V [USAN:USP]; Phenoxymethylpenicillinic acid potassium salt; PENICILLINV; penicillin-v-potassium; 3,3-Dimethyl-7-oxo-6-((phenyloxyacetyl)amino)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenoxyacetyl)amino)-, (2S-(2alpha,5alpha,6beta))-; PC Pen VK; Spectrum_001007; Spectrum2_000495; Spectrum3_000543; Spectrum4_000472; Spectrum5_001409; CHEMBL615; Epitope ID:115011; Epitope ID:116056; SCHEMBL49223; BSPBio_002185; KBioGR_000944; KBioSS_001487; 4-27-00-05884 (Beilstein Handbook Reference); MLS001304105; DivK1c_000779; SPBio_000389; DTXSID3023429; SCHEMBL22099709; CHEBI:53706; GTPL10920; KBio1_000779; KBio2_001487; KBio2_004055; KBio2_006623; KBio3_001685; NINDS_000779; ZINC3831282; 2,2-dimethyl-6beta-[(phenoxyacetyl)amino]penam-3alpha-carboxylic acid; BDBM50370584; 3,3-dimethyl-6beta-[(phenoxyacetyl)amino]penam-2alpha-carboxylic acid (PIN); AKOS015969737; DB00417; IDI1_000779; SMR000539431; SBI-0051477.P003; AB00514745; C08126; D05411; Q422215; W-109316; BRD-K43966364-237-02-2; BRD-K43966364-237-03-0; Phenoxymethylpenicillin 100 microg/mL in Acetonitrile; 6beta-Phenoxyacetamido-2,2-dimethylpenam-3alpha-carboxylic acid; Phenoxymethylpenicillin, Antibiotic for Culture Media Use Only; Penicillin V, United States Pharmacopeia (USP) Reference Standard; Phenoxymethylpenicillin, European Pharmacopoeia (EP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:27446	DB00417	DR00868	.	350.4	C16H18N2O5S	121	547	2.1	24	2	6	5	"1S/C16H18N2O5S/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1"	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)O)C	BPLBGHOLXOTWMN-MBNYWOFBSA-N
DG00588	Foscarnet	3415	"Foscarnet; Phosphonoformic acid; Phosphonoformate; Carboxyphosphonic acid; 4428-95-9; Foscarmet; phosphonocarboxylic acid; Dihydroxyphosphinecarboxylic acid oxide; UNII-364P9RVW4X; phosphonomethanoic acid; CHEMBL666; 364P9RVW4X; CHEBI:127780; dihydroxyphosphanecarboxylic acid oxide; Phgosphonocarboxylic acid; NSC313410; Formic acid, phosphono-; Forscarnet; Phosphinecarboxylic acid, dihydroxy-, oxide; HSDB 8122; 1nki; J05AD01; Foscarnet (PFA); Spectrum_001359; PFA & rIFN.alpha.A; Spectrum2_000668; Spectrum3_001484; Spectrum4_000840; Spectrum5_000932; phosphonoformic acid(PFA); MSL & PFA; Phosphono-formic acid(PFA); hydroxycarbonylphosphonic acid; SCHEMBL23633; BSPBio_003067; Foscarnet & IFN-.ALPHA.; KBioGR_001419; KBioSS_001839; DivK1c_000915; SPBio_000735; GTPL5497; DTXSID0048478; KBio1_000915; KBio2_001839; KBio2_004407; KBio2_006975; KBio3_002567; NINDS_000915; ZINC8101109; BDBM50011181; Phosphonoformic acid & IFN-.ALPHA.; AKOS006281397; DB00529; IDI1_000915; Phosphonoformic acid trisodium salt hexa; (PFA)dihydroxyphosphinecarboxylic acid oxide; dihydroxyphosphinecarboxylic acid oxide(PFA); C06456; Q420387; 6-(2-Nitrophenyl)-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole; Phosphonoformate(trisodium) & Recombinant Alpha-A Interferon; Dihydroxyphosphinecarboxylic acid oxide and MSL, neutralizing monoclonal antibody"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:141644	DB00529	.	.	126.01	CH3O5P	94.8	120	-2	7	3	5	1	"1S/CH3O5P/c2-1(3)7(4,5)6/h(H,2,3)(H2,4,5,6)"	C(=O)(O)P(=O)(O)O	ZJAOAACCNHFJAH-UHFFFAOYSA-N
DG00589	Cidofovir	60613	"Cidofovir; 113852-37-2; Vistide; HPMPC; Cidofovir anhydrous; (S)-HPMPC; GS-504; Cidofovir (Vistide); Cidofovir hydrate; GS 0504; (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine; CDV; UNII-768M1V522C; [1-(4-amino-2-oxo-pyrimidin-1-yl)-3-hydroxy-propan-2-yl]oxymethylphosphonic acid; GS-0504; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine; (S)-(((1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl)oxy)methyl)phosphonic acid; CHEBI:3696; ({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine; 768M1V522C; NSC-742135; NCGC00184994-01; 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine; 1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine; Cidofovir (anhydrous); Cidofovir hydrate (1:2); Cidofovirum; Forvade; (S)-(3-(4-amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid; [(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid; anhydrous cidofovir; Cidofovir [INN]; ({[(2S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; C8H14N3O6P; HSDB 7115; GS504; Hpmpc dihydrate; Cidofovir gel; Cidofovir,Vistide; Cidofovir(Vistide); Forvade (TM); Cidofovir, anhydrous; (S)-HPMPC; Cidovir; CHEMBL152; Cidofovir anhydrous- Bio-X; SCHEMBL3948; DSSTox_CID_23734; DSSTox_RID_80069; DSSTox_GSID_43734; (2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine; MLS003915629; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine; DTXSID3043734; BDBM31915; 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate; BCP03734; EX-A4209; ZINC1530600; Tox21_112994; MFCD00866936; MFCD17215968; NSC742135; s1516; AKOS005145721; AKOS015854828; AC-1666; BCP9000528; CCG-267235; CS-1669; DB00369; GS-6438; (S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid; [(1S)-1-[(4-amino-2-oxo-pyrimidin-1-yl)methyl]-2-hydroxy-ethoxy]methylphosphonic acid; NCGC00184994-02; NCGC00184994-03; BC164304; HY-17438; Phosphonic acid, ((2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-, (S)-; SMR002544687; BCP0726000147; CAS-113852-37-2; AB01566823_01; 394C661; Q423445; SR-01000931969; J-502695; SR-01000931969-2; [[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid; ({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; L8P; Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-; Phosphonic acid,[[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3696	DB00369	DR00066	.	279.19	C8H14N3O6P	146	417	-3.6	18	4	6	6	"1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1"	C1=CN(C(=O)N=C1N)C[C@@H](CO)OCP(=O)(O)O	VWFCHDSQECPREK-LURJTMIESA-N
DG00590	Ganciclovir	135398740	"Ganciclovir; 82410-32-0; Gancyclovir; Cytovene; Vitrasert; Zirgan; RS-21592; Ganciclovirum; Cymevene; BW-759U; 2-Amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1H-purin-6(9H)-one; Virgan; 2'-Nor-2'-deoxyguanosine; BW 759U; 2'-NDG; BW 759; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; UNII-P9G3CKZ4P5; 9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine; MFCD00870588; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; GA2; CHEBI:465284; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; 9-((1,3-Dihydroxy-2-propoxy)methyl)guanine; Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-; Hydroxyacyclovir; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one; P9G3CKZ4P5; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; MLS000028481; 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-1H-purin-6-one; 2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol; NSC-759656; NCGC00015471-02; HHEMG; SMR000058324; Biolf 62; Ganciclovirum [Latin]; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol; CAS-82410-32-0; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one; 2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one; 2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone; DSSTox_CID_21032; DSSTox_RID_79613; DSSTox_GSID_41032; GCV; BIOLF-62; 9-[[2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine; 2-[(2-amino-6-hydroxypurin-9-yl)methoxy]propane-1,3-diol; Citovirax; Cymevan; Cymeven; BW-B 759U; 2-(2-Amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol; DRG-0018; 2-amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1,9-dihydro-6H-purin-6-one; Vitrasert (TN); Cytovene (TN); CCRIS 9212; HSDB 6512; SR-01000075894; GCV & MSL; Ganciclovir (JAN/USP/INN); 2-amino-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-1H-purin-6-one; Ganciclovir,(S); 2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one; BW-795; MB3795; Prestwick_1068; ST-605; Zirgan (TN); 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-; GCV & 1110U81; Ganciclovir [USAN:USP:INN:BAN:JAN]; Opera_ID_284; 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one; Prestwick0_000839; Prestwick1_000839; Prestwick2_000839; Prestwick3_000839; Lopac-G-2536; BIOLF62; CHEMBL182; EC 627-054-3; G 2536; SCHEMBL3033; Lopac0_000539; BSPBio_000797; MLS001077349; BIDD:GT0783; SPBio_002718; BPBio1_000877; ZINC1505; DTXSID8041032; methyl)-1H-purin-6(9H)-one; SCHEMBL14491348; BDBM85707; HMS1570H19; HMS2090K08; HMS2097H19; HMS2235C21; HMS3259B13; HMS3261L19; HMS3371H01; HMS3604L19; HMS3655M18; HMS3714H19; Pharmakon1600-01502362; ACT03317; BCP12705; NSC_3454; Tox21_110160; Tox21_500539; BBL029078; BDBM50237614; NSC759656; PDSP1_000816; PDSP2_000803; s1878; STK801910; STL514515; 2-amino-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-3H-purin-6-one; AKOS004119898; AKOS026749928; AKOS037492029; Tox21_110160_1; Valganciclovir hydrochloride impurity a; AC-8069; CCG-204629; CS-2014; DB01004; Ganciclovir, >=99% (HPLC), powder; KS-1065; LP00539; MCULE-9512761592; NC00647; NSC 759656; SDCCGSBI-0050522.P002; 2-Amino-1,9-dihydro-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6H-purin-6-one; SMP2_000038; NCGC00015471-01; NCGC00015471-03; NCGC00015471-04; NCGC00015471-05; NCGC00015471-06; NCGC00015471-08; NCGC00015471-16; NCGC00093928-01; NCGC00093928-02; NCGC00168567-01; NCGC00188980-01; NCGC00261224-01; 9-(1,3-dihydroxy-2propoxymethyl)guanine; BG164496; HY-13637; SY027981; 9-(1,3-dihydroxy-2-propoxymethyl)guanine; CAS_82410-32-0; 2-amino-9-((1,3-dihydroxypropan-2-yloxy); 9-(1,3-dihydroxy-2-propoxymethyl)-guanine; EU-0100539; FT-0611007; FT-0668948; G0315; SW197135-3; EN300-49857; C07019; D00333; J10127; Ganciclovir 100 microg/mL in Acetonitrile:Water; 410G320; 9-[[(1,3-Dihydroxy-2-propyl)oxy]methyl]guanine; A840322; A935676; Ganciclovir, Antibiotic for Culture Media Use Only; Q417640; SR-01000721941; Q-201148; SR-01000075894-1; SR-01000075894-4; SR-01000721941-3; Z1259084907; Ganciclovir, European Pharmacopoeia (EP) Reference Standard; 2-[(2-amino-6-hydroxy-9H-purin-9-yl)methoxy]propane-1,3-diol; Ganciclovir, United States Pharmacopeia (USP) Reference Standard; Ganciclovir, Pharmaceutical Secondary Standard; Certified Reference Material; 2-((6-Hydroxy-2-imino-2,3-dihydro-9H-purin-9-yl)methoxy)propane-1,3-diol; 2-amino-9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}-1,9-dihydro-6H-purin-6-one; Ganciclovir, 1.0 mg/mL (1% 1M HCl in Methanol), certified reference material; Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- and MSL, neutralizing monoclonal antibody"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:465284	DB01004	DR00027	.	255.23	C9H13N5O4	135	346	-2.5	18	4	6	5	"1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)"	C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N	IRSCQMHQWWYFCW-UHFFFAOYSA-N
DG00591	Valganciclovir	135413535	"Valganciclovir; 175865-60-8; Cymeval; L-Valine, ester with ganciclovir; CHEBI:63635; [2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester; Valganciclovir [INN:BAN]; 2-[(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)methoxy]-3-hydroxypropyl (2S)-2-amino-3-methylbutanoate; Valganciclovir (INN); C14H22N6O5; NCGC00168779-01; HSDB 8085; L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl ester; 5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one; RS 79070; RO1079070/194; SCHEMBL28996; GTPL4716; CHEMBL1201314; DTXSID8048288; SCHEMBL12672612; SCHEMBL22357189; (2S)-2-((2-Amino-6-oxo-1H-purin-9(6H)-yl)methoxy)-3-hydroxypropyl 2-amino-3-methylbutanoate; HY-A0032; AKOS015896083; AKOS015966553; CS-0950; DB01610; 2-[(2-amino-6-oxo-3,6-dihydro-9H-purin-9-yl)methoxy]-3-hydroxypropyl L-valinate; NCGC00387997-02; NCGC00387997-04; AM807983; Y0321; Ro-1079070/194; D02495; AB01563009_01; 865V608; Q423384; BRD-A50922295-003-01-9; [2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]-3-hydroxy-propyl] (2S)-2-amino-3-methyl-butanoate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63635	DB01610	DR00404	.	354.36	C14H22N6O5	167	528	-1.5	25	4	8	9	"1S/C14H22N6O5/c1-7(2)9(15)13(23)24-4-8(3-21)25-6-20-5-17-10-11(20)18-14(16)19-12(10)22/h5,7-9,21H,3-4,6,15H2,1-2H3,(H3,16,18,19,22)/t8 ,9-/m0/s1"	CC(C)[C@@H](C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N	WPVFJKSGQUFQAP-GKAPJAKFSA-N
DG00592	Riluzole	5070	"Riluzole; 1744-22-5; Rilutek; 2-Amino-6-(trifluoromethoxy)benzothiazole; 6-(trifluoromethoxy)benzo[d]thiazol-2-amine; 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; RP-54274; 2-amino-6-trifluoromethoxybenzothiazole; 2-amino-6-(trifluoromethoxy)benzo[d]thiazole; 2-Benzothiazolamine, 6-(trifluoromethoxy)-; PK-26124; RP 54274; C8H5F3N2OS; UNII-7LJ087RS6F; Riluzole (Rilutek); Amino-2 trifluoromethoxy-6 benzothiazole; MLS000069369; 6-Trifluoromethoxy-benzothiazol-2-ylamine; 2-Benzothiazolamine,6-(trifluoromethoxy)-; 2-Amino-6-(trifluoromethoxy)-benzothiazole; CHEMBL744; SMR000058231; 7LJ087RS6F; CHEBI:8863; Riluzol; 2-amino-6-(trifluoromethoxy)-1,3-benzothiazole; BENZOTHIAZOLE, 2-AMINO-6-TRIFLUOROMETHOXY-; MFCD00210213; NSC-753433; NSC-759823; NCGC00015882-09; Riluzolum; Riluzol [INN-Spanish]; Riluzolum [INN-Latin]; DSSTox_CID_25192; DSSTox_RID_80739; DSSTox_GSID_45192; Rilutek (TN); CAS-1744-22-5; Amino-2 trifluoromethoxy-6 benzothiazole [French]; Tiglutik; 2-amino-6-(trifluoromethoxyl)benzothiazole; Riluzole, solid; Riluzole [USAN:USP:INN:BAN]; Riluzole- Bio-X; BF-37; ALBB-006046; Prestwick-03A08; 6-(trifluoromethoxy)-2-benzothiazolamine; Tocris-0768; PK 26124; 6-trifluoromethoxybenzothiazole-2-yl-amine; Opera_ID_548; Lopac-R-116; Riluzole-13C-15N2; Prestwick0_000167; Prestwick1_000167; Prestwick2_000167; Prestwick3_000167; Spectrum2_000550; Biomol-NT_000245; cid_5070; Riluzole (JAN/USP/INN); Lopac0_001064; SCHEMBL78905; BSPBio_000033; BIDD:GT0055; SPBio_000599; SPBio_001954; BPBio1_000037; BPBio1_000837; GTPL2326; ZINC6481; DTXSID3045192; BDBM30705; Bio1_000416; Bio1_000905; Bio1_001394; HMS1773G08; HMS2089O19; HMS2094G07; HMS2233E14; HMS3263E10; HMS3371A09; HMS3657E13; Pharmakon1600-01505348; AMY14166; BCP02142; BHV-0223; HY-B0211; Riluzole - CAS 1744-22-5; Tiglutik (thickened oral suspension); Tox21_110252; Tox21_501064; AC-730; BBL013272; CCG-39528; NSC753433; NSC759823; s1614; STK503686; AKOS000265071; Tox21_110252_1; DB00740; KS-5231; LP01064; MCULE-9362288181; NSC 753433; NSC 759823; SDCCGSBI-0051034.P003; 2-amino-6-trifluoromethoxy-benzothiazole; 6-(trifluoromethoxy)benzothiazol-2-amine; 6-trifluoromethoxy-2-amino-benzothiazole; NCGC00015882-01; NCGC00015882-02; NCGC00015882-03; NCGC00015882-04; NCGC00015882-05; NCGC00015882-06; NCGC00015882-07; NCGC00015882-08; NCGC00015882-10; NCGC00015882-11; NCGC00015882-12; NCGC00015882-13; NCGC00015882-15; NCGC00015882-28; NCGC00023141-02; NCGC00023141-04; NCGC00023141-05; NCGC00023141-06; NCGC00261749-01; 6-(trifluoromethoxy)-2-aminobenzothiazole; 6-trifluoromethoxybenzo[d]thiazol-2-amine; BR164340; H090; SBI-0051034.P002; 2-Amino-6-(Trifluoromethoxy) Benzothiazole; 6-(Trifluoromethoxy)-2-amino-benzothiazole; DB-030335; EU-0101064; FT-0611194; R1174; SW196805-4; EN300-23782; 6-trifluoromethoxy-1,3-benzothiazol-2-ylamine; C07937; D00775; J10184; J10441; VU0239571-11; 744R225; Q415744; SR-01000002997-3; BRD-K21283037-001-02-5; BRD-K21283037-003-03-9; BRD-K21283037-003-06-2; F3282-0020; Z166605314; Rilutek; ; ; Rilutor; ; ; 6-(Trifluoromethoxy)-2-benzothiazolamine; Riluzole, United States Pharmacopeia (USP) Reference Standard; 2-Amino-6-(trifluoromethoxy)-1,3-benzothiazole;2-AMINO-6-(TRIFLUOROMETHOXY)BENZOTHIAZOLE"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8863	DB00740	DR00205	DR1425	234.2	C8H5F3N2OS	76.4	238	3.6	15	1	7	1	"1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)"	C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N	FTALBRSUTCGOEG-UHFFFAOYSA-N
DG00593	Rocuronium	441290	"Rocuronium; 143558-00-3; UNII-WRE554RFEZ; CHEBI:8884; WRE554RFEZ; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate; Org-9426; 1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-14-(acetyloxy)-5-hydroxy-2,15-dimethyl-4-(morpholin-4-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-(prop-2-en-1-yl)pyrrolidin-1-ium; NCGC00167433-01; Rocuronium ion; Rocuronium cation; Epitope ID:174837; C07556; SCHEMBL29958; C32H53BrN2O4; BIDD:GT0360; GTPL4003; CHEMBL1201244; DTXSID6048339; TQP0579; C32H53N2O4; HMS2090E03; ZINC53229445; CS-0733; DB00728; NCGC00167433-05; (2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane; H896; HY-17033; X5020; AB01274786-01; AB01274786-02; AB01274786_03; Q185331; SR-05000001500; SR-05000001500-1; BRD-K43305603-004-02-8; 1-[(2; A,3; A,5; A,16; A,17; A)-17-(Acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl]-1-(2-propenyl)pyrrolidinium"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8884	DB00728	DR00442	.	529.8	C32H53N2O4+	59	898	5	38	1	5	6	"1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1"	CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C	YXRDKMPIGHSVRX-OOJCLDBCSA-N
DG00594	Melamine-based arsenicals	.	.	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00595	Phenobarbital	4763	"Phenobarbital; Phenobarbitone; Phenobarbitol; Luminal; 50-06-6; Phenylethylbarbiturate; Phenobarbituric acid; Phenylethylmalonylurea; Fenobarbital; Phenemal; Adonal; Phenylethylbarbituric acid; Nunol; Neurobarb; Phenaemal; Dormiral; Gardenal; Hysteps; Aphenylbarbit; Aphenyletten; Dezibarbitur; Lepinaletten; Lumofridetten; Aephenal; Agrypnal; Amylofene; Barbenyl; Barbiphenyl; Barbipil; Barbivis; Barbonal; Barbophen; Bialminal; Cabronal; Calmetten; Calminal; Cardenal; Codibarbita; Coronaletta; Cratecil; Doscalun; Ensobarb; Ensodorm; Episedal; Epsylone; Eskabarb; Fenbital; Fenylettae; Gardepanyl; Glysoletten; Haplopan; Hennoletten; Hypnaletten; Hypnette; Hypnogen; Hypnolone; Hypnoltol; Liquital; Lixophen; Lubergal; Lubrokal; Lumesettes; Luphenil; Nirvonal; Parkotal; Pharmetten; Phenemalum; Phenobal; Phenobarbyl; Phenoluric; Phenolurio; Phenomet; Phenonyl; Phenoturic; Phenyletten; Phenyral; Polcominal; Promptonal; Sedizorin; Sedonettes; Solfoton; Sombutol; Somnolens; Somnoletten; Somnosan; Spasepilin; Starifen; Starilettae; Teolaxin; Barbita; Bardorm; Bartol; Chinoin; Duneryl; Epanal; Epidorm; Epilol; Etilfen; Euneryl; Fenemal; Fenosed; Haplos; Henotal; Leonal; Lepinal; Linasen; Lumesyn; Luramin; Molinal; Noptil; Sedabar; Sedicat; Sedlyn; Sedofen; Sedonal; Sevenal; Somonal; Lumen; Seda-Tablinen; Blu-phen; Nova-Pheno; Solu-Barb; Hypno-Tablinetten; Stental Extentabs; Phen-Bar; PHOB; Phenobarb; Sedophen; Talpheno; Triabarb; Versomnal; 5-Ethyl-5-phenylbarbituric acid; 5-Phenyl-5-ethylbarbituric acid; Tridezibarbitur; Triphenatol; Zadoletten; Barbinal; Barbiphen; Damoral; Dormina; Lefebar; Lephebar; Stental; Teoloxin; Theoloxin; Zadonal; SK-Phenobarbital; 5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione; Thenobarbital; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl-; 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione; Dormital; Phenylethylbarbitursaeure; Phenylaethylbarbitursaeure; 5-Ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; Barbituric acid, 5-ethyl-5-phenyl-; 5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione; Barbilehae (barbilettae); UNII-YQE403BP4D; component of Tedral; Sedonal (sedative); component of Slowten; CHEBI:8069; component of Antrocol; component of Hecadrol; component of Bronkotabs; 5-Ethyl-5-phenyl-2,4,6-(1H,3H,5H)pyrimidinetrione; component of Primatene P; CHEMBL40; Phenobarbital (in methanol solution); component of Valpin 50-PB; YQE403BP4D; Austrominal; Phenobarbitalum; Phenobarbitonum; NSC-9848; NSC-128143; NCGC00159493-02; Fenobarbitale; Fenobarbitale [DCIT]; Elixir of phenobarbital; Phenobarbitalum [INN]; DSSTox_CID_1122; Chardonna-2; DSSTox_RID_75953; DSSTox_GSID_21122; Phenylethyl barbituric acid; Fenobarbital [INN-Spanish]; Phenyl-ethyl-barbituric acid; Phenobarbitalum [INN-Latin]; WLN: T6VMVMV FHJ F2 FR; Barbinol; Fenemal recip; CAS-50-06-6; Levsin PB Drops and Tablets; CCRIS 502; Luminal (TN); phenobarbital (PB); Acido 5-fenil-5-etilbarbiturico; HSDB 3157; Acido 5-fenil-5-etilbarbiturico [Italian]; 5-Ethyl-5-phenyl-2,6(1H,3H,5H)-pyrimidinetrione; EINECS 200-007-0; 2,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl-; NSC 128143; Phenobar; AI3-02726; Phenobarbital [USP:INN:BAN:JAN]; Tedral (Salt/Mix); Primidone Impurity B; Kinesed (Salt/Mix); Antrocol (Salt/Mix); Donnatal (Salt/Mix); Donnazyme (Salt/Mix); Quadrinal (Salt/Mix); Mephobarbital M (nor); Barbidonna (Salt/Mix); Bronkotabs (Salt/Mix); PHENOBARBITAL CIV; Chardonna-2 (Salt/Mix); Epitope ID:116048; BIDD:PXR0061; Oprea1_384816; SCHEMBL16583; 5-ethyl-5-phenyl-hexahydropyrimidine-2,4,6-trione; Methylphenobarbital, M(nor-); MLS001240232; DivK1c_000987; GTPL2804; DTXSID5021122; SCHEMBL11114624; HMS503E15; KBio1_000987; NSC9848; Phenobarbital (JP17/USP/INN); NINDS_000987; HMS2272G06; Tox21_111713; Tox21_200510; BDBM50021437; NSC128143; STL367898; ZINC95588079; component of Primatene P (Salt/Mix); Phenobarbital 0.1 mg/ml in Methanol; Phenobarbital 1.0 mg/ml in Methanol; AKOS000605404; AKOS015964976; Barbituric acid, 5-ethyl-5-phenyl-,; AB02704; DB01174; MCULE-1782264021; component of Valpin 50-PB (Salt/Mix); IDI1_000987; NSC-128143-; Levsin PB Drops and Tablets (Salt/Mix); NCGC00159493-03; NCGC00159493-04; NCGC00258064-01; SMR000058986; DB-051722; C07434; D00506; Phenobarbital solution, 1.0 mg/mL in methanol; A827956; Q407241; SR-01000313151; SR-01000313151-1; Phenobarbital, United States Pharmacopeia (USP) Reference Standard; Phenobarbital solution, 1 mg/mL in methanol, ampule of 1 mL, certified reference material; 11097-06-6; UQA"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8069	DB01174	DR00471	DR1275	232.23	C12H12N2O3	75.3	339	1.5	17	2	3	2	"1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)"	CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2	DDBREPKUVSBGFI-UHFFFAOYSA-N
DG00596	Phenytoin	1775	"Phenytoin; 5,5-DIPHENYLHYDANTOIN; 57-41-0; Diphenylhydantoin; Dilantin; 5,5-diphenylimidazolidine-2,4-dione; Phenytoine; Zentropil; Epamin; Dihydantoin; Aleviatin; Dilabid; Diphantoin; Diphenylan; Lepitoin; Diphedan; Fenylepsin; Phentytoin; Sodanton; Difenin; Dihycon; Lehydan; Diphenylhydatanoin; Dantoinal; Di-Hydan; Dilantine; Dillantin; Diphenine; Diphentyn; Ditoinate; Elepsindon; Epilantin; Fenitoina; Fenytoine; Hidantilo; Hidantina; Hidantomin; Hydantoinal; Kessodanten; Phanantin; Phanatine; Phenatoine; Sodantoin; Sylantoic; Thilophenyl; Zentronal; Auranile; Dantinal; Dantoine; Difetoin; Difhydan; Dintoin; Dintoina; Diphedal; Diphenin; Enkelfel; Epifenyl; Epihydan; Fentoin; Hidantal; Hydantal; Idantoil; Idantoin; Labopal; Phentoin; Ritmenal; Saceril; Sanepil; Silantin; Solantin; Danten; Denyl; Epelin; Epinat; Epised; Eptal; Hidan; Lepsin; Ekko; Ictalis simple; Toin unicelles; Dilantin acid; Dantoinal klinos; Om-Hydantoine; Di-Phetine; Epdantoine simple; Hidantina vitoria; Gerot-epilan-D; Epilan-D; Neosidantoina; Comitoina; Hidantina senosian; Hydantol; Minetoin; Novantoina; Causoin; Convul; Di-Lan; Ekko capsules; Neos-Hidantoina; 2,4-Imidazolidinedione, 5,5-diphenyl-; Om hidantoina simple; TOIN; Phenhydanin; Phenytex; Phenytoinum; Sinergina; Sodanthon; Iphenylhydantoin; Phenytoin-Gerot; Difenilhidantoina; Fenytoin Dak; Didan TDC 250; Dilantin-125; Epdantoin Simple; Phenytoin AWD; Epilan D; 5,5-Diphenyl-2,4-imidazolidinedione; Diphenat; Hindatal; Hydantin; Epanutin; Fenitoina [INN-Spanish]; Phenytoine [INN-French]; Phenytoinum [INN-Latin]; Difenilhidantoina [Spanish]; Diphenylhydantoine [French]; 5,5-Dwufenylohydantoina; Antisacer; Fenantoin Mn Pharma; Diphenylhydantoine; Di-Lan (VAN); PHENYTOIN SODIUM; Diphenylhydantoin (VAN); Diphentoin; DILANTIN-30; Solantoin; Solantyl; Eptoin; DPH (VAN); PHENYTEK; 5,5-Diphenylimidazolidin-2,4-dione; 5,5-Diphenyl-imidazolidine-2,4-dione; 5,5-Diphenylhydantoin (IUPAC); 5,5-Dwufenylohydantoina [Polish]; Hydantoin, 5,5-diphenyl-; CCRIS 515; CHEBI:8107; NCI-C55765; 5,5-Diphenylhydantoin (phenytoin); UNII-6158TKW0C5; Diphenylan sodium; AI3-52498; 5,5-diphenyl hydantoin; Dilantin (TN); Novophenytoin; MFCD00005264; MLS000069789; Citrulliamon; Phenitoin; 5,5-diphenyltetrahydro-1H-2,4-imidazoledione; Fenidantoin s; NSC8722; 6158TKW0C5; NSC-8722; Epasmir 5; NCGC00021139-03; SMR000059026; DSSTox_CID_541; Fenidantoin 's'; DSSTox_RID_75650; DSSTox_GSID_20541; Epasmir '5'; Didan-tdc-250; CAS-57-41-0; phenytoin (PHN); component of Mebroin; fenidantoin ''s''; epasmir ''5''; NSC 8722; EINECS 200-328-6; SR-01000075211; IFLab1_000214; Fenidantoin 's'; HSDB 3160; Episar (Salt/Mix); Epasmir '5'; Aladdin (Salt/Mix); Alepsin (Salt/Mix); Epsolin (Salt/Mix); Phenytoin (Lepitoin); Tacosal (Salt/Mix); Phenytoin [USAN:USP:INN:BAN:JAN]; Antisacer (Salt/Mix); Epdantoin (Salt/Mix); Epileptin (Salt/Mix); Hydantoin,5-diphenyl-; Spectrum_001105; Fenigramon (Salt/Mix); Citrullamon (Salt/Mix); Opera_ID_394; 2, 5,5-diphenyl-; CHEMBL16; Spectrum2_001281; Spectrum3_000890; Spectrum4_000984; Spectrum5_001369; Lopac-D-4007; Epitope ID:117723; D 4007; SCHEMBL3440; BIDD:PXR0090; Lopac0_000329; Lopac0_000378; Oprea1_373280; BSPBio_001437; KBioGR_001387; KBioSS_001585; MLS001074087; MLS002454401; BIDD:GT0625; DivK1c_000507; Soluble phenytoin (Salt/Mix); SPBio_001281; Phenytoin (JP17/USP/INN); GTPL2624; 2-hydroxy-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one; DTXSID8020541; KBio1_000507; KBio2_001585; KBio2_004153; KBio2_006721; KBio3_001780; WLN: T5MVMV EHJ ER& ER; 5,5-Diphenylhydantoin, >=99%; NINDS_000507; Phenytoin 1.0 mg/ml in Methanol; SM-88 COMPONENT PHENYTOIN; HMS1412J16; HMS1694O05; HMS1791H19; HMS1989H19; HMS2089E11; HMS2236J06; HMS3261K17; HMS3402H19; HMS3657O03; BCP05960; HY-B0448; Hydantoin, 5,5-diphenyl- (8CI); ZINC2510358; Tox21_110861; Tox21_202299; Tox21_300281; Tox21_500378; AC-376; BDBM50003655; BDBM50101816; s2525; STK058029; STK182871; STL454130; AKOS000416887; AKOS003245432; Tox21_110861_1; 5,5-diphenylimidazolidine-2,4-dione.; CCG-104011; CCG-221682; DB00252; LP00378; MCULE-2376673346; Phenytoin 1000 microg/mL in Methanol; 5,5-di(phenyl)imidazolidine-2,4-dione; IDI1_000507; IDI1_008433; NCGC00015342-01; NCGC00015342-02; NCGC00015342-03; NCGC00015342-04; NCGC00015342-05; NCGC00015342-06; NCGC00015342-07; NCGC00015342-08; NCGC00015342-09; NCGC00015342-10; NCGC00015342-11; NCGC00015342-12; NCGC00021139-01; NCGC00021139-02; NCGC00021139-04; NCGC00021139-05; NCGC00021139-06; NCGC00021139-07; NCGC00021139-08; NCGC00021139-09; NCGC00021139-10; NCGC00021139-11; NCGC00091492-01; NCGC00091492-02; NCGC00091492-03; NCGC00091492-04; NCGC00091492-05; NCGC00093810-01; NCGC00093810-02; NCGC00254135-01; NCGC00259848-01; NCGC00261063-01; 5,5- Diphenyl- 2,4- imidazolidinedione; 5,5-Diphenyl-1H-imidazolidine-2,4-dione; D0894; EU-0100378; FT-0667653; FT-0699999; P-235; SW203757-2; EN300-16818; 5,5-diphenylimidazolidine-2,4-dione;Phenytoin; C07443; D00512; E76094; 2,4-Imidazolidinedione, 5,5-diphenyl- (9CI); 5,5-diphenyl-1H-imidazole-2,4(3H,5H)-dione; AB00374253-10; AB00374253-11; AB00374253_13; A831435; Q410400; SR-01000003141; SR-01000003141-8; SR-01000075211-2; W-105468; BRD-K55930204-001-02-7; BRD-K55930204-236-11-0; Z56786458; 4-hydroxy-5,5-diphenyl-1,5-dihydro-2H-imidazol-2-one; F0020-1370; Phenytoin, European Pharmacopoeia (EP) Reference Standard; Phenytoin, United States Pharmacopeia (USP) Reference Standard; 5,5-Diphenylhydantoin solution, drug standard, 1.0 mg/mL in methanol; Phenytoin, Pharmaceutical Secondary Standard; Certified Reference Material; Phenytoin for system suitability, European Pharmacopoeia (EP) Reference Standard; Phenytoin solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8107	DB00252	DR00431	DR1282	252.27	C15H12N2O2	58.2	350	2.5	19	2	2	2	"1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)"	C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3	CXOFVDLJLONNDW-UHFFFAOYSA-N
DG00597	Actinomycin D	457193	Etoposide; Methotrexate; Actinomycin D; Cyclophosphamide; Vincristine	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00598	SL111	.	.	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00599	Grazoprevir	44603531	"Grazoprevir; 1350514-68-9; MK-5172; MK5172; UNII-8YE81R1X1J; Grazoprevir monohydrate; MK 5172; MK-5172 ANHYDROUS; MK-5172 MONOHYDRATE; 8YE81R1X1J; (1R,18R,20R,24S,27S)-24-tert-butyl-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide; Grazoprevir [INN]; Grazoprevir anhydrous; MK-5172; Grazoprevir; SCHEMBL2175313; CHEMBL2063090; GTPL11573; DTXSID50159234; CHEBI:132975; EX-A2253; BDBM50485492; s3728; ZINC95551509; AKOS030253227; CCG-270451; CS-1374; DB11575; ino[11,12-b]quinoxaline-8-carboxamide; analog 15 [PMID: 24900473]; NCGC00378916-02; AC-29227; AS-55861; HY-15298; D82934; A887766; Zepatier [elbasvir (NS5A inhibitor) + grazoprevir]; Q19786991; (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-((1R,2S)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide; (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide; (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-di; (1R,18R,20R,24S,27S)-24-tert-butyl-N-[(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl]-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetraazapentacyclo[24.2.1.0 ,  .0 ,  .0  ,  ]nonacosa-3,5,7,9,11-pentaene-27-carboxamide; (1R,2S)-N-[[[(1R,2R)-2-[5-(3-hydroxy-6-methoxy-2-quinoxalinyl)pentyl]cyclopropyl]oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, cyclic (1-->2)-ether;MK-5172; (33R,35S,91R,92R,5S)-5-(tert-butyl)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxamide; oxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadec"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11575	.	DR0789	766.9	C38H50N6O9S	204	1580	4.7	54	3	11	8	"1S/C38H50N6O9S/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H,41,48)(H,42,45)(H,43,47)/t21-,22-,24-,29+,30-,31-,38-/m1/s1"	CC(C)(C)[C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCC[C@@H]7C[C@H]7OC(=O)N1	OBMNJSNZOWALQB-NCQNOWPTSA-N
DG00600	Vaniprevir	24765256	"Vaniprevir; vanihep; 923590-37-8; UNII-CV3X74AO1H; MK7009; MK-7009; CV3X74AO1H; Cyclopropanecarboxamide, N-(((6-(2-carboxy-2,3-dihydro-1H-isoindol-4-yl)-2,2-dimethylhexyl)oxy)carbonyl)-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethyl-, (1-2)-lactone, (1R,2R)-; (1R,21S,24S)-21-tert-butyl-N-[(1R,2R)-1-(cyclopropylsulfonylcarbamoyl)-2-ethylcyclopropyl]-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]heptacosa-6(11),7,9-triene-24-carboxamide; Vaniprevir [USAN:INN]; 3su6; vaniprevir; MK-7009; SCHEMBL3264200; CHEMBL4525964; GTPL11570; BDBM103836; BCP09841; MK-7009;MK 7009;Vaniprevir; ZINC95627836; CS-0340; DB11929; MK 7009; analog 35b [PMID: 20163176]; NCGC00485973-01; HY-10243; DS-017783; Q7914945"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB11929	.	.	757.9	C38H55N5O9S	189	1550	5.1	53	3	9	7	"1S/C38H55N5O9S/c1-7-25-18-38(25,33(46)41-53(49,50)27-14-15-27)40-31(44)29-17-26-20-43(29)32(45)30(36(2,3)4)39-34(47)51-22-37(5,6)16-9-8-11-23-12-10-13-24-19-42(21-28(23)24)35(48)52-26/h10,12-13,25-27,29-30H,7-9,11,14-22H2,1-6H3,(H,39,47)(H,40,44)(H,41,46)/t25-,26-,29+,30-,38-/m1/s1"	CC[C@@H]1C[C@@]1(C(=O)NS(=O)(=O)C2CC2)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)OCC(CCCCC5=C6CN(CC6=CC=C5)C(=O)O4)(C)C)C(C)(C)C	KUQWGLQLLVFLSM-ONAXAZCASA-N
DG00601	Glecaprevir	66828839	"Glecaprevir; ABT-493; UNII-K6BUU8J72P; 1365970-03-1; K6BUU8J72P; A-1282576.0; 1365970-03-1 (free); ABT 493; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10-carboxamide; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-{(1R,2R)-2(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10carboxamide; Glecaprevir [USAN]; Maviret; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclop ropyl]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta[18,19][1,10,17, 3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10-carboxamide; O31; ABT-493(Glecaprevir); Glecaprevir (USAN/INN); SCHEMBL883097; ABT493; CHEMBL3545363; GTPL11267; (1R,14E,18R,22R,26S,29S)-26-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-13,13-difluoro-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetrazapentacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5,7,9,11,14-hexaene-29-carboxamide; AMY38157; EX-A1940; s5720; CS-8098; DB13879; AC-33419; HY-17634; J3.646.120I; D10814; A-1282576; A-12825760; 3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10-carboxamide; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-((1R,2R)-2-(difluoromethyl)-1-((1-methylcyclopropane-1-sulfonyl)carbamoyl)cyclopropyl)-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta(18,19)(1,10,17,3,6)trioxadiazacyclononadecino(11,12-b)quinoxaline-10-carboxamide; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclop; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro- 5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12- methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10- carboxamide hydrate; Cyclopropanecarboxamide, N-((((1R,2R)-2-((4,4-difluoro-4-(3-hydroxy-2-quinoxalinyl)-2-buten-1-yl)oxy)cyclopentyl)oxy)carbonyl)-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-2-(difluoromethyl)-N-((1-methylcyclopropyl)sulfonyl)-, cyclic (1->2)-ether, (1R,2R)-; ropyl]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta[18,19][1,10,17,"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB13879	DR01308	DR1768	838.9	C38H46F4N6O9S	204	1760	4.6	58	3	15	7	"1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1"	CC1(CC1)S(=O)(=O)NC(=O)[C@]2(C[C@H]2C(F)F)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)O[C@@H]5CCC[C@H]5OC/C=C/C(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C	MLSQGNCUYAMAHD-ITNVBOSISA-N
DG00602	Paritaprevir	45110509	"Paritaprevir; Veruprevir; ABT-450; Veruprevir anhydrous; ABT450; 1216941-48-8; UNII-OU2YM37K86; 1221573-85-8; OU2YM37K86; Paritaprevir(ABT-450); (2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide; ABT 450; Veruprevir [INN]; Paritaprevir [USAN:INN]; veruprevir (deprecated INN); SCHEMBL3069964; CHEMBL3391662; GTPL11273; AMY6938; Paritaprevir(Veruprevir ABT-450); (2R,6S,12Z,13aR,14aR,16aS)-N-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide; EX-A2278; s5404; AKOS025396424; ZINC197964623; CCG-270449; CS-5051; DB09297; NCGC00509859-02; (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-(5-methylpyrazin-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16atetradecahydrocyclopropa(E)pyrrolo(1,2-a)(1,4)diazacyclopentadecine-14a(5H)-carboxamide; AC-33061; AS-75348; HY-12594; A857160; (1S,4R,6S,7Z,14S,18R)-N-(cyclopropanesulfonyl)-14-(5-methylpyrazine-2-amido)-2,15-dioxo-18-(phenanthridin-6-yloxy)-3,16-diazatricyclo[14.3.0.0 , ]nonadec-7-ene-4-carboxamide; (1S,4R,6S,7Z,14S,18R)-N-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide; (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-{[(5-methyl-2-pyrazinyl)carbonyl]amino}-5,16-dioxo-2-(6-phenanthridinyloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide; Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-, (2R,6S,12Z,13aS,14aR,16aS)-; Veruprevir; ; ; ABT 450; ; ; (2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB09297	DR01312	.	765.9	C40H43N7O7S	198	1600	4.7	55	3	10	7	"1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1"	CC1=CN=C(C=N1)C(=O)N[C@H]2CCCCC/C=C\\[C@@H]3C[C@]3(NC(=O)[C@@H]4C[C@H](CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8	UAUIUKWPKRJZJV-QPLHLKROSA-N
DG00603	Telaprevir	3010818	"Telaprevir; 402957-28-2; VX-950; Incivek; Telaprevir (VX-950); MP-424; Incivo; VX 950; Telavic; LY-570310; UNII-655M5O3W0U; MP 424; VRT 111950; VRT-111950; LY 570310; CHEMBL231813; CHEBI:68595; 655M5O3W0U; (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-6-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-octahydrocyclopenta[c]pyrrole-1-carboxamide; S-Telaprevir; (1S,3aR,6aS)-(2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-((1S)-1-((cyclopropylamino)oxoacetyl)butyl)octahydrocyclopenta(c)pyrrole-1-carboxamide; VX950 cpd; Telaprevir [USAN:INN]; HSDB 8125; Incivek(TM); Telaprevir-[d4]; Incivek (TN); Incivo (TN); Telaprevir,VX-950; Telaprevir (VX950); (1S,3aR,6aS)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-1-carboxamide; VX-950 (Telaprevir); SCHEMBL183996; Telaprevir (JAN/USAN/INN); GTPL7871; DTXSID40193304; EX-A006; AIDS213006; C36H53N7O6; 569364-34-7; AIDS-213006; AOB87136; ZINC3992480; BDBM50326056; FD7166; MFCD11616089; s1538; VRT111950; AKOS005145815; CCG-270366; CS-0285; DB05521; NCGC00346545-03; (3S,3aS,6aR)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethyl-butanoyl]-N-[(1S)-1-[2-(cyclopropylamino)-2-oxo-acetyl]butyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; AS-16995; HY-10235; W9903; WO-00218369; D09012; 957T282; Q408557; Q-101417; (1S,3aR,6aS)-(2S)-2-Cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydrocyclopenta[c]pyrrole-1-carboxamide; (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxo-hexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cydopropylamino)-1,2-dioxo-hexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-3-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-octahydrocyclopenta[c]pyrrole-1-carboxamide; (1S,3aR,6aS)-2-[(2S)-2-({(2S)-2-cyclohexyl-2-[(pyrazin-2-ylcarbonyl)amino]acetyl}amino)-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]octahydrocyclopenta[c]pyrrole-1-carboxamide; (1S,3aR,6aS)-N-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S)-3-{[(1S,3aR,6aS)-2-[(2S)-2-[(2S)-2-cyclohexyl-2-(pyrazin-2-ylformamido)acetamido]-3,3-dimethylbutanoyl]-octahydrocyclopenta[c]pyrrol-1-yl]formamido}-N-cyclopropyl-2-oxohexanamide; 2-(2-{2-Cyclohexyl-2-[(pyrazine-2-carbonyl)-amino]-acetylamino}-3,3-dimethyl-butyryl)-octahydro-cyclopenta[c]pyrrole-1-carboxylic acid (1-cyclopropylaminooxalyl-butyl)-amide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:68595	DB05521	DR00702	DR1543	679.8	C36H53N7O6	180	1240	4.2	49	4	8	14	"1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30+/m0/s1"	CCC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@@H]2[C@H]3CCC[C@H]3CN2C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C4CCCCC4)NC(=O)C5=NC=CN=C5	BBAWEDCPNXPBQM-GDEBMMAJSA-N
DG00604	Boceprevir	10324367	"Boceprevir; 394730-60-0; Victrelis; SCH 503034; EBP 520; UNII-89BT58KELH; SCH503034; SCH-503034; 89BT58KELH; CHEBI:68621; EBP-520; 3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide; (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-((S)-2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; (1R,2S,5S)-N-(4-AMINO-1-CYCLOBUTYL-3,4-DIOXOBUTAN-2-YL)-3-[(2S)-2-(TERT-BUTYLCARBAMOYLAMINO)-3,3-DIMETHYLBUTANOYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE; (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; (1S,4S,5R)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxo-propyl]-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethyl-butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-4-carboxamide; Boceprevir [USAN:INN]; HSDB 8081; Victrelis(TM); Victrelis (TN); Boceprevir & NM107; Boceprevir (INN/USAN); SCHEMBL640836; CHEMBL218394; EBP520; GTPL7876; BDBM12311; DTXSID30960103; BCP02502; EX-A1336; MFCD22208555; s3733; AKOS005145787; EBP-520;SCH503034; CCG-269852; CS-0361; DB08873; DT-0021; NCGC00378631-01; BOC; HY-10237; SCH 503034 & NM107; D08876; Q410551; J-519910; (1R,2S,5S)-N-(3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-((2S)-2-(((1,1-dimethylethyl)carbamoyl)amino)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexane-2-carboxamide; (1r,5s)-n-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(s)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(s)-carboxamide; 3-Azabicyclo(3.1.0)hexane-2-carboxamide, N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-((2S)-2-((((1,1- dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6- dimethyl-, (1R,2S,5S)-; 3-azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-, (1R,2S,5S)-; N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; N-(4-Amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-{N-[(tert-butylamino)(hydroxy)methylidene]-3-methylvalyl}-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboximidic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:68621	DB08873	DR01333	DR0218	519.7	C27H45N5O5	151	959	3.1	37	4	5	10	"1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16 ,17-,18-,20+/m0/s1"	CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C	LHHCSNFAOIFYRV-DOVBMPENSA-N
DG00605	Voxilaprevir	89921642	"Voxilaprevir; 1535212-07-7; GS9857; UNII-0570F37359; (1R,18R,20R,24S,27S,28S)-24-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide; 0570F37359; GS-9857; Voxilaprevir [USAN:INN]; Voxilaprevir (USAN/INN); C40H52F4N6O9S; CHEMBL4474855; SCHEMBL15412621; EX-A5390; DB12026; HY-19840; CS-0017027; J3.665.048F; D10899; Q27236086; (1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1 R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18-difluoro-14- methoxy-3,6-dioxo-1,1a,3,4,5,6,9,1 0,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19]; L9P"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB12026	DR01315	DR1714	868.9	C40H52F4N6O9S	204	1780	5.9	60	3	15	9	"1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1"	CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C	MZBLZLWXUBZHSL-FZNJKFJKSA-N
DG00606	Asunaprevir	16076883	"Asunaprevir; 630420-16-5; BMS-650032; BMS 650032; UNII-S9X0KRJ00S; BMS650032; S9X0KRJ00S; 1,1-dimethylethyl ((1S)-1-{((2S,4R)-4-(7-chloro-4-methoxyisoquinolin-1-yloxy)-2-({(1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-ethenylcyclopropyl}carbamoyl) pyrrolidin-1-yl)carbonyl}-2,2-dimethylpropyl)carbamate; Asunaprevir (BMS-650032); sunvepra; N-(Tert-Butoxycarbonyl)-3-Methyl-L-Valyl-(4r)-4-[(7-Chloro-4-Methoxyisoquinolin-1-Yl)oxy]-N-{(1r,2s)-1-[(Cyclopropylsulfonyl)carbamoyl]-2-Ethenylcyclopropyl}-L-Prolinamide; tert-butyl ((S)-1-((2S,4R)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate; tert-butyl N-[(2S)-1-[(2S,4R)-4-(7-chloro-4-methoxyisoquinolin-1-yl)oxy-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate; Asunaprevir [USAN:INN]; Sunvepratrade; Sunvepra (TN); 2R9; tert-butyl N-[(1S)-1-[(2S,4R)-4-[(7-chloro-4-methoxy-1-isoquinolyl)oxy]-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinyl-cyclopropyl]carbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]carbamate; Asunaprevir (JAN/USAN); Asunaprevir; BMS-650032; SCHEMBL2630655; CHEMBL2105735; GTPL10882; EX-A386; CHEBI:134723; (1R,2S)-N-[(1,1-Dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenylcyclopropanecarboxamide; AMY38775; BCP08230; BDBM50287594; MFCD27987900; ZINC85540202; AKOS037515831; CS-0674; DB11586; compound 24 [PMID: 24564672]; NCGC00378691-02; NCGC00378691-05; HY-14434; Asunaprevir;BMS650032;BMS-650032; D10093; A857563; Q4811881; 1,1-Dimethylethyl ((1S)-1-(((2S,4R)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2- (((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-ethenylcyclopropyl)carbamoyl) pyrrolidin-1-yl)carbonyl)-2,2-dimethylpropyl)carbamate; BMS650032;(1R,2S)-N-[(1,1-Dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenylcyclopropanecarboxamide; Carbamic acid, [(1S)-1-[[(2S,4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-2-[[[(1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethenylcyclopropyl]amino]carbonyl]-1-pyrrolidinyl]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester; Cyclopropanecarboxamide, N-((1,1-dimethylethoxy)carbonyl)-3-methyl-L-valyl-(4R)-4- ((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2- ethenyl-, (1R,2S)-; Cyclopropanecarboxamide, N-((1,1-dimethylethoxy)carbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-, (1R,2S)-"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:134723	DB11586	DR00075	DR0148	748.3	C35H46ClN5O9S	191	1470	4.9	51	3	10	14	"1S/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)/t19-,21-,25+,27-,35-/m1/s1"	CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C	XRWSZZJLZRKHHD-WVWIJVSJSA-N
DG00607	Simeprevir	24873435	"SIMEPREVIR; Olysio; TMC435; 923604-59-5; TMC435350; TMC-435; TMC 435; TMC 435350; TMC-435350; Simeprevir sodium; CHEMBL501849; UNII-9WS5RD66HZ; (1R,4R,6S,7Z,15R,17R)-N-cyclopropylsulfonyl-17-[7-methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxamide; (2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-({7-methoxy-8-methyl-2-[4-(1-methylethyl)-1,3-thiazol-2-yl]quinolin-4-yl}oxy)-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide; 9WS5RD66HZ; HCV-PI; SCHEMBL826061; GTPL7367; C38H47N5O7S2; CHEBI:134743; N-cyclopropylsulfonyl-[[2-(4-isopropylthiazol-2-yl)-7-methoxy-8-methyl-4-quinolyl]oxy]-methyl-dioxo-[ ]carboxamide; 4041AH; BDBM50336504; s5015; ZINC85540268; AKOS025401966; CCG-270435; AC-27651; AS-56205; TMC-00435350; TMC-435, TMC-435350; US8741926, 47; US8754106, 47; Q7517689; (2R,3aR,10Z,11aS,12aR,14aR)-N-(Cyclopropylsulfonyl)-2-({7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl}oxy)-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide; (2R,3aR,10Z,12S,13R,15aR)-N-(Cyclopropylsulfonyl)-2-[[2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methyl-4-quinolyl]oxy]-5-methyl-4,15-dioxo-2,3,3a,4,5,6,7,8,9,12,13,14,15,15a-tetradecahydro-12,13-methano-5,14-diaza-1H-cyclopentacyclotetradecene-13-carboxamide; (2R,3aR,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-(2-(4-isopropylthiazol-2-yl)-7-methoxy-8-methylquinolin-4-yloxy)-5-methyl-4,14-dioxo-1,2,3,3a,4,5,6,7,8,9,11a,12,12a,13,14,14a-hexadecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a-carboxamide; (2R,3aR,11aS,12aR,14aR,Z)-N-(cyclopropylsulfonyl)-2-((2-(4-isopropylthiazol-2-yl)-7-methoxy-8-methylquinolin-4-yl)oxy)-5-methyl-4,14-dioxo-1,2,3,3a,4,5,6,7,8,9,11a,12,12a,13,14,14a-hexadecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a-carboxamide; (2R,3aR,11aS,12aR,14aR,Z)-N-(cyclopropylsulfonyl)-2-(2-(4-isopropylthiazol-2-yl)-7-methoxy-8-methylquinolin-4-yloxy)-5-methyl-4,14-dioxo-1,2,3,3a,4,5,6,7,8,9,11a,12,12a,13,14,14a-hexadecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a-carboxamide; N-[17-[2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diazatricyclo [13.3.0.0''4,6]octadec-7-ene-4-carbonyl](cyclopropyl)sulfonamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:134743	DB06290	DR00014	.	749.9	C38H47N5O7S2	194	1490	4.8	52	2	10	8	"1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)/b10-8-/t23-,24-,27-,28-,38-/m1/s1"	CC1=C(C=CC2=C1N=C(C=C2O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(CCCC/C=C\\[C@@H]5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)C7=NC(=CS7)C(C)C)OC	JTZZSQYMACOLNN-VDWJNHBNSA-N
DG00608	Oseltamivir	65028	"Oseltamivir; 196618-13-0; Tamvir; Tamiflu-Free; GS-4104; (-)-oseltamivir; GS 4104; GS4104; HSDB 7433; Agucort; UNII-20O93L6F9H; (3R,4R,5S)-Ethyl 4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate; Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate; ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate; GOP-A-Flu; Ro-640796; Ro-64-0796; CHEBI:7798; 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3alpha,4beta,5alpha))-; 20O93L6F9H; Ro 640796; ebilfumin; Oseltamivir [INN:BAN]; oseltamivirum; ethyl (3R,4R,5S)-5-amino-4-acetamido-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate; Agucort (TN); Oseltamivir (INN); Tamiflu (*Phosphate salt 1:1*); SR-05000001499; oseltamivir-phosphate; CHEMBL1229; SCHEMBL32035; BIDD:GT0426; BDBM5025; GS-4071 ETHYL ESTER; DTXSID9044291; GTPL11427; HMS2090C11; EX-A3415; ZINC3929508; AKOS015843442; AKOS015960501; CS-0552; DB00198; DT-0013; MCULE-1441617774; ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)cyclohexene-1-carboxylate; ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate; ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxy-cyclohexene-1-carboxylate; Ethyl (5S,3R,4R)-4-(acetylamino)-5-amino-3-(ethylpropoxy)cyclohex-1-enecarboxylate; NCGC00095191-06; NCGC00095191-12; NCGC00095191-16; NCGC00178698-01; NCGC00178698-02; NCGC00178698-04; 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R,4R,5S)-; HY-13317; RO640796; Oseltamivir 100 microg/mL in Acetonitrile; RO64-0796; C08092; D08306; AB00173476-02; AB00173476_04; 618O130; AR-270/43507961; Q211509; SR-05000001499-1; BRD-K76011241-045-01-5; Ethyl (3R, 4R, 5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate; ethyl 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate; (3r,4r,5s)-4-acetylamino-5-amino-3(1-ethylpropoxy) -1-cyclohexene-1-carboxylic acid ethyl ester; (3R,4R,5S)-4-acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid ethyl ester; (3R,4R,5S)-4-acetylamino-5-amino-3-(1-ethyl-propoxy)cyclohex-1-enecarboxylic acid ethyl ester"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7798	DB00198	DR00250	.	312.4	C16H28N2O4	90.6	418	1.1	22	2	5	8	"1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1"	CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)OCC	VSZGPKBBMSAYNT-RRFJBIMHSA-N
DG00609	Bucillamine	656604	"Bucillamine; 65002-17-7; Rimatil; Tiobutarit; N-(2-Mercapto-2-methylpropionyl)-L-cysteine; De-019; UNII-R80LRA5WTF; (R)-3-mercapto-2-(2-mercapto-2-methylpropanamido)propanoic acid; N-(2-Mercapto-2-methylpropanoyl)-L-cysteine; R80LRA5WTF; N-(2-Mercapto-2-methyl-1-oxopropyl)-L-cysteine; (2R)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid; CHEMBL80830; L-CYSTEINE, N-(2-MERCAPTO-2-METHYL-1-OXOPROPYL)-; DSSTox_CID_28513; DSSTox_RID_82785; DSSTox_GSID_48587; SA96; Bucilamina; Bucillaminum; (R)-3-Mercapto-2-(2-mercapto-2-methylpropanamido)-propanoic acid; CAS-65002-17-7; Bucilamina [Spanish]; Bucillaminum [Latin]; Bucillamine [INN:JAN]; Bucilant; C7H13NO3S2; CCRIS 5260; N-(2-Mercaptoisobutyryl)cysteine; SA-96; NCGC00182062-02; NCGC00183271-01; Bucilant (TN); N-(2-Mercaptoisobutyryl)-L-cysteine; Bucillamine (JP17/INN); MLS006010100; SCHEMBL121965; DTXSID2048587; CHEBI:31312; ZINC20222; QCR-239; BCP12127; Tox21_112916; Tox21_113147; BDBM50406934; MFCD00867570; RB3025; AKOS015841445; AKOS015895462; AM62722; DB12160; KS-1449; AC-32465; K055; SMR004701240; D01809; 002B177; A834941; SR-01000883966; Q-101254; Q4982752; SR-01000883966-1; (2R)-2-[(2-methyl-2-sulfanyl-propanoyl)amino]-3-sulfanyl-propanoic acid; (2R)-3-mercapto-2-[(2-mercapto-2-methyl-1-oxopropyl)amino]propanoic acid"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:31312	DB12160	.	.	223.3	C7H13NO3S2	68.4	218	0.4	13	4	5	4	"1S/C7H13NO3S2/c1-7(2,13)6(11)8-4(3-12)5(9)10/h4,12-13H,3H2,1-2H3,(H,8,11)(H,9,10)/t4-/m0/s1"	CC(C)(C(=O)N[C@@H](CS)C(=O)O)S	VUAFHZCUKUDDBC-BYPYZUCNSA-N
DG00610	Betamethasone	9782	"Betamethasone; 378-44-9; Betadexamethasone; Flubenisolone; Betamethazone; Rinderon; Visubeta; Betacorlan; Betacortril; Betamamallet; Betametasone; Betapredol; Betasolon; Betnelan; Betsolan; Celestene; Methazon; Becort; Bedifos; Cidoten; beta-Methasone; Desacort-Beta; Rinderon A; beta-Methasone alcohol; Betametasona; Betamethasonum; Bebate; 9alpha-Fluoro-16beta-methylprednisolone; SCH 4831; Dermabet; 9-Fluoro-16beta-methylprednisolone; NSC-39470; SCH-4831; UNII-9842X06Q6M; Betafluorene; Betamethasone (Celestone); MFCD00062969; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; Betamethasone cream; MLS000859943; CHEBI:3077; Betamethasone alcohol; Betametasone [DCIT]; NCS-39470; 9842X06Q6M; (8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; NCGC00164401-01; SMR000058601; Celestone Syrup and Tablets; Betametasona [INN-Spanish]; Betamethasonum [INN-Latin]; DSSTox_CID_2667; 9a-Fluoro-11b,17a,21-trihydroxy-16b-methylpregna-1,4-diene-3,20-dione; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; DSSTox_RID_76681; DSSTox_GSID_22667; (8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11.beta.,16.beta.)-; .beta.-Methasone; 9-Fluoro-16.beta.-methylprednisolone; (11beta,16beta)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; Rinderon (TN); .beta.-Methasone alcohol; 9.alpha.-Fluoro-16.beta.-methylprednisolone; 9-alpha-Fluoro-16-beta-methylprednisolone; HSDB 3015; EINECS 206-825-4; NSC 39470; Prednisolone, 9-fluoro-16beta-methyl-; BRN 3176546; NSC39470; Desacort-.beta.; .beta.-Corlan; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-16beta-methyl-1,4-pregnadiene-3,20-dione; NCGC00091019-08; CAS-378-44-9; Prestwick_703; Prednisolone, 9-fluoro-16.beta.-methyl-; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16beta)-; Betamethasone, topical; Betamethasone [USAN:USP:INN:BAN:JAN]; Corticosterone, 1-dehydro-9-fluoro-17-hydroxy-16beta-methyl-; Betamethasone, >=98%; Prestwick0_000362; Prestwick1_000362; Prestwick2_000362; Prestwick3_000362; CHEMBL632; EC 206-825-4; cid_9782; SCHEMBL4565; 16-beta-Methyl-1,4-pregnadiene-9-alpha-fluoro-11-beta,17-alpha,21-triol-3,20-dione; 9-alpha-Fluoro-16-beta-methyl-1,4-pregnadiene-11-beta,17-alpha,21-triol-3,20-dione; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-16beta-methyl-; BIDD:PXR0047; BSPBio_000483; 4-08-00-03501 (Beilstein Handbook Reference); MLS001066413; MLS001332616; MLS002153244; SPBio_002404; Corticosterone, 1-dehydro-9-fluoro-17-hydroxy-16.beta.-methyl-; BPBio1_000533; GTPL7061; DTXSID3022667; BDBM73823; Betamethasone (JP17/USP/INN); BCPP000345; HMS1569I05; HMS2096I05; HMS2233I08; HMS3713I05; BCP02020; ZINC3876136; Tox21_112115; Tox21_301455; s1500; AKOS008901360; AKOS015894863; Tox21_112115_1; BCP9000393; CCG-220362; CS-1897; DB00443; KS-5302; 9-Fluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione; SMP1_000043; Betamethasone Dipropionate EP Impurity A; NCGC00164401-02; NCGC00164401-03; NCGC00255195-01; HY-13570; Betamethasone 100 microg/mL in Acetonitrile; D1961; Betamethasone, meets USP testing specifications; C06848; D00244; D88866; 378M449; Betamethasone, VETRANAL(TM), analytical standard; Q416132; SR-01000780582; SR-01000780582-2; W-106509; BRD-K39188321-001-03-9; Betamethasone, British Pharmacopoeia (BP) Reference Standard; Betamethasone, European Pharmacopoeia (EP) Reference Standard; Betamethasone, pharmaceutical impurity standard, >=95.0% (HPLC); Betamethasone, United States Pharmacopeia (USP) Reference Standard; (11.beta.,16.beta.)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-.alpha.-Fluoro-11-.beta.,17,21-trihydroxy-16-.beta.-methylpregna-1,4-diene-3,20-dione; 9-alpha-Fluor-11-beta,17-alpha,21-trihydroxy-16-beta-methylpregna-1,4-dien-3,20-dion; 9-fluoro-16beta-methyl-11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9alpha-Fluoro-16beta-methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione; Betamethasone, Pharmaceutical Secondary Standard; Certified Reference Material; Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17,21-trihydroxy-16.beta.-methyl-; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-16beta-methyl- (8CI); Pregna-1,4-diene-3,20-dione, 9alpha-fluoro-11beta,17alpha,21-trihydroxy-16beta-methyl-; (1R,2S,10S,11S,13S,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one; 16-.beta.-Methyl-1,4-pregnadiene-9-.alpha.-fluoro-11-.beta.,17-.alpha.,21-triol-3,20-dione; 9-.alpha.-Fluoro-11-.beta.,17-.alpha.,21-trihydroxy-16-.beta.-methylpregna-1,4-diene-3,20-dione; 9-.alpha.-Fluoro-16-.beta.-methyl-1,4-pregnadiene-11-.beta.,17-.alpha.,21-triol-3,20-dione; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione, (11.beta.,16.beta.) #; Betamethasone; 9-Fluoro-11 ,17,21-trihydroxy-16 -methylpregna-1,4-diene-3,20-dione; (11 ,16 )-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9 -Fluoro-16 -methylprednisolone"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3077	DB00443	DR01392	.	392.5	C22H29FO5	94.8	805	1.9	28	3	6	2	"1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1"	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C	UREBDLICKHMUKA-DVTGEIKXSA-N
DG00611	Methylprednisolone	6741	"Methylprednisolone; 83-43-2; Medrol; Metilprednisolone; Medrone; Urbason; 6alpha-Methylprednisolone; Metilbetasone; Medrate; Dopomedrol; Promacortine; Besonia; Medesone; Mesopren; Metastab; Metrisone; Moderin; Noretona; Solomet; Urbasone; Wyacort; Methylprednisolon; Methyleneprednisolone; Metilprednisolone [DCIT]; delta(1)-6alpha-Methylhydrocortisone; 1-Dehydro-6alpha-methylhydrocortisone; Metilprednisolona; Methylprednisolonum; NSC-19987; Methylprednisolonum [INN-Latin]; Metilprednisolona [INN-Spanish]; 6-alpha-Methylprednisolone; Suprametil; Medrol dosepak; Medrol adt pak; 6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione; UNII-X4W7ZR7023; CHEBI:6888; 11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione; (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione; (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; Prednisolone, methyl-; Methylprednisolone, 6-alpha; 11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione; 6alpha-Methylprednisolone base; U 7532; MLS000028541; (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; Sieropresol; Esametone; Firmacort; Medixon; Metrocort; Metysolon; Nirypan; Reactenol; Artisone-wyeth; X4W7ZR7023; MEPRDL; Predni N Tablinen; Medlone 21; SMR000058330; 6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione; DSSTox_CID_3300; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6a,11b)-; Prednol- L; DSSTox_RID_76965; DSSTox_GSID_23300; Depo-Medrol (acetate); Summicort; CAS-83-43-2; Prednisolone, 6alpha-methyl-; HSDB 3127; MLS002638721; EINECS 201-476-4; Prednisolone, 6.alpha.-methyl-; BRN 2340300; delta(sup 1)-6-alpha-Methylhydrocortisone; .DELTA.1-6.alpha.-Methylhydrocortisone; NCGC00016330-01; Prestwick_622; Medrol (TN); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6alpha,11beta)-; 6 -Methylprednisolone; Methylprednisolone [USP:INN:BAN:JAN]; Opera_ID_1576; Prestwick0_000279; Prestwick1_000279; Prestwick2_000279; Prestwick3_000279; 6alpha-methyl prednisolone; 11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl-; CHEMBL650; EC 201-476-4; 6.alpha.-Methylprednisolone; SCHEMBL5084; BSPBio_000158; 4-08-00-03498 (Beilstein Handbook Reference); MLS001148159; MLS002207191; SPBio_002377; BPBio1_000174; GTPL7088; DTXSID7023300; HMS1568H20; HMS2090B13; HMS2095H20; HMS2230D16; HMS3259J04; HMS3712H20; 6alpha-Methylprednisolone, >=98%; HY-B0260; NSC19987; ZINC3875560; Tox21_110376; Tox21_302018; BDBM50103616; LMST02030178; Methylprednisolone (JP17/USP/INN); MFCD00010591; s1733; AKOS015969744; Pregna-1,4-diene-3,20-dione, 6-alpha-methyl-11-beta-17,21-trihydroxy-; Tox21_110376_1; CCG-220279; DB00959; J3.872E; KS-1273; NC00691; NCGC00022735-03; NCGC00022735-06; NCGC00255269-01; H972; NCI60_001657; M1665; C16437; D00407; 010M591; A855290; Q417222; SR-01000003089; Q-201395; SR-01000003089-2; BRD-K35240538-001-03-1; BRD-K35240538-001-11-4; BRD-K35240538-001-26-2; 6-alpha-Methylprednisolone 100 microg/mL in Acetonitrile; 6alpha-Methylprednisolone, VETRANAL(TM), analytical standard; 11 ,17 ,21-Trihydroxy-6 -methyl-1,4-pregnadiene-3,20-dione; 11beta,17,21-trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione; Methylprednisolone, British Pharmacopoeia (BP) Reference Standard; Methylprednisolone, European Pharmacopoeia (EP) Reference Standard; Pregna-1,20-dione, 11.beta.,17,21-trihydroxy-6.alpha.-methyl-; Pregna-1,20-dione, 6.alpha.-methyl-11.beta.-17,21-trihydroxy-; (6 ,11 )-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione; (6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione; 11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione; Methylprednisolone, United States Pharmacopeia (USP) Reference Standard; Methylprednisolone for system suitability A, EuropePharmacopoeia (EP) Reference Standard; Methylprednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard; Methylprednisolone, Pharmaceutical Secondary Standard; Certified Reference Material; Pregna-1,20-dione, 11,17,21-trihydroxy-6-methyl-, (6.alpha.,11.beta.)-; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6I+/-,11I(2))-; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6888	DB00959	DR00128	DR1056	374.5	C22H30O5	94.8	754	1.9	27	3	5	2	"1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1"	C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O	VHRSUDSXCMQTMA-PJHHCJLFSA-N
DG00612	Hydrocortisone	5754	"Hydrocortisone; Cortisol; 50-23-7; Acticort; Cetacort; Hydrasson; Hydrocortisyl; Cobadex; Cortef; Hydrocortone; Hycort; Hytone; Signef; 17-Hydroxycorticosterone; Optef; Kendall's compound F; Cortanal; Cortenema; Corticreme; Cortifan; Cortiment; Cortispray; Cortonema; Dermacort; Dermolate; Efcorbin; Efcortelan; Ficortril; Genacort; Hycortol; Hycortole; Permicort; Proctocort; Tarcortin; Traumaide; Alacort; Cleiton; Cortril; Dihydrocostisone; Hytone lotion; Hidro-Colisona; Hydro-Adreson; Scheroson F; Incortin-H; Reichstein's substance M; Cort-Dome; Domolene-HC; Epiderm H; Esiderm H; Otosone-F; Polcort H; Cortolotion; Cortoxide; Cremesone; Eldercort; Heb-Cort; Maintasone; Delacort; Dioderm; Eldecort; Epicort; Mildison; Penecort; Rectoid; Anflam; Hydrocorticosterone; Hydroxycortisone; H-Cort; Hydro-Colisona; Cortisol alcohol; Incortin-hydrogen; Ala-Scalp; Aeroseb-HC; Barseb HC; Dermocortal; Nutracort; Synacort; Timocort; Evacort; Komed HC; Hydrocortisone base; Lacticare-HC; Texacort lotion 25; Ala-Cort; Anti-inflammatory hormone; Hydrocortisone alcohol; Algicirtis; Aquacort; Cortesal; Cortisolonum; Flexicort; Hidalone; Hytisone; Kyypakkaus; Lactisona; Lubricort; Meusicort; Milliderm; Sanatison; Schericur; Sigmacort; Stiefcorcil; Texacort; Amberin; Cutisol; Dermil; Uniderm; Foille Insetti; Gyno-Cortisone; Transderma H; Basan-Corti; Clear aid; Cremicort-H; Dome-cort; Neosporin-H Ear; Remederm HC; Aquanil HC; Cortisporin Otico; Derm-Aid; Heb Cort; Scalpicin Capilar; Systral Hydrocort; Prevex HC; Cortisporin; Efcortelin; Fiocortril; Hidrocortisona; Hydrocortisone free alcohol; Hydrocortisonum; Proctofoam; Alphaderm; Hydracort; Medicort; Otocort; Zenoxone; Drotic; Vytone; 11beta-Hydroxycortisone; Nystaform-HC; Aeroseb HC; CaldeCORT Spray; Pediotic Suspension; VoSol HC; Idrocortisone; 17alpha-Hydroxycorticosterone; Hydrocortal; Hydroskin; Otalgine; Otobiotic; Protocort; Hysone; Racet; Ef corlin; 11beta-Hydrocortisone; Compound F; Lacticare HC; Compound F (kendall); 11-beta-Hydrocortisone; 11-beta-Hydroxycortisone; Hydrocortisone (Cortisol); Chronocort; Hydrocort; Plenadren; Preparation H Hydrocortisone Cream; Neo-Cort-Dome; 11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione; Otic-Neo-Cort-Dome; 11beta,17,21-Trihydroxypregn-4-ene-3,20-dione; NSC 10483; HC; UNII-WI4X0X7BPJ; [3H]cortisol; (11beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione; Prestwick_265; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; 4-Pregnene-11beta,17alpha,21-triol-3,20-dione; CHEBI:17650; 11beta,17alpha,21-Trihydroxypregn-4-ene-3,20-dione; NSC10483; 11.beta.-Hydrocortisone; Dermaspray; MFCD00011654; NSC-10483; WI4X0X7BPJ; 11beta,17,21-Trihydroxyprogesterone; 11.beta.-Hydroxycortisone; Ophthocort; Terra-cortril; MLS000069609; 17.alpha.-Hydroxycorticosterone; Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-; 4-Pregnen-11beta,17alpha,21-triol-3,20-dione; Idrocortisone [DCIT]; Genacort (lotion); Anucort; Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11b)-; Prepcort; SMR000059022; DSSTox_CID_714; Hydrocortisonum [INN-Latin]; Proctozone HC; Scalp-Cort; Hidrocortisona [INN-Spanish]; Rectasol-HC; Anucort-HC; Hydro-RX; DSSTox_RID_75753; DSSTox_GSID_20714; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; HC (HYDROCORTISONE); Corhydron; (11alpha,14beta)-11,17,21-Trihydroxypregn-4-Ene-3,20-Dione; DuoCort; HYDROCORTISONE IN ABSORBASE; Proctosol-HC; HC #1; HC #4; Acticort (TN); Colocort (TN); (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one; SMR000653523; Cortef (TN); Hytone (TN); Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11.beta.)-; CCRIS 5854; component of Otalgine; Anusol HC (TN); component of Lubricort; COR-OTICIN; HSDB 3339; EINECS 200-020-1; component of Neo-Cort-Dome; Cortizol; Efmody; AI3-25006; 3h-cortisol; 11beta-cortisol; CAS-50-23-7; 11-Hydrocortisone; Plenadren (TN); NCGC00022848-06; 11b-Hydrocortisone; Kendalls compound F; Hydrocortisone [USP:INN:BAN:JAN]; Drotic (Salt/Mix); 11b-Hydroxycortisone; Otocort (Salt/Mix); Pregn-4-ene-3,20-dione, 11beta,17,21-trihydroxy-; Otalgine (Salt/Mix); Hydrocortisone, 98%; 11,17,21-Trihydroxypregn-4-ene-3,20-dione; Alphaderm (Salt/Mix); Hydrocortisone, topical; Otobiotic (Salt/Mix); Reichsteins substance M; 4p6x; Cort-Quin (Salt/Mix); Cortisporin (Salt/Mix); VoSol HC (Salt/Mix); 11a-Hydroxycorticosterone; 17a-Hydroxycorticosterone; Opera_ID_1292; Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11-beta)-; Prestwick0_000447; Prestwick1_000447; Prestwick2_000447; Prestwick3_000447; Epitope ID:174851; UPCMLD-DP133; EC 200-020-1; H 4001; SCHEMBL4148; Neo-Cort-Dome (Salt/Mix); Lopac0_000594; 11alpha-Hydroxycorticosterone; BSPBio_000494; MLS001148103; MLS002207135; MLS002222189; MLS002548868; SPBio_002433; BPBio1_000544; CHEMBL389621; GTPL2868; Pediotic Suspension (Salt/Mix); DTXSID7020714; UPCMLD-DP133:001; BDBM13775; Otic-Neo-Cort-Dome (Salt/Mix); 2v95; Hydrocortisone (JP17/USP/INN); HMS1569I16; HMS2090M04; HMS2096I16; HMS2230B18; HMS2235F17; HMS3259C05; HMS3261H10; HMS3713I16; Hydrocortisone, >=98% (HPLC); Vioform-Hydrocortisone (Salt/Mix); 11b,17,21-Trihydroxyprogesterone; BCP09054; HY-N0583; Tox21_110883; Tox21_200815; Tox21_500594; LMST02030001; s1696; ZINC13540519; AKOS001582651; Tox21_110883_1; CCG-204683; DB00741; LP00594; MCULE-8953627920; NC00456; SDCCGSBI-0050576.P003; 11.beta.,17,21-trihydroxyprogesterone; SMP1_000156; NCGC00022848-07; NCGC00022848-09; NCGC00022848-10; NCGC00022848-11; NCGC00022848-12; NCGC00022848-13; NCGC00022848-14; NCGC00022848-15; NCGC00022848-17; NCGC00022848-26; NCGC00258369-01; NCGC00261279-01; (1S,10S,11S,15S,17S,2R,14R)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyl tetracyclo[8.7.0.0<2,7>.0<11,15>]heptadec-6-en-5-one; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one; AC-12902; AS-11651; BP-20390; NCI60_000118; 4-Pregnene-11alpha,21-triol 3,20-dione; B1951; EU-0100594; 4-Pregnene-11b,17a,21-triol-3,20-dione; 50H237; C00735; D00088; J10114; U 1851; Hydrocortisone, meets USP testing specifications; Pregn-4-ene-3, 11.beta.,17,21-trihydroxy-; 11 ,17 ,21-Trihydroxypregn-4-ene-3,20-dione; A929789; Hydrocortisone, VETRANAL(TM), analytical standard; Q190875; SR-01000000139; Q-201211; SR-01000000139-3; 11.beta.,17,21-Trihydroxypregn-4-ene-3,20-dione; BRD-K93568044-001-03-1; BRD-K93568044-001-11-4; BRD-K93568044-001-32-0; Hydrocortisone, BioReagent, suitable for cell culture; 4-Pregnen-11.beta.,17.alpha.,21-triol-3,20-dione; 4-Pregnene-11.beta.,17.alpha.,21-triol-3,20-dione; Pregn-4-ene-3,20-dione, 11.beta.,17,21-trihydroxy-; Z2786051549; (11beta)-11,17,21-Trihydroxy-pregn-4-ene-3,20-dione; 11.beta.,17.alpha.,21-Trihydroxy-4-pregnene-3,20-dione; 11.beta.,17.alpha.,21-Trihydroxypregn-4-ene-3,20-dione; B48448A1-24BA-47CA-8D9E-43E5BC949386; Hydrocortisone, British Pharmacopoeia (BP) Assay Standard; Pregn-4-ene-3, 11,17,21-trihydroxy-, (11.beta.)-; 11,17,21-Trihydroxypregn-4-ene-3,20-dione, (11.beta.)-; Hydrocortisone, European Pharmacopoeia (EP) Reference Standard; Hydrocortisone, United States Pharmacopeia (USP) Reference Standard; Hydrocortisone-Water Soluble, BioReagent, suitable for cell culture; Hydrocortisone, gamma-irradiated, powder, BioXtra, suitable for cell culture; 4-(6-chloro-4-oxoquinazolin-3(4H)-yl)-N-(3-methoxyphenyl)piperidine-1-carboxamide; Cortisol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Hydrocortisone for peak identification, European Pharmacopoeia (EP) Reference Standard; Hydrocortisone solution, 50 muM, sterile-filtered, BioXtra, suitable for cell culture; Hydrocortisone, Pharmaceutical Secondary Standard; Certified Reference Material; (10R,13S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:17650	DB00741	DR00230	DR0819	362.5	C21H30O5	94.8	684	1.6	26	3	5	2	"1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1"	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O	JYGXADMDTFJGBT-VWUMJDOOSA-N
DG00613	Indomethacin	3715	"Indomethacin; 53-86-1; indometacin; Indocin; Indometacine; Indomethacine; Indocid; Metindol; Indomethazine; Reumacide; Imbrilon; Amuno; Tannex; Indomethacinum; Artracin; Artrinovo; Artrivia; Confortid; Idomethine; Indomecol; Indoptic; Indoptol; Inflazon; Infrocin; Metartril; Methazine; Mikametan; Sadoreum; Dolovin; Inacid; Indacin; Indomed; Indomee; Lausit; Metacen; Mobilan; Indo-rectolmin; Indo-tablinen; Inteban sp; Indometacyna; Indometicina; Mezolin; Durametacin; Indometacinum; 2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetic acid; Indometacina; Dolcidium; Elmetacin; Indomethine; Indorektal; Catlep; Indoxen; Vonum; Indo-phlogont; Chibro-amuno; Rheumacin LA; 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-; Osmosin; Aconip; 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid; CCRIS 3502; 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid; HSDB 3101; 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid; NCI-C56144; UNII-XXE1CET956; MFCD00057095; CHEMBL6; 1-(p-Chlorobenzoyl)-2-methyl-5-methoxyindole-3-acetic acid; IMN; Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-; Indo-Lemmon; [1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid; Indocin Sr; XXE1CET956; 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1h-indol-3-yl}acetic acid; N-p-Chlorbenzoyl-5-methoxy-2-methylindole-3-acetic acid; MLS000069402; Indomethacin (Indocid, Indocin); (1-p-Chlorobenzoyl-5-methoxy-2-methylindol-3-yl)acetic acid; CHEBI:49662; 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid; 1-(p-Chlorobenzoyl)-2-methoxy-3-methyl-1H-indole-3-acetic Acid; Indomet 140; alpha-(1-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indolyl)acetic acid; {1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid; NSC-757061; CAS-53-86-1; 1-p-Cloro-benzoil-5-metoxi-2-metilindol-3-acido acetico; NCGC00015562-18; Indmethacine; Indomethancin; 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetic acid; Arthrexin; Bonidin; Bonidon; Indameth; Indomod; Miametan; SMR000058195; Indomo; Flexin continus; Hicin; Kwas 1-(p-chlorobenzoilo)-2-metylo-5-metoksy-3-indolilooctowy; Chrono-indicid; Chrono-indocid; Indometacyna [Polish]; DSSTox_CID_740; Bonidon Gel; Indometicina [Spanish]; 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid; Dolcidium PL; Indo-Spray; Indolar SR; DSSTox_RID_75763; DSSTox_GSID_20740; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indometacina [INN-Spanish]; 1-(4-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid; Tivorbex; 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-indol-3-yl]acetic acid; 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl}acetic acid; Indocin-SR; Indochron E-R; Indocin (TN); Aconip (TN); Indomethacin (USP); FLAM; NSC-77541; Indocid (pharmaceutical); SR-01000000014; EINECS 200-186-5; Indomethacin & MAP-30; Indomethacin [USAN:USP]; BRN 0497341; Indocollyre; Indonol; Innamit; Inteban; 2-{1-((4-chlorophenyl)carbonyl)-5-methoxy-2-methylindol-3-yl}acetic acid; 4kyk; Indomethacin,(S); Prestwick_597; Indometacin [INN]; Opera_ID_56; Spectrum_000919; Tocris-1708; 1z9h; 1-(p-Chlorbenzoyl)-5-methoxy-2-methylindol-3-essigsaeure [German]; 1-p-Cloro-benzoil-5-metoxi-2-metilindol-3-acido acetico [Spanish]; Prestwick0_000272; Prestwick1_000272; Prestwick2_000272; Prestwick3_000272; Spectrum2_000970; Spectrum3_000468; Spectrum4_000018; Spectrum5_000868; Lopac-I-7378; Kwas 1-(p-chlorobenzoilo)-2-metylo-5-metoksy-3-indolilooctowy [Polish]; MolMap_000032; UPCMLD-DP023; EC 200-186-5; I 7378; Indometacin (JP17/INN); SCHEMBL9300; Lopac0_000692; Oprea1_686105; BSPBio_000144; BSPBio_001149; BSPBio_002176; KBioGR_000395; KBioGR_000489; KBioSS_000489; KBioSS_001399; 5-22-05-00239 (Beilstein Handbook Reference); MLS001074194; MLS006011845; BIDD:GT0132; DivK1c_000271; SPECTRUM1500350; SPBio_000979; SPBio_002363; BPBio1_000160; GTPL1909; DTXSID9020740; Indomethacin, >=99% (TLC); UPCMLD-DP023:001; BDBM17638; CGIGDMFJXJATDK-UHFFFAOYSA-; HMS500N13; KBio1_000271; KBio2_000489; KBio2_001399; KBio2_003057; KBio2_003967; KBio2_005625; KBio2_006535; KBio3_000897; KBio3_000898; KBio3_001396; 1-(p-Chlorbenzoyl)-5-methoxy-2-methylindol-3-essigsaeure; Indomethacin - CAS 53-86-1; NINDS_000271; Bio2_000405; Bio2_000885; HMS1362I11; HMS1568H06; HMS1792I11; HMS1920F21; HMS1990I11; HMS2089N19; HMS2091N09; HMS2095H06; HMS2231J10; HMS3262K05; HMS3268A14; HMS3374F07; HMS3403I11; HMS3414N13; HMS3430L03; HMS3649K17; HMS3655O04; HMS3678N11; HMS3712H06; HMS3747K21; HMS3884E08; Pharmakon1600-01500350; ZINC601283; ACT02579; BCP18951; Indomethacin, >=99.0% (TLC); Tox21_113109; Tox21_201791; Tox21_300266; Tox21_500692; AC-532; CCG-40186; NSC757061; s1723; STL257874; AKOS000592893; Tox21_113109_1; AT13679; DB00328; Indometacin 1.0 mg/ml in Acetonitrile; KS-5255; LP00692; MCULE-5636486088; NSC 757061; SDCCGSBI-0050670.P005; IDI1_000271; IDI1_002160; NCGC00015562-01; NCGC00015562-02; NCGC00015562-03; NCGC00015562-04; NCGC00015562-05; NCGC00015562-06; NCGC00015562-07; NCGC00015562-08; NCGC00015562-09; NCGC00015562-10; NCGC00015562-11; NCGC00015562-12; NCGC00015562-13; NCGC00015562-14; NCGC00015562-15; NCGC00015562-16; NCGC00015562-17; NCGC00015562-19; NCGC00015562-20; NCGC00015562-21; NCGC00015562-22; NCGC00015562-24; NCGC00015562-25; NCGC00015562-40; NCGC00024135-02; NCGC00024135-04; NCGC00024135-05; NCGC00024135-06; NCGC00024135-07; NCGC00024135-08; NCGC00024135-09; NCGC00024135-10; NCGC00024135-11; NCGC00024135-12; NCGC00024135-13; NCGC00024135-14; NCGC00024135-15; NCGC00254075-01; NCGC00259340-01; NCGC00261377-01; BI166166; BP-30207; H911; HY-14397; NCI60_041708; SBI-0050670.P004; DB-052413; AB00052022; EU-0100692; FT-0603227; I0655; SW196768-5; Indomethacin, meets USP testing specifications; BIM-0050670.0001; C01926; D00141; J10170; S00108; AB00052022-20; AB00052022-21; AB00052022_23; AB00052022_24; L000959; Q409231; Indomethacin, Antibiotic for Culture Media Use Only; Q-201239; SR-01000000014-2; SR-01000000014-4; SR-01000000014-6; BRD-K57222227-001-06-1; BRD-K57222227-001-18-6; BRD-K57222227-001-27-7; SR-01000000014-10; SR-01000000014-16; Z56784896; 1-p-chlorobenzoyl-2-methyl-5-methoxyindol-3-acetic acid; 1-(p-chlorobenzoyl)-2-methyl-5-methoxy-3-indoleacetic acid; 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid; 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindol-3-acetic acid; 1-(4-chloro-benzoyl)-5-methoxy-2-methyl-3-indolyl-acetic acid; 1-(4-Chlorobenzoyl)-2-methyl-5-methoxyindole-3-acetic acid; 1-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indole-acetic acid; 1-(p-chlorobenzoyl)-2-methyl-5-methoxy-3-indolylacetic acid; 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indol acetic acid; 1-(p-Chlorobenzoyl)-5-methoxy-2-methyl-Indole-3-acetic acid; Indomethacin, European Pharmacopoeia (EP) Reference Standard; N-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indolylacetic acid; Indomethacin, United States Pharmacopeia (USP) Reference Standard; .alpha.-(1-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indolyl)acetic acid; [1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid #; 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid & MAP-30; 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9CI); 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2 methylindol-3-yl}acetic acid; 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2methylindol-3-yl}acetic acid; Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8CI); Indomethacin, Pharmaceutical Secondary Standard; Certified Reference Material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:49662	DB00328	DR00267	DR0875	357.8	C19H16ClNO4	68.5	506	4.3	25	1	4	4	"1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)"	CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O	CGIGDMFJXJATDK-UHFFFAOYSA-N
DG00614	Azathioprine 	2265	"Azathioprine; 446-86-6; Imuran; Azothioprine; Azathioprin; Azatioprin; Azamun; Azanin; Azathiopurine; Imurel; Azasan; Ccucol; Imurek; Muran; Rorasul; BW 57-322; NSC-39084; BW-57-322; NCI-C03474; 6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine; Imuran (TN); NSC 39084; 6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine; UNII-MRK240IY2L; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine; 6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-9H-purine; 6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine; Azathioprine (Azasan, Imuran); 1H-Purine, 6-((1-methyl-4-nitro-1H-imidazol-5-yl)thio)-; 1H-Purine, 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-; Purine, 6-(1-methyl-4-nitro-5-imidazolylthio)-; 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine; 6-(Methyl-p-nitro-5-imidazolyl)-thiopurine; MFCD00069203; MRK240IY2L; BW 57322; Azamun [Czech]; 6-((1-methyl-4-nitro-1H-imidazol-5-yl)thio)-7H-purine; CHEBI:2948; B. W. 57-322; NSC39084; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine; Purine, 6-((1-methyl-4-nitroimidazol-5-yl)thio)-; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine; NCGC00015060-06; NCGC00015060-14; Azatioprina; CAS-446-86-6; DSSTox_CID_119; 6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine; DSSTox_RID_75381; DSSTox_GSID_20119; Azathioprinum [INN-Latin]; Azatioprina [INN-Spanish]; Azamune; Methylnitroimidazolylmercaptopurine; CCRIS 62; Azasan (TN); HSDB 7084; SR-01000075537; Purine, 6-[(1-methyl-4-nitroimidazol-5-yl)thio]-; EINECS 207-175-4; 6-(1-methyl-4-nitro-1H-imidazol-5-ylthio)-9H-purine; 6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine; azanine; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]; Azothioprin; Jayempi; Azoran; AI3-50290; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin; Prestwick_41; Azathiopurine,(S); [Methyl(nitroimidazolyl)mercaptopurine]; Azathioprine [USAN:USP:INN:BAN:JAN]; Spectrum_000064; Azathioprine, >=98%; 6-(Methyl-p-nitro-5-imidazolyl)thiopurine; Prestwick0_000094; Prestwick1_000094; Prestwick2_000094; Prestwick3_000094; Spectrum2_000068; Spectrum3_000308; Spectrum4_000243; Spectrum5_000848; Lopac-A-4638; ChemDiv1_002659; 6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine; A 4638; Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl); SCHEMBL4278; CHEMBL1542; Lopac0_000027; Oprea1_375441; Oprea1_533384; Oprea1_633462; BSPBio_000048; BSPBio_001876; CBDivE_013132; KBioGR_000646; KBioGR_002427; KBioSS_000464; KBioSS_002433; AI-981/34845012; MLS001049307; DivK1c_000586; SPECTRUM1500133; SPBio_000255; SPBio_001987; BPBio1_000054; GTPL7120; DTXSID4020119; Azathioprine (JP17/USP/INN); HMS501N08; HMS594I19; KBio1_000586; KBio2_000464; KBio2_002427; KBio2_003032; KBio2_004995; KBio2_005600; KBio2_007563; KBio3_001376; KBio3_002906; cMAP_000046; NINDS_000586; 6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine; 6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-1H-purine; HMS1568C10; HMS1920E17; HMS2091K19; HMS2095C10; HMS2802J03; HMS3259P03; HMS3260E15; HMS3655M04; HMS3712C10; Pharmakon1600-01500133; ACT02232; BCP09492; HY-B0256; ZINC4258316; Tox21_110074; Tox21_400024; Tox21_500027; BDBM50373919; CCG-16168; CCG-39877; NSC755900; s1721; STK831906; AKOS005609209; AKOS028108935; Tox21_110074_1; AC-4230; CCG-220094; DB00993; KS-1146; LP00027; MCULE-8637589610; NC00614; NSC-755900; SDCCGMLS-0065415.P001; SDCCGSBI-0050016.P005; IDI1_000586; NCGC00015060-01; NCGC00015060-02; NCGC00015060-03; NCGC00015060-04; NCGC00015060-05; NCGC00015060-07; NCGC00015060-08; NCGC00015060-09; NCGC00015060-10; NCGC00015060-11; NCGC00015060-12; NCGC00015060-13; NCGC00015060-15; NCGC00015060-16; NCGC00015060-18; NCGC00015060-19; NCGC00015060-29; NCGC00090836-01; NCGC00090836-02; NCGC00090836-03; NCGC00090836-04; NCGC00090836-05; NCGC00090836-06; NCGC00094593-01; NCGC00094593-02; NCGC00094593-03; NCGC00260712-01; BA166065; L996; SMR000427366; 6-1'-Methyl,5'-imidazolyl mercaptopurine; SBI-0050016.P003; Azathioprine 100 microg/mL in Acetonitrile; 6-(1-Methyl-4-nitromidazol-5-ylthio)purine; AB00443544; EU-0100027; FT-0602904; FT-0662375; SW198560-2; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purine; Azathioprine, meets USP testing specifications; C06837; D00238; D70170; Q18939; AB00443544-03; AB00443544-11; AB00443544_12; AB00443544_13; 055A974; 446A866; A826664; SR-01000762955; 6-(1-Methyl-4-nitro-5-imidazolythio)-9H-pur-ine; SR-01000075537-1; SR-01000075537-4; SR-01000762955-2; BRD-K32821942-001-05-6; BRD-K32821942-001-10-6; BRD-K60324116-001-01-5; WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW; Z57063156; 6-((1-methyl-4-nitro-1h-imidazol-5-yl)thio)-1h-purin; 6-(3-methyl-5-nitro-imidazol-4-yl)sulfanyl-9H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-9H-purine; 9H-Purine, 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-; Azathioprine, European Pharmacopoeia (EP) Reference Standard; 6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-1H-purine #; Azathioprine, United States Pharmacopeia (USP) Reference Standard; Azathioprine, Pharmaceutical Secondary Standard; Certified Reference Material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:2948	DB00993	DR00113	DR0164	277.27	C9H7N7O2S	143	354	0.1	19	1	7	2	"1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)"	CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]	LMEKQMALGUDUQG-UHFFFAOYSA-N
DG00615	Celecoxib	2662	"Celecoxib; 169590-42-5; Celebrex; Celebra; Onsenal; Celocoxib; Celecox; SC 58635; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; SC-58635; YM177; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide; 184007-95-2; YM 177; C17H14F3N3O2S; HSDB 7038; UNII-JCX84Q7J1L; p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; MFCD00941298; SC58635; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide; 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; YM-177; CHEMBL118; JCX84Q7J1L; 194044-54-7; CHEBI:41423; 4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; NSC-719627; NSC-758624; NCGC00091455-01; Xilebao; DSSTox_CID_2777; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonami de; benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-; DSSTox_RID_76725; DSSTox_GSID_22777; Solexa; Benzenesulfonamide, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-; Celebrex (TN); SMR000550473; CAS-169590-42-5; SR-01000837528; Celecoxibum; Celecoxib [USAN:INN:BAN]; CCRIS 9330; TPI-336; Celecoxib- Bio-X; Celecoxib-[d4]; Onsenal (TN); AI-525; CEP-33222; CELEBCOXIB; Spectrum_000432; 1oq5; Spectrum2_001576; Spectrum3_001996; Spectrum4_000182; Spectrum5_001324; cid_2662; SCHEMBL3708; Celecoxib (JAN/USP/INN); DFN15; BSPBio_003596; KBioGR_000723; KBioGR_002351; KBioSS_000912; KBioSS_002354; MLS001165684; MLS001195656; MLS001304708; MLS006011862; BIDD:GT0408; DivK1c_000893; SPECTRUM1503678; SPBio_001512; DFN-15; GTPL2892; Celecoxib, >=98% (HPLC); DTXSID0022777; BDBM11639; HMS502M15; KBio1_000893; KBio2_000912; KBio2_002351; KBio2_003480; KBio2_004919; KBio2_006048; KBio2_007487; KBio3_002830; KBio3_003037; EX-A175; SYN3015; cMAP_000027; NINDS_000893; BCPP000290; Elyxyb (DFN-15; oral solution); HMS1922G14; HMS2089L18; HMS2093I07; HMS2234N18; HMS3259L08; HMS3261A14; HMS3373A09; HMS3654H09; HMS3715F11; HMS3867I03; HMS3884M07; Pharmakon1600-01503678; ACT02648; ALBB-033772; BCP02156; ZINC2570895; Tox21_111135; Tox21_201964; Tox21_300599; Tox21_500406; US8741944, Comparative Compound; 4-[5-(p-tolyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide; BBL029086; CCG-39354; NSC719627; NSC758624; s1261; STL373576; Celecoxib 1.0 mg/ml in Acetonitrile; AKOS015842517; Tox21_111135_1; AC-4228; AM84588; BCP9000507; CS-0570; DB00482; KS-1041; MCULE-4750749400; NC00708; NSC 719627; NSC 758624; SB19318; IDI1_000893; NCGC00091455-02; NCGC00091455-03; NCGC00091455-04; NCGC00091455-05; NCGC00091455-06; NCGC00091455-07; NCGC00091455-08; NCGC00091455-09; NCGC00091455-13; NCGC00254540-01; NCGC00259513-01; NCGC00261091-01; BC164295; BP-30217; HY-14398; NCI60_041049; PHA-00846533; SY064976; SBI-0051875.P002; CJ-016377; CP-598107; UNM-0000305813; FT-0601628; FT-0623536; FT-0700357; SW199611-3; PF-00345549; A25046; C07589; D00567; J10035; AB00052396-07; AB00052396-08; AB00052396-09; AB00052396_10; AB00052396_11; 590C425; Q408801; J-010566; J-520011; Q-200816; SR-01000837528-2; SR-01000837528-3; BRD-K02637541-001-02-4; BRD-K02637541-001-06-5; Z2210694606; Celecoxib, European Pharmacopoeia (EP) Reference Standard; Celecoxib, United States Pharmacopeia (USP) Reference Standard; 4-[5-(p-Tolyl)-3-(trifluoromethyl)-1-pyrazolyl]benzenesulfonamide; 4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-pyrazol-1-yl]benzenesulfonamide; 5-(4-Methylphenyl)-1-(4-sulfamoylphenyl)-3-(trifluoromethyl)pyrazole; Celecoxib, Pharmaceutical Secondary Standard; Certified Reference Material; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyazol-1-yl]benezenesulfonamide; Benzenesulfonamide,4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-; 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-pyrazol-1-yl]benzenesulfonamide;4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:41423	DB00482	DR00520	DR0286	381.4	C17H14F3N3O2S	86.4	577	3.4	26	1	7	3	"1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)"	CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F	RZEKVGVHFLEQIL-UHFFFAOYSA-N
DG00616	Germacrone	6436348	"Germacrone; 6902-91-6; (3E,7E)-3,7-Dimethyl-10-(propan-2-ylidene)cyclodeca-3,7-dienone; Germacron; (3E,7E)-3,7-dimethyl-10-propan-2-ylidenecyclodeca-3,7-dien-1-one; Germacrone,(S); Germacrol (obsol;); UNII-E2WQ6N4FBP; E2WQ6N4FBP; Germacrone, analytical standard; SCHEMBL2551615; SCHEMBL14215872; CHEBI:80830; HY-N0440; MFCD00210050; s9311; ZINC31308583; AKOS016009673; CCG-266711; NCGC00482596-01; AC-34324; CS-0008961; G0519; N1500; V0249; (E,E)-Germacra-3,7(11),9-trien-6-one; C16966; 902G916; Q-100776; Q15410959; trans,trans-3,7-dimethyl-10-isopropylidene-3,7-cyclodecadien-1-one"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	218.33	C15H22O	17.1	363	3.5	16	0	1	0	"1S/C15H22O/c1-11(2)14-9-8-12(3)6-5-7-13(4)10-15(14)16/h7-8H,5-6,9-10H2,1-4H3/b12-8+,13-7+"	C/C/1=C\\CC(=C(C)C)C(=O)C/C(=C/CC1)/C	CAULGCQHVOVVRN-SWZPTJTJSA-N
DG00617	Cabozantinib	25102847	"Cabozantinib; 849217-68-1; Cometriq; XL184; XL-184; BMS-907351; XL 184; BMS 907351; Cabozantinib (XL184, BMS-907351); UNII-1C39JW444G; CHEBI:72317; XL-184 free base; BMS907351; 1C39JW444G; MFCD20926324; N'-[4-[(6,7-DIMETHOXY-4-QUINOLINYL)OXY]PHENYL]-N-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE; Cabometyx (TN); Cometriq (TN); 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; C28H24FN3O5; N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide; N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; XL184 cpd; Cabozantinib [USAN:INN]; Carbozantinib; XL184 free base; Cabozantinib (USAN); Cabozantinib (free base); SCHEMBL360795; GTPL5887; Cabozantinib (BMS-907351); CHEMBL2105717; DTXSID10233968; EX-A075; QCR-122; SYN1138; XL184 free base - Cabozantinib; BCPP000308; BMS-907351 FREE BASE; HMS3654G06; XL-184 free base (Cabozantinib); AOB87755; BCP02591; 849217-68-1 (free base); BDBM50021574; NSC761068; NSC800066; s1119; ZINC70466416; AKOS025142112; BCP9000470; CCG-264678; CS-0278; DB08875; NSC-761068; NSC-800066; SB20062; XL-184 (Cabozantinib,BMS907351); XL-184,Cabozantinib, BMS-907351; NCGC00263164-01; NCGC00263164-14; NCGC00263164-17; 1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-; 1,1-Cyclopropanedicarboxamide,N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-; AC-25082; AS-16277; HY-13016; n-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; SY097158; DB-023624; FT-0664184; SW218093-3; X7477; D10062; AB01565831_02; Q795057; SR-01000941569; J-523016; SR-01000941569-1; BRD-K51544265-001-01-8; 1,1-Cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-; cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide; cyclopropane-1,1-dicarboxylic acid[4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide; N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4 fluorophenyl)cyclopropane-1,1-dicarboxamide; N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; N-[4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl]-N inverted exclamation mark -(4-fluorophenyl)cyclopropane-1,1-dicarboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:72317	DB08875	.	DR0254	501.5	C28H24FN3O5	98.8	795	5.4	37	2	7	8	"1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)"	COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F	ONIQOQHATWINJY-UHFFFAOYSA-N
DG00618	Lenvatinib	9823820	"Lenvatinib; 417716-92-8; E7080; Lenvima; 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide; E7080 (Lenvatinib); Lenvatinib (E7080); E 7080; E-7080; Lenvatinib free base; ER-203492-00; UNII-EE083865G2; 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide; 4-{3-Chloro-4-[(Cyclopropylcarbamoyl)amino]phenoxy}-7-Methoxyquinoline-6-Carboxamide; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide; CHEMBL1289601; CHEBI:85994; 417716-92-8 (free base); EE083865G2; 4-(3-chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide; Lenvatinib [USAN:INN]; Kisplyx; 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; LEV; LenvatinibE7080); Lenvatinib; E7080; Lenvatinib base- Bio-X; Lenvatinib (USAN/INN); MLS006011239; SCHEMBL864638; GTPL7426; AMY9240; DTXSID50194605; EX-A249; QCR-115; SYN1038; BCPP000247; HMS3244A07; HMS3244A08; HMS3244B07; HMS3654A14; AOB87766; BCP01799; ZINC3816292; BDBM50331094; MFCD16038644; NSC755980; NSC800781; s1164; AKOS025401742; BCP9000633; CCG-264842; CS-0109; DB09078; NSC-755980; NSC-800781; SB16580; 4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; NCGC00263198-01; NCGC00263198-04; NCGC00263198-07; AC-25047; AS-16203; BL164616; HY-10981; SMR004702999; DB-070219; FT-0700727; SW219259-1; D09919; 716C928; A825653; J-513372; Q6523413; BRD-K39974922-001-02-7; 4-[3-chloranyl-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide; 4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide; 4-[3-chloro-4-[[(cyclopropylamino)-oxomethyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide; 6-Quinolinecarboxamide, 4-(3-chloro-4- (((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB09078	DR00265	.	426.9	C21H19ClN4O4	116	634	2.8	30	3	5	6	"1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)"	COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl	WOSKHXYHFSIKNG-UHFFFAOYSA-N
DG00619	Vandetanib	3081361	"Vandetanib; 443913-73-3; Zactima; ZD6474; Caprelsa; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; vandetanib (zd6474); ZD 6474; ZD-6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; UNII-YO460OQ37K; C22H24BrFN4O2; CHEMBL24828; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; YO460OQ37K; CHEBI:49960; GNF-PF-2188; MFCD07772346; NSC-744325; NSC-760766; NCGC00167513-01; 4-[(4-Bromo-2-fluorophenyl)amino]-6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]quinazoline; DSSTox_CID_26681; DSSTox_RID_81816; DSSTox_GSID_46681; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-yl)methoxyquinazoline; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine; (4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine; CAS-443913-73-3; Vandetinib; HSDB 8198; 2ivu; Vandetanib [USAN:INN:BAN:JAN]; ZD-64; Caprelsa (TN); AZD-6474; Vandetanib- Bio-X; CH 331; CH-331; Vandetanib (Zactima); DMPC Cyclic Urea 1; Kinome_3316; BDBM21; SCHEMBL9044; MLS006011672; Vandetanib (JAN/USAN/INN); AMY599; F9995-0087; GTPL5717; QCR-37; DTXSID1046681; SCHEMBL21067679; cid_3081361; EX-A422; SYN1090; BCPP000023; HMS3244K03; HMS3244K04; HMS3244L03; HMS3654E11; HMS3672C07; AOB87780; BCP01925; Tox21_112511; 443913-73-3 (free base); NSC744325; NSC760766; NSC800961; s1046; ZINC53683345; AKOS015902350; Tox21_112511_1; AC-5251; CCG-269495; CS-0130; DB05294; MCULE-4705827953; NSC 744325; NSC 760766; NSC-800961; SB16919; 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline; NCGC00167513-02; NCGC00167513-03; NCGC00167513-04; NCGC00167513-09; 338992-00-0; 4-BROMO-2-FLUORO-N-[(4E)-6-METHOXY-7-[(1-METHYLPIPERIDIN-4-YL)METHOXY]QUINAZOLIN-4(1H)-YLIDENE]ANILINE; 4-Quninazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-; AS-11067; BV164508; HY-10260; SMR002530472; SY027438; FT-0656736; SW218092-2; EC-000.2359; A25648; D06407; V-9402; AB01273969-01; AB01273969-02; AB01273969_04; 913V733; SR-00000000462; Q7914515; SR-00000000462-2; BRD-K77625799-001-01-0; 4-(4-Bromo-2-fluoroanilino)-6-methoxy- 7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; 6-[(4R,5S,6S,7R)-4,7-dibenzyl-3-(5-carboxypentyl)-5,6-dihydroxy-2-oxo-1,3-diazepan-1-yl]hexanoic acid; Quinazolin-4-amine, N-(4-bromo-2-fluorophenyl)-6-mthoxy-7-[(1-methyl-4-piperidinyl)methoxy]-; Vandetanib;7-((4-aminocyclohexyl)methoxy)-N-(4-bromo-2-fluorophenyl)-6-methoxyquinazolin-4-amine; ZD6"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:49960	DB05294	DR00618	DR1669	475.4	C22H24BrFN4O2	59.5	539	4.9	30	1	7	6	"1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)"	CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC	UHTHHESEBZOYNR-UHFFFAOYSA-N
DG00620	Ruxolitinib	25126798	"Ruxolitinib; 941678-49-5; INCB018424; Ruxolitinib (INCB018424); (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile; INCB-018424; UNII-82S8X8XX8H; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; INCB 018424; 82S8X8XX8H; INC424; CHEBI:66919; (R)-ruxolitinib; C17H18N6; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile; INCB18424; R-Ruxolitinib; INC-424; INCB-18424; Ruxolitinib [USAN:INN]; INCB 18424; (3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)propanenitrile; INC 424; RXT; Ruxolitinib (USAN/INN); INCB18424,Ruxolitinib; SCHEMBL171319; GTPL5688; INCB018424 - Ruxolitinib; CHEMBL1789941; SCHEMBL16546708; HSDB 8259; DTXSID10240930; SYN1120; ACT06813; AMY24152; AOB87783; EX-A1670; BDBM50355501; MFCD12031592; NSC763371; NSC800874; s1378; ZINC43207851; AKOS016842401; BCP9000784; CCG-264889; CS-0864; DB08877; NSC-763371; NSC-800874; NCGC00244253-01; NCGC00244253-02; NCGC00244253-11; NCGC00244253-12; AC-24280; AS-18619; HY-50856; QC-11806; W9658; 1092939-15-5; A14955; A23578; D09959; AB01565782_02; Q7383611; BRD-K53972329-001-02-1; BRD-K53972329-001-03-9; (3R)-3-cyclopentyl-3-[4-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H -pyrazol-1-yl)-3-cyclopentylpropanenitrile; 3-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(beta-R)-1H-pyrazole-1-propanenitrile; A-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(AR)-1H-pyrazole-1-propanenitrile; (3R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile;Ruxolitinib; 1H-Pyrazole-1-propanenitrile, beta-cyclopentyl-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-,(betaR)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:66919	DB08877	.	.	306.4	C17H18N6	83.2	453	2.1	23	1	4	4	"1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1"	C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3	HFNKQEVNSGCOJV-OAHLLOKOSA-N
DG00621	Amantadine	2130	"Amantadine; 1-Adamantanamine; 768-94-5; adamantan-1-amine; 1-Adamantylamine; 1-Aminoadamantane; Adamantanamine; Adamantylamine; Aminoadamantane; Amantidine; Symmetrel; Symadine; Pk-merz; Adamantamine; 1-Adamantamine; Amantadina; Amantadinum; adamantan-1-ylamine; Gocovri; TCMDC-125869; 1-adamantaneamine; UNII-BF4C9Z1J53; 1-Aminotricyclo(3.3.1.1(sup 3,7))decane; NSC 341865; Tricyclo(3.3.1.13,7)decan-1-amine; tricyclo[3.3.1.1~3,7~]decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-amine; MFCD00074732; CHEMBL660; BF4C9Z1J53; CHEBI:2618; NSC341865; NSC-341865; (3s,5s,7s)-Tricyclo[3.3.1.1~3,7~]decan-1-Amine; 768-94-5 (FREE BASE); NCGC00015036-03; Tricyclo[3.3.1.13,7]decan-1-amine; Tricyclo[3.3.1.13,7]decane-1-amine; Amantadine Base; DSSTox_CID_2117; Amantadine [INN:BAN]; DSSTox_RID_76493; Amantadinum [INN-Latin]; DSSTox_GSID_22117; Amantadina [INN-Spanish]; Amant; Amantadine (INN); CAS-768-94-5; NSC83653; HSDB 3202; Tricyclo(3.3.1.1(3,7))-decan-1-amine; Tricyclo(3.3.1.1(sup 3.7))decan-1-amine; EINECS 212-201-2; 1-Adamantanamine (8CI); ADAMANTANE,1-AMINO; adamantaneamine; BRN 2204333; adamantyl amine; AmantadineHCl; 1-admantaneamine; 1-Amantadine; Tricyclo(3.3.1.1(sup 3,7))decan-1-amine; 1-adamantanylamine; 1-adamantyl amine; Adamant-1-ylamine; 1-amino-adamantane; adamantane-1-amine; Mantadine (Salt/Mix); Symmetrel (Salt/Mix); Spectrum_000030; Tricyclo[3.3.1.1^3,7]decan-1-amine; Prestwick0_000407; Prestwick1_000407; Prestwick2_000407; Prestwick3_000407; Spectrum2_000081; Spectrum3_000291; Spectrum4_000134; Spectrum5_000772; tricyclo[3.3.1.1(3,7)]decan-1-ylamine; tricyclo[3.3.1.1(3,7)]decane-1-amine; 1-Adamantylamine, 97%; Lopac-A-1260; Tricyclo[3.3.1.1(sup3,7)]decan-1-amine; EC 212-201-2; SCHEMBL4098; NCIOpen2_001059; Lopac0_000004; Oprea1_248648; BSPBio_000334; BSPBio_001570; BSPBio_001822; KBioGR_000548; KBioSS_000390; BIDD:GT0757; DivK1c_000815; Exp-105-1 (Salt/Mix); SPBio_000002; SPBio_002273; BPBio1_000368; GTPL4128; SCHEMBL2619248; DTXSID8022117; SCHEMBL15672299; SCHEMBL20409394; SCHEMBL21309814; SCHEMBL21310017; SCHEMBL23419027; KBio1_000815; KBio2_000390; KBio2_002958; KBio2_005526; KBio3_001322; NINDS_000815; (3R,5S,7s)-Adamantan-1-amine; 1-Adamantamine(1-Aminoadamantane); HMS1791O12; HMS1989O12; HMS3604O07; HMS3887I19; ZINC968256; ACT02873; ALBB-013871; BCP09869; HY-B0402; STR04703; Tox21_110068; BDBM50033369; HTS001826; s5499; STK298781; AKOS000113994; AKOS000119324; AKOS007930692; AKOS015935124; Tox21_110068_1; CCG-204100; CS-W008656; DB00915; MCULE-9686682307; SDCCGSBI-0049993.P005; IDI1_000815; NCGC00015036-01; NCGC00015036-02; NCGC00015036-04; NCGC00015036-05; NCGC00015036-06; NCGC00015036-07; NCGC00015036-08; NCGC00015036-09; NCGC00015036-11; NCGC00015036-13; NCGC00015036-24; NCGC00162039-01; NCGC00162039-02; NCGC00162039-03; NCGC00162039-04; NCGC00179597-01; AC-25879; ADS-5102, EXP 105-1; AS-14215; BP-13040; K333; SY017655; SBI-0049993.P004; WLN: L66 B6 A B- C 1B ITJ BZ; AB00514655; FT-0607338; C06818; D07441; AB00053414-14; AB00053414-16; AB00053414_17; AB00053414_18; AB01275427-01; 768A945; A838887; L000868; Q409761; J-650234; W-104338; BRD-K70330367-003-01-2; BRD-K70330367-003-03-8; Q27453436; F0001-1962"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:2618	DB00915	DR00040	DR2259	151.25	C10H17N	26	144	2.4	11	1	1	0	"1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2"	C1C2CC3CC1CC(C2)(C3)N	DKNWSYNQZKUICI-UHFFFAOYSA-N
DG00622	Rimantadine	5071	"Rimantadine; 13392-28-4; 1-(1-Adamantyl)ethanamine; 1-Rimantadine; 1-(adamantan-1-yl)ethan-1-amine; alpha-Methyl-1-adamantanemethylamine; alpha-Methyladamantanemethylamine; 1-(Adamantan-1-yl)ethanamine; RIMANTADIN; 1-Adamantan-1-yl-ethylamine; CHEMBL959; 1-Adamantanemethylamine, .alpha.-methyl-; .alpha.-Methyladamantanemethylamine; 1-(tricyclo[3.3.1.1~3,7~]dec-1-yl)ethanamine; Rimantadina; Rimantadinum; Rimantadine [INN:BAN]; Rimantadinum [INN-Latin]; 1-(1-Adamantyl)ethylamin; Rimantadina [INN-Spanish]; [1-(1-adamantyl)ethyl]amine hydrochloride; (R)-1-(1-Adamantyl)ethylamine; Rimant; Tricyclo[3.3.1.13,7]decane-1-methanamine, alpha-methyl-, (-)-; 1-(1-adamantyl)ethylamine; 117857-51-9; Rimantadine (INN); HSDB 7438; Enamine_005755; NCGC00159491-02; Rimant & .alpha. IFN; Rimantadine (Flumadine); Rimantidine & .alpha.IFN; 1-Adamantan-1-ylethylamine; BRN 2715740; rimantidin; 1-(1-adamantyl)-ethylamine; Rimantadin A; Tricyclo(3.3.1.13,7)decane-1-methanamine, alpha-methyl-; Maybridge1_002066; Tricyclo(3.3.1.1(sup 3,7))decane-1-methanamine, alpha-methyl-; 1-ADAMANTANEMETHYLAMINE, alpha-METHYL-; SCHEMBL2981; 1-tricyclo[3.3.1.1~3,7~]dec-1-ylethanamine; Oprea1_602732; SCHEMBL2619249; CHEMBL1201272; DTXSID2023561; SCHEMBL20409367; CHEBI:94440; HMS1410F13; HMS2090L19; HMS3604N13; HMS3655J05; ALBB-013870; BCP12269; HY-B0338; BBL013215; BDBM50216627; s1964; STK177253; (alpha-methyl-1-adamantyl)methylamine; AKOS000264537; AKOS006238592; AKOS016038537; .alpha.-Methyl-1-adamantanemethylamine; AM84461; CCG-236078; DB00478; MCULE-9027470290; 4-Bromo-7-(trifluoromethyl)- quinoline; IDI1_007990; NCGC00159491-03; NCGC00159491-05; NCGC00159491-11; AS-68744; SBI-0206810.P001; DB-042207; FT-0630403; SW220023-1; C07236; D08483; Q42171; 1-[(3R,5S,7s)-adamantan-1-yl]ethan-1-amine; AB00638368-09; AB00959689-03; AB01506092_02; AB01506092_03; 392R284; BRD-A84282119-003-01-2; Z56757137; Tricyclo[3.3.1.13,7]decane-1-methanamine, a-methyl-; Tricyclo(3.3.1.1^3,7)decane-1-methanamine, .alpha.-methyl-; Tricyclo(3.3.1.1(sup 3,7))decane-1-methanamine, .alpha.-methyl-; Tricyclo[3,3,1,1(3,7)]decane-1-methanamine, .alpha.-methyl-; Tricyclo(3.3.1.1^3,7)decane-1-methanamine, .alpha.-methyl- & IFN.alpha"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:94440	DB00478	DR00832	DR2305	179.3	C12H21N	26	180	2.6	13	1	1	1	"1S/C12H21N/c1-8(13)12-5-9-2-10(6-12)4-11(3-9)7-12/h8-11H,2-7,13H2,1H3"	CC(C12CC3CC(C1)CC(C3)C2)N	UBCHPRBFMUDMNC-UHFFFAOYSA-N
DG00623	Oxcarbazepine	34312	"OXCARBAZEPINE; 28721-07-5; Trileptal; Oxcarbamazepine; Oxcarbazepina; Oxcarbazepinum; GP 47680; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide; KIN-493; GP-47680; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide; UNII-VZI5B1W380; 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo-; MLS000084586; SPN-804; 9-oxo-2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene-2-carboxamide; 5H-Dibenz(b,f)azepine-5-carboxamide, 10,11-dihydro-10-oxo-; CHEMBL1068; SMR000048684; CHEBI:7824; VZI5B1W380; Oxacarbazepine; Timox; MFCD00865307; NSC-758693; NCGC00065934-02; DSSTox_CID_25703; DSSTox_RID_81075; DSSTox_GSID_45703; Oxcarbazepinum [INN-Latin]; Oxcarbazepina [INN-Spanish]; Oxcarbazepime; Epilexter; Epliga; Oxtellar XR; Trileptal (TN); CAS-28721-07-5; SR-01000612612; EINECS 249-188-8; Oxcarbazepin; HSDB 7524; Oxtellar (TN); Oxcarbazepine [USAN:USP:INN:BAN]; OCBZ; Oxcarbazepine solution; Oxcarbazepine- Bio-X; Spectrum_001675; Opera_ID_818; regid866068; Spectrum2_000483; Spectrum3_001669; Spectrum4_000634; Spectrum5_001869; O0363; SCHEMBL35129; BSPBio_003457; KBioGR_001248; KBioSS_002155; cid_34312; MLS000759520; MLS001201742; MLS001424025; MLS006011855; BIDD:GT0078; SPECTRUM1504243; SPBio_000345; GTPL7254; Oxcarbazepine (JAN/USP/INN); ZINC4724; DTXSID0045703; BDBM34179; KBio2_002155; KBio2_004723; KBio2_007291; KBio3_002677; Oxcarbazepine, analytical standard; 10,11-Dihydro-10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide; HMS1922H17; HMS2051O04; HMS2090F13; HMS2093E10; HMS2231B12; HMS3369J22; HMS3393O04; HMS3657O11; HMS3713I10; HMS3884K13; Pharmakon1600-01504243; BCP28260; BCP33398; HY-B0114; Tox21_110983; CCG-39509; NSC758693; s1391; STK594696; AKOS005516529; Tox21_110983_1; AC-3483; CS-1869; DB00776; KS-5197; MCULE-9100100302; NC00088; NSC 758693; Oxcarbazepine, >=98% (HPLC), solid; NCGC00065934-03; NCGC00065934-04; NCGC00065934-05; NCGC00065934-06; BO164187; H038; SBI-0206772.P001; GP-47-680; AM20040094; FT-0630543; FT-0673414; SW197468-3; A13943; C07492; D00533; J10384; M06310; AB00393017-12; AB00393017-14; AB00393017_15; AB00393017_16; 721O075; Q176301; SR-01000612612-4; SR-01000612612-6; W-107033; BRD-K04196797-001-12-9; 10-oxo-10,11-dihydro-5H-dibenz(b,f)azepin-5-carboxamide; 5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepin-5-carbonsaeureamid; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide #; Oxcarbazepine, European Pharmacopoeia (EP) Reference Standard; 10,11-Dihydro-10-oxo-5H-dibenzo(Z)[b,f]azepine-5-carboxamide; Oxcarbazepine, United States Pharmacopeia (USP) Reference Standard; 10-Oxo carbazepine; Oxecarb; 10,11-Dihdyro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide; Oxcarbazepine, Pharmaceutical Secondary Standard; Certified Reference Material; Oxcarbazepine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material; Oxcarbazepine-13C6 solution, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7824	DB00776	DR00453	DR1744	252.27	C15H12N2O2	63.4	382	1.7	19	1	2	0	"1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)"	C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N	CTRLABGOLIVAIY-UHFFFAOYSA-N
DG00624	Ceragenin	16678119	Ceragenin CSA-13; CSA-13; CHEMBL1275763; SCHEMBL14816571; 222022-08-4	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	677.1	C41H80N4O3	118	879	7.3	48	4	7	24	"1S/C41H80N4O3/c1-5-6-7-8-9-10-23-45-24-11-15-31(2)34-16-17-35-39-36(30-38(41(34,35)4)48-27-14-22-44)40(3)19-18-33(46-25-12-20-42)28-32(40)29-37(39)47-26-13-21-43/h31-39,45H,5-30,42-44H2,1-4H3/t31-,32+,33-,34-,35+,36+,37-,38+,39+,40+,41-/m1/s1"	CCCCCCCCNCCC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)OCCCN)C)OCCCN)OCCCN)C	YDYLISNLJUDIGF-GXDYCHSMSA-N
DG00625	D-Allosamine	6915732	"2-Amino-2-Deoxy-Allopyranose; 2-Amino-2-Deoxy-Allopyranoside; 2-Amino-2-Deoxy-Allose; 2-Amino-2-Deoxy-D-Allopyranose; 2-Amino-2-Deoxy-D-Allopyranoside; 2-Amino-2-Deoxy-D-Allose; 2-Deoxy-2-Amino-Allopyranose; 2-Deoxy-2-Amino-Allopyranoside; 2-Deoxy-2-Amino-Allose; 2-Deoxy-2-Amino-D-Allopyranose; 2-Deoxy-2-Amino-D-Allopyranoside; 2-Deoxy-2-Amino-D-Allose; AllN; Allosamine; D-AllN; D-Allosamine; SCHEMBL13985995; C21038; WURCS=2.0/1,1,0/[a2222h-1x_1-5_2*N]/1/"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	179.17	1	C6H13NO5	116	155	-2.8	12	5	6	"InChI=1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5+,6 /m1/s1"	C([C@@H]1[C@H]([C@H]([C@H](C(O1)O)N)O)O)O	MSWZFWKMSRAUBD-RSVSWTKNSA-N
DG00626	GDC-0623	42642654	"GDC-0623; 1168091-68-6; GDC 0623; RG 7421; GDC0623; UNII-HW67545I4Q; G-868; 5-((2-FLUORO-4-IODOPHENYL)AMINO)-N-(2-HYDROXYETHOXY)IMIDAZO[1,5-A]PYRIDINE-6-CARBOXAMIDE; 5-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide; HW67545I4Q; RG-7420; RG-7421; 5-[(2-FLUORO-4-IODOPHENYL)AMINO]-N-(2-HYDROXYETHOXY)IMIDAZO[1,5-A]PYRIDINE-6-CARBOXAMIDE; Imidazo[1,5-a]pyridine-6-carboxamide, 5-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-; MEK inhibitor 1; GTPL9909; SCHEMBL1615104; CHEMBL3330650; CHEBI:167659; AOB87143; BCP28689; EX-A2060; BDBM50025226; MFCD25976760; NSC778590; NSC800998; RG7421; s7553; ZINC43206499; AKOS027253679; CCG-269293; DB11982; NSC-778590; NSC-800998; SB16957; NCGC00351593-05; AS-55986; DA-33609; G868; HY-15610; FT-0769207; G 868; A858271; Q27280129; 5-(2-Fluoro-4-iodophenylamino)-imidazo[1,5-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide; 5-(2-Fluoro-4-iodophenylamino)-imidazo[15-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide; 5-(2-Fluoro-4-iodophenylamino)imidazo[1,5-a]pyridine-6-carboxylic acid N-(2-hydroxyethoxy)amide"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB11982	.	.	456.21	C16H14FIN4O3	87.9	461	3.7	25	3	6	6	"1S/C16H14FIN4O3/c17-13-7-10(18)1-4-14(13)20-15-12(16(24)21-25-6-5-23)3-2-11-8-19-9-22(11)15/h1-4,7-9,20,23H,5-6H2,(H,21,24)"	C1=CC(=C(C=C1I)F)NC2=C(C=CC3=CN=CN32)C(=O)NOCCO	RFWVETIZUQEJEF-UHFFFAOYSA-N
DG00627	SCH772984	24866313	"SCH772984; 942183-80-4; SCH-772984; (R)-1-(2-oxo-2-(4-(4-(pyrimidin-2-yl)phenyl)piperazin-1-yl)ethyl)-N-(3-(pyridin-4-yl)-1H-indazol-5-yl)pyrrolidine-3-carboxamide; SCH 772984; CHEMBL3590107; (3R)-1-[2-Oxo-2-[4-[4-(2-pyrimidinyl)phenyl]-1-piperazinyl]ethyl]-N-[3-(4-pyridinyl)-1H-indazol-5-yl]-3-pyrrolidinecarboxamide; (3~{R})-1-[2-oxidanylidene-2-[4-(4-pyrimidin-2-ylphenyl)piperazin-1-yl]ethyl]-~{N}-(3-pyridin-4-yl-1~{H}-indazol-5-yl)pyrrolidine-3-carboxamide; (3r)-1-(2-Oxo-2-{4-[4-(Pyrimidin-2-Yl)phenyl]piperazin-1-Yl}ethyl)-N-[3-(Pyridin-4-Yl)-2h-Indazol-5-Yl]pyrrolidine-3-Carboxamide; (3R)-1-[2-oxo-2-[4-(4-pyrimidin-2-ylphenyl)piperazin-1-yl]ethyl]-N-(3-pyridin-4-yl-1H-indazol-5-yl)pyrrolidine-3-carboxamide; 38Z; GTPL8056; SCHEMBL12151489; AOB6425; EX-A296; CHEBI:167670; C33H33N9O2; 2711AH; BDBM50094464; MFCD11878503; NSC775636; s7101; ZINC96174209; AKOS025402018; CS-1421; NSC-775636; SCH772984, SCH 984; NCGC00350780-05; NCGC00350780-10; NCGC00350780-11; (R)-1-(2-oxo-2-(4-(4-(pyrimidin-2-yl)phenyl)piperazin-1-yl)ethyl)-N-(3-(pyridin-4-yl)-1H-indazol-5-y; (R)-1-{2-Oxo-2-[4-(4-pyrimidin-2-yl-phenyl)-piperazin-1-yl]-ethyl}-pyrrolidine-3-carboxylic acid (3-pyridin-4-yl-1H-indazol-5-yl)-amide; AC-28198; CID 24866313; HY-50846; QC-11359; F31041; A859514; Q27088760; (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL)PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-1H-INDAZOL-5-YL]PYRROLIDINE-3-CARBOXAMIDE; (R)-1-(2-oxo-2-(4-(4-(pyrimidin-2-yl)phenyl)piperazin-1-yl)ethyl)-N-(3-(pyridin-4-yl)-1H-indazol-5-; F3Z"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	587.7	C33H33N9O2	123	957	2.5	44	2	8	7	"1S/C33H33N9O2/c43-30(42-18-16-41(17-19-42)27-5-2-24(3-6-27)32-35-11-1-12-36-32)22-40-15-10-25(21-40)33(44)37-26-4-7-29-28(20-26)31(39-38-29)23-8-13-34-14-9-23/h1-9,11-14,20,25H,10,15-19,21-22H2,(H,37,44)(H,38,39)/t25-/m1/s1"	C1CN(C[C@@H]1C(=O)NC2=CC3=C(C=C2)NN=C3C4=CC=NC=C4)CC(=O)N5CCN(CC5)C6=CC=C(C=C6)C7=NC=CC=N7	HDAJDNHIBCDLQF-RUZDIDTESA-N
DG00628	INK128	45375953	"1224844-38-5; Sapanisertib; INK-128; MLN0128; INK 128; INK128; TAK-228; INK 128 (MLN0128); Sapanisertib (MLN0128); MLN-0128; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; UNII-JGH0DF1U03; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; JGH0DF1U03; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; C15H15N7O; 5-(4-azanyl-1-propan-2-yl-pyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; Sapanisertib; INK128; Sapanisertib (USAN/INN); Sapanisertib [USAN:INN]; MLS006011012; GTPL7933; SCHEMBL7902875; CHEMBL3545097; CHEBI:91450; EX-A951; INK-128/INK128; SYN1157; BDBM315477; HMS3656H12; HMS3672C21; INK-128;Sapanisertib;MLN0128; AOB87177; INK-0128; 2477AH; MFCD22124893; NSC764658; NSC768435; NSC780880; s2811; ZINC73069271; AKOS025149512; US10172858, Table 1.1; BCP9000789; CCG-265002; CS-0557; DB11836; NSC-764658; NSC-768435; NSC-780880; SB16566; US10172858, Table 1.22; NCGC00346654-01; NCGC00346654-10; AC-26848; AS-16294; BS170924; HY-13328; SMR004702810; BCP0726000086; A8551; FT-0700125; SW220210-1; D11183; INK-128,CAS:1224844-38-5; J-004811; Q27078072; 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-(2-amino-5-benzoxazolyl)-1-(1-methylethyl)-; 2-Benzoxazolamine, 5-(4-amino-1-(1-methylethyl)-1H-pyrazolo(3,4-d)pyrimidin-3-yl)-; 3-(2-Amino-1,3-benzoxazol-5-yl)-1-isopropyl-1H-pyrazolo(3,4-d)pyrimidin-4-amine; 5-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; FE5; INK-128; ; ; MLN-0128; ; ; 5-(4-Amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:91450	DB11836	.	.	309.33	C15H15N7O	122	436	1.7	23	2	7	2	"1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19)"	CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N	GYLDXIAOMVERTK-UHFFFAOYSA-N
DG00629	Echinocandins	9898144	"Echinocandin B; 54651-05-7; UNII-CNW0ZW8ZTQ; CNW0ZW8ZTQ; Antibiotic SL 7810F; Antibiotic A 30912A; (9Z,12Z)-N-((2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-23-((1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl)-2,11,12,15-tetrahydroxy-6,20-bis((R)-1-hydroxyethyl)-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl)octadeca-9,12-dienamide; (9Z,12Z)-N-{(2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-23-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,12,15-tetrahydroxy-6,20-bis[(1R)-1-hydroxyethyl]-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}octadeca-9,12-dienamide; 5.1:6-anhydro{(4R,5R)-4,5-dihydroxy-N(2)-[(9Z,12Z)-octadeca-9,12-dienoyl]-L-ornithyl-L-threonyl-(4R)-4-hydroxy-L-prolyl-(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-threonyl-L-threonyl-(3S,4S)-3-hydroxy-4-methyl-L-proline}; Antibiotic A 22082; NSC 287461; A 30912A; Echinocandin B (9CI); A-22082; SCHEMBL17951640; CHEBI:315018; (9Z,12Z)-N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]octadeca-9,12-dienamide"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	1060.2	C52H81N7O16	368	1940	2.5	75	14	16	20	"1S/C52H81N7O16/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-38(65)53-35-26-37(64)48(71)57-50(73)42-43(66)29(2)27-59(42)52(75)40(31(4)61)55-49(72)41(45(68)44(67)32-21-23-33(62)24-22-32)56-47(70)36-25-34(63)28-58(36)51(74)39(30(3)60)54-46(35)69/h9-10,12-13,21-24,29-31,34-37,39-45,48,60-64,66-68,71H,5-8,11,14-20,25-28H2,1-4H3,(H,53,65)(H,54,69)(H,55,72)(H,56,70)(H,57,73)/b10-9-,13-12-/t29-,30+,31+,34+,35-,36-,37+,39-,40-,41-,42-,43-,44-,45-,48+/m0/s1"	CCCCC/C=C\\C/C=C\\CCCCCCCC(=O)N[C@H]1C[C@H]([C@H](NC(=O)[C@@H]2[C@H]([C@H](CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)[C@@H](C)O)C)O)O)O	FAUOJMHVEYMQQG-HVYQDZECSA-N
DG00630	AP26113	57390074	"AP26113; 1197958-12-5; ALK-IN-1; Brigatinib-analog; (2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; UNII-3DGD69C6PV; AP26113-analog; 5-chloro-2-N-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl]-4-N-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine; 3DGD69C6PV; CHEMBL3397300; 1197958-12-5 (analog); 5-Chloro-N~2~-{4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}-N~4~-[2-(dimethylphosphoryl)phenyl]pyrimidine-2,4-diamine; 2,4-Pyrimidinediamine, 5-chloro-N2-(4-(4-(dimethylamino)-1-piperidinyl)-2-methoxyphenyl)-N4-(2-(dimethylphosphinyl)phenyl)-; 2,4-Pyrimidinediamine, 5-chloro-N2-[4-[4-(dimethylamino)-1-piperidinyl]-2-methoxyphenyl]-N4-[2-(dimethylphosphinyl)phenyl]-; Brigatinib analog; 5-Chloro-N2-(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)-N4-(2-(dimethylphosphoryl)phenyl)pyrimidine-2,4-diamine; 5-CHLORO-N2-{4-[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]-2-METHOXYPHENYL}-N4-[2-(DIMETHYLPHOSPHORYL)PHENYL]PYRIMIDINE-2,4-DIAMINE; Brigatinib(AP26113); C26H34ClN6O2P; SCHEMBL11916416; DTXSID30725416; EX-A770; AP26113;ALK-IN-1; HMS3652H14; HMS3673I09; BCP06648; 2218AH; BDBM50062357; MFCD23704187; NSC776763; NSC800977; s7000; ZINC89630357; AKOS025401944; AKOS032949980; AP 26113-analog, Brigatinib-analog; CCG-264698; CS-1368; NSC-776763; NSC-800977; SB16487; NCGC00351602-02; NCGC00351602-05; NCGC00351602-09; 5-Chloro-N2-(4-(4-(dimethylamino)-1-piperidinyl)-2-methoxyphenyl)-N4-(2-(dimethylphosphinyl)phenyl)-2,4-pyrimidinediamine; AC-27470; AS-75104; DA-35325; HY-13464; QC-11659; FT-0696829; SW219566-1; Q4653190; E5J"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	.	.	.	529	C26H34ClN6O2P	82.6	733	4.8	36	2	8	8	"1S/C26H34ClN6O2P/c1-32(2)18-12-14-33(15-13-18)19-10-11-21(23(16-19)35-3)30-26-28-17-20(27)25(31-26)29-22-8-6-7-9-24(22)36(4,5)34/h6-11,16-18H,12-15H2,1-5H3,(H2,28,29,30,31)"	CN(C)C1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC=CC=C4P(=O)(C)C)Cl)OC	OVDSPTSBIQCAIN-UHFFFAOYSA-N
DG00631	Clozatinib	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00632	ASP3026	25134326	"ASP3026; 1097917-15-1; ASP-3026; ASP 3026; N2-[2-Methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine; UNII-HP4L6MXF10; HP4L6MXF10; 2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)-1,3,5-triazine-2,4-diamine; 4-N-[2-Methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-2-N-(2-propan-2-ylsulfonylphenyl)-1,3,5-triazine-2,4-diamine; N4-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-N2-(2-propan-2-ylsulfonylphenyl)-1,3,5-triazine-2,4-diamine; F6O; MLS006011176; GTPL7740; SCHEMBL2827739; CHEMBL3545360; C29H40N8O3S; AOB6601; DTXSID90149038; EX-A140; QCR-144; CHEBI:167650; HMS3673C17; BCP06436; XTB91715; 2229AH; MFCD21609265; NSC765865; NSC799336; s8054; ZINC68120928; AKOS025142083; CCG-270132; CS-0787; DB12729; NSC-765865; NSC-799336; SB19387; NCGC00345791-01; NCGC00345791-09; AC-28466; AS-16959; DA-35322; HY-13326; N2-(2-(isopropylsulfonyl)phenyl)-N4-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-1,3,5-triazine-2,4-diamine; SMR004702945; FT-0755075; J-523409; Q27074543; N(2)-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N(4)-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine; N-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N'-[2-(propan-2-ylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine; N-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N'-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	580.7	C29H40N8O3S	124	904	4.8	41	2	11	9	"1S/C29H40N8O3S/c1-21(2)41(38,39)27-8-6-5-7-25(27)33-29-31-20-30-28(34-29)32-24-10-9-23(19-26(24)40-4)36-13-11-22(12-14-36)37-17-15-35(3)16-18-37/h5-10,19-22H,11-18H2,1-4H3,(H2,30,31,32,33,34)"	CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=N2)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC	MGGBYMDAPCCKCT-UHFFFAOYSA-N
DG00633	Diclofenac	3033	"Diclofenac; 15307-86-5; Diclofenac acid; dichlofenac; Diclofenacum; Diclophenac; 2-(2-((2,6-Dichlorophenyl)amino)phenyl)acetic acid; Diclofenaco; Diclofenac resinate; Voltarol; 2-(2,6-Dichloroanilino)phenylacetic Acid; 2-[2-(2,6-dichloroanilino)phenyl]acetic acid; 2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid; Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-; 2-((2,6-Dichlorophenyl)amino)benzeneacetic acid; Solaraze; Diclofenac free acid; UNII-144O8QL0L1; {2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid; CHEBI:47381; Voltaren-XR; [2-(2,6-Dichloroanilino)phenyl]acetic acid; 2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid; CHEMBL139; 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID; ACETIC ACID, (o-(2,6-DICHLOROANILINO)PHENYL)-; 144O8QL0L1; Arthrotec; 15307-86-5 (free); ProSorb-D; Olfen; MFCD00056694; Solaraze (TN); 2-[(2,6-dichlorophenyl)amino]-benzeneacetic acid; Enfenamic acid; N-Phenethylanthranilic acid; RH 8; 2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetic acid; Zorovolex; Zorvolex; Diclofenamic acid; Diclofenacum [INN-Latin]; Diclofenaco [INN-Spanish]; DIF; HSDB 7234; GP-45840; EINECS 239-348-5; (2-((2,6-Dichlorophenyl)amino-phenyl)acetic acid (HD); BRN 2146636; Diclofenac [USAN:INN:BAN]; ISV-205; Zorvolex (TN); Spectrum_000930; Diclofenac (USAN/INN); Prestwick0_000594; Prestwick1_000594; Prestwick2_000594; Prestwick3_000594; Spectrum2_000991; Spectrum3_000385; Spectrum4_000506; Spectrum5_000867; Epitope ID:116873; EC 239-348-5; SCHEMBL2799; Lopac0_000441; Oprea1_011155; BSPBio_000468; BSPBio_002169; KBioGR_001051; KBioGR_002306; KBioSS_001410; KBioSS_002308; MLS006011795; BIDD:GT0380; DivK1c_000272; DivK1c_000402; 2-[2-(2,6-dichlorophenyl)aminophenyl]ethanoic acid; SPBio_001081; SPBio_002687; BPBio1_000516; GTPL2714; ZINC1281; DTXSID6022923; BDBM13066; HMS501E04; KBio1_000272; KBio1_000402; KBio2_001410; KBio2_002306; KBio2_003978; KBio2_004874; KBio2_006546; KBio2_007442; KBio3_001389; KBio3_002786; 2b17; cMAP_000014; NINDS_000272; NINDS_000402; HMS2090C10; HMS3886F09; BCP09087; BCP13860; LAS41007; LAS-41007; s6073; STK984493; AKOS001579542; DB00586; KS-1258; MCULE-1824024270; IDI1_000272; IDI1_000402; NCGC00021125-01; NCGC00021125-02; NCGC00021125-11; AC-27673; HY-15036; o-(2,6-dichloroanilino)phenylacetic acid; SMR001550371; SY038623; SBI-0051341.P003; D3748; FT-0624731; FT-0666643; UNM000001216103; [2-(2,6-Dichloroanilino)phenyl]acetic acid #; C01690; D07816; Diclofenac acid 100 microg/mL in Acetonitrile; H10425; [o-(2,6-dichloro-anilino)-phenyl]-acetic acid; 2-[(2,6-dichlorophenyl)amino]phenylacetic acid; 2-[2-(2,6-dichloroanilino)phenyl]acetic acid.; AB01275502-01; AB01275502_02; 056D694; 2-(2-(2,6-dichlorophenylamino)phenyl)acetic acid; 2-[(2,6-dichlorophenyl)amino]-phenyl-acetic acid; Q244408; [2-(2,6-dichloro-phenylamino)-phenyl]-acetic acid; 2-[(2,6-dichlorophenyl)-amino]-benzeneacetic acid; 2-[(2,6-dichlorophenyl)-amino]-phenyl-acetic acid; 2-[2-(2,6-dichlorophenylamino)phenyl]-acetic acid; SR-01000003041-3; 2-[2-(2,6-dichlorophenylamino)-phenyl]-acetic acid; BRD-K08252256-236-05-6; BRD-K08252256-236-17-1; Z57664869; F0722-0745; Benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)- (9CI); 2-[2-[(2,6-Dichlorophenyl)amino]phenyl]acetic Acid (Diclofenac); 128402-48-2"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:47381	DB00586	DR00681	.	296.1	C14H11Cl2NO2	49.3	304	4.4	19	2	3	4	"1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)"	C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl	DCOPUUMXTXDBNB-UHFFFAOYSA-N
DG00634	Puromycin	439530	"Puromycin; 53-79-2; Puromycine; Stylomycin; Puromicina; Puromycinum; Stillomycin; P-638; Puromycin dihydrochloride; CHEBI:17939; UNII-4A6ZS6Q2CL; 3123L; CL 13900; GNF-PF-2016; CL 13,900; 4A6ZS6Q2CL; 3'-(L-alpha-Amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyladenosine; CL-13900; (S)-3'-((2-Amino-3-(4-methoxyphenyl)-1-oxopropyl)amino)-3'-deoxy-N,N-dimethyladenosine; NSC-3055; 9-{3-deoxy-3-[(O-methyl-L-tyrosyl)amino]-beta-D-xylofuranosyl}-N,N-dimethyl-9H-purin-6-amine; Adenosine, 3'-(((2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl)amino)-3'-deoxy-N,N-dimethyl-; Achromycin (purine derivative); P 638; TCMDC-123493; 3'-deoxy-N,N-dimethyl-3'-(O-methyl-L-tyrosinamido)adenosine; 3'-deoxy-N,N-dimethyl-3'-[(O-methyl-L-tyrosyl)amino]adenosine; 58-58-2; 3'-[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3'-deoxy-N,N-diemthyladenosine; CL 16536; (S)-2-amino-N-((2S,3S,4R,5R)-5-(6-(dimethylamino)-9H-purin-9-yl)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)-3-(4-methoxyphenyl)propanamide; NSC3055; NSC 3055; Puromycine [INN-French]; Puromycinum [INN-Latin]; Puromicina [INN-Spanish]; Bacterenomycin; Puromycin [USAN:INN:BAN]; (S)-3'-[[2-Amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3'-deoxy-N,N-dimethyladenosine; Adenosine, 3'-((2-amino-3-(4-methoxyphenyl)-1-oxopropyl)amino)-3'-deoxy-N,N-dimethyl-, (S)-; PUY; Puromycin (USAN); CL13900; Prestwick3_000480; Epitope ID:140945; SCHEMBL4570; BSPBio_000620; BPBio1_000682; CHEMBL469912; DTXSID8036788; HMS2089F18; HY-B1743; CL 16,536 (*Dihydrochloride*); BDBM50277158; MFCD00866328; ZINC53147179; AKOS030485964; CCG-208505; CS-6500; DB08437; 6-Dimethylamino-9-(3'-(p-methoxy-L-phenylalanylamino)-beta-D-ribofuranosyl)-purine; Puromycin, 10 mg/ml in distilled water; NCGC00179500-01; NCGC00179500-07; NCGC00179500-14; (2S)-2-amino-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide; AB00514661; 3123-L; C01610; D05653; AB00514661-07; Q424696; BRD-K36007650-001-01-9; BRD-K36007650-300-02-3; Q27167243; Adenosine, 3'-(alpha-amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyl-, L-; (2S)-2-amino-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl]-3-(4-methoxyphenyl)propanamide; 2-amino-N-[5-[6-(dimethylamino)-9-purinyl]-4-hydroxy-2-(hydroxymethyl)-3-oxolanyl]-3-(4-methoxyphenyl)propanamide; Adenosine, 3'-(-amino-p-methoxyhydrocinnamamido)-3'-deoxy-N, N-dimethyl-, dihydrochloride, L-"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB08437	DR01525	.	471.5	C22H29N7O5	161	680	0	34	4	10	8	"1S/C22H29N7O5/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32)/t14-,15+,16+,18+,22+/m0/s1"	CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)NC(=O)[C@H](CC4=CC=C(C=C4)OC)N)O	RXWNCPJZOCPEPQ-NVWDDTSBSA-N
DG00635	TAK-733	24963252	"TAK-733; 1035555-63-5; TAK733; TAK 733; (R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione; UNII-5J61HSP0QJ; 5J61HSP0QJ; CHEMBL1615025; 3-[(2r)-2,3-Dihydroxypropyl]-6-Fluoro-5-[(2-Fluoro-4-Iodophenyl)amino]-8-Methylpyrido[2,3-D]pyrimidine-4,7(3h,8h)-Dione; Mek inhibitor tak-733; MLS006011054; GTPL9911; SCHEMBL1528606; DTXSID20648089; example 18 [US8470837]; AOB87182; BCP06625; EX-A2164; BDBM50337926; MFCD24386349; NSC761215; NSC800940; s2617; ZINC43196550; AKOS027251050; CCG-264969; CS-1283; DB12241; NSC-761215; NSC-800940; compound 17 [PMID: 21310613]; NCGC00263187-01; 3-[(2R)-2,3-Dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione; HY-13449; SMR004702846; SW220152-1; US8470837, 18; A857992; Q27262384; 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-[(2-fluoro-4-iodophenyl)amino]-8-methylpyrido [2,3-d]pyrimidine-4,7(3h,8h)-dione; IZG; Pyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione,3-[(2R)-2,3-dihydroxy-propyl]-6-fluoro-5-[(2-fluoro-4-iodophenyl)amino]-8-methyl-"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB12241	.	.	504.23	C17H15F2IN4O4	106	772	0.9	28	3	8	5	"1S/C17H15F2IN4O4/c1-23-15-12(16(27)24(7-21-15)5-9(26)6-25)14(13(19)17(23)28)22-11-3-2-8(20)4-10(11)18/h2-4,7,9,22,25-26H,5-6H2,1H3/t9-/m1/s1"	CN1C2=C(C(=C(C1=O)F)NC3=C(C=C(C=C3)I)F)C(=O)N(C=N2)C[C@H](CO)O	RCLQNICOARASSR-SECBINFHSA-N
DG00636	Pingyangmycin	84046	"Pingyangmycin; Bleomycetin; Bleomycinamide, N1-[3-[(4-aminobutyl)amino]propyl]-; (Bleomycin A5); CHEMBL2002141; BCP23597; NSC350895; NSC-350895; Q2095702; Bleomycinamide, N(1)-[3-[(4-aminobutyl)amino]propyl]-"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB12992	.	.	1440.6	C57H89N19O21S2	722	2620	-8.8	99	22	33	40	"1S/C57H89N19O21S2/c1-22-35(73-48(76-46(22)61)27(14-33(60)80)68-15-26(59)47(62)86)52(90)75-37(43(28-16-65-21-69-28)95-56-45(41(84)39(82)31(17-77)94-56)96-55-42(85)44(97-57(63)92)40(83)32(18-78)93-55)53(91)70-24(3)38(81)23(2)49(87)74-36(25(4)79)51(89)67-13-8-34-71-30(20-98-34)54-72-29(19-99-54)50(88)66-12-7-11-64-10-6-5-9-58/h16,19-21,23-27,31-32,36-45,55-56,64,68,77-79,81-85H,5-15,17-18,58-59H2,1-4H3,(H2,60,80)(H2,62,86)(H2,63,92)(H,65,69)(H,66,88)(H,67,89)(H,70,91)(H,74,87)(H,75,90)(H2,61,73,76)"	CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCCNCCCCN)O	QYOAUOAXCQAEMW-UHFFFAOYSA-N
DG00637	Carbamazepine	2554	"Carbamazepine; 298-46-4; Tegretol; Carbamazepen; 5H-Dibenzo[b,f]azepine-5-carboxamide; Finlepsin; Biston; 5H-Dibenz[b,f]azepine-5-carboxamide; Carbazepine; Tegretal; Equetro; Carbamezepine; Neurotol; Timonil; Epitol; Karbamazepin; Carbatrol; Stazepine; Telesmin; Lexin; Tegretol-Xr; benzo[b][1]benzazepine-11-carboxamide; Carbamazepin; Carbamazepinum; 5H-Dibenz(b,f)azepine-5-carboxamide; Carbamazepina; Amizepin; Bipotrol; Teril; Geigy 32883; 5-Carbamyl-5H-dibenzo(b,f)azepine; 5-Carbamoyl-5H-dibenzo(b,f)azepine; Calepsin; Carnexiv; Sirtal; 5-Carbamoyl-5H-dibenz(b,f)azepine; 5-Carbamoyl-5H-dibenz[b,f]azepine; G 32883; G-32883; NSC 169864; MFCD00005073; CHEBI:3387; UNII-33CM23913M; CHEMBL108; 5-Carbamyldibenzo(b,f)azepine; MLS000069652; 5-Carbamoyldibenzo(b,f)azepine; CBZ; NSC169864; 33CM23913M; NSC-169864; NCGC00015234-11; CAS-298-46-4; SMR000058201; Stazepin; DSSTox_CID_2731; 2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene-2-carboxamide; DSSTox_RID_76704; DSSTox_GSID_22731; Carbamazepine Anhydrous; 5H-dibenzo[b,f]azepine-5-carboxamide;Oxcarbazepine IMpurity A; Carbelan; Tegretol Cr; Carbamazepinum [INN-Latin]; Carbamazepina [INN-Spanish]; SMR001227191; HSDB 3019; SR-01000000229; Carbatrol extended-release; EINECS 206-062-7; BRN 1246090; Karbelex; Neurotop; Trimonil; Neurotop retard; dibenzo[b,f]azepine-5-carboxamide; Tegretol (TN); Prestwick_104; Equetro (TN); Carbamazepine-[d2]; Carbamazepine, powder; Opera_ID_72; Spectrum_000096; Carbamazepine [USAN:USP:INN:BAN:JAN]; Prestwick0_000052; Prestwick1_000052; Prestwick2_000052; Prestwick3_000052; Spectrum2_000125; Spectrum3_000325; Spectrum4_000262; Spectrum5_000936; Carbamazepine (Carbatrol); Lopac-C-4024; ChemDiv1_018966; CBChromo1_000350; Epitope ID:174842; Iminostilbene-N-carboxamide; Carbamazepine-[13C,15N]; Lopac0_000292; Oprea1_790775; SCHEMBL21639; BSPBio_000203; BSPBio_001929; Carbamazepine extended release; KBioGR_000724; KBioSS_000516; MLS001055475; MLS001074172; MLS002548877; BIDD:GT0479; DivK1c_000388; DivK1c_003750; SPECTRUM1500159; SPBio_000170; SPBio_002124; BPBio1_000225; GTPL5339; ZINC4785; DTXSID4022731; SCHEMBL19838283; HMS501D10; HMS640O02; KBio1_000388; KBio2_000516; KBio2_003084; KBio2_005652; KBio3_001149; WLN: T C676 BNJ BVZ; AOB5783; Carbamazepine (JP17/USP/INN); CBZ;NSC 169864; dibenz[b,f]azepine-5-carboxamide; SPD-417; Carbamazepine, analytical standard; NINDS_000388; HMS1568K05; HMS1920I17; HMS2090M07; HMS2091O19; HMS2095K05; HMS2233G16; HMS3039K09; HMS3259B21; HMS3260L06; HMS3372J13; HMS3657G03; HMS3712K05; HMS3747E03; Pharmakon1600-01500159; ACT02606; BCP21380; HY-B0246; 5-Carbomoyl-5H-dibenzo(b,f)azepine; Tox21_110104; Tox21_202273; Tox21_300195; Tox21_500292; AC2074; BDBM50003659; CCG-38931; NSC755920; s1693; STK177357; STL453548; 11-benzo[b][1]benzazepinecarboxamide; 5H-Dibenz[b,f]azepine-5-carboxamine; Carbamazepine 1.0 mg/ml in Methanol; AKOS003235644; AKOS025397243; Tox21_110104_1; AC-9538; DB00564; KS-5146; LP00292; MCULE-9121567287; NC00679; NSC-755920; SDCCGSBI-0050280.P005; 5H-Dibenz[ b, f]azepine-5-carboxamide; CDS1_002710; IDI1_000388; 5H-Dibenzo[b,f]azepine-5-carboxamide #; NCGC00015234-01; NCGC00015234-02; NCGC00015234-03; NCGC00015234-04; NCGC00015234-05; NCGC00015234-06; NCGC00015234-07; NCGC00015234-08; NCGC00015234-09; NCGC00015234-10; NCGC00015234-12; NCGC00015234-13; NCGC00015234-14; NCGC00015234-15; NCGC00015234-16; NCGC00015234-18; NCGC00015234-19; NCGC00015234-33; NCGC00023877-03; NCGC00023877-04; NCGC00023877-05; NCGC00023877-06; NCGC00023877-07; NCGC00023877-08; NCGC00253982-01; NCGC00259822-01; NCGC00260977-01; BC166161; H495; SY002823; (z)-5h-dibenzo[b,f]azepine-5-carboxamide; SBI-0050280.P004; 5H-dibenzo[b,f]azepine-5-carboximidic acid; DB-047659; Dibenzo[b,f]azepine-5-carboxylic acid amide; EU-0100292; FT-0602927; FT-0696814; SW220141-1; BIM-0050280.0001; C 4024; C06868; Carbamazepine, meets USP testing specifications; D00252; 5H-Dibenz(b,f)azepine-5-carboxamide maleic acid; 5H-Dibenz(b,f)azepine-5-carboxamide oxalic acid; AB00051931-17; AB00051931-18; AB00051931_19; AB00051931_20; A820074; Q410412; carbamazepine host structure with maleic acid removed; carbamazepine host structure with oxalic acid removed; Q-200792; SR-01000000229-2; SR-01000000229-4; SR-01000000229-7; 5H-Dibenz(b,f)azepine-5-carboxamide DL-tartaric acid; BRD-K71799949-001-06-7; F0348-2551; Z2199879032; carbamazepine host structure with DL-tartaric acid removed; Dibenzo[b,f]azepine-5-carboxylic acid amide(Carbamazepine); carbamazepine host structure with 4-hydroxybenzoic acid removed; Carbamazepine, British Pharmacopoeia (BP) Reference Standard; Carbamazepine, European Pharmacopoeia (EP) Reference Standard; Carbamazepine, United States Pharmacopeia (USP) Reference Standard; Carbamazepine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Carbamazepine, Pharmaceutical Secondary Standard; Certified Reference Material; N6W"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3387	DB00564	DR00395	DR0270	236.27	C15H12N2O	46.3	326	2.5	18	1	1	0	"1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)"	C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N	FFGPTBGBLSHEPO-UHFFFAOYSA-N
DG00638	Valproic acid	3121	"VALPROIC ACID; 2-Propylpentanoic acid; 99-66-1; 2-Propylvaleric acid; Dipropylacetic acid; Depakine; Depakene; Valproate; Ergenyl; Di-n-propylacetic acid; Mylproin; Pentanoic acid, 2-propyl-; 4-Heptanecarboxylic acid; n-Dipropylacetic acid; Propylvaleric acid; Myproic Acid; n-DPA; Dipropylacetate; Convulex; Depakin; Di-n-propylessigsaure; Avugane; Baceca; Stavzor; Acido valproico; Kyselina 2-propylvalerova; Acide valproique; 2-n-Propyl-n-valeric acid; Acidum valproicum; Acetic acid, dipropyl-; 2,2-di-n-propylacetic acid; Valproinsaeure; Savicol; Depakine chrono; Depakin chrono; Abbott 44090; Acide valproique [INN-French]; Acido valproico [INN-Spanish]; Acidum valproicum [INN-Latin]; 2-PROPYL-PENTANOIC ACID; Di-n-propylessigsaure [German]; Valeric acid, 2-propyl-; Epilim; Kyselina 2-propylvalerova [Czech]; Di-n-propylessigsaeure; VPA; VPA;2-Propylpentanoic Acid; UNII-614OI1Z5WI; NSC 93819; Delepsine; Sprinkle; Valcote; Valparin; Epilex; PEAC; Depakene (TN); MFCD00002672; Vupral; CHEMBL109; (n-C3H7)2CHCOOH; 614OI1Z5WI; CHEBI:39867; Valerin; NSC-93819; NCGC00091149-01; Deproic; Alti-Valproic; Novo-Valproic; Penta-Valproic; Dom-Valproic; Med Valproic; Nu-Valproic; DSSTox_CID_3733; DSSTox_RID_77171; DSSTox_GSID_23733; Valproic acid USP; PMS-Valproic Acid; Valproic acid (USP); CAS-99-66-1; Depakote (TM); SMR000499581; HSDB 3582; 2 PP (base); EINECS 202-777-3; BRN 1750447; valproic-acid; Novo-divalproex; Sandoz valproic; Dom-valproate; Gen-divalproex; Apo-valproic; A-44090; AI3-10500; APO-divalproex; DOM-divalproex; Epival er; PHL-valproate; PMS-valproate; PMS-Divalproex; Erganyl; Stavzor; Dom-valproic acid; Apo-valproic syrup; PHL-valproic acid; Epiject I.V.; 2-propyl-Pentanoate; Epical (TM); Epilim (Salt/Mix); Valproic acid [USAN:USP:INN:BAN]; Depacon (Salt/Mix); Convulex (Salt/Mix); Eurekene (Salt/Mix); G2M-777; Valparin (Salt/Mix); Valproic acid solution; Novo-Valproic - ECC; Spectrum_000521; Divalproex (Salt/Mix); Dom-valproic acid syrup; Ratio-Valproic - ECC; Valdisoval (Salt/Mix); 2 -propylpentanoic acid; di-n-propyl acetic acid; S(-)-4-En-valproate; Spectrum2_000946; Spectrum3_001733; Spectrum4_000376; pentanoic acid, 2-propyl; DOM-valproic acid E.C.; PHL-valproic acid E.C.; PMS-valproic acid E.C.; Novo-valproic soft gel cap; EC 202-777-3; SCHEMBL2275; S-2-n-Propyl-4-pentenoate; (S)-2-propyl-4-pentanoate; KBioGR_000871; KBioGR_002277; KBioSS_001001; KBioSS_002278; MLS001076682; MLS001335927; MLS001335928; MLS002415770; BIDD:GT0858; DivK1c_000273; Valproic acid extended release; SPBio_000912; GTPL7009; DTXSID6023733; WLN: QVY3 & 3; KBio1_000273; KBio2_001001; KBio2_002277; KBio2_003569; KBio2_004845; KBio2_006137; KBio2_007413; KBio3_002626; KBio3_002757; NIJJYAXOARWZEE-UHFFFAOYSA-; Valproic acid [USAN:BAN:INN]; NINDS_000273; HMS2089J06; HMS2231E06; HMS3259C18; HMS3370C21; HMS3715B15; HMS3885G14; ACT05281; ALBB-032973; BCP33204; NSC93819; ZINC3008621; Tox21_111091; Tox21_201963; Tox21_300603; BDBM50003616; LMFA01020291; s3944; STL445581; AKOS009156895; Tox21_111091_1; Valproic Acid 1.0 mg/ml in Methanol; CCG-221127; CS-1765; DB00313; MCULE-7136317196; NC00584; SDCCGSBI-0050864.P004; NCGC00091149-02; NCGC00091149-03; NCGC00091149-04; NCGC00091149-05; NCGC00091149-06; NCGC00091149-08; NCGC00091149-09; NCGC00091149-26; NCGC00162288-07; NCGC00254365-01; NCGC00259512-01; AS-11354; HY-10585; SBI-0050864.P003; FT-0609289; FT-0675769; P0823; A19450; C07185; D00399; AB00698315-06; Q240642; Q-200321; Sodium valproate; 2-Propylpentanoic acid sodium salt; SR-01000075242-7; F2191-0115; Z1511532065; Valproic acid, European Pharmacopoeia (EP) Reference Standard; Valproic acid, United States Pharmacopeia (USP) Reference Standard; Valproic acid for system suitability, European Pharmacopoeia (EP) Reference Standard; Valproic acid solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Valproic acid, Pharmaceutical Secondary Standard; Certified Reference Material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:39867	DB00313	DR00399	DR1667	144.21	C8H16O2	37.3	93.4	2.8	10	1	2	5	"1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)"	CCCC(CCC)C(=O)O	NIJJYAXOARWZEE-UHFFFAOYSA-N
DG00639	Lamotrigine	3878	"Lamotrigine; 84057-84-1; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine; Lamictal; Lamictal Cd; Lamictal XR; Lamotriginum [Latin]; Lamotrigina [Spanish]; Lamotriginum; BW 430C; Lamotrigina; Lamictal ODT; BW-430C; 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; 1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl)-; BW430C; 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine; C9H7Cl2N5; LTG;BW430C; UNII-U3H27498KS; MFCD00865333; CHEMBL741; MLS000069685; CHEBI:6367; U3H27498KS; NSC-759171; NCGC00015605-06; Labileno; Lamitor; SMR000058464; Lamotrigine-13C-d3; DSSTox_CID_3195; DSSTox_RID_76918; DSSTox_GSID_23195; Lamictal (TN); LTg; CAS-84057-84-1; SR-01000000187; EINECS 281-901-8; HSDB 7526; EUR-1048; Lamotrigine [USAN:USP:INN:BAN]; zine-3,5-diamine; Lamotrigine- Bio-X; GI 267119X; Opera_ID_12; Tocris-1611; hydroxymethyl progesterone; Lopac-L-3791; L 3791; Lopac0_000688; SCHEMBL35439; MLS000759486; MLS001077325; MLS001423991; BIDD:GT0794; Lamotrigine (JAN/USP/INN); Lamotrigine, >=98%, powder; GTPL2622; DTXSID2023195; ZINC13156; HMS2051C10; HMS2089M08; HMS2093P21; HMS2230L04; HMS3262I17; HMS3268G17; HMS3371O16; HMS3393C10; HMS3657A17; HMS3715H21; HMS3885M03; Pharmakon1600-01505610; AMY40805; BCP12156; HY-B0495; Lamotrigine 1.0 mg/ml in Methanol; Tox21_110179; Tox21_500688; BDBM50031299; NSC746307; NSC759171; s3024; STK628377; AKOS005561147; Tox21_110179_1; 6-(2,2,4-triazine-3,5-diyldiamine; CCG-100856; DB00555; KS-1074; LP00688; MCULE-7648410888; NC00106; NSC 746307; NSC 759171; NSC-746307; SDCCGSBI-0050666.P003; SMP2_000303; NCGC00015605-01; NCGC00015605-02; NCGC00015605-03; NCGC00015605-04; NCGC00015605-05; NCGC00015605-07; NCGC00015605-08; NCGC00015605-09; NCGC00015605-10; NCGC00015605-23; NCGC00015605-24; NCGC00022936-02; NCGC00022936-04; NCGC00022936-05; NCGC00261373-01; AC-10298; AC-32483; BL166799; K499; Lamotrigine 100 microg/mL in Acetonitrile; SBI-0050666.P002; 6-(2,3-Dichloro-phenyl)-[1,2,4]tria; DB-014839; B2249; EU-0100688; FT-0602546; FT-0670713; FT-0670714; L-205; L0241; SW197486-3; 57L841; A11873; D00354; J10032; W13018; AB00384359-16; AB00384359_17; AB00384359_18; A840709; Q410346; 3,5-diamino-(2,3-dichlorophenyl)-1,2,4-triazine; Q-201221; SR-01000000187-2; SR-01000000187-4; SR-01000000187-7; BRD-K93460210-071-01-6; SR-01000000187-10; 3,5-diamino-6-(2,3,-dichlorophenyl)-1,2,4-triazine; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine.; F2173-0540; Z1550648755; 6-(2,3-Dichloro-phenyl)-[1,2,4]triazine-3,5-diamine; 6-[2,3-bis(chloranyl)phenyl]-1,2,4-triazine-3,5-diamine; Lamotrigine, British Pharmacopoeia (BP) Reference Standard; Lamotrigine, European Pharmacopoeia (EP) Reference Standard; 6-(2,3-Dichloro-phenyl)-[1,2,4]triazine-3,5-diamine(lamotrigine); GI 267119X; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine; Lamotrigine, United States Pharmacopeia (USP) Reference Standard; Lamotrigine, Pharmaceutical Secondary Standard; Certified Reference Material; Lamotrigine for peak identification, European Pharmacopoeia (EP) Reference Standard; Lamotrigine for system suitability, European Pharmacopoeia (EP) Reference Standard; Lamotrigine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6367	DB00555	DR00056	DR0913	256.089	C9H7Cl2N5	90.7	242	1.4	16	2	5	1	"1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)"	C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N	PYZRQGJRPPTADH-UHFFFAOYSA-N
DG00640	Levetiracetam	5284583	"Levetiracetam; 102767-28-2; Keppra; (S)-2-(2-Oxopyrrolidin-1-yl)butanamide; Keppra XR; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; ucb L059; UCB-L 059; Levetiracetamum; Spritam; UCB-L059; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; SIB-S1; Levetiracetame; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; UNII-44YRR34555; MFCD03265610; UCB-22059; Levetiracetamum [INN-Latin]; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; CHEBI:6437; Levetiracetam In Sodium Chloride; UCB 22059; 44YRR34555; NSC-760119; Levroxa; (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide; matever; Leviteracetam; Levipil; Torleva; Elepsia XR; (S)-Levetiracetam; SMR000466303; Keppra (TN); Levesam 500; Etiracetam levo-isomer; SR-01000759400; Elepsia; Levetiracetam sun; E Keppra; HSDB 7528; Levetiracetam teva; N03AX14; Levetiracetam accord; Levetiracetam [USAN:USP:INN:BAN]; Levetiracetam actavis; Levetiracetam hospira; E keppra (TN); Levetiracetam solution; Levetiracetam- Bio-X; (S)-2-(2-Oxo-1-pyrrolidinyl)butyramide; L-059; 2(S)-(2-OXOPYRROLIDIN-1-YL)BUTYRAMIDE; CHEMBL1286; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (S)-; MLS000759403; MLS001424069; MLS006010215; BIDD:GT0242; SCHEMBL118843; GTPL6826; Levetiracetam (JAN/USP/INN); DTXSID9023207; AGB-101; Levetiracetam, >=98% (HPLC); Levetiracetam, analytical standard; HMS2051D07; HMS2089L20; HMS2235I18; HMS3262H11; HMS3713P16; HMS3884O11; Pharmakon1600-01502265; ACT02712; ALBB-027275; BCP11856; HY-B0106; ZINC1547851; Tox21_500835; BDBM50422542; NSC760119; s1356; STL388027; Levetiracetam 1.0 mg/ml in Methanol; AKOS015841981; AC-1479; CCG-100928; CS-1854; DB01202; KS-1176; LP00835; LS41261; MCULE-5120797917; NC00178; NSC 760119; SDCCGSBI-0633760.P001; (2S)-(2-Oxopyrrolidin-1-yl)butyramide; NCGC00186028-01; NCGC00186028-13; NCGC00261520-01; (S)-2-(2-oxopyrrolidin-1-yl)butyramide; BL164623; (s)-2-(2-oxopyrrolidin-1-yl) butyramide; AM20070676; L0234; SW197558-3; C07841; D00709; AB00639945-06; AB00639945_07; AB00639945_08; 767L282; A800616; (S)-2-(2-OXO-PYRROLIDIN-1-YL)-BUTYRAMIDE; Q-201292; SR-01000759400-4; SR-01000759400-5; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide;Levetiracetam; (ALPHAS)-ALPHA-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE; UNII-230447L0GL component HPHUVLMMVZITSG-LURJTMIESA-N; Levetiracetam, European Pharmacopoeia (EP) Reference Standard; Levetiracetam, United States Pharmacopeia (USP) Reference Standard; (-)-(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide (2S)-2-(2-Oxo-pyrrolidin-1-yl)butanamide; Levetiracetam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Levitiracetam, Pharmaceutical Secondary Standard; Certified Reference Material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6437	DB01202	DR00180	.	170.21	C8H14N2O2	63.4	203	-0.3	12	1	2	3	"1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1"	CC[C@@H](C(=O)N)N1CCCC1=O	HPHUVLMMVZITSG-LURJTMIESA-N
DG00641	Topiramate	5284627	"Topiramate; 97240-79-4; Topamax; Epitomax; Topamax Sprinkle; Tipiramate; Topiramatum; Topina; McN-4853; Tipiramato; Topiramato; Topimax; Topomax; McN 4853; C12H21NO8S; 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; RWJ-17021-000; RWJ-17021; 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate; UNII-0H73WJJ391; USL255; USL-255; MFCD00865320; RWJ 17021; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate; CHEBI:63631; Tipiramate [French]; Tipiramato [Spanish]; 0H73WJJ391; ((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methyl sulfamate; Topiramatum [INN-Latin]; topiramatum [Latin]; Topiramato [INN-Spanish]; Epitoma; Topamac; DSSTox_CID_3688; DSSTox_RID_77148; DSSTox_GSID_23688; ((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl)methyl sulfamate; [(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.0^{2,6}]dodecan-6-yl]methyl sulfamate; Topiragen; Topax; Trokendi XR; Qudexy XR; SMR000466325; Topiramate (TPM); TOR; TPM; Topamax (TN); CAS-97240-79-4; BRN 5988957; Sincronil; Qudexy; HSDB 7531; Sulfamate 7; 3hku; 3lxe; USL 255; (-)-topiramate; Topiramate [USAN:USP:INN:BAN]; Topiramate solution; NCGC00095181-01; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyl-5,5a,8a,8b-tetrahydrodi[1,3]dioxolo[5,4-b:5',3'-d]pyran-3a-yl]methyl sulfamate; Topiramate- Bio-X; Trokendi xr (TN); KS-1122; Spectrum2_001128; beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate; CBChromo1_000352; BIDD:PXR0127; SCHEMBL34631; BSPBio_002306; Topiramate (JAN/USP/INN); Eprontia (liquid formulation); MLS000759431; MLS001424070; BIDD:GT0854; SPECTRUM1505801; SPBio_000995; CHEMBL220492; GTPL6849; DTXSID8023688; BDBM10887; HMS1922H06; HMS2051L09; HMS2093D20; HMS2232H21; HMS3414C15; HMS3678C15; HMS3715I12; HMS3884C17; Pharmakon1600-01505801; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate (non-preferred name); ACT09031; ALBB-022457; HY-B0122; Tox21_111472; Tox21_302401; 2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate; NSC759251; s1438; ZINC95616603; AKOS000424547; Topiramate 1.0 mg/ml in Acetonitrile; Topiramate, >=98% (HPLC), solid; Tox21_111472_1; CCG-100940; CS-1885; DB00273; MCULE-9403222429; NC00190; NSC 759251; NSC-759251; NCGC00178714-01; NCGC00178714-04; NCGC00178714-18; NCGC00255221-01; BT167048; SBI-0206907.P001; SW197570-3; C07502; D00537; F20536; AB00639961-06; AB00639961-08; AB00639961_09; AB00639961_10; 240T794; A900173; Q221174; SR-01000759409; W-60376; Q-201845; SR-01000759409-4; Z1522553470; 2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulfamate; Topiramate, United States Pharmacopeia (USP) Reference Standard; 2,3:4,5-Bis-O-(1-methylethylidene)- -D-fructopyranose sulfamate; Topiramate, Pharmaceutical Secondary Standard; Certified Reference Material; Topiramate solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; [(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.02,6]dodecan-6-yl]methyl sulfamate; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyl-5,5a,8a,8b-tetrahydrodi[1,3]dioxolo[4,5-a:5',3'-d]pyran-3a-yl]methyl sulfamate; 2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose 1-sulfamate;2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose sulfamate; Topamax; Tracrium; Toiramate:"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63631	DB00273	DR01372	DR1618	339.36	C12H21NO8S	124	556	-0.8	22	1	9	3	"1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1"	CC1(O[C@@H]2CO[C@@]3([C@H]([C@@H]2O1)OC(O3)(C)C)COS(=O)(=O)N)C	KJADKKWYZYXHBB-XBWDGYHZSA-N
DG00642	PLX51107	90448953	"PLX51107; 1627929-55-8; (S)-4-(6-(3,5-dimethylisoxazol-4-yl)-1-(1-(pyridin-2-yl)ethyl)-1H-pyrrolo[3,2-b]pyridin-3-yl)benzoic acid; PLX-51107; PLX 51107; UNII-W758F1L9ND; BRD4 inhibitor PLX51107; W758F1L9ND; 4-{6-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1S)-1-(pyridin-2-yl)ethyl]-1H-pyrrolo[3,2-b]pyridin-3-yl}benzoic acid; 4-(6-(3,5-dimethyl-1,2-oxazol-4-yl)-1-((1S)-1-pyridin-2-ylethyl)pyrrolo(3,2-b)pyridin-3-yl)benzoic acid; 4-[6-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1S)-1-pyridin-2-ylethyl]pyrrolo[3,2-b]pyridin-3-yl]benzoic acid; CHEMBL4521078; SCHEMBL16085681; BDBM425592; CQC92955; EX-A1824; PLX 51107 [WHO-DD]; PXL51107; MFCD31657388; NSC806595; s8739; AKOS037648775; NSC-806595; US10519177, Compound P-0511; AC-32941; BS-15563; HY-111422; CS-0040568; D80522; A930121; 4-[6-(3,5-dimethylisoxazol-4-yl)-1- [(1S)-1-(2-pyridyl)ethyl]pyrrolo[3,2- b]pyridin-3-yl]benzoic acid; 4-[6-(3,5-dimethylisoxazol-4-yl)-1-[(1S)-1-(2-pyridyl)ethyl]pyrrolo[3,2-b]pyridin-3-yl]benzoic acid; 6JF; Benzoic acid, 4-(6-(3,5-dimethyl-4-isoxazolyl)-1-((1S)-1-(2-pyridinyl)ethyl)-1H-pyrrolo(3,2-b)pyridin-3-yl)-"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB16038	.	.	438.5	C26H22N4O3	94	684	4	33	1	6	5	"1S/C26H22N4O3/c1-15-24(17(3)33-29-15)20-12-23-25(28-13-20)21(18-7-9-19(10-8-18)26(31)32)14-30(23)16(2)22-6-4-5-11-27-22/h4-14,16H,1-3H3,(H,31,32)/t16-/m0/s1"	CC1=C(C(=NO1)C)C2=CC3=C(C(=CN3[C@@H](C)C4=CC=CC=N4)C5=CC=C(C=C5)C(=O)O)N=C2	AMSUHYUVOVCWTP-INIZCTEOSA-N
DG00643	BDGR-4	.	.	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB10322	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00644	Galidesivir	10445549	"Galidesivir; Immucillin-A; IMMUCILLIN A; 249503-25-1; BCX4430; BCX 4430 Free Base; BCX-4430; UNII-OLF97F86A7; (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol; OLF97F86A7; BCX4430 freebase; ImmA cpd; 3,4-Pyrrolidinediol,2-(4-Amino-5h-Pyrrolo[3,2-D]pyrimidin-7-Yl)-5-(Hydroxymethyl)-2s,3s,4r,5r; BCX4430 (freebase); UA2; CHEMBL1236524; SCHEMBL12468816; GTPL11920; BDBM50513995; HY-18649A; ZINC13492903; CS-3779; DB11676; NCGC00485882-01; BCX-4430 freebase;Immucillin-A;Galidesivir; P14655; A900809; (1S)-1-(9-Carbaadenine-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol; Galidesivir; BCX4430; BCX 4430; BCX-4430;(2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB11676	.	.	265.27	C11H15N5O3	140	334	-2.1	19	6	7	2	"1S/C11H15N5O3/c12-11-8-6(14-3-15-11)4(1-13-8)7-10(19)9(18)5(2-17)16-7/h1,3,5,7,9-10,13,16-19H,2H2,(H2,12,14,15)/t5-,7+,9-,10+/m1/s1"	C1=C(C2=C(N1)C(=NC=N2)N)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O	AMFDITJFBUXZQN-KUBHLMPHSA-N
DG00645	Artesunate	6917864	"Artesunate; Artesunic acid; Arsumax; 88495-63-0; Dihydroqinghasu hemsuccinate; Artesunatum; Plasmotrin; Qinghaozhi; Saphnate; Arinate; Artesunato; Zysunate; Asumax; Gsunate Forte; Plasmotrim; UNII-60W3249T9M; CHEBI:63918; Succinyl dihydroartemisinin; 60W3249T9M; Arsuamoon; WR-256283; Butanedioic acid, 1-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl] ester; cosunate; Artesunata; SM 804; Cosinate; 4-oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl)oxy)butanoic acid; 4-oxo-4-{[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-yl]oxy}butanoic acid; Armax 200; Artesunatum [INN-Latin]; Artesunato [INN-Spanish]; Artsuna; Nuartez; Artesunate [USAN:INN:BAN]; HSDB 7458; NSC-712571; Quinghaosu reduced succinate ester; D95; Dihydroartemisinine-12alpha-succinate; .alpha.-artesunic acid; WR 256283; Dihydroqinghaosu hemisuccinate; MLS006011590; CHEMBL361497; GTPL9956; SCHEMBL14552891; LJPC-0118; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, hydrogen succinate; ACT02643; HY-N0193; STR09744; BDBM50248021; ZINC14096305; AKOS037515734; CS-8151; DB09274; NCGC00164600-10; NCGC00164600-15; SMR002499399; Q707939; BRD-K54634444-001-05-9; WR-256283;ART;Armax 200;SM-804;HSDB-7458; 4-Oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10-yl hydrogen butanedioate; 4-oxo-4-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoic acid; 4-oxo-4-{[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0 ,(1)(3).0 ,(1)(3)]hexadecan-10-yl]oxy}butanoic acid; Butanedioic acid, mono((3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63918	DB09274	.	.	384.4	C19H28O8	101	623	2.5	27	1	8	5	"1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1"	C[C@@H]1CC[C@H]2[C@H]([C@@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC(=O)CCC(=O)O)C	FIHJKUPKCHIPAT-AHIGJZGOSA-N
DG00646	Albendazole	2082	"Albendazole; 54965-21-8; Albenza; Eskazole; Valbazen; Zentel; Proftril; Albendazolum; SK&F 62979; SKF 62979; Andazol; Methyl 5-(propylthio)-2-benzimidazolecarbamate; SK&F-62979; 5-(Propylthio)-2-carbomethoxyaminobenzimidazole; SKF-62979; methyl N-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; (5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester; methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate; O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate; NSC 220008; UNII-F4216019LN; Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester; Albendazol; Bilutac; MFCD00083232; CHEMBL1483; CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER; methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle; [5-(Propylthio)benzimidazol-2-yl]carbamic Acid Methyl Ester; CHEBI:16664; Zental; F4216019LN; NSC-220008; methyl [6-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; NCGC00016876-01; CAS-54965-21-8; DSSTox_CID_2563; DSSTox_RID_76632; DSSTox_GSID_22563; Albendazol [INN-Spanish]; Albendazolum [INN-Latin]; methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate; methyl 5-(propylthio)-1H-benzo[d]imidazol-2-ylcarbamate; Methyl [5-(Propylthio)benzimidazol-2-yl]carbamate; methyl N-(5-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; methyl N-[5-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate; methyl (NZ)-N-(5-propylsulfanyl-1,3-dihydrobenzimidazol-2-ylidene)carbamate; Albenza (TN); HSDB 7444; EINECS 259-414-7; Albendazole (JAN/USP/INN); Zenteltrade mark; Albenzatrade mark; Andazoltrade mark; Eskazoletrade mark; Albendazole,(S); ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle [French]; Prestwick_675; Albendazole(Albenza); Albendazole (Albenza); Albendazole [USAN:USP:INN:BAN:JAN]; Spectrum_001532; CPD000036735; (5-Propylsulfanyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; Prestwick0_000247; Prestwick1_000247; Prestwick2_000247; Prestwick3_000247; Spectrum4_000201; Spectrum5_001567; ChemDivAM_000003; ChemDiv1_000190; Oprea1_429292; Oprea1_585016; Oprea1_640007; SCHEMBL44682; BSPBio_000034; BSPBio_002548; KBioGR_000801; KBioSS_002012; MLS000069722; BIDD:GT0615; DivK1c_000704; SPECTRUM1503903; methoxy-N-(5-propylthiobenzimidazol-2-yl)carboxamide; SPBio_002253; BPBio1_000038; DTXSID0022563; HMS502D06; HMS587I14; HXHWSAZORRCQMX-UHFFFAOYSA-; KBio1_000704; KBio2_002012; KBio2_004580; KBio2_007148; NINDS_000704; HMS1568B16; HMS1922K04; HMS2090G19; HMS2093K13; HMS2095B16; HMS2231O03; HMS3259B05; HMS3369C03; HMS3651C15; HMS3712B16; Pharmakon1600-01503903; [5-(Propythio)-1H-benzimidazol-2-yl]carbamic acid methyl ester; BCP12108; HY-B0223; Tox21_110659; Tox21_302300; AC-015; BBL005883; BDBM50241293; CCG-39620; MFCD01220143; N-[6-(propylthio)-1H-benzimidazol-2-yl]carbamic acid methyl ester; NSC220008; NSC758644; s1640; STK387550; STL046130; ZINC17146904; AKOS000540882; AKOS005431684; AKOS005699352; Tox21_110659_1; CCG-220247; DB00518; KS-5159; MCULE-5872469561; NC00615; NSC-758644; IDI1_000704; methyl [(2Z)-5-(propylsulfanyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]carbamate; NCGC00016876-02; NCGC00016876-03; NCGC00016876-04; NCGC00016876-05; NCGC00016876-06; NCGC00016876-07; NCGC00016876-08; NCGC00016876-09; NCGC00016876-10; NCGC00016876-12; NCGC00022896-03; NCGC00022896-04; NCGC00022896-05; NCGC00022896-06; NCGC00022896-07; NCGC00022896-08; NCGC00255250-01; Albendazole, analytical standard, >=98%; H152; SMR000036735; Albendazole 100 microg/mL in Acetonitrile; SBI-0051849.P002; DB-052669; AB00052377; FT-0621945; SW196830-3; EN300-49850; methyl 5-propylthio-2-benzimidazole carbamate; VU0239747-6; BIM-0051849.0001; C01779; D00134; H10782; J10424; Methyl 5-n-propylthio-2-benzimidazolecarbamate; AB00052377-13; AB00052377-14; AB00052377_15; AB00052377_16; A830429; Albendazole, Antibiotic for Culture Media Use Only; Q411629; SR-01000000171; SR-05000001875; methyl 5-(propylthio)-1H-benzimidazol-2-ylcarbamate; Q-200603; Q-200604; SR-01000000171-2; SR-05000001875-1; BRD-K79131256-001-04-7; BRD-K79131256-001-08-8; methyl 6-(propylthio)-1H-benzo[d]imidazol-2-ylcarbamate; Z1245635850; 2-[(Methoxycarbonyl)amino]-5-propylthio-1H-benzimidazole; Albendazole, European Pharmacopoeia (EP) Reference Standard; Methyl (6-(propylthio)-1H-benzo[d]imidazol-2-yl)carbamate; Methyl 5-(propylsulfanyl)-1H-benzimidazol-2-ylcarbamate #; Albendazole, United States Pharmacopeia (USP) Reference Standard; Albendazole, Pharmaceutical Secondary Standard; Certified Reference Material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:16664	DB00518	DR01323	DR0055	265.33	C12H15N3O2S	92.3	291	2.9	18	2	4	5	"1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)"	CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC	HXHWSAZORRCQMX-UHFFFAOYSA-N
DG00647	Nitrofurantoin	6604200	"Nitrofurantoin; 67-20-9; Furadantin; 5-Nitrofurantoin; Furadonine; Furadantine; Furadantoin; Furadoine; Furadontin; Furantoin; Nifurantin; Nitrofuradantin; Nitrofurantoine; Berkfurin; Chemiofuran; Furachel; Furadonin; Furatoin; Furobactina; Macrobid; Novofuran; Orafuran; Parfuran; Trantoin; Urantoin; Urofurin; Welfurin; Zoofurin; Cyantin; Cystit; Furalan; Furina; Ituran; Nitoin; Urizept; Urodin; Urolong; Furadantine mc; Uro-Tablinen; Fur-ren; Macrodantin; Macrofuran; Nitrofurantoina; Benkfuran; Dantafur; Furaloid; Nierofu; Macpac; Nitrex; Nitrofurantoinum; Fua Med; N-Toin; Usaf ea-2; 1-(5-Nitro-2-furfurylideneamino)hydantoin; N-(5-Nitrofurfurylidene)-1-aminohydantoin; NITROFURANTOIN, MACROCRYSTALLINE; N-(5-Nitro-2-furfurylidene)-1-aminohydantoin; 1-((5-Nitrofurfurylidene)amino)hydantoin; 1-[(5-Nitrofurfurylidene)amino]hydantoin; 1-(5-Nitro-2-furfurylidenamino)hydantoin; NCI-C55196; NSC 2107; NSC 44150; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina; UNII-927AH8112L; Nitrofurantoin anhydrous; Furadoninum; Nitrofurantoin macrocrystal; 1-(((5-Nitrofuran-2-yl)methylene)amino)imidazolidine-2,4-dione; 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione; Nitrofurantoin, macrocrystals; MLS000028500; Cistofuran; Macrodantina; Macrofurin; Nifuretten; Alfuran; Berkfuran; Ceduran; Furabid; Furedan; Gerofuran; Phenurin; Siraliden; Uerineks; Urofuran; Urolisa; CHEBI:71415; Hydantoin, 1-((5-nitrofurfurylidene)amino)-; PiyEloseptyl; 1-[[(5-Nitro-2-furanyl)methylene]amino]-2,4-imidazolidinedione; Furadantina MC; Furadantine-MC; Furophen T; Nitrofur-C; Ro-Antoin; Furadantin Retard; Uro-Selz; Ivadantin; MFCD00003224; 927AH8112L; SMR000058271; 1-(((5-Nitrofuran-2-yl)methylene)-amino)imidazolidine-2,4-dione; 1-{[(1E)-(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione; Nitrofurantoina [DCIT]; 2,4-Imidazolidinedione, 1-[[(5-nitro-2-furanyl)methylene]amino]-; Nitrofurantoine [INN-French]; Nitrofurantoinum [INN-Latin]; Furodantin; 2,4-Imidazolidinedione, 1-(((5-nitro-2-furanyl)methylene)amino)-; Fuamed; NSC-2107; 1-{[(E)-(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione; Furadantin (TN); Macrobid (TN); CCRIS 1192; Hydantoin, 1-[(5-nitrofurfurylidene)amino]-; HSDB 3135; SR-05000001681; EINECS 200-646-5; NITROFURANTOIN MACROCRYSTALLINE; NSC2107; Furantoina; Furadoin; Furadoxyl; Uvamin; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina [Polish]; NSC44150; 1-[[(5-nitrofuran-2-yl)methylene]amino]imidazolidine-2,4-dione; AI3-26388; Nitrofurantoin (JAN/USP/INN); Furophen T-Caps; NCGC00091505-01; NCGC00091505-07; Prestwick_358; Nitrofurantoin Macro; 5-Nitrofurantoindorn; J01XE01; Nitrofurantoin [USP:INN:BAN:JAN]; ND-3320; ND-7248; Nitrofurantoin, 97%; Nitrofurantoinum anhydrous; Prestwick2_000168; Prestwick3_000168; Spectrum5_001367; Nitrofurantoin, crystalline; CHEMBL572; Nitrofurantoin Macrocrystals; cid_4509; SCHEMBL29470; SCHEMBL29472; BSPBio_000035; BSPBio_002073; BIDD:GT0181; SPECTRUM1500433; BPBio1_000039; BDBM57045; CHEBI:95222; HMS500L06; HMS1568B17; HMS1920P21; HMS2091H16; HMS2095B17; HMS3712B17; Pharmakon1600-01500433; 1-[(E)-(5-nitro-2-furyl)methyleneamino]imidazolidine-2,4-dione; HY-A0090; ZINC7997568; 2,4-Imidazolidenedione, 1-(((5-nitro-2-furanyl)methylene)amino)-; CCG-40108; NSC757243; s4536; STK009471; STL454163; AKOS001678301; DB00698; NSC-757243; IDI1_000224; NCGC00091505-03; NCGC00091505-04; NCGC00091505-05; NCGC00091505-06; NCGC00091505-08; NCGC00091505-09; NCGC00091505-10; LS-13402; 1-((5-nitrofurfurylidene)amino)-hydantoin; SBI-0051457.P003; AB00513815; BB 0310231; N0883; A16008; C07268; D00439; J10193; AB00052052_03; A835659; Hydantoin, n-(5-nitro-2-furfurylidene)-1-amino-; Nitrofurantoin, VETRANAL(TM), analytical standard; Q-201479; SR-05000001681-1; SR-05000001681-2; SR-05000001681-3; SR-05000001681-4; BRD-K76927775-001-05-0; Nitrofurantoin, Antibiotic for Culture Media Use Only; Hydantoin, 1-[(5-nitrofurfurylidene)amino]- (7CI,8CI); 1-((5-nitro-2-furanyl)methylene)amino-2,4-imidazolidenedione; 1-{[(5-nitro-2-furyl)methylene]amino}imidazolidine-2,4-dione; (E)-1-[(5-nitro-2-furyl)methylideneamino]imidazolidine-2,4-dione; 1-([(5-Nitro-2-furyl)methylidene]amino)-2,4-imidazolidinedione #; 1-[(E)-(5-nitro-2-furanyl)methylideneamino]imidazolidine-2,4-dione; 1-{[(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione; Nitrofurantoin, United States Pharmacopeia (USP) Reference Standard; 1-{[(E)-1-(5-nitro-2-furyl)methylidene]amino}-1H-imidazole-2,4(3H,5H)-dione; 4-hydroxy-1-{[(E)-(5-nitrofuran-2-yl)methylidene]amino}-1,5-dihydro-2H-imidazol-2-one; N-(5-Nitro-2-furfurylidine)-1-aminohydantoin; N-(5-Nitrofurfurylidene)-1aminohydantoin; Nitrofurantoin, Pharmaceutical Secondary Standard; Certified Reference Material; 178170-37-1"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:71415	DB00698	DR00886	DR1169	238.16	C8H6N4O5	121	390	-0.5	17	1	6	2	"1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+"	C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-]	NXFQHRVNIOXGAQ-YCRREMRBSA-N
DG00648	Idelalisib	11625818	"Idelalisib; 870281-82-6; CAL-101; Zydelig; GS-1101; CAL 101; CAL101; (S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; 1146702-54-6; Idelalisib (CAL-101); UNII-YG57I8T5M0; CAL-101 (Idelalisib, GS-1101); GS 1101; (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; YG57I8T5M0; CHEMBL2216870; CHEBI:82701; 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one; Idelalisib; CAL-101; 5-fluoro-3-phenyl-2-((1s)-1-(9h-purin-6-ylamino)propyl)-4(3h)-quinazolinone; 5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one; 5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-one; 5-Fluoro-3-Phenyl-2-[(1s)-1-(7h-Purin-6-Ylamino)propyl]quinazolin-4(3h)-One; Idelalisib [USAN:INN]; Idealisib; 5-FLUORO-3-PHENYL-2-[(1S)-1-(9H-PURIN-6-YLAMINO)PROPYL]-4(3H)-QUINAZOLINONE; Zydelig (TN); MLS006010985; Idelalisib (JAN/USAN/INN); SCHEMBL356400; C22H18FN7O; GTPL6741; QCR-36; SCHEMBL16782604; HSDB 8408; AMY9239; CAL-101/CAL101; EX-A330; GS-11CAL-101; BCPP000307; DTXSID701007266; AOB87313; BCP02532; EX-A1242; BDBM50403068; MFCD19443647; NSC759224; NSC762828; NSC800771; s2226; ZINC13986658; AKOS022186334; Idelalisib (CAL-101,GS-1101); BCP9000471; CCG-264949; CS-0256; DB09054; LS41100; NSC-759224; NSC-762828; NSC-800771; CAL-101 (GS-1101); NCGC00262603-01; NCGC00262603-02; NCGC00262603-04; AC-28394; HY-13026; IC489666; SMR004702787; SW219823-1; X7435; A-1138; D10560; J-517532; Q5908266; BRD-K60866521-001-01-4; (S)-5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one; 4(3H)-Quinazolinone,5-fluoro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]-; 5-Fluoro-3-phenyl-2-{1-[(9H-purin-6-yl)amino]propyl}quinazolin-4(3H)-one; 1453810-72-4; 40L"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:82701	DB09054	DR00219	DR0854	415.4	C22H18FN7O	99.2	685	3.7	31	2	7	5	"1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1"	CC[C@@H](C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5	IFSDAJWBUCMOAH-HNNXBMFYSA-N
DG00649	Nitrazepam	4506	"Nitrazepam; Benzalin; 146-22-5; Neozepam; Imeson; Mogadon; Remnos; Neuchlonic; Apodorm; Calsmin; Eunoctin; Imesont; Nitrados; Radedorm; Sonebon; Trazenin; Hipnax; Hipsal; Nelmat; Surem; Epibenzalin; Epinelbon; Nitrenpax; Somitran; Sonnolin; Unisomnia; Cerson; Dumolid; Nelbon; Paxisyn; Pelson; Relact; N-Desmethylnimetazepam; Persopit; Gerson; Ibrovek; Eatan; Dormin-5; Nitrazepamum; 1,3-Dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one; Mogadone; Magadon; Megadon; Mogadan; Ro 4-5360; Nitrazepamum [INN-Latin]; Ro 5-3059; 7-Nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one; LA 1; 7-nitro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one; NSC-58775; 7-Nitro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; S 2000; 7-Nitro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; UNII-9CLV70W7HS; 2,3-Dihydro-7-nitro-5-phenyl-1H-1,4-benzodiazepin-2-on; 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-; Dormo-Puren; Mitidin; 9CLV70W7HS; CHEMBL13209; Eatan N; CHEBI:7581; Somnite; NSC58775; NCGC00159358-02; 2,3-dihydro-7-nitro-5-phenyl-1H-1,4-benzodiazepin-2-one; Calsamin; Eunoktin; Ipersed; Nitravet; Nitrempax; Noctesed; Pacisyn; Somnased; Somnibel; DSSTox_CID_3372; LA 1 (VAN); Dormicum (anticonvulsant); DSSTox_RID_77000; DSSTox_GSID_23372; Nitrazepam [USAN:INN:BAN:JAN]; Nitrazepam (TN); Benzalin (TN); CAS-146-22-5; SMR000058302; CCRIS 1931; EINECS 205-665-2; NSC 58775; BRN 0757185; DEA No. 2834; ISOPROPYLACETATE/NITRAZEPAM; N05CD02; Ro 53-60; ChemDiv1_022312; Oprea1_476234; SCHEMBL35202; 5-24-04-00344 (Beilstein Handbook Reference); MLS001304053; MLS001424061; DTXSID5023372; Nitrazepam (JP17/USAN/INN); HMS650G04; KJONHKAYOJNZEC-UHFFFAOYSA-; 1, 3-Dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one; HMS2051F19; HMS2272G03; HMS3393F19; 7-Nitro-1,4-benzodiazepin-2-one; NITRAZEPAM METHANOL SOLUTION; ZINC4311748; Tox21_111601; BDBM50020856; PDSP1_000120; PDSP2_000120; Ro-45360; Ro-53059; STK806322; AKOS002254707; Nitrazepam 0.1 mg/ml in Acetonitrile; Nitrazepam 1.0 mg/ml in Acetonitrile; Tox21_111601_1; WLN: T67 GMV JN IHJ CNW KR; AB02342; AC-4537; CCG-100977; DB01595; MCULE-3394241963; NC00227; NCGC00159358-03; 2H-1, 1,3-dihydro-7-nitro-5-phenyl-; 7-Nitro-5-phenyl-2,4-benzodiazepin-2-one; DB-042832; RO-4-5360; RO-5-3059; C07487; D00531; 146N225; A808471; Q410078; 7-nitro-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one; Nitrazepam, British Pharmacopoeia (BP) Reference Standard; Nitrazepam, European Pharmacopoeia (EP) Reference Standard; (Z)-7-nitro-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one; 1,3-Dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepine-2-one; 7-Nitro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one #; 7-Nitro-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one; Nitrazepam solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7581	DB01595	.	DR1166	281.27	C15H11N3O3	87.3	452	2.2	21	1	4	1	"1S/C15H11N3O3/c19-14-9-16-15(10-4-2-1-3-5-10)12-8-11(18(20)21)6-7-13(12)17-14/h1-8H,9H2,(H,17,19)"	C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3	KJONHKAYOJNZEC-UHFFFAOYSA-N
DG00650	Ranibizumab	.	.	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	DB01270	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00651	Bevacizumab	.	.	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00652	Afuresertib	46843057	"Afuresertib; 1047644-62-1; GSK-2110183; GSK2110183C; UNII-8739X25QI3; GSK 2110183C; ASB183; Afuresertib (GSK2110183); ASB-183; 8739X25QI3; N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)thiophene-2-carboxamide; Afuresertib [USAN:INN]; 2-Thiophenecarboxamide, N-((1S)-2-amino-1-((3-fluorophenyl)methyl)ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-; 2-Thiophenecarboxamide, N-[(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-; Afuresertib (USAN); SCHEMBL187686; GTPL7890; Afuresrtib (GSK2110183); CHEMBL2219422; DTXSID60146711; CHEBI:131168; AOB87168; BCP08435; EX-A1574; BDBM50502477; NSC778305; NSC781255; NSC800109; NSC829868; s7521; ZINC43197674; CCG-268972; CS-3384; DB11648; NSC-778305; NSC-781255; NSC-800109; NSC-829868; GSK 2110183; NCGC00387879-03; BA166066; BS-14212; HY-15727; A16392; D10381; D71036; A853608; Afuresertib, GSK-2110183, GSK-2110183B; Q27224945; N-((1S)-1-(aminomethyl)-2-(3-fluorophenyl)ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide; N-((S)-1-amino-3-(3-fluorophenyl)propan-2-yl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide; N-((S)-1-amino-3-(3-fluorophenyl)propan-2-yl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide;Afuresertib; N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide; N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methyl-3-pyrazolyl)-2-thiophenecarboxamide; N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:131168	DB11648	.	.	427.3	C18H17Cl2FN4OS	101	520	4	27	2	5	6	"1S/C18H17Cl2FN4OS/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26)/t12-/m0/s1"	CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)N[C@@H](CC3=CC(=CC=C3)F)CN)Cl	AFJRDFWMXUECEW-LBPRGKRZSA-N
DG00653	Mebendazole	4030	"Mebendazole; 31431-39-7; Vermox; Telmin; Mebenvet; Pantelmin; Ovitelmin; Vermirax; Mebenoazole; Vermicidin; Bantenol; Mebutar; Lomper; MBDZ; Besantin; Verpanyl; Noverme; Mebendazol; Mebendazolum; Methyl (5-benzoyl-1H-benzo[d]imidazol-2-yl)carbamate; 5-Benzoyl-2-benzimidazolecarbamic acid methyl ester; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester; Methyl 5-benzoyl-2-benzimidazolecarbamate; Methyl 5-benzoyl-2-benzimidazolylcarbamate; Methyl 5-benzoyl benzimidazole-2-carbamate; methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate; R 17635; methyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate; (5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester; MFCD00057872; R 17,635; Methyl N-(5-benzoyl-1H-benzimidazol-2-yl)carbamate; CCRIS 4479; methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate; NSC 184849; UNII-81G6I5V05I; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester; Sufil; CHEMBL685; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle; CHEBI:6704; Carbamic acid, N-(5-benzoylbenzimidazol-2-yl)-, methyl ester; Versid; Methyl 6-benzoyl-1H-benzimidazol-2-ylcarbamate; 81G6I5V05I; 5-Benzoyl-2-benzimidazolecarbamic acid, methyl ester; NSC184849; NSC-184849; methyl [5-(phenylcarbonyl)-1H-benzimidazol-2-yl]carbamate; NCGC00016806-01; (5-Benzoyl-1H-benzimidazol-2-yl)carbamic acid methyl ester; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester (8CI); Mebex; CAS-31431-39-7; Equivurm Plus; DSSTox_CID_20682; DSSTox_RID_79538; DSSTox_GSID_40682; Mebendazol [INN-Spanish]; Mebendazolum [INN-Latin]; Vermox (TN); Emverm; SMR000036734; HSDB 3232; Mebendazole Polymorph C; SR-01000003109; EINECS 250-635-4; Methyl N-(5-benzoyl-2-benzimidazolyl)carbamate; Zhihuanqing; Mebatreat; Mebendazole (JAN/USP/INN); Equivurmp Plus; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle [French]; Mebendazole,(S); N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle [French]; V95; Prestwick_310; Mebendazole; 4030; Mebendazole [USAN:USP:INN:BAN:JAN]; Spectrum_001298; CPD000036734; Prestwick0_000217; Prestwick1_000217; Prestwick2_000217; Prestwick3_000217; Spectrum2_001401; Spectrum3_001439; Spectrum4_000416; Spectrum5_001381; Probes1_000013; Probes2_000149; Cambridge id 5250893; Methyl [5-(Benzoyl)benzimidazol-2-yl]carbamate; TimTec1_000869; Oprea1_278237; Oprea1_768530; R-17635; SCHEMBL15860; BSPBio_000233; BSPBio_003178; CBDivE_010559; KBioGR_000712; KBioSS_001778; MLS000028491; MLS006011879; BIDD:GT0087; DivK1c_000751; SPECTRUM1501110; SPBio_001442; SPBio_002154; BPBio1_000257; methyl N-[6-(benzoyl)-1H-benzimidazol-2-yl]carbamate; DTXSID4040682; HMS502F13; KBio1_000751; KBio2_001778; KBio2_004346; KBio2_006914; KBio3_002398; NINDS_000751; HMS1536H11; HMS1568L15; HMS1921F03; HMS2090B03; HMS2092B15; HMS2095L15; HMS3259B11; HMS3604N11; HMS3712L15; Pharmakon1600-01501110; ZINC121541; Tox21_110620; BBL008298; BDBM50180753; CCG-39628; MMV003152; NSC757838; s4610; STK093862; AKOS000539066; AKOS015896232; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester (9CI); Tox21_110620_1; CS-3974; DB00643; MCULE-4133611535; NC00639; NSC-757838; IDI1_000751; NCGC00016806-02; NCGC00016806-03; NCGC00016806-04; NCGC00016806-05; NCGC00016806-06; NCGC00016806-07; NCGC00016806-08; NCGC00016806-09; NCGC00016806-10; NCGC00016806-12; NCGC00016806-13; NCGC00021698-03; NCGC00021698-04; NCGC00021698-05; NCGC00021698-06; NCGC00021698-07; AC-12064; AS-12272; HY-17595; SY051142; SBI-0051641.P002; AB00052203; FT-0628179; FT-0628180; M2273; EN300-50844; D00368; D70118; K-6451; 5-Benzoyl-2-benzimidazolylcarbamicacidmethylester; AB00052203-09; AB00052203_10; Mebendazole, VETRANAL(TM), analytical standard; 431M397; A820852; AG-205/04588045; Mebendazole, analytical standard, >=98% (HPLC); Methyl (6-benzoyl-1H-benzimidazol-2-yl)carbamate; Q422194; methyl 5-benzoyl-1H-benzo[d]imidazol-2-ylcarbamate; SR-01000003109-2; SR-01000003109-3; W-106901; BRD-K77987382-001-01-7; BRD-K77987382-001-06-6; BRD-K77987382-001-08-2; SR-01000003109-10; methyl N-(5-benzoyl-1H-1,3-benzimidazol-2-yl)carbamate; Z234895185; 5-Benzoyl-1H-benzimidazol-2-yl carbamic acid methyl ester;; Mebendazole, European Pharmacopoeia (EP) Reference Standard; Mebendazole, United States Pharmacopeia (USP) Reference Standard; Mebendazole for system suitability, European Pharmacopoeia (EP) Reference Standard; Mebendazole Polymorph C, United States Pharmacopeia (USP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6704	DB00643	DR00633	DR1005	295.29	C16H13N3O3	84.1	423	2.8	22	2	4	4	"1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)"	COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3	OPXLLQIJSORQAM-UHFFFAOYSA-N
DG00654	Methimazole	1349907	"Methimazole; 60-56-0; thiamazole; Tapazole; 2-Mercapto-1-methylimidazole; Methimazol; 1-Methylimidazole-2-thiol; Mercazole; Mercazolyl; Metazolo; Thymidazol; Thymidazole; Mercaptazole; Merkazolil; Metothyrin; Metothyrine; Strumazol; Thiamazol; Thycapzol; Basolan; Favistan; 1-Methyl-1H-imidazole-2-thiol; Danantizol; Frentirox; Merkastan; Metotirin; Thacapzol; Thycapsol; Metizol; Mercasolyl; Methylmercaptoimidazole; 1-Methyl-2-mercaptoimidazole; Methiamazole; 2H-Imidazole-2-thione, 1,3-dihydro-1-methyl-; 3-methyl-1H-imidazole-2-thione; Usaf el-30; N-Methyl-2-mercaptoimidazole; Tapuzole; Thimazole; 1-METHYL-1,3-DIHYDRO-2H-IMIDAZOLE-2-THIONE; 1-Methyl-2-imidazolethiol; 1-Methyl-1H-imidazole-2(3H)-thione; 2-Mercaptomethylimidazole; 1,3-Dihydro-1-methyl-2H-imidazole-2-thione; 1-Methylimidazole-2(3H)-thione; Imidazole-2-thiol, 1-methyl-; 1-Metylo 2 merkaptoimidazolem; 1-Methyl-1,3-dihydroimidazole-2-thione; 4-Imidazoline-2-thione, 1-methyl-; MFCD00179321; Methimazole (USP); Methimazole [USP]; UNII-554Z48XN5E; Tiamazol; CHEMBL1515; Mercazolylum; Methimazolum; Metimazol; 1-methyl-2,3-dihydro-1H-imidazole-2-thione; CHEBI:50673; Imidazole, 1-methyl-2-mercapto-; 554Z48XN5E; NSC38608; NSC-38608; CAS-60-56-0; Tiamazolo [DCIT]; NCGC00016273-01; Methamazole; Thiamazolum; Strumazole; Tiamazolo; DSSTox_CID_820; Thiamazol [INN-French]; Tiamazol [INN-Spanish]; DSSTox_RID_75808; DSSTox_GSID_20820; Thiamazolum [INN-Latin]; MMZ; Felimazole; Tapazole (TN); 223768-14-7; 85916-84-3; SMR000058376; 1-Metylo 2 merkaptoimidazolem [Polish]; HSDB 3361; SR-05000001672; EINECS 200-482-4; NSC 38608; 1-Methyl-imidazole-2-thiol; tiamazole; Mercaptizole; AI3-60285; 1,3-Dihydro-1-Methyl-2H-Imidazol-2-Thione; Thiamazole,(S); 2-Mercapto-1-methyl-1H-imidazole; Thiamazole [INN]; Prestwick_1010; Spectrum_000995; Prestwick0_000786; Prestwick1_000786; Prestwick2_000786; Prestwick3_000786; Spectrum2_001273; Spectrum3_000495; Spectrum4_000048; Spectrum5_000954; M0868; Thiamazole (JP17/INN); 1-methylimidazole-2-thione; Methimazole-d3(methyl-d3); N-methyl imidazole-2-thiol; 2-mecapto 1-methylimidazole; 2-Mercapto-1-methylimidazol; 2-mercapto-N-methylimidazole; SCHEMBL41647; 2-mercapto-3-methylimidazole; BSPBio_000892; BSPBio_001989; KBioGR_000515; KBioSS_001475; MLS000028413; MLS002548853; BIDD:GT0163; DivK1c_000188; SPECTRUM1500396; WLN: T5N CNJ A BSH; 1-methyl-2-mercapto-imidazole; 2-mercapto-1-methyl-imidazole; SPBio_001266; SPBio_002831; 1-Methyl-2-mercapto imidazole; Imidazole-2-thio, 1-methyl-; BPBio1_000982; GTPL6649; Methimazole, analytical standard; DTXSID4020820; Methimazole (Tapazole, Northyx); 1-methyl-1H-immidazole-2-thiol; 1-methyl-3H-imidazole-2-thione; HMS500J10; KBio1_000188; KBio2_001475; KBio2_004043; KBio2_006611; KBio3_001489; 1-methyl-1-H-imidazole-2-thiol; NINDS_000188; HMS1570M14; HMS1920L17; HMS2090B17; HMS2091D12; HMS2094C05; HMS2097M14; HMS3259L09; HMS3651I13; HMS3714M14; Pharmakon1600-01500396; 1-Methyl-1H-imidazole-2-thiol #; AMY11202; BCP02147; HY-B0208; STR03572; ZINC1187543; Tox21_110341; Tox21_201341; Tox21_300532; AC-785; BDBM50241361; CCG-39656; HTS001687; NSC757111; s1609; STK300018; STK802184; AKOS000119427; AKOS000269708; Tox21_110341_1; BS-3743; CCG-220786; DB00763; MCULE-9902292741; NC00636; NSC-757111; 2-Mercapto-1-methylimidazole, >=99%; IDI1_000188; NCGC00016273-02; NCGC00016273-03; NCGC00094721-01; NCGC00094721-02; NCGC00094721-03; NCGC00094721-04; NCGC00094721-05; NCGC00094721-06; NCGC00094721-07; NCGC00178875-01; NCGC00254307-01; NCGC00258893-01; Methimazol 100 microg/mL in Acetonitrile; Q813; SBI-0206922.P001; SBI-0206922.P004; DB-053649; Methimazole; ; ; 2-mercapto-1-methylimidazole; 2H-Imidazole-2-thione,3-dihydro-1-methyl-; FT-0603253; SW197088-3; C07190; D00401; H10722; AB00443630-03; AB00443630-04; AB00443630_06; AB00443630_07; Methimazole, VETRANAL(TM), analytical standard; A832780; Q419663; SR-01000695434; Q-201364; SR-01000695434-2; SR-05000001672-1; SR-05000001672-2; BRD-K54416256-001-15-7; Z57901905; F0001-2396; F1679-0258; Thiamazole, European Pharmacopoeia (EP) Reference Standard; Methimazole, United States Pharmacopeia (USP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:50673	DB00763	DR00667	DR2515	114.17	C4H6N2S	47.4	119	-0.3	7	1	1	0	"1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)"	CN1C=CNC1=S	PMRYVIKBURPHAH-UHFFFAOYSA-N
DG00655	Nucleoside analogs	.	.	Approved	1	Approved Drug(s)	Approved	Biotech	.	DB06688	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00656	Pirfenidone	40632	"PIRFENIDONE; 53179-13-8; 5-methyl-1-phenylpyridin-2(1H)-one; Esbriet; Deskar; AMR-69; Pirespa; 5-Methyl-1-phenyl-2-(1H)-pyridone; Pirfenidonum; Pirfenidona; 5-methyl-1-phenylpyridin-2-one; 5-methyl-1-phenyl-2(1H)-pyridinone; 2(1H)-Pyridinone, 5-methyl-1-phenyl-; AMR 69; 5-Methyl-1-phenyl-1H-pyridin-2-one; 5-Methyl-1-phenyl-2(1H)-pyridone; 5-methyl-1-phenyl-2-pyridinone; UNII-D7NLD2JX7U; MFCD00866047; D7NLD2JX7U; AMR69; CHEBI:32016; S-7701; NSC-748456; NCGC00015806-03; DSSTox_CID_25183; DSSTox_RID_80731; DSSTox_GSID_45183; Pirfenidone [USAN:INN]; Pirfenidonum [INN-Latin]; Pirfenidona [INN-Spanish]; CAS-53179-13-8; SR-01000076061; BRN 1526549; Prfendone; Pirfenidone (JAN/USAN/INN); 5-methyl-1-phenyl-pyridin-2-one; Pirfenidone-[d3]; Esbriet (TN); Pirfenidone- Bio-X; Pirfenidone(AMR69); KS-5041; 2(1H)-Pyridone, 5-methyl-1-phenyl-; Tocris-1093; Lopac-P-2116; F-647; P 2116; SCHEMBL4708; Lopac0_000907; 5-21-07-00197 (Beilstein Handbook Reference); MLS000860042; 5-Methyl-1-phenyl-2-pyridone; GTPL7532; ZINC1958; CHEMBL1256391; DTXSID4045183; 1-phenyl-5-methyl-2-pyridinone; HSDB 8340; Pirfenidone, >=97% (HPLC); Bio1_000397; Bio1_000886; Bio1_001375; HMS2234G24; HMS3262F16; HMS3267I06; HMS3372A08; HMS3412G13; HMS3651P08; HMS3676G13; AOB31717; BCP04473; HY-B0673; Tox21 110225; Tox21_110225; Tox21_500907; BDBM50005201; NSC748456; s2907; AKOS006273697; S-7701,AMR-69; Tox21_110225_1; AB07515; AC-6797; AM84939; CCG-204989; DB04951; LP00907; NSC 748456; SDCCGSBI-0050882.P002; NCGC00015806-01; NCGC00015806-02; NCGC00015806-04; NCGC00015806-05; NCGC00015806-06; NCGC00015806-17; NCGC00024992-01; NCGC00024992-02; NCGC00024992-03; NCGC00261592-01; 5-METHYL-N-PHENYL-2-1H-PYRIDONE; BM164275; H960; SMR000326900; SY034783; B2288; EU-0100907; FT-0602686; FT-0672092; P1871; SW220156-1; D01583; J90039; 5-Methyl-N-phenyl-2-1H-pyridone [Pirfenidone]; 179P138; A829431; J-523979; Q2060696; SR-01000076061-1; SR-01000076061-3; BRD-K96862998-001-03-1; BRD-K96862998-001-09-8; Pirfenidone, European Pharmacopoeia (EP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:32016	DB04951	.	DR1299	185.22	C12H11NO	20.3	285	1.9	14	0	1	1	"1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3"	CC1=CN(C(=O)C=C1)C2=CC=CC=C2	ISWRGOKTTBVCFA-UHFFFAOYSA-N
DG00657	Praziquantel	4891	"Praziquantel; 55268-74-1; Biltricide; Droncit; Pyquiton; Cesol; Embay 8440; Praziquantelum; Azinox; 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; MLS000038419; Praziquantel (Biltricide); MFCD00058531; SMR000037139; 2-(cyclohexanecarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-(cyclohexanecarbonyl)-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one; 135526-78-2; Cutter Tape Tabs; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; 2-cyclohexanecarbonyl-1H,2H,3H,4H,6H,7H,11bH-piperazino[2,1-a]isoquinolin-4-one; 4H-Pyrazino(2,1-a)isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-; 4H-Pyrazino[2,1-a]isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-; NSC-757285; Distocide; Prazinon; DSSTox_CID_1182; DSSTox_RID_75995; DSSTox_GSID_21182; Praziquantelum [INN-Latin]; Cutter; Biltricide (TN); CCRIS 4114; SR-01000003100; EINECS 259-559-6; BRN 0761557; Bay-8440; Praziquantel (JAN/USP/INN); EMBAY-8440; Praziquantel,(S); NCGC00016877-01; Prestwick_402; CAS-55268-74-1; (+-)-Praziquantel; Praziquantel [USAN:USP:INN:BAN:JAN]; Spectrum_001119; Opera_ID_378; Prestwick0_000260; Prestwick1_000260; Prestwick2_000260; Prestwick3_000260; Spectrum2_001288; Spectrum3_000550; Spectrum4_000482; Spectrum5_001064; CHEMBL976; P 4668; cid_4891; Lopac0_000909; Oprea1_163497; SCHEMBL44153; BSPBio_000080; BSPBio_002199; KBioGR_000963; KBioSS_001599; 5-24-03-00361 (Beilstein Handbook Reference); MLS000028528; MLS001201812; MLS001304085; MLS002548849; MLS006011880; DivK1c_000130; SPECTRUM1500494; SPBio_001295; SPBio_002299; Praziquantel-(cyclohexyl-d11); BPBio1_000088; DTXSID9021182; SCHEMBL16019896; BDBM74574; CHEBI:91583; HMS500G12; KBio1_000130; KBio2_001599; KBio2_004167; KBio2_006735; KBio3_001699; (S)-2-(Cyclohexanecarbonyl)-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one; NINDS_000130; HMS1568D22; HMS1920J06; HMS2090J19; HMS2092A09; HMS2095D22; HMS3259K07; HMS3262F20; HMS3655O19; HMS3712D22; Pharmakon1600-01500494; AMY16524; BCP17829; BCP28525; BCP30228; HY-B0244; WZB34336; Tox21_110660; Tox21_201950; Tox21_302927; Tox21_500909; CCG-39773; NSC757285; Praziquantel, anthelminic, neurogenic; s1691; STK030186; AKOS000541869; AKOS016398525; Tox21_110660_1; AC-8426; DB01058; LP00909; MCULE-1638759858; NC00468; NSC 757285; SB49202; SDCCGSBI-0050884.P005; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazinoe(2,1a)isoquinolin-4-one; IDI1_000130; NCGC00015818-04; NCGC00015818-05; NCGC00015818-06; NCGC00015818-07; NCGC00015818-08; NCGC00015818-11; NCGC00015818-12; NCGC00015818-14; NCGC00015818-15; NCGC00015818-26; NCGC00089733-02; NCGC00089733-03; NCGC00089733-04; NCGC00089733-05; NCGC00256422-01; NCGC00259499-01; NCGC00261594-01; AS-12459; BP166192; SY052322; SBI-0050884.P004; DB-052707; (S)-Praziquantel; Praziquantel, (S)-Isomer; AB00052075; EU-0100909; FT-0630676; P2125; SW196645-3; 1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one; 2-(cyclohexanecarbonyl)-2,3,6,7-tetrahydro-; C07367; D00471; J10194; AB00052075-13; AB00052075-15; AB00052075_16; AB00052075_17; Praziquantel, VETRANAL(TM), analytical standard; 268P741; A830562; Q424145; Praziquantel, Antibiotic for Culture Media Use Only; Q-201612; SR-01000003100-3; SR-01000003100-5; SR-01000003100-7; BRD-A21858158-001-05-2; BRD-A21858158-001-16-9; SR-01000003100-16; F0037-0136; Z1563145961; Praziquantel, European Pharmacopoeia (EP) Reference Standard; Praziquantel, United States Pharmacopeia (USP) Reference Standard; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro- 4H-pyrazino[2,1-a]-isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino-[2,1- a]isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino[2,1-aisoquinolin-4-one; 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; Praziquantel for system suitability, European Pharmacopoeia (EP) Reference Standard; Praziquantel, Pharmaceutical Secondary Standard; Certified Reference Material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:91583	DB01058	.	DR1329	312.4	C19H24N2O2	40.6	472	2.7	23	0	2	1	"1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2"	C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2	FSVJFNAIGNNGKK-UHFFFAOYSA-N
DG00658	Pregabalin	5486971	"Pregabalin; 148553-50-8; Lyrica; (S)-3-(Aminomethyl)-5-methylhexanoic acid; 3-isobutyl GABA; (3S)-3-(aminomethyl)-5-methylhexanoic acid; CI-1008; (S)-Pregabalin; Hexanoic acid, 3-(aminomethyl)-5-methyl-, (3S)-; CI 1008; PD 144723; UNII-55JG375S6M; PD-144723; (S)-3-Isobutyl GABA; CHEMBL1059; CHEBI:64356; (3S)-3-(aminomethyl)-5-methyl-hexanoic acid; 55JG375S6M; MFCD00917044; Hexanoic acid, 3-(aminomethyl)-5-ethyl-, (3S)-; (R-)-3-isobutyl GABA; Hexanoic acid, 3-(aminomethyl)-5-methyl-, (S)-; Pregabalina; Pregabaline; Vronogabic; Nervalin; Pregablin; Pregabalin mylan; Pregabalin sandoz; HSDB 7530; Pregabalin zentiva; NSC-759256; Pregabalin [USAN:INN:BAN:JAN]; NCGC00095186-01; Pregabalin- Bio-X; Lyrica (TN); Pregabalin sandoz gmbh; (S)-3-(Aminomethyl)-5-methylhexanoicacid; SCHEMBL8227; DSSTox_CID_25950; DSSTox_RID_81246; DSSTox_GSID_45950; Pregabalin (JAN/USAN/INN); (S)-(+)-4-amino-3-(2-methylpropyl)butanoic acid; GTPL5484; ZINC5152; DEA No. 2782; Pregabalin, >=97% (NMR); DTXSID1045950; HMS3715J16; Pregabalin 1.0 mg/ml in Methanol; YNP-1807; Tox21_111475; BDBM50164279; AKOS001476611; AKOS005145504; Lyrica;CI-1008;PD-144723; AC-1158; CCG-221247; CM14412; CS-1247; DB00230; KS-5378; NSC 759256; (S)-3-aminomethyl-5-methylhexanoic acid; NCGC00346738-01; 121GE001; BP163672; HY-17414; (S)-3-Aminomethyl-5-methyl-hexanoic acid; AM20080369; CAS-148553-50-8; EN300-92104; (3S)-3-(aminomethyl)-5-methyl hexanoic acid; (S)-(+)-3-Aminomethyl-5-Methylhexanoic Acid; D02716; AB01563007_01; 553P508; A808784; Q412174; SR-01000942257; SR-01000942257-2; Pregabalin, EuropePharmacopoeia (EP) Reference Standard; Z2757554242; 1414928-41-8"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	. 	DB00230	DR01255	.	159.23	C8H17NO2	63.3	123	-1.6	11	2	3	5	"1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1"	CC(C)C[C@@H](CC(=O)O)CN	AYXYPKUFHZROOJ-ZETCQYMHSA-N
DG00659	Vardenafil	135400189	"Vardenafil; 224785-90-4; Levitra; Vivanza; UNII-UCE6F4125H; Levitra (TN); 2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-5-METHYL-7-PROPYLIMIDAZO[5,1-F][1,2,4]TRIAZIN-4(1H)-ONE; CHEMBL1520; UCE6F4125H; VDN; CHEBI:46295; BAY38-9456; BAY 38-9456; Vardenafil-d5; 224789-15-5; 2-(2-ethoxy-5-((4-ethylpiperazin-1-yl)sulfonyl)phenyl)-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one; 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one; Vardenafil ODT; 2-(2-Ethoxy-5-((4-ethylpiperazin-1-yl)sulfonyl)phenyl)-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(3H)-one; 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propyl-1H,4H-imidazo[4,3-f][1,2,4]triazin-4-one; HSDB 7304; SR-05000001442; NCGC00167533-01; Vardenafil [USAN:INN:BAN]; Vardenafil (Vivanza); 1189685-70-8; 2-(2-Ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3H-imidazo(5,1-f)(1,2,4)triazin-4-one; Vardenafil (USAN/INN); EC 607-088-5; SCHEMBL5772; BSPBio_002392; 1-((3-(3,4-Dihydro-5-methyl-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine; GTPL7320; DTXSID3048318; BDBM14776; HMS2089K04; HMS3715F19; BCP02961; EX-A2806; HY-B0442; STK642629; ZINC18324776; AKOS005574038; AKOS015994765; AKOS022186043; BAY-389456; CCG-221149; DB00862; GS-6519; KS-5073; MCULE-5211071344; SB17349; NCGC00167533-03; 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4-ol; Piperazine, 1-((3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo(5,1-f)(1,2,4)triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethyl-; BCP0726000254; SBI-0206836.P001; FT-0631204; FT-0675783; 85V904; D08668; AB00698215-08; AB01274740-01; AB01274740_02; AB01274740_03; AB01275440-01; Q424161; J-014730; SR-05000001442-1; SR-05000001442-2; BRD-K13926615-003-01-7; BRD-K13926615-003-02-5; Z2790753946; 2-(2-Ethoxy-5-((4-ethylpiperazin-1-yl)sulfonyl)phenyl)-5-methyl-7-propylimidazo(5,1-f)triazin-4(3H)-one; 2-(2-ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)phenyl)-5-methyl-7-propylimidazo[1,5-f][1,2,4]triazin-4(1H)-one; 2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one; 2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazine-4-one; 2-[2-ethoxy-5-(4-ethylpiperazine-1-sulfonyl)phenyl]-5-methyl-7-propyl-1H,4H-imidazo[4,3-f][1,2,4]triazin-4-one; 2-[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]phenyl]-5-methyl-7-propyl-imidazo[5,1-f][1,2,4]triazin-4-one; 2-{2-ethoxy-5-[(4-ethylpiperazine-1-)sulfonyl]phenyl}-5-methyl-7-propyl-3H,4H-imidazo[1,5-a][1,2,4]triazin-4-one; citric acid;2-[2-ethoxy-5-(4-ethylpiperazino)sulfonyl-phenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:46295	DB00862	DR00169	.	488.6	C23H32N6O4S	118	854	2.5	34	1	8	8	"1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30)"	CCCC1=NC(=C2N1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C	SECKRCOLJRRGGV-UHFFFAOYSA-N
DG00660	Sonidegib	24775005	"Sonidegib; Erismodegib; 956697-53-3; LDE225; NVP-LDE225; Odomzo; LDE-225; NVP-LDE 225; LDE 225; UNII-0RLU3VTK5M; Sonidegib (LDE-225); LDE225 (NVP-LDE225,Erismodegib); 0RLU3VTK5M; 956697-53-3 (free base); N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl-3-carboxamide; Odomozo; N-(6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide; n-(6-((2r,6s)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl-3-carboxamide; N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide; N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide; Sonidegib [USAN:INN]; Erismodegib [USAN:INN]; Sonidegib phospate; LDE225 (NVP-LDE225; Erismodegib); Sonidegib (USAN/INN); 1218778-76-7; erismodegib (deleted INN); NVP-LDE225(Erismodegib); Sonidegib (NVP-LDE225); MLS006011198; NVP-LDE-225; SCHEMBL554455; GTPL8199; CHEMBL2105737; CHEBI:90863; EX-A409; C26H26F3N3O3; LDE225(NVP-LDE225); DTXSID501009335; BCP02275; LDE225 - NVP-LDE225; BDBM50394562; HY-16582A; MFCD16038928; NSC761385; NSC761386; s2151; ZINC68202099; AKOS015994541; BCP9001014; CCG-264935; CS-0904; DB09143; EE-0005; NSC-761385; NSC-761386; LDE225 (NVP-LDE225, Erismodegib); NCGC00250382-01; NCGC00250382-05; NCGC00250382-07; (1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- methyl-4'-(trifluoromethoxy)-, rel-; [1,1'-Biphenyl]-3-carboxamide, N-[6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-4'-(t; AC-32799; HY-10296; N-(6-((cis-2,6-Dimethylmorpholin-4-yl)-3-pyridyl)-2-methyl-3-(4-(trifluoromethoxy)phenyl)benzamide; SMR004702967; SW218115-2; X7564; D10119; BRD-K19796430-001-01-5; Q22075856; [1,1'-Biphenyl]-3-carboxamide, N-[6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-4'-(trifluoromethoxy)-, rel-; Erismodegib; ; ; LDE 225; ; ; NVP-LDE 225; ; ; N-[6-[(2S,6R)-2,6-Dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide; N-(6-((2R,6S)-2,6-Dimethylmorpholin-4-yl)pyridin-3-yl)-2-methyl-4'- (trifluoromethoxy)biphenyl-3-carboxamide; N-(6-(cis-2,6-Dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide; N-[6-[(2R,6S)-2,6-Dimethyl-4-morphlinyl]-3-pyridinyl]-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide; N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-3-pyridyl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide; rel-N-[6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide; rel-N-{6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl}-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:90863	DB09143	.	.	485.5	C26H26F3N3O3	63.7	691	5.8	35	1	8	5	"1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+"	C[C@@H]1CN(C[C@@H](O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F	VZZJRYRQSPEMTK-CALCHBBNSA-N
DG00661	Miltefosine	3599	"Miltefosine; 58066-85-6; Hexadecylphosphocholine; Miltex; Impavido; Hexadecylphosphorylcholine; HDPC; n-Hexadecylphosphorylcholine; Miltefosinum; Miltefosina; 1-Hexadecylphosphorylcholine; hexadecyl 2-(trimethylammonio)ethyl phosphate; hexadecyl phosphocholine; Miltefosin C; n-hexadecylphosphocholine; hexadecyl 2-(trimethylazaniumyl)ethyl phosphate; D-18506; miltefosin; C21H46NO4P; UNII-53EY29W7EC; NSC605583; hexadecyl (2-(trimethylAmmonio)ethyl) phosphate; monohexadecylphosphocholine; CHEMBL125; monohexadecylphosphorylcholine; HePC;Hexadecyl phosphocholine; 53EY29W7EC; CHEBI:75283; MFCD00133396; MMV688990; NSC-605583; NSC-758968; NCGC00095169-01; Miltefos; DSSTox_CID_25942; DSSTox_RID_81240; DSSTox_GSID_45942; Miltefosinum [INN-Latin]; Miltefosina [INN-Spanish]; Miltefosine [INN:BAN]; Fos-choline 16; Miltefosine (INN); CAS-58066-85-6; D 18506; Choline hexadecyl phosphate; BRN 3690495; Miltextrade mark; HePC Hydrate; Impavidotrade mark; D18506; Impavido (TN); Choline, inner salt; TF-002; 2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide, inner salt; NSC 605583; Choline hydroxide, hexadecyl hydrogen phosphate, inner salt; Choline phosphate, hexadecyl ester, hydroxide, inner salt (6CI); Hexadecyl Phosphorylcholine; H-1850; M-7200; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, inner salt; SCHEMBL26215; 4-04-00-01460 (Beilstein Handbook Reference); SPECTRUM1505329; DTXSID7045942; GTPL11355; Hexadecyl Phosphorylcholine Hydrate; HMS1922D16; HMS2089J15; HMS3649I09; Pharmakon1600-01505329; hexadecylphosphocholine, miltefosine; BCP04506; miltefosine (hexadecylphosphocholine); Tox21_111466; BDBM50034220; CCG-35584; CCG-36097; CCG-40025; DL-131; Hexadecyl 2-(trimethyl-.lambda.~5~-azanyl)ethyl hydrogen phosphate; NSC758968; s3056; 1-N-HEXADECYLPHOSPHORYLCHOLINE; AKOS015914886; Tox21_111466_1; BCP9000927; DB09031; NCGC00095169-02; NCGC00095169-03; NCGC00095169-05; NCGC00095169-07; HY-13685; BCP0726000071; FT-0608148; M2445; hexadecyloxy-2-trimethylammonioethylphosphorate; D02494; AB00642217-03; AB00642217_04; Miltefosine, >=98% (perchloric acid titration); A831718; Q411787; Hexadecyl 2-(Trimethylammonio)ethyl Phosphate Hydrate; 2-[hexadecoxy(hydroxy)phosphoryl]oxyethyl-trimethyl-ammonium; Phosphoric Acid Hexadecyl 2-(Trimethylammonio)ethyl Ester; [2-(Hexadecyloxy-hydroxy-phosphoryloxy)-ethyl]-trimethyl-ammonium; 3, 4-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide; hexadecyl 2-(trimethyl-lambda~5~-azanyl)ethyl hydrogen phosphate; Phosphoric Acid Hexadecyl 2-(Trimethylammonio)ethyl Ester Hydrate; 2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:75283	DB09031	.	DR1092	407.6	C21H46NO4P	58.6	363	6.7	27	0	4	20	"1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3"	CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C	PQLXHQMOHUQAKB-UHFFFAOYSA-N
DG00662	Acyclovir	135398513	"Acyclovir; Aciclovir; Acycloguanosine; 59277-89-3; Zovirax; Vipral; Virorax; Wellcome-248U; Aciclovirum; 9-[(2-Hydroxyethoxy)methyl]guanine; 2-Amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one; Zovir; Sitavig; 9-(2-Hydroxyethoxy)methylguanine; Acyclovir-side chain-2-3H; 9-HYROXYETHOXYMETHYLGUANINE; W-248-U; 9-((2-Hydroxyethoxy)methyl)guanine; UNII-X4HES1O11F; 2-Amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6-one; NSC 645011; CHEBI:2453; 2-amino-9-(2-hydroxyethoxymethyl)-1H-purin-6-one; 2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one; Acyclovir (Aciclovir); 2-Amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-6H-purin-6-one; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-; Zovirax (TN); MFCD00057880; 141294-79-3; 9-[(2-Hydroxyethoxy)-methyl]guanine; 2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one; X4HES1O11F; MLS000069633; Activir; 9-(2-Hydroxyethoxymethyl)guanine; NSC645011; NSC-645011; NSC-758477; AC2; 2-amino-9-((2-hydroxyethoxy)methyl)-3H-purin-6(9H)-one; NCGC00015061-02; Aciclovirum [Latin]; Aciclovier; Hascovir; SMR000058225; Genvir; Maynar; Zyclir; CAS-59277-89-3; 6H-Purin-6-one, 1,9-dihydro-2-amino-9-((2-hydroxyethoxy)methyl)-; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-; DSSTox_CID_2556; 2-amino-9-(2-hydroxyethoxymethyl)purin-6-ol; DSSTox_RID_76626; Aciclovirum [INN-Latin]; DSSTox_GSID_22556; Acicloftal; Cargosil; Gerpevir; Viropump; AcycloFoam; 2-amino-9-[(2-hydroxyethoxy)methyl]-3,9-dihydro-6H-purin-6-one; 2-amino-9-[(2-hydroxyethoxy)methyl]-6,9-dihydro-3H-purin-6-one; Acic; BW-248U; 2-amino-9-{[(2-hydroxyethyl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; Acyclo-V; Acyclovir Lauriad; DRG-0008; Acyclovir (USP); BW 248U; CCRIS 1953; HSDB 6511; SR-01000075540; Acyclovir [USAN:USP]; EINECS 261-685-1; ACV & Pluronic F-68; Acyclovir & Pluronic F-68; Cyclovir; Novirus; Poviral; Sitavir; 2-amino-9-((2-hydroxyethoxy)methyl)-3,9-dihydro-6H-purin-6-one; Prestwick_6; ACYCLOVIR-SIDECHAIN-2-3H; 1pwy; Aciclovir [INN]; BW-248-U; Sitavig (TN); Spectrum_001739; Opera_ID_1674; Prestwick0_000086; Prestwick1_000086; Prestwick2_000086; Prestwick3_000086; Spectrum2_001563; Spectrum3_001874; Spectrum4_000225; Spectrum5_001093; Lopac-A-4669; Aciclovir (JP17/INN); CHEMBL184; A 4669; SCHEMBL3175; Lopac0_000037; BSPBio_000012; BSPBio_003348; KBioGR_000889; KBioSS_002219; BIDD:GT0646; DivK1c_000185; SPECTRUM1503603; SPBio_001466; SPBio_001951; 2-amino-9-[(2-hydroxyethoxy)methyl]hydropurin-6-one; BPBio1_000014; GTPL4829; SCHEMBL9828560; 9(2-hydroxyethoxymethyl)guanine; DTXSID1022556; HMS500J07; KBio1_000185; KBio2_002219; KBio2_004787; KBio2_007355; KBio3_002850; NINDS_000185; HMS1568A14; HMS1922E08; HMS2090G09; HMS2095A14; HMS2234K21; HMS3259N10; HMS3260G15; HMS3269M15; HMS3372K02; HMS3413D21; HMS3655C14; HMS3677D21; HMS3712A14; Pharmakon1600-01503603; BCP11036; ZINC1530555; 9-(2-hydroxyethoxy methyl) guanine; Tox21_110075; Tox21_500037; 69657-51-8 (Na salt); BBL009642; BDBM50021776; BDBM50103518; CCG-39909; NSC758477; NSC780378; s1807; STK796771; STL257059; STL301862; AKOS000656213; AKOS015995680; AKOS022135433; Tox21_110075_1; AC-8068; CS-1353; DB00787; KS-1027; LP00037; MCULE-2703274259; NC00717; NSC-780378; SDCCGSBI-0050026.P003; IDI1_000185; SMP1_000007; NCGC00015061-01; NCGC00015061-03; NCGC00015061-04; NCGC00015061-05; NCGC00015061-06; NCGC00015061-07; NCGC00015061-08; NCGC00015061-09; NCGC00015061-10; NCGC00015061-12; NCGC00015061-13; NCGC00015061-28; NCGC00015061-29; NCGC00022426-03; NCGC00093555-01; NCGC00093555-02; NCGC00093555-03; NCGC00093555-04; NCGC00167756-01; NCGC00167756-02; NCGC00260722-01; NCGC00381719-03; HY-17422; SY051130; Acycloguanosine, >=99% (HPLC), powder; Aciclovir 1.0 mg/ml in Dimethyl Sulfoxide; AM20100442; EU-0100037; FT-0621607; FT-0657847; SW196324-3; C06810; D00222; J10243; 277A893; A832236; A935190; Q147101; Q-200591; SR-01000075540-1; SR-01000075540-3; SR-01000075540-5; 2-amino-9-[(2-hydroxyethoxy)methyl]-9H-purin-6-ol; 2-azanyl-9-(2-hydroxyethyloxymethyl)-3H-purin-6-one; BRD-K32318651-001-17-9; Aciclovir, British Pharmacopoeia (BP) Reference Standard; F2173-0946; Aciclovir, European Pharmacopoeia (EP) Reference Standard; 2-Amino-9-(2-hydroxy-ethoxymethyl)-5,9-dihydro-purin-6-one; Acyclovir, United States Pharmacopeia (USP) Reference Standard; 2-Amino-9-(2-hydroxy-ethoxymethyl)-5,9-dihydro-purin-6-one (ACV); 2-Amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6-one #; ACV; Acycloguanosine; Acyclovir; NSC 645011; NSC-645011; NSC645011; Acyclovir, Pharmaceutical Secondary Standard; Certified Reference Material; Aciclovir for peak identification 1, European Pharmacopoeia (EP) Reference Standard; Aciclovir for peak identification 2, European Pharmacopoeia (EP) Reference Standard; Aciclovir for system suitability, European Pharmacopoeia (EP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:2453	DB00787	DR00325	.	225.2	C8H11N5O3	115	308	-1.9	16	3	5	4	"1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)"	C1=NC2=C(N1COCCO)N=C(NC2=O)N	MKUXAQIIEYXACX-UHFFFAOYSA-N
DG00663	Bromevinyldeoxyuridine	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00664	Phosphonic acid derivative	.	.	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB01077	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00665	Trabectedin	108150	"Trabectedin; Yondelis; Ecteinascidin; ecteinascidin 743; ET-743; 114899-77-3; Ect 743; UNII-ID0YZQ2TCP; ET743; ID0YZQ2TCP; Et 743; CHEBI:84050; DSSTox_CID_26880; DSSTox_RID_81984; DSSTox_GSID_46880; [(1R,2R,3R,11S,12S,14R,26R)-5,6',12-trihydroxy-6,7'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-3,4-dihydro-2H-isoquinoline]-22-yl] acetate; Ecteinascidine 743; Ecteinascidin-743; CAS-114899-77-3; NSC 648766; NSC 684766; Trabectedin [USAN:INN:BAN]; CCRIS 8133; NSC-648766; C39H43N3O11S; NCGC00181159-01; NCGC00181159-02; Ecteinascidins trabectedin; CHEMBL450449; GTPL2774; DTXSID2046880; SCHEMBL12119916; EX-A4317; Tox21_112762; Tox21_113236; NSC813783; ZINC150338708; CS-1608; DB05109; NSC-684766; NSC-813783; (1'R,6R,6aR,7R,13S,14S,16R)-6',8,14-Trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6,7,12,13,14,16-octahydrospiro(6,16-(epithiopropanooxymethano)-7,13-imino-6aH-1,3-dioxolo(7,8)isoquino(3,2-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-5-yl acetate; AC-27767; Ecteinascidin 743;ET-743;Ecteinascidin; HY-50936; Spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-19-one, 3',4',6,6a,7,13,14,16-octahydro-5-(acetyloxy)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (6R-(6-alpha,6a-beta,7-beta,13-beta,14-beta,16-alpha,20R*))-; Spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-19-one, 5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (1'R,6R,6aR,7R,13S,14S,16R)-; X5006; Q2637746; Ecteinascidin 743; ; ; ET-743; ; ; Yondelis; ; ; NSC-684766; (1R,2R,3R,11S,12S,14R,26R)-5,6',12-trihydroxy-6,7'-dimethoxy-7,21,30-trimethyl-27-oxo-3',4'-dihydro-2'H-17,19,28-trioxa-24-thia-13,30-diazaspiro[heptacyclo[12.9.6.1^{3,11}.0^{2,13}.0^{4,9}.0^{15,23}.0^{16,20}]triacontane-26,1'-isoquinoline]-4(9),5,7,15(23),16(20),21-hexaen-22-yl acetate; (6R,6aR,7R,13S,14S,16R,20R)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6,7,12,13,14,16-octahydro-2'H,6aH-spiro[7,13-epimino-6,16-(epithiopropanooxymethano)[1,3]dioxolo[7,8]isoquinolino[3,2-b][3]benzazocine-20,1'-isoquinolin]-5-yl acetate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	. 	DB05109	DR01213	DR1625	761.8	C39H43N3O11S	194	1450	3.4	54	4	15	4	"1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/m0/s1"	CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O	PKVRCIRHQMSYJX-AIFWHQITSA-N
DG00666	1-Acetyllycorine	.	.	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:31045	DB00069	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00667	Fusidic acid	3000226	"Fusidic acid; Fusidine; 6990-06-3; Ramycin; Fucithalmic; Fucidic acid; Fucidin acid; Fusidate; FUCIDIN; Fucidate; Flucidin; Taksta; SQ 16,603; (-)-Fusidic acid; (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid; SQ 16603; UNII-59XE10C19C; MLS001332649; CHEBI:29013; CEM-102; 59XE10C19C; MFCD00865135; NSC-56192; SMR000857101; (2E)-2-[(3R,4S,5S,8S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid; Acide fusidique; Acido fusidico; Fusidinic Acid; Acidum fusidicum; (-)-16beta-acetoxy-3alpha,11alpha-dihydroxyfusida-17(20)Z,24-diene-21-oic acid; Anhydrous Fusidic Acid; (2Z)-2-[(3alpha,4alpha,5alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17Z)-16-(acetyloxy)-3,11-dihydroxy-4,8,10,14-tetramethylgonan-17-ylidene]-6-methylhept-5-enoic acid; (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methyl-hept-5-enoic acid; (Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-3,11-dihydroxy-4,8,10,14-tetramethyldodecahydro-1H-cyclopenta[a]phenanthren-17(2H,10H,14H)-ylidene)-6-methylhept-5-enoic acid; Fusidic acid (USAN/INN); fusidic-acid; Fusidate Acid; 1qca; FUSIDICACID; C.A.S. 62,602; Prestwick2_000390; SCHEMBL25646; MLS001332650; MLS002207094; Acide fusidique [INN-French]; Acido fusidico [INN-Spanish]; Acidum fusidicum [INN-Latin]; CEM102; CHEMBL374975; DTXSID0023086; Fusidic acid [USAN:INN:BAN]; BDBM58924; cid_3000226; GTPL10815; AOB5628; HMS2235B11; ACT03304; EX-A3797; HY-B1350; NSC56192; ZINC8143796; EINECS 230-256-0; NSC 56192; s3971; 16-(Acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic acid; AKOS005146257; CCG-269829; DB02703; DS-3261; LMPR0106040001; NCGC00485232-01; (2Z)-2-[(17Z)-16beta-acetoxy-3alpha,11alpha-dihydroxy-4alpha,8alpha,10,14beta-tetramethyl-5alpha,9beta,13alpha-gonan-17-ylidene]-6-methylhept-5-enoic acid; 29-Nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3alpha,4alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17Z)-; SQ-16603; C.A.S. 62,602; Diethanolamine fusidate; CS-0013095; F1007; C06694; D04281; 990F063; Q259930; Q-201141; Fusidic acid, European Pharmacopoeia (EP) Reference Standard; Fusidic acid for peak identification, European Pharmacopoeia (EP) Reference Standard; (2Z)-2-[(3beta,4beta,5alpha,8alpha,9beta,11beta,13alpha,16beta,17Z)-16-(acetyloxy)-3,11-dihydroxy-4,8,10,14-tetramethylgonan-17-ylidene]-6-methylhept-5-enoic acid; (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methyl-5-heptenoic acid; (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-4,8,10,14-tetramethyl-3,11-bis(oxidanyl)-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methyl-hept-5-enoic acid; (3a,4a,8a,9b,11a,13a,147b,167b,17Z)-16-(Acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic acid; (3alpha,4alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17Z)-16-(Acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic acid; (Z)-ent-16alpha-(acetyloxy)-3beta,11beta-dihydroxy-4beta,8,14- trimethyl-18-nor-5beta,10alpha-cholesta-17(20),24-dien-21-oate; 29-Nor-8.alpha.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic acid, 3.alpha.,11.alpha.,16.beta.-trihydroxy-, 16-acetate, (Z)-; 29-Nor-8alpha,9beta,13alpha,14beta-dammara-17(20),24-dien-21-oic acid, 3alpha,11alpha,16beta-trihydroxy-, 16-acetate, (Z)- (8CI); 29-Nordammara-17(20), 16-(acetyloxy)-3,11-dihydroxy-, (3.alpha.,4.alpha.,8.alpha.,9.beta.,11.alpha.,13.alpha.,14.beta.,16.beta.,17Z)-; 29-Nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3-alpha,4-alpha,8-alpha,9-beta,11-alpha,13-alpha,14-beta,16-beta,17Z)-; 29-Nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3a,4a,8a,9b,11a,13a,14b,16b,17Z)-; 3.alpha.,16.beta.-Trihydroxy-29-nor-8.alpha.,9.beta.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic acid 16-acetate; 3alpha,11alpha,16beta-Trihydroxy-29-nor-8alpha,9beta,13alpha,14beta-dammara-17(20),24-dien-21-oic acid 16-acetate; ent-(17Z)-16alpha-(Acetyloxy)-3beta,11beta-dihydroxy-4beta,8,14-trimethyl-18-nor-5beta,10alpha-cholesta-17(20),24-dien-21-oic acid hemihydrate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:29013	DB02703	.	DR0758	516.7	C31H48O6	104	994	5.5	37	3	6	6	"1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1"	C[C@H]1[C@@H]2CC[C@]3([C@H]([C@]2(CC[C@H]1O)C)[C@@H](C[C@@H]\\4[C@@]3(C[C@@H](/C4=C(/CCC=C(C)C)\\C(=O)O)OC(=O)C)C)O)C	IECPWNUMDGFDKC-MZJAQBGESA-N
DG00668	Mupirocin	446596	"Mupirocin; 12650-69-0; Pseudomonic acid; Bactroban; Mupirocine; Centany; Pseudomonic acid A; Mupirocina; Mupirocinum; Bactoderm; Turixin; BRL 4910A; BRL-4910A; trans-Pseudomonic acid; 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid; UNII-D0GX863OA5; Bactroban (TN); CHEMBL719; CHEBI:7025; D0GX863OA5; MRC; 6-Chloro-2,4-dimethoxy pyrimidine; MFCD01711620; NSC-759182; NCGC00164554-03; Plasimine; mupirocin calcium salt; 80558-54-9; L-talo-Non-2-enonic acid, 5,9-anhydro-2,3,4,8-tetradeoxy-8-[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methylpropyl]oxiranyl]methyl]-3-methyl-, 8-carboxyoctyl ester, (2E)-; Mupirocine [French]; Mupirocinum [Latin]; Mupirocina [Spanish]; C26H44O9; Bactroban Ointment; BRL-4910F; 9-(((E)-4-((2S,3R,4R,5S)-3,4-dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyl)oxy)nonanoic acid; Centany (TN); Mupirocin Neo-Sensitabs; Mupirocin (USP/INN); SR-05000001947; 115074-43-6; 1jzs; Mupirocin [USAN:USP:INN:BAN]; Mupirocin,(S); 9-((E)-4-((2S,3R,4R,5S)-3,4-dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyloxy)nonanoic acid; mupirocin lithium salt; CPD000471888; SCHEMBL3291; DSSTox_CID_26438; DSSTox_RID_81614; DSSTox_GSID_46438; 8-Carboxyoctyl (E)-4-(2S,3R,4R,5S)-5-((2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl)-3,4-dihydroxytetrahydro-2H-pyran-2-yl)-3-methylcrotonat; MLS001074711; BIDD:GT0320; Mupirocin, Pseudomonic Acid A; cid_446596; SCHEMBL1027618; Pseudomonic acid A lithium salt; DTXSID0046438; CHEBI:94519; GTPL10916; AOB6353; HMS2234E20; HMS3259L05; HMS3712K03; Pharmakon1600-01505706; HY-B0958; ZINC4102194; Tox21_112183; BDBM50290686; MFCD11977847; NSC759182; NSC815348; AKOS015994756; Mupirocin, >=92% (HPLC), powder; CCG-213522; DB00410; FD12069; KS-5137; NC00620; NSC 759182; NSC-815348; NCGC00164554-05; NCGC00164554-06; (E)-(2S,3R,4R,5S)-5-((2S,3S,4S,5S)-2,3-Epoxy-5-hydroxy-4-methylhexyl)tetrahydro-3,4-dihydroxy-beta-methyl-2H-pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid; AS-11580; SMR000471888; SBI-0206892.P001; CAS-12650-69-0; M2955; S4297; D01076; M-8680; AB01563109_01; Mupirocin, Antibiotic for Culture Media Use Only; Q413578; SR-05000001947-1; SR-05000001947-2; BRD-K15262564-001-06-9; Mupirocin, United States Pharmacopeia (USP) Reference Standard; 5,9-Anhydro-2,3,4,8-tetradeoxy-8-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-3-methyl-[2E,8[2S,3S(1S,2S)]]-L-talonon-2-enonic acid 8-carboxyoctyl ester; 9-((E)-4-((2S,3R,4R,5S)-3,4-dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)-tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyloxy)nonanoic acid; 9-((E)-4-{(2S,3R,4R,5S)-3,4-Dihydroxy-5-[(2S,3S)-3-((1S,2S)-2-hydroxy-1-methyl-propyl)-oxiranylmethyl]-tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)-nonanoic acid; 9-((E)-4-{(2S,3R,4R,5S)-3,4-Dihydroxy-5-[(2S,3S)-3-((1S,2S)-2-hydroxy-1-methyl-propyl)oxiranylmethyl]tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)nonanoic acid calcium salt; 9-((E)-4-{(2S,3R,4R,5S)-3,4-Dihydroxy-5-[(2S,3S)-3-((1S,2S)-2-hydroxy-1-methyl-propyl)oxiranylmethyl]tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)nonanoic acid lithium salt; 9-({(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-({(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl)tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoyl}oxy)nonanoic acid; 9-(4-((2S,3R,4R,5S)-3,4-dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)-tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyloxy)nonanoic acid; 9-(4-{3,4-Dihydroxy-5-[3-(2-hydroxy-1-methyl-propyl)-oxiranylmethyl]-tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)-nonanoic acid (Mupirocin); 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3- [(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl] oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid; 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methyl-propyl]oxiran-2-yl]methyl]tetrahydropyran-2-yl]-3-methyl-but-2-enoyl]oxynonanoic acid; 9-{[(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-{[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl}oxan-2-yl]-3-methylbut-2-enoyl]oxy}nonanoic acid; Nonanoic acid, 9-((3-methyl-1-oxo-4-(tetrahydro-3,4-dihydroxy-5-((3-(2-hydroxy-1-methylpropyl)oxiranyl)methyl)-2H-pyran-2-yl)-2-butenyl)oxy)-, (2S-(2alpha(E),3beta,4beta,5alpha(2R*,3R*(1R*,2R*))))-; rel-9-(((E)-4-((2S,3R,4R,5S)-3,4-Dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyl)oxy)nonanoic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7025	DB00410	.	.	500.6	C26H44O9	146	694	3	35	4	9	17	"1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1"	C[C@H]([C@H]1[C@@H](O1)C[C@H]2CO[C@H]([C@@H]([C@@H]2O)O)C/C(=C/C(=O)OCCCCCCCCC(=O)O)/C)[C@H](C)O	MINDHVHHQZYEEK-HBBNESRFSA-N
DG00669	Adamantane	9238	"ADAMANTANE; 281-23-2; Tricyclo[3.3.1.13,7]decane; Adamantan; Tricyclo[3.3.1.1(3,7)]decane; tricyclo[3.3.1.1~3,7~]decane; UNII-PJY633525U; CHEBI:40519; Tricyclo(3.3.1.13,7)decane; PJY633525U; MFCD00074719; A 0696; NSC 527913; tricyclo[3.3.1.1]decane; EINECS 206-001-4; NSC 527913; Adamantine; Adamantane (8CI); Adamantane; >99%; Adamantane, >=99%; EC 206-001-4; AMY793; CHEMBL1230831; DTXSID5022017; ZINC1271109; NSC527913; Tricyclo[3.3.1.1<3,7>]decane; Adamantane Tricyclo[3.3.1.1]decane; AKOS000119960; AKOS004908007; DB03627; DS-4960; NSC-527913; Tricyclo(3,3,1,1,<3,7>)-decane; AS-12242; DB-004015; A0696; CS-0022641; FT-0621893; S2869; D88553; A819332; Q351461; W-107075; F0001-0891"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB03627	.	.	136.23	C10H16	0	75.1	3.8	10	0	0	0	"1S/C10H16/c1-7-2-9-4-8(1)5-10(3-7)6-9/h7-10H,1-6H2"	C1C2CC3CC1CC(C2)C3	ORILYTVJVMAKLC-UHFFFAOYSA-N
DG00670	Anti-TNFalpha	.	.	Approved	1	Approved Drug(s)	Approved	Antibody	.	DB13151	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00671	Darbepoetin alfa	.	.	Approved	1	Approved Drug(s)	Approved	Recombinant protein	. 	DB00012	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00672	Eculizumab	.	.	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	DB01257	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00673	Methoxy polyethylene glycol-epoetin beta	.	.	Approved	1	Approved Drug(s)	Approved	Polymeric compound	. 	DB09107	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00674	Retapamulin	6918462	"Retapamulin; 224452-66-8; Altabax; Altargo; SB-275833; SB 275833; UNII-4MG6O8991R; SB275833; 4MG6O8991R; [(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]sulfanyl]acetate; (3as,4r,5s,6s,8r,9r,9ar,10r)-5-Hydroxy-4,6,9,10-Tetramethyl-1-Oxo-6-Vinyldecahydro-3a,9-Propanocyclopenta[8]annulen-8-Yl {[(3-Exo)-8-Methyl-8-Azabicyclo[3.2.1]oct-3-Yl]thio}acetate; Retapamulin [USAN:INN:BAN]; NSC-759885; CHEMBL1658; SCHEMBL365459; C30H47NO4S; GTPL11035; CHEBI:166679; (3aS,4R,5S,6S,8R,9R,9aR,10R)-2-(exo-8-Methyl-8-azabicyclo[3.2.1]octan-3-ylsulfanyl)acetic acid 5-hydroxy-4,6,9,10-tetramethyl-1-oxo-6-vinylperhydro-3a,9-propanocyclopentacycloocten-8-yl ester; ZINC3931840; MFCD11045316; s4056; AKOS016008865; AKOS030485971; ZINC100013500; ZINC103660515; CCG-269837; CS-0618; DB01256; NSC 759885; NCGC00386248-01; AS-11455; HY-17010; AB01566905_01; 452R668; A851322; Q7316645; BRD-K33082088-001-03-3; (1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxotricyclo[5.4.3.0^{1,8}]tetradecan-6-yl 2-{[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]sulfanyl}acetate; (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyl-5-hydroxy-4,6,9,10-tetramethyl-1-oxodecahydro-3a,9-propano-3aH-cyclopenta(8)annulen-8-yl (((1R,3s,5S)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl)sulfanyl)acetate; (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyl-5-hydroxy-4,6,9,10-tetramethyl-1-oxodecahydro-3a,9-propanocyclopenta[8]annulen-8-yl {[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]sulfanyl}acetate; [(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]sulanyl]acetate; Acetic acid, (((3-exo)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl)thio)-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:166679	DB01256	.	.	517.799	C30H47NO4S	92.1	895	6.1	36	1	6	6	"1S/C30H47NO4S/c1-7-28(4)16-24(35-25(33)17-36-22-14-20-8-9-21(15-22)31(20)6)29(5)18(2)10-12-30(19(3)27(28)34)13-11-23(32)26(29)30/h7,18-22,24,26-27,34H,1,8-17H2,2-6H3/t18-,19+,20-,21+,22 ,24-,26+,27+,28-,29+,30+/m1/s1"	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4C[C@H]5CC[C@@H](C4)N5C)C	STZYTFJPGGDRJD-FJJJPKKESA-N
DG00675	Sodium stibogluconate	16685687	"Sodium Stibogluconate,(S)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	. 	DB05630	.	.	925.9	C12H37Na3O27Sb2	325	739	.	44	16	27	4	"1S/2C6H10O7.3Na.10H2O.3O.2Sb/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;;;;;;;;;;;;;;;;;;/h2*2-5,7-8,10H,1H2,(H,12,13);;;;10*1H2;;;;;/q2*-2;3*+1;;;;;;;;;;;;;-1;+2;+3/p-3/t2*2-,3-,4-,5-;;;;;;;;;;;;;;;;;;/m11................../s1"	C([C@H]([C@@H]1[C@H]([C@@H](O[Sb](=O)(O[C@@H]([C@H]([C@@H](O[Sb](=O)(O1)O)C(=O)[O-])O)[C@@H](CO)O)[O-])C(=O)[O-])O)O)O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+]	VJCZMGLJTJZFEN-ZYPIZMQFSA-K
DG00676	Sulfamethoxazole and Doxycycline	.	.	Approved	1	Approved Drug(s)	Approved	Small molecular drug	. 	DB00015	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00677	Trametinib	11707110	"Trametinib; 871700-17-3; GSK1120212; Mekinist; GSK-1120212; JTP 74057; JTP-74057; GSK 1120212; Trametinib (GSK1120212); N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide; GSK212; UNII-33E86K87QN; TMT212; CHEBI:75998; TMT-212; 33E86K87QN; N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide; N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide; N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide; Trametinib [USAN:INN]; trametinibum; JTP74057; N-(3-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido(4,3-d)pyrimidin-1(2H)-yl)phenyl)acetamide; N-(3-{3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido(4,3-d)pyrimidin-1(2H)-yl}phenyl)acetamide; QOM; Trametinib (USAN); Trametinib (GSK1120212JTP 74057); SCHEMBL170938; C26H23FIN5O4; GTPL6495; QCR-39; GSK1120212 (Trametinib); CHEMBL2103875; EX-A022; BCPP000218; DTXSID901007381; HMS3295I05; HMS3656J11; AOB87707; BCP02307; BDBM50531540; MFCD17215075; NSC758246; NSC800956; s2673; ZINC43100709; AKOS015850628; AM90271; CCG-264976; CS-0060; DB08911; EX-5957; NSC-758246; NSC-800956; SB16553; NCGC00263180-01; NCGC00263180-07; NCGC00263180-14; AC-25891; AS-19382; HY-10999; N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide; FT-0688438; SW218089-2; X7454; A25168; D10175; GSK1120212 - JTP-74057; GSK1120212,JTP-74057, GSK212; SR-01000941589; A1-01871; J-523325; Q7833138; SR-01000941589-1; BRD-K12343256-001-01-4; Acetamide, N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-3,4,6,7-tetrahydro-6,8- dimethyl-2,4,7-trioxopyrido(4,3-d)pyrimidin-1(2H)-yl)phenyl)-; Acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-; N-(3-(3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide; N-[3-[3-Cyclopropyl-5-[(2-Fluoro-4-Iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phe nyl]acetamide; N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxopyrido[3,4-e]pyrimidin-1-yl]phenyl]acetamide; N-{3-[3-Cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl}ethanimidic acid; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:75998	DB08911	.	.	615.4	C26H23FIN5O4	102	1090	3.4	37	2	6	5	"1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)"	CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5	LIRYPHYGHXZJBZ-UHFFFAOYSA-N
DG00678	Ethambutol	14052	"Ethambutol; 74-55-5; Ethambutolum; Aethambutolum; D-Ethambutol; (+)-S,S-Ethambutol; Ethambutol Hydrochloride; (+)-ethambutol; (S,S)-ethambutol; Myambutol; (2S,2'S)-2,2'-(Ethane-1,2-diylbis(azanediyl))bis(butan-1-ol); Etambutolo [DCIT]; Tibutol; Etambutol [INN-Spanish]; Ethambutolum [INN-Latin]; S,S-Ethambutol; Diambutol; Ebutol; CHEBI:4877; UNII-8G167061QZ; (+)-2,2'-(Ethylenediimino)di-1-butanol; Purderal; (+)-N,N'-Bis(1-(hydroxymethyl)propyl)ethylenediamine; EMB; (2S)-2-[2-[[(2S)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol; 8G167061QZ; (2R)-2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol; 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (2S,2'S)-; 1-Butanol,2,2'-(1,2-ethanediyldiimino)bis-, (2S,2'S)-; (2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol; (2S,2'S)-2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol; Etambutolo; C10H24N2O2; D-2,2'-(Ethylenediimino)di-1-butanol; D-2,2'-(Ethylenediimino)bis(1-butanol); 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (S-(R*,R*))-; Ethambutol, racemic mixture; 1-Butanol, 2,2'-(ethylenediimino)di-, (+)-; d,N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; D-N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; Ethambutol [INN:BAN]; (R)-2,2'-(1,2-Ethanediyldiimino)bis-1-butanol; NCGC00178864-03; 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (R-(R*,R*))-; HSDB 3078; Servambutol (TN); 95E; Ethambutol (INN); EINECS 200-810-6; Spectrum_001058; Spectrum2_001014; Spectrum3_000426; Spectrum4_000545; Spectrum5_000702; 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (R)-; Myambutol (dihydrochloride); SCHEMBL3399; BSPBio_002012; KBioGR_001209; KBioSS_001538; CHEMBL44884; DivK1c_000561; SPBio_001167; CL 40881 (dihydrochloride); DTXSID8023006; KBio1_000561; KBio2_001538; KBio2_004106; KBio2_006674; KBio3_001232; NINDS_000561; HY-B0535; 2860AH; BDBM50448407; ZINC19364219; DB00330; MCULE-9663372083; IDI1_000561; NCGC00178864-01; NCGC00178864-04; SBI-0051375.P003; C06984; D07925; D94801; E-3950; AB00053473_04; AB00053473_05; Q412318; (S,S)-2,2'-(1,2-Ethanediyldiimino)bis-1-butanol; BRD-K93231391-300-03-1; (+)-(S,S)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; Ethambutol dihydrochloride, Antibiotic for Culture Media Use Only; (2S)-2-[(2-{[(2S)-1-hydroxybutan-2-yl]amino}ethyl)amino]butan-1-ol; (2S)-2-[2-[[(1S)-1-(hydroxymethyl)propyl]amino]ethylamino]butan-1-ol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4877	DB00330	.	.	204.31	C10H24N2O2	64.5	109	-0.1	14	4	4	9	"1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1"	CC[C@@H](CO)NCCN[C@@H](CC)CO	AEUTYOVWOVBAKS-UWVGGRQHSA-N
DG00679	Furantoin	132988179	"Furantoin-13C,15N3"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7773	DB00904	.	.	242.13	C8H6N4O5	121	390	-0.5	17	1	6	2	"1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3-/i8+1,9+1,10+1,11+1"	C1C(=O)[15NH][13C](=O)[15N]1/[15N]=C\\C2=CC=C(O2)[N+](=O)[O-]	NXFQHRVNIOXGAQ-XFHUPTTISA-N
DG00680	Polymorphism	.	.	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00736	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG00681	Pyrazinamide	1046	"Pyrazinamide; pyrazinecarboxamide; 98-96-4; pyrazine-2-carboxamide; pyrazinoic acid amide; Zinamide; 2-Pyrazinecarboxamide; Aldinamide; Aldinamid; Pirazinamid; Tebrazid; Farmizina; Pirazimida; Pyrazineamide; Unipyranamide; Eprazin; Novamid; Pyrafat; pyrazine carboxylamide; 2-Carbamylpyrazine; Pyrazinecarboxylic acid amide; Pyrazinamidum; Isopas; Pirazinamide; Pyrazine carboxamide; D-50; MK 56; C5H5N3O; PZA; NCI-C01785; UNII-2KNI5N06TI; MFCD00006132; NSC 14911; T 165; Pirazinamida; Tisamid; 2KNI5N06TI; MLS000069730; Pezetamid; Piraldina; Pyrazide; CHEBI:45285; Rozide; NSC14911; Pyrazinamide (Pyrazinoic acid amide); NSC-14911; NCGC00015833-09; Pyrazinamdie; SMR000036662; Pirazinamide [DCIT]; DSSTox_CID_1215; DSSTox_RID_76014; DSSTox_GSID_21215; Pyrazinamidum [INN-Latin]; Pirazinamida [INN-Spanish]; pyramizade; Rifafour; D-50 (VAN); DRG 0124; CAS-98-96-4; CCRIS 545; Pyrazinamide (TN); Rifafour e-200; HSDB 3576; SR-01000076077; EINECS 202-717-6; BRN 0112306; pyrazinamida; Pyrizinamide; pyrazine amide; AZT + Pyrazinamide combination; Pyrazine-2-carboxylic acid amide; Pyrazinamide,(S); Pyrazinamide [USP:INN:BAN:JAN]; Prestwick_811; .alpha.-pyrazinamide; 2-pyrazine carboxamide; Spectrum_000902; Opera_ID_735; Prestwick0_000514; Prestwick1_000514; Prestwick2_000514; Prestwick3_000514; Spectrum2_001305; Spectrum3_001046; Spectrum4_001186; Spectrum5_001026; Lopac-P-7136; CHEMBL614; P 7136; WLN: T6N DNJ BVZ; pyrazine-2-carboximidic acid; Lopac0_001011; SCHEMBL24102; BSPBio_000467; BSPBio_002572; KBioGR_001851; KBioSS_001382; 5-25-04-00178 (Beilstein Handbook Reference); MLS002222347; BIDD:GT0228; DivK1c_000241; SPECTRUM1500518; SPBio_001369; SPBio_002388; BPBio1_000515; GTPL7287; ZINC2005; DTXSID9021215; HMS500M03; KBio1_000241; KBio2_001382; KBio2_003950; KBio2_006518; KBio3_001792; Pyrazinamide (JP17/USP/INN); NINDS_000241; BDBM228814; HMS1569H09; HMS1920N08; HMS2092E09; HMS2096H09; HMS2235G17; HMS3259O04; HMS3263K03; HMS3371G09; HMS3655A10; HMS3713H09; KUC109577N; Pharmakon1600-01500518; ACT01761; AMY14180; BCP30257; HY-B0271; KSC-27-052E; Pyrazine-[d3]-carboxamide-[15N]; Tox21_110237; Tox21_202059; Tox21_302771; Tox21_501011; CCG-39243; NSC757304; s1762; STK801661; AKOS000120280; Tox21_110237_1; DB00339; LP01011; MCULE-6846697749; NC00534; NSC-757304; Pyrazinecarboxamide, analytical standard; SDCCGSBI-0050984.P005; IDI1_000241; NCGC00015833-01; NCGC00015833-02; NCGC00015833-03; NCGC00015833-04; NCGC00015833-05; NCGC00015833-06; NCGC00015833-07; NCGC00015833-08; NCGC00015833-10; NCGC00015833-11; NCGC00015833-12; NCGC00015833-15; NCGC00015833-16; NCGC00015833-25; NCGC00090695-01; NCGC00090695-03; NCGC00090695-04; NCGC00090695-05; NCGC00090695-06; NCGC00090695-07; NCGC00256336-01; NCGC00259608-01; NCGC00261696-01; Pyrazinoic acid amide; pyrazinamide; PZA; CAS- 98-96-4; SY013550; TS-01626; SBI-0050984.P004; DB-002866; AB00052083; B2122; BB 0253141; EU-0101011; FT-0659757; P0633; SW196945-3; C01956; D00144; D70481; J10111; 1,2-dihydro-1,2,4-triazol-3-one;Pyrazinamide; AB00052083-16; AB00052083_17; AB00052083_18; A845937; AC-907/25014068; Q417571; SR-01000076077-1; SR-01000076077-4; SR-01000076077-6; W-100059; Z33546644; Pyrazinamide, British Pharmacopoeia (BP) Reference Standard; Pyrazinamide, European Pharmacopoeia (EP) Reference Standard; 2-Carbamylpyrazine ;Aldinamid ;Aldinamide; Pyrazinoic acid amide; Pyrazinamide, United States Pharmacopeia (USP) Reference Standard; Pyrazinamide, Pharmaceutical Secondary Standard; Certified Reference Material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:45285	DB00339	.	DR1372	123.11	C5H5N3O	68.9	115	-0.6	9	1	3	1	"1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)"	C1=CN=C(C=N1)C(=O)N	IPEHBUMCGVEMRF-UHFFFAOYSA-N
DG00687	Fosmidomycin	572	"Fosmidomycin; 66508-53-0; Fosmidomycina; Fosmidomycine; Fosmidomycinum; 3-[FORMYL(HYDROXY)AMINO]PROPYLPHOSPHONIC ACID; {3-[formyl(hydroxy)amino]propyl}phosphonic acid; UNII-5829E3D9I9; 3-(N-hydroxyformamido)propylphosphonic acid; CHEMBL203125; Fosmidomycin sodium salt hydrate; CHEBI:443725; FR-31564; 5829E3D9I9; (3-(N-Hydroxyformamido)propyl)phosphonic acid; C4H10NO5P; FOM; FR 31564; 66508-37-0; Fosmidomycine [INN-French]; Fosmidomycinum [INN-Latin]; Fosmidomycina [INN-Spanish]; Fosmidomycin [INN]; [3-(N-hydroxyformamido)propyl]phosphonic acid; Antibiotic FR-31705; 3-(Formyl-hydroxy-amino)propylphosphonic acid; 3-(N-Formyl-N-hydroxyamino)-propylphosphonic acid; SCHEMBL301404; GTPL9739; DTXSID70216712; (3-(Formylhydroxyamino)propyl)phosphonic acid, monosodium salt; BDBM50153713; ZINC12502867; AKOS006272014; DB02948; NCGC00264107-01; NCGC00264107-02; R980; 3-(formyl-hydroxyamino)propylphosphonic acid; 3-(N-formyl-N-hydroxyamino)propylphosphonic acid; [3-(Formyl-hydroxy-amino)-propyl]-phosphonic acid; Q905038; (3-(Formylhydroxyamino)propyl)phosphonic acid sodium salt; (3-(N-Hydroxyformamido)propyl)phosphonic acid sodium salt"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:443725	DB02948	.	.	183.1	C4H10NO5P	98.1	166	-2.2	11	3	5	4	"1S/C4H10NO5P/c6-4-5(7)2-1-3-11(8,9)10/h4,7H,1-3H2,(H2,8,9,10)"	C(CN(C=O)O)CP(=O)(O)O	GJXWDTUCERCKIX-UHFFFAOYSA-N
DG00693	Menthol	1254	"MENTHOL; dl-Menthol; 1490-04-6; 2-Isopropyl-5-methylcyclohexanol; Cyclohexanol, 5-methyl-2-(1-methylethyl)-; 15356-70-4; 89-78-1; p-Menthan-3-ol; Racementhol; (+/-)-Menthol; 5-methyl-2-propan-2-ylcyclohexan-1-ol; Hexahydrothymol; Menthol [USP]; rac-Menthol; CHEBI:25187; Menthyl alcohol; (1R,2S,5R)-Menthol; Menthol, dl-; Menthol (USP); MFCD00001484; (1S, 2S, 5R)-(+)-Neomenthol; 5-methyl-2-(propan-2-yl)cyclohexanol; 5-methyl-2-(propan-2-yl)cyclohexan-1-ol; DSSTox_CID_805; DSSTox_RID_78794; DSSTox_GSID_29650; Racemic menthol; FEMA No. 2665; Caswell No. 540; 3-p-Menthanol; Mentholum; Mineral ice; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, [1S-(1.alpha.,2.alpha.,5.beta.)]-; Therapeutic mineral ice; 3-p-Menthol; CAS-1490-04-6; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5R)-rel-; CCRIS 9231; 3-Hydroxy-p-menthane; Fisherman's friend lozenges; Robitussin Cough Drops; (1R,2R,5R)-Isomenthol; EINECS 216-074-4; EPA Pesticide Chemical Code 051601; (+/-)-p-Menthan-3-ol; Menthol, cis-1,3,trans-1,4-; (1S,2R,5R)-(+)-Isomenthol; 5-Methyl-2-(1-methylethyl)-cyclohexanol; NSC-2603; AI3-08161; HSDB 593; Menthol racemate; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1.alpha.,2.beta.,5.alpha.)-; 2-Isopropyl-5-methyl-cyclohexanol; (-)menthol; NCGC00159382-02; (-) menthol; 2-Isopropyl-5-methylcyclohexan-1-ol; 4-Isopropyl-1-methylcyclohexan-3-ol; Menthol, 99%; dl-Menthol (JP17); 1-methyl-4-isopropyl-3-hydroxycyclohexane; EC 216-074-4; SCHEMBL4612; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1S,2S,5R)-; Menthol, (.+/-.)-; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2R,5S)-rel-; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5S)-rel-; Menthol, puriss., 99.0%; CHEMBL256087; DL-Menthol, analytical standard; DTXSID8029650; AMY3077; Fisherman's friend lozenges (TN); BDBM248162; HMS3744K19; 2-Isopropyl-5-methylcyclohexanol #; 3623-52-7; BCP27552; BCP31841; CS-M3737; HY-N1369; menthol crystals; 15356-70-4; Tox21_200010; Tox21_303464; BBL009325; DL-Menthol, >=95%, FCC, FG; STK802468; ( inverted exclamation markA)-Menthol; AKOS000119740; AKOS016843634; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1.alpha.,2.alpha.,5.beta.)-; AM81446; MCULE-3070949324; SB35230; SB44308; SB44857; (2R)-2-isopropyl-5-methyl-cyclohexanol; Menthol 1000 microg/mL in Acetonitrile; Menthol, SAJ special grade, >=98.0%; NCGC00159382-03; NCGC00159382-04; NCGC00159382-05; NCGC00159382-06; NCGC00257403-01; NCGC00257564-01; HY-75161; K601; SY004225; SY010603; VS-02042; DB-063989; Levomenthol; D-(-)-Menthol; (-)-Menthol; CS-0016777; FT-0600039; FT-0604399; FT-0604426; FT-0604430; FT-0620596; FT-0625488; FT-0695077; FT-0695078; FT-0695079; M0321; (+/-)-Menthol, racemic, >=98.0% (GC); 2-Isopropy-5-methylcyclohexanol-1,2,6,6-d4; D04849; D04918; E80543; (1S,2R,5R)-2-isopropyl-5-methyl-cyclohexanol; A808833; A809442; J-500418; Q27109870; Z1258992394; Menthol-plus it inverted exclamation markas 3 isomers-1,2,6,6-d4; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1.alpha.,2.beta.,5.alpha.)-(.+/-.)-; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, [1R-(1.alpha.,2.alpha.,5.beta.)]-; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, [1S-(1.alpha.,2.beta.,5.beta.)]-; L-Menthol; (-)-Menthol; Levomenthol; Menthomenthol;2-isopropyl-5-methyl-cyclohexanol;Menthol; Menthol solution, NMR reference standard, 30 wt. % in chloroform-d (99.8 atom % D), NMR tube size 5 mm x 8 in.; Menthol solution, NMR reference standard, 50% in chloroform-d (99.8 atom % D), chromium(III) acetylacetonate 0.5 %, NMR tube size 5 mm x 8 in."	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:25187	.	.	.	156.26	C10H20O	20.2	120	3	11	1	1	1	"1S/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3"	CC1CCC(C(C1)O)C(C)C	NOOLISFMXDJSKH-UHFFFAOYSA-N
DG00695	Tacrine	1935	"Tacrine; 1,2,3,4-tetrahydroacridin-9-amine; 321-64-2; Tetrahydroaminacrine; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; Tetrahydroaminoacridine; Tetrahydroaminocrine; Cognex; Tetrahydroaminocrin; 9-amino-1,2,3,4-tetrahydroacridine; Tacrinum; 9-Acridinamine, 1,2,3,4-tetrahydro-; CS 12602; UNII-4VX7YNB537; 1,2,3,4-Tetrahydro-9-aminoacridine; Acridine, 1,2,3,4-tetrahydro-9-amino-; CHEMBL95; 5-Amino-6,7,8,9-tetrahydroacridine; 4VX7YNB537; CHEBI:45980; 5,6,7,8-tetrahydroacridin-9-amine; tacrine.HCl; NCGC00015054-06; Tacrina; Tacrine [INN:BAN]; Tacrinum [INN-Latin]; Tacrina [INN-Spanish]; DSSTox_CID_17272; DSSTox_RID_79318; DSSTox_GSID_37272; Tacrinal; Tacrinal (TN); CAS-321-64-2; Tacrine (INN); EINECS 206-291-2; 5-Amino-6,7,8,9-tetrahydroacridine (European); BRN 0147610; 1,2,3,4-Tetrahydro-acridin-9-ylamine; Tracine; 1acj; 2aow; 2aox; 1,2,3,4-Tetrahydro-9-acridineamine; Romotal (Salt/Mix); Spectrum_000416; Tocris-0965; 1mx1; Prestwick0_000329; Prestwick1_000329; Prestwick2_000329; Prestwick3_000329; Spectrum2_001812; Spectrum3_001709; Spectrum4_000819; Spectrum5_001402; Lopac-A-3773; cid_1935; SCHEMBL2828; 9-THA; NCIOpen2_003667; Lopac0_000036; Oprea1_008681; Acridine, 9-aminotetrahydro-; BSPBio_000337; BSPBio_003298; KBioGR_001337; KBioSS_000896; BIDD:GT0090; DivK1c_000936; SPBio_001823; SPBio_002258; BDBM8961; BPBio1_000371; GTPL6687; DTXSID1037272; KBio1_000936; KBio2_000896; KBio2_003464; KBio2_006032; KBio3_002518; NINDS_000936; HMS2089F19; HMS3743C11; BCP03564; Tox21_110073; Tox21_302277; MFCD00046923; PDSP1_000330; PDSP2_000328; STK101308; ZINC19014866; AKOS000277493; Tox21_110073_1; BCP9000019; CCG-204132; DB00382; MCULE-3628803328; SDCCGSBI-0050025.P004; 1,2,3,4-tetra -hydro-9-acridinamine; IDI1_000936; NCGC00015054-01; NCGC00015054-02; NCGC00015054-03; NCGC00015054-04; NCGC00015054-05; NCGC00015054-07; NCGC00015054-08; NCGC00015054-09; NCGC00015054-10; NCGC00015054-12; NCGC00024908-01; NCGC00024908-03; NCGC00024908-04; NCGC00024908-05; NCGC00255540-01; 1,2,3,4-tetrahydro-acridin-9-yl-amine; BS-28027; Acridine, 9-amino-1,2,3,4-tetrahydro-; SBI-0050025.P003; DB-000650; 9-amino-1,2,3,4-tetrahydroacridine (THA); AB00053524; C-110; EU-0010966; FT-0631953; 9-Acridinamine, 1,2,3,4-tetrahydro- (9CI); A18628; C01453; D08555; AB00053524-17; AB00053524_18; AB00053524_19; AE-641/00604043; Q421076; BRD-K81473089-003-03-0; BRD-K81473089-003-04-8; BRD-K81473089-003-15-4; SR-01000075593-13; Z56790573"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:45980	DB00382	DR00183	.	198.26	C13H14N2	38.9	229	2.7	15	1	2	0	"1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)"	C1CCC2=NC3=CC=CC=C3C(=C2C1)N	YLJREFDVOIBQDA-UHFFFAOYSA-N
DG00699	Alprazolam	2118	"Alprazolam; Xanax; 28981-97-7; Trankimazin; Tafil; Tranquinal; Alplax; Constan; Frontal; Niravam; Solanax; Xanor; Apo-Alpraz; 8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; Xanax XR; Alcelam; Anpress; Relaxol; Tricalma; Valeans; Xanagis; Zolarem; Alpaz; Alpram; Alzam; Panix; Prinox; Zoldac; Zotran; Alprazolam intensol; TUS-1; Xanolam; Zolam; Zopax; Zopic; Tafil D; Xanax TS; D 65MT; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; UNII-YU55MQ3IZY; Cassadan; Esparon; Neurol; U 31889; U-31,889; Alpronax; Alzolam; Bestrol; Ralozam; Alprox; Restyl; YU55MQ3IZY; CHEMBL661; U-31889; Novo-Alprazol; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; Nu-Alpraz; 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-1-methyl-6-phenyl-; CHEBI:2611; Alprazolamum; Pharnax; Prazolan; Tensivan; Zacetin; Zanapam; Alprax; Ksalol; Mialin; Prazam; Unilan; Zoldax; Algad; Alzon; Helex; Zaxan; Zenax; Gen-Alprazolan; 4H-s-Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-1-methyl-6-phenyl-; 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-1-methyl-6-phenyl-; NSC-760140; NCGC00159466-02; Alprazolamum [INN-Latin]; Tus 1; Panistat; Alprazolam extended release tablets; Staccato-alprazolam; SMR000149316; Xanax (TN); HSDB 7207; EINECS 249-349-2; AZ-002; TGAR01P; BRN 1223125; Alprazolam civ; DEA No. 2882; 08H; Alprazolam [USAN:USP:INN:BAN:JAN]; AP-1002; 3u5j; DSSTox_CID_2577; SCHEMBL8398; DSSTox_RID_76639; BIDD:PXR0150; DSSTox_GSID_22577; ZINC903; MLS000559000; MLS000759485; MLS001423979; BIDD:GT0475; Alprazolam (JP17/USP/INN); GTPL7111; DTXSID4022577; HMS2051A10; HMS3393A10; Pharmakon1600-01502395; Alprazolam 0.1 mg/ml in Methanol; Alprazolam 1.0 mg/ml in Methanol; BCP28608; Tox21_111692; BBL028160; BDBM50001728; NSC760140; STK590494; AKOS005066050; CCG-100855; DB00404; MCULE-1215564244; NC00105; NSC 760140; 4H-(1,2,4)Triazolo(4,3-alpha)(1,4)benzodiazepine, 8-chloro-1-methyl-6-phenyl-; NCGC00159466-03; 51339-48-1; AC-18721; CAS-28981-97-7; C06817; D00225; 981A977; A819702; Q319877; U 31,889; W-107015; BRD-K32398298-001-01-4; Alprazolam, European Pharmacopoeia (EP) Reference Standard; 8-chloro-1-methyl-6-phenyl-4H-s-triazolo [4,3-a] [1,4] benzodiazepine; 8-chloro-1-methyl-6-phenyl-4H-s-triazolo [4,3-a][1,4] benzodiazepine; 8-chloro-6-phenyl-1-methyl-4H-s-triazolo-[4,3-a][1,4]benzodiazepine; (Z)-8-chloro-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine; 8-chloranyl-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; Alprazolam solution, 1 mg/mL in methanol, analytical standard, for drug analysis; Alprazolam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; 12-chloro-3-methyl-9-phenyl-2,4,5,8-tetraazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,8,11,13-hexaene; 1246182-61-5"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:2611	DB00404	DR01197	DR0075	308.8	C17H13ClN4	43.1	434	2.1	22	0	3	1	"1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3"	CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4	VREFGVBLTWBCJP-UHFFFAOYSA-N
DG00702	Amsacrine	2179	"Amsacrine; 51264-14-3; m-AMSA; Amsidine; Amsidyl; Acridinylanisidide; Amekrin; Amsacrina; Lamasine; mAMSA; AMSA; Acridinyl Anisidide; Amsacrinum; Amsine; 4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide; 4'-(9-Acridinylamino)methanesulfon-m-anisidide; SN-11841; 4'-(9-Acridinylamino)methanesulphon-m-anisidide; N-(4-(Acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide; N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide; CI-880; NSC249992; NSC 156303; NSC 249992; NSC-249992; 4'-(9-Acridinylamino)methanesulfon-meta-anisidide; SN 21429; UNII-00DPD30SOY; Methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-; NSC-156303; CHEMBL43; N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide; m-AMSA;acridinyl anisidide; 00DPD30SOY; CHEBI:2687; Methanesulfonanilide, 4'-(9-acridinylamino)-3'-methoxy-; N-(4-(9-Acridinylamino)-3-methoxyphenyl)methanesulfonamide; Methanesulfonamide, N-(4-(9-acridinylamino)-3-methoxyphenyl)-; meta-Amsacrine; NSC-141549; Methanesulfon-m-anisidide, 4'-(9-acridinylamino)-; N-[4-(acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; Amsacrinum [INN-Latin]; Amsacrina [INN-Spanish]; m-AMSA hydrochloride; acridinyl anisidide hydrochloride; amsidil; Amecrin; MLS002153376; nAMSA; Amsidyl (TN); CCRIS 1027; HSDB 7087; Amsacrine (USAN/INN); SMR000875352; EINECS 257-094-3; CI 880; AMSA, M-; BRN 0500176; Amsacrine [USAN:INN:BAN]; Lopac-A-9809; NCIMech_000607; Neuro_000118; SCHEMBL4047; Lopac0_000154; 5-22-11-00030 (Beilstein Handbook Reference); MLS006010099; cid_148673; DTXSID4022604; BDBM87351; HMS3748E05; N-[4-(9-Acridinylamino)-3-methoxy-phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-methoxy-phenyl]methanesulfonamide; BCA26414; BCP08958; ZINC3812923; CCG-35555; MFCD00242748; AKOS015917522; CS-1942; DB00276; NCI-249992; SDCCGSBI-0050142.P003; NCGC00015113-01; NCGC00015113-02; NCGC00015113-03; NCGC00015113-04; NCGC00093644-10; NCGC00162077-01; AS-11665; HY-13551; NCI60_001995; SMR000857391; SN-21429; WLN: T C666 BNJ IMR BO1 DMSW1; DB-082052; FT-0708980; C01553; C75400; D02321; 4'-(9-Acridinylamino)methanesulfonyl m-anisidide; 301A154; 4'-(9-Acridinylamino)-methylsulfonyl-m-anisidine; A918341; Q2784004; AMSA;m-AMSA;CI-880;SN-11841;acridinyl anisidide; N-[4-(9-acridinylamino)-3-methoxyphenyl]methanesulfonamide;hydrochloride; N-[4-(acridin-9-ylamino)-3-methoxy-phenyl]methanesulfonamide;hydrochloride; N-{4-[(ACRIDIN-9-YL)AMINO]-3-METHOXYPHENYL}METHANESULFONAMIDE; ASW"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:2687	DB00276	DR00917	DR0109	393.5	C21H19N3O3S	88.7	601	4	28	2	6	5	"1S/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23)"	COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42	XCPGHVQEEXUHNC-UHFFFAOYSA-N
DG00705	Bicalutamide	2375	"Bicalutamide; 90357-06-5; Casodex; Cosudex; Bicalutamide (CDX); Calutide; ICI 176334; ICI-176334; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methylpropanamide; Bicalutamide (Casodex); CHEMBL409; ICI 176,334; MFCD00869971; N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide; NSC-759816; Raffolutil; Kalumid; SMR000466329; Casodex (TN); SR-01000759410; BRN 5364666; Bicalutamine; Bicalutamide (JAN/USP/INN); Propanamide,; CCRIS 8728; HSDB 7655; Bicalutamide [USAN:USP:INN:BAN]; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; KS-1161; Bicalutamide - Casodex; CPD000466329; SCHEMBL3611; (R)-(-)-Bicalutamide-d4; MLS000759437; MLS001424047; Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+-)-; S-(+)-Bicalutamide-[d4]; GTPL2863; DTXSID2022678; BDBM18525; CHEBI:91617; AOB5596; EX-A962; CHEBI:144093; BCPP000337; HMS2051B13; HMS2089N12; HMS2232H03; HMS3263M13; HMS3372K05; HMS3393B13; HMS3654K18; HMS3714P13; Pharmakon1600-01504827; ACT06291; AMY33430; BCP02110; Tox21_501026; NSC722665; NSC759816; s1190; AKOS015895073; AC-4232; BCP9000408; CCG-100951; CCG-220876; CCG-222330; CS-1296; DB01128; LP01026; NC00201; NSC 759816; NSC-722665; SB17301; SDCCGSBI-0633779.P001; N-(4-cyano-3-(trifluoromethyl)phenyl); NCGC00167977-01; NCGC00167977-02; NCGC00167977-03; NCGC00167977-09; NCGC00167977-20; NCGC00261711-01; HY-14249; ICI176,334-1; Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-; DB-041165; B3206; FT-0618286; FT-0631069; FT-0663100; SW197581-4; Bicalutamide (CDX), >=98% (HPLC), powder; C08160; D00961; J10442; AB00639963-06; AB00639963-08; AB00639963-09; AB00639963_10; 357B065; A803039; A843528; Q1988832; SR-01000759410-4; SR-01000759410-5; BRD-A29485665-001-03-7; Bicalutamide, British Pharmacopoeia (BP) Reference Standard; Bicalutamide, European Pharmacopoeia (EP) Reference Standard; Bicalutamide, United States Pharmacopeia (USP) Reference Standard; 4'-cyano-3-[(4- fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-trifluoromethylpropionanilide; 4'-cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-trifluoromethylpropionanilide; Bicalutamide for system suitability, European Pharmacopoeia (EP) Reference Standard; Bicalutamide, Pharmaceutical Secondary Standard; Certified Reference Material; N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-N-phenylpropanamide; N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropanamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-methyl-2-oxidanyl-propanamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorobenzene)sulfonyl]-2-hydroxy-2-methylpropanamide; N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropionamide; N-[4-cyano-3-trifluoromethyl-phenyl]-3-[4-fluorophenyl-sulfonyl]-2-hydroxy-2-methyl-propionamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:91617	DB01128	DR00795	DR0210	430.4	C18H14F4N2O4S	116	750	2.3	29	2	9	5	"1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)"	CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O	LKJPYSCBVHEWIU-UHFFFAOYSA-N
DG00707	Brimonidine	2435	"Brimonidine; 59803-98-4; Bromoxidine; UK 14,304; 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine; 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; 5-bromo-6-(imidazolin-2-ylamino)quinoxaline; AGN 190342; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-; UK-14304; UNII-E6GNX3HHTE; UK 14304; AGN-190342; MLS000069370; E6GNX3HHTE; MFCD00153878; CHEMBL844; SMR000058355; CHEBI:3175; NSC-318825; NCGC00016069-09; UK 14304;AGN190342; DSSTox_CID_25221; DSSTox_RID_80758; DSSTox_GSID_45221; UK 14304 (tartrate);AGN190342 (tartrate); 5-Bromo-N-(2-imidazolin-2-yl)-6-quinoxalinamine; Brimonidine [INN:BAN]; [3H]brimonidine; C11H10BrN5; CAS-59803-98-4; N-(5-bromoquinoxalin-6-yl)imidazolidin-2-imine; SR-01000000023; brimonidina; brimonidinum; BRN 0751629; LK 14304-18; Brimonidine (INN); AGN190342; UK14304; Tocris-0425; [3H]-UK14304; Opera_ID_612; Lopac-U-104; cid_2435; Lopac0_001216; SCHEMBL24670; GTPL520; MLS001076349; BIDD:GT0649; GTPL5386; DTXSID3045221; BDBM34572; 5-Bromo-N-(4,5-dihydro-2-imidazolyl)quinoxalin-6-amine; AGN-190342 FREE BASE; HMS3259P09; HMS3263D14; HMS3266O03; HMS3411K05; HMS3675K05; HMS3887K07; AMY22318; BCP12632; EX-A5415; HY-B0659; Tox21_110299; Tox21_501216; UK-1430418 FREE BASE; AC-162; NSC318825; PDSP1_000640; PDSP2_000635; s9508; ZINC21303210; AKOS005267239; Tox21_110299_1; CCG-205290; DB00484; GS-3236; LP01216; MCULE-4542695850; NC00638; NSC 318825; SDCCGSBI-0051183.P002; MRF-0000657; NCGC00016069-01; NCGC00016069-02; NCGC00016069-03; NCGC00016069-04; NCGC00016069-05; NCGC00016069-06; NCGC00016069-07; NCGC00016069-08; NCGC00016069-10; NCGC00016069-11; NCGC00016069-12; NCGC00016069-13; NCGC00016069-24; NCGC00023468-02; NCGC00023468-04; NCGC00023468-05; NCGC00023468-06; NCGC00023468-07; NCGC00261901-01; SY053060; UK14,304; Brimonidine 100 microg/mL in Acetonitrile; B4132; EU-0101216; FT-0630717; FT-0650586; EN300-50880; UK 14304-18; C07886; C75796; D07540; 5-bromo-6-(2-imidazolidinylidenamino)quinoxaline; 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline; 5-Bromo-6-(2-imidazolin-2-ylamino)-quinoxaline; 6-Quinoxalinamine,5-dihydro-1H-imidazol-2-yl)-; 803B984; A832477; L000615; Q577377; SR-01000000023-2; SR-01000000023-4; BRD-K68264559-001-10-0; Z802671510; (5-Bromo-quinoxalin-6-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine; 5-bromanyl-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- (9CI)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3175	DB00484	.	.	292.13	C11H10BrN5	62.2	308	0.6	17	2	3	2	"1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)"	C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br	XYLJNLCSTIOKRM-UHFFFAOYSA-N
DG00717	Cilostazol	2754	"Cilostazol; 73963-72-1; Pletal; Cilostazole; Pletaal; OPC-13013; Cilostazolum; Cilostazolum [INN-Latin]; OPC 13013; OPC 21; OPC-21; 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one; C20H27N5O2; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone; 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one; UNII-N7Z035406B; CHEBI:31401; 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one; 6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one; MLS000028470; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone; MFCD00866780; N7Z035406B; NSC-758936; NCGC00015207-07; SMR000058428; DSSTox_CID_25132; DSSTox_RID_80693; DSSTox_GSID_45132; CAS-73963-72-1; Pletal (TN); SR-01000003107; BRN 3632107; Cilostazol,(S); Cilostazol-[d11]; Cilostazol [USAN:USP:INN:BAN:JAN]; Tocris-1692; Opera_ID_488; Spectrum2_001118; Spectrum3_001170; Spectrum4_000772; Spectrum5_001762; Lopac-C-0737; CHEMBL799; C 0737; Lopac0_000218; REGID_for_CID_2754; SCHEMBL16128; BSPBio_002759; KBioGR_001184; MLS000758281; MLS000759507; MLS001076067; MLS002153891; SPECTRUM1505230; SPBio_001256; Cilostazol (JP17/USP/INN); GTPL7148; DTXSID9045132; HSDB 8312; KBio3_002259; BCPP000279; HMS1922N15; HMS2093M14; HMS2096F16; HMS2234C06; HMS3260L17; HMS3268O09; HMS3412B18; HMS3654J13; HMS3676B18; HMS3713F16; Pharmakon1600-01505230; ACT02663; BCP03724; ZINC1552174; Tox21_110098; Tox21_500218; BDBM50225508; CCG-39646; NSC758936; s1294; AKOS015855512; Cilostazol, >=98% (HPLC), powder; OPC 13013; OPC 21; Pletaal; Tox21_110098_1; AC-4334; AM90304; BCP9000530; CS-1759; DB01166; KS-5154; LP00218; MCULE-8893820969; NSC 758936; SDCCGSBI-0050206.P003; 2(1H)-Quinolinone, 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-; 2(1H)-Quionlinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone; NCGC00015207-01; NCGC00015207-02; NCGC00015207-03; NCGC00015207-04; NCGC00015207-05; NCGC00015207-06; NCGC00015207-08; NCGC00015207-09; NCGC00015207-10; NCGC00015207-11; NCGC00015207-12; NCGC00015207-25; NCGC00022153-02; NCGC00022153-04; NCGC00022153-05; NCGC00022153-06; NCGC00022153-07; NCGC00260903-01; HY-17464; BCP0726000145; RETAL;PLETAL;OPC 21;PLETAAL;Cilostal; SBI-0050206.P002; EU-0100218; FT-0602474; FT-0645036; FT-0665038; SW199053-2; D01896; F20538; J90029; AB00382988-14; AB00382988_15; AB00382988_16; 963C721; A837982; Q258591; Q-200854; SR-01000003107-2; SR-01000003107-4; SR-01000003107-7; BRD-K67017579-001-04-2; BRD-K67017579-001-05-9; BRD-K67017579-001-07-5; BRD-K67017579-001-13-3; BRD-K67017579-001-17-4; SR-01000003107-10; Cilastatin sodium, Antibiotic for Culture Media Use Only; Cilostazol, United States Pharmacopeia (USP) Reference Standard; 6-[4-(1-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril; 6-[4-(l-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxyl]-3,4-dihydrocarbostyril; Cilostazol, Pharmaceutical Secondary Standard; Certified Reference Material; 2(1H)-Quinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-; 6-(4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY)QUINOLINE-2,3(1H,4H)-DIONE; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one; 89332-50-3"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31401	DB01166	DR01322	DR0324	369.5	C20H27N5O2	81.9	485	3.1	27	1	5	7	"1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)"	C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4	RRGUKTPIGVIEKM-UHFFFAOYSA-N
DG00718	Cloperastine	2805	"Cloperastine; 3703-76-2; 1-(2-((4-chlorophenyl)(phenyl)methoxy)ethyl)piperidine; Cloperastine [INN]; 1-[2-[(4-chlorophenyl)-phenylmethoxy]ethyl]piperidine; HT-11; Piperidine, 1-[2-[(4-chlorophenyl)phenylmethoxy]ethyl]-; Cloperastine (hydrochloride); Cloperastine (INN); Cloperastina; Cloperastinum; Cloperastinum [INN-Latin]; Cloperastina [INN-Spanish]; NSC-758635; HT 11; EINECS 223-042-3; 1-{2-[(4-chlorophenyl)(phenyl)methoxy]ethyl}piperidine; BRN 0275589; 1-(2-((4-Chlorophenyl)phenylmethoxy)ethyl)piperidine; cloperastine-fendizoate; Spectrum_001570; Prestwick0_000793; Prestwick1_000793; Prestwick2_000793; Prestwick3_000793; Spectrum2_001596; Spectrum3_001895; Spectrum4_000844; Spectrum5_001448; BSPBio_000926; BSPBio_003430; KBioGR_001447; KBioSS_002050; 5-20-02-00105 (Beilstein Handbook Reference); DivK1c_000840; SCHEMBL284715; SPBio_001592; SPBio_002865; BPBio1_001020; CHEMBL415087; 1- 2-((p-Chloro-alpha-phenylbenzyl)oxy)ethyl piperidine; 1-{2-((p-Chloro-alpha-phenylbenzyl)oxy)ethyl}piperidine; DTXSID7048532; CHEBI:94448; KBio1_000840; KBio2_002050; KBio2_004618; KBio2_007186; KBio3_002933; NINDS_000840; Piperidine, 1-(2-((p-chloro-alpha-phenylbenzyl)oxy)ethyl)-; BDBM50237287; STK646871; AKOS005577799; DB09002; NSC 758635; IDI1_000840; NCGC00178069-01; NCGC00178069-02; NCGC00178069-03; M201; SBI-0051861.P002; AB00053681; FT-0746924; VU0244436-2; D03557; AB00053681_08; Q2055825; BRD-A80908310-003-05-4; BRD-A80908310-003-08-8; 1-[2-[(4-chlorophenyl)-phenyl-methoxy]ethyl]piperidine; 1-(2-[(4-Chlorophenyl)(phenyl)methoxy]ethyl)piperidine #; 1-(2-[(p-Chloro-.alpha.-phenylbenzyl)oxy]ethyl)piperidine; Piperidine, 1-(2-((p-chloro-.alpha.-phenylbenzyl)oxy)ethyl)-; Piperidine, 1-(2-((4-chlorophenyl)phenylmethoxy)ethyl)- (9CI); Piperidine, 1-[2-[(4-chlorophenyl)phenylmethoxy]ethyl]-, hydrochloride"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:94448	DB09002	.	.	329.9	C20H24ClNO	12.5	318	4.8	23	0	2	6	"1S/C20H24ClNO/c21-19-11-9-18(10-12-19)20(17-7-3-1-4-8-17)23-16-15-22-13-5-2-6-14-22/h1,3-4,7-12,20H,2,5-6,13-16H2"	C1CCN(CC1)CCOC(C2=CC=CC=C2)C3=CC=C(C=C3)Cl	FLNXBVJLPJNOSI-UHFFFAOYSA-N
DG00722	Eflornithine	3009	"EFLORNITHINE; 70052-12-9; Ornidyl; 2-(Difluoromethyl)ornithine; dfmo; 2,5-diamino-2-(difluoromethyl)pentanoic acid; Difluoromethylornithine; Vaniqa; alpha-Difluoromethylornithine; 2-(Difluoromethyl)-DL-ornithine; Eflornithine free base; alpha-(Difluoromethyl)-DL-ornithine; Difluromethylornithine; RMI 71782; 67037-37-0; DL-.alpha.-Difluoromethylornithine; CHEMBL830; DFMO HCl; CHEBI:41948; 70052-12-9 (free base); NSC337250; Eflornithinum; Eflornitina; Eflornithinum [Latin]; Eflornitina [Spanish]; 2,5-diamino-2-(difluoromethyl)pentanoic acid.; .alpha.-DFMO HCl; DFMO (growth regulator); Eflornithine [INN:BAN]; 70050-56-5; L-DFMO;L-RMI71782;L-alpha-difluoromethylornithine; DL-alpha-(Difluoromethyl)ornithine; DL-Ornithine, monohydrochloride; MDL 71782; Eflornithine (INN); CCRIS 3295; Ornithine, 2-(difluoromethyl)-; NSC-337250; DL-Ornithine, 2-(difluoromethyl)-; (-)-2-Difluoromethylornithine; BRN 2250529; alpha,delta-Diamino-alpha-(difluoromethyl)valeric acid; SR-01000076229; C6H12F2N2O2; HSDB 7923; alpha-DFMO; (RS)-eflornithine; RFI 7178; Lopac0_000429; SCHEMBL26327; GTPL5176; 2-(difluoromethyl)-L-ornithine; alpha-difluoromethyl-dl-ornithine; DTXSID3020467; H-DL-(a-Difluoromethyl)Orn-OH; BCP10516; HY-B0744; 2-(difluoromethyl)ornithine (DMFO); BDBM50028197; HSCI1_000267; MFCD00221766; AKOS006281180; CCG-204521; DB06243; SDCCGSBI-0050414.P002; NCGC00015316-02; NCGC00015316-03; NCGC00015316-06; NCGC00015316-15; NCGC00162152-01; K100; 2-difluoromethyl-2,5-diaminopentanoic acid; DB-055371; FT-0630795; FT-0720946; FT-0775156; 2-(difluoromethyl)-2,5-diaminopentanoic acid;; C07997; D07883; 020E916; A936641; Q424751; (RS)-2,5-diamino-2-(difluoromethyl)pentanoic acid; DFMO;MDL71782;RMI71782;; A-difluoromethylornithine; SR-01000076229-10"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB06243	DR00843	.	182.17	C6H12F2N2O2	89.3	166	-2.9	12	3	6	5	"1S/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,12)"	C(CC(C(F)F)(C(=O)O)N)CN	VLCYCQAOQCDTCN-UHFFFAOYSA-N
DG00724	Dicyclomine	3042	"Dicyclomine; Dicycloverin; Dicycloverine; Bentyl; Bentylol; Diocyl; Wyovin; 77-19-0; Di-syntramine; Dicicloverina; Dicycloverinum; Merbentyl; Procyclomin; Bentomine; Mamiesan; Sawamin; Atumin; Dyspas; 2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate; Oxityl-P; Diocyl hydrochloride; Wyovin hydrochloride; UNII-4KV4X8IF6V; Dicycloverin hydrochloride; [1,1'-Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester; (1,1'-Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; 4KV4X8IF6V; CHEMBL1123; 2-(diethylamino)ethyl 1-cyclohexylcyclohexanecarboxylate; 2-(diethylamino)ethyl 1,1'-bi(cyclohexyl)-1-carboxylate; CHEBI:4514; (Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; Bicyclohexyl-1-carboxylic acid 2-diethylamino-ethyl ester; NCGC00015368-06; Diethylaminocarbethoxybicyclohexyl hydrochloride; Dicymine; Dicycloverinum [INN-Latin]; Dicicloverina [INN-Spanish]; DSSTox_CID_2926; DSSTox_RID_76790; DSSTox_GSID_22926; Bentyl hydrochloride; Bentylol; Dicyclomine; Dicycloverin; Dicycloverine; Bentylol hydrochloride; Dicycloverine [INN:BAN]; CAS-77-19-0; Dicymine (TN); Dicyclomine [INN]; Dicycloverine (INN); HSDB 3058; NSC-404381; EINECS 201-009-4; Bicyclohexyl-1-carbonsaeure-2'diethylaminoethylester; Byclomine; Kolantyl; [Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester; Bis(cyclohexyl)carboxylic acid diethylaminoethyl ester hydrochloride; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate; Spectrum_000934; Prestwick0_000048; Prestwick1_000048; Prestwick2_000048; Prestwick3_000048; Spectrum2_000590; Spectrum3_000388; Spectrum4_000509; Spectrum5_000873; Lopac-D-7909; Dicycloverine (Dicyclomine); SCHEMBL3317; Lopac0_000432; BSPBio_000175; BSPBio_002175; GTPL355; KBioGR_001057; KBioSS_001414; DivK1c_000162; SPBio_000440; SPBio_002096; BPBio1_000193; DTXSID1022926; CURUTKGFNZGFSE-UHFFFAOYSA-; KBio1_000162; KBio2_001414; KBio2_003982; KBio2_006550; KBio3_001395; NINDS_000162; HMS3604H12; ZINC1530613; Tox21_113571; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate hydrochloride; BDBM50010101; NSC404381; STL356799; [Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester hydrochloride; AKOS022107181; Tox21_113571_1; CCG-204524; DB00804; MCULE-9110194493; SDCCGSBI-0050417.P005; CAS-67-92-5; IDI1_000162; NCGC00015368-01; NCGC00015368-02; NCGC00015368-03; NCGC00015368-04; NCGC00015368-05; NCGC00015368-07; NCGC00015368-08; NCGC00015368-11; NCGC00015368-17; NCGC00016300-01; NCGC00024386-03; NCGC00024386-04; SBI-0050417.P004; AB00053456; WLN: L6TJ A- AL6TJ AVO2N2&2 &GH; (Bicyclohexyl)-1-carboxylic acid, hydrochloride; C06951; D07820; [1, 2-(diethylamino)ethyl ester, hydrochloride; AB00053456_14; AB00053456_15; L000680; Q2662662; 2-diethylaminoethyl 1-cyclohexylcyclohexanecarboxylate; BRD-K68507560-003-05-5; BRD-K68507560-003-15-4; .beta.-Diethylaminoethyl-1-cyclohexylhexahydrobenzoate hydrochloride; .beta.-Diethylaminoethyl 1-cyclohexylcyclohexanecarboxylate hydrochloride; 104959-55-9"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4514	DB00804	DR00767	DR2280	309.5	C19H35NO2	29.5	326	5.5	22	0	3	8	"1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3"	CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2	CURUTKGFNZGFSE-UHFFFAOYSA-N
DG00725	Diethylcarbamazine	3052	"Diethylcarbamazine; 90-89-1; N,N-diethyl-4-methylpiperazine-1-carboxamide; Carbamazine; Diethyl carbamazine; Carbilazine; Ethodryl; Notezine; Bitirazine; Caricide; Cypip; Ditrazine Base; Caracide; Spatonin; N,N-Diethyl-4-methyl-1-piperazinecarboxamide; 1-Piperazinecarboxamide, N,N-diethyl-4-methyl-; N,N-Diethylcarbamazine; UNII-V867Q8X3ZD; RP 3799; 84L; CHEBI:4527; V867Q8X3ZD; Bitirazine; Caracide;Carbamazine; MMV002816; Diaethylcarbamazinum; Dietilcarbamazina; Diethylcarbamazinum; Diethylcarbamazine [INN:BAN]; Camin; Diethylcarbamazinum [INN-Latin]; Dietilcarbamazina [INN-Spanish]; NSC1364; Camin (TN); Diethylcarbamazine (INN); EINECS 202-023-3; 1-Diethylcarbamoyl-4-Methylpiperazine; BRN 0143029; AI3-19612; 1-Diethylcarbamyl-4-methylpiperazine; 1-Methyl-4-diethylcarbamoylpiperazine; Banocide (Salt/Mix); Caritrol (Salt/Mix); Nemacide (Salt/Mix); Spectrum_000938; NN-Diethyl-4-methyl-1-piperazinecarboxamide; Prestwick0_000284; Prestwick1_000284; Prestwick2_000284; Prestwick3_000284; Spectrum2_001022; Spectrum3_000390; Spectrum4_000511; Spectrum5_000877; diethyl carbamazine citrate; CHEMBL684; EC 202-023-3; SCHEMBL67289; BSPBio_000188; BSPBio_002179; KBioGR_001081; KBioSS_001418; 4-23-00-00225 (Beilstein Handbook Reference); DivK1c_000548; SPBio_001203; SPBio_002407; BPBio1_000208; ZINC1288; DTXSID1022928; KBio1_000548; KBio2_001418; KBio2_003986; KBio2_006554; KBio3_001399; NINDS_000548; HMS3604F12; 1-Diethylcarbamoyl-4-methylpiperzine; HY-12642A; MFCD00023288; AKOS003268016; DB00711; DS-9360; MCULE-7296820622; IDI1_000548; s10791; NCGC00178778-01; NCGC00178778-02; NCGC00178778-07; SBI-0051345.P003; DB-080764; R.P. 3799; 1-(N,N-Diethylcarbamoyl)-4-methylpiperazine; AB00053457; CS-0013568; FT-0624832; C07968; D07825; N,N-diethyl-4-methyl-piperazine-1-carboxamide; AB00053457_12; Q409267; SR-01000759234-8; BRD-K45542189-048-05-6; BRD-K45542189-048-15-5"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4527	DB00711	.	.	199.29	C10H21N3O	26.8	184	0.3	14	0	2	2	"1S/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3"	CCN(CC)C(=O)N1CCN(CC1)C	RCKMWOKWVGPNJF-UHFFFAOYSA-N
DG00727	Diphenhydramine	3100	"Diphenhydramine; 58-73-1; Benadryl; Benzhydramine; 2-(Benzhydryloxy)-N,N-dimethylethanamine; Alledryl; Probedryl; Dihidral; Antistominum; Benzhydraminum; Benzhydroamina; Diphantine; Diphenylhydramine; Difenhydramin; Allergical; Bagodryl; Baramine; Benachlor; Benadrin; Benodine; Benzantine; Benzhydril; Betramin; Debendrin; Dermistina; Dermodrin; Desentol; Diabenyl; Diabylen; Dibondrin; Difedryl; Drylistan; Histaxin; Hyadrine; Ibiodral; Medidryl; Mephadryl; Novamina; Syntedril; Amidryl; Antomin; Benapon; Benodin; Benylan; Benylin; Dabylen; Dylamon; Nausen; Antitussive; Difenidramina; Dimedrol base; Difenhidramina; Allergina; Benzhydryl; Hydramine; Beldin; Dibenil; Diphen; Silphen; Belix; Diphenhydraminum; 2-(Benzhydryloxy)-N,N-dimethylethylamine; O-Benzhydryldimethylaminoethanol; Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-; Dimehydrinate; FAR 90X2; 2-(diphenylmethoxy)-N,N-dimethylethanamine; alpha-(2-Dimethylaminoethoxy)diphenylmethane; PM 255; beta-Dimethylaminoethanol diphenylmethyl ether; N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine; 2-(Diphenylmethoxy)-N,N-dimethylethylamine; UNII-8GTS82S83M; N-(Benzhydryloksy-etylo)dwumetyloamina; 2-benzhydryloxy-N,N-dimethylethanamine; [2-(diphenylmethoxy)ethyl]dimethylamine; Automin; Ethylamine, N,N-dimethyl-2-(diphenylmethoxy)-; CHEMBL657; 2-diphenylmethoxy-N,N-demthylethanamine; beta-dimethylaminoethyl benzhydryl ether; N-[2-(BENZHYDRYLOXY)ETHYL]-N,N-DIMETHYLAMINE; 58-73-1 (free base); 8GTS82S83M; CHEBI:4636; Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-; Dimedrolum; Allergan; Benzantin; NCGC00015335-07; Allergeval; Dibendrin; Dimedryl; Dryistan; Rigidil; Syntodril; Aleryl; Ben-allergin; Allergan B; DSSTox_CID_2949; Difenidramina [Italian]; DSSTox_RID_76803; DSSTox_GSID_22949; Difenhidramina [INN-Spanish]; Diphenhydraminum [INN-Latin]; Diphenhydramine [INN:BAN:JAN]; CAS-58-73-1; beta-Dimethylaminoethylbenzhydrylether; Restamin (TN); 2-Diphenylmethoxy-N,N-dimethylethylamine; CCRIS 1959; HSDB 3066; N-[2-(Diphenylmethoxy)ethyl]-N,N-dimethylamine; Benadryl (hydrochloride); NCGC00015335-09; CAS-147-24-0; EINECS 200-396-7; N-(Benzhydryloksy-etylo)dwumetyloamina [Polish]; beta-Dimethylamino-aethyl-benzhydryl-aether [German]; BRN 1914136; Difenhydramine; Diphenhdyra; Dobacen; beta-Dimethylamino-aethyl-benzhydryl-aether; Allergan (Salt/Mix); Eldadryl (Salt/Mix); Histacyl (Salt/Mix); Restamin (Salt/Mix); Spectrum_000980; 2-benzhydryloxyethyl-N,N-dimethylammonium; Antitussive (Salt/Mix); Prestwick0_000065; Prestwick1_000065; Prestwick2_000065; Prestwick3_000065; Spectrum2_000961; Spectrum3_000400; Spectrum4_000520; Spectrum5_000915; Lopac-D-3630; 2-[(diphenylmethyl)oxy]-N,N-dimethylethanamine; EC 200-396-7; Cambridge id 6699980; SCHEMBL4064; Lopac0_000377; Oprea1_254625; BSPBio_000249; BSPBio_002219; Dimethylamine benzhydryl ester; KBioGR_001099; KBioSS_001460; 2PM; MLS002222276; BIDD:GT0152; Diphenhydramine (JP17/INN); DivK1c_000368; SPBio_000961; SPBio_002170; BPBio1_000275; GTPL1224; 2-(Benzhydryloxy)-N,N-dimethylethylamine, hydrochloride; DTXSID4022949; KBio1_000368; KBio2_001460; KBio2_004028; KBio2_006596; KBio3_001439; ZINC20244; N,N-Dimethyl-2-(diphenylmethoxy)-ethylamine hydrochloride; NINDS_000368; O-Benzhydryl(dimethylamino)ethanol; HMS2089E06; HMS2230L19; HMS3373E03; HY-B0303; Tox21_110127; BDBM50017674; MFCD00274173; MFCD31699960; NSC665800; STK103720; AKOS003658554; Tox21_110127_1; (2-Benzhydryloxy-ethyl)-dimethyl-amine; CCG-204472; DB01075; GS-3196; MCULE-6260910826; NSC-665800; SDCCGSBI-0050365.P005; IDI1_000368; NCGC00015335-01; NCGC00015335-02; NCGC00015335-03; NCGC00015335-04; NCGC00015335-05; NCGC00015335-06; NCGC00015335-08; NCGC00015335-10; NCGC00015335-11; NCGC00015335-12; NCGC00015335-13; NCGC00015335-14; NCGC00015335-17; NCGC00015335-28; NCGC00024414-03; NCGC00024414-04; NCGC00024414-06; AC-13704; NCI60_002916; NCI60_022782; S 51; SMR001307259; SY246339; 2-(Benzohydryloxy)-N,N-dimethylethylamine; N,N-Dimethyl-2-diphenylmethyloxyethylamine; SBI-0050365.P004; 2-(Benzhydryloxy)-N,N-dimethylethanamine #; .beta.-(Dimethylamino)ethyl benzhydryl ether; .beta.-Dimethylamino-aethyl-benzhydryl-aether; AB00053460; CS-0013574; D4744; Ethylamine, 2-diphenylmethoxy-N,N-dimethyl-; FT-0625221; 2-[di(phenyl)methoxy]-N,N-dimethylethanamine; .alpha.-(2-Dimethylaminoethoxy)diphenylmethane; C06960; D00300; F19220; AB00053460-22; AB00053460-23; AB00053460_24; AB00053460_25; .beta.-(Dimethylamino)ethanol diphenylmethyl ether; 274D173; A831996; DIPHENHYDRAMINE; ANTISTOMINUM; BENZHYDRAMINE; Diphenylmethanol, (N,N-dimenthylaminoethyl) ether; L000227; Q413486; Q-201002; BRD-K47278471-003-05-7; BRD-K47278471-003-15-6; 110491-04-8"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4636	DB01075	DR00385	DR0514	255.35	C17H21NO	12.5	211	3.3	19	0	2	6	"1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3"	CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2	ZZVUWRFHKOJYTH-UHFFFAOYSA-N
DG00731	Droperidol	3168	"Droperidol; 548-73-2; Droleptan; Inapsine; Dehydrobenzperidol; Dridol; Properidol; Sintodril; Sintosian; Inapsin; Vetkalm; Halkan; Deidrobenzperidolo; Inopsin; Innovar; Inappin; Innovan; McN-JR-4749; Inoval; Dehidrobenzperidol; Droperidolum; Droperidolo; Leptofen; Thalamanol; Thalamonal; Innovar-vet; Dihidrobenzperidol; R-4749; McN-JR 4749; component of Innovar; R 4749; NSC 169874; 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one; UNII-O9U0F09D5X; 1-(1-(3-(p-Fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-(1-(4-(p-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; CHEMBL1108; 1-[1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; MLS000028671; CHEBI:4717; O9U0F09D5X; 2H-Benzimidazol-2-one, 1-[1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1,3-dihydro-; Dehydrobenzoperidol; MFCD00083290; NSC169874; NSC-169874; 1-(1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-benzo[d]imidazol-2(3H)-one; 1-{1-[4-(4-Fluoro-phenyl)-4-oxo-butyl]-1,2,3,6-tetrahydro-pyridin-4-yl}-1,3-dihydro-benzoimidazol-2-one; 2H-Benzimidazol-2-one, 1-(1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridinyl)-1,3-dihydro-; NCGC00016504-01; CAS-548-73-2; Droperidolo [DCIT]; SMR000058855; DSSTox_CID_2973; DSSTox_RID_76811; DSSTox_GSID_22973; 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl}-2,3-dihydro-1H-benzo[d]imidazol-2-one; Droperidolum [INN-Latin]; Neurolidol; Ina.psi.ne; Ina.psi.n; Ino.psi.n; 1-[1-[4-(p-Fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 2-Benzimidazolinone, 1-(1-(3-(p-fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-; 2-Benzimidazolinone, 1-[1-[3-(p-fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-; Droleptan (TN); 1-(1-(4-(4-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridinyl)-1,3-dihydro-2H-benzimidazol-2-one; 1-(1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one; 3-[1-[4-(4-fluorophenyl)-4-oxidanylidene-butyl]-2,3,4,5-tetrahydropyridin-4-yl]-1~{H}-benzimidazol-2-one; CCRIS 9070; HSDB 3320; R4749; SR-05000001546; INAPSINE (TN); EINECS 208-957-8; BRN 0579168; Droperidol USP; 1-(1-[3-(p-fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-[1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1,3-dihydro-2h-benzimidazol-2-one; Prestwick_705; Innovar (Salt/Mix); Droperidol [USAN:USP:INN:BAN:JAN]; HS-0065; Leptanal (Salt/Mix); Leptofen (Salt/Mix); Spectrum_001220; Thalamonal (Salt/Mix); Innovar-vet (Salt/Mix); Opera_ID_1751; Prestwick0_000360; Prestwick1_000360; Prestwick2_000360; Prestwick3_000360; Spectrum2_001386; Spectrum3_001426; Spectrum4_000407; Spectrum5_001305; SCHEMBL41426; BSPBio_000459; BSPBio_003132; KBioGR_000674; KBioSS_001700; 5-24-02-00388 (Beilstein Handbook Reference); MLS000758203; MLS001148120; MLS001424134; MLS002153445; DivK1c_000103; SPECTRUM1501002; SPBio_001372; SPBio_002380; BPBio1_000505; Droperidol (JP17/USP/INN); GTPL7172; DTXSID6022973; HMS500F05; KBio1_000103; KBio2_001700; KBio2_004268; KBio2_006836; KBio3_002352; NINDS_000103; HMS1569G21; HMS1921B03; HMS2051L06; HMS2092O16; HMS2096G21; HMS2232M09; HMS3374B05; HMS3393L06; HMS3652M12; HMS3713G21; HMS3885N03; Pharmakon1600-01501002; HY-B1240; Tox21_110461; BDBM50017705; CCG-39004; NSC757819; s4096; STL453109; ZINC19796080; AKOS015960779; Tox21_110461_1; AC-3537; CCG-101004; CS-4886; DB00450; NC00254; NSC-757819; 1-1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl-2-benzimidazolinone; 3-[1-[4-(4-fluorophenyl)-4-oxo-butyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one; IDI1_000103; NCGC00016504-02; NCGC00016504-03; NCGC00016504-04; NCGC00016504-05; NCGC00016504-06; NCGC00016504-09; NCGC00016504-17; NCGC00094884-01; NCGC00094884-02; H920; SBI-0051628.P002; Droperidol 1.0 mg/ml in Dimethyl Sulfoxide; FT-0655846; SW220019-1; D00308; F17346; AB00052191_04; AB00052191_05; WLN: T56 BMVNJ D3- DT6N CUTJ A3VR DF; 548D732; A830387; L001006; Q174259; SR-05000001546-1; SR-05000001546-2; SR-05000001546-3; W-105600; BRD-K97158071-001-05-8; BRD-K97158071-001-08-2; Droperidol, British Pharmacopoeia (BP) Reference Standard; Droperidol, European Pharmacopoeia (EP) Reference Standard; Droperidol, United States Pharmacopeia (USP) Reference Standard; 2H-Benzimidazol-2-one,2,3,6-tetrahydro-4-pyridinyl]-1,3-dihydro-; 1-[1-[3-(p-Fluorobenzoyl)propyl]-1,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-[1-[4-(p-Fluorophenyl)-4-oxobutyl]-1,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-1-[3-(p-Fluorobenzoyl)propyl]-1,3,6-tetrahydro-4-pyridyl-2-benzimidazolinone; gamma-[4-(2-oxo-1-benzimidazolinyl)-1,2,3,6-tetrahydro-1-pyridyl]-p-fluorobutyrophenone; 1-(4-fluorophenyl)-4-[4-(2-hydroxy-1H-1,3-benzodiazol-1-yl)-1,2,3,6-tetrahydropyridin-1-yl]butan-1-one; 1-[1-[4-(4-fluorophenyl)-4-oxo-butyl]-3,6-dihydro-2H-pyridin-4-yl]-3H-benzoimidazol-2-one; 1-{1-[4-(4-Chloro-phenyl)-4-oxo-butyl]-1,2,3,6-tetrahydro-pyridin-4-yl}-1,3-dihydro-benzoimidazol-2-one(Droperidol); 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,5,6-tetrahydropyridin-4-yl] -1,3-dihydro-2H-benzimidazol}-2-one; 3-[1-[4-(4-fluorophenyl)-4-oxidanylidene-butyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one; USS"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4717	DB00450	DR00771	.	379.4	C22H22FN3O2	52.6	615	3.5	28	1	4	6	"1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)"	C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F	RMEDXOLNCUSCGS-UHFFFAOYSA-N
DG00735	Ethoxzolamide	3295	"Ethoxzolamide; Ethoxyzolamide; 452-35-7; Ethoxazolamide; 6-Ethoxy-2-benzothiazolesulfonamide; Ethamide; Etoxzolamide; Cardrase; 6-Ethoxy-1,3-benzothiazole-2-sulfonamide; Glaucotensil; Diuretic C; Redupresin; 2-Benzothiazolesulfonamide, 6-ethoxy-; 6-Ethoxybenzo[d]thiazole-2-sulfonamide; 6-Ethoxybenzothiazole-2-sulfonamide; 6-Ethoxyzolamide; 6-Ethoxybenzothiazole-2-sulphonamide; U-4191; NSC 10679; UNII-Z52H4811WX; CHEMBL18; Redupresin;L-643786;PNU-4191; MLS000028637; 6-Ethoxy-benzothiazole-2-sulfonic acid amide; Mingoral; CHEBI:101096; Z52H4811WX; 6-Ethoxy-2-benzothiazole8ulfonamide; MFCD00057089; NSC-10679; NCGC00018249-04; SMR000059148; DSSTox_CID_3021; DSSTox_RID_76834; DSSTox_GSID_23021; C9H10N2O3S2; Cardrase (TN); CAS-452-35-7; EZL; Ethoxzolamide [USP]; HSDB 3268; EINECS 207-199-5; BRN 0212240; Athamid; AI3-50805; 3caj; 3dcw; 3mdz; Ethoxzolamide, EZM; 3dd0; Opera_ID_1207; 6-(ethyloxy)-1,3-benzothiazole-2-sulfonamide; SCHEMBL63941; 4-27-00-04404 (Beilstein Handbook Reference); MLS001077357; GTPL6814; DTXSID1023021; BDBM10882; ZINC56721; HMS2093J03; HMS2094M03; HMS2233N09; HMS3373K15; HMS3715F20; HMS3746M15; Pharmakon1600-01505426; BCP24088; HY-B1480; NSC10679; PNU-4191; Tox21_110848; 2179AH; 6-ethoxy-2-benzothiazole sulfonamide; NSC759129; WLN: T56 BN DSJ CSZW GO2; AKOS015915628; Tox21_110848_1; CCG-213432; CS-7836; DB00311; MCULE-3766215049; NSC-759129; VS-0126; Benzothiazole, 6-ethoxy-2-sulfonamide-; NCGC00018249-01; NCGC00018249-02; NCGC00018249-03; NCGC00018249-05; NCGC00022533-04; NCGC00186657-01; 6-Ethoxy-2-benzothiazolesulfonamide, 97%; SBI-0206851.P001; 6-Ethoxy-1,3-benzothiazole-2-sulfonamide #; FT-0707866; SW220095-1; D02441; AB00383049_12; AB00383049_13; Q265352; SR-01000000236; L-643786; SR-01000000236-2; BRD-K18131774-001-10-1; Ethoxzolamide, United States Pharmacopeia (USP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:101096	DB00311	.	DR2284	258.3	C9H10N2O3S2	119	341	2	16	1	6	3	"1S/C9H10N2O3S2/c1-2-14-6-3-4-7-8(5-6)15-9(11-7)16(10,12)13/h3-5H,2H2,1H3,(H2,10,12,13)"	CCOC1=CC2=C(C=C1)N=C(S2)S(=O)(=O)N	OUZWUKMCLIBBOG-UHFFFAOYSA-N
DG00737	Fenofibrate	3339	"Fenofibrate; 49562-28-9; Procetofen; Lipantil; Tricor; Lipanthyl; Fenobrate; Lipidil; Secalip; Antara; Finofibrate; Lipoclar; Lipofene; Proctofene; Triglide; Fenogal; Lipirex; Sedufen; Elasterin; Fenoglide; Fenotard; Protolipan; Ankebin; Lipidex; Lipifen; Lipofen; Liposit; Lipsin; Nolipax; Fenofibratum [INN-Latin]; propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Fenofibrato [INN-Spanish]; Lipantil (TN); Tricor (TN); LF-178; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate; C20H21ClO4; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester; NSC 281319; UNII-U202363UOS; Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate; FNF; Elasterate; Procetofene; Luxacor; MFCD00133314; CHEMBL672; Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester; MLS000028515; CHEBI:5001; isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Lofibra; U202363UOS; Propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-, 1-methylethyl ester; NSC-281319; NCGC00015437-10; Fenofibrato; Fenofibratum; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate; SMR000058299; Supralip; CAS-49562-28-9; DSSTox_CID_9874; propan-2-yl 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoate; DSSTox_RID_78828; DSSTox_GSID_29874; TRICOR (MICRONIZED); Antara (micronized); Fenomax; Isopropyl 2-[p-(p-chlorobenzoyl)phenoxy]-2-methylpropionate; Pharmavit; FENOFIBRATE (MICRONIZED); Fulcro; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid isopropyl ester; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic Acid Isopropyl Ester; CIP-Fenofibrate; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1-methylethyl ester; LCP-FenoChol; LCP-Feno; Triglide (TN); Fenofibrate IDD-P; Lipofen (TN); Antara (TN); CCRIS 7282; SR-01000000091; EINECS 256-376-3; LF 178; BRN 2062462; Procetoken; Isopropyl 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionate; HSDB 7736; Fenofibrate,(S); GRS-027; Fenofibrate [USAN:USP:INN:BAN]; Prestwick_217; Fenofibrate micronized; Spectrum_001250; Opera_ID_328; Prestwick0_000275; Prestwick1_000275; Prestwick2_000275; Prestwick3_000275; Spectrum2_001390; Spectrum3_001431; Spectrum4_000413; Spectrum5_001479; Lopac-F-6020; Fenofibrate delayed release; EC 256-376-3; F 6020; SCHEMBL4670; Lopac0_000486; BSPBio_000150; BSPBio_003162; KBioGR_000706; KBioSS_001730; MLS001148191; MLS002548878; BIDD:GT0574; DivK1c_000557; Fenofibrate (JAN/USP/INN); SPECTRUM1501010; SPBio_001380; SPBio_002369; Fenofibrate, >=99%, powder; BPBio1_000166; Fenofibrate (Tricor, Trilipix); GTPL7186; DTXSID2029874; HMS501L19; KBio1_000557; KBio2_001730; KBio2_004298; KBio2_006866; KBio3_002382; NINDS_000557; HMS1568H12; HMS1921B17; HMS2090G20; HMS2092B05; HMS2095H12; HMS2231B14; HMS3259K03; HMS3261B13; HMS3369M13; HMS3649D20; HMS3655K12; HMS3712H12; isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoate; Pharmakon1600-01501010; ZINC584092; ALBB-028958; BCP21243; Tox21_110147; Tox21_300151; Tox21_500486; BDBM50085042; CCG-38996; NSC281319; NSC757822; s1794; AKOS005107777; Tox21_110147_1; AB03716; AC-4227; CS-0892; DB01039; LP00486; MCULE-9460650238; MS-2223; NC00452; NSC-757822; SDCCGSBI-0050470.P004; IDI1_000557; NCGC00015437-01; NCGC00015437-02; NCGC00015437-03; NCGC00015437-04; NCGC00015437-05; NCGC00015437-06; NCGC00015437-07; NCGC00015437-08; NCGC00015437-09; NCGC00015437-11; NCGC00015437-12; NCGC00015437-13; NCGC00015437-14; NCGC00015437-16; NCGC00015437-17; NCGC00015437-31; NCGC00021475-03; NCGC00021475-04; NCGC00021475-05; NCGC00021475-06; NCGC00021475-07; NCGC00021475-08; NCGC00253945-01; NCGC00261171-01; FENOFIBRATE (MICRONIZED) (fenofibrate; Fenofibrate, analytical reference material; HY-17356; SY052561; SBI-0050470.P003; DB-051642; AB00052196; EU-0100486; F0674; FT-0626400; FT-0654669; SW196525-4; C07586; D00565; J10318; AB00052196-15; AB00052196-16; AB00052196_17; AB00052196_18; 562F289; A827746; Q419724; Q-201111; SR-01000000091-2; SR-01000000091-5; SR-01000000091-6; SR-01000000091-8; BRD-K50388907-001-05-6; BRD-K50388907-001-18-9; BRD-K50388907-001-20-5; SR-01000000091-16; Z2768724415; Fenofibrate, European Pharmacopoeia (EP) Reference Standard; Isopropyl 2-(4-(4-chlorobenzoyl)-phenoxy)-2-methylpropanoate; 1-methylethyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoicacidisopropylester; Fenofibrate, United States Pharmacopeia (USP) Reference Standard; Isopropyl (4''-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1-methyl-ethyl ester; Fenofibrate, Pharmaceutical Secondary Standard; Certified Reference Material; isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoate;Fenofibrate; Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethylester"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:5001	DB01039	DR00415	DR0688	360.8	C20H21ClO4	52.6	458	5.2	25	0	4	7	"1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3"	CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl	YMTINGFKWWXKFG-UHFFFAOYSA-N
DG00739	Fleroxacin	3357	"Fleroxacin; 79660-72-3; Megalone; Fleroxicin; Megalocin; Quinodis; Fleroxacino; Fleroxacinum; 6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; Fleroxacine; AM-833; Ro 23-6240; FLRX; Fleroxacin (Quinodis); Ro 23-6240/000; 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; UNII-N804LDH51K; Ro-236240; CHEBI:31810; 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; N804LDH51K; NCGC00167558-01; Fleroxacine [French]; Fleroxacinum [Latin]; Ro-236240000; Fleroxacino [Spanish]; RO 23-6240;AM-833; AM 833; 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid; DSSTox_CID_26714; DSSTox_RID_81846; DSSTox_GSID_46714; 3-Quinolinecarboxylic acid, 1,4-dihydro-6,8-difluoro-1-(2-fluoroethyl)-7-(4-methyl-1-piperazinyl)-4-oxo-; Megalosin; Megalocin (TN); Megalone (TN); SMR000466302; CAS-79660-72-3; CCRIS 3972; SR-01000759379; BRN 4300996; Fleroxacin (JAN/USAN/INN); Fleroxacin,(S); Fleroxacin [USAN:INN:BAN:JAN]; MFCD00864880; F0646; Ro-23-6240/000; CHEMBL6273; SCHEMBL48145; 3-Quinolinecarboxylic acid, 6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-; MLS000759401; MLS006010715; DTXSID1046714; HMS2090I08; HMS3715B11; BCP28939; HY-B0414; RKL10075; ZINC3786299; Tox21_112553; BDBM50247892; s2469; ZINC03786299; AKOS015907011; Tox21_112553_1; CCG-221125; DB04576; KS-5124; NCGC00167558-02; AM-833;AM833;AM 833; FT-0630874; D01716; Fleroxacin, VETRANAL(TM), analytical standard; J10168; AB00640001-02; AB00640001-03; AB00640001_04; 660F723; A839732; Q3746573; SR-01000759379-2; SR-01000759379-3; 6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid-; 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid;Fleroxacin; 79660-53-0"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31810	DB04576	.	.	369.34	C17H18F3N3O3	64.099	595	-0.1	26	1	9	4	"1S/C17H18F3N3O3/c1-21-4-6-22(7-5-21)15-12(19)8-10-14(13(15)20)23(3-2-18)9-11(16(10)24)17(25)26/h8-9H,2-7H2,1H3,(H,25,26)"	CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F	XBJBPGROQZJDOJ-UHFFFAOYSA-N
DG00746	Hydroxyurea	3657	"Hydroxyurea; 127-07-1; Hydroxycarbamide; N-Hydroxyurea; 1-HYDROXYUREA; Hydrea; Oxyurea; Carbamoyl oxime; Biosupressin; Hydroxycarbamine; Urea, hydroxy-; Onco-carbide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamyl hydroxamate; Hydura; Litalir; Hydurea; N-Carbamoylhydroxylamine; Droxia; Hidrix; Hydroxicarbamidum; Siklos; Hydroxylurea; Hydreia; Litaler; Idrossicarbamide [DCIT]; Hidroxicarbamida; Hydroxyharnstoff; Hydroxycarbamidum; Carbamohydroxyamic acid; N-Hydroxymocovina; Hydroxylamine, N-carbamoyl-; SQ 1089; Hydroxyharnstoff [German]; N-Hydroxymocovina [Czech]; hydroxy urea; NCI-C04831; Hydroxylamine, N-(aminocarbonyl)-; SK 22591; Hydroxycarbamidum [INN-Latin]; Hidroxicarbamida [INN-Spanish]; urea, N-hydroxy-; HU; CCRIS 958; HYDROXY-UREA; NSC 32065; UNII-X6Q56QN5QC; NSC32065; AI3-51139; Hydroxyurea (Cytodrox); MFCD00007943; CHEMBL467; SQ-1089; X6Q56QN5QC; CHEBI:44423; NSC-32065; 8029-68-3; NCGC00015520-03; Hydroxycarbamid; Oncocarbide; Idrossicarbamide; DSSTox_CID_5438; DSSTox_RID_77787; DSSTox_GSID_25438; NHY; Hydroxyurea (D4); N-HYDROXY UREA; Mylocel; carbamide oxide; CAS-127-07-1; SMR000059149; Hydroxyurea (USP); Droxia (TM); Droxia (TN); Hydrea (TM); hydroxyaminomethanamide; HSDB 6887; SR-01000075919; DRG-0253; EINECS 204-821-7; HYDREA (TN); Hydroxyurea [USAN:USP]; BRN 1741548; Hydroxycarbamide (JAN/INN); hydroxyl urea; Xromi; S-phase/G-1 interface inhibitor; aminohydroxamic acid; carbamic acid oxime; Carbomohydroxamic acid; Spectrum_000909; Hydroxycarbamide [INN]; WLN: ZVMQ; Hydrea (Bristol Meyers); Spectrum2_000064; Spectrum3_000462; Spectrum4_000012; Spectrum5_000836; Lopac-H-8627; MolMap_000029; H 8627; NCIMech_000139; Hydroxyurea, 98%, powder; Lopac0_000596; BSPBio_002164; KBioGR_000383; KBioSS_001389; 4-03-00-00170 (Beilstein Handbook Reference); hydroxycarbamide (hydroxyurea); MLS001332381; MLS001332382; MLS002153389; DivK1c_000556; N-(Aminocarbonyl)hydroxylamine; SPECTRUM1500344; SPBio_000247; GTPL6822; DTXSID6025438; tetratogen: inhibits ribonucleoside diphosphate reductase; HMS501L18; KBio1_000556; KBio2_001389; KBio2_003957; KBio2_006525; KBio3_001384; NINDS_000556; Bio1_000451; Bio1_000940; Bio1_001429; HMS1920F09; HMS2091L17; HMS2234I03; HMS3261H14; HMS3373G18; HMS3655K20; HMS3869C03; NCI C04831; Pharmakon1600-01500344; ACT02611; ALBB-028465; AMY40858; HY-B0313; STR02555; ZINC8034120; Tox21_110168; Tox21_300319; Tox21_500596; BBL009928; BDBM50017811; CCG-35236; NSC757072; s1896; STL145898; AKOS005716276; AKOS006222547; Tox21_110168_1; ZINC100019199; DB01005; LP00596; MCULE-9465284053; NSC-757072; SDCCGSBI-0050578.P006; IDI1_000556; NCGC00015520-01; NCGC00015520-02; NCGC00015520-04; NCGC00015520-05; NCGC00015520-06; NCGC00015520-07; NCGC00015520-08; NCGC00015520-09; NCGC00015520-10; NCGC00015520-11; NCGC00015520-20; NCGC00093974-01; NCGC00093974-02; NCGC00093974-03; NCGC00093974-04; NCGC00093974-05; NCGC00254007-01; NCGC00261281-01; AC-22674; NCI60_002773; SBI-0050578.P004; DB-041849; EU-0100596; FT-0627160; FT-0627175; FT-0670210; H0310; SW218071-2; C07044; D00341; Hydroxyurea, Vetec(TM) reagent grade, >=98%; AB00052018-09; AB00052018-10; AB00052018_11; AB00052018_12; 127H071; A805636; Q212272; J-504798; SR-01000075919-1; SR-01000075919-3; SR-01000075919-8; E0723DBA-5AF3-49D1-B5F6-59420AB87AC9; F8880-0905; Z1522566612; Hydroxycarbamide, European Pharmacopoeia (EP) Reference Standard; Hydroxyurea, United States Pharmacopeia (USP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:44423	DB01005	DR01177	.	76.055	CH4N2O2	75.4	42.9	-1.8	5	3	2	0	"1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)"	C(=O)(N)NO	VSNHCAURESNICA-UHFFFAOYSA-N
DG00748	Ibudilast	3671	"Ibudilast; 50847-11-5; Ketas; KC-404; Ibudilastum; Ke Tas; Ibudilastum [Latin]; MN-166; Ibudilast [INN:JAN]; Eyevinal; AV-411; UNII-M0TTH61XC5; Ketas (TN); 3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine; 2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one; 1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)-2-methylpropan-1-one; 3-Isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine; Tocris-1694; Lopac-I-0157; 1-Propanone, 2-methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]-; 2-Isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine; AV411; MFCD00864808; M0TTH61XC5; CHEMBL19449; KC-404;AV-411;MN-166; NCGC00015542-05; 2-Methyl-1-[2-(Propan-2-Yl)pyrazolo[1,5-A]pyridin-3-Yl]propan-1-One; 1-Propanone, 2-methyl-1-(2-(1-methylethyl)pyrazolo(1,5-a)pyridin-3-yl)-; DSSTox_CID_28933; DSSTox_RID_83199; 2-isopropyl-3-isobutyrylpyrazolo[1,5-a]pyridine; DSSTox_GSID_49007; Ibudilast (JAN/INN); CAS-50847-11-5; SR-01000075927; AV 411; BRN 0656579; Pinatos; I0157_SIGMA; Ibudilast,(S); Pyrazolo(1,5-a)pyridine, 3-isobutyryl-2-isopropyl-; 1-(2-Isopropylpyrazolo(1,5-a)pyridin-3-yl)-2-methyl-1-propanone; Ibudilast (JP17/INN); I 0157; Lopac0_000599; SCHEMBL30390; 5-24-03-00396 (Beilstein Handbook Reference); MLS000862198; GTPL7399; ZINC4234; DTXSID7049007; CHEBI:31684; BCPP000209; HMS2089B21; HMS2233H08; HMS3261H20; HMS3268O11; HMS3374P02; HMS3412B20; HMS3676B20; HMS3715L09; HMS3886M03; BCP02335; HY-B0763; Tox21_113503; Tox21_500599; BDBM50240404; s4837; Ibudilast, >=99% (HPLC), solid; 2-Methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl] 1-propanone; AKOS015895123; Tox21_113503_1; AC-1044; BCP9000768; CCG-204688; DB05266; LP00599; SB19092; SDCCGSBI-0050581.P002; NCGC00015542-01; NCGC00015542-02; NCGC00015542-03; NCGC00015542-04; NCGC00015542-06; NCGC00015542-07; NCGC00015542-17; NCGC00025261-01; NCGC00025261-02; NCGC00025261-03; NCGC00025261-04; NCGC00261284-01; SMR000326961; SY051343; EU-0100599; FT-0654591; FT-0670255; I0740; D01385; F20666; AB00698306-06; 3-Isobutyryl-2-isopropyl-Pyrazolo(1,5-a)pyridine; 847I115; A828320; H-20256; L003042; Q261167; J-512714; SR-01000075927-1; SR-01000075927-3; SR-01000075927-6; BRD-K16444452-001-03-4; 1-(2-isopropylH-pyrazolo[1,5-a]pyridin-3-yl)-2-methylpropan-1-one; 1-(2-Isopropyl-pyrazolo[1,5-a]pyridin-3-yl)-2-methyl-propan-1-one; 1-(2-Isopropyl-pyrazolo[1,5-alpha]pyridin-3-yl)-2-methyl-propan-1-one; 1-(2-isopropylpyrazolo[1,5-alpha]pyridin-3-yl)-2-methylpropan-1-one; 2-methyl-1-(2-propan-2-yl-3-pyrazolo[1,5-a]pyridinyl)-1-propanone; 2-methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]-1-propanone; (Ibudilast)1-(2-Isopropyl-pyrazolo[1,5-a]pyridin-3-yl)-2-methyl-propan-1-one; 1-(2-Isopropylpyrazolo[1,5-a]pyridin-3-yl)-2-methylpropan-1-one (Ibudilast); AVL"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31684	DB05266	.	.	230.31	C14H18N2O	34.4	288	3	17	0	2	3	"1S/C14H18N2O/c1-9(2)13-12(14(17)10(3)4)11-7-5-6-8-16(11)15-13/h5-10H,1-4H3"	CC(C)C1=NN2C=CC=CC2=C1C(=O)C(C)C	ZJVFLBOZORBYFE-UHFFFAOYSA-N
DG00750	Lidocaine	3676	"Lidocaine; 137-58-6; Lignocaine; Xylocaine; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; Lidoderm; Anestacon; Esracaine; Duncaine; Alphacaine; Cappicaine; Gravocain; Isicaina; L-Caine; Leostesin; Maricaine; Xylestesin; Xylocain; Xylocitin; Solcain; Isicaine; Rucaina; Xilina; Xycaine; Xylotox; Cito optadren; Lida-Mantle; Dalcaine; 2-(Diethylamino)-2',6'-acetoxylidide; Xyloneural (free base); Cuivasil; Jetocaine; Lidocainum; Remicaine; Xilocaina; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide; Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-; Diethylaminoaceto-2,6-xylidide; ELA-Max; 2',6'-Acetoxylidide, 2-(diethylamino)-; alpha-Diethylamino-2,6-dimethylacetanilide; Lidocaton; alfa-Dietilamino-2,6-dimetilacetanilide; CHEBI:6456; UNII-98PI200987; Xylocaine (TN); CHEMBL79; MFCD00026733; LIDOPEN; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; MLS000069724; Dentipatch; Lignocainum; Xllina; NSC-40030; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; Lidocaine (VAN); .alpha.-Diethylaminoaceto-2,6-xylidide; NCGC00015611-10; Xilocaina [Italian]; Dilocaine; Lidocaina; SMR000058189; .alpha.-(Diethylamino)-2,6-acetoxylidide; Lidocaine Base; .alpha.-Diethylamino-2,6-dimethylacetanilide; .omega.-Diethylamino-2,6-dimethylacetanilide; 98PI200987; Lidocainum [INN-Latin]; DSSTox_CID_25166; DSSTox_RID_80716; DSSTox_GSID_45166; Lidocaina [INN-Spanish]; N-(2,6-Dimethylphenyl)-N2,N2-diethylglycinamide; 2-(Diethylamino)-N-(2,6-Dimethylphenyl)ethanamide; EMBOLEX; Versatis; Ztilido; ZTlido; 2-(Diethylamino)-N-(2,6-dimethylphenyl)-acetamide; Dentipatch (TN); CAS-137-58-6; LQZ; HSDB 3350; EINECS 205-302-8; NSC 40030; alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; BRN 2215784; Qualigens; Xyline; Lignocaine base; LidocaineHClH2O; Lidocaine [USP:INN:BAN:JAN]; Lidocaine, powder; N1-(2,6-dimethylphenyl)-N2,N2-diethylglycinamide; Zingo (Salt/Mix); CDS1_000283; Lidocaine (Alphacaine); Spectrum_001118; Lidothesin (Salt/Mix); Xyloneural (Salt/Mix); Opera_ID_385; Maybridge1_002571; Prestwick0_000050; Prestwick1_000050; Prestwick2_000050; Prestwick3_000050; Spectrum2_001343; Spectrum3_001392; Spectrum4_000070; Spectrum5_001549; Lopac-L-5647; Lidaform HC (Salt/Mix); Epitope ID:116205; Lidamantle HC (Salt/Mix); 2', 2-(diethylamino)-; Neosporin Plus (Salt/Mix); Lopac0_000669; SCHEMBL15689; BSPBio_000179; BSPBio_001359; BSPBio_003004; KBioGR_000079; KBioGR_000599; KBioSS_000079; KBioSS_001598; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; 4-12-00-02538 (Beilstein Handbook Reference); MLS000758263; MLS001074177; MLS001423964; BIDD:GT0342; Diethylaminoacet-2,6-xylidide; DivK1c_000174; DivK1c_001323; Lidocaine, analytical standard; SPBio_001525; SPBio_002100; Lidocaine (JP17/USP/INN); ALGRX 3268; ALGRX-3268; BPBio1_000197; GTPL2623; DTXSID1045166; SCHEMBL17967359; HMS548M19; KBio1_000174; KBio2_000079; KBio2_001598; KBio2_002647; KBio2_004166; KBio2_005215; KBio2_006734; KBio3_000157; KBio3_000158; KBio3_002224; ZINC20237; Lidocaine 1.0 mg/ml in Methanol; NINDS_000174; Bio1_000379; Bio1_000868; Bio1_001357; Bio2_000079; Bio2_000559; HMS1791D21; HMS1989D21; HMS2051C21; HMS2089E15; HMS2235O14; HMS3371J04; HMS3393C21; HMS3428O07; HMS3651G09; AMY25560; BCP09081; HY-B0185; NSC40030; Tox21_110183; BDBM50017662; NSC789222; s1357; STK552033; AKOS001026768; Tox21_110183_1; CCG-100824; CS-2070; DB00281; MCULE-9294700940; NC00074; NSC-789222; SB19118; SDCCGSBI-0050648.P005; WLN: 2N2 & 1VMR B1 F1; .alpha.-Diethylamino-2,6-acetoxylidide; CAS-73-78-9; IDI1_000174; IDI1_033829; NCGC00015611-01; NCGC00015611-02; NCGC00015611-03; NCGC00015611-04; NCGC00015611-05; NCGC00015611-06; NCGC00015611-07; NCGC00015611-08; NCGC00015611-09; NCGC00015611-11; NCGC00015611-12; NCGC00015611-13; NCGC00015611-14; NCGC00015611-15; NCGC00015611-16; NCGC00015611-18; NCGC00015611-31; NCGC00022176-05; NCGC00022176-06; NCGC00022176-07; NCGC00022176-08; NCGC00022176-09; AC-10282; AS-13718; M620; SY052029; 2-(Diethylamino)-2'',6''-acetoxylidide; SBI-0050648.P004; AB00053581; L0156; SW196598-4; A18187; C07073; D00358; J10173; M06299; AB00053581-27; AB00053581-28; AB00053581_29; AB00053581_30; A833036; Q216935; (2,6-dimethylphenyl)carbamoylmethyl-diethyl-azanium; N1-(2,6-dimethylphenyl)-2-(diethylamino)acetamide; W-108233; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide #; BRD-K52662033-001-02-6; BRD-K52662033-003-05-5; BRD-K52662033-003-14-7; Z55135799; Lidocaine, British Pharmacopoeia (BP) Reference Standard; Lidocaine, European Pharmacopoeia (EP) Reference Standard; N~1~-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; Lidocaine, United States Pharmacopeia (USP) Reference Standard; 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide hydrate hydrochloride; Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material; Lidocaine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; 91484-71-8"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6456	DB00281	DR00849	DR0953	234.34	C14H22N2O	32.299	228	2.3	17	1	2	5	"1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)"	CCN(CC)CC(=O)NC1=C(C=CC=C1C)C	NNJVILVZKWQKPM-UHFFFAOYSA-N
DG00751	Idebenone	3686	"Idebenone; 58186-27-9; Idebenona; Idebenonum; CV 2619; 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione; CV-2619; Sovrima; UNII-HB6PN45W4J; BRN 2001459; CHEBI:31687; 2-(10-Hydroxydecyl)-5,6-dimethoxy-3-methyl-1,4-benzoquinone; 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone; HB6PN45W4J; Raxone; 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione; 5,6-DIMETHOXY-2-(10-HYDROXYDECYL)-3-METHYL-1,4-BENZOQUINONE; 2,5-Cyclohexadiene-1,4-dione, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-; MFCD00274552; NSC-759228; NCGC00160514-01; 2-(10-Hydroxydecyl)-5,6-dimethoxy-3-methyl-p-benzoquinone; 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylbenzo-1,4-quinone; 2,5-Cyclohexadiene-1,4-dione, 5,6-dimethoxy-2-(10-hydroxydecyl)-3-methyl-; DSSTox_CID_20678; DSSTox_RID_79536; DSSTox_GSID_40678; Idebenonum [Latin]; Idebenona [Spanish]; hydroxydecyl ubiquinone; Idebenone [INN:JAN]; 2,3-dimethoxy-5-methyl-6-(10'-hydroxydecyl)-1,4-benzoquinone; 2,3-Dimethoxy-6-(10-hydroxydecyl)-5-methyl-1,4-benzoquinone; SMR000466364; CAS-58186-27-9; SR-01000759378; Cerestabon; Catena; Mnesis; Avan; Oristar hdu; Idebenone- Bio-X; Raxone (TN); SNT-MC17; SCHEMBL28320; Idebenone (JAN/USAN/INN); MLS000759487; MLS001032035; MLS001424002; MLS006011882; Idebenone, analytical standard; CHEMBL252556; QSA-10; DTXSID0040678; Idebenone, >=98% (HPLC); FR114; HMS2051O06; HMS2089D08; HMS3393O06; HMS3656K22; HMS3713A10; HMS3884B12; Pharmakon1600-01505755; ALBB-027258; BCP09116; HY-N0303; STR09227; ZINC1542890; Tox21_111864; BBL025842; BDBM50505498; NSC759228; s2605; STK801942; AKOS005622577; Tox21_111864_1; AC-4337; CCG-100846; KS-5193; MCULE-6391829243; NC00096; NSC 759228; SB19130; NCGC00160514-02; NCGC00160514-03; BI164565; SY051193; SBI-0207024.P001; DB-053168; FT-0617205; I0848; SW219495-1; D01750; H10427; J10031; AB00639997-04; AB00639997-06; AB00639997_07; AB00639997_08; 186I279; A-68500; Q4197874; SR-01000759378-4; SR-01000759378-5; SR-01000759378-6; BRD-K37516142-001-01-4; 2,3-Dimethoxy-6-(10-hydroxydecyl)-5-methylbenzoquinone; 2,3-Dimethoxy-6-(10-hydroxydecyl)-5-methyl-1,4benzoquinone; 2-(10-hydroxydecyl)-6-methoxy-3-methyl-5-(trideuteriomethoxy)cyclohexa-2,5-diene-1,4-dione"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31687	DB09081	.	DR0853	338.4	C19H30O5	72.8	502	4.3	24	1	5	12	"1S/C19H30O5/c1-14-15(12-10-8-6-4-5-7-9-11-13-20)17(22)19(24-3)18(23-2)16(14)21/h20H,4-13H2,1-3H3"	CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO	JGPMMRGNQUBGND-UHFFFAOYSA-N
DG00752	Ifosfamide	3690	"Ifosfamide; Isophosphamide; 3778-73-2; Iphosphamide; Isofosfamide; Ifosfamid; Mitoxana; Ifex; Iphosphamid; Isoendoxan; Naxamide; I-Phosphamide; Holoxan; Cyfos; Ifsofamide; Holoxan 1000; ASTA Z 4942; Ifosfamida; Ifosfamidum; MJF 9325; isosfamide; NCI-C01638; MJF-9325; NSC-109724; ifomide; Z4942; NSC 109724; A 4942; Z 4942; Z-4942; 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide; C7H15Cl2N2O2P; NSC109724; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide; N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide; 3-(2-chloroethyl)-2-((2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide; CHEBI:5864; Ifosphamide; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; 3-(2-Chloroethyl)-2-(2-chloroethylamino)tetrahydro-2H-1,3,2-oxaazaphosphorin 2-oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide; NCGC00016639-01; CAS-3778-73-2; DSSTox_CID_760; Ifosfamide Sterile; DSSTox_RID_75775; DSSTox_GSID_20760; Ifosfamidum [INN-Latin]; Ifosfamida [INN-Spanish]; (R)-3-(2-chloroethyl)-2-((2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide; CCRIS 352; HSDB 7023; SR-05000002022; EINECS 223-237-3; IFEX (TN); BRN 0611835; Ifosfamide (JAN/USP/INN); N,3-bis(2-chloroethyl)-2-oxo-1,3,2 ^{5}-oxazaphosphinan-2-amine; Ifosfamid A; (R)-Ifosfamide; (S)-Ifosfamide; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorineoxide; 2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd; Isophosphamide,(S); N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide; MFCD00057374; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]; Ifosfamide - Bio-X; Ifosfamide [USAN:USP:INN:BAN:JAN]; starbld0001221; Ifosfamide, >=98%; Prestwick0_000833; Prestwick1_000833; Prestwick2_000833; Prestwick3_000833; Intermediate of Ifosfamide; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid; SCHEMBL4885; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; CHEMBL1024; BSPBio_000785; MLS002154021; Ifex (TN) (Bristol Meyers); SPBio_002706; BPBio1_000865; GTPL7201; DTXSID7020760; (S)-3-(2-chloroethyl)-2-((2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide; BDBM189358; HMS1570H07; HMS2090M12; HMS2093N07; HMS2097H07; HMS2232O10; HMS3374B08; HMS3654B15; HMS3714H07; Pharmakon1600-01505480; {3-(2-Chloroethyl)-2-[(2-; BCP06596; WLN: T6NPOTJ AM2G BO B2G; Tox21_110539; Tox21_201815; Tox21_302775; BBL028071; N,3-bis(2-chloroethyl)-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine; N,3-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine; NSC759154; s1302; STL058690; AKOS005711213; Tox21_110539_1; AB02316; AC-2113; CCG-213464; CS-1424; DB01181; MCULE-1480299331; NSC-759154; N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine; Ifosfamide, analytical reference material; NCGC00179435-01; NCGC00179435-02; NCGC00179435-03; NCGC00179435-06; NCGC00179435-07; NCGC00256413-01; NCGC00259364-01; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI); AS-10978; BI166243; HY-17419; NCI60_000233; SMR001233348; SBI-0206804.P001; DB-049196; AB00513932; FT-0603650; FT-0670282; SW197177-4; C07047; D00343; J10093; AB00513932-06; AB00513932-07; AB00513932-08; AB00513932_09; AB00513932_10; 778I732; A823873; Q418560; Q-101874; SR-05000002022-1; SR-05000002022-3; SR-05000002022-5; BRD-A67097164-001-11-2; Ifosfamide, British Pharmacopoeia (BP) Reference Standard; Ifosfamide, European Pharmacopoeia (EP) Reference Standard; UNII-UM20QQM95Y component HOMGKSMUEGBAAB-AWEZNQCLSA-N; Ifosfamide, United States Pharmacopeia (USP) Reference Standard; 2,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxy-; 2,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd; N,3-bis(2-chloroethyl)-2-oxo-1,3,2$l;{5}-oxazaphosphinan-2-amine; {3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,} 2-oxazaphosphorine oxide; 1,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 2H-1,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide; 2H-1,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 3-(2-Chloroethyl)-2-(2-chloroethylamino)tetrahydro-2H-1,3,2-oxazaphosphorin-2-one; 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]-1,3,2$l^{5}-oxazaphosphinan-2-one; 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]-1,3,2lambda5-oxazaphosphinan-2-one; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,2-oxazaphosphorineoxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,2-oxazaphosphorine 2-oxide; N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphinan-2-amine 2-oxide #"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:5864	DB01181	.	DR0855	261.079	C7H15Cl2N2O2P	41.6	218	0.9	14	1	4	5	"1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)"	C1CN(P(=O)(OC1)NCCCl)CCCl	HOMGKSMUEGBAAB-UHFFFAOYSA-N
DG00754	Iopromide	3736	"Iopromide; 73334-07-3; Ultravist; Iopromidum; Iopromida; N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-methoxyacetamido)-N1-methylisophthalamide; ZK 35760; UNII-712BAC33MZ; 1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(2-methoxyacetyl)amino]-3-N-methylbenzene-1,3-dicarboxamide; magnesium methanide propan-1-ide(1:1:1); 712BAC33MZ; Ultravist 300; CHEBI:63578; N,N'-Bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-methoxyacetamido)-N-methylisophthalamide; n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-n-methylisophthalamide; Ultravist 370; iopromid; DSSTox_CID_3163; DSSTox_RID_76898; DSSTox_GSID_23163; Proscope; SHL 414C; Iopromidum [INN-Latin]; Iopromida [INN-Spanish]; Ultravist 150; Ultravist 240; EINECS 277-385-9; Ultravist (pharmacy bulk); BRN 7085608; Iopromide [USAN:USP:INN:BAN]; Ultravist (TN); NCGC00016923-01; Proscope (TN); CAS-73334-07-3; BAY86-4877; BAY 86-4877; ZK-35760; Prestwick0_000872; Prestwick1_000872; Prestwick2_000872; Prestwick3_000872; CHEMBL1725; Iopromide (JAN/USP/INN); SCHEMBL24546; BSPBio_000943; MLS002154045; Iopromide, analytical standard; SPBio_002864; BPBio1_001039; DTXSID0023163; C18H24I3N3O8; HMS1570P05; HMS2097P05; HMS2233O23; HMS3370M05; HMS3714P05; BCP08449; HY-B1362; Tox21_110684; Ultravist 300 In Plastic Container; AC-535; MFCD00867924; s3207; AKOS025402129; Tox21_110684_1; CCG-220872; DB09156; Iopromid 100 microg/mL in Acetonitrile; NCGC00179367-01; NCGC00179367-03; 1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-((methoxyacetyl)amino)-N-methyl-; 1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-5-((methoxyacetyl)amino)-N-methyl-2,4,6-triiodo-; BS-17441; I661; SMR001233368; AB00513942; CS-0013103; FT-0627283; D01893; 334I073; SR-01000841262; Q4202805; SR-01000841262-2; Iopromide, European Pharmacopoeia (EP) Reference Standard; Iopromide, United States Pharmacopeia (USP) Reference Standard; Iopromide for system suitability 1, European Pharmacopoeia (EP) Reference Standard; Iopromide for system suitability 2, European Pharmacopoeia (EP) Reference Standard; N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-N-methyl-5-{[(methyloxy)acetyl]amino}benzene-1,3-dicarboxamide; N-(2,3-dihydroxypropyl)-3-[(2,3-dihydroxypropyl)(methyl)carbamoyl]-5-[(1-hydroxy-2-methoxyethylidene)amino]-2,4,6-triiodobenzene-1-carboximidic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63578	DB09156	.	.	791.1	C18H24I3N3O8	169	647	-2.1	32	6	8	11	"1S/C18H24I3N3O8/c1-24(4-9(28)6-26)18(31)12-13(19)11(17(30)22-3-8(27)5-25)14(20)16(15(12)21)23-10(29)7-32-2/h8-9,25-28H,3-7H2,1-2H3,(H,22,30)(H,23,29)"	CN(CC(CO)O)C(=O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)NC(=O)COC)I	DGAIEPBNLOQYER-UHFFFAOYSA-N
DG00759	Isoproterenol	3779	"Isoproterenol; Isoprenaline; Novodrin; Isoprenalin; Isopropydrin; Norisodrine; 7683-59-2; Aludrine; Asiprenol; Assiprenol; Bellasthman; Respifral; Asmalar; Isopropylarterenol; Neodrenal; Proternol; Aludrin; Isadrine; neo-Epinine; N-Isopropylnoradrenaline; Bronkephrine; Isonorene; Isonorin; Isopropyladrenaline; Isorenin; Lomupren; Saventrine; N-Isopropylnorepinephrine; Isopropylnorepinephrine; Isopropylnoradrenaline; Isopropyl noradrenaline; Vapo-N-iso; Isupren; Racemic isoprenaline; dl-Isadrine; Racemic isoproterenol; (+-)-Isoproterenol; Epinephrine isopropyl homolog; Isoprenalinum; Aleudrine; (+-)-Isoprenaline; Isoprenalina; Aleudrin; Dihydroxyphenylethanolisopropylamine; DL-ISOPROTERENOL; WIN 5162; 1-(3,4-Dihydroxyphenyl)-2-(isopropylamino)ethanol; 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol; ICI 46399; 1-(3,4-Dihydroxyphenyl)-2-isopropylaminoethanol; alpha-(Isopropylaminomethyl)protocatechuyl alcohol; N-Isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine; Isoprenaline (INN); 4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol; 1,2-Benzenediol, 4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-; CHEMBL434; 4-(1-Hydroxy-2-(isopropylamino)ethyl)benzene-1,2-diol; 149-53-1; 3,4-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; Isoproterenolum; CHEBI:64317; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-; Isopropylaminomethyl(3,4-dihydroxyphenyl)carbinol; 7683-59-2 (free); NSC-9975; NSC33791; Isoprenaline [INN]; NSC-33791; 3,4-dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol; NCGC00015558-06; 3,4-Dihydroxy-.alpha.-(isopropylaminomethyl)-benzyl alcohol; Isoproterenol [JAN]; Protocatechuyl alcohol,-; DSSTox_CID_3175; DL(+-)-Isoproterenol; L-Isoproterenol; Levisoprenaline; Proternol L; DSSTox_RID_76904; DSSTox_GSID_23175; Isoprenalinum [INN-Latin]; .alpha.-(Isopropylaminomoethyl)protocatechuyl alcohol; Isoprenalina [INN-Spanish]; Isoproterenol Chloride; WLN: QR BQ DYQ1MY1&1; 3,4-Dihydroxy-.alpha.-[(isopropylamino)methyl]benzyl alcohol; 4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol; 4-[1-Hydroxy-2-(isopropylamino)ethyl]-1,2-benzenediol; CAS-7683-59-2; ISOPROP; CCRIS 3081; NSC 9975; 1, 4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-; EINECS 231-687-7; NSC 33791; Isopropylaminomethyl-3,4-dihydroxyphenyl carbinol; 4-[1-hydroxy-2-(isopropylamino)ethyl]benzene-1,2-diol; BRN 2213857; Benzyl alcohol,4-dihydroxy-.alpha.-[(isopropylamino)methyl]-; Isoproterenol-l; Isoproterenol;; Isoproterenol (-); Isoproterenol,(+); Protocatechuyl alcohol, alpha-(isopropylaminomethyl)-; ISOPROTERONOL; Isoproterenol dl-form; Isuprel (Salt/Mix); Izadrin (Salt/Mix); Euspiran (Salt/Mix); (+/-)-isoprenaline; (+/-)-isoproterenol; Spectrum_000949; 114-45-4; Prestwick0_001097; Prestwick1_001097; Prestwick2_001097; Spectrum2_001061; Spectrum3_000474; Spectrum4_000024; Spectrum5_000880; (.+/-.)-Isoprenaline; (.+/-.)-Isoproterenol; SCHEMBL4165; DL(.+/-.)-Isoproterenol; Lopac0_000711; Oprea1_009434; BSPBio_002208; GTPL536; KBioGR_000427; KBioSS_001429; 3-13-00-02387 (Beilstein Handbook Reference); DivK1c_000894; SPBio_001042; SPBio_003057; SGCUT00015; 4-(1-Hydroxy-2(isopropylamino)ethyl)-benzene 1,2-diol; DTXSID4023175; BDBM25392; KBio1_000894; KBio2_001429; KBio2_003997; KBio2_006565; KBio3_001428; NSC9975; NINDS_000894; 4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol; HMS2089A12; HMS3742A11; BCP09043; Benzyl alcohol, 3,4-dihydroxy-alpha-((isopropylamino)methyl)-; to_000062; (A+/-)-Isoproterenol hydrochloride; Tox21_110172; PDSP1_001425; PDSP2_001409; STL558077; AKOS015913894; Tox21_110172_1; CCG-204727; CCG-204796; DB01064; MCULE-6061231962; SDCCGSBI-0050620.P003; SDCCGSBI-0050689.P005; IDI1_000894; NCGC00015558-04; NCGC00015558-05; NCGC00015558-07; NCGC00015558-08; NCGC00015558-09; NCGC00015558-10; NCGC00015558-11; NCGC00015558-12; NCGC00015558-14; NCGC00015558-25; NCGC00016665-02; NCGC00025274-03; NCGC00025274-04; NCGC00162220-01; A-21; SBI-0050689.P004; FT-0724367; C07056; D08090; AB00053487-09; AB00053487-10; AB00053487_11; AB00053487_12; 683I592; AG-219/03618046; L000936; Q415550; .alpha.-(Isopropylaminomethyl)protocatechuyl alcohol; Protocatechuyl alcohol,.alpha.-(isopropylamino-methyl),-; 3,4-dihydroxy-alpha-[(isopropylamino)methyl]-benzyl alcohol; 4-[1-Hydroxy-2-(isopropylamino)ethyl]-1,2-benzenediol #; N-Isopropyl-.beta.-dihydroxyphenyl-.beta.-hydroxyethylamine; 4-[1-hydroxy-2-(isopropylamino)ethyl]pyrocatechol;hydrochloride; 4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol, 2; Benzyl alcohol, 3,4-dihydroxy-.alpha.-((isopropylamino)methyl)-; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)- (9CI); Iso"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:64317	.	.	DR0887	211.26	C11H17NO3	72.7	187	-0.6	15	4	4	4	"1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3"	CC(C)NCC(C1=CC(=C(C=C1)O)O)O	JWZZKOKVBUJMES-UHFFFAOYSA-N
DG00761	Ketoprofen	3825	"Ketoprofen; 22071-15-4; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; Orudis; m-Benzoylhydratropic acid; Capisten; Ketoprofene; Profenid; Oruvail; Actron; 3-Benzoylhydratropic acid; Alrheumun; Aneol; Epatec; Orudis (TN); Iso-K; Ketoprofeno; RP-19583; Ketoprophene; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-(m-Benzoylphenyl)propionic acid; Racemic ketoprofen; 3-BENZOYL-ALPHA-METHYLBENZENEACETIC ACID; RU 4733; Ketoprofen (Actron); CHEBI:6128; Benzeneacetic acid, 3-benzoyl-.alpha.-methyl-; Alrheumat; CHEMBL571; Propionic acid, 2-(3-benzoylphenyl)-; (S)-Ketoprofen;Dexketoprofen; 19583 RP; L'Acide (benzoyl-3-phenyl)-2-propionique; MLS000079024; Orudis KT; MFCD00055790; NSC-758144; Kefenid; Ketopron; Menamin; Meprofen; Orugesic; Oscorel; SMR000040181; Fastum; Lertus; Toprec; Toprek; Dexal; DSSTox_CID_771; R.P. 19,583; racemic-Ketoprofen; DSSTox_RID_75783; DSSTox_GSID_20771; 1189508-77-7; Ketoprofenum; RP 19583; Ketoprofene [INN-French]; Ketoprofenum [INN-Latin]; Ketoprofeno [INN-Spanish]; Ketoprofen (+-); (+-)-m-Benzoylhydratropic acid; Benzeneacetic acid, 3-benzoyl-alpha-methyl-; SR-01000075949; Ketorin; rac Ketoprofen; CCRIS 4508; Actron ketoprofen; (rs)-ketoprofen; (+-)-3-Benzoyl-alpha-methylbenzeneacetic acid; (+) ketoprofen; NCGC00016757-01; Ketoprofen ,(S); Acide (benzoyl-3-phenyl)-2-propionique [French]; Prestwick_617; EINECS 244-759-8; 2-[3-(benzoyl)phenyl]propanoic acid; CAS-22071-15-4; Ketoprofen-13C-D3; 2-(3-benzoylphenyl)-propionic acid; Hydratropic acid, m-benzoyl-, (+-)-; Acide (benzoyl-3-phenyl)-2-propionique; Spectrum_001309; Opera_ID_509; Prestwick0_000219; Prestwick1_000219; Prestwick2_000219; Prestwick3_000219; Spectrum2_000956; Spectrum3_001479; Spectrum4_000028; Spectrum5_001254; m-benzoyl-hydratropic acid; Epitope ID:131783; K 1751; SCHEMBL2896; Lopac0_000686; Oprea1_117113; BSPBio_000237; BSPBio_003037; Hydratropic acid, m-benzoyl-; KBioGR_000435; KBioSS_001789; MLS000028446; MLS001201752; MLS001306444; MLS002548889; MLS006011967; BIDD:GT0443; DivK1c_000598; SPECTRUM1501215; SPBio_000952; SPBio_002158; Benzeneacetic acid, 3-benzoyl-alpha-methyl-, (+-)-; BPBio1_000261; GTPL4795; IDEA-033; Ketoprofen (JP17/USP/INN); Ketoprofen, >=98% (TLC); DTXSID6020771; DKYWVDODHFEZIM-UHFFFAOYSA-; HMS501N20; KBio1_000598; KBio2_001789; KBio2_004357; KBio2_006925; KBio3_002537; (+/-)-m-Benzoylhydratropic acid; NINDS_000598; HMS1568L19; HMS1921B12; HMS2089B16; HMS2092L19; HMS2095L19; HMS2234H16; HMS3259I05; HMS3262I13; HMS3372M08; HMS3373G09; HMS3649N10; HMS3655C15; HMS3712L19; HMS3884K04; Pharmakon1600-01501215; BCP23428; HY-B0227; 2-(3'-benzoylphenyl)propionic acid; 2-(3-benzoylphenyl) propionic acid; alpha(3-benzoylphenyl)propionic acid; Tox21_110594; Tox21_200847; Tox21_500686; (.+/-.)-m-Benzoylhydratropic acid; 2-(3-benzoylphenyl) propionoic acid; alpha-(m-benzoylphenyl)propionic acid; BDBM50022271; CCG-39685; NSC758144; s1645; STL450995; (R)-(-)-Ketoprofen-[13C,d3]; 2-(3-Benzoylphenyl)propanoic acid #; alpha-(3-benzoylphenyl)propionic acid; AKOS007930512; alpha-(m-benzoylphenyl) propionic acid; Tox21_110594_1; 19583RP; AC-1486; BCP9000810; DB01009; Ketoprofen [USAN:USP:INN:BAN:JAN]; KS-5031; LP00686; MCULE-9740144074; NC00459; NSC 758144; RU-4733; SDCCGSBI-0050664.P004; IDI1_000598; (rs)-2-(3-benzoylphenyl)propanoic acid; NCGC00015578-02; NCGC00015578-03; NCGC00015578-04; NCGC00015578-05; NCGC00015578-07; NCGC00015578-08; NCGC00015578-10; NCGC00015578-12; NCGC00015578-23; NCGC00094043-01; NCGC00094043-02; NCGC00094043-03; NCGC00094043-04; NCGC00258401-01; NCGC00261371-01; BK166172; Ketoprofen 100 microg/mL in Acetonitrile; ((c)I)-Ketoprofen-d4(propionic-d4 acid); 3-Benzoyl-.alpha.-methylbenzeneacetic acid; BCP0726000302; SBI-0050664.P003; (+/-)-2-(3-Benzoylphenyl)propionic acid; L''Acide (benzoyl-3-phenyl)-2-propionique; UNM-0000306100; AB00052249; AM20060549; EU-0100686; FT-0602834; FT-0670646; FT-0670647; K0038; Ketoprofen, meets USP testing specifications; Orudis, Profenid, Dexal, Keduril, Ketofen,; R.P. 19583; SW196784-3; BIM-0050664.0001; C01716; D00132; D78110; Ketoprofen, VETRANAL(TM), analytical standard; AB00052249-17; AB00052249-19; AB00052249-20; AB00052249_21; AB00052249_22; 071K154; A815896; Q409192; Q-201268; SR-01000075949-1; SR-01000075949-6; SR-01000075949-9; (.+/-.)-3-Benzoyl-.alpha.-methylbenzeneacetic acid; Benzeneacetic acid, 3-benzoyl-alpha-methyl-, (+/-); BRD-A97739905-001-05-9; BRD-A97739905-001-15-8; SR-01000075949-18; F2173-0960; Z1695709452; Ketoprofen, British Pharmacopoeia (BP) Reference Standard; Ketoprofen, European Pharmacopoeia (EP) Reference Standard; Ketoprofen, United States Pharmacopeia (USP) Reference Standard; N-FMOC-3-AMINO-4-(4-TERT-BUTOXY-PHENYL)-BUTYRICACID; Ketoprofen, Pharmaceutical Secondary Standard; Certified Reference Material; 154907-35-4"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6128	DB01009	DR00690	DR0907	254.28	C16H14O3	54.4	331	3.1	19	1	3	4	"1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)"	CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O	DKYWVDODHFEZIM-UHFFFAOYSA-N
DG00762	Ketorolac	3826	"Ketorolac; 74103-06-3; 5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; Ketorolaco; Ketorolacum [Latin]; Ketorolaco [Spanish]; Ketoralac; Ketorolacum; Macril; (+-)-Ketorolac; 66635-83-4; Acular; rac-ketorolac; RS 37619; (+)-Ketorolac; Toradol (TN); (+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; CHEBI:76223; Acuvail; MFCD00864281; RS37619; 1H-Pyrrolizine-1-carboxylic acid, 2,3-dihydro-5-benzoyl-, (+-)-; 5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; Ketorolac [INN:BAN]; SPRIX; RS-37619; Ketorolac (INN); rac Ketorolac-[d4]; 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-; NCGC00185990-01; CHEMBL469; SCHEMBL14891; MLS006011844; CHEBI:6129; GTPL6661; DTXSID8023189; BDBM85511; HMS3604J05; HMS3884M04; HY-B0580; AC-545; HTS001246; s1646; STL018674; AKOS005657203; AC-1121; CCG-204762; DB00465; KS-5175; SDCCGSBI-0050655.P004; NCGC00185990-02; NCGC00185990-05; NCGC00185990-15; K262; SMR001550090; SY107530; SBI-0050655.P003; CAS_74103-07-4; DB-011403; AB00053682; FT-0653523; FT-0670664; FT-0670665; FT-0670666; C07062; D08104; F16555; J10261; AB00053682-12; AB00053682-14; AB00053682_15; AB00053682_16; 635K834; A934549; Q2014797; BRD-A40639672-234-05-7; BRD-A40639672-234-09-9; KETOROLAC, ketorolactromethamine, Ketorolac Tromethamine; 5-(benzoyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; 5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid #; rac-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; (1RS)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; (.+/-.)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid; (.+/-.)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; 5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid; 1H-Pyrrolizine-1-carboxylic acid, 2,3-dihydro-5-benzoyl-, (.+/-.)-; 5-BENZOYL-2,3-DIHYDRO-1H-PYRROLO[1,2-A]PYRROLE-1-CARBOXYLIC ACID"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:76223	DB00465	.	DR0908	255.27	C15H13NO3	59.3	376	1.9	19	1	3	3	"1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)"	C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O	OZWKMVRBQXNZKK-UHFFFAOYSA-N
DG00764	Lofepramine	3947	"LOFEPRAMINE; Lopramine; 23047-25-8; Amplit; Leo 640; UNII-OCA4JT7PAW; Gamanil; 4'-Chlor-2-((3-(10,11-dihydro-5H-dibenz(b,f)azepin-5-yl)propyl)methylamino)acetophenon; OCA4JT7PAW; CHEBI:47782; 1-(4-chlorophenyl)-2-{[3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl](methyl)amino}ethanone; Ethanone, 1-(4-chlorophenyl)-2-((3-(10,11-dihydro-5H-dibenz(b,f)azepin-5-yl)propyl)methylamino)-; 1-(4-chlorophenyl)-2-[3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl-methylamino]ethanone; Acetophenone, 4'-chloro-2-((3-(10,11-dihydro-5H-dibenz(b,f)azepin5-yl)propyl)methylamino)-; Lofepramina; Lofepraminum; Lomont; Lofepramine [INN:BAN]; Lofepraminum [INN-Latin]; Lofepramina [INN-Spanish]; 4'-chloro-2-((3-(10,11-dihydro-5H-dibenz(b,f)azepin5-yl)propyl)methylamino)acetophenone; 1-(4-Chlorophenyl)-2-((3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)(methyl)amino)ethan-1-one; 1-(4-chlorophenyl)-2-{[3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl]methylamino}ethanone; Ethanone, 1-(4-chlorophenyl)-2-[[3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]methylamino]-; HSDB 7184; NCGC00166397-02; EINECS 245-396-8; DB 2182; Lofepramine (INN); Lofepramine- Bio-X; Gamanil (Salt/Mix); Gamonil (Salt/Mix); Timelit (Salt/Mix); Tymelyt (Salt/Mix); SCHEMBL35028; CHEMBL87708; GTPL7551; DTXSID2023220; BDBM82437; HMS3269O19; HMS3413F21; HMS3677F21; HMS3715L16; NSC_3947; ZINC1542929; Lofepramin hydrochloride (Salt/Mix); AKOS024457158; CCG-221257; DB13411; 4'-Chloro-2-[[3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]methylamino]acetophenone; NCGC00166397-01; NCGC00166397-03; BL164630; HY-12390; US8629135, SW-06; CAS_23047-25-8; B7097; CS-0011244; FT-0670832; D08140; AB00698521-05; A854424; L000944; Q368941; J-014957; 1-(4-Chlorophenyl)-2-[[3-(10,11-dihydro-5H-dibenz(Z)[b,f]azepin-5-yl)propyl]methylamino]ethanone; 1-(4-Chlorophenyl)-2-[[3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl](methyl)amino]ethanone #; N-Methyl-N(4-chlorobenzoylmethyl)-3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propylamine hydrochloride"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:47782	.	.	.	419	C26H27ClN2O	23.6	523	6.8	30	0	3	7	"1S/C26H27ClN2O/c1-28(19-26(30)22-13-15-23(27)16-14-22)17-6-18-29-24-9-4-2-7-20(24)11-12-21-8-3-5-10-25(21)29/h2-5,7-10,13-16H,6,11-12,17-19H2,1H3"	CN(CCCN1C2=CC=CC=C2CCC3=CC=CC=C31)CC(=O)C4=CC=C(C=C4)Cl	SAPNXPWPAUFAJU-UHFFFAOYSA-N
DG00767	Maprotiline	4011	"Maprotiline; 10262-69-8; Maprotylina [Polish]; Maprotylina; Maprotilinum [INN-Latin]; Maprotilina [INN-Spanish]; 276-Ba; UNII-2U1W68TROF; N-Methyl-9,10-ethanoanthracene-9(10H)-propylamine; 9,10-Ethanoanthracene-9(10H)-propanamine, N-methyl-; CHEBI:6690; 3-(9,10-Dihydro-9,10-ethanoanthracen-9-yl)propylmethylamine; 3-(9,10-Dihydro-9,10-ethanoanthracen-9-yl)-N-methylpropan-1-amine; 2U1W68TROF; BA-34276; 9,10-Ethanoanthracene-9(10H)-propylamine, N-methyl-; N-methyl-3-(1-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenyl)propan-1-amine; NCGC00015708-04; Maprotilina; Maprotilinum; BA-34,276 [AS HYDROCHLORIDE]; 3-(9,10-ethanoanthracen-9(10H)-yl)-N-methylpropan-1-amine; DSSTox_CID_25029; DSSTox_RID_80649; DSSTox_GSID_45029; N-Methyl-9,10-ethanoanthracene-9(10H)-propanamine;N-Methyl-9,10-ethanoanthracene-9(10H)-propanamine; CAS-10262-69-8; Maprotiline (USAN); EINECS 233-599-4; CAS-10347-81-6; BRN 2385493; Maprotiline [USAN:INN:BAN]; N-Methyl-9,10-ethanoanthracene-9(10H)-propanamine; Spectrum_000887; Tocris-0935; Prestwick0_000346; Prestwick1_000346; Prestwick2_000346; Prestwick3_000346; Spectrum2_000139; Spectrum3_000483; Spectrum4_000035; Spectrum5_000918; Lopac-M-9651; C07107; Lopac0_000812; SCHEMBL33993; BSPBio_000411; BSPBio_001945; KBioGR_000469; KBioSS_001367; MLS001201766; CHEMBL21731; DivK1c_000891; SCHEMBL121015; SPBio_000218; SPBio_002332; BPBio1_000453; GTPL2402; CHEMBL1201257; DTXSID7045029; SCHEMBL21994200; BA-34276 FREE BASE; KBio1_000891; KBio2_001367; KBio2_003935; KBio2_006503; KBio3_001445; BA-34276 [As Hydrochloride]; NINDS_000891; BA-34,276 FREE BASE; HMS2089K11; HMS2962E12; ZINC1530688; Tox21_110200; 0643AA; AR-111; BBL010079; BDBM50101973; BDBM50378025; STK711156; AKOS005530670; Tox21_110200_1; CCG-204896; DB00934; SDCCGSBI-0050789.P005; IDI1_000891; SMP1_000169; NCGC00015708-01; NCGC00015708-02; NCGC00015708-03; NCGC00015708-05; NCGC00015708-06; NCGC00015708-07; NCGC00015708-08; NCGC00015708-09; NCGC00015708-10; NCGC00015708-11; NCGC00015708-12; NCGC00015708-13; NCGC00015708-15; NCGC00015708-17; NCGC00015708-19; NCGC00015708-25; NCGC00016691-01; NCGC00018217-01; NCGC00024886-01; NCGC00024886-02; NCGC00024886-03; AC-12507; SMR000641863; SBI-0050789.P003; AB00514665; D02566; AB00053679-33; AB00053679_34; AB00053679_35; AB01275432-01; 262M698; L001173; Q418361; J-000745; BRD-K03319035-001-01-3; BRD-K03319035-003-02-7; BRD-K25433859-003-11-4; BRD-K25433859-003-14-8; methyl(3-{tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2(7),3,5,9(14),10,12-hexaen-1-yl}propyl)amine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6690	DB00934	DR00515	.	277.4	C20H23N	12	339	4.6	21	1	1	4	"1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3"	CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24	QSLMDECMDJKHMQ-UHFFFAOYSA-N
DG00768	Mecamylamine	4032	"Mecamylamine; Versamine; Mecamine; Revertina; Mecamilamina; Mekamine; 2-Methylaminoisocamphane; 60-40-2; Mevasine; 3-Methylaminoisocamphane; N,2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine; N-Methyl-2-isocamphanamine; 2-Methylamino-2,3,3-trimethylnorbornane; N,2,3,3-Tetramethyl-2-norbornamine; N,2,3,3-Tetramethyl-2-norcamphanamine; 2-Norbornanamine, N,2,3,3-tetramethyl-; Bicyclo(2.2.1)heptan-2-amine, N,2,3,3-tetramethyl-; CHEBI:6706; CHEMBL267936; Mecamylaminum; Bicyclo[2.2.1]heptan-2-amine, N,2,3,3-tetramethyl-; NCGC00015703-03; Mecamilamina [DCIT]; Mecamilamina [Italian]; DSSTox_CID_3240; DSSTox_RID_76937; DSSTox_GSID_23240; Mecamylamine [INN:BAN]; Mecamylaminum [INN-Latin]; Mecamylamine base; 3-Methylaminoisokamfan; 3-Methylaminoisokamfan [Czech]; CAS-60-40-2; EINECS 200-476-1; 3-beta-Methylamino-2,2,3-trimethylbicyclo(2.2.1)heptane; Inversine (Salt/Mix); Spectrum_000304; SpecPlus_000736; Prestwick0_001111; Prestwick1_001111; Prestwick2_001111; Prestwick3_001111; Spectrum3_000736; Spectrum4_001257; Spectrum5_001616; Lopac0_000841; SCHEMBL34252; BSPBio_001242; BSPBio_002292; KBioGR_001814; KBioSS_000784; DivK1c_006832; SPBio_003111; BPBio1_001367; GTPL3990; DTXSID0023240; KBio1_001776; KBio2_000784; KBio2_003352; KBio2_005920; KBio3_001512; HMS3604D12; 107538-05-6; ALBB-023410; Tox21_110198; BDBM50061565; AKOS003662515; Tox21_110198_1; CCG-204924; DB00657; SDCCGSBI-0050817.P005; NCGC00015703-02; NCGC00015703-04; NCGC00015703-06; NCGC00015703-12; NCGC00162272-01; NCGC00162272-02; SBI-0050817.P004; AB00053764; C07511; AB00053764_03; Q3332124; BRD-A20119038-001-01-5; BRD-A20119038-003-01-1; N,2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine #; Methyl-(2,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amine; (+)Methyl-(2,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amine; (-)Methyl-(2,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amine; 3-.beta.-Methylamino-2,2,3-trimethylbicyclo(2.2.1)heptane; (+/-)Methyl-(2,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amine; methyl(2,3,3-trimethylbicyclo[2.2.1]hept-2-yl)amine hydrochloride; Methyl-(2,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amine(Mecamylamine)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6706	DB00657	.	.	167.29	C11H21N	12	197	2.6	12	1	1	1	"1S/C11H21N/c1-10(2)8-5-6-9(7-8)11(10,3)12-4/h8-9,12H,5-7H2,1-4H3"	CC1(C2CCC(C2)C1(C)NC)C	IMYZQPCYWPFTAG-UHFFFAOYSA-N
DG00770	Meclizine	4034	"Meclizine; Meclozine; 569-65-3; Parachloramine; Chiclida; Bonine; Sea-Legs; Histamethine; Histamethizine; Histametizine; Histametizyne; Bonadettes; Calmonal; Itinerol; Monamine; Navicalm; Peremesin; Postafene; Suprimal; Travelon; Vomisseis; Ancolan; Ravelon; Sabari; Siguran; Marex; Neo-istafene; Neo-suprimal; Neo-suprimel; Antivert; Vomissels; Ancolon; 1-((4-Chlorophenyl)(phenyl)methyl)-4-(3-methylbenzyl)piperazine; Meclizine hydrochloride; UCB 5062; Bonamine; Diadril; UCB 170; U.C.B. 5062; 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine; 1-[(4-chlorophenyl)(phenyl)methyl]-4-[(3-methylphenyl)methyl]piperazine; Postafen; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)diethylenediamine; NSC 169189; UCB 5052; Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]-; U. C. B. 5062; CHEBI:6709; (+-)-Meclizine; Piperazine, 1-(p-chloro-alpha-phenylbenzyl)-4-(m-methylbenzyl)-; Dramamine II; Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((3-methylphenyl)methyl)-; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)piperazine; NSC-169189; Meclozina; Meclozinum; Subari; 1-(p-Chloro-.alpha.-phenylbenzyl)-4-(m-methylbenzyl)piperazine; Piperazine,1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]-; Meclizine [INN:BAN]; Meclozinum [INN-Latin]; Meclozina [INN-Spanish]; 1-[(4-Chlorophenyl)(phenyl)methyl]-4-(3-methylbenzyl)piperazine; Piperazine, 1-(p-chloro-.alpha.-phenylbenzyl)-4-(m-methylbenzyl)-; Nevidoxine (TN); Meclozine (BAN); Meclozine [INN]; HSDB 3113; EINECS 209-323-3; 1-p-Chlorobenzhydryl-4-m-methylbenzylpiperazine; BRN 0332002; Meclozin; 1-(p-Chloro-alpha-phenylbenzyl)-4-(m-methylbenzyl)piperazine; 1-((4-Chlorophenyl)phenylmethyl)-4-((3-methylphenyl)methyl)piperazine; Diadril (Salt/Mix); Bonamine (Salt/Mix); Bonadoxin (Salt/Mix); Vertizine (Salt/Mix); Spectrum_000891; (.+/-.)-Meclizine; Prestwick0_000457; Prestwick1_000457; Prestwick2_000457; Prestwick3_000457; Spectrum2_000110; Spectrum3_000485; Spectrum4_000037; Spectrum5_000919; SCHEMBL4649; CHEMBL1623; BSPBio_000534; BSPBio_001949; KBioGR_000473; KBioSS_001371; 4-Methyl-2-chloroacetophenone; DivK1c_000407; SPBio_000100; SPBio_002473; BPBio1_000588; GTPL2757; DTXSID0023242; BDBM81467; KBio1_000407; KBio2_001371; KBio2_003939; KBio2_006507; KBio3_001449; NINDS_000407; Meclizine;Meclozine; Parachloramine; BCP28339; NSC_4034; MFCD00242697; NSC169189; AKOS015951354; DB00737; MCULE-7463916552; IDI1_000407; NCGC00018296-02; NCGC00018296-04; NCGC00018296-08; BS-17628; CAS_569-65-3; SBI-0051433.P003; WLN: T6N DNTJ AYR&R DG& D1R C1; AB00053493; FT-0659103; EN300-58334; C07116; D08163; D81963; AB00053493_14; AB00053493_15; L001136; Q386441; BRD-A50311610-300-05-4; BRD-A50311610-300-06-2; Z53003552; 1-[(4-Chlorophenyl)(phenyl)methyl]-4-(3-methylbenzyl)piperazine #"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00737	DR00977	DR1006	390.9	C25H27ClN2	6.5	448	5.8	28	0	2	5	"1S/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3"	CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl	OCJYIGYOJCODJL-UHFFFAOYSA-N
DG00775	Midodrine	4195	"Midodrine; Midodrin; 42794-76-3; Midodrina; Midodrinum; Midodrinum [INN-Latin]; Midodrina [INN-Spanish]; ProAmatine; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide; St 1085; Midodrine free base; ST-1085; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol; DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid; Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-; CHEBI:6933; 42794-76-3 (free base); 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide; 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide; Midodrine [INN:BAN]; 97476-58-9; Midodrine (INN); 133163-28-7; EINECS 255-945-3; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamid; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethylacetamide; (RS)-N'-(beta-Hydroxy-2,5-dimethoxy-phenethyl)glycinamid; HSDB 7854; Spectrum_001641; Prestwick0_000191; Prestwick1_000191; Prestwick2_000191; Prestwick3_000191; Spectrum2_001545; Spectrum3_001585; Spectrum4_000192; Spectrum5_000962; BSPBio_000141; BSPBio_003150; KBioGR_000763; KBioSS_002121; DivK1c_000955; SCHEMBL131436; SPBio_001390; SPBio_002062; BPBio1_000157; GTPL7240; CHEMBL1201212; DTXSID0023321; SCHEMBL20996761; KBio1_000955; KBio2_002121; KBio2_004689; KBio2_007257; KBio3_002650; NINDS_000955; HMS3886M20; N-{2-[2,5-bis(methyloxy)phenyl]-2-hydroxyethyl}glycinamide; 2-AMINO-N-[2-(2,5-DIMETHOXYPHENYL)-2-HYDROXY-ETHYL]ACETAMIDE; s5735; AKOS015967099; CS-4688; DB00211; MCULE-7047456030; ( inverted exclamation markA)-Midodrine; IDI1_000955; NCGC00178238-01; NCGC00178238-02; DA-05918; HY-12749; SBI-0051934.P002; AB00053715; FT-0740719; C07890; D08220; AB00053715_08; A913477; Q415051; BRD-A79981887-003-05-7; BRD-A79981887-003-09-9; rac-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]glycinamide; (+-)-2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide; (+/-)-2-amino-n-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]ethanimidic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6933	DB00211	DR01164	DR1088	254.28	C12H18N2O4	93.8	263	-0.6	18	3	5	6	"1S/C12H18N2O4/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16)"	COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O	PTKSEFOSCHHMPD-UHFFFAOYSA-N
DG00777	Moclobemide	4235	"Moclobemide; 71320-77-9; Aurorix; Moclobemid; Manerix; Moclamine; 4-chloro-N-(2-morpholinoethyl)benzamide; Moclaime; Moclobemidum; Moclamide; Moclobemida; Moclobemidum [INN-Latin]; Moclobemida [INN-Spanish]; p-Chloro-N-(2-morpholinoethyl)benzamide; 4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide; 4-Chlor-N-(2-morpholinoethyl)benzamid; 4-chloro-N-(2-morpholin-4-ylethyl)benzamide; 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide; Ro 11-1163; 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide; Moclobemide (Ro 111163); GNF-PF-695; 4-chloro-N-[2-(4-morpholinyl)ethyl]benzamide; UNII-PJ0Y7AZB63; Ro 11-1163/000; Ro111163; BENZAMIDE, 4-CHLORO-N-(2-(4-MORPHOLINYL)ETHYL)-; Benzamide, 4-chloro-N-[2-(4-morpholinyl)ethyl]-; PJ0Y7AZB63; CHEMBL86304; MLS000070549; CHEBI:83531; MFCD00865388; NCGC00027930-02; NCGC00027930-04; SMR000012114; DSSTox_CID_20554; DSSTox_RID_79506; DSSTox_GSID_40554; Moclobemide [USAN:BAN:INN]; Moclobemide [USAN:INN:BAN]; Auromid; Aurorix (TN); CAS-71320-77-9; Ro-11-1163; HSDB 7180; SR-01000357772; CBMicro_048319; Moclobemide (USAN/INN); BRN 0530974; Moclobemide- Bio-X; Moclamine (Salt/Mix); Opera_ID_225; Oprea1_256739; Oprea1_270122; SCHEMBL49708; MLS000759438; MLS001240195; MLS001424077; GTPL7428; BENZAMIDE,4-CHLORO-N-[2-(4-MORPHOLINYL)ETHYL]-; DTXSID9040554; BDBM15613; AOB5012; HMS2051A16; HMS2096G07; HMS2232B20; HMS3262F09; HMS3371A01; HMS3393A16; HMS3657K05; HMS3713G07; HMS3885A15; AMY32534; BCP15783; HY-B0534; Moclobemide 1.0 mg/ml in Methanol; Tox21_110971; Tox21_113614; Tox21_500824; s3212; STK222240; ZINC19606670; AKOS003270184; Moclobemide, >=98% (HPLC), solid; Tox21_110971_1; CCG-100879; DB01171; LP00824; MCULE-5300106938; NC00129; SDCCGSBI-0048213.P003; NCGC00027930-03; NCGC00027930-05; NCGC00027930-07; NCGC00027930-16; NCGC00261509-01; AC-12467; BM164599; H223; p-chloro-N-(2-morpholinoethyl)-benzamide; BIM-0048213.P001; Ro-111163000; FT-0618228; M2733; SW197509-3; Ro-11-1163/000; D02561; AB00400932_12; 320M779; A837152; Q421934; 4-chloro-N-(2-morpholinoethyl)benzamide;Moclobemide; SR-01000357772-1; SR-01000357772-4; Z32409934; Ro11-1163; Ro 11-1163; Ro111163; Ro-111163; Ro 111163; 108375-13-9; MCL"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:83531	DB01171	DR00838	DR1103	268.74	C13H17ClN2O2	41.6	262	1.5	18	1	3	4	"1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)"	C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl	YHXISWVBGDMDLQ-UHFFFAOYSA-N
DG00782	Nicardipine	4474	"Nicardipine; 55985-32-5; Nicardipinum; Nicardipinum [INN-Latin]; Nicardipino [INN-Spanish]; Cardene; Perpidine; CHEBI:7550; YC-93 (free base); Cardene (TN); 2-(Benzylmethylamino)ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate; 3-(2-(benzyl(methyl)amino)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Dagan; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester; 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; NCGC00015747-03; Nicardipino; DSSTox_CID_3363; Nicardipine [INN:BAN]; DSSTox_RID_76992; DSSTox_GSID_23363; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester; Nicardipine (INN); CAS-55985-32-5; EINECS 259-932-3; BRN 0504321; Flusemide; Nicardipine (stn); FlusemideNicardipine; 3-{2-[benzyl(methyl)amino]ethyl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; (R,S)-nicardipine; Spectrum_001372; Prestwick0_000383; Prestwick1_000383; Prestwick2_000383; Prestwick3_000383; Spectrum2_001415; Spectrum3_001452; Spectrum4_000422; Spectrum5_001320; CHEMBL1484; CBiol_001802; Lopac0_000809; Oprea1_436998; SCHEMBL34277; BSPBio_000565; BSPBio_001389; BSPBio_002943; KBioGR_000109; KBioGR_000744; KBioSS_000109; KBioSS_001852; BIDD:GT0621; DivK1c_000540; SPBio_001490; SPBio_002486; BPBio1_000623; GTPL2559; CHEMBL3302409; DTXSID6023363; KBio1_000540; KBio2_000109; KBio2_001852; KBio2_002677; KBio2_004420; KBio2_005245; KBio2_006988; KBio3_000217; KBio3_000218; KBio3_002443; CHEBI:180905; NINDS_000540; Bio1_000088; Bio1_000577; Bio1_001066; Bio2_000109; Bio2_000589; HMS1791F11; HMS1989F11; HMS2089C09; HMS3886G17; BCP21397; EX-A4680; Tox21_110211; BDBM50101815; s5255; AKOS001637090; Tox21_110211_1; CCG-204893; CS-3685; DB00622; SDCCGSBI-0050786.P004; IDI1_000540; IDI1_033859; NCGC00015747-02; NCGC00015747-04; NCGC00015747-05; NCGC00015747-06; NCGC00015747-07; NCGC00015747-09; NCGC00015747-11; NCGC00015747-18; NCGC00162262-01; NCGC00162262-02; NCGC00162262-03; NCGC00162262-04; AC-19947; AS-56335; BN166182; HY-12515; methyl 2-[methyl(phenylmethyl)amino]ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; SBI-0050786.P003; DB-052833; AB00514658; FT-0630688; V1328; C07264; D08270; AB00053604-03; AB00053604_04; AB00053604_05; 985N325; A924111; L000715; Q729213; BRD-A26711594-001-02-7; BRD-A26711594-003-05-6; BRD-A26711594-003-06-4; L-GLUTAMICACID,N-(1-DEOXY-D-FRUCTOS-1-YL)-; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 2-[methy(phenyl-methyl)amino]ethyl ester; 106664-28-2; 2,6-dimethyl-3-methoxycarbonyl-4-(3-nitrophenyl)-5-[ 2-(N-benzyl-N-methylamino)ethoxycarbonyl]-1,4-dihydropyridine; 2-(Benzylmethylamino) ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 2-(N-benzyl-N-methylamino)ethyl methyl 2,6-dimethyl-4(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-(2-[Benzyl(methyl)amino]ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate #; 5-O-[2-[Benzyl(methyl)amino]ethyl] 3-O-methyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Methyl 2-(benzyl-methyl-amino)ethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; O5-methyl O3-[2-(methyl-(phenylmethyl)amino)ethyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7550	DB00622	DR00280	.	479.5	C26H29N3O6	114	856	3.8	35	1	8	10	"1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3"	CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC	ZBBHBTPTTSWHBA-UHFFFAOYSA-N
DG00784	Nimodipine	4497	"Nimodipine; 66085-59-4; Nimotop; Periplum; Admon; Nimodipino; Nimodipinum; Bay-E 9736; Nimodipinum [INN-Latin]; Nimodipino [INN-Spanish]; BAY e 9736; Bay-e-9736; 3-isopropyl 5-(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; CHEBI:7575; Nimodipine (Nimotop); 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester; C21H26N2O7; MLS000863294; 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Nymalize; MFCD00153848; NSC-758476; 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; NCGC00015714-09; SMR000058300; DSSTox_CID_3370; DSSTox_RID_76998; isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; DSSTox_GSID_23370; 2-methoxyethyl propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; nemotan; NimoGel; DRG-0139; Nimotop(TM); 1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2,6-dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-beta-methoxyethyl ester 5-isopropyl ester; SR-01000075335; NIMOTOP (TN); EINECS 266-127-0; BRN 0459792; Nimodipine ap; NimoVent; Nimodipime,(S); Nimodipine [USAN:USP:INN:BAN]; Nymalize (TN); CAS-66085-59-4; EG-1961; Opera_ID_14; Spectrum_001880; SpecPlus_000716; Nimodipine (USP/INN); Prestwick0_000918; Prestwick1_000918; Prestwick2_000918; Prestwick3_000918; Spectrum2_001562; Spectrum3_000766; Spectrum4_000791; Spectrum5_001687; N-149; CBiol_001832; Lopac0_000891; SCHEMBL34041; BSPBio_000796; BSPBio_001397; BSPBio_002412; KBioGR_000117; KBioGR_001262; KBioSS_000117; KBioSS_002408; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-methoxyethyl 1-methylethyl ester; MLS000069381; MLS001076550; MLS001424155; MLS002154061; MLS002172461; MLS003899190; DivK1c_006812; SPECTRUM1503600; SPBio_001464; SPBio_002985; BPBio1_000876; GTPL2523; CHEMBL3197349; DTXSID5023370; SCHEMBL22882841; KBio1_001756; KBio2_000117; KBio2_002403; KBio2_002685; KBio2_004971; KBio2_005253; KBio2_007539; KBio3_000233; KBio3_000234; KBio3_001632; 3-isopropyl 5-(2-methoxyethyl); BRD8407; Bio1_000118; Bio1_000607; Bio1_001096; Bio2_000117; Bio2_000597; HMS1361F19; HMS1570H18; HMS1791F19; HMS1922E04; HMS1989F19; HMS2052M05; HMS2089H13; HMS2093G11; HMS2097H18; HMS2234B05; HMS3262D04; HMS3266O22; HMS3369G07; HMS3394M05; HMS3402F19; HMS3411I12; HMS3657I03; HMS3675I12; HMS3714H18; Pharmakon1600-01503600; 3,5-pyridinecarboxylic acid 2-methoxyethyl 1-methylethyl ester; ACT02628; ALBB-015317; AMY40399; BCP21152; BRD-8407; HY-B0265; 2,6-dimethyl-4-(3-nitrophenyl)-; Nimotop; ; ; Admon; ; ; BAY-e 9736; Tox21_110202; Tox21_500891; BBL028286; BDBM50101971; CA-211; CCG-39340; NSC758476; s1747; STK642934; AKOS005174934; AKOS015852459; Nimodipine - CAS 66085-59-4; Tox21_110202_1; AC-8484; CCG-101085; DB00393; KS-1304; LP00891; MCULE-4717687158; NC00335; NSC 758476; SDCCGSBI-0050866.P004; IDI1_033867; isopropyl 2-methoxyethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; NCGC00015714-04; NCGC00015714-05; NCGC00015714-06; NCGC00015714-07; NCGC00015714-08; NCGC00015714-10; NCGC00015714-11; NCGC00015714-12; NCGC00015714-13; NCGC00015714-16; NCGC00015714-28; NCGC00021456-02; NCGC00024675-02; NCGC00024675-03; NCGC00024675-04; NCGC00024675-05; NCGC00024675-06; NCGC00024675-07; NCGC00024675-08; NCGC00024675-09; NCGC00261576-01; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester; Nimodipine 100 microg/mL in Acetonitrile; O5-isopropyl O3-(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; SMR002530605; SBI-0050866.P003; AB00513963; EU-0100891; FT-0602600; N0896; SW219238-1; C07267; D00438; F20554; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-; AB00053314-03; AB00053314-04; AB00053314_05; AB00053314_06; 085N594; Q421429; SR-01000075335-1; SR-01000075335-2; SR-01000075335-4; SR-01000075335-5; SR-01000075335-7; BRD-A58048407-001-06-3; BRD-A58048407-001-09-7; BAY E 9736 pound>> BAY-E-9736 pound>> BAYE97; Nimodipine, British Pharmacopoeia (BP) Reference Standard; Nimodipine, European Pharmacopoeia (EP) Reference Standard; Nimodipine, United States Pharmacopeia (USP) Reference Standard; Nimodipine, Pharmaceutical Secondary Standard; Certified Reference Material; Nimodipine for peak identification, EuropePharmacopoeia (EP) Reference Standard; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methyloxyethyl 1-methylethyl ester; 2-Methoxyethyl 1-Methylethyl 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; 3-Isopropyl 5-(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate #; isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate; O5-(2-methoxyethyl) O3-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7575	DB00393	DR01211	DR1161	418.4	C21H26N2O7	120	736	3.1	30	1	8	9	"1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3"	CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC	UIAGMCDKSXEBJQ-UHFFFAOYSA-N
DG00788	Oxamniquine	4612	"Oxamniquine; 21738-42-1; Mansil; Vansil; Oxaminiquine; Oxamniquinum; UK 4271; UK-4271; UK 4261; NSC 352888; UNII-00BCY677OT; UNII-7GIJ138H3K; [7-nitro-2-[(propan-2-ylamino)methyl]-1,2,3,4-tetrahydroquinolin-6-yl]methanol; MLS000756891; 00BCY677OT; 7GIJ138H3K; CHEBI:78416; 1,2,3,4-Tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-6-quinolinemethanol; 1,2,3,4-Tetrahydro-2-((isopropylamino)methyl)-7-nitro-6-quinolinemethanol; 2-((Isopropylamino)methyl)-7-nitro-1,2,3,4-tetrahydro-6-quinolinemethanol; 6-Hydroxymethyl-2-isopropylaminomethyl-7-nitro-1,2,3,4-tetrahydroquinoline; NSC352888; NSC-352888; {2-[(Isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl}methanol; 6-Quinolinemethanol, 1,2,3,4-tetrahydro-2-((isopropylamino)methyl)-7-nitro-; 6-Quinolinemethanol, 1,2,3,4-tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-; Oxamniquina; Oxamniquinum [INN-Latin]; Oxamniquina [INN-Spanish]; Mansil (TN); Vansil (TN); Oxamniquine (USAN/INN); CCRIS 4113; HSDB 6510; (2-((Isopropylamino)methyl)-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl)methanol; [2-[(isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl]methanol; 6-Quinolinemethanol, 1,2,3,4-tetrahydro-2-[[(1-methylethyl)amino]methyl]-7-nitro-; (+)-Oxamniquine; NCGC00016755-01; EINECS 244-556-4; (+-)-Oxamniquine; CAS-21738-42-1; Oxamniquine, (+)-; Oxamniquine, (-)-; BRN 0485597; Prestwick0_001026; Prestwick1_001026; Prestwick2_001026; DSSTox_CID_3398; CHEMBL847; DSSTox_RID_77013; DSSTox_GSID_23398; SCHEMBL44921; SPBio_003072; DTXSID3023398; HMS1571M13; HMS2230H11; HMS3371N13; Oxamniquine [USAN:USP:INN:BAN]; Tox21_110593; 2-(Isopropylaminomethyl)-7-nitro-1,2,3,4-tetrahydroquinoline-6-methanol; DB01096; UK-4261; (2-{[(1-methylethyl)amino]methyl}-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl)methanol; (7-nitro-2-{[(propan-2-yl)amino]methyl}-1,2,3,4-tetrahydroquinolin-6-yl)methanol; HY-10416; SMR000528982; CS-0002596; C07341; D00460; 5-22-11-00475 (Beilstein Handbook Reference); Q682497; SR-01000765728; SR-01000765728-2; 1,3,4-Tetrahydro-2-[(isopropylamino)methyl]-7-nitro-6-quinolinemethanol; 2-(Isopropylaminomethyl)-7-nitro-1,3,4-tetrahydroquinoline-6-methanol; 6-Quinolinemethanol,2,3,4-tetrahydro-2-[(isopropylamino)methyl]-7-nitro-; (2-[(Isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydro-6-quinolinyl)methanol #; {2-[(isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydro-6-quinolinyl}methanol; 6-Quinolinemethanol, 1,2,3,4-tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-, (+)-; 6-Quinolinemethanol, 1,2,3,4-tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-, (-)-; 6-Quinolinemethanol,2,3,4-tetrahydro-2-[[(1-methylethyl)amino]methyl]-7-nitro-; 119678-90-9; 40247-39-0"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:78416	DB01096	.	DR1211	279.33	C14H21N3O3	90.1	332	2.2	20	3	5	4	"1S/C14H21N3O3/c1-9(2)15-7-12-4-3-10-5-11(8-18)14(17(19)20)6-13(10)16-12/h5-6,9,12,15-16,18H,3-4,7-8H2,1-2H3"	CC(C)NCC1CCC2=CC(=C(C=C2N1)[N+](=O)[O-])CO	XCGYUJZMCCFSRP-UHFFFAOYSA-N
DG00789	Pamidronate	4674	"PAMIDRONIC ACID; pamidronate; 40391-99-9; Aredia; Amidronate; Aminomux; (3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid; Acide pamidronique [INN-French]; Acido pamidronico [INN-Spanish]; Acidum pamidronicum [INN-Latin]; PAMIDRONATE DISODIUM; (3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid); Disodium pamidronate; UNII-OYY3447OMC; (3-Amino-1-hydroxypropylidene)diphosphonic acid; CHEMBL834; OYY3447OMC; Phosphonic acid, (3-amino-1-hydroxypropylidene)bis-; (3-AMINO-1-HYDROXY-1-PHOSPHONO-PROPYL)PHOSPHONIC ACID; 3-amino-1-hydroxypropane-1,1-diphosphonic acid; CGP-23339AE; NCGC00159433-02; DSSTox_CID_3414; Acido pamidronico; Acide pamidronique; Acidum pamidronicum; DSSTox_RID_77017; DSSTox_GSID_23414; 1159812-33-5; (3-Amino-1-hydroxypropane-1,1-diyl)diphosphonic acid; Pamidronic acid [INN:BAN]; Ribodroat; 57248-88-1; Bisphosphonate 6; Ribodroat (TN); CAS-40391-99-9; (3-Amino-1-hydroxypropylidene)bisphosphonic acid; C3H11NO7P2; Pamidronic acid (INN); EINECS 254-905-2; starbld0044121; ChemDiv1_025240; 3-Amino-1-hydroxypropylidene-1,1-diphosphonate; SCHEMBL18361; BIDD:GT0538; CHEBI:7903; GTPL7259; JMC515594 Compound 62; DTXSID4023414; BDBM12581; HMS658L06; HMS2090C13; HMS3749A11; BCP17709; CCG-2075; HY-B0012; ZINC3812862; Tox21_111664; 2631AH; HSCI1_000312; MFCD00168777; s2063; STL510914; AKOS003599275; Tox21_111664_1; CS-7787; DB00282; MCULE-4373491291; NCGC00159433-03; NCGC00165862-02; DB-049579; FT-0630610; C07395; C75045; D07281; 391P999; A825084; Propane-1-hydroxy-3-amino-1,1-diphosphonic acid; Q627499; SR-01000514873; 3-amino-1-hydroxypropane-1,1-diyldiphosphonic acid; SR-01000514873-1; (3-Amino-1-hydroxy-1-phosphono-propyl)-phosphonic acid; Phosphonic acid, P,P'-(3-amino-1-hydroxypropylidene)bis-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7903	.	.	.	235.07	C3H11NO7P2	161	243	-6.9	13	6	8	4	"1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11)"	C(CN)C(O)(P(=O)(O)O)P(=O)(O)O	WRUUGTRCQOWXEG-UHFFFAOYSA-N
DG00791	Papaverine	4680	"Papaverine; Papaverin; 58-74-2; Papanerine; Robaxapap; Papanerin; Pavabid; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline; Papaverina; Papaverine [BAN]; 6,7-Dimethoxy-1-veratrylisoquinoline; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; Papaverine free base; NSC 136630; UNII-DAA13NKG2Q; Isoquinoline, 6,7-dimethoxy-1-veratryl-; Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-; S-M-R; Papaverine (BAN); 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-isoquinoline; DAA13NKG2Q; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; 58-74-2 (free base); CHEMBL19224; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; CHEBI:28241; HSDB 3147; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-; NSC-136630; Pavacot; Papaverina [Italian]; Ceraspan; Mesotina (TN); EV1; NSC35443; CAS-61-25-6; NCGC00015810-02; EINECS 200-397-2; BRN 0312930; Papaverinum; 2wey; RS 47; TNP00305; Spectrum_000071; Prestwick0_000583; Prestwick1_000583; Prestwick2_000583; Prestwick3_000583; Spectrum2_000978; Spectrum3_000537; Spectrum4_000467; Spectrum5_001188; Lopac-P-3510; Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); Lopac0_000957; Oprea1_387689; Oprea1_810508; SCHEMBL34702; BSPBio_000426; BSPBio_002153; KBioGR_000914; KBioSS_000471; 5-21-06-00182 (Beilstein Handbook Reference); DivK1c_000321; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; SPBio_001015; SPBio_002645; BPBio1_000470; MEGxp0_001880; DTXSID4023418; ACon1_000238; ACon1_002094; BDBM14754; KBio1_000321; KBio2_000471; KBio2_003039; KBio2_005607; KBio3_001653; ZINC56555; 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; NINDS_000321; HMS3561N11; HMS3746M21; ALBB-010475; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; BBL012345; NSC136630; STK039035; Isoquinoline,7-dimethoxy-1-veratryl-; AKOS000277460; CCG-202821; CS-7800; DB01113; KS-5336; MCULE-9598291893; SDCCGMLS-0003037.P003; SDCCGSBI-0050931.P005; IDI1_000321; NCGC00015810-01; NCGC00015810-03; NCGC00015810-04; NCGC00015810-05; NCGC00015810-06; NCGC00015810-07; NCGC00015810-08; NCGC00015810-09; NCGC00015810-13; NCGC00015810-24; NCGC00015810-29; NCGC00024428-03; NCGC00024428-04; HY-18077; NCI60_003183; Papaverine 100 microg/mL in Acetonitrile; SBI-0050931.P004; DB-053252; AB00053515; Y1354; C06533; D07425; AB00053515_14; Isoquinoline, 6,7-dimethoxy-1-veratryl- (8CI); WLN: T66 CNJ B1R CO1 DO1& HO1 IO1; Q410374; 6,7-dimethoxy-1-veratryl-isoquinoline;hydrochloride; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline #; BRD-K15567136-001-01-1; BRD-K15567136-003-06-6; BRD-K15567136-003-18-1; Isoquinoline,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-; SR-01000003098-10; 6,7-DIMETHOXY-1-(3.4-DIMETHOXYBENZYL)-ISOQUINOLINE"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:28241	DB01113	DR00967	DR2299	339.4	C20H21NO4	49.8	407	3.9	25	0	5	6	"1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3"	COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC	XQYZDYMELSJDRZ-UHFFFAOYSA-N
DG00795	Perphenazine	4748	"Perphenazine; 58-39-9; Trilafon; Perphenazin; Etaperazine; Perfenazine; Ethaperazine; Etaperazin; Fentazin; Chlorpiprazine; Perphenan; Thilatazin; Decentan; Chlorperphenazine; Emesinal; Perfenazina; Tranquisan; Trifaron; Trilifan; Triphenot; F-mon; Perphenazinum; 2-(4-(3-(2-Chloro-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol; Sch 3940; 2-[4-[3-(2-Chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol; C21H26ClN3OS; 4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol; UNII-FTA7XXY4EZ; PZC; gamma-(4-(beta-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine; NSC 150866; 4-(3-(2-Chlorophenothiazin-10-yl)propyl)-1-piperazineethanol; 4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol; 1-(2-Hydroxyethyl)-4-(3-(2-chloro-10-phenothiazinyl)propyl)piperazine; 2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethan-1-ol; FTA7XXY4EZ; MFCD00056798; CHEMBL567; 2-Chloro-10-3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl phenothiazine; 2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethanol; 2-Chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine; 2-Chloro-10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazine; MLS000069637; CHEBI:8028; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina; 1-Piperazineethanol, 4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-; 1-Piperazineethanol, 4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-; 2-(4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol; NSC150866; NSC-150866; CAS-58-39-9; NCGC00015826-02; Perfenil; SMR000058180; Perfenazina [Italian]; 1-Piperazineethanol, 4-(3-(2-chlorophenothiazin-10-yl)propyl)-; 1-(2-Hydroxyethyl)-4-[3-(2-chloro-10-phenothiazinyl)propyl]piperazine; DSSTox_CID_3441; DSSTox_RID_77031; DSSTox_GSID_23441; Perfenazina [INN-Spanish]; Perphenazinum [INN-Latin]; 1-Piperazineethanol, 4-[3-(2-chlorophenothiazin-10-yl)propyl]-; 2-Chloro-10-3-[1-(2-hydroxyethyl)-4-piperazinyl]propyl phenothiazine; Piperazineethanol, 4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-; HSDB 3379; SR-01000000137; EINECS 200-381-5; AI3-50151; Piperazineethanol, 4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-; .gamma.-(4-(.beta.-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine; .gamma.-[4-(.beta.-Hydroxyethyl)piperazin-1-yl]propyl-2-chlorophenothiazine; 2-(4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethan-1-ol; Perphenazine [USP:INN:BAN:JAN]; 2-Chloro-10-(3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine; SCH-3940; Prestwick_536; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina [Italian]; Etrafon (Salt/Mix); Spectrum_001610; 130-69-8; Opera_ID_1161; Prestwick0_000125; Prestwick1_000125; Prestwick2_000125; Prestwick3_000125; Spectrum2_001602; Spectrum3_000758; Spectrum4_000843; Spectrum5_001493; Lopac-P-6402; P 6402; Lopac0_000930; Oprea1_603835; REGID_for_CID_4748; SCHEMBL42125; BSPBio_000170; BSPBio_002376; GTPL209; KBioGR_001445; KBioSS_002090; MLS001146929; MLS002548897; 5,7-EICOSADIYNOICACID; BIDD:GT0150; DivK1c_000880; SPECTRUM1503934; SPBio_001603; SPBio_002109; BPBio1_000188; DTXSID1023441; component of Triavil (Salt/Mix); HMS502L22; KBio1_000880; KBio2_002090; KBio2_004658; KBio2_007226; KBio3_001596; Perphenazine (JP17/USP/INN); AOB5376; NINDS_000880; HMS1568I12; HMS1922M14; HMS2093M15; HMS2095I12; HMS2232D21; HMS3259C09; HMS3262J22; HMS3370O14; HMS3712I12; HMS3885H20; Pharmakon1600-01503934; HY-A0077; Perphenazine 1.0 mg/ml in Methanol; Tox21_110233; Tox21_500930; 1-Piperazineethanol, trihydrochloride; BDBM50130273; CCG-39060; NSC758649; s4731; STK019818; ZINC19228902; AKOS000664046; Tox21_110233_1; CS-5137; DB00850; KS-5105; LP00930; MCULE-6019566915; NC00472; NSC-758649; SDCCGSBI-0050904.P004; IDI1_000880; MRF-0000509; NCGC00015826-01; NCGC00015826-03; NCGC00015826-04; NCGC00015826-05; NCGC00015826-06; NCGC00015826-07; NCGC00015826-08; NCGC00015826-09; NCGC00015826-10; NCGC00015826-13; NCGC00015826-20; NCGC00024092-03; NCGC00024092-04; NCGC00024092-05; NCGC00024092-06; NCGC00261615-01; AC-12196; SBI-0050904.P003; DB-053200; AB00052390; EU-0072164; EU-0100930; FT-0603244; P1970; C07427; D00503; D82041; J10210; AB00052390_17; A831863; L000919; Q423520; SR-01000000137-2; SR-01000000137-4; SR-01000000137-5; SR-01000000137-8; W-105390; BRD-K10995081-001-05-5; BRD-K10995081-001-15-4; WLN: T C666 BN ISJ EG B3- AT6N DNTJ D2Q; Z1945707494; Perphenazine, British Pharmacopoeia (BP) Reference Standard; Perphenazine, European Pharmacopoeia (EP) Reference Standard; Perphenazine, United States Pharmacopeia (USP) Reference Standard; 2-[4-[3-(2-Chlorophenothiazin-10-yl)propyl]-piperazin-1-yl]ethanol; 2-(4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol #; Perphenazine for system suitability, European Pharmacopoeia (EP) Reference Standard; 2-Chloro-10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazine / 4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8028	DB00850	DR00759	DR1264	404	C21H26ClN3OS	55.2	463	4.2	27	1	5	6	"1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2"	C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO	RGCVKNLCSQQDEP-UHFFFAOYSA-N
DG00799	Procainamide	4913	"PROCAINAMIDE; 51-06-9; Novocainamide; Biocoryl; Novocamid; 4-Amino-N-[2-(diethylamino)ethyl]benzamide; Procaine amide; Pronestyl; Novocainamid; Procamide; 4-amino-N-(2-diethylaminoethyl)benzamide; Novocaine amide; Procainamida; Procainamidum; Procan; Procapan (free base); p-Aminobenzoic diethylaminoethylamide; p-Amino-N-(2-diethylaminoethyl)benzamide; Pronestyl-Sr; 4-Amino-N-(2-(diethylamino)ethyl)benzamide; UNII-L39WTC366D; NSC 27461; CHEBI:8428; 2-Diethylaminoethylamid kyseliny p-aminobenzoove; Benzamide, 4-amino-N-(2-(diethylamino)ethyl)-; Benzamide, 4-amino-N-[2-(diethylamino)ethyl]-; L39WTC366D; Benzamide, p-amino-N-(2-(diethylamino)ethyl)-; Benzamide, p-amino-N-[2-(diethylamino)ethyl]-; NSC-27461; NCGC00015859-07; Rhythmin; DSSTox_CID_3512; Procanbid; SP 100; SP 100 (pharmaceutical); DSSTox_RID_77059; DSSTox_GSID_23512; Procainamide [INN:BAN]; Procainamidum [INN-Latin]; Procainamida [INN-Spanish]; CAS-51-06-9; Procainamide (INN); HSDB 3170; CAS-614-39-1; EINECS 200-078-8; BRN 2214285; 2-Diethylaminoethylamid kyseliny p-aminobenzoove [Czech]; Spectrum_000836; Maybridge1_004389; Prestwick0_000337; Prestwick1_000337; Prestwick2_000337; Prestwick3_000337; Spectrum2_001295; Spectrum3_000555; Spectrum4_000487; Spectrum5_000986; Lopac-P-9391; CHEMBL640; Epitope ID:135397; Sp 100 (pharmaceutical); Cambridge id 5144127; Lopac0_000995; SCHEMBL15914; BSPBio_000373; BSPBio_001463; BSPBio_002229; CBDivE_003757; KBioGR_000183; KBioGR_000973; KBioSS_000183; KBioSS_001316; 4-14-00-01154 (Beilstein Handbook Reference); cid_66068; BIDD:GT0579; DivK1c_000931; SPBio_001329; SPBio_002294; WLN: ZR DVM2N2&2; BPBio1_000411; GTPL4811; DTXSID7023512; BDBM39344; HMS553P13; HY-A0084A; KBio1_000931; KBio2_000183; KBio2_001316; KBio2_002751; KBio2_003884; KBio2_005319; KBio2_006452; KBio3_000365; KBio3_000366; KBio3_001729; NINDS_000931; Bio1_000391; Bio1_000880; Bio1_001369; Bio2_000183; Bio2_000663; HMS1361J05; HMS1791J05; HMS1989J05; HMS2089E13; HMS3402J05; NSC27461; ZINC1530756; Tox21_110246; 7077AB; MFCD00066880; STK367963; AKOS000271131; Tox21_110246_1; 4-Amino-N-(diethylaminoethyl)benzamide; CCG-205075; CS-W009100; DB01035; FS-5697; MCULE-2863739556; SDCCGSBI-0050968.P005; IDI1_000931; IDI1_033933; SMP1_000055; NCGC00015859-01; NCGC00015859-02; NCGC00015859-03; NCGC00015859-04; NCGC00015859-05; NCGC00015859-06; NCGC00015859-08; NCGC00015859-09; NCGC00015859-10; NCGC00015859-11; NCGC00015859-14; NCGC00015859-16; NCGC00015859-18; NCGC00015859-23; NCGC00024323-03; NCGC00024323-04; NCGC00024323-05; NCGC00024323-06; N-(2-Diethylaminoethyl) 4-aminobenzamide; 4-amino-N-(2-diethylaminoethyl) benzamide; SBI-0050968.P004; AB00053530; BB 0216450; N1-[2-(diethylamino)ethyl]-4-aminobenzamide; 4-{N-[2-(diethylamino)ethyl]carbamoyl}aniline; 4-Amino-N-[2-(diethylamino)ethyl]benzamide #; C07401; C75392; D08421; AB00053530-13; AB00053530-15; AB00053530_16; 051P069; L001052; Q417597; BRD-K75089421-001-02-5; BRD-K75089421-003-04-7; BRD-K75089421-003-05-4; BRD-K75089421-003-15-3; Benzamide, 4-amino-N-(2-(diethylamino)ethyl)- (9CI); F2173-1035; 4-azanyl-N-[2-(diethylamino)ethyl]benzamide;hydrochloride"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8428	DB01035	DR00292	.	235.33	C13H21N3O	58.4	221	0.9	17	2	3	6	"1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17)"	CCN(CC)CCNC(=O)C1=CC=C(C=C1)N	REQCZEXYDRLIBE-UHFFFAOYSA-N
DG00800	Prochlorperazine	4917	"Prochlorperazine; 58-38-8; Prochlorperazin; Prochlorpromazine; Chlormeprazine; Chlorperazine; Procloperazine; Capazine; Prochlorpemazine; Compazine; Proclorperazine; Meterazin; Meterazine; Stemetil; Tementil; Kronocin; Emelent; Nipodal; Temetid; Prochlorpermazine; Novamin; Proclorperazina; Bayer A 173; Prochlorperazine maleate; Prochloroperazine; Prochlorperazinum; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine; Vertigon; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine; SKF 4657; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 6140 RP; RP 6140; UNII-YHP6YLT61T; 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine; 10H-Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-; Buccastem; CHLOPERAZINE; 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine; 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; MLS000028600; N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine; 10H-Phenothiazine, 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine; Compro; YHP6YLT61T; Prochlorperazine Base; SMR000058705; Prochlorperazine mesylate; CHEBI:8435; 2-chloro-10-(3-(4-methylpiperazin-1-yl)propyl)-10h-phenothiazine; Compazine Suppositories; Phenothiazine, 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-; Prochlorperazinum [INN-Latin]; Proclorperazina [INN-Spanish]; Proazine; MLS001148133; Compro (TN); NSC17478; NSC167375; HSDB 3171; CAS-84-02-6; Compazine (*Maleate*); SMR000653454; EINECS 200-379-4; Chloropernazine; Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-; Prochlorperazine (JAN/USP/INN); 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-10H-phenothiazine; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine [French]; Prochlorperazine [USP:INN:BAN:JAN]; Eskatrol (Salt/Mix); Spectrum_000840; Opera_ID_244; Prestwick0_000399; Prestwick1_000399; Prestwick2_000399; Prestwick3_000399; Spectrum2_001297; Spectrum3_000881; Spectrum4_000972; Spectrum5_001339; Lopac-P-9178; CHEMBL728; Probes1_000265; Probes2_000307; Lopac0_001034; SCHEMBL18429; BSPBio_000617; BSPBio_002394; KBioGR_001343; KBioGR_002304; KBioSS_001320; KBioSS_002306; cid_91499; MLS006011830; DivK1c_000413; SPBio_001333; SPBio_002538; BPBio1_000679; GTPL7279; DTXSID7023514; BDBM78434; KBio1_000413; KBio2_001320; KBio2_002304; KBio2_003888; KBio2_004872; KBio2_006456; KBio2_007440; KBio3_001762; KBio3_002784; cMAP_000013; NINDS_000413; HMS2231P21; STL371212; ZINC19796018; AKOS003600762; CCG-205112; DB00433; RP-6140; SDCCGSBI-0051005.P005; IDI1_000413; MRF-0000068; NCGC00015856-01; NCGC00015856-02; NCGC00015856-03; NCGC00015856-04; NCGC00015856-05; NCGC00015856-06; NCGC00015856-07; NCGC00015856-16; NCGC00023036-03; NCI60_022783; P77; SBI-0051005.P004; 6140 R.P.; DB-053199; AB00053532; FT-0603243; C07403; C16030; D00493; AB00053532_29; AB00053532_30; 058P388; A831861; L001030; Q2359690; BRD-K19352500-070-02-5; BRD-K19352500-070-05-8; BRD-K19352500-332-03-7; SR-01000000260-11; 2-Chloro-10-(3-(1-methyl-4-piperazinyl)-propyl)-phenothiazine; N-(.gamma.-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine; Phenothiazine, 2-chloro-10-[3-(1-methyl-4-piperazinyl)propyl]-; 2-Chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-10H-phenothiazine #; 2-chloranyl-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine;ethane-1,2-disulfonic acid; 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine;ethane-1,2-disulfonic acid; 2-chloro-10-[3-(4-methylpiperazino)propyl]phenothiazine;ethane-1,2-disulfonic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8435	DB00433	DR00592	DR1345	373.9	C20H24ClN3S	35	429	4.9	25	0	4	4	"1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3"	CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl	WIKYUJGCLQQFNW-UHFFFAOYSA-N
DG00801	Promazine	4926	"Promazine; Protactyl; Romtiazin; Sinophenin; Prazine; Promazin; Prazin; Ampazine; Berophen; Promazina; Promwill; Verophen; Esparin; Liranol; 58-40-2; Neo-Hibernex; Tomil; Promazinum; Sparine; N-(3-Dimethylaminopropyl)phenothiazine; N-Dimethylamino-1-methylethyl thiodiphenylamine; RP 3276; WY 1094; 10-(3-(Dimethylamino)propyl)phenothiazine; 10H-Phenothiazine-10-propanamine, N,N-dimethyl-; A 145; UNII-O9M39HTM5W; NSC 31447; N,N-dimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; 10-[3-(Dimethylamino)propyl]phenothiazine; 3276 R. P.; O9M39HTM5W; CHEBI:8459; Propazinum; NSC-31447; 10H-Phenothiazine-10-propanamine, N,N-dimethyl- (9CI); Promazina [Italian]; Promazine [INN:BAN]; Phenothiazine, 10-(3-(dimethylamino)propyl)-; Phenothiazine, 10-[3-(dimethylamino)propyl]-; Promazinum [INN-Latin]; dimethyl[3-(10H-phenothiazin-10-yl)propyl]amine; Promazina [INN-Spanish]; Promazine (INN); 10H-Phenothiazine-10-propanamine, N,N-dimethyl-, monohydrochloride; HSDB 3172; CAS-53-60-1; NCGC00015829-02; EINECS 200-382-0; Combelen [veterinary] (TN); SR-01000000228-4; Wy-1094; N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine; P2Z; N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine;hydrochloride; Sparine (Salt/Mix); Spectrum_000866; Dimethyl(3-phenothiazin-10-ylpropyl)amine; Prestwick0_000693; Prestwick1_000693; Prestwick2_000693; Prestwick3_000693; Spectrum2_000839; Spectrum3_001018; Spectrum4_001148; Spectrum5_001116; Lopac-P-6656; CHEMBL564; cid_5887; Lopac0_000961; Oprea1_813117; US9504692, Promazine; BSPBio_000845; BSPBio_002775; Chlorpromazine EP Impurity C; KBioGR_001695; KBioSS_001346; N,N-dimethyl-3-phenothiazin-10-yl-propan-1-amine; DivK1c_000419; SCHEMBL140489; SPBio_000797; SPBio_002766; BPBio1_000931; GTPL7281; DTXSID2023517; BDBM67545; KBio1_000419; KBio2_001346; KBio2_003914; KBio2_006482; KBio3_001995; ZINC10402; NINDS_000419; NSC31447; CCG-205041; DB00420; SDCCGSBI-0050934.P005; IDI1_000419; NCGC00015829-01; NCGC00015829-03; NCGC00015829-04; NCGC00015829-05; NCGC00015829-06; NCGC00015829-07; NCGC00015829-08; NCGC00015829-09; NCGC00015829-14; NCGC00015829-16; NCGC00024337-04; N-[3-(Dimethylamino)propyl]phenothiazine; WLN: T C666 BN ISJ B3N1&1; SBI-0050934.P004; WLN: T C666 BN ISJ BY2&N1&1; AB00053534; C07379; D08430; 10-(3-DIMETHYLAMINOPROPYL)-PHENOTHIAZINE; AB00053534_14; 058P402; A899796; L000671; Q419822; BRD-K06980535-003-15-0; dimethyl(3-phenothiazin-10-ylpropyl)amine;hydrochloride; N,N-Dimethyl-3-(10H-phenothiazin-10-yl)-1-propanamine #; N,N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine; N,N-dimethyl-3-(10-phenothiazinyl)-1-propanamine;hydrochloride; N,N-dimethyl-3-phenothiazin-10-yl-propan-1-amine;hydrochloride; Promazine; Deschloro Chlorpromazine; N,N-Dimethyl-10H-phenothiazine-10-propanamine; 3-(10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8459	DB00420	DR00887	DR1351	284.4	C17H20N2S	31.8	285	4.5	20	0	3	4	"1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3"	CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31	ZGUGWUXLJSTTMA-UHFFFAOYSA-N
DG00802	Mepyramine	4992	"Pyrilamine; Mepyramine; 91-84-9; Pyranisamine; Anthisan; Dorantamin; Mepiramine; Kriptin; Antalergan; Antallergan; Histapyran; Neoantergan; Anhistabs; Anhistol; Antamine; Copsamine; Coradon; Harvamine; Histacap; Histalon; Histasan; Maranhist; Mepyren; Nyscaps; Paraminyl; Pyramal; Stamine; Stangen; Statomin; Thylogen; Dipane; Isamin; Parmal; Neo-Bridal; Afko-Hist; Mepyramin; PYRA; Wait's green mountain antihistamine; Pyrilamide; RP 2786; NCI-C60651; UNII-HPE317O9TL; N',N'-Dimethyl-N-(p-methoxybenzyl)-N-(2-pyridyl)ethylenediamine; 1,2-Ethanediamine, N-((4-methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-; NSC13136; CHEMBL511; HPE317O9TL; N1-(4-Methoxybenzyl)-N2,N2-dimethyl-N1-(pyridin-2-yl)ethane-1,2-diamine; CHEBI:6762; 2-((p-Methoxybenzyl)(2-(dimethylamino)ethyl)amino)pyridine; Pyridine, 2-((p-methoxybenzyl)(2-(dimethylamino)ethyl)amino)-; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridyl-1,2-ethanediamine; [3H]mepyramine; [3H]pyrilamine; 1,2-Ethanediamine, N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-; NSC-13136; 102206-59-7; NCGC00015822-09; 2-((2-(Dimethylamino)ethyl)-(p-methoxybenzyl)amino)pyridine; Pyridine, 2-((2-(dimethylamino)ethyl)(p-methoxybenzyl)amino)-; DSSTox_CID_3542; N-[2-(dimethylamino)ethyl]-N-[(4-methoxyphenyl)methyl]pyridin-2-amine; N-((4-Methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; DSSTox_RID_77071; DSSTox_GSID_23542; Mepyramin [German]; p-Methoxy-benzyl-.alpha.-pyridyl-dimethyl-aethylendiamin; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine; Mepiramina; Mepyraminum; Mepyramine [INN:BAN]; Pyridine, 2-[[2-(dimethylamino)ethyl](p-methoxybenzyl)amino]-; N-(4-methoxybenzyl)-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-diamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(.alpha.-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine; Mepyraminum [INN-Latin]; Mepiramina [INN-Spanish]; N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; CAS-91-84-9; [11C]pyrilamine; [11C]-pyrilamine; [11C]-Mepyramine; CCRIS 4865; HSDB 5187; CAS-59-33-6; EINECS 202-102-2; NSC 13136; BRN 0269019; 2-[(p-Methoxybenzyl)[2-(dimethylamino)ethyl]amino]pyridine; Pyriliamine; Neobridal; 2-[[2-(Dimethylamino)ethyl]-(p-methoxybenzyl)amino]pyridine; Pyridine, 2-[(p-methoxybenzyl)[2-(dimethylamino)ethyl]amino]-; Pyrlex; 3H]pyrilamine; N,N-dimethyl-N'-{[4-(methyloxy)phenyl]methyl}-N'-pyridin-2-ylethane-1,2-diamine; N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-diamine; Mepyramine (INN); Histan (Salt/Mix); Pymafed (Salt/Mix); Antihist (Salt/Mix); Minihist (Salt/Mix); Spectrum_000904; Tocris-0660; Prefrin A (Salt/Mix); N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; N-p-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; p-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin [German]; N-(para-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; N-para-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; Prestwick0_000289; Prestwick1_000289; Prestwick2_000289; Prestwick3_000289; Spectrum2_001306; Spectrum3_000605; Spectrum4_000493; Spectrum5_001264; Lopac-P-5514; Lopac0_000890; Oprea1_317349; SCHEMBL19114; BSPBio_000198; BSPBio_002110; KBioGR_001005; KBioSS_001384; 5-22-08-00381 (Beilstein Handbook Reference); BIDD:GT0215; DivK1c_000175; p-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin; SPBio_001371; SPBio_002417; BPBio1_000218; CCRIS 1330 (Salt/Mix); GTPL1227; GTPL3957; 2-[(2-Dimethylaminoethyl)(p-methoxybenzyl)amino]pyridine; DTXSID9023542; BDBM22567; KBio1_000175; KBio2_001384; KBio2_003952; KBio2_006520; KBio3_001610; NINDS_000175; HMS2089M19; Tox21_110230; Tox21_200978; ZINC19144216; N'-[(4-methoxyphenyl)methyl]-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine; Tox21_110230_1; CCG-204972; DB06691; R.d. 2786; SDCCGSBI-0050865.P005; IDI1_000175; WLN: T6NJ BN2N1&1&1R DO1; WLN: T6NJ DN1R DO1&2N1&1; N-(p-Methoxybenzyl)-N',2-ethanediamine; NCGC00015822-01; NCGC00015822-02; NCGC00015822-03; NCGC00015822-04; NCGC00015822-05; NCGC00015822-06; NCGC00015822-07; NCGC00015822-08; NCGC00015822-10; NCGC00015822-11; NCGC00015822-12; NCGC00015822-13; NCGC00015822-15; NCGC00015822-17; NCGC00015822-21; NCGC00023513-02; NCGC00023513-04; NCGC00023513-05; NCGC00023513-06; NCGC00258531-01; SBI-0050865.P004; AB00053539; FT-0628211; D08183; AB00053539-19; AB00053539_20; AB00053539_21; L000391; Q3800087; BRD-K97564742-050-04-6; BRD-K97564742-050-05-3; BRD-K97564742-103-01-9; 1, N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-; Ethylenediamine, N',N'-dimethyl-N-(p-methoxybenzyl)-N-(2-pyridyl)-; Ethylenediamine,N'-dimethyl-N-(p-methoxybenzyl)-N-(2-pyridyl)-; n,n-dimethyl-n'-(4-methoxybenzyl)-n'-(2-pyridyl)ethylenediamine; N,N-Dimethyl-N'-(p-methoxybenzyl)-N'-(2 -Pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-(pyridylethylene)diamine; N-p-Methoxybenzyl-N',N'-dimethyl-N-.alpha.-pyridylethylenediamine; Pyridine, 2-[[2-(dimethylamino)ethyl][p-methoxybenzyl)amino]]-; N,N-Dimethyl-N'-(4-methoxybenzyl)-N'-(.alpha.-pyridyl)-ethylenediaminene; N-(4-methoxybenzyl)-N ,N -dimethyl-N-pyridin-2-ylethane-1,2-diamine; N-Dimethylamino-aethyl-N-p-methoxy-benzyl-.alpha.-amino-pyridin-maleat; 1,2-Ethanediamine, N-((4-methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl- (9CI); 1,2-Ethanediamine, N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridyl-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6762	DB06691	.	.	285.4	C17H23N3O	28.6	277	3.3	21	0	4	7	"1S/C17H23N3O/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15/h4-11H,12-14H2,1-3H3"	CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2	YECBIJXISLIIDS-UHFFFAOYSA-N
DG00804	Rabeprazole	5029	"Rabeprazole; 117976-89-3; Aciphex; Habeprazole; Pariets; 2-(((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole; CHEBI:8768; LY307640; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; Rabeprazole [INN:BAN]; 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methane}sulfinyl)-1H-1,3-benzodiazole; pariprazole; rabeprazol; Rabeloc; Eraloc; 1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-; Rabeprazole (INN); Eraloc (TN); HSDB 7321; 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole; 2-{[4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl}-1H-benzimidazole; 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2--1H-benzimidazole; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; LY 307640; CHEMBL1219; SCHEMBL23336; MLS001401446; BIDD:GT0019; GTPL7290; DTXSID3044122; HMS2052P03; HMS3394P03; AMY10338; BCP06638; HY-B0656; BDBM50070209; E-3810 (PPI); MFCD00868879; s4845; STL186112; AKOS015895259; CCG-101158; DB01129; MCULE-7848941080; NC00408; PB21725; 2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole; NCGC00388029-07; NCGC00388029-09; AS-34993; SMR000469174; SBI-0206867.P001; DB-020298; DS-002860; FT-0602569; FT-0674301; FT-0674302; Q3515; C07864; D08463; AB00698237-06; 976R893; A803856; SR-01000763041; J-003691; SR-01000763041-3; BRD-A39390670-236-04-0; (R)-2-(((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; (S)-2-(((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; 1H-benzimidazole,2-[(r)-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-; 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1H-benzimidazole; 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole; 2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methylsulfinyl]-1H-benzimidazole;Rabeprazole; 2-{[(3-Methyl-4-(3-methoxypropoxy)-2-pyridinyl)methyl]sulphinyl}1H-benzimidazole; 2-{4-(3-Methoxypropoxy)-3-methylpyridine-2-yl}methylsulfinyl-1H-benzimidazole"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8768	DB01129	DR01195	.	359.4	C18H21N3O3S	96.3	440	1.9	25	1	6	8	"1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)"	CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC	YREYEVIYCVEVJK-UHFFFAOYSA-N
DG00805	Raloxifene	5035	"Raloxifene; 84449-90-1; Keoxifene; Raloxifenum; Evista; Raloxifenum [Latin]; Raloxifeno [Spanish]; Raloxifeno; Pharoxifene; LY 139481; LY-139481; UNII-YX9162EO3I; Optruma; CHEMBL81; (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone; (2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone; [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone; Keoxifene; LY 139481;; CHEBI:8772; YX9162EO3I; NSC-747974; Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-; LY139481; 2-(4-hydroxyphenyl)-3-{4-[2-(piperidin-1-yl)ethoxy]benzoyl}-1-benzothiophen-6-ol; Raloxifene [INN:BAN]; 2-(4-hydroxyphenyl)-3-({4-[2-(piperidin-1-yl)ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol; Methanone, [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-; CCRIS 7129; HSDB 7460; NCGC00015889-05; CAS-82640-04-8; Raloxiphene; Eviden; Raxeto; Raloxifene D4; Raloxifene, 6; [2-(4-Hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-(2-(1-piperidinyl)ethoxy)phenyl]methanone; [2-(4-hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone; [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl]{4-[(2-piperidin-1-ylethyl)oxy]phenyl}methanone; Raloxifene (INN); Eviden (TN); Raxeto (TN); Prestwick0_000862; Prestwick1_000862; Prestwick2_000862; Prestwick3_000862; Lopac-R-1402; DSSTox_CID_3550; SCHEMBL6144; DSSTox_RID_77076; DSSTox_GSID_23550; Lopac0_001051; BSPBio_000903; KBioGR_002361; KBioSS_002364; BIDD:ER0216; BIDD:GT0795; SPBio_002824; BPBio1_000995; GTPL2820; DTXSID3023550; BDBM19441; KBio2_002361; KBio2_004929; KBio2_007497; KBio3_002840; cid_11071264; cMAP_000032; HMS2089F06; HMS3742O11; ZINC538275; BCP09772; Tox21_202603; MFCD00866415; NSC747974; NSC761389; s5781; AKOS015896267; AC-8399; CCG-205128; DB00481; MCULE-4598311006; NSC 747974; NSC-761389; SDCCGSBI-0051021.P003; [6-hydroxy-2-(4-hydroxyphenyl)benzothiophen-3-yl]-[4-[2-(1-piperidyl)ethoxy]phenyl]methanone; MRF-0000684; SMP2_000095; NCGC00015889-01; NCGC00015889-02; NCGC00015889-04; NCGC00015889-06; NCGC00015889-07; NCGC00015889-08; NCGC00015889-10; NCGC00015889-22; NCGC00092353-02; NCGC00092353-04; NCGC00260151-01; [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone; AS-35086; HY-13738; J22.982B; SBI-0051021.P002; CAS-84449-90-1; CS-0007764; FT-0674305; VU0155042-3; C07228; D08465; 449R901; A916152; Q425223; BRD-K63828191-003-11-5; 6-hydroxy-2-(4-hydoxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene; 6-hydroxy-2-(4-hydoxyphenyl)-3[-4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene; 6-Hydroxy-2-(4-Hydroxyphenyl)-3-[4(2-Piperidinoethoxy)benzoyl]benzo[b]thiophene; 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]-thiophene; 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene; 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2piperidinoethoxy)-benzoyl]benzo[b]thiophene; 6-hydroxy-2-(4-hydroxyphenyl)-3[-4-(2-piperidinoethoxy)benzoyl]benzo [b]thiophene; 6-hydroxy-2-(4-hydroxyphenyl)-3[-4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene; 6-hydroxy-2-(4-hydroxyphenyl)-3[-4-(2piperidinoethoxy)benzoyl]benzo[b]thiophene; 6-hydroxy-2-(4-hyroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene; [2-(4-Hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl]methanone; Raloxifeno; [6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone; [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone; [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone; [6-hydroxy-2-(4-hydroxyphenyl)benzo-[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone; [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone; [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1piperidinyl)ethoxy]phenyl]methanone; 1020061-04-4; 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl 4-[2-(1-piperidinyl)ethoxy]phenyl methanone"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8772	DB00481	DR01347	DR1388	473.6	C28H27NO4S	98.2	655	6.1	34	2	6	7	"1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2"	C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O	GZUITABIAKMVPG-UHFFFAOYSA-N
DG00806	Salsalate	5161	"Salsalate; 552-94-3; sasapyrine; Salicylsalicylic acid; Disalicylic acid; Disalcid; 2-Carboxyphenyl salicylate; Sasapyrinum; Saloxium; Salicyloylsalicylic acid; Diacesal; Diplosal; Sasapirin; Sasapyrin; Disalyl; Nobacid; Salical; Salina; Salysal; o-Salicylsalicylic acid; Sal Ester Sal; 2-(2-hydroxybenzoyl)oxybenzoic acid; Disalicylsaeure; Salicylic acid, salicylate; Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester; Salsalato; Salsalatum; Salflex; Salsalatum [INN-Latin]; NSC-49171; Salicylic acid, bimolecular ester; Salicyloxysalicylic acid; 2-((2-Hydroxybenzoyl)oxy)benzoic acid; O-Salicylcylsalicylsaeure; UNII-V9MO595C9I; 2-Hydroxybenzoic acid 2-carboxyphenyl ester; MFCD00020252; Salicylsalicylic acid;Disalicylic acid; CHEBI:9014; V9MO595C9I; Salicylic acid bimolecular ester; NSC49171; NCGC00096014-01; DSSTox_CID_3572; DSSTox_RID_77088; DSSTox_GSID_23572; Salsalato [INN-Spanish]; Mono-gesic; O-Salicyloylsalicylic Acid; Disalicylic acid;; Disalcid (TN); CAS-552-94-3; Sasapyrine (JAN); Salsalate (USP/INN); EINECS 209-027-4; NSC 49171; 2-Salicyloyloxybenzoic Acid; BRN 2590908; Disalgesic; Salicylsalicylic Acid (2-[(2-Hydroxybenzoyl)oxy]benzoic Acid); Disalicyclic acid; Salsalate [USAN:USP:INN:BAN]; Aspirin Impurity E; 2-(2-hydroxybenzoyloxy)benzoic acid; Spectrum_001998; 2-Salicylsalicylic acid; Carboxyphenyl Salicylate ; Spectrum2_000693; Spectrum3_000173; Spectrum4_000940; Spectrum5_000670; 2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic acid; 2-salicyloyloxy-benzoic acid; SCHEMBL15562; BSPBio_001665; KBioGR_001500; KBioSS_002572; SPECTRUM200331; SPBio_000845; Acetylsalicylic Acid Impurity E; CHEMBL154111; ZINC2062; DTXSID1023572; Salsalate, >=98% (HPLC); BDBM85244; KBio2_002563; KBio2_005131; KBio2_007699; KBio3_001165; HMS2091A05; HMS3652P07; HMS3885J09; Pharmakon1600-00200331; HY-B1245; NSC_5161; Benzoic acid, 2-carboxyphenyl ester; Tox21_111548; CCG-39652; NSC755823; s4188; Salicylic Acid 2-Carboxyphenyl Ester; AKOS003368478; Tox21_111548_1; 2-Carboxyphenyl salicylate, AldrichCPR; CS-4891; DB01399; MCULE-7200376848; NSC-755823; NCGC00096014-02; NCGC00096014-03; AC-18298; AS-12645; CAS_552-94-3; 2-[(2-Hydroxybenzoyl)oxy]benzoic acid #; SBI-0206687.P002; DB-020760; FT-0632376; SW219189-1; 2-[(2-hydroxyphenyl)carbonyloxy]benzoic acid; C75590; D00428; AB01563259_01; AB01563259_02; A830578; SR-05000001536; Q-100630; Q1320691; SR-05000001536-1; 2-[(2-Hydroxybenzoyl)oxy]benzoic Acid (Salicylsalicylic Acid); Salsalate, United States Pharmacopeia (USP) Reference Standard; Aspirin Impurity E; 2-Hydroxybenzoic Acid 2-Carboxyphenyl Ester; Salicylic Acid Salicylate; 2-Hydroxybenzoic Acid 2-Carboxyphenyl Ester; Salsalate (Aspirin Impurity E), Pharmaceutical Secondary Standard; Certified Reference Material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9014	DB01399	.	.	258.23	C14H10O5	83.8	341	3	19	2	5	4	"1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)"	C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O	WVYADZUPLLSGPU-UHFFFAOYSA-N
DG00809	Succinylcholine	5314	"Succinylcholine; Suxamethonium; Succinyldicholine; Succinocholine; Succinoylcholine; Dicholine succinate; Succinylbischoline; Quelicin; 306-40-1; Anectine; Ditilin; suxamethonium chloride; Ditiline; Sucostrin; 2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM); UNII-J2R869A8YF; Scoline; CHEBI:45652; CHEMBL703; trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium; J2R869A8YF; Diacetylcholine; Succinyl choline; Choline, succinyl-; Choline, succinate (ester); Succinic acid, diester with choline; trimethyl[2-({4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl}oxy)ethyl]azanium; Choline, succinate (2:1) (ester); HSDB 3254; BRN 1805311; .Succinylcholin; Suxamethonium ion; Succinylcholine ion; Suxamethonium cation; diester with choline; Succinylcholine cation; succinylcholine-chloride; 2ha2; 2ha6; Lopac-S-8251; Epitope ID:116045; Ethanaminium, 2,2'-((1,4-dioxo-1,4-butanediyl)bis(oxy))bis(N,N,N-trimethyl-; Lopac0_001080; SCHEMBL41537; 4-04-00-01451 (Beilstein Handbook Reference); MLS001183716; GTPL4004; DTXSID7048455; AXOIZCJOOAYSMI-UHFFFAOYSA-; HMS2090P14; ZINC1530820; BDBM50061568; STK177290; AKOS022084126; CCG-205157; DB00202; MCULE-7641058357; ETHANAMINIUM,2,2'-[(1,4-DIOXO-1,4-BUTANEDIYL)BIS(OXY)]BIS[N,N,N-TRIMETHYL-; trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio; NCGC00015971-01; NCGC00015971-02; NCGC00015971-03; NCGC00015971-04; NCGC00015971-07; NCGC00162336-01; SMR000677912; C07546; AB00375912-06; L000926; Q424378; 2,2''-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:45652	DB00202	.	.	290.4	C14H30N2O4+2	52.6	284	0.6	20	0	4	11	"1S/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2"	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	AXOIZCJOOAYSMI-UHFFFAOYSA-N
DG00812	Sulfamethazine	5327	"Sulfamethazine; Sulfadimidine; 57-68-1; Sulfamezathine; Sulphamethazine; Sulfadimethyldiazine; Sulfadimerazine; 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide; Sulfadimethylpyrimidine; Sulphamezathine; Sulfadimezine; Sulfadimidin; Sulphadimidine; Sulphadimethylpyrimidine; Sulfadimesin; Sulfadimesine; Sulfadimezin; Sulfadimidinum; Sulfametazyny; Sulfamethiazine; Sulphamethasine; Sulphamidine; Sulphodimezine; Sulfadine; Cremomethazine; Sulfadimidina; Sulfametazina; Sulfodimezine; Azolmetazin; Dimezathine; Intradine; Kelametazine; Pirmazin; Spanbolet; Sulfodimesin; Superseptil; Superseptyl; Vertolan; Diazil; Mermeth; Neasina; Neazina; Sulfa-Isodimerazine; Dimidin-R; Hava-Span; Calfspan Tablets; Sa III; 4,6-Dimethyl-2-sulfanilamidopyrimidine; 4-Amino-N-(4,6-dimethyl-2-pyrimidinyl)benzenesulfonamide; 2-Sulfanilamido-4,6-dimethylpyrimidine; SulfaSURE SR Bolus; N-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; 4,6-Dimethylsulfadiazine; Sulfamidine; Diazil (the sulfanilamide); Primazin; 2-(p-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine; Benzenesulfonamide, 4-amino-N-(4,6-dimethyl-2-pyrimidinyl)-; 4-Amino-N-(2,6-dimethyl-4-pyrimidinyl)benzenesulfonamide; A-502; 6-(4'-Aminobenzol-sulfonamido)-2,4-dimethylpyrimidin; N(1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; NCI-C56600; N(1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; Sulmet; Sulfadimidine;Sulfadimerazine; (p-Aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin; Sulfamethazine (USP); Sulfamethazine [USP]; UNII-48U51W007F; 2-(4-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine; CHEBI:102265; Sulfadimezinum; MFCD00006066; Sulfanilamide, N(sup1)-(4,6-dimethyl-2-pyrimidinyl)-; MLS000069711; 4-Amino-N-(4,6-dimethyl-pyrimidin-2-yl)-benzenesulfonamide; Solfadimidina; n(sup1)-(2,6-Dimethylpyrimid-4-yl)sulfanilamide; N(Sup1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; NSC67457; Sulfadimidine-d4; Sulfanilamide, N1-(4,6-dimethyl-2-pyrimidinyl)-; Sulka S Boluses; N(Sup1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; NSC-67457; NSC683529; 48U51W007F; NSC-683529; NCGC00018243-07; SMR000017409; Solfadimidina [DCIT]; Sulfametazyny [Polish]; DSSTox_CID_1290; DSSTox_RID_76062; DSSTox_GSID_21290; SMZ; Sulfadimidinum [INN-Latin]; Sulfadimidina [INN-Spanish]; Sulfametazina [Italian]; Sulfadimidine [INN:BAN]; CAS-57-68-1; BN 2409; CCRIS 3701; Sulfamezathine (TN); Sulfadimidine (INN); HSDB 4157; EINECS 200-346-4; NSC 67457; BRN 0261304; N(sup 1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; sulfamethazone; Diazilsulfadine; N(sup 1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; Calfspan; Panazin; AI3-26817; Sulka k boluses; S-Dimidine; Dimidim-R; 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzene-1-sulfonamide; (p-Aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin [German]; 6-(4'-Aminobenzol-sulfonamido)-2,4-dimethylpyrimidin [German]; Sulfadimidine,(S); Sulfanilamide, N(1)-(4,6-dimethyl-2-pyrimidinyl)-; Sulfadimidine-13C6; 4-Amino-N-(4,6-dimethyl-2-pyrimidyl)benzenesulfonamide; Sulfanilamide, N(sup1)-(2,6-dimethyl-4-pyrimidinyl)-; Sentry aq mardel biospheres maracyn plus; Spectrum_000990; [(4-Aminophenyl)sulfonyl](4,6-dimethylpyrimidin-2-yl)amine; 4-amino-N-(4; Opera_ID_1374; Prestwick0_000775; Prestwick1_000775; Prestwick2_000775; Prestwick3_000775; Spectrum2_001321; Spectrum3_001700; Spectrum4_000344; Spectrum5_001270; Sulfamethazine, >=99%; CHEMBL446; Epitope ID:122238; Cambridge id 5251384; NCIOpen2_003489; BIDD:PXR0093; Oprea1_142608; Oprea1_677935; BSPBio_000850; BSPBio_003260; CBDivE_012932; KBioGR_000747; KBioSS_001470; 5-25-10-00250 (Beilstein Handbook Reference); MLS000103403; MLS001077331; MLS002454449; DivK1c_000293; SCHEMBL151305; SPECTRUM1500548; SPBio_001441; SPBio_002789; BPBio1_000936; DTXSID6021290; Sulfanilamide, N(sup 1)-(4,6-dimethyl-2-pyrimidinyl)-; ASWVTGNCAZCNNR-UHFFFAOYSA-; HMS500O15; KBio1_000293; KBio2_001470; KBio2_004038; KBio2_006606; KBio3_002480; ZINC57494; NINDS_000293; HMS1921A17; HMS2092I19; HMS3652K03; Pharmakon1600-01500548; ALBB-033473; BCP28439; HY-B0035; Tox21_110847; Tox21_202221; Tox21_303006; CCG-39259; NSC757326; s3133; STK097514; AKOS000119894; Tox21_110847_1; BN-2409; DB01582; MCULE-7831442410; MS-1576; NSC-757326; IDI1_000293; NCGC00018243-01; NCGC00018243-02; NCGC00018243-03; NCGC00018243-04; NCGC00018243-05; NCGC00018243-06; NCGC00018243-08; NCGC00018243-09; NCGC00021490-03; NCGC00021490-04; NCGC00021490-05; NCGC00021490-06; NCGC00256371-01; NCGC00259770-01; Sulfadimidine solution, 1 mg/mL in H2O; WLN: T6N CNJ BMSWR DZ& D1 F1; AC-16126; H462; Sulfanilamide,6-dimethyl-4-pyrimidinyl)-; SBI-0051522.P003; SULFAMETHAZINE (TRISULFAPYRIMIDINES); FT-0655603; FT-0674743; N1-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; SW219689-1; Benzenesulfonamide,6-dimethyl-4-pyrimidinyl)-; Sulfamethazine 100 microg/mL in Acetonitrile; C19530; D02436; N1-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; AB00052097_12; AB00052097_13; A831551; SR-01000000211; Sulfamethazine, Vetec(TM) reagent grade, >=99%; Sulfamethazine, VETRANAL(TM), analytical standard; Q3976823; SR-01000000211-3; W-105450; 4-amino-N-(4,6-dimethyl-2-pyridyl)benzenesulfonamide; BRD-K11640013-001-02-6; BRD-K11640013-236-03-6; 2-(4-Aminobenzenesulfonylamino)-4,6-dimethylpyrimidine; F1443-4796; N(1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide sulfadimidine; Sulfadimidine, European Pharmacopoeia (EP) Reference Standard; (4-AMINO-N-(4,6-DIMETHYL-2-PYRIMIDINYL)BENZENE SULFONAMIDE; 4-amino-N~1~-(4,6-dimethyl-2-pyrimidinyl)-1-benzenesulfonamide; HSDB 4157; HSDB 4157; HSDB 4157;Sulfadimidine;Sulfadimerazine; Sulfamethazine, United States Pharmacopeia (USP) Reference Standard; Sulfadimidine for peak identification, European Pharmacopoeia (EP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:102265	DB01582	DR01210	.	278.33	C12H14N4O2S	106	377	0.3	19	2	6	3	"1S/C12H14N4O2S/c1-8-7-9(2)15-12(14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7H,13H2,1-2H3,(H,14,15,16)"	CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C	ASWVTGNCAZCNNR-UHFFFAOYSA-N
DG00813	Sulfaphenazole	5335	"Sulfaphenazole; 526-08-9; Sulphaphenazole; Sulfabid; Plisulfan; Raziosulfa; Sulfaphenazol; Sulfaphenazon; Depocid; 4-Amino-N-(1-phenyl-1H-pyrazol-5-yl)benzenesulfonamide; Depotsulfonamide; Sulfafenazol; Sulphenazole; Sulfaphenylpyrazole; Sulfaphenylpipazol; Sulfaphenazolum; Merian; Sulfafenazolo; Eftolon; Firmazolo; Paidazolo; Inamil; Isarol; Orisul; 1-Phenyl-5-sulfanilamidopyrazole; 5-Sulfanilamido-1-phenylpyrazole; Microtan pirazolo; N'-(1-Phenylpyrazol-5-yl)sulfanilamide; Sulfafenazolo [Italian]; 3-(p-Aminobenzenesulfonamido)-2-phenylpyrazole; Sulfafenazol [INN-Spanish]; Sulfaphenazol [INN-French]; Sulfaphenazolum [INN-Latin]; Benzenesulfonamide, 4-amino-N-(1-phenyl-1H-pyrazol-5-yl)-; 4-amino-N-(2-phenylpyrazol-3-yl)benzenesulfonamide; UNII-0J8L4V3F81; N1-(1-Phenylpyrazol-5-yl)sulfanilamide; 4-amino-N-(1-phenyl-1H-pyrazol-5-yl)benzene-1-sulfonamide; CHEMBL1109; N(1)-(1-Phenylpyrazol-5-yl)sulfanilamide; CHEBI:77780; 0J8L4V3F81; Sulfaphenylpyrazol; Phenylsulfapyrazole; MFCD00057226; NSC-757859; NCGC00015925-02; Solfafenazolo; CAS-526-08-9; Solfafenazolo [DCIT]; DSSTox_CID_24131; DSSTox_RID_80106; DSSTox_GSID_44131; Orisulf; Isarol V; SMR000326684; Prestwick_454; SR-01000075649; N(sup 1)-(1-Phenylpyrazol-5-yl)sulfanilamide; EINECS 208-384-3; Lopac-S-0758; Sulfaphenazole (JAN/INN); BRN 0308518; Sulfonylpyrazol; Sulfaphenazole [INN:BAN:JAN]; Sulfabid (TN); Spectrum_001406; Prestwick0_000021; Prestwick1_000021; Prestwick2_000021; Prestwick3_000021; Spectrum2_001943; Spectrum3_001741; Spectrum4_000443; Spectrum5_001185; Sulfaphenazole, >=98%; Sulfanilamide, N1-(1-phenylpyrazol-5-yl)-; Lopac0_001095; BSPBio_000081; BSPBio_003442; KBioGR_000826; KBioSS_001886; 5-25-09-00415 (Beilstein Handbook Reference); MLS000859612; MLS001056713; DivK1c_000303; SCHEMBL122040; SPECTRUM1501143; SPBio_002002; SPBio_002005; BPBio1_000091; DTXSID2044131; GTPL11352; HMS500P05; KBio1_000303; KBio2_001886; KBio2_004454; KBio2_007022; KBio3_002662; ZINC57490; 4-Amino-N-(1-phenyl-1H-pyrazol-5-yl)-benzenesulfonamide; 4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide; Sulfanilamide, N(sup 1)-(1-phenylpyrazol-5-yl)- (8CI); NINDS_000303; HMS1568E03; HMS1921J13; HMS2095E03; HMS2235J21; HMS3263K12; HMS3373E16; HMS3712E03; Pharmakon1600-01501143; Sulfaphenazole, >=98% (HPLC); ALBB-025160; BCP27626; HY-B1218; STR05485; Tox21_110262; Tox21_501095; BDBM50090677; CCG-39431; NSC757859; Pyrazole, 1-phenyl-5-sulfanilamido-; s3673; STK663863; AKOS003348743; Tox21_110262_1; CS-4843; DB06729; LP01095; MCULE-5658431414; NSC 757859; SDCCGSBI-0051065.P004; IDI1_000303; NCGC00015925-01; NCGC00015925-03; NCGC00015925-04; NCGC00015925-05; NCGC00015925-06; NCGC00015925-07; NCGC00015925-08; NCGC00015925-09; NCGC00015925-10; NCGC00015925-12; NCGC00015925-13; NCGC00015925-17; NCGC00094368-01; NCGC00094368-02; NCGC00094368-03; NCGC00094368-04; NCGC00094368-05; NCGC00261780-01; SBI-0051065.P003; AB00052218; EU-0101095; FT-0761575; Z3406; Sulfaphenazole 100 microg/mL in Acetonitrile; BIM-0051065.0001; D01954; D70410; S 0758; AB00052218_10; Q6577293; SR-01000075649-2; SR-01000075649-7; SR-01000075649-8; SR-01000075649-9; BRD-K10671814-001-05-6; BRD-K10671814-001-09-8; 4-amino-N-(1-phenyl-1H-pyrazol-5-yl)-1-benzenesulfonamide; BRN-0308518; BRN0308518; BRN 0308518;Sulfabid;Sulfaphenylpyrazol;Sulphaphenazole"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:77780	DB06729	DR01009	.	314.4	C15H14N4O2S	98.4	451	1.5	22	2	5	4	"1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2"	C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N	QWCJHSGMANYXCW-UHFFFAOYSA-N
DG00816	Sulfisoxazole	5344	"Sulfisoxazole; Sulfafurazole; 127-69-5; Sulphafurazole; Sulfisoxazol; Sulfafurazol; Sulfaisoxazole; Sulfofurazole; Sulfisoxasole; Sulphaisoxazole; Gantrisin; Sulfadimethylisoxazole; Alphazole; Amidoxal; Sulfalar; Sulfoxol; Sulfisoxazole dialamine; Sulphafurazolum; Renosulfan; Sulfasoxazole; Sulfisonazole; Accuzole; Soxomide; Sulfazin; Sulfizin; Sulsoxin; Sosol; Roxosul tablets; Sulphafurazol; Sulphisoxazol; Sulphofurazole; Chemouag; Cosoxazole; Gantrisona; Gantrosan; Isoxamin; Neazolin; Neoxazol; Sulfagan; Sulfasol; Uritrisin; Entusil; Entusul; Pancid; Soxisol; Stansin; Sulbio; Thiasin; Unisulf; Sulphadimethylisoxazole; Norilgan-S; Tl-azole; V-Sul; SK-Soxazole; 4-amino-N-(3,4-dimethylisoxazol-5-yl)benzenesulfonamide; Sulfafurazolum; Sulphisoxazole; Dorsulfan; Gantrisine; Novazolo; Novosaxazole; Saxosozine; Sodizole; Soxamide; Soxazole; Soxitabs; Sulfapolar; Sulfisin; Sulfizol; Sulfizole; Urisoxin; Roxosul; Urogan; Vagilia; Azo Gantrisin; Dorsulfan warthausen; Koro-sulf; SOXO; J-Sul; 3,4-Dimethyl-5-sulfonamidoisoxazole; 3,4-Dimethyl-5-sulfanilamidoisoxazole; 5-Sulfanilamido-3,4-dimethylisoxazole; Benzenesulfonamide, 4-amino-N-(3,4-dimethyl-5-isoxazolyl)-; 4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamide; 3,4-Dimethyl-5-sulphonamidoisoxazole; 3,4-Dimethylisoxazole-5-sulfanilamide; G-sox; 3,4-Dimethyl-5-sulphanilamidoisoxazole; 3,4-Dimethylisoxazole-5-sulphanilamide; 5-Sulphanilamido-3,4-dimethyl-isoxazole; 5-(4-Aminophenylsulfonamido)-3,4-dimethylisoxazole; 5-(p-Aminobenzenesulfonamido)-3,4-dimethylisoxazole; 5-(p-Aminobenzenesulphonamido)-3,4-dimethylisoxazole; N1-(3,4-Dimethyl-5-isoxazolyl)sulfanilamide; N'-(3,4)Dimethylisoxazol-5-yl-sulphanilamide; NCI-C50022; ERYZOLE; NU 445; Pediazole; U.S.-67; C11H13N3O3S; 4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulphonamide; 4-amino-N-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide; Sulfafurazole (INN); N(Sup1)-(3,4-Dimethyl-5-isoxazolyl)sulfanilamide; UNII-740T4C525W; CHEBI:102484; Gantrisin (TN); Sulfisoxazolum; component of Azo-Sulfizin; MFCD00003150; component of Azo Gantrisin; CHEMBL453; N(sup 1)-(3,4-Dimethyl-5-isoxazolyl)sulphanilamide; 4-amino-N-(dimethyl-1,2-oxazol-5-yl)benzene-1-sulfonamide; NSC13120; 3,4-Dimethylisoxale-5-sulfanilamide; NSC-13120; NSC683536; Sulfafurazole [INN]; 740T4C525W; NSC-683536; Sulfazin (VAN); NCGC00016384-03; NCGC00016384-10; Azosulfizin; Solfafurazolo; Sulphafuraz; 4-Amino-N-(3,4-dimethyl-isoxazol-5-yl)-benzenesulfonamide; Astrazolo; Bactesulf; Barazae; CAS-127-69-5; Resoxol; Roxoxol; Sulfagen; Suloxsol; Ganda; 4-amino-N-(3,4-dimethyl-1,2-oxazol-5-yl)benzene-1-sulfonamide; Solfafurazolo [DCIT]; DSSTox_CID_1292; NU-445; N(1)-(3,4-dimethyl-5-isoxazolyl)sulfanilamide; DSSTox_RID_76064; DSSTox_GSID_21292; N(1)-(3,4-dimethyl-5-isoxazolyl)sulphanilamide; 5-(p-Aminobenzenesulfonamido)-3,4-dimethylisooxale; Sulfafurazolum [INN-Latin]; WLN: T5NOJ CMSWR DZ& D1 E1; Sulfanilamide,4-dimethyl-5-isoxazolyl)-; SMR000037657; CCRIS 568; HSDB 797; Benzenesulfonamide,4-dimethyl-5-isoxazolyl)-; N1-(3,4-dimethylisoxazole-5-yl)sulfanilamide; SR-01000003085; EINECS 204-858-9; NSC 13120; Sulfisoxazole [USP:JAN]; NSC 683536; BRN 0263871; Gantrizin; AI3-24003; Component of Azo Gantrisin Accuzole; Prestwick_726; N(sup 1)-(3,4-Dimethyl-5-isoxazolyl)sulfanilamide; Spectrum_001024; Tocris-0731; Prestwick0_000334; Prestwick1_000334; Prestwick2_000334; Prestwick3_000334; Spectrum2_001325; Spectrum3_001728; Spectrum4_000349; Spectrum5_001222; Azo-Sulfizin (Salt/Mix); Azo Gantrisin (Salt/Mix); Epitope ID:122240; Sulfisoxazole (JP17/USP); Sulfisoxazole, >=99.0%; Oprea1_680668; Oprea1_828173; SCHEMBL23467; Sulfanilamide, N1-(3,4-dimethyl-5-isoxazolyl)-; BSPBio_000367; BSPBio_003376; KBioGR_000757; KBioSS_001504; 4-27-00-04747 (Beilstein Handbook Reference); MLS000028495; MLS000037737; MLS000563718; BIDD:GT0322; DivK1c_000579; SPECTRUM1500555; SPBio_001449; SPBio_002288; BPBio1_000405; DTXSID6021292; Sulfanilamide, N(sup 1)-(3,4-dimethyl-5-isoxazolyl)-; HMS501M21; KBio1_000579; KBio2_001504; KBio2_004072; KBio2_006640; KBio3_002596; [(4-aminophenyl)sulfonyl](3,4-dimethylisoxazol-5-yl)amine; 4-amino-N-(3,4-dimethylisoxazol-5-yl)-benzenesulfonamide; NINDS_000579; HMS1569C09; HMS2092K13; HMS2096C09; HMS2233G23; HMS3259C06; HMS3266N17; HMS3374K11; HMS3411F03; HMS3655B03; HMS3675F03; HMS3713C09; NU445; Pharmakon1600-01500555; ALBB-014131; HY-B0323; NSC33807; NSC38588; STR04988; Tox21_110409; Tox21_112958; Tox21_202265; Tox21_302851; BDBM50034452; CCG-39263; NSC-33807; NSC-38588; NSC757343; s1916; STK400452; ZINC96006009; AKOS000119074; AKOS000310021; Tox21_110409_1; AC-1941; DB00263; MCULE-3522661051; NC00536; NSC-757343; IDI1_000579; NCGC00016384-01; NCGC00016384-02; NCGC00016384-04; NCGC00016384-05; NCGC00016384-06; NCGC00016384-07; NCGC00016384-08; NCGC00016384-09; NCGC00016384-11; NCGC00016384-12; NCGC00016384-14; NCGC00016384-15; NCGC00023116-02; NCGC00023116-05; NCGC00023116-06; NCGC00023116-07; NCGC00023116-08; NCGC00256605-01; NCGC00259814-01; R536; SBI-0051529.P003; DB-041869; UPCMLD00X127-69-5:001; AB00052104; BB 0259593; FT-0631743; SW196872-3; U0098; C07318; D00450; H10712; J10241; N1-(3,4-Dimethyl-5-isoxazolyl)sulphanilamide; AB00052104-14; AB00052104_15; AB00052104_16; Q372598; Sulfisoxazole, VETRANAL(TM), analytical standard; 5-(4-Aminophenylsulphonamido)-3,4-dimethylisoxazole; J-005528; SR-01000003085-2; SR-01000003085-5; SR-01000003085-6; 5-(p-Aminobenzenesulphonamide)-3,4-dimethylisoxazole; BRD-K50859149-001-05-4; BRD-K50859149-001-10-4; Sulfanilamide, N(sup1)-(3,4-dimethyl-5-isoxazolyl)-; Sulfanilamide, N.sup1.-(3,4-dimethyl-5-isoxazolyl)-; F0848-0391; 4-amino-N-(3,4-dimethyl-5-isoxazolyl)benzene-sulfonamide; 4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamide #; Sulfafurazole, European Pharmacopoeia (EP) Reference Standard; Sulfisoxazole, United States Pharmacopeia (USP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:102484	DB00263	.	DR1510	267.31	C11H13N3O3S	107	374	1	18	2	6	3	"1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3"	CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N	NHUHCSRWZMLRLA-UHFFFAOYSA-N
DG00818	Gatifloxacin	5379	"Gatifloxacin; 112811-59-3; Tequin; Gatiflo; Zymar; AM-1155; Zymaxid; AM 1155; gatifloxacin anhydrous; CG 5501; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; BMS-206584; GTFX; BMS 206584-01; PD 135432; 1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; Gatifloxacin hydrate; CHEMBL31; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; PD-135432; CHEBI:5280; Gatilox; Gatiquin; Gatispan; 160738-57-8; Gaity; CG5501; MFCD00895399; NSC-758701; gatifloxin; NCGC00068236-02; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid; DSSTox_CID_25704; DSSTox_RID_81076; DSSTox_GSID_45704; Gatifloxacin [USAN:INN]; Bonoq; Tymer; Zymer; 1-cyclopropyl-6-fluoro- 8-methoxy-7-(3-methylpiperazin-1-yl)- 4-oxo-quinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid,1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-; SMR000043336; Gatifloxacin (TN); Gatifloxacin (INN); CAS-112811-59-3; Zymer (TN); 1-cyclopropyl-6-fluoro-8-methoxy-7-; SR-01000610458; (3-methylpiperazin-1-yl)-4-oxo-1,4-; gatifloxacino; gatifloxacinum; Gatifloxcin; Tequin in dextrose 5% in plastic container; AM-1155 (*Sesquihydrate*); Gatifloxacin & Gamma Interferon; Gatifloxacin,(S); (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; CG-5501; Kinome_3137; Spectrum_001909; CPD000043336; PD135432; BMS-206584-01; Spectrum2_000487; Spectrum3_000999; Spectrum4_001127; Spectrum5_001468; Gatifloxacin (sesquihydrate); SCHEMBL22591; BSPBio_002697; KBioGR_001613; KBioSS_002448; 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; MLS000040259; MLS000759493; MLS006011836; SPECTRUM1504272; SPBio_000353; Gatifloxacin Sesquihydrate,(S); DTXSID5045704; GTPL10816; KBio2_002442; KBio2_005010; KBio2_007578; KBio3_001917; HMS1922J15; HMS2090K10; HMS2093G06; HMS2233D20; HMS3259P06; HMS3372J10; HMS3372J12; HMS3715N03; Pharmakon1600-01504272; ALBB-028535; AMY17781; BCP13408; RKL10068; Tox21_110984; BBL010485; BDBM50117914; CCG-39529; NSC758701; s1340; STK801620; C19H22FN3O4.1.5H2O; AKOS004119932; AKOS016340697; Tox21_110984_1; AC-1944; CS-1841; DB01044; KS-1066; MCULE-4557972261; NC00702; NSC 758701; NCGC00068236-03; NCGC00068236-04; NCGC00068236-05; NCGC00068236-06; NCGC00068236-07; NCGC00068236-08; NCGC00095126-01; NCGC00095126-02; NCGC00178525-01; BMS-20658401; HY-10581; SBI-0206764.P001; DB-019145; Gatifloxacin 100 microg/mL in Acetonitrile; FT-0626635; FT-0631189; FT-0668952; G0325; C07661; D08011; G-2380; AB00171654-13; AB00171654-14; AB00171654_16; AB00171654_17; 811G593; A802657; Gatifloxacin, Antibiotic for Culture Media Use Only; Q2365016; SR-01000610458-2; SR-01000610458-3; BRD-A74980173-001-02-8; BRD-A74980173-001-06-9; 1-Cyclopropyl-6-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-6-fluoro-1,4-dihydro-8-methoxy-7-(3methylpiperazin-1-yl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic a; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazino)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:5280	DB01044	DR01165	.	375.4	C19H22FN3O4	82.1	653	-0.7	27	2	8	4	"1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)"	CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F	XUBOMFCQGDBHNK-UHFFFAOYSA-N
DG00819	Tazarotene	5381	"Tazarotene; 118292-40-3; Tazorac; Zorac; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Avage; AGN-190168; Fabior; AGN 190168; Tazarotene (Avage); UNII-81BDR9Y8PS; C21H21NO2S; 81BDR9Y8PS; CHEMBL1657; ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate; CHEBI:32184; ethyl 6-[2-(4,4-dimethyl-3,4-dihydro-2H-1-benzothiopyran-6-yl)ethynyl]pyridine-3-carboxylate; NCGC00167525-01; ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate; DSSTox_CID_26691; DSSTox_RID_81825; DSSTox_GSID_46691; tazaroteno; tazarotenum; Suretin; Tazoral; Zora; 6-(4,4-Dimethyl-thiochroman-6-ylethynyl)-nicotinic acid ethyl ester; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate;6-(4,4-dimethyl-thiochroman-6-ylethynyl)-nicotinic acid ethyl ester; Tazorac (TN); Avage (TN); CAS-118292-40-3; Acnitaz; ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]pyridine-3-carboxylate; ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)-ethynyl)nicotinate; Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)-ethynyl]nicotinate; Tazarotene (JAN/USAN/INN); Tazarotene [USAN:INN:BAN]; Zorac; ; ; Tazorac; Tazarotene,(S); Tazarotene- Bio-X; Fabior (TN); 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester; SCHEMBL3134; Idp-123; MLS003915630; BIDD:GT0293; GTPL6952; DTXSID5046691; HMS3655K05; HMS3747C19; HMS3747E19; ACT06773; AMY31169; BCP22966; ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl] nicotinate; ZINC1542199; Tox21 112522; Tox21_112522; AC-755; BDBM50265951; MFCD00867628; s1569; AKOS015902872; Tox21_112522_1; BS-1012; CCG-268046; CS-1029; DB00799; NCGC00167525-02; NCGC00167525-03; 6-[(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester; BT164442; HY-15388; SMR002096194; BCP0726000163; DB-014992; FT-0652578; SW220026-1; T3108; AGN190168, AGN-190168; D01132; AB01274801-01; AB01274801_02; 292T403; A846572; SR-01000931253; Q-102516; Q3981685; SR-01000931253-2; Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate; 6-(4,4-dimethylthiochroman-6-ylethynyl) nicotinic acid ethyl ester; (+/-)OCTAHYDROCYCLOPENTA[B]PYRROLE-2-CARBOXYLICACIDHYDROCHLORIDE; 6-(2-(4,4-dimethyl-thiochroman-6yl)ethynyl)-nicotinic acid ethyl ester; Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate; 6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]- 3-pyridinecarboxylic Acid Ethyl Ester; 6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester; 6-[2-(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylicacidethylester"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:32184	DB00799	.	DR1536	351.5	C21H21NO2S	64.5	547	4.9	25	0	4	5	"1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3"	CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C	OGQICQVSFDPSEI-UHFFFAOYSA-N
DG00823	Thiethylperazine	5440	"Thiethylperazine; Torecan; ETHYLTHIOPERAZINE; 1420-55-9; Tietilperazina; Thiethylperazinum; Norzine; Thiethylperazine maleate; UNII-8ETK1WAF6R; 2-(ethylthio)-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine; 8ETK1WAF6R; 3-Ethylmercapto-10-(1'-methylpiperazinyl-4'-propyl)phenothiazine; 10H-Phenothiazine, 2-(ethylthio)-10-(3-(4-methyl-1-piperazinyl)propyl)-; 2-(ethylsulfanyl)-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine; CHEBI:9544; 1179-69-7; 2-(Ethylthio)-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 2-ethylsulfanyl-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine; Thiethylpipezazine; GS-95; Theithylperazine; 2-(Ethylthio)-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine; Tietilperazina [DCIT]; Phenothiazine, 2-(ethylthio)-10-(3-(4-methyl-1-piperazinyl)propyl)-; 10H-Phenothiazine, 2-(ethylthio)-10-[3-(4-methyl-1-piperazinyl)propyl]-; Thiethylperazinum [INN-Latin]; 2-Ethylthio-10-(3-(4-methylpiperazin-1-yl)propyl)phenothiazine; Thioethylperazine; MLS002154140; Phenothiazine, 2-(ethylthio)-10-[3-(4-methyl-1-piperazinyl)propyl]-; Thiethylperazine [USAN:INN:BAN]; 2-(ethylthio)-10-(3-(4-methylpiperazin-1-yl)propyl)-10H-phenothiazine; NSC130044; HSDB 3400; Norzine (*Dimaleate*); SMR001233447; EINECS 215-819-0; GS-95 (*Dimaleate*); Thiethylperazine (USAN/INN); Norzine (Salt/Mix); Torecan (Salt/Mix); Tresten (Salt/Mix); CHEMBL1378; SCHEMBL49124; GTPL7306; DTXSID1023651; BDBM78436; cid_3085006; BCP09601; Thiethylperazine maleate (Salt/Mix); ZINC22446674; DB00372; NCGC00262537-04; AB00514742; C07132; D02354; L000871; Q372725; 2-(Ethylthio)-10-[3-(4-methyl-1-piperazinyl)propyl]phenthiazine; 2-(ethylthio)-10-[3-(4-methylpiperazino)propyl]phenothiazine;malic acid; 2-(Ethylsulfanyl)-10-[3-(4-methyl-1-piperazinyl)propyl]-10H-phenothiazine #; 2-(ethylthio)-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine;2-hydroxybutanedioic acid; 2-ethylsulfanyl-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine;2-oxidanylbutanedioic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9544	DB00372	.	.	399.6	C22H29N3S2	60.3	455	5.4	27	0	5	6	"1S/C22H29N3S2/c1-3-26-18-9-10-22-20(17-18)25(19-7-4-5-8-21(19)27-22)12-6-11-24-15-13-23(2)14-16-24/h4-5,7-10,17H,3,6,11-16H2,1-2H3"	CCSC1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)C	XCTYLCDETUVOIP-UHFFFAOYSA-N
DG00824	Tiapride	5467	"Tiapride; 51012-32-9; Thiapride; N-(2-(Diethylamino)ethyl)-2-methoxy-5-(methylsulfonyl)benzamide; UNII-LAH70H9JPH; Thiapride; Tiapride; N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide; LAH70H9JPH; Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-5-(methylsulfonyl)-; BENZAMIDE, N-(2-(DIETHYLAMINO)ETHYL)-2-METHOXY-5-(METHYLSULFONYL)-; Tiaprida; Tiapridum; Tiapridum [INN-Latin]; Tiaprida [INN-Spanish]; FLO 1347; Tiapride [INN:BAN:DCF]; NSC-758225; NCGC00015996-02; EINECS 256-907-9; CAS-51012-33-0; BRN 2390588; Tiapridal (TN); Tiapride (INN); Spectrum_001354; Prestwick0_000216; Prestwick1_000216; Prestwick2_000216; Prestwick3_000216; Spectrum2_001521; Spectrum3_001556; Spectrum4_000778; Spectrum5_001048; Lopac-T-0410; Lopac0_001124; SCHEMBL34750; BSPBio_000231; BSPBio_003032; KBioGR_001196; KBioSS_001834; CHEMBL84158; DivK1c_000738; SPBio_001302; SPBio_002152; BPBio1_000255; DTXSID0023664; BDBM82073; CHEBI:94666; JTVPZMFULRWINT-UHFFFAOYSA-; KBio1_000738; KBio2_001834; KBio2_004402; KBio2_006970; KBio3_002532; N-(2-(Diethylamino)ethyl)-5-(methylsulfonyl)-o-anisamide; NINDS_000738; NSC_5467; ZINC1542927; AKOS015888370; CCG-205199; DB13025; MCULE-5546780960; NSC 758225; SDCCGSBI-0051092.P004; IDI1_000738; NCGC00015996-01; NCGC00015996-03; NCGC00015996-04; NCGC00015996-05; NCGC00015996-06; NCGC00015996-07; NCGC00015996-14; NCGC00024353-03; AC-12185; SBI-0051092.P003; CAS_51012-32-9; AB00053640; D08590; AB00053640_12; 012T329; L001185; Q416414; BRD-K57432881-003-05-1; BRD-K57432881-003-14-3; N-(2-Diethylaminoethyl)-2-Methoxy-5-Methylsulfonyl-Benzamide; N-(DIETHYLAMINOETHYL) 2-METHOXY 5-METHYLSULFONYLBENZAMIDE; diethyl-[2-[(2-methoxy-5-methylsulfonylbenzoyl)amino]ethyl]azanium chloride; N-[2-(diethylamino)ethyl]-2-(methyloxy)-5-(methylsulfonyl)benzamide; N-[2-(diethylamino)ethyl]-5-methanesulfonyl-2-methoxybenzene-1-carboximidic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:94666	DB13025	.	.	328.4	C15H24N2O4S	84.1	443	0.9	22	1	5	8	"1S/C15H24N2O4S/c1-5-17(6-2)10-9-16-15(18)13-11-12(22(4,19)20)7-8-14(13)21-3/h7-8,11H,5-6,9-10H2,1-4H3,(H,16,18)"	CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC	JTVPZMFULRWINT-UHFFFAOYSA-N
DG00829	Triamterene	5546	"Triamterene; 396-01-0; 6-phenylpteridine-2,4,7-triamine; 2,4,7-Triamino-6-phenylpteridine; Dyrenium; Dytac; Pterofen; Pterophene; Triamteren; Triamteril; Triteren; Ademin; Ademine; Diurene; Noridil; Taturil; Teridin; Urocaudal; Jatropur; Noridyl; Triampur; Diren; Ditak; Dyren; Teriam; Tri-Span; Triamteril complex; Trispan; 6-Phenyl-2,4,7-pteridinetriamine; 2,4,7-Pteridinetriamine, 6-phenyl-; SK&F 8542; 6-Phenyl-2,4,7-triaminopteridine; SKF 8542; Pteridine, 2,4,7-triamino-6-phenyl-; 2,4,7-Triamino-6-fenilpteridina; C12H11N7; UNII-WS821Z52LQ; BRN 0266723; Diucelpin; NSC-77625; SK-8542; WS821Z52LQ; Masuharmin; Triamizide; Triamthiazid; Amteren; Dinazide; Diutensat; Diuteren; Dyberzide; Dytenzide; Esiteren; Hidiurese; Hydrene; Hypertorr; Jenateren; Kalspare; Nephral; Renezide; Reviten; Tricilone; Triurene; Uretren; Diarol; Isobar; Trizid; Anjal; Dazid; Turfa; Apo-triazide; Thiazid Wolff; NCI-C56042; NSC77625; Ademin(e); MFCD00006708; NCGC00016016-10; Triamterena; Triamterenum; CAS-396-01-0; Triazide; Fluss 40; SALI-PUREN; DSSTox_CID_1373; DSSTox_RID_76117; DSSTox_GSID_21373; Triamterenum [INN-Latin]; Triamterena [INN-Spanish]; Dyrenium (TN); CCRIS 5872; Pteridine deriv. 11; HSDB 3405; 2,4,7-Triamino-6-fenilpteridina [Italian]; NCI C56042; SR-01000002968; EINECS 206-904-3; NSC 77625; NSC 639359; AI3-60017; Prestwick_480; SK&F-8542; Dyazide (Salt/Mix); Triamterene [USAN:USP:INN:BAN:JAN]; Spectrum_000508; Triamterene, >=99%; Prestwick0_000034; Prestwick1_000034; Prestwick2_000034; Prestwick3_000034; Spectrum2_000938; Spectrum3_001372; Spectrum4_000366; Spectrum5_001034; Lopac-T-4143; CHEMBL585; T 4143; NCIOpen2_004741; Lopac0_001196; Oprea1_825704; SCHEMBL40707; BSPBio_000127; BSPBio_002924; KBioGR_000831; KBioSS_000988; 5-26-17-00447 (Beilstein Handbook Reference); MLS000069431; BIDD:GT0534; DivK1c_000433; SPECTRUM1500589; SPBio_000876; SPBio_002048; BDBM6644; BPBio1_000141; CHEBI:9671; GTPL4329; Triamterene (JP17/USP/INN); 2,7-Triamino-6-phenylpteridine; 6-Phenyl-2,7-triaminopteridine; DTXSID6021373; HMS501F15; KBio1_000433; KBio2_000988; KBio2_003556; KBio2_006124; KBio3_002144; SKF8542; NINDS_000433; 3'-Bromobiphenyl-3-carboxylicacid; HMS1568G09; HMS2092O17; HMS2095G09; HMS2232B04; HMS3259C08; HMS3263P13; HMS3371D10; HMS3652E10; HMS3712G09; Pharmakon1600-01500589; ZINC120286; 2,7-Pteridinetriamine, 6-phenyl-; Pteridine,4,7-triamino-6-phenyl-; BCP28855; HY-B0575; 2,4,7-triamino-6-phenyl-pteridine; Tox21_110283; Tox21_202021; Tox21_302833; Tox21_501196; CCG-40090; NSC639359; NSC757367; s4080; STK300348; AKOS003790819; Tox21_110283_1; DB00384; LP01196; MCULE-5832721534; NC00544; NSC-639359; NSC-757367; SDCCGSBI-0051163.P004; IDI1_000433; SMP1_000147; NCGC00016016-01; NCGC00016016-02; NCGC00016016-03; NCGC00016016-04; NCGC00016016-05; NCGC00016016-06; NCGC00016016-07; NCGC00016016-08; NCGC00016016-09; NCGC00016016-11; NCGC00016016-12; NCGC00016016-13; NCGC00016016-14; NCGC00016016-15; NCGC00016016-16; NCGC00016016-18; NCGC00016016-28; NCGC00016016-29; NCGC00023458-03; NCGC00023458-04; NCGC00023458-05; NCGC00023458-06; NCGC00023458-07; NCGC00256495-01; NCGC00259570-01; NCGC00261881-01; AC-14066; AS-12471; SMR000059118; SBI-0051163.P003; DB-049442; AB00052116; B2275; BB 0256885; EU-0101196; SW196688-3; T1288; Triamterene 1.0 mg/ml in Dimethyl Sulfoxide; Dyrenium; ; ; 2,4,7-Triamino-6-phenylpteridine; D00386; D95706; WLN: T66 BN DN GN JNJ CZ EZ HR& IZ; AB00052116_13; AB00052116_14; 396T010; A824641; Q221520; SR-01000002968-2; SR-01000002968-4; SR-01000002968-6; BRD-K92049597-001-05-9; BRD-K92049597-001-10-9; Z275128596; Triamterene, British Pharmacopoeia (BP) Reference Standard; Triamterene, European Pharmacopoeia (EP) Reference Standard; Triamterene, United States Pharmacopeia (USP) Reference Standard; Triamterene, Pharmaceutical Secondary Standard; Certified Reference Material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9671	DB00384	DR01341	DR1636	253.26	C12H11N7	130	307	1	19	3	7	1	"1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)"	C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N	FNYLWPVRPXGIIP-UHFFFAOYSA-N
DG00830	Trifluoperazine	5566	"Trifluoperazine; Trifluperazine; 117-89-5; Trifluoroperazine; Trifluoperazin; Triflurin; Triperazine; Trifluoperazina; Flurazine; Trifluoromethylperazine; Stelazine; Trifluoperazinum; Trifluroperizine; Triphthasine; Eskazine; RP 7623; Fluoperazine; TFP; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; NSC 17474; 10-(3-(4-methylpiperazin-1-yl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; Calmazine; UNII-214IZI85K3; 10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine; 10H-Phenothiazine, 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-; 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine; 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE; SKF 5019; CHEBI:45951; 214IZI85K3; 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-; NSC-17474; NSC17474; Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-; Trifluoperazina [Italian]; Apo-Trifluoperazine; Trifluoperazine [INN:BAN]; Trifluoperazinum [INN-Latin]; Trifluoperazina [INN-Spanish]; MLS001146870; MLS002702821; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; SMR001566649; CCRIS 6994; NSC-46061; C21H24F3N3S; HSDB 3195; Trifluoperazine (INN); 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride; CAS-440-17-5; EINECS 204-219-4; Apo-trifluoperazine (TN); NSC 46061; Stelazine (*Dihydrochloride*); 2-Trifluoromethyl-10-[3'-(1-methyl-4-piperazinyl)propyl]phenothiazine; Phenothiazine, 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-; NCI17474; Synklor (Salt/Mix); Stelazine (Salt/Mix); Triftazin (Salt/Mix); Spectrum_000668; Terfluzine (Salt/Mix); Triftazine (Salt/Mix); Jatroneural (Salt/Mix); Fluoperazine (Salt/Mix); Triphthazine (Salt/Mix); Prestwick0_000313; Prestwick1_000313; Prestwick2_000313; Prestwick3_000313; Spectrum2_000828; Spectrum3_001374; Spectrum4_000368; Spectrum5_001553; Lopac-T-8516; Biomol-NT_000060; CHEMBL422; cid_5566; 2-(((4-chlorophenyl)sulfonyl)amino)-benzoicaci; NCIStruc1_001127; NCIStruc2_001093; BIDD:PXR0132; Lopac0_001232; SCHEMBL24866; BSPBio_000306; BSPBio_001190; BSPBio_002928; GTPL214; KBioGR_000530; KBioGR_000835; KBioGR_002431; KBioSS_000530; KBioSS_001148; KBioSS_002437; MLS006011857; DivK1c_000843; SPBio_000755; SPBio_002525; BPBio1_000338; BPBio1_001345; DTXSID1046928; BDBM79181; cid_2913535; KBio1_000843; KBio2_000530; KBio2_001148; KBio2_002431; KBio2_003098; KBio2_003716; KBio2_004999; KBio2_005666; KBio2_006284; KBio2_007567; KBio3_000959; KBio3_000960; KBio3_002148; KBio3_002910; cMAP_000048; NINDS_000843; Bio1_000458; Bio1_000947; Bio1_001436; Bio2_000435; Bio2_000915; HMS1362L11; HMS1792L11; HMS1990L11; HMS2089J11; HMS3429O07; KUC109776N; BCP32898; EX-A3330; CCG-37306; NCGC00013226; PDSP1_001300; PDSP2_001284; s5856; STK182873; ZINC19418959; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine; AKOS001487920; DB00831; MCULE-3726407978; RP-7623; SDCCGSBI-0051199.P005; IDI1_000843; IDI1_002190; KSC-210-031; MRF-0000088; QTL1_000085; NCGC00013226-02; NCGC00013226-03; NCGC00013226-04; NCGC00013226-05; NCGC00013226-06; NCGC00013226-07; NCGC00013226-08; NCGC00013226-09; NCGC00013226-10; NCGC00013226-11; NCGC00013226-12; NCGC00013226-13; NCGC00013226-15; NCGC00013226-26; NCGC00024251-03; NCGC00024251-04; NCGC00024251-05; NCGC00024251-06; NCGC00024251-07; M989; NCI60_001427; NCI60_004087; SBI-0051199.P003; AB00053558; FT-0650159; C07168; D08636; AB00053558-27; AB00053558_28; AB00053558_29; L001075; Q1752915; SR-01000003020-6; BRD-K89732114-001-02-6; BRD-K89732114-001-03-4; BRD-K89732114-001-05-9; BRD-K89732114-300-05-5; BRD-K89732114-300-07-1; Triphthazine;Trifluperazine;NSC-17474;RP-7623;SKF-5019; 10-(.gamma.-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiozine; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine #; 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)phenothiazine;hydrochloride; 10-[3-(4-methylpiperazino)propyl]-2-(trifluoromethyl)phenothiazine;hydrochloride"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:45951	DB00831	DR00664	DR1641	407.5	C21H24F3N3S	35	510	5	28	0	7	4	"1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3"	CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F	ZEWQUBUPAILYHI-UHFFFAOYSA-N
DG00831	Tropicamide	5593	"Tropicamide; 1508-75-4; Mydriacyl; Mydriaticum; Bistropamide; N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide; Tropicamidum; Visumidriatic; Ro 1-7683; N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide; Mydriafair; Tropicacyl; Minims tropicamide; Epitromina; Tropikamid; Mydrum; Tropimil; MFCD00058580; NSC-757372; NCGC00016065-07; Tropicamida; Benzeneacetamide, N-ethyl-.alpha.-(hydroxymethyl)-N-(4-pyridinylmethyl)-; DSSTox_CID_25220; DSSTox_RID_80757; DSSTox_GSID_45220; Tropicamidum [INN-Latin]; Tropicamida [INN-Spanish]; Tropicamid; Mydriacyl (TN); N-Ethyl-N-(4-pyridylmethyl)tropamid; N-Ethyl-N-(4-pyridylmethyl)tropamide; SMR000058523; SR-01000075351; EINECS 216-140-2; N-Ethyl-alpha-(hydroxymethyl)-N-(4-pyridinylmethyl)benzeneacetamide; BRN 0285563; Tropicamide, solid; Benzeneacetamide, N-ethyl-alpha-(hydroxymethyl)-N-(4-pyridinylmethyl)-; Prestwick_487; CAS-1508-75-4; component of Paremyd; Hydracrylamide, N-ethyl-2-phenyl-N-(4-pyridylmethyl)-; Tropicamide [USAN:USP:INN:BAN:JAN]; (+-)-N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide; Spectrum_000584; Prestwick0_000228; Prestwick1_000228; Prestwick2_000228; Prestwick3_000228; Spectrum2_000936; Spectrum3_000655; Spectrum4_000377; Spectrum5_001585; T 9778; Lopac0_001223; SCHEMBL23975; BSPBio_000275; BSPBio_002289; KBioGR_000873; KBioSS_001064; 5-22-09-00359 (Beilstein Handbook Reference); MLS001306442; MLS002154240; DivK1c_000448; SPECTRUM1500599; SPBio_000872; SPBio_002196; BPBio1_000303; CHEBI:9757; GTPL7319; Tropicamide (JP17/USP/INN); CHEMBL1200604; DTXSID8045220; BDBM82371; HMS501G10; KBio1_000448; KBio2_001064; KBio2_003632; KBio2_006200; KBio3_001509; NINDS_000448; HMS1568N17; HMS1921I09; HMS2089M05; HMS2092A18; HMS2095N17; HMS2235J15; HMS3259M18; HMS3263F08; HMS3267A13; HMS3373B07; HMS3411F14; HMS3651K04; HMS3675F14; HMS3712N17; HMS3742C05; HMS3884E16; Pharmakon1600-01500599; BCP13504; HY-B0321; NSC_5593; Tox21_110297; Tox21_501223; AC-816; BBL028074; CCG-40076; NSC757372; s1913; STK934612; AKOS005664076; Tox21_110297_1; AM84467; DB00809; KS-5174; LP01223; MCULE-4102613027; NC00589; NSC 757372; SDCCGSBI-0051190.P004; Benzeneacetamide, N-ethyl-alpha-(hydroxymethyl)-N-(4-pyridinylmethyl)-, (+-)-; IDI1_000448; SMP1_000304; NCGC00016065-03; NCGC00016065-04; NCGC00016065-05; NCGC00016065-06; NCGC00016065-08; NCGC00016065-09; NCGC00016065-11; NCGC00016065-22; NCGC00024866-02; NCGC00024866-03; NCGC00024866-04; NCGC00024866-05; NCGC00024866-06; NCGC00261908-01; CAS_1508-75-4; SBI-0051190.P003; RO-1-7683; AB00052120; EU-0101223; FT-0657590; SW196691-3; T1470; C72868; D00397; Q29310; AB00052120-10; AB00052120_11; AB00052120_12; 508T754; L001262; Q-201902; SR-01000075351-1; SR-01000075351-3; SR-01000075351-5; SR-01000075351-7; BRD-A79672927-001-05-8; BRD-A79672927-001-10-8; Tropicamide, European Pharmacopoeia (EP) Reference Standard; N-Ethyl-3-hydroxy-2-phenyl-N-(4-pyridinylmethyl)propanamide #; Tropicamide, United States Pharmacopeia (USP) Reference Standard; Tropicamide for peak identification, European Pharmacopoeia (EP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9757	DB00809	.	.	284.35	C17H20N2O2	53.4	310	1.5	21	1	3	6	"1S/C17H20N2O2/c1-2-19(12-14-8-10-18-11-9-14)17(21)16(13-20)15-6-4-3-5-7-15/h3-11,16,20H,2,12-13H2,1H3"	CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2	BGDKAVGWHJFAGW-UHFFFAOYSA-N
DG00833	Reserpine	5770	"Reserpine; 50-55-5; Serpalan; Serpasil; Apoplon; Serpivite; Hypersil; Alserin; Elserpine; Hiserpia; Raunervil; Raupasil; Rausedil; Rausedyl; Rauwasedin; Reserpin; Serpanray; Resine; Rivasin; Sandril; Serpate; (-)-Reserpine; Rau-Sed; Ascoserpina; Austrapine; Bioserpine; Enipresser; Eskaserpine; Helfoserpin; Hiposerpil; Maviserpin; Mayserpine; Mephaserpin; Purserpine; Rauserpine; Reserpamed; Reserpanca; Alkarau; Apsical; Banasil; Benazyl; Carditivo; Carrserp; Escaspere; Eserpine; Eskaserp; Hypersine; Idsoserp; Interpina; Lemiserp; Loweserp; Neoserfin; Neoserp; Quiescin; Raudiford; Raudixoid; Rauloydin; Raumorine; Raunorine; Raupoid; Raurine; Rausedan; Rauserpol; Rausingle; Rautrin; Rauvlid; Rauwilid; Rauwipur; Rauwoleaf; Rawilid; Resedrex; Reserbal; Resercaps; Resercen; Reserjen; Reserlor; Reserpal; Reserpene; Reserpex; Reserpil; Reserpina; Reserpoid; Respital; Restran; Riserpa; Roxinoid; Kitine; Raucap; Raugal; Raulen; Rausan; Reserp; Key-serpine; 3P Reserp; Crystoserpine; Neo-antitensol; Rauserpin-Alk; Deserpine; Reserpinum; Ryser; Reserfia; 3,4,5-Trimethoxybenzoyl methyl reserpate; V-Serp; Carpacil; Gilucard; Klimanosid; Resaltex; Resedril; Reserpidefe; Recipin; Serpine; ENT 50146; Raunova; Residin; Serpivate; Rese-lar; Reser-ar; NCI-C50157; H 520; UNII-8B1QWR724A; Sedaraupina; Temposerpine; Eberpine; Raudixin; Reserpur; Residine; Resocalm; Resperine; Rezerpin; Sandron; Sedaraupin; Sedserp; Serfolia; Serolfia; Serpaloid; Serpasol; Serpazol; Serpena; Serpentil; Serpentina; Serpicon; Serpiloid; Serpogen; Serpoid; Serpone; Sertabs; Sertens; Sertina; Triserpin; Unilord; Serfin; Serpen; Roxel; Vio-Serpine; SK-Reserpine; Renese R; T-Serp; C33H40N2O9; CHEMBL772; Broserpine; R-e-s; Sederaupin; Serpaneurona; Tefaserpina; Tenserpinie; Tepserpine; Eberspine; Reserpka; Resiatric; Resperin; Rivased; Rolserp; Roxynoid; Serpazil; Serpedin; Serpentin; Serpipur; Serpyrit; Sertensin; Serpil; Tempo-Reserpina; 8B1QWR724A; 50-55-5 (free); Mallopress; Rcra waste number U200; Hydropine; Hydroserp; Rauwita; .gamma.-Serpine; CHEBI:28487; Hydromox-R; Diurese-R; NSC59272; Metatensin #2; Metatensin #4; MFCD00005091; NSC-59272; component of Naquival; component of Regroton; Hydropres 25; Hydropres 50; Hydrosine 25; NSC-237659; (3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester; methyl (1S,2R,3R,4aS,13bR,14aS)-2,11-dimethoxy-3-((3,4,5-trimethoxybenzoyl)oxy)-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylate; methyl (3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate; Usaf cb-27; component of Renese R; component of Metatensin; NCGC00091250-04; Hydroserpalan; Diupres 250; Diupres 500; l-Carpserp; component of Butiserpazide; DSSTox_CID_1237; Hydroserpine Plus; Hydroserpine #1; DSSTox_RID_76029; DSSTox_GSID_21237; Chloroserp-250; Chloroserp-500; Chloroserpin-250; Yohimban-16-carboxylic acid,11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-, methyl ester,(3b,16b,17a,18b,20a)-; Serpasil premix; Chloroserpine-500; Hydro-Reserpine-25; Hydro-Reserpine-50; Hydro-Fluserpine #1; l -Carpserp; Caswell No. 722A; Serp-AFD; Reserpina [INN-Spanish]; 3,5-Trimethoxybenzoyl methyl reserpate; Yohimban-16-carboxylic acid, 11,17-dimethoxy-18-((3,4,5-trimethoxybenzoyl)oxy)-, methyl ester, (3beta,16beta,17alpha,18beta,20alpha)-; (1S,2R,3R,4aS,13bR,14aS)-methyl 2,11-dimethoxy-3-((3,4,5-trimethoxybenzoyl)oxy)-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylate; methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate; methyl (3beta,16beta,17alpha,18beta,20alpha)-11,17-bis(methyloxy)-18-({[3,4,5-tris(methyloxy)phenyl]carbonyl}oxy)yohimban-16-carboxylate; SMR000059122; Apoplon (TN); CCRIS 550; Serpine (pharmaceutical); HSDB 213; Methyl reserpate 3,5-trimethyloxybenzoic acid; 11,17-Dimethoxy-18-((3,4,5-trimethoxybenzoyl)oxy)yohimban-16-carboxylic acid methyl ester; Methyl reserpate 3,5-trimethoxybenzoic acid ester; EINECS 200-047-9; RCRA waste no. U200; EPA Pesticide Chemical Code 123101; NSC 237659; BRN 0102014; AI3-50146; WLN: T F6 D5 C666 EM ON&&TTTJ HO1 SOVR CO1 DO1 EO1& TO1 UVO1; Reserpine [USP:INN:BAN:JAN]; CAS-50-55-5; Reserpine,(S); Serpalan (TN); 3-.beta., 18-.beta.-hydroxy-11,17-.alpha.-dimethoxy-,methyl ester, 3,4,5-trimethoxybenzoate (ester); 3.beta., 18.beta.-hydroxy-11,17.alpha.-dimethoxy- methyl ester 3,4,5-trimethoxybenzoate (ester); Benz[g]indolo[2, 1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydro-3-hydroxy-2,11-dimethoxy-, methyl ester, 3,4,5-trimethoxybenzoate; methyl (3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18-{[(3,4,5-trimethoxyphenyl)carbonyl]oxy}yohimban-16-carboxylate; Yohimban-16-carboxylic acid,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-, methyl ester, (3.beta.,16.beta.,17.alpha.,18.beta.,20.alpha.)-; Prestwick_147; Methyl reserpate 3,4,5-trimethoxybenzoic acid ester; Reserpine, 99%; Spectrum_000109; Reserpic acid methyl ester 3,4,5-trimethoxybenzoate (ester); 79 more names available; 1263-94-1; Prestwick0_000875; Prestwick1_000875; Prestwick2_000875; Prestwick3_000875; Spectrum3_000894; Spectrum4_000989; Spectrum5_001415; R 0875; SCHEMBL2589; Lopac0_000073; BSPBio_000949; KBioGR_001397; KBioSS_000549; 4-25-00-01319 (Beilstein Handbook Reference); Methyl 18beta-hydroxy-11,17alpha-dimethoxy-3beta,20alpha-yohimban-16beta-carboxylate 3,4,5-trimethoxybenzoate (ester); methyl dimethoxy-(3,4,5-trimethoxybenzoyl)oxy-[ ]carboxylate; MLS002154046; MLS006011754; DivK1c_000012; SPECTRUM1500526; SPBio_002870; Reserpine (JP17/USP/INN); AMY591; BPBio1_001045; GTPL4823; MEGxp0_001904; DTXSID7021237; ACon1_000086; HMS500A14; KBio1_000012; KBio2_000549; KBio2_003117; KBio2_005685; KBio3_001808; AOB5791; NINDS_000012; HMS1570P11; HMS1920P04; HMS2092G05; HMS2097P11; HMS2234E24; HMS3260O07; HMS3413D20; HMS3677D20; HMS3714P11; HMS3884I21; Pharmakon1600-01500526; HY-N0480; Reserpine, Vetec(TM) reagent grade; RKL10049; ZINC3938746; Tox21_111107; Tox21_202395; Tox21_300537; Tox21_500073; BBL028800; BDBM50017712; ENT-50146; NSC237659; NSC757309; STK801975; AKOS000277559; Tox21_111107_1; CCG-204168; CS-1913; DB00206; KS-5106; LP00073; MCULE-9131256292; MCULE-9946449258; NSC-757309; SDCCGSBI-0050061.P005; IDI1_000012; NCGC00091250-01; NCGC00091250-02; NCGC00091250-03; NCGC00091250-05; NCGC00091250-06; NCGC00091250-07; NCGC00091250-08; NCGC00091250-09; NCGC00091250-10; NCGC00091250-12; NCGC00091250-14; NCGC00091250-25; NCGC00254489-01; NCGC00259944-01; NCGC00260758-01; 3-beta,20-alpha-Yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-11,17-alpha-dimethoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester); AC-13142; AC-34405; BR164333; methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyloxy)-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4,6,8-tetraene-19-carboxylate; NCI60_004446; SBI-0050061.P004; EU-0100073; Reserpine, crystallized, >=99.0% (HPLC); SW196458-3; UNM000011053801; C06539; D00197; J10192; AB01562943_01; 005R091; A913268; Q407841; Q-100566; BRD-K95921201-001-07-0; Methyl reserpate; 3,4,5-Trimethoxybenzoic acid ester; Reserpine, certified reference material, TraceCERT(R); Reserpine solution, 1 pg/muL in methanol: water (1:1); Reserpine, European Pharmacopoeia (EP) Reference Standard; Reserpine Standard for LC-MS, analytical standard, for LC-MS; Reserpine, United States Pharmacopeia (USP) Reference Standard; Reserpine, Pharmaceutical Secondary Standard; Certified Reference Material; (3 ,16 ,17 ,18 ,20 )-11,17-Dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester; (3beta,16beta,17alpha,18beta,20alpha)-11,17-Dimethoxy-18- [(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxyl ic acid methyl ester; 3beta,20alpha-Yohimban-16beta-carboxylic acid, 18beta-hydroxy-11,17alpha-dimethoxy- methyl ester 3,4,5-trimethoxybenzoate (ester) (8CI); methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-[(3,4,5-trimethoxyphenyl)carbonyloxy]-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4,6,8-tetraene-19-carboxylate; Yohimban-16-carboxylic acid, 11,17-dimethoxy-18-(3,4,5-trimethoxybenzoyl)oxy-, methyl ester, (3.beta.,16.beta.,17.alpha.,18.beta.,20.alpha.)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:28487	DB00206	DR00636	DR2310	608.7	C33H40N2O9	118	1000	4	44	1	10	10	"1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1"	CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC	QEVHRUUCFGRFIF-MDEJGZGSSA-N
DG00838	Cantharidin	5944	"Cantharidin; 56-25-7; CANTHARIDINE; Cantharone; Kantaridin; Cantharides camphor; Kantharidin; 1,2-Dimethyl-3,6-epoxyperhydrophthalic anhydride; UNII-IGL471WQ8P; NSC61805; exo-1,2-cis-Dimethyl-3,6-epoxyhexahydrophthalic anhydride; Hexahydro-3a,7a-dimethyl-4,7-epoxyisobenzofuran-1,3-dione; BRN 0085302; AI3-04021; (3ar,4s,7r,7as)-3a,7a-dimethylhexahydro-4,7-epoxy-2-benzofuran-1,3-dione; IGL471WQ8P; CHEMBL48449; 4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-, (3aR,4S,7R,7aS)-rel-; CHEBI:64213; 7a-Dimethylhexahydro-3a,4,7-epoxyisobenzofuran; CAN [Alkaloid]; MFCD00134968; NSC-61805; Cantharidin (USAN); Cantharidin [USAN]; 3a,7a-Dimethylhexahydro-4,7-epoxyisobenzofuran-1,3-dione; NSC 61805; Kantharidin [German]; Caswell No. 157; (3a ,4 ,7 ,7a )-Hexahydro-3a,7a-dimethyl-4,7-epoxyisobenzofuran-1,3-dione; 4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-,(3aR,4S,7R,7aS)-rel-; CCRIS 635; 4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-; 2,3-Dimethyl-7-oxabicyclo(2.2.1)heptane-2,3-dicarboxylic anhydride; 7-Oxabicyclo(2.2.1)heptane-2,3-dicarboxylic anhydride, 2,3-dimethyl-; HSDB 2181; EINECS 200-263-3; EPA Pesticide Chemical Code 013101; Cantaridina; Cantharidinum; CAS-56-25-7; NCGC00016247-01; Prestwick3_000885; (1R,2S,3R,6S)-1,2-Dimethyl-3,6-epoxycyclohexane-1,2-dicarboxylic anhydride; 2,3-dicarboxylic anhydride; Hexahydro-3aalpha,7aalpha-dimethyl-4beta,7beta-epoxyisobenzofuran-1,3-dione; NCIMech_000301; BSPBio_000670; 4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-, (3a-alpha,4-beta,7-beta,7a-alpha); 5-19-05-00051 (Beilstein Handbook Reference); SCHEMBL152262; BPBio1_000738; Cantharides camphor, Cantharone; cid_6708701; HMS2097B12; HMS3412J13; HMS3676J13; 1,6-epoxyperhydrophthalic anhydride; 4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-, (3a.alpha.,4.beta.,7.beta.,7a.alpha.)-; ACT03236; AMY33451; BCP09819; HY-N0209; BDBM50090505; CCG-35382; CCG-36082; WHO 11470; ZINC17611186; AKOS015895930; AC-7967; CS-4979; DB12328; 4,3-dione, hexahydro-3a,7a-dimethyl-; exo-1,6-epoxyhexahydrophthalic anhydride; NCGC00025212-02; NCGC00025212-03; NCGC00025212-04; NCGC00025212-05; NCGC00025212-31; AS-18735; NCI60_005413; WLN: T C555 A AO DVOVTJ C1 G1; AB00513946; Hexahydro-3a,7-epoxyisobenzofuran-1,3-dione; X1105; D11745; 7-Oxabicyclo[2.2.1]heptane-2, 2,3-dimethyl-; 134C968; Q410884; SR-01000597585; SR-01000597585-1; BRD-K80684056-001-01-0; (3aR,4S,7R,7aS)-3a,7a-dimethylhexahydro-4,7-epoxyisobenzofuran-1,3-dione; (1R,2S,6R,7S)-2,6-Dimethyl-4,10-dioxa-tricyclo[5.2.1.0*2,6*]decane-3,5-dione; (1R,7S)-2,6-Dimethyl-4,10-dioxa-tricyclo[5.2.1.0*2,6*]decane-3,5-dione; (1S,2R,6S,7R)-2,6-Dimethyl-4,10-dioxa-tricyclo[5.2.1.0*2,6*]decane-3,5-dione; (1S,2R,6S,7R)-2,6-dimethyl-4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione; (1S,3S,4R,7R)-2,6-dimethyl-4,10-dioxa-tricyclo[5.2.1.0-2,6]decane-3,5-dione; 4,3-dione, hexahydro-3a,7a-dimethyl-, (3a.alpha.,4.beta.,7.beta.,7a.alpha.)-; Cantharidin:4,7-Epoxyisobenzofuran-1,3-dione,hexahydro-3a,7a- dimethyl-, (3a,4,7,7a)-,"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:64213	DB12328	.	.	196.2	C10H12O4	52.6	318	0.6	14	0	4	0	"1S/C10H12O4/c1-9-5-3-4-6(13-5)10(9,2)8(12)14-7(9)11/h5-6H,3-4H2,1-2H3/t5-,6+,9+,10-"	C[C@@]12[C@H]3CC[C@@H]([C@@]1(C(=O)OC2=O)C)O3	DHZBEENLJMYSHQ-XCVPVQRUSA-N
DG00839	L-alanine	5950	"L-alanine; alanine; 56-41-7; (S)-Alanine; L-alpha-alanine; L-2-Aminopropionic acid; (S)-2-Aminopropanoic acid; H-Ala-OH; (2S)-2-Aminopropanoic acid; L-(+)-Alanine; L-2-Aminopropanoic acid; 2-Aminopropionic acid; alpha-Alanine; L-alpha-Aminopropionic acid; alpha-Aminopropionic acid; L-2-Aminopropionsaeure; Alaninum [Latin]; (S)-(+)-Alanine; L-S-Aminopropionic acid; (L)-Alanine; Alanine (VAN); (S)-2-Aminopropionsaeure; Poly-L-alanine; 2-Aminopropanoic acid, L-; (S)-alpha-Aminopropionsaeure; Alanine [USAN:INN]; Alanina [DCIT,Spanish]; ALANINE, L-; L-Alanine, homopolymer; L-a-Aminopropionic acid; L-Alanin; Propanoic acid, 2-amino-, (S)-; HSDB 1801; (S)-2-Aminopropionic acid; NSC 206315; L-Alanine homopolymer; 25191-17-7; MFCD00064410; L-.alpha.-Aminopropionic acid; CHEMBL279597; CHEBI:16977; Alanine (L-Alanine); polyalanine; Alaninum; Poly-DL-alanine; L-a-Alanine; 14C-L-Alanine; a-Aminopropionic acid; (2S)-2-aminopropanoate; (C14)L-Alanine; .alpha.-Alanine; L-.alpha.-Alanine; L-&alpha-alanine; Alanine (USP); L-Alanine (9CI); 2-Ammoniopropanoate; Propanoic acid, 2-amino-; .alpha.-Aminopropionic acid; L-Alanine, labeled with carbon-14; EINECS 200-273-8; Ritalanine; Racemic alanine; L-aAlanine; a-Aminopropionate; L-Alanine, labeled with tritium; 3h-l-alanine; L-Alanine Powder; Propanoic acid, 2-amino-, (S); [3H]alanine; L-a-Aminopropionate; L-Ala; [14C]alanine; [3H]-alanine; alpha-Aminopropanoate; alpha-Aminopropionate; L-2-Aminopropanoate; L-2-Aminopropionate; L-Alanine,(S); [14C]-alanine; L-alpha-Aminopropionate; Tocris-0205; 2-Ammoniopropanoic acid; ALA-OH; starbld0003382; L-Alanine (JP17); (S)-2-Aminopropanoate; alpha-Aminopropanoic acid; L-Ala-2; (S)-2-amino-Propanoate; L-Alanine, >=99%; bmse000028; bmse000994; EC 200-273-8; L-CH3CH(NH2)COOH; GTPL720; (S)-2-amino-Propanoic acid; (2S)-2-azanylpropanoic acid; Alanine, L- (7CI,8CI); GTPL4542; GTPL4543; L-Alanine, Cell Culture Reagent; DTXSID20873899; L-Alanine, >=98% (TLC); L-Alanine, 99%, natural, FG; F4F207FF-8FF8-4789-99A1-147AE0A36673; HY-N0229; STR01663; ZINC4658553; L-Alanine, >=99.0% (NT); AC-014; BDBM50000099; s5631; (S)-2-aminopropanoic acid;H-Ala-OH; AKOS010367904; AKOS015840030; CCG-266017; CS-W020002; DB00160; MCULE-7791919887; L-Alanine, purum, >=98.0% (NT); NCGC00024494-01; AC-24031; BP-13281; L-Alanine, BioUltra, >=99.5% (NT); DB-029940; L-Alanine, SAJ special grade, >=99.0%; A0179; AM20100374; A15652; C00041; D00012; D84362; 064A410; A803529; Q218642; SR-01000597687; J-015860; Q-201274; SR-01000597687-3; L-Alanine, certified reference material, TraceCERT(R); Alanine, European Pharmacopoeia (EP) Reference Standard; F0001-2354; Z940713326; UNII-0O72R8RF8A component QNAYBMKLOCPYGJ-REOHCLBHSA-N; UNII-1FU7983T0U component QNAYBMKLOCPYGJ-REOHCLBHSA-N; UNII-OF5P57N2ZX component QNAYBMKLOCPYGJ-REOHCLBHSA-N; L-Alanine, United States Pharmacopeia (USP) Reference Standard; L-Alanine, Pharmaceutical Secondary Standard; Certified Reference Material; 115967-49-2; 77160-91-9; L-Alanine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, >=98.5%; L-Alanine, PharmaGrade, Ajinomoto, EP, JP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:16977	.	DR00142	.	89.09	C3H7NO2	63.3	61.8	-3	6	2	3	1	"1S/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/m0/s1"	C[C@@H](C(=O)O)N	QNAYBMKLOCPYGJ-REOHCLBHSA-N
DG00842	Edetic acid	6049	"EDTA; Edetic acid; Ethylenediaminetetraacetic acid; 60-00-4; Endrate; Versene; Edathamil; Havidote; Sequestrol; Titriplex; EDTA acid; Cheelox; Sequestric acid; Warkeelate acid; Gluma cleanser; Sequestrene aa; Komplexon ii; Quastal Special; Tetrine acid; Versene acid; Metaquest A; Trilon bw; Complexon II; Hamp-ene acid; Titriplex II; Cheelox BF acid; Trilon BS; Celon A; Chelest 3A; Questex 4H; Celon ATH; Chemcolox 340; Universne acid; Vinkeil 100; Dissolvine E; Nullapon B acid; Nullapon bf acid; Perma kleer 50 acid; Nervanaid B acid; Clewat TAA; (Ethylenedinitrilo)tetraacetic acid; EDTA (chelating agent); Versenate; Ethylenedinitrilotetraacetic acid; Calcium disodium versenate; Acidum edeticum; Edetate disodium; Acide edetique; Acido edetico; Caswell No. 438; Disodium EDTA; Chelaton 3; ICRF 185; Glycine, N,N'-1,2-ethanediylbis[N-(carboxymethyl)-; Cheladrate; SEQ 100; Edetate calcium; Ethylenebisiminodiacetic acid; YD 30; Acide edetique [INN-French]; Acido edetico [INN-Spanish]; Acidum edeticum [INN-Latin]; CCRIS 946; Edetate; ETHYLENEDIAMINE TETRAACETIC ACID; HSDB 809; Acide ethylenediaminetetracetique; Ethylenediamine-N,N,N',N'-tetraacetic acid; 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid; UNII-9G34HU7RV0; Acetic acid, (ethylenedinitrilo)tetra-; EPA Pesticide Chemical Code 039101; Edta disodium; Ethylenebis(iminodiacetic acid); Disodium edetate; Disodium versene; Endrate disodium; Kyselina ethylendiamintetraoctova; Sodium versenate; Edetic acid disodium salt; Ethylenediaminetetraacetate; Kyselina ethylendiamintetraoctova [Czech]; Acide ethylenediaminetetracetique [French]; Metaquest B; ethylene diamine tetraacetic acid; Kiresuto B; Chelaplex III; Complexon III; Diso-Tate; Titriplex III; 3,6-Diazaoctanedioic acid, 3,6-bis(carboxymethyl)-; AI3-17181; Chelaton III; Versene NA; Triplex III; Disodium versenate; Edathamil disodium; Trilon BD; Versene Na2; Disodium sequestrene; Disodium tetracemate; EDTA disodium salt; F 1 (complexon); MFCD00003541; EDTA, ion(4-); CHEMBL858; Sequestrene sodium 2; Acetic acid, 2,2',2'',2'''-(1,2-ethanediyldinitrilo)tetrakis-; N,N'-1,2-Ethanediylbis(N-(carboxymethyl)glycine); Glycine, N,N'-1,2-ethanediylbis(N-(carboxymethyl)-; {[-(BIS-CARBOXYMETHYL-AMINO)-ETHYL]-CARBOXYMETHYL-AMINO}-ACETIC ACID; Disodium salt of EDTA; 9G34HU7RV0; Perma Kleer Di Crystals; Calcium disodium versenate (TN); ethylene-diamine tetraacetic acid; 2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetic acid; CHEBI:42191; 2-({2-[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino)acetic acid; 4-04-00-02449 (Beilstein Handbook Reference); N,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine); Ethylenediaminetetraacetic acid disodium salt; Edetate calcium disodium (USP); Sequestrene Na2; Trilon B; Selekton B2; Disodium ethylenediaminetetraacetate; (ethylenedinitrilo)tetraacetic acid, ion(4-); Perma kleer 50 crystals disodium salt; Disodium (ethylenedinitrilo)tetraacetate; Disodium ethylenediaminetetraacetic acid; SODIUM ETHYLENEDIAMINETETRAACETATE; CaEDTA; CBC 50152966; DR-16133; Ethylenediaminetetraacetate, disodium salt; Disodium diacid ethylenediaminetetraacetate; D'E.d.t.a. disodique; Disodium (ethylenedinitrilo)tetraacetic acid; 2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate; Disodium dihydrogen ethylenediaminetetraacetate; Ethylenediaminetetraacetic acid, disodium salt; Disodium dihydrogen(ethylenedinitrilo)tetraacetate; 139-33-3; NSC2760; 470462-56-7; C10H16N2O8; N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycine]; NCGC00159485-02; 6381-92-6; EINECS 200-449-4; BRN 1716295; disodium-edta; Edetic acid [INN:BAN:NF]; (Ethylenedinitrilo)tetraacetic acid, disodium salt; 2-[2-(bis(carboxymethyl)amino)ethyl-(carboxymethyl)amino]acetic acid; Tricon bw; ([2-(Bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino)-acetic acid; {[2-(Bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid; Calcium Disodium Edetate (JAN); Techrun DO; EDTA, anhydrous; Zonon AO; EDTA, free acid; EDTA, free base; ACETIC ACID, (ETHYLENEDINITRILO)TETRA-, DISODIUM SALT; Versene acid (TN); Acroma DH 700; Spectrum_001018; Edetic acid (NF/INN); 53632-26-1; Spectrum2_000003; Spectrum3_000412; Spectrum4_000531; Spectrum5_000955; Edetic acid [BAN:INN]; DSSTox_CID_2977; EC 200-449-4; EDTA, anhydrous ACS grade; DSSTox_RID_76814; DSSTox_GSID_22977; ethylenediaminetetracetic acid; BSPBio_001964; Diaminoethanetetra-acetic acid; Ethylenediamineteraacetic Acid; KBioGR_001161; KBioSS_001498; ethylenediaminetetraacetic-acid; MLS001249457; BIDD:ER0565; DivK1c_000777; ethylenediamine tetracetic acid; SPBio_000005; ethylenediamine-tetraacetic acid; DTXSID6022977; KBio1_000777; KBio2_001498; KBio2_004066; KBio2_006634; KBio3_001184; (Ethylenedintrilo)tetraacetic acid; ethylen-ediamine tetra-acetic acid; NINDS_000777; CS-B1827; HY-Y0682; STR08855; Tox21_202736; BDBM50330325; s6350; STK386291; ZINC19364242; AKOS001574475; Glycine, (N,N'-1,2-ethanediylbis(N-(carboxymethyl)-, labeled with carbon-14; (ethane-1,2-diyldinitrilo)tetraacetate; DB00974; MCULE-1868494404; CAS-60-00-4; IDI1_000777; NCGC00159485-03; NCGC00159485-04; NCGC00260284-01; 688-55-1; AC-10615; SMR000058776; SBI-0051360.P003; DB-084840; DS-003836; B7197; E0084; Ethylenediaminetetraacetic acid, 2Na (EDTA); Ethylenediaminetetraacetic acid, LR, >=98%; FT-0626319; FT-0668253; FT-0668254; C00284; D00052; Ethylenediaminetetraacetic acid, p.a., 98.0%; AB00053468_03; Ethylenediaminetetraacetic acid solution, 0.02 N; Ethylenediaminetetraacetic acid, >=98.0% (KT); A832566; N,N'-1,2-Ethanediylbis[N-(carboxymethyl)]glycine; Q408032; SR-01000883946; Ethylenediaminetetraacetic acid, Cell Culture Reagent; J-610078; SR-01000883946-1; 37C3C5E7-D921-445F-82D6-FEBF1AE5AEF5; Ethylenediaminetetraacetic acid, Electrophoresis Grade; Z2688689169; Ethylenediaminetetraacetic acid, BioUltra, >=99.0% (KT); Ethylenediaminetetraacetic acid, 0.5M aq. solution, pH 8.0; Ethylenediaminetetraacetic acid, 99.995% trace metals basis; Ethylenediaminetetraacetic acid, SAJ special grade, >=99.0%; Ethylenediaminetetraacetic acid, Vetec(TM) reagent grade, 98%; [{2-[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino]acetic acid; 2,2',2'',2'''-(ethane-1,2-diylbis(azanetriyl))tetraacetic acid; Edetic acid, United States Pharmacopeia (USP) Reference Standard; Ethylenediaminetetraacetic acid, ACS reagent, 99.4-100.6%, powder; Ethylenediaminetetraacetic acid, purified grade, >=98.5%, powder; 2,2'',2'''',2''''''-(ethane-1,2-diylbis(azanetriyl))tetraacetic acid; Ethylenediaminetetraacetic acid, 0.5M aqueous solution, pH 8.0, autoclaved; Ethylenediaminetetraacetic acid, BioUltra, anhydrous, >=99% (titration); Glycine, N,N'-1, {2-ethanediylbis[N-(carboxymethyl)-,} disodium salt; {[2-(Bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid(EDTA); 2-[2-[bis(2-hydroxy-2-oxoethyl)amino]ethyl-(2-hydroxy-2-oxoethyl)amino]ethanoic acid; Ethylenediaminetetraacetic acid, anhydrous, free-flowing, Redi-Dri(TM), >=98%; 124949-23-1; Ethylenediamine-N,N,N inverted exclamation mark ,N inverted exclamation mark -tetraacetic Acid-13C4 (; A-labels); Ethylenediaminetetraacetic acid solution, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture; Ethylenediaminetetraacetic acid solution, BioUltra, for molecular biology, pH 8.0, ~0.5 M in H2O; Ethylenediaminetetraacetic acid, anhydrous, crystalline, BioReagent, suitable for cell culture; Ethylenediaminetetraacetic acid, anhydrous, free-flowing, powder, Redi-Dri(TM), ACS reagent, 99.4-100.6%"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:42191	DB00974	.	.	292.24	C10H16N2O8	156	316	-5.9	20	4	10	11	"1S/C10H16N2O8/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20)"	C(CN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O	KCXVZYZYPLLWCC-UHFFFAOYSA-N
DG00843	Cysteamine	6058	"CYSTEAMINE; 2-Aminoethanethiol; 60-23-1; Mercaptamine; Thioethanolamine; Becaptan; Mercamine; Cysteinamine; beta-Mercaptoethylamine; 2-Mercaptoethylamine; Cysteamin; Lambraten; Lambratene; beta-Aminoethanethiol; Cystagon; Riacon; Decarboxycysteine; Mercaptoethylamine; 2-Amino-1-ethanethiol; Ethanethiol, 2-amino-; Cisteamina; 2-Aminoethyl mercaptan; beta-Aminoethylthiol; 2-Mercaptoethanamine; Mercaptamin; (2-Mercaptoethyl)amine; MEA (mercaptan); Ethanethiolamine; 2-AMINO-ETHANETHIOL; beta-MEA; Aminoethyl mercaptan; Mercaptamina; Mercaptaminum; Cysteamide; Mecramine; Mercamin; Merkamin; Cisteamina [Italian]; Cystaran; Mercaptaminum [INN-Latin]; Mercaptamina [INN-Spanish]; 1-Amino-2-mercaptoethylamine; L-1573; Cysteamine (USAN); WR 347; 2-aminoethane-1-thiol; UNII-5UX2SD1KE2; b-Mercaptoethylamine; NSC 647528; Cysteamine [USAN]; Mercaptamine (INN); .beta.-Mercaptoethylamine; 5UX2SD1KE2; CHEBI:17141; 2-aminoethane-1-thiol; Cysteamine; Mercaptamine [INN]; NSC647528; NSC-647528; NCGC00015691-03; Cysteamine [USAN:BAN]; beta-Mercaptoethylamine;2-Aminoethanethiol;2-Mercaptoethylamine; C2H7NS; Cysteamine bitartate; CCRIS 3083; HSDB 7353; EINECS 200-463-0; L 1573; Cystagone; b-Aminoethylthiol; b-mea; b-Aminoethanethiol; mercapto ethylamine; DHL; MFCD00008196; 2-amino-ethyl thiol; CASH; .beta.-MEA; Cysteamine, ~95%; Cysteamine, free base; .beta.-Aminoethylthiol; Spectrum_001755; .beta.-Aminoethanethiol; SpecPlus_000654; Lopac-M-6500; DSSTox_CID_2875; bmse000388; CHEMBL602; C-9500; DSSTox_RID_76770; DSSTox_GSID_22875; KBioSS_002235; DivK1c_006750; BDBM7968; GTPL7440; 2,3-DESHYDROLANTHIONINE; DTXSID3022875; KBio1_001694; KBio2_002235; KBio2_004803; KBio2_007371; Cysteamine, >=98.0% (RT); BCP15015; ZINC8034121; Tox21_113092; HY-77591A; s6402; STK315355; AKOS003793343; CCG-204834; DB00847; MCULE-1838427828; SDCCGSBI-0050727.P004; CAS-60-23-1; NCGC00015691-01; NCGC00015691-02; NCGC00015691-04; NCGC00015691-14; NCGC00162236-01; NCGC00162236-02; AMY202100105; AS-56218; BP-13401; NCI60_002000; SBI-0050727.P003; DB-053562; A0648; FT-0611243; V0810; C01678; D03634; D88299; D88360; AB00053754_09; AB00053754_10; A832648; Cysteamine, 2-Mercaptoethylamine, Thioethanolamine; Q617563; F0001-1576; 2DFDA1F8-7010-4225-8280-AB1C4C43F546; 2-Aminoethanethiol;cysteamine, beta-Mercaptoethylamine, 2-Mercaptoethylamine, Decarboxycysteine, Thioethanolamine, Mercaptamine; 2-Mercaptoethylamine, polymer-bound, 70-90 mesh, extent of labeling: 0.6-1.1 mmol/g loading, 1 % cross-linked with divinylbenzene"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:17141	DB00847	.	.	77.15	C2H7NS	27	10	-0.4	4	2	2	1	"1S/C2H7NS/c3-1-2-4/h4H,1-3H2"	C(CS)N	UFULAYFCSOUIOV-UHFFFAOYSA-N
DG00844	Methoxamine	6082	"Methoxamine; Methoxamin; Pseudomethoxamine; 390-28-3; Vasoxyl; 2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol; Methoxamedrine; 2,5-Dimethoxynorephedrine; Metossamina; 2-Amino-1-(2,5-dimethoxyphenyl)-1-propanol; CHEMBL524; Benzenemethanol, alpha-(1-aminoethyl)-2,5-dimethoxy-; CHEBI:6839; alpha-(1-Aminoethyl)-2,5-dimethoxybenzyl alcohol; Benzenemethanol, .alpha.-(1-aminoethyl)-2,5-dimethoxy-; Benzyl alcohol, .alpha.-(1-aminoethyl)-2,5-dimethoxy-; Methoxamine (BAN); Benzyl alcohol, alpha-(1-aminoethyl)-2,5-dimethoxy-; Spectrum_001021; Prestwick0_000535; Prestwick1_000535; Prestwick2_000535; Prestwick3_000535; Spectrum2_000776; Spectrum3_000498; Spectrum4_000051; Spectrum5_001821; (1R,2S)-2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol; Lopac0_000769; SCHEMBL34158; BSPBio_000549; BSPBio_001995; GTPL483; KBioGR_000541; KBioSS_001501; 2-amino-1-[2,5-bis(methyloxy)phenyl]propan-1-ol; SPBio_000852; SPBio_002470; BPBio1_000605; NRL001; DTXSID0023290; KBio2_001501; KBio2_004069; KBio2_006637; KBio3_001495; NRL-001; BDBM50026777; CCG-204854; DB00723; MCULE-1220066468; SDCCGSBI-0050747.P004; NCGC00015692-03; NCGC00015692-04; NCGC00015692-06; NCGC00015692-08; NCGC00015692-13; NCGC00089793-02; SBI-0050747.P003; AB00053731; C07513; D08201; 2-Amino-1-(2,5-dimethoxy-phenyl)-propan-1-ol; 2-Amino-1-(2,5-dimethoxyphenyl)-1-propanol #; AB00053731_12; AB00053731_13; 390M283; L000757; Q685119; BRD-A39189014-003-14-4; (.+/-.)-.alpha.-(1-Aminoethyl)-2,5-dimethoxybenzyl alcohol; 2-Amino-1-(2,5-dimethoxy-phenyl)-propan-1-ol (methoxamine); 2-Amino-1-(2,5-dimethoxy-phenyl)-propan-1-ol(Methoxamine); 2-(4-BROMO-PHENYL)-5-METHYL-2H-PYRAZOLE-3-CARBOXYLICACID"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6839	DB00723	DR01182	.	211.26	C11H17NO3	64.7	189	0.5	15	2	4	4	"1S/C11H17NO3/c1-7(12)11(13)9-6-8(14-2)4-5-10(9)15-3/h4-7,11,13H,12H2,1-3H3"	CC(C(C1=C(C=CC(=C1)OC)OC)O)N	WJAJPNHVVFWKKL-UHFFFAOYSA-N
DG00847	Cycloserine	6234	"D-cycloserine; cycloserine; 68-41-7; Seromycin; orientomycin; Oxamycin; Cyclo-D-serine; Cyclorin; D-4-amino-3-isoxazolidinone; Cicloserina; Farmiserina; Miroseryn; Tisomycin; Wasserina; Closina; Cycloserinum; D-4-amino-3-isoxazolidone; alpha-Cycloserine; (4R)-4-amino-1,2-oxazolidin-3-one; (+)-4-Amino-3-isoxazolidinone; Miroserina; Tebemicina; Novoserin; (R)-4-AMINOISOXAZOLIDIN-3-ONE; (+)-Cycloserine; Oxamicina; D-(+)-Cycloserine; (4R)-4-aminoisoxazolidin-3-one; PA 94; Cycloserin; Micoserina; PA-94; (R)-4-AMINO-ISOXAZOLIDIN-3-ONE; D-Oxamycin; RO-1-9213; D-CS; E-733-A; 3-Isoxazolidinone, 4-amino-, (4R)-; D-4-Amino-3-isossazolidone; 3-Isoxazolidinone, 4-amino-, (R)-; HSDB 3218; D-Oxamicina; 3-Isoxazolidinone, 4-amino-, d-; K-300; UNII-95IK5KI84Z; I-1431; 3-Isoxazolidinone, 4-amino-, (+)-; NSC 154851; CHEBI:40009; AI3-50153; D-Cycloserine, synthetic; DCS; (R)-(+)-4-Amino-3-isoxazolidinone; CHEMBL771; SC-49088; 95IK5KI84Z; MFCD00005353; CAS-68-41-7; NCGC00016306-01; Oxamicina [Italian]; Cicloserina [Italian]; DSSTox_CID_2870; 3-Isoxazolidinone, 4-amino-, (+)- (8CI); DSSTox_RID_76766; DSSTox_GSID_22870; Cycloserinum [INN-Latin]; Cicloserina [INN-Spanish]; Cycloserine, D-; Closerin; .alpha.-Cycloserine; (R)-Cycloserine; Seromycin (TN); SMR000058313; D-4-Amino-3-isossazolidone [Italian]; R-(+)-Cycloserine; (R)-4-Amino-3-isoxazolidinone; (4R)-4-Amino-3-isoxazolidinone; CYCLOSERINE (D); SR-01000075432; DRG-0195; (R)-(+)-Cycloserine; EINECS 200-688-4; D-amino-3-isoxazolidinone; BRN 0080798; (R)-4-Amino-3-isoxazolidone; NSC-76029; cycloserine-(d); Serine, cyclo-; NSC-154851; 3-Isoxazolidinone, 4-amino-, D; R(+)-4-Amino-3-isoxazolidinone; Cycloserine [USP:INN:BAN:JAN]; 4AX; 3-Isoxazolidinone, 4-amino-, (R); Cycloserine, D(+); D-Cycloserine, powder; Spectrum_000860; 1pb9; Prestwick0_001089; Prestwick1_001089; Prestwick2_001089; Prestwick3_001089; Spectrum2_000084; Spectrum3_000371; Spectrum4_000305; Spectrum5_000797; Lopac-C-1159; Lopac-C-3909; Lopac-C-7005; 3-Isoxazolidinone, 4-amino-, (4R)- (9CI); C 3909; C-9390; C-9400; Lopac0_000252; SCHEMBL34322; BSPBio_001138; BSPBio_002121; KBioGR_000890; KBioSS_001340; 4-27-00-05549 (Beilstein Handbook Reference); MLS000758215; MLS001423962; MLS002548887; BIDD:GT0707; D-Cycloserine synth. BP 88; DivK1c_000098; SPECTRUM1500215; SPBio_000008; SPBio_003029; BPBio1_001252; FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09; GTPL9489; Cycloserine (JP17/USP/INN); 4-Amino-3-isoxazolidinone, D-; DTXSID8022870; HMS500E20; KBio1_000098; KBio2_001340; KBio2_003908; KBio2_006476; KBio3_001341; NINDS_000098; HMS1571I20; HMS1920C06; HMS2051C15; HMS2091I14; HMS2098I20; HMS2232F03; HMS3259L19; HMS3260D06; HMS3715I14; NJ-21; Pharmakon1600-01500215; (R)-3-Isoxazolidinone, 4-amino-; 4-Amino-3-isoxazolidinone, (R)-; ACT04767; HY-B0030; Tox21_110361; Tox21_500252; BDBM50038178; BDBM50103516; CCG-39705; D-Cycloserine, >=96.0% (NT); LMPK14000007; NSC756712; s1998; ZINC34676245; 4-Isoxazolidinamine, 3-oxo-, (D)-; AKOS015994626; Tox21_110361_1; AC-4721; DB00260; HS-0079; LP00252; MCULE-4212827696; NC00050; NC00676; NSC-756712; SDCCGSBI-0050240.P005; IDI1_000098; SMP1_000167; NCGC00015213-01; NCGC00015213-02; NCGC00015213-03; NCGC00016306-02; NCGC00016306-03; NCGC00016306-04; NCGC00016306-05; NCGC00016306-07; NCGC00016306-08; NCGC00016306-17; NCGC00093713-01; NCGC00093713-02; NCGC00260937-01; CAS-339-72-0; K138; SBI-0050240.P004; AB00443920; EU-0100252; C08057; D00877; AB00443920_09; AB00443920_10; 005C353; A836140; Q418508; SR-01000759389; SR-01000075432-1; SR-01000075432-2; SR-01000075432-5; SR-01000075432-9; SR-01000759389-4; SR-01000075432-10; F2173-1228; Z1522567171; Cycloserine, United States Pharmacopeia (USP) Reference Standard; Cycloserine, Pharmaceutical Secondary Standard; Certified Reference Material; (4R)-4-azaniumyl-4,5-dihydroisoxazol-3-olate;(R)-4-AMINOISOXAZOLIDIN-3-ONE"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:40009	DB00260	DR00197	.	102.09	C3H6N2O2	64.4	92.9	-1.5	7	2	3	0	"1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1"	C1[C@H](C(=O)NO1)N	DYDCUQKUCUHJBH-UWTATZPHSA-N
DG00849	Trifluridine	6256	"Trifluridine; TRIFLUOROTHYMIDINE; 70-00-8; Viroptic; 5-Trifluorothymidine; Trifluoromethyldeoxyuridine; Trifluridina; Virophta; F3DThd; 5-(Trifluoromethyl)deoxyuridine; F3TDR; Trifluridinum; 5-Trifluoromethyl-2-deoxyuridine; Trifluorothymine deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione; TFDU; 2'-Deoxy-5-trifluoromethyluridine; UNII-RMW9V5RW38; alpha,alpha,alpha-Trifluorothymidine; NSC 75520; NSC 529182; Uridine, 2'-deoxy-5-(trifluoromethyl)-; 2'-Deoxy-5-(trifluoromethyl)uridine; Trifluridine (Viroptic); MFCD00006534; CHEMBL1129; RMW9V5RW38; MLS000028361; CHEBI:75179; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione; Triflurdine (Viroptic); Fluridine; SMR000058583; Trifluridinum [INN-Latin]; Trifluridina [INN-Spanish]; F3T; DSSTox_CID_26602; DSSTox_RID_81757; DSSTox_GSID_46602; 5-Trifluoromethyl-2'-deoxyuridine; 5-Trifluoro-2'-deoxythymidine; 5-(Trifluoromethyl)-2'-deoxyuridine; CF3dUrd; Viroptic (TN); Thymidine, alpha,alpha,alpha-trifluoro-; CCRIS 2348; EINECS 200-722-8; BRN 0568095; NSC75520; NSC-75520; NSC529182; Trifluridine [USAN:USP:INN]; HSDB 8126; NSC-529182; CAS-70-00-8; NCGC00166323-01; HS-0007; Opera_ID_1810; 5-Trifluoromethylthymidine; Trifluoromethyl Deoxyuridine; cid_6256; SCHEMBL3479; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-ribofuranosyl)-5-(trifluoromethyl)-; MLS001148248; MLS006010219; Trifluridine (JAN/USP/INN); GTPL8697; DTXSID4046602; cid_6708818; HMS2233N19; HMS3715C14; 5-trifluoromethyl-2''-deoxyuridine; BCP09147; HY-A0061; ZINC3842753; Tox21_112411; BDBM50132298; Trifluorothymidine, >=99% (HPLC); AKOS015919482; Tox21_112411_1; CCG-221056; CS-1602; DB00432; NCGC00166323-02; NCGC00166323-16; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)-1,2,3,4-tetrahydropyrimidine-2,4-dione; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione; SRI-10817-12; SRI-10817_14; AM20100660; S1778; SW199522-2; T2511; D00391; 006T534; A836733; SR-01000721911; J-700255; J-700357; Q2359590; SR-01000721911-2; BRD-K03243820-001-12-1; BRD-K03243820-001-25-3; Trifluridine, British Pharmacopoeia (BP) Reference Standard; Trifluridine;FTD;5-Trifluorothymidine;NSC 529182;NSC 75520; Trifluridine, United States Pharmacopeia (USP) Reference Standard; 1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione; 1-((2R,5R)-4-Hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-trifluoromethyl-1H-pyrimidine-2,4-dione"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:75179	DB00432	DR00096	DR1643	296.2	C10H11F3N2O5	99.1	464	-0.5	20	3	8	2	"1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1"	C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O	VSQQQLOSPVPRAZ-RRKCRQDMSA-N
DG00850	Mestranol	6291	"Mestranol; 72-33-3; Norquen; Menophase; Devocin; Ovastol; Ethynylestradiol 3-methyl ether; EE3ME; Mestranolum; 3-Methoxyethynylestradiol; EE(sub3)ME; Ethynylestradiol methyl ether; 3-Methylethynylestradiol; 3-O-Methylethynylestradiol; Compound 33355; Inostral; 3-Methylethynyloestradiol; 3-Methoxyethynyloestradiol; 3-Methoxy-17alpha-ethynylestradiol; SC 4725; 17-Ethynyloestradiol 3-methyl ether; UNII-B2V233XGE7; component of Norinyl; component of Ortho-Novum; (8R,9S,13S,14S,17R)-17-Ethynyl-3-methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-ol; EE3-ME; Ethinylestradiol 3-methyl ether; Ethinyloestradiol 3-methyl ether; Ethynyloestradiol 3-methyl ether; MLS000028595; B2V233XGE7; CHEBI:6784; 17-Ethynylestradiol 3-methyl ether; component of Ovulen; component of Norquen; delta-MVE; 17alpha-Ethynylestradiol 3-methyl ether; (8R,9S,13S,14S,17R)-17-ethynyl-3-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol; Inostral (steroid); Mestranolo [DCIT]; NCGC00093347-02; Mestranolo; SMR000059128; (17beta)-17-ethynyl-3-(methyloxy)estra-1,3,5(10)-trien-17-ol; DSSTox_CID_814; DSSTox_RID_75804; DSSTox_GSID_20814; Mestranolum [INN-Latin]; Caswell No. 547A; .delta.-MVE; 17alpha-Ethinyl estradiol 3-methyl ether; 17-Ethynyl-3-methoxyestra-1,3,5(10)-trien-17-ol; 3-Methoxy-17alpha-ethinylestradiol; 3-Methoxy-17alpha-ethinyloestradiol; 3-Methoxy-17alpha-ethynyloestradiol; 3-Methoxy-17-alpha-ethinylestradiol; 3-Methoxy-17-alpha-ethynylestradiol; 17alpha-Ethynylestradiol methyl ether; 3-Methoxy-17-alpha-ethinyloestradiol; 3-Methoxy-17-alpha-ethynyloestradiol; CCRIS 377; 17-alpha-Ethynyloestradiol methyl ether; 17alpha-Ethinylestradiol 3-methyl ether; 8027 C. B.; 17alpha-Ethynyloestradiol 3-methyl ether; 3-Methoxy-17-ethynyloestradiol-17-beta; Mestranol [Steroidal oestrogens]; 17alpha-Ethinyl oestradiol 3-methyl ether; HSDB 3588; 17-alpha-Ethinyl estradiol 3-methyl ether; 17-alpha-Ethinyl oestradiol 3-methyl ether; EINECS 200-777-8; NSC 84032; EPA Pesticide Chemical Code 115401; 17beta-Estradiol, 17-ethynyl-, 3-(methyl ether); BRN 2625905; NSC84032; 17-Ethynyl-3-methoxy-1,3,5(10)-oestratien-17-beta-ol; AI3-51798; NSC-84032; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-estratrien-17beta-ol; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-oestratrien-17beta-ol; 17-alpha-Ethynyl-3-methoxy-1,3,5(10)-estratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-estratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-oestratrien-17-beta-ol; CAS-72-33-3; 3-Methoxy-17-alpha-19-norpregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-methoxy-, (17alpha)-; Prestwick_966; Mestranol, 99%; Mestranol [USAN:USP:INN:BAN:JAN]; EEI3ME; Estra-1,3,5(10)-trien-17beta-ol, 17-ethynyl-3-methoxy-; Opera_ID_872; 17alpha-19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-methoxy-; Estra-1,3,5(10)-trien-17-beta-ol, 17-alpha-ethynyl-3-methoxy-; Prestwick0_000846; Prestwick1_000846; Prestwick2_000846; Prestwick3_000846; (+)-17-alpha-Ethynyl-17-beta-hydroxy-3-methoxy-1,3,5(10)-estratriene; (17-alpha)-3-Methoxy-19-norpregna-1,3,5(10)-trien-20-yn-17-ol; 17-ethynyl-3-methoxyestra-1(10),2,4-trien-17-ol; EE-3ME; EE3 ME; (+)-17-alpha-Ethynyl-17-beta-hydroxy-3-methoxy-1,3,5(10)-oestratriene; 17-alpha-Ethynyl-3-methoxy-17-beta-hydroxy-delta-1,3,5(10)-estratriene; 17-alpha-Ethynyl-3-methoxy-17-beta-hydroxy-delta-1,3,5(10)-oestratriene; 3,17-beta-Dihydroxy-17-alpha-ethynyl-1,3,5(10)-estratriene-3-methyl ether; SCHEMBL41391; BSPBio_000831; MLS001077321; MLS001424224; BIDD:ER0199; SPBio_002752; Mestranol (JP17/USP/INN); BPBio1_000915; ethynylestradiol-3-methyl ether; GTPL7087; 17-ethynyl-3-methoxyestra-1(10),2,4-trien-17beta-ol; CHEMBL1201151; DTXSID0020814; 17-ethynyl-3-methoxyoestra-1(10),2,4-trien-17beta-ol; 3-Methoxy-19-norpregna-1,3,5(10)-trien-20-yn-17beta-ol; HMS1570J13; HMS2051J22; HMS2097J13; HMS2230L20; HMS3714J13; HY-B0390; ZINC3815424; Tox21_111200; Tox21_301837; 17-alpha-19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-methoxy-; 19-Nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol, 3-methoxy-; 4-Cyano-3-fluorophenyl4-butylbenzoate; AKOS005267152; Tox21_111200_1; CCG-101067; DB01357; MCULE-6161762887; NC00317; NCGC00093347-03; NCGC00093347-05; NCGC00093347-07; NCGC00179410-01; NCGC00255342-01; AC-13293; AS-56063; H072; S2125; Mestranol, VETRANAL(TM), analytical standard; C07618; C76306; D00575; 003M689; Q904308; SR-01000695429; SR-01000695429-4; BRD-K31920458-001-03-8; BRD-K31920458-001-23-6; Mestranol, European Pharmacopoeia (EP) Reference Standard; (17beta)-17-ethynyl-3-methoxyestra-1(10),2,4-trien-17-ol; Mestranol, United States Pharmacopeia (USP) Reference Standard; 17.Alpha.-19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-meth; (+)-17alpha-Ethynyl-17beta-hydroxy-3-methoxy-1,3,5(10)-estratriene; (+)-17alpha-Ethynyl-17beta-hydroxy-3-methoxy-1,3,5(10)-oestratriene; (+ )-17.alpha.-Ethynyl-17.beta.-hydroxy-3-methoxy-1,3, 5(10)-oestratriene; (+)-17.alpha.-Ethynyl-17.beta.-hydroxy-3-methoxy-1,3, 5(10)-estratriene; (1S,10R,11S,14R,15S)-14-ethynyl-5-methoxy-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-trien-14-ol; (8R,13S,17R)-17-Ethynyl-3-methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-ol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6784	DB01357	.	DR1034	310.4	C21H26O2	29.5	519	4	23	1	2	2	"1S/C21H26O2/c1-4-21(22)12-10-19-18-7-5-14-13-15(23-3)6-8-16(14)17(18)9-11-20(19,21)2/h1,6,8,13,17-19,22H,5,7,9-12H2,2-3H3/t17-,18-,19+,20+,21+/m1/s1"	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC	IMSSROKUHAOUJS-MJCUULBUSA-N
DG00851	Tryptophan	6305	"L-tryptophan; tryptophan; 73-22-3; L-Tryptophane; h-Trp-oh; (S)-Tryptophan; Tryptophane; Optimax; trofan; tryptacin; Ardeytropin; (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid; Pacitron; Indole-3-alanine; Kalma; L-beta-3-Indolylalanine; L-Tryptofan; L-Trp; L-(-)-Tryptophan; 3-Indol-3-ylalanine; Tryptan; Lyphan; Tryptophan (VAN); 1-beta-3-Indolylalanine; Tryptophan (H-3); Triptofano [Spanish]; Tryptophanum [Latin]; 1H-Indole-3-alanine; 1beta-3-Indolylalanine; 2-Amino-3-indolylpropanoic acid; L(-)-Tryptophan; triptofano; Tryptophanum; (S)-alpha-Amino-1H-indole-3-propanoic acid; Tryptophane [French]; Tryptophan, L-; (L)-TRYPTOPHAN; (-)-Tryptophan; alpha'-Amino-3-indolepropionic acid; Tryptophan [USAN:INN]; L-alpha-amino-3-indolepropionic acid; L-alpha-Aminoindole-3-propionic acid; Sedanoct; (S)-alpha-Aminoindole-3-propionic acid; 1H-Indole-3-alanine (VAN); EH 121; trp; Alanine, 3-indol-3-yl-; (S)-2-Amino-3-(3-indolyl)propionic acid; CCRIS 617; L-Alanine, 3-(1H-indol-3-yl)-; 1H-Indole-3-alanine, (S)-; alpha-Amino-3-indolepropionic acid, L-; HSDB 4142; (S)-alpha-amino-beta-(3-indolyl)-propionic acid; NCI-C01729; AI3-18478; UNII-8DUH1N11BX; Indole-3-propionic acid, alpha-amino-; 1H-Indole-3-propanoic acid, alpha-amino-, (S)-; Propionic acid, 2-amino-3-indol-3-yl-; CHEBI:16828; Lopac-T-0254; MFCD00064340; 8DUH1N11BX; (S)-alpha-Amino-beta-indolepropionic acid; CHEMBL54976; (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid; DSSTox_CID_1419; DSSTox_RID_76152; DSSTox_GSID_21419; l-b-3-Indolylalanine; D-Trp-OH; CAS-73-22-3; Propionic acid, 2-amino-3-indol-3-yl; L-Tryptophan (9CI); Tryptophan (USP/INN); (S)-a-Amino-b-indolepropionic acid; (S)-a-Aminoindole-3-propionic acid; Alanine, 3-indol-3-yl; EINECS 200-795-6; NSC 13119; (2S)-2-amino-3-(1H-indol-3-yl)propanoate; trytophan; (S)-a-Amino-1H-indole-3-propanoic acid; TRP-01; Trytophan-; 2-amino-3-indol-3-ylpropanoic acid; L-Trytophan; NSC-13119; 1qaw; L-Tryptophan,(S); L-Trp-OH; 2a4m; H-L-Trp-OH; L-Tryptophan (JP17); S(-)-1-alpha-Aminoindole-3-propionic acid; Tryptophan ((-),l,s); Tryptophan (L-Tryptophan); Tryptophan, L- (8CI); bmse000050; bmse000868; bmse001017; Epitope ID:136043; EC 200-795-6; T 0254; SCHEMBL7328; 2-Amino-3-indolylpropanoate; (S)-(-)-2-Amino-3-(3-indolyl)propionic Acid; (S)-1H-Indole-3-alanine; Lopac0_001183; GTPL717; MLS001056750; DivK1c_000457; (s)-a-amino-b-indolepropionate; 151A3008-4CFE-40C9-AC0B-467EF0CB50EA; DTXSID5021419; (S)-a-Aminoindole-3-propionate; BDBM21974; HMS501G19; KBio1_000457; ZINC83315; 3-(1H-indol-3-yl)-L-Alanine; L-a-Amino-3-indolepropionic acid; NINDS_000457; alpha-Aminoindole-3-propionic acid; HMS3263N07; Pharmakon1600-01500600; ACT08662; HY-N0623; L-Tryptophan, Cell Culture Reagent; STR02722; (S)-alpha-Aminoindole-3-propionate; Tox21_201246; Tox21_300359; Tox21_501183; HTS001390; NSC757373; s3987; (s)-alpha-amino-beta-indolepropionate; L-Tryptophan, Vetec(TM), 98.5%; (S)-a-Amino-1H-indole-3-propanoate; AKOS015854052; Indoe-3-propionic acid, alpha-amino-; 2-Chloro-5-(methylsulfonyl)benzoicacid; AM82273; CCG-205257; CS-W020011; DB00150; LP01183; MCULE-8004234494; NSC-757373; SDCCGSBI-0051150.P002; IDI1_000457; NCGC00015994-01; NCGC00094437-01; NCGC00094437-02; NCGC00094437-03; NCGC00094437-04; NCGC00094437-08; NCGC00254424-01; NCGC00258798-01; NCGC00261868-01; (S)-alpha-Amino-1H-indole-3-propanoate; AC-17050; BP-13286; SMR000326686; TS-04426; DB-029986; L-Tryptophan, BioUltra, >=99.5% (NT); A7403; EU-0101183; T0541; (S)-Tryptophan 1H-Indole-3-alanine, (S)-; 73T223; C00078; D00020; L-Tryptophan, reagent grade, >=98% (HPLC); M02943; P16427; AB00373874_05; L-Tryptophan, Vetec(TM) reagent grade, >=98%; (S)-2-amino-3-(1H-Indol-3-yl)-propionic acid; A837752; Q181003; SR-01000075590; 4-(3-METHOXYANILINO)-4-OXOBUT-2-ENOICACID; SR-01000075590-1; F0001-2364; Z1245635763; L-Tryptophan, certified reference material, TraceCERT(R); Tryptophan, European Pharmacopoeia (EP) Reference Standard; UNII-0O72R8RF8A component QIVBCDIJIAJPQS-VIFPVBQESA-N; UNII-N7U7BXP2OI component QIVBCDIJIAJPQS-VIFPVBQESA-N; UNII-X9U7434L7A component QIVBCDIJIAJPQS-VIFPVBQESA-N; L-Tryptophan, United States Pharmacopeia (USP) Reference Standard; 80206-30-0; L-Tryptophan, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 99.0-101.0%; L-Tryptophan, PharmaGrade, Ajinomoto, EP, JP, USP, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:16828	DB00150	DR00086	DR0991	204.22	C11H12N2O2	79.1	245	-1.1	15	3	3	3	"1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1"	C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)N	QIVBCDIJIAJPQS-VIFPVBQESA-N
DG00855	Amfepramone	7029	"DIETHYLPROPION; Amfepramone; Diethylpropione; Anorex; Tepanil; 90-84-6; Frekentine; Danylen; Magrene; Tylinal; alpha-Benzoyltriethylamine; Amfepramonum; Prefamone; Regenon; Diethylcathinone; Dobesin; alpha-Diethylaminopropiophenone; Anfepramona; 1-Propanone, 2-(diethylamino)-1-phenyl-; Amfepramonum [INN-Latin]; Anfepramona [INN-Spanish]; 2-(Diethylamino)propiophenone; Amfepramone [INN]; 2-(diethylamino)-1-phenylpropan-1-one; 1-Phenyl-2-diethylamino-1-propanone; 2-(Diethylamino)-1-phenyl-1-propanone; Tenuate; Amfepramon; DEA No. 1610; Propiophenone, 2-(diethylamino)-; Amfepramone (INN); Amphepramon; Amphepramone; Nopropiophenone; Adiposon; Neobes; Tenuate Dospan; Amphepramonum hydrochloride; Diethylpropione hydrochloride; Cegramine; Obesitex; Silutin; Derfon; Regenon hydrochloride; CHEBI:4530; Anfamon; Keramik; Keramin; Modulor; Parabolin; C06954; D07444; Tenuate hydrochloride; UR 1423; (+-)-diethylpropion; Diethylpropion (BAN); Fenyl-(1-diethylaminoethyl)keton [Czech]; Fenyl-(1-diethylaminoethyl)keton; HSDB 3059; NCGC00167475-01; EINECS 202-019-1; BRN 2804400; Anferpramon; 1-Phenyl-2-diethylaminopropanone-1 hydrochloride; Propiophenone, 2-(diethylamino)-, hydrochloride; Propiophenone, 2-diethylamino-; (+/-)-diethylpropion; .alpha.-benzoyltriethylamine; SCHEMBL27330; 4-14-00-00144 (Beilstein Handbook Reference); GTPL7161; CHEMBL1194666; DTXSID6022929; MFCD00056154; AKOS025401369; DIETHYLPROPION, DONYLEN,DOBESIN; DB00937; J4.327C; MCULE-3905795013; 2-Diethylaminopropiophenone hydrochloride; AC-13099; 2-(Diethylamino)-1-phenyl-1-propanone #; 1-Phenyl-2-diethylamino-1-propanone hydrochloride; Q2356505; BRD-A37288617-003-01-4"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4530	.	DR01090	.	205.3	C13H19NO	20.3	193	2.8	15	0	2	5	"1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3"	CCN(CC)C(C)C(=O)C1=CC=CC=C1	XXEPPPIWZFICOJ-UHFFFAOYSA-N
DG00856	Proflavine	7099	"Proflavine; acridine-3,6-diamine; Proflavin; 92-62-6; 3,6-Diaminoacridine; 3,6-ACRIDINEDIAMINE; Isoflav base; Proflavine hemisulfate; Proflavina; Proflavinum; 2,8-Diaminoacridinium; Acridine, 3,6-diamino-; 3,6-Diaminoacridinium; 3,7-Diamino-5-azaanthracene; 2,8-Diaminoacridine; UNII-CY3RNB3K4T; 1811-28-5; Proflavine (hemisulfate); CY3RNB3K4T; CHEBI:8452; Proflavine [INN]; Profura; Progarmed; Proflavinum [INN-Latin]; PRL; Proflavina [INN-Spanish]; Proflavin hemisulfate;3,6-Diaminoacridine hemisulfate; 2,8-Diaminoacridine (European); CCRIS 1244; MFCD00149650; HSDB 7071; NCGC00166245-01; EINECS 202-172-4; BRN 0166050; AI3-52128; 1bcu; 1qvt; 1qvu; 3,6-Acridinediamine hydrochloride; 3,6-diaminoacridin; 3,6-Diaminoacridine hemisulfate salt; proflavine-hemisulfate; NCIMech_000209; SCHEMBL27386; 5-22-11-00322 (Beilstein Handbook Reference); AE-562/12222295; CHEMBL55400; Proflavine;3,6-Diaminoacridine; SCHEMBL8149677; YSCH0132; DTXSID9043776; BDBM12590; WDVSHHCDHLJJJR-UHFFFAOYSA-; 2v57; Proflavine hemisulfate salt hydrate; 3,6-diamino acridine hydrochloride; ALBB-024962; HY-B1741; ZINC3775644; MFCD00005030; STK380650; AKOS005449844; AT13412; CCG-339542; DB01123; MCULE-9362278105; NCGC00166245-02; NCI60_004643; NCI60_004767; NCI60_032077; CS-0013756; S5776; AB00375967-03; AB00375967_04; (6-aminoacridin-3-yl)amine;sulfuric acid;hydrate; A909942; Q420454; SR-01000883943; SR-01000883943-1; UNII-1T3A50395T component WDVSHHCDHLJJJR-UHFFFAOYSA-N"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8452	DB01123	.	.	209.25	C13H11N3	64.9	232	1.8	16	2	3	0	"1S/C13H11N3/c14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10/h1-7H,14-15H2"	C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N	WDVSHHCDHLJJJR-UHFFFAOYSA-N
DG00859	Chymopapain	9001	"TIRON; Tiferron; 149-45-1; Disodium 4,5-dihydroxybenzene-1,3-disulfonate; Sodium catechol sulfate; 1,3-Benzenedisulfonic acid, 4,5-dihydroxy-, disodium salt; Sodium 4,5-dihydroxybenzene-1,3-disulfonate; 1,2-Dihydroxybenzene-3,5-disulfonic acid disodium salt; UNII-4X87R5T106; 3,5-Disulfocatechol disodium salt; Sodium pyrocatechol-3,5-disulfonate; Disodium pyrocatechol-3,5-disulfonate; Sodium 1,2-dihydroxybenzenedisulfonate; Dihydroxy benzene disulfonate disodium salt; Disodium 4,5-dihydroxy-m-benzenedisulfonate; Sodium 1,2-dihydroxy-3,5-benzenedisulfonate; CHEBI:9607; Catechol-3,5-disulfonic Acid Disodium Salt; Disodium 1,2-dihydroxybenzene-3,5-disulfonate; Disodium 4,5-dihydroxybenzene-1,3-disulphonate; Disodium 4,5-dihydroxy-1,3-benzenedisulfonate; 4,5-Dihydroxy-m-benzenedisulfonic acid disodium salt; 4X87R5T106; CHYMOPAPAIN; m-Benzenedisulfonic acid, 4,5-dihydroxy-, disodium salt; 1,3-Benzenedisulfonic acid, 4,5-dihydroxy-, sodium salt (1:2); SDD; EINECS 205-741-5; NSC 12861; Pyrocatechol-3,5-disulfonic acid disodium salt; Tiron (1,2-Dihydroxybenzene-3,5-disulfonic acid disodium salt); Tiron, p.a. 99%; DSSTox_CID_23950; DSSTox_RID_80093; DSSTox_GSID_43950; SCHEMBL22220; CHEMBL110526; DTXSID7043950; AMY37894; Tox21_302148; MFCD00007473; AKOS002248727; AKOS015913779; NCGC00255944-01; CAS-149-45-1; CS-0010164; D0567; Q2436330; W-108084; 4,5-Dihydroxy-1,3-benzenedisulfonic acid, Disodium salt"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9607	.	.	.	314.2	C6H4Na2O8S2	172	413	.	18	2	8	0	"1S/C6H6O8S2.2Na/c7-4-1-3(15(9,10)11)2-5(6(4)8)16(12,13)14;;/h1-2,7-8H,(H,9,10,11)(H,12,13,14);;/q;2*+1/p-2"	C1=C(C=C(C(=C1O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+]	ISWQCIVKKSOKNN-UHFFFAOYSA-L
DG00860	Azacitidine	9444	"5-azacytidine; Azacitidine; 320-67-2; Ladakamycin; Azacytidine; Vidaza; Mylosar; 5-azacitidine; Azacitidinum; Azacitidina; Azacitidinum [INN-Latin]; 5-AZAC; Azacitidina [INN-Spanish]; NSC-102816; C8H12N4O5; NSC 102816; U-18496; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; UNII-M801H13NRU; NSC102816; 5AzaC; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; Antibiotic U 18496; CHEBI:2038; M801H13NRU; 4-amino-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; MFCD00006539; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one; WR-183027; NCGC00090851-04; DSSTox_CID_116; U 18496; DSSTox_RID_75378; DSSTox_GSID_20116; U-18,496; CCRIS 60; SMR000857239; Vidaza (TN); HSDB 6879; 5-aza-CR; SR-01000075662; EINECS 206-280-2; BRN 0620461; Onureg; Azacitidine (JAN/USAN/INN); Azacitidine [USAN:INN:BAN]; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; NS-17; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2-one; CAS-320-67-2; Azacitidine (Vidaza); 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; Antibiotic U18496; U18496; Spectrum_001262; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; Spectrum2_000786; Spectrum3_001509; Spectrum4_000922; Spectrum5_001166; MolMap_000062; A 2385; SCHEMBL3741; CHEMBL1489; Azacitidine (5-Azacytidine); Lopac0_000035; BSPBio_003157; KBioGR_001444; KBioGR_002556; KBioSS_001742; KBioSS_002565; MLS001333121; MLS001333122; MLS002153249; MLS002548894; DivK1c_000125; SPECTRUM1502111; SPBio_000892; GTPL6796; DTXSID9020116; BCBcMAP01_000083; HMS500G07; KBio1_000125; KBio2_001742; KBio2_002556; KBio2_004310; KBio2_005124; KBio2_006878; KBio2_007692; KBio3_002657; KBio3_003034; NMUSYJAQQFHJEW-KVTDHHQDSA-; pyrimidine antimetabolite: inhibits nucleic acid replication; cMAP_000082; NINDS_000125; HMS1921J22; HMS2092D08; HMS2231F15; HMS3259D19; HMS3260G11; Pharmakon1600-01502111; ZINC3861768; 5-Azacytidine, >=98% (HPLC); Tox21_111032; Tox21_302985; Tox21_500035; BDBM50424715; CCG-39046; NSC758186; s1782; Onureg (CC-486; oral azacitidine); AKOS015896938; Tox21_111032_1; AM83944; CS-1287; DB00928; LP00035; MCULE-8318770472; NC00672; NSC-758186; NSC103-627; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; IDI1_000125; NCGC00090851-01; NCGC00090851-02; NCGC00090851-03; NCGC00090851-05; NCGC00090851-06; NCGC00090851-07; NCGC00090851-08; NCGC00090851-10; NCGC00090851-14; NCGC00090851-22; NCGC00178234-01; NCGC00256541-01; NCGC00260720-01; AS-13697; HY-10586; SRI-10756_10; SRI-10756_12; WR183027; DB-006955; SL-000003; EU-0100035; D03021; F10504; J10124; 320A672; A821115; Q416451; J-700085; SR-01000075662-1; SR-01000075662-3; SR-01000075662-7; BRD-K03406345-001-02-1; BRD-K03406345-001-27-8; 4-Amino-1- -D-ribofuranosyl-1,3,5-triazin-2(1H)-one; Z1522566611; 4-Amino-1-(bet.-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-tr iazin-2(1H)-one; s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl- (8CI); Azacitidine, United States Pharmacopeia (USP) Reference Standard; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; Ladakamycin; Azacitidine, Pharmaceutical Secondary Standard; Certified Reference Material; 1401238-97-8; 5-Azacytidine, Hybri-Max(TM), gamma-irradiated, lyophilized powder, BioXtra, suitable for hybridoma; 5AE; 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-1,3,5-triazin-3-ium-2-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:2038	DB00928	DR00983	DR0163	244.2	C8H12N4O5	141	384	-2.2	17	4	5	2	"1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1"	C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N	NMUSYJAQQFHJEW-KVTDHHQDSA-N
DG00861	Nandrolone	9904	"Nandrolone; 19-Nortestosterone; 434-22-0; 19-Norandrostenolone; Nortestosterone; 17beta-Hydroxy-4-estren-3-one; 4-Estren-17beta-ol-3-one; Nortestosteronum; Nandrolon; Norandrostenolone; Nortestonate; Menidrabol; Nandrolona; Nandrolonum; Oestrenolon; Norandrostenolon; 17beta-Hydroxy-19-nor-4-androsten-3-one; 17beta-hydroxyestr-4-en-3-one; (17beta)-17-hydroxyestr-4-en-3-one; 17-beta-Hydroestr-4-en-3-one; (17-beta)-17-Hydroxyestr-4-en-3-one; UNII-6PG9VR430D; (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; CHEMBL757; 6PG9VR430D; CHEBI:7466; Estr-4-en-3-one, 17-hydroxy-, (17b)-; NSC 3351; NCGC00159416-02; U 2410; DSSTox_CID_3350; (+)-19-Nortestosterone; DSSTox_RID_76987; DSSTox_GSID_23350; Nandrolonum [INN-Latin]; Nandrolona [INN-Spanish]; decadura (TN); CAS-434-22-0; Nandrolone (INN); SMR000058610; HSDB 3368; Nandrolone [INN:BAN]; EINECS 207-101-0; Estr-4-en-3-one, 17-hydroxy-, (17beta)-; Estr-4-en-3-one, 17beta-hydroxy-; NSC-3351; Nandrolone Base; Nandrolone cIII; NCGC00164479-01; 19-nor-testosterone; Estr-4-en-3-one, 17-beta-hydroxy-; 17.beta.-Nandrolone; Nandrolone Decanoic acid; Estr-4-en-3-one, 17-hydroxy-, (17.beta.)-; enta[a]phenanthren-3-one; 17.beta.-Nortestosterone; EC 207-101-0; SCHEMBL20140; MLS001423989; MLS002222325; Nandrolone(19-nortestosterone); GTPL6949; DTXSID7023350; Deca-Durabolin (decanoate ester); Durabolin (phenylpropionate ester); HMS2051I04; HMS2098E05; HMS2272P06; HMS3715E05; ZINC3814379; Tox21_113167; Tox21_113199; Tox21_201212; BDBM50080092; LMST02010044; AKOS015894933; Nandrolone 1.0 mg/ml in Acetonitrile; Tox21_113167_1; CCG-100835; CS-1416; DB13169; GS-6819; NC00085; NCGC00159416-03; NCGC00159416-04; NCGC00258764-01; (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one; AC-15207; AC-30575; CPD000058610; HY-17432; 19-Nortestosterone, >=99.0% (HPLC); Estr-4-en-3-one, 17beta-hydroxy- (8CI); C07254; D08250; Nandrolone, VETRANAL(TM), analytical standard; 434N220; Q421709; SR-01000781257; SR-01000781257-3; W-106227; Estr-4-en-3-one, 17-hydroxy-, (17beta)- (9CI); Estr-4-en-3-one, 17-hydroxy-, (17-beta)- (9CI); Nandrolone, British Pharmacopoeia (BP) Reference Standard; Nandrolone, United States Pharmacopeia (USP) Reference Standard; (1S,2R,10R,11S,14S,15S)-14-hydroxy-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one; (8~{R},9~{S},10~{R},13~{S},14~{S},17~{S})-13-methyl-17-oxidanyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1~{H}-cyclop; (8~{r},9~{s},10~{r},13~{s},14~{s},17~{s})-13-Methyl-17-Oxidanyl-2,6,7,8,9,10,11,12,14,15,16,17-Dodecahydro-1~{h}-Cyclopenta[a]phenanthren-3-One; (8R,10R,13S,17S)-17-Hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one; 6VW; Nandrolone solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7466	DB13169	DR00854	DR1129	274.4	C18H26O2	37.3	466	2.6	20	1	2	0	"1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1"	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@H]34	NPAGDVCDWIYMMC-IZPLOLCNSA-N
DG00863	Lucanthone	10180	"LUCANTHONE; 479-50-5; Lucanthon; Lucanthonum; Lucantona; Lucanthonum [INN-Latin]; Lucantona [INN-Spanish]; 1-((2-(Diethylamino)ethyl)amino)-4-methylthioxanthen-9-one; 1-{[2-(Diethylamino)ethyl]amino}-4-methyl-9H-thioxanthen-9-one; UNII-FC6D57000M; CHEBI:51052; 1-((2-(diethylamino)ethyl)amino)-4-methyl-9H-thioxanthen-9-one; FC6D57000M; Lucanthone [INN:BAN]; 1-[[2-(Diethylamino)ethyl]amino]-4-methylthioxanthone; 1-diethylaminoethylethylamino-4-methyl-thioxanthenone; 1-{[2-(diethylamino)ethyl]amino}-4-methylthioxanthen-9-one; NSC14574; CCRIS 1106; EINECS 207-532-4; BRN 0312369; AI3-16160; NCIMech_000830; SCHEMBL9156; 5-18-11-00503 (Beilstein Handbook Reference); CHEMBL279014; DTXSID6023230; HY-B2098; Thioxanthen-9-one, 1-((2-(diethylamino)ethyl)amino)-4-methyl-; ZINC3831012; 9H-Thioxanthen-9-one, 1-[[2-(diethylamino)ethyl]amino]-4-methyl-; BDBM50030282; CCG-35817; s6471; CS-6665; DB04967; BS-49111; NCI60_000988; 479L505; Q6696022; 1-(2-diethylaminoethylamino)-4-methyl-thioxanthen-9-one; 1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one; 9H-Thioxanthen-9-one, 1-((2-(diethylamino)ethyl)amino)-4-methyl- (9CI)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:51052	DB04967	.	.	340.5	C20H24N2OS	57.6	426	4	24	1	4	6	"1S/C20H24N2OS/c1-4-22(5-2)13-12-21-16-11-10-14(3)20-18(16)19(23)15-8-6-7-9-17(15)24-20/h6-11,21H,4-5,12-13H2,1-3H3"	CCN(CC)CCNC1=C2C(=C(C=C1)C)SC3=CC=CC=C3C2=O	FBQPGGIHOFZRGH-UHFFFAOYSA-N
DG00865	Melarsoprol	10311	"MELARSOPROL; 494-79-1; Mel B; Arsobal; Melarsoprolum [INN-Latin]; EINECS 207-793-4; RP 3854; CHEBI:6729; [2-[4-[(4,6-diamino-1,3,5-triazin-2-yl)amino]phenyl]-1,3,2-dithiarsolan-4-yl]methanol; RP-3854; Melarsoprolum; (2-(4-((4,6-diamino-1,3,5-triazin-2-yl)amino)phenyl)-1,3,2-dithiarsolan-4-yl)methanol; (2-{4-[(4,6-diamino-1,3,5-triazin-2-yl)amino]phenyl}-1,3,2-dithiarsolan-4-yl)methanol; Melarsoprol [INN:BAN:DCF]; Specia; UNII-ZF3786Q2E8; Melarsoprol (INN); Mel B (TN); CHEMBL166; 1,3,2-Dithiarsolane-4-methanol, 2-(4-((4,6-diamino-1,3,5-triazin-2-yl)amino)phenyl)-; SCHEMBL61707; DTXSID90862033; ZF3786Q2E8; DB12864; 2-(p-(4,6-Diamino-s-triazin-2-ylamino)phenyl)-1,3,2-dithiarsolane-4-methanol; C08001; D00832; Q419753; 2-[4-{(4,6-Diamino-1,3,5-triazin-2-yl)amino}phenyl]-1,3,2-dithiarsolan-e-4-methanol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6729	DB12864	.	.	398.3	C12H15AsN6OS2	174	353	.	22	4	9	4	"1S/C12H15AsN6OS2/c14-10-17-11(15)19-12(18-10)16-8-3-1-7(2-4-8)13-21-6-9(5-20)22-13/h1-4,9,20H,5-6H2,(H5,14,15,16,17,18,19)"	C1C(S[As](S1)C2=CC=C(C=C2)NC3=NC(=NC(=N3)N)N)CO	JCYZMTMYPZHVBF-UHFFFAOYSA-N
DG00867	Medroxyprogesterone	10631	"Medroxyprogesterone; 520-85-4; Medroxyprogesteron; Medroxiprogesteronum; Medroxiprogesterona; Medroxyprogesteronum; 17-Hydroxy-6alpha-methylprogesterone; Hydroxymethylprogesterone; Medrossiprogesterone; 17alpha-Hydroxy-6alpha-methylprogesterone; 6alpha-Methyl-17alpha-hydroxyprogesterone; 6alpha-Methyl-4-pregnen-17alpha-ol-3,20-dione; 17-Hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione; UNII-HSU1C9YRES; Medroxy Progesterone; U 8840; (6alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione; HSU1C9YRES; (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; Pregn-4-ene-3,20-dione, 17-hydroxy-6-alpha-methyl-; MLS000069571; CHEBI:6715; 17alpha-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione; SMR000058769; Medrossiprogesterone [DCIT]; NSC 27408; DSSTox_CID_16508; DSSTox_RID_79284; DSSTox_GSID_36508; Medroxyprogesteronum [INN-Latin]; Medroxiprogesterona [INN-Spanish]; Medroxyprogesterone [INN:BAN]; 17-Hydroxy-6.alpha.-methylprogesterone; 6-Dihydromegestrol; CAS-520-85-4; 17.alpha.-Hydroxy-6.alpha.-methylprogesterone; 6.alpha.-Methyl-17.alpha.-hydroxyprogesterone; HSDB 3114; 6-alpha-Methyl-17-alpha-hydroxyprogesterone; MLS002639162; EINECS 208-298-6; Farlutal inyectable (TN); Medroxyprogesterone (INN); BRN 2510965; NCGC00183122-01; CPD000058769; Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)-; Opera_ID_433; CHEMBL1390; 6alpha-Methyl-5-pregnen-17alpha-ol-3,20-dione; SCHEMBL37494; 4-08-00-02211 (Beilstein Handbook Reference); MLS001076098; MLS001424229; GTPL2879; DTXSID0036508; 17-Hydroxy-6a-methylprogesterone; HMS2052A13; HMS2230B08; HY-B0648; NSC27408; ZINC5763835; Tox21_113401; 3808AH; LMST02030176; MFCD00069474; s3635; AKOS015961681; Tox21_113401_1; CCG-101111; NC00361; MRF-0000022; NCGC00023064-04; NCGC00023064-05; AC-14528; M3113; 17; A-Hydroxy-6; A-methylprogesterone;U8840; Medroxyprogesterone acetate Related Compound B; C07119; C75441; D08166; Pregn-4-ene-3, 17-hydroxy-6.alpha.-methyl-; 520M854; A899740; Q416667; (6 )-17-Hydroxy-6-methylpregn-4-ene-3,20-dione; Medroxyprogesterone, VETRANAL(TM), analytical standard; Pregn-4-ene-3, 17-hydroxy-6-methyl-, (6.alpha.)-; Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)- (9CI); Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6-alpha)- (9CI); (6S,8R,10R,13S,17R)-17-Acetyl-17-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one; (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; Medroxyprogesterone acetate Related Compound B, United States Pharmacopeia (USP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6715	.	.	.	344.5	C22H32O3	54.4	664	3.5	25	1	3	1	"1S/C22H32O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h12-13,16-18,25H,5-11H2,1-4H3/t13-,16+,17-,18-,20+,21-,22-/m0/s1"	C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)O)C)[C@@]4(C1=CC(=O)CC4)C	FRQMUZJSZHZSGN-HBNHAYAOSA-N
DG00868	Methamphetamine	10836	"METHAMPHETAMINE; Metamfetamine; d-Methamphetamine; d-Deoxyephedrine; d-Desoxyephedrine; Metamphetamine; Methylamphetamine; d-N-Methylamphetamine; d-Methylamphetamine; d-Phenylisopropylmethylamine; N-Methylamphetamine; (S)-Methamphetamine; Norodin; (+)-Methylamphetamine; d-(S)-Methamphetamine; D-1-Phenyl-2-methylaminopropane; Desyphed; (+)-N-Methylamphetamine; (S)-Methylamphetamine; (+)-(S)-Deoxyephedrine; Methyl-beta-phenylisopropylamine; 537-46-2; 1-Phenyl-2-methylaminopropane; (S)-(+)-Deoxyephedrine; Metamfetamina; Metamfetaminum; (2S)-N-methyl-1-phenylpropan-2-amine; (+)-methamphetamine; Metanfetamina; S-(+)-Methamphetamine; (S)-N,alpha-Dimethylbenzeneethanamine; D-N,alpha-dimethylphenethylamine; Metamfetaminum [INN-Latin]; Metamfetamina [INN-Spanish]; Metanfetamina [INN-Spanish]; Methamphetaminum [INN-Latin]; (+)-2-(N-Methylamino)-1-phenylpropane; Meth; Metamfetamine [INN]; N-Methyl-beta-phenylisopropylamine; 1-Phenyl-2-methylamino-propan [German]; (+)-N,alpha-Dimethylphenethylamine; d-1-Phenyl-2-methylaminopropan [German]; (+)-N,alpha-Dimethyl-beta-phenylethylamine; D-1-Phenyl-2-methylaminopropan; 2S-(+)-Methamphetamine; dextromethamphetamine; (S)-(+)-Methamphetamine; (+)-(S)-N-alpha-Dimethylphenethylamine; N-Methyl-beta-phenylisopropylamin [German]; NSC 25115; (S)-N,alpha-Dimethylbenzeneethanoamine; UNII-44RAL3456C; CHEBI:6809; (S)-(+)-N,alpha,dimethylphenethylamine; Metamfetamine (INN); (alphaS)-N,alpha-dimethylbenzeneethanamine; Benzeneethanamine, N,alpha-dimethyl-, (S)-; Methyl-.beta.-phenylisopropylamine; d-N,.alpha.-Dimethylphenethylamine; Stimulex; Speed; 44RAL3456C; Benzeneethanamine, N,alpha-dimethyl-, (alphaS)-; 1-Phenyl-2-methylamino-propan; NSC-25115; N-Methyl-beta-phenylisopropylamin; Crank; Methamphetaminum; Methamphetaminum [JP]; Crystal Meth; Metamfetaminum [Latin]; Metanfetamina [Spanish]; Meth (Street Name); ICE [Street Name]; Crank [Street Name]; Speed [Street Name]; Crystal Meth [Street Name]; HSDB 3359; N-Methyl-1-phenyl-2-propanamine; (+ )-Methylamphetamine; EINECS 208-668-7; Phenethylamine, N,alpha-dimethyl-, (+)-; Benzeneethanamine, N,alpha-dimethyl-, (+)-; DEA No. 1105; B40; Benzeneethanamine, N,.alpha.-dimethyl-, (S)-; Methamphetamine, its salts, isomers, and salts of its isomers; Phenethylamine, N,.alpha.-dimethyl-, (S)-(+)-; Epitope ID:178090; intra-venous methamphetamine; Phenethylamine, N,alpha-dimethyl-, (S)-(+)-; (s)-phenylmethylaminopropane; Benzeneethanamine,.alpha.-dimethyl-, (S)-; d-N,a-dimethylphenethylamine; SCHEMBL42615; Phenethylamine,.alpha.-dimethyl-, (S)-(+)-; CHEMBL1201201; DTXSID8037128; WLN: 1MY1&1R -D; N,I+/--Dimethyl-phenethyl amine; Desyphed hydrochloride (Salt/Mix); NSC25115; ZINC6021043; N-Methyl-1-phenyl-2-propanamine #; BDBM50359499; PDSP1_001404; PDSP1_001405; PDSP2_001388; PDSP2_001389; (+)-N,.alpha.-Dimethylphenethylamine; (S)-N-methyl-1-phenylpropan-2-amine; DB01577; J6.362B; Desoxyephedrine hydrochloride (Salt/Mix); methyl[(2S)-1-phenylpropan-2-yl]amine; Phenethylamine,.alpha.-dimethyl-, (+)-; (+)-(S)-N-.alpha.-Dimethylphenethylamine; Benzeneethanamine,.alpha.-dimethyl-, (+)-; Phenethylamine, N,.alpha.-dimethyl-, (+)-; Benzeneethanamine, N,.alpha.-dimethyl-, (+)-; C07164; D08187; (+)-N,.alpha.-Dimethyl-.beta.-phenylethylamine; Q191924; Phenethylamine, N,alpha-dimethyl-, (S)-(+)- (8CI); Benzeneethanamine, N,alpha-dimethyl-, (alphaS)- (9CI); UNII-13ZT6YG5SD component MYWUZJCMWCOHBA-VIFPVBQESA-N; (+)-N,.alpha.-Dimethylphenethylamine hydrochloride (Salt/Mix); S(+)-Methamphetamine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6809	.	DR00256	DR1036	149.23	C10H15N	12	95	2.1	11	1	1	3	"1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m0/s1"	C[C@@H](CC1=CC=CC=C1)NC	MYWUZJCMWCOHBA-VIFPVBQESA-N
DG00869	Acetylcysteine	12035	"N-Acetyl-L-cysteine; acetylcysteine; 616-91-1; N-Acetylcysteine; mercapturic acid; Acetadote; L-Acetylcysteine; Broncholysin; Mucomyst; N-Acetyl-cysteine; Fluimucil; Parvolex; Fluimucetin; Fluprowit; Acetein; Airbron; Fabrol; Flumucetin; Mucosolvin; Mucosil; Respaire; Brunac; Fluimicil Infantil; Acetilcisteina; Acetylcysteinum; Lysomucil; Mucofilin; Exomuc; Inspir; Ac-Cys-OH; Mucolyticum Lappe; Mucolytikum Lappe; (R)-2-Acetamido-3-mercaptopropanoic acid; Acetyl-L-cysteine; N-Acetyl cysteine; Mucolyticum; LNAC; Syntemucol; acetyl cysteine; N-Acetyl-3-mercaptoalanine; Tixair; N-Acetyl-L-(+)-cysteine; Neo-fluimucil; NAC-TB; (2R)-2-acetamido-3-sulfanylpropanoic acid; component of Naxid; Mercapturic acid, (R)-; Cysteine, N-acetyl-, L-; cysteine, N-acetyl-; L-Cysteine, N-acetyl-; (R)-mercapturic acid; Fluatox; Mucolator; Mucret; UNII-WYQ7N0BPYC; (2R)-2-Acetamido-3-sulfanyl-propanoic acid; L-alpha-Acetamido-beta-mercaptopropionic acid; NSC 111180; Mucolyticum-Lappe; WYQ7N0BPYC; MFCD00004880; MLS000028419; CHEBI:28939; NSC-111180; RK-0202; NCGC00022304-05; N-Acetyl-L-cysteine hydrochloride; SMR000058377; DSSTox_CID_21; (R)-2-acetylamino-3-mercaptopropanoic acid; (2R)-2-acetylamino-3-sulfanylpropanoic acid; DSSTox_RID_75324; DSSTox_GSID_20021; Cetylev; Flumil; Ilube; N-acetylcystein; Muco sanigen; MUCOSIL-10; MUCOSIL-20; Acetylcysteinum [INN-Latin]; CAS-616-91-1; Acetilcisteina [INN-Spanish]; CCRIS 3764; HSDB 3003; SR-01000075439; EINECS 210-498-3; Fluimicil; Mucocedyl; Oristar nalc; AcCys; NSC111180; N-acetyl-l-cys; Sodium 2-acetamido-3-mercaptopropionate; SC2; Ilube (eye drops); N-A-C Sustain; N-acetyl-L-cystein; N-acetyi-l-cysteine; Naxid (Salt/Mix); N-Acety-L-Cysteine; Acetyl Cysteine,(S); Acetylcysteine [USAN:USP:INN:BAN:JAN]; N-acetyl-(R)-cysteine; Opera_ID_452; MUCOMYST (TN); Acetylcysteine Ph. Eur.; Spectrum2_000086; Spectrum3_000287; Spectrum4_000137; Spectrum5_000764; CHEMBL600; NAC & TNF; SCHEMBL5292; (2R)-2-(acetylamino)-3-sulfanylpropanoic acid; Lopac0_000081; BSPBio_001794; KBioGR_000554; MLS001076125; MLS006011563; SPECTRUM1500105; SPBio_000012; Acetylcysteine(N-acetylcysteine); DTXSID5020021; GTPL10945; KBio3_001294; N-Acetyl-L-cysteine, USP grade; Acetylcysteine (JP17/USP/INN); HMS1920A11; HMS2091G11; HMS2234J22; HMS3260A04; HMS3655G11; HMS3715D03; HMS3884E04; HY-B0215; ZINC3589203; 2-Acetylamino-3-mercapto-propionate; Tox21_110877; Tox21_201078; Tox21_500081; acetylcysteine (n-acetyl-l-cysteine); BDBM50420190; CCG-38902; s1623; AKOS015841009; Tox21_110877_1; CCG-204176; DB06151; GS-3121; LP00081; SDCCGSBI-0050069.P002; NCGC00015086-04; NCGC00022304-03; NCGC00022304-04; NCGC00022304-06; NCGC00022304-07; NCGC00022304-08; NCGC00022304-17; NCGC00022304-23; NCGC00258631-01; NCGC00260766-01; AC-16071; AC-24117; BP-12854; I630; SBI-0051272.P003; DB-038288; A0905; AM20100502; EU-0100081; SW199597-2; (2R)-2-acetylamino-3-mercapto-propionic acid; EN300-72028; 16A911; A 7250; A-1100; C06809; D00221; L-Cysteine, N-acetyl- & Tumor necrosis factor; N-Acetyl-L-cysteine, BioXtra, >=99% (TLC); AB00051908_02; AB00382974-12; AB00382974_13; L-.alpha.-Acetamido-.beta.-mercaptopropionic acid; Q375613; J-507685; N-Acetyl-L-cysteine & Tumor necrosis factor (TNF); N-Acetyl-L-cysteine 100 microg/mL in Acetonitrile; SR-01000075439-1; SR-01000075439-3; SR-01000075439-5; BRD-K59058747-001-20-9; N-Acetyl-L-cysteine, cell culture tested, BioReagent; N-Acetyl-L-cysteine, Vetec(TM) reagent grade, 98%; F1905-7178; CABC898A-E48B-4E13-9F72-98D0609A1854; N-Acetyl-L-cysteine, SAJ special grade, 98.0-102.0%; N-Acetyl-L-cysteine, Sigma Grade, >=99% (TLC), powder; UNII-2SPH1IMO2V component PWKSKIMOESPYIA-BYPYZUCNSA-N; Acetylcysteine, British Pharmacopoeia (BP) Reference Standard; Acetylcysteine, European Pharmacopoeia (EP) Reference Standard; Acetylcysteine, United States Pharmacopeia (USP) Reference Standard; N-Acetyl-L-cysteine, Pharmaceutical Secondary Standard; Certified Reference Material; N-Acetyl-L-cysteine, PharmaGrade, Ajinomoto, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB06151	.	.	163.2	C5H9NO3S	67.4	148	0.4	10	3	4	3	"1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1"	CC(=O)N[C@@H](CS)C(=O)O	PWKSKIMOESPYIA-BYPYZUCNSA-N
DG00872	Citicoline	13804	"Citicoline; cytidine 5'-diphosphocholine; CDP-choline; 987-78-0; citicholine; cytidine diphosphate choline; Citidoline; Cytidoline; Difosfocin; Cyscholin; Citicolinum; Citicolina; CDP-colina; cyticholine; Cytidine 5'-diphosphoric choline; Haocolin; Nicholin; Niticolin; Recofnan; Recognan; Somazina; Suncholin; Colite; Ensign; Cytidindiphosphocholin; Cytidine 5'-(choline diphosphate); Cytidine 5'-(cholinyl pyrophosphate); Cytidine diphosphocholine; Cytidine diphosphorylcholine; Choline cytidine diphosphate; Cytidine choline diphosphate; citidin difosfato de colina; Emicholin; Meibis; Choline 5'-cytidine diphosphate; CDP-cholin; Cereb; Cytidine 5'-diphosphate choline; Cytidine diphosphate choline ester; Cytidinediphosphoric choline; [2-CYTIDYLATE-O'-PHOSPHONYLOXYL]-ETHYL-TRIMETHYL-AMMONIUM; UNII-536BQ2JVC7; Cytidine 5'-(trihydrogen diphosphate), P'-(2-(trimethylammonio)ethyl) ester, inner salt; IP 302; IP-302; Choline cytidine 5'-pyrophosphate ester; Choline, ester with cytidine 5'-pyrophosphate; CDP-cholin [German]; CDP-colina [Spanish]; Startonyl; Ubelin; Citicoline [INN:JAN]; Citicolinum [INN-Latin]; Citicolina [INN-Spanish]; 536BQ2JVC7; CHEBI:16436; 2-(((((((2R,3S,4R,5R)-5-(4-Amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)oxidophosphoryl)oxy)-N,N,N-trimethylethanaminium; Cytidindiphosphocholin [German]; Cytidine diphosphate cholin ester; C14H26N4O11P2; EINECS 213-580-7; Citidin difosfato de colina [Spanish]; Cytidine 5-diphosphocholine; NSC 122002; BRN 4170138; Cytidine, 5'-pyrophosphate, ester with choline; Cytidine 5'-(trihydrogen diphosphate), P'-[2-(trimethylammonio)ethyl] ester, inner salt; Nicholin (TN); Citicoline (JP17/INN); cytidine diphosphate-choline; CDP-choline (neutral charge); SCHEMBL221081; AOB5033; MFCD00868097; AKOS025312525; CCG-269597; DB04290; DB12153; Choline, hydroxide, 5'-ester with cytidine 5'-(trihydrogen pyrophosphate), inner salt; Cytidine 5'-(trihydrogen diphosphate), mono(2-(trimethylammonio)ethyl) ester, hydroxide, inner salt; K771; C00307; D00057; D81851; A847982; W-100063; Q28529682; 5'-O-[(S)-hydroxy({[2-(trimethylammonio)ethoxy]phosphinato}oxy)phosphoryl]cytidine; 5'-O-[hydroxy({[2-(trimethylammonio)ethoxy]phosphinato}oxy)phosphoryl]cytidine; Cytidine 5'-(trihydrogen diphosphate), P'-[2-(trimethylammonio)ethyl]ester, inner salt; {2-[({[(2R,3S,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl phosphonato)oxy]ethyl}trimethylazanium"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:16436	.	.	DR2077	488.32	C14H26N4O11P2	214	821	-4	31	4	11	10	"1S/C14H26N4O11P2/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H3-,15,16,21,22,23,24,25)/t9-,11-,12-,13-/m1/s1"	C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O	RZZPDXZPRHQOCG-OJAKKHQRSA-N
DG00876	Abametapir	15664	"5,5'-Dimethyl-2,2'-bipyridine; 1762-34-1; Abametapir; 6,6'-Bi-3-picoline; 5,5'-Dimethyl-2,2'-bipyridyl; 5,5'-Dimethyl-2,2'-dipyridyl; 2,2'-BIPYRIDINE, 5,5'-DIMETHYL-; HA-44; BRN 0123183; 6,6'-Di-3-picolyl; 6,6'-Di-3-picoline; UNII-6UO390AMFB; 5-methyl-2-(5-methylpyridin-2-yl)pyridine; 6UO390AMFB; CHEMBL2205807; 5,5'-dimethyl-2,2'-bipyridinyl; MFCD01740554; Xeglyze; Abametapir [USAN:INN]; Xeglyze(Abametapir); Xeglyze (TN); Abametapir (USAN/INN); SCHEMBL351152; HA44; YSSJ3184; 2,2 -Bis-(5-methylpyridyl); 2,2'dimethyl-5,5'-dipyridyl; 5,5'dimethyl-2,2'-dipyridyl; DTXSID00170095; ZINC403335; 9238AA; BDBM50401351; LT0042; s5752; 5,5''-Dimethyl-2,2''-bipyridine; AKOS005257775; CS-W004546; DB11932; HY-W004546; MCULE-8581798506; SB17220; 5,5'-Dimethyl-2,2'-dipyridyl, 98%; DS-15219; SY052805; FT-0689891; D10687; D70523; W-108621; Q27265547; 5,5 inverted exclamation mark -Dimethyl-2,2 inverted exclamation mark -bipyridyl"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11932	.	.	184.24	C12H12N2	25.8	161	2.2	14	0	2	1	"1S/C12H12N2/c1-9-3-5-11(13-7-9)12-6-4-10(2)8-14-12/h3-8H,1-2H3"	CC1=CN=C(C=C1)C2=NC=C(C=C2)C	PTRATZCAGVBFIQ-UHFFFAOYSA-N
DG00880	Doxifluridine	18343	"Doxifluridine; 5'-Deoxy-5-fluorouridine; 5-fluoro-5'-deoxyuridine; Furtulon; 3094-09-5; 5'-Dfur; Flutron; Uridine, 5'-deoxy-5-fluoro-; Doxifluridina; Doxifluridinum; Ro 21-9738; Ro 219738; 5'dFUrd; 1-(beta-D-5-Desoxyribofuranoxyl)-5-fluoruracil; UNII-V1JK16Y2JP; CHEMBL1130; V1JK16Y2JP; Capecitabine related compound b; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoropyrimidine-2,4(1H,3H)-dione; CHEBI:31521; NCGC00093926-03; Doxifluridine (5-Fluoro-5'-deoxyuridine); DSSTox_CID_2967; 5'FDUR; DSSTox_RID_76809; DSSTox_GSID_22967; 5'-Doxifluridine; 5'-dFUrd; Furtulon (TN); 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyl-tetrahydrofuran-2-yl]-5-fluoro-pyrimidine-2,4-dione; SMR000326811; CAS-3094-09-5; Uridine-5'-deoxy-5-fluoro-; SR-01000075886; Doxifluridine [INN:JAN]; 5-DFUR; Doxifluridinum [INN-Latin]; Doxifluridina [INN-Spanish]; Fulturon; MFCD00866530; NSC-758890; EINECS 221-440-1; 5-Deoxy-5-fluorouridine; 5-Fluoro-5`-deoxyuridine; SCHEMBL8094; Doxifluridine (JP17/INN); Lopac0_000537; MLS001332579; MLS001332580; MLS002172440; MLS002207077; DTXSID2022967; HMS2090C22; HMS2231I05; HMS3261L15; AMC 0101; AMY13408; HY-B0021; ZINC1319177; Tox21_111231; Tox21_500537; BDBM50132295; s2045; CAPECITABINE IMPURITY B (USP); AKOS015852921; AKOS015896821; Tox21_111231_1; CCG-204627; CS-1270; DB12947; KS-5065; LP00537; NSC 758890; SDCCGSBI-0050520.P002; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoropyrimidine-2,4-dione; NCGC00093926-01; NCGC00093926-02; NCGC00093926-05; NCGC00093926-11; NCGC00261222-01; Ro-21-9738; SRI-11552-08; SRI-11552_09; 5''-Deoxy-5-Fluorouridine (5''-Dfur); RO-219738; EU-0100537; D01309; F 8791; 094F095; Q1253473; SR-01000075886-1; SR-01000075886-5; 5'-DFUR (5'-Deoxy-5-fluorouridine, Doxifluridine); BRD-K58262659-001-09-7; Capecitabine impurity B, European Pharmacopoeia (EP) Reference Standard; Capecitabine Related Compound B, United States Pharmacopeia (USP) Reference Standard; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyl-tetrahydrofuran-2-yl)-5-fluoropyrimidine-2,4(1H,3H)-dione; 1-((2R,5R)-3,4-Dihydroxy-5-methyl-tetrahydro-furan-2-yl)-5-fluoro-1H-pyrimidine-2,4-dione; 1-((4S,2R,3R,5R)-3,4-Dihydroxy-5-methyloxolan-2-yl)-5-fluoro-1,3-dihydropyrimidine-2,4-dione; 1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoropyrimidine-2,4(1H,3H)-dione (5'-Deoxy-5-fluorouridine)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31521	DB12947	.	.	246.19	C9H11FN2O5	99.1	399	-1.7	17	3	6	1	"1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)/t3-,5-,6-,8-/m1/s1"	C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O	ZWAOHEXOSAUJHY-ZIYNGMLESA-N
DG00882	Cephaloglycin	19150	"Cefaloglycin; CEPHALOGLYCIN; Cephaloglycine; D-Cephaloglycine; Cephaoglycin acid; 3577-01-3; Cefaloglycine; Cephaloglycin anhydrous; Cefaloglicina; Cefaloglycinum; D-(-)-Cephaloglycin; 7-(D-alpha-Aminophenyl-acetamido)cephalosporanic acid; 7-(2-D-alpha-Aminophenylacetamido)cephalosporanic acid; CHEBI:34613; Kefglycin; CEG; Cephaloglycin dihydrate; UNII-HD2D469W6U; HD2D469W6U; (6R,7R)-3-(acetyloxymethyl)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup3)-cephem-4-carboxylic acid; Cefaloglycine [INN-French]; Cefaloglycinum [INN-Latin]; Cefaloglicina [INN-Spanish]; Lilly 39435; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,3-[(acetyloxy)methyl]-7-[[(2R)-aminophenylacetyl]amino]-8-oxo-,(6R,7R)-; Cefaloglycin (JAN); Kefocin; HSDB 3214; EINECS 222-696-7; Cefaloglycin [INN]; Cefaloglycin dihydrate; Cephaloglycin anhdyous; 7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate (ester); Epitope ID:174844; SCHEMBL2947; 7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup 3)-cephem-4-carboxylic acid; 3-((Acetyloxy)methyl)-7-((aminophenylacetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-((aminophenylacetyl)amino)-8-oxo-, (6R-(6alpha,7beta(R*)))-; 7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)octane-2-carboxylic acid, acetate inner salt; CHEMBL1200971; DTXSID4022781; ZINC3830503; DB00689; 3-acetoxymethyl-7beta-[(2R)-2-amino-2-phenylacetamido]-3,4-didehydrocepham-4-carboxylic acid; NCGC00521078-02; (6R,7R)-3-(acetoxymethyl)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-, acetate (ester), D-; HY-16137; CS-0006156; D01949; Q5057214; (6R,7R)-3-[(acetyloxy)methyl]-7-[(2R)-2-amino-2-phenylacetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:34613	DB00689	DR01373	.	405.4	C18H19N3O6S	164	718	-3	28	3	8	7	"1S/C18H19N3O6S/c1-9(22)27-7-11-8-28-17-13(16(24)21(17)14(11)18(25)26)20-15(23)12(19)10-5-3-2-4-6-10/h2-6,12-13,17H,7-8,19H2,1H3,(H,20,23)(H,25,26)/t12-,13-,17-/m1/s1"	CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O	FUBBGQLTSCSAON-PBFPGSCMSA-N
DG00883	Cladribine	20279	"Cladribine; 2-Chloro-2'-deoxyadenosine; 4291-63-8; Leustatin; 2-Chlorodeoxyadenosine; 2-CdA; Chlorodeoxyadenosine; CldAdo; ADENOSINE, 2-CHLORO-2'-DEOXY-; Litak; 2-Chloro-2'-deoxy-beta-adenosine; Cladaribine; RWJ 26251; 2-chloro-deoxyadenosine; 2ClAdo; UNII-47M74X9YT5; MLS000028377; 2CdA; Cladarabine; RWJ-26251; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; Leustat; SMR000058553; (2R,3S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; (2R,3S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; CHEBI:567361; 47M74X9YT5; MFCD00153939; NSC-105014; Movectro; Mylinax; DSSTox_CID_2828; DSSTox_RID_76747; DSSTox_GSID_22828; cladribina; cladribinum; mavenclad; Leustatin (TN); CL9; CAS-4291-63-8; 2 Chlorodeoxyadenosine; SR-01000003063; NSC 105014; BRN 0624220; Cladiribine; CCRIS 9374; Adenosine, 2-chloro-2'-deoxy; HSDB 7564; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; Cladribine [USAN:USP:INN:BAN]; Mavenclad (TN); NCGC00018167-03; Cladribine- Bio-X; S1199; RWJ-26251-000; Opera_ID_1191; SCHEMBL3775; CHEMBL1619; Cladribine (JAN/USP/INN); 2-chloro-2'-deoxy-adenosine; cid_20279; MLS000028484; MLS000759397; MLS001077345; MLS001424194; GTPL4799; DTXSID8022828; BDBM38920; HMS2052K13; HMS2232C23; HMS3715F17; ACT02615; AMY22140; BCP02868; ZINC3798064; Tox21_110834; Tox21_300596; NSC-05014; NSC-105014-F; AKOS015854898; AKOS015892544; AC-7591; BCP9000538; CCG-101116; CS-2057; DB00242; NC00366; NCGC00022567-05; NCGC00022567-06; NCGC00022567-07; NCGC00022567-08; NCGC00164384-01; NCGC00254518-01; 2-Chloro-2'-deoxyadenosine, antileukemic; AS-12366; BC164318; BP-25407; HY-13599; SW197746-4; D01370; AB00382963-17; AB00382963_19; 291C638; A826062; Q414030; 2-Chloro-2 inverted exclamation marka-deoxyadenosine; SR-01000003063-7; SR-01000003063-10; Cladribine, European Pharmacopoeia (EP) Reference Standard; 6-amino-2-chloro-9-(2-deoxy-beta-erythropentofuranosyl)purine; Cladribine, United States Pharmacopeia (USP) Reference Standard; 6-amino-2-chloro-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; (2R,3S,5R)-5-(6-Amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxalan-3-ol; (2R,3S,5R)-5-(6-amino-2-chloro-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol; Cladribine for peak identification, European Pharmacopoeia (EP) Reference Standard; 2-Chloro-2'-deoxyadenosine;(2R,3S,5R)-5-(6-amino-2-chloro-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol; 24757-90-2; Leustatin; ; ; 2-Chloro-2'-deoxyadenosine; ; ; 2-CdA; ; ; NSC-105014-F; ; ; (2R,3S,5R)-5-(6-Amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:567361	DB00242	DR00087	DR1918	285.69	C10H12ClN5O3	119	338	0.8	19	3	7	2	"1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1"	C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O	PTOAARAWEBMLNO-KVQBGUIXSA-N
DG00884	Beclomethasone	20469	"Beclomethasone; Beclometasone; 4419-39-0; Beclomethasone Solution; Beclometasona; Beclometasonum; UNII-KGZ1SLC28Z; 9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; MLS000028668; KGZ1SLC28Z; SMR000058899; CHEBI:3001; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9alpha-Chloro-16beta-methylprednisolone; NCGC00164402-01; DSSTox_CID_20750; DSSTox_RID_79587; DSSTox_GSID_40750; Beclometasonum [INN-Latin]; Beclometasona [INN-Spanish]; (11beta,16beta)-9-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8~{S},9~{R},10~{S},11~{S},13~{S},14~{S},16~{S},17~{R})-9-chloranyl-10,13,16-trimethyl-11,17-bis(oxidanyl)-17-(2-oxidanylethanoyl)-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; CAS-4419-39-0; BMJ 5800; EINECS 224-585-9; Beclometasone [INN:BAN]; pulvinal; 9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione (Beclometasone); Beclometason (TN); Beclometasone (INN); Opera_ID_1081; SCHEMBL3183; CHEMBL1586; cid_20469; MLS001076089; BIDD:GT0556; GTPL7059; DTXSID5040750; BCBcMAP01_000159; BDBM53488; AMY7469; 9alpha-Chloro-16beta-methyl-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione; HMS2233A18; EX-A4423; HY-B1540; ZINC4097285; Tox21_112116; 8060AH; MFCD00135614; AKOS037645177; Tox21_112116_1; CS-5872; Pregna-1,4-diene-3,20-dione, 9-chloro-11,17,21-trihydroxy-16-methyl-, (11beta,16beta)-; SMP1_000039; NCGC00179392-03; AS-58067; C06842; D07495; A905224; SR-01000000273; SR-01000000273-4; Beclometasone. Short expiry date due to chemical nature of component(s); 9alpha-Chloro-11beta,17alpha,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dione,9-chloro-11,17,21-trihydroxy-16-methyl-, (11b,16b)-; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloranyl-10,13,16-trimethyl-11,17-bis(oxidanyl)-17-(2-oxidanylethanoyl)-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-17-glycoloyl-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; Beclometasone; (1R,2S,10S,11S,13S,14R,15S,17S)-1-Chloro-14-(2-glycoloyl)-14,17-dihydroxy-2,13,15-trimethyltetracyclo[8.7.0.02,7.011,15]heptadeca-3,6-dien-5-one; GXR"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3001	.	DR01368	.	408.9	C22H29ClO5	94.8	805	2.2	28	3	5	2	"1S/C22H29ClO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1"	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C	NBMKJKDGKREAPL-DVTGEIKXSA-N
DG00888	Zalcitabine	24066	"Zalcitabine; Dideoxycytidine; 7481-89-2; 2',3'-DIDEOXYCYTIDINE; ddCyd; HIVID; Cytidine, 2',3'-dideoxy-; ddC; Zalcitibine; 4-Amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; NSC 606170; Ro 24-2027/000; UNII-6L3XT8CB3I; CHEMBL853; 6L3XT8CB3I; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; CHEBI:10101; MFCD00012188; NCGC00090705-08; DSSTox_CID_3747; NSC-606170; 4-AMINO-1-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-1,2-DIHYDROPYRIMIDIN-2-ONE; DSSTox_RID_77182; DSSTox_GSID_23747; 2,3-dideoxycytidine; NSC606170; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; SMR000058253; CCRIS 692; Hivid(TM); Hivid (TN); HSDB 7156; Interferon AD + ddC; ddC & GM-CSF; ddC & sCD4; PC-SOD & ddC; Ro-24-2027/000; DDC (DDC); BRN 0654956; Zalcitabine (JAN/USP/INN); DS-4152 & ddC; 1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine; ddC & NP (from PHCA or HSA); SRI-7707; Zalcitabine [USAN:USP:INN:BAN]; CAS-7481-89-2; Zalcitabine- Bio-X; KS-1130; ddC & IFN.alpha.; .beta.-D-DDC; dideoxycytidine (DDC); 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; Prestwick0_001037; Prestwick1_001037; Prestwick2_001037; Prestwick3_001037; ddC & Interferon.alpha.; 2', 3'-dideoxycytidine; bmse000712; UPCMLD-DP115; D 5782; SCHEMBL3598; TimTec1_004969; Lopac0_000360; BSPBio_001253; 3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine; 5-25-14-00313 (Beilstein Handbook Reference); MLS000069636; MLS000759540; MLS001055363; MLS001424210; MLS006011951; SPBio_003104; BPBio1_001378; GTPL4828; ddC; ; ; 2',3'-Dideoxycytidine; DTXSID0023747; UPCMLD-DP115:001; ZINC39906; 2',3'-Dideoxycytidine & sCD4(soluble recombinant protein); AOB5609; HMS1548B19; HMS1571O15; HMS2051H18; HMS2090C12; HMS2098O15; HMS2236N08; HMS3261G21; HMS3715O15; Pharmakon1600-01502360; .beta.-D-2',3'-Dideoxycytidine; Zalcitabine, 2'3'-Dideoxycytidine; BCP13878; Tox21_113491; Tox21_201655; Tox21_303169; Tox21_500360; AC-824; BDBM50145605; Lecithinized superoxide dismutase & .beta.-D-2',3'-Dideoxycytidine; NSC759655; s1719; Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxycytidine; AKOS015854844; AKOS015894505; Tox21_113491_1; CCG-101050; CS-1110; DB00943; LP00360; MCULE-6071296177; NC00300; NSC-759655; SDCCGSBI-0050348.P002; 2',3'-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate); SRI-7707-13; SRI-7707-14; SRI-7707_15; SRI-7707_17; NCGC00090705-01; NCGC00090705-02; NCGC00090705-03; NCGC00090705-05; NCGC00090705-06; NCGC00090705-07; NCGC00090705-09; NCGC00090705-10; NCGC00090705-11; NCGC00090705-13; NCGC00090705-15; NCGC00090705-24; NCGC00090705-25; NCGC00179242-01; NCGC00257202-01; NCGC00259204-01; NCGC00261045-01; BD164564; HY-17392; K278; ddC;Dideoxycytidine;2',3'-Dideoxycytidine; 2',3'-Dideoxycytidine & Interferon.alpha.; 2',3'-Dideoxycytidine, >=98% (HPLC); DB-019728; Ro-242027000; D3581; EU-0100360; Ro-24-2027000; SW197364-4; 2',3'-Dideoxycytidine, >=99.0% (HPLC); C07207; C76390; D00412; Cytidine, 2',3'-dideoxy- & Interferon.alpha.; 481D892; A838234; SR-01000075822; SR-01000736919; J-700276; Q-201941; Q2344582; SR-01000075822-1; SR-01000736919-5; Cytidine, 2',3'-dideoxy- & Colony-stimulating factor; Ro-242027000/Ro-24-2027-000; Z1550648753; Zalcitabine, United States Pharmacopeia (USP) Reference Standard; 4-Amino-1-(5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one; .beta.-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:10101	DB00943	DR00175	DR1724	211.22	C9H13N3O3	88.2	327	-1.3	15	2	3	2	"1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1"	C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N	WREGKURFCTUGRC-POYBYMJQSA-N
DG00890	Stanozolol	25249	"Stanozolol; Winstrol; Androstanazole; Androstanazol; 10418-03-8; Stromba; Stanazolol; Tevabolin; Winstrol Depot; Strombaject; Estazol; Winstroid; Winstrol V; Estanozolol; Stanozololum; WIN 14833; Anabol; UNII-4R1VB9P8V3; Androstanazolestanazol; NSC 233046; 4R1VB9P8V3; CHEBI:9249; 17-Methyl-2'H-5alpha-androst-2-eno(3,2-c)pyrazol-17beta-ol; NSC-43193; WIN-14833; (1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol; Stanozolo [DCIT]; Androstanazole (VAN); Stanozolo; Stanozolol (1'H form); Winstrol-V; Stanozololum [INN-Latin]; Estanozolol [INN-Spanish]; (1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5-dien-17-ol; Cyclopenta(7,8)phenanthro(2,3-c)pyrazol-1-ol, 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-; HSDB 3185; SR-05000001522; Stanozolol (2'H form); 17 -Methyl-5 -androstano[3,2-c]pyrazol-17 -ol; EINECS 233-894-8; NSC 43193; Stanozolol ciii; NSC-233046; Winstrol (TN); 2'H-Androst-2-eno(3,2-c)pyrazol-17-ol, 17-methyl-, (5alpha,17beta)-; Winstrol; ; ; Stanabol; 17-Methyl-5alpha-androstano(3,2-c)pyrazol-17beta-ol; 302-96-5; Stanozolol [USAN:USP:INN:BAN:JAN]; 17-beta-Hydroxy-17-alpha-methylandrostano(3,2-c)pyrazole; 17beta-Hydroxy-17alpha-methyl-androstano(3,2-c)pyrazole; 17-Methyl-pyrazolo(4',3':2,3)-5alpha-androstan-17beta-ol; 17-Methylpyrazolo(4',3':2,3)-5alpha-androstan-17beta-ol; 17beta-Hydroxy-17-methyl-5alpha-androstano(3,2-c)pyrazole; 17alpha-Methyl-17beta-hydroxy-5alpha-androstano(3,2-c)pyrazole; 2'H-5alpha-Androst-2-eno(3,2-c)pyrazol-17beta-ol, 17-methyl-; 2,3-(4',3'-Pyrazolo)-5alpha-androstan-17beta-ol, 17-methyl-; DSSTox_CID_24128; DSSTox_RID_97564; stanozolol--dea schedule iii; DSSTox_GSID_44128; SCHEMBL44099; SCHEMBL44100; Stanozolol (JAN/USP/INN); 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-Hexadecahydro-1,10a,12a-trimethylcyclopenta(7,8)-phenanthro(2,3-c)pyrazol-1-ol; MLS001424321; Stanozolol, analytical standard; CHEMBL2079587; DTXSID3044128; GTPL10369; HMS2052H11; HMS2090P03; HMS3713K06; BCP12548; HY-B0899; NSC43193; WIN14833; ZINC4097376; Tox21_113993; 1'H-Androstano(3,2-c)pyrazol-17-ol, 17-methyl-, (5-alpha,17-beta)-; AKOS005067278; Stanozolol 1.0 mg/ml in Acetonitrile; AM84316; CCG-101186; CCG-220452; CS-4363; DB06718; MCULE-6473940948; NC00436; NCGC00344550-01; (1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol; AC-16140; AC-33164; AS-35198; CPD000058878; Cyclopenta(7,8)phenanthro(2,3-c)pyrazol-1-ol, 1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-; SMR000058878; CAS-10418-03-8; C07311; D00444; 17-Methyl-5a-androstano[3,2-c]pyrazol-17b-ol; AB00443942-03; AB00443942-05; 418S038; SR-05000001522-1; SR-05000001522-2; W-108823; 17a-Methyl-17b-hydroxy-5a-androstano(3,2-c)pyrazole; 17b-Hydroxy-17-methyl-5a-androstano[3,2-c]pyrazole; 17b-Hydroxy-17a-methyl-5a-androstano[3,2-c]pyrazole; Q63409446; 17-Methyl-pyrazolo[4',3':2,3]-5a-androstan-17b-ol; Z1541662177; 17-Methyl-1'H-5alpha-androstano[3,2-c]pyrazol-17beta-ol; Stanozolol, European Pharmacopoeia (EP) Reference Standard; (5a,17b)-17-methyl-2'H-Androst-2-eno[3,2-c]pyrazol-17-ol; 2,3'-Pyrazolo)-5.alpha.-androstan-17.beta.-ol, 17-methyl-; 5alpha-Androstane-17alpha-methyl-17beta-ol-[3,2-c]pyrazole; 2'H-5a-Androst-2-eno[3,2-c]pyrazol-17b-ol, 17-methyl- (8CI); 17alpha-Methyl-17beta-hydroxy-5alpha-androst-2-eno(3,2-c)-pyrazole; Cyclopenta[7,8]phenanthro[2,3-c]pyrazole, 2'H-androst-2-eno[3,2-c]pyrazol-17-ol deriv.; (1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5-dien-17-ol; 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-Cyclopenta[7,8]phenanthro[2,3-c]pyrazol-1-ol; 17966-55-1; Cyclopenta[7,3-c]pyrazol-1-ol, 1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9249	DB06718	.	.	328.5	C21H32N2O	48.9	538	4.5	24	2	2	0	"1S/C21H32N2O/c1-19-11-13-12-22-23-18(13)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,24H,4-11H2,1-3H3,(H,22,23)/t14-,15+,16-,17-,19-,20-,21-/m0/s1"	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(CC5=C(C4)NN=C5)C	LKAJKIOFIWVMDJ-IYRCEVNGSA-N
DG00892	Xipamide	26618	"XIPAMIDE; 14293-44-8; 4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy-5-sulfamoylbenzamide; Diurexan; Xipamid; Aquaphor; Diurex (lacer); Aquaphor (diuretic); UNII-4S9EY0NUEC; Be 1293; C15H15ClN2O4S; MJF 10,938; Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy-; 4-Chloro-5-sulfamoyl-2',6'-salicyloxylidide; MJF-10938; 4S9EY0NUEC; 2',6'-Salicyloxylidide, 4-chloro-5-sulfamoyl-; BE-1293; 4-Chlor-5-sulfamoyl-2',6'-salicyloxylidid; NCGC00182543-01; Aquaphoril; Zipix; Aquaphor(tm), original formula ointment base; DSSTox_CID_3744; DSSTox_RID_77179; DSSTox_GSID_23744; Chronexan; Xipamida; Xipamidum; Xipamidum [INN-Latin]; Xipamida [INN-Spanish]; Xipamide [USAN:INN:BAN]; CAS-14293-44-8; EINECS 238-216-4; MJF 10938; BRN 2778357; Lumitens; Xipamide (USAN); 4-Chlor-5-sulfamoyl-2',6'-salicyloxylidid [German]; SCHEMBL43532; CHEMBL517199; GTPL7900; DTXSID5023744; CHEBI:135499; ZINC538538; 4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy-5-sulfamoyl-benzamide; BEI-1293; Tox21_112975; 5-(Aminosulfonyl)-4-chloro-N-(2,6-dimethylphenyl)-2-hydroxybenzamide; AC-911; MFCD00865927; s5076; AKOS015889012; Tox21_112975_1; CCG-268092; CS-W023041; DB13803; DS-1401; HY-W042301; NCGC00182543-02; FT-0659690; FT-0675876; 4-Chloro-5-sulfamoyl-2',6'-salicyloxilidide; D06341; 293X448; A807988; Q600951; Q-201936; 4-Chloro-N-(2,6-dimethylphenyl)-2-hydroxy-5-sulphamoylbenzamide; 4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy-5-sulfamoyl-benzamide;Xipamide; 5-(Aminosulfonyl)-4-chloro-N-(2,6-dimethylphenyl)-2-hydroxybenzamide #; Benzamide,5-(aminosulfonyl)-4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:135499	.	.	.	354.8	C15H15ClN2O4S	118	526	2.9	23	3	5	3	"1S/C15H15ClN2O4S/c1-8-4-3-5-9(2)14(8)18-15(20)10-6-13(23(17,21)22)11(16)7-12(10)19/h3-7,19H,1-2H3,(H,18,20)(H2,17,21,22)"	CC1=C(C(=CC=C1)C)NC(=O)C2=CC(=C(C=C2O)Cl)S(=O)(=O)N	MTZBBNMLMNBNJL-UHFFFAOYSA-N
DG00895	Danazol	28417	"Danazol; Danocrine; 17230-88-5; Chronogyn; Winobanin; Danol; Cyclomen; Danazolum; Danzol; Ladogal; Danatrol; Danazol, USP; UNII-N29QWW3BUO; WIN-17757; WIN 17,757; Danazole; N29QWW3BUO; WIN 17757; Danovaol; CHEBI:4315; (1R,3aS,3bR,10aR,10bS,12aS)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; Danokrin; NCGC00164400-01; Danogen; Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol, (17alpha)-; DSSTox_CID_2880; Danazolum [INN-Latin]; NSC 270916; DSSTox_RID_76772; DSSTox_GSID_22880; Bonzol; Danocrine (TN); SMR000058321; CCRIS 6747; EINECS 241-270-1; Vasaloc; 17-alpha-Pregn-4-en-20-yno(2,3-d)isoxazol-17-ol; Optina; Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17alpha)-; 17-alpha-2,4-Pregnadien-20-yno(2,3-d)isoxazol-17-ol; 17alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol; NSC270916; NSC-270916; Win 17, 757; Prestwick_150; CAS-17230-88-5; Danazol [USAN:USP:INN:BAN:JAN]; ethynyl(dimethyl)[ ]ol; 2,3-Isoxazolethisterone; Prestwick0_000105; Prestwick1_000105; Prestwick2_000105; Prestwick3_000105; CHEMBL1479; SCHEMBL21107; BSPBio_000090; (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5,9-trien-17-ol; MLS001066617; MLS001306473; Danazol (JP17/USP/INN); SPBio_002029; BPBio1_000100; GTPL6942; DTXSID2022880; 2,4,17alpha-Pregnadien-20-yno[2,3-d]-isoxa-zol-17-ol; Win-17,757; HMS1568E12; HMS2090A22; HMS2095E12; HMS2231M08; HMS3259M10; HMS3712E12; Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol,(17alpha)-; [1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol; 17.Alpha.-Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol}; BCP11914; HY-B1029; ZINC3881958; Tox21_112114; Tox21_301940; BDBM50423541; MFCD00056838; s9506; AKOS015961192; Tox21_112114_1; AC-6836; CCG-220105; CS-4547; Danazol 100 microg/mL in Acetonitrile; DB01406; MCULE-5533294331; NC00557; NCGC00179665-01; NCGC00179665-02; NCGC00179665-04; NCGC00255335-01; (1R,3aS,3bR,10aR,10bS,12aS)-1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d][1,2]oxazol-1-ol; 1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; AS-13035; H066; C06938; D00289; 230D885; Q419652; SR-01000760722; SR-05000000445; SR-01000760722-2; SR-05000000445-2; W-107864; 17a-Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol; BRD-K48970916-001-03-0; (17a)-Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol; 17a-Pregna-2,4-dien-20-yne-[2,3-d]isoxazole-17b-ol; 1-(P-TOSYL)-3,4,4-TRIMETHYL-2-IMIDAZOLINIUMIODIDE; 17 alpha-pregna-2,4-dien-20-yno[2,3-D] isoxazol-17 beta-ol; Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol,} (17.alpha.)-; Pregna-2,4-diene-20-yno[2,3-d ]isoxazol-17-ol, (17.alpha.); (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9-trien-17-ol; 1-ethynyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl-1H-Cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; 1H-Cyclopenta[7,8]phenanthro[3,2-d]isoxazole- pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol deriv."	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4315	DB01406	.	DR2401	337.5	C22H27NO2	46.3	677	3.8	25	1	3	1	"1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1"	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5	POZRVZJJTULAOH-LHZXLZLDSA-N
DG00897	Carbimazole	31072	"Carbimazole; 22232-54-8; Athyromazole; Carbimazol; Neomercazole; Carbethoxymethimazole; Carbinazole; Neo-Thyreostat; Basolest; Thyrostat; Carbimazolum; TYRAZOL; Carbimazolum [INN-Latin]; Ethyl 3-methyl-2-thioimidazoline-1-carboxylate; Carbimazol [INN-Spanish, French]; 1-Ethoxycarbonyl-3-methyl-2-thioxo-4-imidazoline; Ethyl 3-methyl-2-thioxo-2,3-dihydro-1H-imidazole-1-carboxylate; 1H-Imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo-, ethyl ester; UNII-8KQ660G60G; Neo-Mercazole; CHEBI:617099; Atirozidina; Carbotiroid; Mertiran; CG1; 3-Methyl-2-thioxo-4-imidazoline-1-carboxylic acid ethyl ester; 4-Imidazoline-1-carboxylic acid, 3-methyl-2-thioxo-, ethyl ester; Carbimazol spofa; Neo-Tireol; ethyl 3-methyl-2-sulfanylideneimidazole-1-carboxylate; CHEMBL508102; 8KQ660G60G; Ethyl 3-methyl-2-thionoimidazoline-1-carboxylate; MFCD00027421; NSC-758966; NCGC00016760-01; CAS-22232-54-8; DSSTox_CID_2736; DSSTox_RID_76708; DSSTox_GSID_22736; Carbimazole [INN:BAN:DCF]; Carbimazol henning; Carbimazole (INN); 1-Ethoxycarbonyl-3-methyl-2-thioimidazol; SR-01000872660; Carbimazol henning (TN); EINECS 244-854-4; BRN 0144339; Prestwick_788; 1H-Imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo, ethyl ester; Fenobucarb Bassa BPMC; Prestwick0_000439; Prestwick1_000439; Prestwick2_000439; Prestwick3_000439; Spectrum2_001251; Spectrum3_001968; 3-methyl-1-ethoxycarbonylimidazoline-2-thione; Epitope ID:116890; SCHEMBL44211; BSPBio_000458; BSPBio_003568; 4-24-00-00064 (Beilstein Handbook Reference); MLS004734638; SPECTRUM1505323; SPBio_001182; SPBio_002397; BPBio1_000504; ZINC1091; DTXSID9022736; KBio3_002918; HMS1569G20; HMS1922D12; HMS2096G20; HMS3652G04; HMS3713G20; Pharmakon1600-01505323; BCP12935; HY-B0558; Tox21_110596; Tox21_302320; BDBM50275889; CCG-39106; ethyl 3-methyl-2-sulfanylidene-2,3-dihydro-1H-imidazole-1-carboxylate; NSC758966; s4048; AKOS001647527; Tox21_110596_1; AC-8348; AM84794; DB00389; MCULE-1170558032; NSC 758966; NCGC00016760-02; NCGC00016760-03; NCGC00016760-04; NCGC00016760-05; NCGC00016760-08; NCGC00095167-01; NCGC00095167-02; NCGC00177988-01; NCGC00177988-02; NCGC00255133-01; AS-13267; BE164282; H765; SMR001233183; SBI-0207026.P001; FT-0602919; SW196926-3; A16427; C07615; C74138; D07616; A816030; Q414013; SR-01000872660-1; SR-01000872660-2; W-107493; BRD-K87156652-001-05-1; BRD-K87156652-001-06-9; ethyl 3-methyl-2-thioxo-imidazole-1-carboxylate;Carbimazole; Ethyl 3-methyl-2-thioxo-2,3-dihydro-1H-imidazole-1-carboxylate #; Ethyl 3-methyl-2-thioxo-2,3-dihydro-1H-imidazole-1-carboxylate, AldrichCPR"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:617099	DB00389	.	.	186.23	C7H10N2O2S	64.9	240	0.7	12	0	3	2	"1S/C7H10N2O2S/c1-3-11-7(10)9-5-4-8(2)6(9)12/h4-5H,3H2,1-2H3"	CCOC(=O)N1C=CN(C1=S)C	CFOYWRHIYXMDOT-UHFFFAOYSA-N
DG00898	Picrotoxin	31304	"PICROTOXIN; Cocculin; Cocculus; Oriental berry; Indian berry; Fish berry; Coques du levant; Picrotoxinum; 124-87-8; Picrotoxine; Picrotox; Picrotin, compd. with picrotoxinin (1:1); UNII-ZLT174DL7U; Coques du levant [French]; Caswell No. 663A; Picrotoxinin - picrotin; Picrotoxin [NF]; HSDB 6385; Picrotoxinin, compd. with picrotin (1:1); Picrotin, compound with picrotoxinin (1:1); ZLT174DL7U; EINECS 204-716-6; EPA Pesticide Chemical Code 002301; NSC 403139; AI3-17689; GTPL4051; SCHEMBL16319990; DB00466; BP166191; Q416602; 3,6-Methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR,2aR,3S,6R,6aS,8aS,8bR,9S)-, compd. with (1aR,2aR,3S,6R,6aS,8aS,8bR,9R)-hexahydro-2a-hydroxy-8b-methyl-9-(1-methylethenyl)-3,6-methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione (1:1)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00466	DR00640	.	602.6	C30H34O13	191	1290	.	43	3	13	2	"1S/C15H18O7.C15H16O6/c1-12(2,18)6-7-10(16)20-8(6)9-13(3)14(7,19)4-5-15(13,22-5)11(17)21-9;1-5(2)7-8-11(16)19-9(7)10-13(3)14(8,18)4-6-15(13,21-6)12(17)20-10/h5-9,18-19H,4H2,1-3H3;6-10,18H,1,4H2,2-3H3/t5-,6+,7 ,8 ,9-,13-,14-,15+;6 ,7-,8 ,9 ,10+,13+,14+,15-/m10/s1"	CC(=C)[C@@H]1C2[C@@H]3[C@@]4([C@](C1C(=O)O2)(CC5[C@]4(O5)C(=O)O3)O)C.C[C@@]12[C@H]3C4[C@H](C([C@@]1(C[C@@H]5[C@]2(O5)C(=O)O3)O)C(=O)O4)C(C)(C)O	VJKUPQSHOVKBCO-ZTYBEOBUSA-N
DG00901	Benznidazole	31593	"BENZNIDAZOLE; 22994-85-0; Benznidazol; Radanil; Benzonidazole; Benznidazolum; Ro 07-1051; Rochagan; N-benzyl-2-(2-nitro-1H-imidazol-1-yl)acetamide; N-benzyl-2-(2-nitroimidazol-1-yl)acetamide; N-Benzyl-2-nitroimidazole-1-acetamide; N-Benzyl-2-nitroimidazol-1-yl-acetamide; 2-Nitro-N-(phenylmethyl)-1H-imidazole-1-acetamide; N-Benzyl-2-nitro-1H-imidazole-1-acetamide; Ro 71051; 1H-Imidazole-1-acetamide, 2-nitro-N-(phenylmethyl)-; UNII-YC42NRJ1ZD; Imidazole-1-acetamide, N-benzyl-2-nitro-; YC42NRJ1ZD; CHEMBL110; benzonidazol; MMV688773; NSC299972; NSC-299972; Ro-7-1051; NCGC00166238-01; Ro 07-1051;Ro 71051; DSSTox_CID_26570; DSSTox_RID_81729; DSSTox_GSID_46570; Benznidazol [INN-Spanish]; Benznidazolum [INN-Latin]; SMR000857153; NSC 299972; CAS-22994-85-0; CCRIS 2200; SR-01000841264; N-benzyl-2-nitro-1-imidazoleacetamide; BRN 0551486; Ragonil; Acetamide, N-benzyl-2-(nitroimidazol-1-yl)-; benznidazole (TN); Rochagan (TN); Radanil (TN); Benznidazole (USAN/INN); Benznidazole [USAN:INN]; SCHEMBL45081; MLS001332409; MLS001332410; MLS001360496; DTXSID9046570; SCHEMBL22493029; ZINC56949; CHEBI:133833; HMS2233G13; HMS3369C11; HY-B1548; Tox21_112364; BDBM50089916; MFCD00243089; s3741; AKOS015916722; AKOS024283499; Tox21_112364_1; CCG-267054; DB11989; MCULE-5592629788; NCGC00166238-02; AS-68694; QC-10765; CS-0013411; FT-0662547; RO-07-1051; Benznidazol (Ro 07-1051; Ro 71051); C74184; D02489; N-Benzyl-2-(2-nitro-imidazol-1-yl)-acetamide; N-benzyl-2-(2-nitro-1Himidazol-1-yl)acetamide; A912716; N-benzyl-2-(2-nitro-1H-imidazol-5-yl)acetamide; N-Benzyl-2-nitro-1H-imidazole-1-acetamide, 97%; Q425300; 2-(2-nitroimidazol-1-yl)-N-(phenylmethyl)acetamide; J-014932; SR-01000841264-3; SR-01000841264-4; BRD-K56156805-001-05-4; 1H-Imidazole-1-acetamide, 2-nitro-N-(phenylmethyl)- (9CI); N-Benzyl-2-(2-nitro-imidazol-1-yl)-acetamide (Benznidazole); Pyridinium,1-dodecyl-2-[(hydroxyimino)methyl]-,iodide(1:1)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:133833	DB11989	.	.	260.25	C12H12N4O3	92.7	325	0.9	19	1	4	4	"1S/C12H12N4O3/c17-11(14-8-10-4-2-1-3-5-10)9-15-7-6-13-12(15)16(18)19/h1-7H,8-9H2,(H,14,17)"	C1=CC=C(C=C1)CNC(=O)CN2C=CN=C2[N+](=O)[O-]	CULUWZNBISUWAS-UHFFFAOYSA-N
DG00902	Penfluridol	33630	"PENFLURIDOL; 26864-56-2; 1-(4,4-bis(4-fluorophenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)piperidin-4-ol; Semap; TLP-607; McN-JR-16,341; 1-[4,4-Bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol; R-16341; 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]piperidin-4-ol; UNII-25TLU22Q8H; R 16341; CHEMBL47050; 25TLU22Q8H; MFCD00866714; 4-Piperidinol, 1-(4,4-bis(4-fluorophenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)-; 4-Piperidinol, 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-; NSC-759179; NCGC00165865-01; DSSTox_CID_28947; DSSTox_RID_83212; DSSTox_GSID_49021; C28H27ClF5NO; R 16,341; Penfluridolum; Penfluridolum [INN-Latin]; CAS-26864-56-2; EINECS 248-074-5; BRN 1558826; Micefal; Penfluridol [USAN:INN:BAN]; Semap (TN); Penfluridol (USAN/INN); R16341; SCHEMBL93939; 1-(4,4-Bis(p-fluorophenyl)butyl)-4-(4-chloro-alpha,alpha,alpha-trifluoro-m-tolyl)-4-piperidinol; 5-21-02-00409 (Beilstein Handbook Reference); MLS004774011; DTXSID5049021; CHEBI:92278; AOB5341; MCN-JR-16341; HMS3264L13; HMS3652G22; Pharmakon1600-01505691; ACT03196; BCP03695; HY-B1077; ZINC4217252; Tox21_113546; BDBM50026066; NSC759179; PDSP1_000470; PDSP2_000468; AKOS005065828; Tox21_113546_1; BCP9000014; CCG-269878; CS-4633; DB13791; KS-5104; NSC 759179; Penfluridol, >=97% (HPLC), powder; 1-[4,4-Bis(4-fluorophenyl)butyl]-4-[4-chloro-3(trifluoromethyl)phenyl]-4-piperidinol; 4-Piperidinol,1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-; NCGC00165865-02; NCGC00165865-03; 4-Piperidinol, 1-(4,4-bis(p-fluorophenyl)butyl)-4-(4-chloro-alpha,alpha,alpha-trifluoro-m-tolyl)-; 4-Piperidinol, 4-(4-chloro-alpha,alpha,alpha-trifluoro-m-tolyl)-1-(4,4-bis(p-fluorophenyl)butyl)-; AC-15413; SMR003500704; BCP0726000159; SBI-0206898.P001; DB-017683; FT-0645031; P2076; S4151; SW219540-1; D02630; AB01566919_01; 864P562; A818637; L001145; SR-05000001779; Q2149707; SR-05000001779-1; W-107147; BRD-K15409150-001-01-7; 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloranyl-3-(trifluoromethyl)phenyl]piperidin-4-ol; 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-piperidin-4-ol; 1-[4,4-Bis-(4-fluoro-phenyl)-butyl]-4-(4-chloro-3-trifluoromethyl-phenyl)-piperidin-4-ol; 1-[4,4-Bis(p-fluorophenyl)butyl]-4-(4-chloro-.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)-4-piperidinol; 1-[4,4-Bis(p-flurophenyl)butyl]-4-(4-chloro-.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)-4-piperidinol; 4-Piperidinol, 4-(4-chloro-.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)-1-(4,4-bis(p-fluorophenyl)butyl)-; PENFLURIDOL1-[4,4-Bis-(4-fluoro-phenyl)-butyl]-4-(4-chloro-3-trifluoromethyl-phenyl)-piperidin-4-ol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:92278	.	.	.	524	C28H27ClF5NO	23.5	647	7.3	36	1	7	7	"1S/C28H27ClF5NO/c29-26-12-7-21(18-25(26)28(32,33)34)27(36)13-16-35(17-14-27)15-1-2-24(19-3-8-22(30)9-4-19)20-5-10-23(31)11-6-20/h3-12,18,24,36H,1-2,13-17H2"	C1CN(CCC1(C2=CC(=C(C=C2)Cl)C(F)(F)F)O)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F	MDLAAYDRRZXJIF-UHFFFAOYSA-N
DG00904	Amdinocillin	36273	"Mecillinam; AMDINOCILLIN; 32887-01-7; Penicillin HX; Coactin; Hexacillin; Mecillinamum; Mecilinamo; FL 1060; Ro 10-9070; Mecillinam (INN); UNII-V10579P3QZ; Selexidin; (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; V10579P3QZ; Mecillinam [INN]; (2S,5R,6R)-6-[(azepan-1-ylmethylidene)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; DSSTox_CID_2584; DSSTox_RID_76643; DSSTox_GSID_22584; Mecilinamo [INN-Spanish]; Mecillinamum [INN-Latin]; (2S,5R,6R)-6-{[(1E)-azepan-1-ylmethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 79580-20-4; SMR000466361; Coactin (TN); Ro 109070; CAS-32887-01-7; FL-1060; MICILLINAM; Amdinocillin (USAN); EINECS 251-277-1; 6-((Hexahydro-1H-azepin-1-yl)methyleneamino)penicillanic acid; Amdinocillin [USAN:USP]; (2S,5R,6R)-6-(((Hexahydro-1H-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; NCGC00164583-01; Ro-10-9070; CHEMBL530; SCHEMBL34387; SCHEMBL34388; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((hexahydro-1H-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta))-; MLS000759478; MLS001424041; CHEMBL258646; DTXSID3022584; HMS2051E14; ACT03258; HY-A0269; ZINC3830206; Tox21_112209; MFCD00056869; s6584; ZINC12469558; Tox21_112209_1; CCG-100873; DB01163; FS-4354; NC00123; 6beta-[(azepan-1-ylmethylidene)amino]-2,2-dimethylpenam-3alpha-carboxylic acid; NCGC00164583-02; NCGC00188988-01; AC-32602; CS-0017618; C21545; D02888; Mecillinam, VETRANAL(TM), analytical standard; AB01209740-01; BRD-K41051431-001-01-6; Q13019044; 6beta-{[(azepan-1-yl)methylidene]amino}-2,2-dimethylpenam-3alpha-carboxylic acid; (2S,5R,6R)-6-(((E)-Azepan-1-ylmethylene)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-((E)-azepan-1-ylmethyleneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB01163	.	.	325.4	C15H23N3O3S	98.5	500	2.1	22	1	5	3	"1S/C15H23N3O3S/c1-15(2)11(14(20)21)18-12(19)10(13(18)22-15)16-9-17-7-5-3-4-6-8-17/h9-11,13H,3-8H2,1-2H3,(H,20,21)/t10-,11+,13-/m1/s1"	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)O)C	BWWVAEOLVKTZFQ-NTZNESFSSA-N
DG00908	Vindesine	40839	"Vindesine; 53643-48-4; vindesine sulfate; Desacetylvinblastine amide; Vincaleukoblastine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)-; CHEBI:36373; Desacetylvinblastine amide sulfate; C43H55N5O7; Vindesine (USAN/INN); SCHEMBL4420; methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate; CHEMBL219146; DTXSID6023739; HMS2090E15; 3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; EX-A3837; ZINC8214470; STL565153; 3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; AKOS037623357; MCULE-7368625095; methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate; D06304; AB00698294-03; AB01275494-01; hanoazacycloundecino[5,4-b]indole-9-carboxylate; 643V484; Q416660; Q-100607; BRD-K59753975-065-01-3; methyl (13S,15S,17S)-13-[(1R,9R,10S,11R,12R,19R)-10-carbamoyl-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca-2(7),3,5,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.0^{4,12}.0^{5,10}]nonadeca-4(12),5,7,9-tetraene-13-carboxylate; methyl (13S,15S,17S)-13-[(1R,9R,10S,11R,12R,19R)-10-carbamoyl-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraene-13-carboxylate; methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-met"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:36373	DB00309	DR00397	DR1693	753.9	C43H55N5O7	165	1570	2.7	55	5	10	7	"1S/C43H55N5O7/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50)/t25-,34+,35-,36-,39+,40-,41-,42+,43+/m1/s1"	CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O	HHJUWIANJFBDHT-KOTLKJBCSA-N
DG00909	Acarbose	41774	"Acarbose; 56180-94-0; Glucobay; Precose; Acarbosum; Prandase; CHEBI:2376; Bay g 5421; MFCD00869592; BAY-g 5421; C25H43NO18; 4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose; SMR000466376; SR-01000759407; Glucobay;; Prandase;; Precose;; NSC-758915; Acarbose,(S); Precose (TN); Acarbose (JAN/USAN/INN); MLS000759506; MLS001424056; MLS006011898; SPECTRUM1505172; CHEMBL404271; SCHEMBL5316305; CHEMBL3734896; BDBM23406; HMS2051F03; HMS2093I22; HMS2236P06; Pharmakon1600-01505172; C25H43NO18;; BBL030515; BDBM50180587; NSC758915; STK801930; AKOS005622515; CCG-100913; CCG-213345; MCULE-2053937515; MD-0230; NC00163; NCGC00160515-01; SBI-0206777.P001; C06802; D00216; J10300; AB00639959-06; AB00639959_08; Abamectin, Antibiotic for Culture Media Use Only; 180A940; Q-200574; SR-01000759407-4; SR-01000759407-5; SR-01000759407-6; xan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol; BRD-A16444946-001-07-1; (3R,4R,5S,6R)-5-(((2R,3R,4R,5S,6R)-5-(((2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-(((1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl)amino)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4-triol; (3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)o; (3R,4R,5S,6R)-5-{[(2R,3R,4R,5S,6R)-5-{[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}oxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-(hydroxymethyl)oxane-2,3,4-triol; 4',6'-Dideoxy-4'-([1S]-[1,4,6/5]-4,5,6-trihydroxy-3-hydroxymethyl-2-yclohexenylamino)-maltotriose; 4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose; Precose (TN);; WURCS=2.0/3,3,2/[a2122h-1x_1-5][a2122h-1a_1-5][a2122m-1a_1-5_4*NC^SC^SC^SC^RCCO/7=^ZC$3/6O/5O/4O]/1-2-3/a4-b1_b4-c1"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:2376	DB00284	DR00978	.	645.6	C25H43NO18	321	962	-8.5	44	14	19	9	"1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23 ,24-,25-/m1/s1"	C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](OC([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO	XUFXOAAUWZOOIT-UGEKTDRHSA-N
DG00912	Cefoperazone	44187	"Cefoperazone; 62893-19-0; Cefobid; Cefoperazono; Cefoperazonum; Medocef; Cefob; UNII-7U75I1278D; Cefoperazone (Cefobid); CHEBI:3493; Cefoperazine; MFCD00865067; 7U75I1278D; Cefobid (TN); Cefoperazonum [INN-Latin]; Cefoperazono [INN-Spanish]; 62893-20-3; (6R,7R)-7-((R)-2-(4-Ethyl-2,3-dioxo-1-piperazinylcarboxamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; Cefoperazone (sodium salt); Cefozon; (6R,7R)-7-((R)-2-(4-ethyl-2,3-dioxopiperazine-1-carboxamido)-2-(4-hydroxyphenyl)acetamido)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-((R)-2-(4-ethyl-2,3-dioxopiperazine-1-carboxamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1H-tetrazol-5-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; C25H27N9O8S2; 113826-44-1; Cefoperazone [INN:BAN]; Bioperazone; Cefoperazon; Myticef; Pathozone; Peracef; Cefoperazone,(S); EINECS 263-749-4; Cefoperazone (INN); BRN 0603333; CP 52640; Prestwick0_000327; Prestwick1_000327; Prestwick2_000327; Prestwick3_000327; Peracef [veterinary] (TN); SCHEMBL37056; BSPBio_000333; BIDD:GT0677; SPBio_002254; BPBio1_000367; CHEMBL507674; DTXSID2022759; GTPL12025; HMS2090M09; C25H31N9O10S2; HY-B0210; ZINC3830432; BDBM50390999; s1611; AKOS015895629; CCG-270325; DB01329; NCGC00179599-01; (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; AS-13298; H832; SW198793-3; Y0421; C-2485; C06883; D07645; 893C190; Cefoperazone, Antibiotic for Culture Media Use Only; Q2325775; BRD-K02292852-335-03-1; (6R,7R)-7-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)(4-hydroxyphenyl)acetyl)amino)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-(6-alpha,7-beta(R*)))-; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-2-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R,7R)-; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2R)-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-,(6R,7R)-; 7beta-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl-3,4-didehydrocepham-4-carboxylic acid; sodium,(6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3493	DB01329	.	.	645.7	C25H27N9O8S2	271	1250	-0.7	44	4	13	9	"1S/C25H27N9O8S2/c1-3-32-8-9-33(21(39)20(32)38)24(42)27-15(12-4-6-14(35)7-5-12)18(36)26-16-19(37)34-17(23(40)41)13(10-43-22(16)34)11-44-25-28-29-30-31(25)2/h4-7,15-16,22,35H,3,8-11H2,1-2H3,(H,26,36)(H,27,42)(H,40,41)/t15-,16-,22-/m1/s1"	CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O	GCFBRXLSHGKWDP-XCGNWRKASA-N
DG00914	Butoconazole	47472	"Butoconazole; 64872-76-0; Butaconazole; Butoconazol; Butoconazolum; Butoconazol [INN-Spanish]; Butoconazolum [INN-Latin]; Gynazole-1; CHEBI:3240; NSC-758658; Butoconazole [INN:BAN]; C19H17Cl3N2S; Gynofort; MLS002153798; 1-(4-(4-chlorophenyl)-2-((2,6-dichlorophenyl)thio)butyl)-1H-imidazole; 1-[4-(4-Chloro-phenyl)-2-(2,6-dichloro-phenylsulfanyl)-butyl]-1H-imidazole; 1-[4-(4-Chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-1H-imidazole; 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-; Gynofort (TN); Butoconazole (INN); MFCD00058159; SMR001233176; RS 35887-10-3; Prestwick0_000408; Prestwick1_000408; Prestwick2_000408; Prestwick3_000408; 1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)sulfanyl-butyl]imidazole; 1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)sulfanylbutyl]imidazole; 1-{4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)sulfanyl]butyl}-1H-imidazole; CHEMBL1295; SCHEMBL44237; BSPBio_000336; 67085-13-6; cid_47471; MLS006010743; SPBio_002275; BPBio1_000370; 1-[(2S)-4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)sulfanyl-butyl]imidazole; DTXSID2048537; BDBM79206; HY-B0293A; HMS3264E14; Pharmakon1600-01504140; ALBB-028967; AMY32540; BUTOCONAZOLE, Butoconazole Nitrate; (+-)-1-((4-(p-Chlorophenyl)-2-((2,6-dichlorophenyl)thio)imidazole; NSC758658; s5359; AKOS015900067; CCG-213264; DB00639; NSC 758658; (+-)-1-[4-(4-Chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-1H-imidazole; 1H-Imidazole, 1-(4-(4-chlorophenyl)-2-((2,6-dichlorophenyl)thio)butyl)-, (+-)-; NCGC00179596-01; NCGC00179596-04; AC-15961; K049; SMR001550002; DB-054743; AB00513831; CS-0013455; FT-0630751; C08065; D07598; AB00513831-07; AB00513831_08; AB00513831_09; Butoconazole, VETRANAL(TM), analytical standard; 872B760; A834909; Q2928948; BRD-A16665823-001-01-2; BRD-A16665823-008-03-3; 1-(4-(4-chlorophenyl)-2-(2,6-dichlorophenylthio)butyl)-1H-imidazole; 1-[2-[(2,6-Dichlorophenyl)thio]-4-(4-chlorophenyl)butyl]-1H-imidazole; 1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)sulfanylbutyl]imid-azole; 1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenylthio)-n-butyl]-imidazole; (.+/-.)-1-[4-(p-Chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]imidazole; 1-(4-(4-Chlorophenyl)-2-[(2,6-dichlorophenyl)sulfanyl]butyl)-1H-imidazole #; 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, (1)-; 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, nitrate (1:1)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3240	DB00639	.	.	411.8	C19H17Cl3N2S	43.1	383	6.4	25	0	2	7	"1S/C19H17Cl3N2S/c20-15-7-4-14(5-8-15)6-9-16(12-24-11-10-23-13-24)25-19-17(21)2-1-3-18(19)22/h1-5,7-8,10-11,13,16H,6,9,12H2"	C1=CC(=C(C(=C1)Cl)SC(CCC2=CC=C(C=C2)Cl)CN3C=CN=C3)Cl	SWLMUYACZKCSHZ-UHFFFAOYSA-N
DG00915	Nicorandil	47528	"NICORANDIL; 65141-46-0; Ikorel; 2-Nicotinamidoethyl nitrate; SG-75; Dancor; Sigmart; Nicorandilum; Adancor; 2-(nicotinamido)ethyl nitrate; 2-(pyridine-3-carbonylamino)ethyl nitrate; SG 75; N-(2-Hydroxyethyl)nicotinamide nitrate; N-(2-Hydroxyethyl)nicotinamide nitrate (ester); Nicorandil (Ikorel); UNII-260456HAM0; CHEBI:31905; N-[2-(NITROOXY)ETHYL]-3-PYRIDINECARBOXAMIDE; 3-PYRIDINECARBOXAMIDE, N-[2-(NITROOXY)ETHYL]-; MFCD00186520; 260456HAM0; NCGC00025357-01; 2-(PYRIDIN-3-YLFORMAMIDO)ETHYL NITRATE; 3-Pyridinecarboxamide, N-(2-(nitrooxy)ethyl)-; DSSTox_CID_25692; DSSTox_RID_81064; DSSTox_GSID_45692; Nicorandilum [INN-Latin]; 2-[(PYRIDIN-3-YLCARBONYL)AMINO]ETHYL NITRATE; 2-(Nicotinamido)ethyl nitrat; SMR000466365; Sigmart (TN); CAS-65141-46-0; PERISALOL; n-(2-(nitrooxy)ethyl)-3-pyridinecarboxamide; SR-01000597534; EINECS 265-514-1; BRN 0481451; Nicorandilo; 3-Pyridinecarboxamide, N-(2-(nitroxy)ethyl)-; Nicorandil [USAN:INN:BAN:JAN]; Nicorandil- Bio-X; 2-(Pyridine-3-carboxamido)ethyl Nitrate; CPD000466365; RP-46417; n-(2-hydroxyethyl)nicotinamide nitrate ester; N-[2-(Nitrooxy)ethyl]pyridine-3-carboxamide; SCHEMBL34547; MLS000759488; MLS001424162; MLS002222323; MLS006010701; CHEMBL284906; GTPL2411; DTXSID8045692; Nicorandil (JP17/USAN/INN); HMS2051N16; HMS2089L12; HMS2095E14; HMS2232A06; HMS3268L19; HMS3371N18; HMS3393N16; HMS3413G17; HMS3655P05; HMS3677G17; HMS3712E14; BCP09434; HY-B0341; ZINC1533102; Tox21_110968; BDBM50247908; s1971; STL445540; AKOS001589705; AKOS015855406; AKOS025149378; Tox21_110968_1; AB04467; AC-4690; CCG-101045; DB09220; HS-0049; MCULE-6145684901; NC00295; NCGC00025357-02; NCGC00025357-04; 2-(pyridine-3-carbylamino) ethyl nitrate; BN164649; H924; FT-0602677; N0837; SW197675-3; D01810; J10427; T72780; AB00639978-08; AB00639978-09; AB00639978_10; AB00639978_11; A834984; Q862989; SR-01000597534-1; SR-01000597534-5; BRD-K97752965-001-01-6; F0005-2298"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31905	DB09220	DR01017	.	211.17	C8H9N3O4	97	228	0.8	15	1	5	4	"1S/C8H9N3O4/c12-8(7-2-1-3-9-6-7)10-4-5-15-11(13)14/h1-3,6H,4-5H2,(H,10,12)"	C1=CC(=CN=C1)C(=O)NCCO[N+](=O)[O-]	LBHIOVVIQHSOQN-UHFFFAOYSA-N
DG00916	Naftifine	47641	"Naftifine; 65472-88-0; Naftifin; Naftifinum; Naftifina; (E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine; UNII-4FB1TON47A; CHEMBL626; 4FB1TON47A; CHEBI:7451; (E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine; Naftifine [INN:BAN]; Naftifina [INN-Spanish]; Naftifinum [INN-Latin]; Naftifine (INN); (E)-N-methyl-N-(1-naphthylmethyl)-3-phenyl-prop-2-en-1-amine; (E)-N-Cinnamyl-N-methyl-1-naphthylmethylamin; (E)-N-Cinnamyl-N-methyl-1-naphthalinmethylamin; Naft-500; Prestwick2_001063; Prestwick3_001063; SN 105-843; 1-Naphthalenemethanamine, N-methyl-N-(3-phenyl-2-propenyl)-, (E)-; SCHEMBL49141; BSPBio_001046; BPBio1_001152; SCHEMBL3692459; DTXSID6048545; CHEBI:93305; ZINC1530977; BDBM50170647; STL483692; AKOS025310693; N-Methyl-N-(1-naphthyl methyl)-3-phenyl-2-propen-1-amine(E), hydrochloride; NCGC00179332-01; AC-22577; AB00514711; C08071; D08245; AB00514711_07; AB00514711_08; 472N880; A934003; Q413586; trans-N-cinnamyl-N-methyl-(1-naphthylmethyl)amine; Methyl-naphthalen-1-ylmethyl-(3-phenyl-allyl)-amine; BRD-K43813806-003-01-0; BRD-K74141488-003-03-9; N-(3-Phenylallyl)-N-methylnaphthalene-1-methaneamine; Methyl-naphthalen-1-ylmethyl-((E)-3-phenyl-allyl)-amine; (2E)-N-methyl-N-(1-naphthylmethyl)-3-phenylprop-2-en-1-amine; (2E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7451	DB00735	.	.	287.4	C21H21N	3.2	342	5.1	22	0	1	5	"1S/C21H21N/c1-22(16-8-11-18-9-3-2-4-10-18)17-20-14-7-13-19-12-5-6-15-21(19)20/h2-15H,16-17H2,1H3/b11-8+"	CN(C/C=C/C1=CC=CC=C1)CC2=CC=CC3=CC=CC=C32	OZGNYLLQHRPOBR-DHZHZOJOSA-N
DG00917	Triclabendazole	50248	"Triclabendazole; 68786-66-3; Fasinex; 6-Chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzo[d]imidazole; UNII-4784C8E03O; 6-chloro-5-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazole; NVP-EGA230; CPD000466357; EGA230B; MLS001424101; CHEMBL1086440; CGA89317; 4784C8E03O; NSC-759250; NCGC00164610-01; Triclabendazol; SMR000466357; 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)benzimidazole; Egaten; Triclabendazolum; 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole; 6-[2,3-bis(chloranyl)phenoxy]-5-chloranyl-2-methylsulfanyl-1H-benzimidazole; 5-CHLORO-6-(2,3-DICHLOROPHENOXY)-2-(METHYLSULFANYL)-1H-1,3-BENZODIAZOLE; Triclabendazol [INN-Spanish]; Triclabendazolum [INN-Latin]; CCRIS 8988; CGA 89317; 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole; 5-chloro-6-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazole; 6-Chloro-5-(2,3-dichlorophenoxy)-2-methylthio-benzimidazole; Fasinex (TN); Egaten (TN); 1H-BENZIMIDAZOLE, 5-CHLORO-6-(2,3-DICHLOROPHENOXY)-2-(METHYLTHIO)-; DSSTox_CID_23952; DSSTox_RID_80094; DSSTox_GSID_43952; Oprea1_236106; Triclabendazole (USAN/INN); cid_50248; MLS000759473; MLS000876812; SCHEMBL165712; DTXSID7043952; BDBM58491; CHEBI:94759; Triclabendazole [USAN:INN:BAN]; HMS2051E16; HMS2232D14; HMS3370H02; HMS3393E16; HMS3652M16; HMS3715P16; HMS3744I09; KUC103451N; Pharmakon1600-01505786; HY-B0621; ZINC1444556; Tox21_112231; 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylsulfanyl)-1H-benzimidazole; CGA-89317; MFCD00864519; NSC759250; s4114; STK332284; AKOS005439340; AKOS015950804; AC-7627; AT10531; CCG-100881; CCG-268150; DB12245; KS-5329; MCULE-8131756770; NC00131; NSC 759250; SB17173; NCGC00164610-02; I018; SBI-0207022.P001; CAS-68786-66-3; FT-0602564; SW197511-2; T2826; Triclabendazole 100 microg/mL in Acetonitrile; D07364; AB00639964-10; AB00639964_12; AB00639964_13; 786T663; A836250; Q419739; SR-01000759363; SR-01000759363-4; Triclabendazole, VETRANAL(TM), analytical standard; BRD-K81916719-001-05-5; 6-Chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)benzimidazole; Triclabendazole, EuropePharmacopoeia (EP) Reference Standard; 5-Chloro-6-(2',3'-dichlorophenoxy)-2-(methylthio)benzimidazole; 5-chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzo[d]imidazole; 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylsulfanyl)-1H-1,3-benzodiazole; 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylsulfanyl)-1H-benzimidazole; 5-[2,3-bis(chloranyl)phenoxy]-6-chloranyl-2-methylsulfanyl-1H-benzimidazole; 6-chloro-5-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazole;Triclabendazole; Triclabendazole for system suitability, EuropePharmacopoeia (EP) Reference Standard; JA9"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:94759	DB12245	.	DR1639	359.7	C14H9Cl3N2OS	63.2	365	5.7	21	1	3	3	"1S/C14H9Cl3N2OS/c1-21-14-18-9-5-8(16)12(6-10(9)19-14)20-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19)"	CSC1=NC2=CC(=C(C=C2N1)Cl)OC3=C(C(=CC=C3)Cl)Cl	NQPDXQQQCQDHHW-UHFFFAOYSA-N
DG00918	Doxofylline	50942	"DOXOFYLLINE; 69975-86-6; Doxophylline; Ansimar; Dioxyfilline; Maxivent; Ventax; UNII-MPM23GMO7Z; ABC 12/3; 7-(1,3-Dioxolan-2-ylmethyl)theophylline; MPM23GMO7Z; Theophylline, 7-(1,3-dioxolan-2-ylmethyl)-; 7-((1,3-dioxolan-2-yl)methyl)-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione; MFCD00865218; NSC-759645; NCGC00159330-02; DSSTox_CID_2968; 7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; DSSTox_RID_76810; DSSTox_GSID_22968; Doxofilina; Doxofyllinum; Doxofylline [USAN:INN]; Doxofilina [INN-Spanish]; Doxofyllinum [INN-Latin]; 7-((1,3-dioxolan-2-yl)methyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; CAS-69975-86-6; SR-01000789760; EINECS 274-239-6; BRN 0561195; Synasma; 2-(7'-Theophyllinemethyl)-1,3-dioxolane; Doxofylline,(S); Maxivent (TN); 2-(7'-Teofillinmetil)-1,3-diossolano [Italian]; 2-(7'-Teofillinmetil)-1,3-diossolano; Doxofylline (USAN/INN); 1H-Purine-2,6-dione, 7-(1,3-dioxolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-; 7-(1,3-Dioxolon-2-ylmethyl)-1,2,3,6-tetrahydro-1,3-dimethyl-2,6-purindion; SCHEMBL37963; 5-26-14-00120 (Beilstein Handbook Reference); MLS001214637; ZINC3837; CHEMBL1527608; DTXSID7022968; CHEBI:94714; Doxofylline, >=98% (HPLC); 7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethyl-purine-2,6-dione; HMS2090E04; HMS2877P10; HMS3652H03; HMS3714M21; HMS3885B09; Pharmakon1600-01502358; ABC-12/3; ABC-1213; BCP12155; HY-B0004; Tox21 111577; Tox21_111577; BBL012263; DO-309; NSC759645; s4164; STK735429; 7-(1,3-dioxolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione; AKOS005535592; Tox21_111577_1; AC-3492; CCG-213050; CS-8019; DB09273; DS-7424; MCULE-4193802883; NSC 759645; NCGC00159330-03; NCGC00159330-04; NCGC00159330-10; BD164389; H488; SMR000543614; D4302; FT-0630792; SW199176-2; D03898; D90272; AB00828111-06; AB00828111_07; AB00828111_08; 975D866; A836720; L001990; Q425887; 7-(1,3-Dioxolan-2-ylmethyl)-1,3-dimethylxanthine; SR-01000789760-2; SR-01000789760-3; 7-(1,3-Dioxolan-2-ylmethyl)-1,3-dimethyl-1H-purine-2,6-dione; Doxofylline, United States Pharmacopeia (USP) Reference Standard; 1H-Purine-2,6-dione, 3,7-dihydro-7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethyl- (9CI); 7-[(1,3-dioxolan-2-yl)methyl]-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:94714	DB09273	.	DR0545	266.25	C11H14N4O4	76.9	398	-0.9	19	0	5	2	"1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3"	CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3	HWXIGFIVGWUZAO-UHFFFAOYSA-N
DG00919	Cefaclor	51039	"Cefaclor; 53994-73-3; Cephaclor; Ceclor; Cefaclorum; Cefaclor anhydrous; Kefral; Panoral; Raniclor; Cefaclorum [INN-Latin]; UNII-3Z6FS3IK0K; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid; S 6472; Cefaclor Impurity C; CHEBI:3478; CCL; 3Z6FS3IK0K; MLS000069617; (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 143059-69-2; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2R)-aminophenylacetyl]amino]-3-chloro-8-oxo-, (6R,7R)-; 53994-73-3 (free); MFCD00151471; (6R,7R)-7-((R)-2-amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; NCGC00022612-04; Alfacet; SMR000058250; DSSTox_CID_2748; DSSTox_RID_76713; DSSTox_GSID_22748; Dystaclor MR; L-Kefral; Ceclor CD; Alenfral (TN); Cefaclor [INN]; (6R,7R)-7-((R)-2-Amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[(2R)-2-amino-2-phenylacetamido]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CAS-53994-73-3; NSC-757422; S-6472; Cefaclor,(S); EINECS 258-909-5; Cefaclor (JP17); Spectrum_001070; SpecPlus_000947; Prestwick0_000485; Prestwick0_001102; Prestwick1_000485; Prestwick1_001102; Prestwick2_000485; Prestwick2_001102; Prestwick3_000485; Prestwick3_001102; Spectrum2_001189; Spectrum3_001858; Spectrum4_000093; Spectrum5_001727; CHEMBL680; Epitope ID:117133; SCHEMBL33540; BSPBio_000349; BSPBio_001204; BSPBio_003276; KBioGR_000386; KBioSS_001550; cid_51039; MLS001424193; DivK1c_007043; SPECTRUM1500771; SPBio_001237; SPBio_002270; SPBio_003082; BPBio1_000385; BPBio1_001326; DTXSID3022748; BDBM42131; KBio1_001987; KBio2_001550; KBio2_004118; KBio2_006686; KBio3_002777; BCPP000294; HMS1571M06; HMS1921G22; HMS2052C11; HMS2092K08; HMS2233M13; Pharmakon1600-01500771; HY-B0198; ZINC3812869; Tox21_110880; CCG-40264; NSC757422; AKOS024282614; Tox21_110880_1; BCP9000501; Cefaclor, analytical reference material; DB00833; NC00354; 7beta-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-3,4-didehydrocepham-4-carboxylic acid; NCGC00015260-22; NCGC00022612-05; NCGC00022612-06; NCGC00022612-07; NCGC00022612-10; NCGC00022612-11; 7-((2R)-2-amino-2-phenylacetylamino)(7R,7aR)-3-chloro-6-oxo-2H,7H-azetidino[2, 1-b]1,3-thiazine-4-carboxylic acid; AS-74992; SBI-0051606.P002; AB00052174; C-2461; C06877; D00256; AB00052174_15; AB00052174_16; Cefaclor, Antibiotic for Culture Media Use Only; A900728; Q415167; SR-05000001556; SR-05000001556-1; BRD-K20338176-002-03-5; 7-(D-2-AMINO-2-PHENYLACETAMIDO)-3-CHLORO-3-CEPHEM-4-CARBOXYLIC; (6R,7R)-7-((S)-2-amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[(R)-2-AMINO-2-PHENYLACETAMIDO]-3-CHLORO-8-OXO-5-THIA-1-AZABICYCLO[4,2,0]OCT-2-ENE-2-CARBOXYLIC ACID; (6R,7R)-7-[[(2R)-2-amino-2-phenyl-acetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-azaniumyl-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6R-(6-alpha,7-beta(R*)))-; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-, (6R,7R)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3478	DB00833	DR00259	.	367.8	C15H14ClN3O4S	138	606	-1.8	24	3	6	4	"1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1"	C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)Cl	QYIYFLOTGYLRGG-GPCCPHFNSA-N
DG00920	Lovastatin	53232	"Lovastatin; 75330-75-5; mevinolin; Mevacor; MK-803; Altoprev; Lovalord; Nergadan; Artein; Monacolin K; 6alpha-Methylcompactin; Lovalip; Lovastatine [French]; Lovastatinum [Latin]; Lovastatina [Spanish]; 6-alpha-Methylcompactin; Mevinacor; Altocor; Mevlor; Sivlor; Hipovastin; Lovasterol; Cholestra; Closterol; Colevix; Hipolip; Lestatin; Lipivas; Lipofren; Lovastin; Lozutin; Paschol; Rodatin; Rovacor; Tecnolip; Teroltrat; Belvas; Lipdip; Taucor; UNII-9LHU78OQFD; MLS000069585; MSD 803; 9LHU78OQFD; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; MK 803; 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; SMR000058779; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; Lovastatine; CHEBI:40303; L-154803; MFCD00072164; Lovastatin (Mevacor); NSC-758662; (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate; HSDB 6534; NCGC00023509-03; Lovastatina; Lovastatinum; C24H36O5; DSSTox_CID_784; DSSTox_RID_75788; DSSTox_GSID_20784; butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)-; Liposcler; 6 alpha-Methylcompactin; Rextat; Monakolin K; (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (S)-2-methylbutanoate; (S)-(1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2-methylbutanoate; Mevacor (TN); 6.alpha.-Methylcompactin; CHEMBL503; Lovastatin & Primycin; Lovastatin (USP/INN); SR-05000001880; (1S-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))-2-Methylbutanoic acid 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; (S)-2-Methylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one; 1,2,6,7,8,8a-Hexahydro-beta,delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutyoxy)-1-naphthaleneheptanoic acid delta-lactone; BRN 3631989; Mevinolin from Aspergillus sp.; CCRIS 8092; 1cqp; Lovastatin,(S); ML-530B; Lovastatin [USAN:USP:INN:BAN]; (+)-mevinolin; (S)-((1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl) 2-methylbutanoate; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-tetrahydropyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; Lovastatin- Bio-X; Prestwick_819; CAS-75330-75-5; Lovastatin [USAN]; Mevinolin (lovastatin); Lovastatin (Mevinolin); Opera_ID_1578; Prestwick0_000516; Prestwick1_000516; Prestwick2_000516; Prestwick3_000516; Spectrum3_001873; Spectrum5_001294; Lovastatin (MK-803); EC 616-212-7; SCHEMBL3136; US9115116, lovastatin; BIDD:PXR0113; BSPBio_000471; BSPBio_001265; BSPBio_003346; Butanoic acid, 2-methyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))-; cid_53232; MLS001055358; MLS006011867; US9353061, Lovastatina; BIDD:GT0749; DivK1c_001032; SPECTRUM1503977; SPBio_002392; BPBio1_000519; GTPL2739; MEGxm0_000398; DTXSID5020784; SCHEMBL14227102; ACon0_000534; ACon1_000390; BDBM34168; HMS503O05; KBio1_001032; KBio3_002848; AOB5269; C10AA02; Simvastatin impurity, lovastatin-; NINDS_001032; HMS1569H13; HMS1792O07; HMS1923O13; HMS1990O07; HMS2089M06; HMS2093O03; HMS2096H13; HMS2236F07; HMS3039N16; HMS3259F10; HMS3268C03; HMS3403O07; HMS3412H19; HMS3676H19; HMS3713H13; HMS3884B03; Pharmakon1600-01503977; 2-Methyl-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester butanoic acid; ACT02620; ALBB-027272; Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (2S)-; HY-N0504; MK-803; LOVALIP; MEVACOR; ZINC3812841; Tox21_110888; Tox21_201475; Tox21_300268; BBL024473; CCG-39627; NSC633781; NSC758662; NSC779704; s2061; STK801953; AKOS005267139; Tox21_110888_1; CS-1990; DB00227; KS-1082; MCULE-4740518260; MCULE-7087866108; Mevinolin from Aspergillus sp., powder; NC00713; NSC 758662; NSC-633781; NSC-779704; IDI1_001032; NCGC00023509-04; NCGC00023509-05; NCGC00023509-06; NCGC00023509-07; NCGC00023509-08; NCGC00023509-09; NCGC00023509-10; NCGC00023509-11; NCGC00023509-13; NCGC00023509-14; NCGC00023509-16; NCGC00254157-01; NCGC00259026-01; 74133-25-8; AC-13961; BL164644; Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (2S)-; G226; SMR000673570; SBI-0051881.P002; L0214; N1632; EN300-52515; C07074; D00359; J10136; AB00052400-17; AB00052400_18; AB00052400_19; Mevinolin from Aspergillus sp., >=98% (HPLC); 330L755; A838030; A838383; Q417740; SR-01000000123; SR-01000000123-3; SR-05000001880-1; SR-05000001880-2; BRD-K09416995-001-06-8; BRD-K09416995-001-21-7; Z1258578375; (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-8-(2-((4R,6R)-4-hydroxy-2-oxo-2H-pyran-6-yl)ethyl)-3,7-dimethylnaphtyl(S)-2-methylbutyrat; (2S)-(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl-2-methyl butanoate; (2S)-2-Methylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; (2S)-2-methylbutanoic acid [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-2-oxanyl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] ester; (S)-((1S,3R,7S,8S,8AR)-8-(2-((2R,4R)-4-HYDROXY-6-OXO-TETRAHYDRO-2H-PYRAN-2-YL)ETHYL)-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL) 2-METHYLBUTANOATE; (S)-2-Methyl-butyric acid (1S,3R,7S,8S,8aR)-8-[2-((3R,5R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl ester; [(1S,3R,7S,8S,8aR)-3,7-dimethyl-8-[2-[(2R,4R)-4-oxidanyl-6-oxidanylidene-oxan-2-yl]ethyl]-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-Hydroxy-6-oxo-tetrahydropyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2-methylbutanoate; 1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; 8-[2-(4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydro-1-naphthale; Butanoic acid, 2-methyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-- oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:40303	DB00227	DR00410	DR0986	404.5	C24H36O5	72.8	666	4.3	29	1	5	7	"1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1"	CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C	PCZOHLXUXFIOCF-BXMDZJJMSA-N
DG00922	Cabergoline	54746	"Cabergoline; 81409-90-7; Dostinex; Cabaser; Cabergolinum [Latin]; Cabergolina [Spanish]; Cabergolinum; Cabergolina; FCE-21336; FCE 21336; UNII-LL60K9J05T; C26H37N5O2; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; Cabaseril; CHEBI:3286; LL60K9J05T; MFCD00867887; DSSTox_CID_2719; 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea; (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; DSSTox_RID_76698; DSSTox_GSID_22719; (6aR,9R,10aR)-7-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; Sogilen; Dostinex (TN); 1-[3-(dimethylamino)propyl]-3-ethyl-1-{[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]carbonyl}urea; Cabaser (TN); CAS-81409-90-7; SR-05000001493; BRN 6020775; Caberlin; Velactis; NCGC00167821-01; Cabergoline [USAN:USP:INN:BAN]; CG-101; GTPL37; SCHEMBL42292; (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide; BIDD:GT0775; Cabergoline (JAN/USP/INN); CHEMBL1201087; DTXSID6022719; Cabergoline, >=98% (HPLC); HMS2090A09; HMS3886H05; ZINC3800008; Tox21_112589; BDBM50426497; s5842; 1-Ethyl-3-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'beta-carbonyl)urea; AKOS015961587; Tox21_112589_1; DB00248; FCE-21336FCE-21336; NCGC00344544-01; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide; AC-26126; Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-, (8-beta)-; Ergoline-8beta-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-; HY-15296; K450; C08187; D00987; F17353; AB01275484-01; 409C907; Q423308; SR-05000001493-1; SR-05000001493-2; BRD-K86882815-001-01-6; Cabergoline, European Pharmacopoeia (EP) Reference Standard; Cabergoline, United States Pharmacopeia (USP) Reference Standard; ETHYL4-METHYL-2-PYRIDIN-3-YL-1,3-THIAZOLE-5-CARBOXYLATE; 1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea; 6-allyl-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-ergoline-8beta-carboxamide; N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-allyl-ergoline-8beta-carboxamide; (6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide; (9R,10aR)-7-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3286	DB00248	DR00069	DR0253	451.6	C26H37N5O2	71.7	713	3.4	33	2	4	8	"1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1"	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C	KORNTPPJEAJQIU-KJXAQDMKSA-N
DG00923	Bambuterol	54766	"Bambuterol; 81732-65-2; Bambec; Bambuterolum; CHEBI:553827; [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate; (+/-)-Bambuterol;KWD-2183; (+-)-5-(2-(tert-Butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate); Bambuterolum [Latin]; Oxeol; 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diyl bis(dimethylcarbamate); Bambuterol (INN); terbutaline bisdimethylcarbamate; Bambuterol [INN:BAN]; terbutaline bis(dimethylcarbamate); KWD-2183; Prestwick0_000361; Prestwick1_000361; Prestwick2_000361; Prestwick3_000361; SCHEMBL4431; BSPBio_000481; MLS002153785; SPBio_002402; BPBio1_000531; CHEMBL521589; GTPL6601; DTXSID5048550; HMS2089J18; HMS2230O15; HMS3373N13; BCP21793; BDBM50235800; STK643808; AKOS005574764; CS-3157; DB01408; MCULE-5915665286; ( inverted exclamation markA)-Bambutero; ( inverted exclamation markA)-Bambuterol; NCGC00179546-01; NCGC00179546-02; H726; HY-17501; SMR001233168; SBI-0207028.P001; FT-0602901; D07377; 732B652; A840189; L004435; Q3633651; SR-05000001470-1; BRD-A17462676-003-03-3; BRD-A17462676-003-06-6; (+/-)-5-(2-(tert-butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate); (RS)-5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diyl bis(dimethylcarbamate); 5-(2-(tert-butylamino)-1-hydroxyethyl)-1,3-phenylene bis(dimethylcarbamate); [3-[2-(tert-butylamino)-1-oxidanyl-ethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate; N,N-dimethylcarbamic acid [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-[dimethylamino(oxo)methoxy]phenyl] ester"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:553827	DB01408	.	.	367.4	C18H29N3O5	91.3	446	1.2	26	2	6	8	"1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3"	CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O	ANZXOIAKUNOVQU-UHFFFAOYSA-N
DG00924	Mifepristone	55245	"Mifepristone; 84371-65-3; Mifegyne; Mifeprex; RU-486; Corlux; Korlym; RU486; RU 486; RU 38486; Mifepriston; RU-38486; UNII-320T6RNW1F; MLS000069785; 320T6RNW1F; VGX-410C; CHEBI:50692; VGX-410; NCGC00025179-05; SMR000058481; Mifepristonum [Latin]; Mifepristona [Spanish]; DSSTox_CID_3322; C-1073; DSSTox_RID_76976; DSSTox_GSID_23322; (11beta,17beta)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(1-propyn-1-yl)estra-4,9-dien-3-one; (8S,11R,13S,14S,17S)-11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; (8S,11R,13S,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE; Mifepristona; Mifepristonum; (11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-prop-1-yn-1-ylestra-4,9-dien-3-one; RU486 (tetramethyl-rhodamine conjugated); Mifepristone [USAN:INN:BAN]; HSDB 6841; SR-01000076011; R 38486; BRN 5779404; Pictovir; RU 486-6; CCRIS 9332; 1nhz; NSC-759862; 11beta-(p-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one; Mifeprex (TN); Pictovir (TM); Prestwick_570; CAS-84371-65-3; Korlym (TN); 2w8y; Mifepristone (Mifeprex); Opera_ID_562; Mifepristone, >=98%; Prestwick0_000299; Prestwick1_000299; Prestwick2_000299; Prestwick3_000299; Spectrum5_002045; 11beta-(4-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-on; 17-beta-Hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one; BIDD:PXR0123; Lopac0_000801; SCHEMBL16087; BSPBio_000238; 11beta-(4-(Dimethylamino)phenyl)-17-hydroxy-21-methyl-19-nor-17alpha-pregna-4,9-dien-20-m-3-on; 11beta-(4-(N,N-Dimethylamino)phenyl)-17alpha-(prop-1-ynyl)-delta4,9-estradiene-17beta-ol-3-one; MLS001074115; MLS001424271; (non-labelled)Mifepristone-d3; SPBio_002457; RU-486; MIFEPRISTONE; BPBio1_000262; CHEMBL438575; GTPL2805; Mifepristone (JAN/USAN/INN); CHEMBL1276308; DTXSID5023322; BDBM18627; AOB6893; HMS1568L20; HMS2052L05; HMS2090L22; HMS2095L20; HMS2230P21; HMS3262B03; HMS3412D17; HMS3649J08; HMS3676D17; HMS3712L20; HMS3884D12; ACT02598; BCP02145; ZINC3831128; Tox21_110952; Tox21_301841; Tox21_500801; BDBM50072024; HSCI1_000369; MFCD00867226; s2606; VX-410; AKOS015895416; Tox21_110952_1; CCG-101164; CI-1073; CS-1435; DB00834; LP00801; NC00414; NSC 759862; SDCCGSBI-0050778.P002; Mifepristone 1.0 mg/ml in Acetonitrile; NCGC00025179-06; NCGC00025179-07; NCGC00025179-08; NCGC00025179-09; NCGC00025179-12; NCGC00025179-13; NCGC00025179-23; NCGC00179632-01; NCGC00255152-01; NCGC00261486-01; (11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one; AS-13938; CPD000058481; Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-, (11-beta,17-beta)-; HY-13683; RU486;C-1073; EU-0100801; C07652; D00585; M 8046; 371M653; A840767; Q411240; SR-01000721888; Q-201405; SR-01000076011-1; SR-01000076011-3; SR-01000076011-5; SR-01000076011-9; SR-01000721888-4; BRD-K37270826-001-04-5; BRD-K37270826-001-31-8; Mifepristone, United States Pharmacopeia (USP) Reference Standard; (11 ,17 )-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one; 11.beta.-[4-(Dimethylamino)phenyl]-17.beta.-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one; 11beta-(4-Dimethyl-amino)-phenyl-17beta-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one; 11ss-[p-(Dimethylamino)fenyl]-17ss-hydroxy- 17-(1-propynyl)estra-4,9-dien-3-on; (10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-1,6-dien-5-one; (10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-5-one; (11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one; (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-13-methyl-17-oxidanyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 122742-25-0; 83203-42-3; Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11b,17b)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:50692	DB00834	DR00714	DR1091	429.6	C29H35NO2	40.5	921	3.8	32	1	3	3	"1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1"	CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O	VKHAHZOOUSRJNA-GCNJZUOMSA-N
DG00927	Gardiquimod	44592366	"Gardiquimod; 1020412-43-4; UNII-Y3W4QVW5BY; Y3W4QVW5BY; 1-[4-amino-2-(ethylaminomethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol; CHEMBL1085742; 1-{4-amino-2-[(ethylamino)methyl]-1H-imidazo[4,5-c]quinolin-1-yl}-2-methylpropan-2-ol; 1-(4-amino-2-((ethylamino)methyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol; 1-yl]-2-methylpropan-2-ol; SCHEMBL1256396; BCP30187; EX-A5848; VQB41243; BDBM50320067; ZINC40897136; NCGC00387769-01; NCGC00387769-02; NCGC00387769-04; AS-82322; HY-103697; CS-0032943; J3.515.101J; J-000553; 1-[4-Amino-2-(ethylaminomethyl)imidazo[4,5-c]quinolin-; 1-(4-amino-2-ethylaminomethylimidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol; 1-[4-amino-2-(ethylaminomethyl)imidazo[4,5-c]quinolin-1-yl]-2-methyl-propan-2-ol; 1H-Imidazo(4,5-C)quinoline-1-ethanol, 4-amino-2-((ethylamino)methyl)-alpha,alpha-dimethyl-; 4-Amino-2-((ethylamino)methyl)-alpha,alpha-dimethyl-1H-imidazo(4,5-C)quinoline-1-ethanol; 9K3"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	313.4	C17H23N5O	89	404	1	23	3	5	5	"1S/C17H23N5O/c1-4-19-9-13-21-14-15(22(13)10-17(2,3)23)11-7-5-6-8-12(11)20-16(14)18/h5-8,19,23H,4,9-10H2,1-3H3,(H2,18,20)"	CCNCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N	FHJATBIERQTCTN-UHFFFAOYSA-N
DG00928	Imiquimod	57469	"IMIQUIMOD; 99011-02-6; Aldara; Zyclara; 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine; Beselna; 4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline; R 837; 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine; 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline; R-837; 9050-31-1; S-26308; C14H16N4; UNII-P1QW714R7M; MFCD00866946; CHEMBL1282; 1-isobutylimidazo[4,5-c]quinolin-4-amine; P1QW714R7M; 1H-Imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)-; CHEBI:36704; S26308; NSC-369100; NSC-759651; 1H-Imidazo(4,5-c)quinolin-4-amine, 1-(2-methylpropyl)-; NCGC00070736-02; Zartra; Imiquimod acetate; DSSTox_CID_21047; DSSTox_RID_79617; DSSTox_GSID_41047; Aldara (TN); CAS-99011-02-6; S 26308; SR-01000611320; Imiquimodum; Imiquimod [USAN:INN:BAN]; Vyloma; MTD-39; 1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine; HSDB 8129; TMX 101; TMX-101; Aldara; ; ; Beselna; Imiquimod,(S); Imiquimod- Bio-X; 6T0; Imiquimod - Aldara; Zyclara (TN); DZ-2636; (non-labelled)Imiquimod-d9; Imiquimod (JAN/USP/INN); SCHEMBL26136; MLS000083577; BIDD:GT0859; GTPL5003; DTXSID7041047; AOB6939; HMS2090M14; HMS2232G07; HMS3373B13; HMS3715N19; HMS3747A13; Pharmakon1600-01502351; BCP05151; HY-B0180; Tox21_110985; AC-529; BBL010772; BDBM50240849; NSC369100; NSC759651; NSC811538; s1211; STK583860; ZINC19632912; Imiquimod - CAS 99011-02-6; Imiquimod, >=98% (HPLC), solid; AKOS005507352; Tox21_110985_1; 1H-Imidazo[4, 1-(2-methylpropyl)-; CCG-208015; CS-2058; DB00724; KS-5218; MCULE-9421195760; NSC 369100; NSC 741062; NSC 759651; NSC-811538; YH44175; (Hydroxypropyl)methyl cellulose phthalate; Imiquimod 100 microg/mL in Acetonitrile; NCGC00070736-03; NCGC00070736-04; BI164576; SMR000048307; SY017571; FT-0602727; I0747; D02500; J10325; 1-isobutyl-1H-imidazo [4,5-c]quinolin-4-amine; 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-amine; AB00399298-05; AB00399298-06; AB00399298-07; AB00399298_08; AB00399298_09; 011I026; 1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-ylamine; A845945; Q423417; 1-(2-methylpropyl)-4-imidazo[4,5-c]quinolinamine; SR-01000611320-2; SR-01000611320-3; BRD-K26657438-001-01-2; BRD-K26657438-001-13-7; 1-(2-methylpropyl)-1Himidazo[4,5-c]quinolin-4-amine; 1-(2-methylpropyl)-1H-imidazo[4,5-c]-quinolin-4-amine; Imiquimod, United States Pharmacopeia (USP) Reference Standard"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:36704	DB00724	.	DR0864	240.3	C14H16N4	56.7	294	2.6	18	1	3	2	"1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)"	CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N	DOUYETYNHWVLEO-UHFFFAOYSA-N
DG00929	Resiquimod	159603	"Resiquimod; 144875-48-9; 1-(4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol; R-848; 1-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol; R 848; UNII-V3DMU7PVXF; Resiquimod (R-848); R848; V3DMU7PVXF; MFCD00937759; S-28463; CHEMBL383322; CHEBI:36706; 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol; s28463; R848;S28463; Resiquimod [INN]; alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol; 1-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol.; 2252319-44-9; R848 compound; S 28463; 1H-Imidazo(4,5-c)quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-; 1H-Imidazo[4,5-c]quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-; 4-Amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol; 4-Amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-1H-Imidazo[4,5-c]quinoline-1-ethanol; ResiquimodR848; VML-600; RX8; R848; Resiquimod; SCHEMBL34159; MLS006010212; GTPL5051; DTXSID7040603; Resiquimod, >=98% (HPLC); 4-Amino-2-(ethoxymethyl)-alpha; HMS3740O09; BCP09103; EX-A1879; BDBM50241029; s8133; ZINC28572103; AKOS016003509; CCG-267635; CD11301; CS-1706; DB06530; SB17111; 1-(4-Amino-2-ethoxymethyl-imidazo[4,5-c]quinolin-1-yl)-2-methyl-propan-2-ol; NCGC00370784-01; NCGC00370784-05; AS-30885; CD-11301; HY-13740; SMR002530531; SY107476; FT-0763049; R0197; Z4166; Resiquimod, VML-600, R-848, S-28463; A856222; Q426054; SR-01000944954; J-008020; SR-01000944954-1; 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methyl-propan-2-ol; 4-amino-2-ethoxymethyl-alpha,alpha-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol; 4-amino-alpha,alpha-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-ethanol; 4-Amino-alpha,alpha-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinoline-1-ethanol"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:36706	.	.	.	314.4	C17H22N4O2	86.2	406	1.3	23	2	5	5	"1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19)"	CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N	BXNMTOQRYBFHNZ-UHFFFAOYSA-N
DG00931	Esmolol	59768	"ESMOLOL; 81147-92-4; 103598-03-4; (+-)-Esmolol; Brevibloc; ASL 8052-001; methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate; Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate; Benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester; CHEBI:88206; Esmolol [INN:BAN]; methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate; Esmolol (INN); NCGC00185766-01; BRN 5287174; SR-01000763706; Benzenepropanoic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, methyl ester; (+/-)-esmolol; CHEMBL768; SCHEMBL3605; GTPL7178; DTXSID4022995; HMS2090P06; HMS3743M15; HMS3886F03; methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; BDBM50404796; methyl 3-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)propanoate; MFCD00864566; s5778; AKOS015960734; methyl 3-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)propanoate; methyl 3-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]propanoate; DB00187; SL-8052; MRF-0000253; NCGC00185766-02; NCGC00185766-05; AC-12058; ASL-8052-001; DB-015362; E1106; FT-0630886; C06980; D07916; D90594; AB00698516-07; AB00698516-09; AB00698516_10; 147E924; L001332; Q418139; SR-01000763706-3; (+/-)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; Methyl 3-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]propionate; 3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester; 3-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]propionic Acid Methyl Ester; Methyl 3-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]propionate / 3-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]propionic Acid Methyl Ester"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:88206	DB00187	DR00853	DR0626	295.37	C16H25NO4	67.8	288	1.9	21	2	5	10	"1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3"	CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O	AQNDDEOPVVGCPG-UHFFFAOYSA-N
DG00933	Doxacurium	60169	"Doxacurium; bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate; 106791-39-3; Doxacurium ion; Doxacurium cation; C07549; CHEBI:4706; CHEMBL1237123; SCHEMBL10119676; DB01135; L000825"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4706	DB01135	.	.	1035.2	C56H78N2O16+2	163	1540	7.4	74	0	16	29	"1S/C56H78N2O16/c1-57(23-19-37-33-45(65-7)53(69-11)55(71-13)49(37)39(57)27-35-29-41(61-3)51(67-9)42(30-35)62-4)21-15-25-73-47(59)17-18-48(60)74-26-16-22-58(2)24-20-38-34-46(66-8)54(70-12)56(72-14)50(38)40(58)28-36-31-43(63-5)52(68-10)44(32-36)64-6/h29-34,39-40H,15-28H2,1-14H3/q+2"	C[N+]1(CCC2=CC(=C(C(=C2C1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)OC)CCCOC(=O)CCC(=O)OCCC[N+]4(CCC5=CC(=C(C(=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)OC)C	GBLRQXKSCRCLBZ-UHFFFAOYSA-N
DG00937	Atorvastatin	60823	"Atorvastatin; 134523-00-5; Cardyl; Lipitor; Torvast; ATORVASTATIN CALCIUM; 110862-48-1; UNII-A0JWA85V8F; (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid; CI 981; Lipitor (TN); Tozalip; Xavator; A0JWA85V8F; CHEMBL1487; (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; CHEBI:39548; (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 134523-03-8; Atorvastatin [INN:BAN]; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (R-(R*,R*))-; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID; Atorvastatin calcium salt; atorvastatina; atorvastatine; atrovastin; Atofast; Atorcor; Atorlip; Lipilou; Lipinon; Atorin; Ator; Lipitor(TM); (3R,5R)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; Atorvastatin (INN); Sortis (TN); CCRIS 7159; MFCD00899261; C33H35FN2O5; HSDB 7039; NCGC00159458-03; atorvastatinum; rel-Atorvastatin; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; Atorvastatin & Primycin; DSSTox_CID_9868; SCHEMBL3831; DSSTox_RID_78825; DSSTox_GSID_29868; BIDD:GT0336; Atorvastatin (Relative Stereo); GTPL2949; DTXSID8029868; BDBM22164; DTXSID60274003; HMS3715L05; HMS3886C20; Lipilou; Tozalip; Torvast; Cardyl; (3S,5S)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; ACT03225; HY-B0589; ZINC3920719; Tox21_302417; s5715; AKOS000281127; AC-9386; CCG-221172; DB01076; MCULE-2368532812; MRF-0000761; NCGC00159458-02; NCGC00159458-20; NCGC00255181-01; (3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (betaR,deltaR)-; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID; AS-35260; H942; CAS-134523-00-5; C06834; D07474; 523A005; A802259; A806791; A806793; Q668093; SR-01000872702; SR-01000872702-1; BRD-K69726342-001-02-6; UNII-36TN91XZ0V component XUKUURHRXDUEBC-KAYWLYCHSA-N; (3R,5R)-7-[2-(4-FLUOROPHENYL)-3-PHENYL-4-(PHENYLCARBAMOYL)-5-PROPAN-2-YL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID; (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (beta-R,delta-R)-;; sodium 7-[5-(4-fluorophenyl)-2-isopropyl-4-phenyl-3-(phenylcarbamoyl)-2,3-dihydropyrrol-1-yl]-3,5-dihydroxy-heptanoate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:39548	DB01076	DR00030	.	558.6	C33H35FN2O5	112	822	5	41	4	6	12	"1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1"	CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4	XUKUURHRXDUEBC-KAYWLYCHSA-N
DG00938	Valsartan	60846	"Valsartan; 137862-53-4; Diovan; Tareg; CGP 48933; Provas; Exforge; (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid; CGP-48933; 137863-60-6; UNII-80M03YXJ7I; MFCD00865840; (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid; N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine; CHEMBL1069; 80M03YXJ7I; CHEBI:9927; (s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid; L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; NSC-758927; Kalpress; Miten; Nisis; Vals; (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine; L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-; N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine; N-[p-(o-1H-Tetrazol-5-ylphenyl)benzyl]-N-valeryl-L-valine; Valzaar; Valtan; [3H]valsartan; (2~{S})-3-methyl-2-[pentanoyl-[[4-[2-(2~{H}-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid; SMR000466318; Diovan (TN); Prexxartan; Valpression; Varexan; HSDB 7519; L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; Valsartan [USAN:USP:INN:BAN]; Valsartan,(S); Valsartan- Bio-X; (2S)-3-Methyl-2-(pentanoyl-((4-(2-(2H-tetrazol-5-yl)phenyl)phenyl)methyl)amino)butanoic acid; (2S)-3-methyl-2-[pentanoyl-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid; valsartan (Diovan); Spectrum_001796; Spectrum2_001120; Spectrum3_001831; Spectrum4_000749; Spectrum5_001582; Prexxartan (oral solution); EC 604-045-2; SCHEMBL2542; BSPBio_003501; GTPL593; KBioGR_001078; KBioSS_002289; MLS000759423; MLS001424088; BIDD:GT0345; SPECTRUM1505209; SPBio_001260; Valsartan (JP17/USP/INN); GTPL3937; Valsartan, >=98% (HPLC); KBio2_002287; KBio2_004855; KBio2_007423; KBio3_003006; EZR-104; VAL-489; HMS1922L21; HMS2051L12; HMS2093K22; HMS2232F05; HMS3651E04; HMS3715P12; Pharmakon1600-01505209; ACT02671; BCP05184; ZINC3875259; BDBM50049186; NSC758927; s1894; AKOS015914315; AKOS015994698; AC-4543; AM90287; CCG-101028; CCG-221275; CS-1967; DB00177; DS-1248; KS-1194; MCULE-6728882368; NC00278; NSC 758927; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine; NCGC00178027-08; NCGC00178027-11; BV164506; HY-18204; I997; SBI-0206738.P001; SW197658-2; V-120; 62V534; D00400; J10013; AB00639940-06; AB00639940-08; AB00639940_09; AB00639940_11; Q155472; SR-05000001928; J-007068; SR-05000001928-1; BRD-K45158365-001-02-3; BRD-K45158365-001-05-6; Valsartan, European Pharmacopoeia (EP) Reference Standard; N-Valeryl-N-[2'-(5-tetrazolyl)biphenyl-4-ylmethyl]-L-valine; Valsartan, United States Pharmacopeia (USP) Reference Standard; N-Valeryl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-L-valine; Valsartan, Pharmaceutical Secondary Standard; Certified Reference Material; (5)-2-{N-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]pentanamido}-3-methylbutanoic acid; (S)-3-Methyl-2-{pentanoyl-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid; 3-Methyl-2-{pentanoyl-[2''-(1H-tetrazol-5-yl)-biphenyl-4-yl]-amino}-butyric acid; L-Valine,N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]methyl]- (9CI); N-(1-oxopentyl)-N-[[2'-(1h-tetrazol-5-yl) [1,1'-bi-phenyl]-4-yl]methyl]-l-valine; N-(1-Oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(L)-valine; N-(1-OXOPENTYL)-N-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-L-VALINE; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-L-valine; Valsartan for peak identification, European Pharmacopoeia (EP) Reference Standard; Valsartan for system suitability, European Pharmacopoeia (EP) Reference Standard; (2~{S})-3-methyl-2-[pentanoyl-[[4-[2-(2~{H}-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid; Diovan; Tareg; Provas; Exforge; N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine; (2S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid; (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid.; (2S)-3-Methyl-2-{N-pentanoyl-N'-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butanoic acid; (2S)-3-Methyl-2-{pentanoyl-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid; (S)-2-(N-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid; (s)-3-methyl-2-[N-({4-[2-(2h-1,2,3,4-tetrazol-5-yl) phenyl]phenyl}methyl)pentanamido]butanoic acid; (S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid; (s)-3-methyl-2-{pentanoyl-[-2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid; (S)-3-Methyl-2-{pentanoyl-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid; (S)-3-Methyl-2-{pentanoyl-[2''-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid; (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine; (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amine; (S)-N-(1-Carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine; 2-{[2''-(2,3-Dihydro-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-pentanoyl-amino}-3-methyl-butyric acid; 3-Methyl-2-{((S)-pentanoyl)-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid; U35"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9927	DB00177	DR00071	DR1668	435.5	C24H29N5O3	112	608	4.4	32	2	6	10	"1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1"	CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O	ACWBQPMHZXGDFX-QFIPXVFZSA-N
DG00939	Emtricitabine	60877	"Emtricitabine; 143491-57-0; Emtriva; Coviracil; (-)-FTC; 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; 143491-54-7; 524W91; BW-524W91; Racivir; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; BW524W91; (-)-2'-Deoxy-5-fluoro-3'-thiacytidine; UNII-G70B4ETF4S; BW 524W91; FTC; (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine; CHEBI:31536; FTC-(-); (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; G70B4ETF4S; 145213-48-5; Emtritabine; BW1592; MFCD00870151; (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2',3'-Dideoxy-5-fluoro-3'-thiacytidine; NCGC00164564-01; (-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; PSI 5004; PSI-5004; Coviracil(TM); DRG-0208; 4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one; rel-4-Amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; Emtriva(TM); 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, rel-; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, rel-; Emtricitabine (Emtriva); SMR002533604; BW 1592; 2',3',5-FTC; HSDB 7337; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one; FTC, (-)-; Emtricitabine [USAN:INN]; (-)-.beta.-L-FTC; Emtricitabinum; 2(1h)-pyrimidinone,4-amino-5-fluoro-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-; 2(1H)-Pyrimidinone,4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-; (-)-emtricitabine; Emtricitabine- Bio-X; Emtricitabine, (-)-; CHEMBL885; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, cis-; DSSTox_CID_20129; DSSTox_RID_79445; DSSTox_GSID_40129; SCHEMBL39708; MLS003882429; MLS006011556; MLS006011987; DTXSID0040129; GTPL11244; EX-A150; HMS2089I05; HMS3713L12; ZINC3629271; Tox21_112193; ((-))-FTC; BDBM50107843; CS1125; FTC-((-)); NSC804863; s1704; AKOS015853098; AKOS015894950; AM84393; CCG-220615; CS-1370; DB00879; MCULE-7141046266; NSC-804863; 2',3'-Dideoxy-3-thia-5-fluorocytidine; NCGC00164564-06; NCGC00164564-09; NCGC00164564-10; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, cis-(+-)-; AS-14099; BE165946; HY-17427; CAS-143491-57-0; E1007; Emtricitabine 100 microg/mL in Acetonitrile; SW220172-1; D01199; D72669; ent-Emtricitabine; Emtricitabine IP Impurity D; AB01275429-01; 491E570; Q422604; 524-W-91; W-201247; W-201248; Z1739256297; UNII-ULS8902U4O component XQSPYNMVSIKCOC-NTSWFWBYSA-N; .beta.-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; 4-Amino-5-fluoro-1-[(2R,5S)-2-hydroxymethyl)-1,3-oxathiolan-5-yl]-2-(1H-pyrimidinone; 4-Amino-5-fluoro-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; (+)-2'-Deoxy-3'-thia-5-fluorocytidine; (2S-cis)-4-Amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; 5-FLUORO-(-)-L-2',3'-DIDEOXY-3'-THIACYTIDINE; (-)-BETA-2',3'-DIDEOXY-5-FLUORO-3'-THIACYTIDINE; EMTRICITABINE; EMTRIVA"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31536	DB00879	DR00672	.	247.25	C8H10FN3O3S	113	374	-0.6	16	2	5	2	"1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1"	C1[C@H](O[C@H](S1)CO)N2C=C(C(=NC2=O)N)F	XQSPYNMVSIKCOC-NTSWFWBYSA-N
DG00941	Trovafloxacin	62959	"Trovafloxacin; 147059-72-1; TVFX; Trovafloxacin [INN]; UNII-9F388J00UK; Trovafloxacin (INN); 7-[(1R,5S,6s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; CP-99219; CHEBI:9763; 9F388J00UK; 7-[(1R,5S,6s)-6-Amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; Trovan (oral); 7-[(1S,5R)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid; Fluorinated quinolone; CP-99,219; trovafloxacine; trovafloxacino; trovafloxacinum; 7-((1R,5S,6S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; TR6; CP99219; CHEMBL428; SCHEMBL34465; SCHEMBL34466; 7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid; SCHEMBL9177464; DTXSID0041145; EX-A897; BCP12644; HY-A0170; MFCD00871697; ZINC12503149; AKOS000277872; AKOS015909896; ZINC100030989; ZINC147175374; DB00685; (1alpha,5alpha,6alpha)-7-(6-Amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1,8-Naphthyridine-3-carboxylic acid, 7-[(1alpha,5alpha,6alpha)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-; 7-((1R,5S)-6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-(2,4-difluoro-phenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; CS-0017509; C07664; D08654; A935288; Q544393; 1,8-Naphthyridine-3-carboxylic acid, 7-(1.alpha.,5.alpha.,6.alpha.)-6-amino-3-azabicyclo3.1.0hex-3-yl-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-; 1,8-Naphthyridine-3-carboxylic acid, 7-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, (1alpha,5alpha,6alpha)-; 7-[(1.alpha.,5.alpha.,6.alpha.)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid; 7-[(1alpha,5alpha)-6beta-Amino-3-azabicyclo[3.1.0]hexane-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid; 7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9763	DB00685	.	.	416.4	C20H15F3N4O3	99.8	770	0.3	30	2	10	3	"1S/C20H15F3N4O3/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24/h1-4,7,10-11,16H,5-6,24H2,(H,29,30)/t10-,11+,16 "	C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F	WVPSKSLAZQPAKQ-SOSAQKQKSA-N
DG00943	Iopamidol	65492	"Iopamidol; 60166-93-0; Iopamiron; Iopamiro; Isovue; Niopam; Solutrast; Gastromiro; Iopamidolum; B-15000; UNII-JR13W81H44; SQ-13396; 62883-00-5; (S)-N,N'-bis(2-Hydroxy-1-(hydroxymethyl)ethyl)-2,4,6-triiodo-5-lactamidoisophthalamide; L-(+)-N,N'-Bis(2-hydroxy-1-hydroxymethylethyl)-2,4,6-triiodo-5-lactamide isophthalamide; L-5alpha-Hydroxypropionylamino-2,4,6-triiodoisophthalic acid di(1,3-dihydroxy-2-propylamide); SQ 13,396; CHEBI:31711; JR13W81H44; Iopamidol 300; Solutrast 370; iomapidol; NCGC00016892-01; Oypalomin; Isovue 370; CAS-60166-93-0; DSSTox_CID_3158; (S)-N1,N3-bis(1,3-dihydroxypropan-2-yl)-5-(2-hydroxypropanamido)-2,4,6-triiodoisophthalamide; DSSTox_RID_76896; DSSTox_GSID_23158; 1-N,3-N-bis(1,3-dihydroxypropan-2-yl)-5-[[(2S)-2-hydroxypropanoyl]amino]-2,4,6-triiodobenzene-1,3-dicarboxamide; Iopamiron 300; Iopamiron 370; Jopamiron 200; Iopamiro 370; Isovue-370; Niopam 300; Iopamidolum [INN-Latin]; N,N'-bis(1,3-dihydroxypropan-2-yl)-5-{[(2S)-2-hydroxypropanoyl]amino}-2,4,6-triiodobenzene-1,3-dicarboxamide; Iopamidol-200; Iopamidol-250; Iopamidol-300; Iopamidol-370; Scanlux-300; Scanlux-370; Isovue-128; Isovue-200; Isovue-250; Isovue-300; Isovue-M 200; Isovue-M 300; EINECS 262-093-6; B 15000; BRN 6250226; Iopamyron; SQ 13396; HSDB 8075; (S)-N,N'-Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-5-lactamidoisophthalamide; Iopamiron (TN); Iopamidol-200 in plastic container; Iopamidol-250 in plastic container; Iopamidol-300 in plastic container; Iopamidol-370 in plastic container; Isovue (TN); Iopamidol [USAN:USP:INN:BAN:JAN]; Prestwick0_000871; Prestwick1_000871; Prestwick2_000871; Prestwick3_000871; Iopamidol (JP17/USP); L-5alpha-Idrossipropionilamino-2,4,6-triiodoisoftal-di(1,3-diidrossi-2-propilamide); SCHEMBL27781; BSPBio_000941; SPBio_002862; BPBio1_001037; CHEMBL1200932; DTXSID1023158; HMS1570P03; HMS2097P03; HMS3714P03; Pharmakon1600-01502304; ACT03261; HY-B0684; ZINC3830947; Tox21_110668; NSC759636; s4532; AKOS015891034; Tox21_110668_1; CCG-213024; DB08947; KS-1421; NCGC00016892-02; NCGC00016892-04; (S)-N,N'-Bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-((2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodoisophthaldiamide; 1,3-Benzenedicarboxamide, N,N'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-(((2S)-2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodo-; 1,3-Benzenedicarboxamide, N,N'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-((2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodo-, (S)-; AB00513941; D01797; H11976; hydroxypropanamido)-2,4,6-triiodoisophthalamide; AB00513941_02; 166I930; A834067; Q424788; Q-201245; (S)-N1,N3-bis(1,3-dihydroxypropan-2-yl)-5-(2-; BRD-K75868704-001-01-2; (S)-N,N inverted exclamation marka-Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-5-lactamidoisophthalamide; (S)-N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide; N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-{[(2S)-2-hydroxypropanoyl]amino}-2,4,6-triiodobenzene-1,3-dicarboxamide; N1,N3-bis(1,3-dihydroxypropan-2-yl)-5-(2-hydroxypropanoylamino)-2,4,6-triiodo-benzene-1,3-dicarboxamide; N1,N3-bis(1,3-dihydroxypropan-2-yl)-5-[(2S)-2-hydroxypropanamido]-2,4,6-triiodobenzene-1,3-dicarboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31711	DB08947	.	.	777.1	C17H22I3N3O8	188	583	-2.4	31	8	8	10	"1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1"	C[C@@H](C(=O)NC1=C(C(=C(C(=C1I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)O	XQZXYNRDCRIARQ-LURJTMIESA-N
DG00945	Ceftezole	65755	"Ceftezole; 26973-24-0; Ceftezol; Ceftezolum; UNII-2Z86SYP11W; Ceftezole [INN]; ceftezole sodium; 2Z86SYP11W; (6R,7R)-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-3-(1,3,4-thiadiazol-2-ylsulfanylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Ceftezole (INN); Demethylcefazolin; (6R,7R)-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-3-[(1,3,4-thiadiazol-2-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; demethyl cefazolin; CG-B 3 Q; NCGC00182064-02; Ceftezol [INN-Spanish]; Ceftezolum [INN-Latin]; C13H12N8O4S3; MLS006010107; SCHEMBL147529; CHEMBL1697829; DTXSID0022771; J01DB12; CHEBI:135716; BCP12070; HY-N7095; ZINC3830473; MFCD00274176; s5289; AKOS037643294; CCG-269124; DB13821; AS-13011; H011; SMR004701245; CS-0077833; D07656; 973C240; A818761; J-016638; Q5057295; (6R,7R)-3-((1,3,4-thiadiazol-2-ylthio)methyl)-7-(2-(1H-tetrazol-1-yl)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-8-Oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-3-((1,3,4-thiadiazol-2-ylthio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-8-oxo-7-[[1-oxo-2-(1-tetrazolyl)ethyl]amino]-3-[(1,3,4-thiadiazol-2-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-3-(1,3,4-thiadiazol-2-ylsulfanylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;Ceftezole; (6R,7R)-8-oxo-7-[2-(1H-tetrazol-1-yl)acetamido]-3-[(1,3,4-thiadiazol-2-ylsulfanyl)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[2-(1H-tetrazol-1-yl)acetamido]-3-[(1,3,4-thiadiazol-2-ylsulfanyl)methyl]-3,4-didehydrocepham-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:135716	.	.	.	440.5	C13H12N8O4S3	235	709	-0.7	28	2	12	7	"1S/C13H12N8O4S3/c22-7(1-20-4-14-18-19-20)16-8-10(23)21-9(12(24)25)6(2-26-11(8)21)3-27-13-17-15-5-28-13/h4-5,8,11H,1-3H2,(H,16,22)(H,24,25)/t8-,11-/m1/s1"	C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)CN3C=NN=N3)C(=O)O)CSC4=NN=CS4	DZMVCVMFETWNIU-LDYMZIIASA-N
DG00946	Milnacipran	65833	"Milnacipran; 92623-85-3; Dextromilnacipran; Levomilnacipran; Milnacipranum [Latin]; UNII-ES1O38J3C4; 96847-55-1; F 2207; (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; ES1O38J3C4; Dalcipran; (+-)-Milnacipran; F2207; Milnacipranum; Milnace; (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-cyclopropane-1-carboxamide; Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-,(1R,2S)-rel-; (-)-milnacipran; Milnacipran [INN:BAN]; ( )-Milnacipran; Milnacipran (INN); F2696; Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, cis-(+-)-; SCHEMBL8099; CHEMBL252923; DTXSID3048287; BDBM86420; CHEBI:94468; ZINC14037; HY-B0168; (+-)-cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; NCGC00165825-01; HY-14794; R211; CAS_92623-85-3; CS-0003566; C16729; D08222; AB00640027_06; 623M853; Q421058; UNII-G56VK1HF36 component GJJFMKBJSRMPLA-HIFRSBDPSA-N; F0F"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:94468	DB04896	.	DR2421	246.35	C15H22N2O	46.3	295	1.4	18	1	2	5	"1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m1/s1"	CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C2=CC=CC=C2	GJJFMKBJSRMPLA-HIFRSBDPSA-N
DG00948	Balofloxacin	65958	"Balofloxacin; 127294-70-6; 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-(methylamino)piperidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Bilimin; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)piperidino)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acid; NCGC00167532-01; Balofloxacin [INN]; DSSTox_CID_26695; DSSTox_RID_81829; UNII-Q022B63JPM; DSSTox_GSID_46695; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)-1-piperidinyl)-4-oxo-; Q 35; 1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)piperidin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; CAS-127294-70-6; CHEMBL1210954; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-piperidinyl]-4-oxo-; BALOFLOXACIN 2-HYDRATE; SCHEMBL134163; DTXSID5046695; HMS3655N15; HY-B0159; RKL10070; Tox21_112529; MFCD00864925; s2064; AKOS015900452; Tox21_112529_1; CCG-268516; CS-1991; KS-5214; NCGC00167532-02; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)piperidino)-4-oxo-3-quinoline arboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-piperidino]-4-oxo-3-quinolinecarboxylicacid; 1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)-1-piperidyl]-4-oxo-quinoline-3-carboxylic acid; B4354; FT-0602907; SW220155-1; AB01566884_01; Balofloxacin, VETRANAL(TM), analytical standard; 294B706; A805677; SR-01000872576; J-700148; Q3633495; SR-01000872576-1; (+/-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)piperidino]-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methylaminopiperidin-1-yl)-4-oxoquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-piperidyl]-4-oxoquinoline-3-carboxylic Acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)piperidino]-4-oxo-3-quinolinecarboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	389.4	C20H24FN3O4	82.1	668	0.6	28	2	8	5	"1S/C20H24FN3O4/c1-22-11-4-3-7-23(9-11)17-15(21)8-13-16(19(17)28-2)24(12-5-6-12)10-14(18(13)25)20(26)27/h8,10-12,22H,3-7,9H2,1-2H3,(H,26,27)"	CNC1CCCN(C1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F	MGQLHRYJBWGORO-UHFFFAOYSA-N
DG00951	Brodimoprim	68760	"Brodimoprim; 56518-41-3; Brodimoprima; Brodimoprime; Brodimoprimum; Ro 10-5970; 5-(4-bromo-3,5-dimethoxybenzyl)pyrimidine-2,4-diamine; Brodimoprim [INN]; 2,4-Diamino-5-(4-bromo-3,5-dimethoxybenzyl)pyrimidine; Ro 105970; UNII-V1YC7T6LLI; V1YC7T6LLI; CHEMBL31891; Bromdimoprim; Unitrim; 5-((4-Bromo-3,5-dimethoxyphenyl)methyl)-2,4-pyrimidinediamine; 2,4-Pyrimidinediamine, 5-[(4-bromo-3,5-dimethoxyphenyl)methyl]-; Brodimoprim (INN); Hyprim; 2,4-Pyrimidinediamine, 5-((4-bromo-3,5-dimethoxyphenyl)methyl)-; Brodimoprime [INN-French]; Brodimoprimum [INN-Latin]; Brodimoprima [INN-Spanish]; Ro-10-5970; EINECS 260-238-8; BRN 0760113; Brodimoprim-[d6]; 5-[(4-bromo-3,5-dimethoxyphenyl)methyl]pyrimidine-2,4-diamine; SCHEMBL49613; 5-25-13-00394 (Beilstein Handbook Reference); ZINC5824; DTXSID20205070; CHEBI:131726; 5-[(4-bromo-3,5-dimethoxy-phenyl)methyl]pyrimidine-2,4-diamine; BDBM50027970; AKOS016013929; DB13795; NCGC00238470-01; DA-04825; HY-121341; CS-0081497; FT-0663605; D07238; 518B413; Q4973047; 5-(3,5-Dimethoxy-4-bromobenzyl)-2,4-diaminopyrimidine; 2,4-diamino-5-(4-bromo-3,5-dimethoxybenzyl)-pyrimidine; 5-(4-Bromo-3,5-dimethoxy-benzyl)-pyrimidine-2,4-diamine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:131726	.	.	.	339.19	C13H15BrN4O2	96.3	296	2	20	2	6	4	"1S/C13H15BrN4O2/c1-19-9-4-7(5-10(20-2)11(9)14)3-8-6-17-13(16)18-12(8)15/h4-6H,3H2,1-2H3,(H4,15,16,17,18)"	COC1=CC(=CC(=C1Br)OC)CC2=CN=C(N=C2N)N	BFCRRLMMHNLSCP-UHFFFAOYSA-N
DG00952	Brinzolamide	68844	"Brinzolamide; 138890-62-7; Azopt; AL-4862; AL 4862; Birnzolamide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide; MFCD08067749; UNII-9451Z89515; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; 138890-50-3; CHEBI:3176; (R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; (+)-4-ETHYLAMINO-3,4-DIHYDRO-2-(METHOXY)PROPYL-2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE-1,1-DIOXIDE; (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; DSSTox_CID_25531; DSSTox_RID_80934; DSSTox_GSID_45531; 2H-Thieno[3,2-e]-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (4R)-; BZ1; 9451Z89515; C12H21N3O5S3; (4R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; Brinzolamide (BRZ); Azopt (TN); Brinzolamide (JAN/USP/INN); 3znc; NSC-760050; NCGC00016979-01; Brinzolamide [USAN:USP:INN:BAN]; Brinzolamide- Bio-X; CAS-138890-62-7; Prestwick0_000365; Prestwick1_000365; Prestwick2_000365; Prestwick3_000365; SCHEMBL24636; BSPBio_000489; 2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (R)-; MLS002153787; BIDD:GT0039; SPBio_002410; AMY372; BPBio1_000539; CHEMBL220491; GTPL6797; DTXSID6045531; BDBM10885; Brinzolamide, >=98% (HPLC); HMS1569I11; HMS2096I11; HMS2234K06; HMS3713I11; HMS3885I11; BCP22330; HY-B0588; ZINC3953037; Tox21_110722; s3178; AKOS005145708; Tox21_110722_1; AC-5277; CCG-220365; CCG-222516; DB01194; NSC 760050; NCGC00179542-03; NCGC00179542-09; NCGC00179542-10; AS-35084; BB164262; SMR001233169; AB00513824; B4258; SW197152-3; AL4862;AL 4862;AL-4862; C07760; D00652; AB00513824_06; Q411517; SR-01000838832; Q-200751; SR-01000838832-2; BRD-K74913225-001-03-3; Brinzolamide, United States Pharmacopeia (USP) Reference Standard; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2H,3H,4H-1$l^{6},7,2-thieno[3,2-e][1$l^{6},2]thiazine-6-sulfonamide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2H,3H,4H-1$l^{6},7,2-thieno[3,2-e][1,2]thiazine-6-sulfonamide; (4r)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2h-thieno[3,2-e][1,2]thiazine-6-sulfonamide-1,1-dioxide; (4R)-4-ethylamino-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[4,5-e]thiazine-6-sulfonamide; (5R)-5-ethylamino-3-(3-methoxypropyl)-2,2-dioxo-2,9-dithia-3-azabicyclo[4.3.0]nona-1(6)7-diene-8-sulfonamide; (5R)-5-Ethylamino-3-(3-methoxypropyl)-2,2-dioxo-2 6,9-dithia-3-azabicyclo[4.3.0]nona-7,10-diene-8-sulfonamide; (R)- 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-Thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-3,4-Dihydro-4-ethylamino-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide; 2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-,1,1-dioxide, (R)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3176	DB01194	.	DR0229	383.5	C12H21N3O5S3	164	598	-0.3	23	2	9	7	"1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1"	CCN[C@H]1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC	HCRKCZRJWPKOAR-JTQLQIEISA-N
DG00953	Tianeptine	68870	"Tianeptine; 66981-73-5; 72797-41-2; Tianeptine Acid; Tianeptine [INN]; 7-[(3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid; Tianeptine (INN); AKU7QFL9ZT; UNII-AKU7QFL9ZT; Stablon (TN); C21H25ClN2O4S; UNII-XV6773012I; TPI-1062; XV6773012I; 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid; JNJ-39823277; Tianeptina; 7-((3-Chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino)heptanoic acid; 7-[(3-Chloro-6,11-dihydro-6-methyl-5,5-dioxidodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid; Tianeptina [INN-Spanish]; Tianeptineacid; (S)-tianeptine; (+)-Tianeptine; (-)-Tianeptine; EINECS 276-851-9; Tianeptine, (+)-; Tianeptine, (-)-; 1159812-13-1; SCHEMBL49293; (1)-7-((3-Chloro-6,11-dihydro-6-methyldibenzo(c,f)(1,2)thiazepin-11-yl)amino)heptanoic acid S,S-dioxide; MLS006010111; GTPL7558; CHEMBL1289110; DTXSID7048295; CHEBI:91749; CHEBI:190006; CHEBI:190008; HMS3886A13; BCP10101; EX-A2724; MFCD00865376; s5087; ZB1716; AKOS015900590; AC-2091; CCG-269088; CS-0433; DB09289; KS-5099; HY-90003; K099; SMR004701247; FT-0630770; FT-0675218; 23T172; C76315; D02575; A835601; A914696; Q424260; S-16190; S-16191; Q-100759; BRD-A53077924-236-01-4; 169293-31-6; 191172-75-5; 7-[(3-chloro-6-methyl-5,5-dioxo-6,11-dihydro-5H-5lambda(6)-dibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid; 7-[(6-chloro-10-methyl-9,9-dioxo-9$l^{6}-thia-10-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3(8),4,6,11,13-hexaen-2-yl)amino]heptanoic acid; 7-[[3-chloranyl-6-methyl-5,5-bis(oxidanylidene)-11H-benzo[c][2,1]benzothiazepin-11-yl]amino]heptanoic acid; 7-{[(11S)-3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl]amino}heptanoic acid; Heptanoic acid, 7-((3-chloro-6,11-dihydro-6-methyl-5,5-dioxidodibenzo(c,f)(1,2)thiazepin-11-yl)amino)-, (+)-; Heptanoic acid, 7-((3-chloro-6,11-dihydro-6-methyl-5,5-dioxidodibenzo(c,f)(1,2)thiazepin-11-yl)amino)-, (-)-; Heptanoic acid, 7-((3-chloro-6,11-dihydro-6-methyldibenzo(c,f)(1,2)thiazepin-11-yl)amino)-, S,S-dioxide, (+)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:91749	DB09289	DR01101	DR1589	437	C21H25ClN2O4S	95.1	654	1.2	29	2	6	8	"1S/C21H25ClN2O4S/c1-24-18-9-6-5-8-16(18)21(23-13-7-3-2-4-10-20(25)26)17-12-11-15(22)14-19(17)29(24,27)28/h5-6,8-9,11-12,14,21,23H,2-4,7,10,13H2,1H3,(H,25,26)"	CN1C2=CC=CC=C2C(C3=C(S1(=O)=O)C=C(C=C3)Cl)NCCCCCCC(=O)O	JICJBGPOMZQUBB-UHFFFAOYSA-N
DG00956	Artemether	68911	"Artemether; 71963-77-4; beta-Artemether; Dihydroartemisinin methyl ether; Artemetherum; Artemisininelactol methyl ether; Methyl-dihydroartemisinine; Artemetero; Paluther; beta-Dihydroartemisinin methyl ether; SM 224; Artemetheri; Dihydroqinghaosu methyl ether; CHEBI:195280; Artenam; Artemos; Artesaph; CPD000469218; Falcidol; Gvither; Malartem; C16H26O5; (1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane; Larither; SM-224; Artemetero [INN-Spanish]; Artemetherum [INN-Latin]; methoxy(trimethyl)[ ]; 10-methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane; Dihydroquinghaosu methyl ether; HSDB 7456; NSC 665970; UNII-C7D6T3H22J; Artemeter; Artimist; Qinghao; beta artemether; Artemether [USAN:INN:BAN]; CGP 56696; NSC665970; NSC-665970; NSC-759820; .beta.-Artemether; (1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin; Dihydroartemisinin impurity g; MLS001424249; Artemether (JAN/USAN/INN); C7D6T3H22J; CHEMBL566534; GTPL9955; SCHEMBL1650501; Artemether, >=98% (HPLC); DTXSID7040651; HMS2052L09; HMS2232J21; SM224; ACT03313; AMY25769; HY-N0402; BDBM50248200; ZINC14263142; AKOS026750084; CCG-101180; DB06697; MCULE-9916057476; NC00430; 3,12-Epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-trimethyl-, (3-alpha,5a-beta,6-beta,8a-beta,9-alpha,12-beta,12aR)-, (+)-; SMR000469218; D02483; AB00698368-05; AB00698368_06; Q416199; 2-Chloro-3,5-dimethyl-4-methoxypyridinehydrochloride; Z1550675461; Artemether, United States Pharmacopeia (USP) Reference Standard; (1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0;{4,13}.0;{8,13}]hexadecane; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepine; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene; (3r,5as,6r,8as,9r,10s,12r,12ar)-decahydro-10methoxy-3,6,9-trimethyl-3,12-epoxy-12h-pyrano[4,3-j]-1,2benzodioxepin; 3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,10S,12R,12aR)-; D8Z"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:195280	DB06697	.	DR0140	298.37	C16H26O5	46.2	429	3.1	21	0	5	1	"1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1"	C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC)C	SXYIRMFQILZOAM-HVNFFKDJSA-N
DG00959	Nebivolol	71301	"Nebivolol; 99200-09-6; Narbivolol; 2,2'-Azanediylbis(1-(6-fluorochroman-2-yl)ethanol); 1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol; CHEBI:64019; Nebivololum [Latin]; 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol]; R 67145; R 065824; 118457-14-0; (-)-Nebivolol; Levonebivolol; l-Nebivolol; R65,824; R 67138;d-Nebivolol;(+)-Nebivolol; (S,R,R,R)-Nebivolol; R-65824; Nebivolol-d4; rac Nebivolol-[d8]; 2H-1-Benzopyran-2-methanol, alpha,alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro-; SCHEMBL19863; CHEMBL434394; GTPL7246; DTXSID9040556; BDBM84735; HMS3604L09; MFCD00865796; NSC_71301; PDSP1_000244; PDSP2_000243; Ro-67555; AKOS015895102; AC-1611; CCG-357228; DB04861; AS-77015; CAS_99200-09-6; DB-057766; FT-0631000; FT-0672663; FT-0672664; FT-0672665; FT-0672666; FT-0700072; R74714; 200N096; A845981; L001284; Q418130; SR-01000883933; SR-01000883933-1; 2,2-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol]; alpha,alpha'-(iminodimethylene)bis-(6-fluoro-2-chromanmethanol); 1,1'-bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2,2'-iminodiethanol; 1,1'-[bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)]-2,2'-iminodiethanol; 1-(6-fluorochroman-2-yl)-2-[[2-(6-fluorochroman-2-yl)-2-hydroxyethyl]amino]ethanol; alpha,alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol); alpha,alpha'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol]; alpha,alpha'[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol]"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:64019	DB04861	.	.	405.4	C22H25F2NO4	71	483	3	29	3	7	6	"1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2"	C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O	KOHIRBRYDXPAMZ-UHFFFAOYSA-N
DG00961	Epicillin	71392	"Epicillin; Dexacillin; Dihydroampicillin; Epicilline; Epicillinum; Epicilina; 26774-90-3; SQ 11302; UNII-3LU1L73C8Y; CHEBI:58974; 3LU1L73C8Y; SQ-11302; SQ 11,302; Epicilina [INN-Spanish]; Epicilline [INN-French]; Epicillinum [INN-Latin]; Dexacillin (TN); 6beta-[(2R)-2-amino-2-(cyclohexa-1,4-dien-1-yl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid; EINECS 248-001-7; BRN 1091831; Epicillin [USAN:INN:BAN]; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3,3-dimethyl-7-oxo-, D-; Epicillin (USAN/INN); Epitope ID:120382; SCHEMBL34063; 6-((Amino-1,4-cyclohexadien-1-ylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid (2S-(2alpha,5alpha,6beta,(S*)))-; 6-(D-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; CHEMBL2104266; GTPL10804; DTXSID60181288; ZINC4215810; DB13300; SQ11302; (2S,5R,6R)-6-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((amino-1,4-cyclohexadien-1-ylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-; D04020; Q5382578; (2S,6R)-6-((R)-2-amino-2-(cyclohexa-1,4-dienyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:58974	.	.	.	351.4	C16H21N3O4S	138	658	-1.3	24	3	6	4	"1S/C16H21N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-4,7,9-11,14H,5-6,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1"	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CCC=CC3)N)C(=O)O)C	RPBAFSBGYDKNRG-NJBDSQKTSA-N
DG00963	Enocitabine	71734	"Enocitabine; 55726-47-1; Sunrabin; NSC-239336; UNII-9YVR68W306; 9YVR68W306; NCGC00167515-01; Behenoylcytosine arabinoside; Enocitabina; Enocitabinum; Enocitabine [INN:JAN]; BHAC; Enocitabinum [INN-Latin]; Enocitabina [INN-Spanish]; Sunrabin (TN); N-(1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)docosanamide; N(sup 4)-Behenoylcytosine arabinoside; NSC 239336; BRN 0772101; N(sup 4)-Behenoyl-1-beta-D-arabinofuranosylcytosine; Enocitabine (JAN/INN); n4-behenoyl-1-beta-d-arabinofuranosylcytosine; N-(1-beta-D-Arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)docosanamide; SCHEMBL7962; DSSTox_CID_26682; DSSTox_RID_81817; DSSTox_GSID_46682; CHEMBL2106589; DTXSID6046682; SCHEMBL21051876; CHEBI:31537; AOB6809; EX-A2055; ZINC8214554; Tox21_112513; AKOS016014098; Docosanamide, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; NCGC00167515-03; N-[1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]docosanamide; CAS-55726-47-1; HY-123523; CS-0082897; D01633; 726E471; A830776; Q5379350; BRD-K32007074-001-02-9; N-{1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}docosanamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31537	.	.	.	565.8	C31H55N3O6	132	774	9.2	40	4	6	23	"1S/C31H55N3O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-27(36)32-26-22-23-34(31(39)33-26)30-29(38)28(37)25(24-35)40-30/h22-23,25,28-30,35,37-38H,2-21,24H2,1H3,(H,32,33,36,39)/t25-,28-,29+,30-/m1/s1"	CCCCCCCCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O	SAMRUMKYXPVKPA-VFKOLLTISA-N
DG00966	Secnidazole	71815	"Secnidazole; 3366-95-8; Secnidazol; Flagentyl; Secnidazolum; Secnidazolum [INN-Latin]; 1-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol; RP 14539; 1-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol; PM 185184; PM-185184; Secnidazole (Flagentyl); SYM-1219; 1-(2-Methyl-5-nitro-1-imidazolyl)-2-propanol; RP-14539; MLS000559043; 1-(2-Methyl-5-nitro-imidazol-1-yl)-propan-2-ol; NSC-759812; NCGC00095158-01; SMR000149359; RP-14539;PM-185184; DSSTox_CID_25934; DSSTox_RID_81233; DSSTox_GSID_45934; Solosec; Secnidazol [INN-Spanish]; CAS-3366-95-8; SR-01000685111; EINECS 222-134-0; alpha,2-Dimethyl-5-nitro-1H-imidazole-1-ethanol; Secnidal; Sindose; Secnil; 1-(2-Hydroxypropyl)-2-methyl-5-nitroimidazol; Secnidal (TN); Secnidazole-[d6]; Secnidazole [USAN:INN:BAN:DCF]; SYM 1219; Solosec (TN); Secnidazole anhydrous; Secnidazole hemihydrate; Ornidazole metabolite m4; Opera_ID_1811; Spectrum2_000033; Spectrum3_001956; alpha,2-Dimethyl-5-nitroimidazole-1-ethanol; Secnidazole (USAN/INN); 1-(2-Methyl-5-nitroimidazol-1-yl)-2-propanol; Imidazole-1-ethanol, alpha,2-dimethyl-5-nitro-; BSPBio_003556; MLS000759496; MLS001201813; MLS001424126; MLS006011434; SCHEMBL363924; SPECTRUM1505304; SPBio_000125; CHEMBL498847; DTXSID3045934; CHEBI:94433; KBio3_002874; CHEBI:140628; HMS1922B12; HMS2051C20; HMS2090N15; HMS2231G11; HMS3369N08; HMS3393C20; HMS3656G14; HMS3714I05; Pharmakon1600-01505304; BCP12459; HY-B1118; Tox21_111457; BBL010784; BDBM50349330; CCG-39993; MFCD00864656; NSC759812; STK590474; AKOS005512552; AKOS025149490; Tox21_111457_1; CCG-100896; CS-4641; DB12834; KS-1191; MCULE-8220679702; NC00146; NSC 759812; SB19197; NCGC00095158-02; NCGC00095158-03; NCGC00095158-04; NCGC00095158-05; NCGC00095158-08; AC-12065; H737; SBI-0207037.P001; Secnidazole 100 microg/mL in Acetonitrile; DB-000688; FT-0601624; S2537; SW197526-3; D07353; J10074; 1-(2- hydroxypropyl)-2-methyl-5-nitroimidazole; 1H-Imidazole-1-ethanol, a,2-dimethyl-5-nitro-; AB00456738-13; AB00456738-15; AB00456738_16; AB00456738_17; 366S958; A821901; J-019291; Q4413249; SR-01000685111-4; SR-01000685111-6; SR-01000685111-7; BRD-A70083328-001-02-9; BRD-A70083328-001-12-8; 1-(2-methyl-5-nitro-1H-imidazol-1-yl) propan-2- ol; 1-(2-Methyl-5-nitro-imidazol-1-yl)propan-2-ol;Secnidazole"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:94433	DB12834	.	DR2431	185.18	C7H11N3O3	83.9	194	0.2	13	1	4	2	"1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3"	CC1=NC=C(N1CC(C)O)[N+](=O)[O-]	KPQZUUQMTUIKBP-UHFFFAOYSA-N
DG00974	Nonoxynol-9	72385	"Nonoxynol-9; Nonoxynol 9; 14409-72-4; Delfen; 26571-11-9; Tergitol NP-9; PEG-9 Nonyl phenyl ether; Tergitol NP9; Nonaethylene glycol nonylphenyl ether; Nonylphenol octa(oxyethylene) ethanol; Nonaethylene glycol mono(nonylphenyl) ether; NONOXINOL-9; Nonylphenoxypolyethoxyethanol; Polyoxyethylene (9) nonyl phenyl ether; 26-(4-nonylphenoxy)-3,6,9,12,15,18,21,24-octaoxahexacosan-1-ol; 26-(Nonylphenoxy)-3,6,9,12,15,18,21,24-octaoxahexacosan-1-ol; 2-[2-[2-[2-[2-[2-[2-[2-[2-(4-nonylphenoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol; CHEBI:53775; NSC-758941; p-Nonylphenyl polyethylene glycol ether; Conceptrol; Nonoxynol, n=9; N-9; Intercept; Semicid; 3,6,9,12,15,18,21,24-Octaoxahexacosan-1-ol, 26-(4-nonylphenoxy)-; 2-[2-[2-[2-[2-[2-[2-[2-[2-(4-nonylphenoxy)ethoxy]ethoxy]ethoxy]ethoxy]-ethoxy]ethoxy]ethoxy]ethoxy]ethanol; Staycept; Emko; Today Sponge; Nonoxinolum 9; HSDB 8094; Gynol II; C-Film; Norfox np-9; Tergitol TP-9; Nonoxynol-9.5; EINECS 247-816-5; Conco NI-90; K-Y plus nonoxynol-9; Spectrum2_001247; Spectrum3_001946; 3,6,9,12,15,18,21,24-Octaoxahexacosan-1-ol, 26-(nonylphenoxy)-; ALOSETRONHYDROCHLORIDE; CHEMBL1410; SCHEMBL36844; BSPBio_003546; SPECTRUM1505292; SPBio_001154; Dowfax 9N9, Neutronyx 611; CO-630SP; KBio3_002833; DTXSID00858720; HMS2093O22; Pharmakon1600-01505292; ZINC8214629; BDBM50442874; CCG-39124; NSC758941; AKOS015910808; DB06804; NSC 758941; NCGC00095907-02; NCGC00095907-03; N 9; SBI-0206761.P001; Polyethylene glycol 450 nonyl phenyl ether; AB01563056_01; Q420039; SR-05000001885; J-016227; Q-201490; SR-05000001885-1; BRD-K88625236-001-01-8; 1-(4-nonylphenyl)-1,4,7,10,13,16,19,22,25-nonaoxaheptacosan-27-ol; N9"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:53775	DB06804	.	.	616.8	C33H60O10	103	520	4.6	43	1	10	35	"1S/C33H60O10/c1-2-3-4-5-6-7-8-9-32-10-12-33(13-11-32)43-31-30-42-29-28-41-27-26-40-25-24-39-23-22-38-21-20-37-19-18-36-17-16-35-15-14-34/h10-13,34H,2-9,14-31H2,1H3"	CCCCCCCCCC1=CC=C(C=C1)OCCOCCOCCOCCOCCOCCOCCOCCOCCO	FBWNMEQMRUMQSO-UHFFFAOYSA-N
DG00975	Grepafloxacin	72474	"Grepafloxacin; 119914-60-2; Raxar; 146863-02-7; OPC-17116; 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; CHEMBL583; Tomefloxacin; dl-Grepafloxacin; CHEBI:5543; 1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; OPC 17116; 1-CYCLOPROPYL-6-FLUORO-5-METHYL-7-(3-METHYLPIPERAZIN-1-YL)-4-OXO-QUINO LINE-3-CARBOXYLIC ACID; Grepafloxacin (unspecified); 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylicacid; CCRIS 7284; NCGC00167527-01; Grepafloxacin [INN:BAN]; dl-Grepafloxacin; PC 17116; PC-17116; SCHEMBL34155; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-; DTXSID2048321; GTPL10818; HMS3713L05; BCP23880; HY-A0147; OPC17116; RKL10071; BDBM50117924; AKOS016013941; DB00365; 3-Quinolinecarboxylic acid, 1,4-dihydro-1-cyclopropyl-6-fluoro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-; CS-0017472; FT-0703068; Q414846; SR-01000872592; SR-01000872592-1; (+/-)-3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-; 1-Cyclopropyl-6-fluoro-5-methyl-7-(3-methyl-piperazin-1-yl)-4-oxo-1,4,4a,8a-tetrahydro-quinoline-3-carboxylic acid (Grepafloxacin); 1-Cyclopropyl-6-fluoro-5-methyl-7-(3-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-7-(3-methyl-1-piperazinyl)-5-methyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-7-(3-methyl-1-piperazinyl)5-methyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:5543	DB00365	DR00638	DR0790	359.4	C19H22FN3O3	72.9	636	-0.2	26	2	7	3	"1S/C19H22FN3O3/c1-10-8-22(6-5-21-10)15-7-14-16(11(2)17(15)20)18(24)13(19(25)26)9-23(14)12-3-4-12/h7,9-10,12,21H,3-6,8H2,1-2H3,(H,25,26)"	CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F	AIJTTZAVMXIJGM-UHFFFAOYSA-N
DG00976	Atovaquone	74989	"ATOVAQUONE; 95233-18-4; Mepron; Wellvone; Acuvel; Atavaquone; 566C80; 94015-53-9; Mepron (antipneumocystic); cis-Atovaquone; 137732-39-9; BW 566C; 566C; C22H19ClO3; 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione; Atovaquone (Atavaquone); 2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; UNII-Y883P1Z2LT; UNII-F1W7QUV0KI; F1W7QUV0KI; 2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 2-(TRANS-4-(4-CHLOROPHENYL)CYCLOHEXYL)-3-HYDROXY-1,4-NAPHTHALENEDIONE; Y883P1Z2LT; CHEBI:575568; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione; NSC-759582; NCGC00016961-01; CAS-95233-18-4; 2-[trans-4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione; DSSTox_CID_2629; trans-2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione; DSSTox_RID_76664; DSSTox_GSID_22629; 2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione; 2-[trans-4-(p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 1,4-Naphthalenedione, 2-[cis-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-; 2-((1r,4r)-4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione; DRG-0084; BW 566C-80; Mepron (TN); BW-A 566C; HSDB 7083; SR-05000001438; BW-566C-80; CRL-8131 & Atovaquone; 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; Atovaquone & Interleukin 12; 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-naphthalene-1,4-dione; 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione; cis-2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; Cis-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 1,4-Naphthalenedione, 2-(cis-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-; 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione; trans-2-(4-(4-chlorophenyl) cyclohexyl)-3-hydroxynaphthalene-1,4-dione; ATO & IL-12; Atovaquone [USAN:USP:INN:BAN]; Atovaquone-[d5]; Atovaquone- Bio-X; BW 566C80; Spectrum_001743; starbld0018905; SpecPlus_000686; Prestwick0_000534; Prestwick1_000534; Prestwick2_000534; Prestwick3_000534; Spectrum2_001665; Spectrum3_000991; Spectrum4_001117; Spectrum5_001382; Atovaquone EP Impurity B; SCHEMBL21694; SCHEMBL21695; Atovaquone (JAN/USP/INN); BSPBio_000547; BSPBio_002681; KBioGR_001594; KBioSS_002223; Atovaquone Related Compound A; MLS002153863; BIDD:GT0849; DivK1c_006782; SCHEMBL637069; SPECTRUM1504210; SPBio_001849; SPBio_002468; BPBio1_000603; CHEMBL222334; CHEMBL471792; CHEMBL519462; GTPL9695; SCHEMBL1542719; SCHEMBL1649508; SCHEMBL9975142; SCHEMBL9975229; Atovaquone, >=98% (HPLC); CIS-ATOVAQUONE (RACEMIC); DTXSID7022629; CHEBI:95346; KBio1_001726; KBio2_002223; KBio2_004791; KBio2_007359; KBio3_001901; DTXSID20916694; BDBM192009; HMS1569L09; HMS1922F19; HMS2089M14; HMS2093C10; HMS2096L09; HMS2235N08; HMS3369N09; HMS3651N20; HMS3713L09; Pharmakon1600-01504210; AMY15339; BCP09477; Tox21_110714; 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxy-naphthalene-1,2-dione; Atovaquone related compound A [USP]; CCG-39090; FD7252; MFCD00889188; NSC759582; s3079; STK636160; trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; ZINC12504271; 1,4-Naphthalenedione, 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-, trans-; 1,4-Naphthalenedione, 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-; 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-dihydronaphthalene-1,4-dione; AKOS005567953; AKOS015895691; AKOS015961933; Tox21_110714_1; ZINC100017856; ZINC100345537; ZINC116473771; ZINC299873031; BW-556C-80; CCG-220534; DB01117; MCULE-7318126574; NSC 759582; NCGC00016961-02; NCGC00016961-03; NCGC00016961-04; NCGC00016961-06; NCGC00016961-07; NCGC00016961-11; NCGC00095113-01; NCGC00095113-02; AC-30251; AS-12809; Atovaquone 100 microg/mL in Acetonitrile; BA164228; HY-13832; SMR001233220; SBI-0052893.P002; AB00513855; FT-0602868; SW219222-1; A13708; C06835; D00236; F18448; J90007; AB00053222-03; AB00053222_04; AB00053222_05; 233A184; A853147; Q418179; SR-05000001438-1; SR-05000001438-2; SR-05000001438-4; SR-05000001438-5; Z1541632806; 2-[4-(4-chlorophenyl)cyclohexy]-3-hydroxy-1,4-naphthoquinone; 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-napthoquinone; 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1.4-naphthoquinone; 2-Hydroxy-3-[4-(4-chlorophenyl)cyclohexyl]-1,4-naphthoquinone; 3-[4-(p-chlorophenyl)cyclohexyl]-4-hydroxy-1,2-naphthoquinone; 1,4-Naphthalenedione, 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-; 2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxynaphthoquinone, trans-; 3-[4-(4-Chlorophenyl)cyclohexyl]-4-hydroxy-1,2-naphthalenedione; 2-(cis-4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthalenedione; cis -2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:575568	DB01117	.	DR0158	366.8	C22H19ClO3	54.4	595	5.2	26	1	3	2	"1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,24H,5-8H2"	C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O	BSJMWHQBCZFXBR-UHFFFAOYSA-N
DG00977	Cevimeline	83898	"Cevimeline; 107233-08-9; Cevimeline (INN); C10H17NOS; cevimeline trans-sulfoxide; BIDD:GT0265; SCHEMBL188381; CHEMBL1201267; DTXSID2023777; ZINC10163; AKOS025294043; CS-0397; AS-56166; HY-70020; X7254; D07667; UNII-K9V0CDQ56E component WUTYZMFRCNBCHQ-PSASIEDQSA-N; cis-2-Methyl-1'-azaspiro[[1,3]oxathiolane-5,3'-bicyclo[2.2.2]octane]; (3R,2'R)-2'-Methylspiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane]"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00185	.	.	199.32	C10H17NOS	37.8	215	1.5	13	0	3	0	"1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1"	C[C@@H]1O[C@]2(CN3CCC2CC3)CS1	WUTYZMFRCNBCHQ-PSASIEDQSA-N
DG00979	Cefacetrile	91562	"Cefacetrile; Cephacetrile; 10206-21-0; Celospor; Cefacetrilum [INN-Latin]; Cefacetrilo [INN-Spanish]; Cefacetril; 7-Cyanacetylamino-cephalosporansaeure; UNII-FDM21QQ344; (6R,7R)-3-(acetyloxymethyl)-7-[(2-cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; FDM21QQ344; (6R,7R)-3-(Acetoxymethyl)-7-(2-cyanoacetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefacetrilo; Cefacetrilum; cephacetril; Cefacetrile (INN); Cefacetrile [INN:BAN]; EINECS 233-508-8; Vetrimast; Vetrimast [veterinary] (TN); (6R,7R)-3-Acetoxymethyl-7-(2-cyanacetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; 7-(2-Cyanacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carboxylat acetat (ester); SCHEMBL141792; CHEMBL2110602; DTXSID0022779; CHEBI:135437; ZINC3830496; 2,4,6-TRIMETHOXYCINNAMICACID; AKOS030240997; DB01414; NCGC00510891-01; (6R,7R)-3-[(acetyloxy)methyl]-7-[(cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid, 3-[(acetyloxy)methyl]-7-[(2-cyanoacetyl)amino]-8-oxo-, (6R,7R)-; Cefacetrile 100 microg/mL in Acetonitrile; D07629; J-000558; Q4919176; (6R,7R)-3-[(acetyloxy)methyl]-7-(2-cyanoacetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:135437	DB01414	.	.	339.33	C13H13N3O6S	162	664	-0.5	23	2	8	6	"1S/C13H13N3O6S/c1-6(17)22-4-7-5-23-12-9(15-8(18)2-3-14)11(19)16(12)10(7)13(20)21/h9,12H,2,4-5H2,1H3,(H,15,18)(H,20,21)/t9-,12-/m1/s1"	CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC#N)SC1)C(=O)O	RRYMAQUWDLIUPV-BXKDBHETSA-N
DG00980	Gliquidone	91610	"Gliquidone; 33342-05-1; Glurenorm; Gliquidonum; ARDF 26; C27H33N3O6S; UNII-C7C2QDD75P; 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxoisoquinolin-2-yl)ethyl]phenyl]sulfonylurea; Beglynor; MFCD00631870; C7C2QDD75P; ARDF-26; N-(Cyclohexylcarbamoyl)-4-(2-(7-methoxy-4,4-dimethyl-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)benzenesulfonamide; NCGC00016819-01; Gliquidona; CAS-33342-05-1; DSSTox_CID_3096; DSSTox_RID_76873; DSSTox_GSID_23096; Gliquidonum [INN-Latin]; 3-Cyclohexyl-1-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-isoquinolin-2-yl)ethyl]phenyl]sulfonyl-urea; Gliquidona [INN-Spanish]; ARDF 26 SE; AR-DF 26; Glurenorm (TN); 1-cyclohexyl-3-({4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]benzene}sulfonyl)urea; Gliquidone (INN); SMR000685793; Gliquidone [INN:BAN]; EINECS 251-463-2; BRN 1559726; Gliquidon; Gliquidone,(S); Gliquidone, 98%; Prestwick0_000991; Prestwick1_000991; Prestwick2_000991; Prestwick3_000991; Oprea1_069443; SCHEMBL37769; BSPBio_001081; 1-Cyclohexyl-3-((p-(2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isoquinolyl)ethyl)phenyl)sulfonyl)urea; 1-Cyclohexyl-3-(p-beta-(4,4-dimethyl-2-methoxy-1,3-(2H,4H)-isoquinolinedione-2-yl)phenethyl)sulfonylurea; Benzenesulfonamide, N-((cyclohexylamino)carbonyl)-4-(2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isoquinolinyl)ethyl)-; MLS000881123; MLS000881174; MLS002154087; SPBio_002972; BPBio1_001191; CHEMBL383634; DTXSID4023096; CHEBI:93416; HMS1571G03; HMS2098G03; HMS2964J06; HMS3652O05; HMS3715G03; ACT06290; BCP11927; HY-B1114; ZINC1482077; Tox21_110629; BDBM50248247; AKOS001037880; Tox21_110629_1; CCG-220991; CM14378; CS-4646; DB01251; KS-5239; MCULE-6775445815; NCGC00016819-02; NCGC00016819-03; NCGC00016819-05; NCGC00016819-06; NCGC00179315-01; AC-23356; N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide; N-(cyclohexylcarbamoyl)-4-(2-(7-methoxy-; AB00513989; FT-0630570; G0332; S3151; SW197285-3; D02430; J10245; T72318; 4,4-dimethyl-1,3-dioxo-3,4-dihydroisoquinolin; AB00513989_07; 342G051; A821736; SR-01000833866; J-019153; Q5569924; SR-01000833866-2; BRD-K80396088-001-03-9; 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea; 1-Cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolyl)ethyl]phenyl]sulfonyl-urea;Gliquidone; 3-cyclohexyl-1-({4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]benzene}sulfonyl)urea; N-cyclohexylcarbamoyl-4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-1,2,3,4- tetrahydroisoquinolin-2-yl)ethyl]benzenesulfonamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:93416	DB01251	DR00405	DR0779	527.6	C27H33N3O6S	130	948	4.6	37	2	6	7	"1S/C27H33N3O6S/c1-27(2)23-14-11-20(36-3)17-22(23)24(31)30(25(27)32)16-15-18-9-12-21(13-10-18)37(34,35)29-26(33)28-19-7-5-4-6-8-19/h9-14,17,19H,4-8,15-16H2,1-3H3,(H2,28,29,33)"	CC1(C2=C(C=C(C=C2)OC)C(=O)N(C1=O)CCC3=CC=C(C=C3)S(=O)(=O)NC(=O)NC4CCCCC4)C	LLJFMFZYVVLQKT-UHFFFAOYSA-N
DG00981	Hydroxyflutamide	91649	"Hydroxyflutamide; 52806-53-8; 2-hydroxyflutamide; 2-Hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide; Hydroxyniphtholide; hydroxy-flutamide; 2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; Sch 16423; Hydroxy Flutamide; 2-Hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)-phenyl)propanamide; UNII-31D90UKP5Y; CHEMBL491; 31D90UKP5Y; Propanamide, 2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-; MFCD00563126; OH-flutamide; DSSTox_CID_13562; DSSTox_RID_79084; DSSTox_GSID_33562; HFT; Hydroxyflutamid; Liproca Depot; Propanamide, 2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-; SMR001227196; 2-Hydroxy-flutamide; CAS-52806-53-8; 2-hydroxy Flutamide; 2ax6; .alpha.-hydroxyflutamide; alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-lactotoluidide; 2-HOF; cid_91649; MLS001061267; MLS006011954; BIDD:ER0519; GTPL2862; SCHEMBL3079778; DTXSID8033562; SCHEMBL19117358; BDBM35909; HMS3039A05; BCP12495; Hydroxyflutamide, >=98% (HPLC); ZINC4655055; Tox21_201204; Tox21_303659; Hydroxyflutamide (Hydroxyniphtholide); AKOS007930906; CS-W013988; HY-W013272; MCULE-6726517919; SB17029; s10360; NCGC00091014-01; NCGC00091014-02; NCGC00091014-03; NCGC00091014-04; NCGC00091014-06; NCGC00257382-01; NCGC00258756-01; BS-17460; A1728; FT-0627147; H1600; X6072; A21118; Q15633976; 2-Hydroxy-4'-nitro-3'-(trifluoromethyl)isobutyranilide; Z1617901126; 2-Hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; 2-Hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide (hydroxy flutamide); 2-Hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide(Hydroxyflutamide); 2-Hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (2-Hydroxyflutamide); 2-HYDROXY-2-METHYL-N-(4-NITRO-3-(TRIFLUOROMETHYL)PHENYL)PROPANAMIDE; HYDROXYNIPHTHOLIDE"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	292.21	C11H11F3N2O4	95.2	392	2.2	20	2	7	2	"1S/C11H11F3N2O4/c1-10(2,18)9(17)15-6-3-4-8(16(19)20)7(5-6)11(12,13)14/h3-5,18H,1-2H3,(H,15,17)"	CC(C)(C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F)O	YPQLFJODEKMJEF-UHFFFAOYSA-N
DG00982	Argatroban	92722	"Argatroban; 74863-84-6; Argatroban anhydrous; MCI-9038; MD-805; Argipidine; (2R,4R)-1-((2S)-5-Guanidino-2-(3-methyl-1,2,3,4-tetrahydroquinoline-8-sulfonamido)pentanoyl)-4-methylpiperidine-2-carboxylic acid; GN-1600; C23H36N6O5S; Argatroban Injection; DK-7419; CHEMBL1166; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; 74863-84-6 (anhydrous); Argatroban In Sodium Chloride; Argatroban [INN:JAN]; (2R,4R)-1-((2S)-5-Guanidino-2-(3-methyl-1,2,3,4-tetrahydroquinoline-8-sulfonamido)pentanoyl)-4-methy; Argatrobanum; Argatrobanum [Latin]; GN1600; 121785-71-5; (2R,4R)-1-[(2S)-5-[(diaminomethylidene)amino]-2-[(3R)-3-methyl-1,2,3,4-tetrahydroquinoline-8-sulfonamido]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-4-methyl-1-(((3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonyl)-L-arginyl)piperidine-2-carboxylic acid; SMR000466348; SR-05000001529; (2R,4R)-1-[(2S)-5-[(Aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic Acid; (2R,4R)-4-Methyl-1-((S)-N(sup 2)-(((RS)-1,2,3,4-tetrahydro-3-methyl-8-quinolyl)sulfonyl)arginyl)pipecolic acid; (2R,4R)-4-Methyl-1-[N-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl]-2-piperidinecarboxylic acid; MLS000759461; MLS001424093; MLS006010033; GTPL6385; SCHEMBL1145308; SCHEMBL20567702; CHEBI:94385; HSDB 8488; HMS2051N07; HMS2090L12; HMS3713D22; BCP06831; EX-A4276; HY-B0375; 2858AH; BDBM50038001; s2069; AKOS015919612; CCG-100933; CCG-207885; DB00278; NC00183; NCGC00166413-01; NCGC00166413-03; 2-Piperidinecarboxylic acid, 1-((2S)-5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-, (2R,4R)-; 2-Piperidinecarboxylic acid, 1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-; AS-14191; K280; SMR004624627; C72625; AB00639932-04; AB01275532-01; AB01275532_02; 863A846; SR-01000759392; J-500992; J-500996; SR-01000759392-4; SR-05000001529-1; SR-05000001529-2; BRD-A48261811-001-08-1; Q27074501; (2R,4R)-1-((2S)-5-guanidino-2-(3-methyl-1,2,3,4-tetrahydroquinoline; (2R,4R)-1-((S)-5-(diaminomethyleneamino)-2-(3-methyl-1,2,3,4-tetrahydroquinoline-8-sulfonamido)pentanoyl)-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]-1-oxopentyl]-4-methyl-2-piperidinecarboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3R)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methyl-pipe ridine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(DIAMINOMETHYLIDENEAMINO)-2-[[(3R)-3-METHYL-1,2,3,4-TETRAHYDROQUINOLIN-8-YL]SULFONYLAMINO]PENTANOYL]-4-METHYL-PIPERIDINE-2-CARBOXYLIC ACID; (2R,4R)-1-[(2S)-5-guanidino-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methyl-piperidine-2-carboxylic acid; (2R,4R)-1-[(S)-5-Guanidino-2-(3-methyl-1,2,3,4-tetrahydro-quinoline-8-sulfonylamino)-pentanoyl]-4-methyl-piperidine-2-carboxylic acid; (2R,4S)-1-[5-Guanidino-2-(3-methyl-1,2,3,4-tetrahydro-quinoline-8-sulfonylamino)-pentanoyl]-4-methyl-piperidine-2-carboxylic acid; (2S,4S)-1-[5-Guanidino-2-(3-methyl-1,2,3,4-tetrahydro-quinoline-8-sulfonylamino)-pentanoyl]-4-methyl-piperidine-2-carboxylic acid; (S)-1-[5-Guanidino-2-(3-methyl-1,2,3,4-tetrahydro-quinoline-8-sulfonylamino)-pentanoyl]-4-methyl-piperidine-2-carboxylic acid; 1-[(2R,3S)-5-Guanidino-2-(3-methyl-1,2,3,4-tetrahydro-quinoline-8-sulfonylamino)-pentanoyl]-4-methyl-piperidine-2-carboxylic acid; 1-[5-Guanidino-2-(3-methyl-1,2,3,4-tetrahydro-quinoline-8-sulfonylamino)-pentanoyl]-4-methyl-piperidine-2-carboxylic acid; 1-[5-Guanidino-2-(3-methyl-1,2,3,4-tetrahydro-quinoline-8-sulfonylamino)-pentanoyl]-4-methyl-piperidine-2-carboxylic acid (Argatroban)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:94385	DB00278	.	DR0132	508.6	C23H36N6O5S	189	887	1.3	35	5	8	9	"1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15 ,17+,18-/m1/s1"	C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C	KXNPVXPOPUZYGB-IOVMHBDKSA-N
DG00983	Propicillin	92879	"Propicillin; propicilline; 551-27-9; Propicilina; Propicillinum; UNII-8X1R260V33; (1-Phenoxypropyl)penicillin; CHEBI:52429; 8X1R260V33; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenoxybutanoylamino)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxybutanoyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Propicillin potassium salt; 6beta-(2-phenoxybutanamido)-2,2-dimethylpenam-3alpha-carboxylic acid; Propicilina [INN-Spanish]; Propicilline [INN-French]; Propicillinum [INN-Latin]; Propicillin [INN:BAN:DCF]; EINECS 208-995-5; Propicillin (BAN); NCGC00160673-01; DSSTox_CID_26291; DSSTox_RID_81517; DSSTox_GSID_46291; SCHEMBL35608; .alpha.-phenoxypropylpenicillin; CHEMBL2105612; DTXSID3046291; Tox21_111976; DB13660; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(2-phenoxybutanamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; CAS-551-27-9; D08438"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:52429	.	DR00720	.	378.4	C18H22N2O5S	121	590	2.7	26	2	6	6	"1S/C18H22N2O5S/c1-4-11(25-10-8-6-5-7-9-10)14(21)19-12-15(22)20-13(17(23)24)18(2,3)26-16(12)20/h5-9,11-13,16H,4H2,1-3H3,(H,19,21)(H,23,24)/t11 ,12-,13+,16-/m1/s1"	CCC(C(=O)N[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)O)OC3=CC=CC=C3	HOCWPKXKMNXINF-XQERAMJGSA-N
DG00984	2-hydroxy-5-fluoropyrimidine	101498	"2022-78-8; 5-fluoropyrimidin-2-ol; 5-Fluoropyrimidin-2(1H)-one; 5-Fluoro-2-hydroxypyrimidine; 5-Fluoropyrimidin-2-one; 2-Hydroxy-5-fluoropyrimidine; 214290-48-9; 5-fluoro-1H-pyrimidin-2-one; 5-Fluoro-2-pyrimidinol; 2(1H)-Pyrimidinone, 5-fluoro-; 5-fluoro-2-pyrimidone; UNII-1VXI7T1BI5; 5-fluoro-pyrimidin-2-ol; 1VXI7T1BI5; SMR000449315; 2-Pyrimidinol, 5-fluoro- (9CI); 5-FP; NSC529069; NSC 529069; 5-fluoropyrimid-2-one; 5-Fluro-2-pyrimidone; 5-fluoropyrimidine-2-one; 2-Pyrimidinol, 5-fluoro-; MLS000758251; MLS001424161; SCHEMBL309070; AMY113; CHEMBL4303165; 2-Pyrimidinol,5-fluoro-(9CI); DTXSID90174067; CHEBI:125539; HMS2051J14; HMS3393J14; 0373AB; 5-Fluoro-2-hydroxypyrimidine, 97%; MFCD00223678; ZB1820; ZINC16697945; 5-fluoro-1,2-dihydropyrimidin-2-one; AKOS006347205; AKOS016004426; CCG-101035; CS-W008541; GS-6508; NC00285; NSC-529069; SB56948; SB57746; AC-26618; FT-0649189; 2(1H)-Pyrimidinone, 5-fluoro- (8CI)(9CI); A879769; J-013132; Q27216155"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:125539	DB01357	.	.	114.08	C4H3FN2O	41.5	173	-0.4	8	1	2	0	"1S/C4H3FN2O/c5-3-1-6-4(8)7-2-3/h1-2H,(H,6,7,8)"	C1=C(C=NC(=O)N1)F	HPABFFGQPLJKBP-UHFFFAOYSA-N
DG00985	Fotemustine	104799	"Fotemustine; 92118-27-9; Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate; Muphoran; Mustophorane; Fotemustina; Servier-10036; S 10036; Mustoforan; UNII-UPB2NN83AR; UPB2NN83AR; S-10036; UNII-QY93P3GN94; QY93P3GN94; (+-)-Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate; MFCD00866278; Fotemustinum [Latin]; Diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate; Fotemustina [Spanish]; Fotemustinum; C9H19ClN3O5P; SMR002529685; CCRIS 6337; Fotemustine [INN:BAN]; HSDB 7762; Muphoran (TN); Fotemustine, (+)-; Fotemustine, (-)-; 1-(2-chloroethyl)-3-(1-diethoxyphosphorylethyl)-1-nitrosourea; Fotemustine (INN/BAN); SCHEMBL8880; MLS006010211; MLS006010716; CHEMBL549386; 6-Amino-3-hydroxy(1h)indazole; Fotemustine, >=98% (HPLC); DTXSID80869091; CHEBI:131852; BCP07342; HY-B0733; AKOS015920275; DS-1395; P-[1-[[[(2-Chloroethyl)nitrosoamino]carbonyl]amino]ethyl]-phosphonic acid diethyl ester; Phosphonic acid, (1-((((2-chloroethyl)nitrosoamino)carbonyl)amino)ethyl)-, diethyl ester; NCGC00346829-01; NCGC00346829-03; K679; DB-057290; FT-0630979; D07255; 118F279; A844148; SR-01000944936; Q1439555; SR-01000944936-1; diethyl 1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate; 1-(2-chloroethyl)-3-(1-diethoxyphosphorylethyl)-1-nitroso-urea; diethyl (1-{[(2-chloroethyl)(nitroso)carbamoyl]amino}ethyl)phosphonate; diethyl (1-{[N-(2-chloroethyl)-N'-oxohydrazinecarbonyl]amino}ethyl)phosphonate; 191219-77-9; 191220-84-5; Muphoran; ; ; Mustoforan; ; ; S-10036; ; ; 1-(2-Chloroethyl)-3-(1-diethoxyphosphorylethyl)-1-nitrosourea; Phosphonic acid, (1-((((2-chloroethyl)nitrosoamino)carbonyl)amino)ethyl)-, diethyl ester, (+)-; Phosphonic acid, (1-((((2-chloroethyl)nitrosoamino)carbonyl)amino)ethyl)-, diethyl ester, (-)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:131852	DB04106	.	.	315.69	C9H19ClN3O5P	97.3	334	0.9	19	1	6	8	"1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14)"	CCOP(=O)(C(C)NC(=O)N(CCCl)N=O)OCC	YAKWPXVTIGTRJH-UHFFFAOYSA-N
DG00988	Dihydroergocristine	107715	"Dihydroergocristine; 17479-19-5; 9,10-Dihydroergocristine; DHEC; UNII-05D48LUM4Z; GNF-Pf-3462; Ergocristine, dihydro-; Dihydroergocristin; 05D48LUM4Z; CHEMBL601773; CHEBI:59912; NCGC00017401-02; DSSTox_CID_26322; DSSTox_RID_81538; DSSTox_GSID_46322; (6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide; (10alphaH)-5'alpha-benzyl-12'-hydroxy-3',6',18-trioxo-2'-(propan-2-yl)-9,10-dihydroergotaman; CAS-17479-19-5; Ergocristine, 9,10-dihydro-; CCRIS 4027; EINECS 241-493-4; SR-01000075381; NCGC00163163-01; Prestwick0_000562; Prestwick1_000562; Prestwick2_000562; Prestwick3_000562; Dihydroergocristine (BAN); Lopac0_000409; BSPBio_000344; SCHEMBL146691; SPBio_002563; BPBio1_000380; DTXSID3046322; HMS2090H10; ZINC3995616; Tox21_112021; Tox21_113115; BDBM50390992; 5'-Benzyl-9,10-dihydro-12'-hydroxy-2'-isopropyl-3',6',18-ergotamantrion; CCG-204502; DB13345; 9,10-Dihydro-12'-hydroxy-2'-isopropyl-5'alpha-benzylergotaman-3',6',18-trion; 9,10-Dihydro-12'-hydroxy-2'-isopropyl-5'alpha-benzylergotaman-3',6',18-trion [IUPAC]; NCGC00017401-06; NCGC00017401-07; NCGC00017401-08; NCGC00017401-09; NCGC00017401-10; NCGC00023148-04; NCGC00023148-05; NCGC00023148-06; Erotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-(1-methylethyl)-5'-(phenylmethyl)-, (5'alpha,10alpha)-; D07834; Q5276428; SR-01000075381-5; BRD-K97440753-066-03-3; UNII-34HPE9Z8IP component DEQITUUQPICUMR-HJPBWRTMSA-N"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:59912	.	.	.	611.7	C35H41N5O5	118	1210	3.3	45	3	6	5	"1S/C35H41N5O5/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34/h4-7,9-12,18,20,23,25,27-29,36,44H,8,13-17,19H2,1-3H3,(H,37,41)/t23-,25-,27-,28+,29+,34-,35+/m1/s1"	CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C	DEQITUUQPICUMR-HJPBWRTMSA-N
DG00989	Fingolimod	107970	"Fingolimod; 162359-55-9; 2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; 2-Amino-2-(4-octylphenethyl)propane-1,3-diol; 2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol; UNII-3QN8BYN5QF; 2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propandiol; Fingolimod [INN]; 1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-; Gilenya (TN); 3QN8BYN5QF; CHEMBL314854; CHEBI:63115; Fingolimod (INN); 1,3-Propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-; 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol; C19H33NO2; FTY-720A; 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol; fingolimodum; FingoliMod Base; Fingolimod- Bio-X; SCHEMBL7445; 2-(4-octylphenylethyl)-2-aminopropane-1,3-diol; GTPL2407; DTXSID40167363; HMS3743O13; AMY22173; BCP05969; ZINC1542002; 3674AH; BDBM50158336; NSC755643; s5950; STL445699; AKOS015999594; DB05286; DB08868; NSC-755643; NCGC00188399-01; NCGC00188399-03; NCGC00188399-04; NCGC00188399-06; NCGC00188399-16; AC-25899; AS-68987; BF164460; HY-11063; DB-064455; FT-0660847; 2-(4-octylphenethyl)-2-aminopropane-1,3-diol; D70458; 2-amino-2-(4-octylphenyl)ethylpropane-1,3-diol; Q425137; 2-amino-2-hydroxymethyl-4-(4-(octyl)phenyl)butanol; BRD-K88025533-003-01-7; 2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63115	DB08868	.	DR0696	307.5	C19H33NO2	66.5	258	4.2	22	3	3	12	"1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3"	CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N	KKGQTZUTZRNORY-UHFFFAOYSA-N
DG00994	Pramipexole	119570	"Pramipexole; 104632-26-0; (-)-Pramipexole; Sifrol; Mirapexin; Pramipexol; (S)-N6-Propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine; (S)-Pramipexole; Pramipexolum; Mirapex; SUD919CL2Y; U-98528E; SND 919; (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole; (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; UNII-83619PEU5T; SND-919; Pramipexole Teva; PRAMIPEXOLE HCl; CHEBI:8356; CHEMBL301265; 83619PEU5T; 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N(sup 6)-propyl-, (S)-; PRAMIPEXOLE HYDROCHLORIDE; NCGC00167441-01; Oprymea; 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (6S)-; (6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; DSSTox_CID_3496; DSSTox_RID_77054; DSSTox_GSID_23496; Pramipexol [Spanish]; Pramipexolum [Latin]; SND-919CL2Y; (S)-Pramipexole Dihydrochloride; SMR000449298; CAS-104632-26-0; NSC-760426; SR-01000763219; Pramipexole (USAN/INN); (S)-N6-Propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine; SUD 919CL2Y; Pramipexole [USAN:INN:BAN]; MFCD00869076; (-) Pramipexole; Pramipexole (Mirapex); Spectrum_001838; 111GE001; SpecPlus_000820; 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (S)-; Spectrum5_001453; EC 600-593-1; SCHEMBL35376; GTPL953; KBioSS_002343; MLS000758250; MLS001423952; BIDD:GT0250; DivK1c_006916; SUD-919CL2Y; DTXSID6023496; HSDB 8253; KBio1_001860; KBio2_002340; KBio2_004908; KBio2_007476; (s)-2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazole; HMS2051A21; HMS2090C15; HMS2232B03; HMS3884L19; AMY10837; HY-B0410; ZINC3781664; Tox21_112445; BDBM50116766; CX1349; s2460; AKOS016843188; Tox21_112445_1; CCG-100823; DB00413; NC00073; NSC 760426; NCGC00167441-02; NCGC00167441-03; NCGC00167441-10; DS-14807; DB-038042; B1488; SW197453-4; D05575; AB00053772-12; AB00053772-13; AB00053772_14; AB00053772_16; 632P260; A801025; A901248; Q421304; J-001211; SR-01000763219-5; SR-01000763219-6; (6S)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine; (6S)-N'-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (s)-(-)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole; (S)-N 6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; 556801-24-2; N'-Propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine; (S)-2-Amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole;(S)-N6-Propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8356	DB00413	DR00620	.	211.33	C10H17N3S	79.2	188	1.9	14	2	4	3	"1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1"	CCCN[C@H]1CCC2=C(C1)SC(=N2)N	FASDKYOPVNHBLU-ZETCQYMHSA-N
DG00995	Valdecoxib	119607	"Valdecoxib; 181695-72-7; Bextra; 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; Valdyn; SC 65872; SC-65872; 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; Kudeq; 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-; YM-974; UNII-2919279Q3W; CHEMBL865; p-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzene-1-sulfonamide; CHEBI:63634; MFCD00950568; NSC-759846; COX; NCGC00095129-01; 2919279Q3W; DSSTox_CID_24226; DSSTox_RID_80128; DSSTox_GSID_44226; Valecoxib; SMR000466327; CAS-181695-72-7; HSDB 7302; Valdecoxib (USAN/INN); 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide; valdecoxibum; 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide; Valdecoxib [USAN:INN:BAN]; 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide; ND-0214; Spectrum_001747; 2aw1; Spectrum2_000508; Spectrum3_001001; Spectrum4_001129; Spectrum5_001476; SCHEMBL3356; BSPBio_002721; KBioGR_001617; KBioSS_002227; MLS000759433; MLS001165699; MLS001195631; MLS001424105; SPECTRUM1504302; SPBio_000435; 4-(Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide; cid_119607; GTPL2894; ZINC6694; DTXSID6044226; Valdecoxib, >=98% (HPLC); BDBM13063; KBio2_002227; KBio2_004795; KBio2_007363; KBio3_001941; EX-A241; HMS1922J21; HMS2051P07; HMS2232P23; HMS3372D12; HMS3393P07; HMS3652I04; HMS3715L18; HMS3885O20; Pharmakon1600-01504302; AMY31078; BCP02419; Tox21_111438; AC-120; CCG-39589; NSC759846; s4049; AKOS000280920; Tox21_111438_1; CS-1674; DB00580; NC00184; NSC 759846; SB19519; MRF-0000216; NCGC00095129-02; NCGC00095129-03; NCGC00095129-06; Valdecoxib, analytical reference material; HY-15762; DB-044435; UNM-0000305814; FT-0631199; FT-0675755; SW197564-2; A13342; C21552; D02709; AB00639996-08; AB00639996_10; 695V727; A812629; Q347613; SR-01000759421; J-011613; J-513600; SR-01000759421-4; 4-[5-methyl-3-phenylisoxazol-4-yl]benzensulfonamide; BRD-K12994359-001-02-8; BRD-K12994359-001-14-3; 4-(5-Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI); VLX"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63634	DB00580	DR01196	DR1666	314.4	C16H14N2O3S	94.6	462	2.6	22	1	5	3	"1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)"	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N	LNPDTQAFDNKSHK-UHFFFAOYSA-N
DG00998	Tazobactam	123630	"Tazobactam; 89786-04-9; Tazobactam acid; Tazobactamum; YTR-830H; YTR 830H; UNII-SE10G96M8W; CL-298741; CHEMBL404; YTR 830; CHEBI:9421; SE10G96M8W; (2S,3S,5R)-3-((1H-1,2,3-triazol-1-yl)methyl)-3-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; CL 298,741; YTR 830 H; 89786-04-9 (free acid); (2S,3S,5R)-3-METHYL-4,4,7-TRIOXO-3-(1H-1,2,3-TRIAZOL-1-YLMETHYL)-4-THIA-1-AZABICYCLO[3.2.0]HEPTANE-2-CARBOXYLIC ACID; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide; SR-01000872598; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, (2S,3S,5R)-; 89785-84-2; Tazobactamum [INN-Latin]; YTR830H; CCRIS 2203; YTR830; NSC-759887; Tazobactam,(S); Tazobactam [USAN:USP:INN:BAN]; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4 ^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Cl 298741; BRN 4787943; CL298741; Tazobactam;Tazobactan acid; EC 618-303-7; BIDD:GT0212; SCHEMBL122302; CXA201; Tazobactam (JP17/USP/INN); DTXSID8023634; GTPL10789; HMS3714G17; (2S,3S,5S)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; BCP09757; EX-A1377; HY-B1418; ZINC3787060; BDBM50053173; MFCD00867002; s3077; AKOS015960801; AC-7620; CCG-207890; CS-4914; DB01606; DS-8301; NSC 759887; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 4,4-dioxide; T3732; C07771; D00660; D78146; T-1445; 786T049; A843310; Q423376; Tazobactam, Antibiotic for Culture Media Use Only; SR-01000872598-1; SR-01000872598-2; 89786-04-9, 89785-84-2 (sodium salt); BRD-K14312455-001-01-6; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(1-triazolylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-[(1H-1,2,3-triazol-1-yl)methyl]-4lambda(6)-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4lambda 6-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4lambda6-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-methyl-4,4,7-tris(oxidanylidene)-3-(1,2,3-triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4lambda*6*-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, (2S-(2alpha,3beta,5alpha))-; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-methyl-7- oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, [2S- (2alpha,3beta,5alpha)]-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9421	DB01606	.	DR2453	300.29	C10H12N4O5S	131	573	-2	20	1	7	3	"1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1"	C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3	LPQZKKCYTLCDGQ-WEDXCCLWSA-N
DG00999	Desloratadine	124087	"Desloratadine; 100643-71-8; Clarinex; Descarboethoxyloratadine; Desloratidine; Neoclarityn; Aerius; Azomyr; Sch-34117; Denosin; Opulis; Allex; Sch 34117; 8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; Descarboethoxyoratidine; MFCD00871949; UNII-FVF865388R; CHEMBL1172; Loratadine related compound a; C19H19ClN2; 8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine; MLS000559042; CHEBI:291342; FVF865388R; 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-; NSC-759824; NCGC00159325-02; SMR000149358; Clarinex RediTabs; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; DSSTox_CID_24196; DSSTox_RID_80112; DSSTox_GSID_44196; Desalex; 5H-Benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-; 8-chloro-11-piperidin-4-ylidene-5,6-dihydrobenzo[1,2]cyclohepta[2,4-b]pyridine; 8-chloro-6,11-dihydro-11-(4-piperdinylidene)- 5H-benzo[5,6]cyclohepta[1,2-b]pyridine; Clarinex (TN); 13-chloro-2-(piperidin-4-ylidene)-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene; Desloratadine Actavis; CAS-100643-71-8; SR-01000668962; Dasselta; Desloratadine [USAN:INN:BAN]; Desloratadine teva; Clarinex(R); 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta(1,2-b]pyridin-11-ylidene)-piperidine; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine; 4-{8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene}-piperidine; 4-{8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene}piperidine; Desloratadine-[d7]; Desloratadine- Bio-X; MK-4117; CPD000149358; Opera_ID_1891; SCHEMBL4425; MLS000759406; MLS001201801; MLS001424247; Sch34117; Desloratadine (JAN/USP/INN); GTPL7157; ZINC1261; DTXSID1044196; Loratadine related compound a rs; HMS2052H05; HMS2090C06; HMS2093F19; HMS3394H05; HMS3652O15; HMS3715J15; HMS3885C18; Pharmakon1600-01505393; ALBB-027276; BCP02340; HY-B0539; Tox21_111574; BBL010777; BDBM50073179; NSC675447; NSC759824; s4012; STK586537; AKOS000280921; Tox21_111574_1; AC-1279; CCG-101162; DB00967; KS-1048; MCULE-2975958622; NC00412; NSC 675447; NSC 759824; NSC-675447; SB17503; Desloratadine, powder, >=98% (HPLC); NCGC00159325-03; NCGC00159325-04; NCGC00159325-05; 13-chloro-2-piperidin-4-ylidene-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene; BD164361; Loratadine EP Impurity D (Desloratadine); SBI-0206828.P001; D3787; FT-0602522; FT-0666048; SW197792-3; A19515; D03693; H11943; J10309; AB00456701-11; AB00456701-13; AB00456701_14; AB00456701_15; 643D718; L001025; Q418060; Q-200936; SR-01000668962-4; SR-01000668962-5; SR-01000668962-8; BRD-K82357231-001-13-4; Desloratadine, European Pharmacopoeia (EP) Reference Standard; Desloratadine, United States Pharmacopeia (USP) Reference Standard; 4-(8-chloro-5,6-dihydro-11 H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine; 4-(8-chloro-5,6-dihydro-11H-benzo-[5,6]cyclohepta(1,2-b]pyridin-11-ylidene)-piperidine; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta [1,2-b]pyridin-11-ylidene) piperidine; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene) piperidine; 8-chloro-11-(4-piperidinylidene)-6,11-dihydro-5H- benzo[4,5]cyclohepta[2,1-b]pyridine; 8-chloro-11-(4-piperidyliden)-6,11-dihydro-5H-benzo[5,6]cyclohepta [1,2-b]pyridine; 8-chloro-11-(4-piperidyliden)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-chloro-11-(4-piperidylidene)-6,11-dihydro-5h-benzo[5.6]cyclohepta[1,2-b]pyridine; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H- benzo[5,6]cyclohepta[1,2,b]pyridine; 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; Desloratadine for system suitability, European Pharmacopoeia (EP) Reference Standard; Desloratidine, Pharmaceutical Secondary Standard; Certified Reference Material; Loratadine Related Compound A, United States Pharmacopeia (USP) Reference Standard; 13-chloro-2-(piperidin-4-ylidene)-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaene; 8-CHLORO-11-(4-PIPERIDYLIDENE)-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE; 8-Chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (Descarboethoxyloratadine; Desloratadine)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:291342	DB00967	DR00497	DR1761	310.8	C19H19ClN2	24.9	425	4.5	22	1	2	0	"1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2"	C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4	JAUOIFJMECXRGI-UHFFFAOYSA-N
DG01002	Arbidol	131411	"Arbidol; umifenovir; 131707-25-0; UNII-93M09WW4RU; Umifenovir [INN]; ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate; ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylsulfanyl)methyl]-1H-indole-3-carboxylate; MLS000777586; 93M09WW4RU; Umifenovir (INN); SMR000413980; 1H-Indole-3-carboxylic acid, 6-bromo-4-((dimethylamino)methyl)-5-hydroxy-1-methyl-2-((phenylthio)methyl)-, ethyl ester; 1H-Indole-3-carboxylic acid, 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-, ethyl ester; Arbidol base; 6-Bromo-4-dimethylaminomethyl-5-hydroxy-1-methyl-2-phenylsulfanylmethyl-1H-indole-3-carboxylic acid ethyl ester; 75U; Arbidol; Umifenovir; AR-1I9514; ChemDiv1_000732; Oprea1_384852; Oprea1_482224; MLS006011808; cid_131411; SCHEMBL1068701; CHEMBL1214598; BDBM83797; GTPL11089; HMS589B06; DTXSID60895015; CHEBI:134730; HMS2760J21; ALBB-028966; BCP04187; EX-A3050; MFCD01326495; STK021887; ZINC19907652; AKOS001485435; AT13213; DB13609; DT-0014; MCULE-3169804935; NCGC00246387-01; NCGC00246387-02; NCGC00246387-06; NCGC00246387-09; ethyl 6-bromo-4-(dimethylaminomethyl)-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate; Ethyl 6-bromo-5-hydroxy-1-methyl-4-((dimethylamino)methyl)-2-[(phenylthio)methyl]-1H-indole-3-carboxylate; HY-14904; D10558; AB00644670_06; A888382; Q27271599; 1H-indole-3-carboxylic acid, 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-, ethyl ester, hydrochloride; 5674-91-9; 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-3-indolecarboxylic acid ethyl ester; 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]indole-3-carboxylic acid ethyl ester; 6-Bromo-4-dimethylaminomethyl-5-hydroxy-1-methyl-2-phenylsulfanylmethyl-1H-indole-3-carboxylic acid ethyl ester; 6-Bromo-5-hydroxy-4-methylaminomethyl-1-methyl-2-benzenesulfenylmethylindole-3-ethyl carboxylate; ethyl 6-bromanyl-4-[(dimethylamino)methyl]-1-methyl-5-oxidanyl-2-(phenylsulfanylmethyl)indole-3-carboxylate; ethyl 6-bromo-5-hydroxy-4-dimethylaminomethyl-1-methyl-2-phenylthiomethylindole-3-carboxilate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:134730	.	.	.	477.4	C22H25BrN2O3S	80	546	4.4	29	1	5	8	"1S/C22H25BrN2O3S/c1-5-28-22(27)20-18(13-29-14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3/h6-11,26H,5,12-13H2,1-4H3"	CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3	KCFYEAOKVJSACF-UHFFFAOYSA-N
DG01003	Febuxostat	134018	"Febuxostat; 144060-53-7; Adenuric; Uloric; 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid; Tei 6720; Feburic; Tei-6720; TMX 67; 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid; TMX-67; Zurig; C16H16N2O3S; UNII-101V0R1N2E; Febuxostat (Uloric); 2-(3-CYANO-4-ISOBUTOXY-PHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID; CHEMBL1164729; 101V0R1N2E; NSC-758874; NCGC00182059-02; 2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid; 5-Thiazolecarboxylic acid, 2-(3-cyano-4-(2-methylpropoxy)phenyl)-4-methyl-; DSSTox_CID_28576; DSSTox_RID_82848; DSSTox_GSID_48650; 5-Thiazolecarboxylic acid, 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-; SMR002529566; Uloric (TN); CAS-144060-53-7; 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-5-thiazolecarboxylic acid; 2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid; Donifoxate; Febuxostatum; Febuday; Goturic; Febric; Goutex; Febuxostat (JAN/USAN/INN); Febuxostat [USAN:INN:BAN]; 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid; Febuxostat- Bio-X; Feburic (TN); SPIRAMYCINADIPATE; 111GE013; S1547; Febuxostat,Uloric, TMX-67; MLS004774136; MLS006011568; SCHEMBL249339; GTPL6817; ZINC5423; thyl-thiazole-5-carboxylic acid; DTXSID8048650; Febuxostat, >=98% (HPLC); CHEBI:31596; BCPP000233; HMS3264C20; HMS3655C03; HMS3673M21; HMS3743I09; HMS3868J03; MX-67; Pharmakon1600-01504286; ACT06289; BCP02342; WZB81950; Tox21_113004; AC-425; BBL036503; BDBM50320491; FD7322; MFCD00871598; NSC758874; STL559020; AKOS015841695; Tox21_113004_1; BCP9000679; BS-1018; CCG-213303; CS-0403; DB04854; MCULE-6974079178; NSC 758874; PB33929; 2-(3-Cyano-4-isobutoxy-phenyl)-4-me; NCGC00182059-03; BC164443; HY-14268; S033; AM20090760; F0847; FT-0601639; SW219283-1; D01206; J10392; AB01274796-01; AB01274796_02; AB01274796_03; 060F537; Q417296; SR-01000940023; Q-100164; SR-01000940023-2; BRD-K48367671-001-01-8; Z1550648761; 2-(3-cyano-4-isobutyloxy)-phenyl-4-methyl-5-thiazolecarboxylic acid; 2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31596	DB04854	.	DR0681	316.4	C16H16N2O3S	111	448	3.9	22	1	6	5	"1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)"	CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O	BQSJTQLCZDPROO-UHFFFAOYSA-N
DG01004	Pomalidomide	134780	"Pomalidomide; 19171-19-8; Actimid; 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; CC-4047; Pomalyst; Imnovid; 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione; 4-Aminothalidomide; 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide; CC 4047; IMiD 3; Pomalidomide (CC-4047); 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-; (S)-pomalidomide; 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione; IMID-3; CHEBI:72690; MFCD12756407; 4-amino-2-(2,6-dioxo-3-piperidinyl)-1H-Isoindole-1,3(2H)-dione; 4-amino-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione; 4-amino-2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione; Pomalidomide [USAN:INN]; HSDB 8222; Pomalyst (TN); CC4047; Pomalidomide- Bio-X; IMiD1; 3-amino-N-(2,6-dioxo-3-piperidyl)phthalamide; 3-Aminophthalimidoglutarimide; MLS006011261; CHEMBL43452; SCHEMBL369172; GTPL7348; Pomalidomide (JAN/USAN/INN); 3-aminio-phthalimido-glutarimide; SCHEMBL19250920; BDBM65456; IMID-4047; CDC-394; DTXSID40893458; Pomalidomide, >=98% (HPLC); s-3-amino-phthalimido-glutarimide; HMS3655G05; HMS3744K07; Actimid; ; ; CC 4047; ; ; IMiD3; BCP02890; BCP09107; CFC83849; AM9718; NSC767909; NSC775351; s1567; AKOS013400288; CCG-264684; CS-0165; DB08910; LS40023; NSC-767909; NSC-775351; SB16552; NCGC00346551-01; NCGC00346551-03; AC-26970; AS-17905; BP-24477; BP164278; DA-21486; HY-10984; SMR004703012; SY054807; BCP0726000263; FT-0697903; P2074; SW218099-2; V2447; D08976; AB01565777_02; 171P198; SR-01000941573; J-012392; J-514302; Phthalimide, 3-amino-N-(2,6-dioxo-3-piperidyl)-; Q7227206; SR-01000941573-1; 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; 4-amino-2-(2,6-dioxo(3-piperidyl))isoindoline-1,3-dione; 4-Amino-2-(2,6-dioxo-3-piperidinyl)isoindole-1,3-dione; 4-Amino-2-(2,6-dioxo-3-piperidyl) isoindoline -1,3-dione; Lipopolysaccharides from Escherichia coli 055:B5 pound>>Lipopolysaccharides pound>> lipoglycans pound>>endotoxins"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:72690	DB08910	DR00151	DR1313	273.24	C13H11N3O4	110	504	0.2	20	2	5	1	"1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)"	C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N	UVSMNLNDYGZFPF-UHFFFAOYSA-N
DG01006	Nepafenac	151075	"Nepafenac; 78281-72-8; Nevanac; 2-(2-Amino-3-benzoylphenyl)acetamide; 2-Amino-3-benzoylbenzeneacetamide; Ilevro; AL 6515; AHR 9434; AHR-9434; AL-6515; Benzeneacetamide, 2-amino-3-benzoyl-; UNII-0J9L7J6V8C; CHEBI:75922; 0J9L7J6V8C; MFCD08067732; AHR 9434;AL 6515; NCGC00185741-01; DSSTox_CID_28564; DSSTox_RID_82836; DSSTox_GSID_48638; Amfenac amide; SMR002529588; CAS-78281-72-8; nepafenaco; nepafenacum; Nepafena; Nepafenac [USAN:INN:BAN:JAN]; 2-amino-3-benzoyl-benzeneacetamide; Nevanac (TN); 2-(2-amino-3-benzoyl-phenyl)acetamide; 2-[2-amino-3-(benzoyl)phenyl]acetamide; CHEMBL1021; SCHEMBL93835; MLS003915618; MLS004774140; MLS006010644; Nepafenac (JAN/USAN/INN); GTPL7564; DTXSID0048638; Nepafenac, >=98% (HPLC); 2-Amino-3-benzoyl-phenylacetamide; HMS3654P07; HMS3884E07; ACT02914; AMY10899; BCP21333; EX-A1350; WZB81453; ZINC5162311; Tox21_112985; BDBM50228731; s1255; STL451069; AKOS005146108; Tox21_112985_1; AC-6949; CCG-267004; CS-0899; DB06802; NCGC00185741-02; 2-(2-Amino-3-benzoyl-phenyl)-acetamide; AS-19176; HY-17357; 2-Amino-3-benzoylbenzeneacetamide;Nepafenac; FT-0603701; N0932; SW219197-1; X5012; 2-[2-amino-3-(phenylcarbonyl)phenyl]acetamide; A26218; D05143; AB01274763-01; AB01274763_02; 281N728; A890381; Q684379; SR-01000931908; J-507774; SR-01000931908-2; BRD-K04112579-001-02-1; 2-Amino-3-benzoylbenzeneacetamide / 2-(2-Amino-3-benzoylphenyl)acetamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:75922	DB06802	.	.	254.28	C15H14N2O2	86.2	337	1.9	19	2	3	4	"1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)"	C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)N	QEFAQIPZVLVERP-UHFFFAOYSA-N
DG01007	Conivaptan	151171	"Conivaptan; 210101-16-9; YM087; YM-087; Conivaptan (INN); Conivaptan [INN]; UNII-0NJ98Y462X; N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide; CHEBI:681850; 0NJ98Y462X; Conivaptan-d4; 4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide; CHEMBL1755; SCHEMBL49815; GTPL2203; BDBM85095; DTXSID80175220; HMS3745C21; BCP07817; PDSP1_001735; PDSP2_001718; ZINC12503187; AKOS015917893; CAS_151171; DB00872; NSC_151171; NCGC00345881-02; NCGC00345881-03; NCGC00345881-04; NCGC00345881-05; AC-30626; N-{4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl}biphenyl-2-carboxamide; DB-066404; AM20090722; FT-0724257; D07748; AB01565868_02; L001073; L001531; Q5161126; (1,1'-Biphenyl)-2-carboxamide, N-(4-(4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)phenyl)-; [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-; 4'-[(2-Methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-phenylbenzanilide; N-[4-({4-methyl-3,5,9-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),2(6),3,11,13-pentaen-9-yl}carbonyl)phenyl]-2-phenylbenzamide; N-[4-(2-methyl4,5-dihydro-3H-imidazo[5,4-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide; N-[4-[(4,5-Dihydro-2-methylimidazo[4,5-d][benzazepin-6(1H)-yl)carbonyl]phenyl-[1,1'-biphenyl]-2-carboxamide hydrochloride"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:681850	DB00872	.	.	498.6	C32H26N4O2	78.1	820	5.7	38	2	3	4	"1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)"	CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6	IKENVDNFQMCRTR-UHFFFAOYSA-N
DG01008	Peramivir	154234	"Peramivir; 330600-85-6; Rapiacta; BCX-1812; 229614-55-5; RWJ-270201; UNII-9ZS94HQO3B; RAPIVAB; CHEBI:85202; BCX1812; BCX 1812; RWJ270201; (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid; RWJ 270201; 9ZS94HQO3B; (1S,2S,3R,4R)-3-((S)-1-Acetamido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentanecarboxylic acid; 330600-85-6 (free); (1S,2S,3R,4R)-4-carbamimidamido-3-[(1S)-1-acetamido-2-ethylbutyl]-2-hydroxycyclopentane-1-carboxylic acid; 229614-56-6; 3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID; 3-(1'-acetylamino-2'-ethyl)butyl-4-((aminoimino)methyl)amino-2-hydroxycyclopentane-1-carboxylic acid; BCZ; Cyclopentanecarboxylic acid, 3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-[(aminoiminomethyl)amino]-2-hydroxy-, (1S,2S,3R,4R)-; (+/-)-Peramivir; Peramivir [USAN:INN]; PeramiFlu; S-021812; Peramivir anhydrous; Cyclopentanecarboxylic acid, 3-((1S)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1S,2S,3R,4R)-; Peramivir, (+/-)-; SCHEMBL744373; BDBM5024; CHEMBL139367; SCHEMBL12795462; DTXSID10904727; BCPP000117; (1S,2R,3R,4R)-3-(1-acetamido-2-ethyl-butyl)-4-(diaminomethylideneamino)-2-hydroxy-cyclopentane-1-carboxylic acid; ZINC3981610; BDBM50181441; HY-17015A; MFCD09837902; AKOS016007760; AKOS037652424; CS-0638; DB06614; DT-0029; NCGC00346433-06; NCGC00346433-07; (1s,2s,3r,4r)-3-((1s)-1-acetylamino-2-ethylbutyl))-4-((aminoiminomethyl)amino)-2-hydroxycyclopentane; (1S,2S,3R,4R)-3-((S)-1-acetamido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentane-1-carboxylic acid; AC-22715; Cyclopentanecarboxylic acid, 3-((1R)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1R,2R,3S,4S)-rel-; W19713; AB01566838_01; 600P856; A896277; Q412734; (-)-(1S,2S,3R,4R)-3-[(1S)-1-(Acetylamino)-2-ethylbutyl]-4-{[amino(imino)methyl]amino}-2-hydroxycyclopentanecarboxylic Acid; (1S,2S,3R,4R)-3-[(1S)-1-(Acetylamino)-2-ethylbutyl]-4-[(aminoiminomethyl)amino]-2-hydroxycyclopentanecarboxylic acid trihydrate; (1S,2S,3R,4R)-3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-carbamimidamido-2-hydroxycyclopentanecarboxylic acid; (1S,2S,3R,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentanecarboxylic acid; (1S,2S,3R,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-carbamimidamido-2-hydroxycyclopentane-1-carboxylic acid; (1S,2S,3S,4R)-4-[(DIAMINOMETHYLIDENE)AMINO]-3-[(1S)-1-ACETAMIDO-2-ETHYLBUTYL]-2-HYDROXYCYCLOPENTANE-1-CARBOXYLIC ACID"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:85202	DB06614	.	.	328.41	C15H28N4O4	151	460	0	23	5	5	7	"1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9-,10+,11+,12-,13+/m0/s1"	CCC(CC)[C@@H]([C@H]1[C@@H](C[C@@H]([C@H]1O)C(=O)O)N=C(N)N)NC(=O)C	XRQDFNLINLXZLB-CKIKVBCHSA-N
DG01010	Cinacalcet	156419	"Cinacalcet; 226256-56-0; AMG 073; AMG073; (R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; AMG-073; UNII-UAZ6V7728S; Parareg; N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; UAZ6V7728S; CHEBI:48390; N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; N-((1R)-1-(1-Naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-[(1r)-1-(naphthalen-1-yl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; (R)-alpha-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine; CNC; Cinacalcet (USAN); KRN-1493; NCGC00181002-01; Cinacalcet [USAN:INN:BAN]; C22H22F3N; HSDB 7318; KRN1493; SCHEMBL71876; GTPL3308; CHEMBL1201284; DTXSID8048286; ACT06726; AMY13665; BCP07181; ZINC1550499; BDBM50416875; s5191; AKOS015909821; AC-8974; CS-0287; DB01012; NCGC00181002-02; NCGC00181002-03; NCGC00181002-05; BS-16242; HY-70037; X7255; D03504; AB01274759-01; AB01274759_02; 256C560; Q193978; J-520046; (R)-N-(3-(3-trifluoromethylphenyl)propyl)-1-(1-naphthyl)ethylamine; [(1R)-1-(naphthalen-1-yl)ethyl]({3-[3-(trifluoromethyl)phenyl]propyl})amine; 1-Naphthalenemethanamine, alpha-methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-, (alphaR)-; 1025064-29-2; YP4"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:48390	DB01012	.	.	357.4	C22H22F3N	12	422	6.1	26	1	4	6	"1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1"	C[C@H](C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F	VDHAWDNDOKGFTD-MRXNPFEDSA-N
DG01011	Lactitol	157355	"Lactitol; 585-86-4; 4-O-beta-D-Galactopyranosyl-D-glucitol; Importal; D-lactitol; lactitolum; Lacitol; Lactosit; Miruhen; Lactit; UNII-L2B0WJF7ZY; L2B0WJF7ZY; NSC 231323; D-Lactitol monohydrate; CHEBI:75323; NSC-231323; lactositol; D-Glucitol, 4-O-beta-D-galactopyranosyl-; 81025-04-9; DSSTox_CID_24247; DSSTox_RID_80133; DSSTox_GSID_44247; lactobiosit; Emportal; Oponaf; (2S,3R,4R,5R)-4-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexane-1,2,3,5,6-pentaol; CAS-585-86-4; LACTITOL ANHYDROUS; MFCD00150767; Lactitolum [INN-Latin]; Lactitol [INN:BAN:NF]; Floralac; Milchen; Portolac; CCRIS 7077; Finlac dc; Lactosit Miruhen; NSC231323; HSDB 7970; NSC-759131; Lactitol acm 50; NCGC00166295-01; Importal (TN); Lacty (saccharide); EINECS 209-566-5; Pizensy (TN); Lactitol (NF/INN); SCHEMBL3849; CHEMBL1661; Lactitol, analytical standard; INS NO.966; DTXSID9044247; BLI-400; INS-966; HMS3264E13; Pharmakon1600-01301027; HY-N7104; ZINC5225520; Tox21_112397; MFCD00079407; NSC760415; s5368; 4-beta-D-galactopyranosyl-D-glucito1; AKOS030228540; Tox21_112397_1; CCG-213712; DB12942; NSC-760415; NCGC00263893-02; (2S,3R,4R,5R)-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexane-1,2,3,5,6-pentol; 4-O-b-D-Galactopyranosyl-D-glucitol, 9CI; beta-D-galactopyranosyl-(1->4)-D-glucitol; CS-0069039; E-966; A11574; D08266; AB00698230_06; Q415020; W-109090; BRD-K40787673-001-02-1; 262A7827-24F7-47EE-B528-3AF52CA860CE; WURCS=2.0/2,2,1/[h2122h][a2112h-1b_1-5]/1-2/a4-b1; (2S,3R,4R,5R)-4-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)hexane-1,2,3,5,6-pentaol; (2S,3R,4R,5R)-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxyhexane-1,2,3,5,6-pentol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:75323	DB12942	.	.	344.31	C12H24O11	201	343	-5.2	23	9	11	8	"1S/C12H24O11/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12/h4-21H,1-3H2/t4-,5+,6+,7+,8-,9-,10+,11+,12-/m0/s1"	C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](CO)O)O)O)O)O)O	VQHSOMBJVWLPSR-JVCRWLNRSA-N
DG01013	Plicamycin	163659	"MITHRAMYCIN; plicamycin; Mithracin; mithramycin a; Aureolic acid; Mithramycinum; 18378-89-7; Mithramycine; Plicamycine; Plicamycinum; Mitramycin; UNII-NIJ123W41V; Aurelic acid; CHEBI:31856; Antibiotic LA 7017; CHEMBL257619; NIJ123W41V; Mitramycine; Mitramycinum; Aurlelic acid; Plicamycine [French]; Plicamycinum [Latin]; Plicamicina [Spanish]; A-2371; Mitramicina; Plicamicina; Plicamycine [INN-French]; Plicamycinum [INN-Latin]; Mithramycine [INN-French]; Mithramycinum [INN-Latin]; Mitramicina [INN-Spanish]; Plicamicina [INN-Spanish]; CCRIS 5629; HSDB 3238; SR-05000002335; NSC 24559; PA 144; PA-144; Mithracin (TN); Plicamycin [USAN:USP:INN:BAN]; MITHRAMYCINA; Plicamycin (USAN/INN); SCHEMBL4517; GTPL8394; HY-A0122; BDBM50547623; DB06810; 97666-60-9; CS-0014261; D00468; SR-05000002335-2; SR-05000002335-3; (1S)-5-deoxy-1-C-[(2S,3S)-7-{[2,6-dideoxy-3-O-(2,6-dideoxy-beta-D-arabino-hexopyranosyl)-beta-D-arabino-hexopyranosyl]oxy}-3-{[2,6-dideoxy-3-C-methyl-beta-D-ribo-hexopyranosyl-(1->3)-2,6-dideoxy-beta-D-lyxo-hexopyranosyl-(1->3)-2,6-dideoxy-beta-D-arabino-hexopyranosyl]oxy}-5,10-dihydroxy-6-methyl-4-oxo-1,2,3,4-tetrahydroanthracen-2-yl]-1-O-methyl-D-xylulose; (1S)-5-deoxy-1-C-[(2S,3S)-7-{[2,6-dideoxy-3-O-(2,6-dideoxy-beta-D-arabino-hexopyranosyl)-beta-D-arabino-hexopyranosyl]oxy}-3-{[2,6-dideoxy-3-C-methyl-beta-D-ribo-hexopyranosyl-(1->3)-2,6-dideoxy-beta-D-lyxo-hexopyranosyl-(1->3)-2,6-dideoxy-beta-D-arabino-hexopyranosyl]oxy}-5,10-dihydroxy-6-methyl-4-oxo-1,2,3,4-tetrahydroanthracen-2-yl]-1-O-methyl-D-xylulose; D-threo-2-Pentulose, 5-deoxy-1-C-((2S,3S)-7-((2,6-dideoxy-3-O-(2,6-dideoxy-beta-D-arabino-hexopyranosyl)-beta-D-arabino-hexopyranosyl)oxy)-3-((O-2,6-dideoxy-3-C-methyl-beta-D-ribo-hexopyranosyl-(1.fwdarw.3)-O-2,6-dideoxy-beta-D-lyxo-hexopyranosyl-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31856	DB06810	DR01399	.	1085.1	C52H76O24	358	1940	0.6	76	11	24	15	"1S/C52H76O24/c1-18-29(72-34-14-30(43(58)21(4)68-34)73-33-13-28(54)42(57)20(3)67-33)12-26-10-25-11-27(49(66-9)48(63)41(56)19(2)53)50(47(62)39(25)46(61)38(26)40(18)55)76-36-16-31(44(59)23(6)70-36)74-35-15-32(45(60)22(5)69-35)75-37-17-52(8,65)51(64)24(7)71-37/h10,12,19-24,27-28,30-37,41-45,49-51,53-61,64-65H,11,13-17H2,1-9H3/t19-,20-,21-,22-,23-,24-,27+,28-,30-,31-,32-,33+,34+,35+,36+,37+,41+,42-,43-,44-,45+,49+,50+,51-,52+/m1/s1"	C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2C[C@@H](O[C@@H]([C@H]2O)C)OC3=CC4=CC5=C(C(=O)[C@H]([C@@H](C5)[C@@H](C(=O)[C@H]([C@@H](C)O)O)OC)O[C@H]6C[C@H]([C@@H]([C@H](O6)C)O)O[C@H]7C[C@H]([C@H]([C@H](O7)C)O)O[C@H]8C[C@]([C@@H]([C@H](O8)C)O)(C)O)C(=C4C(=C3C)O)O)O)O	CFCUWKMKBJTWLW-BKHRDMLASA-N
DG01014	Arzoxifene	179337	"Arzoxifene; 182133-25-1; LY 353381; UNII-E569WG6E60; 2-(4-methoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)phenoxy]-1-benzothiophen-6-ol; LY353381; E569WG6E60; Benzo[b]thiophene-6-ol, 2-(4-methoxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-; Arzoxifene [INN]; Benzo(b)thiophene-6-ol, 2-(4-methoxyphenyl)-3-(4-(2-(1-piperidinyl)ethoxy)phenoxy)-; LY-353381; SCHEMBL285277; CHEMBL226267; BDBM19442; DTXSID10171255; ZINC1544683; DB06249; SB19713; 2-(4-methoxyphenyl)-3-(4-(2-(piperidin-1-yl)ethoxy)phenoxy)benzo[b]thiophen-6-ol; DA-09024; HY-13556; CS-0007165; FT-0751607; Q4802769; 2-(4-methoxyphenyl)-3-{4-[2-(piperidin-1-yl)ethoxy]phenoxy}-1-benzothiophen-6-ol; 2-(p-Methoxyphenyl)-3-(p-(2-piperidinoethoxy)phenoxy)benzo(b)thiophene-6-ol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	475.6	C28H29NO4S	79.4	601	6.6	34	1	6	8	"1S/C28H29NO4S/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29/h5-14,19,30H,2-4,15-18H2,1H3"	COC1=CC=C(C=C1)C2=C(C3=C(S2)C=C(C=C3)O)OC4=CC=C(C=C4)OCCN5CCCCC5	MCGDSOGUHLTADD-UHFFFAOYSA-N
DG01015	Deflazacort	189821	"DEFLAZACORT; 14484-47-0; Azacort; Calcort; Oxazacort; Flantadin; Emflaza; Cortax; Deflan; MDL 458; UNII-KR5YZ6AE4B; C25H31NO6; DL-458-IT; L-5458; KR5YZ6AE4B; MDL-458; MFCD00866106; Dezacor; Lantadin; DSSTox_CID_378; DSSTox_RID_75552; DSSTox_GSID_20378; 2-((6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-6a,8a,10-trimethyl-4-oxo-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-d]oxazol-8b-yl)-2-oxoethyl acetate; Deflazacortum; Decortil; Deflanil; Enzocort; Deflazacort (Calcort); 2-[(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-4a,6a,8-trimethyl-2-oxo-2,4a,4b,5,6,6a,9a,10,10a,10b,11,12-dodecahydro-6bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]oxazol-6b-yl]-2-oxoethyl acetate; CAS-14484-47-0; Deflazacortum [INN-Latin]; Deflazacort [USAN:INN:BAN]; (11beta,16beta)-21-(Acetyloxy)-11-hydroxy-2'-methyl-5'H-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione; (11beta,16beta)-21-(acetyloxy)-11-hydroxy-2'-methyl-5'H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione; EINECS 238-483-7; Emflaza (TN); Deflazacort (USAN/INN); SCHEMBL4018; DL-458IT; GTPL9477; MDL458; CHEMBL1201891; DTXSID9020378; Deflazacort, >=98% (HPLC); CHEBI:135720; HMS3714D15; BCP08474; ZINC4212809; Tox21_112506; Tox21_301415; BBL036672; s1888; STL559051; AKOS015895199; Tox21_112506_1; CCG-220817; DB11921; KS-1158; NCGC00255189-01; NCGC00263521-01; 11beta,21-Dihydroxy-2'-methyl-5'betaH-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione 21-acetate; H894; HY-13609; D4523; D03671; T70289; AB01274724-01; AB01274724_02; 484D470; Q779118; Q-101371; 3-AMINO-3-(4-CHLORO-3-NITRO-PHENYL)-PROPIONICACID; Deflazacort, United States Pharmacopeia (USP) Reference Standard; 11b,21-Dihydroxy-2'-methyl-5'bH-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 21-acetate; [2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-6,9,13-trimethyl-16-oxo-5-oxa-7-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-6,14,17-trien-8-yl]-2-oxoethyl] acetate; 11beta,21-dihydroxy-2'-methyl-5'betaH-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 2'-acetate; 2-((6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-6a,8a,10-trimethyl-4-oxo-2,4,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d]oxazol-8b-yl)-2-oxoethyl acetate; 5'-beta-H-Pregna-1,4-dieno(17,16-d)oxazole-3,20-dione, 11-beta,21-dihydroxy-2'-methyl-, 21-acetate; 5'-beta-H-Pregna-1,4-dieno(17,16-d)oxazole-3,20-dione, 11-beta,21-dihydroxy-2'-methyl-,21-acetate; 5'H-Pregna-1,4-dieno(17,16-d)oxazole-3,20-dione, 21-(acetyloxy)-11-hydroxy-2'-methyl-, (11beta,16beta)-; pregna-1,4-diene-11beta,21-diol-3,20-dione[17alpha,16alpha-d]-2'-methyloxazoline 21-acetate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:135720	DB11921	.	.	441.5	C25H31NO6	102	996	2	32	1	7	4	"1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1"	CC1=N[C@@]2([C@H](O1)C[C@@H]3[C@@]2(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)C(=O)COC(=O)C	FBHSPRKOSMHSIF-GRMWVWQJSA-N
DG01020	Colistimethate	216258	"Colistimethate; Sodium colistin methanesulfonate; Colistin sodium methanesulfonate; Colistin Sulfomethate; Colimycin M; Sodium colistimethate; Colistinmethanesulfonic acid; Colistrimethate sodium; Colymycin M; Coly-Mycin M; 12705-41-8; Colimyscine; Colimicina; Coly-mycin injectable; Colistin sulfomethate sodium; Coly-Mycin M Parenteral; Sodium colistinemethanesulfonate; Colistinemethanesulfonate sodique; Pentasodium colistinmethanesulfonate; pentasodium;[2-[17-(1-hydroxyethyl)-22-[[2-[[3-hydroxy-2-[[2-(6-methyloctanoylamino)-4-(sulfonatomethylamino)butanoyl]amino]butanoyl]amino]-4-(sulfonatomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15,18,23-heptaoxo-11,14-bis[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-2-yl]ethylamino]methanesulfonate; EINECS 232-516-9; Colistinmethanesulfonic acid, sodium salt; Colistimethate sodium [USAN:USP:INN:BAN]; Colistinmethanesulfonic acid (VAN); NSC 756688; 8068-37-9; SW222239-1"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB01111	.	.	1749.8	C58H105N16Na5O28S5	749	3430	.	112	18	33	39	"1S/C58H110N16O28S5.5Na/c1-9-35(6)12-10-11-13-46(77)65-38(14-20-59-28-103(88,89)90)53(82)74-48(37(8)76)58(87)70-41(17-23-62-31-106(97,98)99)50(79)68-43-19-25-64-57(86)47(36(7)75)73-54(83)42(18-24-63-32-107(100,101)102)67-49(78)39(15-21-60-29-104(91,92)93)69-55(84)44(26-33(2)3)72-56(85)45(27-34(4)5)71-52(81)40(66-51(43)80)16-22-61-30-105(94,95)96;;;;;/h33-45,47-48,59-63,75-76H,9-32H2,1-8H3,(H,64,86)(H,65,77)(H,66,80)(H,67,78)(H,68,79)(H,69,84)(H,70,87)(H,71,81)(H,72,85)(H,73,83)(H,74,82)(H,88,89,90)(H,91,92,93)(H,94,95,96)(H,97,98,99)(H,100,101,102);;;;;/q;5*+1/p-5"	CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+]	IQWHCHZFYPIVRV-UHFFFAOYSA-I
DG01021	Lasofoxifene	216416	"Lasofoxifene; 180916-16-9; rac-Lasofoxifene; Oporia; CP 336156; (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol; CP-336,156; 180915-78-0; Fablyn; UNII-337G83N988; CHEMBL328190; (-)-cis-5,6,7,8-Tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol; 337G83N988; (5R,6S)-6-phenyl-5-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,6,7,8-tetrahydronaphthalen-2-ol; (5R,6S)-6-phenyl-5-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-5,6,7,8-tetrahydronaphthalen-2-ol; (5R,6S)-6-phenyl-5-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,6,7,8-tetrahydronaphthalen-2-ol.; 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-; 180915-85-9; Lasofoxifene [INN:BAN]; LASOFOXIFENE HCL; CP-336156; lasofoxifeno; lasofoxifenum; 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-, (5R,6S)-; C3D; SCHEMBL26815; GTPL7542; BDBM20606; DTXSID50171037; CHEBI:135938; BCP03626; ZINC3918428; AKOS030241621; BCP9000842; DB06202; NCGC00487269-02; BCP0726000177; 916L169; Q644675; J-011550; (-)-cis-5,6,7,8-Tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol.; cis-6-Phenvl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol; cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol; cis-6-Phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol; cis-6Phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol; (-)-cis-(5r,6s)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol; 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-, (5R-cis)-; Rel-(5R,6S)-6-phenyl-5-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,6,7,8-tetrahydronaphthalen-2-ol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:135938	DB06202	.	.	413.5	C28H31NO2	32.7	533	6.1	31	1	3	6	"1S/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1"	C1CCN(C1)CCOC2=CC=C(C=C2)[C@H]3[C@H](CCC4=C3C=CC(=C4)O)C5=CC=CC=C5	GXESHMAMLJKROZ-IAPPQJPRSA-N
DG01022	Santonin	221071	"Santonin; alpha-Santonin; 481-06-1; (-)-alpha-Santonin; Semenen; Santoninic anhydride; Santoninum; (-)-Santonine; UNII-1VL8J38ERO; (-)-Santonin; NSC4900; 1VL8J38ERO; CHEBI:16363; .alpha.-Santonin; NSC-4900; MFCD00135865; (3S,3aS,5aS,9bS)-3,5a,9-trimethyl-3a,4,5,9b-tetrahydro-3H-benzo[g][1]benzofuran-2,8-dione; (3S,3aS,5aS,9bS)-3,5a,9-trimethyl-3a,5,5a,9b-tetrahydronaphtho[1,2-b]furan-2,8(3H,4H)-dione; DSSTox_CID_25312; DSSTox_RID_80795; DSSTox_GSID_45312; NSC 4900; a-Santonin; l-.alpha.-Santonin; L-alpha-Santonin; (3S,3aS,5aS,9bS)-3,5a,9-trimethyl-3a,4,5,9b-tetrahydro-3H-benzo[g]benzofuran-2,8-dione; (-)-.alpha.-Santonin; Santonin [JAN:NF]; SR-01000635568; NCGC00016461-01; Santonin (TN); CAS-481-06-1; naphtho[1,2-b]furan-2,8(3H,4H)-dione, 3a,5,5a,9b-tetrahydro-3,5a,9-trimethyl-, (3S,3aS,5aS,9bS)-; ()-alpha-Santonin; EINECS 207-560-7; NSC 41311; SANTONINE; Santonin (JP17); Spectrum_000790; SpecPlus_000318; AI3-19471; Prestwick0_001070; Prestwick1_001070; Prestwick2_001070; Prestwick3_001070; Spectrum2_000699; Spectrum3_001245; Spectrum4_001476; Spectrum5_000151; UPCMLD-DP084; BSPBio_001060; BSPBio_002750; KBioGR_002051; KBioSS_001270; SPECTRUM300542; MLS002154141; DivK1c_006414; SPBio_000857; SPBio_002970; alpha-Santonin; (-)-Santonin; BPBio1_001166; CHEMBL259254; MEGxp0_001636; SCHEMBL1133565; DTXSID7045312; UPCMLD-DP084:001; KBio1_001358; KBio2_001270; KBio2_003838; KBio2_006406; KBio3_002250; (-)-alpha-Santonin, >=99%; HMS1571E22; HMS2098E22; HMS2268H12; HY-B1761; Naphtho(1,2-b)furan-2,8(3H,4H)-dione, 3a,5,5a,9b-tetrahydro-3,5a,9-trimethyl-, (3S,3aS,5aS,9bS)-; ZINC3881689; Tox21_110445; CCG-40021; s3999; 11-Epiisoeusantona-1,4-dienic acid, 6alpha-hydroxy-3-oxo-, gamma-lactone; AKOS015895177; Tox21_110445_1; LMPR0103190001; MCULE-4974199679; SDCCGMLS-0066491.P001; (3S)-2,3,3a,4,5,5a,8,9bbeta-Octahydro-3,5abeta,9-trimethylnaphtho(1,2-b)furan-2,8-dion; (3S,5aS,9bS)-3a,5,5a,9b-Tetrahydro-3,5a,9-trimethylnaphtho[1,2-b]furan-2,8(3H,4H)dione; Eudesma-1,4-dien-12-oic acid, 6-alpha-hydroxy-3-oxo-, gamma-lactone, (11S)-(-)-; Naphtho(1,2-b)puran-2,8(3H,4H)-dione, 3a,5,5a,9b-tetrahydro-3,5a,9-trimethyl-; (-)-alpha-Santonin, analytical standard; NCGC00161640-01; NCGC00161640-02; NCGC00161640-03; NCGC00263447-01; SMR000112520; AB00376930; CS-0013789; S0521; C02206; D00154; WLN: T B566 COV LV IHTT&J E1 I1 M1; A827469; Q413166; SR-01000635568-1; SR-01000635568-4; SR-01000635568-5; BRD-K58787433-001-05-4; BRD-K58787433-001-08-8; BRD-K58787433-001-12-0; Santonin, European Pharmacopoeia (EP) Reference Standard; 11-Epiisoeusantona-1, 6.alpha.-hydroxy-3-oxo-, .gamma.-lactone; 3-(6-NITRO-2-OXO-1,3-BENZOXAZOL-3(2H)-YL)PROPANOICACID; Eudesma-1, 6.alpha.-hydroxy-3-oxo-, .gamma.-lactone, (11S)-; (11S)-6alpha-hydroxy-3-oxoeudesma-1,4-dien-12-oic acid gamma-lactone; 6alpha-hydroxy-3-oxo-11-epiisoeusantona-1,4-dienic acid gamma-lactone; Eudesma-1, 6.alpha.-hydroxy-3-oxo-, .gamma.-lactone, (11S)-(-)-; Naphtho[1,8(3H,4H)-dione, 3a,5,5a,9b-tetrahydro-3,5a,9-trimethyl-; 3a,5,5a,9b-Tetrahydro-3,5a,9-trimethyl-naphtho[1,2-b]puran-2,8(3H,4H)-dione; Eudesma-1,4-dien-12-oic acid, 6-alpha-hydroxy-3-oxo-, gamma-lactone, (11S)-; Eudesma-1,4-dien-12-oic acid, 6-alpha-hydroxy-3-oxo-, gamma-lactone, (11S)-;; (3S,3aS,5aS,9bS)-2,3,3a,4,5,5a,8,9b-Octahydro-3,5a,9-trimethylnaphtho(1,2-b)furan-2,8-dione; (3S,3aS,5aS,9bS)-3,5a,9-trimethyl-3a,4,5,5a-tetrahydronaphtho[1,2-b]furan-2,8(3H,9bH)-dione; (3S,3aS,5aS,9bS)-3a,5,5a,9b-Tetrahydro-3,5a,9-trimethylnaphtho[1,2-b]furan-2,8(3H,4H)-dione; 1,3,4,4a,7-Hexahydro-1-hydroxy-.alpha., 4a,8-trimethyl-7-oxo-2-naphthaleneacetic acid .gamma.-lactone; Naphtho[1,8(3H,4H)-dione, 3a,5,5a,9b-tetrahydro-3,5a,9-trimethyl-, [3S-(3.alpha.,3a.alpha.,5a.beta.,9b.beta.)]-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:16363	.	.	.	246.3	C15H18O3	43.4	500	2.3	18	0	3	0	"1S/C15H18O3/c1-8-10-4-6-15(3)7-5-11(16)9(2)12(15)13(10)18-14(8)17/h5,7-8,10,13H,4,6H2,1-3H3/t8-,10-,13-,15-/m0/s1"	C[C@H]1[C@@H]2CC[C@]3(C=CC(=O)C(=C3[C@H]2OC1=O)C)C	XJHDMGJURBVLLE-BOCCBSBMSA-N
DG01025	Rosoxacin	287180	"ROSOXACIN; Acrosoxacin; 40034-42-2; Eradacil; Winuron; Roxadyl; Rosoxacine; Rosoxacinum; Win 35,213; Eracine; Rosoxacine [INN-French]; Rosoxacino [INN-Spanish]; 1-Ethyl-4-oxo-7-(4-pyridyl)-1,4-dihydroquinoline-3-carboxylic Acid; 1-Ethyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylic acid; UNII-3Y1OT3J4NW; 1-ethyl-4-oxo-7-(pyridin-4-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid; WIN 35213; 1-Ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)-3-quinolinecarboxylic acid; 3Y1OT3J4NW; 3-Quinolinecarboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)-; Rosoxacino; Eradacin; MFCD00057294; NSC146617; NSC-146617; Rosoxacinum [INN-Latin]; Roxadyl (TN); Rosoxacin (USAN/INN); EINECS 254-758-4; NSC 146617; rosoxacina; Eradicin; Winoxacin; Rosoxacin [USAN:INN:BAN]; Win-35123; PD 107522; Oprea1_128096; SCHEMBL135645; CHEMBL291157; ZINC2042; DTXSID90193091; Win-35,213; CHEBI:131715; HY-A0208; AC1324; WIN-35213; DB00817; CS-12131; DA-06177; SY038205; CS-0017556; FT-0722899; D02305; Q754690; 1-ethyl-4-oxo-7-(4-pyridyl)quinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid,4-dihydro-4-oxo-7-(4-pyridinyl)-; 1-Ethyl-4-oxo-7-(4-pyridinyl)-1,4-dihydro-3-quinolinecarboxylic acid, AldrichCPR"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:131715	DB00817	.	.	294.3	C17H14N2O3	70.5	482	0.6	22	1	5	3	"1S/C17H14N2O3/c1-2-19-10-14(17(21)22)16(20)13-4-3-12(9-15(13)19)11-5-7-18-8-6-11/h3-10H,2H2,1H3,(H,21,22)"	CCN1C=C(C(=O)C2=C1C=C(C=C2)C3=CC=NC=C3)C(=O)O	XBPZXDSZHPDXQU-UHFFFAOYSA-N
DG01027	Glucosamine	439213	"2-Amino-2-Deoxy-D-Glucopyranose; 2-Amino-2-Deoxy-D-Glucopyranoside; 2-Amino-2-Deoxy-D-Glucose; 2-Amino-2-Deoxy-Glucopyranose; 2-Amino-2-Deoxy-Glucopyranoside; 2-Amino-2-Deoxy-Glucose; 2-Deoxy-2-Amino-D-Glucopyranose; 2-Deoxy-2-Amino-D-Glucopyranoside; 2-Deoxy-2-Amino-D-Glucose; 2-Deoxy-2-Amino-Glucopyranose; 2-Deoxy-2-Amino-Glucopyranoside; 2-Deoxy-2-Amino-Glucose; D-GlcN; D-Glucosamine; GlcN; Glucosamine; chitosamine; Glucosamine free base; D-(+)-Glucosamine; 2-amino-2-deoxyglucose; CHEBI:47977; (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; 3416-24-8 (free base); 2-Aminoglucose; D-Glucose, 2-amino-2-deoxy-; (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)tetrahydro-2H-pyran-2,4,5-triol; Glucosaminum [INN-Latin]; Glucosamina [INN-Spanish]; Mediflex; GlcNH2; 2-Deoxy-2-aminoglucose; Glucosamine (USAN/INN); Glucosamine [USAN:INN]; bmse000247; Epitope ID:151531; SCHEMBL167831; 2-Amino-2-deoxyhexopyranose #; CHEMBL493287; BBL009288; STK801823; AKOS005622471; (+)-2-amino-2-deoxy-D-glucopyranose; DB01296; DB-017621; C00329; D04334; Q327506; J-019472; WURCS=2.0/1,1,0/[a2122h-1x_1-5_2*N]/1/"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:47977	DB01296	.	.	179.17	C6H13NO5	116	155	-2.8	12	5	6	1	"1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5-,6 /m1/s1"	C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)N)O)O)O	MSWZFWKMSRAUBD-IVMDWMLBSA-N
DG01031	Griseofulvin	441140	"Griseofulvin; 126-07-8; (+)-Griseofulvin; Amudane; Grisactin; Grisefuline; Griseofulvinum; Griseofulvina; Grizeofulvin; Grifulvin; Grisofulvin; Spirofulvin; Fulcin; Grysio; Lamoryl; Likuden; Fulvicin; Griseofulvine; Poncyl; Curling factor; Grisovin; Griseofulvine [INN-French]; Griseofulvinum [INN-Latin]; Griseofulvina [INN-Spanish]; GRISEOFULVIN, MICROCRYSTALLINE; Delmofulvina; Fulvistatin; Griscofulvin; Fulcine; Fulvina; Fulvinil; Fungivin; Greosin; Gresfeed; Grifulin; Grisactin V; Grisetin; Guservin; Murfulvin; Neo-Fulcin; Biogrisin-FP; Fulvican grisactin; Griseofulvin-forte; Fulvicin-P/G; Fulvicin-U/F; GRISEOFULVIN, ULTRAMICROCRYSTALLINE; Griseofulvin microsize; Xuanjing; C17H17ClO6; UNII-32HRV3E3D5; MFCD00082343; GRISEOFULVIN, ULTRAMICROSIZE; USAF SC-2; Griseomix; Grisactin Ultra; Griseofulvin forte; Fulvicin P/G; 32HRV3E3D5; CHEBI:27779; NSC-755822; (2S,5'R)-7-chloro-3',4,6-trimethoxy-5'-methylspiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione; NCGC00091120-01; DSSTox_CID_674; NSC 34533; DSSTox_RID_75725; DSSTox_GSID_20674; (2S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H,4'H-spiro[1-benzofuran-2,1'-cyclohex[2]ene]-3,4'-dione; (2S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H-spiro[benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione; ULTRAGRIS-165; ULTRAGRIS-330; Fulvicin Bolus; Fulvicin-U/F (Veterinary); Fulvicin Bolus (Veterinary); FULVICIN P/G 165; FULVICIN P/G 330; 7-Chloro-4,6,2'-trimethoxy-6'-methylgris-2'-en-3,4'-dione; Caswell No. 471B; Fulvidex; (1'S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H-spiro[benzofuran-2,1'-cyclohex[2]ene]-3,4'-dione; SMR000718755; CCRIS 320; HSDB 1722; SR-05000001535; EINECS 204-767-4; EPA Pesticide Chemical Code 471400; Griseofulvin and Alpha-IFN; BRN 0095226; Griseoflulvin; GRISEOFULVIN, MICROSIZE; AI3-51015; fulvicin UF; NSC-34533; Griseofulvin,(S); Griseofulvin [USP:INN:BAN:JAN]; (2S,5'R)-7-chloro-3',4,6-trimethoxy-5'-methyl-spiro[benzofuran-2,4'-cyclohex-2-ene]-1',3-dione; Prestwick_247; Grisactin V (TN); Gris-peg (TN); Griseofulvin,microsize; Spectrum_000816; CPD000718755; SpecPlus_000336; Prestwick3_000226; Spectrum2_000213; Spectrum3_000161; Spectrum4_000927; Spectrum5_000648; Griseofulvin [USP:INN]; CHEMBL562; 7-Chloro-2',4,6-trimethoxy-6'beta-methylspiro(benzofuran-2(3H),1'-(2)cyclohexene)-3,4'-dione; 7-Chloro-4,6-dimethoxycoumaran-3-one-2-spiro-1'-(2'-methoxy-6'-methylcyclohex-2'-en-4'-one); SCHEMBL21988; BSPBio_000271; BSPBio_001621; KBioGR_001454; KBioSS_001296; SPECTRUM200046; (2S-trans)-7-Chloro-2',4,6-trimethoxy-6'-methylspiro(benzofuran-2(3H),1'-(2)cyclohexene)-3,4'-dione; 5-18-05-00150 (Beilstein Handbook Reference); MLS001304062; MLS002152905; MLS002154239; Spiro(benzofuran-2(3H),1'-(2)cyclohexene)-3,4'-dione, 7-chloro-2',4,6-trimethoxy-6'-methyl-, (2S-trans)-; BIDD:GT0024; DivK1c_000154; DivK1c_006432; Griseofulvin (JAN/USP/INN); SPBio_000225; BPBio1_000299; MEGxm0_000184; DTXSID8020674; ACon0_000953; ACon1_001843; BDBM31775; Fulvicin-U/F Powder and Tablets; HMS500H16; KBio1_000154; KBio1_001376; KBio2_001296; KBio2_003864; KBio2_006432; KBio3_001121; Griseofulvin permeability diameter; NINDS_000154; HMS1923E09; HMS2091A03; HMS2095N13; HMS2235F13; HMS3259D05; HMS3712N13; interacts with polymerized microtubules and associated proteins; Pharmakon1600-00200046; ZINC622123; 2884-22-2; Tox21_111087; Tox21_202235; Tox21_303005; CCG-38416; LMPK13060001; NSC755822; s4071; AKOS015896380; Tox21_111087_1; CS-3426; DB00400; MCULE-1983595404; NC00616; SDCCGMLS-0066450.P001; IDI1_000154; NCGC00091120-02; NCGC00091120-03; NCGC00091120-04; NCGC00091120-05; NCGC00091120-06; NCGC00091120-07; NCGC00091120-08; NCGC00091120-09; NCGC00091120-13; NCGC00256353-01; NCGC00259784-01; (1'S,6'R)-7-Chloro-2',4,6-trimethoxy-6'-methylspiro(benzofuran-2(3H),1'-(2)cyclohexene)-3,4'-dione; (1'S-trans)- 7-Chloro-2',4,6-trimethoxy-6'-methylspiro(benzofuran-2(3H),1'-cyclohex-2'-ene)-3,4'-dione; AS-13736; BT164513; HY-17583; M542; Griseofulvin 100 microg/mL in Acetonitrile; G0384; EN300-52615; BIM-0051396.0001; C06686; D00209; J10209; AB00052005_07; Griseofulvin, VETRANAL(TM), analytical standard; Q416096; SR-01000837512; Griseofulvin, Antibiotic for Culture Media Use Only; Q-201178; SR-01000837512-2; SR-05000001535-1; SR-05000001535-3; SR-05000001535-4; BRD-K08273968-001-05-9; BRD-K08273968-001-09-1; BRD-K08273968-001-19-0; Z1258578352; Griseofulvin, British Pharmacopoeia (BP) Reference Standard; Griseofulvin, from Penicillium griseofulvum, 97.0-102.0%; Griseofulvin, European Pharmacopoeia (EP) Reference Standard; Griseofulvin, United States Pharmacopeia (USP) Reference Standard; Griseofulvin Permeability Diameter, United States Pharmacopeia (USP) Reference Standard; Griseofulvin, Pharmaceutical Secondary Standard; Certified Reference Material; (2S)-trans-7-Chloro-2',4,6-trimethoxy-6'-methylspiro(benzofuran-2[3H],1'-[2]cyclohexene)-3,4'-dione; 107912-37-8; 7-Chloro-2',4,6-trimethoxy-6'-methylspiro[benzofuran-2(3H),1',- [2]cyclohexene]-3,4'-dione"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:27779	DB00400	.	DR0791	352.8	C17H17ClO6	71.1	575	2.2	24	0	6	3	"1S/C17H17ClO6/c1-8-5-9(19)6-12(23-4)17(8)16(20)13-10(21-2)7-11(22-3)14(18)15(13)24-17/h6-8H,5H2,1-4H3/t8-,17+/m1/s1"	C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC	DDUHZTYCFQRHIY-RBHXEPJQSA-N
DG01033	Mometasone	441335	"Mometasone; 105102-22-5; (+)-Mometasone; Mometasonum; Mometasona; CHEBI:6970; (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; UNII-8HR4QJ6DW8; 8HR4QJ6DW8; Mometasone (INN); Mometasonum [Latin]; Mometasona [Spanish]; mometazone; Mometasone, nasal; Elocon (topical); Mometasone, inhaled; Mometasone, topical; Mometasone [INN:BAN]; SCHEMBL4485; GTPL9029; CHEMBL1201404; DTXSID10872412; ZINC4097440; BDBM50237628; DB00764; 9,21-dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; C07816; D08227; 102M225; A902140; Q28208887; 9a,21-Dichloro-11b,17-dihydroxy-16a-methylpregna-1,4-diene-3,20-dione; 9,21-Dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione (Mometasone); (1R,2S,10S,11S,13R,14R,15S,17S)-1-chloro-14-(2-chloroacetyl)-14,17-dihydroxy-2,13,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one; Pregna-1,4-diene-3,20-dione, 9,21-dichloro-11,17-dihydroxy-16-methyl-, (11beta,16alpha)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6970	DB00764	.	.	427.4	C22H28Cl2O4	74.6	806	2.7	28	2	4	2	"1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1"	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)O)C)O)Cl)C	QLIIKPVHVRXHRI-CXSFZGCWSA-N
DG01035	Tolterodine	443879	"Tolterodine; 124937-51-5; Detrusitol; (+)-Tolterodine; Tolterodinum; Tolterodine tartrate; (R)-(+)-Tolterodine; Kabi 2234; Urotrol; Detrol; S-(-)-Tolterodine; Tolterodinum [INN-Latin]; UNII-WHE7A56U7K; Tolterodina [INN-Spanish]; 2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol; CHEMBL1382; WHE7A56U7K; Tolterodine L-Tartrate; CHEBI:9622; 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-methylphenol; (+)-(R)-2-(alpha-(2-(Diisopropylamino)ethyl)benzyl)-p-cresol; Tolterodine [INN]; NCGC00159519-02; Unidet; DSSTox_CID_3687; Phenol, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-methyl-; DSSTox_RID_77147; DSSTox_GSID_23687; (r)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-methylphenol; SMR000596518; CAS-124937-51-5; MFCD07771985; PHA-686464B; PNU 200583; tolterodin; (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-methylphenol; Tolterodine [USAN:INN:BAN]; 2-[(1R)-3-(di(propan-2-yl)amino)-1-phenylpropyl]-4-methylphenol; (R)-2,3-BIS(1-METHYLETHYL)AMINO-1-PHENYLPROPYL-4-METHYLPHENOL; Phenol, 2-((1R)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-methyl-; TolterodineL-tartrate; Tolterondine Tartrate; 2-[3-[Bis(1-Methylethyl)Amino]-1-Phenylpropyl]-4-Methyl Phenol Monohydrobromide; Tolterodine (USAN/INN); SCHEMBL3064; GTPL360; MLS001195620; MLS001304745; BIDD:GT0318; DTXSID3023687; HMS2230E24; ZINC968336; ACT04387; AMY17772; HY-A0024; tolterodine extended release capsules; Tox21_111737; 2-{(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl}-4-methylphenol; BDBM50165008; AKOS015841711; AKOS015895578; Tox21_111737_1; AC-3472; CS-1799; DB01036; KS-5165; NCGC00159519-04; NCGC00263557-01; C07750; D00646; H10328; AB00698547-12; AB00698547_13; 937T515; Q424312; J-005184; Q-200223; 2-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol; 2-[(1r)3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol; (+)-(R)-3-(2-hydroxy-5-methylphenyl)-N,N-diisopropyl-3-phenylpropylamine; 2-[(1R)-3-[BIS(1-METHYLETHYL)AMINO]-1-PHENYLPROPYL]-4-METHYL-PHENOL TARTRATE"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9622	DB01036	.	.	325.5	C22H31NO	23.5	340	5.6	24	1	2	7	"1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1"	CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2	OOGJQPCLVADCPB-HXUWFJFHSA-N
DG01037	Halcinonide	443943	"Halcinonide; 3093-35-4; Halciderm; Halcimat; Halog; Halcinonida; UNII-SI86V6QNEG; SQ 18566; SI86V6QNEG; Halcort; DSSTox_CID_25375; DSSTox_RID_80836; DSSTox_GSID_45375; (1S,2S,4R,8S,9S,11S,12R,13S)-8-(2-chloroacetyl)-12-fluoro-11-hydroxy-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one; (4R,8S)-8-(2-Chloroacetyl)-12-fluoro-11-hydroxy-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one; SQ-18,566; Betacorton; Halcinonidum; HALOG-E; Ascochrom; Volog; SQ-18566; (1S,2S,4R,8S,9S,11S,12R,13S)-8-(2-chloroacetyl)-12-fluoro-11-hydroxy-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icos-17-en-16-one; Halcinonidum [INN-Latin]; Halcinonida [INN-Spanish]; C24H32ClFO5; NSC-758413; NCGC00016621-01; (11 ,16 )-21-Chloro-9-fluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-pregn-4-ene-3,20-dione; CAS-3093-35-4; EINECS 221-439-6; Prestwick_1069; Halog (TN); BRN 1358242; Halcinonide [USAN:USP:INN:BAN:JAN]; Prestwick0_000655; Prestwick1_000655; Prestwick2_000655; Prestwick3_000655; SCHEMBL4335; BSPBio_000689; 5-19-06-00301 (Beilstein Handbook Reference); MLS002153935; Halcinonide (JAN/USP/INN); SPBio_002610; BPBio1_000759; CHEMBL1200845; DTXSID6045375; CHEBI:31663; HMS1570C11; HMS2097C11; HMS2230O07; HMS3714C11; HY-B0877; ZINC4213474; Tox21_110530; s4098; AKOS015962797; Tox21_110530_1; AC-1114; AC-1774; CCG-220655; DB06786; NSC 758413; N6-(Trifluoroacetyl)-L-lysyl-L-proline; NCGC00179475-01; NCGC00179475-03; 21-Chloro-9-fluoro-11beta,16alpha,17-trihydroxypregn-4-ene-3,20-dione cyclic 16,17-acetal with acetone; AS-74757; P753; Pregn-4-ene-3,20-dione, 21-chloro-9-fluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11beta,16alpha)-; SMR001233277; SO 18566; SO-18566; C74589; D01308; 093H354; Q425991; Q-201180; BRD-K81709173-001-03-8; Halcinonide, United States Pharmacopeia (USP) Reference Standard; (1S,2S,4R,8S,9S,11S,12R,13S)-8-(2-CHLOROACETYL)-12-FLUORO-11-HYDROXY-6,6,9,13-TETRAMETHYL-5,7-DIOXAPENTACYCLO[10.8.0.0(2), .0 , .0(1)(3),(1) ]ICOS-17-EN-16-ONE; (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS)-6b-(chloroacetyl)-4b-fluoro-5-hydroxy-4a,6a,8,8-tetramethyl-3,4,4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-tetradecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; Pregn-4-ene-3,20-dione, 21-chloro-9-fluoro-11-beta,16-alpha,17-trihydroxy-, cyclic16,17-acetal with acetone; Pregn-4-ene-3,20-dione,21-chloro-9-fluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(11b,16a)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31663	DB06786	.	DR0798	455	C24H32ClFO5	72.8	887	3.6	31	1	6	2	"1S/C24H32ClFO5/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,26)17(28)11-22(16,4)24(19,31-20)18(29)12-25/h9,15-17,19,28H,5-8,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1"	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CCl)C)O)F	MUQNGPZZQDCDFT-JNQJZLCISA-N
DG01038	Vinpocetine	443955	"Vinpocetine; 42971-09-5; Cavinton; Ceractin; Apovincaminic acid ethyl ester; Ethyl apovincamin-22-oate; Bravinton; TCV-3B; Ethyl (+)-apovincaminate; Ultra-Vinca; RGH 4405; RGH-4405; cis-Apovincaminic acid ethyl ester; (+)-Apovincaminic acid ethyl ester; Ethyl (+)-cis-apovincaminate; (+)-cis-Apovincaminic acid ethyl ester; AY 27,255; TCV 3B; Ethyl apovincaminate; UNII-543512OBTC; 3-alpha,16-alpha-Apovincaminic acid ethyl ester; Eburnamenine-14-carboxylic acid ethyl ester; CHEMBL71752; MLS000069635; 543512OBTC; MFCD00211233; NSC-760093; (41S,13aS)-ethyl 13a-ethyl-2,3,41,5,6,13a-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate; NCGC00018204-09; Vinpocetinum; C22H26N2O2; SMR000058241; AY-27,255; Eburnamenine-14-carboxylic acid, ethyl ester, (3alpha,16alpha)-; DSSTox_CID_3740; DSSTox_RID_77176; DSSTox_GSID_23740; ethyl (41S,13aS)-13a-ethyl-2,3,41,5,6,13a-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate; Vinpocetinum [INN-Latin]; Eburnamenine-14-carboxylic acid, ethyl ester, (3a,16a)-; Apovincaminate d'ethyle; Vinporal; Apovincaminate d'ethyle [French]; 1H-Indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine, eburnamenine-14-carboxylic acid deriv.; SR-01000075633; EINECS 256-028-0; BRN 0900803; Vinpocetin; Vinpocetine (JAN/USAN/INN); Vinpocetine-ethyl apovincaminate; 3A,16A-Apovincaminic acid ethyl ester; NCGC00016854-03; Vinpocetine [USAN:INN:BAN:JAN]; Prestwick_963; Vinpocetin- Bio-X; CAS-42971-09-5; Spectrum_001400; Vinpocetine (Cavinton); AY 27255; SpecPlus_000327; Opera_ID_1325; Prestwick0_000268; Prestwick1_000268; Prestwick2_000268; Prestwick3_000268; Spectrum2_001529; Spectrum3_000961; Spectrum4_001075; Spectrum5_000966; V 6383; Lopac0_001257; SCHEMBL50081; BSPBio_000116; BSPBio_002561; KBioGR_001430; KBioSS_001880; MLS001076294; DivK1c_006423; SPECTRUM1503115; Vinpocetine, >=98%, solid; ethyl (3alpha,16alpha)-eburnamenine-14-carboxylate; SPBio_001318; SPBio_002335; BPBio1_000128; cid_443955; GTPL5285; Vinpocetine, analytical standard; DTXSID5023740; REGID_for_CID_443955; CHEBI:32297; KBio1_001367; KBio2_001880; KBio2_004448; KBio2_007016; KBio3_001781; HMS1568F18; HMS1922G05; HMS2090J22; HMS2092L06; HMS2095F18; HMS3263L16; HMS3402D12; HMS3411H11; HMS3675H11; HMS3712F18; HMS3887E17; Pharmakon1600-01503115; (3alpha, 16alpha)-Eburnamenine-14-carboxylic acid ethyl ester; 68780-77-8; AMY39087; BCP04123; Tox21_110648; Tox21_110839; Tox21_501257; BDBM50059033; CCG-39307; Eburnamenine-14-carboxylic acid, ethyl ester, (3-alpha,16-alpha)-; NSC760093; PD-185; s2110; ZINC19796031; AKOS015896480; Tox21_110648_1; CS-0545; DB12131; LP01257; NSC 760093; SDCCGSBI-0051224.P003; Vinpocetine 1.0 mg/ml in Acetonitrile; (3S,16S)-apovincaminic acid ethylester; NCGC00018204-05; NCGC00018204-06; NCGC00018204-07; NCGC00018204-08; NCGC00018204-10; NCGC00018204-11; NCGC00018204-13; NCGC00021727-04; NCGC00021727-05; NCGC00021727-06; NCGC00021727-07; NCGC00168782-01; NCGC00261942-01; NCGC00263865-01; NCGC00263865-04; AC-22612; AS-13868; AY-27255; BV164528; HY-13295; Eburnamenine-14-carboxylic acid ethyl ester;; EU-0101257; D01371; J10479; AB00052317_02; 971V095; Q420288; SR-01000000118; SR-01000000118-3; SR-01000075633-1; SR-01000075633-3; SR-01000075633-4; W-202748; BRD-K53318339-001-05-8; (3 ,16 )-Eburnamenine-14-carboxylic acid ethyl ester; Vinpocetine, European Pharmacopoeia (EP) Reference Standard; (3alpha,16alpha)-Eburnamenine-14-carboxylic acid ethyl ester; Vinpocetine, United States Pharmacopeia (USP) Reference Standard; (11aS,11bS)-11a-Ethyl-2,3,4,5,11a,11b-hexahydro-1H-3a,9b-diaza-benzo[cd]fluoranthene-10-carboxylic acid ethyl ester; (3aS,11bS)-3a-ethyl-1,2,3,3a,10,11b-hexahydro-11H-5a,11a-diaza-benzo[cd]fluoranthene-5-carboxylic acid ethyl ester; 115986-87-3; 11a-Ethyl-2,3,4,5,11a,11b-hexahydro-1H-3a,9b-diaza-benzo[cd]fluoranthene-10-carboxylic acid 2-nitrooxy-ethyl ester(Vinpocetine); ethyl (15S,19S)-15-ethyl-1,11-diazapentacyclo[9.6.2.0^{2,7}.0^{8,18}.0^{15,19}]nonadeca-2,4,6,8(18),16-pentaene-17-carboxylate; ethyl (15S,19S)-15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18),16-pentaene-17-carboxylate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:32297	DB12131	.	DR1697	350.5	C22H26N2O2	34.5	617	4.1	26	0	3	4	"1S/C22H26N2O2/c1-3-22-11-7-12-23-13-10-16-15-8-5-6-9-17(15)24(19(16)20(22)23)18(14-22)21(25)26-4-2/h5-6,8-9,14,20H,3-4,7,10-13H2,1-2H3/t20-,22+/m1/s1"	CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4C(=C2)C(=O)OCC	DDNCQMVWWZOMLN-IRLDBZIGSA-N
DG01039	Tibolone	444008	"Tibolone; 5630-53-5; Liviella; Livial; Tibolona; Tibolonum; Xyvion; Org OD 14; Boltin; UNII-FF9X0205V2; (7R,8R,9S,13S,14S,17R)-17-ethynyl-17-hydroxy-7,13-dimethyl-1,2,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one; 17-Hydroxy-7alpha-methyl-19-nor-17alpha-pregn-5(10)-en-20-yn-3-one; CHEBI:32223; FF9X0205V2; (1S,9R,10R,11S,14R,15S)-14-ethynyl-14-hydroxy-9,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-2(7)-en-5-one; DSSTox_CID_3667; (7alpha,17alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one; DSSTox_RID_77135; DSSTox_GSID_23667; 17alpha-ethynyl-17beta-hydroxy-7alpha-methylestr-5(10)-en-3-one; (17R)-17-hydroxy-7alpha-methyl-19-norpregn-5(10)-en-20-yn-3-one; (7alpha,17beta)-17-ethynyl-17-hydroxy-7-methylestr-5(10)en-3-one; CAS-5630-53-5; Tibolonum [INN-Latin]; Tibolona [INN-Spanish]; Tibolone [USAN:INN:BAN]; Tibofem; NSC-759898; NCGC00164632-01; EINECS 227-069-1; Org-OD14; SCHEMBL41172; Tibolone (JAN/USAN/INN); MLS001424234; ORG-OD 14; GTPL9711; CHEMBL2103774; DTXSID5023667; HMS2052K21; HMS2090B10; HMS2232B13; HMS3649J14; HMS3712J15; ZINC3812889; Tox21_112250; KB-889; AKOS015963197; Tox21_112250_1; CCG-101148; DB09070; GS-3562; NC00398; NSC 759898; NCGC00164632-02; (7beta,8xi,9beta,13alpha,14beta,17alpha)-17-ethynyl-17-hydroxy-7-methylestr-5(10)-en-3-one; AC-20036; AC-31722; CPD000469219; H052; SMR000469219; D01639; T-3854; AB00698273-05; 630T535; Q413805; SR-01000763531; SR-01000946727; SR-01000763531-3; SR-01000946727-1; 17.alpha.-Hydroxy-7.alpha.-methyl-19-norpregn-5(10)-en-20-yn-3-one; 19-Norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7alpha,17alpha)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:32223	DB09070	.	DR1590	312.4	C21H28O2	37.3	636	2.4	23	1	2	1	"1S/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,13,17-19,23H,5-12H2,2-3H3/t13-,17-,18+,19-,20+,21+/m1/s1"	C[C@@H]1CC2=C(CCC(=O)C2)[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C#C)O	WZDGZWOAQTVYBX-XOINTXKNSA-N
DG01041	Fluvastatin	446155	"Fluvastatin; Lescol; 93957-54-1; (3R,5S)-fluvastatin; Canef; Cranoc; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (+)-(3R,5S)-fluvastatin; XU-62320; CHEBI:38565; 155229-75-7; Vastin; (+)-3R,5S-Fluvastatin sodium salt; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,E)-7-(3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; CHEMBL1078; Fluvastatin & Primycin; NSC-758896; (-)-fluvastatin; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-isopropyl-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid; DSSTox_CID_636; Prestwick2_000859; SCHEMBL2846; DSSTox_RID_75707; DSSTox_GSID_20636; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; SCHEMBL556754; GTPL2951; DTXSID2020636; BDBM86704; CHEBI:93160; HMS2089P06; HMS3259J15; Pharmakon1600-01504911; ACT03305; ZINC1886617; Tox21_302765; DL-108; HY-14664B; NSC758896; CCG-213323; NC00659; NCGC00256490-01; CAS-93957-54-1; CAS_93957-54-1; CS-0019897; EN300-51915; H11963; 957F541; Q417942; SR-05000001489-1; BRD-K66296774-001-02-0; UNII-4L066368AS component FJLGEFLZQAZZCD-MCBHFWOFSA-N; (E)-(3R,5S)-7-[3-(4-Fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid; 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3R,5S,6E)-; Fluvastatin sodium L1483"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:38565	DB01095	DR00124	.	411.5	C24H26FNO4	82.7	590	3.5	30	3	5	8	"1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1"	CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F	FJLGEFLZQAZZCD-MCBHFWOFSA-N
DG01042	Cerivastatin	446156	"Cerivastatin; Baycol; cerivastatin acid; 145599-86-6; Lipobay; UNII-AM91H2KS67; AM91H2KS67; CHEBI:3558; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,E)-7-(4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl)-3,5-dihydroxyhept-6-enoic acid; 143201-11-0; [S-[R*,S*-(E)]]-7-[4-(4-fluorophenyl)-5-methoxymethyl)-2,6bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-6-heptenoate; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3R,5S,6E)-; 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)-; Cerivastatin [INN:BAN]; Cervastatin; Cerivastatin sodium salt hydrate; HSDB 7357; (3R,5S,6E)-7-{4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(methyloxy)methyl]pyridin-3-yl}-3,5-dihydroxyhept-6-enoic acid; 159813-78-2; Cerivastatin (INN); CHEMBL1477; SCHEMBL16346; SCHEMBL16347; BIDD:GT0367; GTPL2950; DTXSID9022786; BDBM18376; CHEBI:94755; HMS2089B11; ZINC11330186; DB00439; (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (S-(R*,S*-(E)))-; HY-129458; CS-0105635; C07966; D07661; AB01275453-01; 599C866; Q423439; SR-01000763520; SR-01000763520-3; BRD-K81169441-236-04-1; (3R,5S,6E)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid; rel-(3R,5S,E)-7-(4-(4-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl)-3,5-dihydroxyhept-6-enoic acid; rel-(3R,5S,E)-7-(4-(4-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl)-3,5-dihydroxyhept-6-enoicacid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3558	DB00439	DR00391	.	459.5	C26H34FNO5	99.9	620	3.6	33	3	7	11	"1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1"	CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O	SEERZIQQUAZTOL-ANMDKAQQSA-N
DG01044	Fosfomycin	446987	"FOSFOMYCIN; phosphomycin; Phosphonomycin; 23155-02-4; Fosfonomycin; Fosfocina; Monurol; Veramina; Fosfomicina; Fosfomycine; Fosfomycinum; [(2R,3S)-3-methyloxiran-2-yl]phosphonic acid; Antibiotic 833A; Phosphonemycin; Phosphonic acid, (3-methyloxiranyl)-, (2R-cis)-; UNII-2N81MY12TE; Phosphomycin disodium salt; (2R-cis)-(3-Methyloxiranyl)phosphonic acid; (1R,2S)-epoxypropylphosphonic acid; L-cis-1,2-epoxypropylphosphonic acid; (-)-(1R,2S)-(1,2-Epoxypropyl)phosphonic acid; CHEMBL1757; Phosphonicacid, P-[(2R,3S)-3-methyl-2-oxiranyl]-; Fosfomycin disodium salt; 2N81MY12TE; CHEBI:28915; FCM; Phosphonic acid, (1,2-epoxypropyl)-, (1R,2S)-(-)-; (1R,2S)-epoxypropylphosphonate; cis-(1R,2S)-epoxypropylphosphonic acid; Calcium fosfomycin; 1R-cis-(1,2-epoxypropyl)phosphonic acid; ((2R,3S)-3-methyloxiran-2-yl)phosphonic acid; Fosfomicin; Infectophos; 1,2-EPOXYPROPYLPHOSPHONIC ACID; Levo-phosphonomycin; Fosfomycin (USAN/INN); Fosfomycine [INN-French]; Fosfomycinum [INN-Latin]; Fosfomicina [INN-Spanish]; Fosfomycin [USAN:INN:BAN]; J01XX01; EINECS 245-463-1; MK-955; BRN 1680831; 883A; NSC-758170; Fosfomycin (compound 1); Fosfomycinfor culture media; SCHEMBL50951; BIDD:GT0448; BRN 1680831, Fosfocina; ZTI-01; DTXSID4048480; GTPL10813; BCP24891; ZINC1530427; BDBM50024894; cis-(2-Methyloxiranyl)-phosphonic acid; DB00828; (2R,3S)-3-methyloxiran-2-ylphosphonate; 25030-76-6; (1R, 2S)-1,2-epoxypropyl-phosphonic acid; FT-0774116; (2R,3S)-3-methyloxiran-2-ylphosphonic acid; (3-Methyl-oxiranyl)-phosphonic acid(Na salt); C06454; D04253; Q183554; W-107422; BRD-K81101512-234-01-9; Phosphonic acid, P-[(2R,3S)-3-methyl-2-oxiranyl]-; 6F066DFF-696A-4A94-AF78-A28430EBE5BA"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:28915	DB00828	.	DR0749	138.06	C3H7O4P	70.1	138	-1.4	8	2	4	1	"1S/C3H7O4P/c1-2-3(7-2)8(4,5)6/h2-3H,1H3,(H2,4,5,6)/t2-,3+/m0/s1"	C[C@H]1[C@H](O1)P(=O)(O)O	YMDXZJFXQJVXBF-STHAYSLISA-N
DG01046	Diethylstilbestrol	448537	"Diethylstilbestrol; 56-53-1; Stilbestrol; Stilboestrol; Distilbene; Agostilben; Estrobene; Estromenin; Stilboestroform; Antigestil; Palestrol; Stilbetin; Synestrin; Vagestrol; Fonatol; Diethylstilbesterol; Menostilbeen; Oestrogenine; Oestromensyl; Oestromienin; Stilbestrone; Synthoestrin; Comestrol; Cyren A; Domestrol; Dyestrol; Estrosyn; Grafestrol; Iscovesco; Microest; Milestrol; Oestromenin; Pabestrol; Sexocretin; Stilboefral; Stilbofolin; Synthofolin; Syntofolin; Diastyl; Makarol; Micrest; Serral; Stilkap; Bufon; Cyren; Desma; Sibol; OeKolp; Dawe's destrol; Hi-Bestrol; Di-Estryl; Dietilestilbestrol; Neo-Oestranol I; Rumestrol 1; Rumestrol 2; Stil-Rol; Acnestrol; Climaterine; Dibestrol; Dicorvin; Gynopharm; Idroestril; Oestromensil; Oestromon; Protectona; Sedestran; Sintestrol; Stibilium; Tylosterone; Comestrol estrobene; Stilbol; Diethylstilboesterol; Oestrol vetag; trans-Diethylstilbestrol; DiBestrol 2 Premix; Bio-des; Estilbin MCO; (E)-Diethylstilbestrol; STIL; neo-Oestranol 1; Tampovagan stilboestrol; DES; Dibestrol '2' premix; trans-Diethylstilbesterol; Synthestrin; trans-Diethylstilboesterol; DES (synthetic estrogen); Stilbestrol, diethyl-; (E)-3,4-Bis(4-hydroxyphenyl)-3-hexene; New-Estranol 1; Diethylstilbestrolum; Percutatrine oestrogenique iscovesco; (E)-4,4'-(hex-3-ene-3,4-diyl)diphenol; 4,4'-Dihydroxydiethylstilbene; Rcra waste number U089; 4-[(E)-4-(4-hydroxyphenyl)hex-3-en-3-yl]phenol; diethylstilbestrol (DES); 6898-97-1; NSC-3070; Phenol, 4,4'-[(1E)-1,2-diethyl-1,2-ethenediyl]bis-; 4,4'-(3E)-hex-3-ene-3,4-diyldiphenol; cis-Des; (E)-4,4'-(1,2-Diethyl-1,2-ethenediyl)bisphenol; UNII-731DCA35BT; Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-; trans-4,4'-(1,2-Diethyl-1,2-ethenediyl)bisphenol; 4,4'-Dihydroxy-alpha,beta-diethylstilbene; alpha,alpha'-Diethyl-(E)-4,4'-stilbenediol; CHEMBL411; 4,4'-(Hex-3-ene-3,4-diyl)diphenol; 731DCA35BT; Tampovagan; Destrol; CHEBI:41922; Estril; .alpha.,.alpha.'-Diethylstilbenediol; Diethyl stilbestrol; E-Diethylstilbestrol; strobene; Diaethylstilboestrolum; Estrogenine; Stilbestroform; cis-Diethylstilbesterol; Diethylstilbestrol, mixture of cis and trans; DSSTox_CID_465; 3,4-Bis(p-hydroxyphenyl)-3-hexene; Dietilstilbestrolo; DSSTox_RID_75608; DSSTox_GSID_20465; Dietilstilbestrolo [DCIT]; Dietilestilbestrol [Spanish]; 4,4'-Stilbenediol, .alpha.,.alpha.'-diethyl-, (E)-; Phenol, 4,4'-((1E)-1,2-diethyl-1,2-ethenediyl)bis-; alpha,alpha'-Diethylstilbenediol; Diethylstilbestrolum [INN-Latin]; Dietilestilbestrol [INN-Spanish]; MFCD00002373; Stilbestrol (TN); MG 137; SMR000058263; CCRIS 240; Estilbin ''MCO''; HSDB 3060; SR-01000745070; EINECS 200-278-5; RCRA waste no. U089; BRN 2056095; Stilbestro; Bertrol; Diethylstilbestrol (USP/INN); TRANS-DIETHYSTILBESTEROL; cis-alpha,alpha'-Diethyl-4,4'-stilbenediol; 4,4'-(3-HEXENE-3,4-DIYL)DIPHENOL; 3erd; CAS-56-53-1; NCGC00090749-04; Diethylstilbestrol [USP:INN:BAN]; 4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)-; Prestwick_1070; (Z)-4,4'-(1,2-Diethyl-1,2-ethylenediyl)bisphenol; Phenol 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-; trans-Diethyl Stilbestrol; Diethylstilbestrol [Nonsteroidal oestrogens]; Prestwick2_000756; Prestwick3_000756; Spectrum5_000799; 4, 2,2'-diethyl-; SCHEMBL9223; BSPBio_000772; BSPBio_002201; 4,4'-Stilbenediol, alpha,alpha'-diethyl-, (Z)-; MLS000028447; MLS002174252; MLS002222298; BIDD:ER0159; SPECTRUM1500244; 4-[(3E)-4-(4-hydroxyphenyl)hex-3-en-3-yl]phenol; BPBio1_000850; GTPL2801; trans-.alpha.,4'-stilbenediol; ZINC1290; 4, .alpha.,.alpha.-diethyl-; 4-[(E)-1-ethyl-2-(4-hydroxyphenyl)but-1-enyl]phenol; DTXSID3020465; REGID_for_CID_448537; BDBM20625; CHEBI:92795; HMS501J21; RGLYKWWBQGJZGM-ISLYRVAYSA-; 4, .alpha.,.alpha.'-diethyl-; NSC3070; WLN: QR DY2&UY2&R DQ; 3,4'-Dihydroxyphenyl)hex-3-ene; HMS1570G14; HMS1920G08; HMS2090C14; HMS2091M18; HMS2097G14; HMS2232N11; HMS3650A09; HMS3714G14; Pharmakon1600-01500244; 3-Hexene,4-bis(p-hydroxyphenyl)-; NSC 3070; Tox21_202407; Tox21_300526; CCG-38961; Diethylstilbestrol, >=99% (HPLC); NSC756736; Phenol, 4,4'-(1,2-diethyl-1,2-ethylenediyl)bis-, (Z)- (9CI); s1859; STK366318; 3,4-Bis(4-hydroxyphenyl)-3-hexene; AKOS005111142; DIETHYLSTILBESTROL (diethylstilbestr; 4,2-Diethyl-1,2-ethenediyl)bisphenol; DB00255; NSC-756736; IDI1_000519; NCGC00090749-01; NCGC00090749-02; NCGC00090749-03; NCGC00090749-05; NCGC00090749-06; NCGC00090749-07; NCGC00090749-08; NCGC00090749-09; NCGC00090749-15; NCGC00254539-01; NCGC00259956-01; 4, .alpha.,.alpha.'-diethyl-, (E)-; AS-13377; HY-14598; I027; LS-14649; Diethylstilbestrol,mixture of cis and trans; SBI-0051346.P003; 3,4-Bis(p-hydroxyphenyl)-3-hexene, trans; CS-0369240; D0526; SW197137-4; .alpha.,.alpha.'-Diethyl-4,4'-stilbenediol; 3,4-(Di-4-hydroxyphenyl)hex-3-ene, (E)-; 3-Hexene,3,4-bis(p-hydroxyphenyl)-, (E)-; 4,4'-Dihydroxy-.alpha.,.beta.-diethylstilbene; C07620; D00577; D81873; .alpha.,.alpha.'-Diethyl-(E)-4,4'-stilbenediol; 002D373; A831077; Diethylstilbestrol, mixture of cis and trans, 97%; Q423989; SR-01000745070-3; SR-01000745070-4; SR-01000745070-5; SR-01000745070-9; trans-.alpha.,.alpha.'-Diethyl-4,4'-stilbenediol; trans-.alpha.,.alpha.'-diethyl-4-4'-stilbenediol; 4,4'-(1,2-Diethyl-1,2-ethenediyl)bisphenol, trans; 4,4'-Stilbenediol, .alpha.,.alpha.-diethyl-, (E)-; BRD-K17084514-001-01-7; BRD-K45330754-001-09-2; Diethylstilbestrol, VETRANAL(TM), analytical standard; Phenol,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-; 4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8CI); Diethylstilbestrol, European Pharmacopoeia (EP) Reference Standard; Diethylstilbestrol, United States Pharmacopeia (USP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:41922	DB00255	DR00922	DR0492	268.3	C18H20O2	40.5	286	5.1	20	2	2	4	"1S/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3/b18-17+"	CC/C(=C(/CC)\\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O	RGLYKWWBQGJZGM-ISLYRVAYSA-N
DG01047	Octreotide	448601	"Octreotide; Octreotide acetate; 83150-76-9; Sandostatin; SMS 201-995; UNII-RWM8CCW8GP; Longastatin; RWM8CCW8GP; 79517-01-4; SMS-201-995; CHEMBL1680; 83150-76-9 (free base); MFCD00871400; Octreotidum [Latin]; Octreotida [Spanish]; Octrotide; (4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-19-((R)-2-amino-3-phenylpropanamido)-10-(4-aminobutyl)-16-benzyl-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide; [R-(R*,R*)]-D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxy-methyl)propyl]-cysteinamide cyclic(2-->7)-disulfide; Octreotida; Octreotidum; DRG-0115; Octreotide-LAR; SMS-995; Octreotide [USAN:INN:BAN]; Octreotode Acetate; (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide; SMS995; Octreotide, >=98% (HPLC); SCHEMBL10044649; HMS2090C09; 10-(4-Amino-butyl)-19-(2-amino-3-phenyl-propionylamino)-16-benzyl-7-(1-hydroxy-ethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaaza-cycloicosane-4-carboxylic acid (2-hydroxy-1-hydroxymethyl-propyl)-amide; EX-A4865; BDBM50272772; AKOS015994656; CCG-270610; DB00104; HS-2020; AC-28733; L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2-7)-disulfide, (R-(R*,R*))-; 10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate; 17O014; 79517-01-4b; AB01275486-01; Q419935; Q-201501; H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol disulfide bond acetate salt; (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenyl-propanoyl]amino]-16-benzyl-7-[(1R)-1-hydroxyethyl]-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide; 10-(4-Amino-butyl)-19-(2-amino-3-phenyl-propionylamino)-16-benzyl-7-(1-hydroxy-ethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaaza-cycloicosane-4-carboxylic acid (2-hydroxy-1-; 2-{[(13R,16S,19R)-10-(4-Amino-butyl)-19-((S)-2-amino-3-phenyl-propionylamino)-16-benzyl-7-(1-hydroxy-ethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaaza-cycloicosane-4-carbonyl]-amino}-3-hydroxy-butyric acid; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide Cyclic (2-7)-Disulfide Acetate; L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*,R*))-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00104	DR01163	.	1019.2	C49H66N10O10S2	383	1740	1	71	13	14	17	"1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1"	C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O	DEQANNDTNATYII-OULOTJBUSA-N
DG01050	Pretomanid	456199	"Pretomanid; PA-824; 187235-37-6; PA 824; PA824; (S)-2-Nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (S)-PA 824; UNII-2XOI31YC4N; 2XOI31YC4N; CHEMBL227875; MMV688755; (6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (6S)-2-NITRO-6-{[4-(TRIFLUOROMETHOXY)PHENYL]METHOXY}-5H,6H,7H-IMIDAZO[2,1-B][1,3]OXAZINE; Pretomanid [USAN:INN]; Dovprela; C14H12F3N3O5; Pretomanid (TN); PA-824(Pretomanid); Pretomanid (USAN/INN); MLS006011141; SCHEMBL2983011; DTXSID8041163; GTPL11172; AOB1594; EX-A1749; ZINC3821675; BDBM50363237; CS1245; MFCD06809939; s1162; AKOS024464713; CCG-268145; DB05154; DS-7321; PA- 824; QC-5184; 2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo(2,1-b)(1,3)oxazine; NCGC00346682-01; NCGC00346682-02; AC-25501; HY-10844; SMR004702918; SW220281-1; X6951; D10722; A855886; SR-05000022748; Q7118312; SR-05000022748-1; (S)-2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; {4-[((3S)-6-Nitro(2H,3H,4H-imidazolo[2,1-b]1,3-oxazaperhydroin-3-yloxy))methyl]phenoxy}trifluoromethane; 5H-Imidazo(2,1-b)(1,3)oxazine, 6,7-dihydro-2-nitro-6-((4-(trifluoromethoxy)phenyl)methoxy)-, (6S)-; PA-824; ; ; (6S)-2-Nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; Pretomanid;(6S)-6,7-Dihydro-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-5H-imidazo[2,1-b][1,3]oxazine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB05154	.	DR1338	359.26	C14H12F3N3O5	91.3	468	2.8	25	0	9	4	"1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1"	C1[C@@H](COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F	ZLHZLMOSPGACSZ-NSHDSACASA-N
DG01051	Cefamandole	456255	"Cefamandole; Cefadole; 34444-01-4; Cephadole; CEPHAMANDOLE; Cefamandol; Cefamandolum; L-Cefamandole; Compound 83405; UNII-5CKP8C2LLI; CHEBI:3480; 5CKP8C2LLI; (6R,7R)-7-(R)-Mandelamido-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Kefdole; (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Kefamandol; Mancef; (6R,7R)-7-((R)-2-hydroxy-2-phenylacetamido)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[(2-hydroxy-2-phenylacetyl)amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 30034-03-8; Cefamandol [INN-Spanish]; Cefamandole (USAN/INN); Cefamandolum [INN-Latin]; free form; Cefamandole [USAN:INN:BAN]; EINECS 252-030-0; BRN 0598510; Prestwick0_000747; Prestwick1_000747; Prestwick2_000747; Prestwick3_000747; Epitope ID:141490; 7-D-Mandelamido-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-3-cephem-4-carboxylic acid; CHEMBL1146; SCHEMBL37287; BSPBio_000734; COMPOUND-83405; SPBio_002673; BPBio1_000808; DTXSID7022750; J01DC03; HY-B1128; ZINC3830394; BDBM50350468; AKOS025401365; AC-1294; CS-4724; DB01326; (6R,7R)-7-[[(2R)-2-hydroxy-2-phenyl-acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((hydroxyphenylacetyl)amino)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-(6alpha,7beta(R*)))-; 7beta-[(2R)-2-hydroxy-2-phenylacetamido]-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid; C06879; D02344; 444C014; Cefamandole, Antibiotic for Culture Media Use Only; Q2601530; W-106736; BRD-K27130738-236-03-4; (6R,7R)-7-((R)-2-hydroxy-2-phenylacetamido)-3-((1-methyl-1H-tetrazol-5-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[(2R)-2-hydroxy-2-phenylacetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R,7R)-; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, 6R,7R)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3480	DB01326	DR00551	.	462.5	C18H18N6O5S2	201	777	-0.9	31	3	10	7	"1S/C18H18N6O5S2/c1-23-18(20-21-22-23)31-8-10-7-30-16-11(15(27)24(16)12(10)17(28)29)19-14(26)13(25)9-5-3-2-4-6-9/h2-6,11,13,16,25H,7-8H2,1H3,(H,19,26)(H,28,29)/t11-,13-,16-/m1/s1"	CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)[C@@H](C4=CC=CC=C4)O)SC2)C(=O)O	OLVCFLKTBJRLHI-AXAPSJFSSA-N
DG01052	Dactinomycin	457193	"DACTINOMYCIN; actinomycin D; Actinomycin C1; Actinomycin IV; Cosmegen; Meractinomycin; 50-76-0; Dactinomycinum; ActD; Actinomycin I1; Oncostatin K; ACT D; Dactinomycine [INN-French]; Dactinomycinum [INN-Latin]; UNII-1CC1JFE158; Dactinomicina [INN-Spanish]; Lyovac cosmegen; Dactinomycin D; Chounghwamycin B; Actinomycin 7; ACTINOMYCIN-D; NCI-C04682; MFCD00005033; Dilactone actinomycin D acid; Actinomycin Aiv; Actinomycin I; GNF-Pf-2290; MLS001424196; 1CC1JFE158; Actinomycin X1; CHEBI:27666; Actinomycin X 1; Actinomycin A IV; Acto-D; Actactinomycin A IV; Actinomycin C(sub1); Dilactone actinomycindioic D acid; NCGC00161622-02; Actinomycin I(sub 1); SMR000469227; DSSTox_CID_31; Actinomycin 11 cosmegen; Cosmegen Lyovac; Lyovac-Cosmegen; CCRIS 9; DSSTox_RID_75330; DSSTox_GSID_20031; 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide; HSDB 3220; Dactinomicina; Dactinomycine; Actinomycindioic D acid, dilactone; Antibiotic from Streptomyces parvullus; Actinomycin-(threo-val-pro-sar-meval); CAS-50-76-0; ACT [antibiotic]; X 97; 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide; AD (VAN); GNF-PF-1977; NSC3053; NSC-3053; Glycopeptide, 4a; 2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide; NSC 3053; Dactinomycin [USAN:USP:INN:BAN]; EINECS 200-063-6; AI3-26374; UPCMLD-DP055; SCHEMBL3844; CHEMBL1554; cid_457193; DTXSID9020031; UPCMLD-DP055:001; UPCMLD-DP055:002; BDBM43866; HMS2052O17; Tox21_111997; Tox21_202482; BDBM50089528; s8964; AKOS030228553; Tox21_111997_1; CCG-101134; DB00970; NC00384; NCGC00090796-01; NCGC00161622-01; NCGC00260031-01; NCGC00271789-02; 3H-Phenoxazine-1,9-dicarboxamide, 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-; BP-25384; Specific stereoisomer of N,N'-((2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)-bis(carbonylimino(2-hydroxypropylidene)carbonyliminoisobutylidenecarbonyl-1,2-pyrrolidinediylcarbonyl(methylimino)methylenecarbonyl))bis(N-methyl-L-valine) dilactone; Stereoisomer of N,N'-((2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)bis(carbonylimino(2-(1-hydroxyethyl)-1-oxo-2,1-ethanediyl)imino(2-(1-methylethyl)-1-oxo-2,1-ethanediyl)-1,2-pyrrolidinediylcarbonyl(methylimino) (1-oxo-2,1-ethanediyl)))bis(N-methyl-L-valine)di-xi-lactone; AB00514445-05; 050A760; Q186127; SR-01000763161; SR-01000763161-4; Actinomycin D, from Streptomyces sp., >=95% (HPLC); Actinomycin D, from Streptomyces sp., ~98% (HPLC); BRD-K70578146-001-01-8; BRD-K70578146-001-04-2; UNII-0OCC969V50 component RJURFGZVJUQBHK-IIXSONLDSA-N; Dactinomycin, United States Pharmacopeia (USP) Reference Standard; Actinomycin D, for fluorescence, >=90% (HPLC), from Streptomyces sp.; Actinomycin D, from Streptomyces sp., suitable for cell culture, >=95%; 1-N,9-N-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide; 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis-[(18aS)-10c,14,17-trimethyl-5,8,12,15,18-pentaoxo-6c,13t-di(propan-2-yl)-18ar-hexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-9c-yl]-3H-phenoxazine-1,9-dicarboxamide; 2-amino-4,6-dimethyl-3-oxo-N1,N9-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide; 2-amino-N,N''''''''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide; 2-amino-N,N''''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide; 2-amino-N,N''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide; 2-amino-N1,N9-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-phenoxazine-1,9-dicarboxamide; 2-azanyl-4,6-dimethyl-3-oxidanylidene-N1,N9-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentakis(oxidanylidene)-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00970	.	.	1255.4	C62H86N12O16	356	3030	3.8	90	5	18	8	"1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1"	C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C	RJURFGZVJUQBHK-IIXSONLDSA-N
DG01053	Tiazofurin	457954	"TIAZOFURIN; Tiazofurine; 60084-10-8; Riboxamide; 2-b-D-Ribofuranosyl-4-thiazolecarboxamide; Tiazofurinum; Tiazofurina; Tiazofurin [USAN]; TCAR; NSC-286193; UNII-ULJ82834RE; CI-909; Tiazofurine (INN); Tiazofurin (USAN); 2-beta-D-Ribofuranosyl-4-thiazolecarboxamide; ULJ82834RE; CHEBI:90239; Tiazofurine [INN]; 2-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)thiazole-4-carboxamide; Tiazofurinum [Latin]; Tiazofurina [Spanish]; 2-(beta-D-ribofuranosyl)-4-thiazolecarboxamide; (1R)-1,4-anhydro-1-(4-carbamoyl-1,3-thiazol-2-yl)-D-ribitol; (1r)-1-[4-(Aminocarbonyl)-1,3-Thiazol-2-Yl]-1,4-Anhydro-D-Ribitol; BRN 1084555; Cpd-5825; 2-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]thiazole-4-carboxamide; 2-beta-D-Ribofuranosylthiazole-4-carboxamide; 4-Thiazolecarboxamide, 2-beta-D-ribofuranosyl-; SCHEMBL4287; 2-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-thiazole-4-carboxamide; DIBUTYLAMINEHYDROCHLORIDE; CHEMBL108358; DTXSID00208827; ZINC4217560; 8957AB; BDBM50368057; MFCD00866494; DB13243; BS-17271; HY-114570; CS-0063433; C22196; D06130; W18798; Q7800305"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:90239	.	.	DR2129	260.269	C9H12N2O5S	154	305	-1.7	17	4	7	3	"1S/C9H12N2O5S/c10-8(15)3-2-17-9(11-3)7-6(14)5(13)4(1-12)16-7/h2,4-7,12-14H,1H2,(H2,10,15)/t4-,5-,6-,7-/m1/s1"	C1=C(N=C(S1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N	FVRDYQYEVDDKCR-DBRKOABJSA-N
DG01054	Efinaconazole	489181	"EFINACONAZOLE; 164650-44-6; (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; KP-103; JUBLIA; UNII-J82SB7FXWB; KP103; J82SB7FXWB; CHEBI:82718; 164905-19-5; (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; Kp 103; Efinaconazole [USAN:INN]; efinaconazol; efinaconazolum; Clenafin; IDP-108; Clenafin (TN); Jublia (TN); Efinaconazole(KP-103); Efinaconazole; KP-103; SCHEMBL300738; ZINC6251; CHEMBL2103877; Efinaconazole (JAN/USAN/INN); C18H22F2N4O; HSDB 8341; DTXSID40167787; BCP11665; EX-A2643; 2856AH; MFCD00936406; s5025; AKOS027323571; CCG-268012; CS-3500; DB09040; NCGC00390702-01; NCGC00390702-02; NCGC00390702-03; (2R,3R)-2-(2,4-Difluorofenil)-3-(4-metilenopiperidin-1-il)-1-(1H-1,2,4-triazin-1-il)butan-2-ol; AC-30630; AS-30126; HY-15660; D10021; A854585; Q21011225; (2R, 3R)-2-(2,4-Difluorophenyl)-3-(4-methylenepiperidyl)-1-(1,2,4-triazolyl)butan-2-ol; (2R,3R)-2-(2,4-Difluorophenyl)-3-(4-methylene-1-piperidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol; (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylene-1-piperidyl)-1-(1,2,4-triazol-1-yl)butan-2-ol; (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidine-1-yl)-1-(1H-1,2,4-triazole-1-yl)butane-2-ol; (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidino)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; (alphaR,betaR)-alpha-(2,4-Difluorophenyl)-beta-methyl-4-methylene-alpha-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidineethanol; 1-Piperidineethanol, alpha-(2,4-difluorophenyl)-beta-methyl-4-methylene-alpha-(1H-1,2,4-triazol-1- ylmethyl)-, (alphaR,betaR)-; 1-Piperidineethanol, alpha-(2,4-difluorophenyl)-beta-methyl-4-methylene-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (alphaR,betaR)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:82718	DB09040	.	.	348.4	C18H22F2N4O	54.2	470	2	25	1	6	5	"1S/C18H22F2N4O/c1-13-5-7-23(8-6-13)14(2)18(25,10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4,9,11-12,14,25H,1,5-8,10H2,2H3/t14-,18-/m1/s1"	C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)N3CCC(=C)CC3	NFEZZTICAUWDHU-RDTXWAMCSA-N
DG01055	Cefpiramide	636405	"Cefpiramide; 70797-11-4; Cefpiramide acid; Cefpiramido; Cefpiramidum; UNII-P936YA152N; (6R,7R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CHEBI:59213; P936YA152N; NCGC00167444-01; WY-44,635; SM 1652; SM-1652; (7R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; WY-44635; (6R,7R)-7-((R)-2-(4-Hydroxy-6-methylnicotinamido)-2-(4-hydroxyphenyl)acetamido)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; WY 44,635; C25H24N8O7S2; Cefpiramidum [INN-Latin]; Cefpiramido [INN-Spanish]; Cefpiramide [USAN:USP:INN]; NSC-759869; WY 44635; Cefpiramide (USP/INN); DSSTox_CID_26630; DSSTox_RID_81778; DSSTox_GSID_46630; SCHEMBL49253; CHEMBL1201204; DTXSID6046630; GTPL12027; HMS3715H12; ZINC4215257; Tox21_112448; MFCD00864893; s5186; AKOS025311237; CCG-221235; DB00430; NSC 759869; NCGC00167444-04; (6R,7R)-7-((R)-2-(4-Hydroxy-6-methylnicotinamido)-2-(p-hydroxyphenyl)acetamido)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; AS-14170; K197; CAS-70797-11-4; D03428; 797C114; Q4921174; BRD-K92872987-001-02-9; (6R,7R)-7-((R)-2-(4-hydroxy-6-methylnicotinamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1H-tetrazol-5-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[(2R)-2-[(4-hydroxy-6-methylpyridin-3-yl)formamido]-2-(4-hydroxyphenyl)acetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (7R)-7-((R)-2-(4-hydroxy-6-methylnicotinamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1H-tetrazol-5-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((((4-hydroxy-6-methyl-3-pyridinyl)carbonyl)amino)(4-hydroxyphenyl)acetyl)amino)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-(6alpha,7beta(R*)))-; 7beta-[(2R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido]-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:59213	DB00430	.	.	612.6	C25H24N8O7S2	259	1270	-0.1	42	5	13	9	"1S/C25H24N8O7S2/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40)/t17-,18-,23-/m1/s1"	CC1=CC(=O)C(=CN1)C(=O)N[C@H](C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O	PWAUCHMQEXVFJR-PMAPCBKXSA-N
DG01059	Vasopressin	644077	"ARGIPRESSIN; 113-79-1; Arginine vasopressin; Argipressine; Pitressin; beta-Hypophamine; 8-Arginine-vasopressin; Argipressin tannate; Vasopressin (arginine form); UNII-Y4907O6MFD; Arginine-vasopressin; CHEBI:34543; Vasophysin; Arg-vasopressin; CHEMBL373742; Y4907O6MFD; (Arg8)-Vasopressin; [Arg8]-Vasopressin; (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide; 8-L-Arginine vasopressin; Argipresina; Argipressina; Argipressinum; AVP; Arg8-vasopressin; Argipressin [INN]; Argipressina [DCIT]; NCGC00166306-01; Argipressin [INN:BAN]; 8-L-Arginine-vasopressin; Argipresina [INN-Spanish]; Argipressine [INN-French]; Argipressinum [INN-Latin]; Rindervasopressin; [3H]vasopressin; EINECS 204-035-4; 3-(Phenylalanine)-8-arginineoxytocin; Arginine-8-vasopressin; Argipressin or lypressin; [8-Arginine]vasopressin; [3H]Argipressin tannate; antidiuretic hormone (ADH); arginine vasopressin (AVP); Argipressin tannate [USAN]; Arginine antidiuretic hormone; DSSTox_CID_28324; DSSTox_RID_82752; DSSTox_GSID_48349; SCHEMBL43139; Vasopressin, 8-L-arginine-; [cyclo S-S]CYFQNCPRG-NH2; GTPL2168; DTXSID0048349; SCHEMBL17874853; BDBM35667; Tox21_113037; BDBM50044777; MFCD00076738; NCGC00166306-02; NCGC00188439-01; CAS-113-79-1; h-cys-tyr-phe-gln-asn-cys-pro-arg-gly-nh2; Oxytocin, 3-(L-phenylalanine)-8-L-arginine-; Vasopressin, 8-L-arginine- (7CI,8CI,9CI); roxybenzyl-6,9,12,15,18-pentaoxo- (6CI); 113A791; Q183011; Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2[Disulfide Bridge: 1-6]; (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide; 1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane-10-propionamide, 19-amino-13-benzyl-7-(carbamoylmethyl)-4-[2-[[1-[(carbamoylmethyl)carbamoyl]-4-guanidinobutyl]carbamoyl]-1-pyrrolidinylcarbonyl]-16-p-hyd; 1-{[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-L-arginylglycinamide; Glycinamide, L-cysteinyl-L-tyrosyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-arginyl-, cyclic (1>6)-disulfide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:34543	.	DR00247	.	1084.2	C46H65N15O12S2	515	2070	-4.8	75	14	16	19	"1S/C46H65N15O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1"	C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N	KBZOIRJILGZLEJ-LGYYRGKSSA-N
DG01060	Cefsulodin	656575	"Cefsulodin; Cefsulodine; Cefsulodinum; Cefsulodino; 62587-73-9; UNII-OV42LHE42B; OV42LHE42B; (6R,7R)-3-[(4-carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[[(2R)-2-phenyl-2-sulfoacetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; CHEBI:3507; (6R,7R)-3-[(4-carbamoylpyridinium-1-yl)methyl]-8-oxo-7-{[(2R)-2-phenyl-2-sulfoacetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7beta-{[(2R)-2-phenyl-2-sulfoacetyl]amino}-3-(4-carbamoylpyridinium-1-yl)methyl-3,4-didehydrocepham-4-carboxylate; Cefsulodin [INN:BAN]; Cefsulodine [INN-French]; Cefsulodinum [INN-Latin]; Cefsulodino [INN-Spanish]; Cefonomil; Cefsulodin (INN); Epitope ID:120379; SCHEMBL65525; CGP7174/E; GTPL10783; CGP-7174-E; DB13499; (6R,7R)-3-((4-carbamoylpyridinio)methyl)-8-oxo-7-((R)-2-phenyl-2-sulfoacetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carboxylat; 4-Carbamoyl-1-(((6R,7R)-2-carboxy-8-oxo-7-((2R)-2-phenyl-2-sulfoacetaido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)pyridinium hydroxide, inner salt; D07653; Pyridinium, 4-(aminocarbonyl)-1-((2-carboxy-8-oxo-7-((phenylsulfoacetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, (6R-(6alpha,7beta(R*)))-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3507	.	.	.	532.6	C22H20N4O8S2	225	1050	0.2	36	3	9	7	"1S/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34)/t15-,17-,21-/m1/s1"	C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)S(=O)(=O)O)C(=O)[O-])C[N+]4=CC=C(C=C4)C(=O)N	SYLKGLMBLAAGSC-QLVMHMETSA-N
DG01062	Leuprolide	657181	"Leuprorelin; leuprolide; 53714-56-0; Eligard; Leuprorelina; Leuproreline; Leuprorelinum; UNII-EFY6W0M8TG; EFY6W0M8TG; CHEBI:6427; MFCD00167544; Leuprorelin [INN:BAN]; Leuproreline [INN-French]; Leuprorelinum [INN-Latin]; Leuprorelina [INN-Spanish]; Leuporelin; CCRIS 8462; HSDB 6518; NSC-377526; (-)-leuprolide; LH-RH Leuprolide; C59H84N16O12; NSC 377526; Leuprorelin slow release; Leuprorelin acetate (JAN); Leuprolide acetate (USAN); SCHEMBL4585; TAP-144 FREE BASE; GTPL1175; CHEMBL1201199; CKD-841; DTXSID50872411; ABBOTT-43818 FREE BASE; 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide; (D-Leu(sup 6),des-gly-NH2(sup 10),pro-ethylamide(sup 9))-GNRH; (D-Leu(sup 6),des-gly-NH2(sup 10),pro-ethylamide(sup 9))-LHRH; BDBM50369395; AKOS015892744; AKOS030213246; AKOS037515838; CCG-270656; CS-4947; DB00007; HS-2016; (D-Leu(sup 6),des-gly-NH2(sup 10),pro-ethylamide(sup 9))-gonadotropin-releasing hormone; NCGC00485984-01; HY-12553; I025; Leuprolide acetate salt, >=98% (HPLC); C75519; pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt; BISPHENOLA-(3-CHLORO-2-HYDROXYPROPYL)-&; 714L560; Fensolvi (leuprolide acetate injectable suspension); pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHC2H5; Q907160; Leuprolide acetate, United States Pharmacopeia (USP) Reference Standard; (D-Leu(6),des-Gly-NH2(10),Pro-ethylamide(9))-gonadotropin-releasing hormone; (S)-N-ethyl-1-(((S)-5-oxopyrrolidine-2-carbonyl)-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl)pyrrolidine-2-carboxamide; L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide; Luteinizing hormone-releasing factor (pig), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide-; Luteinizing hormone-releasing hormone (pig), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6427	.	.	.	1209.4	C59H84N16O12	432	2390	0.7	87	15	14	32	"1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1"	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6	GFIJNRVAKGFPGQ-LIJARHBVSA-N
DG01064	Prothionamide	666418	"Protionamide; prothionamide; 14222-60-7; 2-propylpyridine-4-carbothioamide; Ektebin; Protionamid; Trevintix; Peteha; 2-Propyl-thioisonicotinamide; 2-Propylthioisonicotinamide; Tuberex; Protionamidum; Protionizina; Tebeform; 2-Propylisonicotinylthioamide; 4-Pyridinecarbothioamide, 2-propyl-; 2-Propyl-4-pyridinecarbothioamide; TH-1321; 2-Propyl-4-thiocarbamoylpyridine; RP 9778; Isonicotinamide, 2-propylthio-; 9778 R.P.; 1321 TH; UNII-76YOO33643; Prothionamidum; RP-9778; Protionamide (Prothionamide); MLS000042521; Protionamida; 76YOO33643; NSC-758962; NCGC00095164-01; SMR000047660; DSSTox_CID_25940; DSSTox_RID_81238; DSSTox_GSID_45940; Protionamidum [INN-Latin]; Protionamida [INN-Spanish]; Trevintix (TN); CAS-14222-60-7; Protionamide (INN); TH 1321; SR-05000001518; EINECS 238-093-7; BRN 0118164; Protion; Protionamide [INN:BAN:DCF]; Prothionamide (JP17); Opera_ID_999; Spectrum2_000019; Spectrum3_001964; SCHEMBL74572; BSPBio_003564; 5-22-02-00376 (Beilstein Handbook Reference); MLS001201789; MLS006011877; SPECTRUM1505316; SPBio_000057; CHEMBL1378024; DTXSID7045940; CHEBI:32066; KBio3_002911; Prothionamide, >=99% (HPLC); 2-Propyl-4-thiocarbamoyl pyridine; HMS1922D06; HMS2090J11; HMS2235M12; HMS3372K04; HMS3655O18; HMS3715G13; KUC109576N; Pharmakon1600-01505316; ALBB-010476; BCP13522; HY-B0306; KSC-27-052D; ZINC3874803; Tox21_111463; BBL010291; BDBM50499814; CCG-40049; MFCD00464119; NSC758962; s1881; STK366469; STL454225; AKOS005172678; Tox21_111463_1; 1321-TH; AC-4518; DB12667; KS-1282; MCULE-3817450515; NSC 758962; 2-propylpyridine-4-carbimidothioic acid; NCGC00095164-02; NCGC00095164-03; NCGC00095164-04; NCGC00095164-05; M860; SBI-0207058.P001; DB-042615; Protionamide 100 microg/mL in Acetonitrile; 4-Pyridinecarbothioamide, 2-propyl- (9CI); FT-0630412; P2302; SW199462-2; D01195; D88012; AB00393463-12; AB01093435-02; AB01093435_03; AB01093435_04; A807874; Q866657; Q-201638; SR-05000001518-1; SR-05000001518-2; SR-05000001518-3; BRD-K75360161-001-09-9"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:32066	.	.	.	180.27	C9H12N2S	71	159	1.5	12	1	2	3	"1S/C9H12N2S/c1-2-3-8-6-7(9(10)12)4-5-11-8/h4-6H,2-3H2,1H3,(H2,10,12)"	CCCC1=NC=CC(=C1)C(=S)N	VRDIULHPQTYCLN-UHFFFAOYSA-N
DG01066	Doxepin	667477	"Doxepin; (e)-doxepin; trans-doxepin; 1668-19-5; Doxepinum [INN-Latin]; Doxepina [INN-Spanish]; UNII-851NLB57HQ; Sinequan; Sinequan (TN); 851NLB57HQ; Doxepin [USAN]; Doxepina; Doxepinum; (3e)-3-(Dibenzo[b,E]oxepin-11(6h)-Ylidene)-N,N-Dimethylpropan-1-Amine; 3607-34-9; 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin; Deptran; 1-Propanamine, 3-dibenz(b,e)oxepin-11(6H)-ylidene-N,N-dimethyl-; MF 10; Doxepin (INN); [11C]doxepin; 3-(Dibenzo[b,e]oxepin-11(6H)-ylidene)-N,N-dimethylpropan-1-amine; [11C]-doxepin; CCRIS 9176; Doxepin, (E)-; (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; HSDB 3069; Doxepin [INN:BAN]; NCGC00015344-03; CAS-1229-29-4; Methyllactate; 11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine; 11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin; N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine; E-DOXEPIN; Tocris-0508; P-3693A; Prestwick2_000263; Prestwick3_000263; Lopac-D-4526; CHEMBL860; Doxepin [USAN:INN:BAN]; Lopac0_000339; BSPBio_000106; SCHEMBL116895; BPBio1_000118; GTPL1225; GTPL3958; ZINC1331; (E)-3-(Dibenzo[b,e]oxepin-11(6H)-ylidene)-N,N-dimethylpropan-1-amine; DTXSID7022966; BDBM112780; Dibenz(b,e)oxepin-delta(sup 11(6H)),gamma-propylamine, N,N-dimethyl-; CCG-204434; SDCCGSBI-0050327.P002; NCGC00015344-01; NCGC00015344-02; NCGC00015344-04; NCGC00015344-12; NCGC00024623-01; NCGC00162127-01; US8629135, SW-07; C06971; D07875; L000699; BRD-K36616567-003-01-5; BRD-K54462405-003-03-3; BRD-K54462405-003-16-5; Q27077103; UNII-5ASJ6HUZ7D component ODQWQRRAPPTVAG-GZTJUZNOSA-N; 5EH"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB01142	DR00542	.	279.4	C19H21NO	12.5	363	4.3	21	0	2	3	"1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11+"	CN(C)CC/C=C/1\\C2=CC=CC=C2COC3=CC=CC=C31	ODQWQRRAPPTVAG-GZTJUZNOSA-N
DG01067	Etomidate	667484	"Etomidate; 33125-97-2; Hypnomidate; (+)-Etomidate; D-Etomidate; Amidate; Etomidato; Etomidatum; (R)-ETHYL 1-(1-PHENYLETHYL)-1H-IMIDAZOLE-5-CARBOXYLATE; ethyl 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylate; Radenarcon; R 16659; UNII-Z22628B598; (+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate; R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate; CHEMBL681; (R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester; Amidate (pharmaceutical); CHEBI:4910; ethyl (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylate; (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester; 1H-Imidazole-5-carboxylic acid, 1-[(1R)-1-phenylethyl]-, ethyl ester; ethyl 3-[(1R)-1-phenylethyl]imidazole-4-carboxylate; 3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester; Z22628B598; 1H-Imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl ester, (R)- [CAS]; (d)-Etomidate; Etomidic acid; Etomidatum [INN-Latin]; Etomidato [INN-Spanish]; 1H-Imidazole-5-carboxylic acid, 1-((1R)-1-phenylethyl)-, ethyl ester; SMR000466277; Amidate (TN); 1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester; MFCD00869295; NSC-759160; Etomidate [USAN:USP:INN:BAN]; R(+)-etomidate; EINECS 251-385-9; R-ETOMIDATE; BRN 0665833; Etomidate (USP/INN); 1-(alpha-Methylbenzyl)-1H-imidazole-5-carboxylic acid ethyl ester; SCHEMBL39487; MLS000758268; MLS001424163; GTPL5463; ZINC1408; 1H-Imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl ester, (+)-; Etomidate 0.1 mg/ml in Methanol; Etomidate 1.0 mg/ml in Methanol; 1-(1-Phenylethyl)-imidazole-5-carboxylic acid, ethyl ester; HMS2051P18; HMS2232A08; HMS3267N06; HMS3412D11; HMS3676D11; HY-B0100; Etomidate, >98% (HPLC), powder; BDBM50125935; AKOS015920052; CCG-101054; CS-1833; DB00292; GS-3208; NC00304; NSC 759160; NCGC00025176-01; AM803710; E0897; C07522; D00548; J10465; AB00639951_06; 125E972; Q418445; R-16659; SR-01000597569; Q-201102; SR-01000597569-1; BRD-K55055802-001-10-2; Etomidate, European Pharmacopoeia (EP) Reference Standard; r-(+)-ethyl-1-(1-phenylethyl)-1h-imidazole-5-carboxylate; Ethyl (R)-(+)-1-(1-Phenylethyl)-1H-imidazole-5-carboxylate; Etomidate, United States Pharmacopeia (USP) Reference Standard; (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylicacid ethyl ester; (R)-(+)-1-(1-Phenylethyl)-1H-imidazole-5-carboxylic Acid Ethyl Ester; Imidazole-5-carboxylic acid, 1-(alpha-methylbenzyl)-, ethyl ester, (R)-(+)-; V8D"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4910	DB00292	.	.	244.29	C14H16N2O2	44.1	277	3	18	0	3	5	"1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3/t11-/m1/s1"	CCOC(=O)C1=CN=CN1[C@H](C)C2=CC=CC=C2	NPUKDXXFDDZOKR-LLVKDONJSA-N
DG01068	Crotamiton	688020	"Crotamiton; 483-63-6; N-Ethyl-o-crotonotoluidide; Crotamitone; Eurax; trans-Crotamiton; 124236-29-9; Crotalgin; Veteusan; Eurasil; Euraxil; Crotamitonum; Crotamitex; Crotonyl-N-ethyl-o-toluidine; (E)-N-ethyl-N-(2-methylphenyl)but-2-enamide; UNII-2EEH27851Y; (E)-N-Ethyl-N-(o-tolyl)but-2-enamide; o-CROTONOTOLUIDIDE, N-ETHYL-; 2-Butenamide, N-ethyl-N-(2-methylphenyl)-; (2E)-N-ethyl-N-(2-methylphenyl)but-2-enamide; 2EEH27851Y; MFCD00026989; NSC-758951; Crotan; Caswell No. 431B; Bestloid; Crotamitonum [INN-Latin]; SMR000059145; N-ethyl-N-(2-methylphenyl)but-2-enamide; Crotamiton, (E)-; SR-01000759366; EINECS 207-596-3; EPA Pesticide Chemical Code 055701; CHEBI:31439; BRN 3275497; N-Ethyl-N-(2-methylphenyl)-2-butenamide; AI3-17732; (E)-crotamiton; Crotamiton [USP:INN:BAN:JAN]; Eurax (TN); Prestwick2_000951; Prestwick3_000951; N-ethylcrotono-o-toluidide; N-Ethyl-o-crotonotoluidine; G 7857; N-Ethyl- o-crotonotoluidide; SCHEMBL32934; BSPBio_000942; BSPBio_002722; Crotamiton (JAN/USP/INN); 3-12-00-01856 (Beilstein Handbook Reference); MLS000759489; MLS001424003; MLS002222307; MLS002695895; N-Ethyl-ortho-crotonotoluidide; SPECTRUM1505271; 2-Butenamide, N-ethyl-N-(2-methylphenyl)-, (E)-; 2-Butenamide, N-ethyl-N-(2-methylphenyl)-, (2E)-; BPBio1_001038; component of Eurax (Salt/Mix); N-Crotonyl-N-ethyl-o-toluidine; CHEMBL1200709; GTPL11165; ZINC56427; N-Ethyl-o-crotonotoluidide, 97%; HMS1570P04; HMS1922P21; HMS2051E10; HMS2090A10; HMS2093O12; HMS2097P04; HMS2234E16; HMS3714P04; Pharmakon1600-01505271; BCP13315; HY-B1177; NSC78382; CCG-39402; NSC-78382; NSC758951; s1711; (E)-N-ethyl-N-o-tolylbut-2-enamide; AKOS015892746; CS-4730; NC00107; NSC 758951; NCGC00094571-01; NCGC00094571-02; NCGC00094571-03; NCGC00094571-04; NCGC00094571-05; AS-11641; trans-N-Ethyl-N-(o-tolyl)-2-butenamide; SBI-0206763.P001; AB00513973; E0814; N-Ethyl-N-(2-methylphenyl)-2-butenamide #; D01381; D70888; AB00513973-09; AB00513973_10; 483C636; A827519; Q-200893; Q2439845; SR-01000759366-4; SR-01000759366-6; BRD-K13240564-001-01-8; BRD-K57179821-001-05-5; BRD-K57179821-001-08-9; Crotamiton, British Pharmacopoeia (BP) Reference Standard; Crotamiton, European Pharmacopoeia (EP) Reference Standard; UNII-D6S4O4XD0H component DNTGGZPQPQTDQF-XBXARRHUSA-N; Crotamiton, United States Pharmacopeia (USP) Reference Standard; N-Ethyl-o-crotonotoluidide; Crotamitone; Crotalgin; Eurasil; Euraxil"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31439	DB00265	.	.	203.28	C13H17NO	20.3	235	2.8	15	0	1	3	"1S/C13H17NO/c1-4-8-13(15)14(5-2)12-10-7-6-9-11(12)3/h4,6-10H,5H2,1-3H3/b8-4+"	CCN(C1=CC=CC=C1C)C(=O)/C=C/C	DNTGGZPQPQTDQF-XBXARRHUSA-N
DG01069	Pyrantel	708857	"PYRANTEL; 15686-83-6; Strongid; Pirantele [DCIT]; Pirantel; Pyrantelum; Pyrequan; Pyrantel [INN:BAN]; UNII-4QIH0N49E7; (E)-1-Methyl-2-(2-(thiophen-2-yl)vinyl)-1,4,5,6-tetrahydropyrimidine; E-1,4,5,6-Tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)pyrimidine; 4QIH0N49E7; CHEBI:8654; Pirantele; Pirantel [INN-Spanish]; Pyrantelum [INN-Latin]; Pin-X; HSDB 3252; EINECS 239-774-1; Konvermex; pyrantel-pamoate; 1-methyl-2-[(E)-2-thiophen-2-ylethenyl]-5,6-dihydro-4H-pyrimidine; Konvermex (TN); Pyrantel (INN); MLS006011881; SCHEMBL164730; 1-methyl-2-(2-thiophen-2-ylethenyl)-5,6-dihydro-4H-pyrimidine; CHEMBL1626223; DTXSID5023538; CHEBI:94685; ZINC97996; HMS1541D15; 1-methyl-2-[(E)-2-(2-thienyl)vinyl]-1,4,5,6-tetrahydropyrimidine; 1-methyl-2-[(E)-2-(2-thienyl)vinyl]-5,6-dihydro-4H-pyrimidine; STK676402; 1-methyl-2-[(E)-2-(thiophen-2-yl)ethenyl]-1,4,5,6-tetrahydropyrimidine; AKOS005594318; Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)-, (E)-; DB11156; NCGC00174007-01; NCGC00174007-02; SMR004703508; C07409; D08451; AB00053538-07; AB00053538_08; A906579; Q426897; SR-01000802778; SR-01000802778-4; BRD-K20672254-046-02-1; BRD-K63072637-046-01-2; 1,4,5,6-Tetrahydro-1-methyl-2-[2-(2-thienyl)ethenyl]pyrimidine; 1-Methyl-2-(2-(thiophen-2-yl)vinyl)-1,4,5,6-tetrahydropyrimidine; 1,4,5,6-tetrahydro-1-methyl-2-[(1e)-2-(2-thienyl)ethenyl]-pyrimidine; 1,4,5,6-Tetrahydro-1-methyl-2-[(E)-2-(2-thienyl)vinyl]pyrimidine; 1-Methyl-2-[(E)-2-(2-thienyl)ethenyl]-1,4,5,6-tetrahydropyrimidine; 1-Methyl-2-[(E)-2-(2-thienyl)ethenyl]-1,4,5,6-tetrahydropyrimidine #; Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)ethenyl]-; Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)ethenyl)-, (E)- (9CI); 5686-02-2"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8654	DB11156	.	DR1371	206.31	C11H14N2S	43.8	248	1.6	14	0	2	2	"1S/C11H14N2S/c1-13-8-3-7-12-11(13)6-5-10-4-2-9-14-10/h2,4-6,9H,3,7-8H2,1H3/b6-5+"	CN1CCCN=C1/C=C/C2=CC=CS2	YSAUAVHXTIETRK-AATRIKPKSA-N
DG01074	Epalrestat	1549120	"Epalrestat; 82159-09-9; Kinedak; Epalrestatum; Ono 2235; Ono-2235; ONO-2; 2-((z)-5-((e)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid; UNII-424DV0807X; C15H13NO3S2; 2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid; CHEMBL56337; 5-((1Z,2E)-2-Methyl-3-phenylpropenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid; CHEBI:31539; ONO2235; 5-((Z,E)-beta-Methylcinnamylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid; MFCD00865484; 424DV0807X; {(5Z)-5-[(2E)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}acetic acid; Epalrestat [INN]; Epalrestatum [Latin]; {5-[(E)-2-Methyl-3-phenyl-prop-2-en-(Z)-ylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid; 2-[(5Z)-5-[(2E)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid; ONO 2; Kinedak (TN); Aldonil; Aldorin; Tanglin; NCGC00164613-01; Epalrestat- Bio-X; 5-[(1Z, 2E)-2-methyl-3-phenylpropenylidene]-4-oxo2-thioxo-3-thiazolidineacetic acid; Epalrestat (JP17/INN); 3-Thiazolidineacetic acid, 5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-, (E,E)-; SCHEMBL49049; MLS000806985; GTPL11371; REGID_for_CID_1549120; HMS2747M09; HMS3887A17; ZINC1533688; BBL029067; BDBM50049730; s2035; STK337187; AKOS000274207; BCP9000649; CCG-267693; DB15293; NCGC00164613-08; NCGC00164613-12; AS-13345; BE164412; H951; HY-66009; SMR000414799; BCP0726000053; E0906; SW219826-1; D01688; AB00647195_06; 159E099; Q5382029; [5-(2-Methyl-3-phenyl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid; 2-(5-(2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid; (5-[(e)-2-methyl-3-phenyl-prop-2-en-(z)-ylidene]-4-oxo-2-thioxo-thiazolidin-3-yl)-acetic acid 82159-; {(5Z)-5-[(2E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}acetic acid; 2-[(5Z)-5-[(E)-3-phenil-2-methylprop-2-enylidene]-4-oxo-2-thioxo-3-thiazolidinyl]acetic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31539	DB15293	.	.	319.4	C15H13NO3S2	115	519	3.8	21	1	5	4	"1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-"	C/C(=C\\C1=CC=CC=C1)/C=C\\2/C(=O)N(C(=S)S2)CC(=O)O	CHNUOJQWGUIOLD-NFZZJPOKSA-N
DG01076	Unithiol	2724039	"Unithiol; 4076-02-2; Sodium 2,3-dimercapto-1-propanesulfonate; DMPS; Sodium 2,3-dimercaptopropane-1-sulfonate; UNITIOL; Dimaval; 1-Propanesulfonic acid, 2,3-dimercapto-, monosodium salt; sodium 2,3-dimercaptopropanesulfonate; sodium;2,3-bis(sulfanyl)propane-1-sulfonate; 2,3-Dimercapto-1-propanesulfonic acid sodium salt; sodium 2,3-disulfanylpropane-1-sulfonate; Sodium 2,3-dimercaptopropanesulphonate; Unithiolum; Sodium 2,3-dithiolpropanesulfonate; EINECS 223-796-3; 2,3-Dimercaptopropane sodium sulphonate; (+)-Dmps; (-)-Dmps; sodium 2,3-bis(sulfanyl)propane-1-sulfonate; C3H7O3S3Na; 2,3-Dimercaptopropanesulfonic acid sodium salt; C3H7NaO3S3.H2O; SCHEMBL164318; NIOSH/TZ6420050; NIOSH/TZ6420100; DTXSID40958410; AMY22488; MFCD00007523; STL372655; AKOS015898653; AKOS015967317; AS-64437; P323; 2,3-DIMERCAPTOPROPANESULFONIC SODIUM; DB-049647; FT-0609675; TZ64200500; TZ64201000; H10946; A923350; (+)-2,3-Dimercapto-1-propanesulfonate sodium salt; (-)-2,3-Dimercapto-1-propanesulfonate sodium salt; d-2,3-Dimercapto-1-propanesulfonic acid sodium salt; l-2,3-Dimercapto-1-propanesulfonic acid sodium salt; Q-201912; Q26841293; 207233-91-8 (. H2O); 1-Propanesulfonic acid, 2,3-dimercapto-, sodium salt, (+)-; 1-Propanesulfonic acid, 2,3-dimercapto-, sodium salt, (-)-; 37260-06-3"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	210.3	C3H7NaO3S3	67.6	160	.	10	2	5	3	"1S/C3H8O3S3.Na/c4-9(5,6)2-3(8)1-7;/h3,7-8H,1-2H2,(H,4,5,6);/q;+1/p-1"	C(C(CS(=O)(=O)[O-])S)S.[Na+]	FGGPAWQCCGEWTJ-UHFFFAOYSA-M
DG01080	Maraviroc	3002977	"Maraviroc; 376348-65-1; Selzentry; Celsentri; UK-427857; UK-427,857; UK 427857; UNII-MD6P741W8A; MD6P741W8A; CHEMBL256907; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; MVC; CHEMBL1201187; CHEBI:63608; NCGC00183109-02; 4,4-difluoro-N-((1S)-3-((1R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexane-1-carboxamide; Celsentri(TM); Selzentry(TM); [3H]maraviroc; 4,4-difluoro-N-((1S)-3-((1R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-Difluoro-N-[(1s)-3-{(3-Exo)-3-[3-Methyl-5-(Propan-2-Yl)-4h-1,2,4-Triazol-4-Yl]-8-Azabicyclo[3.2.1]oct-8-Yl}-1-Phenylpropyl]cyclohexanecarboxamide; PRO 140 & Maraviroc; maravirocum; Maraviroc [INN:BAN:JAN]; Rel-Maraviroc; C29H41F2N5O; HSDB 8021; 4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-isopropyl-5-methyl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenyl-propyl]cyclohexanecarboxamide; UK-427,857 maraviroc (MVC); [3H]UK 427,857; [3H]UK-427,857; (non-labelled)Maraviroc-d6; DSSTox_CID_28875; DSSTox_RID_83144; DSSTox_GSID_48949; SCHEMBL51991; GTPL803; GTPL806; Cyclohexanecarboxamide, 4,4-difluoro-N-((1S)-3-((3-exo)-3-(3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)-; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; MLS006011960; CHEMBL584744; SCHEMBL2177194; SCHEMBL4576508; Maraviroc, >=98% (HPLC); EX-A200; CHEBI:184662; AMY12578; ZINC3817234; Tox21_113369; AC-558; BDBM50334986; BDBM50464147; MFCD13188530; AKOS025402143; AKOS032960315; ZINC100003902; ZINC101160855; CS-0366; DB04835; MCULE-2702173987; NCGC00183109-01; 4,4-Difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]cyclohexanecarboxamide; AS-75265; exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; HY-13004; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; SMR004703532; CAS-376348-65-1; X5004; 348M651; Q421369; SR-01000942244; J-521678; SR-01000942244-1; BRD-A23284911-001-02-4; Z1618161028; 4,4-Difluoro-cyclohexanecarboxylic acid {(S)-3-[(1S,5S)-3-(3-isopropyl-5-methyl-[1,2,4]triazol-4-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-1-phenyl-propyl}-amide; 4,4-difluoro-N-((1S)-3-(3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-Difluoro-N-((S)-3-((1R,3R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexane-1-carboxamide; 4,4-difluoro-N-((S)-3-((1S,3R,5R)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-aza-bicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-difluoro-N-((S)-3-((1S,3S,5R)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-aza-bicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-difluoro-N-((S)-3-(3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-aza-bicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-difluoro-N-[(1S)-3-[(1R,3S,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-isopropyl-5-methyl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenyl-propyl]cyclohexanecarboxamide; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; 4,4-Difluoro-N-[(1S)-3-[(1R,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboximidic acid; 4,4-difluoro-N-{(1S)-3-[(3-exo)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclohexanecarboxamide; 4,4-diluoro-N-[(1S)-3-[(1S,5R)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Cyclohexanecarboxamide,4,4-difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-; MRV"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63608	DB04835	DR00730	.	513.7	C29H41F2N5O	63	751	5.1	37	1	6	8	"1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25 ,26-/m0/s1"	CC1=NN=C(N1C2C[C@H]3CC[C@@H](C2)N3CC[C@@H](C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C	GSNHKUDZZFZSJB-HLMSNRGBSA-N
DG01081	Luliconazole	3003141	"Luliconazole; 187164-19-8; Lulicon; NND-502; Luzu; PR-2699; (2E)-2-[(4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-ylacetonitrile; UNII-RE91AN4S8G; NND 502; RE91AN4S8G; NCGC00182704-01; NCGC00182704-02; CHEBI:34825; (2E)-2-[(4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-yl-acetonitrile; (R,E)-2-(4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene)-2-(1H-imidazol-1-yl)acetonitrile; NCGC00182704-03; 2-[(2E,4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-(1H-imidazol-1-yl)acetonitrile; DSSTox_CID_28533; DSSTox_RID_82805; DSSTox_GSID_48607; NND502; CAS-187164-19-8; Luliconazole [USAN:INN]; 4-(2,4-Dichlorophenyl)-1,3-dithiolan-2-ylidene-1-imidazolylacetonitrile; Lulicon (TN); Imidazole antimycotic; Luzu (TN); Lulicon; ; ; NND 502; SCHEMBL342362; GTPL7366; Luliconazole (JAN/USAN/INN); CHEMBL2105689; DTXSID3048607; Luliconazole, >=98% (HPLC); ZINC3929486; Tox21_112942; Tox21_112974; MFCD00953915; s4258; AKOS015897320; Tox21_112974_1; AM84645; BCP9000863; CCG-268075; CS-0587; DB08933; DS-3278; (2E)-((4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene)(1H-imidazol-1-yl)acetonitrile; NCGC00182704-08; HY-14283; SW219226-1; D01980; 164L198; A813122; SR-01000945039; SR-01000945039-1; Q15624030; UNII-5JA16R08FJ component YTAOBBFIOAEMLL-REQDGWNSSA-N; (-)-(E)-((4R)-4-(2,4-Dichlorophenyl)-1,3-dithiolan-2-ylidene)(1H-imidazol-1-yl)acetonitrile; 1H-Imidazole-1-acetonitrile, alpha-((4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene)-, (alphaE)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:34825	DB08933	.	.	354.3	C14H9Cl2N3S2	92.2	476	4	21	0	4	2	"1S/C14H9Cl2N3S2/c15-9-1-2-10(11(16)5-9)13-7-20-14(21-13)12(6-17)19-4-3-18-8-19/h1-5,8,13H,7H2/b14-12+/t13-/m0/s1"	C1[C@H](S/C(=C(\\C#N)/N2C=CN=C2)/S1)C3=C(C=C(C=C3)Cl)Cl	YTAOBBFIOAEMLL-REQDGWNSSA-N
DG01082	Dezocine	3033053	"DEZOCINE; Dalgan; 53648-55-8; Dezocina; Dezocinum; Dezocinum [INN-Latin]; Dezocina [INN-Spanish]; UNII-VHX8K5SV4X; Wy-16225; VHX8K5SV4X; CHEMBL1685; CHEBI:4474; (-)-13beta-Amino-5,6,7,8,9,10,11alpha,12-octahydro-5alpha-methyl-5,11-methanobenzocyclodecen-3-ol; Wy-16,225; (1R,9S,15S)-15-amino-1-methyltricyclo[7.5.1.02,7]pentadeca-2(7),3,5-trien-4-ol; Dezocine [USAN:INN]; Docozine; Dozocine; Dezocine (USAN); Dalgan (TN); WY 16225; WY 16,225; SCHEMBL3072; DTXSID2022911; (5R,11S,13S)-13-amino-5-methyl-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzo[10]annulen-3-ol; BDBM50276568; AKOS016014025; DB01209; C08010; D00838; Q1109018; (1R,9S,15S)-15-amino-1-methyltricyclo[7.5.1.0^{2,7}]pentadeca-2,4,6-trien-4-ol; 13-Amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-5,11-methanobenzocyclodecenol; (5R,11S,13S)-13-amino-5-methyl-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzocyclodecen-3-ol; 5,11-Methanobenzocyclodecen-3-ol, 13-amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-, (5alpha,11alpha,13S*)-, (-)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4474	DB01209	.	.	245.36	C16H23NO	46.2	306	3.7	18	2	2	0	"1S/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15-,16+/m0/s1"	C[C@]12CCCCC[C@H]([C@@H]1N)CC3=C2C=C(C=C3)O	VTMVHDZWSFQSQP-VBNZEHGJSA-N
DG01087	Pivampicillin	33478	"Pivampicillin; Pivaloylampicillin; 33817-20-8; Pivaloyloxymethyl ampicillinate; Pivampicilina; Pivampicilline; Pivampicillinum; Ampicillin pivaloyloxymethyl ester; Pivampicilina [INN-Spanish]; Pivampicilline [INN-French]; Pivampicillinum [INN-Latin]; UNII-0HLM346LL7; 0HLM346LL7; CHEBI:8255; 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; DSSTox_CID_25459; DSSTox_RID_80890; DSSTox_GSID_45459; 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-[(2-amino-2-phenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; Pivampicillin [INN:BAN]; MK 191; Pondocillin (TN); Pivampicillin (INN); EINECS 251-688-6; NCGC00016823-01; CAS-33817-20-8; Prestwick0_001009; Prestwick1_001009; Prestwick2_001009; Prestwick3_001009; SCHEMBL34182; BSPBio_001137; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (2S-(2alpha,5alpha,6beta(S*)))-; SPBio_003018; BPBio1_001251; CHEMBL3182343; DTXSID1045459; HMS1571I19; HMS2098I19; HMS3715I19; Tox21_110631; MK-191; ZINC34967244; Tox21_110631_1; CCG-221009; DB01604; NCGC00179290-01; NCGC00179290-03; [(2,2-dimethylpropanoyl)oxy]methyl 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylate; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-, hydroxymethyl ester, pivalate (ester), D-(-)-; AB00513999; D08396; SR-01000872693; Q3122143; SR-01000872693-1; (2S,5R,6R)-pivaloyloxymethyl 6-((R)-2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; {[(2S,5R,6R)-6-[(2R)-2-amino-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl]carbonyloxy}methyl 2,2-dimethylpropanoate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8255	DB01604	.	.	463.5	C22H29N3O6S	153	774	2.9	32	2	8	9	"1S/C22H29N3O6S/c1-21(2,3)20(29)31-11-30-19(28)15-22(4,5)32-18-14(17(27)25(15)18)24-16(26)13(23)12-9-7-6-8-10-12/h6-10,13-15,18H,11,23H2,1-5H3,(H,24,26)/t13-,14-,15+,18-/m1/s1"	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)OCOC(=O)C(C)(C)C)C	ZEMIJUDPLILVNQ-ZXFNITATSA-N
DG01088	Lorcainide	42884	"LORCAINIDE; lorcainid; 59729-31-6; UNII-KGJ2T0N7IQ; KGJ2T0N7IQ; Ro 13-1042; Lorcainidum; Lorcainida; N-(4-chlorophenyl)-2-phenyl-N-(1-propan-2-ylpiperidin-4-yl)acetamide; N-(4-Chlorophenyl)-N-(1-isopropylpiperidin-4-yl)-2-phenylacetamide; 4'-Chloro-N-(1-isopropyl-4-piperidinyl)-2-phenylacetanilide; Lorcainide [INN:BAN]; Lorcainidum [INN-Latin]; Benzeneacetamide, N-(4-chlorophenyl)-N-(1-(1-methylethyl)-4-piperidinyl)-; Benzeneacetamide, N-(4-chlorophenyl)-N-[1-(1-methylethyl)-4-piperidinyl]-; Lorcainida [INN-Spanish]; Lorcainide hydrochloride (USAN); BRN 0497568; 4'-Chloro-N-(1-isopropyl-4-piperidyl)-2-phenylacetanilide; Lorcainide (INN); Spectrum_001714; N-(4-Chlorophenyl)-N-(1-(1-methylethyl)-4-piperidinyl)benzeneacetamide; KBioSS_002194; 5-22-08-00059 (Beilstein Handbook Reference); CHEMBL87543; SCHEMBL364045; DTXSID2023226; KBio2_002194; KBio2_004762; KBio2_007330; CHEBI:135568; ZINC537935; BDBM50237589; AKOS027327571; N-(4-chlorophenyl)-2-phenyl-N-[1-(propan-2-yl)piperidin-4-yl]acetamide; DB13653; NCGC00487358-02; FT-0758616; RO-13-1042; D08020; A857054; Q6678811; N-(4-Chlorophenyl)-N-(1-isopropyl-4-piperidinyl)-2-phenylacetamide #; N-(4-chlorophenyl)-N-[1-(1-methylethyl)piperidin-4-yl]-2-phenylacetamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:135568	.	.	.	370.9	C22H27ClN2O	23.6	433	4.6	26	0	2	5	"1S/C22H27ClN2O/c1-17(2)24-14-12-21(13-15-24)25(20-10-8-19(23)9-11-20)22(26)16-18-6-4-3-5-7-18/h3-11,17,21H,12-16H2,1-2H3"	CC(C)N1CCC(CC1)N(C2=CC=C(C=C2)Cl)C(=O)CC3=CC=CC=C3	XHOJAWVAWFHGHL-UHFFFAOYSA-N
DG01090	Sitagliptin	4369359	"Sitagliptin; 486460-32-6; Januvia; Xelevia; MK-0431; (R)-3-AMINO-1-(3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL)-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; UNII-QFP0P1DV7Z; Tesavel; LEZ763; QFP0P1DV7Z; (3R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-5H,6H,7H,8H-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE; 790712-60-6; CHEBI:40237; Sitagliptan; MK0431; Sitagliptin (Prop.INN); sitagliptina; sitagliptine; sitagliptinum; SR-05000001748; HSDB 7516; LEZ 763; (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-A MINE; Sitagliptin (13); (3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; Sitagliptin; MK0431; 1169707-31-6; EC 690-730-1; CHEMBL1422; SCHEMBL17783; BSPBio_002262; Triazolopiperazine Analogue 1; (3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; MLS006011959; Sitagliptin [USAN:INN:BAN]; GTPL6286; BDBM11162; C16H15F6N5O; AMY6930; DTXSID70197572; LEZ-763; 1x70; HMS2093F20; ACT02665; EX-A2816; Sitagliptin (Metformin,MK-0431); WHO 8692; ZINC1489478; MFCD09838015; NSC813215; AKOS015888724; CCG-268731; DB01261; MCULE-2101761133; NSC-813215; NCGC00178734-03; NCGC00178734-06; NCGC00178734-13; 7-((3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)buyl)-5,6,7,8-tetrahydro-3-trifluoromethyl)-1,4-triazolo(4,3-a); AS-19118; HY-13749; SMR002546724; SBI-0206871.P001; Sitagliptin 100 microg/mL in Acetonitrile; S5079; X4663; A14377; A25516; D08516; AB01563393_01; AR-270/43507782; Q419832; Q-101366; Q-201711; SR-05000001748-1; BRD-K19416115-001-01-2; BRD-K19416115-001-03-8; Z1541638523; (1R)-3-oxo-3-[3-(trifluoroethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorobenzyl)propylamine; (2r)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8h)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine; (2r)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8h)-yl]-1-(2,4,5-trifluorophenyl)butan-2-a; (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-alpha]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine; (3r)-3-amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[3,4-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one hydrochloride; (R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine; 1,2,4-Triazolo(4,3-a)pyrazine, 7-((3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl)-5,6,7,8-tetrahydor-3-(trifluoromethyl)-; 1,2,4-Triazolo[4,3-a]pyrazine,7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-; 3-oxo-1-(2,4,5-trifluorobenzyl)-3-(3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)propylamine; 7-[(3r)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB01261	DR00254	DR1490	407.31	C16H15F6N5O	77	566	0.7	28	1	10	4	"1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1"	C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N	MFFMDFFZMYYVKS-SECBINFHSA-N
DG01091	Methacycline	54675785	"Methacycline; Metacycline; 914-00-1; Rondomycin; Methylenecycline; Tri-methacycline; Methacyclinum; 6-Methyleneoxytetracycline; Metacyclinum; Metaciclina; 6-Methylene-5-oxytetracycline; 6-Methylene-5-hydroxytetracycline; GS-2876; 6-Deoxy-6-demethyl-6-methylene-5-oxytetracycline; Bialatan; 6-Demethyl-6-deoxy-5-hydroxy-6-methylenetetracycline; Methacycline base; UNII-IR235I7C5P; Metacycline (INN); Methacycline amphoteric; MOTC; CHEBI:6805; C22H22N2O8; IR235I7C5P; Metacycline [INN]; Oxytetracycline, 6-methylene-; (4S,4aR,5S,5aR,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide; Metacyclinum [INN-Latin]; Methacycline [USAN:BAN]; Metaciclina [INN-Spanish]; Metacycline hydrochloride; 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide; (4S,4aR,5S,5aR,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, (4S,4aR,5S,5aR,12aS)-; GS 2876; Methacycline (USAN); HSDB 3118; EINECS 213-017-5; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,12aalpha))-; Spectrum_000381; Prestwick0_000964; Prestwick1_000964; Prestwick2_000964; Prestwick3_000964; Spectrum2_001398; Spectrum3_000917; Spectrum4_001016; Spectrum5_001576; SCHEMBL4014; SCHEMBL4015; BSPBio_000967; KBioGR_001511; KBioSS_000861; (4S,4aR,5S,5aR,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; DivK1c_000591; SPBio_001416; SPBio_002888; BPBio1_001065; CHEMBL249837; DTXSID2023272; SCHEMBL19555132; KBio1_000591; KBio2_000861; KBio2_003429; KBio2_005997; KBio3_001894; NINDS_000591; KUC106428N; BCP24961; KSC-12-231A; ZINC4019716; 8169AH; BDBM50103629; BDBM50565697; ZINC85650610; AKOS015961140; ZINC100017626; DB00931; MCULE-8490229191; IDI1_000591; NCGC00179358-01; NCGC00179358-03; NCGC00179358-05; AC-13213; SBI-0051637.P002; AB00514707; C07654; D04972; AB00053593-03; AB00053593_04; AB00053593_05; Q2365033; (4S,4aR,5S,5aR,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6805	.	.	.	442.4	C22H22N2O8	182	998	0.3	32	6	9	2	"1S/C22H22N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-6,10,14-15,17,25-27,30,32H,1H2,2-3H3,(H2,23,31)/t10-,14-,15+,17+,22+/m1/s1"	CN(C)[C@H]1[C@@H]2[C@H]([C@@H]3C(=C)C4=C(C(=CC=C4)O)C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O	XIYOPDCBBDCGOE-IWVLMIASSA-N
DG01092	Tolcapone	4659569	"Tolcapone; 134308-13-7; Tasmar; Ro 40-7592; 3,4-Dihydroxy-4'-methyl-5-nitrobenzophenone; (3,4-Dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone; (3,4-dihydroxy-5-nitrophenyl)(p-tolyl)methanone; (3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone; Ro-40-7592; UNII-CIF6334OLY; Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)-; MFCD00866569; CHEMBL1324; CIF6334OLY; CHEBI:63630; Ro-407592; NCGC00181767-01; 3,4-dihydroxy-5-nitro-4'-methylbenzophenone; 4'-methyl-3,4-dihydroxy-5-nitrobenzophenone; DSSTox_CID_3685; DSSTox_RID_77146; DSSTox_GSID_23685; Talcapone; Tasmar (TN); CCRIS 7904; CAS-134308-13-7; Tolcapone [USAN:USP:INN:BAN]; Tolcapone- Bio-X; TCW; Tolcapone (JAN/USP/INN); SCHEMBL33869; MLS006012044; BIDD:GT0032; GTPL6646; DTXSID3023685; Tolcapone, >=98% (HPLC); Methanone,(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)-; 3s68; HMS2089K14; HMS3652M17; HMS3715D16; HMS3872F03; HMS3885G18; BCP09156; Tox21_112963; Tox21_302414; 3,4-dihydroxy-4 inverted exclamation mark -methyl-5-nitrobenzophenone; AC-791; BDBM50108877; s4021; ZINC35342789; AKOS015902328; Tox21_112963_1; AS-7085; CCG-221217; CS-1173; DB00323; KS-1314; NCGC00181767-02; NCGC00181767-03; NCGC00255188-01; BT164481; HY-17406; SMR001614567; SY102278; DB-013561; FT-0631149; SW219511-1; C07949; D00786; O10068; AB01275441-01; AB01275441_02; (3,4-Dihydroxy-5-nitro-phenyl)-p-tolyl-methanone; 308T137; Q413840; SR-05000001444; Q-201840; SR-05000001444-1; BRD-K10852020-001-01-1; 5-[(4-METHYLPHENYL)CARBONYL]-3-NITROBENZENE-1,2-DIOL; Tolcapone, United States Pharmacopeia (USP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63630	DB00323	.	.	273.24	C14H11NO5	103	372	3.3	20	2	5	2	"1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3"	CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-]	MIQPIUSUKVNLNT-UHFFFAOYSA-N
DG01096	Pyrvinium	5281035	"PYRVINIUM; Pyrvinum; 7187-62-4; pyrvinium (cation); HSDB 3178; UNII-6B9991FLU3; CHEBI:8687; 6B9991FLU3; 2-[(E)-2-(2,5-dimethyl-1-phenylpyrrol-3-yl)ethenyl]-N,N,1-trimethylquinolin-1-ium-6-amine; Pyrvinium ion; Pyrvinium cation; pyrvinium-pamoate; Pyrvinum (base); 6-(Dimethylamino)-2-(2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl)-1-methylquinolinium; CHEMBL1201303; DTXSID2043795; ZINC3831401; DB06816; Quinolinium, 6-(dimethylamino)-2-(2-(2,5-dimethyl-1-phenylpyrrol-3-yl)vinyl)-1-methyl-; Quinolinium, 6-(dimethylamino)-2-(2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl)-1-methyl-; C07412; AB00053809_02; Q264039; 2-[(E)-2-(2,5-dimethyl-1-phenyl-pyrrol-3-yl)vinyl]-N,N,1-trimethyl-quinolin-1-ium-6-amine; 6-(dimethylamino)-2-[(E)-2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methylquinolinium"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8687	DB06816	.	.	382.5	C26H28N3+	12	552	5.9	29	0	1	4	"1S/C26H28N3/c1-19-17-21(20(2)29(19)24-9-7-6-8-10-24)11-13-23-14-12-22-18-25(27(3)4)15-16-26(22)28(23)5/h6-18H,1-5H3/q+1"	CC1=CC(=C(N1C2=CC=CC=C2)C)/C=C/C3=[N+](C4=C(C=C3)C=C(C=C4)N(C)C)C	QMHSXPLYMTVAMK-UHFFFAOYSA-N
DG01101	Midecamycin	5282169	"Midecamycin; Rubimycin; Espinomycin A; Platenomycin B1; Turimycin P3; Medecamycin A1; Mydecamycin; 35457-80-8; Midecamycin A1; Medemycin; UNII-N34Z0Y5UH7; Antibiotic SF 837; N34Z0Y5UH7; SF 837; Madecacine; Midecamicina; Midecamycine; Midecamycinum; YL 704 B1; Macro-Dil; Antibiotic SF-837; Turimycin P(sub 3); Midecamycin A(sub 1); Antibiotic SF 837 A1; Antibiotic YL 704 B1; Midecamycine [INN-French]; Midecamycinum [INN-Latin]; NSC 154011; Midecamicina [INN-Spanish]; Midecamycin [INN:DCF:JAN]; Midecamycin,(S); Medemycin (TN); NCGC00016830-01; EINECS 252-578-0; CAS-35457-80-8; Midecamycin (JP17/INN); DSSTox_CID_25463; DSSTox_RID_80894; DSSTox_GSID_45463; SCHEMBL141581; CHEMBL444963; DTXSID5045463; CHEBI:31845; C41H67NO15; (4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-(((2S,3R,4R,5S,6R)-4-(dimethylamino)-3-hydroxy-5-(((2S,4R,5S,6S)-4-hydroxy-4,6-dimethyl-5-(propionyloxy)tetrahydro-2H-pyran-2-yl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)oxacyclohexadeca-11,13-dien-4-yl propionate; ACT02621; HY-B1908; Tox21_110635; s5560; AKOS022185298; ZINC169368401; CCG-270507; CS-5909; DB13456; Leucomycin V, 3,4(sup B)-dipropanoate; Leucomycin V, 3,4B-dipropanoate (9CI); D01339; H10500; Midecamycin), Antibiotic for Culture Media Use Only; Q2636110; W-106669; 7-(Formylmethyl)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-6-yl 3,6-dideoxy-4-O-(2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl)-3-(dimethylamino)-beta-D-glucopyranoside 4',4''-dipropionate (ester); 7-(Formylmethyl)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-6-yl 3,6-dideoxy-4-O-(2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl)-3-(dimethylamino)-beta-D-glucopyranoside 4',4'-dipropionate (ester)"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:31845	DB13456	.	.	814	C41H67NO15	206	1360	2.6	57	3	16	14	"1S/C41H67NO15/c1-11-30(45)54-29-21-32(47)51-24(4)16-14-13-15-17-28(44)23(3)20-27(18-19-43)37(38(29)50-10)57-40-35(48)34(42(8)9)36(25(5)53-40)56-33-22-41(7,49)39(26(6)52-33)55-31(46)12-2/h13-15,17,19,23-29,33-40,44,48-49H,11-12,16,18,20-22H2,1-10H3/b14-13+,17-15+/t23-,24-,25-,26+,27+,28+,29-,33+,34-,35-,36-,37+,38+,39+,40+,41-/m1/s1"	CCC(=O)O[C@@H]1CC(=O)O[C@@H](C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]1OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC)(C)O)N(C)C)O)CC=O)C)O)C	DMUAPQTXSSNEDD-QALJCMCCSA-N
DG01102	Miokamycin	5282188	"Midecamycin acetate; Miocamycin; Miokamycin; Acecamycin; Ponsinomycin; 3'',9-Diacetylmydecamycin; 55881-07-7; UNII-3T48CPS7U2; 3T48CPS7U2; [(4R,5S,6S,7R,9R,10R,11E,13E,16R)-10-acetyloxy-6-[(2S,3R,4R,5S,6R)-5-[(2S,4R,5S,6S)-4-acetyloxy-4,6-dimethyl-5-propanoyloxyoxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-4-yl] propanoate; 9,3''-Diacetylmidecamycin; C45H71NO17; EINECS 259-879-6; Midecamycin acetate [JAN]; Macroral; Miocamen; Mosil; 9,3''-Di-O-Acetylmidecamycin; Miocamycin (TN); Leucomycin V, 3B,9-diacetate 3,4B-dipropanoate; midecamycin diacetate; Midecamycin acetate (JP17); SCHEMBL139293; CHEMBL1091024; DTXSID60905087; Leucomycin V, 3(sup B),9-diacetate 3,4(sup B)-dipropanoate; ZINC169677000; 1532-RB; LeucomycinV,3B,9-diacetate3,4B-dipropanoate; V1793; D01636; Q3858659; W-105540; Midecamycin acetate, Antibiotic for Culture Media Use Only"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	DR1096	898	C45H71NO17	218	1590	3.8	63	1	18	18	"1S/C45H71NO17/c1-13-34(50)59-33-23-36(52)55-26(4)18-16-15-17-19-32(58-29(7)48)25(3)22-31(20-21-47)41(42(33)54-12)62-44-39(53)38(46(10)11)40(27(5)57-44)61-37-24-45(9,63-30(8)49)43(28(6)56-37)60-35(51)14-2/h15-17,19,21,25-28,31-33,37-44,53H,13-14,18,20,22-24H2,1-12H3/b16-15+,19-17+/t25-,26-,27-,28+,31+,32+,33-,37+,38-,39-,40-,41+,42+,43+,44+,45-/m1/s1"	CCC(=O)O[C@@H]1CC(=O)O[C@@H](C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]1OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC)(C)OC(=O)C)N(C)C)O)CC=O)C)OC(=O)C)C	GQNZGCARKRHPOH-RQIKCTSVSA-N
DG01104	Teprenone	5282199	"Teprenone; Geranylgeranylacetone; Tetraprenylacetone; Selbex; 6809-52-5; 3796-63-2; Teprenona; Teprenonum; Teprenonum [INN-Latin]; Teprenona [INN-Spanish]; UNII-S8S8451A4O; UNII-57B67OXM8F; (5E,9E,13E)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one; 57B67OXM8F; 6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one; E-0671; Geranylgeranyl acetone; (5E,9E,13E)-6,10,14,18-Tetramethyl-5,9,13,17-nonadecatetren-2-one; (5E,9E,13E)-Teprenone; Teprenone [INN:JAN]; CHEBI:31649; Selbelle; 5,9,13,17-NONADECATETRAEN-2-ONE, 6,10,14,18-TETRAMETHYL-; 6,10,14,18-Tetramethyl-5,9,13,17-nonadecatetraen-2-one, mixture of (5E,9E,13E) and (5Z,9E,13E) isomers; CHEMBL79686; SCHEMBL157509; SCHEMBL157511; Ea-0671; BCP11723; HY-B0779; ZINC1915509; 4096AH; s5006; 5,9,13,17-Nonadecatetraen-2-one, 6,10,14,18-tetramethyl-, (E,E,E)-; AKOS015894922; CCG-267813; CS-3560; E-671; 809T525; SR-01000944917; Q-201789; Q7701388; SR-01000944917-1; UNII-S8S8451A4O component HUCXKZBETONXFO-NJFMWZAGSA-N; (9E,13E)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31649	.	.	.	330.5	C23H38O	17.1	482	7.4	24	0	1	12	"1S/C23H38O/c1-19(2)11-7-12-20(3)13-8-14-21(4)15-9-16-22(5)17-10-18-23(6)24/h11,13,15,17H,7-10,12,14,16,18H2,1-6H3/b20-13+,21-15+,22-17+"	CC(=CCC/C(=C/CC/C(=C/CC/C(=C/CCC(=O)C)/C)/C)/C)C	HUCXKZBETONXFO-NJFMWZAGSA-N
DG01105	Rokitamycin	5282211	"Rokitamycin; Ricamycin; 74014-51-0; TMS 19Q; Propionylleucomycin; UNII-ZPT03UEM0E; ZPT03UEM0E; TMS-19Q; [(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-6-[[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-2,4-dimethyl-4-propanoyloxyoxan-3-yl] butanoate; Rokitamicina; Rokitamycine; Rokitamycinum; ((4R,5S,6S,7R,9R,10R,11E,13E,16R)-7-(Formylmethyl)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-6-yl)-3,6-dideoxy-4-O-(2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl)-3-(dimethylamino)-beta-D-glucopyranoside 4''-butyrate 3''-propionate; Rokitamycine [French]; Rokitamycinum [Latin]; Rokitamicina [Spanish]; Rokitamycin [INN:JAN]; Ricamycin (TN); 3''-O-propionylleucomycin A5; CCRIS 5267; BRN 5220127; Rokicid; Rokital; Leucomycin V, 4B-butanoate 3B-propanoate; Rokitamycin (JAN/INN); 3''-propionylleucomycin a5; SCHEMBL136367; CHEMBL1908350; DTXSID6023521; Leucomycin V, 4(sup B)-butanoate 3(Sup B)-propanoate; CHEBI:32103; TMS-19-Q DS 200; ZINC169676935; DB13409; ((4R,5S,6S,7R,9R,10R,11E,13E,16R)-7-(Formylmethyl)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-6-yl)-3,6-dideoxy-4-O-(2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl)-3-(dimethylamino)-beta-D-glucopyranoside 4'-butyrate 3'-propionate; D01897; R-6900; Rokitamycin, Antibiotic for Culture Media Use Only; Q3940221"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:32103	.	.	DR1435	828	C42H69NO15	206	1380	3	58	3	16	15	"1S/C42H69NO15/c1-11-16-32(48)55-40-27(6)53-34(23-42(40,7)58-31(47)12-2)56-37-26(5)54-41(36(50)35(37)43(8)9)57-38-28(19-20-44)21-24(3)29(45)18-15-13-14-17-25(4)52-33(49)22-30(46)39(38)51-10/h13-15,18,20,24-30,34-41,45-46,50H,11-12,16-17,19,21-23H2,1-10H3/b14-13+,18-15+/t24-,25-,26-,27+,28+,29+,30-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1"	CCCC(=O)O[C@H]1[C@@H](O[C@H](C[C@@]1(C)OC(=O)CC)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2N(C)C)O)O[C@H]3[C@H](C[C@H]([C@H](/C=C/C=C/C[C@H](OC(=O)C[C@H]([C@@H]3OC)O)C)O)C)CC=O)C)C	VYWWNRMSAPEJLS-MDWYKHENSA-N
DG01107	Tranilast	5282230	"Tranilast; 53902-12-8; Rizaben; trans-Tranilast; 70806-55-2; Tranilastum; MK 341; Tranilast trans-; N-(3,4-Dimethoxycinnamoyl)anthranilic acid; MK-341; UNII-HVF50SMY6E; SB-252218; (E)-2-(3-(3,4-dimethoxyphenyl)acrylamido)benzoic acid; Tranilast (SB 252218); 3,4-DAA; HVF50SMY6E; 2-[[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]benzoic acid; MLS000028468; CHEBI:77572; 2-((3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl)amino)benzoic acid; MFCD00864787; NSC-758970; NCGC00018185-05; SMR000058373; 2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino]benzoic Acid; 2-{[(2e)-3-(3,4-Dimethoxyphenyl)prop-2-Enoyl]amino}benzoic Acid; (E)-2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino]benzoic acid; Tranilastum [INN-Latin]; 2-(3-(3,4-dimethoxyphenyl)acrylamido)benzoic acid; Tranilast [USAN:INN:JAN]; 2-[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enamido]benzoic acid; Tranpro; 2-({(2E)-3-[3,4-bis(methyloxy)phenyl]prop-2-enoyl}amino)benzoic acid; Rizaben (TN); SR-01000003092; n-(3',4'-dimethoxycinnamoyl) anthranilic acid; BENZOIC ACID, 2-((3-(3,4-DIMETHOXYPHENYL)-1-OXO-2-PROPENYL)AMINO)-; Anthranilic acid, N-(3,4-dimethoxycinnamoyl)-; Tranilast- Bio-X; NU-3450; SB 252218; Opera_ID_1657; DSSTox_CID_3693; T 0318; DSSTox_RID_77152; DSSTox_GSID_23693; Lopac0_001193; SCHEMBL29875; BSPBio_003561; ZINC797; 53902-17-3; MLS000759509; MLS001065902; MLS001077269; MLS001424045; MLS002207030; MLS006010043; SPECTRUM1505333; CHEMBL415324; GTPL6326; Tranilast (JP17/USAN/INN); Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]-; DTXSID7023693; BDBM21613; CHEBI:92320; AOB5086; HMS2051F05; HMS2089L07; HMS2094I21; HMS2230F18; HMS3263P07; HMS3412G17; HMS3648A16; HMS3676G17; HMS3713J04; Pharmakon1600-01505333; (2-Phenylthiazol-5-yl)methylamine; AMY14167; BCP06359; BCP15888; HY-B0195; Tox21_110836; Tox21_501193; 2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid; AC-940; CCG-39992; HSCI1_000076; NSC758970; s5871; AKOS002841076; Tranilast, >=98% (HPLC), powder; DB07615; KS-1193; LP01193; NC00171; NSC 758970; SDCCGSBI-0051160.P004; NCGC00018185-04; NCGC00018185-06; NCGC00018185-08; NCGC00018185-09; NCGC00018185-10; NCGC00018185-20; NCGC00018185-23; NCGC00018185-26; NCGC00021458-04; NCGC00021458-05; NCGC00021458-07; NCGC00261878-01; BD164491; I586; SB252218; SBI-0051160.P003; CAS-53902-12-8; EU-0101193; S1439; SW197551-3; N-(3 ,4 -dimethoxycinnamoyl)anthranilic acid; D02027; AB00382987-18; AB00382987-19; AB00382987_21; 902T173; A829819; A923780; 2-(3,4-Dimethoxy-trans-cinnamoylamino)benzoic acid; Q-201849; Q2325594; SR-01000003092-2; SR-01000003092-4; SR-01000003092-9; BRD-K17849083-001-02-2; BRD-K17849083-001-03-0; BRD-K19533706-001-01-9; Q27164069; SR-01000003092-16; 2-[3-(3,4-Dimethoxyphenyl)-acryloylamino]-benzoic acid; 2-[3-(3,4-dimethoxyphenyl)prop-2-enoylamino]benzoic acid; 2-[[3-(3,4-dimethoxyphenyl)-1-oxoprop-2-enyl]amino]benzoic acid; 2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propen-1-yl]amino]benzoic Acid; D27"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:77572	DB07615	.	DR1628	327.3	C18H17NO5	84.9	464	3.2	24	2	5	6	"1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+"	COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC	NZHGWWWHIYHZNX-CSKARUKUSA-N
DG01110	Neocarzinostatin	5282473	ZINOSTATIN; Neocarzinostatin (JAN); Zinostatin (USAN/INN); SCHEMBL1347615; D02046	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	661.6	C35H35NO12	175	1460	2.3	48	4	13	8	"1S/C35H35NO12/c1-16-12-19(42-4)14-22-20(16)8-9-23(37)27(22)32(40)45-24-13-18-10-11-35(26-15-43-34(41)46-26)25(48-35)7-5-6-21(18)31(24)47-33-28(36-3)30(39)29(38)17(2)44-33/h8-9,12-14,17,21,24-26,28-31,33,36-39H,6,15H2,1-4H3/t17-,21 ,24-,25-,26-,28-,29+,30-,31-,33-,35+/m1/s1"	C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@H]2[C@@H](C=C3C2CC#C[C@@H]4[C@@](O4)(C#C3)[C@H]5COC(=O)O5)OC(=O)C6=C(C=CC7=C6C=C(C=C7C)OC)O)NC)O)O	BLXZMHNVKCEIJX-PNKAXBHOSA-N
DG01112	Tacalcitol	5283734	"Tacalcitol; 57333-96-7; Bonalfa; Curatoderm; Tacalcitolum; UNII-C2W72OJ5ZU; TV-02; PRI 2191; 1-alpha,24(R)-Dihydroxyvitamin D3; TV-02H; TV 02; PRI-2191; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,5R)-5-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; C2W72OJ5ZU; 1alpha,24(R)-Dihydroxyvitamin D3; 1,24-Dihydroxyvitamin D3; (24R)-1alpha,24-dihydroxyvitamin D3 / (24R)-1alpha,24-dihydroxycholecalciferol; (5Z,7E)-(1S,3R,24R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol; Bonalfa (TN); Tacalcitolum [INN-Latin]; 1,24(R)-Dihydroxyvitamin D3; CHEBI:32176; Tacalcitol [INN:BAN:JAN]; Vellutan; Apsor; CCRIS 4211; Tacalcitol (INN); tv02; 1alpha,24(OH)2D3; SCHEMBL3945; TV-02HS; 1a,24-Dihydroxycholecalciferol; GTPL2780; CHEMBL2105611; Tacalcitol, >=99% (HPLC); DTXSID90905111; 1.alpha.,24-dihydroxyvitamin d3; EX-A4429; ZINC4474668; 4077AH; BDBM50441892; LMST03020256; AKOS024458008; CS-0391; DB13689; (1-alpha,3-beta,5Z,7E,24R)-9,10-Secocholesta-5,7,10(19)-triene-1,3,24-triol; AS-77643; HY-32337; (1alpha,24R)-1,24-dihydroxyvitamin D3; D08554; 333T967; Q155682; 1,24(R)-Dihydroxyvitamin D3;1.alpha.,24R-Dihydroxyvitamin D3; (1S,3R,5Z,7E,24R)-9,10-secocholesta-5,7,10-triene-1,3,24-triol; (+)-(5Z,7E,24R)-9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta,24-triol; (1 ,3 ,5Z,7E,24R)-9,10-Secocholesta-5,7,10(19)-triene-1,3,24-triol; 9,10-Secocholesta-5,7,10(19)-triene-1,3,24-triol, (1-alpha,3-beta,5Z,7E,24R)-; (1R,3S,Z)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5R)-5-hydroxy-6-methylheptan-2-yl)-7a-methylhexahydro-1H-inden-4(2H)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:32176	.	.	.	416.6	C27H44O3	60.7	676	5.3	30	3	3	6	"1S/C27H44O3/c1-17(2)25(29)13-8-18(3)23-11-12-24-20(7-6-14-27(23,24)5)9-10-21-15-22(28)16-26(30)19(21)4/h9-10,17-18,22-26,28-30H,4,6-8,11-16H2,1-3,5H3/b20-9+,21-10-/t18-,22-,23-,24+,25-,26+,27-/m1/s1"	C[C@H](CC[C@H](C(C)C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C	BJYLYJCXYAMOFT-RSFVBTMBSA-N
DG01114	Codeine	5284371	"Codeine; Methylmorphine; Codeine anhydrous; Codicept; l-Codeine; Coducept; 76-57-3; Morphine monomethyl ether; Morphine 3-methyl ether; (-)-Codeine; codeinum; O3-Methylmorphine; CODEINE BASE; Morphine-3-methyl ether; Codein; Norcodine, N-methyl; Norcodeine, N-methyl; Codeine polistirex; codeina; CCRIS 7555; HSDB 3043; UNII-UX6OWY2V7J; Codeine (CRM); O(3)-methylmorphine; CHEBI:16714; UX6OWY2V7J; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-; 7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol; Codeine Anhydrate; 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methylmorphinan-6alpha-ol; (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol; Morphine-3-methyl ester; CHEMBL369475; DEA No. 9050; (5alpha,6alpha)-17-methyl-3-(methyloxy)-7,8-didehydro-4,5-epoxymorphinan-6-ol; (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol; Codeine [INN:BAN]; EINECS 200-969-1; Codeine Alkaloid; Codeine USP; (Codeine); 10-methoxy-4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-ol(Codeine); 10-methoxy-4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-ol[codeine]; Codeinum monohydricum; DSSTox_CID_341; Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl-; CHEMBL485; Epitope ID:120369; Codeine polistirex [USAN]; SCHEMBL3257; DSSTox_RID_75524; DSSTox_GSID_20341; GTPL1673; Codeine 0.1 mg/ml in Methanol; Codeine 1.0 mg/ml in Methanol; DTXSID2020341; (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol; IDS-NC-005(SECT.-2); ZINC3806721; Tox21_200082; BDBM50019351; BDBM50105098; AKOS015955539; Morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-; DB00318; CAS-76-57-3; NCGC00248518-01; NCGC00257636-01; AC-11114; C06174; Q174723; Codeine, European Pharmacopoeia (EP) Reference Standard; 3-methoxy-17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-6alpha-ol; Codeine solution, 1 mg/mL in methanol, ampule of 1 mL, certified reference material; Codeine solution, analytical standard, for drug analysis, 1.0 mg/mL in methanol; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5-alpha,6-alpha)- (9CI); Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9CI); Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8CI); (1S,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0(1,13).0(5,17).0(7,18)]octadeca-7(18),8,10,15-tetraen-14-ol; (1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraen-14-ol; (1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18),15-tetraen-14-ol; (codeine)10-methoxy-4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-ol; 10-methoxy-4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-ol(Dihydrocodeine); 10-methoxy-4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-ol; 10-methoxy-4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-ol phosphate(codeine); 10-methoxy-4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-ol(codeine (H3PO4)); 10-methoxy-4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-ol(codeine phosphate)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:16714	DB00318	DR00055	DR0366	299.4	C18H21NO3	41.9	509	1.1	22	1	4	1	"1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1"	CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O	OROGSEYTTFOCAN-DNJOTXNNSA-N
DG01117	Dorzolamide	5284549	"Dorzolamide; 120279-96-1; 4S,6S-Dorzolamide; (4S,6S)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; UNII-9JDX055TW1; Trusopt (TN); (4S-TRANS)-4-(ETHYLAMINO)-5,6-DIHYDRO-6-METHYL-4H-THIENO(2,3-B)THIOPYRAN-2-SULFONAMIDE-7,7-DIOXIDE; 9JDX055TW1; CHEBI:4702; (4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide; (4S,trans)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; C10H16N2O4S3.HCl; 4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide; 4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide; Dorzolamide (DZA); Dorzolamide (INN); MK-507; Dorzolamide [INN:BAN]; SR-05000001449; 1cil; 4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, (4S,6S)-; 4H-Thieno[2,3-b]thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, (4S,6S)-; (4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide; Prestwick0_001116; Prestwick1_001116; Prestwick2_001116; Prestwick3_001116; Dorzolamide, trans-(-)-; UNII 9JDX055TW1; SCHEMBL24061; BSPBio_001252; MLS006011430; BIDD:GT0306; SPBio_003116; BPBio1_001377; CHEMBL218490; GTPL6810; DTXSID7022960; BDBM10884; Dorzolamide, >=98% (HPLC); HMS2089O06; HY-B0109; ZINC1530621; STK645522; AKOS005576255; CS-1859; DB00869; NCGC00179244-04; 4H-Thieno[2,3-b]thiopyran-2-sulfonamide,4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, (4S,6S)-; AS-14731; M363; N913; SMR004703245; AB00514687; C06969; D07871; AB00514687-06; AB00514687-07; AB00514687_08; A804484; Q415401; J-520426; Q-201042; SR-05000001449-1; BRD-K48617017-003-03-1; 4-ethylamino-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[5,4-b]thiopyran-2-sulfonamide; 5,6-Dihydro-4H-4-ethyl amino-6-methyl thieno (2,3-B) thiopyran-2-Sulphonamide-7,7-dioxide; (2S,4S)-4-(ethylamino)-2-methyl-1,1-dioxo-2H,3H,4H-1$l^{6},7-thieno[2,3-b][1$l^{6}]thiopyran-6-sulfonamide; (2S,4S)-4-(ethylamino)-2-methyl-1,1-dioxo-2H,3H,4H-1$l^{6},7-thieno[2,3-b]thiopyran-6-sulfonamide; (4S,6S)-4-(ethylamino)-5,6-dihydro-6-methyl-4H-thieno[2,3-b]thiopyran-2-sulfonamide-7,7-dioxide; 139066-77-6; 4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, (4S-trans)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4702	DB00869	.	.	324.4	C10H16N2O4S3	151	534	0.4	19	2	7	3	"1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1"	CCN[C@H]1C[C@@H](S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C	IAVUPMFITXYVAF-XPUUQOCRSA-N
DG01119	Nabilone	5284592	"Nabilone; 51022-71-0; CHEMBL947; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-9-one; Lilly 109514; Nabilona; Nabilonum; Nabilonum [Latin]; Nabilona [Spanish]; Nabilone [USAN:INN:BAN]; CPD 109514; CPD-109514; 9H-Dibenzo(b,d)pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel-; 9H-Dibenzo[b,d]pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel-; Cesamet (TN); (-)-Nabilone; ( )-Nabilone; Nabilone (USAN/INN); SCHEMBL33339; DEA No. 7379; DTXSID8023341; DTXSID401015800; ZINC1542930; BDBM50287941; Nabilone, solid, >=98% (HPLC); DB00486; (+-)-3-(1,1-Dimethylheptyl)-6,6abeta,7,8,10,10aalpha-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one; (+-)-trans-3-(1,1-Dimethylheptyl)-6a,7,8,9,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo(b,d)pyran-9-on; (+-)-trans-3-(1,1-Dimethylheptyl-7,8,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo(b,d)pyran-9(6aH)-on; D05099; N-0100; 022N710; Q419079; UNII-2N4O9L084N component GECBBEABIDMGGL-RTBURBONSA-N; (+-)-trans-3-(1,1-Dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one; (-)-trans-1-hydroxy-3-(1,1-dimethylheptyl)-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]-pyran-9-one; (-)-trans-1-Hydroxy-3-(1,1-dimethylheptyl)-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-one; (-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9h-dibenzo[b,d]pyran-9-one; (6AR,10AR)-1-HYDROXY-6,6-DIMETHYL-3-(2-METHYLOCTAN-2-YL)-6H,6AH,7H,8H,9H,10H,10AH-BENZO[C]ISOCHROMEN-9-ONE; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6H-benzo[c]chromen-9(6aH)-one; (6aR,10aR)-3-(1,1-Dimethyl-heptyl)-1-hydroxy-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-benzo[c]chromen-9-one; (6aR,10aR)-3-(1,1-dimethylheptyl)-1-hydroxy-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromen-9-one; 61617-09-2; 9H-Dibenzo(b,d)pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, trans-, (+-)-; trans-1-hydroxy-3-(1,1-dimethylheptyl)-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]-pyran-9-one; trans-1-hydroxy-3-(1,1-dimethylheptyl)-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-one; trans-3-(1',1'-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00486	.	.	372.5	C24H36O3	46.5	524	6.4	27	1	3	6	"1S/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1"	CCCCCCC(C)(C)C1=CC(=C2[C@@H]3CC(=O)CC[C@H]3C(OC2=C1)(C)C)O	GECBBEABIDMGGL-RTBURBONSA-N
DG01121	Oxycodone	5284603	"Oxycodone; Dihydrone; Dihydrohydroxycodeinone; Oxycodeinone; Dihydroxycodeinone; Oxicon; Diphydrone; Eucodalum; Oxycodon; Percobarb; Roxicodone; Oxycontin; 76-42-6; Dihydro-14-hydroxycodeinone; (-)-14-Hydroxydihydrocodeinone; Oxicodona; Oxycodonum; Oxycodonum [INN-Latin]; Oxicodona [INN-Spanish]; Percodan; Xtampza; Codeinone, dihydrohydroxy-; Codeinone, dihydro-14-hydroxy-; PTI-821; 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one; UNII-CD35PMG570; Oxicone; 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one; 14-Hydroxydihydrocodeinone; Oxanest; Endone; CD35PMG570; CHEBI:7852; Oxyfast; Supendol; PF-00345439; OxyIR; Eubine [France]; NSC-19043; Tekodin (free base); Supendol [Canada]; Endine (Australia); Ossicodone [DCIT]; Ossicodone; NSC 19043; Codeinone, 7,8-dihydro-14-hydroxy-; Oxycodone Concentrate; Oxycodone [USAN:INN:BAN]; Dihydrohydroxycondeinone; Avridi; Oxyneo; Pancodone Retard; Pancodone retard (United Kingdom); Xtampza ER; Apo-oxycodone CR; (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one; (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one; (-)-Oxycodone; CHEMBL656; HSDB 3142; Oxycodone (USAN/INN); EINECS 200-960-2; oxymorphone 3-methyl ether; BRN 0043446; Pavinal; 4,5.alpha.-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one; Oxycodone cii; N02AA05; Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5alpha)-; Morphinan-6-one, 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-; SCHEMBL2737; Pti 821; GTPL7093; IDS-NO-002; PF06; DTXSID5023407; Codeinone,8-dihydro-14-hydroxy-; Oxycodone 0.1 mg/ml in Methanol; Oxycodone 1.0 mg/ml in Methanol; ZINC403533; 14-hydroxy-3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one; NSC19043; BDBM50370595; Morphinan-6-one, 4,5-alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-; (5alpha)-14-hydroxy-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one; DB00497; AC-16043; C08018; D05312; Q407535; Morphinan-6-one,5.alpha.-epoxy-14-hydroxy-3-methoxy-17-methyl-; Morphinan-6-one, 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methyl- (8CI); Morphinan-6-one,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5.alpha.)-; WLN: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ CQ JO1 P1; 4aH-8,5-bcd]furan-5(6H)-one, 7,7a,8,9-tetrahydro-7a-hydroxy-3-methoxy-12-methyl-; Oxycodone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; (1S,5R,13R,17S)-17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7852	DB00497	DR00392	.	315.4	C18H21NO4	59	553	1.2	23	1	5	1	"1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1"	CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O	BRUQQQPBMZOVGD-XFKAJCMBSA-N
DG01126	Desmopressin	5311065	"DESMOPRESSIN; 16679-58-6; DDAVP; Desmopresina; Desmopressine; Desmopressinum; 1-Deamino-8-D-arginine vasopressin; 1-Desamino-8-D-arginine vasopressin; UNII-ENR1LLB0FP; ENR1LLB0FP; CHEMBL1429; CHEBI:4450; 1-(3-mercaptopropionic acid)-8-D-arginine-vasopressin; 1-{[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-D-arginylglycinamide; Desmopressin [INN:BAN]; Deamino Arginine Vasopressin; Desmopresina [INN-Spanish]; Desmopressine [INN-French]; Desmopressinum [INN-Latin]; C46H64N14O12S2; EINECS 240-726-7; Desamino-8-D-arginine vasopressin, l-; Deamino-8-D-arginine, l-, vasopressin; SCHEMBL14027607; H01BA02; Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine-; EX-A4284; (Deamino-Cys1,D-Arg8)-Vasopressin; 3576AH; BDBM50205308; STL581697; AKOS015994650; DB00035; HS-2010; iaminomethylidene)-D-ornithylglycinamide; 679D586; (S)-1-((4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)-N-((R)-1-(2-amino-2-oxoethylamino)-5-guanidino-1-oxopentan-2-yl)pyrrolidine-2-carboxamide; 1-{[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-N~5~-(d; 113-81-5"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:4450	.	.	.	1069.2	C46H64N14O12S2	489	2040	-4	74	13	15	19	"1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1"	C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N	NFLWUMRGJYTJIN-PNIOQBSNSA-N
DG01137	Oxiconazole	5353853	"Oxiconazole; 64211-45-6; Oxiconazol; Oxiconazolum; Oxizole; UNII-C668Q9I33J; CHEBI:7825; Oxiconazol [INN-Spanish]; Oxiconazolum [INN-Latin]; C668Q9I33J; 2',4'-Dichloro-2-imidazol-1-ylacetophenone (Z)-(O-(2,4-dichlorobenzyl)oxime); Oxiconazole [INN:BAN]; (Z)-1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine; 2',4'-Dichloro-2-imidazol-1-ylacetophenone (Z)-[O-(2,4-dichlorobenzyl)oxime]; C18H13Cl4N3O; Oxiconazole (INN); 1-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-yl)ethanone O-(2,4-dichlorobenzyl) oxime; 2',4'-Dichlor-O-(2,4-dichlorbenzyl)-2-(1-imidazolyl)-(Z)-acetophenonoxim; CHEMBL1262; SCHEMBL34519; BSPBio_003582; BIDD:GT0685; SCHEMBL4540297; DTXSID8040690; CHEBI:94548; HMS2090F15; AMY32552; ZINC3873296; BDBM50051844; AKOS015906762; DB00239; NCGC00177980-01; NCGC00177980-07; AC-12722; Ethanone, 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-, O-((2,4-dichlorophenyl)methyl)oxime, (Z)-; SBI-0206749.P001; C08074; D08313; AB01275511-01; AB01275511_02; 211O456; BRD-K56104152-008-02-5; BRD-K56104152-008-03-3; (1Z)-N-[(2,4-dichlorobenzyl)oxy]-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethanimine; (E)-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethan-1-one O-(2,4-dichlorobenzyl) oxime; 1-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-yl)ethanone O-(2,4-dichlorobenzyl)oxime"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7825	DB00239	.	DR1215	429.1	C18H13Cl4N3O	39.4	481	6.1	26	0	3	6	"1S/C18H13Cl4N3O/c19-13-2-1-12(16(21)7-13)10-26-24-18(9-25-6-5-23-11-25)15-4-3-14(20)8-17(15)22/h1-8,11H,9-10H2/b24-18+"	C1=CC(=C(C=C1Cl)Cl)CO/N=C(\\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl	QRJJEGAJXVEBNE-HKOYGPOVSA-N
DG01140	Levallorphan	5359371	"Levallorphan; Naloxiphan; Lorfan; 152-02-3; 17-Allylmorphinan-3-ol; UNII-353613BU4U; N-Allyl-3-hydroxymorphinan; L-N-Allyl-3-hydroxymorphinan; (-)-3-Hydroxy-N-allylmorphinan; CHEBI:6431; Levo-3-hydroxy-N-allyl morphinan; CHEMBL1254682; Levallofano [DCIT]; Morphinan-3-ol, 17-allyl-; Ro-1-7700; 353613BU4U; Levallofano; Levallorphane; Levallorphanum; Levalorfano; Morphinan, 17-allyl-3-hydroxy-; Levalorfano [INN-Spanish]; Levallorphane [INN-French]; Levallorphanum [INN-Latin]; DSSTox_CID_3205; DSSTox_RID_76925; DSSTox_GSID_23205; Levallorphan [INN:BAN]; CAS-152-02-3; HSDB 2148; EINECS 205-799-1; NCGC00162247-02; 17-prop-2-en-1-ylmorphinan-3-ol; Morphinan-3-ol, 17-allyl-, (-)-; SCHEMBL34060; (-)-17-allylmorphinan-3-ol; GTPL7209; (a^ -17-allylmorphinan-3-ol; DTXSID9023205; (levallorphan)17-allyl-(1R,9R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol; 17-allyl-(1R,9R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol( Levallorphan); 17-allyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol (Levallorphan); ZINC3875992; Tox21_112005; BDBM50326673; Tox21_112005_1; DB00504; NCGC00162247-06; C07069; Q6534827; (1R,9R,10R)-17-(prop-2-en-1-yl)-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-trien-4-ol; (1R,9R,10R)-17-prop-2-enyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6431	DB00504	.	.	283.4	C19H25NO	23.5	408	3.5	21	1	2	2	"1S/C19H25NO/c1-2-10-20-11-9-19-8-4-3-5-16(19)18(20)12-14-6-7-15(21)13-17(14)19/h2,6-7,13,16,18,21H,1,3-5,8-12H2/t16-,18+,19+/m0/s1"	C=CCN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)O	OZYUPQUCAUTOBP-QXAKKESOSA-N
DG01143	Butorphanol	5361092	"Butorphanol; Butorfanol; Butorphanol tartrate; Butorphanolum; 42408-82-2; levo-BC-2627; (-)-butorphanol; 17-(CYCLOBUTYLMETHYL)MORPHINAN-3,14-DIOL; Butorphanol (free base); (-)-17-(Cyclobutylmethyl)morphinan-3,14-diol; UNII-QV897JC36D; Butorfanol [INN-Spanish]; Butorphanolum [INN-Latin]; (-)-N-cyclobutylmethyl-3,14-dihydroxymorphinan; CHEMBL33986; CHEBI:3242; QV897JC36D; l-BC 2627; DEA No. 9720; Morphinan-3,14-diol, 17-(cyclobutylmethyl)-; (1S,9R,10S)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol; EINECS 255-808-8; Butorphanol (USAN/INN); Butorphanol [USAN:INN:BAN]; L-3,14-dihydroxy-N-(cyclobutylmethyl)morphinan; SCHEMBL3749; BIDD:GT0549; GTPL7591; DTXSID1022714; 42408-82-2 (free base); ZINC3812988; BDBM50240437; N-cyclobutylmethyl-3,14-dihydroxymorphinan; L-N-Cyclobutylmethyl-3,14-dihydroxymorphinan; C06863; D03197; J-504151; Q-200770; Q1185089; (1S,9R,10S)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-triene-4,10-diol; (4bS,8aS,9R)-11-(cyclobutylmethyl)-5,6,7,8,9,10-hexahydro-8aH-9,4b-(epiminoethano)phenanthrene-3,8a-diol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3242	DB00611	.	.	327.5	C21H29NO2	43.7	492	3.8	24	2	3	2	"1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1"	C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O	IFKLAQQSCNILHL-QHAWAJNXSA-N
DG01145	Perchlozone	5374694	ISONICOTINALDEHYDE THIOSEMICARBAZONE; 4-Formylpyridine thiosemicarbazone; UNII-W2L5NM3ECQ; W2L5NM3ECQ; NSC 731; EINECS 214-848-6; BRN 0132697; perchlozone; Pyridine-4-carboxaldehyde thiosemicarbazone; AI3-52028; pyridine-4-carbaldehyde thiosemicarbazone; [(Z)-pyridin-4-ylmethylideneamino]thiourea; 5-21-07-00360 (Beilstein Handbook Reference); ZINC1587565	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	180.23	C7H8N4S	95.4	174	0.1	12	2	3	2	"1S/C7H8N4S/c8-7(12)11-10-5-6-1-3-9-4-2-6/h1-5H,(H3,8,11,12)/b10-5-"	C1=CN=CC=C1/C=N\\NC(=S)N	QTSJJDIDTYFLFC-YHYXMXQVSA-N
DG01146	Strontium-89	5388880	"Strontium-89; UNII-K59O1PY9WF; K59O1PY9WF; 14158-27-1; Strontium Sr-89; Strontium, isotope of mass 89; Sr 89; Q2404445"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	88.907	Sr	0	0	.	1	0	0	0	1S/Sr/i1+1	[89Sr]	CIOAGBVUUVVLOB-OUBTZVSYSA-N
DG01148	Nitrofurazone	5447130	"Nitrofurazone; Nitrofural; 59-87-0; Furacilin; Furacin; Furacillin; Actin-N; Aldomycin; Furacine; Furaldon; Nifuzon; 5-Nitro-2-furaldehyde semicarbazone; Babrocid; Chemofuran; Furacinetten; Furacoccid; Furacycline; Furaplast; Furaziline; Furazone; Mastofuran; Monafuracin; Nitrofurazan; Nitrozone; Otofuran; Alfucin; Amifur; Furesol; Mammex; Furazol W; 5-Nitrofurfural semicarbazone; Becafurazone; Biofuracina; Dermofural; Furametral; Furaseptyl; Furatsilin; Fuvacillin; Monafuracis; Monofuracin; Nitrofurol; Biofurea; Cocafurin; Coxistat; Dynazone; Eldezol; Fedacin; Flavazone; Fracine; Furacort; Furaderm; Furagent; Furalone; Furaskin; Furazin; Furazina; Furazyme; Furfurin; Furosem; Hemofuran; Ibiofural; Nifucin; Nifurid; Otofural; Sanfuran; Vabrocid; Vadrocid; Yatrocin; Chixin; Nefco; 5-Nitrofurazone; Furan-Ofteno; Spray-Dermis; Spray-Foral; Furacin-Hc; Nitrofuralum; Eldezol F-6; Furacilinum; Nitrofurane; Furacin-E; Nitrofuraldehyde semicarbazone; (5-Nitro-2-furfurylidenamino)urea; 5-Nitrofuraldehyde semicarbazide; Usaf ea-4; Rivafurazon; Fura-septin; Veterinary nitrofurazone; Nitrofuran (bactericide); NF-7; 6-Nitrofuraldehyde semicarbazide; 5-Nitro-2-furfural semicarbazone; 1-(5-Nitro-2-furfurylidene)semicarbazide; NSC-2100; 5-Nitrofuran-2-aldehyde semicarbazone; 5-Nitro-2-furfuraldehyde semicarbazone; NCI-C56064; 5-Nitro-2-furancarboxaldehyde semicarbazone; NFZ; UNII-X8XI70B5Z6; Nitrofural [INN]; Semikarbazon 5-nitrofurfuralu; Hydrazinecarboxamide, 2-[(5-nitro-2-furanyl)methylene]-; MFCD00003225; U-6421; 2-Furaldehyde, 5-nitro-, semicarbazone; 5-nitrofuran-2-carbaldehyde semicarbazone; 2-[(5-Nitro-2-furanyl)methylene]-hydrazinecarboxamide; X8XI70B5Z6; NFS; 2-Furancarboxaldehyde, 5-nitro-, semicarbazone; NSC1602; NSC2100; component of Furea; (5-Nitro-2-furfurylideneamino)urea; Nitrofural (INN); NSC-1602; component of Furadex; component of Furacort; Hydrazinecarboxamide, 2-((5-nitro-2-furanyl)methylene)-; NCGC00090686-04; NCGC00090686-07; Nitrofurazonum; DSSTox_CID_944; [(E)-(5-nitrofuran-2-yl)methylideneamino]urea; DSSTox_RID_75881; DSSTox_GSID_20944; 2-((5-Nitrofuran-2-yl)methylene)hydrazinecarboxamide; 2-[(5-Nitro-2-furanyl)methylene]hydrazinecarboxamide; WLN: T5OJ BNW E1UNMVZ; (2E)-2-[(5-nitrofuran-2-yl)methylidene]hydrazinecarboxamide; Dymazone; Furalcyn; Acutol; 2-Furancarboxaldehyde, semicarbazone; Rivopon-5; SR-05000002027; 2-((5-Nitro-2-furanyl)methylene)hydrazinecarboxamide; Nitrofuralum [INN-Latin]; CHEBI:44368; CCRIS 1195; Nitrofurazone [USP:INN:BAN]; Nfz mix; HSDB 3136; CAS-59-87-0; NSC 1602; NSC 2100; Prestwick_806; 2-[(5-nitro-2-furyl)methylene]hydrazinecarboxamide; EINECS 200-443-1; Furacin (TN); 2((5-Nitro-2-furanyl)methylene)hydrazinecarboxamide; Nitrofurazone (USP); Semikarbazon 5-nitrofurfuralu [Polish]; BRN 0086403; AI3-17333; [(E)-(5-nitro-2-furyl)methyleneamino]urea; Prestwick2_000492; Prestwick3_000492; Spectrum5_001160; Nitrofurazone (Nitrofural); CHEMBL869; SCHEMBL25416; SCHEMBL25417; BSPBio_000383; BSPBio_002075; MLS002153843; SPECTRUM1500434; BPBio1_000423; component of Furea (Salt/Mix); component of Furadex (Salt/Mix); HMS502G20; (E)-2-((5-nitrofuran-2-yl)methylene)hydrazine-1-carboxamide; HMS1569D05; HMS1920B04; HMS2091J04; HMS2096D05; HMS3713D05; Pharmakon1600-01500434; HY-B0226; ZINC4802968; Tox21_110997; Tox21_202988; Tox21_400035; BDBM50420350; CCG-39642; NSC757244; s1644; STK741625; 1-(5-Nitrofurfurylidene)semicarbazide; 5-Nitro-2-furaldehyde, semicarbazone; 5-Nitro-2-furfurylidene semicarbazone; AKOS000304771; Tox21_110997_1; DB00336; LS41202; MCULE-5485227436; NSC-757244; IDI1_000778; NCGC00090686-01; NCGC00090686-02; NCGC00090686-03; NCGC00090686-05; NCGC00090686-06; NCGC00090686-08; NCGC00090686-11; NCGC00260533-01; 112574-44-4; AC-10331; BS-42205; H823; Semioxamazide, 1-(5-nitrofurfurylidene)-; SMR000059012; SBI-0051458.P003; AB00373885; N0200; C08042; D00862; AB00373885-04; AB00373885_05; AB00373885_06; Structure of 5-nitro-2-furaldehyde-semicarbazone; [(E)-[(5-nitrofuran-2-yl)methylidene]amino]urea; Q-201480; SR-05000002027-1; SR-05000002027-3; BRD-K79092138-001-05-2; BRD-K79092138-001-06-0; 5-Nitro-2-furaldehyde semicarbazone, >=97.0% (HPLC); Nitrofural, European Pharmacopoeia (EP) Reference Standard; Nitrofurazone, United States Pharmacopeia (USP) Reference Standard; Nitrofural for peak identification, European Pharmacopoeia (EP) Reference Standard; Nitrofurazone solution, 100 mug/mL in acetonitrile, VETRANAL(TM), analytical standard; Nitrofurazone, Pharmaceutical Secondary Standard; Certified Reference Material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:44368	.	.	DR1168	198.14	C6H6N4O4	126	261	0.2	14	2	5	2	"1S/C6H6N4O4/c7-6(11)9-8-3-4-1-2-5(14-4)10(12)13/h1-3H,(H3,7,9,11)/b8-3+"	C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)N	IAIWVQXQOWNYOU-FPYGCLRLSA-N
DG01149	Calcium	5460341	"7440-70-2; Ca; Calcium; Elemental calcium; Calcium, elemental; UNII-SY7Q814VUP; Calcium hydride (CaH); SY7Q814VUP; MFCD00010897; MFCD00085314; Calcium compounds; HSDB 273; EINECS 231-179-5; UN1401; Kalzium; calcium atom; Calcium ingot; Calcium Chelate; Calcium shot; Calcium granules; Calcium turnings; Bio Lacta Cal; calcium(0); Calcium turnings, 2N; Calcium, Natural Milk; Calcium, granular, 99%; 20Ca; EC 231-179-5; Calcium granules, -9 mesh; Calcium Krebs 21% 40M; Calcium Milk Calcium 28%; Calcium Sweet Chelate 20%; Calcium Oratate 11% 40M; Ca(0); Calcium hydride, coarse powder; Calcium MS Plus 18% 40M; CHEMBL2146121; DTXSID9050484; CHEBI:22984; CHEBI:29320; HSDB 6931; Calcium, pieces, <1 cm, 99%; Calcium crystalline dendritic pieces; 8183AF; Calcium, crystalline, dendritic, 4N; Calcium shot, 1cm (0.4in) & down; DB01373; Calcium granules, redistilled, -6 mesh; Calcium, SAJ first grade, >=99.5%; Calcium granules, redistilled, -16 mesh; BP-31015; Calcium [UN1401] [Dangerous when wet]; Calcium hydride, 99.9% trace metals basis; Calcium, turnings, 99% trace metals basis; Calcium Bio Calcium MS (Maxium Solubility) 40M; Calcium Bio Calcium MS Plus(Maxium Solubility) 40M; Calcium hydride, powder, 99.99% trace metals basis; Calcium hydride, reagent grade, 95% (gas-volumetric); C000001000; Calcium hydride, chunks, +4 mesh, reagent grade, 95%; Calcium, AAS standard solution, Specpure , Ca 1000 g/ml; Calcium, Oil based standard solution, Specpure, Ca 1000g/g; Calcium, Oil based standard solution, Specpure , Ca 5000 g/g; Calcium, plasma standard solution, Specpure , Ca 10,000 g/ml; Calcium, plasma standard solution, Specpure , Ca 1000 g/ml; Calcium hydride, purum p.a., >=97.0% (gas-volumetric), powder; Calcium hydride, powder, 0-2 mm, reagent grade, >=90% (gas-volumetric); Calcium, dendritic pieces, purified by distillation, 99.5% trace metals basis; Calcium, dendritic pieces, purified by distillation, 99.9% trace metals basis; Calcium, dendritic pieces, purified by distillation, 99.99% trace metals basis"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:22984	DB01373	.	.	40.08	Ca	0	0	.	1	0	0	0	1S/Ca	[Ca]	OYPRJOBELJOOCE-UHFFFAOYSA-N
DG01152	Arglabin	5574924	"Arglabin; (+)-arglabin; 84692-91-1; UNII-YS8UOP7QZ1; YS8UOP7QZ1; CHEBI:73228; 3H-Oxireno(8,8a)azuleno(4,5-b)furan-8(4aH)-one, 5,6,6a,7,9a,9b-hexahydro-1,4a-dimethyl-7-methylene-; Arglabin=DMA; (+)-Arglabin(+)-Arglabin; SCHEMBL60010; CHEMBL2206431; BCP09930; ZINC2114142; BDBM50433455; AKOS030485961; MCULE-7361304189; HY-16059; Q24522351; 1beta,10beta-epoxyguaia-3,11(13)-dien-12,6alpha-olide; (1R,3S,6S,10S,11R)-3,12-dimethyl-7-methylidene-2,9-dioxatetracyclo[9.3.0.01,3.06,10]tetradec-12-en-8-one; (1R,3S,6S,10S,11S)-3,12-Dimethyl-7-methylidene-2,9-dioxatetracyclo[9.3.0.01,3.06,10]tetradec-12-en-8-one; (3aR,4aS,6aS,9aS,9bR)-1,4a-dimethyl-7-methylene-5,6,6a,7,9a,9b-hexahydro-3H-oxireno[8,8a]azuleno[4,5-b]furan-8(4aH)-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:73228	.	.	.	246.3	C15H18O3	38.8	506	1.7	18	0	3	0	"1S/C15H18O3/c1-8-4-7-15-11(8)12-10(9(2)13(16)17-12)5-6-14(15,3)18-15/h4,10-12H,2,5-7H2,1,3H3/t10-,11+,12-,14-,15+/m0/s1"	CC1=CC[C@@]23[C@H]1[C@@H]4[C@@H](CC[C@@]2(O3)C)C(=C)C(=O)O4	UVJYAKBJSGRTHA-CUZKYEQNSA-N
DG01153	Guanabenz	5702063	"Guanabenz; Wy 8678 base; Guanabenzum; Wytensin; Wy 8678; Wy-8678; NSC-68982; N-(2,6-Dichlorobenzylidene)-N'-amidinohydrazine; 5051-62-7; ((2,6-Dichlorobenzylidene)amino)guanidine; GBZ; UNII-GGD30112WC; Hydrazinecarboximidamide, 2-((2,6-dichlorophenyl)methylene)-; CHEBI:5553; MLS000736759; 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine; [(2,6-Dichlorobenzylidene)amino]guanidine; GGD30112WC; NSC 68982; Guanabenz [USAN:INN]; Guanabenzum [INN-Latin]; Guanabenzo [INN-Spanish]; Guanabenzo; SMR000528313; Hydrazinecarboximidamide, 2-[(2,6-dichlorophenyl)methylene]-; N-((2,6-Dichlorobenzylidene)amino)guanidine; Guanabenz (USAN/INN); EINECS 225-750-8; NSC68982; 2-((2,6-Dichlorophenyl)methylene)-hydrazinecarboximidamide; NCGC00024846-03; 1-(2,6-Dichlorobenzylideneamino)guanidine; Prestwick2_000096; Prestwick3_000096; Guanidine, ((2,6-dichlorobenzylidene)amino)-; CHEMBL420; (E)-2-(2,6-dichlorobenzylidene)hydrazinecarboximidamide; Lopac0_000601; SCHEMBL15389; BSPBio_000052; BPBio1_000058; GTPL5443; BDBM81979; BDBM96725; CHEBI:92998; cid_5702063; HMS2089G13; NSC_3517; BDBM50225293; CAS_65636; NSC_65636; s4481; ZINC12503139; CCG-204690; SDCCGSBI-0050583.P002; Guanidine,6-dichlorobenzylidene)amino]-; NCGC00024846-02; NCGC00024846-04; NCGC00024846-05; NCGC00024846-06; NCGC00024846-09; NCGC00024846-16; LS-13410; CAS_5051-62-7; CS-0368548; 1-(2,6-dichlorobenzyl-ideneamino)-*guanidine; C07034; D04375; 2-[(E)-(2,6-dichlorobenzylidene)amino]guanidine; L000834; 2-(2,6-Dichlorobenzylidene)hydrazinecarboximidamide; Hydrazinecarboximidamide,6-dichlorophenyl)methylene]-; 2-[(E)-(2,6-dichlorophenyl)methyleneamino]guanidine; 2-{[(2,6-dichlorophenyl)methylidene]amino}guanidine; BRD-K62736196-015-13-6; BRD-K67847053-015-08-8; Guanidine, ((2,6-dichlorobenzylidene)amino)- (8CI); 2-(2,6-Dichlorobenzylidene)hydrazine-1-carboximidamide; (2E)-2-(2,6-Dichlorobenzylidene)hydrazinecarboximidamide; (E)-2-(2,6-Dichlorobenzylidene)hydrazine-1-carboximidamide; 2-[(E)-[2,6-bis(chloranyl)phenyl]methylideneamino]guanidine; 60329-03-5"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:5553	DB00629	DR01410	DR0794	231.08	C8H8Cl2N4	76.8	228	1.7	14	2	2	2	"1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+"	C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl	WDZVGELJXXEGPV-YIXHJXPBSA-N
DG01154	Cefoselis	5748845	"Cefoselis; UNII-0B50MLU3H1; Wincef; 122841-10-5; 0B50MLU3H1; (6R,7R)-3-[[3-amino-2-(2-hydroxyethyl)pyrazol-1-ium-1-yl]methyl]-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; C19H22N8O6S2; SCHEMBL74633; SCHEMBL74635; CHEMBL2105940; DTXSID3048285; BDBM50485614; Q768; (-)-5-Amino-2-(((6R,7R)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-(2-hydroxyethyl)pyrazolium hydroxide, inner salt, 7(sup 2)-(Z)-(O-methyloxime); (-)-5-Amino-2-(((6R,7R)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-(2-hydroxyethyl)pyrazolium hydroxide, inner salt, 7,2-(Z)-(o-methyloxime)."	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	522.6	C19H22N8O6S2	259	930	-0.9	35	4	12	8	"1S/C19H22N8O6S2/c1-33-24-12(10-8-35-19(21)22-10)15(29)23-13-16(30)27-14(18(31)32)9(7-34-17(13)27)6-25-3-2-11(20)26(25)4-5-28/h2-3,8,13,17,20,28H,4-7H2,1H3,(H4,21,22,23,29,31,32)/b24-12-/t13-,17-/m1/s1"	CO/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=C(N4CCO)N)C(=O)[O-]	BHXLLRXDAYEMPP-SBGRAJFYSA-N
DG01155	Proguanil	6178111	"Proguanil; Chloroguanide; Chlorguanide; Chlorguanid; Paludrin; Bigumal; 500-92-5; Proguanilum; 1-(p-Chlorophenyl)-5-isopropylbiguanide; Paludrine; N1-p-Chlorophenyl-N5-isopropylbiguanide; 1-Isopropyl-5-(4-chlorophenyl)biguanide; UNII-S61K3P7B2V; CHEBI:8455; N-(4-Chlorophenyl)-N'-(isopropyl)-imidodicarbonimidic diamide; Imidodicarbonimidic diamide, N-(4-chlorophenyl)-N'-(1-methylethyl)-; N1-(4-Chlorophenyl)-N5-isopropylbiguanide; S61K3P7B2V; BIGUANIDE, 1-(p-CHLOROPHENYL)-5-ISOPROPYL-; Proguanile [DCIT]; Proguanile; N-(4-chlorophenyl)-N'-(propan-2-yl)imidodicarbonimidic diamide; N-(4-Chlorophenyl)-N'-(1-methylethyl)imidodicarbonimidic diamide; Proguanil [INN:BAN]; RP-3359; Proguanilum [INN-Latin]; (hydrochloride); Tirian (hydrochloride); Palusil (hydrochloride); Diguanyl (hydrochloride); Drinupal (hydrochloride); NCGC00016528-01; CAS-637-32-1; Paludrine (hydrochloride); EINECS 207-915-6; M-4888 (hydrochloride); BRN 2811599; SN-12837 (hydrochloride); MFCD00866201; Proguanil (INN); NSC12977; Spectrum_001588; SpecPlus_000667; Prestwick0_000999; Prestwick1_000999; Prestwick2_000999; Prestwick3_000999; Spectrum2_001135; Spectrum3_001659; Spectrum4_000622; Spectrum5_001384; CHEMBL1377; SCHEMBL45726; BSPBio_001097; BSPBio_003417; KBioGR_001204; KBioSS_002068; 4-12-00-01198 (Beilstein Handbook Reference); BIDD:GT0576; DivK1c_006763; SPBio_001029; SPBio_002988; BPBio1_001207; DTXSID3022794; SCHEMBL16894670; SCHEMBL17300525; KBio1_001707; KBio2_002068; KBio2_004636; KBio2_007204; KBio3_002637; HY-B0806; (4-chlorphenyl)-5-isopropylbiguanid; BDBM50227829; s5927; CS-6234; DB01131; N'-4-chlorophenyl-n5-isopropylbiguanide; NCGC00016528-02; NCGC00016528-03; CS-12345; SBI-0052839.P002; AB00053776; V0783; C07631; D08428; AB00053776_05; A901482; BRD-K28183345-003-05-6; BRD-K28183345-003-07-2; 1-(4-Chlorophenyl)-3-(N-isopropylcarbamimidoyl)guanidine; 1-(4-chlorophenyl)-5-isopropylbiguanide;N1-(4-Chlorophenyl)-N5-isopropylbiguanide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8455	DB01131	.	DR1347	253.73	C11H16ClN5	88.8	292	1.5	17	3	1	4	"1S/C11H16ClN5/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9/h3-7H,1-2H3,(H5,13,14,15,16,17)"	CC(C)N=C(N)/N=C(\\N)/NC1=CC=C(C=C1)Cl	SSOLNOMRVKKSON-UHFFFAOYSA-N
DG01156	Rifamycin	6324616	"RIFAMYCIN; Rifamycin SV; Rifocin; Rifamicine SV; Rifomycin SV; Rifamicina; Rifamycine; Rifamycinum; Rifocyn; 6998-60-3; CB-01-11; UNII-DU69T8ZZPA; DU69T8ZZPA; CHEBI:29673; 6998-60-3 (free acid); M-14; Aemcolo; Rifamycine [INN-French]; Rifamycinum [INN-Latin]; Rifamicina [INN-Spanish]; (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-Pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(28),2,4,9,19,21,25(29),26-octaen-13-yl acetate; RIFOMYCIN; C37H47NO12; 15105-92-7; EINECS 230-273-3; Tuborin; rifamycin-sv; NSC133100; Rifamycin [USAN:INN:BAN:DCF]; Rifamycin (USAN/INN); SCHEMBL151824; CHEMBL437765; GTPL4570; DTXSID1032014; 8248AH; BDBM50391000; LMPK05000005; AKOS024281286; ZINC169633673; DB11753; 2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-, 21-acetate; Rifamycin SV, an antibiotic produced by certain strains of Streptomyces mediterranei, or the same substance produced by any other means; D02549; SR-01000872597; SR-01000872597-1; (pentahydroxy-methoxy-heptamethyl-dioxo-[ ]yl) acetate; Q26270990; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate; (7S,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1,3,5(28),9,19,21,25(29),26-octaen-13-yl acetate; (7S,11S,13S,17S,18S,12R,14R,15R,16R)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7 ,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1<4, 7>.0<5,28>]triaconta-1(28),2,4,9,19,21,25(29),26-octaen-13-yl acetate; [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate; 2,7-(Epoxy[1,11,13]pentadecatrienoimino)naphtho[2,1-b]furan-1,11(2H)-dione, 21-(acetyloxy)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-, (2S,16S,17S,18R,19R,20R,21S,22R,23S)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:29673	DB11753	DR00614	.	697.8	C37H47NO12	201	1330	4.9	50	6	12	3	"1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,25-,29-,30+,33+,37-/m0/s1"	C[C@H]1/C=C/C=C(\\C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C	HJYYPODYNSCCOU-ODRIEIDWSA-N
DG01157	Remikiren	6324659	"Remikiren; Ro 42-5892; UNII-LC7FBL96A4; Remikiren [INN]; 126222-34-2; Ro-42-5892; LC7FBL96A4; CHEMBL31601; Remikiren (INN); 135669-48-6; (2S)-2-benzyl-3-tert-butylsulfonyl-N-[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide; Nalpha-[(2S)-2-benzyl-3-(tert-butylsulfonyl)propanoyl]-N-[(1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-L-histidinamide; remikirene; remikireno; remikirenum; CCRIS 6519; SCHEMBL156393; CHEBI:8803; SCHEMBL19792404; 3d91; ZINC4217406; BDBM50077669; DB00212; C07465; D09038; Q417432; (alphaS)-alpha-((alphaS)-alpha-((tert-Butylsulfonyl)methyl)hydrocinnamamido)-N-((1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)imidazole-4-propionamide; (S)-2-Benzyl-N-[(S)-1-((1S,2R,3S)-1-cyclohexylmethyl-3-cyclopropyl-2,3-dihydroxy-propylcarbamoyl)-2-(1H-imidazol-4-yl)-ethyl]-3-(2-methyl-propane-2-sulfonyl)-propionamide; (S)-alpha-[(S)-alpha-[(tert-butylsulphonyl)methyl]hydrocinnamamido]-N-[(1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-imidazole-4-propionamide; (S)-alpha-[(S)-alpha-[(tert-butylsulphonyl)methyl]hydrocinnamamido]-N-[(1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]imidazole-4-propionamide; 1H-Imidazole-4-propanamide, N-(1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)-alpha-((2-(((1,1-dimethylethyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, (1S-(1R*(R*(R*)),2S*,3R*))-; 2-Benzyl-N-[1-(1-cyclohexylmethyl-3-cyclopropyl-2,3-dihydroxy-propylcarbamoyl)-2-(1H-imidazol-4-yl)-ethyl]-3-(2-methyl-propane-2-sulfonyl)-propionamide(remikiren); N-[(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]-Nalpha-{(2S)-2-[(2-methylpropane-2-sulfonyl)methyl]-3-phenylpropanoyl}-L-histidinamide; Nalpha-[(2S)-2-benzyl-3-(tert-butylsulfonyl)propanoyl]-N-[(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]-L-histidinamide; REM"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8803	DB00212	.	.	630.8	C33H50N4O6S	170	1030	4	44	5	7	16	"1S/C33H50N4O6S/c1-33(2,3)44(42,43)20-25(16-22-10-6-4-7-11-22)31(40)37-28(18-26-19-34-21-35-26)32(41)36-27(17-23-12-8-5-9-13-23)30(39)29(38)24-14-15-24/h4,6-7,10-11,19,21,23-25,27-30,38-39H,5,8-9,12-18,20H2,1-3H3,(H,34,35)(H,36,41)(H,37,40)/t25-,27+,28+,29+,30-/m1/s1"	CC(C)(C)S(=O)(=O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3CCCCC3)[C@H]([C@H](C4CC4)O)O	UXIGZRQVLGFTOU-VQXQMPIVSA-N
DG01158	Saralasin	6324663	"Saralasin; 34273-10-4; (Sar1,Val5,Ala8)-Angiotensin II; Sar-Arg-Val-Tyr-Val-His-Pro-Ala; UNII-H2AFV2HE66; CHEMBL938; H2AFV2HE66; (2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid; Saralasina; Saralasine; Saralasinum; Saralasinum [INN-Latin]; Saralasin [INN:BAN]; Saralasine [INN-French]; Saralasina [INN-Spanish]; NCGC00166135-01; Angiotensin II, 1-(N-methylglycine)-5-L-valine-8-L-alanine-; SCHEMBL23; DSSTox_CID_26549; DSSTox_RID_81710; DSSTox_GSID_46549; 1-Sar-8-Ala-angiotensin II; DTXSID2046549; CHEBI:135894; (1-(N-Methylglycin) 5-L-valin, 8-L-alanin)angiotensin II; Tox21_112332; BDBM50009338; BDBM50229504; AKOS024456428; Sar-Arg-Val-Tyr-Val-His-Pro-Ala-OH; ZINC169289386; DB06763; NCGC00167316-01; N-(1-(N-(N-(N-(N-(N2-(N-methylglycly)-L-arginyl)-L-valyl)-L-tyrosyl)-L-valyl)-L-histidyl)-L-prolyl)-L-alanine; CAS-34273-10-4; Sar-Arg-Val-Tyr-Val-His-Pro-Ala (sarlasin); [Sar1-Arg2-Val3-Tyr4-Val5-His6-Pro7-Ala8]; Q410298; (S)-2-((S)-1-((6S,9S,12S,15S,18S)-18-((1H-imidazol-4-yl)methyl)-6-(3-guanidinopropyl)-12-(4-hydroxybenzyl)-9,15-diisopropyl-4,7,10,13,16-pentaoxo-2,5,8,11,14,17-hexaazanonadecane)pyrrolidine-2-carboxamido)propanoic acid; (S)-2-((S)-1-((S)-2-((S)-2-((S)-2-((S)-2-((S)-5-(diaminomethyleneamino)-2-(2-(methylamino)acetamido)pentanamido)-3-methylbutanamido)-3-(4-hydroxyphenyl)propanamido)-3-methylbutanamido)-3-(1H-imidazol-5-yl)propanoyl)pyrrolidine-5-carboxamido)propanoic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:135894	.	.	.	912	C42H65N13O10	358	1670	-2.6	65	12	13	25	"1S/C42H65N13O10/c1-22(2)33(53-35(58)28(50-32(57)20-45-6)9-7-15-47-42(43)44)38(61)51-29(17-25-11-13-27(56)14-12-25)36(59)54-34(23(3)4)39(62)52-30(18-26-19-46-21-48-26)40(63)55-16-8-10-31(55)37(60)49-24(5)41(64)65/h11-14,19,21-24,28-31,33-34,45,56H,7-10,15-18,20H2,1-6H3,(H,46,48)(H,49,60)(H,50,57)(H,51,61)(H,52,62)(H,53,58)(H,54,59)(H,64,65)(H4,43,44,47)/t24-,28-,29-,30-,31-,33-,34-/m0/s1"	C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC	PFGWGEPQIUAZME-NXSMLHPHSA-N
DG01160	Palonosetron	6337614	"Palonosetron; 135729-61-2; Aloxi; (-)-Palonosetron; Palonosetron [INN]; UNII-5D06587D6R; Aloxi (TN); (3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3H-benzo[de]isoquinolin-1-one; CHEBI:85161; Palonosetron (INN); 2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one; 2-Qhbiqo; 5D06587D6R; (3~{a}~{S})-2-[(3~{S})-1-azabicyclo[2.2.2]octan-3-yl]-3~{a},4,5,6-tetrahydro-3~{H}-benzo[de]isoquinolin-1-one; (3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one; NSC-743769; Palonosetronum; 149653-99-6; Palonosetron; Aloxi; SCHEMBL3746; (S-(R*,R*))-2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one; Palonosetron, (3as, 3s)-; GTPL7486; CHEMBL1189679; DTXSID5048342; SCHEMBL13391549; (S)-2-((S)-quinuclidin-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one; HMS3886A22; BCP07225; HY-A0018; ZINC3795819; BDBM50417287; MFCD07783848; s5740; AKOS015967749; AKOS025311243; CS-0385; DB00377; NSC 743769; NCGC00271490-05; AS-35217; P-226; D07175; AB00698542-05; AB00698542_07; 653P996; Q-100993; Z2216208607; (3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3H-benzo[de]isoquinolin-1-one.; (5S)-3-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-3-azatricyclo[7.3.1.0^{5,13}]trideca-1(12),9(13),10-trien-2-one; 1021481-16-2; 1H-Benz(de)isoquinolin-1-one, 2-(1-azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-, (S-(R*,R*))-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:85161	DB00377	DR00394	.	296.4	C19H24N2O	23.6	456	2.8	22	0	2	1	"1S/C19H24N2O/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20/h2,4,6,13,15,17H,1,3,5,7-12H2/t15-,17-/m1/s1"	C1C[C@@H]2CN(C(=O)C3=CC=CC(=C23)C1)[C@@H]4CN5CCC4CC5	CPZBLNMUGSZIPR-NVXWUHKLSA-N
DG01161	Cefonicid	43594	"CEFONICID; 61270-58-4; Cefonicido; Cefonicidum; Cefonicidum [INN-Latin]; Cefonicido [INN-Spanish]; UNII-6532B86WFG; CHEBI:3491; 6532B86WFG; (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefonicid [INN:BAN]; Monocef; Cefonicid (INN); Monocef (TN); BRN 1066181; CHEMBL1601; SCHEMBL60350; BIDD:GT0667; DTXSID7022758; ZINC3830428; DB01328; C06882; D07644; 270C584; A833135; Q5057286; BRD-K34058848-304-03-1; (6R,7R)-7-((R)-2-hydroxy-2-phenylacetamido)-8-oxo-3-((1-(sulfomethyl)-1H-tetrazol-5-ylthio)methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[(2R)-2-hydroxy-2-phenylacetamido]-8-oxo-3-({[1-(sulfomethyl)-1H-1,2,3,4-tetrazol-5-yl]sulfanyl}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-hydroxy-1-oxo-2-phenylethyl]amino]-8-oxo-3-[[[1-(sulfomethyl)-5-tetrazolyl]thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]thio}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-8-oxidanylidene-7-[[(2R)-2-oxidanyl-2-phenyl-ethanoyl]amino]-3-[[1-(sulfomethyl)-1,2,3,4-tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((hydroxyphenylacetyl)amino)-8-oxo-3-(((1-sulfomethyl)-1H-tetrazol-5-yl)thio)methyl)-, (6R-(6-alpha,7-beta(R*)))-; 6beta-[(2R)-2-hydroxy-2-phenylacetamido]-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)ceph-3-em-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3491	DB01328	.	.	542.6	C18H18N6O8S3	264	999	-1.9	35	4	13	9	"1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1"	C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)O)C(=O)O)CSC4=NN=NN4CS(=O)(=O)O	DYAIAHUQIPBDIP-AXAPSJFSSA-N
DG01162	Cefatrizine	6410758	"CEFATRIZINE; 51627-14-6; Cefatrizinum; BL-S640; Antibiotic BL-S 640; BLS 640; BL-S 640; SKF 60771; UNII-8P4W949T8K; Cephatriazine; 8P4W949T8K; (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(2H-triazol-4-ylsulfanylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; NCGC00185755-01; Cepticol; S 640P; Cefatrizino; Orosporina; Cefatrix; Cetrazil; Latocef; Trizina; Bricef; CEFATRIZINE PROPYLENE GLYCOL; Cefatrizinum [INN-Latin]; Cefatrizino [INN-Spanish]; cefatrizina; Cefatrizine [USAN:INN:BAN]; t-amyl; Cefathiamidine,(S); EINECS 257-324-2; S-640P; Cefatrizine (USAN); DSSTox_CID_2752; DSSTox_RID_76716; DSSTox_GSID_22752; SCHEMBL49503; CHEMBL1095284; DTXSID7022752; J01DB07; CHEBI:131730; ZINC3830404; Tox21_113376; DB13266; (6R,7R)-7-((R)-2-Amino-2-(p-hydroxyphenyl)acetamido)-8-oxo-3-((v-triazol-4-ylthio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-8-oxo-3-((1H-1,2,3-triazol-4-ylthio)methyl)-, (6R-(6alpha,7beta(R*)))-; CAS-51627-14-6; D02406; 627C146; A828691; Q3009981; (6R,7R)-3-(((1H-1,2,3-Triazol-5-yl)thio)methyl)-7-((R)-2-amino-2-(4-hydroxyphenyl)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(acetoxymethyl)-7-(2-((E)-N,N'-diisopropylcarbamimidoylthio)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)-1-oxoethyl]amino]-8-oxo-3-[(2H-triazol-4-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-azanyl-2-(4-hydroxyphenyl)ethanoyl]amino]-8-oxidanylidene-3-(2H-1,2,3-triazol-4-ylsulfanylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-8-oxo-3-[(1H-1,2,3-triazol-4-ylsulfanyl)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-8-oxo-3-[(1H-1,2,3-triazol-4-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (7R)-7-(alpha-D-4-hydroxyphenylglycylamino)-3-(1H-1,2,3-triazol-4-ylthiomethyl)-3-cephem-4-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:131730	.	.	.	462.5	C18H18N6O5S2	225	775	-2.3	31	5	10	7	"1S/C18H18N6O5S2/c19-12(8-1-3-10(25)4-2-8)15(26)21-13-16(27)24-14(18(28)29)9(7-31-17(13)24)6-30-11-5-20-23-22-11/h1-5,12-13,17,25H,6-7,19H2,(H,21,26)(H,28,29)(H,20,22,23)/t12-,13-,17-/m1/s1"	C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)CSC4=NNN=C4	UOCJDOLVGGIYIQ-PBFPGSCMSA-N
DG01165	Guggulsterone	6450278	"(Z)-Guggulsterone; Z-Guggulsterone; Guggulsterone; 39025-23-5; 95975-55-6; Guggulsterones Z; Guggulsterone E&Z; GUGGULSTERONE Z; Cis-Guggulsterone; UNII-6CST3U34GN; 6CST3U34GN; (Z)-Pregna-4,17(20)-diene-3,16-dione; Pregna-4,17(20)-diene-3,16-dione; (8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione; (17Z)-Pregna-4,17(20)-diene-3,16-dione; Gugulsterone; Guggulsterone, (Z)-; Pregna-4,17(20)-diene-3,16-dione, (17Z)-; Guggulsterones E&Z; GS; (E&Z)-Guggulsterone; DSSTox_CID_13539; DSSTox_RID_79083; DSSTox_GSID_33539; SCHEMBL141657; CHEMBL410683; DTXSID1033539; BDBM21725; CHEBI:135338; BCP18087; Tox21_202518; MFCD01310757; AKOS015963432; ZINC118912814; (Z)-Guggulsterone, analytical standard; AC-6215; CCG-267610; NCGC00091910-01; NCGC00260067-01; AC-28813; AS-79083; (17Z)-pregna-4,17-diene-3,16-dione; 4,17(20)-trans-Pregnadiene-3,16-dione; CAS-39025-23-5; HY-107738; CS-0029421; S3792; V2228; (Z)-Guggulsterone, >=89% (HPLC), powder; 2-(2-Aminothiazol-3(2H)-yl)-1-phenylethanone; 975G556; BRD-K26674531-001-01-3; Q27264514; UNII-A4PW148END component WDXRGPWQVHZTQJ-OSJVMJFVSA-N; Guggulsterone Z, United States Pharmacopeia (USP) Reference Standard; (1S,2R,10R,11S,14Z,15S)-14-ethylidene-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-ene-5,13-dione"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:135338	.	.	.	312.4	C21H28O2	34.1	640	3.9	23	0	2	0	"1S/C21H28O2/c1-4-16-19(23)12-18-15-6-5-13-11-14(22)7-9-20(13,2)17(15)8-10-21(16,18)3/h4,11,15,17-18H,5-10,12H2,1-3H3/b16-4+/t15-,17+,18+,20+,21-/m1/s1"	C/C=C/1\\C(=O)C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C	WDXRGPWQVHZTQJ-OSJVMJFVSA-N
DG01166	Axitinib	6450551	"Axitinib; 319460-85-0; AG-013736; Inlyta; AG 013736; (E)-N-Methyl-2-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)benzamide; UNII-C9LVQ0YUXG; AG-13736; AG013736; C9LVQ0YUXG; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; CHEBI:66910; (E)-N-methyl-2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-ylthio)benzamide; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; MFCD09837898; NSC757441; N-methyl-2-({3-[(E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide; NSC-757441; NCGC00241108-01; S1005; DSSTox_CID_28975; DSSTox_RID_83240; DSSTox_GSID_49049; Axitinib (AG 013736); C22H18N4OS; N-methyl-2-({3-[(E)-2-(pyridin-2-yl)vinyl]-1H-indazol-6-yl}sulfanyl)benzamide; CAS-319460-85-0; axitinibum; Axitinib [USAN:INN:JAN]; 4agc; Inlyta (TN); AG13736; 4ag8; Axitinib (JAN/USAN); AG-013736;Axitinib; Axitinib,AG-013736; MLS006010164; SCHEMBL172918; GTPL5659; Axitinib, >=98% (HPLC); CHEMBL1289926; DTXSID3049049; N-methyl-2-[[3-[2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide; SCHEMBL22930506; BDBM25117; CHEBI:94568; EX-A337; QCR-109; SYN1014; BCPP000372; AOB87786; BCP01371; ZINC3816287; Tox21_113597; NSC799341; AKOS015902898; Tox21_113597_1; AC-1539; BCP9000345; CCG-264772; CS-0116; DB06626; KS-1448; NSC 757441; NSC-799341; Benzamide, N-methyl-2-((3-((E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)-; NCGC00241108-04; NCGC00241108-06; HY-10065; SMR002530046; AM20090673; SW219464-1; D03218; AB01274739-01; AB01274739_02; 460A850; SR-01000941566; J-502064; Q-200662; Q4830631; SR-01000941566-1; BRD-K29905972-001-01-4; BRD-K29905972-001-02-2; Benzamide, N-methyl-2-((3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazo)-6-yl)thio)-; Benzamide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-; N-Methyl-[[3[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide; N-methyl-2-({3-[(E)-2-pyridin-2-ylethenyl]-2H-indazol-6-yl}sulfanyl)benzamide; N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)-BENZAMIDE"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:66910	DB06626	DR00035	DR0162	386.5	C22H18N4OS	96	557	4.2	28	2	4	5	"1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+"	CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4	RITAVMQDGBJQJZ-FMIVXFBMSA-N
DG01168	Dirithromycin	6473883	"Dirithromycin; 62013-04-1; Dirithromycine; Dirithromycinum; Diritromicina; Dynabac; LY 237216; LY-237216; UNII-1801D76STL; MLS000028564; (9S)-9-Deoxo-11-deoxy-9,11-(imino((1R)-2-(2-methoxyethoxy)ethylidene)oxy)erythromycin; SMR000058954; MLS001074061; CHEBI:474014; 1801D76STL; MFCD00865041; C42H78N2O14; LY237216; (1R,2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)-3-ethyl-2,10-dihydroxy-15-[(2-methoxyethoxy)methyl]-2,6,8,10,12,17-hexamethyl-5-oxo-9-{[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy}-4,16-dioxa-14-azabicyclo[11.3.1]heptadec-7-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranoside; (1R,2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)-9-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-3-ethyl-2,10-dihydroxy-7-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-15-((2-methoxyethoxy)methyl)-2,6,8,10,12,17-hexamethyl-4,16-dioxa-14-azabicyclo[11.3.1]heptadecan-5-one; Dirithromycine [French]; Dirithromycinum [Latin]; Diritromicina [Spanish]; Divitross; Noriclan; Valodin; CCRIS 9506; NSC-758672; NCGC00178154-03; DI0; Dynabac (TN); Dirithromycin [USAN:USP:INN:BAN]; Spectrum_001476; SpecPlus_000868; Opera_ID_1686; Prestwick3_000557; Spectrum2_001655; Spectrum3_001630; Spectrum4_000597; Spectrum5_000715; Dirithromycin (USP/INN); BSPBio_000633; BSPBio_003299; KBioGR_001094; KBioSS_001956; DivK1c_006964; SPECTRUM1504144; SPBio_001809; BPBio1_000697; CHEMBL1237072; CHEMBL3039471; BDBM59397; cid_6473883; KBio1_001908; KBio2_001956; KBio2_004524; KBio2_007092; KBio3_002519; ASE 136; ASE-136; HMS1922D13; HMS2093A06; HMS2096P15; HMS2233M04; HMS3713P15; AS-E 136; CCG-39072; ZINC96095661; AKOS025310151; DB00954; NSC 758672; Erythromycin, 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethylidene)oxy)-, (9S(R))-; NCGC00178154-01; NCGC00178154-02; SBI-0052687.P002; AB00513862; D03865; J10400; T72716; AB00053192_13; 013D041; A833532; SR-01000721832; SR-05000001888; Q1989071; SR-01000721832-3; SR-05000001888-1; (9S)-9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)ethylidene]erythromycin; (1R,2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)-3-ethyl-2,10-dihydroxy-15-[(2-methoxyethoxy)methyl]-2,6,8,10,12,17-hexamethyl-5-oxo-9-{[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy}-4,16-dioxa-14-azabicyclo[11.3.1]heptadecan-7-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranoside; (1R,2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)-9-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-3-ethyl-2,10-dihydroxy-7-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-15-(2-methoxyethoxymethyl)-2,6,8,10,12,17-hexamethyl-4,16-dioxa-14-azabicyclo[11.3.1]heptadecan-5-one; (1S,2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)-9-[(2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-3-ethyl-2,10-dihydroxy-7-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-15-(2-methoxyethoxymethyl)-2,6,8,10,12,17-hexamethyl-4,16-dioxa-14-azabicyclo[11.3.1]heptadecan-5-one; (1S,2R,4R,5R,6S,7S,8R,11R,12R,13R,15R,17S)-5-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-11-ethyl-4,12-dihydroxy-7-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-15-(2-methoxyethoxymethyl)-2,4,6,8,12,17-hexamethyl-10,14-dioxa-16-azabicyclo[11.3.1]heptadecan-9-one; (1S,2R,4R,5R,6S,7S,8R,11R,12R,13R,15R,17S)-5-[(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-oxidanyl-oxan-2-yl]oxy-11-ethyl-7-[(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-oxidanyl-oxan-2-yl]oxy-15-(2-methoxyethoxymethyl)-2,4,6,8,12,17-hexamethyl-4,12-bis(oxidanyl; (1S,2R,4R,5R,6S,7S,8R,11R,12R,13R,15R,17S)-5-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-2-oxanyl]oxy]-11-ethyl-4,12-dihydroxy-7-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-2-oxanyl]oxy]-15-(2-methoxyethoxymethyl)-2,4,6,8,12,17-hexamethyl-10; [9S(R)]-9-Deoxo-11-deoxy-9,11-[imino[2-(2-methoxy)ethylidene]oxy]erthromycin; LY-237216"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:474014	DB00954	DR01366	DR0516	835.1	C42H78N2O14	196	1300	4.2	58	5	16	12	"1S/C42H78N2O14/c1-15-29-42(10,49)37-24(4)32(43-30(56-37)21-52-17-16-50-13)22(2)19-40(8,48)36(58-39-33(45)28(44(11)12)18-23(3)53-39)25(5)34(26(6)38(47)55-29)57-31-20-41(9,51-14)35(46)27(7)54-31/h22-37,39,43,45-46,48-49H,15-21H2,1-14H3/t22-,23-,24+,25+,26-,27+,28+,29-,30-,31+,32+,33-,34+,35+,36-,37-,39+,40-,41-,42-/m1/s1"	CC[C@@H]1[C@@]([C@H]2[C@H]([C@H]([C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C)O)(C)O)C)N[C@H](O2)COCCOC)C)(C)O	WLOHNSSYAXHWNR-DWIOZXRMSA-N
DG01170	Delamanid	6480466	"Delamanid; 681492-22-8; OPC-67683; Delamanid (OPC-67683); UNII-8OOT6M1PC7; OPC 67683; (R)-2-Methyl-6-nitro-2-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)phenoxy)methyl)-2,3-dihydroimidazo[2,1-b]oxazole; 8OOT6M1PC7; MMV688262; (2R)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-3H-imidazo[2,1-b][1,3]oxazole; (2R)-2,3-Dihydro-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]phenoxy]methyl]imidazo[2,1-b]oxazole; (2R)-2-Methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-b][1,3]oxazole; (R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole; (2R)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]-1-piperidyl]phenoxy]methyl]-3H-imidazo[2,1-b]oxazole; (R)-2-methyl-6-nitro-2-(4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole; Deltyba (TN); Delamanid (JAN/USAN); OPC-67683; Delamanid; SCHEMBL57791; Delamanid [USAN:INN:JAN]; CHEMBL218650; DTXSID60218326; CHEBI:134742; BCP07838; EX-A2414; MFCD18251539; NSC794689; s5007; ZINC43100810; AKOS025289781; CCG-269934; CS-5866; DB11637; NSC-794689; SB14863; NCGC00348214-01; (2R)-2-Methyl-6-nitro-2-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1- yl)phenoxy)methyl)-2,3-dihydroimidazo(2,1-b)oxazole; AS-56105; Delamanid; OPC 67683; OPC67683; HY-10846; Imidazo(2,1-b)oxazole, 2,3-dihydro-2-methyl-6-nitro-2-((4-(4-(4-(trifluoromethoxy)phenoxy)-1-piperidinyl)phenoxy)methyl)-, (2R)-; D09785; A856044; Q15408413; (2R)-2-Methyl-6-nitro-2-[4-[4-[4-(trifluoromethoxy)phenoxy]piperidino]phenoxymethyl]-2,3-dihydroimidazo[2,1-b]oxazole; [(2R)-2-methyl-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]-1-piperidyl]phenoxy]methyl]-3H-imidazo[2,1-b]oxazol-6-yl]azinic acid; 2-Methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-b]oxazole, (2R)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:134742	.	.	DR0432	534.5	C25H25F3N4O6	104	795	5.6	38	0	11	7	"1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1"	C[C@@]1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F	XDAOLTSRNUSPPH-XMMPIXPASA-N
DG01171	Carumonam	6540466	"Carumonam; 87638-04-8; Carumonamum; UNII-486890PI06; CHEBI:55486; 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-(carbamoyloxymethyl)-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxyacetic acid; 486890PI06; CRMN; ({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-({(2S,3S)-2-[(carbamoyloxy)methyl]-4-oxo-1-sulfoazetidin-3-yl}amino)-2-oxoethylidene]amino}oxy)acetic acid; Carumonamum [Latin]; Carumonam [INN:BAN]; CCRIS 1924; Carumonam (INN); SCHEMBL49606; CHEMBL1614658; DTXSID3048312; ZINC13831159; AKOS015961995; DB13553; (((2-((2-(((Aminocarbonyl)oxy)methyl)-4-oxo-1-sulfo-3-azetidinyl)amino)-1-(2-amino-4-thiazolyl)-2-oxoethylidene)amino)oxy)acetic acid (2S-(2alpha,3alpha(Z)))-; AC-15442; D07625; A834910; J-505187; Q5047478; 2-((((Z)-1-(2-Aminothiazol-4-yl)-2-(((2S,3S)-2-((carbamoyloxy)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)acetic acid; 2-(((E)-(1-(2-Aminothiazol-4-yl)-2-(((2s,3s)-2-((carbamoyloxy)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)ac etic acid; 2-[(Z)-[1-(2-amino-4-thiazolyl)-2-[[(2S,3S)-2-(carbamoyloxymethyl)-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxyacetic acid; 2-[(Z)-[2-[[(2S,3S)-2-(aminocarbonyloxymethyl)-4-oxidanylidene-1-sulfo-azetidin-3-yl]amino]-1-(2-azanyl-1,3-thiazol-4-yl)-2-oxidanylidene-ethylidene]amino]oxyethanoic acid; 2-{[(Z)-[(2-amino-1,3-thiazol-4-yl)({[(2S,3S)-2-[(carbamoyloxy)methyl]-4-oxo-1-sulfoazetidin-3-yl]carbamoyl})methylidene]amino]oxy}acetic acid; Acetic acid, (((2-((2-(((aminocarbonyl)oxy)methyl)-4-oxo-1-sulfo-3-azetidinyl)amino)-1-(2-amino-4-thiazolyl)-2-oxoethylidene)amino)oxy)-, (2S-(2alpha,3alpha(Z)))-; Acetic acid, (((Z)-(2-(((2S,3S)-2-(((aminocarbonyl)oxy)methyl)-4-oxo-1-sulfo-3-azetidinyl)amino)-1-(2-amino-4-thiazolyl)-2-oxoethylidene)amino)oxy)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:55486	.	.	.	466.4	C12H14N6O10S2	291	858	-1.4	30	5	14	10	"1S/C12H14N6O10S2/c13-11-15-4(3-29-11)7(17-28-2-6(19)20)9(21)16-8-5(1-27-12(14)23)18(10(8)22)30(24,25)26/h3,5,8H,1-2H2,(H2,13,15)(H2,14,23)(H,16,21)(H,19,20)(H,24,25,26)/b17-7-/t5-,8+/m1/s1"	C1=C(N=C(S1)N)/C(=N/OCC(=O)O)/C(=O)N[C@H]2[C@H](N(C2=O)S(=O)(=O)O)COC(=O)N	UIMOJFJSJSIGLV-JNHMLNOCSA-N
DG01172	Nifurtimox	6842999	"NIFURTIMOX; Lampit; Bayer 2502; 23256-30-6; Nifurtimoxum; BAY 2502; CHEBI:7566; BAYER-2502; BAY-A2502; BAY-2502; DNDI1613515; 4-Thiomorpholinamine, 3-methyl-N-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide; 4-Thiomorpholinamine, 3-methyl-N-[(5-nitro-2-furanyl)methylene]-, 1,1-dioxide; Nifurtimox [INN:BAN]; 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine 1,1-dioxide; Nifurtimoxum [INN-Latin]; UNII-X4KCV4ZI9M; CCRIS 2201; X4KCV4ZI9M; UNII-1G5DD3P35C; SR-01000838852; EINECS 245-531-0; 1G5DD3P35C; 4-[(5-Nitrofurfurylidene)amino]-3-methylthiomorpholine 1,1-dioxide; ()-Nifurtimox; (-)-Nifurtimox; Nifurtimox, ()-; Lampit (TN); Nifurtimox, (+)-; Nifurtimox, (-)-; 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide; Nifurtimox (USAN/INN); Prestwick2_001024; Prestwick3_001024; 1-((5-Nitrofurfurylidene)amino)-2-methyltetrahydro-1,4-thiazine-4,4-dioxide; 3-Methyl-N-[(5-nitro-2-furanyl)methylene]-4-thiomorpholinamine 1,1-dioxide; Tetrahydro-3-methyl-4-((5-nitrofurfurylidene)amino)-2H-1,4-thiazine 1,1-dioxide; BSPBio_001207; BPBio1_001329; CHEMBL290960; SCHEMBL1650162; Nifurtimox, >=98% (HPLC); BAY A2502; CHEBI:91472; BAY2502; KUC114565N; EX-A4624; BDBM50259708; s6459; Thiomorpholine, 3-methyl-4-((5-nitrofurfurylidene)amino)-, 1,1-dioxide; CS-W020813; DB11820; HY-W040073; KSC-427-39-1; C08002; D00833; A912676; J-015055; SR-01000838852-2; SR-01000838852-3; BRD-A84020532-001-03-5; BRD-A84020532-001-04-3; (E)-3-methyl-4-(((5-nitrofuran-2-yl)methylene)amino)thiomorpholine 1,1-dioxide; 4-Thiomorpholinamine, 3-methyl-N-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide, ()-; 4-Thiomorpholinamine, 3-methyl-N-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide, (-)-; N-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitro-2-furyl)methanimine; 39072-15-6; 39072-16-7"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7566	DB11820	DR01396	.	287.29	C10H13N3O5S	117	467	1.3	19	0	7	2	"1S/C10H13N3O5S/c1-8-7-19(16,17)5-4-12(8)11-6-9-2-3-10(18-9)13(14)15/h2-3,6,8H,4-5,7H2,1H3/b11-6+"	CC1CS(=O)(=O)CCN1/N=C/C2=CC=C(O2)[N+](=O)[O-]	ARFHIAQFJWUCFH-IZZDOVSWSA-N
DG01173	Dantrolene	6914273	"Dantrolene; 7261-97-4; Dantrolenum [INN-Latin]; Dantroleno [INN-Spanish]; Dantroleno; UNII-F64QU97QCR; F-368; Dantrolenum; Ryanodex; 1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin; C14H10N4O5; F64QU97QCR; Hydantoin, 1-((5-(p-nitrophenyl)furfurylidene)amino)-; 1-(((5-(4-Nitrophenyl)-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 2,4-Imidazolidinedione, 1-(((5-(4-nitrophenyl)-2-furanyl)methylene)amino)-; 1-(((5-(4-Nitrophenyl)furan-2-yl)methylene)amino)imidazolidine-2,4-dione; 833480-90-3; 1-[[5-(p-Nitrophenyl)furfurylidene]amino]hydantoin; 1-[[[5-(4-Nitrophenyl)-2-furanyl]methylene]amino]-2,4-imidazolidinedione; 2,4-Imidazolidinedione, 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-; HSDB 3050; Dantrolene (USAN/INN); EINECS 230-684-8; BRN 0705189; Dantrolene [USAN:INN:BAN]; Prestwick2_000291; Prestwick3_000291; Spectrum5_001752; NCGC00163132-01; 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione; Lopac0_000424; SCHEMBL40893; BSPBio_000222; BSPBio_001305; BSPBio_003074; BIDD:GT0187; BPBio1_000246; CHEMBL1201288; SCHEMBL12417164; BAS-3050F; BCBcMAP01_000067; AMY8921; BAS-305; DTXSID70873546; (E)-1-(((5-(4-nitrophenyl)furan-2-yl)methylene)amino)imidazolidine-2,4-dione; HMS1361B07; HMS1791B07; HMS1989B07; HMS3402B07; 85008-71-5; ZINC7997966; BDBM50198767; DB01219; SHA-458100; 1-({(1E)-[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione; IDI1_000898; IDI1_033775; NCGC00163402-01; NCGC00163402-02; NCGC00163402-03; NCGC00188950-01; BS-48947; HY-12542; R452; CS-0011998; A13928; C06939; D02347; SR-01000076241-8; BRD-K81272440-001-02-6; BRD-K81272440-236-05-1; 1-[5-(4-nitro-phenyl)-furan-2-ylmethyleneamino]-imidazolidine-2,4-dione; 1-(((E)-[5-(4-Nitrophenyl)-2-furyl]methylidene)amino)-2,4-imidazolidinedione #; [4-(5-{(E)-[(2,4-Dioxoimidazolidin-1-yl)imino]methyl}furan-2-yl)phenyl](hydroxy)oxoammonium"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB01219	.	.	314.25	C14H10N4O5	121	524	1.7	23	1	6	3	"1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)/b15-7+"	C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-]	OZOMQRBLCMDCEG-VIZOYTHASA-N
DG01176	Ciclesonide	6918155	"Ciclesonide; Omnaris; Alvesco; 126544-47-6; Zetonna; RPR251526; UNII-S59502J185; RPR-251526; 141845-82-1; S59502J185; [2-[(1S,2S,4R,6R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] 2-methylpropanoate; Osonase; Osonide; Omnair; RPR 251526; Alvesco HFA; Omnaris HFA; Alvesco (TN); Omnaris (TN); [2-[(1S,2S,4R,8S,9S,11S,12S,13R)-6-Cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] 2-methylpropanoate; Ciclesonide [USAN:INN]; BTR-15K; Ciclesonide (JAN/USAN/INN); BTR-15; TBN-15; (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate; NCGC00167484-01; (11 ,16 )-16,17-[[(R)-Cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-pregna-1,4-diene-3,20-dione; Alvesco 80; Zetonna (TN); Alvesco, Ciclesonide; BYK-20426; Alvesco 160; BY-9010; KS-1165; AC1MIWNR; SCHEMBL3688; DSSTox_CID_26659; DSSTox_RID_81802; DSSTox_GSID_46659; B-9207-015; GTPL7469; el-87-6; CHEMBL2040682; DTXSID9046659; CHEBI:31397; Ciclesonide, >=98% (HPLC); HMS3714N07; EX-A4195; HY-B0625; ZINC3915154; Tox21_112486; BDBM50247997; s4646; AKOS015994702; AC-1330; BI54903; CCG-269962; DB01410; NCGC00167972-01; O945; Pregna-1,4-diene-3,20-dione, 16,17-(((R)-cyclohexylmethylene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy)-, (11beta,16alpha)-; Pregna-1,4-diene-3,20-dione, 16,17-((cyclohexylmethylene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy)-, (11beta,16alpha(R))-; Ciclesonide 100 microg/mL in Acetonitrile; CAS-141845-82-1; C72110; D01703; 544C476; A899067; SR-01000942227; Q5119448; SR-01000942227-1; Ciclesonide, European Pharmacopoeia (EP) Reference Standard; (11 ,16 )-16,17-[[(R)-Cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-diene-3,20-dione; 2-((6aR,6bS,7S,8aS,8bS,10R,11aR,12aS,12bS)-10-cyclohexyl-7-hydroxy-6a,8a-dimethyl-4-oxo-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-oxoethyl isobutyrate; 2H-Naphth (2',1':4,5) indeno (1,2-d) (1,3) dioxole, pregna-1,4-diene-3,20-dione deriv."	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:31397	DB01410	DR01408	DR0319	540.7	C32H44O7	99.1	1100	5.3	39	1	7	6	"1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1"	CC(C)C(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)O[C@H](O2)C6CCCCC6	LUKZNWIVRBCLON-GXOBDPJESA-N
DG01180	Prasugrel	6918456	"Prasugrel; 150322-43-3; Effient; Efient; CS-747; Prasugrel (Effient); 5-(2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate; LY640315; LY-640315; CS 747; Pcr 4099; CHEBI:87723; 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate; [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate; 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4H,5H,6H,7H-thieno[3,2-c]pyridin-2-yl acetate; Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)-; Prasita; SMR002533665; Prasugrel [INN:BAN]; NCGC00188690-01; NCGC00188690-02; HSDB 7995; NSC-759625; Prasugrel- Bio-X; Prasugrel-[d5]; Ethanone, 2-(2-(acetyloxy)-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-1-cyclopropyl-2-(2-fluorophenyl)-; 2-[2-(Acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)ethanone; MLS003882595; MLS006012001; SCHEMBL245032; GTPL7562; CHEMBL1201772; Prasugrel, >=98% (HPLC); SCHEMBL14112007; DTXSID70861544; HMS3604B09; HMS3654D09; HMS3884I07; ACT06208; BCP01882; FD7194; MFCD09954140; s1258; STL232602; ZB0747; AKOS015841187; AC-1640; CCG-268338; CS-0657; DB06209; KS-5301; MCULE-1302242257; NSC 759625; PB23765; SB20805; NCGC00188690-03; [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxo-ethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate; 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; BP164290; HY-15284; AM20090728; FT-0650150; P2040; SW219175-1; W0064; AB01274761-01; AB01274761_02; 322P433; A809033; AR-270/43507998; Q416232; Q-101872; [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[4,5-c]pyridin-2-yl] acetate; 2-Acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c] pyridine; 2-Acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 2-acetyloxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 2-acetyloxy-5-(alpha-cycloproylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-C]pyridine; Acetic acid 5-[2-cyclopropyl-1-(2-fluoro-phenyl)-2-oxo-ethyl]-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-2-yl ester"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:87723	DB06209	.	.	373.4	C20H20FNO3S	74.8	555	3.6	26	0	6	6	"1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3"	CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4	DTGLZDAWLRGWQN-UHFFFAOYSA-N
DG01181	Voclosporin	6918486	"Voclosporin; 515814-01-4; Luveniq; ISAtx-247; Voclosporin [USAN]; ISA-247; ISATX247; ISA247; Lupkynis; UNII-2PN063X6B1; R 1524; ISA(TX)247; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhepta-4,6-dienyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; 515814-00-3; R-1524; 2PN063X6B1; LX211; trans-ISA 247; ISA 247; LX-211; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-((1R,2R,E)-1-hydroxy-2-methylhepta-4,6-dien-1-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone; trans-ISA-247; Voclosporin (USAN/INN); Voclosporin [USAN:INN]; Voclera; ISATX 247; 3odi; LX-214; ISAtx-247; Luveniq; E-ISA247; SCHEMBL12632344; GTPL11388; CHEBI:135957; (E)-ISA-247; EX-A5922; AT27977; DB11693; HY-106638; CS-0026210; R1524; D09033; Q7939256; Cyclosporin A, 6-((2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic acid)-; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhepta-4,6-dien-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecone; 1,11-anhydro[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl- N-methyl-L-valyl-[(2S,3R,4R,6E)-3-hydroxy-4-methyl- 2-(methylamino)nona-6,8-dienoyl][(2S)-2-aminobutanoyl]- N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucine]"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:135957	DB11693	.	.	1214.6	C63H111N11O12	279	2380	7.9	86	5	12	16	"1S/C63H111N11O12/c1-25-27-28-29-41(15)53(76)52-57(80)66-44(26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27-28,35-48,50-53,76H,1,26,29-34H2,2-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b28-27+/t41-,42+,43-,44+,45+,46+,47+,48+,50+,51+,52+,53-/m1/s1"	CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C	BICRTLVBTLFLRD-PTWUADNWSA-N
DG01182	Panobinostat	6918837	"Panobinostat; 404950-80-7; LBH589; LBH-589; Farydak; Panobinostat (LBH589); Faridak; LBH 589; (E)-N-Hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)acrylamide; NVP-LBH589; NVP-LBH-589; UNII-9647FM7Y3Z; LBH-589B; CHEBI:85990; 9647FM7Y3Z; 404950-80-7 (free base); (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide; panobinostat hydrate; Farydak (TN); (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide; (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; (E)-N-hydroxy-3-(4-((2-(2-methyl-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide; 2-Propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)-; Panobinostat [USAN:INN]; 2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)-, (2E)-; Panobinostat(LBH589); LBH589 - Panobinostat; Panobinostat (USAN/INN); N-Hydroxy-3-[4-[2-(2-methyl-1H-indol-3-yl)ethylaminomethyl]phenyl]-2(E)-propenamide; MLS006011216; NVP-LBH 589; SCHEMBL164801; SCHEMBL183197; CHEMBL483254; GTPL7489; SCHEMBL22773814; BDBM29589; CHEBI:93774; DTXSID40193506; EX-A169; N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-2-propenamide; BCPP000187; BDBM198124; AOB87727; BCP01816; LBH58,9NVP-LBH589,Panobinostat; (LBH-589); MFCD09833242; NSC761190; s1030; ZINC22010649; AKOS005146046; BCP9000844; CCG-208762; CS-0267; DB06603; EX-8456; NSC-761190; (2E)-N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide; (E)-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enehydroxamic acid; NCGC00263117-05; NCGC00263117-07; 2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino) methyl)phenyl)-, (2E)-; AC-28652; AM808102; AS-17046; HY-10224; QC-10419; SMR004702978; DB-025426; SW219369-1; W6096; EC-000.2287; A25218; D10319; J-523585; Q7131441; BRD-K02130563-001-07-2; (E)-N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indole-3-yl)ethyl]amino]methyl]phenyl]acrylamide; N-hydroxy-3 -[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide; N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide; Panobinostat;(E)-N-hydroxy-3-(4-((2-(2-methyl-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:85990	DB06603	DR00181	.	349.4	C21H23N3O2	77.2	474	3	26	4	3	7	"1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+"	CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO	FPOHNWQLNRZRFC-ZHACJKMWSA-N
DG01183	Chlorhexidine	9552079	"Chlorhexidine; 55-56-1; Rotersept; Fimeil; Hexadol; Soretol; Chlorhexidin; Chlorhexidinum; Cloresidina [DCIT]; Chlorhexidin [Czech]; Chlorhexidinum [INN-Latin]; Clorhexidina [INN-Spanish]; Nolvasan; Hibistat; 1,6-Bis(p-chlorophenyldiguanido)hexane; 1,6-Di(4'-chlorophenyldiguanido)hexane; UNII-R4KO0DY52L; 1,6-Bis(5-(p-chlorophenyl)biguandino)hexane; Chlorohexidine; Exidine; Tubulicid; 1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide); 1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide); 2,4,11,13-Tetraazatetradecanediimidamide, N,N''-bis(4-chlorophenyl)-3,12-diimino-; Sterilon; CHEMBL790; R4KO0DY52L; MLS001332388; CHEBI:3614; Cloresidina; Clorhexidina; 56-95-1; Biguanide, 1,1'-hexamethylenebis(5-(p-chlorophenyl)-; CAS-55-56-1; NCGC00016246-03; SMR000857146; Sterido; Savlon babycare; N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]; DSSTox_CID_13314; DSSTox_RID_79062; N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide; DSSTox_GSID_33314; Chlorhexidine [INN:BAN]; Chlorhexidine dihydrochloride; Merfen-incolore; MLS001304094; 1-(4-chlorophenyl)-3-[N-[6-[[N-[N-(4-chlorophenyl)carbamimidoyl]carbamimidoyl]amino]hexyl]carbamimidoyl]guanidine; N-(4-chlorophenyl)-1-3-(6-{N-[3-(4-chlorophenyl)carbamimidamidomethanimidoyl]amino}hexyl)carbamimidamidomethanimidamide; CCRIS 9230; Chlorhexidine (INN); C22H30Cl2N10; HSDB 7196; Merfen-incolore (TN); SR-01000799135; Nolvasan (*Diacetate*); 1,1'-Hexamethylenebis(5-[p-chlorophenyl]biguanide); 1,1'-hexamethylenebis[5-(p-chlorophenyl)biguanide]; SMR000718621; EINECS 200-238-7; Lisium (*Dihydrochloride*); BRN 2826432; 1,6-Di(N-p-chlorophenyldiguanido)hexane; Chlorhexadine; Dentisept; Dentisept [veterinary] (TN); 1,6-Bis(N5-[p-chlorophenyl]-N1-biguanido)hexane; Prestwick_53; Chlorhexidine (1); Hibidil (Salt/Mix); Hibisol (Salt/Mix); Chlorhexidine diacetate salt hydrate; Hibitane (Salt/Mix); Hibiscrub (Salt/Mix); Hibispray (Salt/Mix); NSC526936; Spectrum_000237; Savloclens (Salt/Mix); 3697-42-5; Prestwick0_000143; Prestwick1_000143; Prestwick2_000143; Prestwick3_000143; Spectrum2_000135; Spectrum3_000339; Spectrum4_000277; Spectrum5_001322; Hexamethylenebis(5-(4-chlorophenyl)biguanide); EC 200-238-7; SCHEMBL3984; Chlorhexidine, >=99.5%; BSPBio_000246; BSPBio_001977; KBioGR_000774; KBioSS_000717; 4-12-00-01201 (Beilstein Handbook Reference); MLS001332387; MLS002154209; DivK1c_000761; SPBio_000210; SPBio_002185; BPBio1_000272; DTXSID2033314; BDBM51937; BDBM64773; cid_9552079; KBio1_000761; KBio2_000717; KBio2_003285; KBio2_005853; KBio3_001197; 2,4,11,13-Tetraazatetradecanediimidamide, N1,N14-bis(4-chlorophenyl)-3,12-diimino-; cid_12303047; NINDS_000761; REGID_for_CID_9552079; BDBM152706; HMS1568M08; HMS2095M08; HMS2233B16; HMS3712M08; (1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine; HY-B1248; Tox21_110325; Tox21_201404; Tox21_303445; BDBM50170723; s5397; STK089248; AKOS005394319; Tox21_110325_1; CCG-220143; CS-4958; DB00878; MCULE-4644073142; 2,4,11,13-Tetraazatetradecanediimidamide, N,N'-bis(4-chlorophenyl)-3,12-diimino-; IDI1_000761; N,N''''-hexane-1,6-diylbis[N'-(4-chlorophenyl)(imidodicarbonimidic diamide)]; N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradeca- nediimidamide; QTL1_000020; NCGC00016246-01; NCGC00016246-02; NCGC00016246-04; NCGC00016246-05; NCGC00016246-06; NCGC00016246-07; NCGC00016246-09; NCGC00016246-13; NCGC00016246-21; NCGC00091025-01; NCGC00091025-02; NCGC00091025-04; NCGC00247766-01; NCGC00257242-01; NCGC00258955-01; (1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylene]amino]methylene]amino]hexyl]-1-[amino-(4-chloroanilino)methylene]guanidine; AS-12648; Chlorhexidine, purum, >=99.0% (HPLC); SBI-0051301.P003; AB00053427; C06902; D07668; AB00053427-24; AB00053427-28; AB00053427_29; 009C673; A830704; Q-200828; SR-01000799135-5; 1,1''-Hexamethylene bis(5-(p-chlorophenyl)biguanide); BRD-K52256627-300-03-3; BRD-K52256627-300-05-8; SR-01000799135-10; SR-01000799135-11; Chlorhexidine, European Pharmacopoeia (EP) Reference Standard; 1,1'-(Hexane-1,6-diyl)bis[5-(4-chlorophenyl)biguanide] diacetate; Chlorhexidine, United States Pharmacopeia (USP) Reference Standard; Chlorhexidine, Pharmaceutical Secondary Standard; Certified Reference Material; N'',N''''''''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]; N,N''-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide; (1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylene]amino]methylene]amino]hexyl]-1-[amino-(4-chloroanilino)methylene]guanidine;hydrochloride; (1E)-2-[6-[[azanyl-[(E)-[azanyl-[(4-chlorophenyl)amino]methylidene]amino]methylidene]amino]hexyl]-1-[azanyl-[(4-chlorophenyl)amino]methylidene]guanidine; (1E)-2-[6-[[azanyl-[(E)-[azanyl-[(4-chlorophenyl)amino]methylidene]amino]methylidene]amino]hexyl]-1-[azanyl-[(4-chlorophenyl)amino]methylidene]guanidine;hydrochloride; 2-[amino-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexylimino]methyl]-1-(4-chlorophenyl)guanidine; 2-[amino-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexylimino]methyl]-1-(4-chlorophenyl)guanidine;hydrochloride"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:3614	DB00878	DR00848	DR2666	505.4	C22H30Cl2N10	178	649	0.1	34	6	2	13	"1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)"	C1=CC(=CC=C1N/C(=N/C(=NCCCCCCN=C(/N=C(/NC2=CC=C(C=C2)Cl)\\N)N)N)/N)Cl	GHXZTYHSJHQHIJ-UHFFFAOYSA-N
DG01184	Thiacetazone	9568512	"Thiacetazone; Thioacetazone; AMITHIOZONE; Ambathizon; Benzothiozane; Conteben; Benzothiozon; Thiocarbazil; Benthiozone; Thioparamizone; Parazone; Thioacetazon; Thibone; Tibon; Tubin; Siocarbazone; Tebethione; Thiacetone; Thiacetozone; Thioazetazone; Thioparamizon; Thiotebesin; Thiotebezin; Thiotebicina; Tiacetazon; Tioacetazon; Tioatsetazon; Tubercazon; Aktivan; Amitiozon; Berkazon; Domakol; Livazone; Mivizon; Myvizone; Neotibil; Neustab; Novakol; Panrone; Seroden; Tebalon; Tebecure; Tebemar; Tebethion; Tebezon; Thiomicid; Thionicid; Thizone; Tibicur; Tibizan; Tiobicina; Tiocarone; Tiosecolo; Tubigal; Antib; Diasan; Ilbion; Thibon; Tibone; Berculon A; Tebesone I; 104-06-3; Nuclon argentinian; Thiosemicarbarzone; TB I (Bayer); 4-Acetylaminobenzaldehyde thiosemicarbazone; TB I; Thiosemicarbazone; Domagk's T.B.1 conteben; Thioacetazonum; Tibione; 4'-Formylacetanilide thiosemicarbazone; Sdt 1041; Magk's T.B.1 conteben; Tb I/698; p-Acetaminobenzylidenethiosemicarbazone; Tibion; CBC 903150; p-Formylacetanilide-3-thiosemicarbazone; SQ 2321; p-Acetamidobenzaldehyde thiosemicarbazone; p-Acetoaminobenzaldehyde thiosemicarbazone; UNII-MMG78X7SSR; A 4081; 4207 RP; RP 4207; Acetamide, N-[4-[[(aminothioxomethyl)hydrazono]methyl]phenyl]-; p-Acetylaminobenzadehyde thiosemicarbazone; MMG78X7SSR; Acetamide, N-(4-(((aminothioxomethyl)hydrazono)methyl)phenyl)-; NSC3550; Acetanilide, 4'-formyl-, 4'-(thiosemicarbazone); NSC-3550; p-Acetamidobenzaldehyde thiosemicarbazon; NCGC00159389-02; NCGC00159389-03; NCGC00159389-04; p-Acetylaminobenzaldehyde thiosemicarbazone; DSSTox_CID_2593; DSSTox_RID_76650; DSSTox_GSID_22593; N-(4-((2-Carbamothioylhydrazono)methyl)phenyl)acetamide; Mirizone neustab; Tioacetazona; Thioacetazone [INN:BAN]; Thioacetazonum [INN-Latin]; Tioacetazona [INN-Spanish]; CAS-104-06-3; Tb I-698; Thiosemicarbazone (pharmaceutical); NSC 3550; EINECS 203-170-6; BRN 2810335; N-[4-[(E)-(carbamothioylhydrazono)methyl]phenyl]acetamide; N-{4-[(E)-(Carbamothioylhydrazono)methyl]phenyl}acetamide; Citazone; Acetamide, N-(4-(((aminothiomethyl)hydrazono)methylene)phenyl)-; Acetamide, N-[4-[[(aminothiomethyl)hydrazono]methylene]phenyl]-; AI3-18591; 4207RP; Citazone (TN); Acetanilide, 4'-formyl-, thiosemicarbazone; Thioacetazone (INN); SCHEMBL42515; Acetanilide, thiosemicarbazone; WLN: SUYZMNU1R DMV1; 4-14-00-00075 (Beilstein Handbook Reference); N-(4-([2-(Aminocarbothioyl)hydrazono]methyl)phenyl)acetamide; N-[4-[(E)-(carbamothioylhydrazinylidene)methyl]phenyl]acetamide; Acetamide, N1-(4-([2-(aminocarbothioyl)hydrazono]methyl)phenyl); CHEMBL375492; TB-1; Acetamide, N-[4-[[2-(aminothioxomethyl)hydrazinylidene]methyl]phenyl]-; DTXSID80859179; EX-A101; CHEBI:134958; HY-B1526; Tox21_111625; Tox21_111626; Acetanilide, 4'-(thiosemicarbazone); BDBM50247903; MFCD00022157; N-{4-[(E)-(2-carbamothioylhydrazinylidene)methyl]phenyl}acetamide; RP4207; SQ2321; STL503688; ZINC32709513; AKOS000304458; Tox21_111625_1; DB12829; SQ-2321; 4-Acetamidobenzaldehyde thiosemicarbazone; AS-71466; CS-0013329; D08584; A800888; SR-01000872620; SR-01000872620-2; N-{4-[(E)-[(carbamothioylamino)imino]methyl]phenyl}acetamide; N-(4-{(E)-[(aminocarbonothioyl)hydrazono]methyl}phenyl)acetamide; 910379-02-1; N-[4-[(2-Carbamothioylhydrazono)methyl]phenyl]acetamide;N-[4-[(E)-(carbamothioylhydrazono)methyl]phenyl]acetamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:134958	.	.	DR2518	236.3	C10H12N4OS	112	285	1	16	3	3	3	"1S/C10H12N4OS/c1-7(15)13-9-4-2-8(3-5-9)6-12-14-10(11)16/h2-6H,1H3,(H,13,15)(H3,11,14,16)/b12-6+"	CC(=O)NC1=CC=C(C=C1)/C=N/NC(=S)N	SRVJKTDHMYAMHA-WUXMJOGZSA-N
DG01185	Esomeprazole	9568614	"Esomeprazole; (S)-Omeprazole; 119141-88-7; (-)-Omeprazole; (S)-(-)-Omeprazole; Nexium; Alenia; Esofag; Escz; Inexium paranova; (S)-Esomeprazole; Omeprazole S-form; Esomeprazole Sodium; UNII-N3PA6559FT; Nexiam; (S)-6-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; N3PA6559FT; CHEBI:50275; esomeprazol; 1H-Benzimidazole, 5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2- pyridinyl)methyl)sulfinyl)-; esomeprazolum; Esomeprazole [INN:BAN]; (S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole; 6-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole; Esomeprazole (INN); Inexium paranova (TN); IZRA 40; HSDB 8158; A02BC05; r-(+)-omeprazole; Omeprazole, (s)-; 5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole; SCHEMBL19535; BIDD:GT0020; GTPL5488; CHEMBL1201320; DTXSID4044292; QCR-180; ZINC4693575; AKOS015900821; AKOS016001455; AM84543; DB00736; 5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; AS-77669; D07917; Q553223; BRD-K61443506-001-01-0; UNII-KG60484QX9 component SUBDBMMJDZJVOS-DEOSSOPVSA-N; (5)6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole; (5)6-methoxy-2-[[(4-methoxy-3,5dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole; (5)6-methoxy-2-[[(4methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole; (5)6-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole; (5)6-methoxy-2[[(4methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole; (5)6-methoxy-2[[(4methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]1H-benzimidazole; (S)-5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; (s)-5-methoxy-2-(4-methoxy-3,5-dimethylpyridin-2-ylmethane-sulfinyl)-1h-benzimidazole; (S)-5-Methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl) methylsulfinyl]1-H-benzimidazole; (S)-5-Methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole; (s)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-3h-benzimidazole; (s)-5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole; (S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole; 6-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole; (+)-(5)6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole; 326602-80-6; 5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methane]sulfinyl]-1H-1,3-benzodiazole"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:50275	DB00736	.	DR0627	345.4	C17H19N3O3S	96.3	453	2.2	24	1	6	5	"1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1"	CC1=CN=C(C(=C1OC)C)C[S@](=O)C2=NC3=C(N2)C=C(C=C3)OC	SUBDBMMJDZJVOS-DEOSSOPVSA-N
DG01186	Cefmenoxime	9570757	"Cefmenoxime; Cefmenoximum; Cefmenoxima; 65085-01-0; Cefmenoxime [INN]; Cefmenoximum [INN-Latin]; Cefmenoxima [INN-Spanish]; UNII-KBZ4844CXN; Cefmenoxime (INN); KBZ4844CXN; SCE-1365; (6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-((1-methyl-1H-5-tetraazolylthio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; CHEBI:55490; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; SCE 1365; CMX; A 50912; AB 50912; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (IUPAC); (6R,7R)-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-(1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure-7-(Z)-(O-methyloxim); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-(6alpha,7beta(Z)))-; SCHEMBL152861; CHEMBL1201224; DTXSID2022755; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; ZINC3871927; AKOS030573275; DB00267; NCGC00373220-03; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid; D07641; 085C010; A834966; (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:55490	DB00267	.	.	511.6	C16H17N9O5S3	270	890	0	33	3	14	8	"1S/C16H17N9O5S3/c1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7/h5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)/b21-8-/t9-,13-/m1/s1"	CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O	HJJDBAOLQAWBMH-YCRCPZNHSA-N
DG01189	Lobeglitazone	9826451	"Lobeglitazone; 607723-33-1; 5-(4-(2-((6-(4-Methoxyphenoxy)pyrimidin-4-yl)(methyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione; Lobeglitazone [INN]; CKD501; SCHEMBL2742697; CHEMBL3585580; CHEBI:136052; DB09198; SB16869; 5-[[4-[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methylamino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; DB-090849; Q18350076"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:136052	DB09198	.	.	480.5	C24H24N4O5S	128	670	4.3	34	1	9	10	"1S/C24H24N4O5S/c1-28(21-14-22(26-15-25-21)33-19-9-7-17(31-2)8-10-19)11-12-32-18-5-3-16(4-6-18)13-20-23(29)27-24(30)34-20/h3-10,14-15,20H,11-13H2,1-2H3,(H,27,29,30)"	CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC(=NC=N3)OC4=CC=C(C=C4)OC	CHHXEZSCHQVSRE-UHFFFAOYSA-N
DG01190	Midostaurin	9829523	"Midostaurin; PKC412; 120685-11-2; Cgp 41251; PKC-412; 4'-N-Benzoylstaurosporine; Benzoylstaurosporine; CGP-41251; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; Cgp 41 251; Midostaurin [USAN:INN]; CGP 41231; NSC-656576; Rydapt (TN); Midostaurin(PKC412); 4-N-benzoylstaurosporine; Staurosporine, N-Benzoyl; NVP-PKC412; Midostaurin (JAN/USAN/INN); GTPL5702; SCHEMBL8295379; HMS3229K17; EX-A1741; BDBM50326053; CGP-41521; MFCD00871372; NSC800791; s8064; AKOS024457372; ZINC100013130; CCG-101288; CS-3331; DB06595; NSC 656576; NSC-800791; NCGC00241102-01; NCGC00241102-02; NCGC00241102-05; NCGC00484987-03; AC-31929; Benzamide, N-(2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-1-oxo-8,12-epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-10-yl)-N-methyl-, (8alpha,9beta,10beta,12alpha)-; HY-10230; N-((9S,10R,11R,13R)-10-methoxy-9-methyl-1-oxo-2,3,10,11,12,13-hexahydro-9,13-epoxy-1H,9H-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-11-yl)-N-methylbenzamide; C71714; D05029; J-004379; Q6842945; BRD-K13646352-001-01-2; [9S-(9 ,10 ,11 ,13 )]-N-(2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methylbenzamide; Benzamide, N-((9S,10R,11R,13R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-11-yl)-N-methyl-; N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8,10,12,14(28),15(19),20(27),21,23,25-nonaen-4-yl]-N-methylbenzamide; N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63452	DB06595	DR01370	DR1090	570.6	C35H30N4O4	77.7	1140	4.8	43	1	4	3	"1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1"	C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC	BMGQWWVMWDBQGC-IIFHNQTCSA-N
DG01191	Cabazitaxel	9854073	"CABAZITAXEL; 183133-96-2; Jevtana; Taxoid XRP6258; Cabazitaxelum; TXD 258; Xrp6258; XRP-6258; UNII-51F690397J; XRP 6258; Jevtana (TN); CHEBI:63584; NSC-761432; 51F690397J; kabazitaxel; Jevtana Kit; Cabazitaxel (Jevtana); (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate.; cabazitaxel acetonate; Cabazitaxel Injection; Cabazitaxel [USAN:INN]; Jevanta; TXD258; RPR 116258A; RPR-116258A; Cabazitaxel (USAN/INN); SCHEMBL179674; GTPL6798; CHEMBL1201748; AMY4317; DTXSID40171389; EX-A838; TXD-258; C45H57NO14; MFCD18827611; NSC761432; NSC794609; s3022; ZINC85536932; AKOS032947285; CCG-270519; CS-0972; DB06772; NSC 761432; NSC-794609; NCGC00346704-01; NCGC00346704-03; AS-75355; HY-15459; X7252; A25044; D09755; AB01273971-01; AB01273971_02; Q412963; SR-01000941585; J-011721; J-519981; SR-01000941585-1; (((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-((2R,3S)-3-; (1S)-5beta,20-Epoxy-9-oxo-7beta,10beta-dimethoxytaxa-11-ene-1,2alpha,4alpha,13alpha-tetraol 2-benzoate 4-acetate 13-[(2R,3S)-2-hydroxy-3-(tert-butoxycarbonylamino)-3-phenylpropionate]; (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3),(1) .0 , ]heptadec-13-en-2-yl benzoate; (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate; (2alpha,5beta,7beta,10beta,13alpha)-4-acetoxy-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; (2AR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,1; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1-hydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate; 1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-ene-2,4,13-triyl 4-acetate 2-benzoate 13-((2R,3S)-3-(((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate); 1-hydroxy-7 ,10 -dimethoxy-9-oxo-5 ,20-epoxytax-11-ene-2 ,4,13 -triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate]; Benzenepropanoic acid, beta-[[(1,1-dimethylethoxy)carbonyl]amino]-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63584	DB06772	.	DR0252	835.9	C45H57NO14	202	1690	2.7	60	3	14	15	"1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1"	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC	BMQGVNUXMIRLCK-OAGWZNDDSA-N
DG01193	Treosulfan	9882105	"Treosulfan; 299-75-2; Treosulphan; Ovastat; NSC 39069; Dihydroxybusulfan; UNII-CO61ER3EPI; NSC-39069; (2S,3S)-Threitol 1,4-bismethanesulfonate; CO61ER3EPI; CHEBI:82557; l-Threitol-1,4-bis(methanesulfonate); CB 40067; (2S,3S)-2,3-dihydroxybutane-1,4-diyl dimethanesulfonate; threosulphan; Treosulfano; Treosulfanum; Treosulfanum [INN-Latin]; Treosulfano [INN-Spanish]; CCRIS 2781; HSDB 6963; DHB; EINECS 206-081-0; L-Threitol, 1,4-bis(methanesulfonate); 1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, (S-(R*,R*))-; Threitol, 1,4-dimethanesulfonate, L-(+)-; Treosulfan (INN); Ovastat (TN); L-Threitol, 1,4-bismethanesulfonate; TreosulphanNSC 39069; Treosulfan [USAN:INN:BAN]; CHEMBL455186; SCHEMBL5399430; (S-(R*,R*))-1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate; WHO 3103; ZINC1671094; l-threitol-1,4-bis-methanesulfonate; s6958; L-threitol 1,4-bis(methanesulfonate); CS-3889; DB11678; HY-16503; PS-12126; C19557; D07253; A912763; Threitol, 1,4-dimethanesulfonate, (2S,3S)- (8CI); (S)-3-BOC-AMINO-1-DIAZO-3-(4-BENZYLOXY)PHENYL-2-BUTANONE; [(2S,3S)-2,3-dihydroxy-4-methylsulfonyloxybutyl] methanesulfonate; 1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, (S-(R*,R*))- (9CI)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:82557	DB11678	.	.	278.3	C6H14O8S2	144	345	-2.2	16	2	8	7	"1S/C6H14O8S2/c1-15(9,10)13-3-5(7)6(8)4-14-16(2,11)12/h5-8H,3-4H2,1-2H3/t5-,6-/m0/s1"	CS(=O)(=O)OC[C@@H]([C@H](COS(=O)(=O)C)O)O	YCPOZVAOBBQLRI-WDSKDSINSA-N
DG01195	Selexipag	9913767	"Selexipag; 475086-01-2; NS-304; Uptravi; ACT-293987; NS 304; UNII-5EXC0E384L; ACT 293987; 5EXC0E384L; 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide; 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide; NS-304;ACT-293987; 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide; 2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide; 2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-N-(methylsulfonyl)acetamide; Selexipag [USAN:INN]; Uptravi (TN); ACT293987; NS-304(Selexipag); Selexipag(NS-304); Selexipag (JAN/USAN/INN); SCHEMBL674122; CHEMBL238804; GTPL7552; CHEBI:90844; AMY10851; BCP09146; ZINC3990451; 3938AH; BDBM50235383; MFCD10567093; s3726; AKOS024457572; CCG-269668; CS-3774; DB11362; SB17055; 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide; NCGC00370833-01; NCGC00370833-02; AC-30209; BS-16872; HY-14870; DB-119997; B7378; FT-0776043; D09994; A857156; Q15424759; 2-(4-((5,6-diphenyl-2-pyrazinyl)(isopropyl)amino)butoxy)-n-(methylsulfonyl)acetamide; 2-(4-((5,6-Diphenylpyrazinyl)(1-methylethyl)amino)butoxy)-N-(methylsulfonyl)-acetamide; 2-[4-[[5,6-di(phenyl)pyrazin-2-yl]-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide; 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-methanesulfonylacetamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:90844	DB11362	.	DR1471	496.6	C26H32N4O4S	110	730	3.8	35	1	7	12	"1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)"	CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3	QXWZQTURMXZVHJ-UHFFFAOYSA-N
DG01197	Tocotrienol	9929901	"Tocotrienol; 6829-55-6; 2-methyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dihydrochromen-6-ol; Tocotrienols; (R)-3,4-Dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2H-1-benzopyran-6-ol; CCRIS 7711; CHEMBL120643; SCHEMBL1081622; SCHEMBL1448780; DB12647; NCGC00186586-01; Q27236375; 2-methyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]-3,4-dihydro-2H-1-benzopyran-6-ol; 3,4-Dihydro-2-methyl-2-[(3E,7E)-4,8,12-trimethyl-3,7,11-tridecatrienyl]-2H-1-benzopyran-6-ol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB12647	.	.	382.6	C26H38O2	29.5	567	8.2	28	1	2	9	"1S/C26H38O2/c1-20(2)9-6-10-21(3)11-7-12-22(4)13-8-17-26(5)18-16-23-19-24(27)14-15-25(23)28-26/h9,11,13-15,19,27H,6-8,10,12,16-18H2,1-5H3/b21-11+,22-13+"	CC(=CCC/C(=C/CC/C(=C/CCC1(CCC2=C(O1)C=CC(=C2)O)C)/C)/C)C	GJJVAFUKOBZPCB-ZGRPYONQSA-N
DG01198	Rucaparib	9931954	"RUCAPARIB; 283173-50-2; Rubraca; Rucaparib free base; AG-14447; Rucaparib (free base); UNII-8237F3U7EH; Kinome_3180; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8237F3U7EH; 283173-50-2 (free base); 8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one; 8-FLUOR-2-{4-[(METHYLAMINO)METHYL]FENYL}-1,3,4,5-TETRAHYDRO-6HAZEPINO[5,4,3-CD]INDOOL-6-ON; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; C19H18FN3O; 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one; Rucaparib [USAN:INN]; PF 01367338; 8-Fluoro-2-[4-[(methylamino)methyl]phenyl]-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one; RPB; Rucaparib (USAN/INN); Rucaparib(AG-014447); SCHEMBL844585; GTPL7736; CHEMBL1173055; CHEBI:94311; ZINC25958; DTXSID10182563; CHEBI:134689; BCP07633; EX-A2700; BDBM50446130; HY-10617A; NSC756644; s4948; AKOS015898427; AG14447; DB12332; NSC-756644; SB16538; NCGC00263173-01; NCGC00263173-03; NCGC00263173-09; NCGC00263173-13; 6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one; 6H-Azepino(5,4,3-cd)indol-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-; 6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-; AC-24390; AS-74779; FT-0696622; A14182; C74459; D10079; Rucaparib; AG 014699; PF-01367338; A856084; Q7376558; BRD-K88560311-011-01-4; 6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.0^{4,13]trideca-1,4,6,8(13)-tetraen-9-one; 6-fluoro-2-{4-[(methylamino)methyl]phenyl}-3,10-diazatricyclo[6.4.1.0 ,(1)(3)]trideca-1,4,6,8(13)-tetraen-9-one; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]; 8-fluoro-5-(4-((methylamino)methyl)phenyl)-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-1-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:94311	DB12332	.	DR1449	323.4	C19H18FN3O	56.9	466	2.5	24	3	3	3	"1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)"	CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2	HMABYWSNWIZPAG-UHFFFAOYSA-N
DG01201	Pimavanserin	10071196	Pimavanserin; 706779-91-1; ACP-103; 1-(4-Fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea; Pimavanserin free base; UNII-JZ963P0DIK; JZ963P0DIK; 706779-91-1 (free base); 1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide; Pimavanserin [INN]; 706782-28-7; Pimanavserin; methyltrimethylacetate; AC-5273; Pimavanserin(ACP-103); SCHEMBL675165; Nuplazid (proposed trade name); GTPL8423; CHEMBL2111101; C25H34FN3O2; DTXSID90990906; CHEBI:133017; BDBM139370; HMS3742A03; BCP11618; EX-A4895; MFCD09953792; ZINC16159083; AKOS015902593; CS-3378; DB05316; ME-0240; SB16963; NCGC00390656-01; NCGC00390656-02; HY-14557; B8019; FT-0653701; Y0393; A14434; 779P911; A836958; J-503297; Q7194603; N-[(4-Fluorophenyl)Methyl]-N-(1-Methyl-4-piperidinyl)-N'-[[4-(2-Methylpropoxy)phenyl]Methyl]urea;; N-[(4-Fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}carbamimidic acid; N-[(4-fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}urea	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:133017	DB05316	.	.	427.6	C25H34FN3O2	44.8	523	4.5	31	1	4	8	"1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)"	CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C	RKEWSXXUOLRFBX-UHFFFAOYSA-N
DG01203	Besifloxacin	10178705	"Besifloxacin; 141388-76-3; UNII-BFE2NBZ7NX; BFE2NBZ7NX; 7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid; (R)-7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 3-Quinolinecarboxylic acid, 7-[(3R)-3-aminohexahydro-1H-azepin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-; Besifloxacin [INN]; SCHEMBL725805; QCR-76; CHEMBL1201760; DTXSID00161706; ISV-403; CHEBI:135622; ZINC3787097; s5941; AKOS005145882; AC-8867; DB06771; NCGC00386381-02; NCGC00386381-04; Z6122; A23458; AB01565807_02; 388B763; Q3638978; (R)-7-(3-aminoazepan-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (R)-7-(3-Aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolin; 3-Quinolinecarboxylic acid, 7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, (R)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:135622	DB06771	.	.	393.8	C19H21ClFN3O3	86.9	656	1.1	27	2	7	3	"1S/C19H21ClFN3O3/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23/h7,9-11H,1-6,8,22H2,(H,26,27)/t10-/m1/s1"	C1CCN(C[C@@H](C1)N)C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4CC4)F	QFFGVLORLPOAEC-SNVBAGLBSA-N
DG01206	Tedizolid	11234049	"Tedizolid; Torezolid; 856866-72-3; TR-700; Sivextro; DA-7157; Da 7157; UNII-97HLQ82NGL; TR 700; CHEBI:82717; 97HLQ82NGL; (5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one; (5R)-3-{3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl}-5-(hydroxymethyl)-1,3-oxazolidin-2-one; (R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one; Tedizolid [USAN:INN]; previously torezolid; torezolid; Sivextro; Tedizolid (USAN/INN); SCHEMBL440398; CHEMBL1257051; GTPL10865; DTXSID10234975; TR700; 1431699-67-0; BCP02830; EX-A5826; BDBM50491954; MFCD19442562; s5278; ZINC43100956; AKOS025401974; CCG-268294; CS-0687; DB14569; NCGC00379072-02; (5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)-3-pyridyl]phenyl]-5-(hydroxymethyl)oxazolidin-2-one; AC-27738; AS-56108; HY-14855; A14965; D09685; Q7825683; (5R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one; (5R)-3-{3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl}-5-(hydroxymethyl)-2-oxazolidinone; (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-on; (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one; 2-Oxazolidinone, 3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl)phenyl)-5-(hydroxymethyl)-, (5R)-; 3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one; 3-(3-fluoro-4-(6-(2-methyl-2h-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-hydroxymethyloxazolidin-2-one; U7V"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:82717	.	.	.	370.3	C17H15FN6O3	106	543	1.4	27	1	8	4	"1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3/t12-/m1/s1"	CN1N=C(N=N1)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4C[C@@H](OC4=O)CO)F	XFALPSLJIHVRKE-GFCCVEGCSA-N
DG01209	Eribulin	11354606	"Eribulin; 253128-41-5; Halaven; UNII-LR24G6354G; ER 086526; CHEBI:63587; LR24G6354G; 2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one; (1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one; Eribulin [INN]; (1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-bis(methylene)-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.1(3,32).1(3,33).1(6,9).1(12,16).0(18,22).0(29,36).0(31,35)]hentetracontan-24-one; NSC-707389; ER-086526; (1s,3s,6s,9s,12s,14r,16r,18s,20r,21r,22s,26r,29s,31r,32s,33r,35r,36s)-20-[(2s)-3-Amino-2-Hydroxypropyl]-21-Methoxy-14-Methyl-8,15-Dimethylidene-2,19,30,34,37,39,40,41-Octaoxanonacyclo[24.9.2.1~3,32~.1~3,33~.1~6,9~.1~12,16~.0~18,22~.0~29,36~.0~31,35~]hentetracontan-24-One (Non-Preferred Name); B 1939; e7389-lf; GTPL6813; CHEMBL1683590; SCHEMBL15783821; DTXSID101009321; ZINC169344691; DB08871; NCGC00510497-02; HY-13442; Q408717; (1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-o"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:63587	DB08871	.	DR0601	729.9	C40H59NO11	146	1380	1.1	52	2	12	4	"1S/C40H59NO11/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41/h19,23-39,43H,2-3,5-18,41H2,1,4H3/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+/m1/s1"	C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O	UFNVPOGXISZXJD-JBQZKEIOSA-N
DG01212	Tavaborole	11499245	"Tavaborole; 174671-46-6; AN-2690; 5-FLUOROBENZO[C][1,2]OXABOROL-1(3H)-OL; Kerydin; AN2690; AN 2690; 2,1-Benzoxaborole, 5-fluoro-1,3-dihydro-1-hydroxy-; UNII-K124A4EUQ3; 5-fluoro-1-hydroxy-3H-2,1-benzoxaborole; 5-fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol; 5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole; K124A4EUQ3; CHEBI:77942; MFCD10699483; 5-fluoro-2,1-benzoxaborol-1(3H)-ol; C7H6BFO2; 5-Fluoro-3H-benzo[c][1,2)oxaborol-1-ol; 5-fluoro-3H-benzo[c][1,2]oxaborol-1-ol; Tavaborole [USAN:INN]; p-fluorbenzoxaborole; Kerydin (TN); Tavaborole (USAN); SCH-900340; AN-2690(Tavaborole); Tavaborole (AN-2690); SCHEMBL500016; CHEMBL443052; HSDB 8342; DTXSID00169888; BCP08730; EX-A1086; 3338AH; BDBM50370987; s4996; AKOS006303927; ZINC169990691; CCG-266215; CS-1058; DB09041; DS-8392; MB08883; 5-Fluoro-1-hydroxy-2,1-benzoxaborolane; NCGC00264110-01; NCGC00264110-02; AC-30887; HY-10980; SY038332; DB-100333; FT-0697827; X3699; A14999; D10169; F11396; 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole; Q21011226; 5-Fluoro-1-hydroxyl-1,3-dihydrobenzo[c][1,2]oxaborole; Z1739256284"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:77942	DB09041	.	.	151.93	C7H6BFO2	29.5	155	.	11	1	3	0	"1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2"	B1(C2=C(CO1)C=C(C=C2)F)O	LFQDNHWZDQTITF-UHFFFAOYSA-N
DG01213	Olodaterol	11504295	"OLODATEROL; 868049-49-4; Olodaterol Free Base; BI-1744; Striverdi; BI 1744; UNII-VD2YSN1AFD; 6-Hydroxy-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-2H-1,4-benzoxazin-3(4H)-one; VD2YSN1AFD; CHEBI:82700; 868049-49-4 (free base); (R)-6-hydroxy-8-(1-hydroxy-2-((1-(4-methoxyphenyl)-2-methylpropan-2-yl)amino)ethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one; Striverdi respimat (TN); 6-Hydroxy-8-((1R)-1-hydroxy-2-((2-(4-methoxyphenyl)-1,1-dimethylethyl)amino)ethyl)-2H-1,4-benzoxazin-3(4H)-one; Olodaterol [USAN:INN]; BI 1744(Olodaterol;Striverdi Respimat); Olodaterol (USAN/INN); Olodaterol (BI 1744); SCHEMBL560926; CHEMBL605846; GTPL7543; AMY16614; BCP11473; EX-A1729; BI1744; s4485; ZINC34636383; CS-6275; DB09080; NCGC00522533-01; AC-29048; AS-74944; HY-14301; C76830; D10145; 049H494; Q7088466; 2H-1,4-Benzoxazin-3(4H)-one, 6-hydroxy-8-((1R)-1-hydroxy-2-((2-(4-methoxyphenyl)- 1,1-dimethylethyl)amino)ethyl)-; 6-hydroxy-8-(1-hydroxy-2-((2-(4-methoxyphenyl)-1,1-dimethylethyl)amino)ethyl)-2H-1,4-benzoxazin-3(4H)-one; 6-hydroxy-8-[(1R)-1-hydroxy-2-{[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino}ethyl]-2H-1,4-benzoxazin-3(4H)-one; 6-hydroxy-8-[(1R)-1-hydroxy-2-{[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino}ethyl]-3,4-dihydro-2H-1,4-benzoxazin-3-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:82700	DB09080	.	.	386.4	C21H26N2O5	100	521	1.8	28	4	6	7	"1S/C21H26N2O5/c1-21(2,10-13-4-6-15(27-3)7-5-13)22-11-18(25)16-8-14(24)9-17-20(16)28-12-19(26)23-17/h4-9,18,22,24-25H,10-12H2,1-3H3,(H,23,26)/t18-/m0/s1"	CC(C)(CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C(=CC(=C2)O)NC(=O)CO3)O	COUYJEVMBVSIHV-SFHVURJKSA-N
DG01214	Dacomitinib	11511120	"Dacomitinib; 1110813-31-4; PF299804; Dacomitinib (PF299804, PF299); PF-00299804; UNII-2XJX250C20; (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide; (E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enaMide; 2XJX250C20; PF 00299804-03; Vizimpro; PF-299804; PF-00299804-03; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide; C24H25ClFN5O2; (2e)-N-{4-[(3-Chloro-4-Fluorophenyl)amino]-7-Methoxyquinazolin-6-Yl}-4-(Piperidin-1-Yl)but-2-Enamide; Dacomitinib [USAN:INN]; dacomitinibum; PF299; (E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide; Dacomitinib (INN); Dacomitinib anhydrous; Dacomitinib (PF299804); MLS006011275; GTPL7422; CHEMBL2110732; PF-00299804 dacomitinib; CHEBI:91466; DTXSID50149493; EX-A030; QCR-174; CHEBI:132268; BDBM112499; Dacomitinib (PF-00299804); AMY21292; AOB87383; AOB87735; BCP02530; MFCD19443734; NSC765888; NSC800084; PF-299; s2727; ZINC72266312; AKOS025401818; CCG-264987; CS-0500; DB11963; NSC-765888; NSC-800084; US8623883, No. 2; NCGC00263185-09; NCGC00263185-10; AC-25915; AS-57686; HY-13272; SMR004703025; PF299804; ; ; PF299; D5450; SW219155-1; Y0338; D09883; Dacomitinib (PF299804, PF-00299804); PF-299804 (Dacomitinib PF-00299804); J-500784; Q17130597; (2E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide; (E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide; (E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide; 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-, (2E)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:91466	DB11963	DR00109	DR0407	469.9	C24H25ClFN5O2	79.4	665	4.4	33	2	7	7	"1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+"	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4	LVXJQMNHJWSHET-AATRIKPKSA-N
DG01216	Finafloxacin	11567473	"Finafloxacin; 209342-40-5; Xtoro; UNII-D26OSN9Q4R; D26OSN9Q4R; CHEBI:85176; Finafloxacin (INN); Finafloxacin [INN]; 8-cyano-1-cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; AL-60371; 7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid; gastrochinolon; gastroquinolone; 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Xtoro (TN); BAY35-3377; QCR-30; SCHEMBL1002869; CHEMBL1908370; GTPL10809; DTXSID10175096; BCP23882; ZINC3985346; AL60371; CS-5557; DB09047; NCGC00510315-02; (-)-8-Cyano-1-cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2H)-yl)-4-oxo-1; AC-29291; HY-13451; D10575; Q21011229; (-)-8-Cyano-1-cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2H)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid,8-cyano-1-cyclopropyl-6-fluoro-7-[(4as,7as)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo-; 7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid,hydrochloride; 8-cyano-1-cyclopropyl-6-fluoro-7-((1S,6S)-2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 8-Cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:85176	DB09047	.	.	398.4	C20H19FN4O4	106	806	-0.7	29	2	9	3	"1S/C20H19FN4O4/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28)/t15-,16-/m0/s1"	C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4C[C@H]5[C@H](C4)OCCN5)F)C(=O)O	FYMHQCNFKNMJAV-HOTGVXAUSA-N
DG01217	Lasmiditan	11610526	"Lasmiditan; 439239-90-4; 2,4,6-Trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl)benzamide; COL-144; lasmitidan; UNII-760I9WM792; LY573144; 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamide; 439239-90-4 (free base); 760I9WM792; 2,4,6-Trifluoro-N-(6-((1-methylpiperidine-4-yl)carbonyl)pyridin-2-yl)benzamide; 2,4,6-tris(fluoranyl)-N-[6-(1-methylpiperidin-4-yl)carbonylpyridin-2-yl]benzamide; Lasmiditan [USAN:INN]; Reyvow; COL 144; Lasmiditan (USAN/INN); SCHEMBL536057; GTPL3928; CHEMBL3039520; DTXSID40469435; QCR-219; AMY27880; BCP04734; EX-A1300; EX-A1653; ZINC3818355; 6063AB; MFCD18633238; s5064; AKOS016000352; BCP9000841; CS-2032; DB11732; Lasmiditan; OL-144; LY573144; SB19007; COL-144; LY573144; Lasmiditan (COL-144; LY573144); AS-35247; HY-14861; BCP0726000027; A14198; D10338; L022410; Q6493750; 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide; 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide; 2,4,6-trifluoro-N-[6-(1-methylpiperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide; Benzamide, 2,4,6-trifluoro-N-(6-((1-methyl-4-piperidinyl)carbonyl)-2-pyridinyl)-; 05X"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11732	.	.	377.4	C19H18F3N3O2	62.3	530	2.8	27	1	7	4	"1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27)"	CN1CCC(CC1)C(=O)C2=NC(=CC=C2)NC(=O)C3=C(C=C(C=C3F)F)F	XEDHVZKDSYZQBF-UHFFFAOYSA-N
DG01223	Cenobamate	11962412	"Cenobamate; 913088-80-9; Xcopri; UNII-P85X70RZWS; YKP-3089; YKP3089; P85X70RZWS; [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] Carbamate; Cenobamate [INN]; Ontozry; Xcopri (TN); YKP-3089 Cenobamate; Cenobamate (USAN/INN); Cenobamate [USAN:INN]; SCHEMBL1682643; CHEMBL3989949; GTPL10773; YKP3089YKP3089; EX-A3604; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, 2-carbamate, (alphaR)-; Carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester; DB06119; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; HY-17607; CS-0014686; D11150; Q27286352; (1R)-1-(2-chlorophenyl)-2-(2H-1,2,3,4-tetrazol-2-yl)ethyl carbamate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	DR0288	267.67	C10H10ClN5O2	95.9	293	1.5	18	1	5	5	"1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1"	C1=CC=C(C(=C1)[C@H](CN2N=CN=N2)OC(=O)N)Cl	GFHAXPJGXSQLPT-VIFPVBQESA-N
DG01224	lifitegrast	11965427	"Lifitegrast; 1025967-78-5; Xiidra; SAR 1118; SAR-1118; SHP606; (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid; UNII-038E5L962W; SHP-606; CHEMBL2048028; 038E5L962W; L-Phenylalanine, N-[[2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl]carbonyl]-3-(methylsulfonyl)-; L-Phenylalanine, N-((2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl)carbonyl)-3-(methylsulfonyl)-; Lifitegrast [USAN:INN]; Xiidra (TN); Lifitegrast (USAN/INN); Lifitegrast; SAR 1118; Lifitegrast ophthalmic solution; GTPL7533; SCHEMBL2632068; AMY4450; DTXSID60145345; SAR1118; CHEBI:133023; EX-A2582; BDBM50386331; MFCD28502439; s3714; ZINC84668739; CCG-270245; CS-6264; DB11611; compound 1g [PMID: 24900456]; (2S)-2-(((2-(Benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6- yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic acid; AC-32534; DS-20052; HY-19344; D10374; A900838; Q23044263; (2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid; N-[[2-(6-Benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl]carbonyl]-3-(methylsulfonyl)-L-phenylalanine; N-[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carbonyl]-3-(methanesulfonyl)-L-phenylalanine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:133023	DB11611	DR00072	.	615.5	C29H24Cl2N2O7S	142	1100	4.7	41	2	7	7	"1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1"	CS(=O)(=O)C1=CC=CC(=C1)C[C@@H](C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl	JFOZKMSJYSPYLN-QHCPKHFHSA-N
DG01226	Verteporfin	11980904	"Visudyne (TN); SCHEMBL6218; Verteporfin (JAN/USP/INN); SCHEMBL1230373; Verteporfin, >=94% (HPLC); HY-B0146; AKOS015896072; AKOS037515819; CS-1950; D01162; Verteporfin, United States Pharmacopeia (USP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00460	.	.	1437.6	C82H84N8O16	347	2990	.	106	6	20	24	"1S/2C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)24(11-14-36(46)47)32(44-30)18-33-25(12-15-37(48)51-6)21(3)28(43-33)16-31(23)42-29;1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h2*9-10,13,16-19,38,42,44H,1,11-12,14-15H2,2-8H3,(H,46,47)/t2*38-,41+/m00/s1"	CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5[C@@]6([C@@H](C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)OC)C(=C3C)CCC(=O)O)C=C.CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5[C@@]6([C@@H](C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)O)C(=C3C)CCC(=O)OC)C=C	NJLRKAMQPVVOIU-IDLGWYNRSA-N
DG01232	Sermorelin	16132413	"SERMORELIN; Sermorelina; 86168-78-7; UNII-89243S03TE; 89243S03TE; Sermoreline; Sermorelinum; Sermoreline [French]; Sermorelinum [Latin]; Sermorelina [Spanish]; Sermorelin [INN:BAN]; SCHEMBL34139; DTXSID70903978; EX-A5534; BDBM50004966; 168S787; UNII-00IBG87IQW component WGWPRVFKDLAUQJ-MITYVQBRSA-N; Growth Hormone Releasing Factor Fragment 1-29 amide human, >=97% (HPLC); Somatoliberin (human pancreatic islet), 29-L-argininamide-30-de-L-glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-argininyl-44-de-L-leucinamide; Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg(GRF(1-29)-NH2); TYR-ALA-ASP-ALA-ILE-PHE-THR-ASN-SER-TYR-ARG-LYS-VAL-LEU-GLY-GLN-LEU-SER-ALA-ARG-LYS-LEU-LEU-GLN-ASP-ILE-MET-SER-ARG-NH2; Tyr-Ala-Asp-Ala-Ile-Phe-Thr-D-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg(D-Asn8,(1-29)-NH2); Tyr-Ala-D-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg(D-Asp3,(1-29)-NH2); Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg(D-Ala2(1-29)-NH2)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	3357.9	C149H246N44O42S	1470	7640	-12.1	236	52	49	118	"1S/C149H246N44O42S/c1-20-77(13)116(191-122(211)81(17)168-132(221)104(66-113(204)205)178-121(210)79(15)167-123(212)88(152)62-84-39-43-86(198)44-40-84)145(234)185-102(63-83-32-23-22-24-33-83)138(227)193-118(82(18)197)146(235)186-103(65-111(155)202)137(226)189-108(71-196)142(231)182-101(64-85-41-45-87(199)46-42-85)136(225)175-93(38-31-56-165-149(161)162)126(215)174-91(35-26-28-53-151)131(220)190-115(76(11)12)143(232)184-97(58-72(3)4)124(213)166-68-112(203)170-94(47-49-109(153)200)128(217)180-100(61-75(9)10)135(224)188-106(69-194)140(229)169-80(16)120(209)172-92(37-30-55-164-148(159)160)125(214)173-90(34-25-27-52-150)127(216)179-99(60-74(7)8)134(223)181-98(59-73(5)6)133(222)176-95(48-50-110(154)201)129(218)183-105(67-114(206)207)139(228)192-117(78(14)21-2)144(233)177-96(51-57-236-19)130(219)187-107(70-195)141(230)171-89(119(156)208)36-29-54-163-147(157)158/h22-24,32-33,39-46,72-82,88-108,115-118,194-199H,20-21,25-31,34-38,47-71,150-152H2,1-19H3,(H2,153,200)(H2,154,201)(H2,155,202)(H2,156,208)(H,166,213)(H,167,212)(H,168,221)(H,169,229)(H,170,203)(H,171,230)(H,172,209)(H,173,214)(H,174,215)(H,175,225)(H,176,222)(H,177,233)(H,178,210)(H,179,216)(H,180,217)(H,181,223)(H,182,231)(H,183,218)(H,184,232)(H,185,234)(H,186,235)(H,187,219)(H,188,224)(H,189,226)(H,190,220)(H,191,211)(H,192,228)(H,193,227)(H,204,205)(H,206,207)(H4,157,158,163)(H4,159,160,164)(H4,161,162,165)/t77-,78-,79-,80-,81-,82+,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,115-,116-,117-,118-/m0/s1"	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N	WGWPRVFKDLAUQJ-MITYVQBRSA-N
DG01234	Degarelix	16136245	"Degarelix; 214766-78-6; Degarelix acetate; Firmagon; UNII-SX0XJI3A11; SX0XJI3A11; CHEMBL415606; FE200486 (AS ACETATE SALT); FE200486; Uglypeptide1; Degarelix (INN/USAN); Degarelix [USAN:INN:BAN]; GTPL5585; SCHEMBL1397034; SCHEMBL21050504; HSDB 7817; CHEBI:135961; BDBM50102450; HY-16168A; NSC771648; CS-5350; DB06699; NSC-771648; AS-82636; QC-10170; D08901; 766D786; Q1182795; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2; Acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide; D-Alaninamide, N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-; N-Acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N(sup 6)-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:135961	DB06699	.	.	1632.3	C82H103ClN18O16	513	3390	3.5	117	17	18	41	"1S/C82H103ClN18O16/c1-45(2)35-60(72(107)92-59(16-9-10-33-87-46(3)4)80(115)101-34-12-17-68(101)79(114)88-47(5)70(84)105)93-74(109)63(38-51-23-30-58(31-24-51)91-81(85)116)95-76(111)64(39-50-21-28-57(29-22-50)90-71(106)66-42-69(104)100-82(117)99-66)97-78(113)67(44-102)98-77(112)65(41-53-13-11-32-86-43-53)96-75(110)62(37-49-19-26-56(83)27-20-49)94-73(108)61(89-48(6)103)40-52-18-25-54-14-7-8-15-55(54)36-52/h7-8,11,13-15,18-32,36,43,45-47,59-68,87,102H,9-10,12,16-17,33-35,37-42,44H2,1-6H3,(H2,84,105)(H,88,114)(H,89,103)(H,90,106)(H,92,107)(H,93,109)(H,94,108)(H,95,111)(H,96,110)(H,97,113)(H,98,112)(H3,85,91,116)(H2,99,100,104,117)/t47-,59+,60+,61-,62-,63-,64+,65-,66+,67+,68+/m1/s1"	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CC5=CN=CC=C5)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C	MEUCPCLKGZSHTA-XYAYPHGZSA-N
DG01236	Tesamorelin	16137828	Egrifta; Tesamorelin; UNII-MQG94M5EEO; MQG94M5EEO; 804475-66-9; TH9507; 218949-48-5; TH 9507; TH-9507; Tesamorelin [USAN:INN]; (3E)-hex-3-enoylsomatoliberin; GTPL6959; DTXSID00583207; PUBCHEM_16137828; UNII-LGW5H38VE3 component QBEPNUQJQWDYKU-BMGKTWPMSA-N	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB08869	.	.	5136	C221H366N72O67S	2360	12800	-23.3	361	83	76	187	"1S/C221H366N72O67S/c1-25-28-30-53-163(308)260-145(92-120-54-58-122(299)59-55-120)198(343)255-116(21)179(324)276-150(96-169(316)317)199(344)256-117(22)180(325)291-172(111(16)26-2)214(359)284-147(91-119-43-31-29-32-44-119)206(351)293-174(118(23)298)215(360)285-149(95-162(230)307)205(350)289-155(104-297)210(355)280-146(93-121-56-60-123(300)61-57-121)203(348)267-130(51-41-83-248-220(240)241)186(331)266-126(46-34-36-78-223)197(342)290-171(110(14)15)212(357)283-141(87-106(6)7)183(328)252-100-166(311)258-133(63-70-157(225)302)190(335)278-144(90-109(12)13)202(347)288-152(101-294)208(353)257-115(20)178(323)262-128(49-39-81-246-218(236)237)185(330)265-125(45-33-35-77-222)189(334)277-143(89-108(10)11)201(346)279-142(88-107(8)9)200(345)272-137(66-73-160(228)305)195(340)282-151(97-170(318)319)207(352)292-173(112(17)27-3)213(358)274-139(76-85-361-24)196(341)287-153(102-295)209(354)268-131(52-42-84-249-221(242)243)187(332)270-135(64-71-158(226)303)192(337)269-132(62-69-156(224)301)182(327)251-99-165(310)259-134(67-74-167(312)313)191(336)286-154(103-296)211(356)281-148(94-161(229)306)204(349)273-136(65-72-159(227)304)193(338)271-138(68-75-168(314)315)194(339)264-124(47-37-79-244-216(232)233)181(326)250-98-164(309)253-113(18)176(321)261-127(48-38-80-245-217(234)235)184(329)254-114(19)177(322)263-129(50-40-82-247-219(238)239)188(333)275-140(175(231)320)86-105(4)5/h28-32,43-44,54-61,105-118,124-155,171-174,294-300H,25-27,33-42,45-53,62-104,222-223H2,1-24H3,(H2,224,301)(H2,225,302)(H2,226,303)(H2,227,304)(H2,228,305)(H2,229,306)(H2,230,307)(H2,231,320)(H,250,326)(H,251,327)(H,252,328)(H,253,309)(H,254,329)(H,255,343)(H,256,344)(H,257,353)(H,258,311)(H,259,310)(H,260,308)(H,261,321)(H,262,323)(H,263,322)(H,264,339)(H,265,330)(H,266,331)(H,267,348)(H,268,354)(H,269,337)(H,270,332)(H,271,338)(H,272,345)(H,273,349)(H,274,358)(H,275,333)(H,276,324)(H,277,334)(H,278,335)(H,279,346)(H,280,355)(H,281,356)(H,282,340)(H,283,357)(H,284,359)(H,285,360)(H,286,336)(H,287,341)(H,288,347)(H,289,350)(H,290,342)(H,291,325)(H,292,352)(H,293,351)(H,312,313)(H,314,315)(H,316,317)(H,318,319)(H4,232,233,244)(H4,234,235,245)(H4,236,237,246)(H4,238,239,247)(H4,240,241,248)(H4,242,243,249)/b30-28+/t111-,112-,113-,114-,115-,116-,117-,118+,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,171-,172-,173-,174-/m0/s1"	CC/C=C/CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N	QBEPNUQJQWDYKU-BMGKTWPMSA-N
DG01238	Ivacaftor	16220172	"Ivacaftor; 873054-44-5; VX-770; Kalydeco; Ivacaftor (VX-770); N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; VX 770; VX770; UNII-1Y740ILL1Z; N-[2,4-Bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide; CHEBI:66901; 1Y740ILL1Z; N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide; 3-Quinolinecarboxamide, N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxo-; 1413431-05-6; 3-Quinolinecarboxamide, N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-; Kalydeco (TN); Ivacaftor [USAN:INN]; ivacaftorum; Ivacaftor D18; VX7; Ivacaftor (USAN/INN); VX-770 - Ivacaftor; MLS006011119; SCHEMBL351373; GTPL4342; VX-770, Ivacaftor, Kalydeco; CHEMBL2010601; DTXSID00236281; EX-A441; QCR-155; BCPP000199; HMS3654E10; HMS3744K05; AOB31714; BCP19794; BDBM50032693; MFCD17171361; s1144; ZINC52509463; AKOS015994762; AKOS032950001; BCP9000799; CCG-268562; CS-0497; DB08820; EX-7211; LE-0002; SB16815; N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; NCGC00242480-01; NCGC00242480-03; AC-28324; HY-13017; SMR004702900; FT-0696681; SW219620-1; X7565; EC-000.2478; A25626; D09916; AB01565806_02; Q6095693; CTP-656; CTP-656; CTP-656; d9-ivacaftor;VX-561; Cystic Fibrosis Transmembrane Conductance Regulator Potentiator; N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide; N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; N-(5-Hydroxy-2,4-bis(2-methyl-2-propanyl)phenyl]-4-oxo-1,4-dihydro-3-quinolinecarboxamide; N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide; 1134822-00-6; Ivacaftor;N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide;Ivacaftor; Kalydeco; ; ; N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:66901	DB08820	DR00466	DR0898	392.5	C24H28N2O3	78.4	671	5.6	29	3	4	4	"1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)"	CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C	PURKAOJPTOLRMP-UHFFFAOYSA-N
DG01239	Fedratinib	16722836	"Fedratinib; 936091-26-8; Tg-101348; TG101348; SAR302503; N-(tert-butyl)-3-((5-methyl-2-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)pyrimidin-4-yl)amino)benzenesulfonamide; TG 101348; SAR-302503; Fedratinib (SAR302503, TG101348); SAR 302503; UNII-6L1XP550I6; TG101348 (SAR302503); N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide; CHEMBL1287853; C27H36N6O3S; 6L1XP550I6; 936091-26-8 (free base); N-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)pyrimidin-4-ylamino)benzenesulfonamide; N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzenesulfonamide; Inrebic; Fedratinib [USAN:INN]; 2TA; Fedratinib (USAN/INN); Fedratinib TG101348; TG101348(Fedratinib); Fedratinib (TG101348); MLS006011155; SCHEMBL263741; GTPL5716; CHEBI:91408; AOB2041; DTXSID90239483; EX-A170; SYN1104; HMS3295I03; HMS3656L19; HMS3744G17; HMS3868L03; BCP02300; BDBM50332294; MFCD12922515; NSC767600; NSC800099; s2736; ZINC19862646; AKOS015842621; CCG-264990; CS-0052; DB12500; EX-5961; NSC-767600; NSC-800099; SB14604; NCGC00244252-01; NCGC00244252-07; AC-30260; AS-16248; Benzenesulfonamide, N-(1,1-dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)ethoxy)phenyl)amino)-4-pyrimidinyl)amino)-; DA-40258; HY-10409; N-Tert-butyl-3-(5-methyl-2-(4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino)-pyrimidin-4-ylamino)-benzenesulfonamide; N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide; SMR004702929; DB-079623; FT-0705969; FT-0763396; FT-0766818; SW218187-2; Y0268; A25534; D10630; F17372; SAR302503 (TG-101348); 091D268; J-523769; Q7670147; BRD-K12502280-001-01-5; 945381-69-1; Fedratinib; ; ; N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-benzenesulfonamide; N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzene-1-sulfonamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:91408	DB12500	.	.	524.7	C27H36N6O3S	117	787	4.8	37	3	9	11	"1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)"	CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4	JOOXLOJCABQBSG-UHFFFAOYSA-N
DG01241	Iothalamate	23672589	"Diatrizoate sodium; Sodium diatrizoate; 737-31-5; Sodium amidotrizoate; Triombrine; Hypaque sodium; Sodium 3,5-diacetamido-2,4,6-triiodobenzoate; Diatrizoic acid sodium salt; Triombrin; Natrii amidotrizoas; Hypaque; Vascoray; Conray 35; Hypaque Cysto; Hpaque - cysto; Amidotrizoato sodico; Iothalamate; Histopaque; Diatrizoate sodium salt; Hypaque sodium 20%; Amidotrizoate de sodium; Urovist sodium; Hypaque 50; MD 50; Sodium diacetyldiaminetriiodobenzoate; Sodium Amidotrizoate (INN); Benzoic acid, 3,5-bis(acetylamino)-2,4,6-triiodo-, monosodium salt; UNII-V5403H8VG7; Urografic acid, sodium salt; Diatrizoate sodium [USP]; Monosodium 3,5-diacetamido-2,4,6-triiodobenzoate; Ml 216; Win 8308-3; 3,5-Diacetamido-2,4,6-triiodobenzoic acid sodium salt; MD-50; MLS000069526; CHEBI:53692; V5403H8VG7; Gastrografin; 3,5-Diacetylamino-2,4,6-trijodbenzosaeure natrium; SMR000058586; Diatrizoate sodium (USP); sodium;3,5-diacetamido-2,4,6-triiodobenzoate; Sodium amidotrizoate [INN]; Diatrizoic acid sodium salt;Sodium amidotrizoate; Benzoic acid, 3,5-diacetamido-2,4,6-triiodo-, monosodium salt; Urovist Sodium 300; Radioselectan; Urovist 300; MFCD00150546; NSC-61815; Natrii amidotrizoas [INN-Latin]; Amidotrizoato sodico [INN-Spanish]; EINECS 212-004-1; NSC 61815; Amidotrizoate de sodium [INN-French]; Renografin 76 Injectable (Veterinary); HSDB 8078; Urographing 370; 3,5-Diacetamido-2,4,6-triiodobenzoic acid, sodium salt; Urovist sodium (TN); 3,5-Diacetylamino-2,4,6-trijodbenzosaeure natrium [German]; Benzoic acid, 3,5-diacetamido-2,4,6-triiodo-, sodium salt; Opera_ID_214; DSSTox_CID_2912; Sodium Diatrizoate [BAN]; DSSTox_RID_76785; DSSTox_GSID_22912; SCHEMBL37116; CHEMBL1200581; DTXSID7022912; HY-B0926A; Diatrizoic acid sodium salt hydrate; Tox21_301439; Diatrizoic acid sodium salt dihydrate; AKOS024371067; CCG-270302; MCULE-8322644190; NCGC00255327-01; CAS-737-31-5; CS-0013563; FT-0603095; A17075; D01013; D97593; sodium 3,5-bis(acetylamino)-2,4,6-triiodobenzoate; 3,5-Diacetamido-2,4,6-tiiodobenzoic acid sodium salt; Q27104811; 3,5-Bis(acetylamino)-2,4,6-triiodobenzoic acid, sodium salt"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:53692	.	.	.	635.89	C11H8I3N2NaO4	98.3	396	.	21	2	4	3	"1S/C11H9I3N2O4.Na/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18;/h1-2H3,(H,15,17)(H,16,18)(H,19,20);/q;+1/p-1"	CC(=O)NC1=C(C(=C(C(=C1I)C(=O)[O-])I)NC(=O)C)I.[Na+]	ZEYOIOAKZLALAP-UHFFFAOYSA-M
DG01242	Auranofin	24199313	"AURANOFIN; 34031-32-8; (1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate; BCP08217; MMV688978; SKF 39162; AKOS026750078; FT-0662343; D78135; A937040; 1-Thio-; A-D-glucopyranosatotriethylphosphine gold-2,3,4,6-tetraacetate; 3,4,5-Triacetyloxy-6-(acetyloxymethyl) oxane-2-thiolate triethylphosphanium; gold(1+);3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate;triethylphosphane; SKF-39162; SKF-D-39162; SKF 39162; SKF D 39162; SKFD-39162; SKFD39162"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00995	DR01329	.	678.5	C20H34AuO9PS	115	532	.	32	0	10	12	"1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1"	CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+]	AUJRCFUBUPVWSZ-UHFFFAOYSA-M
DG01243	Lobaplatin	24202037	"131374-93-1; [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+); Lobaplatine; Lobaplatino; Lobaplatinum; Lobaplatin [INN]; Lobaplatine [INN-French]; Lobaplatinum [INN-Latin]; Lobaplatino [INN-Spanish]; NSC619413; NSC 741422; NSC-619413; 2-(Aminomethyl)cyclobutyl]methanamine 2-hydroxypropanoic acid platinum salt; cis-((trans-1,2-Cyclobutandimethylamine)-(s)-2-oxidopropanoato-platinum(II)); cis-(trans-1,2-Cyclobutanebis(methylamine))((S)-lactato-O(sup 1),O(sup 1))platinum; Platinum, (1,2-cyclobutanedimethanamine-N,N')(2-hydroxypropanoato(2-)-O1,O2)-, (SP-4-3-(S),(trans))-; Platinum, (rel-(1R,2R)-1,2-cyclobutanedimethanamine-kappaN,kappaN')((2S)-2-(hydroxy-kappa-O)propanoato(2-)-kappaO)-, (SP-4-3)-; Platinum,2-cyclobutanedimethanamine-N,N') [2-hydroxypropanoato(2-)-O(1),O(2)]-, (SP-4-3)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	397.33	C9H18N2O3Pt+2	115	171	.	15	2	5	0	"1S/C6H14N2.C3H5O3.Pt/c7-3-5-1-2-6(5)4-8;1-2(4)3(5)6;/h5-6H,1-4,7-8H2;2H,1H3,(H,5,6);/q;-1;+4/p-1"	CC(C(=O)[O-])[O-].C1CC(C1CN)CN.[Pt+4]	XSMVECZRZBFTIZ-UHFFFAOYSA-M
DG01245	Canagliflozin	24812758	"Canagliflozin; 842133-18-0; Invokana; Canagliflozin anhydrous; TA-7284; JNJ-28431754; JNJ 24831754ZAE; canagliflozin hemihydrate; UNII-6S49DGR869; Canagliflozin hydrate; (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; TA 7284; 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene; CHEBI:73274; 6S49DGR869; (2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol; (1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol; D-Glucitol,1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-, (1S)-; JNJ 28431754; (1S)-1,5-Anhydro-1-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4-methylphenyl)-D-glucitol; (1s)-1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4-methylphenyl)-d-glucitol; JNJ 24831754AAA; (2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol; Canagliflozin [INN]; JNJ 24831754; MLS006011126; SCHEMBL157162; C24H25FO5S; GTPL4582; CHEMBL2048484; HSDB 8284; AMY3291; BCPP000303; DTXSID601004469; JNJ 28431754AAA; BDBM50386885; MFCD18251436; s2760; ZINC43207238; AKOS025401827; BCP9000477; CCG-229581; CS-0522; DB08907; KS-1443; NCGC00346691-02; (1S)-1,5-Anhydro-1-c-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-D-glucitol; AC-26303; HY-10451; SMR004702906; SW219119-1; Y0287; A25050; J-500391; Q5030940; (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methyl-phenyl)-D-glucitol; 1,5-Anhydro-1-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)hexitol; D-Glucitol, 1,5-anhydro-1-C-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4- methylphenyl)-, (1S)-; D-glucitol, 1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4- methylphenyl)-, (1s)-; JNJ24831754ZAE; TA 7284;(2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:73274	DB08907	DR00279	DR0262	444.5	C24H25FO5S	118	574	3.2	31	4	7	5	"1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1"	CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F	XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
DG01248	Entrectinib	25141092	"Entrectinib; 1108743-60-7; NMS-E628; RXDX-101; Rozlytrek; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); Entrectinib(rxdx-101); L5ORF0AN1I; N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide; N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide; N-{5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl}-4-(4-methylpiperazin-1-yl)-2-[(oxan-4-yl)amino]benzamide; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Entrectinib [USAN:INN]; Rozlytrek (TN); YMX; Entrectinib, 95%; Kinome_2659; Entrectinib; NMS-E628; Entrectinib (JAN/USAN/INN); GTPL8290; SCHEMBL3512601; CHEMBL1983268; NMS-E-628; NMS-E628;RXDX-101; HMS3886H21; BCP16174; EX-A2261; MFCD28129099; NSC774769; NSC800095; s7998; ZINC43204146; CCG-270048; DB11986; NSC-774769; NSC-800095; SB17194; NCGC00484067-01; NCGC00484067-02; NCGC00484067-03; AC-31286; AS-75092; DA-47850; HY-12678; N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide; B5859; FT-0736318; D10926; A856078; Q25323953; S900006830; RXDX101; RXDX 101; RXDX-101; NMS E628; NMS-E628;NMS E628; N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide; N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide; N-[5-(3,5-Difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide; N-{5-[(3,5-difluorophenyl)methyl]-3H-indazol-3-ylidene}-4-(4-methylpiperazin-1-yl)-2-[(oxan-4-yl)amino]benzamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11986	.	DR0582	560.6	C31H34F2N6O2	85.5	847	5.7	41	3	8	7	"1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40)"	CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6	HAYYBYPASCDWEQ-UHFFFAOYSA-N
DG01249	Capmatinib	25145656	"Capmatinib; 1029712-80-8; INCB28060; INC-280; INC280; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INCB-28060; NVP-INC280; UNII-TY34L4F9OZ; NVP-INC280-NX; Capmatinib (INCB28060); INC28060; 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; TY34L4F9OZ; INCB 28060; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; C23H17FN6O; Tabrecta; Benzamide, 2-fluoro-N-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-;Benzamide, 2-fluoro-N-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-; benzamide hcl; INCB-28060 FREE BASE; Capmatinib [USAN]; Capmatinib (USAN/INN); Capmatinib [USAN:INN]; Capmatinib(INCB28060); INCB28060(Capmatinib); NYP-INC280-NX; MLS006010965; GTPL7904; SCHEMBL1426819; CHEMBL3188267; DTXSID90145595; EX-A446; AMY18553; AOB87335; BCP23444; BDBM50146167; MFCD18633285; NSC777878; NSC800067; s2788; ZINC43195321; AKOS025396439; BCP9000785; CCG-268791; CS-1541; DB11791; NSC-777878; NSC-800067; QC-7530; SB16608; NCGC00346702-01; NCGC00346702-02; NCGC00346702-05; AC-25890; AS-74142; DA-33530; HY-13404; SMR004702769; FT-0746310; Y0337; D10696; J-509516; Q27075685; 2-Fluoro-N-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazolo[1,2-b][1,2,4]triazin-2-yl]benzamide; 2-fluoro-N-methyl-4-{7-[(quinolin-6-yl)methyl]imidazo[1,2-b][1,2,4]triazin-2-yl}benzamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11791	.	.	412.4	C23H17FN6O	85.1	637	2.9	31	1	6	4	"1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)"	CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F	LIOLIMKSCNQPLV-UHFFFAOYSA-N
DG01253	Troleandomycin	202225	"TROLEANDOMYCIN; Triacetyloleandomycin; Oleandomycin triacetate; Oleandocetine; Cyclamycin; Tribiocillina; Oleandomycin triacetyl ester; Evramicina; 2751-09-9; Troleandomicina; Troleandomycine; Micotil; Triocetin; Aovine; Troleandomycinum; Oleandomycin, triacetate (ester); Matromycin T; Triacetyloleandomycinum; Matromicina; Treolmicina; UNII-C4DZ64560D; CHEBI:45735; C4DZ64560D; AI3-50166; TAO; Oleandomycin, triacetyl-; oleandomycin triacetate ester; Triolan; Viamicina; Wytrion; Treis-Micina; WY 651; NSC-108166; ACETYLOLEANDOMYCIN; Tao (VAN); Tao (TN); Prestwick3_000036; Triacetyloleandomycin (JAN); Troleandomycin (USAN/INN); BSPBio_000131; Troleandomycine [INN-French]; Troleandomycinum [INN-Latin]; SCHEMBL125071; Troleandomicina [INN-Spanish]; Triacetyl ester of oleandomycin; BPBio1_000145; CHEMBL564085; T.A.O.; Oleandomycin (as troleandomycin); HMS2089B10; HMS2095G13; HMS3712G13; Fmoc-(R)-3-Amino-5-hexenoicacid; EINECS 220-392-9; BDBM50370258; LMPK04000042; Troleandomycin [USAN:USP:INN:BAN]; ZINC169307271; CCG-220036; DB13179; NSC 108166; NCGC00179654-01; HY-108881; AB00513798; CS-0031241; D01322; AB00513798-02; Q1087499; BRD-K38310698-001-01-9; (3R,5R,6S,7R,8R,11R,12S,13R,14S,15S)-12-[(4-O-acetyl-2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)oxy]-14-{[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy}-5,7,8,11,13,15-hexamethyl-4,10-dioxo-1,9-dioxaspiro[2.13]hexadecan-6-yl acetate; [(3R,5S,6S,7R,8S,9R,12R,13S,14S,15R)-6-[(2S,3R,4S,6R)-3-acetyloxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-8-[(2R,4S,5S,6S)-5-acetyloxy-4-methoxy-6-methyloxan-2-yl]oxy-5,7,9,12,13,15-hexamethyl-10,16-dioxo-1,11-dioxaspiro[2.13]hexadecan-14-yl] acetate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:45735	DB13179	.	.	814	C41H67NO15	184	1430	4.3	57	0	16	12	"1S/C41H67NO15/c1-19-17-41(18-49-41)38(46)23(5)34(53-27(9)43)21(3)25(7)52-39(47)24(6)35(56-32-16-31(48-14)36(26(8)51-32)54-28(10)44)22(4)33(19)57-40-37(55-29(11)45)30(42(12)13)15-20(2)50-40/h19-26,30-37,40H,15-18H2,1-14H3/t19-,20+,21-,22+,23+,24+,25+,26-,30-,31-,32-,33-,34-,35-,36-,37+,40-,41+/m0/s1"	C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C	LQCLVBQBTUVCEQ-QTFUVMRISA-N
DG01254	Nedaplatin	6917890	Nedaplatin; 95734-82-0; Aqupla; NSC 375101D; azane;2-hydroxyacetic acid;platinum; 254-S; NSC-375101D; C2H2O3Pt.2H3N; HMS2089P16; AKOS025311233; M754; 734N820	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB13145	.	.	305.2	C2H10N2O3Pt	59.5	44.1	.	8	4	5	0	"1S/C2H4O3.2H3N.Pt/c3-1-2(4)5;;;/h3H,1H2,(H,4,5);2*1H3;"	C(C(=O)O)O.N.N.[Pt]	ZAXCMPAWRCMABN-UHFFFAOYSA-N
DG01255	Vibegron	44472635	"VIBEGRON; 1190389-15-1; KRP-114V; UNII-M5TSE03W5U; MK-4618; M5TSE03W5U; (S)-N-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide; MK4618; C26H28N4O3; Pyrrolo(1,2-a)pyrimidine-6-carboxamide, 4,6,7,8-tetrahydro-N-(4-(((2S,5R)-5-((R)-hydroxyphenylmethyl)-2-pyrrolidinyl)methyl)phenyl)-4-oxo-, (6S)-; Pyrrolo[1,2-a]pyrimidine-6-carboxamide, 4,6,7,8-tetrahydro-N-[4-[[(2S,5R)-5-[(R)-hydroxyphenylmethyl]-2-pyrrolidinyl]methyl]phenyl]-4-oxo-, (6S)-; Vibegron [USAN:INN]; vibegronum; Gemtesa; Beova; Beova (TN); MK 4618; Vibegron (JAN/USAN); CHEMBL2107826; SCHEMBL11985457; GTPL10100; DTXSID40152299; CHEBI:142418; EX-A3390; BDBM50146154; MFCD28502057; AT23148; compound 7 [PMID: 26709102]; DB14895; (6S)-N-(4-(((2S,5R)-5-((R)-Hydroxyphenylmethyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide; HY-19933; CS-0016926; D10433; A903957; Q27283524; (6S)-4,6,7,8-Tetrahydro-N-[4-[[(2S,5R)-5-[(R)-hydroxyphenylmethyl]-2-pyrrolidinyl]methyl]phenyl]-4-oxo-pyrrolo[1,2-a]pyrimidine-6-carboxamide; (6S)-4,6,7,8-Tetrahydro-N-[4-[[(2S,5R)-5-[(R)-hydroxyphenylmethyl]-2-pyrrolidinyl]methyl]phenyl]-4-oxopyrrolo[1,2-a]pyrimidine-6-carboxamide; (6S)-N-[4-({(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl}methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide; (6S)-N-[4-[[(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidine-6-carboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:142418	.	DR00357	.	444.5	C26H28N4O3	94	782	1.8	33	3	5	6	"1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1"	C1C[C@@H](N[C@@H]1CC2=CC=C(C=C2)NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)[C@@H](C5=CC=CC=C5)O	DJXRIQMCROIRCZ-XOEOCAAJSA-N
DG01256	Dicycloplatin	44475103	"Dicycloplatin; UNII-0KC57I4UNB; 0KC57I4UNB; 287402-09-9; Azane, 1-carboxycyclobutane-1-carboxylate, platinum(2+); Platinum(2+) 1-carboxycyclobutanecarboxylate ammoniate (1:2:2); 1,1-Cyclobutanedicarboxylic acid, compd. with (sp-4-2)-diammine(1,1-cyclobutanedi(carboxylato-kappaO)(2-))platinum (1:1); Platinum, diammine(1,1-cyclobutanedi(carboxylato-kappaO)(2-))-, (sp-4-2)-, 1,1-cyclobutanedicarboxylate (1:1); Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-kappaO,kappaO'')-, (sp-4-2)-, 1,1-cyclobutanedicarboxylate (1:1); DB-119035; Cis-diammine(1,1-cyclobutanedicarboxylate)platinum(II); Q19776556; azane;cyclobutane-1,1-dicarboxylate;cyclobutane-1,1-dicarboxylic acid;platinum(2+)"	Registered	2	Apprpved Drug(s)	Registered	Small molecular drug	.	.	.	.	515.38	C12H20N2O8Pt	157	317	.	23	4	10	2	"1S/2C6H8O4.2H3N.Pt/c2*7-4(8)6(5(9)10)2-1-3-6;;;/h2*1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;;+2/p-2"	C1CC(C1)(C(=O)O)C(=O)O.C1CC(C1)(C(=O)[O-])C(=O)[O-].N.N.[Pt+2]	IIJQICKYWPGJDT-UHFFFAOYSA-L
DG01260	YN-968D1	45139106	"Apatinib; Apatinib Mesylate; 1218779-75-9; Rivoceranib mesylate; YN968D1; YN-968D1; UNII-TK02X14ASJ; YN 968D1; TK02X14ASJ; N-(4-(1-Cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide Mesylate; 3-Pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-, methanesulfonate (1:1); N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;methanesulfonic acid; Apatinib mesylate; 3-Pyridinecarboxamide, N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-, methanesulfonate (1:1); Alitan (TN); Apatinib-YN968D1; Apatinib - YN968D1; Rivoceranib mesylate (USAN); MLS006011286; CHEMBL3545414; SCHEMBL21847695; DTXSID80153427; HMS3655H12; AOB87128; BCP15234; Apatinib (registered name in China); BDBM50152828; s2221; AKOS026750547; BCP9000308; CCG-269641; CS-0694; SB16589; N-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide methanesulfonate; HY-13342; SMR004703036; SW220296-1; D11289; N-(4-(1-cyanocyclopentyl)phenyl)-2-(pyridin-4-ylmethylamino)nicotinamide mesylate; N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridine carboxyamide mesylate; N-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)pyridine-3-carboxamide mesylate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	DR00819	.	493.6	C25H27N5O4S	153	701	.	35	3	8	6	"1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)"	CS(=O)(=O)O.C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4	FYJROXRIVQPKRY-UHFFFAOYSA-N
DG01262	Exenatide	45588096	"Exenatide; Exendin-4; Byetta; Bydureon; UNII-9P1872D4OL; Exendin 4; 141758-74-9; 9P1872D4OL; AC 2993; AC2993A; Bydureon Pen; AC002993; ITCA 650; HSDB 7789; Exenatide [USAN:INN:BAN:JAN]; PT302; AC 2993A; DA 3091; Exenatide; Exendin-4; LY 2148568; SCHEMBL14634818; AKOS015994651; HS-2012; Y-100006; Exendin 3 (Heloderma horridum), 2-glycine-3-L-glutamic acid-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	4187	C184H282N50O60S	1780	10300	-21	295	58	66	135	"1S/C184H282N50O60S/c1-16-94(10)147(178(289)213-114(52-58-144(257)258)163(274)218-121(73-101-77-195-105-39-24-23-38-103(101)105)168(279)215-116(68-90(2)3)165(276)205-107(41-26-28-61-186)158(269)219-122(75-134(189)243)154(265)198-79-135(244)196-83-139(248)231-63-30-43-129(231)175(286)225-127(87-238)174(285)223-125(85-236)155(266)200-80-136(245)202-96(12)181(292)233-65-32-45-131(233)183(294)234-66-33-46-132(234)182(293)232-64-31-44-130(232)176(287)222-124(84-235)150(190)261)229-170(281)119(71-99-34-19-17-20-35-99)217-166(277)117(69-91(4)5)214-159(270)108(42-29-62-194-184(191)192)212-177(288)146(93(8)9)228-151(262)95(11)203-156(267)111(49-55-141(251)252)208-161(272)112(50-56-142(253)254)209-162(273)113(51-57-143(255)256)210-164(275)115(59-67-295-15)211-160(271)110(47-53-133(188)242)207-157(268)106(40-25-27-60-185)206-172(283)126(86-237)224-167(278)118(70-92(6)7)216-169(280)123(76-145(259)260)220-173(284)128(88-239)226-180(291)149(98(14)241)230-171(282)120(72-100-36-21-18-22-37-100)221-179(290)148(97(13)240)227-138(247)82-199-153(264)109(48-54-140(249)250)204-137(246)81-197-152(263)104(187)74-102-78-193-89-201-102/h17-24,34-39,77-78,89-98,104,106-132,146-149,195,235-241H,16,25-33,40-76,79-88,185-187H2,1-15H3,(H2,188,242)(H2,189,243)(H2,190,261)(H,193,201)(H,196,244)(H,197,263)(H,198,265)(H,199,264)(H,200,266)(H,202,245)(H,203,267)(H,204,246)(H,205,276)(H,206,283)(H,207,268)(H,208,272)(H,209,273)(H,210,275)(H,211,271)(H,212,288)(H,213,289)(H,214,270)(H,215,279)(H,216,280)(H,217,277)(H,218,274)(H,219,269)(H,220,284)(H,221,290)(H,222,287)(H,223,285)(H,224,278)(H,225,286)(H,226,291)(H,227,247)(H,228,262)(H,229,281)(H,230,282)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H4,191,192,194)/t94-,95-,96-,97+,98+,104-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,146-,147-,148-,149-/m0/s1"	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC9=CNC=N9)N	HTQBXNHDCUEHJF-XWLPCZSASA-N
DG01263	Larotrectinib	46188928	"Larotrectinib; LOXO-101; 1223403-58-4; ARRY-470; (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide; LOXO 101; UNII-PF9462I9HX; LOXO101; PF9462I9HX; (3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide; BAY2757556; BAY-2757556; Vitrakvi; ARRY 470; 1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-; 1-Pyrrolidinecarboxamide, N-[5-[(2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxy-, (3S)-; ARRY-470; larotrectinib; Larotrectinib (USAN/INN); Larotrectinib [USAN:INN]; ARRY470; AMY264; GTPL8909; SCHEMBL2241012; CHEMBL3889654; BDBM136597; BCP16262; EX-A1981; MFCD28902192; NSC785570; NSC801004; s5860; Larotrectinib (LOXO-101 free base); example 14 [US8865698 B2]; ZINC118399834; CS-5722; DB14723; NSC-785570; NSC-801004; AC-33660; AS-35231; HY-12866; J3.628.138C; D11137; US8865698, 14; Q27081513; ARRY-470;ARRY 470 : LOXO-101; LOXO101; Larotrectinib; ARRY470;ARRY-470;ARRY 470;LOXO 101;LOXO101;Larotrectinib; (3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide; (S)-N-(5 -((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide; (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin -1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide; (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide; (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3 yl)-3-hydroxypyrrolidine-1-carboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	428.4	C21H22F2N6O2	86	659	1.7	31	2	7	3	"1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1"	C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CC[C@@H](C4)O)C5=C(C=CC(=C5)F)F	NYNZQNWKBKUAII-KBXCAEBGSA-N
DG01264	LY2835219	46220502	"Abemaciclib; 1231929-97-7; LY2835219; LY2835219 free base; Verzenio; LY-2835219; UNII-60UAB198HK; N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine; Abemaciclib (ly2835219); 60UAB198HK; N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine; LY 2835219; HY-16297A; CS-1230; N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-1,3-benzodiazol-5-yl)pyrimidin-2-amine; N-{5-[(4-Ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-amine; LY2835219 (free base); Abemaciclib [USAN:INN]; Abemaciclib,LY2835219; Verzenios; rimidin-2-amine; Verzenio (TN); 6ZV; N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]py rimidin-2-amine; CDK4/6 dual inhibitor; LY2835210; Abemaciclib (JAN/USAN); GTPL7382; SCHEMBL2487229; CHEMBL3301610; DTXSID20673119; EX-A521; LY 2835219 (free base); C27H32F2N8; HMS3673I05; BCP13079; EX-A1588; 3798AH; BDBM50110183; MFCD22665744; NSC768073; NSC783671; s5716; ZINC72318121; 1231929-97-7, Verzenio,; AKOS025404907; LY2835219 free base (Abemaciclib); CCG-269750; DB12001; NSC-768073; NSC-783671; SB16476; NCGC00351599-02; NCGC00351599-06; 2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl); 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine; 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)pyrimidin-2-yl)amine; AC-30666; AS-10230; DA-33422; QC-11713; LY2835219 Ms salt, Abemaciclib Ms salt; FT-0700134; LY 2835210; A12989; D10688; J-690083; Q23901483; [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine; 2-Pyrimidinamine, N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-; 2-Pyrimidinamine,N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-; LY-2835219; ; ; N-[5-[(4-Ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine; N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]py"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	DR00097	DR0028	506.6	C27H32F2N8	75	723	3.8	37	1	9	7	"1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)"	CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F	UZWDCWONPYILKI-UHFFFAOYSA-N
DG01265	Palbociclib	5330286	"Palbociclib; 571190-30-2; PD-0332991; Ibrance; PD0332991; PD 0332991; UNII-G9ZF61LE7G; Palbociclib free base; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; PD-332991; 571190-30-2 (free base); MFCD11840850; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; G9ZF61LE7G; Palbociclib(PD0332991); PD 332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; CHEBI:85993; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one; LQQ; C24H29N7O2; 2euf; 571190-30-2 pound not827022-32-2; Palbociclib [USAN:INN]; [d8]-Palbociclib; Ibrance (TN); Palbociclib- Bio-X; Kinome_3823; Kinome_3824; 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one hydrochloride; Palbociclib (JAN/USAN); SCHEMBL462630; BDBM6309; CHEMBL189963; GTPL7380; PD 0332991 (Palbociclib); DTXSID40972590; EX-A408; QCR-200; 2euf; PD 0332991; OTAVA-BB 1115529; BCPP000125; HMS3265M09; HMS3265M10; HMS3265N09; HMS3265N10; HMS3744G13; AMY14886; AOB87334; BCP09274; BCP18381; ZINC3938686; NSC758247; NSC772256; NSC800815; s4482; AKOS022205241; BCP9001058; CA10003; DB09073; NSC-758247; NSC-772256; NSC-800815; SB40426; Pyrido-[2,3-d]-pyrimidin-7-one 43; NCGC00263129-01; NCGC00263129-08; NCGC00263129-21; NCGC00263129-22; AC-25485; AS-17016; BP166224; HY-50767; SY026143; FT-0697059; X7379; A14427; D10372; 190P302; PD 0332991,PD0332991; PD-0332991, PD0332991; BRD-K51313569-001-01-1; P-0332991; Q15269707; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[6,5-d]pyrimidin-7-one; 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one; 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)-pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-cyclopentyl-6-acetyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:85993	DB09073	DR01288	DR1229	447.5	C24H29N7O2	103	775	1.8	33	2	8	5	"1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)"	CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C	AHJRHEGDXFFMBM-UHFFFAOYSA-N
DG01266	Ribociclib	44631912	"Ribociclib; 1211441-98-3; LEE011; Ribociclib (LEE011); LEE-011; Kisqali; LEE 011; UNII-TK8ERE8P56; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; LEE011A; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; 7-Cyclopentyl-N,N-dimethyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-Cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; Ribociclib(LEE011); Ribociclib, LEE011; Ribociclib [USAN:INN]; Ribociclib-[d6]; Ribociclib (USAN/INN); NVP-LEE011; SCHEMBL302310; GTPL7383; LEE-011A; CHEMBL3545110; EX-A304; SYN1213; BDBM148264; HMS3653N03; HMS3673I19; HMS3748M05; example 74 [US8962630]; AMY16792; AOB87725; BCP08804; 2513AH; MFCD27976795; NSC778909; NSC794613; NSC800867; s7440; ZINC72316335; AKOS025404915; AKOS032949987; CCG-269070; CS-1750; DB11730; NSC-778909; NSC-794613; NSC-800867; SB18480; NCGC00386317-10; NCGC00386317-11; AC-30029; AS-10159; DA-35904; HY-15777; LEE-011; LEE 011;LEE011; FT-0700117; SW220101-1; D10883; US8962630, 74; A858033; J-690066; Q27088552; 6-(1H-Indazol-6-yl)-N-[4-(4-morpholinyl)phenyl]-Imidazo[1,2-a]pyrazin-8-amine; 6ZZ; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11730	.	.	434.5	C23H30N8O	91.2	636	2.2	32	2	7	5	"1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)"	CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5	RHXHGRAEPCAFML-UHFFFAOYSA-N
DG01267	Gilteritinib	49803313	"Gilteritinib; 1254053-43-4; ASP2215; ASP-2215; Xospata; UNII-66D92MGC8M; ASP 2215; 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide; 66D92MGC8M; Gilteritinib HCl; 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide; 2-Pyrazinecarboxamide, 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-; 6-ethyl-3-[[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]amino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide; 6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide; Gilteritinib [USAN:INN]; gilteritinibum; 2-Pyrazinecarboxamide, 6-ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2H-pyran-4-yl)amino]-; C6F; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; CHEMBL3301622; CHEBI:145372; BDBM144315; C29H44N8O3; BCP28756; EX-A2775; 3694AH; MFCD28144685; NSC787846; NSC787854; NSC788454; NSC800106; s7754; ZINC113476229; CCG-270016; CS-3885; DB12141; NSC-787846; NSC-787854; NSC-788454; NSC-800106; SB16988; NCGC00481652-01; NCGC00481652-02; AC-29030; AS-35199; BG166434; HY-12432; QC-11768; DB-108103; A14411; D10709; A901674; US8969336, 547; US8969336, 577; Q27077802; 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-2-pyrazinecarboxamide; 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide; 6-Ethyl-3-[3-methoxy-4-[4-(4-methylpiperazine-1-yl)piperidino]anilino]-5-[(tetrahydro-2H-pyran-4-yl)amino]pyrazine-2-carboxamide; 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide; 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:145372	DB12141	DR00358	DR0772	552.7	C29H44N8O3	121	785	3.5	40	3	10	9	"1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)"	CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5	GYQYAJJFPNQOOW-UHFFFAOYSA-N
DG01268	Venetoclax	49846579	"Venetoclax; 1257044-40-8; ABT-199; Venclexta; GDC-0199; ABT199; ABT 199; Venetoclax (ABT199); UNII-N54AIC43PW; GDC 0199; RG7601; Venetoclax; Abt-199; 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; Venetoclax (ABT-199); RG-7601; N54AIC43PW; ABT-199 (GDC-0199); 2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methy; 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide; venclyxto; BDBM189459; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(oxan-4-ylmethyl)amino]benzene}sulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-({3-nitro-4-[(tetrahydro-2h-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide; benzamide, 4-(4-((2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-n-((3-nitro-4-(((tetrahydro-2h-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)-; Venetoclax [USAN:INN]; Venclexta (TN); Benzamide, 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-; Venetoclax(ABT-199); C45H50ClN7O7S; MLS006010298; SCHEMBL523816; Venetoclax (JAN/USAN/INN); AMY343; GTPL8318; CHEMBL3137309; SCHEMBL19236295; BDBM60828; AOB5080; DTXSID30154863; EX-A168; CHEBI:133021; HMS3653J06; HMS3745E07; BCP06811; BDBM50162774; MFCD23160052; NSC766270; AKOS025289539; ZINC150338755; CCG-270543; CS-1155; DB11581; KS-1470; NSC-766270; SB16499; NCGC00345789-01; NCGC00345789-05; NCGC00345789-10; NCGC00345789-11; AC-28754; DA-35360; HY-15531; QC-11704; SMR004701366; FT-0699586; S8048; SW219672-1; X3609; J3.516.625D; D10679; US9174982, 5; A850921; US9174982, 369; J-005269; Q23671272; 2-((1H-Pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide; 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-cyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(tetrahydropyran-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-[(3-nitro-4-{[(oxan-4-yl; ABT-199; ; ; GDC 0199; ; ; 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:133021	DB11581	DR00008	.	868.4	C45H50ClN7O7S	183	1640	8.2	61	3	11	12	"1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)"	CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C	LQBVNQSMGBZMKD-UHFFFAOYSA-N
DG01270	Copanlisib	135565596	"Copanlisib; 1032568-63-0; BAY 80-6946; Aliqopa; BAY-80-6946; BAY80-6946; UNII-WI6V529FZ9; BAY 80-6946 (Copanlisib); 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide; WI6V529FZ9; Copanlisib (BAY 80-6946); 2-Amino-N-[2,3-dihydro-7-methoxy-8-[3-(4-morpholinyl)propoxy]imidazo[1,2-c]quinazolin-5-yl]-5-pyrimidinecarboxamide; 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide; 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide; copanlisibum; Copanlisib tris-HCl; Copanlisib (USAN/INN); Copanlisib [USAN:INN]; GTPL7875; SCHEMBL1655478; BAY 80-6946; Copanlisib; BAY-80-6946 tris-HCl; Copanlisib; BAY-80-6946; CHEMBL3218576; SCHEMBL13084037; DTXSID00145728; CHEBI:173077; C23H28N8O4; BCP04754; EX-A2005; 2253AH; BDBM50204093; MFCD18633201; NSC760443; NSC800076; NSC809693; NSC816437; s2802; ZINC68247389; AKOS025290222; BAY-806946; CS-0741; DB12483; NSC-760443; NSC-800076; NSC-809693; NSC-816437; PB22956; VS-0128; NCGC00346457-01; NCGC00346457-02; NCGC00346457-04; 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide; AC-28438; BC164810; HY-15346; QC-10511; D10867; Q19903876; 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1.2-c]quinazolin-5-yl]pyrimidine-5-carboxamide; 2-amino-N-{7-methoxy-8-[3-(morpholin-4-yl)propoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyrimidine-5-carboxamide; BAY-80-6946; ; ; 2-Amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB12483	.	DR0378	480.5	C23H28N8O4	140	974	0.3	35	2	9	7	"1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14,25H,2,5-12H2,1H3,(H2,24,26,27)"	COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5	MWYDSXOGIBMAET-UHFFFAOYSA-N
DG01271	IPI-145	50905713	"Duvelisib; 1201438-56-3; IPI-145; INK-1197; (S)-3-(1-((9H-Purin-6-yl)amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one; UNII-610V23S0JI; IPI 145; Copiktra; IPI-145 (INK1197); (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one; 610V23S0JI; INK-1147; 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one; Duvelisib (IPI-145, INK1197); Copiktra (TN); Duvelisib monohydrate; IPI145; Duvelisib [USAN:INN]; Duvelisib hydrate; 1(2H)-Isoquinolinone, 8-chloro-2-phenyl-3-((1S)-1-(9H-purin-6-ylamino)ethyl)-; 1(2H)-Isoquinolinone, 8-chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-; INK1197; Duvelisib (USAN/INN); Duvelisib (IPI-145); SCHEMBL153543; GTPL7795; CHEMBL3039502; SCHEMBL18343557; SCHEMBL19670020; SCHEMBL20580104; DTXSID80152697; SYN1175; CHEBI:131169; AMY24208; AOB87713; BCP07042; EX-A1562; BDBM50193013; MFCD15144635; NSC772469; s7028; ZINC88346058; AKOS022186370; AKOS037515795; IPI-145, INK 1197, Duvelisib; CCG-268854; CS-0888; DB11952; NSC-772469; 8-chloro-2-phenyl-3-((1S)-1-(9H-purin-6-ylamino)ethyl)-1(2H)-isoquinolinone; NCGC00351482-01; AC-30239; AS-16309; compound 4904 [Patent US8193182]; HY-17044; QC-10232; SW219822-1; X5816; D10555; Q27077129; IPI-145 pound>>INK1197; IPI 145; IPI145; INK-1197; INK 1197; (S)-3-(1-(7H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one; 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one; INK-1197; ; ; IPI-145; ; ; 8-Chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:131169	.	DR00276	.	416.9	C22H17ClN6O	86.8	668	4.1	30	2	5	4	"1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1"	C[C@@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5	SJVQHLPISAIATJ-ZDUSSCGKSA-N
DG01274	Rimegepant	51049968	"Rimegepant; 1289023-67-1; BMS-927711; BMS 927711; UNII-997WVV895X; BHV-3000; BMS927711; CHEMBL2178422; C28H28F2N6O3; 997WVV895X; Nurtec ODT; [(5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate; (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate; Rimegepant [USAN:INN]; Vydura; Rimegepant (USAN/INN); BMS-927711(Rimegepant); SCHEMBL1670580; Rimegepant (BMS-927711); GTPL10704; BHV3000; DTXSID70156003; EX-A1922; 3504AH; BDBM50400098; s6659; ZINC68267814; AT13249; compound 8 [PMID: 23153230]; CS-1027; DB12457; NCGC00378677-01; BR174969; HY-15498; A13102; D10662; Q27272184; [(5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl]4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB12457	DR00758	.	534.6	C28H28F2N6O3	114	891	2.3	39	2	8	4	"1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1"	C1C[C@H](C2=C(C=CC=N2)[C@H]([C@@H]1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6	KRNAOFGYEFKHPB-ANJVHQHFSA-N
DG01285	Lurbinectedin	57327016	"Lurbinectedin; 497871-47-3; PM01183; UNII-2CN60TN6ZS; 2CN60TN6ZS; PM 01183; PM-01183; [(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] acetate; Tryptamicidin; Zepzelca; Lurbinectedin [USAN:INN]; CHEMBL4297516; SCHEMBL16152477; GTPL10681; DTXSID30198065; EX-A4316; WHO 9397; NSC826275; PM1183; s9603; AT22223; CS-6323; DB12674; NSC-826275; PM-1183; HY-16293; J3.531.659K; J3.652.626B; PM01183;PM-1183;LY-01017;ryptamicidin; Q27254568; [(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB12674	.	.	784.9	C41H44N4O10S	190	1530	3.9	56	4	14	4	"1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1"	CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O	YDDMIZRDDREKEP-HWTBNCOESA-N
DG01286	MK-1439	58460047	"Doravirine; 1338225-97-0; MK-1439; Pifeltro; 3-chloro-5-[1-[(4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile; MK1439; UNII-913P6LK81M; 3-Chloro-5-((1-((4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl)-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)oxy)benzonitrile; Doravirine (MK-1439); 913P6LK81M; 3-Chloro-5-({1-[(4-Methyl-5-Oxo-4,5-Dihydro-1h-1,2,4-Triazol-3-Yl)methyl]-2-Oxo-4-(Trifluoromethyl)-1,2-Dihydropyridin-3-Yl}oxy)benzonitrile; Doravirine [USAN:INN]; 4ncg; Pifeltro (TN); MK 1439; Doravirine, MK-1439; Doravirine; MK-1439; MK-1439(Doravirine); C17H11ClF3N5O3; Doravirine (JAN/USAN/INN); Mk-1439a; SCHEMBL2509885; CHEMBL2364608; DTXSID30158386; AMY16781; BCP02296; EX-A1968; BDBM50508293; MFCD22417167; s6492; ZINC72317283; AKOS030528603; CS-5924; DB12301; SB17104; NCGC00508866-01; AC-33637; HY-16767; DB-091410; D10624; F53303; A856128; Q6885419; S900006160; 2KW; 3-chloro-5-[[1-[(4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-3-pyridyl]oxy]benzonitrile; Benzonitrile, 3-chloro-5-((1-((4,5-dihydro-4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl)-1,2-dihydro-2-oxo-4-(trifluoromethyl)-3-pyridinyl)oxy)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	DR0533	425.7	C17H11ClF3N5O3	98	860	2.1	29	1	8	4	"1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)"	CN1C(=NNC1=O)CN2C=CC(=C(C2=O)OC3=CC(=CC(=C3)C#N)Cl)C(F)(F)F	ZIAOVIPSKUPPQW-UHFFFAOYSA-N
DG01291	Trilaciclib	68029831	"Trilaciclib; 1374743-00-6; G1T28; UNII-U6072DO9XG; U6072DO9XG; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one; Cosela; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Trilaciclib [USAN]; G1T28(Trilaciclib); G1T28 di-HCl; Trilaciclib (USAN/INN); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; BCP25013; EX-A4297; NSC816987; DB15442; NSC-816987; SB19783; US9464092, T; HY-101467; CS-0021431; A17084; D11130; 2'-((5-(4-Methyl-1-piperazinyl)-2-pyridinyl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyrazino[5,6]pyrrolo[1,2-d]pyrimidine-9,1'-cyclohexane]-6-one; 4-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	446.5	C24H30N8O	91.2	707	2.6	33	2	7	3	"1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29)"	CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6	PDGKHKMBHVFCMG-UHFFFAOYSA-N
DG01295	LCZ696	24755604	"LCZ-696; LCZ696 (Valsarta + sacubitril); sodium (S)-5-(4'-((N-(1-carboxylato-2-methylpropyl)pentanamido)methyl)-[1,1'-biphenyl]-2-yl)tetrazol-1-ide 4-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoate hydrate; LCZ-696A; BCP10630; Q6457467; LCZ-696; LCZ 696;Entresto;Valsartan/sacubitril;Sacubitril mixture with Valsartan; Trisodium;4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate;(2S)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]amino]butanoate;hydrate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	931	C48H57N6Na3O9	197	1140	.	66	2	13	20	"1S/C24H29N5O3.C24H29NO5.3Na.H2O/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;;;/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H2,25,26,27,28,31,32);4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;;;1H2/q;;3*+1;/p-3/t22-;17-,21+;;;;/m01..../s1"	CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)[C@@H](C(C)C)C(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].O.[Na+].[Na+].[Na+]	UOLUPHRXIRFONO-JOYYXRJNSA-K
DG01299	Deutetrabenazine	73437646	"Deutetrabenazine; Tetrabenazine-d6; Tetrabenazine D6; 1392826-25-3; Austedo; Ro 1-9569 D6; SD809; (3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one; SD-809; rel-(3R,11bR)-3-isobutyl-9,10-bis(methoxy-d3)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; Austedo (TN); Deutetrabenazine (USAN/INN); GTPL8707; SCHEMBL16227993; HY-B0590S; EX-A4770; D10701; Q27077026; UNII-P341G6W9NB component MKJIEFSOBYUXJB-VFJJUKLQSA-N; [2H6]-(+)-Tetrabenazine; ; ; [2H6]-(+)- 9,10-Dimethoxy-1,3R,4,6,7,11bR-hexahydro-3-isobutyl-2H-benzo[a]quinolizin-2-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB12161	.	.	323.5	C19H27NO3	38.8	425	2.9	23	0	4	4	"1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m1/s1/i3D3,4D3"	[2H]C([2H])([2H])OC1=C(C=C2[C@H]3CC(=O)[C@@H](CN3CCC2=C1)CC(C)C)OC([2H])([2H])[2H]	MKJIEFSOBYUXJB-VFJJUKLQSA-N
DG01300	Tetrabenazine	6018	"TETRABENAZINE; 58-46-8; Nitoman; Tetrabenzaine; 718635-93-9; Rubigen; Tetrabenzine; tetra Benazin; Xenazine; Tetrabenazine (Racemate); Ro 1-9569; 3-isobutyl-9,10-dimethoxy-3,4,6,7-tetrahydro-1H-pyrido[2,1-a]isoquinolin-2(11bH)-one; Tetrabenazine Racemate; Ro 1-9569 Racemate; Tetrabenazinum; Tetrabenazinum [INN-Latin]; Tetrabenazina [INN-Spanish]; 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one; 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; 9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-one; MLS003106727; Ro 1-9569/12; CHEMBL117785; CHEBI:64028; (-)-tetrabenazine; Ro-19569; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine; NSC-169886; NCGC00160421-01; NSC 169886; 1,2,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one; 3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; DSSTox_CID_22614; DSSTox_RID_80059; DSSTox_GSID_42614; 1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo(a)quinolizin-2-one; 2-oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-benzoquinolizine; CAS-58-46-8; Xenazine (TN); SMR000718664; Nitoman (TN); WLN: T B666 DV GNTT&J E1Y1&1 LO1 MO1; Tetrabenazin; Revocon; 2-Oxo-3-isobutyl-9,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine; 2-Oxo-3-isobutyl-9,3,4,6,7,11.beta.-hexahydro-2H-benzoquinolizine; 1,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one; 2H-Benzo[a]quinolizin-2-one,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; 2H-Benzo[a]quinolizin-2-one,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-; 2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; Tetrabenazine- Bio-X; Nitoman;Ro 1-9569; Tetrabenazine (JAN/INN); TimTec1_002217; Oprea1_264344; SCHEMBL62026; MLS001249426; MLS001249497; GTPL4834; HY-B0590A; Tetrabenazine Related Impurity 2; HMS1540E17; HMS2966E06; HMS3263I14; HMS3430F03; HMS3884E10; Tetrabenazine (Nitoman, Xenazine); ACT06890; BCP15831; BCP24156; EX-A2361; Tox21_111803; Tox21_501086; BDBM50017701; MFCD00042740; MFCD08461052; MFCD11519951; NSC169886; NSC172187; s1789; STK678061; AKOS001681311; AKOS016347602; Tox21_111803_1; CCG-118217; CS-5700; DB04844; LP01086; MCULE-5822627411; NSC-172187; PB21652; PB25061; PB38735; SB49797; SDCCGSBI-0633786.P001; 2H-Benzo[a]quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-; 9,10-Dimethoxy-1,3,4,6,7,11b-hexahydro-3-isobutyl-2H-benzo[a]quinolizin-2-one; NCGC00160421-02; NCGC00160421-03; NCGC00160421-06; NCGC00261771-01; AS-35785; BT164463; SY055407; RO-1-9569; FT-0674921; FT-0700948; FT-0771873; FT-0772314; Z3433; 2105-47-7; D08575; A856325; A917912; Q413050; SR-01000833864; SR-01000833864-4; BRD-A47564106-001-01-8; Z1563146114; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7,11b-hexahydro-2H-benzo(a)quinolizine; 2H-Benzo[a]quinolizin-2-one, 1,3,4,6,7, 11b-hexahydro-3-isobutyl-9,10-dimethoxy-,; 3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one #; 3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-pyrido[2,1-a]isoquinolin-2-one; 3-isobutyl-9-,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizin-2-one; Tetrabenazine (3r,11br)-rel-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2h-benzo[a]quinolizin-2-one; Tetrabenazine, racemic mixture; ; ; 9,10-Dimethoxy-1,3,4,6,7,11b-hexahydro-3-isobutyl-2H-benzo[a]quinolizin-2-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:64028	DB12161	DR01035	DR1567	317.4	C19H27NO3	38.8	425	2.9	23	0	4	4	"1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3"	CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC	MKJIEFSOBYUXJB-UHFFFAOYSA-N
DG01301	Valbenazine	24795069	"Valbenazine; 1025504-45-3; Ingrezza; UNII-54K37P50KH; NBI 98854; 54K37P50KH; L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester; Valbenazine [USAN:INN]; L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester; ValbenazineNBI-98854; Valbenazine (USAN/INN); GTPL8694; CHEMBL2364639; SCHEMBL15932979; Mt-5199; EX-A2002; MFCD28963976; ZINC43195697; CS-5908; DB11915; NCGC00522306-02; (2R,3R,11bR)-9,10-Dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H- benzo(a)quinolizin-2-yl L-valinate; [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate; AC-30929; AS-35294; HY-16771; Valine 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester; D10675; NBI-98854;NBI98854;NBI 98854; Q27089118; (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate; (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester; [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl] (2S)-2-amino-3-methylbutanoate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB12161	DR01064	DR1665	418.6	C24H38N2O4	74	569	4.3	30	1	6	8	"1S/C24H38N2O4/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3/t17-,19-,20-,23+/m1/s1"	CC(C)C[C@@H]1CN2CCC3=CC(=C(C=C3[C@H]2C[C@H]1OC(=O)[C@H](C(C)C)N)OC)OC	GEJDGVNQKABXKG-CFKGEZKQSA-N
DG01303	Cefiderocol	77843966	"Cefiderocol; 1225208-94-5; UNII-SZ34OMG6E8; SZ34OMG6E8; GSK2696266; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-3-[[1-[2-[(2-chloro-3,4-dihydroxybenzoyl)amino]ethyl]pyrrolidin-1-ium-1-yl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; S-649266; RSC 649266; Cefiderocol [INN]; Cefiderocol (USAN); Cefiderocol [WHO-DD]; Cefiderocol [USAN:INN]; CHEMBL3989974; SCHEMBL22508010; AKOS037648584; DB14879; GSK 2696266; BS-14716; HY-17628; CS-0016784; D11302; S 649266; Pyrrolidinium, 1-(((6R,7R)-7-(((2Z)-2-(2-amino-4-thiazolyl)-2-((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-(2-((2-chloro-3,4-dihydroxybenzoyl)amino)ethyl)-, inner salt"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	752.2	C30H34ClN7O10S2	310	1440	1	50	6	15	12	"1S/C30H34ClN7O10S2/c1-30(2,28(46)47)48-36-19(16-13-50-29(32)34-16)24(42)35-20-25(43)37-21(27(44)45)14(12-49-26(20)37)11-38(8-3-4-9-38)10-7-33-23(41)15-5-6-17(39)22(40)18(15)31/h5-6,13,20,26H,3-4,7-12H2,1-2H3,(H7-,32,33,34,35,36,39,40,41,42,44,45,46,47)/t20-,26-/m1/s1"	CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4(CCCC4)CCNC(=O)C5=C(C(=C(C=C5)O)O)Cl)C(=O)[O-]	DBPPRLRVDVJOCL-FQRUVTKNSA-N
DG01304	Pemigatinib	86705695	"Pemigatinib; 1513857-77-6; INCB054828; Pemazyre; UNII-Y6BX7BL23K; Y6BX7BL23K; Fgfr inhibitor INCB054828; INCB54828; INCB-54828; INCB-054828; 1513857-77-6 (free base); 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholinomethyl)-1,3,4,6-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-[(morpholin-4-yl)methyl]-1,3,4,7-tetrahydro-2Hpyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; Pemazyre (TN); Pemigatinib [INN]; Pemigatinib [USAN]; Pemigatinib [USAN:INN]; Pemigatinib (JAN/USAN/INN); GTPL9767; Pemigatinib (INCB054828); CHEMBL4297522; SCHEMBL15556271; BDBM301310; INCB 54828; EX-A4049; NSC816556; US10131667, Example 126; AT15587; DB15102; INCB054828INCB054828; NSC-816556; AS-78489; example 126 [WO2014007951]; HY-109099; CS-0039499; D11417; A936247; 11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one; 2H-Pyrrolo(3',2':5,6)pyrido(4,3-d)pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)-; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3'',2'':5,6]pyrido[4,3-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholinomethyl)-3,4-dihydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2(7H)-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	487.5	C24H27F2N5O4	83.2	731	1.8	35	1	8	6	"1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)"	CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5	HCDMJFOHIXMBOV-UHFFFAOYSA-N
DG01305	Vedolizumab	.	.	Approved	1	Approved Drug(s)	Approved	Biotech	.	DB09033	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01306	Avapritinib	118023034	"Avapritinib; BLU-285; 1703793-34-3; Ayvakit; BLU285; (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine; UNII-513P80B4YJ; 513P80B4YJ; Ayvakyt; MFCD31544325; Avapritinib [INN]; Ayvakit (TN); Avapritinib (USAN/INN); Avapritinib (BLU-285); BLU-285 (Avapritinib); CHEMBL4204794; SCHEMBL16652297; GTPL10368; BLU 285; BDBM469269; AMY16753; EX-A1366; US10807985, Compound 44; NSC801082; s8553; AKOS037648993; CCG-269677; CS-7577; DB15233; NSC-801082; AC-31598; BB166456; BS-16206; HY-101561; C-366; 70C366; D11279; X720776; X-720776; Q29213676; (1S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo(2,1-f)(1,2,4)triazin-4-yl)-1-piperazinyl)-5-pyrimidinyl)ethanamine; (S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethan-1-amine; (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethanamine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	498.6	C26H27FN10	106	752	1.9	37	1	9	5	"1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1"	C[C@](C1=CC=C(C=C1)F)(C2=CN=C(N=C2)N3CCN(CC3)C4=NC=NN5C4=CC(=C5)C6=CN(N=C6)C)N	DWYRIWUZIJHQKQ-SANMLTNESA-N
DG01307	Pralsetinib	129073603	"Pralsetinib; BLU-667; 2097132-94-8; Pralsetinib free base; cis-Pralsetinib; Blu667; trans-Pralsetinib; UNII-1WPE73O1WV; 1WPE73O1WV; BLU123244; 2097132-94-8 (free base); 2097132-93-7; N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide; X581238; cis-N-{(1S)-1-[6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl]ethyl}-1-methoxy-4-{4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}cyclohexane-1-carboxamide; Gavreto; Cyclohexanecarboxamide, N-((1S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)-3-pyridinyl)ethyl)-1-methoxy-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)-, cis-; cyclohexanecarboxamide, N-[(1S)-1-[6-(4-fluoro-1H-pyrazol-1-yl)-3-pyridinyl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]-, cis-; Q4J; Pralsetinib [INN]; Pralsetinib [USAN]; Blu667Blu667; cis-BLU-667; Pralsetinib (USAN/INN); BLU-667 (Pralsetinib); CHEMBL4582651; SCHEMBL18789228; SCHEMBL18789229; SCHEMBL18806610; GTPL10033; BDBM435009; BDBM435010; AMY16875; EX-A1944; EX-A3347; NSC811429; s8716; US10584114, Compound 129; US10584114, Compound 130; WHO 11004; AKOS037648884; BLU-123244; HY-112301A; NSC-811429; BS-15942; HY-112301; CS-0043448; CS-0044766; D11712; X-581238; (cis)-N-((S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide; BLU-667; trans-N-{(1S)-1-[6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl]ethyl}-1-methoxy-4-{4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}cyclohexane-1-carboxamide; trans-N-{(1S)-1-[6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl]ethyl}-1-methoxy-4-{4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}cyclohexane-1-carboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	533.6	C27H32FN9O2	136	816	3.1	39	3	9	8	"1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19 ,27 /m0/s1"	CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC	GBLBJPZSROAGMF-SIYOEGHHSA-N
DG01308	Teicoplanin	133065662	Targocid; Antibiotic 8327A; Teichomycin; MDL 507; Tecoplanina; Tecoplanine; Tecoplaninum; Teicoplanina; Teicoplanine; Teicoplaninum; Teico-planin; 61036-62-2; Teicoplanine [French]; Teicoplaninum [Latin]; Teicoplanina [Spanish]; Tecoplanine [INN-French]; Tecoplaninum [INN-Latin]; Tecoplanina [INN-Spanish]; Teicoplanine [INN-French]; Teicoplaninum [INN-Latin]; Teicoplanina [INN-Spanish]; UNII-4U3D3YY81M; Teicoplanin [USAN:INN:BAN]; 4U3D3YY81M; GTPL10924; BDBM512667; NSC 759183; 8327A	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	1879.7	C88H97Cl2N9O33	662	3920	0.5	132	24	34	20	"1S/C88H97Cl2N9O33/c1-3-4-5-6-7-8-9-10-60(108)94-68-74(113)71(110)58(32-101)129-87(68)132-78-55-26-40-27-56(78)126-52-18-14-38(24-47(52)90)77(131-86-67(92-34(2)103)73(112)70(109)57(31-100)128-86)69-84(121)98-66(85(122)123)45-29-42(105)30-54(127-88-76(115)75(114)72(111)59(33-102)130-88)61(45)44-23-37(13-15-49(44)106)63(81(118)99-69)96-83(120)65(40)97-82(119)64-39-21-41(104)28-43(22-39)124-53-25-36(12-16-50(53)107)62(91)80(117)93-48(79(116)95-64)20-35-11-17-51(125-55)46(89)19-35/h11-19,21-30,48,57-59,62-77,86-88,100-102,104-107,109-115H,3-10,20,31-33,91H2,1-2H3,(H,92,103)(H,93,117)(H,94,108)(H,95,116)(H,96,120)(H,97,119)(H,98,121)(H,99,118)(H,122,123)/t48-,57-,58-,59-,62-,63-,64+,65-,66+,67-,68-,69+,70-,71-,72-,73-,74-,75+,76+,77-,86+,87+,88 /m1/s1"	CCCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)OC8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C)Cl)CO)O)O	BJNLLBUOHPVGFT-CAYRISATSA-N
DG01309	Selpercatinib	134436906	"Selpercatinib; 2152628-33-4; LOXO-292; CEGM9YBNGD; UNII-CEGM9YBNGD; LOXO292; 6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile; 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile; LY3527723; 6-(2-Hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]pyrazolo[1,5-a]pyridine-3-carbonitrile; Serpercatinib; Retevmo; 6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitrile; Retevmo (TN); Selpercatinib [INN]; Selpercatinib [USAN]; Ret inhibitor loxo-292; LOXO-292; Selpercatinib; Selpercatinib(LOXO-292); CHEMBL4559134; SCHEMBL20071478; Selpercatinib (JAN/USAN/INN); GTPL10318; BDBM296429; BCP29047; CLD62833; EX-A2859; NSC818434; s8781; WHO 10967; ZB1574; US10112942, Example 163; US10112942, Example 166; US10112942, Example 183; AKOS037649115; NSC-818434; AC-31588; BS-16622; LOXO-292;LOXO 292;LOXO292; Selpercatinib (LOXO-292, ARRY-192); example 163 [WO2018071447A1]; HY-114370; CS-0084279; LY-3527723; D11713; D77980; A929273; Pyrazolo(1,5-a)pyridine-3-carbonitrile, 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxy-3-pyridinyl)methyl)-3,6-diazabicyclo(3.1.1)hept-3-yl)-3-pyridinyl)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	525.6	C29H31N7O3	112	885	2.5	39	1	9	8	"1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3"	CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O	XIIOFHFUYBLOLW-UHFFFAOYSA-N
DG01310	Valaciclovir	135398742	"Valacyclovir; Valaciclovir; 124832-26-4; Valtrex; ValACV; Zelitrex; Valcyclovir; Val-ACV; UNII-MZ1IW7Q79D; L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester; Valtrex (TN); CHEMBL1349; MZ1IW7Q79D; 2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl L-valinate; CHEBI:35854; 2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate; Valcivir; (S)-2-[(2-Amino-6-oxo-6,9-dihydro-3H-purin-9-yl)methoxy]ethyl-2-amino-3-methylbutanoate; Valaciclovir [INN:BAN]; Talavir; Virval; Valacyclover Hydrochloric; Acyclovir-valine; (S)-2-((2-Amino-6-oxo-1H-purin-9(6H)-yl)methoxy)ethyl 2-amino-3-methylbutanoate; 2-[(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate; 256U87 HCl; Valaciclovir (INN); VACV; Valaciclovir, Valtrex; BW256U87; NCGC00159520-02; HSDB 8084; BW-256U; TXC; Valtrex (TM); Valcyclovir [INN:BAN]; 256U87; SCHEMBL28644; BSPBio_002474; MLS001304747; MLS006011776; GTPL4824; DTXSID1023732; HMS2090D20; HMS2234I15; BCP28415; ZINC1530713; BBL033701; BDBM50162073; STK802272; STL535579; ZB0748; 2-{[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]oxy}ethyl L-valinate; AKOS005622706; AKOS007930693; AKOS025149468; AKOS037496964; CS-1356; DB00577; valacyclovir hydrochloride (monohydrate); NCGC00178638-04; NCGC00178638-05; Valaciclovir;Val-ACV; Valtrex; Zelitrex; AC-11128; HY-17425; SMR000752514; SMR004703478; SBI-0206711.P001; D08664; AB00698497-11; AB01275525-01; AB01275525_02; AB01275525_03; 832V264; A805302; Q418594; W-200980; BRD-K46435977-003-01-2; BRD-K46435977-003-03-8; 2-[(2-amino-6-hydroxy-9H-purin-9-yl)methoxy]ethyl L-valinate; 2-[(2-amino-1,6-dihydro-6-oxo-9h-purin-9-yl)methoxy]ethyl-l-valinate; (S)-2-((2-amino-6-oxo-3H-purin-9(6H)-yl)methoxy)ethyl 2-amino-3-methylbutanoate; 2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methyl-butanoate; 2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate; (S)-2-[(2-Amino-6-oxo-6,9-dihydro-3H-purin-9-yl)methoxy]ethyl-2-amino-3-methylbutanoate_x000D_; (S)-2-Amino-3-methyl-butyric acid 2-(2-amino-6-oxo-1,6-dihydro-purin-9-ylmethoxy)-ethyl ester; 2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]ethyl 2-amino-3-methyl-butanoate;L-Valine 2-(guanin-9-ylmethoxy)ethyl ester"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:35854	DB00577	DR00078	.	324.34	C13H20N6O4	147	483	-0.9	23	3	7	8	"1S/C13H20N6O4/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20)/t8-/m0/s1"	CC(C)[C@@H](C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N	HDOVUKNUBWVHOX-QMMMGPOBSA-N
DG01311	Olanzapine	135398745	"Olanzapine; 132539-06-1; Zyprexa; Olansek; Zyprexa Zydis; Zalasta; Zyprexa Velotab; Zyprexa Intramuscular; Zolafren; Zypadhera; LY-170053; 2-Methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; Olzapin; Lanzac; Oferta; Olanzapine Mylan; LY 170053; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; C17H20N4S; UNII-N7U69T4SZR; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine; LY170053; 10H-thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-; CHEMBL715; N7U69T4SZR; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; CHEBI:7735; MFCD00866702; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3(7),5,8,11,13-hexaene; olanzapina; NCGC00096077-03; DSSTox_CID_3388; 2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine; DSSTox_RID_77010; DSSTox_GSID_23388; olanzapinum; Olanzapin; Midax; Olazax; Olanzapine Teva; Olazax Disperzi; 2-methyl-4-(4-methyl-1-piperazinyl)-5H-thieno[3,2-c][1,5]benzodiazepine; Olanzapine Teva; 10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-; Olanzapine Glenmark; SMR000466345; Olanzapine Neopharma; CAS-132539-06-1; SR-01000759343; Olanzapine cipla; Olanzapine apotex; ALKS-7921; HSDB 8155; Olanzapine [USAN:USP:INN:BAN]; Olanzapine solution; Olanzapine- Bio-X; Olanzapine (Zyprexa); KS-1090; GTPL47; BIDD:PXR0138; SCHEMBL28763; Olanzapine (JAN/USP/INN); US8802672, Olanzapine; MLS000759457; MLS001165781; MLS001195646; MLS001424057; BIDD:GT0332; SCHEMBL117695; SPECTRUM1505024; Olanzapine (LY-170053); DTXSID9023388; Olanzapine, >=98% (HPLC); BDBM35254; BDBM82479; CHEBI:94534; AMY7709; HMS2051H05; HMS2089M04; HMS2093I04; HMS2233F24; HMS3374L02; HMS3393H05; HMS3657I15; HMS3714J03; HMS3743A09; HMS3884J21; ACT03231; ALBB-027265; BCP04917; NSC_4585; ZINC3873830; Tox21_111556; AC-665; NSC754829; NSC801187; s2493; STK634338; STL388024; ZINC52957434; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; AKOS000282888; AKOS005566122; Olanzapine 1.0 mg/ml in Acetonitrile; Tox21_111556_1; BCP9001021; CCG-100922; CS-1114; DB00334; MCULE-1620364835; NC00172; NSC-754829; NSC-801187; NCGC00096077-01; NCGC00096077-04; NCGC00096077-05; NCGC00096077-06; NCGC00096077-18; NCGC00389791-02; BO164166; HY-14541; I960; SBI-0206786.P001; CAS_132539-06-1; FT-0673219; O0393; SW220248-1; C07322; D00454; J10363; AB00639907-06; AB00639907-07; AB00639907_08; AB00639907_09; 539O061; A806453; L000455; L005958; Q201872; J-006186; SR-01000759343-4; SR-01000759343-6; Z1868057799; Olanzapine, European Pharmacopoeia (EP) Reference Standard; Olanzapine, United States Pharmacopeia (USP) Reference Standard; Olanzapine, Pharmaceutical Secondary Standard; Certified Reference Material; (E)-2-methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine; 2-Methyl-10-(4-methyl-piperazin-1-yl)-4H-3-thia-4,9-diaza-benzo[f]azulene; 2-methyl-4-(4-methyl-1-piperazinyl) -10h-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine #; 2-Methyl-4-(4-methylpiperazin-1-yl)-10H- thieno[2,3-b][1,5]benzodiazepin; Olanzapine for system suitability, European Pharmacopoeia (EP) Reference Standard; Olanzapine-d8, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material; Olanzapine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:7735	DB00334	DR00462	DR1186	312.4	C17H20N4S	59.1	432	2.9	22	1	4	1	"1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3"	CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C	KVWDHTXUZHCGIO-UHFFFAOYSA-N
DG01312	Allopurinol	135401907	"Allopurinol; 315-30-0; 1H-Pyrazolo[3,4-d]pyrimidin-4-ol; Zyloprim; Zyloric; Lopurin; Atisuril; Bleminol; Caplenal; Suspendol; Uripurinol; Embarin; Foligan; Milurit; Progout; Urosin; Anoprolin; Cellidrin; Epidropal; Takanarumin; Ailural; Allopur; Allural; Alositol; Bloxanth; Cosuric; Hamarin; Ledopur; Lysuron; Uricemil; Uriprim; Xanturat; Aloral; Anzief; Apurin; Apurol; Geapur; Gotax; Remid; Urbol; Urolit; Urtias; Ketobun-A; Apulonga; Dabrosin; Dabroson; Ketanrift; Miniplanor; Nektrohan; Urobenyl; Adenock; Allozym; Aluline; Gichtex; Monarch; Riball; 4-Hydroxypyrazolo[3,4-d]pyrimidine; Hexanuret; Epuric; 1H-Pyrazolo[3,4-d]pyrimidin-4(5H)-one; Allo-Puren; 4-HPP; Allopurinol(I); Dura Al; Allopurinolum; Aloprim; Urtias 100; 4-Hydroxypyrazolopyrimidine; 1H-Pyrazolo(3,4-d)pyrimidin-4-ol; 4-Hydroxy-1H-pyrazolo(3,4-d)pyrimidine; Alopurinol; 4-Hydroxy-3,4-pyrazolopyrimidine; 4-Hydroxypyrazolo(3,4-d)pyrimidine; Alopurinol [INN-Spanish]; Allopurinolum [INN-Latin]; 180749-08-0; NSC-1390; 180749-06-8; 1H-pyrazolo[3,4-d]pyrimidin-4(7H)-one; 4-Hydroxypyrazolyl(3,4-d)pyrimidine; 4H-Pyrazolo(3,4-d)pyrimidin-4-one; 4'-Hydroxypyrazolol(3,4-d)pyrimidine; AL-100; BW 56-158; Zyloprim (TN); 73334-58-4; 1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one; 2H-Pyrazolo[3,4-d]pyrimidin-4-ol; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-; B. W. 56-158; 1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one; BW-56-158; UNII-63CZ7GJN5I; 180749-09-1; 1,5-Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; MLS000069453; 4H-Pyrazolo(3,4-d)pyrimidin-4-one, 1,5-dihydro-; CHEBI:40279; 1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one; MFCD00599413; 180749-07-9; 184789-03-5; 63CZ7GJN5I; SMR000059083; 4-Hydroxy-1H-pyrazolo[3,4-d]pyrimidine; 1H-Pyrazolo[3,4-d]pyrimidin-4-ol (9CI); 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,7-dihydro- (9CI); 1,5-Dihydropyrazolo[3,4-d]pyrimidin-4-one; 1H,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one; NSC1390; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,2-dihydro-; NSC101655; NSC-101655; NCGC00015094-02; NCGC00094580-04; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 2,5-dihydro- (9CI); 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 2,7-dihydro- (9CI); BW 56158; BW-56158; Sigapurol; Uritas; 1H,2H,4H-pyrazolo[3,4-d]pyrimidin-4-one; DSSTox_CID_2573; 1,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-one; DSSTox_RID_76636; DSSTox_GSID_22573; 4H-Pyrazolo[3, 1,5-dihydro-; Ailurial; WLN: T56 BMN GN INJ FQ; 4-Hydroxypyrazolyl[3,4-d]pyrimidine; 4'-Hydroxypyrazolol[3,4-d]pyrimidine; NSC 1390; CAS-315-30-0; CCRIS 626; NSC 101655; HSDB 3004; SR-05000001983; EINECS 206-250-9; Hexanurat; Uricto; ATH008; Xanthine oxidase; Prestwick_511; Xanthomax-100; Xanthomax-300; 4H-Pyrazolo[3,4-d]pyrimidin-4-one,1,2-dihydro-; Aluline 100; Aluline 300; Hamarin 100; Hamarin 300; Zyloric-300; Allopurinol [USAN:USP:INN:BAN:JAN]; Allopurinol (Zyloprim); Spectrum_000026; Opera_ID_1680; Spectrum2_000098; Spectrum3_000289; Spectrum4_000135; Spectrum5_000768; Lopac-A-8003; 1,4-d]pyrimidin-4-one; A 8003; cid_2094; SCHEMBL4627; CHEMBL1467; NCIOpen2_001825; Lopac0_000102; BSPBio_001798; KBioGR_000550; KBioSS_000386; MLS001148183; US9138393, Allopurinol; US9144538, Allopurinol; DivK1c_000685; SPECTRUM1500108; SPBio_000056; GTPL6795; SCHEMBL1128219; Allopurinol (JP17/USP/INN); DTXSID4022573; BDBM35440; HMS502C07; KBio1_000685; KBio2_000386; KBio2_002954; KBio2_005522; KBio3_001298; NINDS_000685; BDBM181133; HMS1920A15; HMS2091G15; HMS2234M09; HMS3259K13; HMS3260E06; HMS3371I11; HMS3651O13; HMS3714L22; Pharmakon1600-01500108; 4-Hydroxypyrazol[3,4-D]pyrimidine; ACT02732; AMY18272; BCP26973; HY-B0219; STR05189; Tox21_110082; Tox21_200922; Tox21_500102; 2204AH; 4-Hydroxy-pyrazolo[3,4-d]pyrimidin; AC-019; BBL009959; BDBM50016784; BDBM50140241; CCG-38916; NSC755858; s1630; SC1118; SC2251; STK378584; STK711106; ZINC13298313; AKOS000267490; AKOS000269759; AKOS024255717; Tox21_110082_1; Allopurinol, xanthine oxidase inhibitor; CCG-204197; CCG-221406; CCG-266128; DB00437; LP00102; MCULE-5186178136; NC00492; NSC-755858; SB10164; SDCCGSBI-0050090.P005; IDI1_000685; NCGC00015094-01; NCGC00015094-03; NCGC00015094-04; NCGC00015094-05; NCGC00015094-06; NCGC00015094-07; NCGC00015094-08; NCGC00015094-22; NCGC00091134-01; NCGC00091134-02; NCGC00091134-03; NCGC00094580-01; NCGC00094580-02; NCGC00094580-05; NCGC00188948-01; NCGC00258476-01; NCGC00260787-01; 291279-53-3; TS-00028; 2h-pyrazolo[3,4-d]pyrimidin-4(5h)-one; 2H-pyrazolo[3,4-d]pyrimidin-4(7H)-one; SBI-0050090.P004; DB-065332; 2H-Pyrazolo[3,4-d]pyrimidin-4-ol (9CI); A0907; EU-0100102; FT-0602537; FT-0661492; FT-0685730; FT-0764079; SW199406-4; 1,5-dihydropyrazolo[3,4-d]-pyrimidin-4-one; VU0611037-1; BIM-0061756.0001; D00224; F18007; AB00173448-03; AB00173448-04; AB00173448_05; AB01274719-01; AB01274719_02; 4h-pyrazolo[3,4-d]pyrimidin-4-one,1,7-dihydro-; 4h-pyrazolo[3,4-d]pyrimidin-4-one,2,5-dihydro-; 4h-pyrazolo[3,4-d]pyrimidin-4-one,2,7-dihydro-; AB-323/25048497; Allopurinol (4-Hydroxypyrazolo[3,4-d]pyrimidine); Q412486; SR-01000075595; 4H-pyrazolo[3,4-d]pyrimidin-4-one, 1,7-dihydro-; J-504736; SR-01000075595-1; SR-05000001983-1; SR-05000001983-2; W-106892; 1,2-DIHYDRO-4H-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE; 1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one (9CI); F2173-0394; F3329-0375; Z228474686; Allopurinol, British Pharmacopoeia (BP) Reference Standard; Allopurinol, European Pharmacopoeia (EP) Reference Standard; Allopurinol, United States Pharmacopeia (USP) Reference Standard; 1,5-Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one Synonym: Allopurinol; Allopurinol, Pharmaceutical Secondary Standard; Certified Reference Material; 1H-Pyrazolo[3,4-d]pyrimidin-4-ol;1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE; 9002-17-9"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:40279	DB00437	DR00074	DR0066	136.11	C5H4N4O	70.1	190	-0.7	10	2	3	0	"1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)"	C1=NNC2=C1C(=O)NC=N2	OFCNXPDARWKPPY-UHFFFAOYSA-N
DG01314	Anagrelide	135409400	"Anagrelide; 68475-42-3; Anagrelida; Xagrid; Anagrelidum; 6,7-Dichloro-5,10-dihydroimidazo[2,1-b]quinazolin-2(3H)-one; UNII-K9X45X0051; CHEMBL760; 6,7-Dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one; CHEBI:142290; Imidazo[2,1-b]quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-; K9X45X0051; Anagrelide [INN:BAN]; Anagrelidum [INN-Latin]; Anagrelida [INN-Spanish]; 6,7-Dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one; 6,7-bis(chloranyl)-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one; Imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-; C10H7Cl2N3O; HSDB 7325; BL 416201; Anagrelide (INN/BAN); BRN 0619582; 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one; 6,7-Dichlor-1,5-dihydroimidazo(2,1-b)chinazolin-2(3H)-on; 6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one; SCHEMBL9411; BIDD:GT0711; GTPL7114; 6,7-dichloro-1,5-dihydroimidazo[2,1-]quinazolin-2(3H)-one; 6,7-dichloro-3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one; HMS2089D21; HMS3715J06; HMS3742K13; BCP21314; HY-B0523; ZINC3871541; BDBM50000334; MFCD00866794; AKOS015899342; AKOS016340524; AC-3401; CCG-221242; DB00261; KS-5176; NCGC00161408-02; NCGC00161408-08; NCGC00247665-01; AS-14157; K139; SBI-0206823.P001; DB-055153; CS-0009495; FT-0602855; FT-0630776; D07455; AB00698496-05; AB00698496-07; AB00698496_08; AB01566808_01; 475A423; A915719; Q408163; 6,7-dichloro-3H,5H-imidazo[2,1-b]quinazolin-2-ol; BRD-K62200014-003-05-5; BRD-K62200014-003-08-9; 6,7-Dichloro-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one; 6,7-dichloro-1h,5h-imidazo[2,1-b]quinazoline-2(3h)-one; 6,7-dichloro-1, 5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one; 6,7-Dichloro-1,5-dihydroimidazo[2,1-b]-quinazolin-2(3H)-one; 6,7-dichloro-1,5dihydroimidazo[2,1-b]quinazolin-2[3H]-one; 6,7-dichloro-1H,2H,3H,5H-imidazolidino[2,1-b]quinazolin-2-one; Imidazo[2,1-b]quinazolin-2(3H)-one,6,7-dichloro-1,5-dihydro-; 6,7-di-chloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3 H ]-one base; 6,7-Dichloro-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one(anagrelide); 6,7-Dichloro-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one(BL-4162A); J33"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:142290	DB00261	.	.	256.079	C10H7Cl2N3O	44.7	360	1.6	16	1	2	0	"1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)"	C1C2=C(C=CC(=C2Cl)Cl)N=C3N1CC(=O)N3	OTBXOEAOVRKTNQ-UHFFFAOYSA-N
DG01315	Tegaserod	135409453	"Tegaserod; 145158-71-0; Tegaserod maleate; 2-((5-Methoxy-1H-indol-3-yl)methylene)-N-pentylhydrazinecarboximidamide; CHEMBL76370; CHEBI:51043; NCGC00095192-01; 1-(((5-Methoxyindol-3-yl)methylene)amino)-3-pentylguanidine; DSSTox_CID_25955; DSSTox_RID_81251; DSSTox_GSID_45955; UNII-458VC51857; 189188-57-6; MLS001401406; 2-[(5-methoxy-2,3-dihydro-1H-indol-3-yl)methylene]-N-pentylhydrazinecarboximidamide; CAS-145158-71-0; Tegaserod (USAN/INN); SMR000471618; tegaserodum; SDZ-HTF-919; 458VC51857; Spectrum5_001691; SCHEMBL16464; BSPBio_002344; BSPBio_003270; SPECTRUM1505823; SCHEMBL8194377; SCHEMBL8229619; DTXSID6045955; SCHEMBL15654154; BDBM79022; CHEBI:94540; cid_6918369; HMS1922J08; Tox21_111481; BDBM50240618; ZINC11676968; AKOS015913793; Tox21_111481_1; AC-4564; AM84414; DB01079; NCGC00095192-02; NCGC00095192-03; NCGC00095192-04; NCGC00095192-05; NCGC00095192-08; NCGC00095192-11; HY-14153; LS-14526; CS-0003233; 58T710; D06056; AB01209613-01; AB01209613-03; AB01563050_01; A909403; J-008063; BRD-K88743730-001-01-0; (2E)-2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentylhydrazinecarboximidamide; (Z)-2-butenedioic acid;1-[[(Z)-(5-methoxy-3-indolylidene)methyl]amino]-2-pentylguanidine; (Z)-but-2-enedioic acid;1-[[(Z)-(5-methoxyindol-3-ylidene)methyl]amino]-2-pentylguanidine; 2-amyl-1-[[(Z)-(5-methoxyindol-3-ylidene)methyl]amino]guanidine;maleic acid; (Z)-but-2-enedioic acid;1-[[(Z)-(5-methoxyindol-3-ylidene)methyl]amino]-2-pentyl-guanidine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:51043	DB01079	.	DR1541	301.39	C16H23N5O	87.8	385	2.6	22	3	3	8	"1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+"	CCCCCN=C(N)N/N=C/C1=CNC2=C1C=C(C=C2)OC	IKBKZGMPCYNSLU-RGVLZGJSSA-N
DG01320	Abatacept	.	.	Approved	1	Approved Drug(s)	Approved	.	.	DB01281	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01321	Abciximab	.	.	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01322	Adalimumab	.	.	Approved	1	Approved Drug(s)	Approved	Antibody	.	.	DR00441	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01333	Belatacept	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01348	Chymotrypsin	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01350	CNTO-1959	.	.	Approved	1	Approved Drug(s)	Approved	Antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01363	Durvalumab	.	.	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	DB11714	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01366	Enfortumab	.	.	Approved	1	Approved Drug(s)	Approved	Antibody drug conjugate	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01368	Eptinezumab	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01369	Erenumab	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01370	Estrogen	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01375	Fibrinogen	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01376	Fremanezumab	.	.	Approved	1	Approved Drug(s)	Approved	Antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01377	Furazolidinone	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01378	Galcanezumab	.	.	Approved	1	Approved Drug(s)	Approved	Antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01385	Idarucizumab	.	.	Approved	1	Approved Drug(s)	Approved	Antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01388	Ipilimumab	.	.	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01397	Mefenamic	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01401	Mogamulizumab	.	.	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01405	Nimotuzumab	.	.	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01406	Nivolumab	.	.	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	DB09035	.	DR2826	.	.	.	.	.	.	.	.	.	.	.	.
DG01408	OM-89	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01412	Palivizumab	.	.	Approved	1	Approved Drug(s)	Approved	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01417	Protamine	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01418	Rasburicase	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01419	RBPI-21	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01423	RHuEPO	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01429	Sargramostim	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01431	Sintilimab	.	.	Approved	1	Approved Drug(s)	Approved	Antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01436	Tagraxofusp	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01439	Tecartus	.	.	Approved	1	Approved Drug(s)	Approved	CAR T Cell Therapy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01442	Thyrotropin	.	.	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01443	Tildrakizumab	.	.	Approved	1	Approved Drug(s)	Approved	Antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01450	Trumenba	.	.	Approved	1	Approved Drug(s)	Approved	Vaccine	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01451	Tuberculin	.	.	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01460	Abiraterone acetate	9821849	"Abiraterone acetate; 154229-18-2; Zytiga; CB7630; CB-7630; CB 7630; Yonsa; UNII-EM5OCB9YJ6; 17-(3-Pyridyl)-5,16-androstadien-3beta-acetate; EM5OCB9YJ6; [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; CHEBI:68639; NSC-748121; NSC-749227; (3S,8R,9S,10R,13S,14S)-10,13-DIMETHYL-17-(PYRIDIN-3-YL)-2,3,4,7,8,9,10,11,12,13,14,15-DODECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-3-YL ACETATE; 17-(pyridin-3-yl)androsta-5,16-dien-3beta-yl acetate; 3beta-17-(3-Pyridyl)androsta-5,16-dien-3-ol Acetate; (3beta)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate; Abiraterone Acotate; 17-(3-Pyridyl)androsta-5, acetate; Androsta-5, 17-(3-pyridinyl)-, 3-acetate,; Abiraterone acetate [USAN]; MFCD00934213; abiraterone-acetate; NCGC00186462-01; 3S,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol, 3-acetate; Abiraterone Acetate; Zytiga (TN); Abiraterone (acetate); Abiraterone acetate- Bio-X; DSSTox_CID_28969; DSSTox_RID_83234; DSSTox_GSID_49043; SCHEMBL93715; MLS006010090; CHEMBL271227; GTPL9288; Abiraterone acetate (JAN/USP); DTXSID3049043; EX-A107; BCP02949; ZINC3809191; Tox21_113589; BDBM50407398; NSC748121; NSC749227; s2246; Abiraterone acetate, >=98% (HPLC); AKOS015896502; CS-0544; DS-2007; JNJ 212082; NSC 748121; NSC 749227; JNJ-2012082; NCGC00379022-06; AC-25760; BA164133; HY-75054; SMR004701235; CAS-154229-18-2; X6144; D09701; 3b-acetoxy-17-(3-pyridyl)androsta-5,16-diene; 17-(3-Pyridyl)-5,16-androstadien-3-b-acetate; A809510; 3beta-Acetoxy-17-(3-pyridyl)androsta-5,16-diene; W-201385; BRD-K24048528-001-02-5; Q27888393; (3S)-3-Acetoxy-17-(pyridin-3-yl)androsta-5,16-diene; (3 )-17-(3-Pyridinyl)androsta-5,16-dien-3-yl acetate; (3beta)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol acetate (ester); Abiraterone acetate, United States Pharmacopeia (USP) Reference Standard; Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3beta)-; (1S,2R,5S,10R,11S,15S)-2,15-dimethyl-14-(pyridin-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-7,13-dien-5-yl acetate; [(3S,10R,13S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] ethanoate; acetic acid [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(3-pyridinyl)-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] ester"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:68639	DB05812	DR0030	DR01327	391.5	3	C26H33NO2	39.2	739	5.2	29	0	3	"InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1"	CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC=C4C5=CN=CC=C5)C)C	UVIQSJCZCSLXRZ-UBUQANBQSA-N
DG01461	Ampicillin-sulbactam	119561	"Ampicillin sodium and sulbactam sodium; 94935-63-4; Ampicillin mixture with Sulbactam; Sulacillin; Ampicillin-sulbactam; (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(1R,4S)-3,3-dimethyl-2,2,6-trioxo-2lambda6-thiabicyclo[3.2.0]heptane-4-carboxylic acid; Sulbactam-Ampicillin mixt. (1:2); Ampicillin-sulbactam mixt.; AMPICILLIN AND SULBACTAM; DTXSID60241694; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((2R)-aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S,5R,6R)-, mixt. with (2S,5R)-3,3-dimethyl-7-oxo-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2-alpha,5-alpha,6-beta(S*)))-, mixt. with (2S-cis)-3,3-dimethyl-7-oxo-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	581.7	5	C25H31N3O9S2	235	1000	.	39	4	11	"InChI=1S/C16H19N3O4S.C9H12O5S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8;1-9(2)7(8(11)12)6-4(10)3-5(6)15(9,13)14/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23);5-7H,3H2,1-2H3,(H,11,12)/t9-,10-,11+,14-;5-,6 ,7+/m11/s1"	CC1([C@@H](C2[C@H](S1(=O)=O)CC2=O)C(=O)O)C.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C	KMEGBUCIGMEPME-LQYKFRDPSA-N
DG01462	PD173074	1401	"219580-11-7; PD173074; PD 173074; PD-173074; 1-(tert-Butyl)-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea; 1-tert-butyl-3-[2-{[4-(diethylamino)butyl]amino}-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea; UNII-A4TLL8634Y; A4TLL8634Y; CHEMBL189584; PD-0173074; CHEBI:63448; C28H41N7O3; MFCD08705327; 1-tert-butyl-3-(2-(4-(diethylamino)butylamino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea; 1-tert-butyl-3-[2-[4-(diethylamino)butylamino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea; 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea; 3-tert-butyl-1-(2-{[4-(diethylamino)butyl]amino}-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea; 2fgi; SMR000568412; MLS001074892; MLS006011101; SCHEMBL177946; Pyrido[2,3-d]pyrimidine 12; BDBM6190; GTPL5037; AOB2517; DTXSID30176363; EX-A197; SYN1176; BCPP000121; HMS2233G17; HMS3265E09; HMS3265E10; HMS3265F09; HMS3265F10; HMS3371E08; HMS3648A10; HMS3654L09; BCP02368; ZINC3870533; NSC766908; s1264; AKOS016008595; BCP9001065; CCG-264881; CS-0182; NSC-766908; QC-7737; SB19382; NCGC00165863-01; NCGC00165863-02; NCGC00165863-17; AC-24850; AS-16310; BP162784; HY-10321; N-[2-[[4-(Diethylamino)butyl]amino] -6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-y l]-N'-(1,1-dimethylethyl)urea; FT-0673540; P2474; SW218104-2; X7486; PD 173074, >=96% (HPLC), powder; A25450; SR-01000837541; J-014372; J-523314; SR-01000837541-2; Q27088276; FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 - CAS 219580-11-7; 1-(tert-Butyl)-3-[7-[[4-(diethylamino)butyl]amino]-3-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-2-yl]urea; 1-tert-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)pyrido(2,3-d)pyrimidin-7-yl)urea; N-(tert-Butyl)-N -[2-[[4-(diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea; N-[2-[[4-(Dethylamno)butyl]amno]-6-(3,5-dmethoxyphenyl)pyrdo[2,3-d ]pyrmdn-7-yl]-n'-(1,1-dmethylethyl)urea; N-[2-[[4-(Diethylamino)butyl]amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)urea; N-[2-[[4-(Diethylamino)butyl]amino]-6-(3,5- dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1- dimethylethyl)urea; N-[2-[[4-(diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea; N-[2-[[4-(Diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)urea; PD 173074;n-[2-[[4-(diethylamino)butyl]amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-n'-(1,1-dimethylethyl)urea"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:63448	.	.	.	523.7	13	C28H41N7O3	114	690	4.5	38	3	8	"InChI=1S/C28H41N7O3/c1-8-35(9-2)13-11-10-12-29-26-30-18-20-16-23(19-14-21(37-6)17-22(15-19)38-7)25(31-24(20)32-26)33-27(36)34-28(3,4)5/h14-18H,8-13H2,1-7H3,(H3,29,30,31,32,33,34,36)"	CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C	DXCUKNQANPLTEJ-UHFFFAOYSA-N
DG01463	AG1296	2049	"146535-11-7; Tyrphostin AG 1296; 6,7-dimethoxy-2-phenylquinoxaline; AG-1296; AG 1296; 6,7-Dimethoxy-3-phenylquinoxaline; ag1296; Tyrphostin AG-1296; Quinoxaline, 6,7-dimethoxy-2-phenyl-; Tyrphostin AG1296; CHEMBL71191; MFCD00270913; tyrphostin-AG1296; 6,7-Dimethoxy-2-phenylquinozaline; tyrphostin-AG-1296; BiomolKI_000055; BiomolKI2_000061; BMK1-F7; BSPBio_001422; KBioGR_000142; KBioSS_000142; SCHEMBL595944; GTPL5915; QCR-71; ZINC8082; CHEBI:93335; KBio2_000142; KBio2_002710; KBio2_005278; KBio3_000283; KBio3_000284; DTXSID70163393; Bio2_000142; Bio2_000622; HMS1361H04; HMS1791H04; HMS1989H04; HMS3229M21; HMS3402H04; HMS3653H21; BCP06928; EX-A4245; Tyrphostin AG 1296, >=98%; 6,7-Dimethoxy-2-phenyl-quinoxaline; 2090AH; 2774AH; BDBM50154227; s8024; AKOS025287463; CCG-100659; Quinozaline, 6,7-dimethoxy-2-phenyl-; Tyrphostin AG 1296 (AG 1296); IDI1_033892; NCGC00163386-01; NCGC00163386-02; NCGC00163386-03; NCGC00163386-04; AS-62520; HY-13894; CS-0008498; SW220231-1; AG-1296; ; ; 6,7-Dimethoxy-2-phenylquinoxaline; SR-03000001061; J-008233; SR-03000001061-1; AG 1296 - CAS 146535-11-7; BRD-K76064317-001-03-2; BRD-K76064317-001-04-0; Q27074335"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:93335	.	.	.	266.29	3	C16H14N2O2	44.2	307	2.8	20	0	4	"InChI=1S/C16H14N2O2/c1-19-15-8-12-13(9-16(15)20-2)18-14(10-17-12)11-6-4-3-5-7-11/h3-10H,1-2H3"	COC1=C(C=C2C(=C1)N=CC(=N2)C3=CC=CC=C3)OC	QNOXYUNHIGOWNY-UHFFFAOYSA-N
DG01464	Flutamide	3397	"Flutamide; 13311-84-7; Eulexin; Niftolide; Niftholide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; Sch 13521; NFBA; niftolid; Drogenil; Flutamin; Cebatrol, veterinary; Flutamida; Flutamidum; 4'-Nitro-3'-trifluoromethylisobutyranilide; Sch-13521; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; N-(4-NITRO-3-(TRIFLUOROMETHYL)PHENYL)ISOBUTYRAMIDE; SCH13521; MFCD00072009; NSC 215876; Flutamide (Eulexin); alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; UNII-76W6J0943E; CHEMBL806; Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-; 4-Nitro-3-(trifluoromethyl)isobutyranilide; CHEBI:5132; Propanamide, 2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-; 76W6J0943E; NSC-215876; NCGC00015452-09; Eulexine; Chimax; 4'-Nitro-3'-trifluoromethylisobutyramilide; CAS-13311-84-7; Ham's F-12 medium; Flutamidum [INN-Latin]; DSSTox_CID_11121; DSSTox_RID_78899; DSSTox_GSID_32004; Flutamida [INN-Spanish]; Flutamide USP25; N-[4-Nitro-3-(trifluoromethyl)phenyl]isobutyramide; Prostandril; Odyne; SMR000058187; Eulexin (TN); CCRIS 7246; m-Propionotoluidide,.alpha.,.alpha.-trifluoro-; SR-01000075888; EINECS 236-341-9; BRN 2157663; .alpha.,.alpha.-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; m-Propionotoluidide,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; Flutamide [USAN:USP:INN:BAN]; Flutamide,(S); Prestwick_228; NK-601; Spectrum_001210; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; CPD000058187; Prestwick0_000180; Prestwick1_000180; Prestwick2_000180; Prestwick3_000180; Spectrum2_001201; Spectrum3_001421; Spectrum4_000829; Spectrum5_001450; Lopac-F-9397; F0663; Flutamide (pubertal study); F 9397; SCHEMBL3934; Lopac0_000557; BSPBio_000079; BSPBio_003122; KBioGR_001377; KBioSS_001690; MLS000069634; MLS001065596; MLS002548892; DivK1c_000459; SPECTRUM1500995; SPBio_000982; SPBio_002000; Flutamide (JP17/USP/INN); BPBio1_000087; GTPL6943; CHEMBL4759307; DTXSID7032004; SCHEMBL12932289; HMS501G21; KBio1_000459; KBio2_001690; KBio2_004258; KBio2_006826; KBio3_002342; NINDS_000459; HMS1568D21; HMS1921O16; HMS2090I18; HMS2092O14; HMS2095D21; HMS2230P19; HMS3259I03; HMS3261P15; HMS3373C12; HMS3655G22; HMS3712D21; Pharmakon1600-01500995; AMY32524; BCP23006; HY-B0022; ZINC3812944; Tox21_110154; Tox21_202169; Tox21_300536; Tox21_500557; BDBM50131270; CCG-39105; m-Propionotoluidide, 2-methyl-4'-nitro-alpha,alpha,alpha-triflouro-; NSC147834; NSC215876; NSC757817; s1908; AKOS001025465; AKOS025243203; m-Propionotoluidide, .alpha.,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-; Tox21_110154_1; AB02835; DB00499; KS-5091; LP00557; MCULE-7498839065; NC00451; NSC-147834; NSC-757817; SDCCGSBI-0050540.P004; IDI1_000459; NCGC00015452-01; NCGC00015452-02; NCGC00015452-03; NCGC00015452-04; NCGC00015452-05; NCGC00015452-06; NCGC00015452-07; NCGC00015452-08; NCGC00015452-10; NCGC00015452-11; NCGC00015452-12; NCGC00015452-13; NCGC00015452-14; NCGC00015452-15; NCGC00015452-16; NCGC00015452-19; NCGC00015452-20; NCGC00015452-32; NCGC00091460-01; NCGC00091460-02; NCGC00091460-03; NCGC00091460-04; NCGC00091460-05; NCGC00091460-06; NCGC00091460-07; NCGC00091460-08; NCGC00091460-09; NCGC00254495-01; NCGC00259718-01; NCGC00261242-01; AC-24192; BF166239; SY036411; SBI-0050540.P003; DB-042163; 3'-Trifluoromethyl-4'-Nitro-Isobutyranilide; AB00052188; EU-0100557; FT-0626493; FT-0668764; SW196536-4; 4''-nitro-3''-trifluoromethylisobutyranilide; C07653; D00586; J10037; AB00052188-09; AB00052188_10; AB00052188_11; 311F847; A806562; Q418669; Q-201131; SR-01000075888-1; SR-01000075888-6; SR-01000075888-7; SR-01000075888-9; BRD-K28307902-001-05-0; Flutamide, certified reference material, TraceCERT(R); Z56755651; a,a,a-Trifluoro-2-methyl-4'-nitro- m-propionotoluidide; Flutamide, European Pharmacopoeia (EP) Reference Standard; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide #; Flutamide, United States Pharmacopeia (USP) Reference Standard; 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide;Flutamide; alpha,alpha,alpha-trifluoro-2-methyl-4''-nitro-m-propionotoluidide; .alpha.,.alpha.,.alpha.-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; m-Propionotoluidide, 2-methyl-4'-nitro-.alpha.,.alpha.,.alpha.-trifluoro-; m-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro- (8CI); Flutamide for system suitability, European Pharmacopoeia (EP) Reference Standard; 37209-54-4"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:5132	DB00499	DR0733	DR00846	276.21	2	C11H11F3N2O3	74.9	352	3.3	19	1	6	"InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)"	CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F	MKXKFYHWDHIYRV-UHFFFAOYSA-N
DG01465	GO6976	3501	"Go 6976; 136194-77-9; GO6976; Go-6976; Goe 6976; UNII-B9IQO7JZ16; 5,6,7,13-Tetrahydro-13-Methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile; 3-(13-Methyl-5-oxo-6,7-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12(13H)-yl)propanenitrile; B9IQO7JZ16; CHEMBL302449; C24H18N4O; CHEBI:51913; 12-(2-Cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole; 12H-Indolo(2,3-a)pyrrolo(3,4-c)carbazole-12-propanenitrile, 5,6,7,13-tetrahydro-13-methyl-5-oxo-; 12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile, 5,6,7,13-tetrahydro-13-methyl-5-oxo-; 12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo[2,3-a]pyrolo[3,4-c]carbazole; 3-(13-methyl-5-oxo-5,6,7,13-tetrahydro-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12-yl)propanenitrile; Kinome_3630; Gouml 6976; CBiol_001871; BSPBio_001101; KBioGR_000441; KBioSS_000441; 12-(2-Cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole; 13-Methyl-5-oxo-5,6,7,13-tetrahydro-12H-indolo(2,3-a)pyrrolo(3,4-c)carbazole-12-propanenitrile; Goe-6976; BDBM3033; GTPL5973; QCR-45; SCHEMBL2175239; BCBcMAP01_000156; KBio2_000441; KBio2_003009; KBio2_005577; KBio3_000821; KBio3_000822; AOB4516; DTXSID70159731; Bio1_000157; Bio1_000646; Bio1_001135; Bio2_000381; Bio2_000861; HMS1362G03; HMS1792G03; HMS1990G03; HMS3229E13; HMS3403G03; BCP06797; ZINC1554668; 2437AH; 3-[methyl(oxo)[ ]yl]propanenitrile; EI-269; MFCD00236434; s7119; AKOS024457007; AT23580; CCG-206755; IDI1_002136; NCGC00163451-01; NCGC00163451-02; NCGC00163451-03; NCGC00163451-04; AS-16804; BG168444; HY-10183; CS-0002498; FT-0697606; EC-000.2399; G   6976, >=98% (HPLC), powder; A924795; G  6976; InSolution Go 6976 - CAS 136194-77-9; Go 6976 - CAS 136194-77-9; J-006821; BRD-K59304176-001-02-5; BRD-K59304176-001-03-3; Q27077832; 3-(13-methyl-5-oxo-5,6,7,13-tetrahydro-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12-yl)propionitrile; 3-(23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.0^{2,10.0^{4,9.0^{11,15.0^{17,22]tricosa-1,4,6,8,10,15,17,19,21-nonaen-3-yl)propanenitrile; 3-(23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4,6,8,10,15,17,19,21-nonaen-3-yl)propanenitrile; 3-(9-methyl-1-oxo-2,3-dihydro-1H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-8(9H)-yl)propanenitrile; 3-{23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.0^{2,10}.0^{4,9}.0^{11,15}.0^{17,22}]tricosa-1(16),2(10),4(9),5,7,11(15),17,19,21-nonaen-3-yl}propanenitrile; 3-{23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.0^{2,10}.0^{4,9}.0^{11,15}.0^{17,22}]tricosa-1(16),2(10),4,6,8,11(15),17,19,21-nonaen-3-yl}propanenitrile"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:51913	.	.	.	378.4	2	C24H18N4O	62.8	730	3.2	29	1	2	"InChI=1S/C24H18N4O/c1-27-17-9-4-2-7-14(17)20-21-16(13-26-24(21)29)19-15-8-3-5-10-18(15)28(12-6-11-25)23(19)22(20)27/h2-5,7-10H,6,12-13H2,1H3,(H,26,29)"	CN1C2=CC=CC=C2C3=C4C(=C5C6=CC=CC=C6N(C5=C31)CCC#N)CNC4=O	VWVYILCFSYNJHF-UHFFFAOYSA-N
DG01466	JANEX-1	3794	"JANEX-1; 202475-60-3; WHI-P131; jak3 inhibitor i; Janex 1; 4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol; 4-(6,7-dimethoxyquinazolin-4-ylamino)phenol; 4-((6,7-dimethoxyquinazolin-4-yl)amino)phenol; UNII-1J8Q49TR3I; 1J8Q49TR3I; CHEMBL405130; 4-[(6,7-Dimethoxy-4-quinazolinyl)amino]phenol; 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-phenol; 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline; 4-((6,7-dimethoxy-4-quinazolinyl)amino)phenol; WHI P131; WHI-P131(Janex 1); Lopac0_001238; SCHEMBL29295; ZINC9851; WHI-P131; JANEX-1; WHI-P 131; WHI-P-131; AOB1974; BCP14722; EX-A2590; 1808AH; BDBM50227519; MFCD01862614; NSC800774; s5903; AKOS002350929; CS-1604; NSC-800774; NCGC00379000-03; AS-35320; HY-15508; QC-11660; 4-(4-hydroxyanilino)-6,7-dimethoxyquinazoline; A925799; J-013147; Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-; 4-(4'-Hydroxylphenyl)-amino-6,7-dimethoxyquinazoline hydrochloride dihydrate"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	297.31	4	C16H15N3O3	76.5	350	3	22	2	6	"InChI=1S/C16H15N3O3/c1-21-14-7-12-13(8-15(14)22-2)17-9-18-16(12)19-10-3-5-11(20)6-4-10/h3-9,20H,1-2H3,(H,17,18,19)"	COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)O)OC	HOZUXBLMYUPGPZ-UHFFFAOYSA-N
DG01467	LY-294002	3973	"154447-36-6; LY294002; LY 294002; 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; LY-294002; 2-morpholino-8-phenyl-4H-chromen-4-one; 2-morpholin-4-yl-8-phenyl-4H-chromen-4-one; UNII-31M2U1DVID; 2-morpholin-4-yl-8-phenylchromen-4-one; 2-(morpholin-4-yl)-8-phenylchromen-4-one; 15447-36-6; 2-(morpholin-4-yl)-8-phenyl-4H-chromen-4-one; NSC 697286; 31M2U1DVID; 2-MORPHOLIN-4-YL-7-PHENYL-4H-CHROMEN-4-ONE; CHEMBL98350; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-; CHEBI:65329; SF 1101; LY2; Ly 294002 HCl; LY-294,002; 2-Morpholin-4-yl-8-phenyl-chromen-4-one; BMK1-D5; Lys 294002; 4azt; 2-morpholino-8-phenyl-chromen-4-one; Kinome_3543; Tocris-1130; 1yi3; BiomolKI_000029; Lopac-L-9908; 8-Phenyl-2-(morpholin-4-yl)-chromen-4-one; BiomolKI2_000037; CBiol_002046; Lopac0_000710; SCHEMBL94377; BSPBio_001223; KBioGR_000563; KBioSS_000563; MLS006010131; 2-Morpholino-8-phenylchromone; 2-(4-morpholino)-8-phenyl-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl; GTPL6004; ZINC6014; DTXSID6042650; BCBcMAP01_000117; BDBM12915; KBio2_000563; KBio2_003131; KBio2_005699; KBio3_001005; KBio3_001006; EX-A073; SYN1108; BCPP000177; Bio1_000332; Bio1_000821; Bio1_001310; Bio2_000442; Bio2_000922; HMS1362M05; HMS1792M05; HMS1990M05; HMS3229G17; HMS3403M05; HMS3649E04; HMS3654M21; AMY40921; BCP00195; HSCI1_000206; NSC697286; NSC755769; s1105; AKOS017344742; BCP9000880; CCG-100633; CS-0150; DB02656; NSC-697286; NSC-755769; QC-7260; SB10965; SDCCGSBI-0050688.P003; SF-1101; IDI1_002197; NCGC00015622-01; NCGC00015622-02; NCGC00015622-03; NCGC00015622-04; NCGC00015622-05; NCGC00015622-06; NCGC00015622-07; NCGC00015622-23; NCGC00015622-27; NCGC00025020-01; NCGC00025020-02; NCGC00025020-03; NCGC00025020-04; NCGC00179253-01; AC-30295; AS-16252; HY-10108; NCI60_034712; SMR002530642; LY-924002; FT-0660382; M2410; SW217688-2; X7411; EC-000.2341; 2-Morpholino-8-phenyl-4-oxo-4H-1-benzopyran; K00235; J-510126; Q4042503; SR-01000076245-7; 4H-1-Benzopyran-4-one,2-(4-morpholinyl)-8-phenyl-; BRD-K27305650-001-05-9; InSolution LY 294002 - CAS 154447-36-6; LY-294,002 hydrochloride, solid, >=98% (HPLC); LY 294002 - CAS 154447-36-6; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl- (9CI); H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl- (9CI); LY 294002; 2-(4-Morpholino)-8-phenyl-4H-1-benzopyran-4-one"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	CHEBI:65329	DB02656	.	.	307.3	2	C19H17NO3	38.8	463	3.1	23	0	4	"InChI=1S/C19H17NO3/c21-17-13-18(20-9-11-22-12-10-20)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2"	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4	CZQHHVNHHHRRDU-UHFFFAOYSA-N
DG01468	PD98059	4713	"167869-21-8; PD 98059; PD98059; 2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one; PD 98,059; PD-98059; 2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 2-(2-amino-3-methoxyphenyl)chromen-4-one; 2'-AMINO-3'-METHOXYFLAVONE; PD-098059; 4H-1-Benzopyran-4-one, 2-(2-Amino-3-methoxyphenyl)-; UNII-SJE1IO5E3I; SJE1IO5E3I; CHEMBL35482; C16H13NO3; CHEBI:77954; MFCD00671789; 2-(2-Amino-3-methoxy-phenyl)-chromen-4-one; SR-01000076097; PD 098059; 2-(2-Amino-3-methoxyphenyl)-chromen-4-one; NSC 679829; Tocris-1213; PD098059; Lopac-P-215; BiomolKI_000001; 2-(2-amino-3-methoxy-phenyl)chromen-4-one; BiomolKI2_000011; PD 98,059, solid; Lopac0_001028; BMK1-B1; BSPBio_000996; KBioGR_000336; KBioSS_000336; 2-(2'-amino-3'-methoxyphenyl)oxanaphthalen-4-one; MLS006010134; SCHEMBL157826; 4H-1-Benzopyran-4-one,2-(2-amino-3-methoxyphenyl)-; GTPL5241; QCR-14; 2''-amino-3''-methoxyflavone; BCBcMAP01_000049; KBio2_000336; KBio2_002904; KBio2_005472; KBio3_000671; KBio3_000672; AOB2598; DTXSID40168416; BCPP000123; Bio1_000475; Bio1_000964; Bio1_001453; Bio2_000338; Bio2_000818; HMS1362B17; HMS1792B17; HMS1990B17; HMS3229M08; HMS3263M17; HMS3267D03; HMS3403B17; HMS3412O09; HMS3649N14; HMS3654I16; HMS3676O09; BCP02423; EX-A2127; ZINC1420826; Tox21_501028; BDBM50108771; NSC679828; s1177; AKOS015995212; BCP9001060; BP34124; CCG-100605; CS-0169; LP01028; NSC 679828; NSC-679828; SB16629; SDCCGSBI-0051000.P003; IDI1_002093; SMP2_000052; NCGC00015790-01; NCGC00015790-02; NCGC00015790-03; NCGC00015790-04; NCGC00015790-05; NCGC00015790-06; NCGC00015790-07; NCGC00015790-08; NCGC00025045-01; NCGC00025045-02; NCGC00025045-03; NCGC00025045-04; NCGC00025045-05; NCGC00179347-01; NCGC00261713-01; AC-28412; AS-19374; HY-12028; NCI60_028554; SMR001456459; EU-0101028; FT-0716482; P-215; SW218254-2; X7398; EC-000.2425; A25454; P-4313; PD 98059 & Z-100; InSolution PD 98059 - CAS 167869-21-8; J-505513; SR-01000076097-1; SR-01000076097-3; SR-01000076097-6; 2-(2-amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran; BRD-K62810658-001-05-6; BRD-K62810658-001-06-4; Q27088281; 2-(2-Amino-3-methoxy-phenyl)-chromen-4-one(PD98059); PD 98059 - CAS 167869-21-8; 4H-1-Benzopyran-4-one, 2-(2-amino-3-methoxyphenyl)- & Z-100"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:77954	.	.	.	267.28	2	C16H13NO3	61.6	407	2.9	20	1	4	"InChI=1S/C16H13NO3/c1-19-14-8-4-6-11(16(14)17)15-9-12(18)10-5-2-3-7-13(10)20-15/h2-9H,17H2,1H3"	COC1=CC=CC(=C1N)C2=CC(=O)C3=CC=CC=C3O2	QFWCYNPOPKQOKV-UHFFFAOYSA-N
DG01469	Tegafur	5386	"Tegafur; Ftorafur; 17902-23-7; Futraful; Fluorofur; Sinoflurol; Citofur; Fental; Neberk; Furofutran; Coparogin; Florafur; Fulfeel; Furafluor; Nitobanil; Exonal; Lamar; Lifril; Tefsiel C; 5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; Franroze; Furflucil; Sunfral; Riol; FT-207; Phthorafur; 1-(2-Tetrahydrofuryl)-5-fluorouracil; 5-Fluoro-1-(tetrahydro-2-furyl)uracil; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-; MJF-12264; Fluorafur; Franrose; Sunfural; Fulaid; NSC-148958; 5-FLUORO-1-(TETRAHYDRO-2-FURFURYL)URACIL; FT 207; 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione; N1-(2-tetrahydrofuryl)-5-fluorouracil; 1-(Tetrahydrofuran-2-yl)-5-fluorouracil; 5-Fluoro-1-(tetrahydrofuran-2-yl)uracil; URACIL, 5-FLUORO-1-(TETRAHYDRO-2-FURYL)-; Uracil, 1-(tetrahydrofuran-2-yl)-5-fluoro-; MFCD00012351; 5-Fluoro-1-(tetrahydro-3-furyl)uracil; 1-(Tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione; MLS000069497; CHEBI:32188; 1-(2-TETRAHYDROFORMYL)-5-FLUOROURACIL; 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione; C8H9FN2O3; 5-fluoro-1-tetrahydrofuran-2-yl-pyrimidine-2,4-dione; NCGC00159418-02; NCGC00159418-05; SMR000059106; Racemic Ftorafur; DSSTox_CID_1305; DSSTox_RID_76070; DSSTox_GSID_21305; Phthorafur [Czech]; FT-207 (NSC 148958); Tegafurum; Tegafurum [INN-Latin]; NSC 148958; CAS-37076-68-9; CCRIS 2762; FT207; EINECS 241-846-2; BRN 0525766; Atillon; N1-(2'-Tetrahydrofuryl)-5-fluorouracil; 1-(Tetrahydro-2-furanyl)-5-fluorouracil; N(sub 1)-(2-Tetrahydrofuryl)-5-fluorouracil; Tegafur [USAN:INN:BAN:JAN]; N(sub 1)-(2'-Furanidyl)-5-fluouracil [Czech]; Atillon (TN); Tegafur ,(S); N(sub 1)-(2'-Furanidyl)-5-fluouracil; TS-1 (Salt/Mix); Opera_ID_1726; UPCMLD-DP063; SCHEMBL4552; 5-24-06-00285 (Beilstein Handbook Reference); MLS000759414; MLS001076521; MLS001424119; CHEMBL20883; Tegafur (JP17/USAN/INN); F-5-FU; UPCMLD-DP063:001; GTPL10513; DTXSID001009966; HMS1665I05; HMS2051B15; HMS2090K04; HMS2232E05; HMS3371H21; HMS3393B15; HMS3654P13; HMS3715D14; N1-(2'-Furanidyl)-5-fluouracil; 2,4(1H,3H)Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-; 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione; BCP22714; 5-fluoro-1-(tetrahydrofuran-2-yl); N1-(2'-Furanidyl)-5-fluorouracil; Tox21_111649; Tox21_301812; BBL027795; CCG-50110; STK528044; Tegafur, >=98% (HPLC), powder; 5-Fluoro-1-(2-tetrahydrofuryl)uracil; AKOS000121279; Tox21_111649_1; AC-2112; CCG-100959; CS-1128; DB09256; MCULE-1366455644; NC00209; 1-(tetrahydro-2-furyl)-5-fluorouracil; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, didehydroderiv.; 5-fluoro-1-(2-tetrahydrofuranyl)uracil; N1 -(2-tetrahydrofuryl)-5-fluorouracil; NCGC00159418-04; NCGC00255222-01; 79107-97-4; 82294-77-7; AS-13528; HY-17400; I580; Tegafur (FT-207; NSC 148958); J356.722B; FT-0653732; FT-0654170; FT-0674829; FT-0693965; D01244; J10344; AB00572620-15; 902T237; A812417; Q413370; SR-01000639511; Q-201784; SR-01000639511-1; SR-01000639511-4; 5-fluoro-1-tetrahydro-furan-2-yl-1H-pyrimidine-2,4-dione; 5-Fluoro-1-tetrahydro-2-furanyl-2,4(1H,3H)-pyrimidinedione; 2, 4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, (R)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:32188	DB09256	DR1539	.	200.17	1	C8H9FN2O3	58.6	316	-0.3	14	1	4	"InChI=1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)"	C1CC(OC1)N2C=C(C(=O)NC2=O)F	WFWLQNSHRPWKFK-UHFFFAOYSA-N
DG01470	Amiloride	16231	"AMILORIDE; Amipramidin; 2609-46-3; Midamor; Guanamprazine; Amipramizid; Amipramizide; Guanamprazin; Amilorida; 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide; Amiloridum; Amyloride; Amiloridum [INN-Latin]; Amilorida [INN-Spanish]; N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide; N-Amidino-3,5-diamino-6-chlorpyrazincarboxamid; UNII-7DZO8EB0Z3; 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide; 3,5-Diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide; MK-870; Amiloride hydrochloride hydrate; CHEMBL945; Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-; 7DZO8EB0Z3; CHEBI:2639; N-amidino-3,5-diamino-6-chloro-2-pyrazinecarboxamide; 137053-86-2; NCGC00015089-08; Amiloride [INN:BAN]; AMIPRAMIDINE; DSSTox_CID_23853; DSSTox_RID_80077; DSSTox_GSID_43853; Amiclaran; C6H8ClN7O; Amiclaran (TN); Amiloride (INN); CAS-2609-46-3; CCRIS 6545; EINECS 220-024-7; AmilorideHCl; Amikal (Hydrochloride dihydrate); Midamor (Hydrochloride dihydrate); MK-870 (Hydrochloride dihydrate); Spectrum_000034; Tocris-0890; 1f5l; Prestwick0_000007; Prestwick1_000007; Prestwick2_000007; Prestwick3_000007; Spectrum2_000118; Spectrum3_000293; Spectrum4_000132; Spectrum5_000776; Lopac-A-7410; Lopac0_000111; SCHEMBL27562; BSPBio_000013; BSPBio_001572; BSPBio_001826; KBioGR_000292; KBioGR_000544; KBioSS_000292; KBioSS_000394; MLS001060798; BIDD:GT0466; DivK1c_000182; SPBio_000136; SPBio_001934; BPBio1_000015; GTPL2421; DTXSID9043853; BCBcMAP01_000101; BDBM16173; KBio1_000182; KBio2_000292; KBio2_000394; KBio2_002860; KBio2_002962; KBio2_005428; KBio2_005530; KBio3_000583; KBio3_000584; KBio3_001326; NINDS_000182; Bio1_000359; Bio1_000848; Bio1_001337; Bio2_000292; Bio2_000772; HMS1791O14; HMS1989O14; HMS2089H05; HMS2213E05; HMS3355K04; ACT05635; ACT05652; BCP16815; HY-B0285; ZINC4340269; Tox21_110080; 3,5-diamino-N-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide; BBL028157; STL373007; AKOS015961348; Tox21_110080_1; CCG-204206; DB00594; MCULE-5948863568; SB74937; SDCCGSBI-0050099.P005; IDI1_000182; IDI1_034042; NCGC00015089-01; NCGC00015089-02; NCGC00015089-03; NCGC00015089-04; NCGC00015089-05; NCGC00015089-06; NCGC00015089-07; NCGC00015089-09; NCGC00015089-11; NCGC00015089-12; NCGC00015089-13; NCGC00015089-14; NCGC00015089-15; NCGC00015089-16; NCGC00015089-17; NCGC00015089-24; NCGC00024443-02; NCGC00024443-05; NCGC00024443-06; NCGC00024443-07; NCGC00024443-09; AC-13631; LS-13128; SMR000486264; U460; (3,5-Diamino-6-chloropyrazinoyl)guanidine; SBI-0050099.P004; N-amidino-3,5-diamino-6-chloropyrazinamide; AB00053415; FT-0703177; C06821; D07447; AB00053415-24; AB00053415-25; AB00053415_26; AB00053415_27; AB00053415_28; 609A463; Q419995; J-016249; BRD-K97181089-003-02-3; BRD-K97181089-310-03-0; N-amidino 3,5-diamino-6-chloro-2-pyrazinecarboxamide; F2173-0531; N-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-guanidine; 3,5-diamino-N-carbamimidoyl-6-chloro-pyrazine-2-carboxamide; 3,5-diamino-6-chloro-N-(diaminomethylene)pyrazinamide;hydrochloride"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:2639	DB00594	.	DR00207	229.63	1	C6H8ClN7O	159	279	-0.7	15	4	5	"InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15)"	C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N	XSDQTOBWRPYKKA-UHFFFAOYSA-N
DG01471	Idarubicin	42890	"IDARUBICIN; 58957-92-9; 4-Demethoxydaunorubicin; 4-Demethoxydaunomycin; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Idarubicina [INN-Spanish]; UNII-ZRP63D75JW; NSC 256439; NSC-256439; ZRP63D75JW; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; Idarubicina; CHEBI:42068; (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; 5,12-Naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S-cis)-; Idarubicine; Idarubicinum; Idarubicin [INN:BAN]; Idarubicinhydrochloride; DM5; MLS001401448; Daunomycin, 4-demethoxy-; NSC256439; (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,9,11-trihydroxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione; Idarubicin (INN); Zavedos (TN); CCRIS 5083; NCGC00093976-03; SMR000466355; 4-DMD; SR-01000075934; I 1656; SCHEMBL3750; CHEMBL1117; Lopac0_000600; KBioSS_002388; Idarubicin hydrochloride, solid; cid_636362; GTPL7083; 4-DEMETHOXY-DAUNORUBICIN; DTXSID7023142; IDARUBICIN(Hydrochloride form); BDBM58490; BCPP000207; HMS2089D05; HMS3261H22; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; ZINC3920266; Tox21_500600; AKOS015895563; AC-9384; BCP9000773; CCG-204689; DB01177; LP00600; SDCCGSBI-0050582.P002; NCGC00093976-01; NCGC00093976-02; NCGC00093976-04; NCGC00093976-05; NCGC00093976-18; NCGC00261285-01; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-6,9,11-trihydroxy-, (7S-cis)-; EU-0100600; D08062; AB00698511-06; AB00698511-08; AB00698511-09; AB00698511-10; AB00698511_11; 957I929; A832088; A935911; Q1063862; SR-01000075934-1; BRD-K69650333-001-01-1; BRD-K69650333-001-02-9; BRD-K69650333-003-14-0; Idarubicin, United States Pharmacopeia (USP) Reference Standard; (7S,9S)-7-[(2R,4S,5S,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-9-ethanoyl-6,9,11-tris(oxidanyl)-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5S,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-9-ethanoyl-6,9,11-tris(oxidanyl)-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (7S,9S)-9-Acetyl-7-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione; (7S,9S)-9-acetyl-7-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-quinone;hydrochloride; (7S,9S)-9-acetyl-7-[[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; 4-Demethoxydaunorubicin; ; ; IMI-30; ; ; NSC-256439; ; ; (7S,9S)-9-Acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-9-acetyl-7-((3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy)-6,9,11-trihydroxy-, (7S-cis)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:42068	DB01177	DR0852	DR00386	497.5	3	C26H27NO9	177	912	1.9	36	5	10	"InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1"	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O	XDXDZDZNSLXDNA-TZNDIEGXSA-N
DG01472	Staurosporine	44259	"Staurosporine; Staurosporin; 62996-74-1; (+)-Staurosporine; Antibiotic 230; Antibiotic AM 2282; AM-2282; CCRIS 3272; Antibiotic AM-2282; UNII-H88EPA0A3N; Alkaloid AM-2282 from Streptomyces; H88EPA0A3N; CHEMBL388978; CHEBI:15738; 8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-1-one, 2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-10-(methylamino)-, (8alpha,9beta,10beta,12alpha)-(+)-; (5S,6R,7R,9R)-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5H,14H-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-14-one; (5S,6R,7R,9R)-6-methoxy-5-methyl-7-methylamino-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one; GNF-PF-1389; methoxy-methyl-(methylamino)[ ]one; SR-00000001485; Staurosporin, 4; 1nvr; 1stc; 1xbc; 1xjd; 1yhs; 2gcd; Staurosporine, 8; CGP 39360; Staurosporine & TNF; 1q3d; 1sm2; 2dq7; MolMap_000047; SCHEMBL8157; CBiol_001978; BSPBio_001146; GTPL346; BDBM2579; MEGxm0_000307; DTXSID6041131; 1u59; BCPP000063; Bio1_000264; Bio1_000753; Bio1_001242; HMS1990J07; HMS3650B17; EX-A1777; ZINC3814434; AM2282; NSC755774; s1421; AKOS015897119; AM 2282; CCG-208052; DB02010; NSC-755774; QTL1_000078; NCGC00162400-01; NCGC00162400-02; NCGC00162400-03; NCGC00162400-04; NCGC00162400-05; NCGC00162400-06; NCGC00162400-09; 9,13-Epoxy-1H,9H-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)-benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, (9S-(9alpha,10beta,11beta,13alpha)-; HY-15141; Staurosporine & Tumor necrosis factor (TNF); Staurosporine 100 microg/mL in Acetonitrile; Q5957181; SR-00000001485-4; BRD-K17953061-001-02-8; BRD-K17953061-001-04-4; BRD-K17953061-001-05-1; BRD-K17953061-001-08-5; BRD-K17953061-001-10-1; BRD-K17953061-001-11-9; (2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14(28),15(19),20(27),21(26),22,24-nonaen-16-one; (2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8,10,12,14(28),15(19),20(27),21,23,25-nonaen-16-one; (2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one; (5S,6R,7R,9R)-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one; [9S-(9 ,10 ,11 ,13 )]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; 109189-95-9; 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, (9S,10R,11R,13R)- & Tumor necrosis factor (TNF); 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, (9S,10R,11R,13R)- (9CI); 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, [9S-(9alpha,10beta,11beta,13alpha)]-"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:15738	DB02010	.	DR00790	466.5	2	C28H26N4O3	69.4	901	3.2	35	2	4	"InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1"	C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)NC)OC	HKSZLNNOFSGOKW-FYTWVXJKSA-N
DG01473	3-Deazaneplanocin	73087	"3-Deazaneplanocin; 3-Deazaneplanocin A; 102052-95-9; (1s,2r,5r)-5-(4-amino-1h-imidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol; 3-Deazaneplanocin,DZNep; 3-Deazaneplanocin-A; UNII-544SH4020S; DZNep; (1S,2R,5R)-5-(4-aminoimidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol; CHEMBL154745; 544SH4020S; 3-Deaza-neplanocin; c^Neplanocin A; 3-Deazaneplanocin A (DZNep) hydrochloride; 3-Deazaneplanocin A (DZNep; SCHEMBL863851; SCHEMBL12280736; DTXSID30144562; InSolution EZH2 Inhibitor, DZNep; AVS-4275; CEA05295; 3238AH; BDBM50096906; ZINC21290121; AKOS005146283; CS-0357; AC-27393; HY-10442; BRD-K77791657-001-01-1; Q15410156; (-)-1-[(1R,4R,5S)-3-(Hydroxymethyl)-4,5-dihydroxy-2-cyclopenten-1-yl]4-aminoimidazo[4,5-c]pyridine; 3-Cyclopentene-1,2-diol, 5-(4-amino-1H-imidazo(4,5-c)pyridiny-1-yl)-3-(hydroxymethyl)-, (1S-(alpha,2alpha,5beta))-"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	262.26	2	C12H14N4O3	117	378	-1.7	19	4	6	"InChI=1S/C12H14N4O3/c13-12-9-7(1-2-14-12)16(5-15-9)8-3-6(4-17)10(18)11(8)19/h1-3,5,8,10-11,17-19H,4H2,(H2,13,14)/t8-,10-,11+/m1/s1"	C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N	OMKHWTRUYNAGFG-IEBDPFPHSA-N
DG01474	Perifosine	148177	"Perifosine; 157716-52-4; KRX-0401; 1,1-Dimethylpiperidin-1-ium-4-yl octadecyl phosphate; (1,1-dimethylpiperidin-1-ium-4-yl) octadecyl phosphate; Perifosine (KRX-0401); NSC 639966; D 21266; 1,1-dimethylpiperidinium-4-yl octadecyl phosphate; UNII-2GWV496552; KRX 0401; NSC639966; D-21266; NSC-639966; CHEBI:67272; 2GWV496552; NCGC00187909-01; Piperidinium, 4-[[hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethyl-, inner salt; 1,1-dimethylpiperidin-1-ium-4-yl octadecyl phosphate.; Piperidinium, 4-((hydroxy(octadecyloxy)phosphinyl)oxy)-1,1-dimethyl-, inner salt; Perifosine [INN]; NKA17; C25H52NO4P; octadecyl-(1,1-dimethyl-4-piperidylio)phosphate; 4-((Hydroxy(octadecyloxy)phosphinyl)oxy)-1,1-dimethylpiperidinium inner salt; DSSTox_CID_28872; DSSTox_RID_83141; DSSTox_GSID_48946; SCHEMBL93872; CHEMBL372764; GTPL7424; DTXSID3048946; AOB3006; QCR-270; BCP00245; EX-A2229; YHI-1003; Tox21_113365; BDBM50431630; MFCD00927554; NSC800842; s1037; Piperidinium,1-dimethyl-, inner salt; AKOS005146344; CCG-269358; CS-0209; DB06641; EX-3388; GS-3834; NSC-800842; NCGC00187909-02; NCGC00187909-13; AC-25019; AM808092; HY-50909; CAS-157716-52-4; FT-0651459; W3423; A23834; D21266; Octadecyl-(1,1-dimethyl-4-piperidylio) phosphate; J-500086; Q3411917; Perifosine; KRX-0401; NSC 639966; D21266; 4-Hydroxy-1,1-dimethylpiperidinium hydroxide, octadecyl hydrogen phosphate, inner salt"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	CHEBI:67272	DB06641	.	.	461.7	20	C25H52NO4P	58.6	454	8.3	31	0	4	"InChI=1S/C25H52NO4P/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-24-29-31(27,28)30-25-20-22-26(2,3)23-21-25/h25H,4-24H2,1-3H3"	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C	SZFPYBIJACMNJV-UHFFFAOYSA-N
DG01475	Lonafarnib	148195	"Lonafarnib; 193275-84-2; Sarasar; Sch66336; Sch 66336; Sch-66336; UNII-IOW153004F; CHEMBL298734; IOW153004F; (R)-4-(2-(4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl)-2-oxoethyl)piperidine-1-carboxamide; 1-PIPERIDINECARBOXAMIDE, 4-[2-[4-[(11R)-3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDIN-11-YL]-1-PIPERIDINYL]-2-OXOETHYL]-; 4-[2-[4-(6,15-Dibromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl)piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamide; 4-[2-[4-[(2R)-6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl]piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamide; Zokinvy; 1-Piperidinecarboxamide, 4-(2-(4-((11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-; 4-(2-{4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]piperidin-1-yl}-2-oxoethyl)piperidine-1-carboxamide; SMR004701448; Lonafarnib (USAN/INN); Lonafarnib [USAN:INN]; C27H31Br2ClN4O2; Lonafarnib (SCH66336); lonafarnibum; 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide; SCH-066336; 4-[2-[4-[(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide; 1o5m; (non-labelled)Lonafarnib-d9; SCHEMBL19032; Sarasar; ; ; SCH 66336; (+)-4-(2-(4-(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-piperidin-1-yl))-2-oxoethyl)-piperidine-1-carboxamide; MLS006010423; MLS006011106; GTPL8024; Lonafarnib, >=98% (HPLC); BDBM14459; CHEBI:47097; DTXSID90172927; BCP07027; EX-A1630; ZINC3950115; NSC719467; s2797; AKOS005145760; CCG-270312; CS-0792; DB06448; NSC-719467; NCGC00346707-01; 1-Piperidinecarboxamide, 4-(2-(4-((11R-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-; AC-32661; AS-56182; HY-15136; SW220034-1; Y0240; C73675; D04768; J-514232; Q3258910; (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidin-yl]-2-oxo-ethyl]-1-piperidinecarboxamide; (+)-4[2-[4-(8-Chloro-3,11-dihydro-5H-benzo[5,6] cyclohepta[1,2-b]-pyridin-11(R)-yl-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide; 4-(2-{4-[(2R)-6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-2-yl]piperidin-1-yl}-2-oxoethyl)piperidine-1-carboxamide; 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[1,2]cyclohepta[2,4-b]pyridin-11-yl]piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamide; 4-[2-[4-[(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5h-Benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-Piperidinyl]-2-oxoethyl]-1-Piperidi necarboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:47097	DB06448	DR1861	.	638.8	3	C27H31Br2ClN4O2	79.5	790	4.8	36	1	3	"InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1"	C1CN(CCC1CC(=O)N2CCC(CC2)[C@@H]3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N	DHMTURDWPRKSOA-RUZDIDTESA-N
DG01476	Cryptotanshinone	160254	"Cryptotanshinone; 35825-57-1; Tanshinone c; Cryptotanshinon; (R)-1,2,6,7,8,9-Hexahydro-1,6,6-trimethyl-phenanthro(1,2-b)furan-10,11-dione; UNII-5E9SXT166N; C19H20O3; (1R)-1,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[1,2-g][1]benzofuran-10,11-dione; (R)-1,6,6-trimethyl-1,2,6,7,8,9-hexahydrophenanthro[1,2-b]furan-10,11-dione; MLS001049002; 5E9SXT166N; MFCD07636810; SMR000387041; 4733-35-1; 1,2,6,7,8,9-Hexahydro-1,6,6-trimethyl[1,2-b]furan-10,11-dione; (-)-Cryptotanshinone; (1R)-1,6,6-trimethyl-2,3a,7,8,9,11a-hexahydro-1H-naphtho[1,2-g]benzofuran-10,11-dione; SR-01000758222; NSC686518; starbld0002638; SPECTRUM1505812; CHEMBL187460; cid_160254; SCHEMBL5940386; BDBM57938; CHEBI:149838; Phenanthro(1,2-b)furan-10,11-dione, 1,2,6,7,8,9-hexahydro-1,6,6-trimethyl-, (R)-; HMS2269A22; BCP02909; Cryptotanshinone, >=90% (HPLC); Cryptotanshinone, >=98% (HPLC); HY-N0174; ZINC2109876; Cryptotanshinone, analytical standard; s2285; AKOS015895392; BCP9000554; CCG-208561; CS-3276; DB15579; MCULE-9919031730; NSC-686518; NCGC00163650-01; NCGC00163650-02; BS-17094; NCI60_031208; BCP0726000307; N1843; W2147; 825C571; A822990; Q-100429; SR-01000758222-3; SR-01000758222-4; BRD-K33336844-001-05-3; Q27261913; Phenanthro[1,11-dione, 1,2,6,7,8,9-hexahydro-1,6,6-trimethyl-, (1R)-; (1R)-1,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[1,2-g]benzofuran-10,11-dione; (1R)-1,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[1,2-g]benzofuran-10,11-quinone; (R)-(-)-1,6,6-Trimethyl-1,2,6,7,8,9-hexahydrophenanthro[1,2-b]furan-10,11-dione; (R)-1,2,6,7,8,9-Hexahydro-1,6,6-trimethylphenanthro[1,2-b]furan-10,11-dione; 1,2,6,7,8,9-hexahydro-1,6,6-trimethyl- (R)-phenanthro(1,2-b)furan-10,11-dione; Phenanthro[1,2-b]furan-10,11-dione,1,2,6,7,8,9-hexahydro-1,6,6-trimethyl-, (R)-"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	DB15579	.	.	296.4	0	C19H20O3	43.4	571	3.8	22	0	3	"InChI=1S/C19H20O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,10H,4-5,8-9H2,1-3H3/t10-/m0/s1"	C[C@H]1COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C	GVKKJJOMQCNPGB-JTQLQIEISA-N
DG01477	Seliciclib	160355	"Roscovitine; Seliciclib; 186692-46-6; R-Roscovitine; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; Seliciclib (Roscovitine); Roscovitine (Seliciclib,CYC202); UNII-0ES1C2KQ94; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; NSC-701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; MFCD02266401; NSC701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (2R)-2-{[6-(benzylamino)-9-(propan-2-yl)-9H-purin-2-yl]amino}butan-1-ol; RRC; C19H26N6O; Rosco; (2R)-2-{[6-(benzylamino)-9-(1-methylethyl)-9H-purin-2-yl]amino}butan-1-ol; (2R)-2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; Seliciclib [INN]; NSC 701554; 2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; BMK1-E12; 1unl; 3ddq; (2R)-2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-1-butanol; 2a4l; BiomolKI_000048; 1-Butanol, (2R)-; ROSCOVITINE(Seliciclib); BiomolKI2_000054; M02443; CBiol_002016; Lopac0_001102; SCHEMBL94728; BSPBio_001078; KBioGR_000418; KBioSS_000418; MLS006011028; BDBM7533; cid_160355; GTPL6035; Roscovitine, >=98% (TLC); BCBcMAP01_000013; KBio2_000418; KBio2_002986; KBio2_005554; KBio3_000795; KBio3_000796; AOB2095; DTXSID20171928; EX-A052; BCPP000087; Bio1_000302; Bio1_000791; Bio1_001280; Bio2_000379; Bio2_000859; CC205; HMS1362F19; HMS1792F19; HMS1990F19; HMS3229N13; HMS3403F19; AMY10845; BCP01760; Roscovitine (Seliciclib, CYC202); ZINC1649340; HSCI1_000092; NSC800881; s1153; (2R)-2-((6-benzylamino-9-(propan-2-yl)-9h-purin-2-yl)amino)butan-1-ol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine; AKOS005146319; AC-2416; CCG-100652; DB06195; NSC-800881; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; IDI1_002134; Roscovitine - CAS 186692-46-6; SMP1_000266; 2,6,9-Trisubstituted purine deriv. 28; NCGC00094374-01; NCGC00094374-02; NCGC00094374-03; NCGC00094374-04; NCGC00094374-05; NCGC00094374-13; NCGC00094374-15; AS-56277; HY-30237; NCI60_036420; SMR004702823; SW220195-1; X7381; K00020; 692R466; A813074; J-011999; J-524224; Q3494619; BRD-K07691486-001-03-1; BRD-K07691486-001-05-6; UNII-AIR55KO85E component BTIHMVBBUGXLCJ-OAHLLOKOSA-N; (2R)-2-[[6-(benzylamino)-9-propan-2-yl-purin-2-yl]amino]butan-1-ol; (2R)-2-[[6-[(phenylmethyl)amino]-9-propan-2-yl-2-purinyl]amino]-1-butanol; (2R)-2-[[6-[(phenylmethyl)amino]-9-propan-2-yl-purin-2-yl]amino]butan-1-ol; (R)-2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-1-butanol; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-, (2R)-; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-, (R)-; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]- 9H-purin-2-yl]amino]-(R)-1-butanol; Seliciclib; ; ; CYC-202; ; ; (2R)-2-[[6-(Benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:45307	DB06195	DR1858	DR01494	354.4	8	C19H26N6O	87.9	417	3.2	26	3	6	"InChI=1S/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1"	CC[C@H](CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=CC=C3	BTIHMVBBUGXLCJ-OAHLLOKOSA-N
DG01478	Enzastaurin	176167	"Enzastaurin; 170364-57-5; Enzastaurin (LY317615); LY317615; 3-(1-Methyl-1H-indol-3-yl)-4-(1-(1-(pyridin-2-ylmethyl)piperidin-4-yl)-1H-indol-3-yl)-1H-pyrrole-2,5-dione; LY-317615; UNII-UC96G28EQF; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione; UC96G28EQF; LY 317615; CHEMBL300138; DB102; DSSTox_CID_24029; DSSTox_RID_80101; DSSTox_GSID_44029; 3-(1-Methyl-1H-indol-3-yl)-4-(1-(1-(pyridin-2-ylmethyl)-piperidin-4-yl)-1H-indol-3-yl)-1H-pyrrole-2,5-dione; C32H29N5O2; 3-(1-Methyl-1H-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; CAS-170364-57-5; 3-(1-Methyl-1H-indol-3-yl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-1H-indol-3-yl]-1H-pyrrole-2,5-dione; LE-0014; Enzastaurin [USAN:INN]; Enzastaurin,LY317615; Enzastaurin; LY317615; LY317615 - Enzastaurin; SCHEMBL678748; GTPL5693; DTXSID5044029; CHEBI:91368; AMY7827; BCPP000241; HMS3265M05; HMS3265M06; HMS3265N05; HMS3265N06; HMS3654A13; HMS3748E03; BCP02703; EX-A1055; WHO 8426; ZINC1494900; Tox21_113367; BDBM50128285; DB-102; MFCD11040980; NSC767124; NSC800096; s1055; AKOS015994764; Tox21_113367_1; AC-5900; BCP9000648; CCG-264797; CS-0132; DB06486; NSC-767124; NSC-800096; SB16481; NCGC00238452-01; NCGC00238452-02; NCGC00238452-03; NCGC00238452-11; HY-10342; DB-064781; FT-0667873; SW219797-1; W3715; EC-000.2315; 364E575; J-510442; Q5381479; BRD-K79404599-001-01-0; 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1H-indol-3-yl)-; 3-(1-Methyl-1H-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1H-indol-3-yl)-1H-pyrrole-2,5-; 3-(1-Methyl-1H-indol-3-yl)-4-[1-(1-pyridin-2-ylmethyl-piperidin-4-yl)-1H-indol-3-yl]-pyrrole-2,5-dione; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-2,5-dihydro-1H-pyrrole-2,5-dione"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:91368	DB06486	DR1898	.	515.6	5	C32H29N5O2	72.2	974	3.7	39	1	4	"InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)"	CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7	AXRCEOKUDYDWLF-UHFFFAOYSA-N
DG01479	NSC348884	335974	"NSC348884; 81624-55-7; NSC 348884; NSC-348884; N,N,N',N'-tetrakis[(6-methyl-1H-benzimidazol-2-yl)methyl]ethane-1,2-diamine; NSC348884 hydrate; CHEMBL4584341; SCHEMBL12126212; DTXSID90319638; BCP09001; EX-A2342; s8149; ZINC77029766; BCP9000996; CCG-270304; CS-5564; LP01178; SDCCGSBI-0633803.P001; NSC 348884; AC-32976; BS-17560; HY-13915; C76613; N,N',N'-tetrakis[(6-methyl-1H-benzimidazol-2-yl)methyl]ethane-1,2-diamine; N,N,N',N'-Tetrakis-(5-methyl-1H-benzoimidazol-2-ylmethyl)-ethane-1,2-diamine; N1,N1,N2,N2-Tetrakis((6-methyl-1H-benzo[d]imidazol-2-yl)methyl)ethane-1,2-diamine; (2-{bis[(6-methyl-1H-1,3-benzodiazol-2-yl)methyl]amino}ethyl)bis[(6-methyl-1H-1,3-benzodiazol-2-yl)methyl]amine"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	636.8	11	C38H40N10	121	891	6.1	48	4	6	"InChI=1S/C38H40N10/c1-23-5-9-27-31(15-23)43-35(39-27)19-47(20-36-40-28-10-6-24(2)16-32(28)44-36)13-14-48(21-37-41-29-11-7-25(3)17-33(29)45-37)22-38-42-30-12-8-26(4)18-34(30)46-38/h5-12,15-18H,13-14,19-22H2,1-4H3,(H,39,43)(H,40,44)(H,41,45)(H,42,46)"	CC1=CC2=C(C=C1)N=C(N2)CN(CCN(CC3=NC4=C(N3)C=C(C=C4)C)CC5=NC6=C(N5)C=C(C=C6)C)CC7=NC8=C(N7)C=C(C=C8)C	KZOLQEUQAFTQFM-UHFFFAOYSA-N
DG01480	JW67	644733	"JW 67; 442644-28-2; JW67; CHEMBL1459534; SMR000013289; Trispiro[3H-indole-3,2'-[1,3]dioxane-5',5''-[1,3]dioxane-2'',3'''-[3H]indole]-2,2'''(1H,1'''H)-dione (9CI); trispiro[indole-3,2'-[1,3]dioxane-5',5''-[1,3]dioxane-2'',3'''-indole]-2,2'''(1H,1'''H)-dione; ChemDiv1_018326; Oprea1_749592; MLS000076453; MLS001385179; SCHEMBL21843254; HMS639A22; HMS2324F10; HMS3429N11; JW-67; ZINC4126706; BDBM50380615; STK056247; AKOS000550561; CID 644733; JW67, >=98% (HPLC); HY-108442; CS-0028671; SR-01000537125; SR-01000537125-1; Trispiro[3H-indole-3,2'-[1,3]dioxane-2'',3'''-[3H]indole]-2,2'''(1H,1'''H)-dione"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	394.4	0	C21H18N2O6	95.1	647	0.5	29	2	6	"InChI=1S/C21H18N2O6/c24-17-20(13-5-1-3-7-15(13)22-17)26-9-19(10-27-20)11-28-21(29-12-19)14-6-2-4-8-16(14)23-18(21)25/h1-8H,9-12H2,(H,22,24)(H,23,25)"	C1C2(COC3(O1)C4=CC=CC=C4NC3=O)COC5(C6=CC=CC=C6NC5=O)OC2	BTXRSHKJNDFHGA-UHFFFAOYSA-N
DG01481	TASIN-1	1329829	"TASIN-1; 792927-06-1; 1'-((4-methoxyphenyl)sulfonyl)-4-methyl-1,4'-bipiperidine; 1-[1-(4-methoxyphenyl)sulfonylpiperidin-4-yl]-4-methylpiperidine; 1'-[(4-methoxyphenyl)sulfonyl]-4-methyl-1,4'-bipiperidine; CHEMBL4514756; SCHEMBL17007497; ZINC4744379; NSC766210; STK193520; AKOS003649063; HY-116572A; MCULE-6685404683; NSC-766210; AT-057/43468793; 1-[(4-methoxyphenyl)sulfonyl]-4'-methyl-4,1'-bipiperidine"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	352.5	4	C18H28N2O3S	58.2	481	2.9	24	0	5	"InChI=1S/C18H28N2O3S/c1-15-7-11-19(12-8-15)16-9-13-20(14-10-16)24(21,22)18-5-3-17(23-2)4-6-18/h3-6,15-16H,7-14H2,1-2H3"	CC1CCN(CC1)C2CCN(CC2)S(=O)(=O)C3=CC=C(C=C3)OC	XCBHYDPDIJQQGM-UHFFFAOYSA-N
DG01482	NAV-2729	2257249	"NAV-2729; 419547-11-8; 2-benzyl-3-(4-chlorophenyl)-5-(4-nitrophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one; CHEMBL3716578; NAV 2729; 2-benzyl-3-(4-chlorophenyl)-5-(4-nitrophenyl)-1H-pyrazolo[1,5-a]pyrimidin-7-one; 3-(4-Chlorophenyl)-5-(4-nitrophenyl)-2-(phenylmethyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one; NAV-2729Grassofermata; Oprea1_305395; SCHEMBL13516218; NAV2729; CHEBI:132811; AMY23749; EX-A2011; BDBM50168142; AKOS030211129; ZINC106616565; BS-16805; HY-112473; CS-0046101; D80454; 2-benzyl-3-(4-chlorophenyl)-5-(4-nitrophenyl)-4H-pyrazolo[1,5-a]pyrimidin-7-one"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	456.9	4	C25H17ClN4O3	90.5	871	5.3	33	1	5	"InChI=1S/C25H17ClN4O3/c26-19-10-6-18(7-11-19)24-22(14-16-4-2-1-3-5-16)28-29-23(31)15-21(27-25(24)29)17-8-12-20(13-9-17)30(32)33/h1-13,15,28H,14H2"	C1=CC=C(C=C1)CC2=C(C3=NC(=CC(=O)N3N2)C4=CC=C(C=C4)[N+](=O)[O-])C5=CC=C(C=C5)Cl	WHYGBVWGARJOCS-UHFFFAOYSA-N
DG01483	U0126	3006531	"U0126; 109511-58-2; U-0126; 1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene; U 0126; UNII-8027P94HLL; CHEBI:64208; (2Z,3Z)-2,3-bis(amino((2-aminophenyl)thio)methylene)succinonitrile; 8027P94HLL; C18H16N6S2; (2Z,3Z)-bis{amino[(2-aminophenyl)sulfanyl]methylidene}butanedinitrile; 109511-58-2 (free); 218601-62-8; FT-1069-1; (2z)-Bis{amino[(2-Aminophenyl)sulfanyl]methylidene}butanedinitrile; (2Z,3Z)-bis{amino[(2-aminophenyl)sulfanyl]methylene}succinonitrile; 1,4-Diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene; (2Z,3Z)-2,3-bis[amino-(2-aminophenyl)sulfanylmethylidene]butanedinitrile; UO-126; BiomolKI_000002; BiomolKI2_000012; BMK1-B2; BSPBio_001224; CHEMBL34704; GTPL5282; Succinonitrile, bis(amino(o-aminophenylthio)methylene)-; CHEBI:90693; CHEBI:91463; Butanedinitrile, bis(amino((2-aminophenyl)thio)methylene)-; DTXSID10892034; HMS1362N05; HMS1792N05; HMS1990N05; HMS3403N05; HMS3414K05; HMS3678K05; AMY31125; BCP01851; EX-A1754; HY-12031A; (2Z,3Z)-2,3-bis[amino-(2-aminophenyl)sulfanyl-methylene]butanedinitrile; (2Z,3Z)-bis({amino[(2-aminophenyl)sulfanyl]methylidene})butanedinitrile; AKOS024456414; ZINC100007148; CCG-100606; LS40194; IDI1_002207; SMP2_000197; NCGC00025029-02; NCGC00025029-03; NCGC00025029-04; CS-0003351; U 126; V2422; A846574; A906530; SR-01000597365; J-002297; Q7863562; SR-01000597365-1; BRD-K18787491-001-04-5; BRD-K46419649-001-01-8; 2,3-Bis(amino((2-aminophenyl)thio)methylene)succinonitrile; Butanedinitrile,2,3-bis[amino[(2-aminophenyl)thio]methylene]-; (2Z,3Z)-2,3-Bis[amino[(2-aminophenyl)thio]methylene]butanedinitrile; Butanedinitrile, bis(amino((2-aminophenyl)thio)methylene)-, (2Z,3Z)-; 5BM"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:64208	.	.	.	380.5	5	C18H16N6S2	202	610	2	26	4	8	"InChI=1S/C18H16N6S2/c19-9-11(17(23)25-15-7-3-1-5-13(15)21)12(10-20)18(24)26-16-8-4-2-6-14(16)22/h1-8H,21-24H2/b17-11+,18-12+"	C1=CC=C(C(=C1)N)S/C(=C(/C(=C(/SC2=CC=CC=C2N)\\N)/C#N)\\C#N)/N	DVEXZJFMOKTQEZ-JYFOCSDGSA-N
DG01484	Amrubicin	3035016	"Amrubicin; 110267-81-7; UNII-93N13LB4Z2; C25H25NO9; 93N13LB4Z2; (+-)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione; (7S,9S)-9-acetyl-9-amino-7-(((2S,4S,5R)-4,5-dihydroxytetrahydro-2H-pyran-2-yl)oxy)-6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione; Amrubicin [USAN:INN]; amrubicina; amrubicine; amrubicinum; Amrubicin Api; (7S,9S)-9-acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-9-amino-7-{[(2S,4S,5R)-4,5-dihydroxytetrahydro-2H-pyran-2-yl]oxy}-6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione; Amrubicin (USAN/INN); Amrubicin(SM-5887); SCHEMBL9140; CHEMBL1186894; EX-A161; CHEBI:135779; HY-B0067; ZINC3780800; 3441AH; DB06263; LS41109; AC-31129; D08854; W-60403; Q4748723; W-200813; (1S,3S)-3-acetyl-3-amino-5,12-dihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 2-deoxy-beta-D-erythro-pentopyranoside; 5,12-Naphthacenedione, 9-acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-, (7S,9S)-"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:135779	DB06263	.	.	483.5	3	C25H25NO9	177	881	0.9	35	5	10	"InChI=1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3/t14-,15+,16-,17-,25-/m0/s1"	CC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=CC=CC=C4C3=O)O)O[C@H]5C[C@@H]([C@@H](CO5)O)O)N	VJZITPJGSQKZMX-XDPRQOKASA-N
DG01485	K252a	3035817	"K-252a; Antibiotic K 252a; 99533-80-9; Antibiotic SF 2370; K252a; SF 2370; UNII-IV7H45AM5B; IV7H45AM5B; CHEMBL281948; CHEBI:43616; SF-2370; K 252a; methyl (5S,6R,8R)-6-hydroxy-5-methyl-13-oxo-5,6,7,8,14,15-hexahydro-13H-16-oxa-4b,8a,14-triaza-5,8-methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacene-6-carboxylate; methyl (5S,6R,8R)-6-hydroxy-5-methyl-13-oxo-5,6,7,8,14,15-hexahydro-13H-5,8-epoxy-4b,8a,14-triazadibenzo[b,h]cycloocta[1,2,3,4-jkl]cyclopenta[e]-as-indacene-6-carboxylate; (+)-Antibiotic K 252a; (+)-K-252A; 1r0p; SCHEMBL968886; BDBM6760; DTXSID40880065; K-252a, from Nocardiopsis sp.; 3f69; (+)-k252a; HY-N6732; ZINC3872984; MFCD00161522; NSC800777; SF2370; AKOS024456746; DB02152; NSC-800777; CS-0014825; Q5931064; K-252a, from Nocardiopsis sp., >=96.0% (HPLC); K-252a, from Nonomuraea longicatena, >=98% (HPLC); K-252a, Ready Made Solution, from Nonomuraea longicatena, >98%; (9S,10R,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester; 9,1-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9-alpha,10-beta,12-alpha)-; 9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9alpha,10beta,12alpha)-; methyl (15S,16R,18R)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-16-carboxylate"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:43616	.	.	.	467.5	2	C27H21N3O5	94.7	977	2.8	35	2	5	"InChI=1S/C27H21N3O5/c1-26-27(33,25(32)34-2)11-18(35-26)29-16-9-5-3-7-13(16)20-21-15(12-28-24(21)31)19-14-8-4-6-10-17(14)30(26)23(19)22(20)29/h3-10,18,33H,11-12H2,1-2H3,(H,28,31)/t18-,26+,27+/m1/s1"	C[C@@]12[C@](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(C(=O)OC)O	KOZFSFOOLUUIGY-SOLYNIJKSA-N
DG01486	Tandutinib	3038522	"Tandutinib; 387867-13-2; MLN-518; MLN518; CT53518; Tandutinib (MLN518); MLN 518; CT 53518; 4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide; UNII-E1IO3ICJ9A; CT-53518; N-(4-isopropoxyphenyl)-4-(6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-yl)piperazine-1-carboxamide; E1IO3ICJ9A; CHEMBL124660; CHEBI:90237; MLN-0518; MFCD09954147; NSC726292; NSC-759851; NCGC00241097-01; D06005; DSSTox_CID_28873; DSSTox_RID_83142; DSSTox_GSID_48947; 4-{6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl}-N-[4-(propan-2-yloxy)phenyl]piperazine-1-carboxamide; CAS-387867-13-2; Tandutinib [USAN:INN]; tandutinibum; Kinome_3320; MLN518, Tandutinib; Tandutinib(MLN518); Tandutinib - MLN518; Tandutinib (USAN/INN); Tandutinib(CT 53518); MLS006010972; SCHEMBL927974; DTXSID8048947; BDBM13535; cid_3038522; AOB5045; SYN1088; TANDUTINIB (CT53518); BCPP000051; HMS3244A21; HMS3244A22; HMS3244B21; HMS3264G08; HMS3654O09; HMS3745A09; Pharmakon1600-01502277; AMY32698; BCP01370; EX-A1637; ZINC3966243; Tox21_113366; NSC759851; NSC760841; NSC800942; s1043; AKOS015902621; Tox21_113366_1; AC-1659; CCG-213017; CS-0128; DB05465; ES-0051; NSC 759851; NSC-726292; NSC-760841; NSC-800942; SB19380; NCGC00241097-02; NCGC00241097-03; NCGC00241097-07; HY-10202; SMR004702776; B1526; FT-0653217; SW218125-2; EC-000.2262; Tandutinib pound MLN518, CT53518 pound(c); AB01562955_01; 867T132; A824282; Q-201778; BRD-K89162000-001-01-5; Q27095683; MLN518;CT53518;MLN 518;CT 53518;MLN-518;CT-53518; 1-Piperazinecarboxamide, 4-(6-methoxy-7-(3-(1-piperidinyl)propoxy)-4-quinazolinyl)-N-(4-(1-methylethoxy)phenyl)-; 1227636-17-0; 4-(6-Methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-yl)-N-(4-(1-methylethoxy)phenyl)piperazine-1-carboxamide; 4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-[4-(1-methylethoxy)phenyl]piperazine-1-carboxamide; 4-[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-(4-propan-2-yloxyphenyl)-1-piperazinecarboxamide; 4-[6-Methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-methylethoxy)phenyl]-1-piperazinecarboxamide; 4-[7-(3-Piperidin-1-yl-propoxy)-quinazolin-4-yl]-piperazine-1-carboxylic acid (4-isopropoxy-phenyl)-amide; N-(4-isopropoxyphenyl)-4-[6-methoxy-7-(3-piperidinopropoxy)quinazolin-4-yl]piperazine-1-carboxamide"	Discontinued in Phase 2	12	Discontinued Drug(s)	Discontinued in Phase 2	Small molecular drug	CHEBI:90237	DB05465	.	.	562.7	10	C31H42N6O4	92.3	783	4.6	41	1	8	"InChI=1S/C31H42N6O4/c1-23(2)41-25-10-8-24(9-11-25)34-31(38)37-17-15-36(16-18-37)30-26-20-28(39-3)29(21-27(26)32-22-33-30)40-19-7-14-35-12-5-4-6-13-35/h8-11,20-23H,4-7,12-19H2,1-3H3,(H,34,38)"	CC(C)OC1=CC=C(C=C1)NC(=O)N2CCN(CC2)C3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCCC5	UXXQOJXBIDBUAC-UHFFFAOYSA-N
DG01487	BPTES	3372016	"BPTES; 314045-39-1; Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide; 3uo9; N,N'-[sulfanediylbis(Ethane-2,1-Diyl-1,3,4-Thiadiazole-5,2-Diyl)]bis(2-Phenylacetamide); CHEMBL2177757; 2,2'-(5,5'-(2,2'-thiobis(ethane-2,1-diyl))bis(1,3,4-thiadiazole-5,2-diyl))bis(azanediyl)bis(1-phenylethanone); 2-phenyl-N-[5-[2-[2-[5-[(2-phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]ethylsulfanyl]ethyl]-1,3,4-thiadiazol-2-yl]acetamide; N,N'-((thiobis(ethane-2,1-diyl))bis(1,3,4-thiadiazole-5,2-diyl))bis(2-phenylacetamide); 2-phenyl-N-{5-[2-({2-[5-(2-phenylacetamido)-1,3,4-thiadiazol-2-yl]ethyl}sulfanyl)ethyl]-1,3,4-thiadiazol-2-yl}acetamide; 4jkt; 04A; SCHEMBL2640644; Glutaminase Inhibitor II, BPTES; SNX1770; HMS3866K13; BCP15991; BPTES, >=95% (HPLC); EX-A2297; SNX-1770; ZINC4426660; BDBM50400050; MFCD01079848; NSC798303; s7753; AKOS027470168; CCG-269883; CS-4586; NSC-798303; NCGC00420698-04; AC-29967; AS-70948; HY-12683; A14954; US8604016, 1; Q27449834; Bis[2-[5-[(2-phenylacetyl)amino]-1,3,4-thiadiazole-2-yl]ethyl] sulfide; (N,N'-[thiobis(2,1-ethanediyl-1,3,4-thiadiazole-5,2-diyl)]bisbenzeneacetamide); N,N'-[Thiobis(2,1-ethanediyl-1,3,4-thiadiazole-5,2-diyl)]bis[benzeneacetamide]; N,N'-[Thiobis(2,1-ethanediyl-1,3,4-thiadiazole-5,2-diyl)]bisbenzeneacetamide; 2,2-(5,5-(2,2-thiobis(ethane-2,1-diyl))bis(1,3,4-thiadiazole-5,2-diyl))bis(azanediyl)bis(1-phenylethanone)"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	524.7	12	C24H24N6O2S3	192	609	4	35	2	9	"InChI=1S/C24H24N6O2S3/c31-19(15-17-7-3-1-4-8-17)25-23-29-27-21(34-23)11-13-33-14-12-22-28-30-24(35-22)26-20(32)16-18-9-5-2-6-10-18/h1-10H,11-16H2,(H,25,29,31)(H,26,30,32)"	C1=CC=C(C=C1)CC(=O)NC2=NN=C(S2)CCSCCC3=NN=C(S3)NC(=O)CC4=CC=CC=C4	MDJIPXYRSZHCFS-UHFFFAOYSA-N
DG01488	N-arachidonoyl dopamine	5282105	"NADA; N-Arachidonoyl dopamine; Arachidonoyl dopamine; 199875-69-9; N-Arachidonyldopamine; N-Arachidonyl dopamine; Arachidonyl dopamine; N-arachidonoyldopamine; (5Z,8Z,11Z,14Z)-N-[2-(3,4-dihydroxyphenyl)ethyl]icosa-5,8,11,14-tetraenamide; CHEMBL138921; CHEBI:31231; N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-dopamine; N-[2-(3,4-Dihydroxyphenyl)ethyl]-5Z,8Z,11Z,14Z-eicosatetraenamide; NADA dopamine; 5,8,11,14-Eicosatetraenamide, N-[2-(3,4-dihydroxyphenyl)ethyl]-,(5Z,8Z,11Z,14Z)-; AA-DA; n-arachidonoyl-dopamine; SCHEMBL154051; BML3-G03; GTPL4261; N-arachidonoyl-dopamine (NADA); BDBM20462; DTXSID70415208; HMS3649B19; ZINC4102443; 1907AH; LMFA08020084; AKOS015951332; NCGC00161231-03; NCGC00161231-04; NCGC00161231-05; HY-110018; SR-01000946639; Q3869319; SR-01000946639-1; Arachidonoyl dopamine, >=98% (HPLC), ethanol solution"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:31231	.	.	.	439.6	17	C28H41NO3	69.6	579	7.3	32	3	3	"InChI=1S/C28H41NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-28(32)29-23-22-25-20-21-26(30)27(31)24-25/h6-7,9-10,12-13,15-16,20-21,24,30-31H,2-5,8,11,14,17-19,22-23H2,1H3,(H,29,32)/b7-6-,10-9-,13-12-,16-15-"	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCCC1=CC(=C(C=C1)O)O	MVVPIAAVGAWJNQ-DOFZRALJSA-N
DG01489	PD-180970	5311104	"287204-45-9; PD180970; PD-180970; PD 180970; UNII-TSO2IAD7WJ; TSO2IAD7WJ; 6-(2,6-Dichlorophenyl)-2-[(4-fluoro-3-methylphenyl)amino]-8-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one; 6-(2,6-DICHLORO-PHENYL)-2-(4-FLUORO-3-METHYL-PHENYLAMINO)-8-METHYL-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE; 6-(2,6-Dichlorophenyl)-2-[(4-Fluoro-3-Methylphenyl)amino]-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2hzi; 6-(2,6-Dichlorophenyl)-2-((4-fluoro-3-methylphenyl)amino)-8-methylpyrido(2,3-d)pyrimidin-7(8H)-one; 6-(2,6-dichlorophenyl)-2-((4-fluoro-3-methylphenyl)amino)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one; PD-180790; PD-0180970; PF-1515965; SCHEMBL256711; BDBM6572; CHEMBL574058; DTXSID90415508; ZINC602675; MFCD10565929; AKOS024458440; CCG-221312; 6-(2,6-dichlorophenyl)-2-(4-fluoro-3-methylanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; NCGC00379241-02; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluoro-3-methylphenyl)amino)-8-methyl-; HY-103274; CS-0026795; FT-0765936; PD-180970, >=98% (HPLC); J-017220; Q27290258; 6-(2,6-dichlorophenyl)-2-[(4-fluoro-3-methylphenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one; JIN"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	429.3	3	C21H15Cl2FN4O	58.1	640	5.4	29	1	5	"InChI=1S/C21H15Cl2FN4O/c1-11-8-13(6-7-17(11)24)26-21-25-10-12-9-14(20(29)28(2)19(12)27-21)18-15(22)4-3-5-16(18)23/h3-10H,1-2H3,(H,25,26,27)"	CC1=C(C=CC(=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl)F	SLCFEJAMCRLYRG-UHFFFAOYSA-N
DG01490	BI-69A11	5343381	"Bi-69a11; 1233322-09-2; (E)-3-(1H-benzo[d]imidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenylquinolin-3-yl)prop-2-en-1-one; CHEMBL190313; (E)-3-(3-(1H-benzo[d]imidazol-2-yl) acryloyl)-6-chloro-4-phenylquinolin-2(1H)-one; 3-[(E)-3-(1H-benzimidazol-2-yl)prop-2-enoyl]-6-chloro-4-phenyl-1H-quinolin-2-one; compound 5809365; SCHEMBL2578486; SCHEMBL2578489; BDBM15187; AOB1376; BDBM50540082; ZINC13641346; AKOS001579464; AKOS024574175; AT27462; NCGC00402356-02; AS-16644; BIM-0034205.P001; F0016-1319; F0266-2668; (E)-3-(3-(1H-benzo[d]imidazol-2-yl)acryloyl)-6-chloro-4-phenylquinolin-2(1H)-one; 3-[(E)-3-(1H-1,3-benzimidazol-2-yl)-2-propenoyl]-6-chloro-4-phenyl-2(1H)-quinolinone; (E)-3-(1H-1,3-benzimidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenyl-3-quinolyl)-2-propen-1-one; 3-[(2E)-3-(1H-1,3-benzodiazol-2-yl)prop-2-enoyl]-6-chloro-4-phenyl-1,2-dihydroquinolin-2-one"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	425.9	4	C25H16ClN3O2	74.8	773	4.7	31	2	3	"InChI=1S/C25H16ClN3O2/c26-16-10-11-18-17(14-16)23(15-6-2-1-3-7-15)24(25(31)29-18)21(30)12-13-22-27-19-8-4-5-9-20(19)28-22/h1-14H,(H,27,28)(H,29,31)/b13-12+"	C1=CC=C(C=C1)C2=C(C(=O)NC3=C2C=C(C=C3)Cl)C(=O)/C=C/C4=NC5=CC=CC=C5N4	SBOKKVUBLNZTCT-OUKQBFOZSA-N
DG01491	NSC319726	5351307	"NSC319726; 71555-25-4; NSC 319726; CID 5351307; N'-(1-(Pyridin-2-yl)ethylidene)azetidine-1-carbothiohydrazide; N-[(E)-1-pyridin-2-ylethylideneamino]azetidine-1-carbothioamide; (E)-N'-(1-(pyridin-2-yl)ethylidene)azetidine-1-carbothiohydrazide; NSC-319726; MLS002703052; AZETIDINE CARBOTHIOIC ACID, [1-(2-PYRIDINYL)ETHYLIDENE]HYDRAZIDE; CHEMBL1976486; SCHEMBL17975335; Azetidinecarbothioic acid, [1-(2-pyridinyl)ethylidene] hydrazide; EX-A2113; WCA55525; 2597AH; CCG-35689; s7149; ZINC17122727; AKOS024458479; CS-3542; AC-32867; AS-56104; HY-18634; LS-13960; A899911; BRD-K99170882-001-01-9; Azetidine-1-carbothioic acid(1-pyridin-2-yl-ethylidene)hydrazide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	234.32	2	C11H14N4S	72.6	286	1.4	16	1	3	"InChI=1S/C11H14N4S/c1-9(10-5-2-3-6-12-10)13-14-11(16)15-7-4-8-15/h2-3,5-6H,4,7-8H2,1H3,(H,14,16)/b13-9+"	C/C(=N\\NC(=S)N1CCC1)/C2=CC=CC=N2	XDHBUMNIQRLHGO-UKTHLTGXSA-N
DG01492	NSC59984	5356520	"NSC59984; 803647-40-7; NSC 59984; (E)-1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one; NSC-59984; MLS000737358; SMR000528276; 1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one; CHEMBL1979662; SCHEMBL17071991; SCHEMBL17654893; BDBM96260; cid_5356520; EX-A776; HMS2885J20; BCP16647; MFCD29905462; s8106; ZINC59727553; NSC59984,NCI59984; CCG-267098; CS-5382; AC-32965; BS-18159; HY-19726; NSC59984, >=98% (HPLC); A13413; J-690353; (E)-1-(4-methylpiperazino)-3-(5-nitro-2-furyl)prop-2-en-1-one; (E)-1-(4-methyl-1-piperazinyl)-3-(5-nitro-2-furanyl)-2-propen-1-one; N-[1,3-Dimethyl-2-oxo-6-(1-pyrrolidinyl)-2,3-dihydro-1H-benzimidazol-5-yl]-2-methoxybenzamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	265.26	2	C12H15N3O4	82.5	372	0.4	19	0	5	"InChI=1S/C12H15N3O4/c1-13-6-8-14(9-7-13)11(16)4-2-10-3-5-12(19-10)15(17)18/h2-5H,6-9H2,1H3/b4-2+"	CN1CCN(CC1)C(=O)/C=C/C2=CC=C(O2)[N+](=O)[O-]	QKTRIGNWBRHBFV-DUXPYHPUSA-N
DG01493	Pyridone 6	5494425	"Pyridone 6; 457081-03-7; JAK Inhibitor I; Merck-5; CMP 6; Merck 5; CMP-6; 2-tert-butyl-9-fluoro-3H-benzo[h]imidazo[4,5-f]isoquinolin-7(6H)-one; LDX3F0CCST; UNII-LDX3F0CCST; CHEMBL21156; 2-(1,1-Dimethylethyl)-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinolin-7-one; CHEBI:87103; Compound # 2; 2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE; 2-(1,1-Dimethylethyl)-9-fluoro-1,6-dihydro-7H-benz[h]imidazo[4,5-f]isoquinolin-7-one; 2-TERT-BUTYL-9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLINE-7-ONE; C18H16FN3O; JAK Inhibitor; 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one; 2-tert-butyl-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one; JAK I inhibitor; Jak Inhibitor 1; PDK1 inhibitor, 1; Kinome_3740; pan-JAK inhibitor P6; 2b7a; Merck-5;CMP 6; Tetracyclic Pyridone, 1; JAK Inhibitor I(Merck 5); SCHEMBL904545; GTPL5992; STO185; SCHEMBL23199918; BDBM26198; DTXSID40420526; EX-A123; SYN1054; BCPP000167; HMS3229G07; HMS3244K21; HMS3244K22; HMS3244L21; BCP01959; Janus-Associated Kinase Inhibitor I; 3809AH; MFCD17019334; ZINC12504479; AKOS026750650; AKOS030240416; AKOS032949970; BCP9000906; CCG-206761; CS-1056; DB04716; SB18936; 2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one; NCGC00345828-01; NCGC00345828-07; AM806646; AS-16211; HY-14435; QC-10171; FT-0700310; Y0239; H11177; K00013; K00225; SR-03000000978-1; Q27096425; 2-(tert-butyl)-9-fluoro-3H-benzo[h]imidazo[4,5-f]isoquinolin-7(6H)-one; 2-(1,1-dimethylethyl)-9-fluoro-3,6-dihydro-7h-benz [h]-imidazo [4,5-f]isoquinolin-7-one; 2-tert-butyl-9-fluoro-1,6-dihydro-7h-benz[h]imidazo[4,5-f]isoquinolin-7-one; 2-tert-butyl-9-fluoro-1,6-dihydro-7h-benzo[h]imidazo[4,5-f]isoquinolin-7-one; 4-tert-butyl-15-fluoro-3,5,10-triazatetracyclo[11.4.0.0(2),.0,(1)(2)]heptadeca-1(13),2(6),4,7(12),8,14,16-heptaen-11-one; 4-tert-butyl-15-fluoro-3,5,10-triazatetracyclo[11.4.0.0,.0,]heptadeca-1(13),2(6),4,7(12),8,14,16-heptaen-11-one; 4-tert-butyl-15-fluoro-3,5,10-triazatetracyclo[11.4.0.0^{2,6.0^{7,12]heptadeca-1(13),2(6),4,7(12),8,14,16-heptaen-11-one; 4-tert-butyl-15-fluoro-3,5,10-triazatetracyclo[11.4.0.0^{2,6}.0^{7,12}]heptadeca-1(13),2(6),3,7(12),8,14,16-heptaen-11-one; 4-tert-butyl-15-fluoro-3,5,10-triazatetracyclo[11.4.0.0^{2,6}.0^{7,12}]heptadeca-1(17),2(6),4,7(12),8,13,15-heptaen-11-one; 4-tert-butyl-15-fluoro-3,5,10-triazatetracyclo[11.4.0.02,6.07,12]heptadeca-1(13),2(6),4,7(12),8,14,16-heptaen-11-one; JAK Inhibitor I; 2-(1,1-Dimethylethyl)-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinolin-7-one"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:87103	.	.	.	309.3	1	C18H16FN3O	57.8	529	4	23	2	3	"InChI=1S/C18H16FN3O/c1-18(2,3)17-21-14-10-5-4-9(19)8-12(10)13-11(15(14)22-17)6-7-20-16(13)23/h4-8H,1-3H3,(H,20,23)(H,21,22)"	CC(C)(C)C1=NC2=C(N1)C3=C(C=C(C=C3)F)C4=C2C=CNC4=O	VNDWQCSOSCCWIP-UHFFFAOYSA-N
DG01494	Tanespimycin	6505803	"Tanespimycin; 75747-14-7; 17-AAG; 17-(Allylamino)-17-demethoxygeldanamycin; 17-(Allylamino)geldanamycin; 17AAG; NSC-330507; 17-Allylaminogeldanamycin; KOS-953; Cp 127374; NSC 330507; 17-Demethoxy-17-allylamino geldanamycin; UNII-4GY0AVT3L4; CHEBI:64153; 17-AAG (Tanespimycin); BMS-722782; 4GY0AVT3L4; MFCD04973892; NCGC00163424-01; 17-N-allylamino-17-demethoxygeldanamycin; 17-demethoxy-17-(2-propenylamino)geldanamycin; [(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-enylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate; Geldanamycin, 17-demethoxy-17-(2-propenylamino)-; NSC330507; (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-en-1-ylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate; [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; Tanespimycin [USAN:INN]; KOS 953; tanespimycina; tanespimycine; tanespimycinum; CCRIS 9401; 17-Demethoxy-17-allylaminogeldanamycin; C31H43N3O8; Tanespimycin (USAN); Tanespimycin (17-AAG); Geldanamycin, 17-(Allylamino)-17-demethoxy-; DSSTox_CID_26352; DSSTox_RID_81555; DSSTox_GSID_46352; BSPBio_001434; SCHEMBL2604976; DTXSID5046352; SCHEMBL13037468; SCHEMBL16226295; CHEBI:94756; CNF-101; CNF1010; HMS1361H16; HMS1791H16; HMS1989H16; HMS3402H16; (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(allylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate; CNF-1010; EX-A4668; NSC-330507D; Tox21_112054; BDBM50008057; s1141; AKOS024456643; ZINC100014666; BCP9000064; CCG-208039; CS-0161; DB05134; NSC-704057; IDI1_033904; NCGC00163424-02; NCGC00163424-04; NCGC00163424-05; NCGC00163424-06; NCGC00163424-07; Allylamino-17-demethoxygeldanamycin, 17-; HY-10211; Geldanamycin, des-O-methyl-17-allylamino-; CAS-75747-14-7; CP-127374; Geldanamycin, 17-allylamino-17-demethoxy-; X7553; D06650; 747A147; Geldanamycin,17-demethoxy-17-(2-propenylamino)-; J-504153; BRD-K81473043-001-03-9; BRD-K81473043-001-08-8; 17-(Allylamino)-17-demethoxygeldanamycin, >=98% (HPLC), solid; (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-Hydroxy-8,14-dimethoxy-4,10,12,16- tetramethyl-3,20,22-trioxo-19-(prop-2-enylamino)-2-azabicyclo(16.3.1)docosa- 1(21),4,6,10,18-penten-9-yl carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-21-(allylamino)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; 17-AAG; ; ; 17-(Allylamino)-17-demethoxy-geldanamycin; ; ; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:64153	DB05134	.	.	585.7	7	C31H43N3O8	166	1210	2.6	42	4	9	"InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1"	C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)/C)OC)OC(=O)N)\\C)C)O)OC	AYUNIORJHRXIBJ-TXHRRWQRSA-N
DG01495	SU5614	6536806	"SU-5614; 1055412-47-9; su5614; (Z)-5-Chloro-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one; CHEMBL2062155; CHEBI:87159; 186611-56-3; SU 5614; (Z)-SU5614; AC1NS4RE; (3Z)-5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one; (3Z)-5-Chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-2H-indol-2-one; MFCD08443928; 5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone; 5-CHLORO-3-(3,5-DIMETHYL-1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-INDOL-2-ONE; EX-A821; ZINC3875026; BDBM50415432; HY-18952A; AKOS030527565; CID:6536806; NCGC00480782-01; AS-70968; DS-019384; SU5614, >=98% (HPLC); CS-0029269; A895990; J-690017; Q27159416; 5-chloro-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one; 5-chloro-3-(3,5-dimethyl-1h-pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; (3Z)-5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; (3Z)-5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-2,3-dihydro-1H-indol-2-one; 3-Chloro-N-[(1S)-2-[[2-(dimethylamino)acetyl]amino]-1-[[4-[8-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl]phenyl]methyl]ethyl]-4- (1-methylethoxy)-benzamide"	Terminated	10	Discontinued Drug(s)	Terminated	Small molecular drug	CHEBI:87159	.	.	.	272.73	1	C15H13ClN2O	44.9	409	3.1	19	2	1	"InChI=1S/C15H13ClN2O/c1-8-5-9(2)17-14(8)7-12-11-6-10(16)3-4-13(11)18-15(12)19/h3-7,17H,1-2H3,(H,18,19)/b12-7-"	CC1=CC(=C(N1)/C=C\\2/C3=C(C=CC(=C3)Cl)NC2=O)C	XLBQNZICMYZIQT-GHXNOFRVSA-N
DG01496	CI-1040	6918454	"212631-79-3; CI-1040; PD184352; PD 184352; PD-184352; 2-(2-chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide; CI 1040; PD184352 (CI-1040); CI1040; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide; 2-((2-Chloro-4-iodophenyl)amino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide; 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide; PD-18435; UNII-R3K9Y00J04; C.I. 1040; CHEMBL105442; R3K9Y00J04; MFCD02683961; NCGC00189074-01; PD 184352CI-1040; CI-1040 (PD184352); DSSTox_CID_28871; DSSTox_RID_83140; DSSTox_GSID_48945; C17H14ClF2IN2O2; 2-[(2-CHLORO-4-IODOPHENYL)AMINO]-N-(CYCLOPROPYLMETHOXY)-3,4-DIFLUOROBENZAMIDE; CAS-212631-79-3; PD 184,352; MLS006010176; SCHEMBL570330; PD 184352, Free Base; GTPL5676; QCR-25; DTXSID8048945; CHEBI:91353; SYN1031; HMS3244G05; HMS3244G06; HMS3244H05; HMS3265I07; HMS3265I08; HMS3265J07; HMS3265J08; HMS3654I05; AOB87195; BCP01791; EX-A2202; ZINC1489691; Tox21_113363; BDBM50132260; NSC765695; s1020; AKOS022184333; Tox21_113363_1; CCG-269529; CS-0058; DB12429; NSC-765695; SB19417; NCGC00189074-03; NCGC00189074-05; AC-25483; AS-19373; HY-50295; SMR004701284; CI-1040,PD184352; DB-014962; CI-1040; PD184352; FT-0673543; SW219604-1; X7396; EC-000.2331; PD 184352(CI-1040); PD184352 - CI-1040; A25744; PD184352, >=98% (HPLC); 631C793; US8575391, 341; J-505572; BRD-K05104363-001-01-9; Q27076005; 2-(2-Chloro4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide; 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide; 2-[(2-Chloro-4-iodophenyl)amino]-N-cyclopropylmethoxy)-3,4-difluorobenzamide; Benzamide, 2-((2-chloro-4-iodophenyl)amino)-N-(cyclopropylmethoxy)-3,4-difluoro-; CI-1040; ; ; 2-(2-Chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:91353	DB12429	.	.	478.7	6	C17H14ClF2IN2O2	50.4	472	5.6	25	2	5	"InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)"	C1CC1CONC(=O)C2=C(C(=C(C=C2)F)F)NC3=C(C=C(C=C3)I)Cl	GFMMXOIFOQCCGU-UHFFFAOYSA-N
DG01497	Rigosertib	6918736	"Rigosertib; 592542-59-1; UNII-67DOW7F9GL; ON 01910; ON-01910; 67DOW7F9GL; 2-[2-methoxy-5-[[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]anilino]acetic acid; (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetic acid; N-[2-Methoxy-5-({[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine; ON-01910.Na; Rigosertib [USAN:INN]; rigosertibum; 6FS; Rigosertib (USAN); Estybon (proposed trade name); SCHEMBL498623; SCHEMBL498624; GTPL7833; CHEMBL1241855; ON01910.Na; DTXSID30207984; 2-[2-methoxy-5-[2-(2,4,6-trimethoxyphenyl)ethenylsulfonylmethyl]anilino]acetic acid; CHEBI:124939; CHEBI:145417; BCP08296; EX-A4346; ZINC3942646; 4006AH; BDBM50060917; AKOS015966442; DB12146; N-[2-Methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]glycine; (E)-ON 01910; 2-[[2-methoxy-5-[[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]phenyl]amino]acetic Acid; AC-32479; AS-35249; ON-01910ON-01910; D10154; ON-01910;ON01910;ON 01910; BRD-K55187425-236-01-1; Q21099552; (e)-2-(5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenylamino)acetic acid; [2-methoxy-5-({[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)anilino]acetic acid; [2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)anilino]acetic acid; N-(2-Methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl)methyl) phenyl)glycine; N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine; Glycine, N-(2-methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl) methyl)phenyl)-; Glycine, N-[2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]phenyl]-; ON-01910; ; ; 2-[2-Methoxy-5-[[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]anilino]acetic acid"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:124939	DB12146	.	.	451.5	11	C21H25NO8S	129	678	2.5	31	2	9	"InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+"	COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)NCC(=O)O	OWBFCJROIKNMGD-BQYQJAHWSA-N
DG01498	SU11274	9549297	"SU11274; 658084-23-2; Met Kinase Inhibitor; SU-11274; SU 11274; PKI-SU11274; SU-MI-2; CHEMBL261641; (3Z)-N-(3-Chlorophenyl)-3-({3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl}methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide; MFCD08276928; (Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxoindoline-5-sulfonamide; (3Z)-N-(3-Chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide; (3Z)-N-(3-Chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-methyl-2-oxo-1H-indole-5-sulfonamide; (3z)-N-(3-Chlorophenyl)-3-({3,5-Dimethyl-4-[(4-Methylpiperazin-1-Yl)carbonyl]-1h-Pyrrol-2-Yl}methylene)-N-Methyl-2-Oxoindoline-5-Sulfonamide; (3Z)-N-(3-chlorophenyl)-3-({3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl}methylidene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide; (Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-(1-methylpiperazine-4-carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxoindoline-5-sulfonamide; (3Z)-N-(3-chlorophenyl)-3-[[3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-yl]methylidene]-N-methyl-2-oxo-1H-indole-5-sulfonamide; C28H30ClN5O4S; SCHEMBL93711; SCHEMBL93713; MLS006010961; GTPL5057; AOB6383; DTXSID20429552; EX-A183; CHEBI:190974; BCPP000061; HMS3229G21; K00593a; BDBM50341636; NSC747693; s1080; ZINC16052811; AKOS015994564; CCG-206768; ES-0032; EX-5962; NSC-747693; QC-2155; NCGC00165902-01; NCGC00165902-04; AC-28396; SMR004702765; SU-011274; SU11274 (PKI-SU11274); SU 11274, >=98% (HPLC), powder; X7471; EC-000.2357; A15738; Met Kinase Inhibitor - CAS 658084-23-2; J-522999; BRD-K02965346-001-01-8; BRD-K02965346-001-07-5; Q27088888; (3Z)-N-(3-chlorophenyl)-3-[[3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-yl]methylidene]-N-methyl-2-oxo-1H-indole-5-sulonamide; 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)-; N-(3-chlorophenyl)-3-((3,5-dimethyl-4-(1-methylpiperazine-4-carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxoindoline-5-sulfonamide; N-(3-chlorophenyl)-3-((3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxoindoline-5-sulfonamide; N-(3-Chlorophenyl)-n-methyl-3-[[3,5-dmethyl-4-[(4-methylpperazn-1-yl)carbonyl]-1h-pyrrol-2-yl]methylene]-2-oxo-2,3-dhydro-1h-ndole-5 -sulfonamde"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	568.1	5	C28H30ClN5O4S	114	1070	3.1	39	2	6	"InChI=1S/C28H30ClN5O4S/c1-17-25(30-18(2)26(17)28(36)34-12-10-32(3)11-13-34)16-23-22-15-21(8-9-24(22)31-27(23)35)39(37,38)33(4)20-7-5-6-19(29)14-20/h5-9,14-16,30H,10-13H2,1-4H3,(H,31,35)/b23-16-"	CC1=C(NC(=C1C(=O)N2CCN(CC2)C)C)/C=C\\3/C4=C(C=CC(=C4)S(=O)(=O)N(C)C5=CC(=CC=C5)Cl)NC3=O	FPYJSJDOHRDAMT-KQWNVCNZSA-N
DG01499	AV-412	9806229	"451492-95-8; AV-412 free base; AV-412; AV-412 (free base); UNII-41OXH4FE7B; MP-412; AV412; N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-yn-1-yl)quinazolin-6-yl)acrylamide; N-[4-(3-chloro-4-fluoroanilino)-7-[3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl]quinazolin-6-yl]prop-2-enamide; 41OXH4FE7B; CHEMBL2138625; AV-412(MP-412); C27H28ClFN6O; 2-Propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-methyl-3-(4-methyl-1-piperazinyl)-1-butyn-1-yl]-6-quinazolinyl]-; N-(4-(3-chloro-4-fluorophenylamino)-7-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl)quinazolin-6-yl)acrylamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-methyl-3-(4-methyl-1-piperazinyl)-1-butyn-1-yl)-6-quinazolinyl)-; 2-propenamide,n-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-methyl-3-(4-methyl-1-piperazinyl)-1-butyn-1-yl)-6-quinazolinyl)-; 2-Propenamide,N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-methyl-3-(4-methyl-1-piperazinyl)-1-butyn-1-yl]-6-quinazolinyl]-; MP-412 free base; SCHEMBL1818495; AV-412 free base;MP-412; DTXSID10196403; EX-A755; SYN1012; BCPP000375; HMS3244M15; HMS3244M16; HMS3244N15; BCP01955; 3459AH; BDBM50468245; HY-10346A; MFCD16038939; NSC799340; ZINC22453472; AKOS027251058; BCP9000342; NSC-799340; NCGC00263195-01; NCGC00263195-04; AS-16187; B3236; FT-0700308; A872418; J-523023; Q27258451; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-methyl-3-(4-methyl-1-piperazinyl)-1-butyn-1-yl]-6-quinazolinyl]-2-propenamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	DB06021	.	.	507	7	C27H28ClFN6O	73.4	850	4.5	36	2	7	"InChI=1S/C27H28ClFN6O/c1-5-25(36)33-23-16-20-24(30-17-31-26(20)32-19-6-7-22(29)21(28)15-19)14-18(23)8-9-27(2,3)35-12-10-34(4)11-13-35/h5-7,14-17H,1,10-13H2,2-4H3,(H,33,36)(H,30,31,32)"	CC(C)(C#CC1=CC2=C(C=C1NC(=O)C=C)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)N4CCN(CC4)C	ZAJXXUDARPGGOC-UHFFFAOYSA-N
DG01500	AS602868	9820526	"219773-55-4; SPC-839; CHEMBL129857; SPC 839; UNII-Y1FZ8P93E0; Y1FZ8P93E0; AS-602868; 1-(5-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione; 1-(5-methoxy-2-(thiophen-2-yl)quinazolin-4-ylamino)-3-methyl-1H-pyrrole-2,5-dione; 1H-Pyrrole-2,5-dione,1-[[5-methoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl-; AS602868; SCHEMBL7859927; DTXSID00431335; ZINC1489583; BDBM50135482; NCGC00161703-01; NCGC00161703-02; NCGC00161703-03; A4715; CU-00000000266-1; 1-((5-Methoxy-2-(2-thienyl)-4-quinazolinyl)amino)-3-methyl-1H-pyrrole-2,5-dione; 1-((5-Methoxy-2-(thiophen-2-yl)quinazolin-4-yl)amino)-3-methyl-1H-pyrrole-2,5-dione; 1-[(5-methoxy-2-thiophen-2-ylquinazolin-4-yl)amino]-3-methylpyrrole-2,5-dione; 1H-Pyrrole-2,5-dione, 1-((5-methoxy-2-(2-thienyl)-4-quinazolinyl)amino)-3-methyl-"	Discontinued in Phase 1	13	Discontinued Drug(s)	Discontinued in Phase 1	Small molecular drug	.	.	.	.	366.4	4	C18H14N4O3S	113	613	3	26	1	7	"InChI=1S/C18H14N4O3S/c1-10-9-14(23)22(18(10)24)21-17-15-11(5-3-6-12(15)25-2)19-16(20-17)13-7-4-8-26-13/h3-9H,1-2H3,(H,19,20,21)"	CC1=CC(=O)N(C1=O)NC2=NC(=NC3=C2C(=CC=C3)OC)C4=CC=CS4	GZGLPBNOIFLLRE-UHFFFAOYSA-N
DG01501	Tofacitinib	9926791	"Tofacitinib; Tasocitinib; 477600-75-2; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; 1259404-17-5; rac-Tofacitinib; CP-690,550; UNII-87LA6FU830; Tofacitinib (CP-690550,Tasocitinib); 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; racemic-tofacitinib; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; CP690550; CHEMBL221959; CHEBI:71200; 87LA6FU830; 477600-75-2 (free base); MFCD11035919; 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-[(3R*,4R*)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile; 3-[(3R,4R)-4-methyl-3-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile; 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile; 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; Tofacitinib [USAN:INN]; C16H20N6O; tofacitinibum; 3eyg; 3fup; 3lxk; 4oti; MI1; Tofacitinib (USAN); Cp-690 free base; 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-, (3R,4R)-; SCHEMBL322753; Tofacitinib (CP-690550); GTPL5677; QCR-53; HSDB 8311; AMY3992; DTXSID90197271; EX-A205; BCPP000274; CP-690550 FREE BASE; AOB87470; ZINC3818808; CP-690,550 FREE BASE; BDBM50193995; CP-690; NSC782351; NSC800953; s2789; AKOS005145814; AKOS005258733; AC-8193; BCP9000550; CA10005; CCG-264998; CS-0050; DB08895; GS-6106; NSC-782351; NSC-800953; NCGC00229511-02; NCGC00229511-04; NCGC00229511-10; NCGC00244463-01; Tofacitinib (CP-690550, Tasocitinib); HY-40354; CP690,550; CP-690-550; W6440; CP- 690 550; D09970; AB01565786_02; 600M752; AR-270/43507983; J-524314; Q3530324; BRD-K31283835-001-01-9; BRD-K31283835-048-04-4; 3-((3R,4R)-4-Methyl(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yi)Amino)Piperidin-1-Yl-3-Oxopropaneni; (3R,4R)-3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine propanenitrile; 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidyl]-3-oxo-propanenitrile; 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]piperidin-1-yl}-3-oxo-propionitrile; 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; 3-{4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidinyl}-3-oxopropanenitrile; 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo(2,3-d)pyrimidin-4-yl-, (3R,4R)-; Tofacitinib;3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:71200	DB08895	.	.	312.37	3	C16H20N6O	88.9	488	1.5	23	1	5	"InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1"	C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N	UJLAWZDWDVHWOW-YPMHNXCESA-N
DG01502	Cediranib	9933475	"Cediranib; 288383-20-0; Recentin; AZD2171; Cedirannib; Cediranib (AZD2171); AZD 2171; AZD-2171; 4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline; Cediranib free base; 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline; Cediranib (AZD217); UNII-NQU9IPY4K9; NQU9IPY4K9; ZD-2171; AZD-2171 maleate; 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline; 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline; CHEMBL491473; 288383-20-0 (free base); NSC-732208; 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline; C25H27FN4O3; Cediranib (USAN/INN); Cediranib [USAN:INN:BAN]; 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline; Cediranib,AZD2171; Kinome_3318; Cediranib dihydrochloride; AZD2171, Cediranib; Cediranib - AZD2171; SCHEMBL63147; MLS006010063; GTPL5664; QCR-93; CHEBI:94782; AOB1949; DTXSID10183035; BCPP000295; HMS3654G05; HMS3674G17; HMS3744O21; AMY16021; BCP01378; EX-A2039; ZINC3948085; BDBM50331096; MFCD09954115; NSC755606; NSC800069; s1017; AKOS005145767; BCP9000500; CCG-264679; CS-0119; DB04849; ES-0052; NSC-755606; NSC-800069; SB16536; ZD 2171; NCGC00263097-01; NCGC00263097-09; AC-25033; HY-10205; Quinazoline,4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-; SMR004701223; FT-0751000; SW219261-1; X2636; EC-000.2328; A24280; D08881; Q-101399; Q5057052; BRD-K86930074-001-01-9; 4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-yl-propoxy)-quinazoline; AV3; Quinazoline, 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(1-pyrrolidinyl)propoxy)-"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:94782	DB04849	DR1886	.	450.5	8	C25H27FN4O3	72.5	625	4.9	33	1	7	"InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3"	CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5	XXJWYDDUDKYVKI-UHFFFAOYSA-N
DG01503	TAE226	9934347	"761437-28-9; NVP-TAE 226; NVP-TAE226; TAE226; 2-((5-Chloro-2-((2-methoxy-4-morpholinophenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide; TAE226 (NVP-TAE226); 2-({5-Chloro-2-[(2-Methoxy-4-Morpholin-4-Ylphenyl)amino]pyrimidin-4-Yl}amino)-N-Methylbenzamide; CHEMBL458997; TAE-226; CTx0152960; 1042432-58-5; 2-((5-CHLORO-2-((2-METHOXY-4-MORPHOLINOPHENYL)-AMINO)PYRIMIDIN-4-YL)AMINO)-N-METHYLBENZAMIDE; CTx-0152960;CTx 0152960; C23H25ClN6O3; 2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-N-methylbenzamide; 2jkk; 2-[[5-chloro-2-[(2-methoxy-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl]amino]-N-methylbenzamide; BI9; Kinome_1212; NVP TAE226; NVPTAE 226; MLS006011059; SCHEMBL375524; GTPL9382; CHEBI:91452; DTXSID90433025; EX-A716; TAE 226; HMS3656L12; HMS3672E03; HMS3747C09; AOB87333; BCP06482; 1836AC; BDBM50334594; MFCD12031516; NSC787252; s2820; ZINC20148986; AKOS016004135; CCG-269438; CS-0594; DB07460; NSC-787252; SB19397; 2-({5-Chloro-2-[2-methoxy-4-(morpholin-4-yl)anilino]pyrimidin-4-yl}amino)-N-methylbenzamide; NCGC00346931-01; NCGC00346931-05; 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide; AC-27408; AS-56281; HY-13203; SMR004702851; FT-0700360; SW219314-1; NVP-TAE 226,CAS:761437-28-9; A865545; J-690348; Q27096680; 2-({5-Chloro-2-[2-methoxy-4-(4-morpholinyl)anilino]-4-pyrimidinyl}amino)-N-methylbenzamide; 2-(5-chloro-2-(2-methoxy-4-morpholinophenylamino)pyrimidin-4-ylamino)-N-methylbenzamide; 2-[5-chloro-2-[2-methoxy-4-(4-morpholinyl)phenylamino]pyrimidin-4-ylamino]-N-methylbenzamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	468.9	7	C23H25ClN6O3	101	625	4.1	33	3	8	"InChI=1S/C23H25ClN6O3/c1-25-22(31)16-5-3-4-6-18(16)27-21-17(24)14-26-23(29-21)28-19-8-7-15(13-20(19)32-2)30-9-11-33-12-10-30/h3-8,13-14H,9-12H2,1-2H3,(H,25,31)(H2,26,27,28,29)"	CNC(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCOCC4)OC	UYJNQQDJUOUFQJ-UHFFFAOYSA-N
DG01504	CP-31398	9950868	"UNII-IN3WH41H3A; 259199-65-0; CP-31398; IN3WH41H3A; N-[2-[(E)-2-(4-methoxyphenyl)ethenyl]quinazolin-4-yl]-N',N'-dimethylpropane-1,3-diamine; 1,3-Propanediamine, N3-[2-[2-(4-methoxyphenyl)ethenyl]-4-quinazolinyl]-N1,N1-dimethyl-; CP-31,398; CHEMBL186928; SCHEMBL13158851; SCHEMBL17890250; BDBM389561; ZINC3933040; US9951029, 12; Q27280804; N''-{2-[(E)-2-(4- methoxyphenyl)vinyl]quinazolin-4- yl}-N,N-dimethylpropane-1,3- diamine"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	362.5	8	C22H26N4O	50.3	448	4.5	27	1	5	"InChI=1S/C22H26N4O/c1-26(2)16-6-15-23-22-19-7-4-5-8-20(19)24-21(25-22)14-11-17-9-12-18(27-3)13-10-17/h4-5,7-14H,6,15-16H2,1-3H3,(H,23,24,25)/b14-11+"	CN(C)CCCNC1=NC(=NC2=CC=CC=C21)/C=C/C3=CC=C(C=C3)OC	NIHSNFSFDGHHRG-SDNWHVSQSA-N
DG01505	Selumetinib	10127622	"Selumetinib; 606143-52-6; AZD6244; AZD 6244; ARRY-142886; 5-[(4-BROMO-2-CHLOROPHENYL)AMINO]-4-FLUORO-N-(2-HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE; AZD-6244; Selumetinib (AZD6244); ARRY 142886; AZD6244 (Selumetinib); ARRY-886; UNII-6UH91I579U; 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide; 5-(4-broMo-2-chlorophenylaMino)-4-fluoro-N-(2-hydroxyethoxy)-1-Methyl-1H-benzo[d]iMidazole-6-carboxaMide; CHEMBL1614701; CHEBI:90227; 6UH91I579U; NCGC00189073-01; NCGC00189073-02; C17H15BrClFN4O3; 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; DSSTox_CID_28870; DSSTox_RID_83139; DSSTox_GSID_48944; 1H-Benzimidazole-6-carboxamide, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-; 6-[(4-bromo-2-chlorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; AZD 6244;5-((4-Bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide;6-(4-bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; CAS-606143-52-6; ARRY142886; Selumetinib [USAN:INN]; selumetinibum; Koselugo; 1H-Benzimidazole-6-carboxamide, 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-; 3EW; Selumetinib (USAN/INN); AZD6244 - Selumetinib; AZD 6244 (Selumetinib); SCHEMBL155456; GTPL5665; QCR-91; Selumetinib, ARRY-142886; DTXSID3048944; EX-A020; SYN1016; BCPP000367; HMS3244G03; HMS3244G04; HMS3244H03; HMS3265K01; HMS3265K02; HMS3265L01; HMS3265L02; HMS3654O03; NSC 741O78; AOB87732; BCP01739; Tox21_113362; BDBM50355497; MFCD11977472; NSC741078; NSC800882; s1008; ZINC31773258; AKOS015904255; Tox21_113362_1; BCP9000354; CCG-264774; CS-0059; DB11689; EX-8621; NSC-741078; NSC-800882; SB14707; NCGC00189073-07; AC-25059; AM808016; AZD6244,Selumetinib, ARRY-142886; BC004624; HY-50706; Selumetinib (ARRY142886/AZD6244); AZD6244 (Selumetinib,ARRY-142886); FT-0674552; SW202561-3; X2640; D09666; 143A526; Q-101405; Q7448840; BRD-K57080016-001-01-9; 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboxamide; 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy -ethoxy)-amide; 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide; 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid(2-hydroxy-ethoxy)-amide; 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide; 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid(2-hydroxyethoxy)-amide; 6-(4-bromo-2chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:90227	DB11689	.	.	457.7	6	C17H15BrClFN4O3	88.4	523	3.6	27	3	6	"InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)"	CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO	CYOHGALHFOKKQC-UHFFFAOYSA-N
DG01506	E6201	10172827	"E6201; UNII-CZP9GB25HO; E-6201; CZP9GB25HO; E 6201; 603987-35-5; ER-806201; (3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,10-tetrahydro-1H-benzo[c][1]oxacyclotetradecine-1,7(8H)-dione; (4~{S},5~{R},6~{Z},9~{S},10~{S},12~{E})-16-(ethylamino)-4,5-dimethyl-9,10,18-tris(oxidanyl)-3-oxabicyclo[12.4.0]octadeca-1(14),6,12,15,17-pentaene-2,8-dione; GTPL7836; SCHEMBL6983345; CHEMBL1097999; BDBM50515043; ZINC34374629; DB11687; (3S,4R,5Z,8S,9S,11E)-14-(Ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione; HY-15496; CS-0006796; J-504641; Q27077143; (4S,5R,6Z,9S,10S,12E)-16-(ethylamino)-9,10,18-trihydroxy-4,5-dimethyl-3-oxabicyclo[12.4.0]octadeca-1(14),6,12,15,17-pentaene-2,8-dione; (4S,5R,6Z,9S,10S,12E)-16-ethylamino-9,10,18-trihydroxy-4,5-dimethyl-3-oxabicyclo[12.4.0]octadeca-1(14),6,12,15,17-pentaene-2,8-dione; 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)-; 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E) -"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	.	.	.	389.4	2	C21H27NO6	116	604	3.3	28	4	7	"InChI=1S/C21H27NO6/c1-4-22-15-10-14-6-5-7-16(23)20(26)17(24)9-8-12(2)13(3)28-21(27)19(14)18(25)11-15/h5-6,8-13,16,20,22-23,25-26H,4,7H2,1-3H3/b6-5+,9-8-/t12-,13+,16+,20+/m1/s1"	CCNC1=CC\\2=C(C(=C1)O)C(=O)O[C@H]([C@@H](/C=C\\C(=O)[C@H]([C@H](C/C=C2)O)O)C)C	MWUFVYLAWAXDHQ-HMNLTAHHSA-N
DG01507	Binimetinib	10288191	"Binimetinib; 606143-89-9; MEK162; ARRY-162; ARRY-438162; MEK-162; Mektovi; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; ARRY 162; Binimetinib (MEK-162); ARRY 438162; UNII-181R97MR71; MEK162 (ARRY-162, ARRY-438162); NVP-MEK162; MFCD22124525; Binimetinib (MEK162, ARRY-162, ARRY-438162); 181R97MR71; 6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide; 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide.; 5-(4-Bromo-2-fluoroanilino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; Binimetinib [USAN:INN]; binimetinibum; Mektovi (TN); ARRY-162; ARRY-438162; MEK 162; ARRY 162; ARRY 438162; Binimetinib; Mek162; Mek162, Binimetinib; MEK162(Binimetinib); Binimetinib (MEK162); Binimetinib (JAN/USAN); MLS006011180; C17H15BrF2N4O3; SCHEMBL570088; GTPL7921; CHEMBL3187723; MEK162 (Arry-162); AMY9056; AOB2072; DTXSID70209422; QCR-138; ARRY-162,MEK-162; CHEBI:145371; BDBM520649; HMS3652J14; HMS3747G09; BCP06780; EX-A1024; NSC764042; NSC788187; NSC799361; s7007; ZINC38460704; AKOS026750517; CCG-269133; CS-0627; DB11967; NSC-764042; NSC-788187; NSC-799361; SB16501; NCGC00345804-01; NCGC00345804-10; 1073666-70-2; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methylbenzimidazole-6-carboxamide; 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; AC-29023; AS-16706; DA-35030; HY-15202; SMR004702949; SY284756; cas:606143-89-9;MEK162; FT-0697088; SW219910-1; Y1468; D10604; Binimetinib;MEK-162; ARRY-162;ARRY-438162; J-516581; Q19903515; US11147816, Binimetinib (ARRY-162, ARRY-438162); 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboxamide; 5-[(4-Bromo-2-Fluorophenyl)Amino]-4-Fluoro-N-(2-Hydroxyethoxy)-1-Methyl-1H-Benzimidazole-6-Carboxami; 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide; 6-[(4-bromo-2-fluorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; N-(2-hydroxyethoxy)-4-fluoro-5-(2-fluoro-4-bromophenylamino)-1-methyl-1H-benzoimidazole-6-carboxamide; QO7"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:145371	DB11967	DR0214	DR01336	441.2	6	C17H15BrF2N4O3	88.4	521	3.1	27	3	7	"InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)"	CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO	ACWZRVQXLIRSDF-UHFFFAOYSA-N
DG01508	Sotrastaurin	10296883	"Sotrastaurin; 425637-18-9; AEB071; Sotrastaurin (AEB071); AEB-071; 3-(1H-Indol-3-yl)-4-(2-(4-methylpiperazin-1-yl)quinazolin-4-yl)-1H-pyrrole-2,5-dione; UNII-7I279E1NZ8; 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione; NVP-AEB071; CHEBI:90531; 7I279E1NZ8; AEB 071; 3-(1h-Indol-3-Yl)-4-[2-(4-Methylpiperazin-1-Yl)quinazolin-4-Yl]-1h-Pyrrole-2,5-Dione; Sotrastaurin [USAN:INN]; sotrastaurina; sotrastaurine; sotrastaurinum; Kinome_2717; Sotrastaurin (USAN/INN); NVP-AEB-071; CHEMBL565612; GTPL7946; SCHEMBL2500835; BDBM33971; DTXSID70915192; HMS3656D10; HMS3673M05; HMS3744G03; AMY10736; AOB87472; BCP07456; EX-A2802; ZINC3973984; NSC766819; NSC800935; s2791; CCG-264999; CS-0090; DB12369; NSC-766819; NSC-800935; SB16638; NCGC00238621-01; NCGC00238621-09; AC-32050; AS-56373; HY-10343; SW220235-1; Y6229; D09671; L10095; A857807; Q26331952; 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(2-(4-methyl-1-piperazinyl)-4-quinazolinyl)-; 3-(1H-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-dione; 1058706-31-2; 5-Hydroxy-4-(1H-indol-3-yl)-3-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]-2H-pyrrol-2-one; 949935-06-2; LW4"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	DB12369	.	.	438.5	3	C25H22N6O2	94.2	822	2.6	33	2	6	"InChI=1S/C25H22N6O2/c1-30-10-12-31(13-11-30)25-27-19-9-5-3-7-16(19)22(28-25)21-20(23(32)29-24(21)33)17-14-26-18-8-4-2-6-15(17)18/h2-9,14,26H,10-13H2,1H3,(H,29,32,33)"	CN1CCN(CC1)C2=NC3=CC=CC=C3C(=N2)C4=C(C(=O)NC4=O)C5=CNC6=CC=CC=C65	OAVGBZOFDPFGPJ-UHFFFAOYSA-N
DG01509	AEE-788	10297043	"497839-62-0; AEE788; AEE-788; AEE 788; NVP-AEE788; (R)-6-(4-((4-Ethylpiperazin-1-yl)methyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; AEE788 (NVP-AEE788); UNII-F9JLR95I3I; GNF-Pf-5343; F9JLR95I3I; NVP-AEE-788; 6-{4-[(4-Ethylpiperazin-1-Yl)methyl]phenyl}-N-[(1r)-1-Phenylethyl]-7h-Pyrrolo[2,3-D]pyrimidin-4-Amine; 6-[4-[(4-Ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine; C27H32N6; (R)-6-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine.; 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-; 6-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 7h-pyrrolo[2,3-d]pyrimidin-4-amine,6-(4-((4-ethyl-1-piperazinyl)methyl)phenyl)-n-((1r)-1-phenylethyl)-; AEE; MLS006011277; SCHEMBL613756; CHEMBL587723; GTPL7643; BDBM26105; CHEBI:40629; AEE788; NVP-AEE788; BCPP000427; EX-A2259; MFCD11100351; NSC765949; NSC799325; s1486; ZINC22453679; AEE-788 (NVP-AEE788); AKOS016011091; BCP9000241; CCG-264897; CS-1452; DB12558; NSC-765949; NSC-799325; QC-8215; NCGC00263149-01; 7H-pyrrolo(2,3-d)pyrimidin-4-amine, 6-(4-((4-ethyl-1-piperazinyl)methyl)phenyl)-N-((1R)-1-phenylethyl)-; AC-32829; AEE788, >=98% (HPLC); AS-55853; HY-10045; SMR004703027; SW219869-1; X7492; J-518187; Q4651286; UNII-F9JLR95I3I component OONFNUWBHFSNBT-HXUWFJFHSA-N; [6-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-((r)-1-phenylethyl)amine; 1H-Pyrrolo(2,3-d)pyrimidin-4-amine, 6-(4-((4-ethyl-1-piperazinyl)methyl)phenyl)-N-((1R)-1-phenylethyl)-; 6-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[3,2-e]pyrimidin-4-amine; 6-{4-[(4-ethyl-1-piperazinyl)methyl]phenyl}-N-[(1R)-1-phenylethyl]-1H-pyrrolo[2,3-d]pyrimidin-4-amine; NVP-AEE788; ; ; 6-[4-[(4-Ethylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine"	Phase 1/2	8	Clinical Trial Drug(s)	Phase 1/2	Small molecular drug	.	DB12558	.	.	440.6	7	C27H32N6	60.1	579	4.6	33	2	5	"InChI=1S/C27H32N6/c1-3-32-13-15-33(16-14-32)18-21-9-11-23(12-10-21)25-17-24-26(28-19-29-27(24)31-25)30-20(2)22-7-5-4-6-8-22/h4-12,17,19-20H,3,13-16,18H2,1-2H3,(H2,28,29,30,31)/t20-/m1/s1"	CCN1CCN(CC1)CC2=CC=C(C=C2)C3=CC4=C(N3)N=CN=C4N[C@H](C)C5=CC=CC=C5	OONFNUWBHFSNBT-HXUWFJFHSA-N
DG01510	Napabucasin	10331844	"Napabucasin; 83280-65-3; 2-Acetylfuro-1,4-naphthoquinone; BBI608; 2-acetylnaphtho[2,3-b]furan-4,9-dione; 2-acetylbenzo[f][1]benzofuran-4,9-dione; BBI-608; UNII-Z1HHM49K7O; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; Z1HHM49K7O; BBI 608; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; Napabucasin [USAN:INN]; FNQ; Napabucasin; BBI608; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; GTPL11358; AMY27812; BCP07628; EX-A1314; BDBM50366597; MFCD28155270; NSC788900; s7977; ZINC13306865; AKOS027470201; CCG-266871; CS-1747; DB12155; NSC-788900; 2-acetyl naphtho2,3-bfuran-4,9-dione; AC-32935; AS-60519; HY-13919; 2-Acetyl-naphtho[2,3-b]furan-4,9-dione; A13474; D10717; F17379; Q27294876"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	.	DB12155	.	.	240.21	1	C14H8O4	64.4	414	2.3	18	0	4	"InChI=1S/C14H8O4/c1-7(15)11-6-10-12(16)8-4-2-3-5-9(8)13(17)14(10)18-11/h2-6H,1H3"	CC(=O)C1=CC2=C(O1)C(=O)C3=CC=CC=C3C2=O	DPHUWDIXHNQOSY-UHFFFAOYSA-N
DG01511	Crenolanib	10366136	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); CP-868596; ARO-002; UNII-LQF7I567TQ; CP-868,596; Crenolanib [USAN]; CP 868596; ARO 002; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; LQF7I567TQ; CP868569; 1-(2-{5-[(3-Methyloxetan-3-yl)methoxy]-1H-benzimidazol-1-yl}quinolin-8-yl)piperidin-4-amine; CP-868596 (Crenolanib); Crenolanib (USAN); MFCD21609260; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; 1-(2-(5-((3-methyloxetan-3-yl)methoxy)-1H-benzo[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine.; 1-(2-{5-[(3-methyloxetan-3-yl)methoxy]-1H-1,3-benzodiazol-1-yl}quinolin-8-yl)piperidin-4-amine; CP868596; Crenolanib [USAN:INN]; crenolanibum; 6T2; CP-868569; Crenolanib,CP-868596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; MLS006010956; Crenolanib - CP-868569; GTPL7882; SCHEMBL2730601; CHEMBL2105728; DTXSID50985873; EX-A215; CHEBI:145365; BDBM185149; HMS3656F19; AOB87312; BCP02384; ZINC3820043; NSC763526; NSC800079; s2730; AKOS026750597; BCP9000551; CCG-264988; CS-0566; DB11832; NSC-763526; NSC-800079; SB16603; NCGC00346658-01; NCGC00346658-09; 1-(2-(5-((3-methyloxetan-3-yl)methoxy)-1H-benzo[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; AC-32071; AS-57698; HY-13223; SMR004702760; SY237889; FT-0665221; SW218293-2; X7517; D10102; J-502712; Q5184160; CP-868596;CP 868596;CP868596;ARO 002; 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1H-benzimidazol-1-yl]-8-quinolinyl]-4-piperidinamine; 1-{2-[5-(3-Methyl-oxetan-3-ylmethoxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-ylamine"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:145365	DB11832	.	.	443.5	5	C26H29N5O2	78.4	667	3.7	33	1	6	"InChI=1S/C26H29N5O2/c1-26(14-32-15-26)16-33-20-6-7-22-21(13-20)28-17-31(22)24-8-5-18-3-2-4-23(25(18)29-24)30-11-9-19(27)10-12-30/h2-8,13,17,19H,9-12,14-16,27H2,1H3"	CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4	DYNHJHQFHQTFTP-UHFFFAOYSA-N
DG01512	Spliceostatin A	10673568	"Spliceostatin A; [(Z,2S)-4-[[(2R,3R,5S,6S)-6-[(2E,4E)-5-[(3R,4R,5R,7S)-4-hydroxy-7-methoxy-7-methyl-1,6-dioxaspiro[2.5]octan-5-yl]-3-methylpenta-2,4-dienyl]-2,5-dimethyloxan-3-yl]carbamoyl]but-3-en-2-yl] acetate; 391611-36-2; CHEMBL1221942; SCHEMBL18134895; BP-28004; Q59780090; (2Z,4S)-N-[(2R,3R,5S,6S)-2,5-Dimethyl-6-[(2E)-3-methyl-5-[(3R,4R,5R,7S)-4-hydroxy-7-methoxy-7-methyl-1,6-dioxaspiro[2.5]octane-5-yl]-2,4-pentadienyl]tetrahydro-2H-pyran-3-yl]-4-acetoxy-2-penteneamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	521.6	10	C28H43NO8	116	916	2.6	37	2	8	"InChI=1S/C28H43NO8/c1-17(9-12-24-26(32)28(16-34-28)15-27(6,33-7)37-24)8-11-23-18(2)14-22(20(4)36-23)29-25(31)13-10-19(3)35-21(5)30/h8-10,12-13,18-20,22-24,26,32H,11,14-16H2,1-7H3,(H,29,31)/b12-9+,13-10-,17-8+/t18-,19-,20+,22+,23-,24+,26+,27-,28+/m0/s1"	C[C@H]1C[C@H]([C@H](O[C@H]1C/C=C(\\C)/C=C/[C@@H]2[C@H]([C@@]3(C[C@@](O2)(C)OC)CO3)O)C)NC(=O)/C=C\\[C@H](C)OC(=O)C	XKSGIJNRMWHQIQ-CGPJBNNXSA-N
DG01513	Regorafenib	11167602	"Regorafenib; 755037-03-7; BAY 73-4506; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; Regorafenibum; Regorafenib (BAY 73-4506); BAY73-4506; UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; Regorafenib-13C-d3; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide; Regorafenib [USAN:INN]; Fluoro-Sorafenib; 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl}amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide; Regorafenib (USAN/INN); RegorafenibBAY73-4506; MLS006010303; C21H15ClF4N4O3; Regorafenib crystalline form I; SCHEMBL432230; Regorafenib,BAY 73-4506; GTPL5891; QCR-85; Bay-734506; DTXSID60226441; EX-A058; Regorafenib - BAY 73-4506; SYN1169; BCPP000352; HMS3654K16; HMS3672E15; AOB87754; BCP02105; BKD17855; ZINC6745272; BDBM50363397; MFCD16038047; NSC763932; NSC800865; s1178; AKOS015951107; AM81251; BAY 734506; BCP9000384; CCG-269571; CS-0170; DB08896; NSC-763932; NSC-800865; SB16819; NCGC00263138-01; NCGC00263138-13; NCGC00263138-19; 2-Pyridinecarboxamide,4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-; AC-25075; AC-31116; AS-16304; HY-10331; SMR004701370; FT-0674338; R0142; SW218097-2; cas:835621-07-3;Regorafenib hydrochloride; Regorafenib (BAY73-4506,Fluoro-Sorafenib); A25020; D10138; AB01565826_02; SR-01000941571; Q3891664; SR-01000941571-1; BRD-K16730910-001-02-4; 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-; 4-[4-({[4-Chloro-3-(trifluoromethy)phenyl]carbamoyl}amino)-3-fluorophenoxy]-1-methylpyridine-2-carboxamide; 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide; 835621-08-4; Regorafenib;1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:68647	DB08896	DR1401	DR00136	482.8	5	C21H15ClF4N4O3	92.4	686	4.2	33	3	8	"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)"	CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F	FNHKPVJBJVTLMP-UHFFFAOYSA-N
DG01514	DEL-22379	11224574	"DEL-22379; 181223-80-3; DEL22379; CHEBI:90905; AMY16577; EX-A1739; AKOS027470285; ZINC137055150; CCG-269173; CS-5355; (Z)-N-(3-((5-methoxy-1H-indol-3-yl)methylene)-2-oxoindolin-5-yl)-3-(piperidin-1-yl)propanamide; CID 11224574; HY-18932; Q21044462; 181222-54-8; N-[2,3-Dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-1H-indol-5-yl]-1-piperidinepropanamide; N-{(3Z)-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-2,3-dihydro-1H-indol-5-yl}-3-(piperidin-1-yl)propanamide; N-{(3Z)-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-2,3-dihydro-1H-indol-5-yl}-3-(piperidin-1-yl)propionamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	444.5	6	C26H28N4O3	86.5	750	3	33	3	4	"InChI=1S/C26H28N4O3/c1-33-19-6-8-23-20(15-19)17(16-27-23)13-22-21-14-18(5-7-24(21)29-26(22)32)28-25(31)9-12-30-10-3-2-4-11-30/h5-8,13-16,27H,2-4,9-12H2,1H3,(H,28,31)(H,29,32)/b22-13-"	COC1=CC2=C(C=C1)NC=C2/C=C\\3/C4=C(C=CC(=C4)NC(=O)CCN5CCCCC5)NC3=O	INQUULPXCZAKMS-XKZIYDEJSA-N
DG01515	Brivanib	11234052	"Brivanib; 649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; BMS540215; Brivanib [USAN]; CHEMBL377300; DDU33B674I; (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; Brivanib (USAN); (R)-1-((4-((4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY)-5-METHYLPYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL)OXY)PROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol; (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo(2,1-f)(1,2,4)triazin-6-yloxy)propan-2-ol; (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-6-yloxy)propan-2-ol; (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol; Brivanib,BMS-540215; Brivanib (BMS540215); MLS006011288; Brivanib - BMS-540215; GTPL5671; QCR-57; SCHEMBL1227589; CHEBI:94562; DTXSID60215294; EX-A011; SYN1134; CHEBI:167686; BCPP000317; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-propanol; BDBM50184807; MFCD13194684; NSC799368; s1084; ZINC13684256; AKOS015920386; AKOS015949459; BMS 540215;Unii-ddu33B674i; AC-5252; BCP9000449; CCG-268296; CS-0148; DB11958; NSC-799368; NCGC00263160-01; AS-16273; HY-10337; SMR004703038; SW219896-1; X2635; EC-000.2327; A24076; D09589; 735B466; J-500907; BRD-K28428262-001-01-7; Q27075503; (2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol; (r)-1-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol; 2-Propanol, 1-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo(2,1-f)(1,2,4)triazin-6-yl)oxy)-, (2R)-"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:94562	DB11958	.	.	370.4	5	C19H19FN4O3	84.7	515	3	27	2	6	"InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1"	CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)O)C	WCWUXEGQKLTGDX-LLVKDONJSA-N
DG01516	Sapitinib	11488320	Sapitinib; 848942-61-0; AZD8931; AZD-8931; AZD8931 (Sapitinib); 2-(4-((4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)-n-methylacetamide; Sapitinib(AZD8931); Sapitinib (AZD-8931); UNII-3499328002; CHEMBL2408045; 2-[4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)piperidin-1-yl]-N-methylacetamide; 2-[4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-N-methylacetamide; Sapitinib [INN]; 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-((1-(n-methylcarbamoylmethyl)piperidin-4-yl)oxy)quinazoline; 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-[[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy]quinazoline; Sapitinib [WHO-DD]; sapitinibum; AZD 8931; AZD-8931(Sapitinib); Sapitinib (AZD8931); MLS006011283; SCHEMBL202358; GTPL7717; DTXSID50233942; EX-A036; CHEBI:132986; BCPP000365; HMS3655J08; AOB87778; BCP02835; BDBM50437353; MFCD18385011; NSC758005; NSC800876; s2192; ZINC34587071; AKOS025404911; BCP9000357; CCG-264744; CS-3951; DB12183; NSC-758005; NSC-800876; QC-7257; SB16597; NCGC00346573-01; NCGC00346573-05; AC-32815; AS-17066; HY-13050; SMR004703033; FT-0700374; SW219260-1; J-513371; Q27088689; 2-(4-(4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-N-methylacetamide; 2-(4-{[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy}piperidin-1-yl)-N-methylacetamide; 2-[4-[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-N-methylacetamide	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:132986	DB12183	.	.	473.9	7	C23H25ClFN5O3	88.6	641	4	33	2	8	"InChI=1S/C23H25ClFN5O3/c1-26-21(31)12-30-8-6-14(7-9-30)33-20-10-15-18(11-19(20)32-2)27-13-28-23(15)29-17-5-3-4-16(24)22(17)25/h3-5,10-11,13-14H,6-9,12H2,1-2H3,(H,26,31)(H,27,28,29)"	CNC(=O)CN1CCC(CC1)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC	DFJSJLGUIXFDJP-UHFFFAOYSA-N
DG01517	Tivantinib	11494412	"Tivantinib; 905854-02-6; ARQ 197; ARQ-197; ARQ197; (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; Tivantinib (ARQ 197); PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; 905853-99-8; rel-(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-pyrrolidinedione; Tivantinib [USAN:INN]; Tivantinib; ARQ197; ARQ 197 (Tivantinib); Tivantinib (ARQ-197); SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; DTXSID60920316; QCR-102; ARQ-197,Tivantinib, ARQ197; ARQ197; ARQ-197;Tivantinib; BCPP000042; AOB87130; BCP02529; EX-A2169; CAS:905854-02-6;Tivantinib; BDBM50146168; NSC758242; NSC800951; s2753; AKOS022182739; ZINC100016063; CCG-268285; DB12200; NSC-758242; NSC-800951; (-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; AC-25009; AS-16991; HY-50686; J3.496.311H; C77073; D10173; E82820; A857990; J-501255; BRD-K33379087-001-01-8; Q17123902; (+/-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4(1H-indol-3-yl)pyrrolidine-2,5-dione; (+/-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine-2,5-dione; (+/-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; (_)-trans-3-(5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-1-yl)-4(1h-indol-3-yl)pyrrolidine-2,5-dione; (3R,4R)-3-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; (3R,4R)-3-(2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-pyrrolidine-2,5-dione; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinoline-1-yl)-4-(1H-indole-3-yl)pyrrolidine-2,5-dione; 2,5-Pyrrolidinedione, 3-(5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)-, (3R,4R)-; 2,5-Pyrrolidinedione,3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-,(3R,4R)-rel-; 3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-5-hydroxy-4-(1H-indol-3-yl)-3,4-dihydro-2H-pyrrol-2-one; TIV; trans 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-pyrrolidine-2,5-dione"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:91398	DB12200	.	.	369.4	2	C23H19N3O2	66.9	666	2.9	28	2	2	"InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1"	C1CC2=C3C(=CC=C2)C(=CN3C1)[C@H]4[C@@H](C(=O)NC4=O)C5=CNC6=CC=CC=C65	UCEQXRCJXIVODC-PMACEKPBSA-N
DG01518	RO4927350	11526671	"876755-27-0; RO4927350; Ro 4927350; (2S,3S)-2-((R)-4-(4-(2-hydroxyethoxy)phenyl)-2,5-dioxoimidazolidin-1-yl)-3-phenyl-N-(4-propionylthiazol-2-yl)butanamide.; SCHEMBL1204725; CHEMBL2396994; CHEBI:132984; ZINC43203214; RO-4927350; (2S,3S)-2-[(4R)-4-[4-(2-hydroxyethoxy)phenyl]-2,5-dioxoimidazolidin-1-yl]-3-phenyl-N-(4-propanoyl-1,3-thiazol-2-yl)butanamide; (2S,3S)-2-{(4R)-4-[4-(2-hydroxyethoxy)phenyl]-2,5-dioxoimidazolidin-1-yl}-3-phenyl-N-(4-propionyl-1,3-thiazol-2-yl)butanamide; (2s,3s)-2-{(r)-4-[4-(2-hydroxy-ethoxy)-phenyl]-2,5-dioxo-imidazolidin-1-yl}-3-phenyl-n-(4-propionyl-thiazol-2-yl)-butyramide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	536.6	11	C27H28N4O6S	166	861	3.2	38	3	8	"InChI=1S/C27H28N4O6S/c1-3-21(33)20-15-38-26(28-20)30-24(34)23(16(2)17-7-5-4-6-8-17)31-25(35)22(29-27(31)36)18-9-11-19(12-10-18)37-14-13-32/h4-12,15-16,22-23,32H,3,13-14H2,1-2H3,(H,29,36)(H,28,30,34)/t16-,22+,23-/m0/s1"	CCC(=O)C1=CSC(=N1)NC(=O)[C@H]([C@@H](C)C2=CC=CC=C2)N3C(=O)[C@H](NC3=O)C4=CC=C(C=C4)OCCO	RKKBPPTYPGTSEA-FNVCAUGXSA-N
DG01519	RO4987655	11548630	"RO4987655; 874101-00-5; RO-4987655; CH4987655; CH-4987655; UNII-I3733P75ML; 3,4-Difluoro-2-[(2-Fluoro-4-Iodophenyl)amino]-N-(2-Hydroxyethoxy)-5-[(3-Oxo-1,2-Oxazinan-2-Yl)methyl]benzamide; 3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-5-((3-oxomorpholino)methyl)benzamide; CHEMBL1614766; I3733P75ML; RO 4987655; 3,4-Difluoro-2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-5-((3-oxo-1,2-oxazinan-2-yl)methyl)benzamide; C20H19F3IN3O5; 3,4-Difluoro-2-(2-fluoro-4-iodo-anilino)-N-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide; 3orn; GTPL9910; SCHEMBL1562083; SYN1188; BCP12182; EX-A2312; 4014AH; BDBM50338038; NSC762521; NSC800870; RG7167; ZINC43103796; AKOS005266648; DB12933; NSC-762521; NSC-800870; SB16732; r-7167; compound 24 [PMID: 21316218]; NCGC00378595-03; AS-16322; HY-14719; DS-016573; B3261; US8575391, 334; RO4987655; CH-4987655; Q27280303; 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)-5-(3-oxo-[1,2]oxazinan-2-ylmethyl)-benzamide; 3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-5-[(3-oxo-2-oxazinanyl)methyl]benzamide; 3,4-difluoro-2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide; 3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide; 3OR; Benzamide, 3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-5-[(tetrahydro-3-oxo-2H-1,2-oxazin-2-yl)methyl]-"	Discontinued in Phase 1	13	Discontinued Drug(s)	Discontinued in Phase 1	Small molecular drug	.	DB12933	.	.	565.3	8	C20H19F3IN3O5	100	652	3	32	3	9	"InChI=1S/C20H19F3IN3O5/c21-14-9-12(24)3-4-15(14)25-19-13(20(30)26-31-7-5-28)8-11(17(22)18(19)23)10-27-16(29)2-1-6-32-27/h3-4,8-9,25,28H,1-2,5-7,10H2,(H,26,30)"	C1CC(=O)N(OC1)CC2=CC(=C(C(=C2F)F)NC3=C(C=C(C=C3)I)F)C(=O)NOCCO	FIMYFEGKMOCQKT-UHFFFAOYSA-N
DG01520	RAF-265	11656518	"RAF265; 927880-90-8; CHIR-265; RAF 265; RAF-265; RAF265(CHIR-265); CHIR 265; RAF265 (CHIR-265); 1-Methyl-5-[[2-[5-(trifluoromethyl)-1h-imidazol-2-yl]-4-pyridinyl]oxy]-n-[4-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine; 1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine; CHIR265; UNII-8O434L3768; RAF-265 (CHIR-265); 8O434L3768; 1-Methyl-5-({2-[5-(Trifluoromethyl)-1h-Imidazol-2-Yl]pyridin-4-Yl}oxy)-N-[4-(Trifluoromethyl)phenyl]-1h-Benzimidazol-2-Amine; 1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine; 1-Methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]-oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine; NVP-RAF265; SCHEMBL686452; CHEMBL558752; GTPL5674; BDBM31088; C24H16F6N6O; CHEBI:91451; EX-A072; cid_11656518; HMS3655B06; HMS3672I21; AMY24172; AOB87162; RAF265 - CHIR-265; MFCD16659061; NSC754357; NSC800861; s2161; ZINC18710085; CHIR 265 (RAF 265); AKOS025117575; CCG-264703; CS-0232; DB05984; EX-8671; NSC-754357; NSC-800861; SB16578; NCGC00250407-01; NCGC00250407-04; 1-methyl-5-((2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yl)oxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine; AC-30291; AS-56738; HY-10248; QC-11760; FT-0746327; SW219923-1; X7407; A25488; J-504965; Q27075961; [1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridyl]oxy]benzimidazol-2-yl]-[4-(trifluoromethyl)phenyl]amine; {1-Methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzo-imidazol-2-yl}-(4-trifluoromethyl-phenyl)-amine; {1-Methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)-amine; 1-methyl-5-({2-[4-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl}oxy)-N-[4-(trifluoromethyl)phenyl]-1H-1,3-benzodiazol-2-amine; 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine; 1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)pyridin-4-yloxy]-N-(4-trifluoromethylphenyl)-1H-benzo[d]imidazol-2-amine; 1H-Benzimidazol-2-amine, 1-methyl-5-((2-(5-(trifluoromethyl)-1H-imidazol-2-yl)-4-pyridinyl)oxy)-N-(4-(trifluoromethyl)phenyl)-; 1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]; 55J; CHIR-265;1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:91451	DB05984	.	.	518.4	5	C24H16F6N6O	80.6	763	5.4	37	2	11	"InChI=1S/C24H16F6N6O/c1-36-19-7-6-15(10-17(19)34-22(36)33-14-4-2-13(3-5-14)23(25,26)27)37-16-8-9-31-18(11-16)21-32-12-20(35-21)24(28,29)30/h2-12H,1H3,(H,32,35)(H,33,34)"	CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=CC=C(C=C5)C(F)(F)F	YABJJWZLRMPFSI-UHFFFAOYSA-N
DG01521	Motesanib	11667893	"Motesanib; 453562-69-1; AMG 706; AMG-706; N-(3,3-dimethylindolin-6-yl)-2-(pyridin-4-ylmethylamino)nicotinamide; AMG706; UNII-U1JK633AYI; N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide; N-(2,3-Dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide; U1JK633AYI; CHEBI:51098; 453562-69-1 (free base); N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide; N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide; C22H23N5O; N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4- ylmethyl)amino]pyridine-3-carboxamide; Motesanib [USAN:INN]; N-(3,3-Dimethyl-2,3-dihydro-1H-indol-6-yl)-2-((pyridin-4-ylmethyl)amino)pyridine-3-carboxamide; Motesanib (USAN); AMG706/ Motesanib; Motesanib (AMG-706); SCHEMBL187470; CHEMBL572881; GTPL5660; QCR-80; BDBM24773; DTXSID10196488; EX-A487; SYN1055; cid_11667893; BCPP000407; HMS3244A09; HMS3244A10; HMS3244B09; HMS3265G19; HMS3265G20; HMS3265H19; HMS3265H20; AOB87176; BCP01982; AMG 706; AMG-706; MFCD10567689; NSC760843; NSC800801; s5793; ZINC18710082; AKOS005146333; N-(3,3-dimethylindolin-6-yl)-2-((pyridin-4-ylmethyl)amino)nicotinamide; BCP9000289; DB05575; EX-8571; NSC-760843; NSC-800801; SB14621; NCGC00263205-01; NCGC00263205-06; AC-32664; AS-16212; HY-10228; FT-0706483; X4931; A19395; D06678; 562M691; J-522983; Q6917202; BRD-K99616396-316-01-2; N-(3,3-dimethylindolin-6-yl)-2-(4-pyridylmethylamino)nicotinamide; N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)-3-pyridinecarboxamide; 3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-"	Discontinued in Phase 3	11	Discontinued Drug(s)	Discontinued in Phase 3	Small molecular drug	CHEBI:51098	DB05575	.	.	373.5	5	C22H23N5O	78.9	533	3.9	28	3	5	"InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)"	CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C	RAHBGWKEPAQNFF-UHFFFAOYSA-N
DG01522	AZ628	11676786	"878739-06-1; AZ 628; AZ-628; AZ628; 3-(2-Cyanopropan-2-yl)-N-(4-methyl-3-((3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)phenyl)benzamide; AZD628; UNII-560S6B5D79; 3-(2-cyanopropan-2-yl)-N-(4-methyl-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)benzamide; 3-(1-Cyano-1-methylethyl)-N-[3-[(3,4-dihydro-3-methyl-4-oxo-6-quinazolinyl)amino]-4-methylphenyl]benzamide; 3-(Cyano-dimethyl-methyl)-N-[4-methyl-3-(3-methyl-4-oxo-3,4-dihydro-quinazolin-6-ylamino)-phenyl]-benzamide; CHEMBL2144069; 3-(2-cyanopropan-2-yl)-N-[4-methyl-3-[(3-methyl-4-oxoquinazolin-6-yl)amino]phenyl]benzamide; 560S6B5D79; C27H25N5O2; 3-(2-Cyanopropan-2-Yl)-N-{4-Methyl-3-[(3-Methyl-4-Oxo-3,4-Dihydroquinazolin-6-Yl)amino]phenyl}benzamide; B1E; MLS006010314; GTPL8475; SCHEMBL4209241; CHEBI:91354; DTXSID70236677; EX-A302; QCR-186; HMS3265I11; HMS3265I12; HMS3265J11; HMS3265J12; HMS3656F21; HMS3743G19; BCP02117; BDBM50430022; MFCD17392577; NSC782007; s2746; ZINC38226503; AKOS016011304; BCP9000346; CCG-264992; CS-0091; NSC-782007; SB19421; NCGC00250380-01; NCGC00250380-03; NCGC00250380-10; AC-26863; Benzamide, 3-(1-cyano-1-methylethyl)-N-(3-((3,4-dihydro-3-methyl-4-oxo-6-quinazolinyl)amino)-4-methylphenyl)-; BS-42436; HY-11004; SMR004701380; FT-0700393; SW219448-1; Y0332; J-510421; BRD-K05804044-001-01-1; Q27074677; 3-(1-Cyano-1-methylethyl)-N-{4-methyl-3-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino]phenyl}benzamide"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:91354	.	.	.	451.5	5	C27H25N5O2	97.6	845	4.2	34	2	5	"InChI=1S/C27H25N5O2/c1-17-8-9-21(31-25(33)18-6-5-7-19(12-18)27(2,3)15-28)14-24(17)30-20-10-11-23-22(13-20)26(34)32(4)16-29-23/h5-14,16,30H,1-4H3,(H,31,33)"	CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(C)(C)C#N)NC3=CC4=C(C=C3)N=CN(C4=O)C	ZGBGPEDJXCYQPH-UHFFFAOYSA-N
DG01523	GDC0879	11717001	"GDC-0879; 905281-76-7; (E)-5-(1-(2-hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime; CHEBI:83405; GDC0879; UNII-E488J6BA6E; (E)-5-(1-(2-hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydroinden-1-one oxime; CHEMBL525191; E488J6BA6E; GDC 0879; 2-[4-[(1E)-1-hydroxyimino-2,3-dihydroinden-5-yl]-3-pyridin-4-ylpyrazol-1-yl]ethanol; 2,3-dihydro-5-(1-(2-hydroxyethyl)-3-(4-pyridinyl)-1h-pyrazol-4-yl)-1h-inden-1-one oxime; 2,3-Dihydro-5-[1-(2-hydroxyethyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl]-1H-inden-1-one oxime; 2-{4-[(1e)-1-(Hydroxyimino)-2,3-Dihydro-1h-Inden-5-Yl]-3-(Pyridin-4-Yl)-1h-Pyrazol-1-Yl}ethanol; SCHEMBL2467603; DTXSID00471110; BCPP000222; AMY20724; EX-A2357; GDC-0879,GDC0879; BDBM50029085; s1104; ZINC34640412; AKOS015856553; BCP9000714; CCG-264821; CS-0158; NCGC00263179-09; HY-50864; QC-11137; BCP0726000314; DB-000743; GDC-0879, >=98% (HPLC); X7405; EC-000.2334; J-506998; BRD-K67578145-001-01-4; BRD-K67578145-001-12-1; (E)-5-(1-(2-Hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one; (E)-5-(1-(2-hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydroinden-1-oneoxime; 5-(1-(2-Hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydroinden-1-one oxime; 5-[1-(2-Hydroxy-ethyl)-3-pyridin-4-yl-1H-pyrazol-4-yl]-indan-1-one oxime; 1H-Inden-1-one, 2,3-dihydro-5-(1-(2-hydroxyethyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl)-, oxime; 1H-Inden-1-one, 2,3-dihydro-5-(1-(2-hydroxyethyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl)-, oxime, (1E)-; 2-{4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-pyridin-4-yl-1H-pyrazol-1-yl}ethanol;(E)-5-(1-(2-hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydroinden-1-one oxime; 2230954-03-5"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	334.4	4	C19H18N4O2	83.5	480	1.7	25	2	5	"InChI=1S/C19H18N4O2/c24-10-9-23-12-17(19(21-23)13-5-7-20-8-6-13)15-1-3-16-14(11-15)2-4-18(16)22-25/h1,3,5-8,11-12,24-25H,2,4,9-10H2/b22-18+"	C1C/C(=N\\O)/C2=C1C=C(C=C2)C3=CN(N=C3C4=CC=NC=C4)CCO	DEZZLWQELQORIU-RELWKKBWSA-N
DG01524	Ulixertinib	11719003	"Ulixertinib; 869886-67-9; VRT752271; BVD-523; Ulixertinib (BVD-523); UNII-16ZDH50O1U; Ulixertinib [INN]; 16ZDH50O1U; CHEMBL3590106; Ulixertinib (INN); 869886-67-9 (free base); VRT-752271; Ulixertinib (BVD-523, VRT752271); (S)-4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-2-carboxamide; (S)-4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-2-carboxamide.; 4-[5-chloranyl-2-(propan-2-ylamino)pyridin-4-yl]-~{N}-[(1~{S})-1-(3-chlorophenyl)-2-oxidanyl-ethyl]-1~{H}-pyrrole-2-carboxamide; N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1H-pyrrole-2-carboxamide; BVD-ERK; Ulixertinib (BVD-523,VRT752271); 4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-N-((S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-2-carboxamide; BVD523 HCl; BVD-523 HCl; VRT752271 HCl; GTPL9210; SCHEMBL14211742; BCP04232; EX-A1332; BDBM50094465; NSC797771; NSC800959; s7854; ZINC34642570; AKOS025396467; CCG-269049; DB13930; NSC-797771; NSC-800959; NCGC00378692-02; NCGC00378692-05; NCGC00378692-07; 1H-Pyrrole-2-carboxamide, 4-(5-chloro-2-((1-methylethyl)amino)-4-pyridinyl)-N-((1S)-1-(3-chlorophenyl)-2-hydroxyethyl)-; AC-33165; AS-56114; HY-15816; QC-10489; BCP0726000085; D11038; J-690368; Q27089081; 3,5-Dichloro-2-hydroxy-N-(4-methoxy-3-biphenylyl)benzenesulfonamide; 4-[5-Chloro-2-(isopropylamino)-4-pyridinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB13930	.	.	433.3	7	C21H22Cl2N4O2	90	539	4.1	29	4	4	"InChI=1S/C21H22Cl2N4O2/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29)/t19-/m1/s1"	CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(=CC=C3)Cl)Cl	KSERXGMCDHOLSS-LJQANCHMSA-N
DG01525	IRAK-1 or IRAK-4 inhibitors	11983295	"IRAK-1-4 Inhibitor I; 509093-47-4; IRAK-1/4 Inhibitor; IRAK-1/4 Inhibitor I; N-[1-(2-morpholin-4-ylethyl)benzimidazol-2-yl]-3-nitrobenzamide; Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor; CHEMBL379787; N-(1-(2-morpholinoethyl)-1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide; N-[1-[2-(4-morpholinyl)ethyl]-1H-benzimidazol-2-yl]-3-nitrobenzamide; IRAK-1-4 Inhibitor; IRAK1/4 Inhibitor I; MLS006010636; GTPL5990; SCHEMBL3600534; DTXSID50475143; HMS3229G05; HMS3263A20; HMS3744A07; BCP16164; EX-A1254; Tox21_501049; 3747AH; BDBM50184706; MFCD09752602; s6598; ZINC16052821; AKOS026750497; Benzamide, N-[1-[2-(4-morpholinyl)ethyl]-1H-benzimidazol-2-yl]-3-nitro-; CCG-206760; CS-0704; LP01049; SDCCGSBI-0086683.P002; NCGC00186035-01; NCGC00186035-02; NCGC00186035-03; NCGC00186035-04; NCGC00186035-10; NCGC00261734-01; BS-17437; HY-13329; SMR001456469; J3.545.430F; F17398; IRAK-1/4 Inhibitor I, >=98% (HPLC), solid; Q27078097; 1-[2-(4-Morpholinyl)ethyl]-2-(3-nitrobenzoylamino)-1H-benzoimidazole; 3-nitro-N-(1-(2-morpholin-4-yl-ethyl)-1H-benzoimidazol-2-yl)-benzamide; N-{1-[2-(morpholin-4-yl)ethyl]-1H-1,3-benzodiazol-2-yl}-3-nitrobenzamide"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	395.4	5	C20H21N5O4	105	580	2	29	1	6	"InChI=1S/C20H21N5O4/c26-19(15-4-3-5-16(14-15)25(27)28)22-20-21-17-6-1-2-7-18(17)24(20)9-8-23-10-12-29-13-11-23/h1-7,14H,8-13H2,(H,21,22,26)"	C1COCCN1CCN2C3=CC=CC=C3N=C2NC(=O)C4=CC(=CC=C4)[N+](=O)[O-]	QTCFYQHZJIIHBS-UHFFFAOYSA-N
DG01526	FR900359	14101198	"FR900359; [(1R)-1-[(3S,6S,9S,12S,18R,21S,22R)-21-acetamido-18-benzyl-3-[(1R)-1-methoxyethyl]-4,9,10,12,16-pentamethyl-15-methylidene-2,5,8,11,14,17,20-heptaoxo-22-propan-2-yl-1,19-dioxa-4,7,10,13,16-pentazacyclodocos-6-yl]-2-methylpropyl] (2S,3R)-3-hydroxy-4-methyl-2-(propanoylamino)pentanoate; 107530-18-7; CHEMBL4171381; UBO-QIC; FR-900359; GTPL9336; SCHEMBL22133450; CHEBI:178012; BDBM50514449"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	1002.2	15	C49H75N7O15	286	1940	3.5	71	5	15	"InChI=1S/C49H75N7O15/c1-17-34(58)52-35(39(59)24(2)3)47(65)70-40(25(4)5)36-46(64)56(15)38(30(11)68-16)49(67)71-41(26(6)7)37(51-31(12)57)48(66)69-33(23-32-21-19-18-20-22-32)45(63)55(14)28(9)42(60)50-27(8)44(62)54(13)29(10)43(61)53-36/h18-22,24-27,29-30,33,35-41,59H,9,17,23H2,1-8,10-16H3,(H,50,60)(H,51,57)(H,52,58)(H,53,61)/t27-,29-,30+,33+,35-,36-,37-,38-,39+,40+,41+/m0/s1"	CCC(=O)N[C@@H]([C@@H](C(C)C)O)C(=O)O[C@@H]([C@H]1C(=O)N([C@H](C(=O)O[C@@H]([C@@H](C(=O)O[C@@H](C(=O)N(C(=C)C(=O)N[C@H](C(=O)N([C@H](C(=O)N1)C)C)C)C)CC2=CC=CC=C2)NC(=O)C)C(C)C)[C@@H](C)OC)C)C(C)C	IMXKHFILKMPFGB-ZWYWTTNJSA-N
DG01527	MRK-003	15953832	"MRK003; 623165-93-5; CHEMBL196215; (1'R,4R,10'S)-2-(2,2,2-Trifluoroethyl)-5'-[(E)-3-[4-(trifluoromethyl)piperidin-1-yl]prop-1-enyl]spiro[1,2,5-thiadiazolidine-4,13'-tricyclo[8.2.1.03,8]trideca-3(8),4,6-triene] 1,1-dioxide; MRK 003; MRK-003; SCHEMBL14181954; BDBM50171224; ZINC28526589; AKOS025149447; (3'R,6S,9R)-5,6,7,8,9,10-Hexahydro-5'-(2,2,2-trifluoroethyl)-2-[(1E)-3-[4-(trifluoromethyl)-1-piperidinyl]-1-propen-1-yl]spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazolidine] 1',1'-dioxide; (3R,6'S,9'R)-5-(2,2,2-Trifluoroethyl)-2'-((E)-3-(4-(trifluoromethyl)piperidin-1-yl)prop-1-en-1-yl)-5',6',7',8',9',10'-hexahydrospiro[[1,2,5]thiadiazolidine-3,11'-[6,9]methanobenzo[8]annulene] 1,1-dioxide; 423167-89-9; Rel-(3R,6'S,9'R)-5-(2,2,2-trifluoroethyl)-2'-((E)-3-(4-(trifluoromethyl)piperidin-1-yl)prop-1-en-1-yl)-5',6',7',8',9',10'-hexahydrospiro[[1,2,5]thiadiazolidine-3,11'-[6,9]methanobenzo[8]annulene] 1,1-dioxide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	551.6	4	C25H31F6N3O2S	61	957	5.3	37	1	11	"InChI=1S/C25H31F6N3O2S/c26-24(27,28)16-34-15-23(32-37(34,35)36)21-5-6-22(23)14-19-12-17(3-4-18(19)13-21)2-1-9-33-10-7-20(8-11-33)25(29,30)31/h1-4,12,20-22,32H,5-11,13-16H2/b2-1+/t21-,22+,23+/m0/s1"	C1C[C@@H]2CC3=C(C[C@H]1[C@]24CN(S(=O)(=O)N4)CC(F)(F)F)C=CC(=C3)/C=C/CN5CCC(CC5)C(F)(F)F	NKHUILHBYOOZDF-NCOIWELASA-N
DG01528	JW74	16013152	"JW74; 863405-60-1; CHEMBL1552719; JW-74; 5-(((4-(4-methoxyphenyl)-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)thio)methyl)-3-(p-tolyl)-1,2,4-oxadiazole; SCHEMBL11919898; HMS1844M08; JW 74; ZINC8614303; BDBM50380592; CCG-68686; STL406359; AKOS001512198; CS-5463; MCULE-3805212654; JW74, >=98% (HPLC); NCGC00115449-01; NCGC00115449-04; HY-19739; D065-0024; 3-(4-Methylphenyl)-5-[[[4-(4-methoxyphenyl)-5-(4-pyridinyl)-4H-1,2,4-triazole-3-yl]thio]methyl]-1,2,4-oxadiazole; 4-[4-(4-methoxyphenyl)-5-({[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]methyl}sulfanyl)-4H-1,2,4-triazol-3-yl]pyridine; 4-[4-(4-methoxyphenyl)-5-({[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]methyl}thio)-4H-1,2,4-triazol-3-yl]pyridine; 4-[4-(4-Methoxyphenyl)-5-[[[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]methyl]thio]-4H-1,2,4-triazol-3-yl]-pyridine; 5-[[4-(4-methoxyphenyl)-5-pyridin-4-yl-1,2,4-triazol-3-yl]sulfanylmethyl]-3-(4-methylphenyl)-1,2,4-oxadiazole"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	456.5	7	C24H20N6O2S	117	596	4.3	33	0	8	"InChI=1S/C24H20N6O2S/c1-16-3-5-17(6-4-16)22-26-21(32-29-22)15-33-24-28-27-23(18-11-13-25-14-12-18)30(24)19-7-9-20(31-2)10-8-19/h3-14H,15H2,1-2H3"	CC1=CC=C(C=C1)C2=NOC(=N2)CSC3=NN=C(N3C4=CC=C(C=C4)OC)C5=CC=NC=C5	KRIKILRRJCIWNB-UHFFFAOYSA-N
DG01529	Voxtalisib	16123056	"Voxtalisib; 934493-76-2; SAR245409; 2-amino-8-ethyl-4-methyl-6-(1h-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7(8h)-one; UNII-CVL1685GPH; CVL1685GPH; Voxtalisib (XL765, SAR245409); Voxtalisib [USAN:INN]; Voxtalisib (USAN/INN); Voxtalisib (XL-765); SCHEMBL189573; CHEMBL3545366; CHEBI:124914; BCP16243; EX-A4140; BDBM50519385; NSC791226; NSC800972; s7646; ZINC35308805; 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one; AKOS037515701; CCG-267162; CS-3163; DB12400; NSC-791226; NSC-800972; SAR 245409; SB16573; Pyrido(2,3-d)pyrimidin-7(8H)-one, 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-3-yl)-; NCGC00387875-03; NCGC00387875-04; AC-29029; AS-56112; HY-15900; QC-11818; J3.527.559B; D11727; A855661; Q27215232; 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:124914	DB12400	.	.	270.29	2	C13H14N6O	101	425	0.5	20	2	5	"InChI=1S/C13H14N6O/c1-3-19-11-8(7(2)16-13(14)17-11)6-9(12(19)20)10-4-5-15-18-10/h4-6H,3H2,1-2H3,(H,15,18)(H2,14,16,17)"	CCN1C2=NC(=NC(=C2C=C(C1=O)C3=CC=NN3)C)N	RGHYDLZMTYDBDT-UHFFFAOYSA-N
DG01530	E7107	16202132	"E7107; UNII-R60DZX1E2N; R60DZX1E2N; 630100-90-2; (3R,6R,7S,8E,10S,11S,12E,14E,16R,18R,19R,20R,21S)-7-[(4-cycloheptylpiperazin-1-yl)carbonyl]oxy-3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-18,19-epoyxtrichosa-8,12,14-trien-11-olide; [(2S,3S,4E,6S,7R,10R)-7,10-dihydroxy-2-[(2E,4E,6R)-6-hydroxy-7-[(2R,3R)-3-[(2R,3S)-3-hydroxypentan-2-yl]oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-3,7-dimethyl-12-oxo-1-oxacyclododec-4-en-6-yl] 4-cycloheptylpiperazine-1-carboxylate; E 7107; SCHEMBL3624011; CHEMBL4297278; BDBM36359; DB12508; CID16202132; Q27287836; 1-Piperazinecarboxylic acid, 4-cycloheptyl-, (2S,3S,4E,6S,7R,10R)-7,10-dihydroxy-2-((1E,3E,5R)-5-hydroxy-6-((2R,3R)-3-((1R,2S)-2-hydroxy-1-methylbutyl)oxiranyl)-1,5-dimethyl-1,3-hexadienyl)-3,7-dimethyl-12-oxooxacyclododec-4-en-6-yl ester"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	DB12508	.	.	719	11	C40H66N2O9	153	1220	5.2	51	4	10	"InChI=1S/C40H66N2O9/c1-7-32(44)29(4)37-33(49-37)26-39(5,47)19-12-13-27(2)36-28(3)16-17-34(40(6,48)20-18-31(43)25-35(45)51-36)50-38(46)42-23-21-41(22-24-42)30-14-10-8-9-11-15-30/h12-13,16-17,19,28-34,36-37,43-44,47-48H,7-11,14-15,18,20-26H2,1-6H3/b17-16+,19-12+,27-13+/t28-,29+,31+,32-,33+,34-,36+,37+,39-,40+/m0/s1"	CC[C@@H]([C@@H](C)[C@@H]1[C@H](O1)C[C@](C)(/C=C/C=C(\\C)/[C@@H]2[C@H](/C=C/[C@@H]([C@](CC[C@H](CC(=O)O2)O)(C)O)OC(=O)N3CCN(CC3)C4CCCCCC4)C)O)O	MNOMBFWMICHMKG-MGYWSNOQSA-N
DG01531	Cobimetinib	16222096	"Cobimetinib; 934660-93-2; GDC-0973; XL518; Cotellic; Xl-518; GDC 0973; RG7420; XL 518; RG 7420; UNII-ER29L26N1X; ER29L26N1X; C21H21F3IN3O2; CHEMBL2146883; XL518 (GDC-0973); Cobimetinib (GDC-0973, RG7420); (S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone; [3,4-Bis(Fluoranyl)-2-[(2-Fluoranyl-4-Iodanyl-Phenyl)amino]phenyl]-[3-Oxidanyl-3-[(2s)-Piperidin-2-Yl]azetidin-1-Yl]methanone; [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone; [3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-((s)-3-hydroxy-3-piperidin-2-yl-azetidin-1-yl)-methanone; EUI; Cobimetinib Butyrate; Cobimetinib [USAN:INN]; cometinib; Cobimetinib (USAN/INN); SCHEMBL189565; GTPL7626; QCR-87; XL518;RG7420;Cobimetinib; CHEBI:90851; DTXSID60239435; EX-A673; GDC0973; GDC0973; XL518; Cobimetinib; 3556AH; BDBM50391802; MFCD22124461; NSC768068; NSC781257; NSC800075; s8041; ZINC60325170; BCP9000716; CCG-264727; CS-0521; DB05239; NSC-768068; NSC-781257; NSC-800075; VS-0129; NCGC00346455-03; NCGC00346455-05; (3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone; HY-13064; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-((2S)-2-piperidinyl)-1-azetidinyl)-; RO-5514041; D10405; J-525162; Q15708292; (3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-((S)-piperidin-2-yl)cyclobutyl)methanone; [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin; [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]{3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl}methanone; [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone; {3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}{3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl}methanone"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:90851	DB05239	.	.	531.3	4	C21H21F3IN3O2	64.599	624	3.9	30	3	7	"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1"	C1CCN[C@@H](C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O	BSMCAPRUBJMWDF-KRWDZBQOSA-N
DG01532	Buparlisib	16654980	"Buparlisib; 944396-07-0; NVP-BKM120; BKM120; 5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine; NVP-BKM-120; BKM-120; 1202777-78-3; BKM 120; Buparlisib (BKM120); UNII-0ZM2Z182GD; NVP-BKM 120; BKM120 (NVP-BKM120, Buparlisib); 5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[2,6-Di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine; 5-[2,6-Di(Morpholin-4-Yl)pyrimidin-4-Yl]-4-(Trifluoromethyl)pyridin-2-Amine; 0ZM2Z182GD; CHEMBL2017974; CHEBI:71954; 944396-07-0 (free base); C18H21F3N6O2; 2-Pyridinamine,5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-; 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-2-Pyridinamine; 5-[2,6-Di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine.; Buparlisib [USAN:INN]; BKM 120NX; SD5; Buparlisib; BKM120; 3sd5; Buparlisib (USAN/INN); QCR-4; BKM-120NX; BKM120-NX; MLS006010984; SCHEMBL146956; GTPL7878; BKM120,NVP-BKM120; AMMD00049; BKM-120 (PI3K); DTXSID50241486; EX-A189; SYN1200; HMS3295I15; HMS3655D16; AOB87379; BKM120 (NVP-BKM120); BKM120 - NVP-BKM120; BDBM50380363; MFCD18251596; NSC754353; NSC799370; s2247; ZINC43154039; 2-Pyridinamine, 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-; AKOS016005372; AM85983; BCP9001011; CCG-264954; CS-0089; DB11666; NSC-754353; NSC-799370; SB16577; NCGC00262604-01; NCGC00262604-08; AC-32077; AS-40568; HY-70063; SMR004702786; DB-079882; FT-0755923; SW218149-2; X7578; A25436; D10584; A892274; J-516601; BRD-K42191735-001-01-2; Q25100534; 4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine; 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine; 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:71954	DB11666	.	.	410.4	3	C18H21F3N6O2	89.6	530	1.5	29	1	11	"InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)"	C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4	CWHUFRVAEUJCEF-UHFFFAOYSA-N
DG01533	AZD1480	16659841	"AZD1480; 935666-88-9; AZD-1480; AZD 1480; UNII-KL2Z2TLF01; (S)-5-chloro-N2-(1-(5-fluoropyrimidin-2-yl)ethyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine; C14H14ClFN8; KL2Z2TLF01; CHEMBL1231124; 5-Chloro-N2-[(1s)-1-(5-Fluoropyrimidin-2-Yl)ethyl]-N4-(5-Methyl-1h-Pyrazol-3-Yl)pyrimidine-2,4-Diamine; 5-chloro-2-N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine; 2,4-Pyrimidinediamine,5-chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-; 2xa4; MLS006011153; GTPL5933; QCR-23; SCHEMBL3345019; AMMD00048; DTXSID50239469; EX-A450; BCPP000361; AOB87317; BCP02413; AZD1480,AZD 1480; BDBM50335201; NSC756648; NSC799344; s2162; ZINC58631551; AKOS027322548; AM85979; BCP9000361; CCG-268021; DB12588; NSC-756648; NSC-799344; NCGC00242486-01; NCGC00242486-02; NCGC00242486-05; 2,4-Pyrimidinediamine, 5-chloro-N2-((1S)-1-(5-fluoro-2-pyrimidinyl)ethyl)-N4-(5-methyl-1H-pyrazol-3-yl)-; AC-32807; AS-17011; HY-10193; SMR004702927; SW219486-1; X7497; J3.540.767G; J-502241; Q27074711; 935666-88-9, 1260222-79-4 (TFA); (R)-5-chloro-N2-(1-(5-fluoropyrimidin-2-yl)ethyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine; 5-chloro-2-N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-N-(3-methyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine; 5-chloro-N~2~-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N~4~-(3-methyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine; 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- 2,4-pyrimidinediamine; 5-Chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-2,4-pyrimidine-2,4-diamine; AZ5"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB12588	.	.	348.76	5	C14H14ClFN8	104	397	2.4	24	3	8	"InChI=1S/C14H14ClFN8/c1-7-3-11(24-23-7)21-13-10(15)6-19-14(22-13)20-8(2)12-17-4-9(16)5-18-12/h3-6,8H,1-2H3,(H3,19,20,21,22,23,24)/t8-/m0/s1"	CC1=CC(=NN1)NC2=NC(=NC=C2Cl)N[C@@H](C)C3=NC=C(C=N3)F	PDOQBOJDRPLBQU-QMMMGPOBSA-N
DG01534	AZD-8330	16666708	"AZD8330; 869357-68-6; AZD-8330; ARRY-424704; ARRY-704; AZD 8330; 2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; UNII-G4990BOZ66; ARRY-424704, ARRY-704; 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; G4990BOZ66; 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxopyridine-3-carboxamide; C16H17FIN3O4; 2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide.; ARRY 424704; ARRY704; MLS006011055; SCHEMBL388533; GTPL8474; CHEMBL3182621; CHEBI:91424; DTXSID50235986; QCR-188; SYN1195; ARRY424704; BCPP000359; BDBM520648; HMS3295M05; HMS3655B04; AOB87392; BCP02466; EX-A2349; NSC772563; NSC799353; s2134; ZINC43152942; AKOS027420927; BCP9000368; CCG-269348; CS-0217; DB06061; NSC-772563; NSC-799353; ARRY-704, ARRY-424704; NCGC00346567-01; NCGC00346567-12; 2-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxopyridine-3-carboxamide; AC-32863; AS-16990; HY-12058; SMR004702847; SW219692-1; US11147816, AZD8330; X7393; AZD8330,ARRY-424704, ARRY-704; AZD8330(ARRY-424704; ARRY-704); J-505617; BRD-K37687095-001-01-0; Q27074802; 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxyl)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; ARRY-424704; ; ; 2-(2-Fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxopyridine-3-carboxamide"	Discontinued in Phase 1	13	Discontinued Drug(s)	Discontinued in Phase 1	Small molecular drug	CHEBI:91424	DB06061	.	.	461.23	6	C16H17FIN3O4	90.9	596	2.2	25	3	6	"InChI=1S/C16H17FIN3O4/c1-9-7-11(15(23)20-25-6-5-22)14(21(2)16(9)24)19-13-4-3-10(18)8-12(13)17/h3-4,7-8,19,22H,5-6H2,1-2H3,(H,20,23)"	CC1=CC(=C(N(C1=O)C)NC2=C(C=C(C=C2)I)F)C(=O)NOCCO	RWEVIPRMPFNTLO-UHFFFAOYSA-N
DG01535	RO-5126766 free base	16719221	"946128-88-7; RO5126766; RO-5126766; CH5126766; Ro 5126766; RO-5126766 free base; RO5126766(CH5126766); CHEBI:78825; CH-5126766; Ro 5126766 - Bio-X; RG-7304; CKI-27; 3-[[2-[(methylaminosulfonyl)amino]-3-fluoropyridin-4-yl]methyl]-4-methyl-7-[(pyrimidin-2-yl)oxy]-2H-1-benzopyran-2-one; CHEMBL3264002; UNII-D0D4252V97; RO5126766 (CH5126766); D0D4252V97; VS-6766; N-(3-Fluoro-4-{[4-Methyl-2-Oxo-7-(Pyrimidin-2-Yloxy)-2h-Chromen-3-Yl]methyl}pyridin-2-Yl)-N'-Methylsulfuric Diamide; avutometinib; 3wig; CHU; SCHEMBL960093; GTPL11867; BCP21067; EX-A2151; BDBM50010462; NSC758248; NSC800871; s7170; ZINC68247388; AKOS030527032; CCG-269457; compound 1 [PMID: 24900832]; CS-5254; DB15254; NSC-758248; NSC-800871; SB16628; DA-40233; HY-18652; B5820; CH 5126766; FT-0737411; R-7304; A916428; RO5126766; CH5126766; Q27147976; RO 5126766; RO5126766; CH5126766; CH5126766; CH 5126766; 3-[(2-((N-methylsulfamoyl)amino)-3-fluoropyridin-4-yl)methyl]-4-methyl-7-(pyrimidin-2-yloxy)-chromen-2-one; 3-[[3-fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]-4-methyl-7-pyrimidin-2-yloxychromen-2-one; Sulfamide, N-(3-fluoro-4-((4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2H-1-benzopyran-3-yl)methyl)-2-pyridinyl)-N'-methyl-"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:78825	DB15254	.	.	471.5	7	C21H18FN5O5S	141	845	2	33	2	11	"InChI=1S/C21H18FN5O5S/c1-12-15-5-4-14(31-21-25-7-3-8-26-21)11-17(15)32-20(28)16(12)10-13-6-9-24-19(18(13)22)27-33(29,30)23-2/h3-9,11,23H,10H2,1-2H3,(H,24,27)"	CC1=C(C(=O)OC2=C1C=CC(=C2)OC3=NC=CC=N3)CC4=C(C(=NC=C4)NS(=O)(=O)NC)F	LMMJFBMMJUMSJS-UHFFFAOYSA-N
DG01536	Pictilisib	17755052	"957054-30-7; GDC-0941; PICTILISIB; Pictrelisib; GDC0941; GDC 0941; 4-(2-(1H-Indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine; 2-(1H-Indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine; UNII-ICY00EMP8P; GDC-0941 (Pictilisib); Pictilisib (GDC-0941); ICY00EMP8P; 4-[2-(1H-indazol-4-yl)-6-[(4-methylsulfonylpiperazin-1-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine; CHEBI:65326; 957054-30-7 (free base); RG7321; 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine; C23H27N7O3S2; 2-(1H-indazol-4-yl)-6-{[4-(methylsulfonyl)piperazin-1-yl]methyl}-4-(morpholin-4-yl)thieno[3,2-d]pyrimidine; 2-(1h-Indazol-4-Yl)-6-{[4-(Methylsulfonyl)piperazin-1-Yl]methyl}-4-Morpholin-4-Yl-Thieno[3,2-D]pyrimidine; 4-(2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno(3,2-d)pyrimidin-4-yl)morpholine; GD9; Pictilisib [USAN:INN]; Pictilisib (USAN); Kinome_3719; GDC0941(Pictilisib); 957054-50-1; Pictilisib; GDC-0941; 2-(1H-Indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)thieno[3,2-d]pyrimidine; MLS006010057; SCHEMBL190812; CHEMBL521851; GTPL5682; BDBM25028; DTXSID40241930; EX-A167; SYN1041; HMS2043A16; HMS3244H06; HMS3244H10; HMS3244H14; HMS3265I05; HMS3265I06; HMS3265J05; HMS3265J06; HMS3654K13; HMS3744A19; AOB87310; BCP01714; CDC-0941; EX-A1536; GNE 0941; MFCD11616196; NSC755385; NSC800852; s1065; ZINC16052714; AKOS015966503; BCP9000715; CCG-264801; CS-0081; DB11663; NSC-755385; NSC-800852; QC-4780; RG-7321; SB19941; NCGC00187482-01; NCGC00187482-03; NCGC00187482-10; 2-(1H-indazol-4-yl)-6-((4-(methanesulfonyl)piperazin-1-yl)methyl)-4-(morpholin-4-yl)thieno(3,2-d)pyrimidine; AC-32623; AS-19377; HY-50094; SMR004701219; Thieno(3,2-d)pyrimidine, 2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)-1-piperazinyl]methyl)-4-(4-morpholinyl)-; FT-0696889; SW202556-4; X7409; EC-000.2335; D10189; 054G307; A845396; J-513238; BRD-K52911425-001-02-3; Q27088388; C532162000; 2-(1H-indazol-4-yl)-6-{[4-(methylsulfonyl)piperazin-1-yl]methyl}-4-morpholin-4-ylthieno[3,2-d]pyrimidine; 4-[2-(1H-indazol-4-yl)-6-[(4-methanesulfonylpiperazin-1-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine; 4-[2-(1H-indazol-4-yl)-6-[(4-methylsulfonyl-1-piperazinyl)methyl]-4-thieno[3,2-d]pyrimidinyl]morpholine; Thieno[3,2-d]pyrimidine,2-(1H-indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)-"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:65326	DB11663	.	.	513.6	5	C23H27N7O3S2	144	832	1.6	35	1	10	"InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)"	CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6	LHNIIDJUOCFXAP-UHFFFAOYSA-N
DG01537	Tirbanibulin	23635314	"KX2-391; 897016-82-9; Tirbanibulin; KX-01; N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide; UNII-4V9848RS5G; KX-2-391; KX-2391; CHEMBL571546; 4V9848RS5G; KX2391; KX2-391;KX-01; 2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]-~{N}-(phenylmethyl)ethanamide; Klisyri; KX 01; Tirbanibulin [USAN]; Tirbanibulin (USAN/INN); KX2-391 (Tirbanibulin); Tirbanibulin (KX2-391); MLS006011272; SCHEMBL153779; GTPL7957; KX01; DTXSID30237862; HMS3656J15; HMS3673E15; BCP02845; EX-A2434; XKB01682; BDBM50303801; NSC756643; NSC800779; s2700; WHO 10864; ZINC43152787; N-benzyl-2-(5-{4-[2-(morpholin-4-yl)ethoxy]phenyl}pyridin-2-yl)acetamide; N-benzyl-2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]acetamide; BCP9000828; CCG-264983; CS-0248; DB06137; KX2-391; KX-01; NSC-756643; NSC-800779; SB16619; 2-Pyridineacetamide, 5-(4-(2-(4-morpholinyl)ethoxy)phenyl)-n-(phenylmethyl)-; NCGC00346644-01; NCGC00346644-05; AS-73245; HY-10340; KX 2-391; SMR004703022; DB-119272; SW219670-1; X7515; C77028; D11691; A915990; BRD-K29968218-001-01-6; Q27888424; 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide; 2-(5-(4-(2-morpholinoethoxyl)phenyl)pyridin-2-yl)-N-benzylacetamide; 2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]-N-(phenylmethyl)acetamide; 2-Pyridineacetamide,5-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-(phenylmethyl)-; 5-[4-[2-(4-Morpholinyl)ethoxy]phenyl]-N-(phenylmethyl)-2-pyridineacetamide; DN0"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB06137	.	.	431.5	9	C26H29N3O3	63.7	540	2.9	32	1	5	"InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)"	C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4	HUNGUWOZPQBXGX-UHFFFAOYSA-N
DG01538	PLX4720	24180719	"PLX-4720; 918505-84-7; PLX4720; N-(3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide; PLX 4720; N-[3-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide; UNII-EQY31RO8HA; N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide; EQY31RO8HA; CHEBI:90295; N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]propane-1-sulfonamide; N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide; C17H14ClF2N3O3S; N-[3-({5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl}carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide; a,a-dimethoxytoluene; 3c4c; MLS006010065; SCHEMBL133733; GTPL5703; CHEMBL1230020; BDBM25617; AMY2871; DTXSID10238711; EX-A186; SYN1069; HMS3244C03; HMS3244C04; HMS3244D03; HMS3265I09; HMS3265I10; HMS3265J09; HMS3265J10; HMS3654M10; HMS3750K11; HMS3884C05; ACT06829; AOB87700; BCP01754; PLX-4720,PLX4720; BBL102256; MFCD14635203; NSC757438; s1152; STL556055; ZINC39059267; AKOS015919071; CCG-268810; CS-0094; DB06999; NSC-757438; NCGC00187911-01; NCGC00187911-02; NCGC00187911-06; 1-Propanesulfonamide, N-[3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl]-; AC-23171; AS-19376; HY-51424; SMR004701225; DB-003736; FT-0673969; SW218119-2; X7406; A19411; Raf Kinase Inhibitor V - CAS 918505-84-7; 505P847; J-522979; BRD-K16478699-001-01-9; Q27088418; N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]pr opane-1-sulfonamide; propane-1-sulfonic acid [3-(5-chloro-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide; Propane-1-sulfonic acid[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]-amide"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	CHEBI:90295	DB06999	.	.	413.8	6	C17H14ClF2N3O3S	100	648	3.3	27	2	7	"InChI=1S/C17H14ClF2N3O3S/c1-2-5-27(25,26)23-13-4-3-12(19)14(15(13)20)16(24)11-8-22-17-10(11)6-9(18)7-21-17/h3-4,6-8,23H,2,5H2,1H3,(H,21,22)"	CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)Cl)F	YZDJQTHVDDOVHR-UHFFFAOYSA-N
DG01539	CUDC-101	24756910	"CUDC-101; 1012054-59-9; CUDC 101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; CUDC101; UNII-1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; CHEMBL598797; 1A7Y9MP123; 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; CUDC-101, Free Base; SCHEMBL93769; MLS006010163; GTPL8894; AOB6495; DTXSID00143784; EX-A842; QCR-203; HMS3654C20; BCP01935; BDBM50307768; MFCD15528940; NSC800081; s1194; ZINC43196377; AKOS022526176; BCP9000556; CCG-264856; compound 8 [PMID: 20143778]; DB12174; NSC-800081; SB19287; NCGC00263177-01; NCGC00263177-05; NCGC00263177-12; 1313875-12-5; AC-28428; AS-16955; HY-10223; SMR004701272; FT-0665231; SW219934-1; X7526; J-000340; J-519062; Q27076925; Heptanamide, 7-[[4-[(3-ethynylphenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-hydroxy-"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	DB12174	.	.	434.5	12	C24H26N4O4	106	624	4	32	3	7	"InChI=1S/C24H26N4O4/c1-3-17-9-8-10-18(13-17)27-24-19-14-22(21(31-2)15-20(19)25-16-26-24)32-12-7-5-4-6-11-23(29)28-30/h1,8-10,13-16,30H,4-7,11-12H2,2H3,(H,28,29)(H,25,26,27)"	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCCCCCC(=O)NO	PLIVFNIUGLLCEK-UHFFFAOYSA-N
DG01540	Ipatasertib	24788740	"Ipatasertib; GDC-0068; 1001264-89-6; Ipatasertib (GDC-0068); UNII-524Y3IB4HQ; RG7440; GDC0068; GDC 0068; RG-7440; GDC-0068 (RG7440); 524Y3IB4HQ; CHEMBL2177390; (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one; RG 7440; (2S)-2-(4-Chlorophenyl)-1-[4-[(5R,7R)-6,7-dihydro-7-hydroxy-5-methyl-5H-cyclopentapyrimidin-4-yl]-1-piperazinyl]-3-[(1-methylethyl)amino]-1-propanone; (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one; C24H32ClN5O2; (2s)-2-(4-Chlorophenyl)-1-{4-[(5r,7r)-7-Hydroxy-5-Methyl-6,7-Dihydro-5h-Cyclopenta[d]pyrimidin-4-Yl]piperazin-1-Yl}-3-(Propan-2-Ylamino)propan-1-One; 1-Propanone, 2-(4-chlorophenyl)-1-(4-((5R,7R)-6,7-dihydro-7-hydroxy-5-methyl-5H-cyclopentapyrimidin-4-yl)-1-piperazinyl)-3-((1-methylethyl)amino)-, (2S)-; Ipatasertib [USAN:INN]; MFCD22124514; 1-Propanone, 2-(4-chlorophenyl)-1-[4-[(5R,7R)-6,7-dihydro-7-hydroxy-5-methyl-5H-cyclopentapyrimidin-4-yl]-1-piperazinyl]-3-[(1-methylethyl)amino]-, (2S)-; GDC0068 di-HCl; Ipatasertib (USAN/INN); GDC-0068 di-HCl; Ipatasertib; GDC-0068; RG-7440 di-HCl; SCHEMBL191659; GTPL7887; CHEBI:95089; AOB87386; EX-A2077; BDBM50398379; NSC767898; NSC781451; NSC800986; NSC832484; s2808; ZINC68250459; AKOS025396463; BCP9000712; CCG-269312; CS-0975; DB11743; NSC-767898; NSC-781451; NSC-800986; NSC-832484; NCGC00346714-01; (2S)-2-(4-Chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta(d)pyrimidin-4-yl)piperazin-1-yl(-3-((propan-2-yl)amino)propan-1-one; 2-(4-chlorophenyl)-1-(4-(7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta(d)pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one; AC-28420; AS-17027; HY-15186; QC-10488; BCP0726000195; X6541; J3.478.537F; D10641; Q27078088; (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[e]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one; 0RF"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:95089	DB11743	.	.	458	6	C24H32ClN5O2	81.6	622	2.5	32	2	6	"InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1"	C[C@@H]1C[C@H](C2=C1C(=NC=N2)N3CCN(CC3)C(=O)[C@H](CNC(C)C)C4=CC=C(C=C4)Cl)O	GRZXWCHAXNAUHY-NSISKUIASA-N
DG01541	BMS-777607	24794418	"BMS-777607; 1025720-94-8; BMS 777607; 1196681-44-3; BMS777607; ASLAN-002; UNII-A3MMS6HDO1; ASLAN002; N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; A3MMS6HDO1; N-[4-(2-amino-3-chloropyridin-4-yl)oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide; BMS 817378; 3-Pyridinecarboxamide, N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-; N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-{4-[(2-amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl}-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; 3-Pyridinecarboxamide, N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-;3-Pyridinecarboxamide, N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-; N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide.; MLS006010958; C25H19ClF2N4O4; CHEMBL460702; GTPL7953; SCHEMBL2588311; BDBM28031; CHEBI:91409; DTXSID50145278; EX-A004; 3f82; HMS3295I07; HMS3655C05; AMY24190; AOB87395; BCP02303; BCP13190; BMS777606; MFCD16495773; NSC764090; NSC799365; s1561; ZINC39716080; AKOS026750587; BCP9000432; CCG-264913; CS-0227; DB12064; EX-7213; NSC-764090; NSC-799365; QC-7244; SB16607; NCGC00263157-01; NCGC00263157-09; AC-30912; AC-31421; AS-17034; DA-35016; HY-12076; N-[4-[(2-Amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-3-pyridinecarboxamide; N-{4-[(2-Amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl}-4-ethoxy -1-(4-fluorophenyl)-2-oxo-1,2-dihydro-3-pyridinecarboxamide; SMR004702762; BMS-777607;BMS777607; FT-0701277; FT-0722977; SW219298-1; X7495; A25030; BMS-777607, >=98% (HPLC); J-004169; J-523337; BRD-K40738845-001-01-9; Q27075371; N-(4-(2-amino-3-chloropyridin-4-yloxy )-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-[4-[(2-Amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-3-pyridinecarboxamide,; N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide;BMS-817378;BMS-777607"	Phase 1/2	8	Clinical Trial Drug(s)	Phase 1/2	Small molecular drug	CHEBI:91409	DB12064	.	.	512.9	7	C25H19ClF2N4O4	107	867	4	36	2	8	"InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)"	CCOC1=C(C(=O)N(C=C1)C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C(=NC=C4)N)Cl)F	VNBRGSXVFBYQNN-UHFFFAOYSA-N
DG01542	SGI-1776	24795070	"SGI-1776; 1025065-69-3; SGI-1776 free base; N-[(1-methylpiperidin-4-yl)methyl]-3-[3-(trifluoromethoxy)phenyl]imidazo[1,2-b]pyridazin-6-amine; SGI 1776; SGI1776; N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine; UNII-72AUA0603W; N-[(1-Methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-imidazo[1,2-b]pyridazin-6-amine; CHEMBL1952329; 72AUA0603W; CHEMBL1952141; Imidazo[1,2-b]pyridazin-6-amine, N-[(1-methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-;Imidazo[1,2-b]pyridazin-6-amine, N-[(1-methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-; Imidazo(1,2-b)pyridazin-6-amine, N-((1-methyl-4-piperidinyl)methyl)-3-(3-(trifluoromethoxy)phenyl)-; Imidazo[1,2-b]pyridazin-6-amine, N-[(1-methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-; N-((1-Methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo(1,2-b)pyridazin-6-amine; Pim-Kinase Inhibitor IX; SGI 1776 free base; MLS006011076; SCHEMBL102498; GTPL8784; CHEBI:95061; AOB2259; DTXSID10647329; QCR-216; HMS3655P08; HMS3672I15; HMS3747C17; BCP02279; EX-A1373; SGI 1776;SGI1776; BDBM50364776; MFCD16659064; NSC757333; NSC800883; s2198; ZINC68205235; AKOS026750649; CCG-264941; CS-0513; DB12494; NSC-757333; NSC-800883; SB19298; NCGC00263186-01; NCGC00263186-02; NCGC00263186-11; AC-28432; AS-16326; HY-13287; SMR004702864; DB-058820; FT-0702224; SW218133-2; X7567; A25500; J-000709; J-523286; Q27088795; N-[(1-methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-imidazo[1,2-beta]pyridazin-6-amine; N-[(1-methylpiperidin-4-yl)methyl]-3-[3-(trifluoromethoxy)phenyl]imidazo[2,1-f]pyridazin-6-amine"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB12494	.	.	405.4	5	C20H22F3N5O	54.7	529	4.3	29	1	8	"InChI=1S/C20H22F3N5O/c1-27-9-7-14(8-10-27)12-24-18-5-6-19-25-13-17(28(19)26-18)15-3-2-4-16(11-15)29-20(21,22)23/h2-6,11,13-14H,7-10,12H2,1H3,(H,24,26)"	CN1CCC(CC1)CNC2=NN3C(=NC=C3C4=CC(=CC=C4)OC(F)(F)F)C=C2	MHXGEROHKGDZGO-UHFFFAOYSA-N
DG01543	Apalutamide	24872560	"Apalutamide; ARN-509; 956104-40-8; Erleada; ARN 509; JNJ-56021927; ARN509; Apalutamide (ARN-509); UNII-4T36H88UA7; 4-(7-(6-CYANO-5-(TRIFLUOROMETHYL)PYRIDIN-3-YL)-8-OXO-6-THIOXO-5,7-DIAZASPIRO[3.4]OCTAN-5-YL)-2-FLUORO-N-METHYLBENZAMIDE; 4T36H88UA7; 956104-40-8 (free base); 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide; 4-{7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl}-2-fluoro-N-methylbenzamide; Apalutamide [INN]; AR509; 4-(7-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro(3.4)octan-5-yl)-2-fluoro-N-methylbenzamide; ApalutamideARN509; Erleada (TN); JNJ 56021927; Apalutamide (JAN/INN); MLS006011109; SCHEMBL909297; GTPL9043; C21H15F4N5O2S; CHEMBL3183409; DTXSID40241899; EX-A089; QCR-211; HMS3656N12; AMY24182; BCP05829; AR509/AR-509; BDBM50094975; MFCD22380626; NSC771649; NSC794776; s2840; ZINC43174901; AKOS025401932; CCG-264760; CS-0885; DB11901; NSC-771649; NSC-794776; PB27306; NCGC00346725-01; NCGC00346725-02; NCGC00346725-06; 4-(7-(6-cyano-5-(trifluoroMethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspirooctan-5-yl)-2-fluoro-N-MethylbenzaMide; AC-27403; AS-35181; HY-16060; SMR004702891; SW220300-1; Y0375; 24872560, Erleada, C21H15F4N5O2S; D11040; J-519596; Q21098975; Benzamide, 4-[7-[6-cyano-5-(trifluoromethyl)-3-pyridinyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11901	DR0121	.	477.4	3	C21H15F4N5O2S	121	886	3	33	1	9	"InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)"	CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F	HJBWBFZLDZWPHF-UHFFFAOYSA-N
DG01544	Niraparib	24958200	"Niraparib; 1038915-60-4; MK-4827; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; ZEJULA; MK4827; UNII-HMC2H89N35; MK 4827; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; HMC2H89N35; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; CHEMBL1094636; Niraparib [USAN:INN]; MK 4827 (Base); 3JD; Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); GTPL8275; SCHEMBL1421875; AMY4192; DTXSID50146129; EX-A290; CHEBI:176844; MK-4827 (PARP-1); 0919AA; BDBM50316226; MFCD17779309; NSC754355; NSC800020; s2741; ZINC43206370; AKOS016004869; BCP9000940; CCG-267709; compound 56 [PMID 19873981]; CS-0780; DB11793; MK-4827/MK4827; NSC-754355; NSC-800020; ZL-2306; NCGC00346435-01; NCGC00346435-04; AC-28447; AS-35248; HY-10619; JNJ-64091742; BCP0726000077; A3617; D10140; A857972; Q25326660; 2-[4-[(3S)-3-Piperidyl]phenyl]indazole-7-carboxamide; 2-[4-(3S)-3-Piperidinylphenyl]-2H-indazole-7-carboxamide; 2H-Indazole-7-carboxamide, 2-[4-(3S)-3-piperidinylphenyl]"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	.	DB11793	DR1164	.	320.4	3	C19H20N4O	72.9	449	2.2	24	2	3	"InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1"	C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N	PCHKPVIQAHNQLW-CQSZACIVSA-N
DG01545	MK-2206	24964624	"MK-2206; 1032349-93-1; UNII-51HZG6MP1K; MK 2206; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; MK2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; DSSTox_CID_28874; DSSTox_RID_83143; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-ol; 8-(4-(1-Aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthy ridin-3(2H)-one; 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; CAS-1032350-13-2; 1032349-77-1; MK-2206 free base; SCHEMBL530721; GTPL7945; DTXSID3048948; BCP20200; Tox21_113368; BDBM50313650; NSC756656; NSC800794; ZINC36382821; AKOS032945686; Tox21_113368_1; BCP9000938; MK 2206;MK2206; NSC-756656; NSC-800794; SB16805; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; NCGC00186465-02; NCGC00186465-03; NCGC00186465-04; NCGC00186465-08; DB-058959; FT-0738942; A25240; MK2206;MK 2206;MK-2206 dihydrochloride; cas:1032350-13-2;MK 2206; BRD-K68065987-300-02-6; Q25100065; 1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-; 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride;MK-2206 Dihydrochloride; 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-3(2H)-one"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:67271	.	.	.	407.5	3	C25H21N5O	83.6	760	3	31	2	4	"InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31)"	C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N	ULDXWLCXEDXJGE-UHFFFAOYSA-N
DG01546	Patidegib	25027363	"SARIDEGIB; Patidegib; IPI-926; 1037210-93-7; IPI 926; UNII-JT96FPU35X; JT96FPU35X; CHEMBL538867; N-((2S,3R,3aS,3'R,4a'R,6S,6a'R,6b'S,7aR,12a'S,12b'S)-3,6,11',12b'-tetramethyl-2',3a,3',4,4',4a',5,5',6,6',6a',6b',7,7a,7',8',10',12',12a',12b'-icosahydro-1'H,3H-spiro[furo[3,2-b]pyridine-2,9'-naphtho[2,1-a]azulen]-3'-yl)methanesulfonamide; N-[(3R,3'R,3'aS,4aR,6'S,6aR,6bS,7'aR,9S,12aS,12bS)-3',6',11,12b-tetramethylspiro[1,2,3,4,4a,5,6,6a,6b,7,8,10,12,12a-tetradecahydronaphtho[2,1-a]azulene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-3-yl]methanesulfonamide; Patidegib [USAN:INN]; Saridegib [Rescinded USAN]; Patidegib (USAN); IP9 FREE BASE; FIN-5; IPI-926 FREE BASE; SCHEMBL421999; GTPL8198; IP-9; DTXSID40146032; CHEBI:177425; Saridegib (IPI-926; Patidegib); WHO 9619; BDBM50293788; ZINC43197072; DB12655; HY-16587; CS-0007501; D10324; Q15426668; Methanesulfonamide, N-((2S,3R,3'R,3aS,4'aR,6S,6'aR,6'bS,7aR,12'aS,12'bS)- 2',3',3a,4,4',4'a,5,5',6,6',6'a,6'b,7,7',7a,8',10',12',12'a,12'b-eicosahydro-3,6,11',12'b-tetramethylspiro(furo(3,2-b)pyridine-2(3H),9'(1'H)-naphth(2,1-a)azulen)-3'-yl)-; N-((2S,3R,3aS,3''R,4a''R,6S,6a''R,6b''S,7aR,12a''S,12b''S)-3,6,11'',12b''-tetramethyl-2'',3a,3'',4,4'',4a'',5,5'',6,6'',6a'',6b'',7,7a,7'',8'',10'',12'',12a'',12b''-icosahydro-1''H,3H-spiro[furo[3,2-b]pyridine-2,9''-naphtho[2,1-a]azulene]-3''-yl)methanesulfonamide; N-[(3R,3'R,3'aS,4aR,6'S,6aR,6bS,7'aR,9S,12aS,12bS)-3',6',11,12b-tetramethylspiro[1,2,3,4,4a,5,6,6a,6b,7,8,10,12,12a-tetradecahydronaphtho[2,1-a]azulene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-uro[3,2-b]pyridine]-3-yl]methanesulonamide"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB12655	.	.	504.8	2	C29H48N2O3S	75.8	988	4.6	35	2	5	"InChI=1S/C29H48N2O3S/c1-17-12-26-27(30-16-17)19(3)29(34-26)11-9-22-23-7-6-20-13-21(31-35(5,32)33)8-10-28(20,4)25(23)14-24(22)18(2)15-29/h17,19-23,25-27,30-31H,6-16H2,1-5H3/t17-,19+,20+,21+,22-,23-,25-,26+,27-,28-,29-/m0/s1"	C[C@H]1C[C@@H]2[C@H]([C@H]([C@]3(O2)CC[C@H]4[C@@H]5CC[C@@H]6C[C@@H](CC[C@@]6([C@H]5CC4=C(C3)C)C)NS(=O)(=O)C)C)NC1	HZLFFNCLTRVYJG-WWGOJCOQSA-N
DG01547	PF-04691502	25033539	"PF-04691502; 1013101-36-4; PF 04691502; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; PF04691502; UNII-4W39NS61KI; 4W39NS61KI; CHEMBL1234354; PF-4691502; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-(cis-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; 2-Amino-8-(cis-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; 4tv3; MLS006010979; GTPL7936; SCHEMBL1381425; SCHEMBL1381431; SCHEMBL1984896; SCHEMBL10092210; SCHEMBL13976989; EX-A032; QCR-137; HMS3656B21; AOB87714; BCP02895; BDBM50380313; MFCD18782794; NSC760536; NSC800846; s2743; ZINC58660483; AKOS005266645; AKOS030257531; ZINC100015733; ZINC117704832; CCG-268947; CS-0919; DB11974; NSC-760536; NSC-800846; SB20066; NCGC00346659-01; NCGC00381752-02; NCGC00381752-06; AC-28429; AS-17042; HY-15177; SMR004702782; BCP0726000275; PF4691502; SW220185-1; X7464; US8633204, 286; J-000360; PF-04691502, >=98% (HPLC); Q27088316; 2-Amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one; Pyrido(2,3-d)pyrimidin-7(8H)-one, 2-amino-8-(trans-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxy-3-pyridinyl)-4-methyl-; trans-2-Amino-8-((1R,4R)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB11974	.	.	425.5	6	C22H27N5O4	124	654	1.6	31	2	8	"InChI=1S/C22H27N5O4/c1-13-17-11-18(14-3-8-19(30-2)24-12-14)21(29)27(20(17)26-22(23)25-13)15-4-6-16(7-5-15)31-10-9-28/h3,8,11-12,15-16,28H,4-7,9-10H2,1-2H3,(H2,23,25,26)"	CC1=C2C=C(C(=O)N(C2=NC(=N1)N)C3CCC(CC3)OCCO)C4=CN=C(C=C4)OC	XDLYKKIQACFMJG-UHFFFAOYSA-N
DG01548	Momelotinib	25062766	"Cyt387; 1056634-68-4; MOMELOTINIB; Cyt-387; CYT 387; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide; CYT 11387; UNII-6O01GMS00P; N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide; Momelotinib (CYT387); N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide; 6O01GMS00P; CHEMBL1078178; CYT11387; N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide; CYT-11387; MFCD16038899; GS-0387; LM-1149; N-(Cyanomethyl)-4-(2-((4-(morpholin-4-yl)phenyl)amino)pyrimidin-4-yl)benzamide; N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide; Benzamide, N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)-; Momelotinib [USAN:INN]; momelotinibum; benzamide, n-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-; C87; Momelotinib (USAN/INN); MLS006011154; GTPL7791; SCHEMBL2237234; CHEBI:91407; AOB4616; EX-A260; QCR-259; SYN1035; HMS3244K19; HMS3244K20; HMS3244L19; HMS3295I01; HMS3655D12; HMS3744C15; BCP02328; CYT-0387; CYT387, CYT11387; CYT387,CYT 11387; Momelotinib (CYT387,CYT-387); BDBM50311017; NSC767598; NSC800800; s2219; ZINC43199890; AKOS015904624; N-(Cyanomethyl)-4-[2-[(4-morpholinophenyl)amino]-4-pyrimidinyl]benzamide; BCP9000570; CCG-264946; CS-0053; DB11763; LS41099; NSC-767598; NSC-800800; SB14602; NCGC00244257-01; NCGC00244257-08; AC-23162; AS-19389; HY-10961; SMR004702928; SY060668; FT-0755949; SW219679-1; X7506; D10315; A857769; Q252602; J-001468; J-523159; BRD-K87737963-001-01-1; N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide; N-(cyanomethyl)-4-[2-[4-(4-morpholinyl)anilino]-4-pyrimidinyl]benzamide; N-(cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide; Benzamide,N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-; N-(Cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide;CYT387"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:91407	DB11763	DR1880	.	414.5	6	C23H22N6O2	103	615	2.6	31	2	7	"InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)"	C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N	ZVHNDZWQTBEVRY-UHFFFAOYSA-N
DG01549	AZ960	25099184	"905586-69-8; AZ 960; AZ-960; AZ960; UNII-M63IS9PTJF; (S)-5-Fluoro-2-(1-(4-fluorophenyl)ethylamino)-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile; M63IS9PTJF; (S)-5-fluoro-2-((1-(4-fluorophenyl)ethyl)amino)-6-((5-methyl-1H-pyrazol-3-yl)amino)nicotinonitrile; CHEMBL1774055; 5-fluoro-2-[[(1S)-1-(4-fluorophenyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridine-3-carbonitrile; C18H16F2N6; 5-Fluoro-2-[[(1S)-1-(4-fluorophenyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-3-pyridinecarbonitrile; 5-fluoro-2-{[(1S)-1-(4-fluorophenyl)ethyl]amino}-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridine-3-carbonitrile; MLS006011063; GTPL8476; SCHEMBL14840365; DTXSID60238201; SYN1015; BCPP000371; BCP27683; EX-A1802; AZ 960;AZ960; BDBM50343725; s2214; ZINC43205072; AKOS027420925; BCP9000348; CCG-268082; CS-6209; NCGC00346581-01; NCGC00346581-02; NCGC00346581-04; NCGC00346581-06; 3-Pyridinecarbonitrile, 5-fluoro-2-(((1S)-1-(4-fluorophenyl)ethyl)amino)-6-((5-methyl-1H-pyrazol-3-yl)amino)-; AC-32981; AS-74896; HY-10411; SMR004702855; SW219623-1; X7504; A19389; C77068; 586F698; J-502242; Q27074679; (R)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile; (S)-5-Fluoro-2-(1-(4-fluorophenyl)ethylamino)-6-(5-methyl-1H-pyrazol-3-ylamino) nicotinonitrile; (S)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile;AZ 960"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	354.4	5	C18H16F2N6	89.4	503	4.4	26	3	7	"InChI=1S/C18H16F2N6/c1-10-7-16(26-25-10)23-18-15(20)8-13(9-21)17(24-18)22-11(2)12-3-5-14(19)6-4-12/h3-8,11H,1-2H3,(H3,22,23,24,25,26)/t11-/m0/s1"	CC1=CC(=NN1)NC2=C(C=C(C(=N2)N[C@@H](C)C3=CC=C(C=C3)F)C#N)F	SUNXHXDJOIXABJ-NSHDSACASA-N
DG01550	Poziotinib	25127713	"Poziotinib; 1092364-38-9; UNII-OEI6OOU6IK; HM781-36B; NOV120101; NOV-120101; 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one; OEI6OOU6IK; 1-(4-((4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one; HM-781-36B; 1-[4-[[4-[(3,4-Dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-2-propen-1-one; MFCD28044290; HM 781-36B; HM-781-36; 2-Propen-1-one, 1-[4-[[4-[(3,4-dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-; 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one; Poziotinib [INN]; 1-[4-({4-[(3,4-DICHLORO-2-FLUOROPHENYL)AMINO]-7-METHOXYQUINAZOLIN-6-YL}OXY)PIPERIDIN-1-YL]PROP-2-EN-1-ONE; HM-78136B; Poziotinib [USAN]; C23H21Cl2FN4O3; Poziotinib (HM781-36B); GTPL7903; SCHEMBL3391764; CHEMBL3545154; DTXSID80148853; EX-A528; HMS3673K03; AMY24248; BCP08270; NOV-1201; WHO 9736; BDBM50468247; NSC783296; NSC800856; s7358; ZINC95930125; AKOS026674078; CCG-264748; CS-3942; DB12114; NOV 120101; NSC-783296; NSC-800856; SB16882; NCGC00386427-01; NCGC00386427-02; AC-29021; AS-74851; BP161454; DA-47945; HY-15730; SY235762; HM 781-36; B5827; FT-0752903; A13044; J-690026; Q27088426; 1-[4-[4-(3,4-Dichloro-2-fluorophenylamino)-7-methoxyquinazoline-6-yloxy]-1-piperidinyl]-2-propene-1-one"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB12114	.	.	491.3	6	C23H21Cl2FN4O3	76.6	684	5.4	33	1	7	"InChI=1S/C23H21Cl2FN4O3/c1-3-20(31)30-8-6-13(7-9-30)33-19-10-14-17(11-18(19)32-2)27-12-28-23(14)29-16-5-4-15(24)21(25)22(16)26/h3-5,10-13H,1,6-9H2,2H3,(H,27,28,29)"	COC1=C(C=C2C(=C1)N=CN=C2NC3=C(C(=C(C=C3)Cl)Cl)F)OC4CCN(CC4)C(=O)C=C	LPFWVDIFUFFKJU-UHFFFAOYSA-N
DG01551	Omipalisib	25167777	"Omipalisib; 1086062-66-9; GSK2126458; GSK-2126458; GSK 2126458; 2,4-difluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide; 2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-yl]benzenesulfonamide; UNII-1X8F5A3NA0; 2,4-Difluoro-N-[2-methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]benzenesulfonamide; 1X8F5A3NA0; Omipalisib (GSK2126458, GSK458); C25H17F2N5O3S; 2,4-difluoro-N-(2-(methyloxy)-5-(4-(4-pyridazinyl)-6-quinolinyl)-3-pyridinyl)benzenesulfonamide; GSK-212; Omipalisib [USAN:INN]; GSK458; GSK 212; 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide; Omipalisib (USAN/INN); MLS006011258; Omipalisib; GSK2126458; SCHEMBL623194; GTPL8974; Omipalisib (GSK2126458); CHEMBL1236962; CHEBI:95093; DTXSID10148604; EX-A003; GSK-458; SYN1126; 3l08; HMS3656D09; AOB87781; BCP02252; BDBM50145416; MFCD16038929; NSC764092; NSC800807; s2658; ZINC43208634; AKOS015904655; CCG-264973; CS-0085; DB12703; NSC-764092; NSC-800807; QC-7243; SB16572; NCGC00250408-01; NCGC00250408-05; AC-28458; AS-16266; Benzenesulfonamide, 2,4-difluoro-N-(2-methoxy-5-(4-(4-pyridazinyl)-6-quinolinyl)-3-pyridinyl)-; GSK2126458 (GSK458); HY-10297; SMR004703011; FT-0669061; SW219502-1; X7449; A25172; D10718; GSK-2126458;GSK 2126458; Omipalisib; J-507217; Q27088179; N-[2-Methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]benzenesulfonamide; ZIG"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	CHEBI:95093	DB12703	.	.	505.5	6	C25H17F2N5O3S	115	833	3.3	36	1	10	"InChI=1S/C25H17F2N5O3S/c1-35-25-23(32-36(33,34)24-5-3-18(26)12-21(24)27)11-17(13-29-25)15-2-4-22-20(10-15)19(7-8-28-22)16-6-9-30-31-14-16/h2-14,32H,1H3"	COC1=C(C=C(C=N1)C2=CC3=C(C=CN=C3C=C2)C4=CN=NC=C4)NS(=O)(=O)C5=C(C=C(C=C5)F)F	CGBJSGAELGCMKE-UHFFFAOYSA-N
DG01552	Tepotinib	25171648	"Tepotinib; 1100598-32-0; EMD-1214063; EMD 1214063; MSC2156119J; UNII-1IJV77EI07; EMD1214063; MSC2156119; 1IJV77EI07; 3-[1-[[3-[5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl]phenyl]methyl]-6-oxopyridazin-3-yl]benzonitrile; Tepotinib (EMD 1214063); MSC-2156119J; MSC-2156119; 3-(1-(3-(5-((1-methylpiperidin-4-yl)methoxy)pyrimidin-2-yl)benzyl)-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; 3-[1-(3-{5-[(1-Methylpiperidin-4-Yl)methoxy]pyrimidin-2-Yl}benzyl)-6-Oxo-1,6-Dihydropyridazin-3-Yl]benzonitrile; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo-3-pyridazinyl)-; Tepmetko; Tepotinib [USAN]; Tepotinib (USAN/INN); MLS006010785; GTPL8293; SCHEMBL1296895; Tepotinib(EMD-1214063); CHEMBL3402762; AOB5729; DTXSID70149132; EX-A394; WHO 9934; BDBM50065457; MFCD18452823; NSC758244; NSC781256; NSC800945; s7067; ZINC43202335; CCG-269632; CS-0647; DB15133; NSC-758244; NSC-781256; NSC-800945; SB16609; compound 22 [PMID: 25736998]; NCGC00345793-01; NCGC00345793-08; AS-16915; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; HY-14721; QC-11720; SMR004701471; Y0358; D11717; J-002366; Q27088961; 1100598-30-8; 3-(1-(3-(5-((1-Methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)benzyl)-6-oxo-1,6-dihydro-3-pyridazinyl)benzonitrile; 3-(1-{3-[5-(1-methylpiperidin-4-yl-methoxy)pyrimidin-2-yl]benzyl}-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile; 3-(1-{3-[5-(1-methylpiperidin-4-ylmethoxy)pyrimidin-2-yl]benzyl}-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile; 3-[1,6-Dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]benzonitrile; 3E8"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB15133	.	.	492.6	7	C29H28N6O2	94.7	880	3.4	37	0	7	"InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3"	CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N	AHYMHWXQRWRBKT-UHFFFAOYSA-N
DG01553	Glesatinib	25181472	"Glesatinib; 936694-12-1; MG90265gly; UNII-7Q29OXD98N; 7Q29OXD98N; MG90265X; MG90265H9; MG90265; N-((3-fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)carbamothioyl)-2-(4-fluorophenyl)acetamide; N-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide; Glesatinib free base; Glesatinib [USAN]; Glesatinib (USAN/INN); SCHEMBL106319; GTPL9133; CHEMBL3989914; EX-A4139; MG-90265X; NSC791059; ZINC113139653; DB06302; NSC-791059; SB19664; compound 10a [PMID: 18434145]; NCGC00483925-01; AC-31426; HY-19642; MG-90265; CS-0016148; D11136; A857537; Q27895580; Benzeneacetamide, 4-fluoro-N-(((3-fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)-2-pyridinyl)thieno(3,2-b)pyridin-7-yl)oxy)phenyl)amino)thioxomethyl)-; N-((3-fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)carbamothioyl)-2-(4-fluorophenyl)acetamid; N-(3-fluoro-4-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-(4-fluorophenyl)acetamide; N-(3-fluoro-4-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridine-7-yloxy)phenylcarbamothioyl)-2-(4-fluorophenyl)acetamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	DB06302	.	.	619.7	11	C31H27F2N5O3S2	158	902	5.1	43	3	10	"InChI=1S/C31H27F2N5O3S2/c1-40-13-12-34-17-20-4-8-24(36-18-20)28-16-25-30(43-28)27(10-11-35-25)41-26-9-7-22(15-23(26)33)37-31(42)38-29(39)14-19-2-5-21(32)6-3-19/h2-11,15-16,18,34H,12-14,17H2,1H3,(H2,37,38,39,42)"	COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=S)NC(=O)CC5=CC=C(C=C5)F)F	YRCHYHRCBXNYNU-UHFFFAOYSA-N
DG01554	Mps1-IN-1	25195352	"Mps1-IN-1; 1125593-20-5; 1-(4-(4-(2-(Isopropylsulfonyl)phenylamino)-1H-pyrrolo[2,3-b]pyridin-6-ylamino)-3-methoxyphenyl)piperidin-4-ol; 1-[3-methoxy-4-[[4-(2-propan-2-ylsulfonylanilino)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]phenyl]piperidin-4-ol; 1-(4-((4-((2-(isopropylsulfonyl)phenyl)amino)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino)-3-methoxyphenyl)piperidin-4-ol; 1MPS1-IN-1; 3gfw; MLS003230944; GTPL9271; SCHEMBL4051419; CHEMBL1235786; BDBM36485; CHEBI:91379; DTXSID60649015; AVB59320; BCP27688; 3868AH; ZINC58661129; CS-3776; QC-8177; NCGC00387463-01; NCGC00387463-04; HY-13298; SMR001913509; A925638; J-503190; Q27087728; 1-(3-methoxy-4-{[4-({2-[(1-methylethyl)sulfonyl]phenyl}amino)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino}phenyl)piperidin-4-ol; 1-[3-Methoxy-4-({4-[2-(propane-2-sulfonyl)anilino]-1H-pyrrolo[2,3-b]pyridin-6-yl}amino)phenyl]piperidin-4-ol; s22"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	535.7	8	C28H33N5O4S	128	862	5.3	38	4	8	"InChI=1S/C28H33N5O4S/c1-18(2)38(35,36)26-7-5-4-6-23(26)30-24-17-27(32-28-21(24)10-13-29-28)31-22-9-8-19(16-25(22)37-3)33-14-11-20(34)12-15-33/h4-10,13,16-18,20,34H,11-12,14-15H2,1-3H3,(H3,29,30,31,32)"	CC(C)S(=O)(=O)C1=CC=CC=C1NC2=CC(=NC3=C2C=CN3)NC4=C(C=C(C=C4)N5CCC(CC5)O)OC	NMJMRSQTDLRCRQ-UHFFFAOYSA-N
DG01555	Capivasertib	25227436	"AZD5363; capivasertib; 1143532-39-1; AZD-5363; AZD 5363; UNII-WFR23M21IE; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; WFR23M21IE; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; C21H25ClN6O2; CHEMBL2325741; cc-638; 4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)piperidine-4-carboxamide; Capivasertib (JAN/USAN); Capivasertib (AZD5363); MLS006011179; SCHEMBL390243; GTPL7709; AZC5363; DTXSID40150710; EX-A285; US10654855, Example 9; BDBM443385; 2241AH; MFCD22628785; NSC764039; NSC782347; NSC799347; s8019; ZINC43204023; AKOS027323693; BCP9000365; CCG-268989; CS-1284; DB12218; NSC-764039; NSC-782347; NSC-799347; NCGC00345795-01; NCGC00345795-04; AC-32685; HY-15431; SMR004702948; BCP0726000111; A1387; SW220158-1; D11371; J-514447; Q27074756; 0XZ; ALTERNATIVE ROUTE 1: (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	.	DB12218	.	.	428.9	6	C21H25ClN6O2	120	580	1.7	30	4	6	"InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1"	C1CN(CCC1(C(=O)N[C@@H](CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4	JDUBGYFRJFOXQC-KRWDZBQOSA-N
DG01556	Apitolisib	25254071	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; GNE 390; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; GDC-0980 (Apitolisib); UNII-1C854K1MIJ; RG 7422; GDC-0980 (RG7422); GDC 0980; 1C854K1MIJ; CHEMBL1922094; Apitolisib (GDC-0980, RG7422); RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; C23H30N8O3S; (2S)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one.; GNE 390; GDC 0980; RG 7422; Apitolisib [USAN:INN]; Apitolisib (USAN/INN); Apitolisib(GDC-0980); Gne-390; Apitolisib (GDC-0980); SCHEMBL466297; GTPL7888; DTXSID50145738; EX-A041; QCR-182; SYN1150; AOB87742; BCP02622; BDBM50358204; GDC-0980,RG7422; GDC0980(RG7422); MFCD20274520; NSC764091; NSC799334; s2696; ZINC59224388; AKOS027250725; BCP9000717; CCG-269678; CS-0590; DB12180; GDC-0980.1; NSC-764091; NSC-799334; GDC-0980 - RG7422; NCGC00263109-03; NCGC00263109-13; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperaz; AS-16289; HY-13246; SW219472-1; X7458; D10543; CAS:1032754-93-0;GDC-0980; G-038390; GDC-0980,CAS:1032754-93-0; J-502360; Q27074481; G-038390.1; (S)-1-[4-[[2-(2-Aminopyrimidin-5-yl)-7-methyl-4-(morpholin-4-yl)thieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1 -one"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB12180	.	.	498.6	5	C23H30N8O3S	162	715	0.2	35	2	11	"InChI=1S/C23H30N8O3S/c1-14-17(13-29-3-5-31(6-4-29)22(33)15(2)32)35-19-18(14)27-20(16-11-25-23(24)26-12-16)28-21(19)30-7-9-34-10-8-30/h11-12,15,32H,3-10,13H2,1-2H3,(H2,24,25,26)/t15-/m0/s1"	CC1=C(SC2=C1N=C(N=C2N3CCOCC3)C4=CN=C(N=C4)N)CN5CCN(CC5)C(=O)[C@H](C)O	YOVVNQKCSKSHKT-HNNXBMFYSA-N
DG01557	WYE-125132	25260757	"1144068-46-1; WYE-125132; WYE125132; WYE-132; N-[4-[1-(1,4-Dioxaspiro[4.5]dec-8-yl)-4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-N'-methylurea; WYE 125132; CHEMBL601661; WYE-125132 (WYE-132); 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl)-3-methylurea; 1-[4-(1-{1,4-dioxaspiro[4.5]decan-8-yl}-4-{8-oxa-3-azabicyclo[3.2.1]octan-3-yl}pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]-3-methylurea; N-[4-[1-(1,4-Dioxaspiro[4.5]dec-8-yl)-4-(8-oxa-3-azabicyclo[3.2.1]-oct-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-N'-methylurea; 1-[4-[1-(1,4-dioxaspiro[4.5]decan-8-yl)-4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-3-methylurea; SCHEMBL54355; MLS006011010; WYE132; CHEBI:91364; DTXSID70649521; HMS3265K19; HMS3265K20; HMS3265L19; HMS3265L20; HMS3656J09; AOB87378; BCP02227; EX-A2183; BDBM50306633; s2661; AKOS025405223; CCG-269851; CS-0066; SB19261; NCGC00346635-01; NCGC00346635-10; AC-31521; HY-10044; SMR004702808; Urea, N-[4-[1-(1,4-dioxaspiro[4.5]dec-8-yl)-4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1H-pyrazolo[3,4-d]; WYE-132; WYE-125132; SW219487-1; WYE-125132 - WYE-132; A25638; J-003090; J-523341; BRD-A45498368-001-02-2; Q27163233; 1-[4-[1-(1,4-dioxaspiro[4.5]decan-8-yl)-4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-pyrazolo[3,4-d]pyrimidinyl]phenyl]-3-methylurea; N-[1-(1.4-dioxaspiro[4.5]dec-8-yl)-4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1H-pyrazolo[3.4-d]pyrimidin-6-yl]phenyl]-N-methyl-urea; N-{4-[1-(1,4-Dioxaspiro[4.5]decan-8-yl)-4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl}-N'-methylurea"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	519.6	4	C27H33N7O4	116	829	2.2	38	2	8	"InChI=1S/C27H33N7O4/c1-28-26(35)30-18-4-2-17(3-5-18)23-31-24(33-15-20-6-7-21(16-33)38-20)22-14-29-34(25(22)32-23)19-8-10-27(11-9-19)36-12-13-37-27/h2-5,14,19-21H,6-13,15-16H2,1H3,(H2,28,30,35)"	CNC(=O)NC1=CC=C(C=C1)C2=NC3=C(C=NN3C4CCC5(CC4)OCCO5)C(=N2)N6CC7CCC(C6)O7	QLHHRYZMBGPBJG-UHFFFAOYSA-N
DG01558	II-B08	25262527	"1143579-78-5; II-B08; CHEMBL590043; 3-(1-(3-([1,1'-Biphenyl]-4-ylamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1h-indole-5-carboxylic acid; 3-{1-[3-(biphenyl-4-ylamino)-3-oxopropyl]-1H-1,2,3-triazol-4-yl}-6-hydroxy-1-methyl-2-phenyl-1H-indole-5-carboxylic acid; 3-(1-(3-(Biphenyl-4-ylamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1H-indole-5-carboxylic Acid; SCHEMBL13883165; II- B08; BDBM50308158; MFCD32645102; F51980; Q27461817; 3-(1-(3-([1,1'-BiPh]-4-ylamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-Ph-1H-indole-5-carboxylic acid; 6-hydroxy-1-methyl-3-[1-[3-oxo-3-(4-phenylanilino)propyl]triazol-4-yl]-2-phenylindole-5-carboxylic acid; JZG"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	557.6	8	C33H27N5O4	122	916	5.2	42	3	6	"InChI=1S/C33H27N5O4/c1-37-28-19-29(39)26(33(41)42)18-25(28)31(32(37)23-10-6-3-7-11-23)27-20-38(36-35-27)17-16-30(40)34-24-14-12-22(13-15-24)21-8-4-2-5-9-21/h2-15,18-20,39H,16-17H2,1H3,(H,34,40)(H,41,42)"	CN1C2=CC(=C(C=C2C(=C1C3=CC=CC=C3)C4=CN(N=N4)CCC(=O)NC5=CC=C(C=C5)C6=CC=CC=C6)C(=O)O)O	RATFAFAWIWHLMR-UHFFFAOYSA-N
DG01559	ER2	42626654	ER2	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	355.7	0	Fe4H4S4-4	4	8	.	8	4	4	InChI=1S/4Fe.4H2S/h;;;;4*1H2/p-4	[SH-].[SH-].[SH-].[SH-].[Fe].[Fe].[Fe].[Fe]	PTTXNOSMDBWCQD-UHFFFAOYSA-J
DG01560	ALW-II-41-27	42628503	"ALW-II-41-27; 1186206-79-0; N-(5-((4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)-2-methylphenyl)-5-(thiophen-2-yl)nicotinamide; ALW II-41-27; Benzamide, N-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]amino]-; N-[5-[[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]carbamoyl]-2-methylphenyl]-5-thiophen-2-ylpyridine-3-carboxamide; MLS002232274; CHEMBL556140; SCHEMBL20136698; DTXSID80655254; BDBM163701; HMS2043H01; HMS2218G07; HMS3333E20; BCP26205; EX-A2618; s6515; ZINC42966573; Eph receptor tyrosine kinase inhibitor; CS-1203; NCGC00390558-01; AS-78559; BA164807; HY-18007; SMR001307828; A907856; N-[5-({4-[(4-Ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}carbamoyl)-2-methylphenyl]-5-(thiophen-2-yl)pyridine-3-carboxamide; N-[5-({4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}carbamoyl)-2-methylphenyl]-5-(thiophen-2-yl)pyridine-3-carboxamide (6)"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	607.7	8	C32H32F3N5O2S	106	933	5.1	43	2	9	"InChI=1S/C32H32F3N5O2S/c1-3-39-10-12-40(13-11-39)20-23-8-9-26(17-27(23)32(33,34)35)37-30(41)22-7-6-21(2)28(16-22)38-31(42)25-15-24(18-36-19-25)29-5-4-14-43-29/h4-9,14-19H,3,10-13,20H2,1-2H3,(H,37,41)(H,38,42)"	CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)C3=CC(=C(C=C3)C)NC(=O)C4=CN=CC(=C4)C5=CC=CS5)C(F)(F)F	HYWXBDQAYLPMIX-UHFFFAOYSA-N
DG01561	CCT196969	42628843	"CCT196969; 1163719-56-9; 1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea; CHEMBL4216588; 1-(5-tert-butyl-2-phenylpyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea; GTPL9815; SCHEMBL3761639; BCP19551; EX-A1598; BDBM50457449; MFCD28384201; s7743; ZINC43205799; AKOS027422849; CCG-269799; CCT-196969; CS-6229; HY-12846; 1-(3-(t-Butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea; 1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-(3-oxo-3,4-dihydropyrido[3,2-b]pyrazin-8-yloxy)phenyl)urea"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	513.5	6	C27H24FN7O3	123	877	4.2	38	3	7	"InChI=1S/C27H24FN7O3/c1-27(2,3)21-14-22(35(34-21)16-7-5-4-6-8-16)32-26(37)31-19-10-9-17(13-18(19)28)38-20-11-12-29-25-24(20)30-15-23(36)33-25/h4-15H,1-3H3,(H,29,33,36)(H2,31,32,37)"	CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C(=NC=C3)NC(=O)C=N4)F)C5=CC=CC=C5	KYYKGSDLXXKQCR-UHFFFAOYSA-N
DG01562	A66	42636535	"1166227-08-2; A66; A 66; (S)-N1-(2-(tert-butyl)-4'-methyl-[4,5'-bithiazol]-2'-yl)pyrrolidine-1,2-dicarboxamide; CHEMBL3218581; C17H23N5O2S2; A-66; (2S)-1-N-[5-(2-tert-butyl-1,3-thiazol-4-yl)-4-methyl-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide; (2S)-N1-[2-(tert-Butyl)-4'-methyl[4,5'-bithiazol]-2'-yl]-1,2-pyrrolidinedicarboxamide; MLS006010983; SCHEMBL14833311; CHEBI:91449; AOB2329; DTXSID80655299; BCPP000449; BCP03474; EX-A1124; BDBM50042922; s2636; ZINC43206649; AKOS025293511; BA41291; BCP9000211; CCG-268577; CS-0477; A66, >=98% (HPLC); AC-33133; AS-74623; HY-13261; SMR004702785; BCP0726000206; A 66; A-66; SW218196-2; X7447; C71541; J-501023; Q27163295; (2S)-N1-(5-(2-tert-butylthiazol-4-yl)-4-methylthiazol-2-yl)pyrrolidine-1,2-dicarboxamide; (2S)-N1-[5-(2-tert-butyl-4-thiazolyl)-4-methyl-2-thiazolyl]pyrrolidine-1,2-dicarboxamide; (S)-N1-(2-tert-butyl-4'-methyl-4,5'-bithiazol-2'-yl)pyrrolidine-1,2-dicarboxamide; (2S)-N~1~-(2-tert-Butyl-4'-methyl[4,5'-bi-1,3-thiazol]-2'-yl)pyrrolidine-1,2-dicarboxamide; (2S)-N1-[2-(1,1-Dimethylethyl)-4'-methyl[4,5'-bithiazol]-2'-yl]-1,2-pyrrolidinedicarboxamide; (2S)-N1-[5-(2-TERT-BUTYL-1,3-THIAZOL-4-YL)-4-METHYL-1,3-THIAZOL-2-YL]PYRROLIDINE-1,2-DICARBOXAMIDE; 1,2-Pyrrolidinedicarboxamide, N1-[2-(1,1-dimethylethyl)-4'-methyl[4,5'-bithiazol]-2'-yl]-, (2S)-"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	393.5	4	C17H23N5O2S2	158	556	2.8	26	2	6	"InChI=1S/C17H23N5O2S2/c1-9-12(10-8-25-14(20-10)17(2,3)4)26-15(19-9)21-16(24)22-7-5-6-11(22)13(18)23/h8,11H,5-7H2,1-4H3,(H2,18,23)(H,19,21,24)/t11-/m0/s1"	CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CSC(=N3)C(C)(C)C	HBPXWEPKNBHKAX-NSHDSACASA-N
DG01563	Foretinib	42642645	"Foretinib; 849217-64-7; GSK1363089; XL880; EXEL-2880; Foretinib (GSK1363089); XL-880; GSK 1363089; XL 880; GSK089; EXEL 2880; GSK-1363089; UNII-81FH7VK1C4; 81FH7VK1C4; GSK-089; GSK1363089G; 937176-80-2; N-[3-Fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; C34H34F2N4O6; 88Z; n-(3-fluoro-4-((6-methoxy-7-(3-(4-morpholinyl)propoxy)-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; N-(3-Fluoro-4-{[6-Methoxy-7-(3-Morpholin-4-Ylpropoxy)quinolin-4-Yl]oxy}phenyl)-N'-(4-Fluorophenyl)cyclopropane-1,1-Dicarboxamide; N-[3-fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-(3-Fluoro-4-((6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl]oxy)phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; Foretinib(XL880); xl-880, Foretinib; Foretinib (USAN/INN); Foretinib [USAN:INN]; MLS006010302; SCHEMBL371804; Foretinib - GSK1363089; GTPL5679; QCR-49; CHEMBL1230609; CHEBI:91418; AOB6031; DTXSID20918193; EX-A050; SYN1129; BCPP000236; HMS3295K13; HMS3654G04; BCP02231; BDBM50399540; GSK 1363089G; GSK-1363089G; MFCD16038048; NSC755775; NSC800101; s1111; ZINC43204048; Foretinib,XL880, GSK1363089; AKOS015904319; BCP9000675; CCG-270292; CS-0153; DB12307; NSC-755775; NSC-800101; PB27007; SB20469; Foretinib (GSK1363089, XL880); NCGC00263104-01; NCGC00263104-10; AC-25081; AS-16268; HY-10338; SMR003599144; SW219390-1; W8766; EC-000.2326; A25642; D09618; XL880, GSK1363089G, Exel 2880; J-523004; Q5469311; BRD-K03449891-001-01-1; 1,1-Cyclopropanedicarboxamide, N-(3-fluoro-4-((6-methoxy-7-(3-(4-morpholinyl)propoxy)-4-quinolinyl)oxy)phenyl)-N'-(4-fluorophenyl)-; 1-N'-[3-fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; 1-N'-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; GSK1363089;EXEL-2880;Foretinib;N-[3-Fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide;Foretinib; N-(4-(7-(3-MORPHOLINOPROPOXY)-6-METHOXYQUINOLIN-4-YLOXY)-3-FLUOROPHENYL)-N-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE; N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin 4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-[3-Fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-1-[(4-fluorophenyl)carbamoyl]cyclopropane-1-carboximidic acid"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:91418	DB12307	.	.	632.7	12	C34H34F2N4O6	111	1010	5.5	46	2	10	"InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)"	COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F	CXQHYVUVSFXTMY-UHFFFAOYSA-N
DG01564	CCT241161	44132853	"CCT241161; 1163719-91-2; CHEMBL4204895; 1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(2-(methylthio)-4-(3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yloxy)phenyl)urea; 1-(5-tert-butyl-2-phenylpyrazol-3-yl)-3-[2-methylsulfanyl-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea; GTPL9814; SCHEMBL3173602; BDBM50457448; CCT241161 pan RAF/SFK inhibitor; AKOS037653304; GS-9003"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	541.6	7	C28H27N7O3S	148	893	4.6	39	3	7	"InChI=1S/C28H27N7O3S/c1-28(2,3)22-15-23(35(34-22)17-8-6-5-7-9-17)32-27(37)31-19-11-10-18(14-21(19)39-4)38-20-12-13-29-26-25(20)30-16-24(36)33-26/h5-16H,1-4H3,(H,29,33,36)(H2,31,32,37)"	CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C(=NC=C3)NC(=O)C=N4)SC)C5=CC=CC=C5	DPMYVVGAYAPQNS-UHFFFAOYSA-N
DG01565	AZD-6482	44137675	"AZD6482; 1173900-33-8; AZD-6482; AZD 6482; (R)-2-(1-(7-methyl-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethylamino)benzoic acid; CHEMBL2165191; 2-[[(1R)-1-[7-Methyl-2-(4-morpholinyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino]benzoic acid; UNII-78G6MP5PZ5; 2-[[(1R)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoic acid; 78G6MP5PZ5; 2-{[(1R)-1-[7-methyl-2-(morpholin-4-yl)-4-oxopyrido[1,2-a]pyrimidin-9-yl]ethyl]amino}benzoic acid; 2-({(1R)-1-[7-Methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl}amino)benzoic acid; 4urk; 2-(((1R)-1-(7-Methyl-2-(4-morpholinyl)-4-oxo-4H-pyrido(1,2-a)pyrimidin-9-yl)ethyl)amino)benzoic acid; 2-{[(1R)-1-[7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino}benzoic acid; 2-[[(1r)-1-(7-Methyl-2-Morpholin-4-Yl-4-Oxidanylidene-Pyrido[1,2-A]pyrimidin-9-Yl)ethyl]amino]benzoic Acid; MLS006010986; GTPL8059; SCHEMBL1812377; CHEBI:91359; AOB3536; DTXSID00657619; KIN 193; KIN-193; AZD 6482 [WHO-DD]; ACT06822; EX-A1807; 2243AH; BDBM50395821; MFCD16659062; NSC799349; s1462; ZINC38628584; AKOS015935014; BCP9000355; CCG-268743; CS-0086; DB14980; NSC-799349; NCGC00263154-01; AC-32792; AS-74808; HY-10344; SMR004702788; SW219187-1; J-507622; BRD-K58772419-001-01-3; Q27074771; (-) 2-{[(1R)-1-(7-Methyl-2-morpholin-4-yl-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethyl]amino}benzoic acid; (-)-2-[[(1R)-1-[7-Methyl-2-(4-morpholinyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino]benzoic acid; (R)-2-((1-(7-Methyl-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethyl)amino)benzoic acid; 2-[[(1R)-1-[7-methyl-2-(4-morpholinyl)-4-oxo-4H-pyrido[1.2-a]pyrimidin-9-yl]ethyl]amino]-benzoic acid; Benzoic acid, 2-[[(1R)-1-[7-methyl-2-(4-morpholinyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino]-"	Terminated	10	Discontinued Drug(s)	Terminated	Small molecular drug	CHEBI:91359	DB14980	.	.	408.4	5	C22H24N4O4	94.5	838	2	30	2	7	"InChI=1S/C22H24N4O4/c1-14-11-17(15(2)23-18-6-4-3-5-16(18)22(28)29)21-24-19(12-20(27)26(21)13-14)25-7-9-30-10-8-25/h3-6,11-13,15,23H,7-10H2,1-2H3,(H,28,29)/t15-/m1/s1"	CC1=CN2C(=O)C=C(N=C2C(=C1)[C@@H](C)NC3=CC=CC=C3C(=O)O)N4CCOCC4	IRTDIKMSKMREGO-OAHLLOKOSA-N
DG01566	Refametinib	44182295	"Refametinib; 923032-37-5; RDEA119; RDEA 119; BAY 869766; UNII-JPX07AFM0N; (S)-N-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; JPX07AFM0N; Refametinib (RDEA119); BAY-869766; BAY 8697661; Refametinib (RDEA119, Bay 86-9766); N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide; Refametinib R enantiomer; Refametinib [INN]; BAY 86-9766; RDEA-119; 3e8n; BAY 86-97661; Refametinib; RDEA119; SCHEMBL345333; C19H20F3IN2O5S; GTPL7942; Refametinib (BAY86-9766); CHEMBL1236682; DTXSID40238961; BDBM520650; 923032-38-6; AOB87134; EX-A2481; 2254AH; MFCD18633256; NSC800864; s1089; ZINC39187987; AKOS025401896; BAY86-9766; CCG-270103; CS-1818; DB06309; NSC-800864; BAY 86-9766;RDEA119; BAY-86-9766; BAY-8697661; NCGC00188380-01; NCGC00188380-02; NCGC00188380-03; AC-26962; AS-16994; Cyclopropanesulfonamide, N-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-6-methoxyphenyl)-1-((2S)-2,3-dihydroxypropyl)-; HY-14691; SW218136-2; J3.661.482J; F51934; US11147816, Refametinib (RDEA119, Bay; Q27088526; BAY 869766;BAY 86-97661;RDEA-119;RDEA119; (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; 923032-36-4; N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[(2S)-2,3-dihydroxypropyl]cyclopropanesulfonamide; RDEA-119 S enantiomer; ; ; BAY-86-9766 S enantiomer; ; ; N-[3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide; VRA"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	.	DB06309	DR1879	.	572.3	9	C19H20F3IN2O5S	116	711	2.8	31	4	10	"InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1"	COC1=CC(=C(C(=C1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)NC3=C(C=C(C=C3)I)F)F)F	RDSACQWTXKSHJT-NSHDSACASA-N
DG01567	Pimasertib	44187362	"Pimasertib; 1236699-92-5; AS703026; AS-703026; Pimasertib (AS-703026); MSC1936369B; AS 703026; UNII-6ON9RK82AL; 1204531-26-9; 6ON9RK82AL; SAR 245509; MSC-1936369; N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodo-anilino)pyridine-4-carboxamide; N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]pyridine-4-carboxamide; C15H15FIN3O3; (S)-N-(2,3-dihydroxypropyl)-3-(2-fluoro-4-iodophenylamino)isonicotinamide; (S)-N-(2,3-dihydroxypropyl)-3-((2-fluoro-4-iodophenyl)amino)isonicotinamide; (S)-N-(2,3-dihydroxypropyl)-3-((2-fluoro-4-iodophenyl)amino)isonicotinamide.; 4-Pyridinecarboxamide, N-((2S)-2,3-dihydroxypropyl)-3-((2-fluoro-4-iodophenyl)amino)-; 4-Pyridinecarboxamide, N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]-; N-((2S)-2,3-dihydroxypropyl)-3-((2-fluoro-4-iodophenyl)amino)pyridine-4-carboxamide; N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)pyridine-4-carboxamide; Pimasertib [USAN:INN]; Pimasertib (USAN/INN); Pimasertib; AS703026; N-[(2S)-2,3-Dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]-4-pyridinecarboxamide; MLS006010177; GTPL7872; QCR-17; SCHEMBL2720659; CHEMBL2107832; CHEBI:94793; DTXSID40152870; EX-A403; SYN1190; BCPP000386; AOB87391; BCP02094; MSC1936369A; BDBM50014412; MSC-1936369A; NSC755763; NSC800854; ZINC38226009; AKOS022186348; BCP9000325; CCG-269018; CS-0198; DB14904; NSC-755763; NSC-800854; EMD 1036239; EMD-1036239; NCGC00346530-01; AC-32862; AS-16324; HY-12042; SMR004701285; AS703026,MSC1936369B; SW219691-1; X7392; C71933; D10426; A857420; J-523298; BRD-K89014967-001-01-9; Q27088393; G-02443714; AS7030261236699-92-5; AS-703026;N-[(2S)-2,3-Dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]-4-pyridinecarboxamide;AS-703026"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:94793	DB14904	DR1835	.	431.2	6	C15H15FIN3O3	94.5	391	1.7	23	4	6	"InChI=1S/C15H15FIN3O3/c16-12-5-9(17)1-2-13(12)20-14-7-18-4-3-11(14)15(23)19-6-10(22)8-21/h1-5,7,10,20-22H,6,8H2,(H,19,23)/t10-/m0/s1"	C1=CC(=C(C=C1I)F)NC2=C(C=CN=C2)C(=O)NC[C@@H](CO)O	VIUAUNHCRHHYNE-JTQLQIEISA-N
DG01568	TAK-441	44187367	"TAK-441; 1186231-83-3; UNII-CY3QT94KWP; CY3QT94KWP; CHEMBL2205230; 6-ethyl-N-[1-(2-hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-phenacyl-3-(2,2,2-trifluoroethoxy)pyrrolo[3,2-c]pyridine-2-carboxamide; TAK 441; GTPL8200; SCHEMBL1061476; BCP20946; BDBM50401323; NSC771858; ZINC43207688; NSC-771858; SB18887; LM2094; TAK441; TAK 441; Q27088929; 6-ethyl-N-(1-(2-hydroxyacetyl)piperidin-4-yl)-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	.	.	.	576.6	9	C28H31F3N4O6	121	1020	2.6	41	2	9	"InChI=1S/C28H31F3N4O6/c1-3-19-13-20-23(27(40)35(19)14-21(37)17-7-5-4-6-8-17)25(41-16-28(29,30)31)24(33(20)2)26(39)32-18-9-11-34(12-10-18)22(38)15-36/h4-8,13,18,36H,3,9-12,14-16H2,1-2H3,(H,32,39)"	CCC1=CC2=C(C(=C(N2C)C(=O)NC3CCN(CC3)C(=O)CO)OCC(F)(F)F)C(=O)N1CC(=O)C4=CC=CC=C4	ZADWXQMNNVICKB-UHFFFAOYSA-N
DG01569	IWR-1	44483163	"IWR-1-endo; IWR-1; 1127442-82-3; endo-IWR-1; CHEBI:62882; CHEMBL562310; 4-[(3aR,4S,7R,7aS)-1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2H-4,7-methanoisoindol-2-yl]-N-(quinolin-8-yl)benzamide; C25H19N3O3; IWR1-endo; exo-IWR 1; rel-4-((3aR,4S,7R,7aS)-1,3-Dioxo-1,3,3a,4,7,7a-hexahydro-2H-4,7-methanoisoindol-2-yl)-N-(quinolin-8-yl)benzamide; IWR-1 endo; 4tkf; 4-((3aR,4S,7R,7aS)-1,3-Dioxo-1,3,3a,4,7,7a-hexahydro-2H-4,7-methanoisoindol-2-yl)-N-(quinolin-8-yl)benzamide; IRW1; SCHEMBL15315470; EX-A642; BCP05700; ZINC2483738; 1806AH; 2489AH; BDBM50007583; MFCD18086875; NSC756646; CCG-208104; NSC-756646; IWR-1, >=98% (HPLC); HY-12238; rel-4-[(3aR,4S,7R,7aS)-1,3,3a,4,7,7a-Hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl]-N-8-quinolinylbenzamide; B2306; C71420; BRD-K61314889-001-01-0; Q27132252; 4-[(1R,2S,6R,7S)-3,5-dioxo-4-azatricyclo[5.2.1.0{2,6}]dec-8-en-4-yl]-N-(quinolin-8-yl)benzamide; 4-[(1S,2R,6S,7R)-3,5-dioxo-4-azatricyclo[5.2.1.02,6]dec-8-en-4-yl]-N-quinolin-8-ylbenzamide; Benzamide, 4-[(3aR,4S,7R,7aS)-1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl]-N-8-quinolinyl-"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	409.4	3	C25H19N3O3	79.4	772	2.9	31	1	4	"InChI=1S/C25H19N3O3/c29-23(27-19-5-1-3-14-4-2-12-26-22(14)19)15-8-10-18(11-9-15)28-24(30)20-16-6-7-17(13-16)21(20)25(28)31/h1-12,16-17,20-21H,13H2,(H,27,29)/t16-,17+,20-,21+"	C1[C@@H]2C=C[C@H]1[C@@H]3[C@H]2C(=O)N(C3=O)C4=CC=C(C=C4)C(=O)NC5=CC=CC6=C5N=CC=C6	ZGSXEXBYLJIOGF-ALFLXDJESA-N
DG01570	NMS-P715	44556162	"NMS-P715; 1202055-32-0; CHEMBL1236095; N-(2,6-Diethylphenyl)-1-Methyl-8-({4-[(1-Methylpiperidin-4-Yl)carbamoyl]-2-(Trifluoromethoxy)phenyl}amino)-4,5-Dihydro-1h-Pyrazolo[4,3-H]quinazoline-3-Carboxamide; N-(2,6-diethylphenyl)-1-methyl-8-[4-[(1-methylpiperidin-4-yl)carbamoyl]-2-(trifluoromethoxy)anilino]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide; NMSP715; GTPL9401; NMS P715; SCHEMBL1558596; NMSP715; NMSP 715; BCP28244; NMS P715;NMS-P 715; BDBM50349102; ZINC58649424; CS-3396; compound 15 [PMID: 21723120]; NCGC00390549-01; AC-30241; HY-12382; B5819; FT-0702072; A910501; Q27465504; 1H-Pyrazolo[4,3-h]quinazoline-3-carboxamide, N-(2,6-diethylphenyl)-4,5-dihydro-1-methyl-8-[[4-[[(1-methyl-4-piperidinyl)amino]carbonyl]-2-(trifluoromethoxy)phenyl]amino]-"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	676.7	9	C35H39F3N8O3	126	1110	6.2	49	3	11	"InChI=1S/C35H39F3N8O3/c1-5-20-8-7-9-21(6-2)28(20)42-33(48)30-25-12-10-23-19-39-34(43-29(23)31(25)46(4)44-30)41-26-13-11-22(18-27(26)49-35(36,37)38)32(47)40-24-14-16-45(3)17-15-24/h7-9,11,13,18-19,24H,5-6,10,12,14-17H2,1-4H3,(H,40,47)(H,42,48)(H,39,41,43)"	CCC1=C(C(=CC=C1)CC)NC(=O)C2=NN(C3=C2CCC4=CN=C(N=C43)NC5=C(C=C(C=C5)C(=O)NC6CCN(CC6)C)OC(F)(F)F)C	JFOAJUGFHDCBJJ-UHFFFAOYSA-N
DG01571	Merestinib	44603533	"Merestinib; 1206799-15-6; LY2801653; LY-2801653; N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; UNII-5OGS5K699E; Merestinib (LY2801653); 5OGS5K699E; N-[3-fluoro-4-[1-methyl-6-(1H-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide; N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide; C30H22F2N6O3; N-(3-Fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; N-[3-Fluoro-4-[[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-6-methyl-2-oxo-3-pyridinecarboxamide; Merestinib [USAN]; L1X; Merestinib (USAN/INN); SCHEMBL679002; LY2801653 (Merestinib); GTPL9841; CHEMBL3545307; DTXSID20659635; QCR-139; SYN1222; HMS3741E21; BCP06826; EX-A1264; 3797AH; BDBM50172078; NSC772197; NSC800788; s7014; ZINC95926668; AKOS027323283; CCG-270011; CS-1192; DB12381; NSC-772197; NSC-800788; SB16550; NCGC00378921-02; NCGC00378921-07; 3-Pyridinecarboxamide, N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-1,2-dihydro-6-methyl-2-oxo-; AS-16348; DA-21192; HY-15514; FT-0745076; LY 2801653; J3.563.073B; D11763; Q27262653"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB12381	.	.	552.5	6	C30H22F2N6O3	105	1050	4.7	41	2	7	"InChI=1S/C30H22F2N6O3/c1-17-3-9-23(30(40)38(17)22-7-4-20(31)5-8-22)29(39)36-21-6-10-27(25(32)12-21)41-28-11-18-16-35-37(2)26(18)13-24(28)19-14-33-34-15-19/h3-16H,1-2H3,(H,33,34)(H,36,39)"	CC1=CC=C(C(=O)N1C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C=C5C(=C4)C=NN5C)C6=CNN=C6)F	QHADVLVFMKEIIP-UHFFFAOYSA-N
DG01572	WZ4002	44607530	"WZ4002; 1213269-23-8; WZ-4002; N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide; WZ 4002; UNII-6BQ432Z61M; CHEBI:61400; CHEMBL1229592; 6BQ432Z61M; N-(3-((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)acrylamide; N-[3-[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]oxyphenyl]prop-2-enamide; N-{3-[(5-chloro-2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)oxy]phenyl}prop-2-enamide; SMR001913510; SCHEMBL93699; MLS003230945; MLS006011213; AMY370; GTPL9176; QCR-55; DTXSID30153230; EX-A416; HMS3265O15; HMS3265O16; HMS3265P15; HMS3265P16; HMS3654C16; BCP02515; BDBM50383274; NSC755927; s1173; ZINC52509385; AKOS025401946; CCG-264847; CS-0167; NSC-755927; SB19360; NCGC00263144-01; NCGC00263144-02; NCGC00263144-11; AC-27472; AS-19387; DA-47168; HY-12026; N-(3-((5-chloro-2-((2-methoxy-4-(4-methyl-1-piperazinyl)phenyl)amino)-4-pyrimidinyl)oxy)phenyl)acrylamide; N-[3-[[5-Chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide; WZ4002, >=98% (HPLC); FT-0730384; SW219315-1; X7482; EC-000.2280; A25634; J-004480; J-523322; Q27089236; N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazine-1-yl)phenylamino)pyrimidin-4yloxy)phenyl)acrylam; N-[3-[[5-Chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide HBr"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	495	8	C25H27ClN6O3	91.8	694	4.2	35	2	8	"InChI=1S/C25H27ClN6O3/c1-4-23(33)28-17-6-5-7-19(14-17)35-24-20(26)16-27-25(30-24)29-21-9-8-18(15-22(21)34-3)32-12-10-31(2)11-13-32/h4-9,14-16H,1,10-13H2,2-3H3,(H,28,33)(H,27,29,30)"	CN1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)OC4=CC=CC(=C4)NC(=O)C=C)Cl)OC	ITTRLTNMFYIYPA-UHFFFAOYSA-N
DG01573	DS-7423	45378170	"DS-7423; 5-{8-[(3R)-4-Acetyl-3-methylpiperazin-1-yl]-6-morpholin-4-yl-9-(2,2,2-trifluoroethyl)-9H-purin-2-yl}pyrimidin-2-amine; SCHEMBL336466; HY-124036; CS-0084006"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	520.5	4	C22H27F3N10O2	131	795	0.9	37	1	13	"InChI=1S/C22H27F3N10O2/c1-13-11-33(3-4-34(13)14(2)36)21-29-16-18(32-5-7-37-8-6-32)30-17(15-9-27-20(26)28-10-15)31-19(16)35(21)12-22(23,24)25/h9-10,13H,3-8,11-12H2,1-2H3,(H2,26,27,28)/t13-/m1/s1"	C[C@@H]1CN(CCN1C(=O)C)C2=NC3=C(N2CC(F)(F)F)N=C(N=C3N4CCOCC4)C5=CN=C(N=C5)N	SOJJMSYMCLIQCZ-CYBMUJFWSA-N
DG01574	TAK-632	46209401	"TAK-632; 1228591-30-7; TAK632; N-(7-cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide; N-{7-Cyano-6-[4-Fluoro-3-({[3-(Trifluoromethyl)phenyl]acetyl}amino)phenoxy]-1,3-Benzothiazol-2-Yl}cyclopropanecarboxamide; N-[7-CYANO-6-(4-FLUORO-3-{2-[3-(TRIFLUOROMETHYL)PHENYL]ACETAMIDO}PHENOXY)-1,3-BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE; N-[7-cyano-6-[4-fluoro-3-[[2-[3-(trifluoromethyl)phenyl]acetyl]amino]phenoxy]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide; C27H18F4N4O3S; 4ksp; 1SU; N-[7-Cyano-6-[4-fluoro-3-[[[3-(trifluoromethyl)phenyl]acetyl]amino]phenoxy]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide; SCHEMBL823682; CHEMBL3125890; BDBM99471; GTPL10387; EX-A242; SYN1203; TAK 632; CHEBI:167673; HMS3653M08; HMS3673M07; AOB87729; BCP08426; TAK 632; TAK 632; 2742AH; MFCD26960965; NSC778809; s7291; ZINC68208189; AKOS025405225; CCG-270021; CS-1697; NSC-778809; compound 8B [PMID: 23906342]; NCGC00371156-09; AS-16332; DA-47029; HY-15767; QC-10896; FT-0700129; SW219895-1; US8497274, 32; A890929; J-690078; Q27452417; Benzeneacetamide, N-[5-[[7-cyano-2-[(cyclopropylcarbonyl)amino]-6-benzothiazolyl]oxy]-2-fluorophenyl]-3-(trifluoromethyl)-; N-[5-[[7-cyano-2-[(cyclopropylcarbonyl)amino]-6-benzothiazolyl]oxy]-2-fluorophenyl]-3-(trifluoromethyl)-benzeneacetamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	554.5	7	C27H18F4N4O3S	132	957	5.3	39	2	10	"InChI=1S/C27H18F4N4O3S/c28-19-7-6-17(12-21(19)33-23(36)11-14-2-1-3-16(10-14)27(29,30)31)38-22-9-8-20-24(18(22)13-32)39-26(34-20)35-25(37)15-4-5-15/h1-3,6-10,12,15H,4-5,11H2,(H,33,36)(H,34,35,37)"	C1CC1C(=O)NC2=NC3=C(S2)C(=C(C=C3)OC4=CC(=C(C=C4)F)NC(=O)CC5=CC(=CC=C5)C(F)(F)F)C#N	OJFKUJDRGJSAQB-UHFFFAOYSA-N
DG01575	Gandotinib	46213929	"GANDOTINIB; 1229236-86-5; LY2784544; LY 2784544; LY-2784544; UNII-ANC71R916O; Gandotinib (LY2784544); 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine; ANC71R916O; 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(3-methyl-1H-pyrazol-5-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine; C23H25ClFN7O; 3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholin-4-ylmethyl)imidazo[1,2-b]pyridazin-6-amine; Gandotinib [USAN:INN]; LY2784544(Gandotinib); Gandotinib (USAN); LY2784544;Gandotinib; Gandotinib(LY2784544); Gandotinib; LY2784544; 3-[(4-Chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(4-morpholinylmethyl)imidazo[1,2-b]pyridazin-6-amine; GTPL7909; SCHEMBL2513132; CHEMBL2107823; SCHEMBL15458955; DTXSID20153789; SYN1196; CHEBI:188757; HMS3655L06; HMS3750I09; AOB87108; BCP02309; EX-A1114; MFCD20482143; NSC764820; s2179; ZINC68245097; AKOS026673949; AKOS037643413; BCP9000875; CCG-269448; CS-0426; DB13040; NSC-764820; QC-8978; SB13346; NCGC00345461-02; NCGC00345461-08; 3-((4-Chloro-2-fluorophenyl)methyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8- (morpholin-4-ylmethyl)imidazo(1,2-b)pyridazin-6-amine; 3-(4-Chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8- (morpholinomethyl)imidazo(1,2-b)pyridazin-6-amine; AC-32810; AS-16329; HY-13034; Imidazo(1,2-b)pyridazin-6-amine, 3-((4-chloro-2-fluorophenyl)methyl)-2-methyl-N-(5- methyl-1H-pyrazol-3-yl)-8-(4-morpholinylmethyl)-; FT-0700131; SW219960-1; X7498; A25226; D10365; J-511428; Q27077770; 3-[(4-chloro-2-luorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholin-4-ylmethyl)imidazo[1,2-b]pyridazin-6-amine; Gandotinib;3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(3-methyl-1H-pyrazol-5-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine; Imidazo[1,2-b]pyridazin-6-amine, 3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(4-morpholinylmethyl)-"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB13040	.	.	469.9	6	C23H25ClFN7O	83.4	644	3.8	33	2	7	"InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)"	CC1=CC(=NN1)NC2=NN3C(=C(N=C3C(=C2)CN4CCOCC4)C)CC5=C(C=C(C=C5)Cl)F	SQSZANZGUXWJEA-UHFFFAOYSA-N
DG01576	Derazantinib	46834118	"Derazantinib; 1234356-69-4; ARQ-087; ARQ087; UNII-N9B0H171MJ; N9B0H171MJ; ARQ 087; (6R)-6-(2-fluorophenyl)-N-(3-{2-[(2-methoxyethyl)amino]ethyl}phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine; Benzo[h]quinazolin-2-amine, 6-(2-fluorophenyl)-5,6-dihydro-N-[3-[2-[(2-methoxyethyl)amino]ethyl]phenyl]-, (6R)-; Benzo(H)quinazolin-2-amine, 6-(2-fluorophenyl)-5,6-dihydro-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-, (6R)-; Derazantinib [USAN]; Derazantinib(ARQ-087); Derazantinib (ARQ 087); GTPL9785; CHEMBL4297187; SCHEMBL13273847; ARQ-087ARQ-087; AMY16754; BCP29103; EX-A1717; s8609; WHO 10488; AKOS037648596; CS-7922; DB14889; AC-30343; BS-14785; HY-19981; A16825; C71924; (6R)-6-(2-fluorophenyl)-5,6-dihydro-N-[3-[2-[(2-methoxyethyl)amino]ethyl]phenyl]-Benzo[h]quinazolin-2-amine; (R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	.	DB14889	.	.	468.6	9	C29H29FN4O	59.1	638	5.3	35	2	6	"InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1"	COCCNCCC1=CC(=CC=C1)NC2=NC=C3C[C@H](C4=CC=CC=C4C3=N2)C5=CC=CC=C5F	KPJDVVCDVBFRMU-AREMUKBSSA-N
DG01577	Flumatinib	46848036	"Flumatinib; 895519-90-1; HHGV678; HH-GV678; Flumatinib free base; flumbatinib; UNII-R4009Y24AI; HHGV-678; R4009Y24AI; 895519-90-1 (free base); 4-[(4-methylpiperazin-1-yl)methyl]-N-[6-methyl-5-[(4-pyridin-3-ylpyrimidin-2-yl)amino]pyridin-3-yl]-3-(trifluoromethyl)benzamide; HHGV678 mesylate; BenzaMide, 4-[(4-Methyl-1-piperazinyl)Methyl]-N-[6-Methyl-5-[[4-(3-pyridinyl)-2-pyriMidinyl]aMino]-3-pyridinyl]-3-(trifluoroMethyl)-; N-(6-methyl-5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)pyridin-3-yl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide; HH-GV-678; Hansoh Xinfu; flumatinib (pseudo INN); GTPL9913; SCHEMBL4883843; CHEMBL3545413; DTXSID60237779; BCP23797; EX-A3572; VKB51990; BDBM50529313; NSC830368; ZINC68244727; CS-5550; DB11904; NSC-830368; SB17192; NCGC00378614-01; 4-(4-Methylpiperazin-1-ylmethyl)-N-(6-methyl-5-(4-pyridin-3-ylpyrimidin-2-ylamino)pyridin-3-yl)-3-trifluoromethylbenzamide; DA-33625; HY-13904; FT-0739882; Q27287759; N-[5-[[4-(3-Pyridinyl)pyrimidine-2-yl]amino]-6-methylpyridine-3-yl]-3-(trifluoromethyl)-4-[(4-methylpiperazine-1-yl)methyl]benzamide"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB11904	.	.	562.6	7	C29H29F3N8O	99.2	841	3.4	41	2	11	"InChI=1S/C29H29F3N8O/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38)"	CC1=C(C=C(C=N1)NC(=O)C2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5	BJCJYEYYYGBROF-UHFFFAOYSA-N
DG01578	NS-018	46866319	"NS-018; ilginatinib; 1239358-86-1; UNII-56R994WX4L; 56R994WX4L; 6-N-[(1S)-1-(4-fluorophenyl)ethyl]-4-(1-methylpyrazol-4-yl)-2-N-pyrazin-2-ylpyridine-2,6-diamine; (S)-N2-(1-(4-fluorophenyl)ethyl)-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine; (S)-N2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine; GTPL7839; CHEMBL4303389; SCHEMBL14954406; NS018; HY-19631A; NS-018NS-018; ZINC68245917; CS-5358; DB12784; A922051; Q27088043; (S)-N-(1-(4-Fluorophenyl)ethyl)-4-(1-methyl-1H-pyrazol-4-yl)-N'-(pyrazin-2-yl)pyridine-2,6-diamine; (S)-N2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2yl)pyridine-2,6-diamine; 2,6-Pyridinediamine, N2-((1S)-1-(4-fluorophenyl)ethyl)-4-(1-methyl-1H-pyrazol-4-yl)-N6-2-pyrazinyl-; N2-[(1S)-1-(4-Fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine"	Phase 1/2	8	Clinical Trial Drug(s)	Phase 1/2	Small molecular drug	.	DB12784	.	.	389.4	6	C21H20FN7	80.6	501	3.2	29	2	7	"InChI=1S/C21H20FN7/c1-14(15-3-5-18(22)6-4-15)26-19-9-16(17-11-25-29(2)13-17)10-20(27-19)28-21-12-23-7-8-24-21/h3-14H,1-2H3,(H2,24,26,27,28)/t14-/m0/s1"	C[C@@H](C1=CC=C(C=C1)F)NC2=CC(=CC(=N2)NC3=NC=CN=C3)C4=CN(N=C4)C	UQTPDWDAYHAZNT-AWEZNQCLSA-N
DG01579	JQ1	46907787	"1268524-70-4; (+)-JQ1; (+)-JQ-1; JQ1 compound; JQ1; JQ-1; (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-triMethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; UNII-1MRH0IMX0W; (S)-JQ1; Bromodomain Inhibitor, (+)-JQ1; 1MRH0IMX0W; C23H25ClN4O2S; CHEMBL1957266; tert-butyl (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; 6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetic acid, 4-(4-chlorophenyl)-2,3,9-trimethyl-, 1,1-dimethylethyl ester, (6S)-; 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid, 4-(4-chlorophenyl)-2,3,9-trimethyl-, 1,1-dimethylethyl ester, (6S)-; tert-Butyl 2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-6-yl)acetate; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-6-yl)acetate; 3mxf; 4flp; 4qzs; (6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester; tert-butyl 2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; MLS006011158; SCHEMBL881227; GTPL7511; CHEBI:95080; DTXSID20155309; EX-A457; SYN3004; CHEBI:137113; BDBM50365262; NSC760183; NSC764043; s7110; ZINC57318556; AKOS016344680; (+)JQ-1; CCG-269306; CS-0581; JQ1 (+); JQ1-(+); NSC-760183; NSC-764043; NCGC00250412-01; NCGC00250412-15; NCGC00250412-21; (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-triMethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diaz; AC-32617; AS-16352; BP-21590; HY-13030; SMR004702930; BB 0262647; (+)-JQ1, >=98% (HPLC); A854208; Q3156953; (6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]di azepine-6-acetic acid 1,1-dimethylethyl ester; tert-butyl (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate;(S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; tert-butyl [(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetate; tert-butyl 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate; tert-butyl[(S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetate"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	CHEBI:95080	.	.	.	457	5	C23H25ClN4O2S	97.6	706	4.9	31	0	6	"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1"	CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C	DNVXATUJJDPFDM-KRWDZBQOSA-N
DG01580	MPI-0479605	46909588	"MPI-0479605; 1246529-32-7; N6-Cyclohexyl-N2-(2-methyl-4-morpholinophenyl)-9H-purine-2,6-diamine; CHEMBL2047943; MPI0479605; MPI 0479605; 6-N-cyclohexyl-2-N-(2-methyl-4-morpholin-4-ylphenyl)-7H-purine-2,6-diamine; C22H29N7O; WITJ0018D; MPI-0479605 hydrochloride; GTPL9399; SCHEMBL2946927; US11208696, Example 1; BDBM532282; HMS3653P07; HMS3740O21; BCP27897; EX-A1092; WZB52932; 2574AH; BDBM50386816; MFCD28099811; ZINC68246140; AKOS026750424; AKOS027289040; CCG-268735; CS-4665; SB19447; NCGC00386327-02; NCGC00386327-03; AC-33011; DA-46740; HY-12660; B3706; FT-0699832; S7488; SW220076-1; A14290; n6-cyclohexyl-n2-(2-methyl-4-morpholino-phenyl)-9h-purine-2,6-diamine; N~-6~-cyclohexyl-N~2~-[2-methyl-4-(morpholin-4-yl)phenyl]-9H-purine-2,6-diamine; 9H- Purine- 2, 6- diamine, N6- cyclohexyl- N2- [2- methyl- 4- (4- morpholinyl) phenyl] -"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	407.5	5	C22H29N7O	91	540	4.2	30	3	7	"InChI=1S/C22H29N7O/c1-15-13-17(29-9-11-30-12-10-29)7-8-18(15)26-22-27-20-19(23-14-24-20)21(28-22)25-16-5-3-2-4-6-16/h7-8,13-14,16H,2-6,9-12H2,1H3,(H3,23,24,25,26,27,28)"	CC1=C(C=CC(=C1)N2CCOCC2)NC3=NC4=C(C(=N3)NC5CCCCC5)NC=N4	OVJBNYKNHXJGSA-UHFFFAOYSA-N
DG01581	VS-5584	46912230	"VS-5584; 1246560-33-7; 5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; SB2343; SB-2343; VS-5584 (SB2343); UNII-W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; CHEMBL3393066; W71J4X250V; VS5584; 5-[9-Isopropyl-8-methyl-2-(morpholin-4-yl)purin-6-yl]pyrimidin-2-amine; 2-Pyrimidinamine, 5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl]-; C17H22N8O; 2-Pyrimidinamine, 5-(8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl)-; SCHEMBL539098; GTPL8382; DTXSID10677328; EX-A288; HMS3652B16; BCP08247; WZB56033; 2797AH; BDBM50059635; MFCD25372027; NSC778810; NSC800991; s7016; ZINC95644685; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; AKOS024465057; CCG-268087; CS-1202; DB12986; NSC-778810; NSC-800991; SB 2343; SB16877; 5-[8-Methyl-2-(morpholin-4-yl)-9-(propan-2-yl)-9H-purin-6-yl]pyrimidin-2-amine; NCGC00386370-03; NCGC00386370-06; AC-33121; AS-80075; DA-46738; HY-16585; FT-0700143; SW220201-1; A857790; J-690096; Q27089164; 5-[8-Methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl]-2-pyrimidinamine; SB-2343; ; ; 5-(8-Methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	DB12986	.	.	354.4	3	C17H22N8O	108	466	0.8	26	1	8	"InChI=1S/C17H22N8O/c1-10(2)25-11(3)21-14-13(12-8-19-16(18)20-9-12)22-17(23-15(14)25)24-4-6-26-7-5-24/h8-10H,4-7H2,1-3H3,(H2,18,19,20)"	CC1=NC2=C(N=C(N=C2N1C(C)C)N3CCOCC3)C4=CN=C(N=C4)N	QYBGBLQCOOISAR-UHFFFAOYSA-N
DG01582	WNT-974	46926973	"1243244-14-5; LGK974; LGK-974; 2-(2',3-Dimethyl-[2,4'-bipyridin]-5-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide; WNT-974; WNT974; LGK 974; UNII-U27F40013Q; CHEBI:78030; LGK974 (WNT974); CHEMBL3188386; 2-[5-methyl-6-(2-methylpyridin-4-yl)pyridin-3-yl]-N-(5-pyrazin-2-ylpyridin-2-yl)acetamide; U27F40013Q; 2-[5-Methyl-6-(2-methyl-4-pyridyl)-3-pyridyl]-N-(5-pyrazin-2-yl-2-pyridyl)acetamide; [2,4'-Bipyridine]-5-acetamide, 2',3-dimethyl-N-[5-(2-pyrazinyl)-2-pyridinyl]-; 2-(2',3-Dimethyl-(2,4'-bipyridin)-5-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide; 2-(2',3-dimethyl-2,4'-bipyridin-5-yl)-N-[5-(pyrazin-2-yl)pyridin-2-yl]acetamide; NVP-LGK974; MLS006011002; SCHEMBL1723611; GTPL11167; HMS3653G11; BCP08495; EX-A1402; LGK-974 (WNT974); 2140AH; BBL102809; BDBM50133870; CS3177; NSC777639; s7143; STL556617; ZINC95930187; AKOS025211913; CCG-264701; DB12561; NSC-777639; SB19314; NCGC00347950-01; NCGC00347950-02; NCGC00347950-07; NCGC00347950-11; AC-30231; HY-17545; MS-20504; QC-11701; SMR004702800; SW211728-2; J3.551.731F; A890524; AU-004/43508401; J-005066; Q27147596; LGK 974;LGK974; WNT974; WNT 974; WNT-974; 2',3-Dimethyl-N-[5-(2-pyrazinyl)-2-pyridinyl]-[2,4'-bipyridine]-5-acetamide; 2-(2',3-diMethyl-[2,4'-bipyridin]-5-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetaMide;LGK974"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	CHEBI:78030	DB12561	.	.	396.4	5	C23H20N6O	93.6	560	1.8	30	1	6	"InChI=1S/C23H20N6O/c1-15-9-17(12-28-23(15)18-5-6-25-16(2)10-18)11-22(30)29-21-4-3-19(13-27-21)20-14-24-7-8-26-20/h3-10,12-14H,11H2,1-2H3,(H,27,29,30)"	CC1=CC(=CN=C1C2=CC(=NC=C2)C)CC(=O)NC3=NC=C(C=C3)C4=NC=CN=C4	XXYGTCZJJLTAGH-UHFFFAOYSA-N
DG01583	MK2206	46930998	"1032350-13-2; MK-2206 dihydrochloride; MK-2206 2HCl; MK2206; UNII-Q34I3E28IO; 8-(4-(1-Aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride; MK-2206 HCl salt; 8-[4-(1-AMINOCYCLOBUTYL)PHENYL]-9-PHENYL-1,2,4-TRIAZOLO[3,4-F][1,6]NAPHTHYRIDIN-3(2H)-ONE DIHYDROCHLORIDE; Q34I3E28IO; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one;dihydrochloride; C25H21N5O; MK 2206 2HCl; 1032349-77-1; MK 2206 dihydrochloride; C25H21N5O.HCl; C25H21N5O.2HCl; CHEMBL4635254; SCHEMBL17100521; EX-A259; SYN1162; AOB87741; MFCD14584463; s1078; AKOS015966903; CCG-264809; PB19401; 1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-, hydrochloride (1:2); 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one;dihydrochl; AC-28437; AS-16298; FT-0672430; SW202557-3; X7427; Z1978; P11738; J-000912; J-519356; Q27286944; (2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic acid ethyl ester; 4-[[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid calcium salt; 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid; 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one 2HCl; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H,3H-[1,2,4]triazolo[3,4-f]1,6-naphthyridin-3-one hydrochloride"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	480.4	3	C25H23Cl2N5O	83.6	760	.	33	4	4	"InChI=1S/C25H21N5O.2ClH/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31;;/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31);2*1H"	C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N.Cl.Cl	HWUHTJIKQZZBRA-UHFFFAOYSA-N
DG01584	LY-2874455	46944259	"LY2874455; 1254473-64-7; LY-2874455; UNII-E9M363811V; LY 2874455; CHEMBL3828009; E9M363811V; (R,E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol; C21H19Cl2N5O2; (R,E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol.; 2-[4-[(E)-2-[5-[(1R)-1-(3,5-dichloropyridin-4-yl)ethoxy]-1H-indazol-3-yl]ethenyl]pyrazol-1-yl]ethanol; (R,E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)-ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol; LY2874455 monohydrate; SCHEMBL298445; SCHEMBL298446; GTPL8104; QCR-90; DTXSID20154776; BCP04756; EX-A1340; 2529AH; BDBM50189781; NSC771750; NSC783670; s7057; ZINC73069242; AKOS027251051; BCP9000878; CCG-269169; CS-0907; DB13022; LM 1476; NSC-771750; NSC-783670; (R,E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethan-1-ol; AC-33003; AS-74798; HY-13304; BCP0726000015; C72002; LY2874455/LY-2874455; J-690104; Q27082753; (R)-(E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol; 2-{4-[(1E)-2-{5-[(1R)-1-(3,5-dichloropyridin-4-yl)ethoxy]-1H-indazol-3-yl}ethenyl]-1H-pyrazol-1-yl}ethan-1-ol"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB13022	.	.	444.3	7	C21H19Cl2N5O2	88.8	576	3.5	30	2	5	"InChI=1S/C21H19Cl2N5O2/c1-13(21-17(22)10-24-11-18(21)23)30-15-3-5-20-16(8-15)19(26-27-20)4-2-14-9-25-28(12-14)6-7-29/h2-5,8-13,29H,6-7H2,1H3,(H,26,27)/b4-2+/t13-/m1/s1"	C[C@H](C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3/C=C/C4=CN(N=C4)CCO	GKJCVYLDJWTWQU-CXLRFSCWSA-N
DG01585	CH-5132799	49784945	"CH5132799; 1007207-67-1; CH-5132799; 5-(7-(methylsulfonyl)-2-morpholino-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine; CH 5132799; UNII-JCL936W835; CHEMBL1684984; CH5132799 (PA-799); JCL936W835; 5-(7-methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine; 5-(7-Methanesulfonyl-2-Morpholin-4-Yl-6,7-Dihydro-5h-Pyrrolo[2,3-D]pyrimidin-4-Yl)-Pyrimidin-2-Ylamine; C15H19N7O3S; (5-(7-Methylsulfonyl-2-(morpholin-4-yl)-6,7-dihydro-5H-pyrrolo(2,3-d)pyrimidin-4-yl)pyrimidin-2-yl)amine; izorlisib; [5-[7-Methylsulfonyl-2-(morpholin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]pyrimidin-2-yl]amine; MLS006010989; GTPL7743; QCR-47; SCHEMBL2377154; DTXSID40678540; EX-A997; MEN1611; SYN1146; HMS3656H15; HMS3750I19; PA799; AOB87718; BCP02894; MEN-1611; 2316AH; BDBM50338197; MFCD22419020; NSC762382; NSC800984; PA-799; s2699; ZINC66074200; AKOS025404886; BCP9000513; CCG-264982; CS-0981; DB13051; NSC-762382; NSC-800984; SB20410; NCGC00346650-01; NCGC00346650-06; 5-[7-(Methanesulfonyl)-2-(morpholin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]pyrimidin-2-amine; AC-28422; AS-16285; HY-15466; SMR004702790; BCP0726000261; SW220190-1; J-000203; Q27075949; 2-Pyrimidinamine, 5-[6,7-dihydro-7-(methylsulfonyl)-2-(4-morpholinyl)-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-; 5-[7-(methylsulfonyl)-2-(morpholin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]pyrimidin-2-amine; 5-[7-methanesulfonyl-2-(morpholin-4-yl)-5H,6H,7H-pyrrolo[2,3-d]pyrimidin-4-yl]pyrimidin-2-amine"	Phase 1/2	8	Clinical Trial Drug(s)	Phase 1/2	Small molecular drug	.	DB13051	.	.	377.4	3	C15H19N7O3S	136	587	-0.6	26	1	10	"InChI=1S/C15H19N7O3S/c1-26(23,24)22-3-2-11-12(10-8-17-14(16)18-9-10)19-15(20-13(11)22)21-4-6-25-7-5-21/h8-9H,2-7H2,1H3,(H2,16,17,18)"	CS(=O)(=O)N1CCC2=C(N=C(N=C21)N3CCOCC3)C4=CN=C(N=C4)N	JEGHXKRHKHPBJD-UHFFFAOYSA-N
DG01586	Taladegib	49848070	"Taladegib; 1258861-20-9; LY2940680; LY-2940680; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; UNII-QY8BWX1LJ5; LY 2940680; QY8BWX1LJ5; Taladegib (LY2940680); 4-fluoro-N-methyl-N-[1-[4-(2-methylpyrazol-3-yl)phthalazin-1-yl]piperidin-4-yl]-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; Benzamide, 4-fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)-; Benzamide, 4-fluoro-N-methyl-N-[1-[4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl]-4-piperidinyl]-2-(trifluoromethyl)-; Taladegib [USAN:INN]; 4-Fluoro-N-methyl-N-{1-[4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl]-4-piperidinyl}-2-(trifluoromethyl)benzamide; Taladegib (USAN/INN); MLS006011066; LY-2940680(Taladegib); SCHEMBL2128615; CHEMBL2142592; C26H24F4N6O; GTPL10333; DTXSID50154986; EX-A156; BCP02512; BDBM50545020; MFCD21609264; NSC767896; s2157; ZINC68247898; AKOS026674116; BCP9000881; CCG-269788; CS-0459; DB12550; NSC-767896; SB16504; NCGC00263170-01; NCGC00263170-06; AC-33096; AS-75020; HY-13242; QC-11811; SMR004702857; X7613; D10671; J-515412; Q27287564; 1KS; LY 2940680; ; ; 4-fluoro-N-methyl-N-[1-[4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl]-4-piperidinyl]-2-(trifluoromethyl)-benzamide"	Phase 1/2	8	Clinical Trial Drug(s)	Phase 1/2	Small molecular drug	.	DB12550	DR1816	.	512.5	4	C26H24F4N6O	67.2	794	4.3	37	0	9	"InChI=1S/C26H24F4N6O/c1-34(25(37)20-8-7-16(27)15-21(20)26(28,29)30)17-10-13-36(14-11-17)24-19-6-4-3-5-18(19)23(32-33-24)22-9-12-31-35(22)2/h3-9,12,15,17H,10-11,13-14H2,1-2H3"	CN1C(=CC=N1)C2=NN=C(C3=CC=CC=C32)N4CCC(CC4)N(C)C(=O)C5=C(C=C(C=C5)F)C(F)(F)F	SZBGQDXLNMELTB-UHFFFAOYSA-N
DG01587	Encorafenib	50922675	"Encorafenib; LGX818; 1269440-17-6; LGX-818; Braftovi; Encorafenib (LGX818); UNII-8L7891MRB6; LGX 818; 8L7891MRB6; methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate; Carbamic acid, N-[(1S)-2-[[4-[3-[5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl]-1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-1-methylethyl]-, methyl ester; Encorafenib [USAN:INN]; Braftovi (TN); LGX-818(Encorafenib); NVP-LGX818-NXA; NVP-LGX-818-NXA; NVP-LGX818; Encorafenib (JAN/USAN/INN); GTPL7908; SCHEMBL8228295; CHEMBL3301612; DTXSID00155347; BDBM221688; BCP08458; EX-A1587; MFCD25976758; NSC778304; NSC800093; s7108; ZINC68249103; CCG-269960; DB11718; NSC-778304; NSC-800093; NCGC00378599-03; AC-30230; AS-35201; HY-15605; A13226; D11053; US9314464, 9; Q15409405; (S)-Methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate; Methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11718	DR0578	.	540	10	C22H27ClFN7O4S	149	836	2.7	36	3	10	"InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1"	C[C@@H](CNC1=NC=CC(=N1)C2=CN(N=C2C3=C(C(=CC(=C3)Cl)NS(=O)(=O)C)F)C(C)C)NC(=O)OC	CMJCXYNUCSMDBY-ZDUSSCGKSA-N
DG01588	BMS-911543	50922691	"BMS-911543; 1271022-90-2; BMS911543; BMS 911543; UNII-7N03P021J8; N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide; 7N03P021J8; N,N-Dicyclopropyl-4-[(1,5-Dimethyl-1h-Pyrazol-3-Yl)amino]-6-Ethyl-1-Methyl-1,6-Dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-Carboxamide; N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide; GTPL7954; SCHEMBL1512419; CHEMBL3545215; DTXSID00155403; HMS3747C07; AOB87390; BCP07258; EX-A1551; WAC02290; BDBM50122318; MFCD22200575; NSC766821; NSC799366; s7144; AKOS027251175; JAK2 INHIBITOR BMS-911543; ZINC100468481; CCG-269045; CS-3237; DB12591; NSC-766821; NSC-799366; SB16625; NCGC00345798-01; NCGC00345798-06; AC-29054; AS-17031; HY-15270; Imidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide, N,N-dicyclopropyl-4-[(1,5-dimethyl-1H-pyrazol-3-yl)amino]-6-ethyl-1,6-dihydro-1-methyl-; QC-11446; FT-0697510; A908362; Q27075379; 50V; N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d); N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide; N,N-dicyclopropyl-7-[(1,5-dimethylpyrazol-3-yl)amino]-10-ethyl-3-methyl-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaene-11-carboxamide"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB12591	.	DR00775	432.5	6	C23H28N8O	85.8	717	2.9	32	1	5	"InChI=1S/C23H28N8O/c1-5-30-17(23(32)31(14-6-7-14)15-8-9-15)11-16-20-19(24-12-28(20)3)21(26-22(16)30)25-18-10-13(2)29(4)27-18/h10-12,14-15H,5-9H2,1-4H3,(H,25,26,27)"	CCN1C(=CC2=C3C(=C(N=C21)NC4=NN(C(=C4)C)C)N=CN3C)C(=O)N(C5CC5)C6CC6	JCINBYQJBYJGDM-UHFFFAOYSA-N
DG01589	NIBR3049	50925411	"TCS 21311; 1260181-14-3; NIBR3049; TCS-21311; 3-[5-[4-(2-Hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]-2-(trifluoromethyl)phenyl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; CHEMBL1650951; NIBR3049NIBR3049; SCHEMBL16113848; NIBR-3049; DTXSID40678984; BDBM50335231; ZINC66103171; AKOS016355213; NCGC00387150-01; HY-108264; CS-0027898; FT-0674827; J-005320; JAK3/GSK-3beta/PKCalpha Inhibitor - CAS 1260181-14-3; 3-[5-[4-(2-hydroxy-2-methylpropanoyl)piperazin-1-yl]-2-(trifluoromethyl)phenyl]-4-(1H-indol-3-yl)pyrrole-2,5-dione; 3-{5-[4-(2-Hydroxy-2-methyl-propionyl)-piperazin-1-yl]-2-trifluoromethyl-phenyl}-4-(1H-indol-3-yl)-pyrrole-2,5-dione; 3-{5-[4-(2-Hydroxy-2-methylpropanoyl)piperazin-1-yl]-2-(trifluoromethyl)phenyl}-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	526.5	4	C27H25F3N4O4	106	1000	2.9	38	3	8	"InChI=1S/C27H25F3N4O4/c1-26(2,38)25(37)34-11-9-33(10-12-34)15-7-8-19(27(28,29)30)17(13-15)21-22(24(36)32-23(21)35)18-14-31-20-6-4-3-5-16(18)20/h3-8,13-14,31,38H,9-12H2,1-2H3,(H,32,35,36)"	CC(C)(C(=O)N1CCN(CC1)C2=CC(=C(C=C2)C(F)(F)F)C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54)O	CLGRAWDGLMENOD-UHFFFAOYSA-N
DG01590	VE-821	51000408	"VE-821; 1232410-49-9; 3-Amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide; VE 821; VE821; 3-Amino-6-[4-(methylsulfonyl)phenyl]-N-phenyl-2-pyrazinecarboxamide; UNII-BF884TQ935; CHEMBL1766779; 3-amino-6-(4-methylsulfonylphenyl)-N-phenylpyrazine-2-carboxamide; BF884TQ935; 3-AMINO-6-(4-METHANESULFONYLPHENYL)-N-PHENYLPYRAZINE-2-CARBOXAMIDE; 3-Amino-6-(4-(methylsulfonyl)phenyl)-N-phenyl-2-pyrazinecarboxamide; 2-Pyrazinecarboxamide, 3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenyl-; 2-Pyrazinecarboxamide, 3-amino-6-[4-(methylsulfonyl)phenyl]-N-phenyl-; ATR Inhibitor IV; MLS006011215; GTPL8042; SCHEMBL2483543; DTXSID60679574; EX-A530; CHEBI:124916; HMS3653B19; HMS3673C07; HMS3744G05; BCP02617; 2788AH; BDBM50341733; MFCD19443686; NSC761070; s8007; ZINC68244543; AKOS025212610; CCG-268268; CS-0238; NSC-761070; SB19277; NCGC00346444-01; NCGC00346444-07; AC-30933; AS-72494; BV168070; HY-14731; SMR004702977; VE-821, >=98% (HPLC); FT-0700135; SW219507-1; J-690084; Q27089128; 3-Amino-6-[4-(methlsulfonyl)phenyl)-N-phenyl-2-pyrazinecarboxamide; 3-Azanyl-6-(4-methylsulfonylphenyl)-N-phenyl-pyrazine-2-carboxamide; 3-amino-6-(4-(methyl sulfonyl)phenyl)-n-phenyl-2-pyrazinecarboxamide; 3-Amino-6-[4-(methanesulfonyl)phenyl]-N-phenylpyrazine-2-carboxamide"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:124916	.	.	.	368.4	4	C18H16N4O3S	123	578	2.1	26	2	6	"InChI=1S/C18H16N4O3S/c1-26(24,25)14-9-7-12(8-10-14)15-11-20-17(19)16(22-15)18(23)21-13-5-3-2-4-6-13/h2-11H,1H3,(H2,19,20)(H,21,23)"	CS(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C(=O)NC3=CC=CC=C3)N	DUIHHZKTCSNTGM-UHFFFAOYSA-N
DG01591	Taselisib	51001932	"Taselisib; GDC-0032; 1282512-48-4; GDC 0032; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; GDC0032; Taselisib (GDC0032); UNII-L08J2O299M; RG7604; RG-7604; CHEMBL2387080; L08J2O299M; RG 7604; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; TaselisibGDC-0032; Taselisib (USAN/INN); Taselisib (GDC-0032); GTPL7794; SCHEMBL1485247; DTXSID00155842; SYN1202; HMS3674G19; AMY39941; BCP09253; EX-A1581; BDBM50434806; MFCD26142641; NSC777425; NSC800985; s7103; ZINC68267049; AKOS026750303; CCG-269338; CS-1817; DB12108; GDC-0032, Taselisib; RG-7604; NSC-777425; NSC-800985; SB16576; NCGC00387039-02; 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide; AC-32794; AS-10662; BG166285; HY-13898; QC-11626; D11774; J-690119; Q27088940; 1H-Pyrazole-1-acetamide, 4-[5,6-dihydro-2-[3-methyl-1-(1-methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-alpha,alpha-dimethyl-; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide(GDC-0032); 3-({[(3R,5R)-3-Butyl-3-ethyl-7-methoxy-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioic aci d; 4-[5,6-Dihydro-2-[3-methyl-1-(1-methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-; A,; A-dimethyl-1H-pyrazole-1-acetamide"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	.	DB12108	.	.	460.5	5	C24H28N8O2	119	751	1.8	34	1	6	"InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)"	CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C	BEUQXVWXFDOSAQ-UHFFFAOYSA-N
DG01592	Pyrotinib	51039030	"Pyrotinib; 1269662-73-8; UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8 (free base); (R,E)-N-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; Airuini; 1246089-97-3; Pyrotinib(SHR-1258); GTPL9662; SCHEMBL9948753; CHEMBL3647420; BDBM139991; BCP29458; WZB08997; s8852; CS-7940; DB14993; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; 4679B; A17068; US8901140, 5; SHR-1258; SHR1258; SHR 1258; Q27275495; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	DB14993	.	.	583.1	10	C32H31ClN6O3	112	960	5.4	42	2	8	"InChI=1S/C32H31ClN6O3/c1-3-41-30-17-27-25(16-28(30)38-31(40)12-10-24-8-6-14-39(24)2)32(21(18-34)19-36-27)37-22-9-11-29(26(33)15-22)42-20-23-7-4-5-13-35-23/h4-5,7,9-13,15-17,19,24H,3,6,8,14,20H2,1-2H3,(H,36,37)(H,38,40)/b12-10+/t24-/m1/s1"	CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/[C@H]5CCCN5C	SADXACCFNXBCFY-IYNHSRRRSA-N
DG01593	Tucatinib	51039094	"Irbinitinib; Tucatinib; 937263-43-9; ONT-380; 6-DIAMINE; Tukysa; UNII-234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 234248D0HH; Irbinitinib; ARRY-380; ONT-380; N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; 6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine; N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine; Irbitinib; ONT 380; Tukysa (TN); ONT-380;Tucatinib; Tucatinib (USAN/INN); Tucatinib [USAN:INN]; Irbinitinib(ARRY-380); Irbinitinib; ARRY-380; GTPL9922; SCHEMBL1193050; CHEMBL3989868; BDBM471617; BCP15983; EX-A1031; MFCD22380467; NSC764581; NSC799335; s8362; ZINC68250462; ARRY-380 (ONT-380); AKOS026750449; CCG-264747; CS-3906; DB11652; NSC-764581; NSC-799335; SB17126; US10822334, Compound ONT380; NCGC00482879-02; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; AC-33037; AS-56109; BT177688; HY-16069; Example 11 [WO2007059257A2]; DB-130430; A16413; D11141; A857335; Q25100690; 4,6-QuinazolinediaMine,N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine;; N6-(4,5-dihydro-4,4-dmethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-A)pyridin-7-Yloxy)phenyl)-4,6-quinazolinediamine"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11652	.	.	480.5	6	C26H24N8O2	111	796	4	36	2	8	"InChI=1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31)"	CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5	SDEAXTCZPQIFQM-UHFFFAOYSA-N
DG01594	AZD-4547	51039095	"AZD4547; 1035270-39-3; AZD-4547; AZD 4547; UNII-2167OG1EKJ; N-(5-(3,5-dimethoxyphenethyl)-1H-pyrazol-3-yl)-4-((3S,5R)-3,5-dimethylpiperazin-1-yl)benzamide; 2167OG1EKJ; CHEBI:63453; rel-N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]benzamide; N-{3-[2-(3,5-Dimethoxyphenyl)ethyl]-1h-Pyrazol-5-Yl}-4-[(3r,5s)-3,5-Dimethylpiperazin-1-Yl]benzamide; N-{5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl}-4-(cis-3,5-dimethylpiperazin-1-yl)benzamide; N-{5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl}-4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]benzamide; 66T; KB-74810; N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]benzamide; SCHEMBL63884; N-(5-(3,5-Dimethoxyphenethyl)-1H-pyrazol-3-yl)-4-((3R,5S)-rel-3,5-dimethylpiperazin-1-yl)benzamide; GTPL7707; QCR-89; SCHEMBL15250892; DTXSID80145887; AMY16612; AOB87745; EX-A1578; 2240AH; MFCD22580423; NSC764239; NSC765338; NSC799346; s2801; ZINC95616598; AKOS024464898; BCP9000364; CCG-269382; CS-0971; DB12247; NSC-764239; NSC-765338; NSC-799346; NCGC00346713-01; NCGC00346713-05; AC-28442; AS-17054; HY-13330; rel-N-(5-(3,5-Dimethoxyphenethyl)-1H-pyrazol-3-yl)-4-((3R,5S)-3,5-dimethylpiperazin-1-yl)benzamide; SW219341-1; J-000994; J-524217; Q27074746; N-(5-(3,5-dimethoxyphenethyl)-1H-pyrazol-3-yl)-4-((3R,5S)-3,5-dimethylpiperazin-1-yl)benzamide, rel-; N-(5-(3,5-Dimethoxyphenethyl)-4H-pyrazol-3-yl)-4-((3S,5R)-3,5-dimethylpiperazin-1-yl)benzamide; N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-Benzamide; N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3S,5R)-3,5-dimethylpiperazin-1-yl]benzamide; N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethylpiperazin -1-yl]benzamide; N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]benzamide"	Phase 2/3	6	Clinical Trial Drug(s)	Phase 2/3	Small molecular drug	CHEBI:63453	DB12247	.	.	463.6	8	C26H33N5O3	91.5	622	3.9	34	3	6	"InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+"	C[C@@H]1CN(C[C@@H](N1)C)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)CCC4=CC(=CC(=C4)OC)OC	VRQMAABPASPXMW-HDICACEKSA-N
DG01595	Uprosertib	51042438	"Uprosertib; 1047634-65-0; GSK2141795; UNII-ZXM835LQ5E; GSK795; GSK2141795C; GSK-2141795; ZXM835LQ5E; Uprosertib (GSK2141795); N-((S)-1-Amino-3-(3,4-difluorophenyl)propan-2-yl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)furan-2-carboxamide; N-[(2S)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide; Uprosertib [USAN:INN]; Uprosertib (USAN/INN); Akt inhibitor gsk2141795; SCHEMBL168584; Uprosertib, GSK2141795; Akt inhibitor gsk-2141795; GTPL7902; CHEMBL3137336; BCP28204; EX-A1593; BDBM50170284; GSK-2141795C; MFCD28144686; NSC778368; NSC800960; s7492; ZINC43197676; AKOS027323909; CCG-268992; DB11969; NSC-778368; NSC-800960; NCGC00390653-01; AC-30940; HY-15965; D10674; F20800; Q27089099; GSK-2141795; GSK2141795; GSK 2141795; GSK795; GSK-795; GSK 795.; 2-Furancarboxamide, N-((1S)-2-amino-1-((3,4-difluorophenyl)methyl)ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-; N-((1S)-1-(Aminomethyl)-2-(3,4-difluorophenyl)ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)furan-2-carboxamide; N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB11969	.	.	429.2	6	C18H16Cl2F2N4O2	86.1	550	3.4	28	2	6	"InChI=1S/C18H16Cl2F2N4O2/c1-26-16(12(19)8-24-26)11-6-15(28-17(11)20)18(27)25-10(7-23)4-9-2-3-13(21)14(22)5-9/h2-3,5-6,8,10H,4,7,23H2,1H3,(H,25,27)/t10-/m0/s1"	CN1C(=C(C=N1)Cl)C2=C(OC(=C2)C(=O)N[C@@H](CC3=CC(=C(C=C3)F)F)CN)Cl	AXTAPYRUEKNRBA-JTQLQIEISA-N
DG01596	APR-246	52918385	"APR-246; 5291-32-7; PRIMA-1MET; Eprenetapopt; APR 246; 2-(Hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one; 2-(Hydroxymethyl)-2-(methoxymethyl)quinuclidin-3-one; Prima 1MET; Eprenetapopt [USAN]; MLS006010767; APR246; SCHEMBL2228161; 3-Quinuclidinone, 2-(hydroxymethyl)-2-(methoxymethyl)-; CHEMBL3186011; SCHEMBL21636035; PRIMA-1MET(APR-246); APR-246 (PRIMA-1MET); BCP20294; EX-A2772; MFCD20620963; NSC791496; s7724; WHO 11387; 1-Azabicyclo(2.2.2)octan-3-one, 2-(hydroxymethyl)-2-(methoxymethyl)-; AKOS024457764; CCG-266578; CS-7614; DB11684; NSC-791496; SB19737; NCGC00346881-01; AC-32964; AS-72033; BA176962; HY-19980; SMR004701457; A901731; Q27294965; 2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2.2.2]octan-3-one"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB11684	.	.	199.25	3	C10H17NO3	49.8	236	-0.1	14	1	4	"InChI=1S/C10H17NO3/c1-14-7-10(6-12)9(13)8-2-4-11(10)5-3-8/h8,12H,2-7H2,1H3"	COCC1(C(=O)C2CCN1CC2)CO	BGBNULCRKBVAKL-UHFFFAOYSA-N
DG01597	Miransertib	53262401	"Miransertib; 1313881-70-7; ARQ-092; AKT inhibitor 2; ARQ 092 Free Base; ARQ092; ARQ 092; UNII-T1DQI1B52Y; T1DQI1B52Y; 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine; 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine; 3-[3-[4-(1-Azanylcyclobutyl)phenyl]-5-Phenyl-Imidazo[4,5-B]pyridin-2-Yl]pyridin-2-Amine; 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo(4,5-b)pyridin-2-yl)pyridin-2-amine; Miransertib [INN]; Miransertib [USAN]; Miransertib [WHO-DD]; Miransertib (USAN/INN); Miransertib [USAN:INN]; Miransertib (ARQ-092); GTPL9429; SCHEMBL2187875; CHEMBL4297188; BCP19821; EX-A1268; NSC791328; WHO 10490; ZINC72315647; CS-5377; DB14982; NSC-791328; SB19688; compound 21a [PMID: 27305487]; HY-19719; DB-105304; S6811; J3.532.768A; D11409; A922251; Q27456535; 2-Pyridinamine, 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo(4,5-b)pyridin-2-yl)-; 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo(4,5-b)pyridin-2-yl)-2-pyridinamine; 6S1"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB14982	.	.	432.5	4	C27H24N6	95.6	653	3.8	33	2	5	"InChI=1S/C27H24N6/c28-24-21(8-4-17-30-24)25-32-23-14-13-22(18-6-2-1-3-7-18)31-26(23)33(25)20-11-9-19(10-12-20)27(29)15-5-16-27/h1-4,6-14,17H,5,15-16,29H2,(H2,28,30)"	C1CC(C1)(C2=CC=C(C=C2)N3C4=C(C=CC(=N4)C5=CC=CC=C5)N=C3C6=C(N=CC=C6)N)N	HNFMVVHMKGFCMB-UHFFFAOYSA-N
DG01598	FIIN-1	53348188	"FIIN-1; 1256152-35-8; CHEMBL2216830; N-(3-((3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-(4-(diethylamino)butylamino)-2-oxo-3,4- dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)methyl)phenyl)acrylamide; N-(3-{[3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-{[4-(diethylamino)butyl]amino}-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl]methyl}phenyl)prop-2-enamide; FIIN1; SCHEMBL17010767; BDBM50403060; ZINC95564544; NCGC00378818-01; HY-15813; CS-0009282; N-[3-[[3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-[4-(diethylamino)butylamino]-2-oxo-4H-pyrimido[4,5-d]pyrimidin-1-yl]methyl]phenyl]prop-2-enamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	656.6	15	C32H39Cl2N7O4	112	947	5.3	45	2	8	"InChI=1S/C32H39Cl2N7O4/c1-6-26(42)37-23-13-11-12-21(16-23)19-41-30-22(18-36-31(38-30)35-14-9-10-15-39(7-2)8-3)20-40(32(41)43)29-27(33)24(44-4)17-25(45-5)28(29)34/h6,11-13,16-18H,1,7-10,14-15,19-20H2,2-5H3,(H,37,42)(H,35,36,38)"	CCN(CC)CCCCNC1=NC=C2CN(C(=O)N(C2=N1)CC3=CC(=CC=C3)NC(=O)C=C)C4=C(C(=CC(=C4Cl)OC)OC)Cl	DNVFTXQYIYFQBW-UHFFFAOYSA-N
DG01599	Altiratinib	54576299	"Altiratinib; 1345847-93-9; DCC-2701; DP-5164; Altiratinib [USAN]; UNII-T678746713; Altiratinib (USAN); 1,1-Cyclopropanedicarboxamide, N-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-N'-(4-fluorophenyl)-; T678746713; 1,1-Cyclopropanedicarboxamide, N-(4-((2-((cyclopropylcarbonyl)amino)-4-pyridinyl)oxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)-; 1-N'-[4-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-2,5-difluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-(4-((2-(cyclopropanecarboxamido)pyridin-4-yl)oxy)-2,5-difluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.; N-[4-[[2-[(Cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; Altiratinib;DCC2701; Altiratinib(DCC-2701); SCHEMBL139906; GTPL9174; CHEMBL3545365; DCC-270; DCC2701; EX-A902; AOB87118; BCP15682; HY-B0791; BDBM50193395; MFCD28900672; NSC784590; s6412; AKOS026750329; ZINC113198271; CS-3944; NSC-784590; SB18876; NCGC00480913-04; N-(4-((2-((Cyclopropylcarbonyl)amino)pyridin-4-yl)oxy)-2,5-difluorophenyi)-N-(4- fluorophenyl)cyclopropane-1,1-dicarboxamide; B5832; FT-0700171; A14387; D10862; F11464; A887875; J-690136; Q27074416; 1,1-CYCLOPROPANEDICARBOXAMIDE, N-[4-[[2-[(CYCLOPROPYLCARBONYL)AMINO]-4-PYRIDINYL]OXY]-2,5-DIFLUOROPHENYL]-N-(4-FLUOROPHENYL)-; 4-{5-[(E)-2-{4-(2-Chlorophenyl)-5-[5-(methylsulfonyl)-2-pyridinyl]-4H-1,2,4-triazol-3-yl}vinyl]-1,3,4-oxadiazol-2-yl}benzonitrile; N-(4-(2-(cyclopropanecarboxamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	.	.	.	510.5	8	C26H21F3N4O4	109	863	4.3	37	3	8	"InChI=1S/C26H21F3N4O4/c27-15-3-5-16(6-4-15)31-24(35)26(8-9-26)25(36)32-20-12-19(29)21(13-18(20)28)37-17-7-10-30-22(11-17)33-23(34)14-1-2-14/h3-7,10-14H,1-2,8-9H2,(H,31,35)(H,32,36)(H,30,33,34)"	C1CC1C(=O)NC2=NC=CC(=C2)OC3=C(C=C(C(=C3)F)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F)F	GNNDEPIMDAZHRQ-UHFFFAOYSA-N
DG01600	AZD3463	56599293	AZD3463; 1356962-20-3; AZD-3463; ALK/IGF1R inhibitor; N-(4-(4-Aminopiperidin-1-yl)-2-methoxyphenyl)-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine; N-[4-(4-aminopiperidin-1-yl)-2-methoxyphenyl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine; CS-1382; HY-15609; AZD 3463; C24H25ClN6O; N-(4-(4-aminopiperidin-1-yl)-2-methoxyphenyl)-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine.; KB-154896; SCHEMBL517412; GTPL7706; CHEMBL4203266; DTXSID50717792; EX-A328; CHEBI:167653; BDBM192752; HMS3653G05; AOB87394; BCP07685; 2238AH; NSC776787; s7106; ZINC95616580; AKOS026750287; CCG-269224; NSC-776787; NCGC00351596-09; AC-32961; AS-17033; DA-35311; QC-11775; FT-0749742; SW219925-1; F20803; Q27074737; ALK/IGF1R inhibitor; ; ; N-(4-(4-aminopiperidin-1-yl)-2-methoxyphenyl)-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine; N-[4-(4-amino-1-piperidinyl)-2-methoxyphenyl]-5-chloro-4-(1H-indol-3-yl)-2-pyrimidinamine	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	448.9	5	C24H25ClN6O	92.1	605	4.2	32	3	6	"InChI=1S/C24H25ClN6O/c1-32-22-12-16(31-10-8-15(26)9-11-31)6-7-21(22)29-24-28-14-19(25)23(30-24)18-13-27-20-5-3-2-4-17(18)20/h2-7,12-15,27H,8-11,26H2,1H3,(H,28,29,30)"	COC1=C(C=CC(=C1)N2CCC(CC2)N)NC3=NC=C(C(=N3)C4=CNC5=CC=CC=C54)Cl	GCYIGMXOIWJGBU-UHFFFAOYSA-N
DG01601	Pilaralisib	56599306	"Pilaralisib; 934526-89-3; XL-147; SAR245408; SAR-245408; UNII-60ES45KTMK; Pilaralisib (XL147); 60ES45KTMK; 2-amino-N-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide; 2-amino-N-(3-(N-(3-((2-chloro-5-methoxyphenyl)amino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methylpropanamide.; SAR 245408; Pilaralisib [USAN:INN]; Pilaralisib, SAR245408; SCHEMBL189422; CHEMBL3360203; SCHEMBL14921345; SCHEMBL16154579; EX-A196; AMY10846; BCP15312; BDBM50197062; MFCD26142605; NSC791227; NSC800853; s7645; AKOS026750450; ZINC100472223; CCG-264704; CS-1546; DB11772; NSC-791227; NSC-800853; SB16574; Pilaralisib(XL-147; SAR245408); NCGC00378973-02; 2-Amino-n-(3-(N-(3-((2-chloro-5-methoxyphenyl)amino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methylpropanamide; 2-amino-N-[3-({3-[(2-chloro-5-methoxyphenyl)amino]quinoxalin-2-yl}sulfamoyl)phenyl]-2-methylpropanamide; AC-33122; AS-56300; DA-40388; HY-16526; FT-0744481; A859771"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	DB11772	.	.	541	8	C25H25ClN6O4S	157	887	3.4	37	4	9	"InChI=1S/C25H25ClN6O4S/c1-25(2,27)24(33)28-15-7-6-8-17(13-15)37(34,35)32-23-22(29-19-9-4-5-10-20(19)30-23)31-21-14-16(36-3)11-12-18(21)26/h4-14H,27H2,1-3H3,(H,28,33)(H,29,31)(H,30,32)"	CC(C)(C(=O)NC1=CC(=CC=C1)S(=O)(=O)NC2=NC3=CC=CC=C3N=C2NC4=C(C=CC(=C4)OC)Cl)N	QINPEPAQOBZPOF-UHFFFAOYSA-N
DG01602	AGI-5198	56645356	AGI-5198; 1355326-35-0; IDH-C35; N-cyclohexyl-2-(N-(3-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido)-2-(o-tolyl)acetamide; AGI 5198; AGI-5198(IDH C35); N-cyclohexyl-2-(N-(3-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido)-2-o-tolylacetamide; CHEMBL2180727; AGI5198; N-cyclohexyl-2-(3-fluoro-N-[2-(2-methylimidazol-1-yl)acetyl]anilino)-2-(2-methylphenyl)acetamide; AGI-5198 (IDH-C35); MLS006010252; GTPL9240; SCHEMBL15118942; C27H31FN4O2; AOB5947; DTXSID30718166; EX-A171; QCR-214; HMS3653K15; HMS3865J13; AMY24200; BCP07382; BDBM50400272; MFCD24848688; NSC773096; s7185; AKOS026674117; CCG-269371; CS-1429; NSC-773096; SB19576; NCGC00347934-01; NCGC00347934-09; BS-14968; DA-35355; HY-18082; SMR004701328; FT-0768624; SW220036-1; X5817; A854356; Q27074345; S900006220; N-[2-(Cyclohexylamino)-1-(2-methylphenyl)-2-oxoethyl]-N-(3-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamide	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	462.6	7	C27H31FN4O2	67.2	686	4.9	34	1	4	"InChI=1S/C27H31FN4O2/c1-19-9-6-7-14-24(19)26(27(34)30-22-11-4-3-5-12-22)32(23-13-8-10-21(28)17-23)25(33)18-31-16-15-29-20(31)2/h6-10,13-17,22,26H,3-5,11-12,18H2,1-2H3,(H,30,34)"	CC1=CC=CC=C1C(C(=O)NC2CCCCC2)N(C3=CC(=CC=C3)F)C(=O)CN4C=CN=C4C	FNYGWXSATBUBER-UHFFFAOYSA-N
DG01603	Agerafenib	56846693	"CEP-32496; 1188910-76-0; Agerafenib; CEP 32496; RXDX-105; UNII-78I4VEX88N; 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea; CEP32496; 78I4VEX88N; CHEMBL2029988; 1-[3-[(6,7-Dimethoxyquinazolin-4-yl)oxy]phenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl]urea; 1-(3-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea; Rxdx 105; CEP-32496 free base; CEP-32496 (free base); GTPL7880; SCHEMBL1015932; HMS3653J19; BCP16304; EX-A1481; 2310AH; AB-024; BDBM50382959; MFCD22124524; NSC776043; NSC800070; s8015; ZINC43207440; AKOS023600525; AKOS032949984; CCG-269834; CS-1115; DB15068; NSC-776043; NSC-800070; SB20796; NCGC00386234-02; NCGC00386234-03; AC-30297; AC013773; AS-74934; HY-15200; AC-013773; SW220118-1; A856125; Q27075853; 1-{3-[(6,7-DIMETHOXYQUINAZOLIN-4-YL)OXY]PHENYL}-3-[5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)-1,2-OXAZOL-3-YL]UREA; Urea, N-[3-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N-[5-(2,2,2-trifluoro-1,1-dimethylethyl)-3-isoxazolyl]-"	Phase 1/2	8	Clinical Trial Drug(s)	Phase 1/2	Small molecular drug	.	DB15068	.	DR00774	517.5	7	C24H22F3N5O5	121	776	5	37	2	11	"InChI=1S/C24H22F3N5O5/c1-23(2,24(25,26)27)19-11-20(32-37-19)31-22(33)30-13-6-5-7-14(8-13)36-21-15-9-17(34-3)18(35-4)10-16(15)28-12-29-21/h5-12H,1-4H3,(H2,30,31,32,33)"	CC(C)(C1=CC(=NO1)NC(=O)NC2=CC(=CC=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(F)(F)F	DKNUPRMJNUQNHR-UHFFFAOYSA-N
DG01604	CEP-28122	57325421	"CEP-28122; 1022958-60-6; CHEMBL2064666; compound 25b [PMID: 22564207]; (1S,2S,3R,4R)-3-((5-chloro-2-(((S)-1-methoxy-7-morpholino-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)bicyclo[2.2.1]hept-5-ene-2-carboxamide.; CEP28122; CEP 28122; GTPL8139; SCHEMBL2061951; (1S,2S,3R,4R)-3-[(5-chloro-2-{[(7S)-1-methoxy-7-(morpholin-4-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]amino}pyrimidin-4-yl)amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide; EX-A1541; BDBM50389154; ZINC84654307; CS-5176; NCGC00387821-03; HY-18030; Q27076467; (1S,2S,3R,4R)-3-[(5-Chloro-2-{[(7S)-1-methoxy-7-(4-morpholinyl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]amino}-4-pyrimidinyl)amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide; (1S,2S,3R,4R)-3-[[5-chloro-2-[[(7S)-4-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide; (1S,2S,3R,4R)-3-[5-Chloro-2-((S)-1-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-ylamino)-pyrimidin-4-ylamino]-bicyclo[2.2.1]hept-5-ene-2-carboxylic acid amide"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	539.1	7	C28H35ClN6O3	115	858	4.1	38	3	8	"InChI=1S/C28H35ClN6O3/c1-37-25-20-8-7-19(35-10-12-38-13-11-35)6-4-16(20)5-9-22(25)32-28-31-15-21(29)27(34-28)33-24-18-3-2-17(14-18)23(24)26(30)36/h2-3,5,9,15,17-19,23-24H,4,6-8,10-14H2,1H3,(H2,30,36)(H2,31,32,33,34)/t17-,18+,19+,23+,24-/m1/s1"	COC1=C(C=CC2=C1CC[C@H](CC2)N3CCOCC3)NC4=NC=C(C(=N4)N[C@@H]5[C@@H]6C[C@H]([C@@H]5C(=O)N)C=C6)Cl	LAJAFFLJAJMYLK-CVOKMOJFSA-N
DG01605	SR-9009	57394020	"SR9009; 1379686-30-2; SR-9009; SR 9009; ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate; Stenabolic (SR9009); CHEMBL1961796; 1-Pyrrolidinecarboxylic acid, 3-((((4-chlorophenyl)methyl)((5-nitro-2-thienyl)methyl)amino)methyl)-, ethyl ester; Stenabolic; 1-pyrrolidinecarboxylic acid, 3-[[[(4-chlorophenyl)methyl][(5-nitro-2-thienyl)methyl]amino]methyl]-, ethyl ester; REV-ERB Agonist II; GTPL8901; EX-A726; BCP16215; BDBM50366238; MFCD29472236; NSC810521; s8692; AKOS027470307; CCG-269102; CS-4669; DB14013; NSC-810521; SB19006; NCGC00384202-01; AC-30219; AS-55859; HY-16989; A886340; J-690150; Q15410184; ethyl 3-(4-chlorobenzyl)((5-nitrothiophen-2-yl)methylaminomethyl)pyrrolidine-1-carboxylate; N'-[(1E)-1-(5-Chloro-2-hydroxyphenyl)ethylidene]-3-(4-morpholinylsulfonyl)benzohydrazide; ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitro-2-thienyl)methyl]amino]methyl]pyrrolidine-1-carboxylate; Ethyl 3-[[[(4-chlorophenyl)methyl][(5-nitro-2-thienyl)methyl]amino]methyl]-1-pyrrolidinecarboxylate"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	DB14013	.	.	437.9	8	C20H24ClN3O4S	107	556	4.4	29	0	6	"InChI=1S/C20H24ClN3O4S/c1-2-28-20(25)23-10-9-16(13-23)12-22(11-15-3-5-17(21)6-4-15)14-18-7-8-19(29-18)24(26)27/h3-8,16H,2,9-14H2,1H3"	CCOC(=O)N1CCC(C1)CN(CC2=CC=C(C=C2)Cl)CC3=CC=C(S3)[N+](=O)[O-]	MMJJNHOIVCGAAP-UHFFFAOYSA-N
DG01606	SR-9011	57394021	"SR9011; 1379686-29-9; SR-9011; 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]-N-pentylpyrrolidine-1-carboxamide; CHEMBL1961797; 1-Pyrrolidinecarboxamide, 3-((((4-chlorophenyl)methyl)((5-nitro-2-thienyl)methyl)amino)methyl)-n-pentyl-; GTPL8900; BDBM50366239; CS-4668; DB14014; SB19005; SR 9011; NCGC00347956-01; AS-55867; HY-16988; H12052; A927677; Q15410183; 3-(((4-Chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)methyl)-N-pentylpyrrolidine-1-carboxamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	DB14014	.	.	479	10	C23H31ClN4O3S	110	600	5.3	32	1	5	"InChI=1S/C23H31ClN4O3S/c1-2-3-4-12-25-23(29)27-13-11-19(16-27)15-26(14-18-5-7-20(24)8-6-18)17-21-9-10-22(32-21)28(30)31/h5-10,19H,2-4,11-17H2,1H3,(H,25,29)"	CCCCCNC(=O)N1CCC(C1)CN(CC2=CC=C(C=C2)Cl)CC3=CC=C(S3)[N+](=O)[O-]	PPUYOYQTTWJTIU-UHFFFAOYSA-N
DG01607	LY-3023414	57519748	"LY3023414; Samotolisib; 1386874-06-1; LY-3023414; GTPL8918; UNII-C88817F47Y; Samotolisib (USAN); Samotolisib [USAN]; C88817F47Y; LY 3023414; 8-[5-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methylimidazo[4,5-c]quinolin-2-one; 2H-Imidazo(4,5-C)quinolin-2-one, 1,3-dihydro-8-(5-(1-hydroxy-1-methylethyl)-3-pyridinyl)-1-((2S)-2-methoxypropyl)-3-methyl-; 8-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; example 1 [US8440829]; 2H-Imidazo[4,5-c]quinolin-2-one, 1,3-dihydro-8-[5-(1-hydroxy-1-methylethyl)-3-pyridinyl]-1-[(2S)-2-methoxypropyl]-3-methyl-; CHEMBL4297181; SCHEMBL10321700; BCP16703; EX-A2728; NSC789968; NSC800994; s8322; WHO 10889; ZINC143116580; AT19320; CCG-264765; CS-5361; DB12167; NSC-789968; NSC-800994; NCGC00485487-01; AC-30224; HY-12513; A16126; D11501; A856859; LY-3023414;LY 3023414; Q27082852; (S)-8-(5-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(2-methoxypropyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; (S)-8-(5-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(2-methoxypropyl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-one; 1,3-Dihydro-8-[5-(1-hydroxy-1-methylethyl)-3-pyridinyl]-1-[(2S)-2-methoxypropyl]-3-methyl-2H-imidazo[4,5-c]quinolin-2-one"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB12167	.	.	406.5	5	C23H26N4O3	78.8	630	1.7	30	1	5	"InChI=1S/C23H26N4O3/c1-14(30-5)13-27-21-18-9-15(16-8-17(11-24-10-16)23(2,3)29)6-7-19(18)25-12-20(21)26(4)22(27)28/h6-12,14,29H,13H2,1-5H3/t14-/m0/s1"	C[C@@H](CN1C2=C3C=C(C=CC3=NC=C2N(C1=O)C)C4=CC(=CN=C4)C(C)(C)O)OC	ACCFLVVUVBJNGT-AWEZNQCLSA-N
DG01608	AZD1208	58423153	"AZD1208; 1204144-28-4; AZD-1208; UNII-S98NFM1378; (R,Z)-5-((2-(3-aminopiperidin-1-yl)-[1,1'-biphenyl]-3-yl)methylene)thiazolidine-2,4-dione; CHEMBL2048872; S98NFM1378; (5Z)-5-({2-[(3R)-3-Aminopiperidin-1-yl]-3-phenylphenyl}methylidene)-1,3-thiazolidine-2,4-dione; AZD 1208; 5-[[2-[(3R)-3-Aminopiperidin-1-yl]biphenyl-3-yl]methylidene]-1,3-thiazolidine-2,4-dione; (5Z)-5-[[2-[(3R)-3-aminopiperidin-1-yl]-3-phenylphenyl]methylidene]-1,3-thiazolidine-2,4-dione; GTPL7698; SCHEMBL1580644; AOB87151; EX-A1804; 2236AH; BDBM50387298; MFCD25976757; NSC776066; NSC799343; s7104; ZINC84670255; AKOS025404917; CCG-268400; CS-1668; NSC-776066; NSC-799343; AC-33162; AS-35166; HY-15604; QC-11435; SW219766-1; A13203; Q27074698; (R,Z)-5-((2-(3-Aminopiperidin-1-yl)biphenyl-3-yl)methylene)thiazolidine-2,4-dione"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	.	.	.	379.5	3	C21H21N3O2S	101	602	3.6	27	2	5	"InChI=1S/C21H21N3O2S/c22-16-9-5-11-24(13-16)19-15(12-18-20(25)23-21(26)27-18)8-4-10-17(19)14-6-2-1-3-7-14/h1-4,6-8,10,12,16H,5,9,11,13,22H2,(H,23,25,26)/b18-12-/t16-/m1/s1"	C1C[C@H](CN(C1)C2=C(C=CC=C2C3=CC=CC=C3)/C=C\\4/C(=O)NC(=O)S4)N	MCUJKPPARUPFJM-UWCCDQBKSA-N
DG01609	A-1155463	59447577	"A-1155463; 1235034-55-5; CHEMBL3342332; A1155463; 2-[8-(1,3-Benzothiazol-2-Ylcarbamoyl)-3,4-Dihydroisoquinolin-2(1h)-Yl]-5-(3-{4-[3-(Dimethylamino)prop-1-Yn-1-Yl]-2-Fluorophenoxy}propyl)-1,3-Thiazole-4-Carboxylic Acid; 2-[8-[(2-Benzothiazolylamino)carbonyl]-3,4-dihydro-2(1H)-isoquinolinyl]-5-[3-[4-[3-(dimethylamino)-1-propyn-1-yl]-2-fluorophenoxy]propyl]-4-thiazolecarboxylic acid; A 1155463; SCHEMBL2501550; BCP18309; EX-A1060; BDBM50030754; MFCD29924714; s7800; ZINC163914635; CCG-270355; CS-5398; BS-14688; HY-19725; Q27453707; 2-(8-(benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-5-(3-(4-(3-(dimethylamino)prop-1-yn-1-yl)-2-fluorophenoxy)propyl)thiazole-4-carboxylic acid; 2-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1H-isoquinolin-2-yl]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]-2-fluorophenoxy]propyl]-1,3-thiazole-4-carboxylic acid; 3CQ"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	669.8	11	C35H32FN5O4S2	164	1150	4.8	47	2	11	"InChI=1S/C35H32FN5O4S2/c1-40(2)17-6-8-22-14-15-28(26(36)20-22)45-19-7-13-30-31(33(43)44)38-35(47-30)41-18-16-23-9-5-10-24(25(23)21-41)32(42)39-34-37-27-11-3-4-12-29(27)46-34/h3-5,9-12,14-15,20H,7,13,16-19,21H2,1-2H3,(H,43,44)(H,37,39,42)"	CN(C)CC#CC1=CC(=C(C=C1)OCCCC2=C(N=C(S2)N3CCC4=C(C3)C(=CC=C4)C(=O)NC5=NC6=CC=CC=C6S5)C(=O)O)F	SOYCFODXNRVBTI-UHFFFAOYSA-N
DG01610	Berzosertib	59472121	"VE-822; 1232416-25-9; Berzosertib; VX-970; VE822; UNII-L423PRV3V3; VE 822; VX970; VE-822 (VX-970); 5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine; L423PRV3V3; 3-(3-{4-[(METHYLAMINO)METHYL]PHENYL}-1,2-OXAZOL-5-YL)-5-[4-(PROPANE-2-SULFONYL)PHENYL]PYRAZIN-2-AMINE; 3-[3-[4-(methylaminomethyl)phenyl]-1,2-oxazol-5-yl]-5-(4-propan-2-ylsulfonylphenyl)pyrazin-2-amine; M6620; 2-Pyrazinamine, 3-(3-(4-((methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-; BDBM50226746; 2-Pyrazinamine, 3-[3-[4-[(methylamino)methyl]phenyl]-5-isoxazolyl]-5-[4-[(1-methylethyl)sulfonyl]phenyl]-; 3-(3-(4-((METHYLAMINO)METHYL)PHENYL)-1,2-OXAZOL-5-YL)-5-(4-(PROPANE-2-SULFONYL)PHENYL)PYRAZIN-2-AMINE; 3-[3-[4-[(Methylamino)methyl]phenyl]-5-isoxazolyl]-5-[4-[(1-methylethyl)sulfonyl]phenyl]-2-pyrazinamine; 5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine.; Berzosertib [USAN]; VX-970;Berzosertib; Berzosertib (USAN/INN); Berzosertib (VE-822); AGN-PC-0CXKB3; GTPL8003; SCHEMBL3061890; CHEMBL3989870; EX-A529; CHEBI:131166; BDBM350085; HMS3653C05; HMS3747I11; AOB87712; BCP07948; 2789AH; MFCD27976794; NSC777718; s7102; US10208027, Compound II-1; US10208027, Compound II-2; US10208027, Compound II-3; US10208027, Compound II-4; VX 970; ZINC96170459; AKOS025404905; CCG-264673; CS-1861; DB11794; NSC-777718; SB17265; NCGC00386313-07; AC-32951; AS-17041; DA-46989; HY-13902; QC-10953; FT-0700136; SW220202-1; A13289; D11148; M-6620; A857986; Q27089129; 5-(4-isopropylsulfonylphenyl)-3-[3-[4-(methylaminomethyl)phenyl]isoxazol-5-yl]pyrazin-2-amine; Synthesis of 3-[3-[4-[dideuterio(methylamino)methyl]phenyl]isoxazol-5-yl]-5-(4-isopropylsulfonylphenyl)pyrazin-2-amine"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	CHEBI:131166	DB11794	.	.	463.6	7	C24H25N5O3S	132	714	2.3	33	2	8	"InChI=1S/C24H25N5O3S/c1-15(2)33(30,31)19-10-8-18(9-11-19)21-14-27-24(25)23(28-21)22-12-20(29-32-22)17-6-4-16(5-7-17)13-26-3/h4-12,14-15,26H,13H2,1-3H3,(H2,25,27)"	CC(C)S(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C3=CC(=NO3)C4=CC=C(C=C4)CNC)N	JZCWLJDSIRUGIN-UHFFFAOYSA-N
DG01611	EPZ005687	60160561	"EPZ005687; 1396772-26-1; EPZ-005687; 1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-(morpholinomethyl)phenyl)-1H-indazole-4-carboxamide; EPZ 005687; 1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-6-[4-(morpholin-4-ylmethyl)phenyl]indazole-4-carboxamide; EZH2 Inhibitor, EPZ005687; UNII-GQ4LD5KG1E; GQ4LD5KG1E; GTPL8387; SCHEMBL12684069; AOB1761; DTXSID80733849; EX-A429; CHEBI:124922; EPZ 5687 [WHO-DD]; C32H37N5O3; BCP07899; EPZ 5687; EPZ-5687; WFC77226; 2398AH; MFCD25372029; NSC783332; s7004; ZINC98043813; AKOS026750254; CCG-269957; CS-1215; NSC-783332; SB19050; NCGC00351604-01; NCGC00351604-09; NCGC00351604-12; AC-32708; AS-16367; DA-34778; HY-15555; QC-11445; FT-0700189; Q27077206; 1-Cyclopentyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-6-{4-[(morpholin-4-yl)methyl]phenyl}-1H-indazole-4-carboxamide; 1H-Indazole-4-carboxamide, 1-cyclopentyl-N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-6-(4-(4-morpholinylmethyl)phenyl)-; cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-(morpholinomethyl)phenyl)-1H-indazole-4-carboxamide"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:124922	.	.	.	539.7	7	C32H37N5O3	88.5	991	3.7	40	2	5	"InChI=1S/C32H37N5O3/c1-21-15-22(2)35-32(39)28(21)18-33-31(38)27-16-25(17-30-29(27)19-34-37(30)26-5-3-4-6-26)24-9-7-23(8-10-24)20-36-11-13-40-14-12-36/h7-10,15-17,19,26H,3-6,11-14,18,20H2,1-2H3,(H,33,38)(H,35,39)"	CC1=CC(=C(C(=O)N1)CNC(=O)C2=C3C=NN(C3=CC(=C2)C4=CC=C(C=C4)CN5CCOCC5)C6CCCC6)C	ZOIBZSZLMJDVDQ-UHFFFAOYSA-N
DG01612	DEBIO-1347	66555680	"1265229-25-1; CH5183284; Debio-1347; zoligratinib; CH-5183284; CH5183284 (Debio-1347); Debio 1347; UNII-NR9ZYH80Z8; FF284; NR9ZYH80Z8; CHEMBL3907479; (5-Amino-1-(2-methyl-1H-benzo[d]imidazol-6-yl)-1H-pyrazol-4-yl)(1H-indol-2-yl)methanone; [5-Amino-1-(2-Methyl-1h-Benzimidazol-6-Yl)-1h-Pyrazol-4-Yl](1h-Indol-2-Yl)methanone; [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone; Fgfr inhibitor debio 1347; DEBIO1347; GTPL9787; SCHEMBL10002991; HMS3674G21; HMS3748K13; BCP14354; EX-A1122; BDBM50197683; MFCD28502053; NSC782363; NSC800074; s7665; ZINC98209140; AKOS027427006; CH5183284; Debio-1347; CCG-264725; CS-5504; DB12903; NSC-782363; NSC-800074; SB16908; Methanone, (5-amino-1-(2-methyl-1H-benzimidazol-6-yl)-1H-pyrazol-4-yl)-1H-indol-2-yl-; NCGC00386433-01; AC-32960; BS-14797; HY-19957; CH 5183284; J3.616.632K; A14415; A901067; Q27285013; (5-amino-1-(2-methyl-3H-benzo[d]imidazol-5-yl)-1H-pyrazol-4-yl)(1H-indol-2-yl)methanone; [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl) methanone; [5-Amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl)-methanone; [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl)methanone; [5-amino-1-(2-methyl-3h-benzimidazol-5-yl)pyrazol-4-yl](1h-indol-2-yl)methanone; 1-(2-Methyl-1H-benzoimidazole-6-yl)-4-(1H-indole-2-ylcarbonyl)-1H-pyrazole-5-amine; LWJ"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB12903	.	.	356.4	3	C20H16N6O	105	573	3.9	27	3	4	"InChI=1S/C20H16N6O/c1-11-23-16-7-6-13(9-17(16)24-11)26-20(21)14(10-22-26)19(27)18-8-12-4-2-3-5-15(12)25-18/h2-10,25H,21H2,1H3,(H,23,24)"	CC1=NC2=C(N1)C=C(C=C2)N3C(=C(C=N3)C(=O)C4=CC5=CC=CC=C5N4)N	BEMNJULZEQTDJY-UHFFFAOYSA-N
DG01613	Tazemetostat	66558664	"Tazemetostat; 1403254-99-8; EPZ-6438; EPZ6438; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; E7438; UNII-Q40W93WPE1; EPZ 6438; E-7438; Tazemetostat (EPZ-6438); Q40W93WPE1; MFCD24849415; N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide; Tazemetostat [INN]; Tazverik; Tazemetostat [USAN]; Tazemetostat (USAN/INN); Tazemetostat [USAN:INN]; E 7438; Tazemetostat(EPZ-6438); GTPL7011; CHEMBL3414621; SCHEMBL13276848; SCHEMBL19325409; SCHEMBL22210809; EX-A509; HMS3653O07; HMS3747A09; AOB87748; BCP07409; EPZ-7438; 2399AH; NSC777109; NSC791066; s7128; AKOS026750211; ZINC100285161; CCG-264672; CS-1758; DB12887; NSC-777109; NSC-791066; SB22955; NCGC00381562-01; NCGC00381562-10; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-; AC-30931; AS-55991; DA-34776; HY-13803; N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide; QC-11696; SY040988; FT-0700193; SW220030-1; A12712; D11444; J-690163; J-690164; Q27088941; EPZ-6438; EPZ 6438; E7438; Tazemetostat; E-7438; E 7438; (R,Z)-1-(1-(1-(ethylsulfonyl)piperidin-4-yl)ethyl)-N-((2-hydroxy-4-methoxy-6-methylpyridin-3-yl)methyl)-2-methyl-1H-indole-3-carbimi dic acid; 5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((2-hydroxy-4,6-dimethylpyridin-3-yl)methyl)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl) methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)biphenyl-3-carboxamide; N-[(4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-5-[ethyl(tetrahydropyran-4-yl)amino]-4-methyl-4 inverted exclamation mark -(morpholinomethyl)biphenyl-3-carboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB12887	.	.	572.7	9	C34H44N4O4	83.1	992	4.2	42	2	6	"InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40)"	CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5	NSQSAUGJQHDYNO-UHFFFAOYSA-N
DG01614	G007-LK	67960134	"G007-LK; 1380672-07-0; CHEMBL2325503; (E)-4-(5-(2-(4-(2-chlorophenyl)-5-(5-(methylsulfonyl)pyridin-2-yl)-4H-1,2,4-triazol-3-yl)vinyl)-1,3,4-oxadiazol-2-yl)benzonitrile; 4-[5-[(E)-2-[4-(2-chlorophenyl)-5-(5-methylsulfonylpyridin-2-yl)-1,2,4-triazol-3-yl]ethenyl]-1,3,4-oxadiazol-2-yl]benzonitrile; 4-{5-[(E)-2-{4-(2-Chlorophenyl)-5-[5-(Methylsulfonyl)pyridin-2-Yl]-4h-1,2,4-Triazol-3-Yl}ethenyl]-1,3,4-Oxadiazol-2-Yl}benzonitrile; benzonitrile, 4-[5-[(1E)-2-[4-(2-chlorophenyl)-5-[5-(methylsulfonyl)-2-pyridinyl]-4H-1,2,4-triazol-3-yl]ethenyl]-1,3,4-oxadiazol-2-yl]-; 4hyf; C25H16ClN7O3S; SCHEMBL9904844; SCHEMBL9904845; AOB4444; EX-A656; G007 LK;G007LK; G-007-LK; 3686AH; BDBM50427989; s7239; ZINC95582938; CCG-269912; NCGC00390587-01; NCGC00390587-03; AC-33045; AS-75199; B5830; A900891; A1-02247; J-690154; Q27451850; (E)-4-(5-(2-(4-(2-Chlorophenyl)-5-(5-(methylsulfonyl)pyridin-2-yl)-4H-1,2,4-triazol-3-yl)vinyl)-1,3,4-oxadiazol-2-yl)benzonitrile;G007-LK; 1-[6-(3,5-Dichloro-4-hydroxyphenyl)-4-({trans-4-[(dimethylamino)methyl]cyclohexyl}amino)-1,5-naphthyridin-3-yl]ethanone hydrochlorid e (1:1); 1AK; 4-{5-[(1E)-2-[4-(2-chlorophenyl)-5-(5-methanesulfonylpyridin-2-yl)-4H-1,2,4-triazol-3-yl]ethenyl]-1,3,4-oxadiazol-2-yl}benzonitrile"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	530	6	C25H16ClN7O3S	149	961	3.1	37	0	9	"InChI=1S/C25H16ClN7O3S/c1-37(34,35)18-10-11-20(28-15-18)24-31-29-22(33(24)21-5-3-2-4-19(21)26)12-13-23-30-32-25(36-23)17-8-6-16(14-27)7-9-17/h2-13,15H,1H3/b13-12+"	CS(=O)(=O)C1=CN=C(C=C1)C2=NN=C(N2C3=CC=CC=C3Cl)/C=C/C4=NN=C(O4)C5=CC=C(C=C5)C#N	HIWVLHPKZNBSBE-OUKQBFOZSA-N
DG01615	Mps-BAY2b	67974488	"CHEMBL3410060; N-cyclopropyl-4-{8-[(2-methylpropyl)amino]imidazo[1,2-a]pyrazin-3-yl}benzamide; 1263420-68-3; SCHEMBL9938616; BDBM50072833; N-cyclopropyl-4-[8-(2-methylpropylamino)imidazo[1,2-a]pyrazin-3-yl]benzamide; 8Q5"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	349.4	6	C20H23N5O	71.3	487	3.8	26	2	4	"InChI=1S/C20H23N5O/c1-13(2)11-22-18-19-23-12-17(25(19)10-9-21-18)14-3-5-15(6-4-14)20(26)24-16-7-8-16/h3-6,9-10,12-13,16H,7-8,11H2,1-2H3,(H,21,22)(H,24,26)"	CC(C)CNC1=NC=CN2C1=NC=C2C3=CC=C(C=C3)C(=O)NC4CC4	QTOFVYOMOKYCEQ-UHFFFAOYSA-N
DG01616	MTOR inhibitors	68026984	"UNII-843G0TDV51; ME-344; 843G0TDV51; 1374524-68-1; 4,4'-(7-Hydroxy-8-methylchroman-3,4-diyl)diphenol; GTPL7961; SCHEMBL10073998; DB13062; 2H-1-Benzopyran-7-ol, 3,4-dihydro-3,4-bis(4-hydroxyphenyl)-8-methyl-, (3R,4S)-; Q27083823; 4,4'-((3R,4S)-7-Hydroxy-8-methylchroman-3,4-diyl)diphenol; (3R,4S)-3,4-bis(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H-chromen-7-ol"	Phase 1/2	8	Clinical Trial Drug(s)	Phase 1/2	Small molecular drug	.	.	.	.	348.4	2	C22H20O4	69.9	453	4.4	26	3	4	"InChI=1S/C22H20O4/c1-13-20(25)11-10-18-21(15-4-8-17(24)9-5-15)19(12-26-22(13)18)14-2-6-16(23)7-3-14/h2-11,19,21,23-25H,12H2,1H3/t19-,21-/m0/s1"	CC1=C(C=CC2=C1OC[C@H]([C@H]2C3=CC=C(C=C3)O)C4=CC=C(C=C4)O)O	QVCAATSEPLQVBX-FPOVZHCZSA-N
DG01617	Brigatinib	68165256	"Brigatinib; 1197953-54-0; ALUNBRIG; AP-26113; UNII-HYW8DB273J; Brigatinib (AP-26113); HYW8DB273J; AP 26113; (2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine; 2,4-Pyrimidinediamine, 5-chloro-N4-(2-(dimethylphosphinyl)phenyl)-N2-(2-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)-; 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-; 5-Chloro-N~4~-[2-(Dimethylphosphoryl)phenyl]-N~2~-{2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl)piperidin-1-Yl]phenyl}pyrimidine-2,4-Diamine; Brigatinib [USAN]; Brigatiib; Alunbrig (TN); 5-Chloro-N4-(2-(dimethylphosphoryl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine; 6GY; Brigatinib (JAN/USAN); Brigatinib [USAN:INN]; Brigatinib; AP26113; Brigatinib (AP26113); GTPL7741; CHEMBL3545311; SCHEMBL11916361; EX-A775; AMY10294; BCP17214; BDBM50185140; MFCD29472221; NSC784728; NSC787457; AKOS030257612; ZINC148723177; CS-4278; DB12267; NSC-784728; NSC-787457; SB40412; compound 11q [PMID: 27144831]; NCGC00483924-01; (2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone; 5-Chloro-N4-(2-(dimethylphosphoryl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1- yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-2,4-Pyrimidinediamine; AC-29958; AS-75176; HY-12857; DB-118419; FT-0700112; S8229; J3.535.964H; D10866; Q27456393"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB12267	DR0228	DR00368	584.1	8	C29H39ClN7O2P	85.9	835	4.6	40	2	9	"InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)"	CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC	AILRADAXUVEEIR-UHFFFAOYSA-N
DG01618	GSK126	68210102	"GSK126; 1346574-57-9; GSK-126; GSK 126; GSK2816126; (S)-1-(sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide; EZH2 inhibitor; UNII-W4OGW9QZ97; GSK-2816126; W4OGW9QZ97; CHEMBL3287735; 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-3-methyl-6-[6-(piperazin-1-yl)pyridin-3-yl]-1H-indole-4-carboxamide; 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-(6-piperazin-1-ylpyridin-3-yl)indole-4-carboxamide; A9G; N-((1,2-Dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-3-methyl-1-((1S)-1-methylpropyl)-6-(6-(1-piperazinyl)-3-pyridinyl)-1H-indole-4-carboxamide; N-[(1,2-Dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide; GSK126 HCl; GSK-126 HCl; MLS006010251; GTPL7012; SCHEMBL12180401; AOB1764; EX-A499; SYN5012; CHEBI:124921; BCP06129; BDBM50017293; GSK-2816126A; NSC780041; NSC789702; s7061; ZINC72318146; AKOS027322309; CCG-269895; CS-1401; NSC-780041; NSC-789702; QC-9703; NCGC00347286-01; 1H-Indole-4-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-3-methyl-1-((1S)-1-methylpropyl)-6-(6-(1-piperazinyl)-3-pyridinyl)-; AS-16379; HY-13470; SMR004701327; X5824; Q27077865; EZH2 inhibitor;GSK-126;GSK 126;GSK2816126A;GSK-2816126A;GSK 2816126A; (S)-1-sec-butyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide; N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	CHEBI:124921	.	.	.	526.7	7	C31H38N6O2	91.3	972	3.9	39	3	5	"InChI=1S/C31H38N6O2/c1-6-22(5)37-18-20(3)29-25(30(38)34-17-26-19(2)13-21(4)35-31(26)39)14-24(15-27(29)37)23-7-8-28(33-16-23)36-11-9-32-10-12-36/h7-8,13-16,18,22,32H,6,9-12,17H2,1-5H3,(H,34,38)(H,35,39)/t22-/m0/s1"	CC[C@H](C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(C=C(NC5=O)C)C)C	FKSFKBQGSFSOSM-QFIPXVFZSA-N
DG01619	BAY1125976	70817911	"BAY1125976; 1402608-02-9; BAY-1125976; UNII-ZL7A1UM87X; ZL7A1UM87X; 2-[4-(1-aminocyclobutyl)phenyl]-3-phenylimidazo[1,2-b]pyridazine-6-carboxamide; Imidazo[1,2-b]pyridazine-6-carboxamide, 2-[4-(1-aminocyclobutyl)phenyl]-3-phenyl-; 1402608-02-9 (free base); 2-(4-(1-aminocyclobutyl)phenyl)-3-phenylimidazo[1,2-b]pyridazine-6-carboxamide; 2-(4-(1-Aminocyclobutyl)phenyl)-3-phenylimidazo(1,2-b)pyridazine-6-carboxamide; Imidazo(1,2-b)pyridazine-6-carboxamide, 2-(4-(1-aminocyclobutyl)phenyl)-3-phenyl-; CHEMBL4751394; SCHEMBL12986078; US9604989, Example 5; GTPL10908; BDBM312517; BCP20659; CGC60802; EX-A3015; BAY112576; NSC793324; s8500; ZINC205604296; BAY-112576; CS-6212; NSC-793324; SB19771; BAY 1125976; Example 5 [WO2012136776A1]; AC-33646; HY-100018; BAY1125976;BAY 1125976; A921724"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	.	.	.	383.4	4	C23H21N5O	99.3	594	2.4	29	2	4	"InChI=1S/C23H21N5O/c24-22(29)18-11-12-19-26-20(21(28(19)27-18)16-5-2-1-3-6-16)15-7-9-17(10-8-15)23(25)13-4-14-23/h1-3,5-12H,4,13-14,25H2,(H2,24,29)"	C1CC(C1)(C2=CC=C(C=C2)C3=C(N4C(=N3)C=CC(=N4)C(=O)N)C5=CC=CC=C5)N	JBGYKRAZYDNCNV-UHFFFAOYSA-N
DG01620	ARQ 751	71138858	"Vevorisertib; UNII-V6SX910Y31; V6SX910Y31; 1416775-46-6; Vevorisertib [INN]; CHEMBL4802156; SCHEMBL14322498; ARQ-751; EX-A5803; HY-137458; CS-0138665; Acetamide, N-(1-(3-(3-(4-(1-aminocyclobutyl)phenyl)-2-(2-amino-3-pyridinyl)-3H-imidazo(4,5-b)pyridin-5-yl)phenyl)-4-piperidinyl)-N-methyl-; N-[1-[3-[3-[4-(1-aminocyclobutyl)phenyl]-2-(2-aminopyridin-3-yl)imidazo[4,5-b]pyridin-5-yl]phenyl]piperidin-4-yl]-N-methylacetamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	586.7	6	C35H38N8O	119	976	4	44	2	7	"InChI=1S/C35H38N8O/c1-23(44)41(2)26-15-20-42(21-16-26)28-7-3-6-24(22-28)30-13-14-31-34(39-30)43(33(40-31)29-8-4-19-38-32(29)36)27-11-9-25(10-12-27)35(37)17-5-18-35/h3-4,6-14,19,22,26H,5,15-18,20-21,37H2,1-2H3,(H2,36,38)"	CC(=O)N(C)C1CCN(CC1)C2=CC=CC(=C2)C3=NC4=C(C=C3)N=C(N4C5=CC=C(C=C5)C6(CCC6)N)C7=C(N=CC=C7)N	NZDSLYATTDIDPH-UHFFFAOYSA-N
DG01621	AGI-6780	71299339	"AGI-6780; 1432660-47-3; AGI6780; N-cyclopropyl-4-(thiophen-3-yl)-3-(3-(3-(trifluoromethyl)phenyl)ureido)benzenesulfonamide; AGI 6780; 1-[5-(Cyclopropylsulfamoyl)-2-Thiophen-3-Yl-Phenyl]-3-[3-(Trifluoromethyl)phenyl]urea; 1-[5-(CYCLOPROPYLSULFAMOYL)-2-(THIOPHEN-3-YL)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA; MLS006011046; CHEMBL3392845; SCHEMBL15702521; AOB2268; C21H18F3N3O3S2; DTXSID50744321; EX-A356; QCR-283; BDBM339679; HMS3653I21; HMS3744K17; HMS3865L13; BCP07383; 2198AH; FD5013; MFCD26097285; NSC781409; s7241; US10202339, Compound 124; ZINC95803998; AKOS024462890; CCG-269561; CS-1556; NSC-781409; SB19578; NCGC00347935-01; NCGC00347935-02; NCGC00347935-08; AS-55922; DA-35354; HY-15734; SMR004702838; FT-0764734; SW220033-1; Q27452174; S900006230; 1-[5-(cyclopropylsulfamoyl)-2-thiophen-3-ylphenyl]-3-[3-(trifluoromethyl)phenyl]urea; 3-(5-(cyclopropylsulfamoyl)-2-(thiophen-3-yl)phenyl)-1-(3-(trifluoromethyl)phenyl)urea; N-Cyclopropyl-3-[3-[3-(trifluoromethyl)phenyl]ureido]-4-(3-thienyl)benzenesulfonamide; 1K9; N-Cyclopropyl-4-(thiophen-3-yl)-3-({[3-(trifluoromethyl)phenyl]carbamoyl}amino)benzene-1-sulfonamide; N-Cyclopropyl-4-(thiophen-3-yl)-3-(3-(3-(trifluoromethyl)phenyl)ureido)benzenesulfonamide  "	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	481.5	6	C21H18F3N3O3S2	124	771	4.2	32	3	8	"InChI=1S/C21H18F3N3O3S2/c22-21(23,24)14-2-1-3-16(10-14)25-20(28)26-19-11-17(32(29,30)27-15-4-5-15)6-7-18(19)13-8-9-31-12-13/h1-3,6-12,15,27H,4-5H2,(H2,25,26,28)"	C1CC1NS(=O)(=O)C2=CC(=C(C=C2)C3=CSC=C3)NC(=O)NC4=CC=CC(=C4)C(F)(F)F	CCAWRGNYALGPQH-UHFFFAOYSA-N
DG01622	AZ5104	71496460	"AZ5104; 1421373-98-9; AZ-5104; N-(5-((4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-2DWZ6SE1E1; 2DWZ6SE1E1; CHEMBL3353411; N-[2-[2-(dimethylamino)ethyl-methylamino]-5-[[4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-4-methoxyphenyl]prop-2-enamide; AZD5104; AZ 5104; Osimertinib metabolite M6; SCHEMBL14663428; GTPL11580; EX-A824; AMY16678; AOB87166; BCP08428; HY-B0793; BDBM50029689; MFCD28899992; s7298; AKOS025404698; ZINC147059673; CCG-269587; CS-5192; NCGC00387805-01; AS-55926; DA-45003; QC-11825; B5836; FT-0733191; F14245; A885228; 2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-5-((4-(1H-indol-3-yl)-2-pyrimidinyl)amino)-4-methoxyphenyl)-; N-(2-((2-(Dimethylamino)ethyl)methylamino)-5-((4-(1H-indol-3-yl)-2-pyrimidinyl)amino)-4-methoxyphenyl)-2-propenamide; N-(2-[2-Dimethylaminoethyl-methylamino]-5-{[4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-4-methoxyphenyl)prop-2-enamide; N-(2-{[2-(DIMETHYLAMINO)ETHYL](METHYL)AMINO}-5-{[4-(1H-INDOL-3-YL)PYRIMIDIN-2-YL]AMINO}-4-METHOXYPHENYL)PROP-2-ENAMIDE; N-[2-(2-Dimethylaminoethylmethylamino)-5-[[4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-4-methoxyphenyl]prop-2-enamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	485.6	10	C27H31N7O2	98.4	722	3.8	36	3	7	"InChI=1S/C27H31N7O2/c1-6-26(35)30-22-15-23(25(36-5)16-24(22)34(4)14-13-33(2)3)32-27-28-12-11-21(31-27)19-17-29-20-10-8-7-9-18(19)20/h6-12,15-17,29H,1,13-14H2,2-5H3,(H,30,35)(H,28,31,32)"	CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CNC4=CC=CC=C43)OC	IQNVEOMHJHBNHC-UHFFFAOYSA-N
DG01623	Ripretinib	71584930	"1442472-39-0; DCC-2618; N-{4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3- yl]-2-fluorophenyl}-N'-phenylurea; Ripretinib; Urea, N-[4-bromo-5-[1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6- naphthyridin-3-yl]-2-fluorophenyl]-N'-phenyl-39-0; Ripretinib free base; Ripretinib (DCC-2618); UNII-9XW757O13D; 9XW757O13D; Ripretinib (USAN); Ripretinib [USAN]; 1442472-39-0 (free base); 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea; 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea; Quinlock; Qinlock (TN); GTPL9175; CHEMBL4216467; SCHEMBL14999718; DCC2618; BCP29218; EX-A4883; s8757; AT18473; DB14840; HY-112306; CS-0044835; D11353; DCC 2618;DCC2618;KIT/PDGFR inhibitor;Ripretinib; N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenylurea; Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenyl-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB14840	.	.	510.4	5	C24H21BrFN5O2	86.4	746	4.1	33	3	5	"InChI=1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)"	CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC	CEFJVGZHQAGLHS-UHFFFAOYSA-N
DG01624	BAY1161909	71599640	"Empesertib; 1443763-60-7; Mps1-IN-5; BAY 1161909; BAY-1161909; BAY1161909; UNII-02Y3Z2756M; 02Y3Z2756M; (2R)-2-(4-fluorophenyl)-N-[4-[2-(2-methoxy-4-methylsulfonylanilino)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]phenyl]propanamide; (-)-BAY-1161909; (2R)-2-(4-Fluorophenyl)-N-(4-(2-((2-methoxy-4-(methylsulfonyl)phenyl)amino)(1,2,4)triazolo(1,5-a)pyridin-6-yl)phenyl)propanamide; (2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]propanamide; Empesertib [INN]; Empesertib [WHO-DD]; GTPL9427; CHEMBL4303241; SCHEMBL15036597; BDBM329334; BCP23811; EX-A3543; BAY1161909;Mps1-IN-5; NSC787025; AKOS028109757; ZINC206769279; CS-4887; NSC-787025; US9663510, Example 01.01; NCGC00488781-01; AS-82506; BB177693; Benzeneacetamide, 4-fluoro-N-[4-[2-[[2-methoxy-4-(methylsulfonyl)phenyl]amino][1,2,4]triazolo[1,5-a]; Benzeneacetamide, 4-fluoro-N-[4-[2-[[2-methoxy-4-(methylsulfonyl)phenyl]amino][1,2,4]triazolo[1,5-a]pyridin-6-yl]phenyl]- -methyl-, ( R)-; HY-12858; D83662; A908652; BAY1161909; BAY-1161909; BAY 1161909;Mps1-IN-5; (2R)-2-(4-Fluorophenyl)-N-(4-(2-((4-(methanesulfonyl)-2-methoxyphenyl)amino)(1,2,4)triazolo(1,5-a)pyridin-6-yl)phenyl)propanamide; (2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]-amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]propanamide; (2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5-alpha]pyridin-6-yl)phenyl]propanamide; (alphaR)-4-Fluoro-N-(4-(2-((2-methoxy-4-(methylsulfonyl)phenyl)amino)(1,2,4)triazolo(1,5-a)pyridin-6-yl)phenyl)-alpha-methylbenzeneacetamide; Benzeneacetamide, 4-fluoro-N-(4-(2-((2-methoxy-4-(methylsulfonyl)phenyl)amino)(1,2,4)triazolo(1,5-a)pyridin-6-yl)phenyl)-alpha-methyl-, (alphaR)-"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	.	.	.	559.6	8	C29H26FN5O4S	123	951	4.9	40	2	8	"InChI=1S/C29H26FN5O4S/c1-18(19-4-9-22(30)10-5-19)28(36)31-23-11-6-20(7-12-23)21-8-15-27-33-29(34-35(27)17-21)32-25-14-13-24(40(3,37)38)16-26(25)39-2/h4-18H,1-3H3,(H,31,36)(H,32,34)/t18-/m1/s1"	C[C@H](C1=CC=C(C=C1)F)C(=O)NC2=CC=C(C=C2)C3=CN4C(=NC(=N4)NC5=C(C=C(C=C5)S(=O)(=O)C)OC)C=C3	NRJKIOCCERLIDG-GOSISDBHSA-N
DG01625	Ivosidenib	71657455	"Ivosidenib; 1448347-49-6; AG-120; Tibsovo; AG120; UNII-Q2PCN8MAM6; Q2PCN8MAM6; (2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide; (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide; RG120; ivosidenibum; (2S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide; Ivosidenib [INN]; Tibsovo (TN); Ivosidenib [USAN]; Ivosidenib [WHO-DD]; Ivosidenib (USAN/INN); Ivosidenib [USAN:INN]; GTPL9217; CHEMBL3989958; SCHEMBL15122512; EX-A992; CHEBI:145430; BDBM363689; AMY38924; US9850277, Compound 176; MFCD29036964; NSC789102; s8206; ZINC205136523; CCG-270141; CS-5122; DB14568; NSC-789102; NCGC00476170-04; NCGC00476170-06; (S)-N-((S)-1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-; AC-32624; AS-35058; HY-18767; A14386; D11090; A900315; Q27895417; (2S)-1-(4-Cyano-2-pyridinyl)-5-oxo-L-prolyl-2-(2-chloroPh)-N-(3,3-difluorocyclobutyl)-N2-(5-fluoro-3-pyridinyl)-glycinamide; (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide;AG-120; (S)-N-((S)-1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide; Glycinamide, 1-(4-cyano-2-pyridinyl)-5-oxo-L-prolyl-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-N2-(5-fluoro-3-pyridinyl)-, (2S)-; N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxo-L-prolinamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:145430	DB14568	.	DR00362	583	7	C28H22ClF3N6O3	119	1050	3.4	41	1	9	"InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1"	C1CC(=O)N([C@@H]1C(=O)N(C2=CC(=CN=C2)F)[C@@H](C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N	WIJZXSAJMHAVGX-DHLKQENFSA-N
DG01626	Naquotinib	71667668	"Naquotinib; 1448232-80-1; ASP8273; UNII-47DD4548PB; 2-Pyrazinecarboxamide, 6-ethyl-3-[[4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[[(3R)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]oxy]-; 47DD4548PB; ASP-8273; 6-ethyl-3-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-[(3R)-1-prop-2-enoylpyrrolidin-3-yl]oxypyrazine-2-carboxamide; (R)-5-((1-acryloylpyrrolidin-3-yl)oxy)-6-ethyl-3-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrazine-2-carboxamide; e-2-carboxamide; 2-Pyrazinecarboxamide, 6-ethyl-3-((4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-(((3R)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl)oxy)-; Naquotinib [USAN]; Naquotinib (USAN/INN); ASP8273 (Naquotinib); Naquotinib; ASP-8273; GTPL9248; CHEMBL3663929; SCHEMBL16196078; BDBM170514; EX-A2669; YHC23280; NSC793322; s8412; ZINC205341959; CCG-270060; CS-5469; DB12036; NSC-793322; AS-75247; HY-19729; J3.496.214F; A14408; C91356; D10958; US9085540, 54; A857977; Q27074546; 5-[[(3R)-1-Acryloylpyrrolidine-3-yl]oxy]-6-ethyl-3-[4-[4-(4-methylpiperazine-1-yl)piperidino]anilino]pyrazine-2-carboxamide; 6-Ethyl-3-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-(((3R)-1-(1-oxoprop-2-en-1-yl)pyrrolidin-3-yl)oxy)pyrazine-2-carboxamide; 6-ethyl-3-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-{[(3R)-1-(prop-2-enoyl)pyrrolidin-3-yl]oxy}pyrazine-2-carboxamide; 6-Ethyl-3-(4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)anilino)-5-(((3R)-1-(prop-2-enoyl)pyrrolidin-3-yl)oxy)pyrazine-2-carboxamide; 6-Ethyl-3-[[4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[[(3R)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]oxy]-2-pyrazinecarboxamide; 6-ethyl-3-[[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]amino]-5-[(3R)-1-prop-2-enoylpyrrolidin-3-yl]oxy-pyrazin"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB12036	.	.	562.7	9	C30H42N8O3	120	883	3.4	41	2	9	"InChI=1S/C30H42N8O3/c1-4-25-30(41-24-12-15-38(20-24)26(39)5-2)34-29(27(33-25)28(31)40)32-21-6-8-22(9-7-21)36-13-10-23(11-14-36)37-18-16-35(3)17-19-37/h5-9,23-24H,2,4,10-20H2,1,3H3,(H2,31,40)(H,32,34)/t24-/m1/s1"	CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)O[C@@H]5CCN(C5)C(=O)C=C	QKDCLUARMDUUKN-XMMPIXPASA-N
DG01627	TAS-121	71682991	"UNII-Z36593C4RW; Z36593C4RW; SCHEMBL15220964; TAS-121; (S)-N-(4-amino-5-(quinolin-3-yl)-6,7,8,9-tetrahydropyrimido[5,4-b]indolizin-8-yl)acrylamide; 1451370-01-6; 2-Propenamide, N-((8S)-4-amino-6,7,8,9-tetrahydro-5-(3-quinolinyl)pyrimido(5,4-b)indolizin-8-yl)-; N-((8S)-4-Amino-6,7,8,9-tetrahydro-5-(3-quinolinyl)pyrimido(5,4-b)indolizin-8-yl)-2-propenamide"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	384.4	3	C22H20N6O	98.7	628	2.5	29	2	5	"InChI=1S/C22H20N6O/c1-2-18(29)27-15-7-8-17-19(14-9-13-5-3-4-6-16(13)24-10-14)20-21(23)25-12-26-22(20)28(17)11-15/h2-6,9-10,12,15H,1,7-8,11H2,(H,27,29)(H2,23,25,26)/t15-/m0/s1"	C=CC(=O)N[C@H]1CCC2=C(C3=C(N=CN=C3N2C1)N)C4=CC5=CC=CC=C5N=C4	POOPTPRMXSYFRV-HNNXBMFYSA-N
DG01628	LY3009120	71721540	"LY3009120; 1454682-72-4; LY-3009120; DP-4978; UNII-1GDT36RARO; LY 3009120; 1GDT36RARO; DP 4978; 1-(3,3-dimethylbutyl)-3-[2-fluoro-4-methyl-5-[7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl]phenyl]urea; CHEMBL3577124; 1-(3,3-Dimethylbutyl)-3-{2-Fluoro-4-Methyl-5-[7-Methyl-2-(Methylamino)pyrido[2,3-D]pyrimidin-6-Yl]phenyl}urea; 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)urea; N-(3,3-Dimethylbutyl)-N'-[2-fluoro-4-methyl-5-[7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl]phenyl]urea; Urea, N-(3,3-dimethylbutyl)-N'-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)-; 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea; Urea, N-(3,3-dimethylbutyl)-N'-[2-fluoro-4-methyl-5-[7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl]phenyl]-; GTPL8943; SCHEMBL15241297; CHEBI:167662; BCP23869; EX-A1638; BDBM50096279; DP4978; NSC781761; NSC801010; s7842; ZINC205861291; CCG-268937; NSC-781761; NSC-801010; SB16924; NCGC00481604-01; AC-30240; AS-74984; HY-12558; QC-11801; DP-4978;LY-3009120; J3.580.324F; C72761; Q27082823; B2693-470864; 1-(2-Fluoro-4-methyl-5-(2-methylamino-7-methylpyrido[2,3-d]pyrimidine-6-yl)phenyl)-3-(3,3-dimethylbutyl)urea; 3-(3,3-DIMETHYLBUTYL)-1-{2-FLUORO-4-METHYL-5-[7-METHYL-2-(METHYLAMINO)PYRIDO[2,3-D]PYRIMIDIN-6-YL]PHENYL}UREA; 4Z5"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	.	.	.	424.5	6	C23H29FN6O	91.8	599	4.7	31	3	6	"InChI=1S/C23H29FN6O/c1-13-9-18(24)19(29-22(31)26-8-7-23(3,4)5)11-16(13)17-10-15-12-27-21(25-6)30-20(15)28-14(17)2/h9-12H,7-8H2,1-6H3,(H2,26,29,31)(H,25,27,28,30)"	CC1=CC(=C(C=C1C2=C(N=C3C(=C2)C=NC(=N3)NC)C)NC(=O)NCCC(C)(C)C)F	HHCBMISMPSAZBF-UHFFFAOYSA-N
DG01629	ACY-957	72374405	"1609389-52-7; ACY-957; N-[2-Amino-5-(2-thienyl)phenyl]-2-(1-piperazinyl)-6-quinolinecarboxamide; HDAC Inhibitor C001; N-(2-amino-5-thiophen-2-ylphenyl)-2-piperazin-1-ylquinoline-6-carboxamide; CHEMBL3927842; SCHEMBL15666003; BDBM182757; BCP25969; BA168232; US9145412, Table 1, Compound 23; ACY957;ACY 957;HDAC Inhibitor C001; HY-104008; CS-0023625; N-(2-Amino-5-(thiophen-2-yl)phenyl)-2-(piperazin-1-yl)quinoline-6-carboxamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	429.5	4	C24H23N5OS	112	615	3.5	31	3	6	"InChI=1S/C24H23N5OS/c25-19-6-3-17(22-2-1-13-31-22)15-21(19)28-24(30)18-4-7-20-16(14-18)5-8-23(27-20)29-11-9-26-10-12-29/h1-8,13-15,26H,9-12,25H2,(H,28,30)"	C1CN(CCN1)C2=NC3=C(C=C2)C=C(C=C3)C(=O)NC4=C(C=CC(=C4)C5=CC=CS5)N	VURDNNVAYZDGDK-UHFFFAOYSA-N
DG01630	Nazartinib	72703790	"Nazartinib; EGF816; 1508250-71-2; EGF-816; UNII-KE7K32EME8; EGF 816; NVP-EGF816-NX; KE7K32EME8; CHEMBL3787344; NVS-816; N-[7-chloro-1-[(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]benzimidazol-2-yl]-2-methylpyridine-4-carboxamide; N-{7-chloro-1-[(3R)-1-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-1H-1,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide; Nazartinib [USAN]; Nazartinib(EGF816); Nazartinib (USAN/INN); GTPL9204; SCHEMBL16767232; SCHEMBL16767240; EX-A1640; BDBM50160870; NSC787027; s7824; Nazartinib (EGF816, NVS-816); ZINC210610738; CCG-269658; NSC-787027; compound 47 [PMID: 27433829]; (R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide; AC-29881; AS-75243; HY-12872; B5889; J3.535.960E; A14416; C72867; D11430; A884136; Q27087855; 4-Pyridinecarboxamide, N-[7-chloro-1-[(3R)-1-[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]hexahydro-1H-azepin-3-yl]-1H-benzimidazol-2-yl]-2-methyl-; N-[7-chloro-1-[(3r)-1-[(2e)-4-(dimethylamino)-1-oxo-2-buten-1-yl]hexahydro-1h-azepin-3-yl]-1h-benzimidazol-2-yl]-2-methyl-4-pyridinecarboxamide"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	.	DB16250	.	.	495	6	C26H31ClN6O2	83.4	764	3.2	35	1	5	"InChI=1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33(26)20-8-4-5-15-32(17-20)23(34)11-7-14-31(2)3/h6-7,9-13,16,20H,4-5,8,14-15,17H2,1-3H3,(H,29,30,35)/b11-7+/t20-/m1/s1"	CC1=NC=CC(=C1)C(=O)NC2=NC3=C(N2[C@@H]4CCCCN(C4)C(=O)/C=C/CN(C)C)C(=CC=C3)Cl	IOMMMLWIABWRKL-WUTDNEBXSA-N
DG01631	Abivertinib	72734520	"Avitinib; Abivertinib; 1557267-42-1; AC0010; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; UNII-CER0OPG92L; CER0OPG92L; AC0010MA; EX-ACEA0010; ACEA100610; Abivertinib (USAN); Abivertinib [USAN]; 1557267-42-1 (free base); AC-0010; A610; N-[3-[[2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]-; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy-phenyl)-acrylamide; Avitinib free base; 2-Propenamide, N-(3-((2-((3-fluoro-4-(4-methyl-1-piperazinyl)phenyl)amino)-7H-pyrrolo(2,3-d)pyrimidin-4-yl)oxy)phenyl)-; FUJOVEE; Avitinib (AC0010); avitinib (superceded INN); CHEMBL4297865; SCHEMBL15453394; GTPL10044; EX-A783; BDBM294480; Avitinib(AC0010/AC0010MA); BCP16381; US9586965, Cpd 3; MFCD29089376; s8741; ZINC142081723; AC 0010; CS-W008904; DB15327; DS-19269; HY-19816; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; CS-0016789; A16826; D11308; F17427; A927386; N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1- yl)phenyl)amino)-7H-pyrrolo[2,3-d]- pyrimidin-4-yl)oxy)phenyl)acrylamide; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo(2,3-d)pyrimidin-4-yl)oxy)phenyl)prop-2-enamide; N-(3-(2-(3-Fluoro-4-(4-methylpiperazin-1-yl)phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl)acrylamide; N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]-2-propenamide"	Patented	3	Patented Agent(s)	Patented	Small molecular drug	.	DB15327	.	.	487.5	7	C26H26FN7O2	98.4	752	4.2	36	3	8	"InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)"	CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC4=C(C=CN4)C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)F	UOFYSRZSLXWIQB-UHFFFAOYSA-N
DG01632	EBI-907	73427153	CHEMBL3751896; EBI-907; 1581764-31-9; SCHEMBL15577685; BDBM50140046; SB19682	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	507	8	C23H21ClF2N4O3S	105	817	4.6	34	2	8	"InChI=1S/C23H21ClF2N4O3S/c1-33-18-10-14-13(11-27-23-20(14)22(28-29-23)12-3-4-12)9-15(18)19-16(26)5-6-17(21(19)24)30-34(31,32)8-2-7-25/h5-6,9-12,30H,2-4,7-8H2,1H3,(H,27,28,29)"	COC1=C(C=C2C=NC3=NNC(=C3C2=C1)C4CC4)C5=C(C=CC(=C5Cl)NS(=O)(=O)CCCF)F	JSKJFDXTKYWPAH-UHFFFAOYSA-N
DG01633	AZD-8835	76685059	"AZD8835; AZD-8835; 1620576-64-8; AZD 8835; 1-(4-(5-(5-Amino-6-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1H-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one; UNII-8B97A88D35; 8B97A88D35; 1-(4-{5-[5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl]-1-ethyl-1H-1,2,4-triazol-3-yl}piperidin-1-yl)-3-hydroxypropan-1-one; 1-Propanone, 1-[4-[5-[5-amino-6-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-2-pyrazinyl]-1-ethyl-1H-1,2,4-triazol-3-yl]-1-piperidinyl]-3-hydroxy-; 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1H-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one; 1-Propanone, 1-(4-(5-(5-amino-6-(5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl)-2-pyrazinyl)-1-ethyl-1H-1,2,4-triazol-3-yl)-1-piperidinyl)-3-hydroxy-; compound 25 [PMID: 26475521]; GTPL8915; CHEMBL3894518; SCHEMBL15877923; AZD 8835 [WHO-DD]; BDBM185362; BCP20347; EX-A2295; NSC786099; s7966; ZINC145460849; CCG-269444; CS-4984; NSC-786099; NCGC00484075-01; AC-32648; HY-12869; A16352; US9156831, 3; Q27074810; 1-[4-[5-[5-amino-6-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-2-; 1-[4-[5-[5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl]-1-ethyl-1,2,4-triazol-3-yl]piperidin-1-yl]-3-hydroxypropan-1-one"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	469.5	7	C22H31N9O3	162	685	0.1	34	2	10	"InChI=1S/C22H31N9O3/c1-5-31-19(26-18(29-31)13-6-9-30(10-7-13)15(33)8-11-32)14-12-24-17(23)16(25-14)20-27-28-21(34-20)22(2,3)4/h12-13,32H,5-11H2,1-4H3,(H2,23,24)"	CCN1C(=NC(=N1)C2CCN(CC2)C(=O)CCO)C3=CN=C(C(=N3)C4=NN=C(O4)C(C)(C)C)N	ZGRDYKFVDCFJCZ-UHFFFAOYSA-N
DG01634	AZD-3759	78209992	"AZD3759; 1626387-80-1; zorifertinib; AZD-3759; AZD 3759; (R)-4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate; UNII-67SX9H68W2; CHEMBL3623290; 67SX9H68W2; 4-[(3-CHLORO-2-FLUOROPHENYL)AMINO]-7-METHOXYQUINAZOLIN-6-YL (2R)-2,4-DIMETHYLPIPERAZINE-1-CARBOXYLATE; (2R)-2,4-dimethyl-1-piperazinecarboxylic acid, 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl ester; [4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl] (2R)-2,4-dimethylpiperazine-1-carboxylate; 4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl (2R)-2,4-dimethylpiperazine-1-carboxylate; SCHEMBL16010006; GTPL10456; EX-A720; AMY10302; BDBM50123453; MFCD29058564; NSC788121; NSC800978; s7971; AKOS027327321; ZINC221149242; CCG-269329; CS-5029; DB14795; NSC-788121; NSC-800978; compound 1m [PMID: 26313252]; NCGC00483922-01; NCGC00483922-02; AC-29957; AS-74755; HY-18750; A882818; (2R)-2,4-Dimethyl-1-piperazinecarboxylic acid 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl ester; (2R)-2,4-Dimethylpiperazine-1-carboxylic acid (4-(2-fluoro-3-chloroanilino)-7-methoxyquinazoline-6-yl) ester; (R)-4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	DB14795	.	.	459.9	5	C22H23ClFN5O3	79.8	649	4.1	32	1	8	"InChI=1S/C22H23ClFN5O3/c1-13-11-28(2)7-8-29(13)22(30)32-19-9-14-17(10-18(19)31-3)25-12-26-21(14)27-16-6-4-5-15(23)20(16)24/h4-6,9-10,12-13H,7-8,11H2,1-3H3,(H,25,26,27)/t13-/m1/s1"	C[C@@H]1CN(CCN1C(=O)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC)C	MXDSJQHFFDGFDK-CYBMUJFWSA-N
DG01635	BAY1217389	78320750	"1554458-53-5; BAY1217389; Bay 1217389; BAY-1217389; UNII-M964LB1114; M964LB1114; Benzamide, N-cyclopropyl-4-[6-(2,3-difluoro-4-methoxyphenoxy)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-b]pyridazin-3-yl]-2-methyl-; N-cyclopropyl-4-[6-(2,3-difluoro-4-methoxyphenoxy)-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide; N-Cyclopropyl-4-(6-(2,3-difluoro-4-methoxyphenoxy)-8-((3,3,3-trifluoropropyl)amino)imidazo[1,2-b]pyridazin-3-yl)-2-methylbenzamide; Benzamide, N-cyclopropyl-4-(6-(2,3-difluoro-4-methoxyphenoxy)-8-((3,3,3-trifluoropropyl)amino)imidazo(1,2-b)pyridazin-3-yl)-2-methyl-; N-cyclopropyl-4-[6-(2,3-difluoro-4-methoxyphenoxy)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide; CHEMBL4456085; SCHEMBL15555839; EX-A948; BDBM258444; BCP17401; NSC787026; s8215; ZINC221039372; CCG-265387; CS-6182; NSC-787026; HY-12859; FT-0700219; US9512130, 2; J-690208; 1-(6-Isoquinolinyl)-3-[2-oxo-2-(1-pyrrolidinyl)ethyl]urea"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	561.5	9	C27H24F5N5O3	89.8	867	5.7	40	2	11	"InChI=1S/C27H24F5N5O3/c1-14-11-15(3-6-17(14)26(38)35-16-4-5-16)19-13-34-25-18(33-10-9-27(30,31)32)12-22(36-37(19)25)40-21-8-7-20(39-2)23(28)24(21)29/h3,6-8,11-13,16,33H,4-5,9-10H2,1-2H3,(H,35,38)"	CC1=C(C=CC(=C1)C2=CN=C3N2N=C(C=C3NCCC(F)(F)F)OC4=C(C(=C(C=C4)OC)F)F)C(=O)NC5CC5	WNEILUNVMHVMPH-UHFFFAOYSA-N
DG01636	E7090	78323434	"E-7090; E7090; 1622204-21-0; tasurgratinib; TN7CUD1NGA; UNII-TN7CUD1NGA; 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamido)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide; 5-[2-[[4-[1-(2-hydroxyethyl)piperidin-4-yl]benzoyl]amino]pyridin-4-yl]oxy-6-(2-methoxyethoxy)-N-methylindole-1-carboxamide; CHEMBL3686884; SCHEMBL15955142; GTPL11414; BDBM142256; Fgf/fgfr pathway inhibitor E7090; BCP29727; EX-A2908; NSC806388; NSC-806388; SB18854; Example 22 [WO2014129477A1]; HY-101466; CS-0021430; E 7090; E7090; US8933099, 22; Q27896113; 1H-Indole-1-carboxamide, 5-((2-((4-(1-(2-hydroxyethyl)-4-piperidinyl)benzoyl)amino)-4-pyridinyl)oxy)-6-(2-methoxyethoxy)-N-methyl-; 5-((2-(((4-(1-(2-Hydroxyethyl)piperidin-4-yl)phenyl)carbonyl)amino)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	587.7	11	C32H37N5O6	127	880	3.1	43	3	8	"InChI=1S/C32H37N5O6/c1-33-32(40)37-14-10-25-19-29(28(21-27(25)37)42-18-17-41-2)43-26-7-11-34-30(20-26)35-31(39)24-5-3-22(4-6-24)23-8-12-36(13-9-23)15-16-38/h3-7,10-11,14,19-21,23,38H,8-9,12-13,15-18H2,1-2H3,(H,33,40)(H,34,35,39)"	CNC(=O)N1C=CC2=CC(=C(C=C21)OCCOC)OC3=CC(=NC=C3)NC(=O)C4=CC=C(C=C4)C5CCN(CC5)CCO	IBHOLSBDZMIPPT-UHFFFAOYSA-N
DG01637	G-749	78357765	"G-749; 1457983-28-6; G749; UNII-B06W426B66; 8-bromo-2-[(1-methylpiperidin-4-yl)amino]-4-(4-phenoxyanilino)-6H-pyrido[4,3-d]pyrimidin-5-one; B06W426B66; 8-Bromo-2-((1-methylpiperidin-4-yl)amino)-4-((4-phenoxyphenyl)amino)pyrido[4,3-D]pyrimidin-5(6H)-one; C25H25BrN6O2; GTPL8108; CHEMBL4544478; SCHEMBL15265027; AOB87764; BCP11201; EX-A1074; 2183AH; MFCD28167815; s7545; ZINC95644293; AKOS026750566; CCG-269863; CS-3343; NCGC00386412-04; AC-33000; BS-15433; DA-33613; HY-12333; QC-11719; FT-0700207; G 749; G 749;G749; A14214; A899265; J-690186; Q27077763; 8-bromo-2-[(1-methylpiperidin-4-yl)amino]-4-[(4-phenoxyphenyl)amino]-5H,6H-pyrido[4,3-d]pyrimidin-5-one"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	521.4	6	C25H25BrN6O2	91.4	716	4.9	34	3	7	"InChI=1S/C25H25BrN6O2/c1-32-13-11-17(12-14-32)29-25-30-22-20(26)15-27-24(33)21(22)23(31-25)28-16-7-9-19(10-8-16)34-18-5-3-2-4-6-18/h2-10,15,17H,11-14H2,1H3,(H,27,33)(H2,28,29,30,31)"	CN1CCC(CC1)NC2=NC3=C(C(=O)NC=C3Br)C(=N2)NC4=CC=C(C=C4)OC5=CC=CC=C5	SXWMIXPJPNCXQQ-UHFFFAOYSA-N
DG01638	Ropeginterferon alfa-2b	86278347	Ropeginterferon-alfa-2b; SCHEMBL23594684	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	.	DB15119	.	.	447.5	18	C20H37N3O8	136	535	-1.3	31	3	9	"InChI=1S/C20H37N3O8/c1-28-12-14-30-19(26)21-9-4-3-6-16(22-20(27)31-15-13-29-2)8-11-23-10-5-7-17(23)18(24)25/h16-17H,3-15H2,1-2H3,(H,21,26)(H,22,27)(H,24,25)/t16 ,17-/m0/s1"	COCCOC(=O)NCCCCC(CCN1CCC[C@H]1C(=O)O)NC(=O)OCCOC	LICFWYDUJZDCLK-DJNXLDHESA-N
DG01639	MRX-2843	89495685	"MRX-2843; 1429882-07-4; UNC-2371A; UNII-2MT30EHI63; 2MT30EHI63; CHEMBL3326007; (1r,4r)-4-(2-((2-cyclopropylethyl)amino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol; Cyclohexanol, 4-(2-((2-cyclopropylethyl)amino)-5-(4-((4-methyl-1-piperazinyl)methyl)phenyl)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)-, trans-; trans-4-(2-((2-Cyclopropylethyl)amino)-5-(4-((4-methyl-1-piperazinyl)methyl)phenyl)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)cyclohexanol; UNC2371A; SCHEMBL14854108; SCHEMBL17175579; UNC2371UNC2371; BDBM350861; BCP30180; BDBM50055490; MFCD28502224; s6839; ZINC299829706; CS-8117; SB17283; AS-35252; HY-101549; MRX-2843; (UNC-2371A); US9795606, B20; A16958; UNC2371;UNC-2371;UNC 2371;MRX 2843 ;MRX2843; 4-[2-(2-cyclopropylethylamino)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-ol; trans-(1R,4R)-4-(2-((2-cyclopropylethyl)amino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	.	.	.	488.7	8	C29H40N6O	69.4	681	4.2	36	2	6	"InChI=1S/C29H40N6O/c1-33-14-16-34(17-15-33)19-22-4-6-23(7-5-22)27-20-35(24-8-10-25(36)11-9-24)28-26(27)18-31-29(32-28)30-13-12-21-2-3-21/h4-7,18,20-21,24-25,36H,2-3,8-17,19H2,1H3,(H,30,31,32)"	CN1CCN(CC1)CC2=CC=C(C=C2)C3=CN(C4=NC(=NC=C34)NCCC5CC5)C6CCC(CC6)O	LBEJYFVJIPQSNX-UHFFFAOYSA-N
DG01640	Lifirafenib	89670174	"Lifirafenib; BGB-283; Beigene-283; 1446090-77-2; 1446090-79-4; 5-(((1R,1aS,6bR)-1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one; Bgb 283; UNII-8762XZS5ZF; 8762XZS5ZF; 5-(((1R,1aS,6bR)-1-(6-(Trifluoromethyl)-1H-benzimidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa(b)benzofuran-5-yl)oxy)-3,4-dihydro-1H-1,8-naphthyridin-2-one; BGB283; 5-({(1r,1as,6br)-1-[5-(Trifluoromethyl)-1h-Benzimidazol-2-Yl]-1a,6b-Dihydro-1h-Cyclopropa[b][1]benzofuran-5-Yl}oxy)-3,4-Dihydro-1,8-Naphthyridin-2(1h)-One; 5-[[(1R,1aS,6bR)-1-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one; compound 2.2b; 5-{{(1r,1as,6br)-1-[5-(trifluoromethyl)-1h-benzimidazol-2-yl]-1a,6b-dihydro-1h-cyclopropa[b][1]benzofuran-5-yl}oxy}-3,4-dihydro-1,8-naphthyridin-2(1h)-one; Lifirafenib [USAN]; Lifirafenib (USAN/INN); BGB-283;Beigene-283; GTPL8958; CHEMBL4209157; SCHEMBL15085288; BDBM372968; EX-A1473; US9895376, Compound 2.2b; WHC09077; WHC09079; Lifirafenib;BGB-283;Beigene-283; BDBM50453816; WHO 10554; ZINC68764621; CS-6308; DB14773; HY-18957; D11410; A900647; Q27075193; 1,8-Naphthyridin-2(1H)-one, 5-(((1R,1aS,6bR)-1a,6b-dihydro-1-(6-(trifluoromethyl)-1H-benzimidazol-2-yl)-1H-cyclopropa(b)benzofuran-5-yl)oxy)-3,4-dihydro-; 3K3"	Phase 1/2	8	Clinical Trial Drug(s)	Phase 1/2	Small molecular drug	.	DB14773	.	.	478.4	3	C25H17F3N4O3	89.1	845	3.7	35	2	8	"InChI=1S/C25H17F3N4O3/c26-25(27,28)11-1-4-15-16(9-11)31-24(30-15)21-20-14-10-12(2-5-17(14)35-22(20)21)34-18-7-8-29-23-13(18)3-6-19(33)32-23/h1-2,4-5,7-10,20-22H,3,6H2,(H,30,31)(H,29,32,33)/t20-,21-,22-/m0/s1"	C1CC(=O)NC2=NC=CC(=C21)OC3=CC4=C(C=C3)O[C@H]5[C@@H]4[C@@H]5C6=NC7=C(N6)C=C(C=C7)C(F)(F)F	NGFFVZQXSRKHBM-FKBYEOEOSA-N
DG01641	Enasidenib	89683805	"Enasidenib; 1446502-11-9; AG-221; AG-221 (Enasidenib); CC-90007 Free Base; IDHIFA; UNII-3T1SS4E7AG; AG 221; 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol; CC-90007; 3T1SS4E7AG; 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol; 2-Methyl-1-[(4-[6-(Trifluoromethyl)pyridin-2-Yl]-6-{[2-(Trifluoromethyl)pyridin-4-Yl]amino}-1,3,5-Triazin-2-Yl)amino]propan-2-Ol; 2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol; 2-Propanol, 2-methyl-1-[[4-[6-(trifluoromethyl)-2-pyridinyl]-6-[[2-(trifluoromethyl)-4-pyridinyl]amino]-1,3,5-triazin-2-yl]amino]-; 2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-; Enasidenib [INN]; enasidenibum; AG221; 2-methyl-1-({4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl}amino)propan-2-ol; AG-221(Enasidenib); AG-221; Enasidenib; Enasidenib; AG-221; Enasidenib (USAN/INN); Enasidenib [USAN:INN]; GTPL8960; CHEMBL3989908; SCHEMBL15102202; EX-A654; CHEBI:145374; HMS3873D03; AMY38698; BCP16041; BDBM50503251; MFCD29472245; NSC788120; s8205; AKOS026750439; ZINC222731806; CCG-269476; CS-5017; DB13874; NSC-788120; SB19193; NCGC00479249-03; NCGC00479249-05; AC-31318; AS-75164; HY-18690; FT-0700204; D10901; A857662; J-690181; Q27077182; B0084-470859; AG-221; AG 221; AG221; CC-90007; CC 90007; CC90007; 69Q"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:145374	DB13874	DR0574	.	473.4	6	C19H17F6N7O	109	635	3.5	33	3	14	"InChI=1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32)"	CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O	DYLUUSLLRIQKOE-UHFFFAOYSA-N
DG01642	M2698	89808643	"M2698 free base; M2698; 1379545-95-5; MSC2363318A; UNII-0DXG50I4WD; 0DXG50I4WD; 1379545-95-5 (free base); M-2698; (S)-4-((2-(Azetidin-1-yl)-1-(4-chloro-3-(trifluoromethyl)phenyl)ethyl)amino)quinazoline-8-carboxamide; SCHEMBL15262358; BCP19488; EX-A1187; MSC-2363318A; NSC795142; DB15431; NSC-795142; HY-100501; CS-0019628; M2698(MSC-2363318A); M-2698;M 2698; MSC-2363318A; MSC 2363318A; MSC2363318A; 4-[[(1S)-2-(azetidin-1-yl)-1-[4-chloro-3-(trifluoromethyl)phenyl]ethyl]amino]quinazoline-8-carboxamide; 8-Quinazolinecarboxamide, 4-(((1S)-2-(1-azetidinyl)-1-(4-chloro-3-(trifluoromethyl)phenyl)ethyl)amino)-"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	.	.	.	449.9	6	C21H19ClF3N5O	84.1	635	3.9	31	2	8	"InChI=1S/C21H19ClF3N5O/c22-16-6-5-12(9-15(16)21(23,24)25)17(10-30-7-2-8-30)29-20-14-4-1-3-13(19(26)31)18(14)27-11-28-20/h1,3-6,9,11,17H,2,7-8,10H2,(H2,26,31)(H,27,28,29)/t17-/m1/s1"	C1CN(C1)C[C@H](C2=CC(=C(C=C2)Cl)C(F)(F)F)NC3=NC=NC4=C3C=CC=C4C(=O)N	HXAUJHZZPCBFPN-QGZVFWFLSA-N
DG01643	FF-10101	90052320	"FF-10101; 1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; CHEMBL4650283; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; Ff-10101-01; HY-109584; CS-0032038; FF 10101; FF10101; D87147; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	Phase 1/2	8	Clinical Trial Drug(s)	Phase 1/2	Small molecular drug	.	.	.	.	530.7	14	C29H38N8O2	126	906	3.6	39	3	8	"InChI=1S/C29H38N8O2/c1-6-17-31-27-24(21-33-29(35-27)34-25-15-13-23(20-30)14-16-25)11-8-7-9-18-32-28(39)22(2)37(5)26(38)12-10-19-36(3)4/h10,12-16,21-22H,6-7,9,17-19H2,1-5H3,(H,32,39)(H2,31,33,34,35)/b12-10+/t22-/m0/s1"	CCCNC1=NC(=NC=C1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C)NC2=CC=C(C=C2)C#N	HJFSVYUFOXAVAA-YUAYGMJFSA-N
DG01644	PLX8394	90116675	"PLX8394; 1393466-87-9; PLX-8394; UNII-J2L7Z273SG; J2L7Z273SG; PLX 8394; (3R)-N-[3-[5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-3-fluoropyrrolidine-1-sulfonamide; (R)-N-(3-(5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)-3-fluoropyrrolidine-1-sulfonamide; GTPL9131; CHEMBL4303729; SCHEMBL15666953; BDBM317826; BCP19619; EX-A1461; PLX 8394;PLX8394; NSC797932; NSC801007; s7965; ZINC144705377; CS-5123; NSC-797932; NSC-801007; US9624213, Compound P-0338; NCGC00483921-01; BP168493; BS-15485; HY-18972; A16840; D83660; A900333; Q27088419; 1-Pyrrolidinesulfonamide, N-(3-((5-(2-cyclopropyl-5-pyrimidinyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-3-fluoro-, (3R)-"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB16038	.	.	542.5	7	C25H21F3N6O3S	129	976	2.8	38	2	11	"InChI=1S/C25H21F3N6O3S/c26-16-5-6-34(12-16)38(36,37)33-20-4-3-19(27)21(22(20)28)23(35)18-11-32-25-17(18)7-14(8-31-25)15-9-29-24(30-10-15)13-1-2-13/h3-4,7-11,13,16,33H,1-2,5-6,12H2,(H,31,32)/t16-/m1/s1"	C1CN(C[C@@H]1F)S(=O)(=O)NC2=C(C(=C(C=C2)F)C(=O)C3=CNC4=C3C=C(C=N4)C5=CN=C(N=C5)C6CC6)F	YYACLQUDUDXAPA-MRXNPFEDSA-N
DG01645	PLX7904	90116945	"PLX7904; 1393465-84-3; PB04; PLX-7904; 5-(2-Cyclopropylpyrimidin-5-yl)-3-[3-[[ethyl(methyl)sulfamoyl]amino]-2,6-difluorobenzoyl]-1H-pyrrolo[2,3-b]pyridine; N'-(3-{[5-(2-Cyclopropylpyrimidin-5-Yl)-1h-Pyrrolo[2,3-B]pyridin-3-Yl]carbonyl}-2,4-Difluorophenyl)-N-Ethyl-N-Methylsulfuric Diamide; Sulfamide, N'-[3-[[5-(2-cyclopropyl-5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-N-ethyl-N-methyl-; CHEMBL4206836; SCHEMBL15667328; BDBM317744; PLX7904(PB04); BCP18248; EX-A2872; s7964; ZINC144822687; CCG-269789; CS-5129; US9624213, Compound P-0240; HY-18997; A901658; Q27456931; ({3-[5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl}sulfamoyl)(ethyl)methylamine; N'-[3-[[5-(2-cyclopropyl-5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-N-ethyl-N-methyl-sulfamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	512.5	8	C24H22F2N6O3S	129	895	2.6	36	2	10	"InChI=1S/C24H22F2N6O3S/c1-3-32(2)36(34,35)31-19-7-6-18(25)20(21(19)26)22(33)17-12-30-24-16(17)8-14(9-29-24)15-10-27-23(28-11-15)13-4-5-13/h6-13,31H,3-5H2,1-2H3,(H,29,30)"	CCN(C)S(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CN=C(N=C4)C5CC5)F	DKNZQPXIIHLUHU-UHFFFAOYSA-N
DG01646	RAF709	90408826	"RAF709; 1628838-42-5; RAF-709; N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide; N-{2-Methyl-5'-(Morpholin-4-Yl)-6'-[(Oxan-4-Yl)oxy][3,3'-Bipyridin]-5-Yl}-3-(Trifluoromethyl)benzamide; CHEMBL3962812; SCHEMBL16035801; BDBM202784; BCP19140; EX-A1298; s8690; AKOS030632027; CCG-269969; CS-6074; BS-15948; HY-100510; J3.655.460F; A16842; C73133; US9242969, 131; 92J; N-(2-methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide; N-(2-Methyl-5'-morpholino-6'-(tetrahydro-2H-pyran-4-yloxy)-3,3'-bipyridin-5-yl)-3-(trifluoromethyl)benzamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	542.5	6	C28H29F3N4O4	85.8	793	4	39	1	10	"InChI=1S/C28H29F3N4O4/c1-18-24(15-22(17-32-18)34-26(36)19-3-2-4-21(13-19)28(29,30)31)20-14-25(35-7-11-38-12-8-35)27(33-16-20)39-23-5-9-37-10-6-23/h2-4,13-17,23H,5-12H2,1H3,(H,34,36)"	CC1=C(C=C(C=N1)NC(=O)C2=CC(=CC=C2)C(F)(F)F)C3=CC(=C(N=C3)OC4CCOCC4)N5CCOCC5	FYNMINFUAIDIFL-UHFFFAOYSA-N
DG01647	FIIN-2	91825767	"FIIN-2; 1633044-56-0; FIIN2; CHEMBL4065323; N-(4-((3-(3,5-Dimethoxyphenyl)-7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)methyl)phenyl)acrylamide; FIIN 2; SCHEMBL17857061; BCP14779; EX-A1742; BDBM50232829; s7714; AKOS025287401; ZINC250363839; CCG-270298; CS-5343; NCGC00484066-01; AC-32963; BF179868; HY-18602; DS-015817; A900505; N-(4-{[3-(3,5-dimethoxyphenyl)-7-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-2-oxo-1H,2H,3H,4H-[1,3]diazino[4,5-d]pyrimidin-1-yl]methyl}phenyl)prop-2-enamide; N-[4-[[3-(3,5-dimethoxyphenyl)-7-[4-(4-methylpiperazin-1-yl)anilino]-2-oxo-4H-pyrimido[4,5-d]pyrimidin-1-yl]methyl]phenyl]prop-2-enamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	634.7	10	C35H38N8O4	115	1030	4	47	2	9	"InChI=1S/C35H38N8O4/c1-5-32(44)37-26-8-6-24(7-9-26)22-43-33-25(23-42(35(43)45)29-18-30(46-3)20-31(19-29)47-4)21-36-34(39-33)38-27-10-12-28(13-11-27)41-16-14-40(2)15-17-41/h5-13,18-21H,1,14-17,22-23H2,2-4H3,(H,37,44)(H,36,38,39)"	CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C4CN(C(=O)N(C4=N3)CC5=CC=C(C=C5)NC(=O)C=C)C6=CC(=CC(=C6)OC)OC	DVBPRWJMHURKHP-UHFFFAOYSA-N
DG01648	GSK321	91864709	"GSK321; (R)-1-(4-fluorobenzyl)-N-(3-((S)-1-hydroxyethyl)phenyl)-7-methyl-5-(1H-pyrrole-2-carbonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3-carboxamide; 1816331-63-1; (7r)-1-(4-Fluorobenzyl)-N-{3-[(1s)-1-Hydroxyethyl]phenyl}-7-Methyl-5-(1h-Pyrrol-2-Ylcarbonyl)-4,5,6,7-Tetrahydro-1h-Pyrazolo[4,3-C]pyridine-3-Carboxamide; CHEMBL4215717; SCHEMBL20067448; GSK-321; BDBM195601; Q27455571; (7R)-1-[(4-fluorophenyl)methyl]-N-[3-[(1S)-1-hydroxyethyl]phenyl]-7-methyl-5-(1H-pyrrole-2-carbonyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-3-carboxamide; 59D"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	501.6	6	C28H28FN5O3	103	809	3.1	37	3	5	"InChI=1S/C28H28FN5O3/c1-17-14-33(28(37)24-7-4-12-30-24)16-23-25(27(36)31-22-6-3-5-20(13-22)18(2)35)32-34(26(17)23)15-19-8-10-21(29)11-9-19/h3-13,17-18,30,35H,14-16H2,1-2H3,(H,31,36)/t17-,18+/m1/s1"	C[C@@H]1CN(CC2=C1N(N=C2C(=O)NC3=CC=CC(=C3)[C@H](C)O)CC4=CC=C(C=C4)F)C(=O)C5=CC=CN5	IVFDDVKCCBDPQZ-MSOLQXFVSA-N
DG01649	CHZ868	91885989	"CHZ868; 1895895-38-1; CHZ-868; CHZ 868; SCHEMBL20548035; CHEBI:90828; CHZ-868;CHZ 868; BCP19574; EX-A1610; VAD89538; AKOS032960476; ZINC263614455; CS-6363; AC-33597; HY-18960; Q27162807; N-[4-[2-(2,4-difluoroanilino)-1,4-dimethylbenzimidazol-5-yl]oxypyridin-2-yl]acetamide; N-(4-{[2-(2,4-difluoroanilino)-1,4-dimethyl-1H-benzimidazol-5-yl]oxy}pyridin-2-yl)acetamide; N-[4-[2-[[2,4-bis(fluoranyl)phenyl]amino]-1,4-dimethyl-benzimidazol-5-yl]oxypyridin-2-yl]ethanamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	423.4	5	C22H19F2N5O2	81.1	629	3.8	31	2	7	"InChI=1S/C22H19F2N5O2/c1-12-19(31-15-8-9-25-20(11-15)26-13(2)30)7-6-18-21(12)28-22(29(18)3)27-17-5-4-14(23)10-16(17)24/h4-11H,1-3H3,(H,27,28)(H,25,26,30)"	CC1=C(C=CC2=C1N=C(N2C)NC3=C(C=C(C=C3)F)F)OC4=CC(=NC=C4)NC(=O)C	KQQLBXFPTDVFAJ-UHFFFAOYSA-N
DG01650	PZ-1	102004343	"Pz-1; Pz-1, >=98% (HPLC); 1800505-64-9; N-(5-tert-butyl-1,2-oxazol-3-yl)-2-[4-[5-(1-methylpyrazol-4-yl)benzimidazol-1-yl]phenyl]acetamide; SCHEMBL17315095; HY-U00437; NSC792733; ZINC526061663; NSC-792733; CS-0035381; B0084-267746"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	454.5	6	C26H26N6O2	90.8	706	4.3	34	1	5	"InChI=1S/C26H26N6O2/c1-26(2,3)23-13-24(30-34-23)29-25(33)11-17-5-8-20(9-6-17)32-16-27-21-12-18(7-10-22(21)32)19-14-28-31(4)15-19/h5-10,12-16H,11H2,1-4H3,(H,29,30,33)"	CC(C)(C)C1=CC(=NO1)NC(=O)CC2=CC=C(C=C2)N3C=NC4=C3C=CC(=C4)C5=CN(N=C5)C	NJLMIILZNLZZFW-UHFFFAOYSA-N
DG01651	TAS6417	117918742	"TAS6417; 1661854-97-2; Zipalertinib; TAS-6417; UNII-T4YMU8TW9H; T4YMU8TW9H; (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide; CLN-081; N-[(8S)-4-Amino-6-methyl-5-quinolin-3-yl-8,9-dihydropyrimido[5,4-b]indolizin-8-yl]prop-2-enamide; Zipalertinib [INN]; CLN081; CHEMBL4650281; SCHEMBL16525948; GTPL11889; EX-A3391; NSC812926; s8814; NSC-812926; AS-79368; HY-112299; CS-0044757; D93895; A937514; 2-Propenamide, N-((8S)-4-amino-8,9-dihydro-6-methyl-5-(3-quinolinyl)pyrimido(5,4-b)indolizin-8-yl)-"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	396.4	3	C23H20N6O	98.7	710	2.3	30	2	5	"InChI=1S/C23H20N6O/c1-3-18(30)28-16-8-13(2)21-19(15-9-14-6-4-5-7-17(14)25-10-15)20-22(24)26-12-27-23(20)29(21)11-16/h3-10,12,16H,1,11H2,2H3,(H,28,30)(H2,24,26,27)/t16-/m0/s1"	CC1=C[C@@H](CN2C1=C(C3=C(N=CN=C32)N)C4=CC5=CC=CC=C5N=C4)NC(=O)C=C	MKCYPWYURWOKST-INIZCTEOSA-N
DG01652	PRN1371	118295624	"PRN1371; 1802929-43-6; PRN-1371; 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one; UNII-S3OPE9IA3Q; S3OPE9IA3Q; 6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)-8-[3-(4-prop-2-enoylpiperazin-1-yl)propyl]pyrido[2,3-d]pyrimidin-7-one; GTPL9788; CHEMBL4068509; SCHEMBL16993012; US9567334, Example 6; BDBM286984; BCP20493; EX-A2927; NSC801089; s8578; CCG-270053; CS-7485; NSC-801089; compound 34 [PMID: 28665128]; BP179867; HY-101768; J3.662.238E; C92492; A936037; Q29213602"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	.	.	.	561.5	9	C26H30Cl2N6O4	100	870	3.5	38	1	8	"InChI=1S/C26H30Cl2N6O4/c1-5-20(35)33-11-9-32(10-12-33)7-6-8-34-24-16(15-30-26(29-2)31-24)13-17(25(34)36)21-22(27)18(37-3)14-19(38-4)23(21)28/h5,13-15H,1,6-12H2,2-4H3,(H,29,30,31)"	CNC1=NC=C2C=C(C(=O)N(C2=N1)CCCN3CCN(CC3)C(=O)C=C)C4=C(C(=CC(=C4Cl)OC)OC)Cl	PUIXMSRTTHLNKI-UHFFFAOYSA-N
DG01653	BAY1436032	118310260	"BAY-1436032; 1803274-65-8; BAY1436032; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid; BAY 1436032; CHEMBL4206033; SCHEMBL17009632; BDBM404661; EX-A1606; NSC794487; s8530; NSC-794487; US10344004, Test compound Table 3; HY-100020; CS-0017982; 3-[2-[4-(trifluoromethoxy)anilino]-1-[(1R,5R)-3,3,5-trimethylcyclohexyl]benzimidazol-5-yl]propanoic acid"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	.	.	.	489.5	7	C26H30F3N3O3	76.4	726	7.2	35	2	8	"InChI=1S/C26H30F3N3O3/c1-16-12-19(15-25(2,3)14-16)32-22-10-4-17(5-11-23(33)34)13-21(22)31-24(32)30-18-6-8-20(9-7-18)35-26(27,28)29/h4,6-10,13,16,19H,5,11-12,14-15H2,1-3H3,(H,30,31)(H,33,34)/t16-,19+/m0/s1"	C[C@H]1C[C@H](CC(C1)(C)C)N2C3=C(C=C(C=C3)CCC(=O)O)N=C2NC4=CC=C(C=C4)OC(F)(F)F	RNMAUIMMNAHKQR-QFBILLFUSA-N
DG01654	EAI045	121231412	"EAI045; 1942114-09-1; EAI-045; 2-(5-fluoro-2-hydroxyphenyl)-2-(3-oxo-1H-isoindol-2-yl)-N-(1,3-thiazol-2-yl)acetamide; CHEMBL4214567; 2-(5-Fluoro-2-hydroxyphenyl)-2-(1-oxoisoindolin-2-yl)-N-(thiazol-2-yl)acetamide; 2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-(1,3-thiazol-2-yl)acetamide; GTPL9222; SCHEMBL18472992; AMY9112; BCP17698; EX-A1735; BDBM50453891; s8242; AKOS030573300; CCG-268438; CS-5835; AC-29880; AS-55933; BE162167; HY-100213; F20673; Q27077145"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	383.4	4	C19H14FN3O3S	111	580	2.7	27	2	6	"InChI=1S/C19H14FN3O3S/c20-12-5-6-15(24)14(9-12)16(17(25)22-19-21-7-8-27-19)23-10-11-3-1-2-4-13(11)18(23)26/h1-9,16,24H,10H2,(H,21,22,25)"	C1C2=CC=CC=C2C(=O)N1C(C3=C(C=CC(=C3)F)O)C(=O)NC4=NC=CS4	YTUFHOKUFOQRDF-UHFFFAOYSA-N
DG01655	SBI-0640756	121241171	"SBI-0640756; 1821280-29-8; SCHEMBL19857722; SCHEMBL19857734; SBI-756; BCP23633; EX-A2800; WXC28029; s8181; ZINC521836536; CCG-268701; CS-5696; SBI0640756; SBI 0640756; BS-15707; HY-19560; D80610; SBI-0640756, >=98% (HPLC); SBI 0640756;SBI0640756;SBI 756;SBI756;SBI-756; (E)-6-Chloro-3-(3-(5-fluoropyridin-3-yl)acryloyl)-4-phenylquinolin-2(1H)-one; 6-chloro-3-[(E)-3-(5-fluoropyridin-3-yl)prop-2-enoyl]-4-phenyl-1H-quinolin-2-one"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	404.8	4	C23H14ClFN2O2	59.1	701	4.1	29	1	4	"InChI=1S/C23H14ClFN2O2/c24-16-7-8-19-18(11-16)21(15-4-2-1-3-5-15)22(23(29)27-19)20(28)9-6-14-10-17(25)13-26-12-14/h1-13H,(H,27,29)/b9-6+"	C1=CC=C(C=C1)C2=C(C(=O)NC3=C2C=C(C=C3)Cl)C(=O)/C=C/C4=CC(=CN=C4)F	VVWGPQZBDQVQRC-RMKNXTFCSA-N
DG01656	Lazertinib	121269225	"Lazertinib; 1903008-80-9; GNS-1480; YH25448; YH-25448; GNS1480; JNJ-73841937-AAA; UNII-4A2Y23XK11; N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide; C-18112003-G; 4A2Y23XK11; N-(5-((4-(4-((Dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamide; Leclaza; Lazertinib [USAN]; Lazertinib [INN]; Lazertinib (YH25448); CHEMBL4558324; SCHEMBL17670400; GTPL10136; BCP30440; EX-A1912; BDBM50555575; s8724; WHO 10587; AKOS037515597; CCG-270023; Lazertinib (YH25448,GNS-1480); YH-25448;GNS-1480; BS-15742; Compound 73 [WO2016060443A2]; HY-109061; CS-0032992; A16827; A903188; YH-25448; YH 25448; YH25448; GNS-1480; GNS 1480; GNS1480; 2-Propenamide, N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)-; N-(5-((4-(4-((Dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)acrylamide; N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	DB16216	.	.	554.6	10	C30H34N8O3	110	837	3.4	41	2	9	"InChI=1S/C30H34N8O3/c1-5-28(39)32-23-17-24(26(40-4)18-25(23)37-13-15-41-16-14-37)33-30-31-12-11-27(34-30)38-20-22(19-36(2)3)29(35-38)21-9-7-6-8-10-21/h5-12,17-18,20H,1,13-16,19H2,2-4H3,(H,32,39)(H,31,33,34)"	CN(C)CC1=CN(N=C1C2=CC=CC=C2)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N5CCOCC5)OC	RRMJMHOQSALEJJ-UHFFFAOYSA-N
DG01657	ReACp53	121596091	ReACp53	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	2617.1	104	C108H206N52O24	1340	5720	-12.8	184	55	36	"InChI=1S/C108H206N52O24/c1-11-55(7)75(92(178)154-72(52-54(5)6)90(176)158-77(57(9)161)94(180)151-68(34-22-48-141-107(128)129)88(174)156-76(56(8)12-2)93(179)159-78(58(10)162)95(181)155-71(51-53(3)4)89(175)153-70(97(183)184)37-38-74(163)164)157-91(177)73-36-24-50-160(73)96(182)69(35-23-49-142-108(130)131)152-87(173)67(33-21-47-140-106(126)127)150-86(172)66(32-20-46-139-105(124)125)149-85(171)65(31-19-45-138-104(122)123)148-84(170)64(30-18-44-137-103(120)121)147-83(169)63(29-17-43-136-102(118)119)146-82(168)62(28-16-42-135-101(116)117)145-81(167)61(27-15-41-134-100(114)115)144-80(166)60(26-14-40-133-99(112)113)143-79(165)59(109)25-13-39-132-98(110)111/h53-73,75-78,161-162H,11-52,109H2,1-10H3,(H,143,165)(H,144,166)(H,145,167)(H,146,168)(H,147,169)(H,148,170)(H,149,171)(H,150,172)(H,151,180)(H,152,173)(H,153,175)(H,154,178)(H,155,181)(H,156,174)(H,157,177)(H,158,176)(H,159,179)(H,163,164)(H,183,184)(H4,110,111,132)(H4,112,113,133)(H4,114,115,134)(H4,116,117,135)(H4,118,119,136)(H4,120,121,137)(H4,122,123,138)(H4,124,125,139)(H4,126,127,140)(H4,128,129,141)(H4,130,131,142)/t55-,56-,57+,58+,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,75-,76-,77-,78-/m0/s1"	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)N	IEWOQULQWITCAT-CMEOGBNNSA-N
DG01658	NTRC 0066-0	122632882	"NTRC-0066-0; NTRC 0066-0; 1817791-73-3; JGS79C; CHEMBL4449557; SCHEMBL18163318; BDBM532292; US11208696, Example 11; NSC794589; NSC-794589; SB19776; HY-100024; CS-0017983; E77323; N-(2,6-diethylphenyl)-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5,6-dihydropyrimido[4,5-e]indolizine-7-carboxamide; N66"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	565.7	8	C33H39N7O2	87.6	873	5.5	42	2	7	"InChI=1S/C33H39N7O2/c1-5-22-8-7-9-23(6-2)30(22)36-32(41)26-14-15-40-28(26)13-10-24-21-34-33(37-31(24)40)35-27-12-11-25(20-29(27)42-4)39-18-16-38(3)17-19-39/h7-9,11-12,14-15,20-21H,5-6,10,13,16-19H2,1-4H3,(H,36,41)(H,34,35,37)"	CCC1=C(C(=CC=C1)CC)NC(=O)C2=C3CCC4=CN=C(N=C4N3C=C2)NC5=C(C=C(C=C5)N6CCN(CC6)C)OC	HGEIUFJVGHMGRR-UHFFFAOYSA-N
DG01659	EED226	123132228	"EED226; 2083627-02-3; EED-226; N-(Furan-2-Ylmethyl)-8-(4-Methylsulfonylphenyl)-[1,2,4]triazolo[4,3-C]pyrimidin-5-Amine; N-(furan-2-ylmethyl)-8-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine; N-(Furan-2-ylmethyl)-8-(4-(methylsulfonyl)phenyl)[1,2,4]-triazolo[4,3-c]pyrimidin-5-amine; EED 226 monohydrate; CHEMBL4065484; SCHEMBL20867769; BDBM225230; BCP19849; EX-A1724; NSC803408; s8496; AKOS030632048; CCG-268284; CS-6391; NSC-803408; SB40406; AC-29879; AS-74203; BE165158; HY-101117; J3.609.221A; A901401; N-(Furan-2-ylmethyl)-8-(4-(methylsulfonyl)phenyl)[1,2,4]-triazolo[4,3-c]pyrimidin-5-amine;MAK683; N-[(furan-2-yl)methyl]-8-(4-methanesulfonylphenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	369.4	5	C17H15N5O3S	111	575	2.3	26	1	7	"InChI=1S/C17H15N5O3S/c1-26(23,24)14-6-4-12(5-7-14)15-10-19-17(22-11-20-21-16(15)22)18-9-13-3-2-8-25-13/h2-8,10-11H,9H2,1H3,(H,18,19)"	CS(=O)(=O)C1=CC=C(C=C1)C2=CN=C(N3C2=NN=C3)NCC4=CC=CO4	DYIRSNMPIZZNBK-UHFFFAOYSA-N
DG01660	JBJ-04-125-02	124173751	"JBJ-04-125-02; (2R)-2-(5-fluoro-2-hydroxyphenyl)-2-{1-oxo-6-[4-(piperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindol-2-yl}-N-(1,3-thiazol-2-yl)acetamide; 2060610-53-7; (2R)-2-(5-fluoro-2-hydroxyphenyl)-2-[3-oxo-5-(4-piperazin-1-ylphenyl)-1H-isoindol-2-yl]-N-(1,3-thiazol-2-yl)acetamide; SCHEMBL18360815; BCP32863; EX-A4047; HY-135805; CS-0114212"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	543.6	6	C29H26FN5O3S	126	870	3.8	39	3	8	"InChI=1S/C29H26FN5O3S/c30-21-5-8-25(36)24(16-21)26(27(37)33-29-32-11-14-39-29)35-17-20-2-1-19(15-23(20)28(35)38)18-3-6-22(7-4-18)34-12-9-31-10-13-34/h1-8,11,14-16,26,31,36H,9-10,12-13,17H2,(H,32,33,37)/t26-/m1/s1"	C1CN(CCN1)C2=CC=C(C=C2)C3=CC4=C(CN(C4=O)[C@H](C5=C(C=CC(=C5)F)O)C(=O)NC6=NC=CS6)C=C3	VHQVOTINPRYDAO-AREMUKBSSA-N
DG01661	SEL201	129052025	SLV-2436; 2095704-43-9; SEL-201; CID 129052025; CHEMBL4764756; 5-(3-Amino-1H-indazol-6-yl)-1-[(3-chlorophenyl)methyl]pyridin-2-one; SEL201; SCHEMBL18764462; SLV2436; BCP29427; SLV 2436; VID70443; BDBM50562615; s6888; SEL201-88; BS-15825; HY-112113; CS-0043363; D80426; 5-(3-amino-1H-indazol-6-yl)-1-(3-chlorobenzyl)pyridin-2(1H)-one; SLV 2436 pound>>SLV2436 pound>>SEL201-88; SEL-201 pound>>SEL201 88; SEL 201 pound>>SEL20188; SEL201	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	350.8	3	C19H15ClN4O	75	578	3	25	2	3	"InChI=1S/C19H15ClN4O/c20-15-3-1-2-12(8-15)10-24-11-14(5-7-18(24)25)13-4-6-16-17(9-13)22-23-19(16)21/h1-9,11H,10H2,(H3,21,22,23)"	C1=CC(=CC(=C1)Cl)CN2C=C(C=CC2=O)C3=CC4=C(C=C3)C(=NN4)N	YQVUADHJKWJHAF-UHFFFAOYSA-N
DG01662	RMC-4550	134183206	"RMC-4550; 2172651-73-7; UNII-2Q6NVG4EXB; 2Q6NVG4EXB; CHEMBL4752026; (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl)methanol; [3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl]methanol; {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl}methanol; 2-Pyrazinemethanol, 3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro(4.5)dec-8-yl)-6-(2,3-dichlorophenyl)-5-methyl-; 2-Pyrazinemethanol, 3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-6-(2,3-dichlorophenyl)-5-methyl-; SCHEMBL19785503; RMC-4550 (SHP2 Inhibitor); AMY16974; EX-A3075; XLD65173; BDBM50546219; MFCD31746888; s8718; ZB1559; AKOS037648879; AC-31540; BS-15923; HY-116009; CS-0063450; D70060; A929920; [3-[(3S,4S)-4-AMINO-3-METHYL-2-OXA-8-AZASPIRO[4.5]DECAN-8-YL]-6-(2,3-DICHLOROPHENYL)-5-METHYL-PYRAZIN-2-YL]METHANOL"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	437.4	3	C21H26Cl2N4O2	84.5	563	2.5	29	2	6	"InChI=1S/C21H26Cl2N4O2/c1-12-18(14-4-3-5-15(22)17(14)23)26-16(10-28)20(25-12)27-8-6-21(7-9-27)11-29-13(2)19(21)24/h3-5,13,19,28H,6-11,24H2,1-2H3/t13-,19+/m0/s1"	C[C@H]1[C@H](C2(CCN(CC2)C3=NC(=C(N=C3CO)C4=C(C(=CC=C4)Cl)Cl)C)CO1)N	IKUYEYLZXGGCRD-ORAYPTAESA-N
DG01663	Necitumumab	135263756	SCHEMBL20425500	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	DB09559	.	.	467.5	8	C26H21N5O4	119	828	2.9	35	1	7	"InChI=1S/C26H21N5O4/c1-4-26(33)30-19-8-18(9-21(10-19)34-3)24-11-22-23(17-5-6-28-20(7-17)12-27)14-31(15-35-16(2)32)25(22)13-29-24/h4-11,13-14H,1,15H2,2-3H3,(H,30,33)"	CC(=O)OCN1C=C(C2=CC(=NC=C21)C3=CC(=CC(=C3)OC)NC(=O)C=C)C4=CC(=NC=C4)C#N	HGDHLYSCURABOE-UHFFFAOYSA-N
DG01664	Cixutumumab	135338442	SCHEMBL20511307	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB12250	.	.	528.5	6	C29H25FN4O5	106	947	5.1	39	1	8	"InChI=1S/C29H25FN4O5/c1-3-7-23(35)33-16-5-4-8-20(33)28-32-25(27-26(29(36)37)31-15-17-34(27)28)18-11-13-19(14-12-18)39-22-10-6-9-21(38-2)24(22)30/h6,9-15,17,20H,4-5,8,16H2,1-2H3,(H,36,37)/t20-/m0/s1"	CC#CC(=O)N1CCCC[C@H]1C2=NC(=C3N2C=CN=C3C(=O)O)C4=CC=C(C=C4)OC5=CC=CC(=C5F)OC	BPGVVRUPKNFLHW-FQEVSTJZSA-N
DG01666	XAV939	135418940	"XAV-939; 284028-89-3; XAV939; XAV 939; 3,5,7,8-Tetrahydro-2-[4-(trifluoromethyl)phenyl]-4H-thiopyrano[4,3-d]pyrimidin-4-one; 2-[4-(trifluoromethyl)phenyl]-1,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidin-4-one; CHEBI:62878; C14H11F3N2OS; CHEMBL1086580; CID 2726824; 2-(4-(trifluoromethyl)phenyl)-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-4-ol; 2-[4-(trifluoromethyl)phenyl]-7,8-dihydro-5H-thiino[4,3-d]pyrimidin-4-ol; 2-[4-(Trifluoromethyl)phenyl]-7,8-Dihydro-5h-Thiopyrano[4,3-D]pyrimidin-4-Ol; NVP-XAV-939; 2-(4-(trifluoromethyl)phenyl)-7,8-dihydro-3H-thiopyrano[4,3-d]pyrimidin-4(5H)-one; NVP-XAV 939; XAV; MFCD16879017; 3kr8; 3uh4; Maybridge3_005018; NVP-XAV939; MLS006012021; SCHEMBL7783488; TB3748-GMP; SCHEMBL15315468; AOB4150; DTXSID60369423; XAV939,XAV-939; BCPP000009; HMS1445E02; HMS3414D07; HMS3648B17; HMS3654O16; HMS3678D07; HMS3743E05; BCP02128; EX-A1760; BDBM50188594; BDBM50318567; NSC755761; s1180; ZINC13467799; AKOS015954858; AKOS024457786; AKOS026750243; CCG-208105; CS-0494; MCULE-6143908878; NSC-755761; SB19432; IDI1_016405; NCGC00250397-01; NCGC00484998-01; AC-28393; CS-10386; HY-15147; SMR003874205; XAV939, >=98% (HPLC); DB-067924; FT-0675873; SW218311-2; X7558; A25698; SR-01000946403; J-511234; SR-01000946403-1; BRD-K12762134-001-01-3; BRD-K12762134-001-05-4; Q27132250; 6,8-Dihydro-2-[4-(trifluoromethyl)phenyl]-5H-thiopyrano[3,4-d]pyrimidine; 2-(4-(trifluoromethyl)phenyl)-7,8-dihydro-1H-thiopyrano[4,3-d]pyrimidin-4(5H)-one; 2-(4-(Trifluoromethyl)phenyl)-7,8-dihydro-5H-thiopyrano-[4,3-d]pyrimidin-4-ol; 2-[4-(trifluoromethyl)phenyl]-1H,4H,5H,7H,8H-thiopyrano[4,3-d]pyrimidin-4-one"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	312.31	1	C14H11F3N2OS	66.8	505	2.3	21	1	6	"InChI=1S/C14H11F3N2OS/c15-14(16,17)9-3-1-8(2-4-9)12-18-11-5-6-21-7-10(11)13(20)19-12/h1-4H,5-7H2,(H,18,19,20)"	C1CSCC2=C1N=C(NC2=O)C3=CC=C(C=C3)C(F)(F)F	KLGQSVMIPOVQAX-UHFFFAOYSA-N
DG01667	SB590885	135421339	"SB590885; 405554-55-4; SB-590885; 5-(2-(4-(2-(dimethylamino)ethoxy)phenyl)-5-(pyridin-4-yl)-1H-imidazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime; SB 590885; (NE)-N-[5-[2-[4-[2-(dimethylamino)ethoxy]phenyl]-5-pyridin-4-yl-1H-imidazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine; (E)-5-(2-(4-(2-(dimethylamino)ethoxy)phenyl)-5-(pyridin-4-yl)-1H-imidazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime; (E)-SB-590885; (Z)-SB-590885; SCHEMBL131578; CHEMBL477989; SCHEMBL12518520; SCHEMBL16111665; SCHEMBL17378611; EX-A612; CHEBI:131881; BCPP000070; 1H-Inden-1-one, 5-[2-[4-[2-(dimethylamino)ethoxy]phenyl]-5-(4-pyridinyl)-1H-imidazol-4-yl]-2,3-dihydro-, oxime; 5-[2-[4-[2-(Dimethylamino)ethoxy]phenyl]-5-(4-pyridinyl)-1H-imidazol-4-yl]-2,3-dihydro-1H-inden-1-one oxime; AMY20674; BDBM50457452; NSC754362; NSC756456; s2220; SB-590885 (RAF); ZINC100061199; CCG-264947; NSC-754362; NSC-756456; (E)--(2-(dimethylamino)ethoxy)phenyl)-5-(pyridin-4-yl)-1H-imidazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime; (E)-SB590885; AS-16232; (E)-SB 590885; A25514; J-501805; BRD-K78809024-001-05-7; Q27120375; Q27225284; (1E)-N-{5-[2-{4-[2-(dimethylamino)ethoxy]phenyl}-4-(pyridin-4-yl)-1H-imidazol-5-yl]-2,3-dihydro-1H-inden-1-ylidene}hydroxylamine; 5-[2-[4-[2-(Dimethylamino)ethoxy]phenyl]-5-(4-pyridinyl)-1H-imidazol-4-yl]-2,3-dihydro-1H-inden-1-one oxime;SB-590885"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	453.5	7	C27H27N5O2	86.6	674	4	34	2	6	"InChI=1S/C27H27N5O2/c1-32(2)15-16-34-22-7-3-19(4-8-22)27-29-25(18-11-13-28-14-12-18)26(30-27)21-5-9-23-20(17-21)6-10-24(23)31-33/h3-5,7-9,11-14,17,33H,6,10,15-16H2,1-2H3,(H,29,30)/b31-24+"	CN(C)CCOC1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC5=C(C=C4)/C(=N/O)/CC5	MLSAQOINCGAULQ-QFMPWRQOSA-N
DG01668	AUY922	135539077	"Luminespib; NVP-AUY922; 747412-49-3; AUY922; VER-52296; AUY-922; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide; AUY922 (NVP-AUY922); Luminespib (NVP-AUY922); UNII-C6V1DAR5EB; Luminespib (AUY-922 ); VER 52296; NVP-AUY 922; C6V1DAR5EB; Luminespib (AUY-922, NVP-AUY922); 5-[2,4-DIHYDROXY-5-ISOPROPYLPHENYL]-N-ETHYL-4-[4-(4-MORPHOLINYLMETHYL)PHENYL]-3-ISOXAZOLECARBOXAMIDE; CHEMBL3900791; CHEBI:83656; 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide; 5-[2,4-Dihydroxy-5-(1-methylethyl)phenyl]-N-ethyl-4-[4-(4-morpholinylmethyl)phenyl]-3-isoxazolecarboxamide; 5-[2,4-Dihydroxy-5-(1-Methylethyl)phenyl]-N-Ethyl-4-[4-(Morpholin-4-Ylmethyl)phenyl]isoxazole-3-Carboxamide; Luminespib [USAN:INN]; NVR-AUY 922; Isoxazole, 40f; 2GJ; VER-52296/NVP-AUY922; Luminespib (USAN/INN); Luminespib; NVP-AUY922; NVP-AUY922-NX; MLS006011081; NVP-AUY-922; SCHEMBL892205; CHEMBL252164; GTPL9261; SCHEMBL2682235; AUY922,NVP-AUY922; LUMINESPIB(NVP-AUY922); NVP-AUY922, LUMINESPIB; BDBM20926; CHEBI:91422; EX-A611; QCR-179; BCPP000145; HMS3295K23; HMS3654C15; AOB87330; AUY922 - NVP-AUY922; BCP01827; BDBM50274536; MFCD14635361; NSC755762; s1069; ZINC14974931; AKOS015966502; AKOS026750297; ZINC100015656; ZINC109565971; BCP9001007; CCG-264804; CS-0136; NSC-755762; SB16640; NCGC00247878-01; NCGC00387853-03; 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide; AC-33144; AS-17014; HY-10215; SMR004702869; A9562; FT-0700359; SW219319-1; X7556; CAS:747412-49-3;NVP-AUY922; D10646; 412D493; J-516600; BRD-K41859756-001-01-9; Q10859697; Q27082304; Q27163272; AUY922; VER-52296; AUY 922; VER 52296; AUY-922; VER-52296; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide; 5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide; AUY-922; ; ; NVP-AUY922; ; ; VER-52296; ; ; (5Z)-N-Ethyl-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-[4-(morpholin-4-ylmethyl)phenyl]-2H-1,2-oxazole-3-carboxamide; N-ethyl-5-(4-hydroxy-6-oxo-3-propan-2-yl-1-cyclohexa-2,4-dienylidene)-4-[4-(4-morpholinylmethyl)phenyl]-2H-isoxazole-3-carboxamide"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:83656	DB11881	.	DR00742	465.5	7	C26H31N3O5	108	650	3.5	34	3	7	"InChI=1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32)"	CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C	NDAZATDQFDPQBD-UHFFFAOYSA-N
DG01669	Ganetespib	135564985	"Ganetespib; 888216-25-9; Ganetespib (STA-9090); STA-9090; STA9090; STA 9090; UNII-2E8412Y946; 5-[2,4-Dihydroxy-5-(1-methylethyl)phenyl]-2,4-dihydro-4-(1-methyl-1H-indol-5-yl)-3H-1,2,4-triazol-3-one; 2E8412Y946; 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one; (5Z)-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-(1-methylindol-5-yl)-1,2,4-triazolidin-3-one; 4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol; 5-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-4-(1-methyl-1H-indol-5-yl)-2,4-dihydro-3H- 1,2,4-triazol-3-one; 5-[2,4-Dihydroxy-5-(Propan-2-Yl)phenyl]-4-(1-Methyl-1h-Indol-5-Yl)-2,4-Dihydro-3h-1,2,4-Triazol-3-One; Ganetespib [USAN:INN]; Genetespib; 5-(2,4-Dihydroxy-5-(1-methylethyl)phenyl)-4-(1-methyl-1H-indol-5-yl)-2,4-dihydro-3H- 1,2,4-triazol-3-one; Ganetespib (USAN); Ganetespib,STA-9090; Ganetespib (STA9090); Ganetespib(STA-9090); Ganetespib - STA-9090; SCHEMBL419750; CHEMBL2103879; EX-A250; QCR-148; CHEBI:177770; HMS3654K12; HMS3673E09; AMY16782; AOB87158; BCP22669; 2422AH; BDBM50439621; MFCD22420818; NSC765435; NSC777169; s1159; ZINC43130413; AKOS026750420; AKOS032947228; ZINC109565954; ZINC109565957; CCG-268213; CS-0697; DB12047; NSC-765435; NSC-777169; SB16526; 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4]triazole; NCGC00346678-01; NCGC00346678-04; AC-32480; AS-35117; HY-15205; BCP0726000115; A4385; FT-0700397; SW220253-1; D10126; STA-9090; STA9090; STA 9090; Q27254612; 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(N-methyl-indol-5-yl)-5-hydroxy-[1,2,4]triazole; 2,4-Dihydro-5-[2,4-dihydroxy-5-isopropylphenyl]-4-(1-methyl-1H-indol-5-yl)-3H-1,2,4-triazol-3-one; 3-(2,4-Dihydroxy-5-isopropylphenyl)-4-(1-methyl-1H-indol-5-yl)-1H-1,2,4-triazol-5(4H)-one; 3-[2,4-Dihydroxy-5-(propan-2-yl)phenyl]-4-(1-methyl-1H-indol-5-yl)-4,5-dihydro-1H-1,2,4-triazol-5-one; 3H-1,2,4-Triazol-3-one, 5-(2,4-dihydroxy-5-(1-methylethyl)phenyl)-2,4-dihydro-4-(1- methyl-1H-indol-5-yl)-"	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	.	DB12047	.	.	364.4	3	C20H20N4O3	90.1	610	3.1	27	3	4	"InChI=1S/C20H20N4O3/c1-11(2)14-9-15(18(26)10-17(14)25)19-21-22-20(27)24(19)13-4-5-16-12(8-13)6-7-23(16)3/h4-11,25-26H,1-3H3,(H,22,27)"	CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)O	RVAQIUULWULRNW-UHFFFAOYSA-N
DG01670	Talazoparib	135565082	"Talazoparib; 1207456-01-6; BMN-673; BMN673; BMN 673; Talzenna; Talazoparib (BMN 673); UNII-9QHX048FRV; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one; LT-673; 9QHX048FRV; (8s,9r)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1h-1,2,4-Triazol-5-Yl)-2,7,8,9-Tetrahydro-3h-Pyrido[4,3,2-De]phthalazin-3-One; (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one; (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazine-3-one; Talazoparib [USAN:INN]; BMN-673 8R,9S; 4pjt; 2YQ; Talazoparib(BMN-673); Talazoparib (USAN/INN); Talazoparib (BMN-673); 3H-Pyrido(4,3,2-de)phthalazin-3-one, 5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-, (8S,9R)-; GTPL8313; SCHEMBL2299348; CHEMBL3137320; AOB5705; BMN673,BMN-673; AMY27900; EX-A1356; BDBM50084621; MFCD22666357; NSC767125; ZINC72318110; ZINC138126699; CS-0937; DB11760; NSC-767125; QC-4556; NCGC00390231-01; AC-30927; AS-57491; HY-16106; LT 00673; S7048; SW219655-1; X5821; D10732; A892079; Q25100990; Q27453411; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one;BMN-673"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11760	.	DR00366	380.4	2	C19H14F2N6O	84.2	654	2.3	28	2	7	"InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1"	CN1C(=NC=N1)[C@@H]2[C@H](NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F	HWGQMRYQVZSGDQ-HZPDHXFCSA-N
DG01671	BI-847325	135567102	"BI-847325; 1207293-36-4; BI 847325; QXD8ZW7UVZ; UNII-QXD8ZW7UVZ; (Z)-3-(3-(((4-((dimethylamino)methyl)phenyl)amino)(phenyl)methylene)-2-oxoindolin-6-yl)-N-ethylpropiolamide; BI847325; 3-(3-(((4-((Dimethylamino)methyl)phenyl)amino)(phenyl)methylene)-2-oxoindolin-6-yl)-N-ethylpropiolamide; 3-[(3~{z})-3-[[[4-[(Dimethylamino)methyl]phenyl]amino]-Phenyl-Methylidene]-2-Oxidanylidene-1~{h}-Indol-6-Yl]-~{n}-Ethyl-Prop-2-Ynamide; (Z)-3-(3-((4-((dimethylamino)methyl)phenylamino)(phenyl)methylene)-2-oxoindolin-6-yl)-N-ethylpropiolamide; 2128698-24-6; 3-(3-(((4-((Dimethylamino)methyl)phenyl)amino)phenylmethylene)-2,3-dihydro-2-oxo-1H-indol-6-yl)-N-ethyl-2-propynamide; 3-[3-[[[4-[(Dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-6-yl]-N-ethyl-2-propynamide; 5U5; SCHEMBL4081822; CHEMBL3699142; CHEMBL4303500; SCHEMBL10326049; BDBM142744; BCP15994; EX-A1727; NSC799360; s7843; AKOS030238788; ZINC143989489; ZINC143989696; CCG-269395; CS-6291; NSC-799360; SB23246; NCGC00481575-01; AC-29870; AS-56076; HY-18955; US8937095, 6; Q27456034; 2-Propynamide, 3-((3Z)-3-(((4-((dimethylamino)methyl)phenyl)amino)phenylmethylene)-2,3-dihydro-2-oxo-1H-indol-6-yl)-N-ethyl-; 2-Propynamide, 3-(3-(((4-((dimethylamino)methyl)phenyl)amino)phenylmethylene)-2,3-dihydro-2-oxo-1H-indol-6-yl)-N-ethyl-; 3-((3Z)-3-((4-(Dimethylaminomethyl)anilino)-phenyl-methylene)-2-oxo-indolin-6-yl)-N-ethyl-prop-2-ynamide; 3-[(3Z)-3-[({4-[(dimethylamino)methyl]phenyl}amino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indol-6-yl]-N-ethylprop-2-ynamide; 3-[3-[N-[4-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-1H-indol-6-yl]-N-ethylprop-2-ynamide"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	.	.	.	464.6	7	C29H28N4O2	80.7	798	5.3	35	3	4	"InChI=1S/C29H28N4O2/c1-4-30-26(34)17-13-20-12-16-24-25(18-20)32-29(35)27(24)28(22-8-6-5-7-9-22)31-23-14-10-21(11-15-23)19-33(2)3/h5-12,14-16,18,32,35H,4,19H2,1-3H3,(H,30,34)"	CCNC(=O)C#CC1=CC2=C(C=C1)C(=C(N2)O)C(=NC3=CC=C(C=C3)CN(C)C)C4=CC=CC=C4	OCUQMWSIGPQEMX-UHFFFAOYSA-N
DG01672	Folfox protocol	135659064	Folfox protocol; Folfox regimen; FOLFOX-4 protocol; FOLFOX-6 protocol; FOLFOX-7 protocol; Folfox; FOLFOX-4; FOLFOX-6; FOLFOX-7; C410216000; Fluorouracil regimen with leucovorin calcium and oxaliplatin	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	998.8	9	C34H42FN9O13Pt	348	1290	.	58	11	19	"InChI=1S/C20H23N7O7.C8H14.C4H3FN2O2.C2H2O4.Pt/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30;1-7-5-3-4-6-8(7)2;5-2-1-6-4(9)7-3(2)8;3-1(4)2(5)6;/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32);7-8H,1-6H2;1H,(H2,6,7,8,9);(H,3,4)(H,5,6);/q;-2;;;+2/t12 ,13-;7-,8-;;;/m01.../s1"	[CH2-][C@@H]1CCCC[C@H]1[CH2-].C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O.C1=C(C(=O)NC(=O)N1)F.C(=O)(C(=O)O)O.[Pt+2]	YXTKHLHCVFUPPT-YYFJYKOTSA-N
DG01673	MRT-92	136235465	"MRT-92; CHEMBL4302587; SCHEMBL14809192; GTPL10332; 3,4,5-trimethoxy-N-[N'-[4-methyl-3-[[4-(2-phenylethyl)benzoyl]amino]phenyl]carbamimidoyl]benzamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	566.6	11	C33H34N4O5	124	872	6.1	42	3	6	"InChI=1S/C33H34N4O5/c1-21-10-17-26(35-33(34)37-32(39)25-18-28(40-2)30(42-4)29(19-25)41-3)20-27(21)36-31(38)24-15-13-23(14-16-24)12-11-22-8-6-5-7-9-22/h5-10,13-20H,11-12H2,1-4H3,(H,36,38)(H3,34,35,37,39)"	CC1=C(C=C(C=C1)N=C(N)NC(=O)C2=CC(=C(C(=C2)OC)OC)OC)NC(=O)C3=CC=C(C=C3)CCC4=CC=CC=C4	TVUOHEUCOWBVRU-UHFFFAOYSA-N
DG01674	NVP-TNKS656	136237316	"NVP-TNKS656; 1419949-20-4; TNKS656; NVP-TNKS-656; TNKS-656; CHEMBL2419706; N-(cyclopropylmethyl)-2-[4-(4-methoxybenzoyl)piperidin-1-yl]-N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide; N-(Cyclopropylmethyl)-2-(4-(4-methoxybenzoyl)piperidin-1-yl)-N-((4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrimidin-2-yl)methyl)acetamide; N-(cyclopropylmethyl)-2-[4-(4-methoxybenzoyl)piperidin-1-yl]-N-({4-oxo-3H,4H,5H,7H,8H-pyrano[4,3-d]pyrimidin-2-yl}methyl)acetamide; NVPTNKS656; TNK-S656; TNKS 656; SCHEMBL14638273; SCHEMBL21843258; GTPL10674; BCP28685; EX-A2627; BDBM50439791; ZINC96283562; AKOS027323458; CCG-269654; example 5 [WO2013012723A1]; compound 43 [PMID: 23844574]; NCGC00390606-01; NCGC00390606-02; AC-33044; AS-75191; HY-13990; S7238; C72648; A901730; N-(Cyclopropylmethyl)-2-(4-(4-methoxybenzoyl)piperidin-1-yl)-N-((4-oxo-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-2-yl)methyl)acetamide; N-(cyclopropylmethyl)-2-[4-(4-methoxybenzoyl)piperidin-1-yl]-N-[(4-oxo-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide; N-Cyclopropylmethyl-2-[4-(4-methoxy-benzoyl)-piperidin-1-yl]-N-(4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrimidin-2-ylmethyl)-acetamide"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	494.6	9	C27H34N4O5	101	911	1.1	36	1	7	"InChI=1S/C27H34N4O5/c1-35-21-6-4-19(5-7-21)26(33)20-8-11-30(12-9-20)16-25(32)31(14-18-2-3-18)15-24-28-23-10-13-36-17-22(23)27(34)29-24/h4-7,18,20H,2-3,8-17H2,1H3,(H,28,29,34)"	COC1=CC=C(C=C1)C(=O)C2CCN(CC2)CC(=O)N(CC3CC3)CC4=NC5=C(COCC5)C(=O)N4	DYGBNAYFDZEYBA-UHFFFAOYSA-N
DG01675	AMGMDS3	139033635	AMGMDS3; Q59770979	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	506.4	9	C26H29Cl2NO5	83.9	749	5.3	34	1	5	"InChI=1S/C26H29Cl2NO5/c1-4-20(25(33)34-5-2)29-21(30)14-26(3,15-22(31)32)23(16-8-6-10-18(27)12-16)24(29)17-9-7-11-19(28)13-17/h6-13,20,23-24H,4-5,14-15H2,1-3H3,(H,31,32)/t20-,23+,24+,26-/m0/s1"	CC[C@@H](C(=O)OCC)N1[C@@H]([C@H]([C@](CC1=O)(C)CC(=O)O)C2=CC(=CC=C2)Cl)C3=CC(=CC=C3)Cl	SZACTBIUKXKQGM-YLJDOISLSA-N
DG01676	BEZ235/Ruxolitinib	.	BEZ235/Ruxolitinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01677	Bevacizumab/FOLFIRI Regimen	.	Bevacizumab/FOLFIRI Regimen	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01678	Omipalisib/Trametinib	.	Omipalisib/Trametinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01679	Ibrutinib/Ruxolitinib	.	Ibrutinib/Ruxolitinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01680	AEB071/Binimetinib	.	AEB071/Binimetinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01681	PI3K pathway inhibitors/MEK inhibitors	.	PI3K pathway inhibitors/MEK inhibitors	Preclinical	14	Preclinical Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01682	Letrozole/Ribociclib	.	Letrozole/Ribociclib	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01683	Alpelisib/Binimetinib	.	Alpelisib/Binimetinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01684	Cetuximab/Trametinib	.	Cetuximab/Trametinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01685	Everolimus/Binimetinib	.	Everolimus/Binimetinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01686	Pimasertib/Regorafenib	.	Pimasertib/Regorafenib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01687	Selumetinib/Dactolisib	.	Selumetinib/Dactolisib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01688	Sirolimus/Trametinib	.	Sirolimus/Trametinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01689	Everolimus/Selumetinib	.	Everolimus/Selumetinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01690	Binimetinib/Everolimus	.	Binimetinib/Everolimus	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01691	AZD-8055/Binimetinib	.	AZD8055/Binimetinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01692	Alpelisib/Fulvestrant	.	Alpelisib/Fulvestrant	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01693	Buparlisib/Paclitaxel	.	Buparlisib/Paclitaxel	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01694	Pictilisib/Sorafenib	.	Pictilisib/Sorafenib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01695	Cisplatin/Pictilisib	.	Cisplatin/Pictilisib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01696	Gemcitabine/LY2780301	.	Gemcitabine/LY2780301	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01697	PD-0325901/Pictilisib	.	PD-0325901/Pictilisib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01698	AZD5363/Trastuzumab	.	AZD5363/Trastuzumab	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01699	MK2206/Temsirolimus	.	MK2206/Temsirolimus	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01700	Bevacizumab/Temsirolimus	.	Bevacizumab/Temsirolimus	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01701	BRAF/MEK inhibitors	.	BRAF/MEK inhibitors	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01702	Panitumumab/Trametinib	.	Panitumumab/Trametinib	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01703	G007-LK/Imatinib	.	G007-LK/Imatinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01704	Infigratinib/Imatinib	.	Infigratinib/Imatinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01705	Bevacizumab/Sorafenib	.	Bevacizumab/Sorafenib	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01706	AGI-5198/Talazoparib	.	AGI-5198/Talazoparib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01707	AGI-5198/Olaparib	.	AGI-5198/Olaparib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01708	Cisplatin/Talazoparib	.	Cisplatin/Talazoparib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01709	AGI-5198/Metformin	.	AGI-5198/Metformin	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01710	Temozolomide/Vandetanib	.	Temozolomide/Vandetanib	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01711	Crenolanib/Trametinib	.	Crenolanib/Trametinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01712	Cytarabine/Daunorubicin/Midostaurin	.	Cytarabine/Daunorubicin/Midostaurin	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01713	Azacitidine/Sorafenib	.	Azacitidine/Sorafenib	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01714	ACY-957/GSK126	.	ACY-957/GSK126	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01715	ACY-957/DZNEP	.	ACY-957/DZNeP	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01716	AZD3463/Doxorubicin	.	AZD3463/Doxorubicin	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01717	BRAF inhibitors/MEK inhibitors/Anti-EGFR mAb	.	BRAF inhibitors/MEK inhibitors or anti-EGFR mAb	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01718	Docetaxel/Selumetinib	.	Docetaxel/Selumetinib	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01719	Irinotecan/Selumetinib	.	Irinotecan/Selumetinib	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01720	Gemcitabine/Trametinib	.	Gemcitabine/Trametinib	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01721	Dactolisib/Selumetinib	.	Dactolisib/Selumetinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01722	MK-2206/PD184352	.	MK-2206/PD184352	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01723	LY-294002/Capivasertib	.	LY-294002/Capivasertib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01724	Ruxolitinib/SGI-1776	.	Ruxolitinib/SGI-1776	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01725	AZD1208/Ruxolitinib	.	AZD1208/Ruxolitinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01726	Ruxolitinib/ZSTK474	.	Ruxolitinib/ZSTK474	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01727	JQ1/Osimertinib	.	JQ1/Osimertinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01728	EGFR TKIs	.	EGFR TKIs	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01729	Unspecified CTLA4 antibody/Unspecified PD-1 antibody	.	Unspecified CTLA4 antibody/unspecified PD-1 antibody	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01730	Cabozantinib/Erlotinib	.	Cabozantinib/Erlotinib	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01731	Bevacizumab/Gefitinib	.	Bevacizumab/Gefitinib	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01732	Osimertinib/Selumetinib	.	Osimertinib/Selumetinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01733	Buparlisib/Osimertinib	.	Buparlisib/Osimertinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01734	Bevacizumab/Erlotinib	.	Bevacizumab/Erlotinib	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01735	Trametinib/WZ4002	.	Trametinib/WZ4002	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01736	Erlotinib/Ganetespib	.	Erlotinib/Ganetespib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01737	APR-246/Cisplatin	.	APR-246/Cisplatin	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01738	Dabrafenib/Trametinib	.	Dabrafenib/Trametinib	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01739	Vemurafenib/Cobimetinib	.	Vemurafenib/Cobimetinib	Phase 3	5	Clinical Trial Drug(s)	Phase 3	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01740	Binimetinib/Encorafenib	.	Binimetinib/Encorafenib	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01741	Panitumumab/Dabrafenib/Trametinib	.	Panitumumab/Dabrafenib/Trametinib	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01742	Binimetinib/Cetuximab/Encorafenib	.	Binimetinib/Cetuximab/Encorafenib	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01743	Cobimetinib/Vemurafenib	.	Cobimetinib/Vemurafenib	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01744	Encorafenib/Trametinib	.	Encorafenib/Trametinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01745	Trametinib/Dabrafenib	.	Trametinib/Dabrafenib	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01747	Encorafenib/Cetuximab	.	Encorafenib/Cetuximab	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01748	Palbociclib/PD-0325901	.	Palbociclib/PD-0325901	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01749	Cetuximab/Selumetinib	.	Cetuximab/Selumetinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01750	Alpelisib/Cetuximab/Encorafenib	.	Alpelisib/Cetuximab/Encorafenib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01751	Dasatinib/Trametinib	.	Dasatinib/Trametinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01752	Dasatinib/SCH772984	.	Dasatinib/SCH772984	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01753	Everolimus/PLX4720	.	Everolimus/PLX4720	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01754	Dabrafenib/Trametinib/Vemurafenib	.	Dabrafenib/Trametinib/Vemurafenib	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01755	Trametinib/Vemurafenib	.	Trametinib/Vemurafenib	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01756	Cediranib/PLX4720	.	Cediranib/PLX4720	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01757	Navitoclax/Trametinib	.	Navitoclax/Trametinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01758	Ganetespib/TAK-733	.	Ganetespib/TAK-733	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01759	Selumetinib/Vemurafenib	.	Selumetinib/Vemurafenib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01760	Buparlisib/Vemurafenib	.	Buparlisib/Vemurafenib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01761	MK2206/Vemurafenib	.	MK2206/Vemurafenib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01762	PLX4720/Pictilisib	.	PLX4720/Pictilisib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01763	Vemurafenib/Capecitabine/Bevacizumab	.	Vemurafenib/Capecitabine/Bevacizumab	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01764	Futuximab	.	Futuximab	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01765	EGFR inhibitors	.	EGFR inhibitors	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01766	"1,2-Dichloroethane"	11	"1,2-dichloroethane; Ethylene dichloride; 107-06-2; Ethylene chloride; Ethane, 1,2-dichloro-; Glycol dichloride; Dichloroethylene; Dutch liquid; Dutch oil; Ethane dichloride; Aethylenchlorid; Dichloro-1,2-ethane; Dichloremulsion; 1,2-Dichlorethane; Brocide; 1,2-Ethylene dichloride; Bichlorure D'ethylene; Borer sol; Di-chlor-mulsion; 1,2-DCE; Freon 150; sym-Dichloroethane; alpha,beta-Dichloroethane; EDC (halocarbon); Destruxol borer-sol; 1,2-Bichloroethane; Ethyleendichloride; Cloruro di ethene; Rcra waste number U077; 1,2-Dicloroetano; Chlorure D'ethylene; 1,2-Dichloorethaan; DCE; 1,2-Dichlor-aethan; 1, 2-dichloroethane; Aethylendichlorid; s-Dichloroethane; HCC 150; ethylenedichloride; NCI-C00511; EDC; ENT 1,656; 1,2-Dichloraethan; 1.2-dichloroethane; UNII-55163IJI47; 1,2-Dichloro-Ethane; MFCD00000963; .alpha.,.beta.-Dichloroethane; CHEBI:27789; Ethane, 1,2-dichloro-, homopolymer; 55163IJI47; Dichlor-Mulsion; Caswell No. 440; Aethylenchlorid [German]; RY Dichloro-1,2-ethane; Ethyleendichloride [Dutch]; 1,2-Ethylidene dichloride; 1,2-Dichloroethane, analytical standard; Cloruro di ethene [Italian]; 29561-65-7; HSDB 65; 1,2-Dichloorethaan [Dutch]; 1,2-Dicloroetano [Italian]; CCRIS 225; Chlorure d'ethylene [French]; 1,2 dichloroethane; 1,2-Dichlor-aethan [German]; Bichlorure d'ethylene [French]; Dichlorure d'ethylene; Dichloro-1,2-ethane [French]; ClCH2CH2Cl; Ethylene dichloride [BSI:ISO]; 1,2-Dichloroethane 100 microg/mL in Methanol; Dichlorure d'ethylene [ISO-French]; EINECS 203-458-1; UN1184; RCRA waste no. U077; EPA Pesticide Chemical Code 042003; ethylenechloride; ethylendichloride; AI3-01656; alpha,Bet; dichloro ethylene; ethylene-chloride; ethylene dichoride; 1,2-DICHLOROETHANE, ACS; 1,2dichlorethane; Ethylen dichloride; 1,2dichloroethane; ehtylene dichloride; 1,2 dichlorethane; 1,2 dichoroethane; 1,2-dichloroetane; 1,2-dichloroethan; 1,2-dichoroethane; 1,2-dicloroethane; 1,2-dichioroethane; 1,2-dichloroetharie; 1 ,2-dichloroethane; 1, 2 dichloroethane; 1,2 -dichloroethane; 1,2 dichloro ethane; 1,2,-dichloroethane; 1,2- dichloroethane; 1,2-di-chloroethane; 1,2-dichloro ethane; 1.2-di-chloroethane; CH2ClCH2Cl; 1,2-ethylenedichloride; ClCH2-CH2Cl; dichloro-1, 2-ethane; C1CH2CH2Cl; ClCH2CH2C1; EDC, JMAF; Cl(CH2)2Cl; DSSTox_CID_438; 12-DICHLOROETHANE; bmse000568; EC 203-458-1; DSSTox_RID_75587; DSSTox_GSID_20438; CHEMBL16370; 1,2-Dichloroethane ACS grade; 1,2-Dichloroethane, for HPLC; Ethylene dichloride, BSI, ISO; DTXSID6020438; Dichloroethane Reagent Grade ACS; 1,2-Dichloroethane, ACS reagent; 1,2-Dichloroethane, HPLC Grade; AMY33455; ZINC8220695; Tox21_202466; 1,2-Dichloroethane, LR, >=99%; STL264187; AKOS000120021; 1,2-Dichloroethane, p.a., 99.5%; DB03733; MCULE-3493741440; UN 1184; 1,2-Dichloroethane, AR, >=99.5%; 1,2-Dichloroethane, anhydrous, 99.8%; NCGC00091763-01; NCGC00091763-02; NCGC00091763-03; NCGC00260015-01; CAS-107-06-2; 1,2-Dichloroethane, for HPLC, 99.8%; 1,2-Dichloroethane, ACS reagent, >=99%; 1,2-Dichloroethane, ReagentPlus(R), 99%; 1,2-Dichloroethane, for HPLC, >=99.8%; 1,2-Dichloroethane, Spectrophotometric Grade; D0310; D0364; E0289; FT-0626325; FT-0771283; R 150; 1,2-Dichloroethane 10 microg/mL in Methanol; 1,2-Dichloroethane, ACS reagent, >=99.0%; C06752; 1,2-Dichloroethane 1000 microg/mL in Methanol; 1,2-Dichloroethane, SAJ first grade, >=99.0%; Q161480; 1,2-Dichloroethane, JIS special grade, >=99.5%; Ethylene dichloride [UN1184] [Flammable liquid]; J-503815; 1,2-Dichloroethane, anhydrous, ZerO2(TM), 99.8%; 1,2-Dichloroethane, spectrophotometric grade, >=99%; UNII-9D6S017631 component WSLDOOZREJYCGB-UHFFFAOYSA-N; 1,2-Dichloroethane, puriss., absolute, over molecular sieve (H2O <=0.005%), >=99.5% (GC); 52399-93-6"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	98.96	1	C2H4Cl2	0	6	1.5	4	0	0	InChI=1S/C2H4Cl2/c3-1-2-4/h1-2H2	C(CCl)Cl	WSLDOOZREJYCGB-UHFFFAOYSA-N
DG01767	Ammonia	222	"Ammonia; 7664-41-7; azane; Ammonia gas; Spirit of hartshorn; Nitro-sil; Ammonia, anhydrous; Ammoniakgas; Ammonia solution; Ammonia anhydrous; Anhydrous ammonia; Ammoniak; AM-Fol; Liquid Ammonia; Ammoniak Kconzentrierter; Amoniak [Polish]; Ammoniac [French]; Ammoniak [German]; ammoniac; Ammoniaca [Italian]; Caswell No. 041; Ammonia (conc 20% or greater); CCRIS 2278; HSDB 162; Ammonia solution, strong; NH3; UN 2073 (>44% solution); UN1005; Aminomethyl Polystyrene Resin; Refrigerent R717; EPA Pesticide Chemical Code 005302; UNII-5138Q19F1X; Strong Ammonia Solution; R 717; UN 1005 (anhydrous gas or >50% solution); UN 2672 (between 12% and 44% solution); Ammonia, 7M in methanol; Ammonia anhydrous, 99.98%; CHEBI:16134; MFCD00011418; 5138Q19F1X; Ammonia solution, strong (NF); Ammonia solution, strong [NF]; amoniaco; Ammoniaca; Amoniak; (Aminomethyl)polystyrene; EINECS 231-635-3; tertiaeres Amin; Aminyl radical; ammonia ca; primaeres Amin; Ammonia inhalant; Ammonia,aromatic; Ammonia-solution; Ammoniacum gummi; sekundaeres Amin; anyhydrous ammonia; Ammonium causticum; (Aminomethyl)polystyrene, 100-200 mesh, extent of labeling: ~0.5 mmol/g amine loading; NH4; UNX; Strong-ammonia solution; R 717 (ammonia); Ammonia (8CI,9CI); Ammonia water (JP15); Aromatic ammonia vaporole; Ammonia, 2M in methanol; Dowex(R) 66 free base; Ammonia, 0.5M in THF; Aromatic Ammonia, Vaporole; EC 231-635-3; Ammonia solution strong (NF); Ammonia solution strong [usan]; INS NO.527; N H3; ammonium isovalerate 30% in pg; CHEMBL1160819; DTXSID0023872; DTXSID40912315; DTXSID80420101; INS-527; [NH3]; NH(3); 2-Methylamino-5-nitro-benzonitrile; Ammonia solution, 0.4 M in THF; Ammonia solution, 4 M in methanol; Ammonia solution, 7 N in methanol; Ammonia, anhydrous, >=99.98%; ACT02989; Ammonia solution 2.0 M in ethanol; Ammonia solution 2.0 M in methanol; Ammonia solution, 0.5 M in dioxane; Ammonia solution, 2.0 M in ethanol; AKOS015916403; Ammonia anhydrous 170g Lecture bottle; Ammonia solution, 2.0 M in methanol; Ammonia solution 2.0 M in isopropanol; MCULE-5646000632; Ammonia 0.5M solution in 1,4-Dioxane; Ammonia solution, 2.0 M in isopropanol; Ammonia (includes anhydrous ammonia and aqueous ammonia from water dissociable ammonium salts and other sources; 10% of total aqueous ammonia is reportable under this listing); Ammonia, anhydrous, liquefied or ammonia solutions, relative density <0.880 at 15 C in water, with >50% ammonia [UN1005] [Nonflammable gas]; Ammonia, anhydrous, liquefied or ammonia solutions, relative density <0.880 at 15 C in water, with >50% ammonia [UN1005] [Poison gas, Corrosive]; Ammonia, puriss., anhydrous, >=99.9%; Ammonia solution 0.25M in tetrahydrofuran; Ammonia, puriss., anhydrous, >=99.95%; E-527; Q4087; R-717; C00014; D02916; Dowex(R) Marathon(TM) WBA free base, free base; Q4832241; Q6004010; Q27110025; (Aminomethyl)polystyrene, 100-200 mesh, extent of labeling: ~2 mmol/g amine loading; (Aminomethyl)polystyrene, 200-400 mesh, extent of labeling: ~0.6 mmol/g amine loading; (Aminomethyl)polystyrene, 200-400 mesh, extent of labeling: ~1.5 mmol/g amine loading; (Aminomethyl)polystyrene, 400-500 mum, extent of labeling: 1-2 mmol/g amine loading; (Aminomethyl)polystyrene, 100-200 mesh, extent of labeling: 0.5-1.0 mmol/g N loading, 1 % cross-linked; (Aminomethyl)polystyrene, 100-200 mesh, extent of labeling: 1.0 mmol/g N loading, 1 % cross-linked; (Aminomethyl)polystyrene, 200-400 mesh, extent of labeling: 1.0-1.5 mmol/g N loading, 1 % cross-linked; (Aminomethyl)polystyrene, 200-400 mesh, extent of labeling: 1.0-2.0 mmol/g loading, 2 % cross-linked; (Aminomethyl)polystyrene, 200-400 mesh, extent of labeling: 4.0 mmol/g loading, 2 % cross-linked; (Aminomethyl)polystyrene, 50-100 mesh, extent of labeling: 2.0 mmol/g loading, 1 % cross-linked; (Aminomethyl)polystyrene, 70-90 mesh, extent of labeling: 1.0-1.5 mmol/g N loading, 1 % cross-linked; (Aminomethyl)polystyrene, 70-90 mesh, extent of labeling: 1.5-2.0 mmol/g N loading, 1 % cross-linked; (Aminomethyl)polystyrene, macroporous, 30-60 mesh, extent of labeling: 1.5-3.0 mmol/g loading; (Aminomethyl)polystyrene, macroporous, 70-90 mesh, extent of labeling: 1.5-3.0 mmol/g loading; Ammonia (includes anhydrous ammonia and aqueous ammonia from water dissociable ammonium salts and other sources 10% of total aqueous ammonia is reportable under this listing); Ammonia, anhydrous, liquefied or ammonia solutions, relative density <0.880 at 15 C in water, with >50% ammonia; Ammonia, anhydrous, liquefied or ammonia solutions, relative density <0.880 at 15 C in water, with >50% ammonia [UN1005] [Nonflammable gas]; Ammonia, anhydrous, liquefied or ammonia solutions, relative density <0.880 at 15 C in water, with >50% ammonia [UN1005] [Poison gas, Corrosive]; StratoSpheres(TM) PL-AMS resin, 100-200 mesh, extent of labeling: ~1.0 mmol/g loading, 1 % cross-linked with divinylbenzene; StratoSpheres(TM) PL-AMS resin, 100-200 mesh, extent of labeling: 2.0 mmol/g loading, 1 % cross-linked; StratoSpheres(TM) PL-AMS resin, 30-40 mesh, extent of labeling: 1.0 mmol/g loading, 1 % cross-linked; StratoSpheres(TM) PL-AMS resin, 30-40 mesh, extent of labeling: 2.0 mmol/g loading, 1 % cross-linked; StratoSpheres(TM) PL-AMS resin, 50-100 mesh, extent of labeling: 2.0 mmol/g loading, 1 % cross-linked"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:16134	DB11118	DR0100	DR00194	17.031	0	H3N	1	0	-0.7	1	1	1	InChI=1S/H3N/h1H3	N	QGZKDVFQNNGYKY-UHFFFAOYSA-N
DG01768	Benzene	241	"Benzene; benzol; 71-43-2; Cyclohexatriene; benzole; Pyrobenzole; Benzine; Benzen; Phenyl hydride; Pyrobenzol; Phene; Mineral naphtha; Coal naphtha; Bicarburet of hydrogen; Benzolene; Benzin; [6]Annulene; Motor benzol; Carbon oil; Benzeen; Benzolo; Fenzen; Nitration benzene; (6)Annulene; Benzol 90; Rcra waste number U019; NCI-C55276; NSC 67315; UN 1114; CHEBI:16716; UNII-J64922108F; CHEMBL277500; MFCD00003009; Hydrocarbons, C4-8; J64922108F; Benzeen [Dutch]; Benzen [Polish]; Fenzen [Czech]; Benzolo [Italian]; BNZ; Benzine (Obs.); Benzin (Obs.); Caswell No. 077; Benzol diluent; Benzene 100 microg/mL in Methanol; Benzene, ACS reagent, >=99.0%; Benzene, pure; CCRIS 70; 54682-86-9; HSDB 35; 1,3,5-cyclohexatriene; EINECS 200-753-7; UN1114; EPA Pesticide Chemical Code 008801; Annulene; Benzinum; Benzolum; Aromatic alkane; Benzene (including benzene from gasoline); p-benzene; benzene solution; benzene-; AI3-00808; 1hyz; 1swi; [6]-annulene; 68956-52-5; Benzene ACS Grade; Benzene, for HPLC; {[6]Annulene}; Ph-H; Phenyl; Phenyl Radical; 2z9g; 4i7j; Benzene + aniline combo; DSSTox_CID_135; Benzene, labeled with carbon-14 and tritium; WLN: RH; Epitope ID:116867; Benzene, purification grade; EC 200-753-7; Benzene, analytical standard; DSSTox_RID_79433; Benzene, LR, >=99%; DSSTox_GSID_39242; ghl.PD_Mitscher_leg0.503; 26181-88-4; Benzene, anhydrous, 99.8%; Benzene, AR, >=99.5%; DTXSID3039242; 3,4-DNH; 1l83; 220l; 223l; Benzene 10 microg/mL in Methanol; ZINC967532; trans-N-Methylphenylcyclopropylamine; ACT02832; BCP26158; Benzene, for HPLC, >=99.8%; Benzene, for HPLC, >=99.9%; NSC67315; Tox21_202487; 1,3-Cyclohexadiene-5,6-diylradical; BDBM50167939; BM 613; NSC-67315; STL264205; Benzene 5000 microg/mL in Methanol; Benzene, purum, >=99.0% (GC); AKOS008967253; MCULE-4899719484; Benzene, SAJ first grade, >=99.0%; CAS-71-43-2; Benzene [UN1114] [Flammable liquid]; Benzene, JIS special grade, >=99.5%; erythro-Phenyl-2-piperidyl-carbinol,(-); NCGC00090744-01; NCGC00090744-02; NCGC00163890-01; NCGC00163890-02; NCGC00260036-01; trans-N, N-Dimethylphenylcyclopropylamine; Cc-34,(+/-); RNG; DS-002542; B0020; FT-0622636; FT-0622637; FT-0622667; FT-0627856; FT-0657604; Q0038; Q2270; Benzene, ACS spectrophotometric grade, >=99%; C01407; Benzene, ReagentPlus(R), thiophene free, >=99%; Benzene, puriss. p.a., Reag. Ph. Eur., >=99.7%; Q26841227; Z57120059; Benzene, for residue analysis, suitable for 5000 per JIS; Benzene, suitable for 300 per JIS, >=99.5%, for residue analysis; Benzene, Pharmaceutical Secondary Standard; Certified Reference Material; Benzene, suitable for 1000 per JIS, >=99.5%, for residue analysis; Benzene, puriss., absolute, over molecular sieve (H2O <=0.005%), >=99.5% (GC)"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	78.11	0	C6H6	0	15.5	2.1	6	0	0	InChI=1S/C6H6/c1-2-4-6-5-3-1/h1-6H	C1=CC=CC=C1	UHOVQNZJYSORNB-UHFFFAOYSA-N
DG01769	Hydrogen sulfide	402	"Hydrogen sulfide; sulfane; Hydrosulfuric acid; Hydrogen sulphide; Stink DAMP; Dihydrogen monosulfide; Dihydrogen sulfide; Sulfureted hydrogen; Sewer gas; Netzschwefel; Kolospray; Liquamat; Micowetsulf; Microflotox; Colsul; Crystex; Elosal; Hexasul; Kolofog; Kumulus; Sastid; 7783-06-4; Cosan; Polsulkol Extra; Hydrogene sulfure; Acide sulfhydrique; Schwefelwasserstoff; Corosul D and S; RC-Schwefel Extra; Hydrogen sulfide (H2S); Kolloidschwefel 95; Siarkowodor; Zwavelwaterstof; Cosan 80; Hepatic acid; Hydrogen-sulfide; Idrogeno solforato; Kolo 100; Hydrogen monosulfide; Sulfuretted hydrogen; Hepatic gas; RCRA waste number U135; H2S; CHEBI:16136; CHEBI:26833; UNII-YY9FVM7NSN; YY9FVM7NSN; UN 1053; NSC-403664; Collokit; Kristex; Microthiol; Shreesul; Kumulus FL; Magnetic 6; Caswell No. 812; azufre; Proactiv; Transact; Schwefel, feinverteilter; Hydrogene sulphure; Acide sulphhydrique; Siarkowodor [Polish]; Hydrogen sulfide H2S; Hydrogen sulfuric acid; Magnetic 70, 90, and 95; HSDB 5166; Zwavelwaterstof [Dutch]; EINECS 231-722-6; NA1350; NA2448; UN1350; UN2448; Hydrogen sulfure [French]; RCRA waste no. U135; EPA Pesticide Chemical Code 077501; Hydrogene sulfure [French]; NSC 403664; Acide sulfhydrique [French]; dihydridosulfur; monosulfane; Schwefelwasserstoff [German]; theion; Hydrosulfurate; Idrogeno solforato [Italian]; Acnaveen; Cuticura; Eskamel; Hepatate; Schwefel; Acnil; Meted; Sulfur,sublimed; FEMA No. 3779; Thio radical; HSDB 576; Hydrogen sulfure; Sulfur,colloidal; Liu huang; Sour gas; Colloidal sulphur; Sulfur,micronized; Dome-Acne; intracellular S0; .alpha.-sulfur; Sulfur, colloidal; Bensulfoid (TN); Sulfur,precipitated; dihydrogen(sulfide); sulfure d'hydrogene; EINECS 231-977-3; Sastid (TN); UN1053; component of Bensulfoid; Sour gas (Salt/Mix); Dicyclopropylketone, 90%; Magnetic 70, and 95; EC 231-722-6; Hydrogen sulfide (solution); 37331-50-3; 63705-05-5; Hydrogen sulfide, >=99.5%; CHEMBL1200739; CHEMBL2105487; DTXSID4024149; DTXSID9034941; NIOSH/MX1229000; [SH2]; Sulfur [NA1350] [Class 9]; 8984AF; BDBM50147625; BDBM50498447; NSC403664; Hydrogen sulfide, purum, >=99.0%; AKOS015833648; AKOS015950634; Sulfur [UN1350] [Flammable solid]; BP-21056; Sulfur, molten [NA2448] [Class 9]; Hydrogen sulfide solution, 0.8 M in THF; Hydrogen sulfide [UN1053] [Poison gas]; FT-0698736; MX12290000; Sulfur, powder, 99.998% trace metals basis; C00087; C00283; D00024; EC 231-977-3; F21255; Sulfur, molten [UN2448] [Flammable solid]; A857440; Q170591; Q7636182; Q60998679; F5FD384D-E823-4920-B313-6476A1F3F0C5"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	34.08	0	H2S	1	0	0.5	1	1	1	InChI=1S/H2S/h1H2	S	RWSOTUBLDIXVET-UHFFFAOYSA-N
DG01770	Dimethyl sulfoxide	679	"Dimethyl sulfoxide; DMSO; 67-68-5; Methyl sulfoxide; Methylsulfinylmethane; Dimethylsulfoxide; Dimethyl sulphoxide; Methane, sulfinylbis-; Demsodrox; Demasorb; Demavet; Dimexide; Domoso; Dromisol; Durasorb; Infiltrina; Somipront; Syntexan; Deltan; Demeso; Dolicur; Hyadur; sulfinylbismethane; Dimethyl sulfur oxide; Dermasorb; Dipirartril-tropico; Doligur; Kemsol; Gamasol 90; Sulfinylbis(methane); Sclerosol; Topsym; Dimethylsulphoxide; Rimso-50; Dimethylsulfoxid; Dimethylsulfoxyde; Rimso 50; SQ 9453; NSC-763; Caswell No. 381; Dimetil sulfoxido; Dimethyli sulfoxidum; CCRIS 943; (methylsulfinyl)methane; (CH3)2SO; DMS-90; NSC 763; A 10846; Methyl sulphoxide; dimethyl-sulfoxide; S(O)Me2; M 176; UNII-YOW8V9698H; Methane, 1,1'-sulfinylbis-; EPA Pesticide Chemical Code 000177; DMS 70; DMS 90; AI3-26477; MFCD00002089; CHEMBL504; NSC763; YOW8V9698H; Dimethyl sulfoxide, HPLC Grade; CHEBI:28262; SQ-9453; Dimethyl sulfoxide, 99%; Sulfinylbis-methane; 103759-08-6; Topsym (rescinded); Rimso-5; Domoso (Veterinary); methylsulfoxide; Dimexidum; sulfinyldimethane; Dimetilsolfossido; Dimetilsolfossido [DCIT]; Dimethyl sulpoxide; Fatty acids, tall-oil, polymers with Me epoxyoctadecanoate and tetraethylenepentamine; HSDB 80; Sulfoxide, dimethyl; methanesulfinylmethane; DMS-70; Dimethylsulfoxyde [INN-French]; Dimetil sulfoxido [INN-Spanish]; (methanesulfinyl)methane; Dimethyli sulfoxidum [INN-Latin]; EINECS 200-664-3; C2H6OS; Diluent; dimethysulfoxide; dimethlysulfoxide; dimethvlsulfoxide; dimethyisulfoxide; dimethylsulphoxid; dimethy sulfoxide; dimetyl sulfoxide; dimethyisulphoxide; dimethyl sulfoxyde; dimethyl-sulfoxyde; dimethyl suiphoxide; dimethyl-sulphoxide; dirnethyl sulfoxide; Dimethyl sulfoxixde; methylsulfmylmethane; dimethyl sulf oxide; Sulfinyl bis(methane); 2-Thiapropane2-oxide; Dimethyl sulfoxide [USAN:USP:INN:BAN]; DMSO, sterile filtered; dimethylsulfoxide solution; Methyl sulfoxide (8CI); Rimso-50 (TN); Dimethyl sulfoxide(DMSO); DMSO (Sterile-filtered); DMSO, Dimethyl Sulfoxide; DSSTox_CID_1735; Dimethyl sulfoxide solution; (DMSO); DMSO (Dimethyl sulfoxide); EC 200-664-3; Sulfinylbis-methane (9CI); DSSTox_RID_76298; H3C-SO-CH3; BIDD:PXR0182; DSSTox_GSID_21735; Dimethyl sulfoxide, >=99%; Dimethyl sulfoxide, anhydrous; Dimethyl sulfoxide, for HPLC; Methane, sulfinylbis- (9CI); WLN: OS1&1; Dimethyl sulfoxide, >=99.5%; Dimethyl sulfoxide, PCR Reagent; DTXSID2021735; Dimethyl sulfoxide, ACS reagent; Methyl sulfoxide, >=99%, FG; Dimethyl sulfoxide, p.a., 99%; Dimethyl sulfoxide, LR, >=99%; Pharmakon1600-01506122; AMY14894; CS-B1637; Dimethyl sulfoxide (JAN/USP/INN); HY-Y0320; ZINC5224188; Tox21_300957; BDBM50026472; NSC760436; STL264194; Dimethyl sulfoxide, AR, >=99.5%; AKOS000121107; CCG-213615; DB01093; Dimethyl sulfoxide, analytical standard; MCULE-2005841258; NSC-760436; CAS-67-68-5; MRF-0000764; (methanesulfinyl)methanedimethyl sulfoxide; Dimethyl sulfoxide, for molecular biology; NCGC00163958-01; NCGC00163958-02; NCGC00163958-03; NCGC00254859-01; Dimethyl sulfoxide, anhydrous, >=99.9%; Dimethyl sulfoxide, HPLC grade, 99.9%; Dimethyl Sulfoxide [for Spectrophotometry]; Dimethyl sulfoxide, for HPLC, >=99.5%; Dimethyl sulfoxide, for HPLC, >=99.7%; DS-015031; D0798; D1159; D5293; Dimethyl sulfoxide, ACS reagent, >=99.9%; Dimethyl sulfoxide, AldraSORB(TM), 99.8%; FT-0625099; FT-0625100; D01043; Dimethyl sulfoxide solution, 50 wt. % in H2O; Dimethyl sulfoxide, >=99.6%, ReagentPlus(R); Dimethyl sulfoxide, ReagentPlus(R), >=99.5%; AB01563146_01; Dimethyl sulfoxide, p.a., ACS reagent, 99.9%; Dimethyl sulfoxide, SAJ first grade, >=99.0%; Dimethyl sulfoxide, JIS special grade, >=99.0%; Dimethyl sulfoxide, Vetec(TM) reagent grade, 99%; Q407927; Dimethyl sulfoxide, UV HPLC spectroscopic, 99.9%; Dimethyl sulfoxide, anhydrous, ZerO2(TM), >=99.9%; Dimethyl sulfoxide, meets EP, USP testing specifications; Dimethyl sulfoxide, ACS spectrophotometric grade, >=99.9%; Dimethyl sulfoxide, puriss. p.a., dried, <=0.02% water; 4H-1,3-oxazine,2-cyclopentyl-5,6-dihydro-4,4,7-trimethyl-; Dimethyl sulfoxide, >=99.5% (GC), plant cell culture tested; Dimethyl sulfoxide, BioUltra, for molecular biology, >=99.5% (GC); Dimethyl sulfoxide, European Pharmacopoeia (EP) Reference Standard; Dimethyl sulfoxide, puriss. p.a., ACS reagent, >=99.9% (GC); Dimethyl sulfoxide, Vetec(TM) reagent grade, anhydrous, >=99.7%; Dimethyl sulfoxide, >=99.0%, suitable for absorption spectrum analysis; Dimethyl sulfoxide, United States Pharmacopeia (USP) Reference Standard; Dimethyl sulfoxide, for inorganic trace analysis, >=99.99995% (metals basis); Dimethyl sulfoxide, meets EP testing specifications, meets USP testing specifications; Dimethyl sulfoxide, Hybri-Max(TM), sterile-filtered, BioReagent, suitable for hybridoma, >=99.7%; Dimethyl sulfoxide, puriss., absolute, over molecular sieve (H2O <=0.005%), >=99.5% (GC); Dimethyl sulfoxide, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:28262	DB01093	.	DR01178	78.14	0	C2H6OS	36.3	29	-0.6	4	0	2	InChI=1S/C2H6OS/c1-4(2)3/h1-2H3	CS(=O)C	IAZDPXIOMUYVGZ-UHFFFAOYSA-N
DG01771	Ethanol	702	"Ethanol; ethyl alcohol; alcohol; 64-17-5; grain alcohol; Methylcarbinol; Ethyl hydroxide; Ethyl hydrate; Tecsol; EtOH; Algrain; Anhydrol; Denatured alcohol; Hydroxyethane; Alkohol; Jaysol S; Potato alcohol; Cologne Spirit; Absolute ethanol; Ethanol 200 proof; Molasses alcohol; Spirits of wine; etanol; Aethylalkohol; Denatured ethanol; Aethanol; Alcool ethylique; 1-Hydroxyethane; Fermentation alcohol; Alcohol, diluted; Tecsol C; Alcohols; Alcool etilico; Dehydrated ethanol; Etanolo; Jaysol; Etylowy alkohol; absolute alcohol; Ethanol solution; Alcohol, ethyl; Alcohol dehydrated; Alkoholu etylowego; Ethyl alcohol usp; Alcohol, anhydrous; Synasol; Ethyl alcohol anhydrous; Denatured alcohol CD-5; Denatured alcohol SD-1; Distilled spirits; Denatured alcohol CD-5a; Denatured alcohol SD-3a; Dehydrated alcohol; Denatured alcohol CD-10; Denatured alcohol SD-17; Denatured alcohol SD-28; Denatured alcohol SD-30; Denatured alcohol SD-13a; Denatured alcohol SD-23a; Denatured alcohol SD-39b; Denatured alcohol SD-39c; Denatured alcohol SD-40m; Ethylalcohol; Spirit; SD Alchol 23-hydrogen; Alcohol anhydrous; Alkohol [German]; Aethanol [German]; Etanolo [Italian]; Alcohol, dehydrated; Ethyl alcohol & water, 5%; Thanol; Ethanol, undenatured; Spirt; Alcare Hand Degermer; Ethyl alcohol & water, 10%; Ethyl alcohol & water, 20%; Ethyl alcohol & water, 30%; Ethyl alcohol & water, 40%; Ethyl alcohol & water, 50%; Ethyl alcohol & water, 60%; Ethyl alcohol & water, 70%; Ethyl alcohol & water, 80%; Ethyl alcohol & water, 95%; Ethyl alcohol & water, 96%; Ethyl alc; Ethylalcohol [Dutch]; Ethyl alcohol and water; NCI-C03134; Alcohol (ethyl alcohol); Alcohol [USP]; Ethicap; Hinetoless; Cologne spirits; Caswell No. 430; Reagent Alcohol; Infinity Pure; Aethylalkohol [German]; Desinfektol EL; Anhydrous alcohol; Ethyl alcohol in alcoholic beverages; FEMA No. 2419; FEMA Number 2419; Alcool etilico [Italian]; Etylowy alkohol [Polish]; Ethyl alcohol, undenatured; Alcool ethylique [French]; C2H5OH; Alkoholu etylowego [Polish]; HSDB 82; SDM No. 37; AI3-01706; CCRIS 945; Ethanol Vapor; SD alcohol 23-hydrogen; Alcohol denatured; Ru-Tuss Hydrocodone Liquid; Alcohol, denatured; Ethanol, denatured; Ethanol, Anhydrous; NSC 85228; Alcohol (USP); EPA Pesticide Chemical Code 001501; Absolute ethyl alcohol; UNII-3K9958V90M; Punctilious ethyl alcohol; Ethanol Absolute; Ethanol, anhydrous, denatured; CHEBI:16236; NSC-85228; 3K9958V90M; Ethanol, CDA 19; Ethanol, 200 Proof; Ethyl Alcohol Denatured; Ethylol; Alcohols, C1-3; Ethanol Anhydrous; Alcohol, Absolute; EOH; Ethanol [JAN]; Sekundasprit; alcohol etilico; spiritus vini; MFCD00003568; Anhydrous ethanol; Ethanol denatured; C2H6O; Lux; SY Fresh M; Esumiru WK 88; Ethanol (9CI); Ethanol, silent spirit; ALCOHOL DENAT.; Anhydrol PM 4085; Ethyl alcohol, anhydrous; Ethyl alcohol (Ethanol); Higher alcohol distillate; ALCOHOL 5% IN DEXTROSE 5%; EINECS 200-578-6; Cologne spirits (alcohol); SDA 3A; Alcoholum; Ethanolum; Ethylicum; silent spirit; diluted Alcohol; Ethanol in alcoholic beverages; Vodka; Alcohol,ethyl; Edible alcohol; Alcohol,sda; ethanol-; 100C.NPA; CDA 19; IMS 99; Sd alcohol; Ethanol, dimer; Alcohol,denatured; Alcohol (ethyl); Alcohol,dehydrated; undenatured Ethanol; AHD 2000; Ethanol, dehydrated; SDA 40-2; VANILLA Powder; EINECS 270-649-4; Eosin Y, Alcoholic; Alcohol 95%; Alcohol 190 proof; CDA 19-200; Ethyl Alcohol 40%; Ethyl Alcohol 70%; Ethyl Alcohol 75%; Ethyl Alcohol 80%; Ethyl Alcohol 90%; Ethyl alcohol, absolute; Ethanol, 99.8%; Ethanol, technical grade; Fatty Alcohol C8-10; Reagent Alcohol, 70%; Reagent Alcohol, 80%; Reagent Alcohol, 95%; CH3CH2OH; Dehydrated ethanol (TN); Ethyl Alcohol 47.5%; DSSTox_CID_584; Ethyl alcohol, dehydrated; Ethanol, standard for GC; Industrial Alcohol (IMS); bmse000297; CHEMBL545; EC 200-578-6; Ethanol, >=99.5%; Aerosol  OT Solution; Anhydrous ethanol (JP17); Reagent Alcohol, for HPLC; Ethanol, analytical standard; DSSTox_RID_75674; SD 3A; DSSTox_GSID_20584; Ru-Tuss Liquid (Salt/Mix); Ethanol, USP, 99.5%; WLN: Q2; 68475-56-9; Ethanol, for residue analysis; Reagent Alcohol, ACS reagent; Alcohol determination--alcohol; Duplicating Fluid 100C.NPA; Ethanol, p.a., 99.8%; Reagent Alcohol, reagent grade; SDM No. 37 (Salt/Mix); GTPL2299; Alcohol dehydrated, >=85.0%; DTXSID4028331; DTXSID9020584; Ethanol, technical grade, 93%; Ethanol, technical grade, 99%; UNII-7528N5H79B; CHEBI:17246; Ethanol, 95.1-96.9%; poly(vinyl alcohol) macromolecule; Ru-Tuss Expectorant (Salt/Mix); Ethyl alcohol (6CI,7CI,8CI); Ethanol, technical grade, 93.8%; Ethanol, technical grade, 99.5%; Ethanol, >=99.5%, for HPLC; NSC85228; STR05604; Ethyl Alcohol 95% ACS/USP Grade; Tox21_202510; 6869AF; STL264245; Ethanol 2000 microg/mL in Methanol; Ethanol, 95.0%, (190 proof); Ethanol, p.a., ACS reagent, 96%; Ethanol, tested according to Ph.Eur.; Ethanol, USP, 70.0-72.0%; Ethanol, USP, 94.9-96.0%; AKOS009104571; Ethanol, Reagent (Denatured SDA 3A); 7528N5H79B; DB00898; Ethanol 10000 microg/mL in Methanol; Ethanol, absolute, >=99.8% (GC); Ethanol, UV HPLC spectroscopic, 95%; MCULE-8818474596; UN 1170; CAS-64-17-5; Ethanol, denatured, (UK IDA standard); Ethanol, SAJ first grade, >=99.5%; Ethyl Alcohol Absolute, ACS/USP Grade; Ethanol, JIS special grade, >=99.5%; Ethanol, p.a., ACS reagent, 95.0%; Ethanol, technical grade, 92.6-93.8; NCGC00091458-01; NCGC00091458-02; NCGC00260059-01; Reagent Alcohol, spectrophotometric grade; Ethanol, >50% in a non hazardous diluent; Ethanol, absolute, for HPLC, >=99.8%; Ethanol, anhydrous, denatured, HPLC Grade; Ethyl Alcohol 95% (Synthetic) FCC Grade; Ethanol, ACS reagent, 99.8, 200 proof; Ethanol, JIS first grade, 94.8-95.8%; Ethyl Alcohol Absolute (Organic) USP Grade; E1510; Ethanol solution, EP, BP, 69.5-70.4%; Ethanol, denatured, Spectrophotometric Grade; Ethanol, JIS special grade, 94.8-95.8%; FT-0625729; FT-0625731; FT-0625732; FT-0668048; Ethanol, >=99.5%, SAJ super special grade; PM-6193-200; Reagent Alcohol, anhydrous, <=0.003% water; Reagent Alcohol, anhydrous, <=0.005% water; C00469; D00068; Ethanol, >=99.5%, suitable for fluorescence; Ethanol, Alcohol Reagent, anhydrous, denatured; Ethyl Alcohol 95% (Grain Derived) FCC Grade; Ethyl Alcohol 95% (Synthetic) ACS/USP Grade; Ethanol, >10 - 24% in a non hazardous diluent; Ethanol, >24 - 50% in a non hazardous diluent; Ethyl Alcohol Absolute (Synthetic) ACS/USP Grade; SR-01000944357; Ethanol, puriss. p.a., absolute, >=99.8% (GC); SR-01000944357-1; Ethanol, denatured (5 % IPA, 5 % n-propylacetate); Reagent Alcohol, used for histology tissue preparation; Ethanol, anhydrous, denatured, Spectrophotometric Grade; Ethyl alcohol, Pure, 190 proof, for molecular biology; Ethyl alcohol, Pure, 200 proof, anhydrous, >=99.5%; Ethyl alcohol, Pure, 200 proof, for molecular biology; Ethanol, absolute, >=99.8% (GC), sales not in Germany; Ethyl Alcohol Absolute (Dehydrated) USP, BP/EP, JP Grade; Ethyl alcohol, Pure, 200 proof, ACS reagent, >=99.5%; Reagent Alcohol, 70%, used for histology tissue preparation; Reagent Alcohol, 80%, used for histology tissue preparation; 1E37B0D2-6209-4B03-A57D-500F3223C2DA; Alcohol, United States Pharmacopeia (USP) Reference Standard; Ethanol, >=99.5%, suitable for absorption spectrum analysis; Ethanol-water solutions, NIST(R) SRM(R) 1828b, six levels; Ethyl alcohol, Pure, 200 proof, HPLC/spectrophotometric grade; Reagent Alcohol, 95%, Used for histology tissue preparation; Ethanol solution, NIST(R) SRM(R) 2897a, nominal mass fraction 2%; Ethanol solution, NIST(R) SRM(R) 2898a, nominal mass fraction 6%; Ethanol solution, NIST(R) SRM(R) 2899a, nominal 25% by mass; Ethanol, p.a., ACS reagent, reag. ISO, reag. Ph. Eur., 99.9%; Ethanol, suitable for 300 per JIS, >=99.5%, for residue analysis; Ethyl alcohol, Pure, 190 proof, meets USP testing specifications; Ethyl alcohol, Pure, 200 proof, anhydrous, ZerO2(TM), >=99.5%; Ethyl alcohol, Pure, 200 proof, meets USP testing specifications; Specially Denatured Alcohol, 190 proof, SDA 23A, contains Acetone; Specially Denatured Alcohol, 190 proof, SDA 2B-3, contains Toluene; Specially Denatured Alcohol, 190 proof, SDA 30, contains Methanol; Specially Denatured Alcohol, 190 proof, SDA 3A, contains Methanol; Specially Denatured Alcohol, 200 proof, SDA 23A, contains Acetone; Specially Denatured Alcohol, 200 proof, SDA 2B-3, contains Toluene; Specially Denatured Alcohol, 200 proof, SDA 30, contains Methanol; Specially Denatured Alcohol, 200 proof, SDA 3A, contains Methanol; Alcohol, Pharmaceutical Secondary Standard; Certified Reference Material; Dehydrated Alcohol, United States Pharmacopeia (USP) Reference Standard; Ethanol Fixative 80% v/v, suitable for fixing solution (blood films); Ethanol solution, certified reference material, 2000 mug/mL in methanol; Ethanol standards 10% (v/v), 10 % (v/v) in H2O, analytical standard; Ethanol, absolute, for gradient elution, sales not in Germany, >=99.9%; Ethanol, absolute, for HPLC, sales not in Germany1, >=99.8% (GC); Ethanol, absolute, semiconductor grade PURANAL(TM) (Honeywell 17826); Ethanol, suitable for 1000 per JIS, >=99.5%, for residue analysis; Ethanol-water solution, NIST(R) SRM(R) 2894, nominal mass fraction 0.1%; Ethanol-water solution, NIST(R) SRM(R) 2895, nominal mass fraction 0.2%; Ethanol-water solution, NIST(R) SRM(R) 2896, nominal mass fraction 0.3%; Ethanol-water solution, NIST(R) SRM(R) 2900, nominal 95.6% by mass; Ethyl Alcohol Absolute (Dehydrated, Synthetic) USP, BP/EP, JP Grade; Ethyl alcohol, Pure, 140 proof, Excise Tax-free, Permit for use required; Ethyl alcohol, Pure, 160 proof, Excise Tax-free, Permit for use required; Ethyl alcohol, Pure, 190 proof, ACS spectrophotometric grade, 95.0%; Specially Denatured Alcohol, 190 proof, SDA 2B-4, contains Heptanes; Specially Denatured Alcohol, 190 proof, SDA 2B-4, contains n-Heptane; Specially Denatured Alcohol, 190 proof, SDA 2B-5, contains n-Hexane; Specially Denatured Alcohol, 190 proof, SDA 35A, contains Ethyl acetate; Specially Denatured Alcohol, 190 proof, SDA 3C, contains Isopropanol; Specially Denatured Alcohol, 200 proof, SDA 2B-4, contains Heptanes; Specially Denatured Alcohol, 200 proof, SDA 2B-4, contains n-Heptane; Specially Denatured Alcohol, 200 proof, SDA 2B-5, contains n-Hexane; Specially Denatured Alcohol, 200 proof, SDA 35A, contains Ethyl acetate; Specially Denatured Alcohol, 200 proof, SDA 3C, contains"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:16236	DB00898	DR0655	DR00377	46.07	0	C2H6O	20.2	2.8	-0.1	3	1	1	"InChI=1S/C2H6O/c1-2-3/h3H,2H2,1H3"	CCO	LFQSCWFLJHTTHZ-UHFFFAOYSA-N
DG01772	Hydrogen peroxide	784	"Hydrogen peroxide; 7722-84-1; perhydrol; oxydol; Hydrogen dioxide; hydroperoxide; Superoxol; Interox; Inhibine; Peroxaan; Peroxide; Albone; Hioxyl; Kastone; Albone 35; Albone DS; Dihydrogen dioxide; T-Stuff; Lensept; Elawox; Perone; Albone 50; Albone 70; Perone 50; Albone 35CG; Albone 50CG; Albone 70CG; Hydrogen peroxide solution; H2O2; Hydrogen peroxide (H2O2); Peroxan; Hydrogen peroxide, 30%; Hydrogen dioxide solution; Hydrogen peroxide, 90%; Perone 30; Perone 35; Hydrogen peroxide, solution; Waterstofperoxyde; Hydrogen peroxide, 3%; Wasserstoffperoxid; Caswell No. 486AAA; Peroxyde d'hydrogene; Perossido di idrogeno; Asepticper; Baquashock; Crystacide; Peroxclean; CCRIS 1060; Dentasept; HSDB 547; Hybrite; Metrokur; Mirasept; Oxigenal; Oxyfull; Oxysept; Pegasyl; Hipox; Select Bleach; Hydrogen peroxide, solution, 3%; Hydrogen peroxide solution (DOT); Xtra White; Hydrogen peroxide (conc > 52%); Oxysept I; Hydrogen peroxide solutions; Hydrogen peroxide, solution, 30%; Hydrogen peroxide, solution, 35%; Lensan A; Odosat D; UNII-BBX060AN9V; Adeka Super EL; Crestal Whitestrips; UN2014; UN2015; UN2984; EPA Pesticide Chemical Code 000595; Anti-Keim 50; Hydrogen peroxide, 8% to 20%; Hydrogen peroxide, 20% to 60%; Hydrogen peroxide (> 52% conc.); Hydrogen peroxide [USP]; MFCD00011333; UN 2015 (>52%); BBX060AN9V; UN 2984 (8%-20%); UN 2014 (20%-52%); CHEBI:16240; NSC-19892; Hydrogen peroxide solutions (over 8% but not over 60%); Hydrogen peroxide solutions (over 60% but not over 70%); Hydrogen peroxide (USP); PEO; dioxidane; Puresept; hydrogenperoxide; Waterstofperoxyde [Dutch]; Accel Concentrate; Wasserstoffperoxid [German]; Astri-UC; HTP [peroxide]; High Test Peroxide; CIX; Peroxyde d'hydrogene [French]; Teat dip HP 5; Perossido di idrogeno [Italian]; Pre milk HP 0.5; Pre milk HP 1.0; Hydrogen peroxide 35%; EINECS 231-765-0; NSC 19892; Pre milk HP 0.5 10; Whitespeed; Eskata; Magic Bleaching; Clarigel Gold; Hyrogen peroxide; Lase Peroxide; Quasar Brite; Opalescence Xtra; Whiteness HP; Deslime LP; Hydrogen peroxide (conc >52%); hydrogen per oxide; dihydrogen peroxide; dihydrogen(peroxide); Oxyfull (TN); HOOH; hydrogen hydroperoxide; Nite White Excel 2; Oxydol (JP17); Hydrogen peroxide 50%; HYDROGEN-PEROXIDE; Hydrogen peroxide aqueous; Hydrogen Peroxide, 50%; Hydrogen peroxide (8CI); MolMap_000025; bis(hydridooxygen)(O--O); EC 231-765-0; 30 %Hydrogen peroxide(aq); CHEMBL71595; Hydrogen peroxide 32 wt. %; OXTERIL  350 SPRAY; [OH(OH)]; DTXSID2020715; Hydrogen peroxide, 6% in water; Hydrogen peroxide (H2O2) (9CI); NSC19892; WLN: H2 O2 90%; Hydrogen Peroxide [Topical Solution]; AKOS015856794; DB11091; QTL1_000041; Hydrogen peroxide, aqueous solutions with >40% but not >60% hydrogen peroxide (stabilized as necessary) [UN2014] [Oxidizer]; Hydrogen peroxide, aqueous solutions with not <20% but not >40% hydrogen peroxide (stabilized as necessary) [UN2014] [Oxidizer]; Hydrogen peroxide, aqueous solutions with not <8% but <20% hydrogen peroxide (stabilized as necessary) [UN2984] [Oxidizer]; Hydrogen peroxide, stabilized or hydrogen peroxide aqueous solutions, stabilized with >60% hydrogen peroxide [UN2015] [Oxidizer]; FT-0627133; H1222; C00027; D00008; Hydrogen peroxide solution, 3%, for microbiology; Hydrogen peroxide solution, for ultratrace analysis; Q171877; Q1088474; Hydrogen peroxide solution, extra pure, 30.0-32.0%; Hydrogen peroxide solution, purum p.a., >=30% (RT); Hydrogen peroxide solution, purum p.a., >=35% (RT); Hydrogen peroxide solution, >=30%, for trace analysis; Hydrogen peroxide solution, SAJ first grade, >=30.0%; Hydrogen peroxide solution, tested according to Ph.Eur.; Hydrogen peroxide solution, 50 wt. % in H2O, stabilized; Hydrogen peroxide solution, JIS special grade, 30.0-35.5%; Hydrogen peroxide solution, 30 % (w/w) in H2O, contains stabilizer; Hydrogen peroxide solution, contains inhibitor, 35 wt. % in H2O; Hydrogen peroxide solution, p.a., ACS reagent, reag. ISO, 30.0%; Hydrogen peroxide 30%, meets the analytical specifications of Ph. Eur., stabilized; Hydrogen Peroxide Solution, 30% (w/w), puriss. p.a., reag. ISO, reag. Ph. Eur.; Hydrogen peroxide solution, AR, contains sodium pyrophosphate as stabilizer, >=30 % (w/v); Hydrogen peroxide solution, contains ~200 ppm acetanilide as stabilizer, 3 wt. % in H2O; Hydrogen peroxide solution, contains inhibitor, 30 wt. % in H2O, ACS reagent; Hydrogen peroxide solution, LR, contains sodium pyrophosphate as stabilizer, >=30 % (w/v); Hydrogen peroxide solution, LR, contains sodium pyrophosphate as stabilizer, >=50 % (w/v); Hydrogen peroxide solution, meets analytical specification of Ph. Nord., 34.5-36.5%; Hydrogen peroxide solution, puriss. p.a., ACS reagent, not stabilized, >=30% (RT); Hydrogen peroxide solution, semiconductor grade MOS PURANAL(TM) (Honeywell 17937), >=30%; Hydrogen peroxide solution, semiconductor grade PURANAL(TM) (Honeywell 17948), >=30%; Hydrogen peroxide solution, semiconductor grade ULSI PURANAL(TM) (Honeywell 17024), >=30%; Hydrogen peroxide solution, semiconductor grade VLSI PURANAL(TM) (Honeywell 17606), >=30%; Hydrogen peroxide solution, contains inhibitor, 30 wt. % in H2O, meets USP testing specifications; Hydrogen peroxide solution, contains potassium stannate as inhibitor, 30-32 wt. % in water, semiconductor grade, 99.999% trace metals basis; Hydrogen peroxide, aqueous solutions with >40% but not >60% hydrogen peroxide (stabilized as necessary); Hydrogen peroxide, aqueous solutions with >40% but not >60% hydrogen peroxide (stabilized as necessary) [UN2014] [Oxidizer]; Hydrogen peroxide, aqueous solutions with not <20% but not >40% hydrogen peroxide (stabilized as necessary); Hydrogen peroxide, aqueous solutions with not <20% but not >40% hydrogen peroxide (stabilized as necessary) [UN2014] [Oxidizer]; Hydrogen peroxide, aqueous solutions with not <8% but <20% hydrogen peroxide (stabilized as necessary); Hydrogen peroxide, aqueous solutions with not <8% but <20% hydrogen peroxide (stabilized as necessary) [UN2984] [Oxidizer]; Hydrogen peroxide, stabilized or hydrogen peroxide aqueous solutions, stabilized with >60% hydrogen peroxide; Hydrogen peroxide, stabilized or hydrogen peroxide aqueous solutions, stabilized with >60% hydrogen peroxide [UN2015] [Oxidizer]"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:16240	DB11091	DR0832	.	34.015	0	H2O2	40.5	0	-0.9	2	2	2	InChI=1S/H2O2/c1-2/h1-2H	OO	MHAJPDPJQMAIIY-UHFFFAOYSA-N
DG01773	Hydroquinone	785	"Hydroquinone; Benzene-1,4-diol; 1,4-benzenediol; 123-31-9; Quinol; 1,4-Dihydroxybenzene; p-Benzenediol; p-Hydroquinone; p-Hydroxyphenol; p-Dihydroxybenzene; 4-Hydroxyphenol; Benzoquinol; Eldoquin; hydroquinol; Eldopaque; Phiaquin; p-Dioxybenzene; Dihydroquinone; Hydroquinole; Idrochinone; Tecquinol; Dihydroxybenzene; Solaquin forte; Benzohydroquinone; Arctuvin; Hidroquinone; Tequinol; Derma-Blanch; Tenox HQ; Hydrochinon; Hydrochinone; Artra; Eldopaque Forte; Eldoquin Forte; Diak 5; Benzene, p-dihydroxy-; 1,4-Dihydroxy-benzol; Usaf ek-356; 1,4-Diidrobenzene; p-Dioxobenzene; 1,4-Dihydroxybenzen; para-Dioxybenzene; para-Hydroquinone; Pyrogentistic acid; 1,4-Dihydroxy-benzeen; NCI-C55834; HE 5; para-Dihydroxybenzene; Black and White Bleaching Cream; Melanex; Idrochinone [Italian]; Hydrochinon [Czech, Polish]; 1,4-Dihydroxybenzen [Czech]; 1,4-Diidrobenzene [Italian]; 1,4-Dihydroxy-benzeen [Dutch]; 1,4-Dihydroxy-benzol [German]; UNII-XV74C1N1AE; NSC 9247; UN2662; Hydroquinone [USP]; CHEBI:17594; AI3-00072; 4-DIHYDROXYBENZENE; MFCD00002339; HQ; CHEMBL537; XV74C1N1AE; 1,4-Benzenediol, homopolymer; DTXSID7020716; NSC-9247; Hydroquinone [UN2662] [Poison]; Hydroquinone (USP); NCGC00015523-02; beta-quinol; DSSTox_CID_716; para-Hydroxyphenol; DSSTox_RID_75754; DSSTox_GSID_20716; Eldopacque; Hydroquinone (Benzene-1,4-diol); Epiquin; Sunvanish; p Benzendiol; p-Dihydroquinone; alpha-hydroquinone; 26982-52-5; CAS-123-31-9; SMR000059154; CCRIS 714; 1,4-Hydroxybenzene; HSDB 577; SR-01000075920; EINECS 204-617-8; hydroquinon; Hydroquinoue; hydroq uinone; hydroquinone gr; a-Hydroquinone; Black & White Bleaching Cream; p-Hydroxybenzene; b-Quinol; 4-Benzenediol; Hydroquinone, HQ; .beta.-Quinol; 1,4 benzenediol; Hydroquinone,(S); p-dihydroxy benzene; HQE; Hydroquinone polymer; PLQ; Artra (Salt/Mix); 1, 4-Benzenediol; HYDROP; .alpha.-Hydroquinone; phenol derivative, 4; 4-hydroxyphenyl alcohol; Spectrum_001757; 4e3h; SpecPlus_000769; 1,4-Dihydrobenzoquinone; ELDOQUIN (TN); hydroquinone for synthesis; Spectrum2_001672; Spectrum3_000656; Spectrum4_000633; Spectrum5_001430; Lopac-H-9003; 1,2 BENZOLDIOL; WLN: QR DQ; bmse000293; Epitope ID:116206; EC 204-617-8; Lopac0_000577; SCHEMBL15516; BSPBio_002291; KBioGR_001246; KBioSS_002237; 1,4-Dihydroxybenzene, XIII; Hydroquinone-1,4-Benzenediol; MLS000069815; MLS001074911; BIDD:ER0340; DivK1c_006865; Hydroquinone, LR, >=99%; SPECTRUM1504237; Hydrochinon(CZECH, POLISH); SPBio_001883; BDBM26190; Hydroquinone, puriss., 99.0%; KBio1_001809; KBio2_002237; KBio2_004805; KBio2_007373; KBio3_001511; NSC9247; Benzene-1,4-diol (Hydroquinone); HMS1922H15; HMS2093E08; HMS3261D16; LABOTEST-BB LTBB001931; Pharmakon1600-01504237; HY-B0951; ZINC5133378; Tox21_110169; Tox21_202345; Tox21_300015; Tox21_500577; CCG-39082; NSC758707; s4580; STK397446; AKOS000119003; Tox21_110169_1; AM10548; AS00174; DB09526; LP00577; MCULE-3953269041; NSC-758707; SDCCGSBI-0050559.P003; UN 2662; Hydroquinone, ReagentPlus(R), >=99%; Hydroquinone, USP, 99.0-100.5%; NCGC00015523-01; NCGC00015523-03; NCGC00015523-04; NCGC00015523-05; NCGC00015523-06; NCGC00015523-07; NCGC00015523-08; NCGC00015523-09; NCGC00015523-10; NCGC00015523-11; NCGC00015523-12; NCGC00015523-13; NCGC00015523-19; NCGC00090880-01; NCGC00090880-02; NCGC00090880-03; NCGC00090880-04; NCGC00090880-05; NCGC00254037-01; NCGC00259894-01; NCGC00261262-01; BP-21160; DA-33570; Hydroquinone, ReagentPlus(R), >=99.5%; SBI-0050559.P002; Hydroquinone, SAJ first grade, >=99.0%; EU-0100577; FT-0606877; H0186; Hydroquinone, SAJ special grade, >=99.0%; Hydroquinone, meets USP testing specifications; C00530; D00073; H 9003; AB00053361_08; Quinol; 1,4-Benzenediol; 1,4-Dihydroxybenzene; Q419164; J-004910; J-521469; SR-01000075920-1; SR-01000075920-4; Q27102742; Z57127551; 094CADDB-59BF-4EDF-B278-59791B203EA2; F1908-0167; Hydroquinone, certified reference material, TraceCERT(R); Hydroquinone, United States Pharmacopeia (USP) Reference Standard; Hydroquinone, Pharmaceutical Secondary Standard; Certified Reference Material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:17594	DB09526	DR0835	.	110.11	0	C6H6O2	40.5	54.9	0.6	8	2	2	"InChI=1S/C6H6O2/c7-5-1-2-6(8)4-3-5/h1-4,7-8H"	C1=CC(=CC=C1O)O	QIGBRXMKCJKVMJ-UHFFFAOYSA-N
DG01774	Indole-3-acetic acid	802	"Indole-3-acetic acid; 87-51-4; 3-Indoleacetic acid; indoleacetic acid; Heteroauxin; 1H-Indole-3-acetic acid; 1H-indol-3-ylacetic acid; 2-(1H-Indol-3-yl)acetic acid; Rhizopin; Indol-3-ylacetic acid; 3-Iaa; Rhizopon A; 3-Indolylacetic acid; Hexteroauxin; beta-Indoleacetic acid; 3-(Carboxymethyl)indole; auxin; indoleacetate; Acetic acid, indolyl-; Heteroauxinhexteroauxiniaa; Indolylacetic acid; beta-Indolylacetic acid; IAA; indole-3-acetate; Indolyl-3-acetic acid; omega-Skatole carboxylic acid; Kyselina 3-indolyloctova; (1H-Indol-3-yl)-acetic acid; Indoleacetic acid (VAN); 3-indole acetic acid; (indol-3-yl)acetate; CCRIS 1014; EPA Pesticide Chemical Code 128915; Kyselina 3-indolyloctova [Czech]; (indol-3-yl)acetic acid; AI3-24131; 2-(3-Indolyl)acetic acid; NSC 3787; (1H-Indol-3-yl)acetic acid; 2-(indol-3-yl)ethanoic acid; 3-Indolylessigsaeure; UNII-6U1S09C61L; .alpha.-IAA; .beta.-IAA; Indole 3-acetic acid; 3-Indole-Acetic acid; 1H-Indole-3-acetic acid (9CI); .beta.-Indoleacetic acid; MFCD00005636; .beta.-Indolylacetic acid; .beta.-Indole-3-acetic acid; CHEMBL82411; Indole-3-acetic acid (8CI); .omega.-Skatole carboxylic acid; CHEBI:16411; .alpha.-Indol-3-yl-acetic acid; NSC3787; 6U1S09C61L; Heteroauxine; 3-indoleacetate; DSSTox_CID_738; DSSTox_RID_75762; DSSTox_GSID_20738; 1H-Indole-3-acetate; (1H-indol-3-yl)acetate; CAS-87-51-4; IES; SMR000471855; EINECS 201-748-2; Indolylacetate; b-Indoleacetate; b-Indolylacetate; 3-Indolylacetate; alpha-IAA; beta-Indoleacetate; beta-IAA; beta-Indolylacetate; Indol-3-ylacetate; Indolyl-3-acetate; Skatole carboxylate; b-Indoleacetic acid; IAC; b-Indolylacetic acid; Indole-3acetic acid; indol-3-acetic acid; indole-3-acetic aicd; 3-indolyl acetic acid; 3-indolyl-acetic acid; Skatole carboxylic acid; Acid, 6; 2-(3-Indolyl)acetate; Indole-3-acetic-t acid; 1H-indol-3-acetic acid; Maybridge1_006755; 1H-Indole 3-acetic acid; beta-Indole-3-acetic acid; bmse000177; (1H-Indol-3-yl)-acetate; 3-Indoleacetic acid, 98%; 3-Indoleacetic acid, 99%; Oprea1_602123; SCHEMBL26344; MLS001066408; MLS001331664; MLS001332399; MLS001332400; 3-Indolylmethylcarboxylic acid; alpha-Indol-3-yl-acetic acid; WLN: T56 BMJ D1VQ; [3H]-IAA; DTXSID5020738; HMS560L01; ZINC83860; AMY2736; 2-(1H-indol-3-yl)-acetic acid; HMS2269G24; HMS3604M04; ACT03586; ALBB-006264; BCP26623; NSC-3787; Tox21_202284; Tox21_302731; BBL009348; BDBM50201883; CCG-51070; HTS001756; s4799; STK397461; AKOS000119890; 1H-Indole-3-acetic-a-t acid (9CI); AC-2974; CG-0522; CS-6287; DB07950; MCULE-9266736782; SDCCGMLS-0066204.P001; 3-Indoleacetic acid, >=98.0% (T); NCGC00247039-01; NCGC00247039-02; NCGC00256391-01; NCGC00259833-01; HY-18569; SY003464; DB-011566; BB 0242380; EU-0099905; FT-0627215; FT-0695803; I0022; 3-Indoleacetic acid, technical, >=95% (T); 87I514; C00954; I-1000; I-1040; Q411208; SR-01000596909; 2-(1H-indol-3-yl)acetic acid;Indole-3-acetic acid; 3-Indoleacetic acid, SAJ special grade, >=98.5%; SR-01000596909-1; SR-01000596909-2; 3-Indolyl acetic acid 100 microg/mL in Acetonitrile; 2-(3-Indolyl)acetic acid 3-(Carboxymethyl)-1H-indole; 3-Indoleacetic acid, PESTANAL(R), analytical standard; F0722-8837; 0A0524AE-D755-4E91-A73A-2AD867FE676A; 3-Indoleacetic acid, plant cell culture tested, crystalline"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB07950	.	.	175.18	2	C10H9NO2	53.1	205	1.4	13	2	2	"InChI=1S/C10H9NO2/c12-10(13)5-7-6-11-9-4-2-1-3-8(7)9/h1-4,6,11H,5H2,(H,12,13)"	C1=CC=C2C(=C1)C(=CN2)CC(=O)O	SEOVTRFCIGRIMH-UHFFFAOYSA-N
DG01775	Melatonin	896	"Melatonin; 73-31-4; Melatonine; N-Acetyl-5-methoxytryptamine; N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide; Circadin; 5-Methoxy-N-acetyltryptamine; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide; Melatol; Melovine; Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-; N-[2-(5-methoxyindol-3-yl)ethyl]acetamide; N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide; UNII-JL5DK93RCL; N-acetyl-5-methoxy-tryptamine; NSC 113928; 8041-44-9; CHEMBL45; MFCD00005655; JL5DK93RCL; Acetamide, N-(2-(5-methoxyindol-3-yl)ethyl)-; 3-(n-acetyl-2-aminoethyl)-5-methoxyindole; Melatonex; CHEBI:16796; Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]-; NSC-56423; NSC113928; NSC-113928; CAS-73-31-4; NCGC00015680-11; DSSTox_CID_2421; DSSTox_RID_76585; DSSTox_GSID_22421; Melapure; Posidorm; Primex; WLN: T56 BMJ D2MV1 GO1; [3H]melatonin; Melatonina (TN); [3H]-melatonin; ML1; SMR000326666; CCRIS 3472; N-(2-(5-methoxyindol-3-yl)ethyl)-Acetamide; N-[2-(5-methoxyindol-3-yl)ethyl]-Acetamide; N-[2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide; SR-01000075559; EINECS 200-797-7; BRN 0205542; [3H]MLT; Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)- (9CI); Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI); Melatonine;; Guna-dermo; HSDB 7509; Melatobel (TN); Melatonin (JAN); TNP00300; Prestwick_312; N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide; Spectrum_000185; Guna-dermo (Salt/Mix); Primex (8CI,9CI); Prestwick0_000458; Prestwick1_000458; Prestwick2_000458; Prestwick3_000458; Spectrum2_001344; Spectrum3_001393; Spectrum4_000066; Spectrum5_001745; Lopac-M-5250; M1105; ChemDiv2_003916; M 5250; M-1200; M-1250; Melatonin, >=99.5%; Lopac0_000787; Oprea1_104553; Oprea1_814234; SCHEMBL19018; BSPBio_000536; BSPBio_003006; GTPL224; KBioGR_000591; KBioSS_000665; 5-22-12-00042 (Beilstein Handbook Reference); Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}; MLS000859594; MLS001055382; MLS001240204; 5-methoxy n-acetyl-tryptamine; BIDD:ER0618; DivK1c_000353; SPECTRUM1500690; SPBio_001527; SPBio_002475; Melatonin (synth.) ultra-pure; BDBM9019; BPBio1_000590; GTPL1357; Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}; DTXSID1022421; HMS501B15; KBio1_000353; KBio2_000665; KBio2_003233; KBio2_005801; KBio3_002226; ZINC57060; BCI-049; Melatonin 1.0 mg/ml in Methanol; NINDS_000353; 3-N-Acetyl-5-methoxyl tryptamine; HMS1380B22; HMS1569K18; HMS1921E04; HMS2089F09; HMS2096K18; HMS2233D23; HMS3262M16; HMS3370J20; HMS3413P14; HMS3654A22; HMS3677P14; HMS3713K18; HMS3884M05; Melatonin (synth.) standard-grade; ACT03490; AMY33320; BCP28154; HY-B0075; NSC56423; Tox21_110195; Tox21_201527; Tox21_302926; Tox21_500787; CCG-38837; HSCI1_000400; Melatonin, powder, >=98% (TLC); STK386880; AKOS000276269; Tox21_110195_1; CS-1769; DB01065; J5.258B; KS-1454; LP00787; MCULE-1497884152; SDCCGMLS-0065812.P001; SDCCGMLS-0065812.P002; SDCCGSBI-0050765.P003; IDI1_000353; IDI1_002631; SMP2_000309; N-acetyl-5-methoxy-tryptamine Melatonine; NCGC00015680-01; NCGC00015680-02; NCGC00015680-03; NCGC00015680-04; NCGC00015680-05; NCGC00015680-06; NCGC00015680-07; NCGC00015680-08; NCGC00015680-09; NCGC00015680-10; NCGC00015680-12; NCGC00015680-13; NCGC00015680-14; NCGC00015680-15; NCGC00015680-16; NCGC00015680-18; NCGC00015680-35; NCGC00090727-01; NCGC00090727-02; NCGC00090727-03; NCGC00090727-04; NCGC00090727-05; NCGC00090727-06; NCGC00090727-07; NCGC00090727-08; NCGC00090727-09; NCGC00256404-01; NCGC00259077-01; NCGC00261472-01; AC-10019; BA164660; NCI60_004378; SY051401; AB00053279; EU-0100787; FT-0628191; FT-0658928; FT-0670984; S1204; SW196607-4; C01598; D08170; J10164; AB00053279-10; AB00053279_12; {N-[2-(5-methoxyindol-3-yl)ethyl]-} Acetamide; 005M655; A929721; L001261; N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-Acetamide; Q180912; SR-01000075559-1; SR-01000075559-6; SR-01000075559-7; SR-01000075559-8; {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-} Acetamide; BRD-K97530723-001-07-6; BRD-K97530723-001-11-8; F1929-1777; Melatonin, British Pharmacopoeia (BP) Reference Standard; 0E2B08C1-B325-45B1-8939-6F9081EFDFA4; Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]- (6CI,8CI); Melatonin, United States Pharmacopeia (USP) Reference Standard; Melatonin, Pharmaceutical Secondary Standard; Certified Reference Material; Melatonin solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:16796	DB01065	DR1018	.	232.28	4	C13H16N2O2	54.1	270	0.8	17	2	2	"InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)"	CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC	DRLFMBDRBRZALE-UHFFFAOYSA-N
DG01776	Nickel	935	"7440-02-0; Ni; Nickel; Raney alloy; Nickel ion; niccolum; niquel; Nickel foil; Nickel, ion (Ni1+); Nickel,Raney Nickel; UNII-7OV03QG267; nickel(1+); UNII-NUZ5T2QN2V; NICKEL (III) ION; NUZ5T2QN2V; 28Ni; Nickel powder; Nickel rod; Nickel wire; Nickel nanowires; CHEBI:28112; 7OV03QG267; MFCD00011137; Fibrex; Nickel catalyst; Fibrex P; Nickel, elemental; Nichel [Italian]; Nickel 207; Alcan 756; Metallic nickel; Niccolum metallicum; NI 0901-S (harshaw); Nickel Ultrathin foil, 1.0 micron thick; CCRIS 427; EL12; NP 2; Ni 4303T; HSDB 1096; Ni 270; Nickel wire, 0.5mm (0.02in) dia, annealed; Nickel wire, 1.0mm (0.04in) dia, annealed; Nickel wire, 2.0mm (0.08in) dia, annealed; Nickel, elemental/metal; Ni 0901-S; RCH 55/5; Nickel foil, 0.025mm (0.001in) thick, annealed; Nickel, soluble compounds; EINECS 231-111-4; Nickel [Nickel and nickel compounds]; CI 77775; Nickel hydride; Nickel pellets; Nickel pieces; Nickel tubing; Nickel Nanorods; Nickel Nanowire; Nickel, crucible, cylindrical, length 1 pcs, outside diameter 33mm; Nickel, crucible, cylindrical, length 1 pcs, outside diameter 47mm; Raney Nickle; Raney-Nickel; Raney-Nickle; RaneyTM nickel; Nano Nickel; Raney's nickel; C.I. 77775; Ni on silica; Nickel on silica; RaNi; Nickel Nanoprisms; nickel on alumina; Raney(R) nickel; Nickel Monohydride; nickel(I) cation; Nickel Metal Foam; Nickel Nanoparticle; Nickel Metal Wires; 3NI; Nickel atomic spectroscopy standard concentrate 10.00 g Ni, 10.00 g/L, for 1L standard solution, analytical standard; Raney nickel, fine; Raney (R) nickel; Nickel metal and insoluble compounds; Nickel Nanoparticles; nickel(1+) ion; Ra-Ni; Nickel ion(1+); Nickel, metal and insoluble compounds; Nickel Nano Dispersion; Nickel on silica/alumina; Skeletal Nickel Catalyst; Activated Nickel Catalyst; Nickel [Nickel and certain nickel compounds]; Epitope ID:113234; Nanocrystalline Nickel Foil; Nickel Nanowires Properties; Ultra Thin Nickel Nanofoil; EC 231-111-4; nickel sponge metal catalyst; Nickel powder, -100 mesh; Nickel powder, -325 mesh; Nickel, metal, soluble, insoluble, and inorganic; Ni(+); Nickel ~60wt% on kieselguhr; Nickel Metal Organic Framework; Nickel Metal-Organic Framework; Nickel, p.a., 99.8%; DTXSID2020925; Nickel Powder, 99.5+% Nano; CHEBI:30399; Carbon Coated Nickel Nanoparticle; DTXSID20872443; Nickel nanopowder, APS 5-20nm; Nickel powder, -50+100 mesh; Nickel powder, APS 3-7 micron; Submicron Superfine Nickel Powder; Nickel powder, -150+200 mesh; BCP27597; Nickel wire cloth, 34 x 34 mesh; Nickel plating solution, electroless; MFCD06798735; Nickel based Metal Organic Framework; Nickel-based Metal-Organic Framework; Nickel rod, 12.7mm (0.5in) dia; Nickel rod, 3.2mm (0.12in) dia; AKOS005259071; Nickel powder, spherical, -300 mesh; Nickel powder, spherical, -400 mesh; Nickel Silica Core Shell Nanoparticles; Nickel Silver Core/Shell Nanoparticles; Nickel pieces, 5x5cm (2.0x2.0in); Nickel rod, 6.35mm (0.25in) dia; Nickel foil, 1.0mm (0.04in) thick; Nickel foil, 2.0mm (0.08in) thick; Nickel foil, 0.1mm (0.004in) thick; Nickel foil, 0.25mm (0.01in) thick; Nickel powder, -120 mesh, Puratronic ; BP-12712; Nickel lump, vacuum remelted, low Oxygen; Nickel plate, 6.35mm (0.25in) thick; Nickel powder, low carbon, Puratronic(R); Nickel wire, 0.38mm (0.015in) dia; Nickel wire, 0.63mm (0.025in) dia; Nickel, hollow spheres, ca. 3.5mm dia.; Nickel shot, 3-25mm (0.1-0.98in); Nickel Ultrathin foil, 0.25 micron thick; Copper Telluride (CuTe) Sputtering Targets; Nickel foil, 0.025mm (0.001in) thick; Nickel plating solution, semi-bright finish; Nickel powder, spherical, -100+325 mesh; Nickel wire, 1.0mm (0.04in) dia, hard; Nickel, rod, 50mm, diameter 30mm, 99%; Nickel, rod, 50mm, diameter 40mm, 99%; FT-0703645; Nickel, foil, thickness 1.0 mm, 99.98%; Nickel, rod, 100mm, diameter 30mm, 99%; Nickel, rod, 100mm, diameter 40mm, 99%; Nickel, rod, 200mm, diameter 30mm, 99%; Nickel, rod, 200mm, diameter 40mm, 99%; Nickel, foil, thickness 1.0 mm, 99.995%; Nickel, rod, 100mm, diameter 3.0mm, 99%; Nickel, rod, 100mm, diameter 9.5mm, 99%; Nickel, rod, 200mm, diameter 3.0mm, 99%; Nickel, rod, 200mm, diameter 9.5mm, 99%; Nickel, rod, 500mm, diameter 3.0mm, 99%; Nickel, rod, 500mm, diameter 9.5mm, 99%; Nickel, wire, diam. 0.25 mm, >=99.9%; C00291; Nickel flake, -325 mesh, 0.37 micron thick; Nickel Thinfoil, 0.01mm (0.0004in) thick; Nickel wire, 0.01mm (0.0004in) dia, hard; Nickel wire, 0.025mm (0.001in) dia, hard; Nickel, rod, 1000mm, diameter 3.0mm, 99%; Nickel, rod, 1000mm, diameter 9.5mm, 99%; Nickel, rod, 100mm, diameter 12.0mm, 99%; Nickel, rod, 100mm, diameter 20.0mm, 99%; Nickel, rod, 100mm, diameter 6.35mm, 99%; Nickel, rod, 200mm, diameter 12.0mm, 99%; Nickel, rod, 200mm, diameter 20.0mm, 99%; Nickel, rod, 200mm, diameter 6.35mm, 99%; Nickel, rod, 500mm, diameter 12.0mm, 99%; Nickel, rod, 500mm, diameter 20.0mm, 99%; Nickel, rod, 500mm, diameter 6.35mm, 99%; Nickel foil, 0.5mm (0.02in) thick, annealed; Nickel isotopic standard, NIST(R) SRM(R) 986; Nickel wire, 0.25mm (0.01in) dia, annealed; Nickel wire, 1.6mm (0.063in) dia, annealed; Nickel, foil, thickness 0.125 mm, >=99.9%; Nickel, rod, 1000mm, diameter 12.0mm, 99%; Nickel, rod, 1000mm, diameter 20.0mm, 99%; Nickel, rod, 1000mm, diameter 6.35mm, 99%; Nickel, rod, 50mm, diameter 16mm, 99.99+%; A838111; Nickel foil, 0.05mm (0.002in) thick, annealed; Nickel plating solution, electroless, ammonia free; Nickel Thinfoil, 0.0025mm (0.0001in) thick; Nickel wire, 1.0mm (0.04in) dia, Puratronic ; Nickel, foil, 50x50mm, thickness 1.6mm, 99%; Nickel, rod, 100mm, diameter 16mm, 99.99+%; Nickel, rod, 200mm, diameter 16mm, 99.99+%; Nickel, rod, 50mm, diameter 25.4mm, 99.98%; Nickel, rod, 50mm, diameter 3.3mm, 99.99+%; Nickel, rod, 50mm, diameter 5.0mm, 99.99+%; Nickel foil, 0.127mm (0.005in) thick, annealed; Nickel foil, 0.787mm (0.031in) thick, annealed; Nickel Thinfoil, 0.0125mm (0.000492in) thick; Nickel, foil, 100x100mm, thickness 1.6mm, 99%; Nickel, foil, 150x150mm, thickness 1.6mm, 99%; Nickel, foil, 1m coil, thickness 0.02mm, 99.9%; Nickel, foil, 1m coil, thickness 0.03mm, 99.9%; Nickel, foil, 1m coil, thickness 0.05mm, 99.9%; Nickel, foil, 2m coil, thickness 0.02mm, 99.9%; Nickel, foil, 2m coil, thickness 0.03mm, 99.9%; Nickel, foil, 2m coil, thickness 0.05mm, 99.9%; Nickel, foil, 300x300mm, thickness 1.6mm, 99%; Nickel, pellets, 20g, max. size 5mm, 99.99+%; Nickel, pellets, 50g, max. size 5mm, 99.99+%; Nickel, powder, <1 mum, 99.8% trace metals basis; Nickel, rod, 100mm, diameter 1.5mm, 99.99+%; Nickel, rod, 100mm, diameter 12.7mm, 99.98%; Nickel, rod, 100mm, diameter 2.0mm, 99.99+%; Nickel, rod, 100mm, diameter 25.4mm, 99.98%; Nickel, rod, 100mm, diameter 3.3mm, 99.99+%; Nickel, rod, 100mm, diameter 5.0mm, 99.99+%; Nickel, rod, 200mm, diameter 1.5mm, 99.99+%; Nickel, rod, 200mm, diameter 12.7mm, 99.98%; Nickel, rod, 200mm, diameter 2.0mm, 99.99+%; Nickel, rod, 200mm, diameter 25.4mm, 99.98%; Nickel, rod, 200mm, diameter 3.3mm, 99.99+%; Nickel, rod, 200mm, diameter 5.0mm, 99.99+%; Nickel, rod, 500mm, diameter 1.5mm, 99.99+%; Nickel, rod, 500mm, diameter 12.7mm, 99.98%; Nickel, rod, 500mm, diameter 2.0mm, 99.99+%; Nickel, rod, 500mm, diameter 3.3mm, 99.99+%; Nickel, rod, 50mm, diameter 10.0mm, 99.99+%; Nickel, rod, 50mm, diameter 25.4mm, 99.99+%; Nickel Powder, 99.9+% (metal basis, O<10%) Nano; Nickel, foil, 1m coil, thickness 0.015mm, 99.9%; Nickel, foil, 1m coil, thickness 0.01mm, 99.95%; Nickel, foil, 1m coil, thickness 0.025mm, 99.9%; Nickel, foil, 1m coil, thickness 0.038mm, 99.9%; Nickel, foil, 2m coil, thickness 0.015mm, 99.9%; Nickel, foil, 2m coil, thickness 0.01mm, 99.95%; Nickel, foil, 2m coil, thickness 0.025mm, 99.9%; Nickel, foil, 2m coil, thickness 0.038mm, 99.9%; Nickel, foil, 4mm disks, thickness 0.02mm, 99.9%; Nickel, foil, 4mm disks, thickness 0.03mm, 99.9%; Nickel, foil, 4mm disks, thickness 0.05mm, 99.9%; Nickel, foil, 5m coil, thickness 0.01mm, 99.95%; Nickel, foil, 6mm disks, thickness 0.02mm, 99.9%; Nickel, foil, 6mm disks, thickness 0.03mm, 99.9%; Nickel, foil, 6mm disks, thickness 0.05mm, 99.9%; Nickel, foil, 8mm disks, thickness 0.02mm, 99.9%; Nickel, foil, 8mm disks, thickness 0.03mm, 99.9%; Nickel, foil, 8mm disks, thickness 0.05mm, 99.9%; Nickel, pellets, 100g, max. size 10mm, 99.99+%; Nickel, pellets, 100g, max. size 10mm, 99.999%; Nickel, pellets, 100g, max. size 15mm, 99.99+%; Nickel, pellets, 100g, max. size 20mm, 99.99+%; Nickel, pellets, 100g, max. size 5mm, 99.99+%; Nickel, pellets, 20g, max. size 10mm, 99.99+%; Nickel, pellets, 20g, max. size 10mm, 99.999%; Nickel, pellets, 20g, max. size 15mm, 99.99+%; Nickel, pellets, 20g, max. size 20mm, 99.99+%; Nickel, pellets, 50g, max. size 10mm, 99.99+%; Nickel, pellets, 50g, max. size 10mm, 99.999%; Nickel, pellets, 50g, max. size 15mm, 99.99+%; Nickel, pellets, 50g, max. size 20mm, 99.99+%; Nickel, powder, <50 mum, 99.7% trace metals basis; Nickel, rod, 1000mm, diameter 1.5mm, 99.99+%; Nickel, rod, 1000mm, diameter 12.7mm, 99.98%; Nickel, rod, 1000mm, diameter 2.0mm, 99.99+%; Nickel, rod, 100mm, diameter 10.0mm, 99.99+%; Nickel, rod, 100mm, diameter 2.0mm, annealed, 99%; Nickel, rod, 100mm, diameter 25.4mm, 99.99+%; Nickel, rod, 200mm, diameter 10.0mm, 99.99+%; Nickel, rod, 200mm, diameter 2.0mm, annealed, 99%; Nickel, rod, 200mm, diameter 25.4mm, 99.99+%; Nickel, rod, 500mm, diameter 2.0mm, annealed, 99%; Q27113549; Nickel, foil, 0.5m coil, thickness 0.015mm, 99.9%; Nickel, foil, 0.5m coil, thickness 0.01mm, 99.95%; Nickel, foil, 0.5m coil, thickness 0.025mm, 99.9%; Nickel, foil, 0.5m coil, thickness 0.02mm, 99.9%; Nickel, foil, 0.5m coil, thickness 0.038mm, 99.9%; Nickel, foil, 0.5m coil, thickness 0.03mm, 99.9%; Nickel, foil, 0.5m coil, thickness 0.05mm, 99.9%; Nickel, foil, 10m coil, thickness 0.01mm, 99.95%; Nickel, foil, 10mm disks, thickness 0.015mm, 99.9%; Nickel, foil, 10mm disks, thickness 0.01mm, 99.95%; Nickel, foil, 10mm disks, thickness 0.025mm, 99.9%; Nickel, foil, 10mm disks, thickness 0.02mm, 99.9%; Nickel, foil, 10mm disks, thickness 0.038mm, 99.9%; Nickel, foil, 10mm disks, thickness 0.03mm, 99.9%; Nickel, foil, 10mm disks, thickness 0.05mm, 99.9%; Nickel, foil, 15mm disks, thickness 0.015mm, 99.9%; Nickel, foil, 15mm disks, thickness 0.01mm, 99.95%; Nickel, foil, 15mm disks, thickness 0.025mm, 99.9%; Nickel"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	58.693	0	Ni	0	0	.	1	0	0	InChI=1S/Ni	[Ni]	PXHVJJICTQNCMI-UHFFFAOYSA-N
DG01777	Oxygen	977	"7782-44-7; O; Oxygen; Molecular oxygen; oxygen molecule; Dioxygen; Pure oxygen; Oxygenium; Liquid oxygen; Hyperoxia; Sauerstoff; Oxygen-16; Oxygen (liquid); Oxygen, liquified; Oxygenium medicinale; oxygene; CCRIS 1228; HSDB 5054; O2; UN1072; UN1073; UNII-S88TT14065; Peroxide Ion; CHEBI:15379; S88TT14065; LOX; E948; E-948; Oxygene [French]; Oxigeno [Spanish]; OXY; Compressed oxygen; Oxygen [USP]; EINECS 231-956-9; dioxidanediyl; dioxygene; Disauerstoff; oxygen monoxide; Peroxy radical; singlet dioxygen; triplet dioxygen; Oxygen USP; Oxygen, compressed; Oxygen 93 percent; singlet molecular oxygen; triplet molecular oxygen; Oxygen (8CI,9CI); Oxygen (JP17/USP); dioxygen(2.) (triplet); Oxygen, >=99.6%; Oxygen, compressed [UN1072] [Nonflammable gas]; RNS60 COMPONENT OXYGEN; [OO]; INS NO.948; Oxygen, >=99.998%; CHEMBL1234886; DTXSID2037681; RNS-60 COMPONENT OXYGEN; CHEBI:26689; CHEBI:27140; INS-948; Oxygen, refrigerated liquid (cryogenic liquid) [UN1073] [Nonflammable gas]; DB09140; UN 1072; UN 1073; Oxygen, Messer(R) CANGas, 99.999%; DS-014940; (1)O2; E 948; C00007; D00003; O2(2.); Oxygen, refrigerated liquid (cryogenic liquid); Oxygen, compressed [UN1072] [Nonflammable gas]; (O2)(..); (O2)(2.); Q5203615; UNII-K21NZZ5Y0B component MYMOFIZGZYHOMD-UHFFFAOYSA-N; AQUANAL(TM)-plus oxygen (O2) 1-12 mg/L, refill pack for 37428; AQUANAL(TM)-plus oxygen (O2) 1-12 mg/L, test set with color comparator; 4-Chloro-3-(chloro-difluoro-methyl)-4,4-difluoro-1-thiophen-2-yl-but-2-en-2-one; Oxygen, refrigerated liquid (cryogenic liquid) [UN1073] [Nonflammable gas]"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	31.999	0	O2	34.1	0	-1.1	2	0	2	InChI=1S/O2/c1-2	O=O	MYMOFIZGZYHOMD-UHFFFAOYSA-N
DG01778	Acetaminophen	1983	"Acetaminophen; Paracetamol; 4-Acetamidophenol; 103-90-2; N-(4-Hydroxyphenyl)acetamide; APAP; Tylenol; Panadol; Acetaminofen; Datril; N-Acetyl-p-aminophenol; p-Hydroxyacetanilide; 4'-Hydroxyacetanilide; p-Acetamidophenol; Algotropyl; Lonarid; Naprinol; Acamol; Acenol; Anelix; Multin; p-Acetaminophenol; Abensanil; Acetagesic; Acetalgin; Clixodyne; Doliprane; Gelocatil; Injectapap; Liquagesic; Pyrinazine; Servigesic; Alvedon; Anaflon; Apamide; Dymadon; Febridol; Febrilix; Febrolin; Finimal; Homoolan; Lestemp; Paracet; Tabalgin; Tralgon; Tussapap; Valadol; Valgesic; Alpiny; Amadil; Anhiba; Calpol; Dirox; Eneril; Fendon; Hedex; Lyteca; Pacemo; Panets; Parmol; Tapar; Tempra; Paracetamolo; Biocetamol; Dolprone; Momentum; Ortensan; Paldesic; Vermidon; Banesin; Captin; Disprol; Enelfa; Neopap; Salzone; Exdol; p-Acetylaminophenol; Acetamide, N-(4-hydroxyphenyl)-; Febro-Gesic; NEBS; Paracetamolum; Dafalgan; Dolgesic; Elixodyne; Febrectal; Tempanal; Abenol; Apacet; Apadon; Cetadol; Fensum; Janupap; Minoset; Napafen; Neodol; Nobedon; Pacemol; Panodil; Parapan; Pedric; Phendon; Rounox; Suppap; Korum; Pinex; Temlo; 4-(Acetylamino)phenol; Ben-u-ron; Dial-A-Gesic; Anacin-3; Calmanticold; Codoliprane; Demogripal; Dolegrippin; Doloreduct; Dristancito; Duracetamol; Eu-Med; Grippostad; Gynospasmine; Medocodene; Paedialgon; Paracetanol; Parakapton; Pediapirin; Phenipirin; Phogoglandin; Predualito; Sanicopyrine; Scentalgyl; Sunetheton; Tachiprina; Termalgine; Treuphadol; Abrolet; Acertol; Acetamol; Acetofen; Afebrin; Afebryl; Aferadol; Algesidal; Algomol; Alpinyl; Analter; Antidol; Apitrelal; Atralidon; Babikan; Bacetamol; Cadafen; Calapol; Causalon; Cefalex; Codabrol; Codalgin; Codapane; Codicet; Codisal; Cofamol; Cosutone; Cuponol; Curadon; Custodial; Darocet; Daygrip; Deminofen; Democyl; Desfebre; Dimindol; Dolefin; Dolofugin; Dolorfug; Dolorstop; Dolotec; Dorocoff; Dularin; Durapan; Ecosetol; Excipain; Fanalgic; Farmadol; Febranine; Febrectol; Febricet; Febrinol; Fepanil; Finiweh; Fluparmol; Geluprane; Ildamol; Inalgex; Infadrops; Kataprin; Labamol; Lekadol; Lemgrip; Lupocet; Magnidol; Malidens; Maxadol; Mexalen; Minafen; Miralgin; Nealgyl; Neodolito; Neotrend; Neuridon; Nodolex; Oralgan; Oxycocet; Pacimol; Panacete; Panadeine; Panadiene; Panaleve; Panamax; Panasorbe; Panofen; Pantalgin; Paracemol; Paracenol; Paracetol; Paracin; Paracod; Paracodol; Parador; Paradrops; Paralen; Paralief; Paralink; Paralyoc; Paramol; Paramolan; Paranox; Parasedol; Parasin; Paraspen; Parcetol; Parogal; Pediatrix; Piramin; Pirinasol; Polmofen; Predimol; Prontina; Puernol; Pulmofen; Pyrigesic; Pyromed; Remedol; Rivalgyl; Rubophen; Rupemol; Sanicet; Schmerzex; Sedalito; Semolacin; Seskamol; Setakop; Setamol; Sifenol; Sinaspril; Sinedol; Stanback; Stopain; Supofen; Tazamol; Termacet; Termalgin; Termofren; Titralgan; Tricoton; Upsanol; Utragin; Veralgina; Viruflu; Vivimed; Zatinol; Abrol; Algina; Anapap; Andox; Arfen; Asetam; Asomal; Aspac; Asplin; Benmyo; Curpol; Dhamol; Dolcor; Dolko; Dresan; Dypap; Febrex; Febrin; Lemsip; Malgis; Oltyl; Paceco; Pacet; Paedol; Painex; Pamol; Panex; Parake; Paroma; Plicet; Prodol; Reliv; Scanol; Setol; Sinmol; Tiffy; Tylex; Tylol; Tymol; Verpol; Volpan; Zolben; NeoCitran; NilnOcen; Nina; RubieMol; Vips; Supadol mono; Treupel mon; Bickie-mol; Fortalidon P; Gattaphen T; Gripin Bebe; Influbene N; Lonarid Mono; Lyteca Syrup; Panadeine Co; Dymadon Co; Toximer P; Treupel N; Accu-Tap; 4-Acetaminophenol; Helon N; Malex N; Spalt N; Tylex CD; N-Acetyl-4-aminophenol; SK-Apap; Paracetamole; Conacetol; Darvocet; Empracet; Panasorb; Perfalgan; A-Per; Apamid; Ofirmev; Parelan; Prompt; Vicodin; Fevor; Freka-cetamol; Codisal Forte; Croix Blanche; Dolorol Forte; Dymadon Forte; Junior Disprol; Kinder Finimal; Liquigesic Co; Mono Praecimed; Percocet-Demi; Perdolan Mono; Rockamol Plus; Viclor Richet; Actifed Plus; Kratofin simplex; Neo-Fepramol; Paracetamol AL; Paracetamol BC; Paracetamol PB; Acetanilide, 4'-hydroxy-; Claradol Codeine; Geralgine-P; Melabon Infantil; Migraleve Yellow; Paracetamol Saar; Pyregesic-C; Anti-Algos; Para-Suppo; Pasolind N; Supramol-M; No-Febril; Panado-Co; Para-Tabs; Paracetamol Hexal; Paracetamol Raffo; Paracetamol Rosch; Paracetamol Stada; Dol-Stop; Anadin dla dzieci; p-Hydroxyphenolacetamide; Percocet-5; Cod-Acamol Forte; Contra-Schmerz P; Hy-Phen; Medinol Paediatric; Paracetamol Basics; Panado-Co Caplets; Paracetamol von ct; Pe-Tam; Paracetamol Fecofar; Paracetamol Harkley; Paracetamol Heumann; Paracetamol Nycomed; Codral Pain Relief; Paracetamol Hanseler; Paracetamol Winthrop; 4-Hydroxyacetanilide; Phenaphen W/Codeine; Spalt fur die nacht; A.F. Anacin; Capital with Codeine; Paracetamol Genericon; Anexsia; Demilets; Endecon; Intensin; Naldegesic; Propacet; Resfenol; Theraflu; Wygesic; Paracetamol Ratiopharm; Coricidin Sinus; Paracetamol Italfarmaco; Sudafed Sinus; Coricidin D; Paracetamol DC; Quiet World; Paracetamol Antipanin P; St Joseph Aspirin-Free; New Cortal for Children; INFANTS' FEVERALL; St. Joseph Fever Reducer; Midol Teen Formula; Paracetamol Dr. Schmidgall; Acetamide, N-(p-hydroxyphenyl)-; Aspirin-Free Anacin; Children's Tylenol Chewable; NCI-C55801; PCM Paracetamol Lichtenstein; Tylenol Allergy Sinus; p-(Acetylamino)phenol; Rhinex D-Lay Tablets; acetaminophene; Midol Regular Strength; Paracetamol SmithKline Beecham; Scherzatabletten Rezeptur 534; Efferalgan; Percogesic with Codeine; 4-Hydroxyanilid kyseliny octove; Bayer Select Head Cold; Bayer Select Allergy-Sinus; Bayer Select Headache Pain; Dristan Cold No Drowsiness; Prestwick_13; St Joseph Aspirin-Free for Children; UNII-362O9ITL9D; 4-acetylaminophenol; Children's Acetaminophen Elixir Drops; MFCD00002328; Children's Acetaminophen Oral Solution; Midol PM Night Time Formula; Triaminic Sore Throat Formula; p-hydroxy-acetanilid; N-(4-hydroxyphenyl)ethanamide; Bayer Select Sinus Pain Relief; Phenol, p-acetamido-; Sine-Off Sinus Medicine Caplets; CHEBI:46195; Roxicet 5/500; Tocris-1706; N-acetyl-para-aminophenol; 4-(N-Acetylamino)phenol; Acetaminophen (4-hydroxyacetanilide); Bayer Select Menstrual Multi-Symptom; Acetaco; n-acetyl-4-hydroxyaniline; St. Joseph Cold Tablets for Children; CHEMBL112; N-(4-Hydroxyphenyl)acetamide (Tylenol); N-(4-hydroxyphenyl)-acetamide; 362O9ITL9D; Aminofen; DTXSID2020006; Atasol; Duaneo; Duorol; component of Dialog; component of Dilone; Fever All; NSC-3991; component of Endecon; component of Percocet; NSC-109028; component of Phenaphen; TYL; component of Percogesic; DSSTox_CID_6; NCGC00016361-07; Acetominophen; Actamin; CAS-103-90-2; Pasolind; Redutemp; Robigesic; Valorin; Aceta Elixir; Dafalgan Codeine; Jin Gang; WLN: QR DMV1; DSSTox_RID_75318; DSSTox_GSID_20006; component of Hycomine Compound; Acetavance; Paracetamolo [Italian]; Calonal; Flexsure; Acenol (pharmaceutical); N-(4-Hydroxyphenyl)acetanilide; Drixoral Sinus; Aceta Tablets; Paracetamol [INN:BAN]; Valorin Extra; CCRIS 3; Snaplets-FR; Oraphen-PD; Phenaphen Caplets; Paracetamolum [INN-Latin]; Tylenol (caplet); Tylenol (geltab); Tylenol 8-Hour; SMR000112065; Tavist Allergy/Sinus/Headache; Dapa X-S; Drixoral Cold & Flu; HSDB 3001; SR-01000597517; EINECS 203-157-5; 222 AF; Acetaminophen [USP:JAN]; paracetamol (acetaminophen); NSC 109028; acetominophene; 4-Hydroxyanilid kyseliny octove [Czech]; Children's Acetaminophen Elixir Solution; Claratal; Daphalgan; Resprin; Apacet Capsules; Atasol Caplets; Atasol Tablets; Tempra Caplets; Tylenol Caplets; Tylenol Elixir; Tylenol Gelcaps; Tylenol Tablets; Actamin Extra; Actamin Super; Aminofen Max; ANEXSIA 10/660; Apacet Elixir; Atasol Drops; Exdol Strong; p-Acetoaminophen; Tempra Drops; Tempra Syrup; Tylenol Drops; alpha-Per; Citramon P; Excedrin Caplets; Dial-alpha-gesic; Apo-Acetaminophen; 4-acetominophenol; Genebs X-Tra; Paracetamol;Tylenol; 4-acetamido phenol; 4-acetamido-phenol; Tempra D.S; APAP, Paracetamol; p-hydroxyacetoanilide; Paracetamol (INN); Tylenol (TN); Supac (Salt/Mix); Tylox (Salt/Mix); Zydone (Salt/Mix); Atasol Forte Caplets; Atasol Forte Tablets; Atasol Oral Solution; para-acetylaminophenol; Anexsia (Salt/Mix); Endecon (Salt/Mix); Sinubid (Salt/Mix); Talacen (Salt/Mix); Vicodin (Salt/Mix); Wygesic (Salt/Mix); Acetaminophen Uniserts; Datril Extra-Strength; Tylenol Infants Drops; Demilets (Salt/Mix); Empracet (Salt/Mix); Intensin (Salt/Mix); Propacet (Salt/Mix); Suppap-120; Suppap-325; Suppap-650; Panadol Extra Strength; TheraFlu (Salt/Mix); Coricidin (Salt/Mix); Liquiprin (Salt/Mix); Hy-Phen (Salt/Mix); IV-APAP; phenol derivative, 11; Spectrum_000016; Tempra Chewable Tablets; Naldegesic (Salt/Mix); Actimol Chewable Tablets; Feverall Junior Strength; Darvocet-N (Salt/Mix); Anacin-3 Extra Strength; Liquiprin Infants' Drops; N-acetyl para aminophenol; Prestwick0_000868; Prestwick1_000868; Prestwick2_000868; Prestwick3_000868; Spectrum2_000085; Spectrum3_000283; Spectrum4_000140; Spectrum5_000736; Coricidin D (Salt/Mix); Quiet World (Salt/Mix); Genapap Children's Elixir; Tylenol Children's Elixir; 4-Acetamidophenol, 98%; Actifed Plus (Salt/Mix); Epitope ID:117710; Genapap Children's Tablets; Sudafed Sinus (Salt/Mix); EC 203-157-5; Actimol Infants' Suspension; Drixoral Sinus (Salt/Mix); Liquiprin Children's Elixir; SCHEMBL3480; Acetaminophen (JP17/USP); Coricidin Sinus (Salt/Mix); N-(4-hydroxyfenyl)ethanamid; BSPBio_000915; BSPBio_001786; DDS-06A; KBioGR_000560; KBioSS_000356; 4-13-00-01091 (Beilstein Handbook Reference); Actimol Children's Suspension; Apacet Extra Strength Caplets; Apacet Extra Strength Tablets; Aspirin-Free Excedrin Caplets; Genebs Extra Strength Caplets; MLS001146925; MLS001331684; MLS002154041; BIDD:GT0005; DivK1c_000660; SPECTRUM1500101; Genapap Extra Strength Caplets; Genapap Extra Strength Tablets; SPBio_000010; SPBio_002836; Tapanol Extra Strength Caplets; Tapanol Extra Strength Tablets; Tylenol Extra Strength Caplets; Tylenol Extra Strength Gelcaps; Tylenol Extra Strength Tablets; Actimol Junior Strength Caplets; Apacet Regular Strength Tablets; BPBio1_001007; Excedrin Extra Strength Caplets; Genebs Regular Strength Tablets; GTPL5239; Panadol Junior Strength Caplets; SGCUT00014; Tylenol Junior Strength Caplets; Midol Teen Formula (Salt/Mix); Genapap Regular Strength Tablets; Panadol Maximum Strength Caplets; Panadol Maximum Strength Tablets; SCHEMBL19474893; Tylenol Regular Strength Caplets; Tylenol Regular Strength Tablets; Aspirin-Free Anacin (Salt/Mix); BDBM26197; HMS502A22; KBio1_000660; KBio2_000356; KBio2_002924; KBio2_005492; KBio3_001286; NSC3991; Tylenol Arthritis Extended Relief; Acetaminophen, analytical standard; NINDS_000660; Tylenol Infants' Suspension Drops; BCPP000441; Drixoral Cold & Flu (Salt/Mix); HMS1570N17; HMS1920A03; HMS2091G03; HMS2097N17; HMS2269G20; HMS3268A10; "	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:46195	DB00316	DR0037	DR01006	151.16	1	C8H9NO2	49.3	139	0.5	11	2	2	"InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)"	CC(=O)NC1=CC=C(C=C1)O	RZVAJINKPMORJF-UHFFFAOYSA-N
DG01779	Arecoline	2230	"Arecoline; 63-75-2; Arecolin; Arecaline; Arecholine; Methylarecaiden; Methylarecaidin; Arekolin; Arecoline base; Arecaidine methyl ester; 3-Pyridinecarboxylic acid, 1,2,5,6-tetrahydro-1-methyl-, methyl ester; methyl 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxylate; Methyl N-methyltetrahydronicotinate; N-Methyltetrahydronicotinic acid, methyl ester; Methyl 1,2,5,6-tetrahydro-1-methylnicotinate; UNII-4ALN5933BH; NSC 56321; methyl 1-methyl-3,6-dihydro-2H-pyridine-5-carboxylate; Methyl N-methyl-1,2,5,6-tetrahydronicotinate; 1,2,5,6-Tetrahydro-1-methylnicotinic acid, methyl ester; NICOTINIC ACID, 1,2,5,6-TETRAHYDRO-1-METHYL-, METHYL ESTER; 1-Methyl-delta(sup 3,4)tetrahydro-3-pyridinecarboxylate; 4ALN5933BH; CHEBI:2814; 63-75-2 (free); 1,2,5,6-Tetrahydro-1-methyl-3-pyridinecarboxylic acid methyl ester; NSC-56321; NCGC00015075-04; Arecholin; 1-Methyl-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid methyl ester; DSSTox_CID_2617; DSSTox_RID_76661; DSSTox_GSID_22617; N-Methyl-.delta.-tetrahydronicotinic acid methyl ester; methyl 1-methyl-5,6-dihydro-2H-pyridine-3-carboxylate; N-Methyltetrahydropyridine-.beta.-carboxylic acid methyl ester; MLS000028840; Arecaidine methyl ester;Arecoline base;Methyl arecaidin; Methylarecaidine; NSC56321; CAS-63-75-2; CCRIS 7688; SMR000058258; EINECS 200-565-5; BRN 0123045; Methylarecaidine; arecoline;hydrobromide; Spectrum_000055; N-Methyltetrahydropyridine-beta-carboxylic acid methyl ester; Prestwick0_000402; Prestwick1_000402; Prestwick2_000402; Prestwick3_000402; Spectrum2_000051; Spectrum3_001387; Spectrum4_000810; Spectrum5_001316; Lopac-A-6134; cid_9301; CHEMBL7303; Lopac0_000049; SCHEMBL44065; BSPBio_000324; BSPBio_002974; GTPL296; KBioGR_001299; KBioSS_000435; DivK1c_000810; SPBio_000201; SPBio_002263; BPBio1_000358; MEGxp0_001891; DTXSID3022617; ACon1_002372; BDBM46858; KBio1_000810; KBio2_000435; KBio2_003003; KBio2_005571; KBio3_002194; pyranosyl)- -D-galactopyranoside; Methyl 1-methyl-1,2,5,6-tetrahydro-3-pyridinecarboxylate; NINDS_000810; WLN: T6N CUTJ A1 CVO1; ALBB-035732; NSC56321; Tox21_110079; 7928AF; BBL036229; ZINC52541469; AKOS000520752; Tox21_110079_1; CCG-204145; DB04365; MCULE-7085698770; SB54186; SDCCGMLS-0066647.P001; SDCCGSBI-0050038.P004; IDI1_000810; NCGC00015075-01; NCGC00015075-02; NCGC00015075-03; NCGC00015075-05; NCGC00015075-06; NCGC00015075-07; NCGC00015075-10; NCGC00015075-19; NCGC00162053-01; NCGC00162053-02; NCGC00162053-03; AC-34025; CAS-300-08-3; SBI-0050038.P003; Methyl N-methyl-1,5,6-tetrahydronicotinate; N-Methyl-beta -carboxylic acid methyl ester; FT-0622470; Methyl 1,5,6-tetrahydro-1-methylnicotinate; A13071; AB00053580_08; AB00053580_09; Methyl 1,2,5, 6-tetrahydro-1-methylnicotinate; Methyl N-methyl-1,2,5, 6-tetrahydronicotinate; A820142; L000795; Q423515; n-methyltetrahydronicotinicacidmethylesterhydrobromide; SR-01000075307-9; BRD-K88646909-004-05-5; BRD-K88646909-004-06-3; BRD-K88646909-004-10-5; 1,5,6-Tetrahydro-1-methylnicotinic acid, methyl ester; Nicotinic acid,2,5,6-tetrahydro-1-methyl-, methyl ester; Methyl 1-methyl-1,2,5,6-tetrahydro-3-pyridinecarboxylate #; 3-Pyridinecarboxylic acid,2,5,6-tetrahydro-1-methyl-, methyl ester; methyl 1-methyl-3,6-dihydro-2H-pyridine-5-carboxylate;hydrobromide; 1,2,5,6-Tetrahydro-1-methyl-3-pyridinecarboxylic acid, methyl ester; 1-Methyl-1,2,5,6-tertrahydro-pyridine-3-carboxylicacid methyl ester; 4-Nitrophenyl 2-Acetamido-2-deoxy-(6-O-2-acetamido-2-deoxy- -D-gluco-; 1-methyl-3,6-dihydro-2H-pyridine-5-carboxylic acid methyl ester;hydrobromide"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	CHEBI:2814	DB04365	.	.	155.19	2	C8H13NO2	29.5	187	0.3	11	0	3	"InChI=1S/C8H13NO2/c1-9-5-3-4-7(6-9)8(10)11-2/h4H,3,5-6H2,1-2H3"	CN1CCC=C(C1)C(=O)OC	HJJPJSXJAXAIPN-UHFFFAOYSA-N
DG01780	Benzpyrene	2336	"Benzo[a]pyrene; 50-32-8; 3,4-Benzopyrene; benzo[pqr]tetraphene; BENZO(A)PYRENE; 3,4-Benzpyrene; benzo[def]chrysene; Benzpyrene; 6,7-Benzopyrene; Benz[a]pyrene; 3,4-BP; 3,4-Benz[a]pyrene; 3,4-Benzopirene; 3,4-Benzpyren; Benzo[d,e,f]chrysene; B[a]p; Benz(a)pyrene; (B(a)P); B(a)P; BP; 3,4 Benzpyrene; RCRA waste number U022; 3,4-Benz(a)pyrene; Benzo(d,e,f)chrysene; NSC 21914; Benzo[A]-Pyrene; Benzo(def)chrysene; UNII-3417WMA06D; CHEBI:29865; CHEMBL31184; 3417WMA06D; MFCD00003602; 6699-27-0; 3,4-Benzo(a)pyrene; 3,4-Benzpyren [German]; CCRIS 76; 3,4 Benzopyrene; 3,4-benzylpyrene; 3,4-Benzopirene [Italian]; HSDB 2554; Benzo[a]pyrene solution; Benzo[a]pyrene (BaP); EINECS 200-028-5; RCRA waste no. U022; Benzo(a)pyrene radical cation; AI3-50461; 3,4-Benzypyrene; Benzo(a)pyrene, radical ion(1+); Benzo(a)pyrene, radical ion(1-); Benzo[d,f]chrysene; Benzo(a)pyrene, labeled with tritium; Benzo Pyrene[BAP]; Benzo(3,4)pyrene, radical ion(1+); Spectrum_001871; Coal tar pitch volatiles: benzo(a)pyrene; SpecPlus_000953; DSSTox_CID_139; Spectrum2_001081; Spectrum3_001695; Spectrum4_000609; Spectrum5_001824; Epitope ID:117721; Benzo(a)pyrene [Polycyclic aromatic compounds]; DSSTox_RID_75392; Benzo(a)pyrene [Polycyclic aromatic hydrocarbons]; DSSTox_GSID_20139; BSPBio_003250; KBioGR_001138; KBioSS_002390; MLS002695983; BIDD:ER0497; DivK1c_007049; SPBio_001122; 3,4-Benzopyrene (carcinogen); DTXSID2020139; KBio1_001993; KBio2_002385; KBio2_004953; KBio2_007521; KBio3_002470; HMS3089C04; HMS3746C17; NSC21914; ZINC1530818; Benzo[a]pyrene, >=96% (HPLC); Tox21_200710; BDBM50137506; CCG-39759; NSC-21914; AKOS015907666; AM61580; CS-7789; MCULE-1109963029; CAS-50-32-8; WLN: L D6 B6666 2AB TJ; NCGC00178185-01; NCGC00178185-02; NCGC00258264-01; 34505-58-3; 42299-33-2; NCI60_001824; SMR000393676; SY048151; 3,4-Benzopyrene (purified by sublimation); Benzo[a]pyrene 1000 microg/mL in Acetone; DB-071166; HY-107377; B0085; Benzo[a]pyrene 10 microg/mL in Acetonitrile; FT-0614185; W6563; Benzo[a]pyrene 100 microg/mL in Acetonitrile; Benzo[a]pyrene 100 microg/mL in Cyclohexane; C07535; J10073; A828066; A828067; Benzo[a]pyrene, vial of 1 g, analytical standard; Q306051; BRD-K09668667-001-02-0; Benzo[a]pyrene, certified reference material, TraceCERT(R); UNII-0TNN3Q0D4D component FMMWHPNWAFZXNH-UHFFFAOYSA-N; Benzo[a]pyrene, analytical standard, for environmental analysis; Benzo[a]pyrene solution, 100 mug/mL in cyclohexane, analytical standard; Benzo[a]pyrene solution, certified reference material, 100 mug/mL in methylene chloride; Benzo[a]pyrene solution, certified reference material, TraceCERT(R), 1000 mug/mL in acetone; Benzo[a]pyrene solution, certified reference material, TraceCERT(R), 200 mug/mL in methylene chloride"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	DR01618	252.3	0	C20H12	0	372	6	20	0	0	InChI=1S/C20H12/c1-2-7-17-15(4-1)12-16-9-8-13-5-3-6-14-10-11-18(17)20(16)19(13)14/h1-12H	C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3	FMMWHPNWAFZXNH-UHFFFAOYSA-N
DG01781	Bupivacaine	2474	"Bupivacaine; 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; 2180-92-9; DL-Bupivacaine; Marcaine; 38396-39-3; Bupivacaina; Anekain; Sensorcaine; Carbostesin; (+-)-Bupivacaine; Bupivacainum; 1-Butyl-2',6'-pipecoloxylidide; Exparel; Bupivacainum [INN-Latin]; Bupivacaina [INN-Spanish]; dl-1-Butyl-2',6'-pipecoloxylidide; 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-; 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide; AH 250; Win 11318; Bloqueina; (+/-)-Bupivacaine; 2',6'-Pipecoloxylidide, 1-butyl-; 1-butyl-N-(2,6-dimethylphenyl)-piperidine-2-carboxamide; Marcain; C18H28N2O; SKY0402; CHEBI:77431; Xaracoll; LAC-43; cBupivacaine; Bupivacaine HCL KIT; Bucaine; bupivacaine base; (R)-Bupivacaine HCl; Bucaine (TN); DUR-843; EINECS 218-553-3; EINECS 253-911-2; 14252-80-3 (HCl); 73360-54-0 (HCl.H2O); Posimir; Bupivacaine [USAN:INN:BAN]; HSDB 7790; racemic bupivacaine; (RS)-bupivacaine; Bupivacaine liposome; SKY 0402; Exparel (TN); Liposomal bupivacaine; Bupivacaine-[13C]; Spectrum_001524; (1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; Bupivacaine liposome injectable suspension; Prestwick0_000305; Prestwick1_000305; Prestwick2_000305; Prestwick3_000305; Spectrum2_001589; Spectrum3_000974; Spectrum4_001098; Spectrum5_001483; (.+/-.)-1-Butyl-2',6'-pipecoloxylidide; (.+/-.)-Bupivacaine; Bupivacaine (USAN/INN); LAC-43 (Salt/Mix); Epitope ID:122662; Marcaine spinal (Salt/Mix); CHEMBL1098; SCHEMBL25438; BSPBio_000270; BSPBio_002607; KBioGR_001516; KBioSS_002004; DivK1c_000758; SPBio_001558; SPBio_002489; BPBio1_000298; CHEBI:3215; GTPL2397; LIQ865; DTXSID2022703; KBio1_000758; KBio2_002004; KBio2_004572; KBio2_007140; KBio3_001827; LIQ-865; dl-1-Butyl-2,6-pipecoloxylidide; NINDS_000758; AH250; HMS2090F12; HMS3428P06; Marcaine hydrochloride (Salt/Mix); 1217442-06-2; 3-Ethyl-2-methylbenzoxazoliumiodide; BCP12242; BCP21825; HY-B0405; SKY-0402; 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (+-)-; AH-250; BDBM50350790; MFCD00243007; MFCD00941462; STL484283; AKOS001637202; AKOS016842516; AC-2096; BS-5224; CS-W023182; DB00297; MCULE-2286784276; IDI1_000758; NCGC00178579-01; NCGC00178579-02; BB166160; R962; SBI-0051846.P002; 18010-40-7 (HCl); DB-119016; AB00053674; FT-0623286; FT-0660567; FT-0699781; FT-0771900; C07529; D07552; J10217; Ropivacaine hydrochloride impurity, bupivacaine-; AB00053674-08; AB00053674-09; AB00053674_10; AB00053674_11; 180B929; A873847; L000695; Q422806; Q-100271; BRD-A01636364-003-05-2; BRD-A01636364-003-08-6; 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboximidic acid; (plusmn)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (+/-)-; 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (.+/-.)-; 119427-31-5"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:77431	.	.	.	288.4	5	C18H28N2O	32.299	321	3.4	21	1	2	"InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)"	CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C	LEBVLXFERQHONN-UHFFFAOYSA-N
DG01782	Ketamine	3821	"Ketamine; dl-Ketamine; Ketaject; Ketalar; CI 581 base; Special K; (+-)-Ketamine; Ketaminum; CLSTA 20; 6740-88-1; Ketanest; Ketalar base; 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; (+/-)-Ketamine; KETAMINE HCL; 2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone; Ketolar; 2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone; NSC 70151; 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one; CHEMBL742; CHEBI:6121; Calypsol; 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone; 2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-; NSC-70151; 100477-72-3; DEA No. 7285; NCGC00159480-02; NCGC00159480-03; Cetamina; Ketamine Base; Ketamine [INN:BAN]; DSSTox_CID_3187; Ketaminum [INN-Latin]; Cetamina [INN-Spanish]; DSSTox_RID_76912; Special K [street name]; DSSTox_GSID_23187; narketan; Ketoject; Tekam; (+)-Ketamine; Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI); Ketamine (INN); PMI-150; CAS-6740-88-1; Tekam (TN); EINECS 229-804-1; (+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone; BRN 2216965; ketamina; Ursotamin; Vetaket; Anaket v; HSDB 2180; Clorketam 1000; Ketasol 100; Imalgene 1000; Ketolar (Salt/Mix); Vetalar (Salt/Mix); Kalipsol (Salt/Mix); Ketanest (Salt/Mix); Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+-)-; (.+/-.)-Ketamine; EC 229-804-1; Cyclohexanone, (.+-.)-; SCHEMBL16103; MLS001331674; DivK1c_000217; cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-; GTPL4233; (+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; DTXSID8023187; SCHEMBL17084881; KBio1_000217; NINDS_000217; HMS2272G05; NSC70151; Tox21_111703; Tox21_111704; BDBM50044140; DB01221; MCULE-4905246871; IDI1_000217; SMR000238141; C07525; D08098; Q243547; 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone #; J-505587; (.+/-.)-2-(O-Chlorophenyl)-2-(methylamino)cyclohexanone; 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone(Ketamine); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+/-)-; Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (.+/-.)-; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (.+/-.)-; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:6121	DB01221	DR0903	DR00685	237.72	2	C13H16ClNO	29.1	269	2.2	16	1	2	"InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3"	CNC1(CCCCC1=O)C2=CC=CC=C2Cl	YQEZLKZALYSWHR-UHFFFAOYSA-N
DG01783	Pioglitazone	4829	"Pioglitazone; 111025-46-8; Actos; Glustin; 105355-27-9; Zactos; Pioglitazona; Pioglitazonum; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; Duetact; U 72107; AD-4833; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; CHEBI:8228; Pioglitazone (Actos); 105390-47-4; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; Actos (TN); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U-72107; 2,4-thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-; 5-({4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione; MFCD00865504; Pioglitazone [BAN:INN]; Pioglitazone [INN:BAN]; Piozone; Pioglu; [( inverted exclamation markA)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochlorid; pioglitazone (INN); HSDB 7322; NSC-758876; DRX-065; 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4-thiazolidinedione; SR-01000763737; Pioglitazone-[d4]; Pioglitazone- Bio-X; HS-0047; Spectrum_001623; Spectrum2_001679; Spectrum3_001002; Spectrum4_001130; Spectrum5_001480; Spectrum5_002067; SCHEMBL4121; BSPBio_002723; KBioGR_001619; KBioSS_002103; MLS006011848; SPBio_001897; GTPL2694; DTXSID3037129; KBio2_002103; KBio2_004671; KBio2_007239; KBio3_001943; HMS2089H14; HMS3651D09; HMS3712E16; HMS3884L10; Pharmakon1600-01504401; ACT02635; BCP26474; BBL029068; BDBM50103521; NSC758876; s2590; STL309607; STL373406; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; AKOS015894953; AKOS022109420; AC-1021; CCG-220107; CS-1700; DB01132; MCULE-2346786634; SB17323; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-, (+-)-; NCGC00163128-01; NCGC00163128-02; NCGC00163128-03; NCGC00163128-04; NCGC00163128-05; NCGC00163128-06; NCGC00163128-07; BP164273; HY-13956; SMR002204015; SY017473; SBI-0206791.P001; DB-027350; FT-0601906; FT-0645030; SW197561-3; C07675; D08378; J10289; AB00698454-10; AB00698454_11; AB00698454_12; AB00698454_13; 355P279; A802277; Q417765; J-002506; J-516181; SR-01000763737-5; BRD-A48430263-003-02-4; BRD-A48430263-003-06-5; 5-[4-[2-(5-ethyl-2-pyridyl) ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[2-(5-ethyl-2-pyridyl)eth-oxy]benzyl]-2,4-thiazolidinedione; 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4thiazolidinedione; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)-thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl-2,4-thiazolidinedione; 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy] phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (5S)-5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione;Pioglitazone; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI); 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, (+/-)-; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione; 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-4-hydroxy-1,3-thiazol-2(5H)-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8228	DB01132	.	DR00518	356.4	7	C19H20N2O3S	93.6	466	3.8	25	1	5	"InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)"	CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3	HYAFETHFCAUJAY-UHFFFAOYSA-N
DG01784	Urethane	5641	"Urethane; ETHYL CARBAMATE; 51-79-6; Urethan; Ethylurethane; Carbamic acid, ethyl ester; Carbamic acid ethyl ester; Leucethane; Pracarbamine; Ethyl urethane; Ethylcarbamate; Pracarbamin; Ethyl urethan; O-Ethylurethane; U-Compound; Aethylcarbamat; Aethylurethan; Ethylurethan; Leucothane; Estane 5703; Uretan; Uretano [DCIT]; Uretan etylowy; NSC 746; Aethylurethan [German]; Aethylcarbamat [German]; ethyl aminoformate; O-Ethyl urethane; Carbamidsaeure-aethylester; RCRA waste number U238; Ethyl ester of carbamic acid; Ethylester kyseliny karbaminove; X 41; MFCD00007966; UNII-3IN71E75Z5; A 11032; NH2COOC2H5; NSC746; CHEBI:17967; NSC-746; Urethane + ethanol (combination); 3IN71E75Z5; Aethylurethan (german); NCGC00095041-01; Aethylcarbamat (german); DSSTox_CID_1427; Urethanum [INN-Latin]; Uretan etylowy [Polish]; DSSTox_RID_76156; DSSTox_GSID_21427; Ethyl carbamate;Carbamic acid ethyl ester;Ethylurethane; Uretano; Urethanum; Carbamate, Ethyl; Carbamidsaeure-aethylester [German]; o-Ethyl carbamate; Ethyl Carbamate (Urethane); CAS-51-79-6; Urethane [INN:BAN:DCF]; CCRIS 619; Ethylester kyseliny karbaminove [Czech]; HSDB 2555; Urethane [INN:DCF]; SR-05000001854; EINECS 200-123-1; RCRA waste no. U238; AI3-00553; Urethane, INN; Spectrum_001685; Urethane, >=99%; Spectrum2_000909; Spectrum3_000965; Spectrum4_001082; Spectrum5_001651; WLN: ZVO2; BSPBio_002569; KBioGR_001464; KBioSS_002165; Urethane, analytical standard; BIDD:ER0508; DivK1c_000060; SPECTRUM1503304; SPBio_000758; CHEMBL462547; DTXSID9021427; HMS500C22; KBio1_000060; KBio2_002165; KBio2_004733; KBio2_007301; KBio3_001789; NINDS_000060; Urethane, >=99.0% (GC); HMS1922A10; HMS2093C21; HMS3885F08; Pharmakon1600-01503304; ZINC901020; HY-B1207; Tox21_111398; Tox21_201761; Tox21_300494; CCG-39905; NSC758452; s4544; STL257390; AKOS000118772; Tox21_111398_1; CS-4731; DB04827; MCULE-1776877276; NSC-758452; IDI1_000060; NCGC00095041-02; NCGC00095041-03; NCGC00095041-04; NCGC00095041-05; NCGC00095041-06; NCGC00095041-08; NCGC00254522-01; NCGC00259310-01; SBI-0051812.P002; SBI-0051812.P003; DB-052027; AM20100253; FT-0626365; FT-0675741; C01537; F21294; AB00052344_04; Q422884; SR-05000001854-1; SR-05000001854-2; BRD-K24297741-001-01-1; Carbamic acid ethyl ester;Ethyl carbamate;Ethylurethane; Z33546369; F0001-1333"	Approved	1	Discontinued Drug(s)	Discontinued	Small molecular drug	.	DB04827	DR1663	.	89.09	2	C3H7NO2	52.3	52.8	-0.2	6	1	2	"InChI=1S/C3H7NO2/c1-2-6-3(4)5/h2H2,1H3,(H2,4,5)"	CCOC(=O)N	JOYRKODLDBILNP-UHFFFAOYSA-N
DG01785	Estradiol	5757	"Estradiol; beta-Estradiol; 17beta-Estradiol; 50-28-2; Oestradiol; Dihydrofolliculin; Estrace; Ovocyclin; Vivelle; progynon; Dihydrotheelin; Dihydroxyestrin; Aquadiol; Diogynets; Gynergon; Gynoestryl; Diogyn; Oestroglandol; Aerodiol; Corpagen; Dimenformon; Estrovite; Femestral; Follicyclin; Ginosedol; Macrodiol; Oestergon; Ovahormon; Ovasterol; Ovastevol; Perlatanol; Primofol; Profoliol; Altrad; Bardiol; Climara; Divigel; Evorel; Femogen; Lamdiol; Syndiol; Vagifem; Dihydromenformon; estradiol-17beta; cis-Estradiol; Estraderm TTS; Estraderm; Estraldine; Estroclim; Trocosone; Estrogel; Menorest; Nordicol; Zumenon; Systen; D-Oestradiol; D-Estradiol; Progynon DH; Climaderm; Compudose; Dermestril; Estrasorb; Ovocycline; Encore; Estring; Menest; Oesclim; Dihydroxyoestrin; SK-Estrogens; Progynon-DH; Gynestrel; Microdiol; Oestrogynal; Ovociclina; Ovocylin; Tradelia; Estroclim 50; Innofem; Macrol; Zerella; 17beta-Oestradiol; Alora; Oestradiol R; Estring vaginal ring; Dihydrofollicular hormone; Trial SAT; Theelin, dihydro-; Elestrin; Fempatch; Gynodiol; Oestrogel; Esclim; Compudose 200; Compudose 365; Profoliol B; 17b-Oestradiol; 17-beta-estradiol; Estradiol-17-beta; Estradot; Estrogen; Gelestra; 3,17-Epidihydroxyestratriene; Zesteem; Dihydroxyesterin; cis-Oestradiol; Estraderm TTS 50; Estrogens, esterified; B-Estradiol; Epiestriol 50; 17beta oestradiol; NSC-9895; 17 beta-Estradiol; Estradiol-17 beta; Evamist; Amnestrogen; Femanest; 17.beta.-Estradiol; Estra-1,3,5(10)-triene-3,17beta-diol; 3,17-Epidihydroxyoestratriene; Sandrena 1; 17b-Estradiol; (17beta)-Estra-1,3,5(10)-triene-3,17-diol; Estraderm (TN); [3H]-estradiol; 17; A-estradiol; 17; A-Oestradiol; Estrogel (TN); Climara (TN); Divigel (TN); Estrace (TN); Estring (TN); Innofem (TN); Vagifem (TN); Vivelle (TN); 17.beta.-Oestradiol; 3,17.beta.-Estradiol; .beta.-Estradiol; (8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; .beta.-Oestradiol; [3H]]estradiol; UNII-4TI98Z838E; Estradiol, .beta.-; Estradiol-17.beta.; CHEBI:16469; Estra-1,3,5(10)-triene-3,17-diol (17beta)-; Oestradiol-17.beta.; ESTRADIOL HEMIHYDRATE; Oestra-1,3,5(10)-triene-3,17beta-diol; Estrasorb (TN); 17.beta.-OH-estradiol; 17.beta.-OH-oestradiol; 17beta estradiol (E2); Extrasorb; 17beta-Estra-1,3,5(10)-triene-3,17-diol; Estreva; Estrifam; Femtran; Ginedisc; CHEMBL135; GynPolar; (17beta)-estra-1(10),2,4-triene-3,17-diol; Sandrena Gel; D-3,17.beta.-Estradiol; D-3,17.beta.-Oestradiol; Sisare Gel; Estra-1,3,5(10)-triene-3,17-diol, (17beta)-; Estrofem 2; MLS000069494; 3,17b-Dihydroxyestra-1,3,5(10)-triene; Oestradiolum; Climara Forte; 4TI98Z838E; Oestradiol Berco; Estraderm MX; VIVELLE-DOT; 1,3,5-Estratriene-3,17beta-diol; [3H]E2; Oestradiol-17beta; Estrapak 50; (1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-triene-5,14-diol; (8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 141290-02-0; Estradiolum [INN]; Estradiolo [DCIT]; NCGC00091544-04; Oestradiol-17-beta; Estradiolum; Estrodiolum; Estradiolo; Femestrol; SMR000059126; Estradiol-3,17beta; DSSTox_CID_573; 17-beta-OH-estradiol; 3,17-beta-Estradiol; 3,17beta-Dihydroxy-1,3,5(10)-estratriene; 3,17beta-Dihydroxyestra-1,3,5(10)-triene; 3,17-beta-Oestradiol; D-3,17beta-Estradiol; E(sub 2); DSSTox_RID_75666; Methyl 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate.; Benzogynestry; DSSTox_GSID_20573; Estropause; Estasorb; [2,4,6,7-3H]-E2; E 2; E2; Destradiol; Minivelle; Yuvvexy; Zesteen; .alpha.-Estradiol; 17-beta-OH-oestradiol; 17 -Estradiol; D-3,17beta-Oestradiol; D-3,17-beta-Estradiol; Estrodiolum [INN-Latin]; NSC-20293; D-3,17-beta-Oestradiol; Activella (Salt/Mix); Estradiol Anhydrous; Combipatch (Salt/Mix); CCRIS 280; component of Menrium; Estradiol-17 alpha; Climara Pro (Salt/Mix); 3,17beta-Estradiol; 3,17-.beta.-Oestradiol; Estraderm TTS 100; HSDB 3589; 3,3,5(10)-triene; SR-01000075866; 17-.BETA.-Estradiol; EINECS 200-023-8; (+)-3,17.beta.-Estradiol; 1,3,5-Estratriene-3,17-beta-diol; oestrodiol; Estradiol [USP:INN:BAN]; 3,17beta-Dihydroxyestra-1,3,5-triene; 3,17beta-Dihydroxyoestra-1,3,5-triene; Elestrim; delta-Estradiol; dihydro-Theelin; 3,17-beta-Dihydroxyoestra-1,3,5-triene; delta-Oestradiol; TX-004HR; MFCD00003693; Estra-1,3,5(10)-triene-3,17-beta-diol; Estradiol complex; Estrogel HBF; Oestra-1,3,5(10)-triene-3,17-beta-diol; 1jgl; 1lhu; 1qkt; 1qku; 3,17-beta-Dihydroxyestra-1,3,5(10)-triene; [3H]estradiol; 1,3,5-Estratriene-3,17.beta.-diol; 3,17-beta-Dihydroxy-1,3,5(10)-oestratriene; CAS-50-28-2; 17-beta-Estra-1,3,5(10)-triene-3,17-diol; 17beta-Oestra-1,3,5(10)-triene-3,17-diol; .alpha.-Oestradiol; 17-beta-Oestra-1,3,5(10)-triene-3,17-diol; Estra-1,3,5(10)-triene-3,17-diol; Prestwick_207; 17-beta-oestradiol; 3,17b-Estradiol; Bio-E-Gel; Estradiol 17-beta; Fem7; [3H]-Estrogen; 17  -Estradiol; 3,17.beta.-Dihydroxyestra-1,3,5-triene; 3,17.beta.-Dihydroxyoestra-1,3,5-triene; CMC_11154; 1,3,5,(10)-Estratrien-3,17.beta.-diol; SL-1100; Estra-1,3,5(10)-triene-3,17.beta.-diol; Oestra-1,3,5(10)-triene-3,17.beta.-diol; 17-.beta.-oestradiol; 2j7x; 3,17.beta.-Dihydroxy-1,3,5(10)-estratriene; 3,17.beta.-Dihydroxy-1,3,5(10)-oestratriene; 3,17.beta.-Dihydroxyestra-1,3,5(10)-triene; 3,3,5-triene; [3H]17beta-estradiol; (17 )-Estra-1,3,5(10)-triene-3,17-diol; 17.beta.-Estra-1,3,5(10)-triene-3,17-diol; 17.beta.-Oestra-1,3,5(10)-triene-3,17-diol; Opera_ID_1688; Prestwick0_000441; Prestwick1_000441; Prestwick2_000441; Prestwick3_000441; Spectrum5_002055; 17beta-estradiol (E2); alpha-estradiol (obsolete); beta-Estradiol, >=98%; bmse000642; Epitope ID:136018; (+)-3,17b-Estradiol; E 8875; EC 200-023-8; SCHEMBL8049; (+)-3,17beta-Estradiol; Estradiol (JAN/USP/INN); Tritiated estradiol-17-beta; BIDD:PXR0065; Lopac0_000503; S-21400; BSPBio_000482; BSPBio_001065; KBioGR_000405; KBioGR_002269; KBioSS_000405; KBioSS_002270; Oestradiol-17beta and esters; MLS000758312; MLS001076331; MLS001424022; BIDD:ER0125; Oestradiol-17beta and esters [Steroidal oestrogens]; SPBio_002421; BPBio1_000532; GTPL1012; GTPL1013; DTXSID0020573; Estradiol valerate metabolite e2; NIOSH/KG7030000; BDBM17292; KBio2_000405; KBio2_002269; KBio2_002973; KBio2_004837; KBio2_005541; KBio2_007405; KBio3_000769; KBio3_000770; KBio3_002749; AOB5963; NSC9895; 1a52; 1g50; 2d06; cMAP_000005; Bio1_000403; Bio1_000892; Bio1_001381; Bio2_000363; Bio2_000843; HMS1362E07; HMS1569I04; HMS1792E07; HMS1990E07; HMS2051C17; HMS2090E18; HMS2096I04; HMS2236H04; HMS3261F07; HMS3403E07; HMS3713I04; HMS3884A08; beta-Estradiol, analytical standard; (8S,9S,13S,14S,17S)-13-Methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; BCP08579; HY-B0141; Tox21_111148; Tox21_202057; Tox21_300288; Tox21_500503; 1,5-Estratriene-3,17.beta.-diol; LMST02010001; s1709; WC3011; ZINC13520815; Estradiol-17-beta-6,7-(sup 3)H; [2,4,6,7-3H]-17beta-estradiol; AKOS015896570; CCG-100808; CS-1938; DB00783; LP00503; NC00058; SDCCGSBI-0050487.P002; WC-3011; IDI1_002118; SMP1_000121; NCGC00091544-00; NCGC00091544-01; NCGC00091544-02; NCGC00091544-05; NCGC00091544-06; NCGC00091544-07; NCGC00091544-09; NCGC00091544-10; NCGC00091544-11; NCGC00091544-12; NCGC00091544-13; NCGC00091544-14; NCGC00091544-15; NCGC00091544-16; NCGC00091544-18; NCGC00091544-27; NCGC00179321-01; NCGC00179321-02; NCGC00254177-01; NCGC00259606-01; NCGC00261188-01; 17-E; AC-22346; AS-13729; CPD000059126; H061; Estra-1,3,5(10)-triene-3,17b-diol; Oestra-1,3,5(10)-triene-3,17b-diol; WLN: L E5 B666TTT&J E1 FQ OQ; Estra-1,5(10)-triene-3,17.beta.-diol; Estradiol, meets USP testing specifications; 3,17beta-dihydroxyestra-1,3,5(10)-trien; EU-0100503; KG70300000; Oestra-1,5(10)-triene-3,17.beta.-diol; C00951; D00105; J10189; (17b)-Estra-1,3,5(10)-triene-3,17-diol; 13b-Methyl-1,3,5(10)-gonatriene-3,17b-ol; 17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 17.beta.-Estra-1,5(10)-triene-3,17-diol; 17.beta.-Oestra-1,5(10)-triene-3,17-diol; 003E693; 17-beta-Estradiol 100 microg/mL in Acetonitrile; Q422416; SR-01000721892; 13beta-Methyl-1,3,5(10)-gonatriene-3,17beta-ol; Estra-1,5(10)-triene-3,17-diol (17.beta.)-; Q-201503; SR-01000075866-1; SR-01000075866-4; SR-01000721892-3; BRD-K18910433-001-04-4; BRD-K18910433-001-43-2; estra-1(10),2,4-triene-3,17-diol, (17beta)-; Estra-1,5(10)-triene-3,17-diol, (17.beta.)-; Z1847670481; B8B5AEF5-4957-49EB-A14F-444A8212C482; beta-Estradiol, BioReagent, powder, suitable for cell culture; Estradiol, United States Pharmacopeia (USP) Reference Standard; beta-Estradiol, powder, gamma-irradiated, suitable for cell culture; Estra-1,3,5(10)-triene-3,17-diol, (6,7-(sup 3)H,17-beta)-; (9beta,13alpha,14beta,17alpha)-estra-1,3,5(10)-triene-3,17-diol; Estradiol, Pharmaceutical Secondary Standard; Certified Reference Material; (13S,17S)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-beta-diol; (1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-2,4,6-triene-5,14-diol; 17beta-Estradiol solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:16469	.	DR0007	DR00129	272.4	0	C18H24O2	40.5	382	4	20	2	2	"InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1"	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O	VOXZDWNPVJITMN-ZBRFXRBCSA-N
DG01786	D-Glucose	5793	"D-Glc; D-Glucopyranose; D-Glucopyranoside; D-Glucose; Glc; Glucopyranose; Glucopyranoside; Glucose; 2280-44-6; Grape sugar; D-Glcp; Traubenzucker; Glucose solution; (3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; Dextrose solution; CHEBI:4167; Corn sugar; Glucopyranose, D-; (3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; DSSTox_CID_2910; Glucodin; Goldsugar; Meritose; 54-17-1; Vadex; Clintose L; CPC hydrate; Roferose ST; Glucose Anhydrous; a-D-Glucose; Clearsweet 95; Staleydex 95M; Staleydex 111; (+)-Glucose; Cerelose 2001; rel-(3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; Tabfine 097(HS); 2h-pyran-2,3,4,5-tetraol; D-Glucopyranose, anhydrous; Liquid glucose; glc-ring; anhydrous glucose; Cartose Cerelose; D-aGlucopyranose; D-glucose-ring; Glucose injection; Glucose 40; Staleydex 130; EINECS 218-914-5; Glc-OH; Meritose 200; nchembio867-comp4; Dextrose, unspecified; Glucose (JP17); starbld0000491; 6-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetraol; Anhydrous Glucose ,(S); Glucose, unspecified form; Dextrose, unspecified form; Purified glucose (JP17); Epitope ID:142342; D-(+)-DEXTROSE; DSSTox_RID_76784; DSSTox_RID_82925; DSSTox_GSID_22910; DSSTox_GSID_48729; GTPL4536; CHEMBL1222250; BDBM34103; DTXSID501015215; DTXSID901015217; Tox21_113165; Tox21_200145; AKOS025147374; NSC 287045; CAS-50-99-7; NCGC00166293-01; NCGC00257699-01; BS-48662; CAS-58367-01-4; G0048; (3R,4S,5S,6R)-6-(hydroxymethyl)tetrahydro-; C00031; D00009; Q37525; Q23905964; N_FULL/O_FULL_10000000000000_GS_656; D-glucose (closed ring structure, complete stereochemistry); WURCS=2.0/1,1,0/[a2122h-1x_1-5]/1/"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:4167	DB01914	DR2081	DR00165	180.16	1	C6H12O6	110	151	-2.6	12	5	6	"InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5-,6 /m1/s1"	C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)O)O)O	WQZGKKKJIJFFOK-GASJEMHNSA-N
DG01787	Carbon tetrachloride	5943	"CARBON TETRACHLORIDE; Tetrachloromethane; 56-23-5; Perchloromethane; Tetrasol; Vermoestricid; Benzinoform; Necatorine; Tetrafinol; Carbona; Univerm; Methane, tetrachloro-; Carbon tet; Methane tetrachloride; Flukoids; Necatorina; Tetraform; Carbon chloride; Tetrachlormethan; Tetrachloormetaan; Tetrachlorocarbon; Freon 10; carbontetrachloride; CCl4; Tetraclorometano; Tetrachloorkoolstof; Czterochlorek wegla; Halon 1040; Carbon chloride (CCl4); Chlorid uhlicity; R 10 (Refrigerant); Tetrachlorure de carbone; Tetracloruro di carbonio; Refrigerant R10; tetrachloro-methane; RCRA waste number U211; Tetrachlorkohlenstoff, tetra; HSDB 53; ENT 4,705; Thawpit; Tetra; R 10; UNII-CL2T97X0V0; ENT 27164; NSC 97063; CHEBI:27385; Halon 104; CL2T97X0V0; MFCD00000785; NCGC00091016-02; DSSTox_CID_250; DSSTox_RID_75464; DSSTox_GSID_20250; Caswell No. 164; CC m0; Chlorid uhlicity [Czech]; Tetrachlormethan [German]; Tetraclorometano [Italian]; Tetrachloorkoolstof [Dutch]; CAS-56-23-5; Carbon tetrachloride, analytical standard; Czterochlorek wegla [Polish]; CCRIS 123; Kohlenstofftetrachlorid; Carbon tetrachloride [BSI:ISO]; Tetrachlorure de carbone [French]; Tetracloruro di carbonio [Italian]; EINECS 200-262-8; UN1846; Tetrachlorkohlenstoff, tetra [German]; RCRA waste no. U211; EPA Pesticide Chemical Code 016501; Tetrachlorure de carbone [ISO-French]; Benzenoform; Katharin; Seretin; perchorormethane; tetrachorocarbon; tetrachlormethane; AI3-04705; Carbon chloride ; tetrachloridocarbon; carbon tetracloride; tetra-chloromethane; tetrachloro methane; carbon tetrachioride; carbon-tetrachloride; F10; Tetrachlorkohlenstoff; carbon tetra-chloride; Cl4C; carbon tetra- chloride; Tetrachloromethane, 9CI; WLN: GXGGG; Carbon tetrachloride [NF]; EC 200-262-8; Carbon tetrachloride, 99%; CHEMBL44814; SCHEMBL2466909; DTXSID8020250; NSC97063; ZINC8214515; Tox21_111057; Tox21_200039; BDBM50237610; NSC-97063; AKOS015903411; UN 1846; NCGC00091016-01; NCGC00091016-03; NCGC00091016-04; NCGC00257593-01; Carbon tetrachloride (1mg/ml in methanol); Carbon tetrachloride [UN1846] [Poison]; Carbon tetrachloride, anhydrous, >=99.5%; Carbon tetrachloride, for HPLC, >=99.9%; Carbon tetrachloride, reagent grade, 99.9%; Tetrachloromethane 100 microg/mL in Methanol; C07561; Carbon tetrachloride 100 microg/mL in Methanol; Carbon tetrachloride 5000 microg/mL in Methanol; L023972; Q225045; BRD-K24169676-001-01-1; F0001-1467"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:27385	.	.	.	153.8	0	CCl4	0	19.1	2.8	5	0	0	"InChI=1S/CCl4/c2-1(3,4)5"	C(Cl)(Cl)(Cl)Cl	VZGDMQKNWNREIO-UHFFFAOYSA-N
DG01788	Medroxyprogesterone acetate	6279	"Medroxyprogesterone acetate; Medroxyprogesterone 17-acetate; 71-58-9; Provera; Metigestrona; Farlutin; Gestapuran; Perlutex; Veramix; Methylacetoxyprogesterone; Medroxyacetate progesterone; Depo-Provera; Depcorlutin; Deporone; Lutopolar; Nadigest; Prodasone; Progestalfa; Progevera; Proverone; Repromix; Sirprogen; Supprestral; Lutoral; Nidaxin; Oragest; Depo-Promone; Promone-E; 6-alpha-Methyl-17-alpha-acetoxyprogesterone; Medroxyprogesteroneacetate; NSC-26386; 6-alpha-Methyl-17-alpha-hydroxyprogesterone acetate; 17alpha-Hydroxy-6alpha-methylprogesterone acetate; 6alpha-Methyl-17alpha-hydroxyprogesterone acetate; Amen; 6alpha-Methyl-4-pregnene-3,20-dion-17alpha-ol acetate; Depot medroxyprogesterone acetate; Depot-medroxyprogesterone acetate; UNII-C2QI4IOI2G; DP150; Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6alpha)-; 17-Acetoxy-6alpha-methylprogesterone; Aragest; Clinovir; Ralovera; 6alpha-Methyl-17-acetoxy progesterone; Hysron; Provera dosepak; Depo-clinovir; Depo-Ralovera; (6alpha)-6-methyl-3,20-dioxopregn-4-en-17-yl acetate; U 8839; C2QI4IOI2G; Medroxyprogesterone (acetate); Medroxyprogesterone-17-acetate; MLS000069442; (6alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione; CHEBI:6716; ONCO-Provera; NSC-21171; Medrosterona; Clinofem; Cykrina; Depocon; Indivina; Mepastat; Meprate; Repromap; SMR000059125; Sumiferm; Suprestral; Veraplex; Dugen; Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6a)-; Depo-progestin; Depo-Prodasone; Depo-Progevera; Perlutex Leo; DSSTox_CID_5527; Depo-Map; Aragest 5; Med-Pro; MPA-beta; DSSTox_RID_77819; MPA Hexal; MPA-Noury; DSSTox_GSID_25527; [(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate; MAP (steroid); 17alpha-Acetoxy-6alpha-methylprogesterone; Depomedroxyprogesterone acetate; MPA GYM; Depo-Medroxyprogesterone acetate; Depo-subq provera; CAS-71-58-9; CCRIS 371; 17.alpha.-Acetoxy-6.alpha.-methylprogesterone; EINECS 200-757-9; 6alpha-Methyl-17-acetoxyprogesterone; NSC 21171; Depo-Provera Contraceptive; 17-Acetoxy-6-alpha-methylprogesterone; (6.alpha.-Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-; 17.alpha.-Hydroxy-6-.alpha.-methylprogesterone acetate; Pregn-4-ene-3, 17-hydroxy-6.alpha.-methyl-, acetate; 6-alpha-Methyl-17-acetoxy progesterone; BRN 2066112; Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-, (6.alpha.)-; AI3-60127; 17-Acetoxy-6.alpha.-methylprogesterone; 6.alpha.-Methyl-17-acetoxyprogesterone; Farlutal inyectable; NCGC00094713-01; 17alpha-Hydroxy-6-alpha-methylprogesterone acetate; Progesterone, 17-hydroxy-6alpha-methyl-, acetate; 17-alpha-Hydroxy-6-alpha-methylprogesterone acetate; Provera (TN); Depo-provera (TN); 6alpha-Methyl-17alpha-acetoxypregn-4-ene-3,20-dione; Medroxyprogesterone acetate [USP:JAN]; 17-alpha-Acetoxy-6-alpha-methylpregn-4-ene-3,20-dione; 17alpha-Acetoxy-6-alpha-methylpregn-4-ene-3,20-dione; 6-alpha-Methyl-17-alpha-acetoxypregn-4-ene-3,20-dione; Progesterone, 17-alpha-hydroxy-6-alpha-methyl-, acetate; Medroxyprogesterone acetate [Progestins]; 6-alpha-Methyl-4-pregnene-3,20-dion-17-alpha-ol acetate; 6.alpha.-Methyl-17.alpha.-acetoxyprogesterone; (6-alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione; 17alpha-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione acetate; 6alpha-Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-; CPD000653524; 17-alpha-Hydroxy-6-alpha-methylpregn-4-ene-3,20-dione acetate; Medroxyprogesteroni acetas; Opera_ID_1110; medroxyprogesterone-acetate; 17.alpha.-Hydroxy-6.alpha.-methylprogesterone acetate; 6.alpha.-Methyl-17.alpha.-hydroxyprogesterone acetate; Medroxiprogesterone Acetate; CHEMBL717; SCHEMBL4276; 6.alpha.-Methyl-17.alpha.-acetoxypregn-4-ene-3,20-dione; 17.alpha.-Acetoxy-6-.alpha.-methylpregn-4-ene-3,20-dione; 4-08-00-02212 (Beilstein Handbook Reference); 6.alpha.-Methyl-4-pregnene-3,20-dion-17.alpha.-ol acetate; MLS001148217; MLS002207115; 17.alpha.-Hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione acetate; Depo-subq provera 104 (TN); DTXSID0025527; G03AC06; HMS2233O07; HMS2235E05; HMS3259O14; HMS3884B10; (6-alpha)-Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-; (6S,8R,9S,10R,13S,14S,17R)-17-Acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate; CBP-1011; HY-B0469; NSC21171; NSC26386; ZINC5029557; Tox21_111319; Tox21_200141; BDBM50067678; s2567; AKOS015894870; Tox21_111319_1; AC-2174; CCG-264965; DB00603; NC00574; Medroxyprogesterone acetate (JP17/USP); MRF-0000023; NCGC00022037-03; NCGC00022037-04; NCGC00022037-05; NCGC00022037-07; NCGC00257695-01; NCGC00263480-01; AS-13981; I028; SMR000653524; TV-46046; C08150; C76275; D00951; AB00384270-14; AB00384270_15; Medroxyprogesterone 17-acetate, >=97% (HPLC); 010M483; Q2823834; (6 )-6-Methyl-3,20-dioxopregn-4-en-17-yl acetate; 6.alpha.-Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-; Medroxyprogesterone-17-acetate 100 microg/mL in Acetonitrile; Medroxyprogesterone 17-acetate, VETRANAL(TM), analytical standard; Medroxyprogesterone acetate, European Pharmacopoeia (EP) Reference Standard; Pregn-4-ene-3,20-dione, 17-hydroxy-6alpha-methyl-, acetate (8CI); Medroxyprogesterone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material; Medroxyprogesterone acetate, United States Pharmacopeia (USP) Reference Standard; Medroxyprogesterone acetate for peak identification, European Pharmacopoeia (EP) Reference Standard; Medroxyprogesterone acetate for system suitability, European Pharmacopoeia (EP) Reference Standard; Medroxyprogesterone acetate, for performance test, European Pharmacopoeia (EP) Reference Standard"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00603	DR1012	.	386.5	3	C24H34O4	60.4	767	4.1	28	0	4	"InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1"	C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C	PSGAAPLEWMOORI-PEINSRQWSA-N
DG01789	Rotenone	6758	"Rotenone; 83-79-4; Dactinol; Paraderil; Barbasco; (-)-Rotenone; Tubatoxin; Derrin; (-)-cis-Rotenone; Rotocide; Derris; Rotenon; Cube root; Nicouline; Noxfish; Ronone; Canex; Deril; Liquid Derris; Cube-Pulver; Dri-Kil; Rotessenol; Noxfire; Rotefive; Rotefour; Rotenox; Cubor; Extrax; Haiari; Mexide; Cube extract; Derris root; Powder and root; Chem-Mite; Pro-nox fish; Fish-Tox; Cenol garden dust; Curex flea duster; Prenfish; Tubotoxin; Gerane; Prentox; Ro-Ko; Synpren; Derris (insecticide); Chem fish; Pb-nox; Rotenox 5EC; 5'-beta-Rotenone; Green Cross Warble Powder; Chem-Fish Synergized; Prentox Synpren-Fish; Caswell No. 725; Rotenone, dehydro; Foliafume E.C.; ENT 133; Rotenone, commercial; CCRIS 895; HSDB 1762; NCI-C55210; 5'beta-Rotenone; EPA Pesticide Chemical Code 071003; UNII-03L9OT429T; AI3-00133; NSC26258; Rotenona; Derris resins; MLS000738056; CHEMBL429023; CHEBI:28201; 03L9OT429T; Rotacide E.C.; CUBE; (1)Benzopyrano(3,4-b)furo(2,3-h)(1)benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-2-alpha-isopropenyl-8,9-dimethoxy-; (12aS,6aS,2R)-8,9-dimethoxy-2-(1-methylvinyl)-1,2-dihydrochromano[3,4-b]furano [2,3-h]chroman-6-one; (2R,6aS,12aS)-8,9-dimethoxy-2-(prop-1-en-2-yl)-1,2,12,12a-tetrahydrochromeno[3,4-b]furo[2,3-h]chromen-6(6aH)-one; (2R-(2alpha,6aalpha,12aalpha))-1,2,12,12a-Tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)(1)benzopyrano(3,4-b)furo(2,3-h)benzopyran-6(6aH)-one; 1,2,12,12a-Tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-(1)benzopyrano(3,4-b)furo(2,3-h)(1)benzopyran-6(6aH)-one; 1,2,12,12aalpha-Tetrahydro-2a-isopropenyl-8,9-dimethoxy(1)benzopyrano(3,4-b)furo(2,3-h)(1)benzopyran-6(6aH)-one; NCGC00017358-05; Nekoe; DSSTox_CID_1248; DSSTox_RID_76038; DSSTox_GSID_21248; (1)Benzopyrano(3,4-b)furo(2,3-h)(1)benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-, (2R-(2alpha,6aalpha,12aalpha))-; (1S,6R,13S)-16,17-dimethoxy-6-prop-1-en-2-yl-2,7,20-trioxapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-3(11),4(8),9,14,16,18-hexaen-12-one; (2R,6aS,12aS)-1,2,6,6a,12,12a-hexahydro-2-isopropenyl-8,9-dimethoxychromeno[3,4-b]furo[2,3-h]chromen-6-one; (2R,6aS,12aS)-8,9-Dimethoxy-2-(prop-1-en-2-yl)-1,2,12,12a-tetrahydrofuro[2',3':7,8][1]benzopyrano[2,3-c][1]benzopyran-6(6aH)-one; [2R-(2alpha,6aalpha,12aalpha)]-1,2,12,12a-tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)[1]benzopyrano[3,4-b]furo[2,3-H][1]benzopyran-6(6aH)-one; Rotenona [Spanish]; Rotenone [BSI:ISO]; Protax; MFCD09025614; 5'.beta.-Rotenone; CAS-83-79-4; (1)Benzopyrano(3,4-b)furo(2,3-h)(1)benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-, (2R,6aS,12aS)-; (2R,6aS,12aS)-1,2,12,12a-Tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-[1]benzopyrano[3,4-b]furo[2,3-h][1]benzopyran-6(6aH)-one; (2R,6aS,12aS)-1,2,6,6a,12,12a- hexahydro-2-isopropenyl-8,9- dimethoxychromeno[3,4-b] furo(2,3-h)chromen-6-one; (2R,6aS,12aS)-1,2,6,6a,12,12a-hexahydro-2-isopropenyl-8,9-dimethoxychromeno(3,4-b)furo(2,3-h)chromen-6-one; (2R,6aS,12aS)-2-isopropenyl-8,9-dimethoxy-1,2,12,12a-tetrahydrochromeno[3,4-b]furo[2,3-h]chromen-6(6aH)-one; [1]Benzopyrano[3,4-b]furo[2,3-h][1]benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-, (2R,6aS,12aS)-; SR-01000076110; EINECS 201-501-9; NSC 26258; Rotenoid; Roteonone; WLN: T G5 D6 B666 CV HO MO POT&TT&J IY1&U1 SO1 TO1; 5''beta-rotenone; 5'b-Rotenone; Rotocide E.C.; (1)Benzopyrano[3,3-h](1)benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-2-.alpha.-iospropenyl-8,9-dimethoxy-; [1]Benzopyrano[3,3-h][1]benzopyran-6(6a.alpha.H)-one, 1,2,12,12a.alpha.-tetrahydro-2.alpha.-isopropenyl-8,9-dimethoxy-; [1]Benzopyrano[3,3-h][1]benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-, [2R-(2.alpha.,6a.alpha.,12a.alpha.)]-; [1]Benzopyrano[3,4-b]furo[2,3-h][1]benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-, [2R-(2alpha,6aalpha,12aalpha)]-; Derris, JMAF; Prestwick_542; Rotenone (7CI); Rotenone, >=95%; Spectrum_000065; Spectrum2_000457; Spectrum3_000158; Spectrum4_001638; Spectrum5_000455; Lopac0_001112; SCHEMBL42253; BSPBio_001896; isopropenyl(dimethoxy)[ ]one; KBioGR_002075; KBioSS_000465; SPECTRUM200013; (2R-(6aalpha,12aalpha)-1,2-Dihydro-2-isopropenyl-8,9-dimethoxychromano(3,4-b)furo(2,3-h)chroman-6-on; DivK1c_000947; SPBio_000534; DTXSID6021248; HMS502P09; KBio1_000947; KBio2_000465; KBio2_003033; KBio2_005601; KBio3_001116; inhibits NADH2 oxidation to NAD; NSC8505; NINDS_000947; HMS3263O06; 12679-58-2; BCP07278; HY-B1756; NSC-8505; TNP00301; ZINC3860715; Tox21_110819; Tox21_201904; Tox21_300695; Tox21_501112; 2901AC; BDBM50135527; CCG-39886; LMPK12060007; NSC-26258; AKOS004910398; Tox21_110819_1; CS-6067; DB11457; LP01112; MCULE-7287067191; MCULE-7415617623; SDCCGMLS-0066415.P001; SDCCGSBI-0051081.P003; IDI1_000947; Rotenone 100 microg/mL in Acetonitrile; NCGC00017358-01; NCGC00017358-02; NCGC00017358-03; NCGC00017358-04; NCGC00017358-06; NCGC00017358-07; NCGC00017358-08; NCGC00017358-09; NCGC00017358-10; NCGC00017358-11; NCGC00017358-14; NCGC00017358-15; NCGC00017358-22; NCGC00094382-01; NCGC00094382-02; NCGC00094382-03; NCGC00094382-04; NCGC00094382-05; NCGC00254603-01; NCGC00259453-01; NCGC00261797-01; AC-31290; AS-10183; NCI60_002093; SMR000393729; EU-0101112; R0090; Rotenone, PESTANAL(R), analytical standard; C07593; R 8875; 599T610; Q412388; SR-01000076110-2; SR-01000076110-5; SR-01000076110-6; W-104134; BRD-K08316444-001-01-9; BRD-K08316444-001-05-0; (2R-(6aalpha,12aalpha)-1,2-Dihydro-2-isopropenyl-8,9-dimethoxychromano(3,4-b)furo(2,3-h)chroman-6-one; [1]Benzopyrano[3,3-h][1]benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-2-.alpha.-isopropenyl-8,9-dimethoxy-; [1]Benzopyrano[3,3-h][1]benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-2-isopropenyl-8,9-dimethoxy-; [1]Benzopyrano[3,4-b]furo[2,3-h][1]benzopyran-6(6aalphaH)-one, 1,2,12,12aalpha-tetrahydro-2alpha-isopropenyl-8,9-dimethoxy- (8CI); [1]Benzopyrano[3,4-b]furo[2,3-h][1]benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-, (2R,6aS,12aS)- (9CI); 1,2,12,12a-Tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-[1]benzopyrano[3,4-b]furo[2,3-h][1]benzopyran-6(6aH)-one, 9CI; Tubatoxin 1,2,12,12a,-Tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-[1]benzopyrano[3,4-b]furo[2,3-h][1]-benzopyran-6(6aH)-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:28201	DB11457	.	.	394.4	3	C23H22O6	63.2	664	4.1	29	0	6	"InChI=1S/C23H22O6/c1-11(2)16-8-14-15(28-16)6-5-12-22(24)21-13-7-18(25-3)19(26-4)9-17(13)27-10-20(21)29-23(12)14/h5-7,9,16,20-21H,1,8,10H2,2-4H3/t16-,20-,21+/m1/s1"	CC(=C)[C@H]1CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC	JUVIOZPCNVVQFO-HBGVWJBISA-N
DG01790	Picric acid	6954	"PICRIC ACID; 2,4,6-Trinitrophenol; Trinitrophenol; 88-89-1; Acide picrique; Carbazotic acid; Picronitric acid; Melinite; Phenol trinitrate; Picral; Nitroxanthic acid; Pikrinsaeure; Phenol, 2,4,6-trinitro-; Pikrinezuur; Acido picrico; Pikrynowy kwas; 2-Hydroxy-1,3,5-trinitrobenzene; Kyselina pikrova; 1,3,5-Trinitrophenol; C.I. 10305; 2,4,6-Trinitrofenol; 2,4,6-Trinitrofenolo; 2,4,6-Trinitrophenyl; UNII-A49OS0F91S; NSC 36947; CI 10305; A49OS0F91S; CHEBI:46149; Picric acid, dry; Picric acid, wet; 2,6-Trinitrofenol; Pertite; Picric acid (dry); Picric acid (wet); 1,5-Trinitrophenol; 2,6-Trinitrofenolo; 2,6-Trinitrophenol; Phenol,4,6-trinitro-; Phenoltrinitrate; Acidum picrinicum; WLN: WNR BQ CNW ENW; 2-Hydroxy-1,5-trinitrobenzene; Pikrinezuur [Dutch]; Pikrinsaeure [German]; Picricum acidum; Acide picrique [French]; Acido picrico [Italian]; Pikrynowy kwas [Polish]; Kyselina pikrova [Czech]; 2,4,6-Trinitrophenol (Picric Acid); CCRIS 3106; Trinitrophenol [NF]; 2,4,6-Trinitrofenol [Dutch]; HSDB 2040; 2,4,6-Trinitrofenolo [Italian]; EINECS 201-865-9; NA1344; UN0154; UN1344; Reflorit; AI3-15403; Hager's reagent; Picric acid solution; Picric acid, p.a.; Lyddite (Salt/Mix); Ecrasite (Salt/Mix); Schimose (Salt/Mix); SCHEMBL8745; NA 1344 (Salt/Mix); UN 1344 (Salt/Mix); CHEMBL108541; DTXSID4025909; Picric acid, dry or wetted with < 30% water, by mass; SCHEMBL14419782; BDBM34612; cid_3241713; Trinitrophenol, dry or wetted with < 30% water, by mass; NSC36947; NSC56147; ZINC1883067; 3-Hydroxy-2,4,6-trinitrobenzenide; NSC-36947; NSC-56147; STL199171; ZINC71129432; AKOS008966816; DB03651; MCULE-8917344355; UN 0154; Picric acid, wet, with not <10% water; DB-057108; Picric acid, moistened with water, >=98%; FT-0609916; Picric acid, SAJ special grade, >=99.5%; 2-methylbenzo[g][1,3]benzoxazole;picric acid; Picric acid solution, 0.9-1.1% (alkalimetric); Picric acid solution, 1.3% in H2O (saturated); A842990; Q189298; SR-01000944524; 1-methyl-3,4-dihydro-2H-beta-carboline;picric acid; 2,4,6-Trinitrophenol 10 microg/mL in Acetonitrile; SR-01000944524-1; 2,4,6-Trinitrophenol 100 microg/mL in Acetonitrile; Trinitrophenol, wetted with not <30% water, by mass; 2-methylbenzo[g][1,3]benzoxazole;2,4,6-trinitrophenol; Picric acid solution, ~1.3% in H2O, solution (saturated aqueous); Picric acid, wet, with not <10% water [NA1344] [Flammable solid]; Trinitrophenol or picric acid, dry or wetted with <30% water, by mass; Picric acid solution, 100 mug/mL in acetonitrile, PESTANAL(R), analytical standard; Picric acid, purum, moistened with >=40% water, >=98.0% (calc. on dry substance, T); Trinitrophenol, wetted with not <30% water, by mass [UN1344] [Flammable solid]; Trinitrophenol or picric acid, dry or wetted with <30% water, by mass [UN0154] [Explosive 1.1D]"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	229.1	0	C6H3N3O7	158	292	0.9	16	1	7	"InChI=1S/C6H3N3O7/c10-6-4(8(13)14)1-3(7(11)12)2-5(6)9(15)16/h1-2,10H"	C1=C(C=C(C(=C1[N+](=O)[O-])O)[N+](=O)[O-])[N+](=O)[O-]	OXNIZHLAWKMVMX-UHFFFAOYSA-N
DG01791	Glycidyl methacrylate	7837	"GLYCIDYL METHACRYLATE; 106-91-2; 2,3-Epoxypropyl methacrylate; Glycidol methacrylate; SY-Monomer G; oxiran-2-ylmethyl 2-methylprop-2-enoate; Blemmer G; Blemmer GMA; Light Ester G; oxiran-2-ylmethyl methacrylate; glycidylmethacrylate; 2-((Methacryloxy)methyl)oxirane; Methacrylic acid, 2,3-epoxypropyl ester; Glycidyl alpha-methylacrylate; 2-Propenoic acid, 2-methyl-, oxiranylmethyl ester; CP 105; NSC 24156; Methacrylic Acid Glycidyl Ester; Polyglycidyl methacrylate; poly(glycidyl methacrylate); 1-Propanol, 2,3-epoxy-, methacrylate; Glycidyl methacrylate(GMA); 2,3-Epoxypropanol methacrylate; Glycidyl .alpha.-methylacrylate; DTXSID0025361; Acriester G; NSC24156; NSC-24156; (oxiran-2-yl)methyl 2-methylprop-2-enoate; Glycidyl Methacrylate (stabilized with MEHQ); DSSTox_CID_5361; 25067-05-4; DSSTox_RID_77762; DSSTox_GSID_25361; GMA; 2-Propenoic acid, 2-methyl-, 2-oxiranylmethyl ester; oxiran-2-ylmethyl 2-methylacrylate; Methacrylic acid,3-epoxypropyl ester; MFCD00005137; WLN: T3OTJ B1OVY1 & U1; CAS-106-91-2; Glycidyl alpha-methyl acrylate; CCRIS 2626; HSDB 494; EINECS 203-441-9; SR 379; 2,3-Epoxypropyl methacrylic acid ester; BRN 0002506; Acryester G; glycidyl-methacrylate; 2-Propenoic acid, 2-methyl-, oxiranylmethyl ester, homopolymer; methacrylic acid glycidyl; EC 203-441-9; NCIOpen2_000036; SCHEMBL15617; 5-17-03-00035 (Beilstein Handbook Reference); methacrylic acid-glycidyl ester; CHEMBL1333073; CHEBI:132844; NSC67195; Tox21_201494; Tox21_303145; 2-Oxiranylmethyl 2-methylacrylate #; BBL010914; NSC-67195; SR-379; STK801798; AKOS000276065; AKOS016041668; MCULE-2297059991; Methacrylic acid 2,3-epoxypropyl ester; Glycidyl methacrylate, >=97.0% (GC); NCGC00091055-01; NCGC00091055-02; NCGC00256974-01; NCGC00259045-01; VS-02747; 2-methyl-acrylic acid oxiranylmethyl ester; CS-0063449; Epoxypropyl methacrylate,5 cp(25 degrees c); FT-0609742; M0590; Glycidyl Methacrylate, (stabilized with MEHQ); 2-methyl-acrylic acid oxiran-2-yl-methyl ester; E75837; Glycidyl methacrylate, purum, >=97.0% (GC); A801532; Q2013175; W-108764; Methacrylic Acid Glycidyl Ester (stabilized with MEHQ); Glycidyl methacrylate, stab. with 100ppm 4-methoxyphenol; 2-Propenoic acid, 2-methyl-, 2-oxiranylmethyl ester, homopolymer; Glycidyl methacrylate, 97%, contains 100 ppm monomethyl ether hydroquinone as inhibitor"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	142.15	4	C7H10O3	38.8	162	0.8	10	0	3	"InChI=1S/C7H10O3/c1-5(2)7(8)10-4-6-3-9-6/h6H,1,3-4H2,2H3"	CC(=C)C(=O)OCC1CO1	VOZRXNHHFUQHIL-UHFFFAOYSA-N
DG01792	1-Dodecene	8183	"1-DODECENE; Dodec-1-ene; 112-41-4; DODECENE; Adacene 12; n-Dodec-1-ene; Dodecene-1; Dodecylene; alpha-Dodecene; alpha-Dodecylene; .alpha.-Dodecene; UNII-WYE669F3GR; 25378-22-7; NSC 12016; .alpha.-Dodecylene; Neodene 12; Dodecylene .alpha.-; 1-Dodecene, dimer; MFCD00008961; WYE669F3GR; CHEBI:89713; 1-Dodecene, 95%; DSSTox_CID_6914; DSSTox_RID_78251; DSSTox_GSID_26914; 62132-67-6; N-Dodec-1-Ene A-Dodecylene; CAS-112-41-4; HSDB 1076; EINECS 203-968-4; Propene, polymers, tetramer; n-dodecene; 1-dodecen; HSDB 2793; dodec-11-ene; EINECS 246-922-9; Tetrapropylene (petroleum); EC 203-968-4; EC 246-922-9; 1-Dodecene (standard material); 1-Dodecene, analytical standard; CHEMBL1872885; DTXSID5026914; NSC12016; ZINC1718715; EINECS 271-215-7; Tox21_201382; Tox21_303303; 1-Dodecene, >=99.0% (GC); 2179AA; LMFA11000313; NSC-12016; AKOS015904161; CS-W017788; MCULE-4843306057; 1-Dodecene, technical, >=90% (GC); NCGC00164290-01; NCGC00164290-02; NCGC00257096-01; NCGC00258933-01; BS-14425; DB-041090; D0974; FT-0607712; S0342; D70997; A802575; Q161620; J-002769; UNII-2U283N3346 component CRSBERNSMYQZNG-UHFFFAOYSA-N"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	168.32	9	C12H24	0	84	6.8	12	0	0	"InChI=1S/C12H24/c1-3-5-7-9-11-12-10-8-6-4-2/h3H,1,4-12H2,2H3"	CCCCCCCCCCC=C	CRSBERNSMYQZNG-UHFFFAOYSA-N
DG01793	Kainic acid	10255	"Kainic acid; 487-79-6; Digenin; Digenic acid; Helminal; Kainate; L-alpha-Kainic acid; alpha-Kainic acid; Digensaeure; Kainsaeure; Acidum kainicum; Acide kainique; Acido kainico; C10H15NO4; 3-Pyrrolidineacetic acid, 2-carboxy-4-(1-methylethenyl)-, (2S,3S,4S)-; UNII-SIV03811UC; alpha- Kainic acid; rac Kainic Acid; CHEMBL275040; SIV03811UC; CHEBI:31746; 3-Pyrrolidineacetic acid, 2-carboxy-4-isopropenyl-; (2S,3S,4S)-3-(Carboxymethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylic acid; NSC136038; 3-(Carboxymethyl)-4-isopropenylproline; (3S,4S)-3-(carboxymethyl)-4-prop-1-en-2-yl-L-proline; NCGC00024504-05; (3S,4R)-3-(carboxymethyl)-4-(prop-1-en-2-yl)-L-proline; NSC 136038; (2S-(2alpha,3beta,4beta))-2-carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid; DSSTox_CID_20526; DSSTox_RID_79503; DSSTox_GSID_40526; (2S,3S,4S)-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid; Kainic acid [INN:JAN]; CAS-487-79-6; Acide kainique [INN-French]; Acido kainico [INN-Spanish]; Acidum kainicum [INN-Latin]; 2-Carboxy-4-isopropenyl-3-pyrrolidineacetic acid; SR-01000075454; 2-Carboxy-3-carboxymethyl-4-isopropenylpyrrolidine; BRN 0086660; kainic-acid; (2S,3S,4S)-3-(carboxymethyl)-4-prop-1-en-2-ylpyrrolidine-2-carboxylic acid; NSC-759587; KAI; 1p1n; Kainic acid (synthetic); Biomol-NT_000217; UPCMLD-DP146; 3-Pyrrolidineacetic acid, 2-carboxy-4-(1-methylethenyl)-, (2S-(2alpha,3beta,4beta))-; Lopac0_000656; SCHEMBL15777; 4-22-00-01523 (Beilstein Handbook Reference); MLS001074661; BPBio1_001306; (-)-(.alpha.)-Kainic Acid; DTXSID7040526; UPCMLD-DP146:001; UPCMLD-DP146:002; HMS2233K05; HMS3262C13; HMS3266C11; HMS3411A21; HMS3675A21; HY-N2309; ZINC3995575; Tox21_110905; Tox21_500656; BDBM50002369; Kainic Acid - CAS 487-79-6; AKOS024456995; Tox21_110905_1; CCG-204742; LP00656; NSC-136038; SDCCGSBI-0050635.P002; NCGC00024504-02; NCGC00024504-03; NCGC00024504-04; NCGC00024504-06; NCGC00024504-07; NCGC00024504-08; NCGC00024504-09; NCGC00024504-15; NCGC00261341-01; R081; SMR000471885; B6226; CS-0020451; EU-0100656; K 0250; Q390239; SR-01000597728; SR-01000075454-1; SR-01000075454-5; SR-01000075454-6; SR-01000075454-7; SR-01000597728-1; rel-(3R,4R)-3-(carboxymethyl)-4-isopropenyl-D-proline; 2S-CARBOXY-4S-(1-METHYLETHENYL)-3S-PYRROLDINEACETIC ACID; L-proline, 3-(carboxymethyl)-4-(1-methylethenyl)-, (3S,4S)-; (2S,3S,4S)-3-(Carboxymethyl)-4-Prop-1-En-2-yl-Pyrrolidine-2-Carboxylicacid; 3-Pyrrolidineacetic acid, 2-carboxy-4-(1-methylethenyl)-, (2S-(2-alpha,3-beta,4-beta))- (9CI); 4071-38-9"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	213.23	4	C10H15NO4	86.6	300	-1.8	15	3	5	"InChI=1S/C10H15NO4/c1-5(2)7-4-11-9(10(14)15)6(7)3-8(12)13/h6-7,9,11H,1,3-4H2,2H3,(H,12,13)(H,14,15)/t6-,7+,9-/m0/s1"	CC(=C)[C@H]1CN[C@@H]([C@H]1CC(=O)O)C(=O)O	VLSMHEGGTFMBBZ-OOZYFLPDSA-N
DG01794	"Hexane-1,6-diol"	12374	"1,6-HEXANEDIOL; Hexane-1,6-diol; 629-11-8; Hexamethylene glycol; 1,6-Dihydroxyhexane; Hexamethylenediol; alpha,omega-Hexanediol; .alpha.,.omega.-Hexanediol; UNII-ZIA319275I; 6-hydroxy-1-hexanol; 1,6-Hexanediol, homopolymer; CHEBI:43078; ZIA319275I; 27236-13-1; HEZ; CCRIS 8982; 1,6-Hexylene Glycol; HSDB 6488; NSC 508; 1,6-Hexanediol solution; EINECS 211-074-0; BRN 1633461; AI3-03307; 1,6hexanediol; 1,6 hexanediol; 1.6-hexanediol; 1,6-hexandiol; 1.6-hexandiol; .omega.-Hexanediol; 1,6-hexane diol; 1,6-hexan-diol; hexan-1,6-diol; Hexanediol-(1,6); DSSTox_CID_7265; 1,6-Hexanediol, 97%; 1,6-Hexanediol, 99%; EC 211-074-0; WLN: Q6Q; DSSTox_RID_78376; HO(CH2)6OH; DSSTox_GSID_27265; SCHEMBL15343; CHEMBL458616; NSC508; DTXSID1027265; NSC-508; ZINC1555566; Tox21_200450; MFCD00002985; AKOS003242194; CS-W011221; DB02210; MCULE-8817570517; NCGC00248624-01; NCGC00258004-01; AS-12686; BP-21412; CAS-629-11-8; DB-027344; FT-0607014; H0099; 1,6-Hexanediol solution, BioUltra, ~6 M in H2O; 1,6-Hexanediol, >=99% C6-Dioles basis (GC); A834086; Q161563; J-504039; F0001-1701"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:43078	.	.	.	118.17	5	C6H14O2	40.5	31.5	0.3	8	2	2	"InChI=1S/C6H14O2/c7-5-3-1-2-4-6-8/h7-8H,1-6H2"	C(CCCO)CCO	XXMIOPMDWAUFGU-UHFFFAOYSA-N
DG01795	Silicon dioxide	24261	"SILICON DIOXIDE; Silica; Quartz; Dioxosilane; 7631-86-9; Diatomaceous earth; Cristobalite; Silica gel; Tridymite; Sand; Infusorial earth; Silicic anhydride; KIESELGUHR; 112945-52-5; 14808-60-7; Aerosil; Crystalline silica; Diatomaceous silica; Dicalite; Wessalon; Glass; Ludox; Nyacol; Zorbax sil; 112926-00-8; 61790-53-2; Silica, amorphous; Cab-O-sil; Christensenite; Crystoballite; Silicon(IV) oxide; Siliceous earth; Synthetic amorphous silica; Amorphous silica; Silica, colloidal; 60676-86-0; QUARTZ (SIO2); 14464-46-1; Chalcedony; Diatomite; Agate; Cab-o-sil M-5; colloidal silica; Fused silica; Quartz glass; Quartz sand; Silica slurry; Silicone dioxide; SILICA, VITREOUS; Colloidal silicon dioxide; Siliceous earth, purified; Min-U-Sil; Silicon dioxide (amorphous); 15468-32-3; Silicon dioxide, fumed; Siliziumdioxid; 91053-39-3; UNII-ETJ7Z6XBU4; 68855-54-9; Kieselsaeureanhydrid; Silica Gel, 40-63 Micron Particles; CHEBI:30563; SiO2; (SiO2)n; 43-63C; ETJ7Z6XBU4; Silicon dioxide, colloidal; 15723-40-7; ENT 25,550; [SiO2]; Silica, crystalline - fused; Silicagel; Silicon dioxide, amorphous gel; 13778-37-5; 13778-38-6; 17679-64-0; Silicondioxide; Silica gel desiccant, indicating; Celite; Sand, Ottawa; Sand, Sea; silica gel desiccant; MFCD00011232; MFCD00217788; Silica, mesostructured; Sillikolloid; Acticel; Aerosil 380; Amethyst; Aquafil; Carplex; Cataloid; Crysvarl; Extrusil; Flintshot; Nalcoag; Novaculite; Porasil; Santocel; Silikil; Silikill; Siloxid; Sipernat; Superfloss; Vulkasil; Cherts; Neosil; Neosyl; Snowit; Aerosil-degussa; Imsil; Metacristobalite; Silica vitreous; Zipax; Quartz silica; alpha-Quartz; Fossil flour; Fumed silica; Quartz dust; Rock crystal; Rose quartz; Silica dust; White carbon; Chromosorb P; Silica particles; Tiger-eye; Vulkasil S; Celite superfloss; Cristobalite dust; Snowtex O; Corasil II; Silver bond B; Cab-O-sperse; alpha-Cristobalite; alpha-Crystobalite; Calcined diatomite; Tokusil TPLM; Dri-Die; Gold bond R; Cabosil st-1; Manosil vn 3; Sil-Co-Sil; Ultrasil VH 3; Ultrasil VN 3; Aerosil bs-50; Aerosil K 7; Cabosil N 5; Carplex 30; Carplex 80; Pigment White 27; Siderite (SiO2); Snowtex 30; Syton 2X; Tridymite 118; Zeofree 80; Cab-O-grip II; Silicon(IV) oxide, amorphous; Tridimite [French]; Amorphous silica gel; HI-Sil; Tridymite (SiO2); Glass wool, for laboratory use; Positive sol 232; Aerogel 200; Aerosil 300; Amorphous silica dust; Ludox hs 40; Silanox 101; Silica (SiO2); Vitasil 220; Positive sol 130M; Siliceous earth, purified (NF); Siliceous earth, purified [NF]; Silicon Oxide Hollow Nanospheres; Aerosil A 300; Aerosil E 300; Aerosil M-300; Cristobalite (SiO2); Nyacol 830; Sibelite M 3000; Sibelite M 4000; Sibelite M 6000; Quazo puro [Italian]; Caswell No. 734A; Nalfloc N 1050; Quso 51; Sicron F 300; Sikron F 100; Spectrosil; Accusand; Coesite; Fuselex; Nalcast; Nyacol 1430; Optocil; Quartzine; Quarzsand; Rancosil; Suprasil; Tridimite; Silica, amorphous fused; Siltex; Vitreous quartz; Vitreous silica; Tridymite dust; W 12 (Filler); beta-Quartz; Fused quartz; MIN-U-sil alpha quartz; Quartz-beta; Quso G 30; Silica glass; Amorphous quartz; Dri-Die insecticide 67; Nalco 1050; Quazo puro; Silica, amorphous, fumed; Vitrified silica; MFCD00163736; Pyrogenic colloidal silica; Silica gel, spherical, 60 angstroms; Hydrophobic silica 2482; Silica, fused; Suprasil W; Vitreosil IR; Borsil P; Calcined diatomaceous earth; Silica gel, spherical, 100 angstroms; Silica gel, spherical, 300 angstroms; Silane, dioxo-; Crystallized silicon dioxide; Optocil (quartz); CP-SilicaPLOT; Diatomaceous earth, calcined; Silicon oxide, di- (sand); Quarzsand [German]; S-Col; Admafine SO 25H; Admafine SO 25R; Admafine SO 32H; Admafine SO-C 2; Admafine SO-C 3; Cristobalite asbestos; Keatite (SiO2); Sg-67; Silica, amorphous, fumed, cryst.-free; Fumed silica, crystalline-free; Stishovite (SiO2); ED-C (silica); Fuselex ZA 30; As 1 (silica); CCRIS 2475; CCRIS 3699; DQ12; Agate (SiO2); Celite 545; Dimethyl siloxanes and silicones; Fumed synthetic amorphous silica; Silica, crystalline - tridymite; FB 5 (silica); Fuselex RD 120; Corning 7940; Microcrystalline quartz; Synthetic amorphous silica, fumed; Denka F 90; Denka FB 30; Denka FB 44; Denka FB 74; Denka FS 30; Dri-Die 67; Silica gel spherical, 40-75 mum particle size; WGL 300; Cryptocrystalline quartz; FB 20 (silica); Elsil 100; F 44 (filler); D & D; SF 35; Elsil BF 100; F 125 (silica); F 160 (silica); Fuselex RD 40-60; Silica, amorphous, fused; Silicon dioxide, chemically prepared; EINECS 231-545-4; EINECS 238-455-4; EINECS 238-878-4; EINECS 239-487-1; HK 400; TGL 16319; Silica gel 60, 0.060-0.2mm (70-230 mesh); Silica, crystalline quartz; Silicon dioxide (vitreous); EPA Pesticide Chemical Code 072605; Silica 2482, hydrophobic; CI 7811; Silica, crystalline, quartz; Silica, crystalline: quartz; GP 7I; CAB-O-SIL N-70TS; Silica, crystalline tridymite; Kieselgel; Seesand; Silica, crystalline - quartz; AF-SO 25R; Quartz [Silica, crystalline]; Siilca; Zorbax; quartz-glass; Silicom dioxide; Silica flour (powdered crystalline silica); Silica, crystalline: tridymite; silica-gel; Fused-silica; Silica,fumed; AI3-25549; GP 11I; RD 8; silica-; Silica, fumed; U 333; W 006; Silicon di-oxide; Tridymite [Silica, crystalline]; CRS 1102RD8; Silica Dispersion; SiO2 Nanopowder; Silica gel G; Silica, crystalline: cristobalite; Silica, tridymite; SiO2 Nanospheres; Diatomaceous earth, flux-calcined, filter aid, treated with sodium carbonate, flux calcined; Silica gel 60 ADAMANT(TM) on TLC plates, with fluorescent indicator 254 nm; EF 10; FS 74; MR 84; Silica, crystalline - cristobalite; Silica Microspheres; Cristobalite [Silica, crystalline]; Amorphous silica: Pyrogenic (fumed); EINECS 262-373-8; Silica gel, ASTM; Silica Nanoparticles; Methyl3-oxohexanoate; Siliceous sand, CP; BF 100; EQ 912; QG 100; RD 120; Celite 503; Nettles p.e. extract; Silicon Dioxide Powder; Sea sand, acid washed; Silica, fumed, powder; Silicon dioxide (NF); Activated Silica Powder; Activated Silicon Oxide; Sand 50-70 mesh; F 44; Silica gel, large pore; Y 40; SiO2.xH2O; Hollow Silica Nanosphere; Silicon Oxide Dispersion; Silicon Oxide Nanopowder; Activated Silicon Dioxide; Celite (R) 545; Crystalline Silica Quartz; Silica gel, ACS reagent; Celite(R) 512 medium; Kieselguhr, -325 mesh; Silica, 99.8%; SBA-15 Molecular Sieve; Silicon dioxide Nanopowder; Diatomaceous earth, powder; DSSTox_CID_9677; Silicon Dioxide Dispersion; Epitope ID:158537; Silica, fumed, hydrophobic; Silicon Dioxide Nanospheres; Silicon Dioxide, Amorphous; Silicon Oxide Nanoparticles; EC 231-545-4; Celite(R) 503, CP; Celite(R) 535, CP; Celite(R) 545, CP; Nano Silicon Dioxide Powder; DSSTox_RID_78805; CELATOM(R) FW-60; DSSTox_GSID_29677; Silicon dioxide, acid washed; Silica, hydrate(8CI,9CI); Silicon(IV) oxide (SiO2); 99439-28-8; Silicon Dioxide, Precipitated; Silica fibers, 1/4'' long; Kieselguhr, calcined, purified; Silica gel, CP, blue, beads; Silica Nanoparticles Dispersion; Silica, fused, respirable dust; 25wt% Silicon Oxide in Water; AW Standard Super-Cel(R) NF; MCM-41; Silica gel, CP, mixed, beads; Silica gel, CP, white, beads; Silicates (<1% crystalline silica):Graphite, natural; Hyflo(R) Super-Cel(R), CP; CHEMBL3188292; DTXSID1029677; Filter agent, Celite(R) 545; Sand, white quartz, CP, beads; Quarz cryst., 0.6-1.3 mm; Silicon dioxide, colloidal (NF); Diatomaceous earth, flux-calcined; Silicon dioxide, SAJ first grade; Diatomaceous earth non-washed, CP; Silica Gel Dessicant (Grade 03); Silica gel, CP, blue, bead size; Filter agent, Celatom(R) FW-14; Filter agent, Celatom(R) FW-50; Filter agent, Celatom(R) FW-60; Filter agent, Celatom(R) FW-80; Silica, fused [Silica, amorphous]; Silicon dioxide, JIS special grade; Silicon Oxide Mesoporous Nanopowder; AMY37125; Chromosorb(R) G, 80-100 mesh; 2-Mercaptoethyl ethyl sulfide silica; Celite(R) 545 AW, reagent grade; Silica gel 60, 230-400 mesh; Silica Hollow Nanospheres Dispersion; Silicon(IV) oxide, electronic grade; Tox21_301288; MFCD00148266; MFCD00603035; MFCD02100519; MFCD06202255; MFCD07370733; Sand, white quartz, CP, crystalline; Silica gel, indicating, 6-16 mesh; Chromosorb(R) W/AW, 45-60 mesh; Light anhydrous silicic acid (JP17); Quarz fine, cryst., 0.4-0.8 mm; Silica gel, 70-200 mesh (TLC); Silica, fumed, powder, 0.008 mum; AKOS009085429; Silicon Dioxide Nanospheres Properties; DB11132; Iron Sulfide (FeS) Sputtering Targets; Silicon Dioxide Nanoparticle Dispersion; Glass spheres, 9-13 mum particle size; Quartz (silicon dioxide), silver, pure; s25266; Silica gel, CP, white, medium granules; Silica gel, technical grade, 3-9 mesh; Silica, mesostructured, HMS (wormhole); NCGC00257531-01; Sand, white quartz, purum p.a., powder; Silica gel orange, granular, 0.2-1 mm; SILICON DIOXIDE amorphous fumed silica; Silicon Oxide Nanoparticles / Nanopowder; Silicon(IV) oxide, powder, 0.5 micron; Silicon(IV) oxide, powder, 1.0 micron; Silicon(IV) oxide, powder, 1.5 micron; 14639-89-5; 92283-58-4; E551; Silica gel, CP, blue, bead size, medium; Silica gel, technical grade, 6-16 mesh; Silicon oxide powder, 99% Nano, 20 nm; CAS-7631-86-9; Silica gel desiccant, -3+8 mesh granules; Silica gel, 12-24 mesh (liquid drying); Silica gel, CP, mixed, bead size, medium; Silica gel, for column chromatography, 60; Silicon Dioxide Nanoparticles / Nanopowder; Celite(R) 281, filter aid, flux calcined; Celite(R) S, filter aid, dried, untreated; Chromosorb(R) W/AW-DMCS, 80-100 mesh; Quarz min. 99% powdered, up to 125  m; Silica gel desiccant, -6+12 mesh granules; Silicon dioxide, purum p.a., acid purified; White Silica Gel Beads, 3 mm (2-5 mm); FT-0624621; FT-0645127; FT-0689145; FT-0689270; FT-0696592; FT-0696603; FT-0697331; FT-0697389; FT-0700917; Quartz rod, fused, 2.0mm (0.079in) dia; Quartz rod, fused, 5.0mm (0.197in) dia; S0822; Silica gel, with 1-4 mm moisture indicator; Silica, amorphous, fumed (crystalline free); Silicon dioxide Nanopowder KH550 processing; Silicon dioxide Nanopowder KH570 processing; Silicon(IV) oxide, 99.0% (metals basis); Celite(R) 110, filter aid, flux calcinated; Celite(R) 512 medium, filter aid, calcined; Chromosorb(R) G/AW-DMCS, 100-120 mesh; Chromosorb(R) W/AW-DMCS, 120-140 mesh; K-411 Glass microspheres, NIST SRM 2066; Quartz rod, fused, 10.0mm (0.394in) dia; Silica gel, technical grade 40, 6-12 mesh; C18 Silica Gel, Endcapped, 60A, 40-63um; D05839; D06521; D06522; D78143; Sand, white quartz, 50-70 mesh particle size; Silica gel, large pore, P.V. ca. 1.65cc/g; Silica, mesostructured, MSU-F (cellular f"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11132	.	.	60.084	0	O2Si	34.1	18.3	.	3	0	2	InChI=1S/O2Si/c1-3-2	O=[Si]=O	VYPSYNLAJGMNEJ-UHFFFAOYSA-N
DG01796	Streptozocin	29327	"Streptozocin; STREPTOZOTOCIN; streptozosin; 18883-66-4; Zanosar; Estreptozocina; Streptozocine; Streptozocinium; Streptozocinum; 2-Desoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 66395-18-4; N-D-Glucosyl-(2)-N'-nitrosomethylurea; C8H15N3O7; alpha-Streptozocin; streptozotocin (stz); CHEBI:9288; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; UNII-8H27GUR065; 8H27GUR065; MFCD00006607; STZ; alkylating agent; NSC-85998; DSSTox_CID_1282; DSSTox_RID_76055; DSSTox_GSID_21282; binds to DNA; Zanosar (TN); SR-05000001720; 2-deoxy-2-[[(methylnitrosoamino)carbonyl]amino]-D-glucose; 2-deoxy-2-({[methyl(nitroso)amino]carbonyl}amino)-alpha-D-glucopyranose; NCGC00016738-01; CAS-18883-66-4; Spectrum_000960; Streptozotocin - Zanosar; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose; Prestwick3_000732; Spectrum2_000062; Spectrum3_001087; Spectrum4_001244; Spectrum5_001047; Epitope ID:134282; N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; SCHEMBL4748; Streptozocin; Streptozotocin; CHEMBL1603; BSPBio_000684; BSPBio_002734; KBioGR_001768; KBioSS_001440; MLS004774123; DivK1c_000531; SPECTRUM1500543; SPBio_000243; BPBio1_000754; Streptozocin (JAN/USAN/INN); DTXSID2021282; BCBcMAP01_000142; HMS501K13; KBio1_000531; KBio2_001440; KBio2_004008; KBio2_006576; KBio3_001954; NINDS_000531; HMS1921A07; HMS2092I09; HMS2097C06; HMS3714C06; Pharmakon1600-01500543; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; ACT03364; ZINC3977737; Streptozocin, >=98.0% (HPLC); Tox21_110585; Tox21_201859; Tox21_302974; CCG-39870; NSC757321; s1312; AKOS025310730; Tox21_110585_1; DB00428; NSC-757321; IDI1_000531; SMP1_000282; NCGC00178500-01; NCGC00178500-02; NCGC00178500-03; NCGC00178500-04; NCGC00178500-07; NCGC00256594-01; NCGC00259408-01; 1-methyl-1-nitroso-3-((2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)urea; SMR001233317; SBI-0051517.P003; AB00513906; SW199198-2; C07313; D05932; AB00052092-03; AB00052092_04; AB00052092_05; 883S664; A937380; N-(METHYLNITROSOCARBAMOYL)-A-D-GLUCOSAMINE; Q257331; SR-01000939745; SR-01000939745-3; SR-05000001720-1; SR-05000001720-2; W-201687; Streptozocin, Vetec(TM) reagent grade, 98%, powder; Streptozocin, >=75% alpha-anomer basis, >=98% (HPLC), powder; alpha-D-Glucopyranose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-; WURCS=2.0/1,1,0/[a2122h-1a_1-5_2*NCNN=O/4C/3=O]/1/; 3-methyl-3-nitroso-1-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 1-Methyl-1-nitroso-3-((2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-3-yl)urea; 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-3-yl]urea"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9288	DB00428	.	.	265.22	2	C8H15N3O7	152	315	-1.4	18	5	8	"InChI=1S/C8H15N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,12-15H,2H2,1H3,(H,9,16)/t3-,4-,5-,6-,7+/m1/s1"	CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O	ZSJLQEPLLKMAKR-GKHCUFPYSA-N
DG01797	"N-[(5,7-dichloro-2,3-dihydro-1-benzofuran-2-yl)methyl]propan-2-amine"	36806	NULL	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	260.16	3	C12H15Cl2NO	21.3	237	3.6	16	1	2	"InChI=1S/C12H15Cl2NO/c1-7(2)15-6-10-4-8-3-9(13)5-11(14)12(8)16-10/h3,5,7,10,15H,4,6H2,1-2H3"	CC(C)NCC1CC2=C(O1)C(=CC(=C2)Cl)Cl	FCFGRTQYVIIVRZ-UHFFFAOYSA-N
DG01798	Cyperquat	39484	"Cyperquat; MPP+; 1-METHYL-4-PHENYLPYRIDINIUM; N-Methyl-4-phenylpyridine; 48134-75-4; N-Methyl-4-phenylpyridinium ion; 1-methyl-4-phenylpyridin-1-ium; N-Methyl-4-phenylpyridinium; Pyridinium,1-methyl-4-phenyl-; UNII-R865A5OY8J; CHEBI:641; R865A5OY8J; Cyperquat [ANSI]; Pyridinium, 1-methyl-4-phenyl-; 1 Methyl 4 Phenylpyridinium; CCRIS 2187; BRN 1618932; Cyperquat [ANSI:ISO]; SCHEMBL37321; CHEMBL311617; GTPL4568; DTXSID4058106; BDBM81945; ZINC967769; CAS_39484; NSC_39484; Pyridinium, 1-methyl-4-phenyl- (9CI); 5-20-07-00550 (Beilstein Handbook Reference); Q161645"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:641	.	.	DR01488	170.23	1	C12H12N+	3.9	141	2.7	13	0	0	"InChI=1S/C12H12N/c1-13-9-7-12(8-10-13)11-5-3-2-4-6-11/h2-10H,1H3/q+1"	C[N+]1=CC=C(C=C1)C2=CC=CC=C2	FMGYKKMPNATWHP-UHFFFAOYSA-N
DG01799	4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone	47289	"64091-91-4; 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; NNK (carcinogen); NNK; 4-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; 1-Butanone, 4-(methylnitrosoamino)-1-(3-pyridinyl)-; 4-(N-Nitroso-N-methylamino)-1-(3-pyridyl)-1-butanone; UNII-7S395EDO61; N-methyl-N-(4-oxo-4-pyridin-3-ylbutyl)nitrous amide; MFCD00274580; 4-Methylnitrosoamino-1-(3-pyridinyl)-1-butanone; 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone; N-Methyl-N-nitroso-4-oxo-4-(3-pyridyl)butyl amine; 4-(Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; 4-[methyl(nitroso)amino]-1-(pyridin-3-yl)butan-1-one; CHEBI:32692; 7S395EDO61; 4-(Nitrosomethylamino)-1-(3-pyridyl)-1-butanone; 4-(Methylnitrosamino)-1-(3-pyridyl)-1-(butanone); 4-[methyl(nitroso)amino]-1-pyridin-3-ylbutan-1-one; Ketone, 3-pyridyl 3-(N-methyl-N-nitrosamino)propyl; N-methyl-N-(4-oxo-4-(pyridin-3-yl)butyl)nitrous amide; N-Methyl-N-[4-oxo-4-(pyridin-3-yl)butyl]nitrous amide; 4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one; CCRIS 1150; BRN 3548355; HSDB 7771; Ozone/NNK; 4-(Nitrosoamino-N-methyl)-1-(3-pyridyl)-1-butanone; 4-(N-Methyl-N-nitrosoamino)-4-(3-pyridyl)-1-butanone; 64091-50-5; DSSTox_CID_881; N-Nitrosonornicotine ketone; N-Nitrosonornicotine-ketone; DSSTox_GSID_20881; 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone; SCHEMBL454516; 1-Butanone, 4-(methylnitrosamino)-1-(3-pyridyl)-; CHEMBL2311069; DTXSID3020881; Nicotine-derived nitrosamine ketone; BCP32075; ZINC5239470; Tox21_303771; AKOS028109857; NCGC00163358-01; NCGC00357285-01; SY062201; CAS-64091-91-4; HY-126477; FT-0616837; FT-0672061; FT-0672062; A50811; Q6138931; 1-Butanone,4-(methylnitrosoamino)-1-(3-pyridinyl)-; 1-Butanone, 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl); 4-(1-Methyl-2-oxohydrazino)-1-(3-pyridinyl)-1-butanone #; 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) solution; 4-(Methylnitrosoamino)-1-(3-pyridinyl)-1-butanone, analytical standard; 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	DR0011	.	207.23	5	C10H13N3O2	62.6	221	0.8	15	0	5	"InChI=1S/C10H13N3O2/c1-13(12-15)7-3-5-10(14)9-4-2-6-11-8-9/h2,4,6,8H,3,5,7H2,1H3"	CN(CCCC(=O)C1=CN=CC=C1)N=O	FLAQQSHRLBFIEZ-UHFFFAOYSA-N
DG01800	Simvastatin	54454	"Simvastatin; 79902-63-9; Zocor; Synvinolin; Sinvacor; Denan; Lipex; MK-733; Sivastin; Lodales; Simvastatine; Cholestat; Colemin; Simovil; Medipo; Pantok; Simvastatina; Simvastatinum; Velostatin; Zocord; Zorced; Simvastatin lactone; Simvastatin (Zocor); Lipovas; Simcard; Simvacor; Simvoget; Rechol; Simlup; (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; MK-0733; UNII-AGG2FN16EV; MK 733; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one; AGG2FN16EV; CHEBI:9150; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; Labistatin; Coledis; Corolin; Nivelipol; Rendapid; Vasotenal; NSC-758706; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; C25H38O5; Simvastatine [French]; Simvastatinum [Latin]; Simvastatina [Spanish]; DSSTox_CID_3581; DSSTox_RID_77090; DSSTox_GSID_23581; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; Zosta; Simvast CR; DRG-0320; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-tetrahydropyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; SMR000718785; MK 0733; CCRIS 7558; Zocor (TN); HSDB 7208; Simvastatin & Primycin; MK733; SR-05000001894; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; L 644128-000U; BRN 4768037; Kolestevan; Lipinorm; Modutrol; Simvotin; Sinvascor; Valemia; Eucor; MFCD00072007; Nor-Vastina; Simvastatin,(S); C10AA01; simvastatin predrug; (+)-Simvastatin; NCGC00016940-01; inactive simvastatin; Simvastatin [USAN:USP:INN:BAN]; TNP00259; Prestwick_171; Simvastatin- Bio-X; CAS-79902-63-9; KS-1113; Spectrum_001717; SpecPlus_000895; Prestwick0_000865; Prestwick1_000865; Prestwick2_000865; Prestwick3_000865; Spectrum2_001671; Spectrum3_000669; Spectrum4_000632; Spectrum5_001428; SCHEMBL2471; CHEMBL1064; BSPBio_000909; BSPBio_002337; KBioGR_001244; KBioSS_002197; MLS001304029; MLS001333077; MLS001333078; MLS002154038; MLS006011866; BIDD:GT0769; DivK1c_006991; SPECTRUM1504236; SPBio_001881; SPBio_002830; BPBio1_001001; GTPL2955; Simvastatin (JP17/USP/INN); Simvastatin, analytical standard; DTXSID0023581; BCBcMAP01_000007; KBio1_001935; KBio2_002197; KBio2_004765; KBio2_007333; KBio3_001557; RYMZZMVNJRMUDD-HGQWONQESA-; HMS1570N11; HMS1922H13; HMS2089D12; HMS2093E06; HMS2097N11; HMS2231N22; HMS3259B12; HMS3412P08; HMS3676P08; HMS3714N11; HMS3884G10; Pharmakon1600-01504236; ZINC3780893; Tox21_110696; Tox21_300400; BBL024390; BDBM50139181; CCG-39069; NSC633782; NSC758706; s1792; STK801938; AKOS005111006; AKOS015842733; Simvastatin, >=97% (HPLC), solid; Tox21_110696_1; AC-1530; DB00641; MCULE-8390617062; NC00719; NSC 758706; NSC-633782; MRF-0000729; NCGC00017324-01; NCGC00017324-02; NCGC00017324-03; NCGC00017324-04; NCGC00017324-05; NCGC00017324-07; NCGC00017324-08; NCGC00017324-09; NCGC00254418-01; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; BS164407; Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha,3alpha,7beta,8beta(2S*,4S*),8abeta))-; HY-17502; SBI-0206773.P001; Simvastatin 100 microg/mL in Acetonitrile; S0509; D00434; J10128; AB00053395-07; AB00053395-08; AB00053395-10; AB00053395_11; AB00053395_13; 902S639; A839783; Q670131; SR-05000001894-1; SR-05000001894-2; BRD-K22134346-001-05-8; BRD-K22134346-001-11-6; BRD-K22134346-001-15-7; Z1741982918; Simvastatin, British Pharmacopoeia (BP) Reference Standard; Simvastatin, European Pharmacopoeia (EP) Reference Standard; Simvastatin, United States Pharmacopeia (USP) Reference Standard; Simvastatin, Pharmaceutical Secondary Standard; Certified Reference Material; Simvastatin for peak identification, European Pharmacopoeia (EP) Reference Standard; (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyly-2,2-dimethyl butanoate; (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbu; (1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:9150	DB00641	DR1485	DR00435	418.6	7	C25H38O5	72.8	706	4.7	30	1	5	"InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1"	CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C	RYMZZMVNJRMUDD-HGQWONQESA-N
DG01801	Adenosine	60961	"Adenosine; 58-61-7; Adenocard; Adenoscan; Adenine riboside; beta-D-Adenosine; Nucleocardyl; Adenosin; Boniton; Sandesin; Myocol; Adenine nucleoside; Adenocor; beta-Adenosine; 9-beta-D-Ribofuranosyladenine; 9-beta-D-Ribofuranosidoadenine; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; Adenosin [German]; USAF CB-10; 9beta-D-Ribofuranosyladenine; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; Ade-Rib; Caswell No. 010B; Adenosine [USAN:BAN]; (2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; beta-D-Ribofuranoside, adenine-9; 6-Amino-9beta-D-ribofuranosyl-9H-purine; SR 96225; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; CHEBI:16335; Quinquefolan B; D-Adenosine; 3H-adenosine; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; NSC 7652; Dehydran 240; UNII-K72T3FS567; Adenosine (Adenocard); AI3-52413; 9H-Purin-6-amine, 9beta-D-ribofuranosyl-; MFCD00005752; CHEMBL477; SR-96225; beta-D-Ribofuranose, 1-(6-amino-9H-purin-9-yl)-1-deoxy-; adenine-D-ribose; 9-.beta.-d-Ribofuranosyladenine; 5536-17-4; K72T3FS567; CCRIS 2557; Adenine-9-beta-D-ribofuranoside; NCGC00023673-05; Pallacor; DSSTox_CID_2558; DSSTox_RID_76628; DSSTox_GSID_22558; 109767-06-8; 133248-01-8; Adenine 9-beta-D-arabinofuranoside; .beta.-D-Adenosine; CAS-58-61-7; Adenocard (TN); Adenoscan (TN); 41547-82-4; SMR000058216; MEDR-640; Adenosine (JAN/USP); SR-05000001981; EINECS 200-389-9; Adenine-beta-D-arabinofuranoside; NSC 627048; NSC7652; Adenogesic; Adenosine [USAN:USP:BAN]; Adenin riboside; NSC-7652; .beta.-D-Ribofuranoside, adenine-9; 9-.alpha.-D-Arabinofuranosyladenine; MFCD00065471; NSC627048; b-D-Adenosine; HSDB 7774; SUN-Y4001; N6-Methylado; 1dgm; 1odi; 2fqy; 2ydo; 3axz; 4cki; 4ckj; Adenosine,(S); adenosine-N-15N; adenosine-8-13C; adenosine-9-15N; beta-delta-Adenosine; [U-14C]adenosine; 6-Amino-9.beta.-D-ribofuranosyl-9H-purine; 2gl0; 3ay0; 4pd9; Adenosine, >=99%; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; Spectrum2_001257; Spectrum3_000288; cid_191; SCHEMBL731; bmse000061; bmse000996; Epitope ID:140947; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; 9-ss-D-Ribofuranosyladenine; BSPBio_001796; .beta.-D-Ribofuranose, 1-(6-amino-9H-purin-9-yl)-1-deoxy-; cid_60961; MLS000069638; MLS002153227; MLS006010946; SPECTRUM1500107; Adenine-9-ss-D-ribofuranoside; REGID_for_CID_60961; SPBio_001194; adenine-9beta-D-Ribofuranoside; GTPL2844; 9beta-delta-Ribofuranosyladenine; DTXSID1022558; BDBM14487; KBio3_001296; 9-beta-delta-Ribofuranosyladenine; EA6C60C2-6AFB-4264-A2F0-541373DB950E; 9-.beta.-D-Ribofuranosidoadenine; 9-beta-delta-Ribofuranosidoadenine; adenine-9beta-delta-Ribofuranoside; Bio1_000437; Bio1_000926; Bio1_001415; HMS1920A13; HMS2091G13; HMS2235E24; HMS3884O04; Pharmakon1600-01500107; ACT02616; ALBB-032827; AMY30083; XYA; ZINC2169830; 9-beta-delta-Arabinofuranosyladenine; Tox21_110891; AC7861; adenosine-2-13C-N,1,3-15N3; CCG-38824; NSC755857; s1647; AKOS015888594; Tox21_110891_1; AC-8229; AM83931; DB00640; MCULE-7071766082; NSC-755857; SDCCGMLS-0003108.P003; 9- -D-Ribofuranosyl-9H-purin-6-amine; 9beta-D-ribofuranosyl-9H-Purin-6-amine; NCGC00023673-03; NCGC00023673-04; NCGC00023673-06; NCGC00023673-07; NCGC00023673-10; NCGC00023673-20; NCGC00178869-03; 9-  -D-Ribofuranosyl-9H-purin-6-amine; AC-27494; AS-12664; Adenosine, Vetec(TM) reagent grade, 98%; SBI-0206673.P002; 9beta-delta-ribofuranosyl-9H-Purin-6-amine; DB-022408; 6-Amino-9beta-delta-ribofuranosyl-9H-purine; 9-.beta.-D-Ribofuranosyl-9H-purin-6-amine; 9-beta-delta-Ribofuranosyl-9H-purin-6-amine; A0152; 9H-Purin-6-amine, 9-.beta.-d-ribofuranosyl-; C00212; D00045; AB00384349-11; AB00384349_13; AB00384349_14; Adenosine, BioReagent, suitable for cell culture; Q190012; UNII-F2 component OIRDTQYFTABQOQ-KQYNXXCUSA-N; SR-05000001981-1; SR-05000001981-2; Z1741978458; 1-(6-amino-9H-purin-9-yl)-1-deoxy-beta-D-Ribofuranose; Adenosine, European Pharmacopoeia (EP) Reference Standard; Formycin A, from Streptomyces kaniharaensis, >=98% (HPLC); 1-(6-amino-9H-purin-9-yl)-1-deoxy-beta-delta-Ribofuranose; Adenosine, United States Pharmacopeia (USP) Reference Standard; Adenosine, Pharmaceutical Secondary Standard; Certified Reference Material; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; 142796-17-6; 158749-77-0; 177030-94-3; 244769-76-4"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:16335	DB00640	DR0046	DR00904	267.24	2	C10H13N5O4	140	335	-1.1	19	4	8	"InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1"	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N	OIRDTQYFTABQOQ-KQYNXXCUSA-N
DG01802	Delphinidin	68245	"Delphinidin chloride; 528-53-0; Delphinidin; Delphinidine; Delphinidol; Delfinidol chloride; Ephdine; 8012-95-1; UNII-EM6MD4AEHE; Delphinidin (chloride); 1-Benzopyrylium, 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-, chloride; EM6MD4AEHE; 2-(3,4,5-trihydroxyphenyl)chromenylium-3,5,7-triol chloride; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)benzopyrylium chloride; IdB 1056; 2-(3,4,5-trihydroxyphenyl)chromenylium-3,5,7-triol;chloride; CHEBI:38701; 3,3',4',5,5',7-Hexahydroxyflavylium chloride; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyrylium chloride; MFCD00016663; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)chromenylium chloride; Delphinidine; Delphinidol; Ephdine; IdB 1056;Delfinidol chloride; Delphinidin; CHEMBL590878; Delphinidin chloride, analytical standard; 3,3',4',5,5',7-Hexahydroxy-2-phenylbenzopyrylium chloride; CCRIS 2518; EINECS 208-437-0; C15H11O7.Cl; Delphinidinchloride; 2-(3,4,5-trihydroxyphenyl)-1-benzopyrylium-3,5,7-triol; SCHEMBL22369; IdB-1056; DTXSID701019982; 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromenium chloride; BCP15819; HY-N2409; 6267AF; AKOS027326494; AC-35150; AS-78369; CS-0022610; FT-0645153; FT-0665679; Q367258; Flavylium 3,3',4',5,5',7-hexahydroxy-, chloride (8CI); UNII-R911H793SU component FFNDMZIBVDSQFI-UHFFFAOYSA-N"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	CHEBI:38701	.	.	.	338.69	1	C15H11ClO7	122	380	.	23	6	7	"InChI=1S/C15H10O7.ClH/c16-7-3-9(17)8-5-12(20)15(22-13(8)4-7)6-1-10(18)14(21)11(19)2-6;/h1-5H,(H5-,16,17,18,19,20,21);1H"	C1=C(C=C(C(=C1O)O)O)C2=[O+]C3=CC(=CC(=C3C=C2O)O)O.[Cl-]	FFNDMZIBVDSQFI-UHFFFAOYSA-N
DG01803	Chloroquinine phosphate	83818	"Chloroquinine phosphate; TCMDC-123988; Tanakan; 1446-17-9; Chloroquine monophosphate; Araten phosphate; Chloroin; Delagil; Khingamin; Miniquine; Resochin; Rivoquine; Tanakene; Arolen; Aralen diphosphate; Gontochin phosphate; Chloroquin diphosphate; Ipsen 225; Chloroquine, phosphate; NSC14050; NSC-14050; 3377 RP; 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine;phosphoric acid; SN 7,618; EGb761; Resochin diphosphate; Quinoline, diphosphate; CQ; CHEMBL1326; SCHEMBL40829; DTXSID10932343; Pharmakon1600-01500179; NSC756681; AKOS025310652; NSC-756681; 1,4-Pentanediamine, N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-, phosphate (1:1)-; Quinoline, 7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)-, phosphate (1:1); NCGC00180905-01; NCGC00180905-02; 941C583; WLN: T66 BNJ EMY1&3N2&2 IG &P2-O6; Q27268205; 1, N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-, phosphate (1:2); 7-Chloro-4-[(4'-diethylamino-1-methylbutyl)amino]quinoline diphosphate; Quinoline, 7-chloro-4-[(4-diethylamino-1-methylbutyl)amino]-, diphosphate (6CI); Phosphoric acid--N~4~-(7-chloroquinolin-4-yl)-N~1~,N~1~-diethylpentane-1,4-diamine (1/1)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB01381	.	.	417.9	8	C18H29ClN3O4P	106	359	.	27	4	7	"InChI=1S/C18H26ClN3.H3O4P/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18;1-5(2,3)4/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21);(H3,1,2,3,4)"	CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl.OP(=O)(O)O	AEUAEICGCMSYCQ-UHFFFAOYSA-N
DG01804	Catalpol	91520	"Catalpol; 2415-24-9; Catalpinoside; CHEMBL513223; CHEBI:69797; De(p-hydroxybenzoyl)catalposide; UNII-JCX5L7JIC2; JCX5L7JIC2; Catalposide, des-p-hydroxybenzoyl-; EINECS 219-324-0; Digitalis purpurea L; SCHEMBL420515; Catalpol, >=96% (HPLC); DTXSID60178850; HY-N0820; ZINC8234298; BDBM50259972; AKOS024264429; AC-8052; AM84820; CCG-208299; LMPR0102070007; NCGC00163523-01; (1AS-(1aalpha,1bbeta,2beta,5abeta,6beta,6aalpha))-1a,1b,2,5a,6,6a-hexahydro-6-hydroxy-1a-(hydroxymethyl)oxireno(4,5)cyclopenta(1,2-c)pyran-2-yl-beta-D-glucopyranoside; AS-75213; beta-D-Glucopyranoside, 1a,1b,2,5a,6,6a-hexahydro-6-hydroxy- 1a-(hydroxymethyl)oxireno(4,5)cyclopenta(1,2-c)pyran-2-yl, (1aS-(1a-alpha,1b-beta,2-beta,5a-beta,6-beta,6a-alpha))-; beta-D-Glucopyranoside, 1a,1b,2,5a,6,6a-hexahydro-6-hydroxy-1a-(hydroxymethyl)oxireno(4,5)cyclopenta(1,2-c)pyran-2-yl, (1aS-(1aalpha,1bbeta,2beta,5abeta,6beta,6aalpha))-; N1352; SR-05000002315; Q1050267; SR-05000002315-2; (1aS,1bS,2S,5aR,6S,6aS)-1a,1b,2,5a,6,6a-Hexahydro-6-hydroxy-1a-(hydroxymethyl)oxireno[4,5]cyclopenta[1,2-c]pyran-2-yl beta-D-glucopyranoside; (1S,5R,6R)-2-[(1S,1bS,2S,5aR,6S)-6-hydroxy-1a-((S)-hydroxymethyl)-1a,1b,2,5a,6,6a-hexahydro-1,3-dioxa-cyclopropa[a]inden-2-yloxy]-6-((S)-hydroxymethyl)-tetrahydro-pyran-3,4,5-triol; (2S,3R,4S,5S,6R)-2-(((1aS,1bS,2S,5aR,6S,6aS)-6-hydroxy-1a-(hydroxymethyl)-1a,1b,2,5a,6,6a-hexahydrooxireno[2',3':4,5]cyclopenta[1,2-c]pyran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4S,5S,6R)-2-[[(1S,2S,4S,5S,6R,10S)-5-hydroxy-2-(hydroxymethyl)-3,9-dioxatricyclo[4.4.0.02,4]dec-7-en-10-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol; (2S,3R,4S,5S,6R)-2-{[(1S,2S,4S,5S,6R,10S)-5-HYDROXY-2-(HYDROXYMETHYL)-3,9-DIOXATRICYCLO[4.4.0.0(2), ]DEC-7-EN-10-YL]OXY}-6-(HYDROXYMETHYL)OXANE-3,4,5-TRIOL"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	362.33	4	C15H22O10	162	542	-3.2	25	6	10	"InChI=1S/C15H22O10/c16-3-6-9(19)10(20)11(21)14(23-6)24-13-7-5(1-2-22-13)8(18)12-15(7,4-17)25-12/h1-2,5-14,16-21H,3-4H2/t5-,6-,7-,8+,9-,10+,11-,12+,13+,14+,15-/m1/s1"	C1=CO[C@H]([C@H]2[C@@H]1[C@@H]([C@H]3[C@@]2(O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O	LHDWRKICQLTVDL-PZYDOOQISA-N
DG01805	Homocysteine	91552	"L-Homocysteine; homocysteine; 6027-13-0; (2S)-2-amino-4-sulfanylbutanoic acid; (s)-2-amino-4-mercaptobutanoic acid; UNII-0LVT1QZ0BA; 2-AMINO-4-MERCAPTO-BUTYRIC ACID; CHEBI:17588; L-2-Amino-4-mercaptobutyric acid; 0LVT1QZ0BA; CHEMBL469662; Hcy; MFCD00151320; homo-cys; H-Hcys-OH; Butyric acid, 2-amino-4-mercapto-; HCS; Homocysteine (VAN); 454-28-4; 2-amino-4-sulfanylbutanoate; EINECS 227-891-0; NSC 43117; NSC 118376; 2-Amino-4-mercaptobutyric acid (VAN); Butanoic acid, 2-amino-4-mercapto- (VAN); Butanoic acid, 2-amino-4-mercapto-, (S)-; Epitope ID:143650; SCHEMBL35837; 2-amino-4-mercapto-Butanoate; GTPL5198; DTXSID3041039; 2-amino-4-mercapto-DL-Butyrate; 2-amino-4-mercapto-Butanoic acid; ZINC895077; (S)-2-amino-4-mercapto-Butanoate; L-2-amino-4-mercapto-Butyric acid; (S)-2-Amino-4-mercaptobutyric acid; 2-amino-4-mercapto-DL-Butyric acid; BDBM50242405; DL-2-amino-4-mercapto-Butyric acid; L-Homocysteine, >=98.0% (NT); AKOS006272166; (S)-2-amino-4-mercapto-Butanoic acid; CS-W011063; DB04422; FS-6405; HY-W010347; Butyric acid, 2-amino-4-mercapto- (8CI); C00155; H-2800; I11579; Butyric acid, 2-amino-4-mercapto-, L- (8CI); A832662; Q26992833; UNII-S7IJP4A89K component FFFHZYDWPBMWHY-VKHMYHEASA-N"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:17588	DB04422	.	.	135.19	3	C4H9NO2S	64.3	86.1	-3.4	8	3	4	"InChI=1S/C4H9NO2S/c5-3(1-2-8)4(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m0/s1"	C(CS)[C@@H](C(=O)O)N	FFFHZYDWPBMWHY-VKHMYHEASA-N
DG01806	Norcantharidin	93004	"Norcantharidin; 5442-12-6; Norcantharadine; 29745-04-8; 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride; Endothall anhydride; Hexahydro-4,7-epoxyisobenzofuran-1,3-dione; 4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-; NCTD; (+/-)-Norcantharidin; 3,6-Endoxohexahydrophthalic anhydride; (+/-)-NCTD; 4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione; 7-Oxabicyclo(2.2.1)heptane-2,3-dicarboxylic anhydride; Isocantharidin; DEMETHYL-CANTHARIDIN; exo-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride; MFCD00213361; NSC-14003; NSC-59023; 3, hexahydro-; NSC 14003; Norcantharidin, solid; Spectrum_001667; 3,6-Endooxyphthalic anhydride, hexahydro-; SpecPlus_000904; Phthalic anhydride, hexahydro-3,6-endoxo-; 4,3-dione, hexahydro-; Spectrum2_001683; Spectrum3_001634; Spectrum4_000601; Spectrum5_001514; CHEMBL8327; Lopac0_000830; BSPBio_003327; KBioGR_001122; KBioSS_002147; Phthalic anhydride,6-endoxo-; MLS002153470; DivK1c_007000; SCHEMBL177729; SPECTRUM1504153; SPBio_001606; YSCH0101; 4,10-dioxatricyclo[5.2.1.0<2,6>]decane-3,5-dione; KBio1_001944; KBio2_002147; KBio2_004715; KBio2_007283; KBio3_002547; DTXSID30884158; HMS3262F21; HMS3370H07; 4,7-Epoxyisobenzofuran-1,3-dione; BCP09826; BCP25426; HY-N0585; NSC14003; NSC59023; Tox21_500830; WLN: T C555 A AO DVOVTJ; CCG-39454; NSC148536; s3759; STK424286; Hexahydro-3,6-epoxyphthalic anhydride; AKOS003267901; FS-4623; LP00830; MCULE-7561066553; NSC-148536; SDCCGSBI-0050807.P003; NCGC00015756-03; NCGC00015756-04; NCGC00015756-05; NCGC00015756-06; NCGC00015756-07; NCGC00015756-08; NCGC00015756-09; NCGC00015756-14; NCGC00094161-01; NCGC00094161-02; NCGC00094161-03; NCGC00094161-04; NCGC00094161-05; NCGC00094161-06; NCGC00261515-01; NCI60_001019; SMR000326693; DB-050518; CS-0009119; EU-0100830; FT-0614776; FT-0621477; FT-0626378; N1662; hexahydro-4,7-epoxy-2-benzofuran-1,3-dione; N 8784; 3,6-Endoxohexahydrophthalic anhydride, exo isomer; SR-01000076037; SR-01000076037-1; 4,10-dioxatricyclo[5.2.1.0 , ]decane-3,5-dione; BRD-A66914119-001-04-0; Q15425762; 4,10-Dioxa-tricyclo[5.2.1.02,6]decane-3,5-dione; 3-(5'-(4-(diphenylamino)phenyl)-[2,2'-bithiophen]-5-yl)cyclohex-2-enone; EXO-7-OXA-BICYCLO(2.2.1)-HEPTANE-2,3-DICARBOXYLIC ANHYDRIDE; Exo-cis-Hexahydro-4,7-epoxyisobenzofuran-1,3-dione; Endothall anhydride; 4,10-Dioxatricyclo[5.2.1.0(2,6)]decane-3,5-dione; 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride; 51154-98-4; TIMTEC-BB SBB005955;4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-;4,10-Dioxatricyclo[5.2.1.0(2,6)]decane-3,5-dione"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	168.15	0	C8H8O4	52.6	246	-0.1	12	0	4	"InChI=1S/C8H8O4/c9-7-5-3-1-2-4(11-3)6(5)8(10)12-7/h3-6H,1-2H2"	C1CC2C3C(C1O2)C(=O)OC3=O	JAABVEXCGCXWRR-UHFFFAOYSA-N
DG01807	N6-Methyladenosine	102175	"N6-Methyladenosine; 1867-73-8; N-Methyladenosine; 6-Methyladenosine; N(6)-Methyladenosine; 6-Methylaminopurinosine; 6-Methylaminopurine riboside; 6-Methylaminopurine D-riboside; 6-Methylaminopurine ribonucleoside; (2R,3S,4R,5R)-2-(Hydroxymethyl)-5-(6-(methylamino)-9H-purin-9-yl)tetrahydrofuran-3,4-diol; N6-methyladenosine (m6A); (N-6)-Methyladenosine; UNII-CLE6G00625; M6A; CHEBI:21891; N(6)-monomethyladenosine; CHEMBL383144; CLE6G00625; NSC-29409; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methylamino)purin-9-yl]oxolane-3,4-diol; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methylamino)-9H-purin-9-yl]oxolane-3,4-diol; (2R,3S,4R,5R)-2-Hydroxymethyl-5-(6-methylamino-purin-9-yl)-tetrahydro-furan-3,4-diol; NSC627045; 4rdn; 6MD; Prestwick_343; N6 -methyladenosine; Prestwick0_000338; Prestwick1_000338; Prestwick2_000338; Prestwick3_000338; Epitope ID:140951; SCHEMBL40634; BSPBio_000375; MLS002153780; SPBio_002296; BPBio1_000413; DTXSID6020858; HMS1569C17; HMS2096C17; HMS2234N05; HMS3713C17; HY-N0086; ZINC4245632; 2575AH; BDBM50163023; MFCD00005739; PDSP1_001030; PDSP2_001014; s3190; Adenosine, N-methyl- (8CI)(9CI); AKOS024260287; CCG-220338; CS-3285; GS-6701; NCGC00162241-01; NCGC00162241-02; NCGC00162241-04; NCGC00162241-09; SMR001233164; 6-methylamino-9-beta-D-ribofuranosyl-Purine; SW196617-3; 6-methylamino-9-beta-delta-ribofuranosyl-Purine; F12902; Purine, 6-methylamino-9-beta-D-ribofuranosyl-; J-700317; Q6951996; BRD-K81807412-001-03-1; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methylamino)purin-9-yl]tetrahydrofuran-3,4-diol"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	281.27	3	C11H15N5O4	126	349	-0.4	20	4	8	"InChI=1S/C11H15N5O4/c1-12-9-6-10(14-3-13-9)16(4-15-6)11-8(19)7(18)5(2-17)20-11/h3-5,7-8,11,17-19H,2H2,1H3,(H,12,13,14)/t5-,7-,8-,11-/m1/s1"	CNC1=C2C(=NC=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O	VQAYFKKCNSOZKM-IOSLPCCCSA-N
DG01808	Heliox	123812	"Heliox; helium;molecular oxygen; 58933-55-4; Helium, mixed with oxygen; Helium-oxygen mixture; Helium:oxygen mixture; Compressed gas, N.O.S.; Oxygen mixture with helium; Oxygen, mixed with helium; Heliox gas; Helium oxygen gas; Heliox, hyperbaric; Helium, mixt. with oxygen; Compressed gas, N.O.S. (helium, oxygen) gas; 70356-00-2"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	36.001	0	HeO2	34.1	0	.	3	0	2	InChI=1S/He.O2/c;1-2	[He].O=O	GWUAFYNDGVNXRS-UHFFFAOYSA-N
DG01809	Succinate	160419	"Succinate; Butanedioate; Succinate dianion; Butanedioic acid, ion(2-); 56-14-4; UNII-AJ326AG789; AJ326AG789; succ; monosuccinate; Butanedioate(2-); Succinate ion; succinate(2-); Succinate ion(2-); suc; Succinic acid, ion(2-); DTXSID4036772; CHEBI:30031; ANION STANDARD - SUCCINATE; STL302037; (-)OOC-CH2-CH2-COO(-); AKOS022140212; A802155; Q27104100"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	DR01246	116.07	1	C4H4O4-2	80.3	81.6	0.7	8	0	4	"InChI=1S/C4H6O4/c5-3(6)1-2-4(7)8/h1-2H2,(H,5,6)(H,7,8)/p-2"	C(CC(=O)[O-])C(=O)[O-]	KDYFGRWQOYBRFD-UHFFFAOYSA-L
DG01810	Tanshinone IIA	164676	"Tanshinone IIA; 568-72-9; Tanshinone II; Dan Shen Ketone; Tanshinone B; Tanshinon II; 1,6,6-Trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione; UNII-4GPC9FQG6L; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g][1]benzofuran-10,11-dione; Phenanthro[1,2-b]furan-10,11-dione, 6,7,8,9-tetrahydro-1,6,6-trimethyl-; C19H18O3; 4GPC9FQG6L; MLS001048863; MFCD00238692; NSC686519; SMR000387068; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g]benzofuran-10,11-dione; Phenanthro(1,2-b)furan-10,11-dione, 6,7,8,9-tetrahydro-1,6,6-trimethyl-; tanshinone II A; SR-01000758926; NSC 686518; tanshinone-IIA; HSDB 8104; Tanshinone centoA; Tanshinone 2-A; Tanshinone Iia ,(S); BSPBio_001597; BSPBio_002426; KBioGR_000317; KBioSS_000317; MLS006011834; SPECTRUM1505824; CHEMBL187266; cid_164676; SCHEMBL2026738; Tanshinone IIA (Tanshinone B); BDBM83922; KBio2_000317; KBio2_002885; KBio2_005453; KBio3_000633; KBio3_000634; DTXSID60205352; CHEBI:108595; Bio2_000317; Bio2_000797; HMS1361P19; HMS1791P19; HMS1989P19; HMS2089H08; HMS2270D15; HMS3402P19; HMS3656C11; NP474; BCP28199; HY-N0135; Tanshinone IIA, analytical standard; ZINC1650576; BBL028449; s2365; STK801917; Tanshinone IIA, >=97% (HPLC); AKOS004120032; AC-1440; CCG-207955; CCG-208275; NSC-686519; IDI1_034067; NCGC00095709-01; NCGC00095709-02; NCGC00095709-03; NCGC00095709-04; NCGC00095709-05; NCGC00095709-06; NCGC00095709-08; AS-16136; NCI60_031209; S594; NCGC00095709-02!TANSHINONE IIA; FT-0652880; N1846; SW220025-1; T2987; 568T729; A831217; Q-100654; SR-01000758926-2; SR-01000758926-4; SR-01000758926-5; BRD-K00141480-001-03-0; Q27187517; Phenanthro[1,11-dione, 6,7,8,9-tetrahydro-1,6,6-trimethyl-; Tanshinone IIA, European Pharmacopoeia (EP) Reference Standard; Tanshinone IIA, United States Pharmacopeia (USP) Reference Standard; 1,6,6-Trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione #; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g]benzofuran-10,11-quinone; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[8,7-g]benzofuran-10,11-dione; 6,7,8,9-Tetrahydro-1,6,6-trimethylphenanthro[1,2-b]furan-10,11-dione"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	294.3	0	C19H18O3	47.3	509	4.3	22	0	3	"InChI=1S/C19H18O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,9H,4-5,8H2,1-3H3"	CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C	HYXITZLLTYIPOF-UHFFFAOYSA-N
DG01811	Angiotensin II	172198	"ANGIOTENSIN II; 4474-91-3; Angiotensin II human; Hypertensin; Human angiotensin II; Angiotensin II (human); Giapreza; Ang II; 5-L-Isoleucineangiotensin II; Angiotensin II (mouse); 5-Isoleucine-angiotensin II; Asp-Arg-Val-Tyr-Ile-His-Pro-Phe; DRVYIHPF; 1-8-Angiotensin I; Ile(5)-angiotensin II; Isoleucine5-angiotensin II; UNII-M089EFU921; CHEBI:2719; ANG-(1-8)Octapeptide; isoleucine(5)-angiotensin II; CHEMBL408403; M089EFU921; 1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide; Delivert; Angiotensin II (USAN); 11128-99-7; L-alpha-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-prolyl-L-phenylalanine; (2S,5S,8S,11S,14S,17S)-2-((1H-imidazol-5-yl)methyl)-17-amino-5-((S)-sec-butyl)-1-((S)-2-(((S)-1-carboxy-2-phenylethyl)carbamoyl)pyrrolidin-1-yl)-14-(3-((diaminomethylene)amino)propyl)-8-(4-hydroxybenzyl)-11-isopropyl-1,4,7,10,13,16-hexaoxo-3,6,9,12,15-pentaazanonadecan-19-oic acid; N-(1-(N-(N-(N-(N-(N(2)-L-alpha-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine; ANGIOTENSINII,HUMAN; Angiotensin II, human; Angiotensin II, ile(5)-; Angiotensin ii [INN:JAN]; Hypertensin II; Angiotensin 2; Angiotensin II, 5-L-isoleucine-; Delivert (TN); C50H71N13O12; Angiotensin II heavy; Ile5-angiotensin II; Angiotensin II (rat); Angiotensin II (9CI); ANGIOTENSIN II-HUMAN; Angiotensin II acetate salt; SCHEMBL1189; Angiotensin II (human type); Angiotensin II [Sar1 Ile8]; GTPL2504; LJPC-501; SCHEMBL9013957; SCHEMBL20502357; DTXSID30196288; CHEBI:131170; ty-10721; Angiotensin II (human type) (JAN); BDBM50228195; BDBM50236697; AKOS016010178; ZINC169676920; DB11842; H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH; NCGC00167130-01; HY-13948; L-Phenylalanine, N-(1-(N-(N-(N-(N-(N2-L-alpha-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-; Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7-Phe8; C02135; C75211; D02014; DRVY-I*-HPF [I*= I(13C6,15N)]; A872469; Q412999; ANG-(1-8)Octapeptide, Hypertensin, 4474-91-3, Giapreza; Conalbumin (328-332), 1226776-54-0, RVPSL peptide; ProteoMass(TM) Angiotensin II MALDI-MS Standard, vial of 10 nmol; (3S)-3-amino-3-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S,2S)-1-{[(2S)-1-[(2S)-2-{[(1S)-1-carboxy-2-phenylethyl]carbamoyl}pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]carbamoyl}-2-methylbutyl]carbamoyl}-2-(4-hydroxyphenyl)ethyl]carbamoyl}-2-methylpropyl]carbamoyl}-4-[(diaminomethylidene)amino]butyl]carbamoyl}propanoic acid; Alanine, N-(1-(N-(N-(N-(N-(N2-L-alpha-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-3-phenyl-, L-; L-phenylalanine, L-alpha-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-prolyl-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:2719	.	.	.	1046.2	29	C50H71N13O12	409	1980	-1.7	75	13	15	"InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1"	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N	CZGUSIXMZVURDU-JZXHSEFVSA-N
DG01812	Anisomycin	253602	"Anisomycin; 22862-76-6; Flagecidin; (-)-Anisomycin; TCMDC-125504; (2R,3S,4S)-4-hydroxy-2-(4-methoxybenzyl)pyrrolidin-3-yl acetate; Upjohn 204t3; UNII-6C74YM2NGI; (2R,3S,4S)-2-(p-Methoxybenzyl)-3,4-pyrrolidinediol 3-acetate; NSC76712; NSC 76712; NSC-76712; Anisomycin from Streptomyces griseolus; 2-(p-Methoxybenzyl)-3,4-pyrrolidinediol 3-acetate; 6C74YM2NGI; 1,4,5-Trideoxy-1,4-imino-5-(p-methoxyphenyl)-D-xylo-pentitol 3-acetate; [(2R,3S,4S)-4-hydroxy-2-[(4-methoxyphenyl)methyl]pyrrolidin-3-yl] acetate; MLS001066392; Anisomycin,streptomyces griseolus; CHEBI:338412; (2R,3S,4S)-2-[(4-Methoxyphenyl)methyl]-3,4-pyrrolidinediol 3-acetate; MFCD00077650; SMR000471874; 3,4-Pyrrolidinediol, 2-[(4-methoxyphenyl)methyl]-, 3-acetate,(2R,3S,4S)-; 2-p-Methoxyphenylmethyl-3-acetoxy-4-hydroxypyrrolidine; (2R,3S,4S)-2-((4-Methoxyphenyl)methyl)-3,4-pyrrolidinediol 3-acetate; 3,4-Pyrrolidinediol, 2-((4-methoxyphenyl)methyl)-, 3-acetate, (2R,3S,4S)-; 3,4-Pyrrolidinediol, 2-[(4-methoxyphenyl)methyl]-, 3-acetate, (2R,3S,4S)-; ANM; Antibiotic PA-106; NSC 147340; SR-01000597397; GNF-Pf-4549; Wuningmeisu C; (2R,3S,4S)-2-(p-Methoxyphenylmethyl)-3-acetoxy-4-hydroxypyrrolidine; 6185-RBK-10; (-) Anisomycin; EINECS 245-269-7; BRN 0020705; Spectrum_001534; AI3-50846; Prestwick3_000412; Spectrum2_000632; Spectrum4_000748; Spectrum5_001495; 2-[(4-Methoxyphenyl)methyl]-3,4-pyrrolidinediol 3-acetate; CBiol_002064; BSPBio_000364; BSPBio_001436; KBioGR_001076; KBioSS_002014; ZINC954; 5-21-05-00523 (Beilstein Handbook Reference); DivK1c_000855; SPECTRUM1503906; SPBio_000624; (2R,3S,4S)-2-(4-Methoxybenzyl)-3,4-pyrrolidinediol-3-acetate; BPBio1_000402; CHEMBL423192; cid_253602; SCHEMBL2270183; DTXSID5040966; BDBM63919; HMS502K17; KBio1_000855; KBio2_002014; KBio2_004582; KBio2_007150; NINDS_000855; Bio1_000350; Bio1_000839; Bio1_001328; HMS1922K06; HMS2096C06; HMS2231E05; HMS3267L11; HMS3414L17; HMS3678L15; CCG-39185; (2R,3S,4S)-4-hydroxy-2-[(4-methoxyphenyl)methyl]pyrrolidin-3-yl acetate; AKOS015916532; CS-4981; DB07374; SDCCGMLS-0066810.P001; 3,4-Pyrrolidinediol, 2-((4-methoxyphenyl)methyl)-, 3-acetate, (2R-(2alpha,3alpha,4beta))-; IDI1_000855; QTL1_000009; NCGC00025097-02; NCGC00025097-03; NCGC00025097-04; 3,4-Pyrrolidinediol, 2-((4-methoxyphenyl)methyl)-, 3-acetate, (2R-(2-alpha,3-alpha,4-beta))-; AC-35125; AS-44380; HY-18982; NCI60_041689; AB00513833; B6674; A-7940; A927918; Anisomycin, Antibiotic for Culture Media Use Only; Q378498; SR-01000597397-1; SR-01000597397-3; BRD-K91370081-001-04-6; BRD-K91370081-001-17-8; 3, 2-(p-methoxybenzyl)-, 3-acetate, (2S,3R,4R)-; Anisomycin from Streptomyces griseolus, >=98% (HPLC), solid; (2R,3S,4S)-2-(4-Methoxybenzyl)-3,4-pyrrolidinediol 3-Acetate; (2R,3S,4S)-4-Hydroxy-2-(4-methoxybenzyl)-3-pyrrolidinyl acetate; acetic acid [(2R,3S,4S)-4-hydroxy-2-p-anisyl-pyrrolidin-3-yl] ester; [(2R,3S,4S)-2-[(4-methoxyphenyl)methyl]-4-oxidanyl-pyrrolidin-3-yl] ethanoate; 3, 2-[(4-methoxyphenyl)methyl]-, 3-acetate, [2S-(2.alpha.,3.alpha.,4.beta.)]-; 3,4-Pyrrolidinediol, 2-(p-methoxybenzyl)-, 3-acetate, (2S,3R,4R)- (8CI); acetic acid [(2R,3S,4S)-4-hydroxy-2-[(4-methoxyphenyl)methyl]-3-pyrrolidinyl] ester; [[4-[2-[[(3-Ethyl-2,5-dihydro-4-methyl-2-oxo-1H-pyrrol-1-yl)carbonyl]amino]ethyl]phenyl]sulfonyl]carbamicacidethylester; 11023-48-6"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB07374	.	.	265.3	5	C14H19NO4	67.8	302	0.9	19	2	5	"InChI=1S/C14H19NO4/c1-9(16)19-14-12(15-8-13(14)17)7-10-3-5-11(18-2)6-4-10/h3-6,12-15,17H,7-8H2,1-2H3/t12-,13+,14+/m1/s1"	CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O	YKJYKKNCCRKFSL-RDBSUJKOSA-N
DG01813	Alpha-solanine	262500	"SOLANINE; alpha-Solanine; a-solanine; 20562-02-1; .alpha.-Solanine; (2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-5-Hydroxy-6-(hydroxymethyl)-2-[[(1S,2S,7S,10R,11S,14S,15R,16S,17S,20S,23S)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.02,11.05,10.015,23.017,22]tetracos-4-en-7-yl]oxy]-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol; 2-[5-Hydroxy-6-(hydroxymethyl)-2-[(10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.02,11.05,10.015,23.017,22]tetracos-4-en-7-yl)oxy]-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol; SCHEMBL2380177; CHEMBL1975187; NSC96019; NSC-96019; NCI60_042141; FT-0645058; Q373791"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	868.1	8	C45H73NO15	241	1590	1.8	61	9	16	"InChI=1S/C45H73NO15/c1-19-6-9-27-20(2)31-28(46(27)16-19)15-26-24-8-7-22-14-23(10-12-44(22,4)25(24)11-13-45(26,31)5)57-43-40(61-41-37(54)35(52)32(49)21(3)56-41)39(34(51)30(18-48)59-43)60-42-38(55)36(53)33(50)29(17-47)58-42/h7,19-21,23-43,47-55H,6,8-18H2,1-5H3"	CC1CCC2C(C3C(N2C1)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)O)OC8C(C(C(C(O8)CO)O)O)O)OC9C(C(C(C(O9)C)O)O)O)C)C)C	ZGVSETXHNHBTRK-UHFFFAOYSA-N
DG01814	Cisplatinum	441203	"Cis-Platin; cis-DDP; Cisplatine; Cisplatino; Cisplatinum; Lederplatin; Briplatin; Cismaplat; Neoplatin; Platamine; Platinex; Randa; trans-platin; cis-Dichlorodiammineplatinum(II); Peyrone's salt; cis-Diamminedichloroplatinum; Peyrone's chloride; trans-Platinum(II) ammonium chloride; cis-[PtCl2(NH3)2]; trans-Dichlorodiammine platinum; trans-Platinumdiammine dichloride; CHEBI:27899; CHEBI:35852; TRANS-DIAMMINEDICHLOROPLATINUM; trans-Platinum(II) diamminedichloride; trans-DDP, 8; Cisplatin, 1; Epitope ID:194799; Epitope ID:194800; BDBM92386; cis-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloroplatinum; trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloridoplatinum; AKOS025117566; DB00515; EU-0100918"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB12117	DR0332	DR00291	300.05	0	Cl2H6N2Pt+2	2	7.6	.	5	2	2	InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+4/p-2	N.N.Cl[Pt+2]Cl	BSJGASKRWFKGMV-UHFFFAOYSA-L
DG01815	5-Ethynyl-2'-deoxyuridine	472172	"5-Ethynyl-2'-deoxyuridine; 61135-33-9; 2'-Deoxy-5-ethynyluridine; 5-Ethynyl-2'-dU; Uridine, 2'-deoxy-5-ethynyl-; UNII-G373S00W2J; EdU (5-ethynyl-2'-deoxyuridine); G373S00W2J; MFCD01675687; 5-ethynyl-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 5'-Ethynyl-2'-deoxyuridine; 5-Ethynyl-dUrd; 5-ethynyl-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione; 5-Ethynyl-dU; EDU; BRN 0756841; 5-EdU; 2'deoxy-5-ethynyluridine; EdU (ethynyldeoxyuridine); SCHEMBL868882; CHEMBL222932; DTXSID20976652; ZINC3794605; s1661; AKOS024462948; 5-Ethynyl-2'-deoxy-uridine (5-EdU); AC-32360; AS-59368; HY-118411; CS-0065850; C75857; 5-Ethynyl-2'-deoxyuridine, (EdU), AldrichCPR; J-700091; J-700347; Q4639590; 1-(2-Deoxypentofuranosyl)-5-ethynyl-4-hydroxypyrimidin-2(1H)-one; 5-ethynyl-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione; 5-ethynyl-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	252.22	3	C11H12N2O5	99.1	463	-1.3	18	3	5	"InChI=1S/C11H12N2O5/c1-2-6-4-13(11(17)12-10(6)16)9-3-7(15)8(5-14)18-9/h1,4,7-9,14-15H,3,5H2,(H,12,16,17)/t7-,8+,9+/m0/s1"	C#CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)O	CDEURGJCGCHYFH-DJLDLDEBSA-N
DG01816	Piperlongumine	637858	"Piperlongumine; Piplartine; 20069-09-4; Piperlongumin; UNII-SGD66V4SVJ; (E)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one; PPLGM; CHEBI:8241; SGD66V4SVJ; MFCD00075706; 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one; 1-[(2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-1,2,5,6-tetrahydropyridin-2-one; 5,6-Dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]-2(1H)-pyridinone; BRD2293; Piplartin; BRD-2293; 2(1H)-Pyridinone, 5,6-dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]-; (E)-1-[3-(3,4,5-Trimethoxyphenyl)acryloyl]-5,6-dihydropyridin-2(1H)-one; 5,6-Dihydro-1-(1-oxo-3-[3,4,5-trimethoxyphenyl]-trans-2-propenyl)-2[1H]-pyridinone; 5,6-Dihydro-1-[1-oxo-3-(3,4,5-trimethoxyphenyl)-trans-2-propenyl]-2(1H)-pyridinone; Piplartine;PPLGM; Prestwick_399; FERROUSFLUOBORATE; ST079382; Prestwick2_000604; Prestwick3_000604; Piperlongumine; Piplartine; BSPBio_000508; MLS002153903; SCHEMBL173092; SPECTRUM1505135; BPBio1_000560; CHEMBL465843; SCHEMBL2465593; 1-[3-(3,4,5-Trimethoxy-phenyl)-acryloyl]-5,6-dihydro-1H-pyridin-2-one; ACon1_001541; CHEBI:92424; HMS1569J10; HMS2096J10; HMS2234K24; Piperlongumine, >=97% (HPLC); ZINC899053; BCP13030; EX-A2925; HY-N2329; 2659AH; BDBM50462013; NSC794671; s7551; AKOS024284776; CCG-214375; NSC-794671; 2(1H)-Pyridinone, 5,6-dihydro-1-(1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl)-, (E)-; NCGC00096028-01; NCGC00096028-02; NCGC00096028-03; NCGC00096028-04; NCGC00096028-14; AC-32683; AS-74140; BP-25401; LS-14579; SMR001233252; CS-0021113; P2361; A14124; A920539; SR-01000841248; A1-00162; J-012992; N-(3,4,5-Trimethoxycinnamoyl)-D3-piperidin-2-one; Q7197361; SR-01000841248-2; BRD-K24132293-001-05-3; BRD-K24132293-001-09-5; BRD-K24132293-001-16-0; 5,6-Dihydro-1-(3,4,5-trimethoxycinnamoyl)-2(1H)-pyridinone; 1-[(2E)-3-(3,4,5-Trimethoxyphenyl)-2-propenoyl]-5,6-dihydro-2(1H)-pyridinone #; 1-[(2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-5,6-dihydropyridin-2(1H)-one; 5,6-Dihydro-1-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-2(1H)-pyridinone, 9CI; 5,6-dihydro-1-[1-oxo-3-(3,4,5-triMethoxyphenyl)-allyl]-2(1H)-pyridinone; Prop-2-en-1-one, 3-(3,4,5-trimethoxyphenyl)-1-(2,3-dihydropyridin-6(1H)-one-1-yl)-; (2E)-1-(1,2,5,6-Tetrahydro-2-oxopyridine-1-yl)-3-(3,4,5-trimethoxyphenyl)-2-propene-1-one"	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	CHEBI:8241	.	.	.	317.34	5	C17H19NO5	65.099	473	2.1	23	0	5	"InChI=1S/C17H19NO5/c1-21-13-10-12(11-14(22-2)17(13)23-3)7-8-16(20)18-9-5-4-6-15(18)19/h4,6-8,10-11H,5,9H2,1-3H3/b8-7+"	COC1=CC(=CC(=C1OC)OC)/C=C/C(=O)N2CCC=CC2=O	VABYUUZNAVQNPG-BQYQJAHWSA-N
DG01817	Isoliquiritigenin	638278	"Isoliquiritigenin; 961-29-5; 2',4,4'-Trihydroxychalcone; (E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; 4,2',4'-Trihydroxychalcone; 6'-deoxychalcone; 2',4',4-Trihydroxychalcone; isoliquirtigenin; UNII-B9CTI9GB8F; C15H12O4; Chalcone, 2',4,4'-trihydroxy-; B9CTI9GB8F; 13745-20-5; 42'4'-trihydroxychalcone; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; (2E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-, (2E)-; Acrylophenone, 2',4'-dihydroxy-3-(p-hydroxyphenyl)-; CHEMBL129795; GU17; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; CHEBI:310312; (E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; trans-2',4,4'-trihydroxychalcone; 2-PROPEN-1-ONE, 1-(2,4-DIHYDROXYPHENYL)-3-(4-HYDROXYPHENYL)-; MFCD00075907; (E)-1-(2,4-Dihydroxy-phenyl)-3-(4-hydroxy-phenyl)-propenone; 1060-19-1; (E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propene-1-one; GU 17; GU-17; SMR000112969; CCRIS 7676; SR-01000075499; EINECS 237-316-5; BRN 1914295; Isoliquiritigen; iso-Liquiritigenin; ILTG; ISLQ; Isoliquiritigenin, powder; Spectrum5_000612; (2E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-, (E)-; Lopac0_000681; BSPBio_003411; 1-08-00-00707 (Beilstein Handbook Reference); MLS000438943; MLS002207240; MLS006010045; BIDD:ER0235; SCHEMBL161168; SPECTRUM1504200; cid_638278; MEGxp0_001326; 2',4,4'-Trihydroxy-Chalcone; DTXSID2022466; 2'',4'',4-trihydroxychalcone; 2'',4,4''-trihydroxychalcone; ACon1_000047; CHEBI:94010; BCPP000201; HMS2233H18; HMS3262I03; 2,4''-dihydroxy-4-hydroxychalcone; BCP02312; HY-N0102; ZINC3869608; Tox21_500681; BDBM50042944; CCG-40334; CMLD3_000056; LMPK12120096; s2404; 2',4,4'-Trihydroxychalcone, 97%; Isoliquiritigenin, analytical standard; AKOS001590146; BCP9000795; CS-1745; DB03285; KS-5256; LP00681; MCULE-1557671934; SDCCGMLS-0066751.P001; SDCCGSBI-0050660.P004; NCGC00090504-01; NCGC00090504-02; NCGC00090504-03; NCGC00090504-04; NCGC00090504-05; NCGC00090504-06; NCGC00090504-07; NCGC00090504-08; NCGC00090504-24; NCGC00261366-01; AC-33981; O271; EU-0100681; I0822; N1288; SW219658-1; C08650; I 3766; I11575; 961I295; A845551; NCGC00090504-04!2',4,4'-Trihydroxychalcone; 2',4'-Dihydroxy-3-(p-hydroxyphenyl)-Acrylophenone; Q-100904; Q3155537; SR-01000075499-1; SR-01000075499-5; BRD-K33583600-001-03-9; BRD-K33583600-001-04-7; 1-(2,4-Dihydroxy-phenyl)-3-(4-hydroxy-phenyl)-propenone; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-prop-2-en-1-one; (E)-1-[2,4-bis(oxidanyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB03285	.	.	256.25	3	C15H12O4	77.8	331	3.2	19	3	4	"InChI=1S/C15H12O4/c16-11-4-1-10(2-5-11)3-8-14(18)13-7-6-12(17)9-15(13)19/h1-9,16-17,19H/b8-3+"	C1=CC(=CC=C1/C=C/C(=O)C2=C(C=C(C=C2)O)O)O	DXDRHHKMWQZJHT-FPYGCLRLSA-N
DG01818	Protirelin	638678	"Protirelin; Thyroliberin; 24305-27-9; Lopremone; Thyrotropin-releasing hormone; Thyrotropin releasing hormone; Rifathyroin; Synthetic TRH; Thypinone; TSH-releasing factor; TSH-releasing hormone; Thyrotropin-releasing factor; Thyrotropic-releasing factor; Thyrotropic releasing hormone; 5-Oxo-L-prolyl-L-histidyl-L-prolinamide; TRH; Abbott 38579; Thyroid releasing hormone; Thyrotropin-ReleasingHormone; Synthetic tsh-releasing factor; Synthetic tsh-releasing hormone; ABBOTT-38579; L-Pyroglutamyl-L-histidyl-L-prolineamide; UNII-5Y5F15120W; C16H22N6O4; Protirelin tartrate; FDA 1725; Protirelina; Ro 8-6270/9; L-Prolinamide, 5-oxo-L-prolyl-L-histidyl-; 11096-37-0; 117217-40-0; CHEBI:35940; 24305-27-9 (free base); L-Pyroglutamyl-L-histidyl-L-prolinamide; 5Y5F15120W; Synthetic thyrotropin-releasing hormone; (2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide; NCGC00160616-01; L-Pyroglutamyl-L-histidinyl-L-prolinamide; A-38579; (S)-N-((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)-5-oxopyrrolidine-2-carboxamide; THYREL TRH; Protireline; Protirelinum; TRF; Protireline [INN-French]; Protirelinum [INN-Latin]; Protirelina [INN-Spanish]; Thyrothropin relasing hormone; Thyrefact; CCRIS 2593; trh-sr; Synthetic TRF; Relefact TRH; Relefact-TRH; NSC-760113; Protirelin [USAN:INN:BAN:JAN]; Stimu-TSH; Thyrotropin-releasing factor (pig); EINECS 246-143-4; PR 546; PR-546; Protirelin, synthetic; pGlu-His-Pro-NH2; Relefact TRH (TN); HOLO-TRANSFERRIN; PyroGlu-His-prolinamide; TSH-RF; 5-oxo-pro-his-pro-nh2; DSSTox_CID_3533; CHEMBL1472; DSSTox_RID_77067; DSSTox_GSID_23533; SCHEMBL33419; Thyrotrophin releasing hormone; [3H]-TRH; GTPL2139; GTPL3836; pyroglutamyl-histidyl-prolinamide; DTXSID0023533; Protirelin (JP17/USAN/INN); SCHEMBL19825647; [3H]TRH (human, mouse, rat); [3H]-thyrotropin-releasing hormone; BCP12450; HY-P0002; Thyrotropic hormone-releasing factor; ZINC4096261; Synthetic thyrotopin releasing factor; Thyrotropic hormone-releasing hormone; Tox21_111939; BDBM50072394; s4680; Synthetic thyrotropin-releasing factor; Thyrotrophic hormone releasing hormone; AKOS015994636; CCG-268193; DB09421; HS-2023; NSC 760113; L-Pyroglutamyl-L-histidyl-L-proline amide; CAS-24305-27-9; Thyroid-stimulating hormone-releasing factor; C03958; C74244; D00176; Prolinamide, 5-oxo-L-prolyl-L-histidyl-, L-; (Pyro)-L-glutamic acid-L-histidine-L-proline-NH2; 305T279; A858244; Q24726011; Thyrotropin releasing hormone, >=98% (HPLC), powder; Prolinamide, 1-[N-(5-oxo-L-prolyl)-L-histidyl]-, L-; Protirelin, European Pharmacopoeia (EP) Reference Standard; Thyrotropin releasing hormone, powder, gamma-irradiated, cell culture tested; Thyroliberin;Lopremone;Synthetic TRH;Thyrotropin-releasing hormone; Rifathyroin; (2S)-N-[(1S)-2-[(2S)-2-carbamoylpyrrolidino]-1-(1H-imidazol-5-ylmethyl)-2-keto-ethyl]-5-keto-pyrrolidine-2-carboxamide; (2S)-N-[(2S)-1-[(2S)-2-aminocarbonylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxidanylidene-propan-2-yl]-5-oxidanylidene-pyrrolidine-2-carboxamide; (2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide; (2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(3H-imidazol-4-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide; (S)-N-((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl)-5-oxopyrrolidine-2-carboxamide; 1-(3-(1H-Imidazol-5-yl)-2-([(5-oxo-2-pyrrolidinyl)carbonyl]amino)propanoyl)-2-pyrrolidinecarboxamide #; 1-[3-(1H-4-imidazolyl)-2-(5-oxotetrahydro-1H-2-pyrrolylcarboxamido)propanoyl]tetrahydro-1H-2-pyrrolecarboxamide; 2-Pyrrolidinecarboxamide, N-[1-[(2-carbamoyl-1-pyrrolidinyl)carbonyl]-2-imidazol-4-ylethyl]-5-oxo-,; 2-Pyrrolidinecarboxamide, N-[1-[(2-Carbamoyl-1-pyrrolidinyl)carbonyl]-2-imidazol-4-ylethyl]-5-oxo-, (S,S,S)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:35940	.	DR2128	.	362.38	6	C16H22N6O4	150	597	-2.5	26	4	5	"InChI=1S/C16H22N6O4/c17-14(24)12-2-1-5-22(12)16(26)11(6-9-7-18-8-19-9)21-15(25)10-3-4-13(23)20-10/h7-8,10-12H,1-6H2,(H2,17,24)(H,18,19)(H,20,23)(H,21,25)/t10-,11-,12-/m0/s1"	C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CCC(=O)N3)C(=O)N	XNSAINXGIQZQOO-SRVKXCTJSA-N
DG01819	Gonadorelin	638793	"GONADORELIN; Luliberin; 33515-09-2; LH-Releasing hormone; LH-Releasing factor; Gonadorelina; Gonadorelinum; Luteostimulin; Fertagyl; Hypocrine; Gonadotropin-releasing factor; Luteinizing hormone-releasing factor; Gonadotropin-releasing hormone; Gonadoliberin I; Gonadorelin hydrochloride; Human gonadoliberin-i; GnRH-I; UNII-9O7312W37G; GnRH; 5-oxo-PHWSYGLRPGNH2; p-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2; 9034-40-6; LH-RH; CHEBI:5520; Dirigestran; Gonadotropin-releasing hormone I; 9O7312W37G; Follicle-stimulating hormone-releasing factor; Luteinizing Hormone Releasing Hormone (LHRH); AY-24031; Gn-RH; Luforan; Lutrefact; Nialutin; Relefact; Lutal; Relisorm l; Mammalian GnRH; LH-FSH Releasing Hormone; Synthetic LRF; Dirigestran Spofa; Synthetic Gn-RH; Mammalian LH-RH; Synthetic LH-RF; Synthetic LH-RH; Porchine LH-RH; 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycinamide; LRF; Human LH-RH; Ovine LH-RH; LH-RH (swine); Synthetic gonadoliberin; Synthetic LH-FSH-RH; LH-RF; Gonadorelin [INN:BAN]; 71447-49-9; Synthetic LH-RH/FSH-RH; Gonadorelinum [INN-Latin]; LH-Releasing factor (pig); Porcine LH-releasing factor; Gonadorelina [INN-Spanish]; Synthetic LH-releasing factor; Synthetic LH-releasing hormone; LH-Releasing hormone (porcine); Luteinizing hormone-releasing factor (swine); Synthetic decapeptide FSH/LH-RH; HOE 471; Fertagyl (TN); Synthetic LH-FSH releasing hormone; Ovine gonadotropin-releasing hormone; EINECS 232-895-0; EINECS 251-553-1; Gonadorelin (INN); Gonadorelin decapeptide; Mammalian gonadotropin-releasing hormone; Synthetic gonadotropin-releasing hormone; AY 24031; AY 24034; Luteinizing hormone-releasing factor (pig); Luteinizing hormone-releasing factor (rat); Gonadotropin, pituitary luteinizing hormone; Luteinizing hormone-releasing factor (human); Luteinizing hormone-releasing factor (sheep); Luteinizing hormone-releasing hormone (swin); Synthetic gonadotropic hormone-releasing hormone; CHEMBL1007; Gonadotropin,luteinizing hormone-releasing hormone; Follicle-stimulating hormone-releasing factor (pig); SCHEMBL143114; Synthetic LH-releasing hormone/FSH-releasing hormone; [125I]-GnRH I; GTPL3786; DTXSID20873490; Gonadotropin, luteinizing hormone-releasing hormone, synthetic; BDBM50422274; AKOS015895122; AKOS030213247; CCG-270650; HS-2014; [125I]GnRH I (human, mouse, rat); [125I]-gonadotropin-releasing hormone I; Glycinamide, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolyl-; A1147; Luteinizing hormone-areleasing factor (swine); D08027; pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-GlyNH2; 515G092; A837181; pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH(2); Q20817116; Luteinizing hormone releasing hormone human acetate salt (LHRH); L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycinamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:5520	DB00644	.	.	1182.3	31	C55H75N17O13	475	2390	-2.4	85	16	15	"InChI=1S/C55H75N17O13/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60)/t36-,37-,38-,39-,40-,41-,42-,43-/m0/s1"	CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6	XLXSAKCOAKORKW-AQJXLSMYSA-N
DG01820	Cardamonin	641785	"Cardamonin; 19309-14-9; 18956-16-6; CARDAMOMIN; Alpinetin chalcone; Dihydroxymethoxychalcone; 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one; 2',4'-dihydroxy-6'-methoxychalcone; (E)-1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one; UNII-H8KP1OJ8JX; 2-Propen-1-one, 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenyl-, (2E)-; H8KP1OJ8JX; CHEMBL378104; (E)-1-(2,4-Dihydroxy-6-methoxyphenyl)-3-phenyl-2-propen-1-one; (E)-Cardamonin; (2E)-1-(2,4-Dihydroxy-6-methoxyphenyl)-3-phenyl-2-propen-1-one; (E)-1-(2,4-Dihydroxy-6-methoxy-phenyl)-3-phenyl-propenone; (E)-1-(2,4-dihydroxy-6-methoxy-phenyl)-3-phenyl-prop-2-en-1-one; Cardamoni; (E)-Cardamoni; Cardamonin ,(S); 2'4'-Dihydroxy-6'-methoxy-chalcone; MLS000876992; SCHEMBL449220; MEGxp0_000534; Cardamonin, >=98% (HPLC); ACon1_000221; CHEBI:125601; CHEBI:186253; HMS2271N04; 2-Propen-1-one, 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenyl-; HY-N0279; ZINC4716487; BDBM50185446; LMPK12120245; MFCD00238554; s3867; AKOS015896716; CCG-208127; DB14122; MCULE-6098713539; NCGC00180767-01; AC-34864; DS-15713; SMR000440601; B7085; CS-0008777; W1234; 309C149; A813330; J-012229; Q-100234; Q5038242; BRD-K61559475-001-01-0; 1-(2\\',4\\'-Dihydroxy-6\\'-methoxy-phenyl)-3-phenyl-propenone; (2E)-1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one; NCGC00180767-02!(E)-1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB14122	.	.	270.28	4	C16H14O4	66.8	346	3.5	20	2	4	"InChI=1S/C16H14O4/c1-20-15-10-12(17)9-14(19)16(15)13(18)8-7-11-5-3-2-4-6-11/h2-10,17,19H,1H3/b8-7+"	COC1=CC(=CC(=C1C(=O)/C=C/C2=CC=CC=C2)O)O	NYSZJNUIVUBQMM-BQYQJAHWSA-N
DG01821	IWP 4	2155264	"686772-17-8; IWP-4; IWP 4; wnt inhibitor iwp-4; 2-((3-(2-methoxyphenyl)-4-oxo-3,4,6,7-tetrahydrothieno[3,2-d]pyrimidin-2-yl)thio)-N-(6-methylbenzo[d]thiazol-2-yl)acetamide; CHEMBL1257090; N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-3-(2-methoxyphenyl)-4-oxothieno[3,2-d]pyrimidin-2-yl)thio]-acetamide; N-(6-Methylbenzo[d]thiazol-2-yl)-2-(3-(2-methoxyphenyl)-4-oxo-3,4,6,7-tetrahydrothieno[3,2-d]pyrimidin-2-ylthio)acetamide; Inhibitor of Wnt Production-4; SCHEMBL12571760; C26H29ClN2O4S.H3PO4; EX-A2455; ZINC2719825; BDBM50428027; MFCD04457754; AKOS024584894; MCULE-3532196300; IWP-4, >=95% (HPLC); NCGC00387247-04; 2-[[3-(2-methoxyphenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]-N-(6-methyl-1,3-benzothiazol-2-yl)acetamide; AC-33202; AS-35152; BI162786; HY-12879; CS-0012738; EU-0088918; AB00668741-01; F0579-0237; N-[2-[[[3-(4-Chlorophenyl)-2-propen yl]methylamino]methyl]phenyl]-N-(2-hydroxyethyl)-4 -methoxybenzenesulphonamide phosphate"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	496.6	6	C23H20N4O3S3	163	851	4.8	33	1	8	"InChI=1S/C23H20N4O3S3/c1-13-7-8-14-18(11-13)33-22(24-14)26-19(28)12-32-23-25-15-9-10-31-20(15)21(29)27(23)16-5-3-4-6-17(16)30-2/h3-8,11H,9-10,12H2,1-2H3,(H,24,26,28)"	CC1=CC2=C(C=C1)N=C(S2)NC(=O)CSC3=NC4=C(C(=O)N3C5=CC=CC=C5OC)SCC4	RHUJMHOIQBDFQR-UHFFFAOYSA-N
DG01822	Quercetin	5280343	"Quercetin; 117-39-5; Meletin; Sophoretin; Quercetine; Xanthaurine; Quercetol; Quertine; 3,3',4',5,7-Pentahydroxyflavone; Quercitin; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; Flavin meletin; 3,5,7,3',4'-Pentahydroxyflavone; Cyanidelonon 1522; T-Gelb bzw. grun 1; Quertin; C.I. Natural Yellow 10; Quercetin content; Kvercetin; C.I. Natural red 1; C.I. 75670; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; 3',4',5,7-Tetrahydroxyflavan-3-ol; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-; C.I. Natural yellow 10 & 13; Cyanidenolon 1522; NSC 9219; CCRIS 1639; HSDB 3529; Flavone, 3,3',4',5,7-pentahydroxy-; NCI-C60106; UNII-9IKM0I5T1E; 3',4',5,7-tetrahydroxyflavon-3-ol; 3,5,7-Trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-on; CHEBI:16243; AI3-26018; NSC9219; CHEMBL50; MFCD00006828; 9IKM0I5T1E; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromen-4-one; 2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one; NSC-9219; Ericin; Kvercetin [Czech]; Natural Yellow 10; DSSTox_CID_1218; CI Natural Yellow 10; DSSTox_RID_76017; DSSTox_GSID_21218; QUE; BRD9794; BRD-9794; CAS-117-39-5; NSC57655; NSC58588; NSC-57655; SR-01000076098; EINECS 204-187-1; MixCom3_000183; BRN 0317313; Lipoflavon; CI 75670; Korvitin; Ritacetin; Quer; 4dfu; 4mra; Quercetin2H2O; KUC104418N; KUC107684N; 3,3',4,5,7-Pentahydroxyflavone; Quercetin-[d3]; LIM-5662; LNS-5662; TNP00070; TNP00089; 3'-hydroxykaempferol; KSC-23-76; Quercetin_sathishkumar; KSC-10-126; Quercetin (Sophoretin); Quercetin - Sophoretin; Spectrum_000124; Tocris-1125; 3cf8; BiomolKI_000062; Maybridge1_008992; Prestwick0_000507; Prestwick1_000507; Prestwick2_000507; Prestwick3_000507; Spectrum2_000059; Spectrum3_000642; Spectrum4_000807; Spectrum5_001389; Lopac-Q-0125; P0042; C.I. natural yellow 13; BiomolKI2_000068; Enicostemma Littorale Blume; UPCMLD-DP081; Q 0125; NCIOpen2_007628; NCIOpen2_007882; BIDD:PXR0007; Lopac0_000999; SCHEMBL19723; BSPBio_000433; BSPBio_001068; BSPBio_002243; KBioGR_000408; KBioGR_001293; KBioSS_000408; KBioSS_000584; 5-18-05-00494 (Beilstein Handbook Reference); MLS006011766; BIDD:ER0315; DivK1c_000485; SCHEMBL219729; SPECTRUM1500672; CU-01000012502-3; SPBio_000217; SPBio_002354; BDBM7460; BPBio1_000477; GTPL5346; MEGxp0_000381; SGCUT00001; 3,4',5,7-Pentahydroxyflavone; DTXSID4021218; NIOSH/LK8760000; UPCMLD-DP081:001; ACon1_000560; HMS501I07; KBio1_000485; KBio2_000408; KBio2_000584; KBio2_002976; KBio2_003152; KBio2_005544; KBio2_005720; KBio3_000775; KBio3_000776; KBio3_001463; 3,7,3',4'-Pentahydroxyflavone; NINDS_000485; 3',5,7-Tetrahydroxyflavan-3-ol; 3,5,7-trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-one; Bio1_000369; Bio1_000858; Bio1_001347; Bio2_000374; Bio2_000854; HMS1362F09; HMS1792F09; HMS1923O19; HMS1990F09; HMS3263G19; HMS3267M12; HMS3414J21; HMS3649D04; HMS3656C15; HMS3678J19; to_000078; ZINC3869685; 3,5,7,3',4'-Pentahydroxyflavon; Tox21_202308; Tox21_300285; Tox21_500999; BBL005513; CCG-40054; Ci-75670; Flavone,3',4',5,7-pentahydroxy-; LMPK12110004; NSC 57655; NSC324608; NSC756660; s2391; STK365650; Quercetin, >=95% (HPLC), solid; 3,4',5,5',7-pentahydroxy-Flavone; AKOS000511724; Quercetin 1000 microg/mL in Acetone; CS-3981; DB04216; DS-3416; LP00999; MCULE-2433372790; NSC-756660; SDCCGSBI-0050972.P003; IDI1_000485; IDI1_002129; LDN 0052529; LDN-0052529; SMP1_000252; Flavone, 3,4',5,5',7-pentahydroxy-; NCGC00015870-01; NCGC00015870-02; NCGC00015870-03; NCGC00015870-05; NCGC00015870-06; NCGC00015870-07; NCGC00015870-08; NCGC00015870-09; NCGC00015870-10; NCGC00015870-11; NCGC00015870-12; NCGC00015870-13; NCGC00015870-14; NCGC00015870-15; NCGC00015870-16; NCGC00015870-17; NCGC00015870-18; NCGC00015870-19; NCGC00015870-21; NCGC00015870-22; NCGC00015870-23; NCGC00015870-24; NCGC00015870-25; NCGC00015870-28; NCGC00015870-48; NCGC00015870-50; NCGC00025016-01; NCGC00025016-02; NCGC00025016-03; NCGC00025016-04; NCGC00025016-05; NCGC00025016-06; NCGC00025016-07; NCGC00025016-08; NCGC00168962-01; NCGC00168962-02; NCGC00168962-03; NCGC00168962-04; NCGC00254218-01; NCGC00259857-01; NCGC00261684-01; Quercetin 100 microg/mL in Acetonitrile; 74893-81-5; AC-19596; AC-29756; HY-18085; NCI60_042036; S295; SMR000112559; SY057722; (+)-3,3',4',5,7-Pentahydroxyflavone; Quercetin, Sophoretin, Meletin, Quercetine; EU-0100999; FT-0603318; FT-0655108; LK87600000; N1841; Q0025; SW148203-4; Quercetin; 3,3',4',5,7-Pentahydroxyflavone; 17Q395; C00389; K00029; S00057; WLN: T66 BO EVJ CR CQ DQ & DQ GQ IQ; Flavone, 3,3',4',5,7-pentahydroxy-, (+)-; Q409478; Q-200333; SR-01000076098-1; SR-01000076098-3; SR-01000076098-7; SR-01000076098-8; BRD-K97399794-001-02-1; BRD-K97399794-001-07-0; BRD-K97399794-001-09-6; BRD-K97399794-001-11-2; BRD-K97399794-335-03-1; SR-01000076098-11; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromone;hydrate; 49643640-FD4C-4B93-BD28-0D7C2021CC52; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one #; (+)-4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-; 4H-1-Benzopyran-4-one,2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-, zirconium(2+) salt (1:1)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:16243	DB04216	DR2630	DR00225	302.23	1	C15H10O7	127	488	1.5	22	5	7	"InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H"	C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O	REFJWTPEDVJJIY-UHFFFAOYSA-N
DG01823	Formononetin	5280378	"Formononetin; 485-72-3; Biochanin B; Formononetol; 7-hydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; 7-Hydroxy-4'-methoxyisoflavone; 7-hydroxy-3-(4-methoxyphenyl)chromen-4-one; Neochanin; 4'-O-methyldaidzein; Flavosil; 7-Hydroxy-3-(4-methoxyphenyl)-4-benzopyrone; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)-; UNII-295DQC67BJ; MFCD00016948; NSC 93360; 7-Hydroxy-3-(4-methoxyphenyl)chromone; CHEBI:18088; Isoflavone, 7-hydroxy-4'-methoxy-; NSC-93360; 295DQC67BJ; NSC93360; 7-hydroxy-3-(4-methoxyphenyl)-4H-benzopyran-4-one; SMR000470932; SR-01000765510; EINECS 207-623-9; formononetine; Formonentin; Formoononetin; Myconate; Mycotech; 7-hydroxy-4'-methoxy-isoflavone; Formononetin,(S); Spectrum_000373; SpecPlus_000223; Daidzein 4-methyl ether; Spectrum2_000560; Spectrum3_000660; Spectrum4_001429; Spectrum5_000258; DSSTox_CID_2311; Formononetin (Formononetol); DSSTox_RID_76544; NCIOpen2_005983; DSSTox_GSID_22311; Oprea1_139748; Oprea1_815287; SCHEMBL62915; BSPBio_002299; KBioGR_001878; KBioSS_000853; SPECTRUM102007; MLS000697593; MLS006011897; BIDD:ER0119; DivK1c_006319; SPBio_000639; CHEMBL242341; 7-Hydroxy-3-(4-methoxyphenyl)-4H-1-benzopyran-4-one; DTXSID4022311; Formononetin, analytical standard; KBio1_001263; KBio2_000853; KBio2_003421; KBio2_005989; KBio3_001519; HMS1922N18; HMS2231I04; HMS3369C07; HMS3655N22; ALBB-030789; BCP29929; Formononetin, >=99.0% (TLC); HY-N0183; TNP00176; Tox21_301848; BBL010458; BDBM50021398; CCG-38727; LMPK12050037; s2299; STK801612; ZINC18847036; AKOS000270811; AC-8001; DB15335; MCULE-4171151967; SDCCGMLS-0066428.P001; 7-hydroxy-4'-methoxy-Isoflavone (8CI); NCGC00017269-01; NCGC00017269-02; NCGC00017269-03; NCGC00017269-04; NCGC00017269-05; NCGC00017269-06; NCGC00017269-07; NCGC00095207-01; NCGC00095207-02; NCGC00095207-03; NCGC00178715-01; NCGC00255167-01; AS-11642; CAS-485-72-3; NCI60_042081; Isoflavone, 7-hydroxy-4'-methoxy- (8CI); Neochanin; Flavosil;NEOCHANIN;Formononetol; F0868; FT-0626540; FT-0632204; K-080; N1625; SW219915-1; C00858; AB00052676-07; 485F723; A827555; AE-641/01968055; Q408859; 7-hydroxy-3-(4-methoxyphenyl)-1-benzopyran-4-one; Q-100540; SR-01000765510-3; SR-01000765510-4; BRD-K55567017-001-02-4; BRD-K55567017-001-06-5; F3139-1207; 7-hydroxy-3-(4-methoxyphenyl)-4H-benzopyran-4-one(9CI); 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)- (9CI); Formononetin, United States Pharmacopeia (USP) Reference Standard; 7-Hydroxy-3-(4-methoxyphenyl)chromone, 7-Hydroxy-4'-methoxyisoflavone; Biochanin B; Flavosil; Formononetol; NSC 93360; NSC93360; NSC-93360"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:18088	DB15335	.	DR00955	268.26	2	C16H12O4	55.8	395	2.8	20	1	4	"InChI=1S/C16H12O4/c1-19-12-5-2-10(3-6-12)14-9-20-15-8-11(17)4-7-13(15)16(14)18/h2-9,17H,1H3"	COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O	HKQYGTCOTHHOMP-UHFFFAOYSA-N
DG01824	Mangostin	5281650	"Alpha-Mangostin; Mangostin; 6147-11-1; 1,3,6-Trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one; Mangostine; Alpha-Mangostin, 95%; a-Mangostin; NSC27593; NSC30552; NSC-30552; UNII-U6RIV93RU1; U6RIV93RU1; CHEMBL323197; CHEBI:67547; 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-enyl)xanthen-9-one; 1,3,6-trihydroxy-7-methoxy-2,8-diprenylxanthone; TNP00140; 1,3,6-Trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-9H-xanthen-9-one; MFCD00135200; 3,6,8-trihydroxy-2-methoxy-1,7-bis(3-methylbut-2-enyl)xanthen-9-one; 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-enyl)-9H-xanthen-9-one; 9H-Xanthen-9-one,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-; Xanthen-9-one,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-; 9H-Xanthen-9-one, 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-; NSC 27593; NSC 30552; NSC 139154; Spectrum_001726; SpecPlus_000574; Spectrum2_001620; Spectrum3_001297; Spectrum4_001911; Spectrum5_000622; BSPBio_002933; KBioGR_002529; KBioSS_002206; BIDD:ER0576; DivK1c_006670; SCHEMBL354735; SPECTRUM1504015; SPECTRUM1505128; SPBio_001659; HSDB 8103; KBio1_001614; KBio2_002206; KBio2_004774; KBio2_007342; KBio3_002153; DTXSID00210420; 1,3,6-Trihydroxy-7-methoxy-2,8-bis(3,3-dimethylallyl)xanthone; ACT09245; BCP13253; HY-N0328; ZINC5430812; alpha-Mangostin, >=98% (HPLC); 1,7-bis(3-methylbut-2-enyl)-3,6,8-trihydroxy-2-methoxyxanthen-9-one; BDBM50214969; CCG-36465; NSC-27593; NSC139154; s3804; 9H-Xanthen-9-one,1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-; AKOS015912806; AC-6089; CS-6435; DS-3359; MCULE-1080742368; NSC-139154; SDCCGMLS-0066796.P001; 1,3,6-Trihydroxy-7-methoxy-2,8-bis(3-methyl-2-buten-1-yl)-9H-xanthen-9-one; NCGC00017251-01; NCGC00017251-02; NCGC00017251-03; NCGC00017251-04; NCGC00017251-05; NCGC00095730-01; NCGC00095730-02; NCGC00095730-03; NCGC00178385-01; DB-053898; FT-0635997; M2793; N1590; N2590; W2645; 147M111; A833244; Q909638; SR-05000002649; Q-100010; SR-05000002649-1; BRD-K11991978-001-02-6; BRD-K11991978-001-03-4; 1,3,6-Trihydroxy-7-methoxy-2,8-di(3-methyl-2-butenyl)xanthone; 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-enyl)-9-xanthenone; 1,3,6-Trihydroxy-7-methoxy-2,8-bis-(3-methyl-but-2-enyl)-xanthen-9-one; 2-methoxy-1,7-bis(3-methylbut-2-enyl)-3,6,8-tris(oxidanyl)xanthen-9-one; (c) paragraph sign-mangostin pound>>alpha-Mangostin; NSC 139154; NSC 27593; NSC 30552; 9H-Xanthen-9-one, 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-buten-1-yl)-; 9H-Xanthen-9-one, 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)- (9CI); Xanthen-9-one, 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)- (8CI)"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:67547	.	.	.	410.5	5	C24H26O6	96.2	677	6.3	30	3	6	"InChI=1S/C24H26O6/c1-12(2)6-8-14-16(25)10-19-21(22(14)27)23(28)20-15(9-7-13(3)4)24(29-5)17(26)11-18(20)30-19/h6-7,10-11,25-27H,8-9H2,1-5H3"	CC(=CCC1=C(C2=C(C=C1O)OC3=C(C2=O)C(=C(C(=C3)O)OC)CC=C(C)C)O)C	GNRIZKKCNOBBMO-UHFFFAOYSA-N
DG01825	Morphine	5288826	"Morphine; Morphia; Morphium; Morphinum; Morphin; (-)-Morphine; Morphina; Ospalivina; DepoDur; 57-27-2; Duromorph; Meconium; Morphinism; Moscontin; MS Contin; l-Morphine; Dulcontin; Morfina; Nepenthe; Roxanol; MORPHINE SULFATE; Infumorph; Dreamer; Morpho; Avinza; Hocus; Kadian; Unkie; Cube juice; Hard stuff; Statex SR; Ms Emma; Morphin [German]; Morfina [Italian]; Duramorph; Morphina [Italian]; M-Eslon; Morphine [BAN]; CCRIS 5762; HSDB 2134; Anhydrous morphine; (5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol; UNII-76I7G6D29C; CHEBI:17303; CHEMBL70; (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; 4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol; 7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol; (7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL; Morphine Anhydrate; 76I7G6D29C; Morphine (BAN); Dolcontin; RMS; (5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5alpha,6alpha)-; (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol; methyl[ ]diol; Aguettant; Dinamorf; Sevredol; Dimorf; (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; D-(-)-Morphine; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-; EINECS 200-320-2; Oramorph; DEA No. 9300; (Morphine); Morphine anhydrous; N02AA01; Morphine polistirex; Substitol (TN); MOR; (-)-(etorphine); (-)Morphine sulfate; Morphine (anhydrous); Morfina Dosa (TN); NSC11441; Morphine extended release; Epitope ID:116646; SCHEMBL2997; BIDD:GT0147; GTPL1627; IDS-NM-009; DTXSID9023336; Morphine 0.1 mg/ml in Methanol; Morphine 1.0 mg/ml in Methanol; ZINC3812983; BDBM50000092; AKOS015966554; DB00295; MOI; C01516; D08233; Hydromorphone hydrochloride impurity, morphine-; Q81225; 7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; UNII-1M5VY6ITRT component BQJCRHHNABKAKU-KBQPJGBKSA-N; 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol; 7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol(morphine); (5alpha,6beta)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; 3-(4-Hydroxy-phenyl)-1-propyl-piperidine-3-carboxylic acid ethyl ester; 6-tert-Butyl-3-methyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine; (-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5..alpha.,6.alpha.)-; Morphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; (1S,5R,13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; (1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraene-10,14-diol; (1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18),15-tetraene-10,14-diol; (morphine) 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; 2-{4-[2,4-diamino-6-pteridinylmethyl(methyl)amino]phenylcarboxamido}pentanedioic acid(morphine); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol ; HydroChloride; 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol ;sulphate salt(morphine); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol((Morphine)); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(morphine sulfate); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(morphine); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine)(HCl); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol,sulfate(Morphinesulfate); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diolMorphine; 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol (morphine); 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine); 6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol(Morphine); 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4alpha,5,7alpha,8-tetrahydro-12-methyl-; MORPHINE; (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL; MORPHIUM; MORPHIA; DOLCONTIN; DUROMORPH; MORPHINA; NEPENTHE; Morphine;4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:17303	DB00295	DR1112	DR00467	285.34	0	C17H19NO3	52.9	494	0.8	21	2	4	"InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1"	CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O	BQJCRHHNABKAKU-KBQPJGBKSA-N
DG01826	Andrographolide	5318517	"Andrographolide; 5508-58-7; Andrographis; UNII-410105JHGR; CHEBI:65408; (S,E)-4-Hydroxy-3-(2-((1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethylidene)dihydrofuran-2(3H)-one; 410105JHGR; 3alpha,14,15,18-tetrahydroxy-5b,9bH,10a-labda-8(20),12-dien-16-oic acid gamma-Lactone; (3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethylidene]-4-hydroxyoxolan-2-one; 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one; Andro; (1R-(1-alpha(E(S)),4abeta,5alpha,6alpha,8aalpha))-3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl)ethylidene)dihydro-4-hydroxy-2(3H)-furanone; (3E,4S)-3-{2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-decahydronaphthalen-1-yl]ethylidene}-4-hydroxyoxolan-2-one; (3E,4S)-4-hydroxy-3-{2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidenedecahydronaphthalen-1-yl]ethylidene}dihydrofuran-2(3H)-one; HMPL-004; NSC383468; NSC-383468; NCGC00095597-01; EINECS 226-852-5; NSC 383468; Andrographolide, 98%; DSSTox_CID_25980; DSSTox_RID_81270; DSSTox_GSID_45980; HMPL004; BIDD:ER0530; CHEMBL186141; GTPL9675; MEGxp0_000978; DTXSID3045980; SCHEMBL12056309; ACon1_002113; ACT03252; Andrographolide, analytical standard; HY-N0191; ZINC3881797; Tox21_111508; BDBM50084419; MFCD07778082; AKOS015920075; CCG-208428; CS-3334; DB05767; MCULE-5521128905; NCGC00179817-01; NCGC00179817-02; 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)-; AS-13637; CAS-5508-58-7; C20214; J10022; 508A587; A830479; Q-100624; Q4759444; BRD-K89282837-001-01-0; Andrographolide, United States Pharmacopeia (USP) Reference Standard; (3E)-3-[2-[(1R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-decalin-1-yl]ethylidene]-4-hydroxy-tetrahydrofuran-2-one;Andrographolide; (3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-decalin-1-yl]ethylidene]-4-hydroxy-tetrahydrofuran-2-one; (5beta,9R,10alpha,14S)-3alpha,14,15,18-Tetrahydroxylabdane-8(20),12-diene-16-oic acid gamma-lactone; (S,E)-4-Hydroxy-3-(2-((1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethylidene)dihydrofuran-2; 2(3H)-Furanone, 3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl)ethylidene)dihydro-4-hydroxy-, (1R-(1-alpha(E(S*)),4a-beta,5-alpha,6-alpha,8a-alpha))-; 2(3H)-Furanone,3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-,(3E,4S)-"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:65408	DB05767	.	.	350.4	3	C20H30O5	87	597	2.2	25	3	5	"InChI=1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5,14-17,21-23H,1,4,6-11H2,2-3H3/b13-5+/t14-,15-,16+,17-,19+,20+/m1/s1"	C[C@@]12CC[C@H]([C@@]([C@H]1CCC(=C)[C@H]2C/C=C/3\\[C@@H](COC3=O)O)(C)CO)O	BOJKULTULYSRAS-OTESTREVSA-N
DG01827	Arsenic	5359596	"7440-38-2; Arsenic; As; ARSENIC METAL; UNII-V1I29R0RJQ; V1I29R0RJQ; Arsenic compounds; Agent SA; Arsenic, inorganic; HSDB 510; EINECS 232-066-3; UN2188; arsenico; arsenicum; arsenic atom; Arsenic lump; 33As; EC 232-066-3; CHEMBL1231052; DTXSID3023760; DTXSID4023886; CHEBI:27563; Arsenic, >=99.999%, pieces; Arsine [UN2188] [Poison gas]; 5482AF; AKOS015902733; LS41729; Arsenic, 99.999% trace metals basis; FT-0696579; C06269; Arsenic, powder, >=99.997% trace metals basis; Q21060492"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	DR0139	.	74.921	0	As	0	0	.	1	0	0	InChI=1S/As	[As]	RQNWIZPPADIBDY-UHFFFAOYSA-N
DG01828	Boron	5462311	"7440-42-8; B; Boron; Boron powder; UNII-N9E3X5056Q; N9E3X5056Q; MFCD00134034; Boron powder, crystalline; Boron, metallic; Boron and compounds; boro; Boron-elemental; Boron, elemental; Boron, Amorphous; 14798-13-1; HSDB 4482; EINECS 231-151-2; boracium; bore; boron atom; Boron Nanorods; Boron Chelate; Boron Nanopowder; Boron Nanoprisms; Boron Proteinate; Boron MicroPowder; Boron Nanoparticles; BORaN; Boron Micro Powder; 5B; Boron Citrate Blend; Boron Picolinate Blend; Boron powder, amorphous; Boron nitride nanoplates; Boron Krebs 5% 40M; Boron Nanorods Properties; Boron Glycinate 5% 40M; EC 231-151-2; Boron Trituration 1% 40M; Boron Nanoparticle Dispersion; Boron Nanoparticles Dispersion; Boron Nanopowder/Nanoparticles; boron citrate/aspartate/glycinate; Copper Sulfide Sputtering Target; DTXSID3023922; Hexagonal Boron Nitride crystals; Boron Nanoparticles / Nanopowder; Boron Nitride Nanotubes (BNNT); CHEBI:27560; Hexagonal Nitride Boron Nanoplates; MFCD00151272; AKOS015832923; AKOS030228749; Boron powder, crystalline, elec. gr.; Multilayer h-BN (Boron Nitride) film; Boron Citrate/Aspartate 5% 40M Bld; Boron powder, crystalline, -325 mesh; Boron, amorphous, powder, (submicron); DB11203; Boron amorphous B GRADE I (H gan s); Boron amorphous B GRADE II (H gan s); Boron amorphous B GRADE III (H gan s); Single Layer Hexagonal Boron Nitride Film; Boron crystalline B GRADE K1 (H gan s); Boron crystalline B GRADE K2 (H gan s); Boron crystalline B GRADE P1 (H gan s); Boron, >=95% (boron), amorphous powder; Boron, monofilament, 5m, diameter 0.1mm; Boron, monofilament, 5m, diameter 0.2mm; Boron crystalline B GRADE KT1 (H gan s); Boron, monofilament, 10m, diameter 0.1mm; Boron, monofilament, 10m, diameter 0.2mm; Boron, monofilament, 20m, diameter 0.1mm; Boron, monofilament, 20m, diameter 0.2mm; Boron, monofilament, 50m, diameter 0.1mm; Boron, monofilament, 50m, diameter 0.2mm; Boron, crystalline, 90-95%, -325 mesh; Boron, monofilament, 100m, diameter 0.1mm; Boron, monofilament, 200m, diameter 0.1mm; Y1405; METHYL-(2Z)3-IODO-2N-ACETYLCROTANOATE; Tantalum Pentoxide (Ta2O5) Sputtering Targets; Boron amorphous, Nano powder, 98.5%, <350 nm; Boron, purum p.a., >=99.0%, pieces, crystalline; Boron, crystalline, 1 cm, 99.7% trace metals basis; Boron, monofilament, 0.080 mm diameter, length 5 m; Q15634214; Boron, AAS solution standard, Specpure , B 1000 g/ml; Boron, crystalline, -60 mesh, 99% trace metals basis; Boron, monofilament, 0.080 mm diameter, length 10 m; Boron, monofilament, 0.080 mm diameter, length 100 m; Boron, monofilament, 0.080 mm diameter, length 20 m; Boron, monofilament, 0.080 mm diameter, length 50 m; Boron, monofilament, length 200 m, 0.080 mm diameter; Boron, Oil based standard solution, Specpure, B 1000g/g; Boron, Oil based standard solution, Specpure, B 5000g/g; Boron, plasma standard solution, Specpure , B 10,000 g/ml; Boron 11, 11B, plasma standard solution, Specpure, 11B 100g/ml; Boron, granule, 15 mm nominal granule size, weight 100 g, purity 99%; Boron, granule, 15 mm nominal granule size, weight 20 g, purity 99%; Boron, granule, 15 mm nominal granule size, weight 50 g, purity 99%; Boron, plasma standard solution, Specpure , B 1000 g/ml, H3BO3 in H2O; Boron, powder, 45 max. part. size (micron), weight 10 g, purity 98.%; Boron, powder, max. particle size 45 micron, weight 20 g, purity 98.%; Boron, powder, max. particle size 45 micron, weight 50 g, purity 98.%; Boron, plasma standard solution, Specpure , B 1000 g/ml, H3BO3 in 1% NH4OH; Boron, powder, mean particle size (fsss) 0.9 micron, weight 10 g, purity 95+%; Boron, powder, mean particle size (fsss) 0.9 micron, weight 20 g, purity 95+%; Boron, powder, mean particle size (fsss) 0.9 micron, weight 200 g, purity 95+%; Boron, powder, mean particle size (fsss) 0.9 micron, weight 50 g, purity 95+%; Boron, powder, mean particle size (fsss) 1 micron, weight 10 g, purity 92.1%; Boron, powder, mean particle size (fsss) 1 micron, weight 100 g, purity 92.1%; Boron, powder, mean particle size (fsss) 1 micron, weight 200 g, purity 92.1%; Boron, powder, mean particle size (fsss) 1 micron, weight 50 g, purity 92.1%; Boron, powder, weight 100 g, mean particle size (fsss) 0.9 micron, purity 95+%; Boron, powder, weight 20 g, mean particle size (fsss) 1 micron, purity 92.1%; Bor; Boron, microfoil, disks, 10mm, thinness 0.1mum, specific density 23.5mug/cm2, permanent mylar 3.5mum support, 99.6%; Boron, microfoil, disks, 25mm, thinness 0.1mum, specific density 23.5mug/cm2, 6 micron aluminum permanent support, 99.6%; Boron, microfoil, disks, 25mm, thinness 0.1mum, specific density 23.5mug/cm2, permanent mylar 3.5mum support, 99.6%"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB11203	.	.	10.81	0	B	0	0	.	1	0	0	InChI=1S/B	[B]	ZOXJGFHDIHLPTG-UHFFFAOYSA-N
DG01829	Glycylcysteine	7408690	Glycylcysteine; Gly-Cys; 57281-78-4; H-Gly-Cys-OH; Glycyl-Cysteine; glycyl-L-cysteine; (2R)-2-[(2-aminoacetyl)amino]-3-sulfanylpropanoic acid; (R)-2-(2-Aminoacetamido)-3-mercaptopropanoic acid; Gly-L-Cys; SCHEMBL358953; CHEBI:73890; DTXSID30428632; Gc; ZINC4899852; MFCD00672396; AKOS006271691; Q27144214	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	178.21	4	C5H10N2O3S	93.4	162	-3.7	11	4	5	"InChI=1S/C5H10N2O3S/c6-1-4(8)7-3(2-11)5(9)10/h3,11H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1"	C([C@@H](C(=O)O)NC(=O)CN)S	MFBYPDKTAJXHNI-VKHMYHEASA-N
DG01830	Bufalin	9547215	"Bufalin; 465-21-4; UNII-U549S98QLW; 3-beta,14-Dihydroxy-5-beta-bufa-20,22-dienolide; 3,14-Dihydroxy-bufa-20,22-dienolide; U549S98QLW; CHEBI:517248; 3beta,14beta-dihydroxy-5beta-bufa-20,22-dienolide; 5-((3S,5R,8R,9S,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2H-pyran-2-one; 5-[(3S,5R,8R,9S,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one; Ch'an su; BUF; NSC 89595; BRN 5141601; (3beta,5beta)-3,14-dihydroxybufa-20,22-dienolide; SCHEMBL165666; CHEMBL399680; Bufa-20,22-dienolide, 3,14-dihydroxy-, (3b,5b)-; DTXSID90873563; AMY40632; Bufalin: Bufa-20,22-dienolide, 3,14-dihydroxy-, (3b,5b)-,; HY-N0877; ZINC4215121; HSCI1_000110; LMST01130001; s7821; AKOS015965454; CS-3694; SMP2_000290; AC-20197; AC-34068; BS-17080; C16922; BRD-K63606607-001-01-8; BRD-K63606607-001-02-6; Q18379323; 5-beta-BUFA-20,22-DIENOLIDE, 3-beta,14-DIHYDROXY-; 5beta-Bufa-20,22-dienolide, 3beta,14-dihydroxy- (8CI); (3beta,5beta,10alpha,17alpha)-3,14-dihydroxybufa-20,22-dienolide; Bufa-20,22-dienolide, 3,14-dihydroxy-, (3-beta,5-beta)- (9CI); Bufa-20,22-dienolide, 3,14-dihydroxy-, (3beta,5beta)- (9CI)"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	386.5	1	C24H34O4	66.8	741	3.2	28	2	4	"InChI=1S/C24H34O4/c1-22-10-7-17(25)13-16(22)4-5-20-19(22)8-11-23(2)18(9-12-24(20,23)27)15-3-6-21(26)28-14-15/h3,6,14,16-20,25,27H,4-5,7-13H2,1-2H3/t16-,17+,18-,19+,20-,22+,23-,24+/m1/s1"	C[C@]12CC[C@@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@@]3(CC[C@@H]4C5=COC(=O)C=C5)O)C)O	QEEBRPGZBVVINN-BMPKRDENSA-N
DG01831	Afeletecan	9941008	"Afeletecan; Afeletecan free base; UNII-IX0QAD6RD2; IX0QAD6RD2; 215604-75-4; (S)-4-ethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ((4-(((2R,3S,4R,5R,6S)-3,5-dihydroxy-4-methoxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)phenyl)carbamothioyl)-L-histidyl-L-valinate; Afeletecan [INN]; CHEMBL2105857; Q27280930; [(19S)-19-ethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl] (2S)-2-[[(2S)-2-[[4-[(2R,3S,4R,5R,6S)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxyphenyl]carbamothioylamino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-methylbutanoate; Camptothecin, ester with N-((p-((3-O-methyl-beta-L-fucopyranosyl)oxy)phenyl)thiocarbamoyl)-L-histidyl-L-valine"	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	.	.	.	896	14	C45H49N7O11S	268	1840	2.6	64	6	14	"InChI=1S/C45H49N7O11S/c1-6-45(30-17-33-35-25(15-24-9-7-8-10-31(24)49-35)19-52(33)40(56)29(30)20-60-43(45)58)63-41(57)34(22(2)3)51-39(55)32(16-27-18-46-21-47-27)50-44(64)48-26-11-13-28(14-12-26)62-42-37(54)38(59-5)36(53)23(4)61-42/h7-15,17-18,21-23,32,34,36-38,42,53-54H,6,16,19-20H2,1-5H3,(H,46,47)(H,51,55)(H2,48,50,64)/t23-,32-,34-,36+,37-,38+,42+,45-/m0/s1"	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)OC(=O)[C@H](C(C)C)NC(=O)[C@H](CC6=CN=CN6)NC(=S)NC7=CC=C(C=C7)O[C@@H]8[C@H]([C@@H]([C@@H]([C@@H](O8)C)O)OC)O	SLOJCSGNHWIKIG-JNYZSSQASA-N
DG01832	Polyphyllin I	11018329	"Polyphyllin I; 50773-41-6; (2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-5-[(2S,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)-2-[(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol; CHEMBL3931203; HY-N0047; NSC805340; s9114; AKOS037515173; ZINC252491736; CCG-270534; NSC-805340; CS-0007105"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	855	8	C44H70O16	236	1570	1.5	60	8	16	"InChI=1S/C44H70O16/c1-19-8-13-44(53-18-19)20(2)30-27(60-44)15-26-24-7-6-22-14-23(9-11-42(22,4)25(24)10-12-43(26,30)5)55-41-38(59-39-35(51)33(49)31(47)21(3)54-39)36(52)37(29(17-46)57-41)58-40-34(50)32(48)28(16-45)56-40/h6,19-21,23-41,45-52H,7-18H2,1-5H3/t19-,20+,21+,23+,24-,25+,26+,27+,28+,29-,30+,31+,32+,33-,34-,35-,36+,37-,38-,39+,40+,41-,42+,43+,44-/m1/s1"	C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H](O8)CO)O)O)O)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)C)C)C)OC1	LRRDDWMXYOSKIC-IPKCVOQPSA-N
DG01833	Wnt agonist	11210285	"BML-284; Wnt Agonist; 853220-52-7; 2-Amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine; N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine; 4-N-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine; N4-(Benzo[d][1,3]dioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine; BML 284; 2-Amino-4-[3,4-(methylenedioxy)benzylamino]-6-(3-methoxyphenyl)pyrimidine; Wnt agonist 1;AMBMP; SCHEMBL430891; Wnt agonist 1(BML-284); Wnt agonist 1 (BML-284); CHEMBL4303671; BML 284;BML284; CHEBI:125559; BCP17186; EX-A2428; HSCI1_000334; NSC762367; ZINC44063027; CCG-208089; CS-5516; NSC-762367; NCGC00386697-01; NCGC00386697-05; AS-56297; HY-19987; C76745; BRD-K42624714-001-01-7; Q27216172; N4-[(2H-1,3-benzodioxol-5-yl)methyl]-6-(3-methoxyphenyl)pyrimidine-2,4-diamine; FW9"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	350.4	5	C19H18N4O3	91.5	455	3.1	26	2	7	"InChI=1S/C19H18N4O3/c1-24-14-4-2-3-13(8-14)15-9-18(23-19(20)22-15)21-10-12-5-6-16-17(7-12)26-11-25-16/h2-9H,10-11H2,1H3,(H3,20,21,22,23)"	COC1=CC=CC(=C1)C2=CC(=NC(=N2)N)NCC3=CC4=C(C=C3)OCO4	FABQUVYDAXWUQP-UHFFFAOYSA-N
DG01834	Erastin	11214940	"ERASTIN; 571203-78-6; 2-[1-[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4(3H)-Quinazolinone; 2-(1-(4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)ethyl)-3-(2-ethoxyphenyl)quinazolin-4(3H)-one; MFCD09837984; 2-[1-[4-[2-(4-chlorophenoxy)acetyl]piperazin-1-yl]ethyl]-3-(2-ethoxyphenyl)quinazolin-4-one; CHEMBL401989; SCHEMBL4457820; Erastin, >=98% (HPLC); CHEBI:94287; AOB6043; DTXSID80458949; EX-A295; HMS3653K21; HMS3868M03; BCP27907; WXA20378; 2400AH; BDBM50376126; s7242; AKOS025147365; CCG-269987; CS-1675; Erastin - CAS 571203-78-6; SB19588; NCGC00351608-10; NCGC00351608-14; AS-55898; DA-42059; HY-15763; QC-11375; FT-0700333; SW208651-2; C21478; A869751; BRD-A25004090-001-01-9; BRD-A25004090-001-02-7; BRD-A25004090-001-06-8; Q27166099; 2-[1-[4-[2-(4-chlorophenoxy)-1-oxoethyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4-quinazolinone; 4(3H)-Quinazolinone, 2-[1-[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-"	Patented	3	Patented Agent(s)	Patented	Small molecular drug	CHEBI:94287	.	.	.	547	8	C30H31ClN4O4	74.7	871	4.8	39	0	6	"InChI=1S/C30H31ClN4O4/c1-3-38-27-11-7-6-10-26(27)35-29(32-25-9-5-4-8-24(25)30(35)37)21(2)33-16-18-34(19-17-33)28(36)20-39-23-14-12-22(31)13-15-23/h4-15,21H,3,16-20H2,1-2H3"	CCOC1=CC=CC=C1N2C(=O)C3=CC=CC=C3N=C2C(C)N4CCN(CC4)C(=O)COC5=CC=C(C=C5)Cl	BKQFRNYHFIQEKN-UHFFFAOYSA-N
DG01835	Artenimol	11358077	"Alpha-Dihydroartemisinin; Dihydroartemisinin; Artenimol; 81496-81-3; UNII-X0UIV26ABX; X0UIV26ABX; 71939-50-9; 123930-80-3; (1R,4S,5R,8S,9R,10R,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol; Dihydroartemisinin (DHA); (1S,4S,5R,8S,9R,12R,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-ol; CHEMBL511326; SCHEMBL18744731; CHEBI:168754; MFCD00236467; s2290; ZINC15449189; AKOS022168199; CCG-267307; NSC 758682; NCGC00346590-02; N1713; 496D813; Q-100792; Q27293233; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3,-j)-1,2-benzodioxepin-10-ol"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB11638	.	.	284.35	0	C15H24O5	57.2	415	2.5	20	1	5	"InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12-,13-,14-,15-/m1/s1"	C[C@@H]1CC[C@H]2[C@H]([C@@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)O)C	BJDCWCLMFKKGEE-KDTBHNEXSA-N
DG01836	Lipopolysaccharide	11970143	Lipopolysaccharide; Lipopolysaccharides; LPSLPS; NCGC00188939-01	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	4900	154	C205H366N3O117P5	1890	10000	-5	330	62	118	"InChI=1S/C205H366N3O117P5/c1-10-16-22-28-34-40-42-43-45-50-55-61-67-73-109-130(101-326(269,270)271)292-127(147(245)164(109)302-135(235)78-106(222)70-64-58-52-46-36-30-24-18-12-3)98-283-186-138(208-132(232)79-107(71-65-59-53-47-37-31-25-19-13-4)290-133(233)74-68-62-56-49-39-33-27-21-15-6)173(303-136(236)80-108(72-66-60-54-48-38-32-26-20-14-5)291-134(234)75-69-63-57-51-44-41-35-29-23-17-11-2)172(322-327(272,273)274)129(301-186)100-286-203(199(262)263)84-119(318-205(201(266)267)83-118(144(242)166(320-205)114(227)86-210)317-204(200(264)265)82-112(225)139(237)165(319-204)113(226)85-209)171(169(321-203)116(229)88-212)308-194-161(259)178(182(167(305-194)115(228)87-211)324-330(280,281)325-329(278,279)287-77-76-206)313-195-160(258)177(181(323-328(275,276)277)168(306-195)117(230)97-282-188-162(260)184(261)202(268,102-285-188)131(231)96-220)312-193-159(257)175(148(246)128(300-193)99-284-189-154(252)150(248)141(239)121(90-214)294-189)310-196-179(152(250)143(241)123(92-216)297-196)315-197-180(314-187-137(207-105(9)221)149(247)140(238)120(89-213)293-187)157(255)170(126(95-219)299-197)307-192-158(256)174(145(243)124(93-217)296-192)309-190-156(254)153(251)163(104(8)289-190)304-198-183(316-191-155(253)151(249)142(240)122(91-215)295-191)176(146(244)125(94-218)298-198)311-185-111(224)81-110(223)103(7)288-185/h103-104,106-131,137-198,209-220,222-231,237-261,268H,10-102,206H2,1-9H3,(H,207,221)(H,208,232)(H,262,263)(H,264,265)(H,266,267)(H,278,279)(H,280,281)(H2,269,270,271)(H2,272,273,274)(H2,275,276,277)/t103 ,104-,106 ,107 ,108 ,109 ,110+,111 ,112 ,113 ,114 ,115 ,116 ,117 ,118 ,119 ,120 ,121 ,122 ,123 ,124 ,125 ,126 ,127 ,128 ,129 ,130+,131 ,137-,138-,139+,140+,141-,142-,143-,144+,145-,146+,147+,148+,149 ,150 ,151 ,152 ,153 ,154 ,155 ,156+,157 ,158 ,159 ,160+,161+,162+,163 ,164+,165 ,166 ,167 ,168 ,169 ,170+,171+,172+,173 ,174 ,175 ,176 ,177 ,178 ,179 ,180 ,181+,182+,183 ,184 ,185+,186+,187+,188-,189-,190 ,191+,192+,193+,194-,195+,196+,197+,198+,202-,203+,204+,205+/m0/s1"	CCCCCCCCCCCCCCCC1[C@H](OC([C@H]([C@@H]1OC(=O)CC(CCCCCCCCCCC)O)O)CO[C@H]2[C@H](C([C@@H](C(O2)CO[C@@]3(CC([C@H](C(O3)C(CO)O)O[C@H]4[C@@H](C([C@@H](C(O4)C(CO)O)OP(=O)(O)OP(=O)(O)OCCN)O[C@@H]5[C@@H](C([C@@H](C(O5)C(CO[C@@H]6[C@@H](C([C@](CO6)(C(CO)O)O)O)O)O)OP(=O)(O)O)O[C@@H]7C(C([C@@H](C(O7)CO[C@@H]8C(C([C@H](C(O8)CO)O)O)O)O)O[C@@H]9C(C([C@H](C(O9)CO)O)O)O[C@@H]1C(C([C@@H](C(O1)CO)O[C@@H]1C(C([C@H](C(O1)CO)O)OC1[C@@H](C(C([C@@H](O1)C)O[C@@H]1C(C([C@@H](C(O1)CO)O)O[C@@H]1C(C[C@H](C(O1)C)O)O)O[C@@H]1C(C([C@H](C(O1)CO)O)O)O)O)O)O)O)O[C@@H]1[C@H](C([C@@H](C(O1)CO)O)O)NC(=O)C)O)O)O)O[C@@]1(CC([C@H](C(O1)C(CO)O)O)O[C@@]1(CC([C@H](C(O1)C(CO)O)O)O)C(=O)O)C(=O)O)C(=O)O)OP(=O)(O)O)OC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)CP(=O)(O)O	YPXVSQSYDIMPDZ-AUUHBOKRSA-N
DG01837	BTI-2571E	11970413	"3-(4-Methylsulfonylstyryl)-1,2,4-oxadiazole; 24664-14-0; 3-[(E)-2-(4-methylsulfonylphenyl)ethenyl]-1,2,4-oxadiazole; Bti 2571E; Bti 2571(E); SCHEMBL11763943; BTI-2571E; BTI-2571(E); (E)-BTI-2571; 1,2,4-Oxadiazole, 3-(2-(4-(methylsufonyl)phenyl)ethenyl)-, (E)-"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	250.28	3	C11H10N2O3S	81.4	367	1.7	17	0	5	"InChI=1S/C11H10N2O3S/c1-17(14,15)10-5-2-9(3-6-10)4-7-11-12-8-16-13-11/h2-8H,1H3/b7-4+"	CS(=O)(=O)C1=CC=C(C=C1)/C=C/C2=NOC=N2	IYACHGURRCRVBZ-QPJJXVBHSA-N
DG01838	Aspirin CD3	12280114	"Aspirin CD3; Acetylsalicylic acid-d3; 921943-73-9; Aspirin-d3; UNII-7F6Y89636M; Acetylsalicylic Acid;ASA; 2-(2,2,2-trideuterioacetyl)oxybenzoic acid; 7F6Y89636M; Trideuteriomethylaspirin; Benzoic acid, (acetyl-2,2,2-D3-oxy)-; [2H3]-Acetylsalicylic acid; 2-(Acetoxy-d3)benzoic acid; HY-14654S; MFCD09752106; CS-0214015; A935842; Acetylsalicylic acid-(methyl-d3), analytical standard; Q27268193"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB00945	.	.	183.18	3	C9H8O4	63.6	212	1.2	13	1	4	"InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)/i1D3"	[2H]C([2H])([2H])C(=O)OC1=CC=CC=C1C(=O)O	BSYNRYMUTXBXSQ-FIBGUPNXSA-N
DG01839	Astragaloside IV	13943297	"Astragaloside IV; 84687-43-4; Astragaloside A; Cyclosiversioside F; UNII-1J6XA9YCFV; 1J6XA9YCFV; CHEBI:65457; (2R,3R,4S,5S,6R)-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol; 83207-58-3; (2R,3R,4S,5S,6R)-2-[[(1S,3R,8R,9S,11S,12S,14S,15R,16R)-14-Hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol; 3-O-beta-D-xylopyranosyl-6-O-beta-D-glucopyranosylcycloastragenol; C41H68O14; AS-IV; MFCD16036240; Cyclosieversioside F; AST-IV; Astragaloside IV 95%; Astragaloside IV, >98.0%; CHEMBL3121562; SCHEMBL21888259; HMS3885E12; HY-N0431; s3901; AKOS025311424; ZINC238809356; CCG-270470; AS-19402; beta-D-Glucopyranoside, (3beta,6alpha,16beta,20R,24S)-20,24-epoxy-16,25-dihydroxy-3-(beta-D-xylopyranosyloxy)-9,19-cyclolanostan-6-yl; K514; X7614; C17799; 846A434; Q27133900; Astragaloside IV, European Pharmacopoeia (EP) Reference Standard; Astragaloside IV, United States Pharmacopeia (USP) Reference Standard; (2R,3R,4S,5S,6R)-2-(((2aR,3R,4S,5aS,5bS,7S,7aR,9S,11aR,12aS)-4-hydroxy-3-((2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-2a,5a,8,8-tetramethyl-9-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetradecahydro-1H,12H-cyclopenta[a]cyclopropa[e]phenanthren-7-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	785	7	C41H68O14	228	1460	1.3	55	9	14	"InChI=1S/C41H68O14/c1-35(2)24(54-33-29(48)26(45)20(44)17-51-33)9-11-41-18-40(41)13-12-37(5)31(39(7)10-8-25(55-39)36(3,4)50)19(43)15-38(37,6)23(40)14-21(32(35)41)52-34-30(49)28(47)27(46)22(16-42)53-34/h19-34,42-50H,8-18H2,1-7H3/t19-,20+,21-,22+,23-,24-,25-,26-,27+,28-,29+,30+,31-,32-,33-,34+,37+,38-,39+,40-,41+/m0/s1"	C[C@]12CC[C@@]34C[C@@]35CC[C@@H](C([C@@H]5[C@H](C[C@H]4[C@@]1(C[C@@H]([C@@H]2[C@]6(CC[C@H](O6)C(C)(C)O)C)O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)(C)C)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O	QMNWISYXSJWHRY-YLNUDOOFSA-N
DG01840	Ceruletide	16129675	"Caerulein; Ceruletide; 17650-98-5; Cerulein; Ceruletida; Ceruletidum; 5-Oxo-L-prolyl-L-glutaminyl-L-alpha-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-alpha-aspartyl-L-phenylalaninamide; UNII-888Y08971B; FI-6934; CHEBI:59219; Tymtran; 888Y08971B; Ceruletidum [INN-Latin]; Ceruletida [INN-Spanish]; Ceruletide [USAN:INN:BAN]; 5-oxo-L-prolyl-L-glutaminyl-L-a-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-a-aspartyl-L-phenylalaninamide; CCRIS 3063; Ceruletide (USAN/INN); Caerulein, sulfated; FI-6934Caerulein; 5-Oxo-L-prolyl-L-glutaminyl-L-aspartyl-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-aspartylphenyl-L-alaninamide 4-(hydrogen sulfate) (ester); SCHEMBL29520; GTPL7589; CHEMBL1201355; DTXSID8040434; HY-A0190; Pyr-QD-Tyr(SO3H)-TGWMDF-NH2; MFCD00076478; CS-5876; DB00403; AS-56061; C73362; D03442; Q5065299; (3S)-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}-3-[(2S)-2-[(2S)-2-{2-[(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-4-carbamoyl-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}butanamido]-3-carboxypropanamido]-3-[4-(sulfooxy)phenyl]propanamido]-3-hydroxybutanamido]acetamido}-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]propanoic acid"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:59219	DB00403	.	.	1352.4	38	C58H73N13O21S2	585	2840	-3	94	17	22	"InChI=1S/C58H73N13O21S2/c1-29(72)49(71-57(87)40(23-31-12-14-33(15-13-31)92-94(89,90)91)68-56(86)43(26-48(78)79)69-52(82)37(16-18-44(59)73)65-51(81)36-17-19-45(74)63-36)58(88)62-28-46(75)64-41(24-32-27-61-35-11-7-6-10-34(32)35)54(84)66-38(20-21-93-2)53(83)70-42(25-47(76)77)55(85)67-39(50(60)80)22-30-8-4-3-5-9-30/h3-15,27,29,36-43,49,61,72H,16-26,28H2,1-2H3,(H2,59,73)(H2,60,80)(H,62,88)(H,63,74)(H,64,75)(H,65,81)(H,66,84)(H,67,85)(H,68,86)(H,69,82)(H,70,83)(H,71,87)(H,76,77)(H,78,79)(H,89,90,91)/t29-,36+,37+,38+,39+,40+,41+,42+,43+,49+/m1/s1"	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]5CCC(=O)N5)O	YRALAIOMGQZKOW-HYAOXDFASA-N
DG01841	Rhodium trichloride hydrate	16211510	"Rhodium trichloride hydrate; Rhodium(III) chloride xhydrate; CDDP;cis-Diaminodichloroplatinum; Cl3H2ORh; trichlororhodium hydrate; trichlororhodium;hydrate; rhodium chloride hydrate; rhodiumtrichloride hydrate; Rhodium(III) chloride 3-hydrate; BCP26055; 0627AB; AKOS015924295; Rhodium chloride (RhCl3), hydrate (9CI); Rhodium(III) chloride hydrate, Rh =>39%; Rhodium(III) chloride hydrate, Rh 38-40 %; A814863; trichlororhodium hydrate;Rhodium(III) Chloride Hydrate; Rhodium(III) chloride hydrate, 99.98% trace metals basis; Rhodium(III) chloride hydrate, Rh =>39% trace metal grade 99.99%; Rhodium(III) chloride hydrate, crystalline, >=99.9% trace metals basis"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00515	.	.	227.28	0	Cl3H2ORh	1	8	.	5	1	1	InChI=1S/3ClH.H2O.Rh/h3*1H;1H2;/q;;;;+3/p-3	O.Cl[Rh](Cl)Cl	HSSMNYDDDSNUKH-UHFFFAOYSA-K
DG01842	YK-4-279	44632017	"YK-4-279; 1037184-44-3; YK 4-279; 4,7-dichloro-3-hydroxy-3-(2-(4-methoxyphenyl)-2-oxoethyl)indolin-2-one; 4,7-dichloro-3-hydroxy-3-[2-(4-methoxyphenyl)-2-oxoethyl]-1H-indol-2-one; CHEMBL2011500; 4,7-Dichloro-1,3-dihydro-3-hydroxy-3-[2-(4-methoxyphenyl)-2-oxoethyl]-2H-indol-2-one; C17H13Cl2NO4; 4,7-dichloro-1,3-dihydro-3-hydroxy-3-[2-(4-methoxyphenyl)-2-oxoethyl]-2H-indole-2-one; MLS006010813; SCHEMBL3486735; CHEBI:94301; DTXSID80660065; EX-A524; HMS3741G19; AOB87740; BCP13213; BDBM50379275; MFCD18382120; NSC765436; s7679; AKOS024457962; CCG-268236; CS-0667; NSC-765436; YK4-279; NCGC00346886-01; NCGC00346886-04; NCGC00346886-09; AC-33063; AS-17053; HY-14507; QC-11745; SMR004701745; FT-0753857; Y0289; F51067; BRD-A62182663-001-02-2; Q27166120; 4,7-dichloro-3-hydroxy-3-(2-(4-methoxyphenyl)-2-oxoethyl)indolin-2-one(YK-4-279)"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	366.2	4	C17H13Cl2NO4	75.6	509	3.1	24	2	4	"InChI=1S/C17H13Cl2NO4/c1-24-10-4-2-9(3-5-10)13(21)8-17(23)14-11(18)6-7-12(19)15(14)20-16(17)22/h2-7,23H,8H2,1H3,(H,20,22)"	COC1=CC=C(C=C1)C(=O)CC2(C3=C(C=CC(=C3NC2=O)Cl)Cl)O	HLXSCTYHLQHQDJ-UHFFFAOYSA-N
DG01843	Chembl2042164	44776615	"CHEMBL2042164; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(4-phenylpiperazin-1-yl)-9H-purin-9-yl]tetrahydrofuran-3,4-diol; BDBM50524391; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(4-phenylpiperazin-1-yl)-9H-purin-9-yl]tetrahydrofuran-3,4-diol (non-preferred name); (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(4-phenylpiperazin-1-yl)purin-9-yl]tetrahydrofuran-3,4-diol; ERS"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	412.4	4	C20H24N6O4	120	574	1.3	30	3	9	"InChI=1S/C20H24N6O4/c27-10-14-16(28)17(29)20(30-14)26-12-23-15-18(21-11-22-19(15)26)25-8-6-24(7-9-25)13-4-2-1-3-5-13/h1-5,11-12,14,16-17,20,27-29H,6-10H2/t14-,16-,17-,20-/m1/s1"	C1CN(CCN1C2=CC=CC=C2)C3=NC=NC4=C3N=CN4[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O	FVRJZHPJEJJPPT-WVSUBDOOSA-N
DG01844	5-FU-CDDP	56842080	5-FU-CDDP protocol; 5-FU-CDDP regimen; 5-FU-CDDP; SCHEMBL5916102; Cisplatin regimen with Fluorouracil; C112530000	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	428.11	0	C4H7Cl2FN4O2Pt	60.2	206	.	14	4	5	"InChI=1S/C4H3FN2O2.2ClH.2H2N.Pt/c5-2-1-6-4(9)7-3(2)8;;;;;/h1H,(H2,6,7,8,9);2*1H;2*1H2;/q;;;2*-1;+4/p-2"	C1=C(C(=O)NC(=O)N1)F.[NH2-].[NH2-].Cl[Pt+2]Cl	LVOCGPWBRTUSAU-UHFFFAOYSA-L
DG01845	Nonesterified	57426056	"NEFA; JMF9RU2BLC; UNII-JMF9RU2BLC; Fatty Acids, Nonesterified; SCHEMBL15273327; Q6953452; (4aR,9aS)-N-Ethyl-4,4a,9,9a-tetrahydro-1H-fluoren-4a-amine; 4Ah-fluoren-4a-amine, N-ethyl-1,4,9,9a-tetrahydro-, (4ar-cis)-; 127140-88-9"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	213.32	2	C15H19N	12	283	3	16	1	1	"InChI=1S/C15H19N/c1-2-16-15-10-6-5-8-13(15)11-12-7-3-4-9-14(12)15/h3-7,9,13,16H,2,8,10-11H2,1H3/t13-,15+/m0/s1"	CCN[C@]12CC=CC[C@H]1CC3=CC=CC=C23	DRCWOKJLSQUJPZ-DZGCQCFKSA-N
DG01846	Hydrochloride	69797958	"(E)-SIS3; SMAD3; (E)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride; DS-015902"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	490	5	C28H28ClN3O3	56.6	724	.	35	1	4	"InChI=1S/C28H27N3O3.ClH/c1-30-27(19-8-5-4-6-9-19)22(23-10-7-14-29-28(23)30)11-12-26(32)31-15-13-20-16-24(33-2)25(34-3)17-21(20)18-31;/h4-12,14,16-17H,13,15,18H2,1-3H3;1H"	CN1C(=C(C2=C1N=CC=C2)C=CC(=O)N3CCC4=CC(=C(C=C4C3)OC)OC)C5=CC=CC=C5.Cl	CDKIEBFIMCSCBB-UHFFFAOYSA-N
DG01847	Insulin recombinant	70678557	"9004-10-8; Iletin; Endopancrine; Decurvon; Dermulin; Humilin; Insular; Insulyl; Iszilin; Musulin; insulin-human; Dal-insulinum; Intesulin B; AERx; Insulin, dalanated; Insulina dalanatada; Insulinum dalanatum; Imusay-131; INSULIN INJECTION; Dalanated insulin [INN]; Insulina iniettabile neutra; Insulini injectio neutralis; Injectable insulini neutrale; Inyectable neutro de insulina; CCRIS 5464; HSDB 3102; Insulin, dalanated [USAN:INN]; Insulinum dalanatum [INN-Latin]; AERx [Insulin management system]; Insulina dalanatada [INN-Spanish]; Solute neutre injectable d'insuline; HMR 4006; Insulina iniettabile neutra [DCIT]; EINECS 232-672-8; S.N. 44; Insulini injectio neutralis [INN-Latin]; Inyectable neutro de insulina [INN-Spanish]; Solute neutre injectable d'insuline [INN-French]"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB00030	.	DR00408	5794	178	C256H381N65O77S6	2450	14600	-12.8	404	78	89	"InChI=1S/C256H381N65O77S6/c1-29-130(23)202(311-190(337)103-258)250(391)315-200(128(19)20)246(387)286-158(75-82-197(347)348)216(357)281-154(70-77-186(261)333)220(361)306-181-115-402-403-116-182-241(382)303-176(110-323)238(379)293-161(88-122(7)8)224(365)294-167(95-139-53-61-145(328)62-54-139)227(368)282-153(69-76-185(260)332)217(358)289-160(87-121(5)6)222(363)283-157(74-81-196(345)346)219(360)301-173(101-188(263)335)233(374)297-169(97-141-57-65-147(330)66-58-141)230(371)307-180(240(381)302-174(254(395)396)102-189(264)336)114-401-400-113-179(213(354)272-106-191(338)277-152(72-79-194(341)342)215(356)280-150(51-42-84-270-256(266)267)211(352)271-107-192(339)278-165(93-137-46-36-32-37-47-137)226(367)296-166(94-138-48-38-33-39-49-138)229(370)298-170(98-142-59-67-148(331)68-60-142)236(377)318-205(134(27)326)253(394)321-85-43-52-184(321)244(385)284-151(50-40-41-83-257)221(362)319-206(135(28)327)255(397)398)309-247(388)199(127(17)18)314-234(375)163(90-124(11)12)291-228(369)168(96-140-55-63-146(329)64-56-140)295-223(364)159(86-120(3)4)288-209(350)132(25)276-214(355)156(73-80-195(343)344)285-245(386)198(126(15)16)313-235(376)164(91-125(13)14)292-232(373)172(100-144-105-269-119-275-144)300-237(378)175(109-322)279-193(340)108-273-212(353)178(112-399-404-117-183(308-242(181)383)243(384)317-204(133(26)325)251(392)304-177(111-324)239(380)316-203(131(24)30-2)249(390)310-182)305-225(366)162(89-123(9)10)290-231(372)171(99-143-104-268-118-274-143)299-218(359)155(71-78-187(262)334)287-252(393)207(208(265)349)320-248(389)201(129(21)22)312-210(351)149(259)92-136-44-34-31-35-45-136/h31-39,44-49,53-68,104-105,118-135,149-184,198-207,322-331H,29-30,40-43,50-52,69-103,106-117,257-259H2,1-28H3,(H2,260,332)(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,349)(H,268,274)(H,269,275)(H,271,352)(H,272,354)(H,273,353)(H,276,355)(H,277,338)(H,278,339)(H,279,340)(H,280,356)(H,281,357)(H,282,368)(H,283,363)(H,284,385)(H,285,386)(H,286,387)(H,287,393)(H,288,350)(H,289,358)(H,290,372)(H,291,369)(H,292,373)(H,293,379)(H,294,365)(H,295,364)(H,296,367)(H,297,374)(H,298,370)(H,299,359)(H,300,378)(H,301,360)(H,302,381)(H,303,382)(H,304,392)(H,305,366)(H,306,361)(H,307,371)(H,308,383)(H,309,388)(H,310,390)(H,311,337)(H,312,351)(H,313,376)(H,314,375)(H,315,391)(H,316,380)(H,317,384)(H,318,377)(H,319,362)(H,320,389)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,395,396)(H,397,398)(H4,266,267,270)/t130-,131-,132+,133+,134+,135+,149+,150+,151+,152+,153+,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182-,183+,184+,198+,199+,200+,201+,202+,203+,204+,205+,206+,207+/m1/s1"	CC[C@@H](C)[C@H]1C(=O)N[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@H](C)CC)NC(=O)CN	YAJCHEVQCOHZDC-QMMNLEPNSA-N
DG01848	Interferon alfa-2B	71306834	"INTERFERON ALFA-2B; 98530-12-2; Interferon alfa-2b, recombinant; C16H17Cl3I2N3NaO5S; SCHEMBL6041041; K779; Q4391540"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB05258	.	.	746.5	7	C16H17Cl3I2N3NaO5S	113	511	.	31	0	6	"InChI=1S/C15H16Cl3N3O2.CH2I2O3S.Na/c1-2-4-20(15(22)21-5-3-19-10-21)6-7-23-14-12(17)8-11(16)9-13(14)18;2-1(3)7(4,5)6;/h3,5,8-10H,2,4,6-7H2,1H3;1H,(H,4,5,6);/q;;+1/p-1"	CCCN(CCOC1=C(C=C(C=C1Cl)Cl)Cl)C(=O)N2C=CN=C2.C(S(=O)(=O)[O-])(I)I.[Na+]	MIXCUJKCXRNYFM-UHFFFAOYSA-M
DG01849	Preimplantation factor	134687212	"UNII-3K6A6FJ98O; 3K6A6FJ98O; Preimplantation factor; SPIF peptide; PIF-1; Synthetic preimplantation factor; Preimplantation factor, synthetic; 485818-40-4; L-Aspartic acid, L-methionyl-L-valyl-L-arginyl-L-isoleucyl-L-lysyl-L-prolylglycyl-L-seryl-L-alanyl-L-asparaginyl-L-lysyl-L-prolyl-L-seryl-L-alpha-aspartyl-; L-Methionyl-L-valyl-L-arginyl-L-isoleucyl-L-lysyl-L-prolylglycyl-L-seryl-L-alanyl-L-asparaginyl-L-lysyl-L-prolyl-L-seryl-L-alpha-aspartyl-L-aspartic acid"	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	1614.8	53	C67H115N21O23S	753	3300	-15	112	23	28	"InChI=1S/C67H115N21O23S/c1-7-34(4)52(86-55(99)37(17-12-23-74-67(72)73)78-62(106)51(33(2)3)85-54(98)36(70)20-26-112-6)63(107)80-39(16-9-11-22-69)65(109)87-24-13-18-45(87)60(104)75-30-48(92)77-43(31-89)58(102)76-35(5)53(97)81-40(27-47(71)91)56(100)79-38(15-8-10-21-68)64(108)88-25-14-19-46(88)61(105)84-44(32-90)59(103)82-41(28-49(93)94)57(101)83-42(66(110)111)29-50(95)96/h33-46,51-52,89-90H,7-32,68-70H2,1-6H3,(H2,71,91)(H,75,104)(H,76,102)(H,77,92)(H,78,106)(H,79,100)(H,80,107)(H,81,97)(H,82,103)(H,83,101)(H,84,105)(H,85,98)(H,86,99)(H,93,94)(H,95,96)(H,110,111)(H4,72,73,74)/t34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,51-,52-/m0/s1"	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCSC)N	GLXYOFXNKBTMQL-YKCHQESGSA-N
DG01850	DX-8951	146160902	BCP32858; FT-0777984; Exatecan derivative for ADC;Exatecan derivative; DX-8951 derivative; DX-8951; DX8951; Trastuzumab Deruxtecan (DS-8201a)	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	DB16301	.	.	493.5	3	C26H24FN3O6	129	1080	0	36	3	8	"InChI=1S/C26H24FN3O6/c1-3-26(35)15-6-19-23-13(8-30(19)24(33)14(15)10-36-25(26)34)22-17(28-20(32)9-31)5-4-12-11(2)16(27)7-18(29-23)21(12)22/h6-7,17,31,35H,3-5,8-10H2,1-2H3,(H,28,32)"	CCC1(C2=C(COC1=O)C(=O)N3CC4=C5C(CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)NC(=O)CO)O	PLXLYXLUCNZSAA-UHFFFAOYSA-N
DG01851	Sacubitril/Valsartan	156599206	Sacubitril/Valsartan	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	1922	40	C96H126N12Na6O21-6	396	1140	.	135	7	35	"InChI=1S/2C24H29N5O3.2C24H29NO5.6Na.5H2O.6H/c2*1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;2*1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;;;;;;;;;;;;;;;;/h2*6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H2,25,26,27,28,31,32);2*4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;;;;;;5*1H2;;;;;;/q;;;;6*+1;;;;;;6*-1/p-6/t2*22-;2*17-,21+;;;;;;;;;;;;;;;;;/m0011................./s1"	[H-].[H-].[H-].[H-].[H-].[H-].CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)[C@@H](C(C)C)C(=O)[O-].CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)[C@@H](C(C)C)C(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]	FMZBKXKGHKJGMO-VDKBMKBSSA-H
DG01852	HSP90 inhibitor	.	HSP90 inhibitor	Preclinical	14	Preclinical Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01853	Induction therapy	.	Induction therapy	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01854	Teprotumumab	.	Teprotumumab	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	DB06343	.	.	148000	.	.	.	.	.	.	.	.	.	.	.
DG01855	HG-6-63-01	.	HG-6-63-01	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01856	XMD15-44	.	XMD15-44	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01857	SU5402	.	SU5402	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01858	R3Mab	.	R3Mab	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01859	Spliceosome inhibitors	.	Spliceosome inhibitors	Preclinical	14	Preclinical Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01860	Unspecified VEGFR2 antibody	.	Unspecified VEGFR2 antibody	Preclinical	14	Preclinical Drug(s)	Preclinical	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01861	VEGFR inhibitors	.	VEGFR inhibitors	Preclinical	14	Preclinical Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01862	Pan-TRK inhibitors	.	Pan-TRK inhibitors	Preclinical	14	Preclinical Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01863	ACLY siRNA	.	ACLY SiRNA	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01864	PI3K pathway inhibitors	.	PI3K pathway inhibitors	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01865	Anti-HER3 mAbs	.	Anti-HER3 mAbs	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01866	Compound 3144	.	Compound 3144	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01867	ERK inhibitors	.	ERK inhibitors	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01868	NS1	.	NS1	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01869	SF1126	.	SF1126	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01870	SHR-A1307	.	SHR-A1307	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01871	CYH33	.	CYH33	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01872	DHM25	.	DHM25	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01873	LY2780301	.	LY2780301	Phase 1	9	Clinical Trial Drug(s)	Phase 1	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01874	YM-024	.	YM-024	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01875	PW12	.	PW12	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01876	PKI-402	.	PKI-402	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01877	PI103	.	PI103	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01878	IMG-2005-5	.	IMG-2005-5	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01879	MEK inhibitors	.	MEK inhibitors	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01880	BPR1J373	.	BPR1J373	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01881	PARP inhibitors	.	PARP inhibitors	Preclinical	14	Preclinical Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01882	IDH1 inhibitors	.	IDH1 inhibitors	Preclinical	14	Preclinical Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01883	GSK3052230	.	GSK3052230	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01884	EZH2 inhibitors	.	EZH2 inhibitors	Preclinical	14	Preclinical Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01885	UNC1999	.	UNC1999	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01886	Anti-estrogens	.	Anti-estrogens	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01887	Hormone therapy	.	Hormone therapy	Preclinical	14	Preclinical Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01888	Non-allosteric AKT inhibitors	.	Non-allosteric AKT inhibitors	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01889	Allosteric AKT inhibitors	.	Allosteric AKT inhibitors	Preclinical	14	Preclinical Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01891	SHP099	.	SHP099	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01892	MET inhibitors	.	MET inhibitors	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01893	Peginterferon alfa-2a	.	Peginterferon alfa-2a	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01894	IDH2 inhibitors	.	IDH2 inhibitors	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01895	ERBB2 TKIs	.	ERBB2 TKIs	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01896	EKI-285	.	EKI-285	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01897	Trastuzumab-based chemotherapy	.	Trastuzumab-based chemotherapy	Approved	1	Approved Drug(s)	Approved	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01898	Unspecified PD-L1 antibody	.	Unspecified PD-L1 antibody	Investigative	15	Investigative Drug(s)	Investigative	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01899	OBX1-012	.	OBX1-012	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01900	hEGFR vIII-CD3 bi-scFv	.	HEGFRvIII-CD3 bi-scFv	Preclinical	14	Preclinical Drug(s)	Preclinical	Bispecific antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01901	MM-151	.	MM-151	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01902	ALRN-6924	.	ALRN-6924	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01903	YW3-56	.	YW3-56	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01904	EAP Protocol	.	EAP Protocol	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01905	SBI-0640726	.	SBI-0640726	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01906	INU-152	.	INU-152	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01907	LSN3074753	.	LSN3074753	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01908	DETD-35	.	DETD-35	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01909	SBI-755199	.	SBI-755199	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01910	BI-2536	.	BI2536	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01911	CLM3	.	CLM3	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01912	S3I-201	.	S3I-201	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01913	Pictilisib/Ruxolitinib	.	Pictilisib/Ruxolitinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG01914	Afabicin	72696796	"UNII-DMM8663H2R; DMM8663H2R; 1518800-35-5; Afabicin [INN]; SCHEMBL15479062; SCHEMBL16262317; (6-((1E)-3-(Methyl((3-methyl-1-benzofuran-2-yl)methyl)amino)-3-oxoprop-1-en-1-yl)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl)methyl dihydrogen phosphate; 2-Propenamide, N-methyl-N-((3-methyl-2-benzofuranyl)methyl)-3-(5,6,7,8-tetrahydro-7-oxo-8-((phosphonooxy)methyl)-1,8-naphthyridin-3-yl)-, (2E)-"	Phase 2	7	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	DB15268	.	.	485.4	7	C23H24N3O7P	133	833	1	34	2	8	"1S/C23H24N3O7P/c1-15-18-5-3-4-6-19(18)33-20(15)13-25(2)21(27)9-7-16-11-17-8-10-22(28)26(23(17)24-12-16)14-32-34(29,30)31/h3-7,9,11-12H,8,10,13-14H2,1-2H3,(H2,29,30,31)/b9-7+"	CC1=C(OC2=CC=CC=C12)CN(C)C(=O)/C=C/C3=CC4=C(N=C3)N(C(=O)CC4)COP(=O)(O)O	HFYMDQMXVPJNTH-VQHVLOKHSA-N
DG02034	Pazopanib	10113978	"Pazopanib; Pazopanib (GW-786034); 444731-52-6; 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide; 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; 790713-33-6; 7RN5DR86CK; CHEBI:71219; DSSTox_CID_28659; DSSTox_GSID_48733; DSSTox_RID_82929; GW 78603; GW 786034; GW-786034; GW786034; MFCD11616589; NCGC00188865-01; UNII-7RN5DR86CK"	Approved	1	Approved Drug(s)	Approved	.	CHEBI:71219	.	.	DR1248	437.5	C21H23N7O2S	127	717	3.1	31	2	8	5	CUIHSIWYWATEQL-UHFFFAOYSA-N	CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N	"1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)"
DG02001	Bafetinib	11387605	"Bafetinib; 859212-16-1; INNO-406; NS-187; UNII-NVW4Z03I9B; CNS-9; NVW4Z03I9B; INNO406; CHEMBL206834; (S)-N-(3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl)-4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzamide; 4-[[(3S)-3-DIMETHYLAMINOPYRROLIDIN-1-YL]METHYL]-N-[4-METHYL-3-[(4-PYRIMIDIN-5-YLPYRIMIDIN-2-YL)AMINO]PHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE; INNO 406; NS 187; N-[3-(4,5'-Bipyrimidin-2-Ylamino)-4-Methylphenyl]-4-{[(3s)-3-(Dimethylamino)pyrrolidin-1-Yl]methyl}-3-(Trifluoromethyl)benzamide"	Phase 2	4	Clinical Trial Drug(s)	Phase 2	Small molecular drug	.	.	.	.	576.6	C30H31F3N8O	99.2	872	4.2	42	2	11	8	"InChI=1S/C30H31F3N8O/c1-19-4-7-23(13-27(19)39-29-36-10-8-26(38-29)22-14-34-18-35-15-22)37-28(42)20-5-6-21(25(12-20)30(31,32)33)16-41-11-9-24(17-41)40(2)3/h4-8,10,12-15,18,24H,9,11,16-17H2,1-3H3,(H,37,42)(H,36,38,39)/t24-/m0/s1"	CC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C=C2)CN3CC[C@@H](C3)N(C)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CN=C5	ZGBAJMQHJDFTQJ-DEOSSOPVSA-N
DG02009	27-Hydroxycholesterol	123976	27-OHC; 26-hydroxycholesterol	Investigative	7	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	C27H46O2	40.5	612	7.1	29	2	2	6	"InChI=1S/C27H46O2/c1-18(17-28)6-5-7-19(2)23-10-11-24-22-9-8-20-16-21(29)12-14-26(20,3)25(22)13-15-27(23,24)4/h8,18-19,21-25,28-29H,5-7,9-17H2,1-4H3/t18-,19-,21+,22+,23-,24+,25+,26+,27-/m1/s1"	C[C@H](CCC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)CO	FYHRJWMENCALJY-YSQMORBQSA-N	"(3S,8S,9S,10R,13R,14S,17R)-17-[(2R,6R)-7-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol"
DG02013	BAY2402234	134470179	KNVJMHHAXCPZHF-JTQLQIEISA-N; BAY-2402234; SCHEMBL20108031; HY-112645; CS-0058850	Phase 1	5	Clinical Trial Drug(s)	Phase 1	.	.	.	.	.	C21H18ClF5N4O4	94.5	819	4	35	2	10	7	"InChI=1S/C21H18ClF5N4O4/c1-3-30-17(9-32)29-31(20(30)34)15-8-16(35-10(2)21(25,26)27)11(7-14(15)24)19(33)28-18-12(22)5-4-6-13(18)23/h4-8,10,32H,3,9H2,1-2H3,(H,28,33)/t10-/m0/s1"	CCN1C(=NN(C1=O)C2=C(C=C(C(=C2)O[C@@H](C)C(F)(F)F)C(=O)NC3=C(C=CC=C3Cl)F)F)CO	KNVJMHHAXCPZHF-JTQLQIEISA-N	"N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-3-(hydroxymethyl)-5-oxo-1,2,4-triazol-1-yl]-5-fluoro-2-[(2S)-1,1,1-trifluoropropan-2-yl]oxybenzamide"
DG02024	Antimycin A	14957	"Antimycin A; Antipiricullin; Fintrol; Virosin; Antimycin A1b; antimycin A1; Caswell No. 052B; Antimycin-A; CCRIS 924; HSDB 6417; UNII-75G3NMU1TS; EPA Pesticide Chemical Code 006314; 75G3NMU1TS; CHEMBL211501; CHEBI:22584; 1397-94-0; (2R,3S,6S,7R,8R)-3-[(3-formamido-2-hydroxybenzoyl)amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl 3-methylbutanoate; 642-15-9; 116095-18-2; [(2r,3s,6s,7r,8r)-3-[(3-Formamido-2-Oxidanyl-Phenyl)carbonylamino]-8-Hexyl-2,6-Dimethyl-4,9-Bis(Oxidanylidene)-1,5-Dioxonan-7-Yl] 3-Methylbutanoate"	Investigative	7	Investigative Drug(s)	Investigative	Small molecular drug	. 	.	.	.	C28H40N2O9	157	849	5.3	39	3	9	12	"InChI=1S/C28H40N2O9/c1-6-7-8-9-11-20-25(39-22(32)14-16(2)3)18(5)38-28(36)23(17(4)37-27(20)35)30-26(34)19-12-10-13-21(24(19)33)29-15-31/h10,12-13,15-18,20,23,25,33H,6-9,11,14H2,1-5H3,(H,29,31)(H,30,34)/t17-,18+,20-,23+,25+/m1/s1"	CCCCCC[C@@H]1[C@H]([C@@H](OC(=O)[C@H]([C@H](OC1=O)C)NC(=O)C2=C(C(=CC=C2)NC=O)O)C)OC(=O)CC(C)C	UIFFUZWRFRDZJC-SBOOETFBSA-N	"[(2R,3S,6S,7R,8R)-3-[(3-formamido-2-hydroxybenzoyl)amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl] 3-methylbutanoate"
DG02031	Pimozide	16362	"Antalon; Neoperidole; Opiran; Orap; Pimozida; Pimozidum; Primozida; ASTA Medica Brand of Pimozide; Janssen Brand of Pimozide;Orap forte; Pharmascience Brand of Pimozide; P 1793; R 6238; McN-JR 6238; Orap (TN); Pimozida [INN-Spanish]; Pimozidum [INN-Latin]; Primozida [INN-Spanish]; R-6238; McN-JR-6238; Pimozide (JAN/USP/INN); Pimozide [USAN:INN:BAN:JAN]; 1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone; 1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:8212	.	DR00484	DR1291	461.5	C28H29F2N3O	35.6	632	6.3	34	1	4	7	"InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)"	C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F	YVUQSNJEYSNKRX-UHFFFAOYSA-N
DG02038	Orlistat	3034010	"orlistat; 96829-58-2; Tetrahydrolipstatin; Xenical; Alli; Orlipastat; (-)-Tetrahydrolipstatin; Orlipastatum; Orlipastatum [INN-Latin]; THLP; Ro-18-0647; UNII-95M8R751W8; C29H53NO5; Ro 18-0647/002; N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester; (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate; Orlistat (Alli, Xenical); MLS002207022; [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate; CHEMBL175247;  Alli; GlaxoSmithKline brand of orlistat; Roche brand of orlistat; Alli (TN); Hoffmann-La Roche brand of orlistat; KS-1183; Orlistat [USAN:INN]; R-212; Xenical (TN); Orlistat (USAN/INN); Ro 18-0647/008; Alli, Xenical, Tetrahydrolipstatin, Orlistat; N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-((2S)-2-hydroxytridecyl)-2-oxetanone; L-Leucine, N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; L-Leucine,N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate; TETRAHYDROLIPSTATIN"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:94686	.	.	.	495.7	C29H53NO5	81.7	579	10	35	1	5	23	"InChI=1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1"	CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O	AHLBNYSZXLDEJQ-FWEHEUNISA-N
DG02035	Resveratrol	445154	"Resveratrol; Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	Phase 3	3	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:45713	.	DR00287	DR1406	228.24	C14H12O3	60.7	246	3.1	17	3	3	2	"InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+"	C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O	LUKBXSAWLPMMSZ-OWOJBTEDSA-N
DG02020	PF-04620110	46926360	"PF-04620110; 1109276-89-2; CHEMBL1835919; 2-(trans-4-(4-(4-Amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl)cyclohexyl)acetic acid; PF-4620110; trans-4-[4-(4-Amino-7,8-dihydro-5-oxopyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]cyclohexaneacetic acid; 2-(trans-4-(4-(4-Amino-5-oxo-7,8-dihydropyrimido[5,4-f]-[1,4]oxazepin-6(5H)-yl)phenyl)cyclohexyl)acetic acid; UNII-CQ4M18RLJW; CQ4M18RLJW; SCHEMBL1424362; SCHEMBL1425038; GTPL7829; SCHEMBL1424359; SCHEMBL13954265; DTXSID90677361; GEVVQZHMFVFGLN-HDJSIYSDSA-N"	Terminated	.	Discontinued Drug(s)	Terminated	Small molecular drug	.	.	.	.	C21H24N4O4	119	587	3.3	29	2	7	4	"InChI=1S/C21H24N4O4/c22-19-18-20(24-12-23-19)29-10-9-25(21(18)28)16-7-5-15(6-8-16)14-3-1-13(2-4-14)11-17(26)27/h5-8,12-14H,1-4,9-11H2,(H,26,27)(H2,22,23,24)"	C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)N3CCOC4=NC=NC(=C4C3=O)N	GEVVQZHMFVFGLN-UHFFFAOYSA-N	"2-[4-[4-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6-yl)phenyl]cyclohexyl]acetic acid"
DG02016	Pitavastatin	5282452	"Pitavastatin; Itavastatin; Livalo; NK 104; Pitavastatin [INN]; Pitavastatin calcium; UNII-M5681Q5F9P; NK-104; C25H24FNO4; M5681Q5F9P; Zypitamag; Flovas; (3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; P 872441; P-872441; (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; ( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; NK 104 (acid); Pitavastatin calcium (JAN)"	Approved	1	Approved Drug(s)	Approved	.	CHEBI:32020	.	DR01545	.	421.5	C25H24FNO4	90.6	631	.	31	3	6	8	"InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m1/s1"	C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)O)O)O)C4=CC=C(C=C4)F	VGYFMXBACGZSIL-MCBHFWOFSA-N
DG02014	Selinexor	71481097	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	Phase 3	3	Clinical Trial Drug(s)	Phase 3	Small molecular drug	.	.	.	DR1472	443.3	C17H11F6N7O	97.6	621	3	31	2	12	5	"InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1-"	C1=CN=C(C=N1)NNC(=O)/C=C\\N2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F	DEVSOMFAQLZNKR-RJRFIUFISA-N
DG02019	Etomoxir	9840324	"ETOMOXIR; 82258-36-4; rac- Etomoxir; Etomoxirum [Latin]; Ethyl 2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylate; BRN 4496620; Oxiranecarboxylic acid, 2-(6-(4-chlorophenoxy)hexyl)-, ethyl ester; B 807-54; Ethyl 2-(6-(4-chlorophenoxy)hexyl)oxiranecarboxylate; Oxiranecarboxylic acid, 2-[6-(4-chlorophenoxy)hexyl]-, ethyl ester- [CAS]; Etomoxirum; etomoxir[inn]; SMR000449321; Rac-Etomoxir Ethyl Ester; C17H23ClO4; ethyl 2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate; etoxomir; AC1L3XCY; MLS001424024; MLS000758228; SCHEMBL681359"	Terminated	.	Discontinued Drug(s)	Terminated	Small molecular drug	.	.	.	.	C17H23ClO4	48.1	342	4.3	22	0	4	11	"InChI=1S/C17H23ClO4/c1-2-20-16(19)17(13-22-17)11-5-3-4-6-12-21-15-9-7-14(18)8-10-15/h7-10H,2-6,11-13H2,1H3/t17-/m1/s1"	CCOC(=O)[C@]1(CO1)CCCCCCOC2=CC=C(C=C2)Cl	DZLOHEOHWICNIL-QGZVFWFLSA-N	ethyl (2R)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate
DG02029	BX795	10077147	"702675-74-9|BX795|BX-795|BX 795|N-[3-[[5-IODO-4-[[3-[(2-THIENYLCARBONYL)AMINO]PROPYL]AMINO]-2-PYRIMIDINYL]AMINO]PHENYL]-1-PYRROLIDINECARBOXAMIDE|N-(3-((5-iodo-4-((3-(thiophene-2-carboxamido)propyl)amino)pyrimidin-2-yl)amino)phenyl)pyrrolidine-1-carboxamide|N-[3-[[5-iodo-4-[3-(thiophene-2-carbonylamino)propylamino]pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide|N-{3-[(5-iodo-4-{[3-(thiophen-2-ylformamido)propyl]amino}pyrimidin-2-yl)amino]phenyl}pyrrolidine-1-carboxamide|N-(3-{[5-Iodo-4-({3-[(Thiophen-2-Ylcarbonyl)amino]propyl}amino)pyrimidin-2-Yl]amino}phenyl)pyrrolidine-1-Carboxamide|N-(3-(4-(3-(Thiophene-2-carbonylamino)propylamino)-5-iodopyrimidin-2-ylamino)phenyl)pyrrolidine-1-carboxamide|C23H26IN7O2S|BX7|MFCD12546134|CID 10077147|MLS006011190|CHEMBL577784|GTPL8006|SCHEMBL3865995|BDBM17051|CHEBI:91439|DTXSID50435186|EX-A262|BCPP000310|GLXC-04290|HMS3244G15|HMS3244G16|HMS3244H15|HMS3651A07|HMS3672K09|BCP01899|BX795/BX-795|BX795?|s1274|AKOS016369934|BCP9000467|CCG-264884|CS-0259|SB13079|SDCCGSBI-0645948.P001|NCGC00250386-01|NCGC00250386-02|NCGC00250386-12|AC-32825|AS-16196|HY-10514|SMR004702959|BCP0726000131|BX-795, 3|SW208681-3|BRD-K47983010-001-01-3|BRD-K47983010-001-09-6|BRD-K47983010-001-12-0|BRD-K47983010-001-14-6|Q27075609|N-(3-((5-Iodo-4-((3-(2-thienylcarbonyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide|Pyrrolidine-1-carboxylic acid [3-(5-iodo-4-{3-[(thiophene-2-carbonyl)-amino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide"	Investigative	7	Investigative Drug(s)	Investigative	Small molecular drug	CHEBI:91439	.	.	.	591.5	C23H26IN7O2S	140	669	4.6	34	4	7	9	"InChI=1S/C23H26IN7O2S/c24-18-15-27-22(30-20(18)25-9-5-10-26-21(32)19-8-4-13-34-19)28-16-6-3-7-17(14-16)29-23(33)31-11-1-2-12-31/h3-4,6-8,13-15H,1-2,5,9-12H2,(H,26,32)(H,29,33)(H2,25,27,28,30)"	C1CCN(C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)NCCCNC(=O)C4=CC=CS4)I	VAVXGGRQQJZYBL-UHFFFAOYSA-N
DG02002	Endoxifen	10090750	"Endoxifen|112093-28-4|Z-Endoxifen|4-Hydroxy-N-desmethyltamoxifen|Endoxifen Z-Isomer|N-Desmethyl-4-hydroxytamoxifen|(Z)-Endoxifen|110025-28-0|(E/Z)-Endoxifen|NSC-749798|4OHNDtam|ENDOXIFEN [WHO-DD]|(Z)-4-Hydroxy-N-desmethyl Tamoxifen (contains up to 10% E isomer)|Endoxifen (Z-isomer)|4-[(Z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol|4-Hydroxy-N-desmethyl-tamoxifen|CHEBI:80555|46AF8680RC|NSC 749798|MFCD09840374|4-[(~{Z})-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol|4-[(1Z)-1-{4-[2-(methylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl]phenol|Phenol, 4-(1-(4-(2-(methylamino)ethoxy]phenyl)-2-phenyl-1-butenyl)-, (Z)-|UNII-46AF8680RC|4-hydroxy-N-desmethyl tamoxifen|Endoxifen?|4-hydroxy-N-desmethyltamoxifen, (Z)-isomer|(Z)-4-(1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol|4-((~(Z))-1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol|4-(1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol|EndoxifenZ-Isomer|phenol, 4-((1Z)-1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenyl-1-buten-1-yl)-|4-[1-[4-[2-(Methylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenol; (E/Z)-Endoxifen; 4OHNDtam;|Endoxifen(E/Z=1:1)|CHEMBL1093458|SCHEMBL10107920|GTPL10203|DTXSID80149880|EX-A645|MHJBZVSGOZTKRH-IZHYLOQSSA-N|Phenol, 4-[(1Z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]-|BCP15866|EX-A1970|4-[1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol|BDBM50435003|HY-18719E|NSC746494|NSC749798|NSC777380|NSC833479|AKOS030526256|FE15969|NSC-746494|NSC-777380|NSC-833479|NCGC00386714-01|AC-36810|BE172975|BS-42369|CS-0028594|NS00093647|EN300-822190|BRD-K62752296-003-01-3|Q27149598|N-Desmethyl-4-hydroxy tamoxifen(approx. 1:1 e/z mixture)|(Z)-4-Hydroxy-N-desmethyl tamoxifen(contains up to 10% e isomer)|(E/Z)-4-(1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol|(Z)-4-(1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol|(E/Z)-4-[1-[4-[2-(Methylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]-phenol;4-Hydroxy-N-desmethyltamoxifen"	Phase 2	4	Clinical Trial Drug(s)	Phase 2	.	CHEBI:80555	.	DR01627	.	373.5	C25H27NO2	41.5	467	6.3	28	2	3	8	"InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24-"	CC/C(=C(\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCNC)/C3=CC=CC=C3	MHJBZVSGOZTKRH-IZHYLOQSSA-N
DG02030	Mycro-3	1045147	"Mycro3|Mycro 3|944547-46-0|Mycro-3|Ethyl 5-(7-(chlorodifluoromethyl)-5-(furan-2-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamido)-1-phenyl-1H-pyrazole-4-carboxylate|ethyl 5-[[7-[chloro(difluoro)methyl]-5-(furan-2-yl)pyrazolo[1,5-a]pyrimidine-2-carbonyl]amino]-1-phenylpyrazole-4-carboxylate|5-[[[7-(Chlorodifluoromethyl)-5-(2-furanyl)pyrazolo[1,5-a]pyrimidin-2-yl]carbonyl]amino]-1-phenyl-1H-pyrazole-4-carboxylic acid ethyl ester|ethyl 5-[7-(chlorodifluoromethyl)-5-(furan-2-yl)pyrazolo[1,5-a]pyrimidine-2-amido]-1-phenyl-1H-pyrazole-4-carboxylate|Mycro3; Mycro 3|Mycro-3?|CHEMBL3222135|SCHEMBL14725138|YPPNLSKYXDXQGD-UHFFFAOYSA-N|BCP32791|EX-A8521|STK679353|AKOS001742879|CS-7586|NCGC00402295-03|AC-38098|AS-16565|DA-55786|HY-100669|N16804|ethyl 5-({[7-[chloro(difluoro)methyl]-5-(2-furyl)pyrazolo[1,5-a]pyrimidin-2-yl]carbonyl}amino)-1-phenyl-1H-pyrazole-4-carboxylate|ethyl 5-[({7-[chloro(difluoro)methyl]-5-(furan-2-yl)pyrazolo[1,5-a]pyrimidin-2-yl}carbonyl)amino]-1-phenyl-1H-pyrazole-4-carboxylate|ETHYL 5-[7-(CHLORODIFLUOROMETHYL)-5-(FURAN-2-YL)PYRAZOLO[1,5-A]PYRIMIDINE-2-AMIDO]-1-PHENYLPYRAZOLE-4-CARBOXYLATE"	.	.	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	526.9	C24H17ClF2N6O4	117	837	4.5	37	1	9	8	"InChI=1S/C24H17ClF2N6O4/c1-2-36-23(35)15-13-28-32(14-7-4-3-5-8-14)21(15)30-22(34)17-12-20-29-16(18-9-6-10-37-18)11-19(24(25,26)27)33(20)31-17/h3-13H,2H2,1H3,(H,30,34)"	CCOC(=O)C1=C(N(N=C1)C2=CC=CC=C2)NC(=O)C3=NN4C(=CC(=NC4=C3)C5=CC=CO5)C(F)(F)Cl	YPPNLSKYXDXQGD-UHFFFAOYSA-N
DG02036	Arenobufagin	12305198	"Arenobufagin|464-74-4|5-[(3S,5R,8R,9S,10S,11S,13R,14S,17R)-3,11,14-trihydroxy-10,13-dimethyl-12-oxo-2,3,4,5,6,7,8,9,11,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]pyran-2-one|12-Oxo-3-beta,11-alpha,14-trihydroxy-5-beta-bufa-20,22-dienolide|27R42QLM25|3,11,14-trihydroxy-12-oxo-bufa-20,22-dienolide|5beta-Bufa-20,22-dienolide, 3beta,11alpha,14-trihydroxy-12-oxo-|5-beta-BUFA-20,22-DIENOLIDE, 12-OXO-3-beta,11-alpha,14-TRIHYDROXY-|Bufa-20,22-dienolide, 3,11,14-trihydroxy-12-oxo-, (3beta,5beta,11alpha)-|5-((3S,5R,8R,9S,10S,11S,13R,14S,17R)-3,11,14-trihydroxy-10,13-dimethyl-12-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2H-pyran-2-one|5-((3S,5R,10S,11S,13R,14S,17R)-3,11,14-trihydroxy-10,13-dimethyl-12-oxo-2,3,4,5,6,7,8,9,11,15,16,17-dodecahydro-1H-cyclopenta(a)phenanthren-17-yl)pyran-2-one|5-((3S,5R,8R,9S,10S,11S,13R,14S,17R)-3,11,14-trihydroxy-10,13-dimethyl-12-oxo-2,3,4,5,6,7,8,9,11,15,16,17-dodecahydro-1H-cyclopenta(a)phenanthren-17-yl)pyran-2-one|5-(5,11,17-trihydroxy-2,15-dimethyl-16-oxotetracyclo(8.7.0.02,7.011,15)heptadecan-14-yl)-2H-pyran-2-one|5-[(3S,5R,10S,11S,13R,14S,17R)-3,11,14-trihydroxy-10,13-dimethyl-12-oxo-2,3,4,5,6,7,8,9,11,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]pyran-2-one|5-{5,11,17-trihydroxy-2,15-dimethyl-16-oxotetracyclo[8.7.0.02,7.011,15]heptadecan-14-yl}-2H-pyran-2-one|UNII-27R42QLM25|12-Oxo-3-.beta.,11-.alpha.,14-trihydroxy-5-.beta.-bufa-20,22-dienolide|5.beta.-Bufa-20,22-dienolide, 3.beta.,11.alpha.,14-trihydroxy-12-oxo-|CHEMBL4086974|SCHEMBL21578402|DTXSID00963565|5-.beta.-Bufa-20,22-dienolide, 12-oxo-3-.beta.,11-.alpha.,14-trihydroxy-|Bufa-20,22-dienolide, 3,11,14-trihydroxy-12-oxo-, (3.beta.,5.beta.,11.alpha.)-|CHEBI:197067|GLXC-13270|HY-N0876|AKOS030526814|CS-3693|FA74189|NCGC00485924-01|AC-34734|AS-76734|DA-50681|C20035|(3beta,5beta,11alpha)-3,11,14-Trihydroxy-12-oxobufa-20,22-dienolide|Bufa-20,22-dienolide, 3,11,14-trihydroxy-12-oxo- (3-beta,5-beta,11-alpha)-|Bufa-20,22-dienolide, 3,11,14-trihydroxy-12-oxo-(3-beta,5-beta,11-alpha)-|5-((3S,5R,10S,11S,13R,14S,17R)-3,11,14-trihydroxy-10,13-dimethyl-12-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2H-pyran-2-one"	Investigative	7	Preclinical Drug(s)	Investigative	Small molecular drug	.	.	.	.	416.5	C24H32O6	104	847	1.7	30	3	6	1	"InChI=1S/C24H32O6/c1-22-9-7-15(25)11-14(22)4-5-17-19(22)20(27)21(28)23(2)16(8-10-24(17,23)29)13-3-6-18(26)30-12-13/h3,6,12,14-17,19-20,25,27,29H,4-5,7-11H2,1-2H3/t14-,15+,16-,17-,19-,20+,22+,23+,24+/m1/s1"	C[C@]12CC[C@@H](C[C@H]1CC[C@@H]3[C@@H]2[C@@H](C(=O)[C@]4([C@@]3(CC[C@@H]4C5=COC(=O)C=C5)O)C)O)O	JGDCRWYOMWSTFC-AZGSIFHYSA-N
DG02003	Imexon	135564735	"(S)-Imexon|Imexon, (S)-|N691NU86WU|1,3-Diazabicyclo(3.1.0)hex-3-en-2-one, 4-amino-, (5S)-|1018810-26-8|UNII-N691NU86WU|Q27284609"	Terminated	.	discontinued Drug(s)	Terminated	Small molecular drug	.	.	.	.	111.1	C4H5N3O	56	176	-1	8	2	2	0	"InChI=1S/C4H5N3O/c5-3-2-1-7(2)4(8)6-3/h2H,1H2,(H2,5,6,8)/t2-,7?/m0/s1"	C1[C@@H]2N1C(=O)NC2=N	BIXBBIPTYBJTRY-VBMBUWLQSA-N
DG02007	Alisertib	24771867	"Alisertib|1028486-01-2|MLN8237|MLN-8237|MLN 8237|4-((9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)amino)-2-methoxybenzoic acid|MLN8237 (Alisertib)|Alisertib [USAN]|4-[[9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid|Alisertib [USAN:INN]|Alisertib (USAN)|T66ES73M18|ALISERTIB [INN]|ALISERTIB [WHO-DD]|CHEMBL483158|DTXSID30145539|MLN 8237 (Contain 10% DMSO)|4-((9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-yl)amino)-2-methoxybenzoic acid|Benzoic acid, 4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido(5,4-d)(2)benzazepin-2-yl)amino)-2-methoxy-|4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid|alisertibum|UNII-T66ES73M18|4-((13-chloro-10-(2-fluoro-6-methoxyphenyl)-3,5,9-triazatricyclo(9.4.0.0^(2,7))pentadeca-1(15),2,4,6,9,11,13-heptaen-4-yl)amino)-2-methoxybenzoic acid|4-((9-CHLORO-7-(2-FLUORO-6-METHOXYPHENYL)-5H-PYRIMIDO(5,4-D)(2)BENZAZEPIN-2-YL)AMINO)-2-METHOXY-BENZOIC ACID|4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido(5,4-d)(2)benzazepin-2-yl)amino)-2-methoxybenzoic acid|4-{[13-chloro-10-(2-fluoro-6-methoxyphenyl)-3,5,9-triazatricyclo[9.4.0.0^{2,7}]pentadeca-1(15),2,4,6,9,11,13-heptaen-4-yl]amino}-2-methoxybenzoic acid|4-{[9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxy-benzoic acid|Benzoic acid, 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxy-; 4-[[9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid; MLN 8237|MFCD16621243|MLN8237,Alisertib|Kinome_3770|Alisertib; MLN8237|Alisertib (MLN8237)|MLN8237 (Alisertib)?|MLS006011041|SCHEMBL855823|GTPL7790|DTXCID4068030|EX-A024|CHEBI:125628|ZLHFILGSQDJULK-UHFFFAOYSA-N|HMS3654E08|HMS3673I07|HMS3743E17|BCP01823|Aurora A Kinase Inhibitor MLN8237|BDBM50277545|NSC759677|NSC799329|s1133|AKOS015924647|BCP9000956|CCG-264832|CS-0106|DB05220|FM16476|NSC-759677|NSC-799329|SB16658|SDCCGSBI-0646927.P001|NCGC00263271-01|NCGC00263271-02|NCGC00263271-10|4-(9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-2-methoxybenzoic acid|AC-25236|AS-17005|HY-10971|SMR004702834|NS00072479|SW219771-1|D10085|EN300-6482023|BRD-K75295174-001-03-5|BRD-K75295174-001-05-0|Q15633917|Z2037281068|4-(9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[e]pyrimido[5,4-c]azepin-2-ylamino)-2-methoxybenzoic acid|4-[[9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxy-benzoic acid;Alisertib|4-{[13-chloro-10-(2-fluoro-6-methoxyphenyl)-3,5,9-triazatricyclo[9.4.0.0,2,7]pentadeca-1(11),2(7),3,5,9,12,14-heptaen-4-yl]amino}-2-methoxybenzoic acid|4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl) -5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid|A5B"	Phase 3	3	Clinical Trial Drug(s)	Phase 3	Small molecular drug	CHEBI:125628	.	.	.	518.9	C27H20ClFN4O4	106	836	5	37	2	9	6	"InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)"	COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC	ZLHFILGSQDJULK-UHFFFAOYSA-N
DG02017	Anlotinib	25017411	"Anlotinib|1058156-90-3|catequentinib|AL3818|AL-3818|UNII-GKF8S4C432|GKF8S4C432|1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine|CATEQUENTINIB [INN]|AL 3818|CATEQUENTINIB [WHO-DD]|1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinolin-7-yl)oxy)methyl)cyclopropan-1-amine|1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine|1-[({4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-6-METHOXYQUINOLIN-7-YL}OXY)METHYL]CYCLOPROPAN-1-AMINE|Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-|Anlotinib?|1-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinolin-7-yl)oxymethyl)cyclopropan-1-amine|Cyclopropanamine, 1-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinolinyl]oxy]methyl]-|Catequentinib (USAN/INN)|CATEQUENTINIB [USAN]|GTPL9601|SCHEMBL2063386|CHEMBL4303201|KSMZEXLVHXZPEF-UHFFFAOYSA-N|GLXC-10628|BCP24991|EX-A2427|ISB15690|NSC832523|AKOS030526233|CS-5396|DB11885|NSC-832523|SB19798|HY-19716|4678B|NS00073391|C13643|D12526|BRD-K36949735-001-01-1|Q27279141|1-(((4-((4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY)-6-METHOXY-7-QUINOLINYL)OXY)METHYL)CYCLOPROPANAMINE"	Phase 3	3	Clinical Trial Drug(s)	Phase 3	.	.	.	.	DR1881	407.4	C23H22FN3O3	82.4	606	3.7	30	2	6	6	"InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3"	CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC	KSMZEXLVHXZPEF-UHFFFAOYSA-N
DG02025	Caffine	2519	"caffeine|58-08-2|Guaranine|1,3,7-Trimethylxanthine|Methyltheobromine|Theine|Thein|Cafeina|Koffein|Mateina|Alert-pep|Caffein|Cafipel|Coffeine|Refresh'n|Stim|Anhydrous caffeine|Cafamil|Cafecon|Caffedrine|Caffine|Vivarin|Nodaca|No-Doz|Eldiatric C|Hycomine|Coffein|Dexitac|Organex|7-Methyltheophylline|Nix Nap|Methyltheobromide|Coffeinum|Durvitan|Caffeine, synthetic|3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione|Phensal|Tirend|1,3,7-Trimethyl-2,6-dioxopurine|1,3,7-Trimethylpurine-2,6-dione|Quick-Pep|Theophylline, 7-methyl|Tri-Aqua|Synalgos|Kofein|Miudol|Caffeine, anhydrous|DHCplus|Theobromine, 1-methyl-|1-methyltheobromine|1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl-|Caffeine (natural)|Xanthine, 1,3,7-trimethyl|Propoxyphene Compound 65|Methylxanthine theophylline|Kofein [Czech]|Coffein [German]|Koffein [German]|caffenium|teina|Caffeina|Caffeina [Italian]|NCI-C02733|Theophylline Me|Theobromine Me|1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione|CAFFEINE ANHYDROUS|FEMA No. 2224|1,3,7-trimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione|cafeine|SK-65 Compound|Caffeinum|Anacin|HSDB 36|Anacin Maximum Strength|P-A-C Analgesic Tablets|BRN 0017705|NSC 5036|CCRIS 1314|1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione|AI3-20154|NSC-5036|EINECS 200-362-1|A.S.A. and Codeine Compound|UNII-3G6A5W338E|Caffeine melting point standard|DTXSID0020232|CHEBI:27732|3G6A5W338E|MFCD00005758|CHEMBL113|Caffeine [USP:BAN:JAN]|DTXCID40232|ESGIC COMPONENT CAFFEINE|TRIAD COMPONENT CAFFEINE|CFF|DIMENHYDRINATE IMPURITY C|FEMCET COMPONENT CAFFEINE|TREZIX COMPONENT CAFFEINE|ANOQUAN COMPONENT CAFFEINE|NSC5036|CAFERGOT COMPONENT CAFFEINE|EC 200-362-1|EXCEDRIN COMPONENT CAFFEINE|FIORICET COMPONENT CAFFEINE|FIORINAL COMPONENT CAFFEINE|MIGERGOT COMPONENT CAFFEINE|NORGESIC COMPONENT CAFFEINE|WIGRAINE COMPONENT CAFFEINE|DHC PLUS COMPONENT CAFFEINE|INVAGESIC COMPONENT CAFFEINE|LANORINAL COMPONENT CAFFEINE|5-26-13-00558 (Beilstein Handbook Reference)|ORPHENGESIC COMPONENT CAFFEINE|SYNALGOS-DC COMPONENT CAFFEINE|Caffeine-13C|1,3,7-trimethyl-2,6-dioxo-1,2,3,6-tetrahydropurine|MEDIGESIC PLUS COMPONENT CAFFEINE|SYNALGOS-DC-A COMPONENT CAFFEINE|Caffeine-13C3|SK 65 Compound|DARVON COMPOUND COMPONENT CAFFEINE|INVAGESIC FORTE COMPONENT CAFFEINE|CAFFEINE (IARC)|CAFFEINE [IARC]|CAFFEINE (II)|CAFFEINE [II]|ORPHENGESIC FORTE COMPONENT CAFFEINE|Caffeine [BAN:JAN]|CAFFEINE (MART.)|CAFFEINE [MART.]|CAFFEINE (USP-RS)|CAFFEINE [USP-RS]|Caffeine (USP:BAN:JAN)|3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion|CAFFEINE (EP MONOGRAPH)|CAFFEINE [EP MONOGRAPH]|CAFFEINE (USP MONOGRAPH)|CAFFEINE [USP MONOGRAPH]|CAS-58-08-2|Caffeine (USP)|SMR000326667|THEOPHYLLINE IMPURITY A (EP IMPURITY)|THEOPHYLLINE IMPURITY A [EP IMPURITY]|DIMENHYDRINATE IMPURITY C (EP IMPURITY)|DIMENHYDRINATE IMPURITY C [EP IMPURITY]|PENTOXIFYLLINE IMPURITY F (EP IMPURITY)|PENTOXIFYLLINE IMPURITY F [EP IMPURITY]|SR-01000075187|Anhydrous caffeine (TN)|Monomethyl derivative of Theophylline|Anhydrous caffeine (JP15)|metilteobromina|DiurexUltimate|Kafeina|DiurexUltra|Respia|trimetilksantina|Awake|NoSnooze|Allertness Aid|Uplift Chewable|Alertness Aid|Conrx Alert|Sprayable Energy|Stay Awake|Alert Aid|Methyltheophylline|NoSnoozeCircle K|1gfz|careone stay awake|Caffeine, BioXtra|Caffeine 200mg|Diurex Water Pills|Topcare Stay Awake|TNP00310|Monohydrate Caffeine|Caffeine1508|NoDoz Alertness Aid|Respia (TN)|AwakeMaximum Strength|Sohmed Alertness Aid|1-methyl-Theobromine|357 Super Magnum|7-methyl Theophylline|Cafergot (Salt/Mix)|1,7-Trimethylxanthine|Diurex Water PillsXPL|Spectrum_001301|1l5q|1l7x|2a3b|3g6m|3,7-dihydro-1,3,7-trimethyl-1H-purine|CAFFEINE [FHFI]|CAFFEINE [HSDB]|CAFFEINE [FCC]|Xanthine,3,7-trimethyl|CAFFEINE [MI]|1 3 7-trimetilksantina|CAFFEINE [VANDF]|CAFFEINUM [HPUS]|1,3,7-Trimethylxantine|Alertness Aid Stay Awake|Spectrum2_001261|Spectrum3_000321|Spectrum4_001782|Spectrum5_000423|Lopac-C-0750|1 3 7-Trimethylxanthine|Caffeine 200 mg Tablets|Jet Alert Double Strength|Stay AwakeMaximum Strength|bmse000206|CAFFEINE [WHO-DD]|CAFFEINE [WHO-IP]|Jet Alert Regular Strength|MolMap_000054|Probes1_000150|Probes2_000128|C 0750|SCHEMBL5671|Caffeine Tablets, 200 mg|Anhydrous caffeine (JP18)|NCIOpen2_008255|BIDD:PXR0172|Caffeine tablet, film-coated|Lopac0_000228|BSPBio_001921|GTPL407|KBioGR_002325|KBioSS_001781|1,3,7-trimethyl-1,3,7-trihydropurine-2,6-dione|MLS001055341|MLS001056714|MLS001066409|BIDD:ER0554|BIDD:GT0632|Caffeine, 1mg/ml in methanol|DivK1c_000730|SPECTRUM1500155|CU-01000012617-3|SPBio_001222|CAFFEINE [ORANGE BOOK]|829 - Tea quality parameters|MEGxp0_001350|ANHYDROUS CAFFEINE [JAN]|component of Dilone (Salt/Mix)|1,7-Trimethyl-2,6-dioxopurine|ACon1_000085|BDBM10849|HMS502E12|KBio1_000730|KBio2_001781|KBio2_004349|KBio2_006917|KBio3_001141|Caffeine 1.0 mg/ml in Methanol|CAFFEINE(3-METHYL-13C)|COFFEINUM [WHO-IP LATIN]|Caffeine, powder, ReagentPlus(R)|component of Percodan (Salt/Mix)|NINDS_000730|Bio1_000473|Bio1_000962|Bio1_001451|CAFFEINE COMPONENT OF ESGIC|CAFFEINE COMPONENT OF TRIAD|HMS1920I09|HMS2091O11|HMS2232M13|HMS3260N17|HMS3372J18|HMS3435F10|HMS3715D13|Pharmakon1600-01500155|Topcare Stay AwakeMaximum Strength|NoDoz Caplets and Chewable Tablets|Caffeine 10 microg/mL in Methanol|CAFFEINE ANHYDROUS [WHO-IP]|CAFFEINE COMPONENT OF FEMCET|CIA28298|CS-M0795|DDA07266|NoDoz Alertness AidMaximum Strength|XCA23885|CAFFEINE COMPONENT OF ANOQUAN|Tox21_201685|Tox21_300010|Tox21_500228|caffeine (1,3,7-trimethylxanthine)|Caffeine 100 microg/mL in Methanol|Carolina Cannabis Uplifting Chewables|CCG-38825|HB2846|NSC755917|PDSP1_001016|PDSP1_001235|PDSP2_001000|PDSP2_001219|STK177283|Valumeds Maximum Strength Stay Awake|CAFFEINE COMPONENT OF CAFERGOT|CAFFEINE COMPONENT OF DHC PLUS|CAFFEINE COMPONENT OF EXCEDRIN|CAFFEINE COMPONENT OF FIORICET|CAFFEINE COMPONENT OF FIORINAL|CAFFEINE COMPONENT OF MIGERGOT|CAFFEINE COMPONENT OF NORGESIC|CAFFEINE COMPONENT OF WIGRAINE|Propoxyphene Compound 65 (Salt/Mix)|AKOS000121334|CAFFEINE COMPONENT OF INVAGESIC|CAFFEINE COMPONENT OF LANORINAL|5-26-13-00558 (Beilstein)|Bayer Select Headache Pain (Salt/Mix)|Caffeine, anhydrous, 99%, FCC, FG|DB00201|FT05891|LP00228|NSC-755917|SDCCGMLS-0064595.P001|SDCCGMLS-0064595.P002|SDCCGSBI-0050216.P005|CAFFEINE COMPONENT OF ORPHENGESIC|IDI1_000730|USEPA/OPP Pesticide Code: 000660|3,3,7-trimethyl-1H-purine-2,6-dione|CAFFEINE COMPONENT OF SYNALGOS-DC|NCGC00015208-01|NCGC00015208-02|NCGC00015208-03|NCGC00015208-04|NCGC00015208-05|NCGC00015208-06|NCGC00015208-07|NCGC00015208-08|NCGC00015208-10|NCGC00015208-11|NCGC00015208-12|NCGC00015208-13|NCGC00015208-14|NCGC00015208-15|NCGC00015208-16|NCGC00015208-17|NCGC00015208-18|NCGC00015208-20|NCGC00015208-27|NCGC00015208-29|NCGC00090699-01|NCGC00090699-02|NCGC00090699-03|NCGC00090699-04|NCGC00090699-05|NCGC00090699-06|NCGC00090699-07|NCGC00090699-08|NCGC00090699-09|NCGC00168808-01|NCGC00168808-02|NCGC00254057-01|NCGC00259234-01|NCGC00260913-01|95789-13-2|AC-12774|AS-15340|Caffeine, SAJ special grade, >=98.5%|component of P-A-C Compound (Salt/Mix)|CAFFEINE COMPONENT OF SYNALGOS-DC-A|component of A.S.A. Compound (Salt/Mix)|SBI-0050216.P004|CAFFEINE COMPONENT OF MEDIGESIC PLUS|DB-023002|WLN: T56 BN DN FNVNVJ B1 F1 H1|C2042|CAFFEINE COMPONENT OF DARVON COMPOUND|CAFFEINE COMPONENT OF INVAGESIC FORTE|EU-0100228|NS00000273|526 - Nutritional Analysis of Energy Drinks|CAFFEINE COMPONENT OF ORPHENGESIC FORTE|EN300-21663|BIM-0050216.0001|C07481|D00528|Q60235|1,3,7-trimethyl-3,7-dihydropurine-2,6-dione|1H-Purine-2, 3,7-dihydro-1,3,7-trimethyl-|AB00051930-09|AB00051930_10|Caffeine, purum, anhydrous, >=99.0% (HPLC)|3,7-dihydro-1,3,7-trimethyl-1H-purine (9CI)|Caffeine, anhydrous, tested according to Ph.Eur.|L000155|Caffeine, Sigma Reference Standard, vial of 250 mg|SR-01000075187-1|SR-01000075187-4|SR-01000075187-7|SR-01000075187-8|BRD-K02404261-001-02-7|BRD-K02404261-001-03-5|BRD-K02404261-001-07-6|BRD-K02404261-001-16-7|Caffeine, certified reference material, TraceCERT(R)|Caffeine, meets USP testing specifications, anhydrous|Melting point standard 235-237C, analytical standard|1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione #|Caffeine, British Pharmacopoeia (BP) Reference Standard|Caffeine, European Pharmacopoeia (EP) Reference Standard|F3371-0262|THEOPHYLLINE MONOHYDRATE IMPURITY A [EP IMPURITY]|Z104507896|07E4FB58-FD79-4175-8E3D-05BF96954522|3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion (coffein)|Caffeine, United States Pharmacopeia (USP) Reference Standard|Caffeine, Pharmaceutical Secondary Standard; Certified Reference Material|Caffeine anhydrous;3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione;7-Methyltheophylline|Caffeine for system suitability, European Pharmacopoeia (EP) Reference Standard|Caffeine melting point standard, United States Pharmacopeia (USP) Reference Standard|InChI=1/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H|114303-55-8|200-362-1|Caffeine Melting Point Standard, Pharmaceutical Secondary Standard; Certified Reference Material|Mettler-Toledo Calibration substance ME 18872, Caffeine, analytical standard, for the calibration of the thermosystem 900, traceable to primary standards (LGC)"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	CHEBI:27732	.	DR00593	DR0257	194.19	C8H10N4O2	58.4	293	-0.1	14	0	3	0	"InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3"	CN1C=NC2=C1C(=O)N(C(=O)N2C)C	RYYVLZVUVIJVGH-UHFFFAOYSA-N
DG02010	Donafenib	25191001	"Sorafenib-d3|Donafenib|1130115-44-4|CM-4307|Sorafenib D3|Zepsun|Donafenib (Sorafenib D3)|UNII-41XGO0VS1U|DONAFENIB [WHO-DD]|41XGO0VS1U|CM4307|4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-(methyl-d3)-2-pyridinecarboxamide|4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-(trideuteriomethyl)pyridine-2-carboxamide|2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-(methyl-d3)-|2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(methyl-d3)-|4-(4-((4-Chloro-3-(trifluoromethyl)phenyl)carbamoylamino)phenoxy)-N-(trideuteriomethyl)pyridine-2-carboxamide|Sorafenib-methyl-d3|d3-sorafenib|4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)phenoxy)-N-(2H3)methylpyridine-2-carboxamide|4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-(2H3)methylpyridine-2-carboxamide|Sorafenib, Free Base|Donafenib (Sorafenib D3)?|CHEMBL4297490|SCHEMBL14480690|GTPL11830|DTXSID90648995|MLDQJTXFUGDVEO-FIBGUPNXSA-N|284461-73-0 (unlabeled)|ARD162733D3|HY-10201S|s9621|AKOS025310175|AT23955|DB15414|1ST162733D3|MS-28634|CS-0019863|Q27258473|4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-(methyl-d3)picolinamide|4-(4-(((4-Chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)phenoxy)-N-(2H3)methyl-2-pyridinecarboxamide|4-[4-({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYL}AMINO)PHENOXY]-N-((2)H?)METHYLPYRIDINE-2-CARBOXAMIDE|4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-(~2~H_3_)methylpyridine-2-carboxamide"	Approved	1	Approved Drug(s)	Approved	Small molecular drug	.	.	.	.	467.8	C21H16ClF3N4O3	92.4	646	4.1	32	3	7	5	"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)/i1D3"	[2H]C([2H])([2H])NC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F	MLDQJTXFUGDVEO-FIBGUPNXSA-N
DG02023	4OH-Tamoxifen	449459	"4-Hydroxytamoxifen|(Z)-4-Hydroxytamoxifen|Afimoxifene|68047-06-3|Hydroxytamoxifen|4-Monohydroxytamoxifen|Tamogel|trans-4-Hydroxytamoxifen|68392-35-8|(Z)-4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol|(E/Z)-4-Hydroxytamoxifen|65213-48-1|4-OHT|1077-29-8|CHEMBL489|R-LIPOIC ACID POTASSIUM COMPUND|TAMOXIFEN, 4-HYDROXY-, (Z)-|MLS000069742|DTXSID7022384|C26H29NO2|CHEBI:44616|4-[(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol|95K54647BZ|SMR000058939|(Z)-4-Hydroxy Tamoxifen|4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol|4-[(1Z)-1-{4-[2-(dimethylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl]phenol|Ici 79280|[3H]4-OHT|SR-01000759243|Afimoxifene [USAN:INN]|ICI 79,280|BRN 4910749|Afimoxifeno|UNII-17197F0KYM|CCRIS 8580|UNII-95K54647BZ|(Z)-4-OHT|(Z)-Afimoxifene|4-OH tamoxifen|(Z)-4-(1-(4-(2-(Dimethylamino)ethoxy)-phenyl)-2-phenylbut-1-en-1-yl)phenol|Tamogel (TN)|MFCD00468090|Z-4-hydroxytamoxifen|2bj4|Opera_ID_600|Afimoxifene (USAN/INN)|4-((1Z)-1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)phenol|Phenol, 4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)-,|trans-4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)phenol|SCHEMBL9189|(Z)-4-hydroxy Tamoxifen?|BIDD:PXR0104|AFIMOXIFENE, Z-ISOMER|MLS001077346|BIDD:ER0193|cid_449459|DTXCID802384|BDBM20608|17197F0KYM|GLXC-26379|HMS2231F20|HY-16950AR|EX-A4661|Tox21_200943|HB2508|HB6040|HB6095|HSCI1_000353|HY-16950A|ICI-79280|MFCD00278780|s8956|(E/Z)-4-Hydroxytamoxifen (Standard)|(Z)-4-Hydroxytamoxifen (Z-4-OHT)|4-{1-[4-(2-Dimethylamino-ethoxy)-phenyl]-2-phenyl-but-1-enyl}-phenol|AKOS016010361|DB04468|FH24132|FH24133|Phenol, 4-((1Z)-1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)-|Phenol, 4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)-, (Z)-|NCGC00164399-01|NCGC00164399-02|NCGC00258497-01|DA-60360|MS-26417|(Z)-4-Hydroxytamoxifen, >=98% Z isomer|CAS-68047-06-3|CS-0003592|NS00068435|C05011|D06551|Q4689254|SR-01000759243-3|SR-01000759243-5|BRD-K04210847-001-01-1|BRD-K04210847-001-21-9|(Z)-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol|4-{(1Z)-1-[4-(2-Dimethylaminoethoxy)phenyl]-2-phenylbut-1-enyl}phenol|4-[(1Z)-1-[4-[2-(Dimethylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]phenol|4-[(1Z)-1-[4-[2-(Dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenol;(Z)-4-Hydroxytamoxifen;trans-4-Hydroxytamoxifen|4-[1-[4-[2-(Dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenol;(E/Z)-4-Hydroxytamoxifen;4-Hydroxytamoxifen"	.	.	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	387.5	C26H29NO2	32.7	493	6.8	29	1	3	8	"InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-"	CC/C(=C(\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3	TXUZVZSFRXZGTL-QPLCGJKRSA-N
DG02026	PD-166866	5328127	"192705-79-6|PD-166866|PD166866|PD 166866|1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea|Urea, N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-|NA856793UT|1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea|1-(2-Amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)-3-(tert-butyl)urea|CHEMBL299763|CHEBI:156259|DTXSID20416144|1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea|Urea, N-(2-amino-6-(3,5-dimethoxyphenyl)pyrido(2,3-d)pyrimidin-7-yl)-N'-(1,1-dimethylethyl)-|1-(2-amino-6-(3,5-dimethoxy-phenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl-urea|1-(2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)-3-(tert-butyl)urea.|N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea|UNII-NA856793UT|N-(2-amino-6-(3,5-dimethoxyphenyl)pyrido(2,3-d)pyrimidin-7-yl)-N'-(1,1-dimethylethyl)-urea|MFCD12922514|6-arylpyrido[2,3-d]pyrimidine deriv. 25|PFE-PKIS 3|Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-|FGF Receptor Tyrosine Kinase|BDBM3443|SCHEMBL1248489|DTXCID20366993|HMS3263L17|BCP20054|EX-A1324|Tox21_501178|PDSP1_000683|PDSP2_000673|s8493|AKOS025286334|CCG-222482|CS-6407|FP26777|NCGC00261863-01|AC-35802|AS-74459|HY-101296|PD166866?|C73670|PD-166866, >=98% (HPLC)|PD-166866 (PD166866)|Q27284760|FGF Receptor Tyrosine Kinase Inhibitor - CAS 192705-79-6|N-[2-Amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)|663-082-2"	Phase 4	2	Approved Drug(s)	Phase 4	Small molecular drug	CHEBI:156259	.	.	.	396.4	C20H24N6O3	124	545	2.3	29	3	7	5	"InChI=1S/C20H24N6O3/c1-20(2,3)26-19(27)25-17-15(8-12-10-22-18(21)24-16(12)23-17)11-6-13(28-4)9-14(7-11)29-5/h6-10H,1-5H3,(H4,21,22,23,24,25,26,27)"	CC(C)(C)NC(=O)NC1=C(C=C2C=NC(=NC2=N1)N)C3=CC(=CC(=C3)OC)OC	NHJSWORVNIOXIT-UHFFFAOYSA-N
DG02039	"10,12-Tricosadiynoic Acid"	538457	"10,12-Tricosadiynoic acid|66990-30-5|tricosa-10,12-diynoic acid|10,12-Tricosadiynoicacid|DTXSID40337084|10,12- Tricosadiynoic acid|SCHEMBL302150|DTXCID30288172|CHEBI:190947|MFCD00041683|AKOS015839844|10,12-Tricosadiynoic Acid, >/=98%|PD127433|HY-135425|CS-0112754|T1200|10,12-Tricosadiynoic acid, >=98.0% (GC)|D92469|677-355-9"	.	.	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	346.5	C23H38O2	37.3	438	8.3	25	1	2	17	"InChI=1S/C23H38O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23(24)25/h2-10,15-22H2,1H3,(H,24,25)"	CCCCCCCCCCC#CC#CCCCCCCCCC(=O)O	DIEDVCMBPCRJFQ-UHFFFAOYSA-N
DG02028	Dichloroacetic acid	6597	"DICHLOROACETIC ACID|79-43-6|2,2-Dichloroacetic acid|Dichloracetic acid|Acetic acid, dichloro-|Dichloroethanoic acid|Urner's liquid|Dichlorethanoic acid|Bichloracetic acid|Bichloroacetic Acid|DCA (acid)|DICHLORO-ACETIC ACID|Acetic acid, 2,2-dichloro-|Kyselina dichloroctova|NSC 2654|Dichloroacetic acid (IUPAC)|Kyselina dichloroctova [Czech]|CCRIS 4016|HSDB 6894|Dichloressigsaeure|UNII-9LSH52S3LQ|NSC-2654|EINECS 201-207-0|9LSH52S3LQ|DKhUK|UN1764|BRN 1098596|DTXSID2020428|CHEBI:36386|AI3-18370|DCA|MFCD00004223|DTXCID20428|DICHLOROACETIC ACID [MI]|Dichloroacetate, Potassium|DICHLOROACETIC ACID [HSDB]|DICHLOROACETIC ACID [IARC]|DICHLOROACETIC ACID [VANDF]|4-02-00-00498 (Beilstein Handbook Reference)|DICHLOROACETIC ACID [WHO-DD]|UN 1764|NCGC00091444-02|Kyselina dichloroctova (Czech)|2,2-Dichloroacetic Acid-2-13C|DICHLOROACETIC ACID (IARC)|CAS-79-43-6|SMR000059158|TF4|Acid, Bichloroacetic|Acid, Dichloroacetic|dicloroacetic acid|WLN: QVYGG|2,2-dichloro-acetic acid|SCHEMBL7777|MLS000028893|MLS001074861|MLS001424165|CHEMBL13960|NSC2654|BDBM227588|HMS2051P22|HMS2232H11|HMS3370D12|HMS3393P22|YGA47070|Dichloroacetic acid, puriss., 99%|Tox21_111133|Tox21_202363|Tox21_300419|Acetic acid, dichloro- (8CI,9CI)|BBL011449|LMFA01090070|MSK000808|STL146561|AKOS005720869|Tox21_111133_1|AT42091|CCG-101070|DB08809|NC00320|NCGC00091444-01|NCGC00091444-03|NCGC00091444-04|NCGC00167845-02|NCGC00254261-01|NCGC00259912-01|AS-14228|DB-056364|D0308|Dichloroacetic acid [UN1764]  [Corrosive]|Dichloroacetic acid, biotech. grade, >=98%|NS00001485|Dichloroacetic acid, ReagentPlus(R), >=99%|EN300-20014|Q412845|DCA Deblock (0.36M dichloroacetic acid in toluene)|Dichloroacetic acid, PESTANAL(R), analytical standard|F2191-0226|Z104476414|Dichloroacetic acid 1000 microg/mL in Methyl-tert-butyl ether|5% Dichloroacetic Acid in Toluene (for AKTA oligopilottrade mark) NC-0406 emp Biotech GmbH|201-207-0"	Phase 1/2	.	Clinical Trial Drug(s)	Phase 1/2	Small molecular drug	.	.	.	.	128.94	C2H2Cl2O2	37.3	60.6	0.9	6	1	2	1	"InChI=1S/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6)"	C(C(=O)O)(Cl)Cl	JXTHNDFMNIQAHM-UHFFFAOYSA-N
DG02008	HA344	6993756	"36061-08-2|(R)-2-Amino-5-phenylpentanoic acid|(2R)-2-amino-5-phenylpentanoic acid|(R)-2-Amino-5-phenyl-pentanoic acid|D-2-Amino-5-phenyl-pentanoic acid|Benzenepentanoic acid, a-amino-, (R)-|(2R)-2-azaniumyl-5-phenylpentanoate|H-D-Phe{#(CH2)2}-OH|(R)-2-Amino-5-phenylpentanoicacid|MFCD03844654|(2R)-2-amino-5-phenyl-pentanoic acid|SCHEMBL2130589|XOQZTHUXZWQXOK-SNVBAGLBSA-N|2(r)-amino-5-phenyl-pentanoic acid|2-(R)-Amino-5-phenylpentanoic acid|AKOS006343927|AC-9944|PS-12532|DS-018116|CS-0005262|W15607|848-211-4"	Investigative	7	Preclinical Drug(s)	Investigative	Small molecular drug	.	.	.	.	193.24	C11H15NO2	63.3	176	-0.4	14	2	3	5	"InChI=1S/C11H15NO2/c12-10(11(13)14)8-4-7-9-5-2-1-3-6-9/h1-3,5-6,10H,4,7-8,12H2,(H,13,14)/t10-/m1/s1"	C1=CC=C(C=C1)CCC[C@H](C(=O)O)N	XOQZTHUXZWQXOK-SNVBAGLBSA-N
DG02021	PF-06424439	71766156	"PF-06424439|1469284-78-3|[(3R)-1-[2-[1-(4-chloropyrazol-1-yl)cyclopropyl]-1H-imidazo[4,5-b]pyridin-5-yl]piperidin-3-yl]-pyrrolidin-1-ylmethanone|CHEMBL4098964|SCHEMBL15322997|PZHNKPBYOPQTRG-OAHLLOKOSA-N|BDBM215552|EX-A5493|AKOS040734393|NCGC00485074-01|DA-56731|HY-108341|CS-0028405|US9296745, 109-A|US9296745, 109-B|US9296745, 190|(3R)-1-{2-[1-(4-chloropyrazol-1-yl)cyclopropyl]-1H-imidazo[4,5-b]pyridin-5-yl}-3-(pyrrolidine-1-carbonyl)piperidine|(R)-(1-(2-(1-(4-chloro-1H-pyrazol-1-yl)cyclopropyl)-3H-imidazo[4,5-b]pyridin-5-yl)piperidin-3-yl)(pyrrolidin-1-yl)methanone|[(3r)-1-[2-[1-(4-chloro-1h-pyrazol-1-yl)cyclopropyl]-3h-imidazo[4,5-b]pyridin-5-yl]-3-piperidinyl]-1-pyrrolidinyl-methanone"	Investigative	7	Preclinical Drug(s)	Investigative	Small molecular drug	.	.	.	.	439.9	C22H26ClN7O	82.9	685	2.6	31	1	5	4	"InChI=1S/C22H26ClN7O/c23-16-12-24-30(14-16)22(7-8-22)21-25-17-5-6-18(26-19(17)27-21)29-11-3-4-15(13-29)20(31)28-9-1-2-10-28/h5-6,12,14-15H,1-4,7-11,13H2,(H,25,26,27)/t15-/m1/s1"	C1CCN(C1)C(=O)[C@@H]2CCCN(C2)C3=NC4=C(C=C3)NC(=N4)C5(CC5)N6C=C(C=N6)Cl	PZHNKPBYOPQTRG-OAHLLOKOSA-N
DG02037	TVB-3166	72947731	"FASN inhibitor 1|TVB-3166|FASN-IN-3|1533438-83-3|2097262-60-5|4-(1-(5-(3,4-Dimethyl-1H-pyrazol-5-yl)-2,4-dimethylbenzoyl)azetidin-3-yl)benzonitrile|4-[1-[5-(4,5-dimethyl-1H-pyrazol-3-yl)-2,4-dimethylbenzoyl]-3-azetidinyl]-benzonitrile|4-[1-[5-(4,5-dimethyl-1H-pyrazol-3-yl)-2,4-dimethylbenzoyl]azetidin-3-yl]benzonitrile|4-(1-(5-(4,5-Dimethyl-1H-pyrazol-3-yl)-2,4-dimethylbenzoyl)azetidin-3-yl)benzonitrile|4-{1-[5-(4,5-Dimethyl-2H-pyrazol-3-yl)-2,4-dimethyl-benzoyl]-azetidin-3-yl}-benzonitrile|4-{1-[5-(4,5-dimethyl-1H-pyrazol-3-yl)-2,4-dimethylbenzoyl]azetidin-3-yl}benzonitrile|starbld0000754|CHEMBL3923704|SCHEMBL15559827|BDBM244633|GLXC-10018|EX-A4622|XID26260|HY-U00436|TVB-3166?|AKOS040733375|AKOS040742789|BS-45242|DA-63382|DB-153395|CS-0035379|TVB-3166, >=98% (HPLC)|E74928|US9428502, 242|4-[1-[5-(4,5-Dimethyl-1H-pyrazol-3-yl)-2,4-dimethylbenzoyl]-3-azetidinyl]benzonitrile"	Investigative	7	Preclinical Drug(s)	Investigative	Small molecular drug	.	.	.	.	384.5	C24H24N4O	72.8	643	4.1	29	1	3	3	"InChI=1S/C24H24N4O/c1-14-9-15(2)22(10-21(14)23-16(3)17(4)26-27-23)24(29)28-12-20(13-28)19-7-5-18(11-25)6-8-19/h5-10,20H,12-13H2,1-4H3,(H,26,27)"	CC1=CC(=C(C=C1C2=NNC(=C2C)C)C(=O)N3CC(C3)C4=CC=C(C=C4)C#N)C	ICDQFUFDAFKCAX-UHFFFAOYSA-N
DG02015	IACS-010759	86711931	"1570496-34-2|IACS-010759|IACS-10759|5-(5-methyl-1-(3-(4-(methylsulfonyl)piperidin-1-yl)benzyl)-1H-1,2,4-triazol-3-yl)-3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole|IACS-010759 free base|IACS 010759 - Bio-X|IACS 010759 [WHO-DD]|Iacs 010759|5-[5-methyl-1-[[3-(4-methylsulfonylpiperidin-1-yl)phenyl]methyl]-1,2,4-triazol-3-yl]-3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole|42W52V11DJ|Oxidative phosphorylation inhibitor IACS-010759|1570496-34-2 (free base)|IACS-010759 (IACS-10759)|4-Methanesulfonyl-1-{3-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,4-triazol-1-yl)methyl]phenyl}piperidine|Piperidine, 4-(methylsulfonyl)-1-(3-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-1,2,4-triazol-1-yl)methyl)phenyl)-|4-(Methylsulfonyl)-1-[3-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-1,2,4-triazol-1-yl]methyl]phenyl]piperidine (IACS-010759)|UNII-42W52V11DJ|C25H25F3N6O4S|CHEMBL4778699|SCHEMBL15498716|IACS10759|GLXC-15124|BCP20596|EX-A1907|OXPHOS Inhibitor IACS-010759|IACS-010759?|NSC809972|s8731|AKOS030527987|NSC-809972|AC-31606|BS-15465|FM165719|DB-196077|HY-112037|CS-0042459|C72972|4-(Methylsulfonyl)-1-(3-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-1,2,4-triazol-1-yl)methyl)phenyl)piperidine|4-(Methylsulfonyl)-1-[3-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-1,2,4-triazol-1-yl]methyl]phenyl]piperidine (IACS-010759); 4-(Methylsulfonyl)-1-[3-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-1,2,4-triazol-1-yl]methyl]phenyl]piperidine (IACS-010759)|4-methanesulfonyl-1-{3-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1,2,4-triazol-1-yl)methyl]phenyl}piperidine|4-Methanesulfonyl-1-{3-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,4-triazol-1-yl)methyl]phenyl}piperi  dine"	Terminated	.	discontinued Drug(s)	Terminated	Small molecular drug	.	.	.	.	562.6	C25H25F3N6O4S	125	908	4.8	39	0	12	7	"InChI=1S/C25H25F3N6O4S/c1-16-29-23(24-30-22(32-38-24)18-6-8-20(9-7-18)37-25(26,27)28)31-34(16)15-17-4-3-5-19(14-17)33-12-10-21(11-13-33)39(2,35)36/h3-9,14,21H,10-13,15H2,1-2H3"	CC1=NC(=NN1CC2=CC(=CC=C2)N3CCC(CC3)S(=O)(=O)C)C4=NC(=NO4)C5=CC=C(C=C5)OC(F)(F)F	HWJWNWZJUYCGKV-UHFFFAOYSA-N
DG02004	Icariin-Curcumol	.	.	Investigative	7	Preclinical Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02005	V9302	.	.	Investigative	7	Preclinical Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02006	CB839	71577426	.	Phase 2	4	Clinical Trial Drug(s)	Phase 2	.	.	.	.	.	571.6	C26H24F3N7O3S	160	812	3.6	40	2	12	12	"InChI=1S/C26H24F3N7O3S/c27-26(28,29)39-20-9-5-6-17(14-20)15-22(37)31-21-12-11-18(33-34-21)7-1-2-10-24-35-36-25(40-24)32-23(38)16-19-8-3-4-13-30-19/h3-6,8-9,11-14H,1-2,7,10,15-16H2,(H,31,34,37)(H,32,36,38)"	C1=CC=NC(=C1)CC(=O)NC2=NN=C(S2)CCCCC3=NN=C(C=C3)NC(=O)CC4=CC(=CC=C4)OC(F)(F)F	PRAAPINBUWJLGA-UHFFFAOYSA-N
DG02011	Folate-polySia	.	.	Investigative	7	Preclinical Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02012	H-mMnO2	.	.	Investigative	7	Preclinical Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02018	2DG	.	.	Phase 1/2	.	Clinical Trial Drug(s)	Phase 1/2	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02022	Anthracyclines	.	.	.	.	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02027	DCPR049_12	.	.	Investigative	7	Preclinical Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02033	l-gamma-Glutamyl-p-nitroanilide (GPNA)	.	.	Investigative	7	Preclinical Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02040	Anti-PD-1 mAb	.	.	.	.	Approved Drug(s)	Approved	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02041	Anti-isotype IgG mAb	.	.	.	.	Approved Drug(s)	Approved	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02042	PD-1 mAb	.	.	.	.	Approved Drug(s)	Approved	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02043	IgG isotype	.	.	.	.	Approved Drug(s)	Approved	Monoclonal antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02144	Gemcitabine/Huaier	.	Gemcitabine/Huaier	Investigative	15	Investigative Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02145	Erlotinib/Gemcitabine	.	Erlotinib/Gemcitabine	Investigative	15	Investigative Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02146	MB2Py	.	MB2Py	Investigative	15	Investigative Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02147	DB2Py	.	DB2Py	Investigative	15	Investigative Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02148	DET	.	DET	Investigative	15	Investigative Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02149	Enasidinib	.	Enasidinib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02150	2-DG	.	2-DG	Investigative	15	Investigative Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02151	ATO-Digoxin	.	ATO-Digoxin	Investigative	15	Investigative Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02152	BRD4	.	BRD4	Investigative	15	Investigative Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02153	JNK1 inhibitors	.	JNK1 inhibitors	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02154	Inhibitory peptide L-JNKi	.	Inhibitory peptide L-JNKi	Investigative	15	Investigative Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02155	BTK inhibitors	.	BTK inhibitors	Preclinical	14	Preclinical Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02156	PI3K inhibitors	.	PI3K inhibitors	Investigative	15	Investigative Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02157	IFN-DC	.	IFN-DC	Investigative	15	Investigative Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02158	IMC-HA	.	IMC-HA	Investigative	15	Investigative Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02159	IMC-OPD	.	IMC-OPD	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02160	Nirogacestat-Ipatasertib	.	Nirogacestat-Ipatasertib	Preclinical	14	Preclinical Drug(s)	Preclinical	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02161	Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors	.	Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02162	IRAK-1 and -4 dual inhibitor	.	IRAK-1 and -4 dual inhibitor	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02163	MA-D1	.	MA-D1	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02164	Farnesyltransferase Inhibition	.	Farnesyltransferase Inhibition	Preclinical	14	Preclinical Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02165	Alk Tyrosine Kinase Inhibitors	.	Alk Tyrosine Kinase Inhibitors	Preclinical	14	Preclinical Drug(s)	Preclinical	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02166	Alpha-Mangostin-4	.	alpha-Mangostin-4	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02167	Neurotrophic Tropomyosin Receptor Kinase-Tyrosine Kinase Inhibitor	.	Neurotrophic Tropomyosin Receptor Kinase-Tyrosine Kinase Inhibitor	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02168	Polymethoxylated Flavones	.	Polymethoxylated Flavones	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02169	CMU-0101	.	CMU-0101	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02170	Topscience	.	Topscience	Investigative	15	Investigative Drug(s)	Investigative	Small molecular drug	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG02171	Peg-Loxenatide	.	Peg-Loxenatide	Investigative	15	Investigative Drug(s)	Investigative	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.